AUTHENTICATED U.S. GOVERNMENT INFORMATION GPO

# Federal Register

8–05–04 Thursday
Vol. 69 No. 150 August 5, 2004

Pages 47353–47762

The **FEDERAL REGISTER** (ISSN 0097–6326) is published daily, Monday through Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Committee of the Federal Register (1 CFR Ch. I). The Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition. Periodicals postage is paid at Washington, DC.

The **FEDERAL REGISTER** provides a uniform system for making available to the public regulations and legal notices issued by Federal agencies. These include Presidential proclamations and Executive Orders, Federal agency documents having general applicability and legal effect, documents required to be published by act of Congress, and other Federal agency documents of public interest.

Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing. For a list of documents currently on file for public inspection, *www.archives.gov.*

**The seal of the National Archives and Records Administration authenticates the Federal Register** as the official serial publication established under the Federal Register Act. Under 44 U.S.C. 1507, the contents of the **Federal Register** shall be judicially noticed.

The **Federal Register** is published in paper and on 24x microfiche. It is also available online at no charge as one of the databases on GPO Access, a service of the U.S. Government Printing Office.

The online edition of the **Federal Register** *www.gpoaccess.gov/nara,* available through GPO Access, is issued under the authority of the Administrative Committee of the Federal Register as the official legal equivalent of the paper and microfiche editions (44 U.S.C. 4101 and 1 CFR 5.10). It is updated by 6 a.m. each day the **Federal Register** is published and includes both text and graphics from Volume 59, Number 1 (January 2, 1994) forward.

For more information about GPO Access, contact the GPO Access User Support Team, call toll free 1-888-293-6498; DC area 202-512-1530; fax at 202-512-1262; or via email at *gpoaccess@gpo.gov.* The Support Team is available between 7:00 a.m. and 9:00 p.m. Eastern Time, Monday–Friday, except official holidays.

The annual subscription price for the **Federal Register** paper edition is $749 plus postage, or $808, plus postage, for a combined **Federal Register, Federal Register** Index and List of CFR Sections Affected (LSA) subscription; the microfiche edition of the **Federal Register** including the **Federal Register** Index and LSA is $165, plus postage. Six month subscriptions are available for one-half the annual rate. The prevailing postal rates will be applied to orders according to the delivery method requested. The price of a single copy of the daily **Federal Register,** including postage, is based on the number of pages: $11 for an issue containing less than 200 pages; $22 for an issue containing 200 to 400 pages; and $33 for an issue containing more than 400 pages. Single issues of the microfiche edition may be purchased for $3 per copy, including postage. Remit check or money order, made payable to the Superintendent of Documents, or charge to your GPO Deposit Account, VISA, MasterCard, American Express, or Discover. Mail to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250-7954; or call toll free 1-866-512-1800, DC area 202-512-1800; or go to the U.S. Government Online Bookstore site, *bookstore@gpo.gov.*

There are no restrictions on the republication of material appearing in the **Federal Register.**

**How To Cite This Publication:** Use the volume number and the page number. Example: 69 FR 12345.

**Postmaster:** Send address changes to the Superintendent of Documents, Federal Register, U.S. Government Printing Office, Washington DC 20402, along with the entire mailing label from the last issue received.

## SUBSCRIPTIONS AND COPIES

**PUBLIC**

**Subscriptions:**

| | |
|---|---|
| Paper or fiche | **202–512–1800** |
| Assistance with public subscriptions | **202–512–1806** |

**General online information** **202–512–1530; 1–888–293–6498**

**Single copies/back copies:**

| | |
|---|---|
| Paper or fiche | **202–512–1800** |
| Assistance with public single copies | **1–866–512–1800 (Toll-Free)** |

**FEDERAL AGENCIES**

**Subscriptions:**

| | |
|---|---|
| Paper or fiche | **202–741–6005** |
| Assistance with Federal agency subscriptions | **202–741–6005** |

**What's NEW!**

**Federal Register** Table of Contents via e-mail

Subscribe to FEDREGTOC, to receive the **Federal Register** Table of Contents in your e-mail every day.

If you get the HTML version, you can click directly to any document in the issue.

To subscribe, go to **http://listserv.access.gpo.gov** and select:

*Online mailing list archives*
*FEDREGTOC-L*
*Join or leave the list*

Then follow the instructions.

**What's NEW!**

**Regulations.gov,** the award-winning Federal eRulemaking Portal

Regulations.gov is the one-stop U.S. Government web site that makes it easy to participate in the regulatory process.

Try this fast and reliable resource to find all rules published in the *Federal Register* that are currently open for public comment. Submit comments to agencies by filling out a simple web form, or use available email addresses and web sites.

The Regulations.gov e-democracy initiative is brought to you by NARA, GPO, EPA and their eRulemaking partners.

Visit the web site at: **http://www.regulations.gov**

Printed on recycled paper.

# Contents

**Federal Register**

Vol. 69, No. 150

Thursday, August 5, 2004

**Agriculture Department**
*See* Food Safety and Inspection Service
*See* Rural Utilities Service

**Alcohol, Tobacco, Firearms, and Explosives Bureau**
NOTICES
Agency information collection activities; proposals, submissions, and approvals, 47462–47465

**Army Department**
*See* Engineers Corps

**Centers for Disease Control and Prevention**
NOTICES
Grant and cooperative agreement awards:
Tropical Disease Foundation, Inc., 47445–47446
Meetings:
Scientific Counselors Board, 47446

**Centers for Medicare & Medicaid Services**
PROPOSED RULES
Medicare:
Physician fee schedule (2005 CY); payment policies and relative value units, 47487–47730
NOTICES
Meetings:
Medicare—
Ambulatory Payment Classification Groups Advisory Panel, 47446–47448

**Children and Families Administration**
NOTICES
Grant and cooperative agreement awards:
Center for Economic Progress, 47448

**Coast Guard**
RULES
Alternate hull examination program for passenger vessels, and underwater surveys for nautical school, offshore supply, passenger, and sailing school vessels, 47378–47384
NOTICES
Pollution:
Ballast water treatment systems; approval program development; comment request, 47453–47454
Waterfront facilities:
Sabine Pass Channel waterway, LA; liquefied natural gas marine traffic suitability; letter of recommendation and comment request, 47455–47456

**Commerce Department**
*See* International Trade Administration
*See* National Oceanic and Atmospheric Administration
NOTICES
Agency information collection activities; proposals, submissions, and approvals, 47402–47404

**Commodity Futures Trading Commission**
NOTICES
Agency information collection activities; proposals, submissions, and approvals, 47419–47420

**Copyright Office, Library of Congress**
PROPOSED RULES
Copyright office and procedure:
Unpublished audio and audiovisual transmission programs; acquisition and deposit, 47396–47399

**Corporation for National and Community Service**
NOTICES
Agency information collection activities; proposals, submissions, and approvals, 47420–47421

**Defense Department**
*See* Engineers Corps
NOTICES
Arms sales notification, transmittal letter, etc., 47421–47429
Meetings:
Dependents' Education Advisory Council, 47429

**Energy Department**
*See* Energy Efficiency and Renewable Energy Office
*See* Energy Information Administration
*See* Federal Energy Regulatory Commission

**Energy Efficiency and Renewable Energy Office**
PROPOSED RULES
Energy conservation:
Commercial and industrial equipment; energy efficiency program—
Commercial unitary air conditioners and heat pumps; meeting; correction, 47486

**Energy Information Administration**
NOTICES
Agency information collection activities; proposals, submissions, and approvals, 47430–47431

**Engineers Corps**
NOTICES
Environmental statements; availability, etc.:
Los Angeles County, CA; Pier J South Marine Terminal Expansion Project, 47429–47430

**Environmental Protection Agency**
RULES
Air quality implementation plans; approval and promulgation; various States; air quality planning purposes; designation of areas:
Colorado, 47366–47377
Air quality implementation plans; approval and promulgation; various States:
Pennsylvania; withdrawn, 47366
Washington, 47365–47366
Superfund program:
National oil and hazardous substances contingency plan—
National priorities list update, 47377
PROPOSED RULES
Air quality implementation plans; approval and promulgation; various States; air quality planning purposes; designation of areas:
Colorado, 47399

NOTICES
Agency information collection activities; proposals, submissions, and approvals, 47432–47434
Grants and cooperative agreements; availability, etc.:
Environmental management systems local resource centers, 47434–47437
Pesticide registration, cancellation, etc.:
Sumitomo Chemical Co., Ltd., et al., 47437–47439
Water pollution control:
Total maximum daily loads—
Barataria river basin, LA, 47439

**Export-Import Bank**
NOTICES
China; semiconductor manufacturing equipment; finance application, 47439

**Federal Aviation Administration**
RULES
Airworthiness standards:
Special conditions—
Garmin AT, Inc. Piper PA-32 airplane, 47354–47356
Class E airspace, 47357–47358
Restricted areas, 47358–47360
PROPOSED RULES
Airworthiness directives:
Airbus, 47391–47395
McDonnell Douglas, 47388–47391
NOTICES
Advisory circulars; availability, etc.:
Charles Taylor "Master Mechanic" Award; eligibility, application, and selection guidance, 47481
Commercial space transportation:
Launch site operation at Mojave Airport, CA; liquid propellant storage and handling requirements; waiver; correction, 47486
Environmental statements; record of decision:
Dane County Regional Airport, WI; capital improvement projects, 47481–47482
Passenger facility charges; applications, etc.:
Key West International Airport, FL, 47482
Walker Field Airport, CO, 47482–47483

**Federal Communications Commission**
RULES
Digital television stations; table of assignments:
Arkansas, 47385
Florida, 47385
PROPOSED RULES
Digital television stations; table of assignments:
Montana, 47399–47400

**Federal Election Commission**
NOTICES
Meetings; Sunshine Act, 47439

**Federal Energy Regulatory Commission**
NOTICES
Electric rate and corporate regulation filings, 47431–47432

**Federal Highway Administration**
NOTICES
Environmental statements; notice of intent:
Cache County, UT, 47483–47484

**Federal Motor Carrier Safety Administration**
RULES
Motor carrier safety standards:
Household goods transportation; consumer protection regulations
Correction, 47386–47387

**Federal Reserve System**
NOTICES
Banks and bank holding companies:
Formations, acquisitions, and mergers, 47439–47440

**Fish and Wildlife Service**
RULES
Endangered Species Act:
Joint counterpart consultation regulations, 47731–47762

**Food and Drug Administration**
RULES
Animal drugs, feeds, and related products:
Ceftiofur, 47362
Gentamicin sulfate ophthalmic ointment, 47363
Romifidine hydrochloride injectable solution, 47362–47363
Sponsor name and address changes—
Hess & Clark, Inc., 47360
Sparhawk Laboratories, Inc., 47361–47362
NOTICES
Agency information collection activities; proposals, submissions, and approvals, 47448–47450
Withdrawn, 47450

**Food Safety and Inspection Service**
NOTICES
Committees; establishment, renewal, termination, etc.:
Meat and Poultry Inspection National Advisory Committee, 47401

**Health and Human Services Department**
*See* Centers for Disease Control and Prevention
*See* Centers for Medicare & Medicaid Services
*See* Children and Families Administration
*See* Food and Drug Administration
*See* National Institutes of Health
NOTICES
Grants and cooperative agreements; availability, etc.:
Safe and Bright Futures for Children Initiative, 47440–47445

**Homeland Security Department**
*See* Coast Guard

**Indian Affairs Bureau**
NOTICES
Environmental statements; notice of intent:
Navajo Nation, AZ and NM; Ten-year Forest Management Plan, 47456
Liquor and tobacco sale or distribution ordinance:
Seneca Nation of Indians, NY, 47456–47459
Tribal-State Compacts approval; Class III (casino) gambling:
Mescalero Apache Tribe, NM, 47459

**Interior Department**
*See* Fish and Wildlife Service
*See* Indian Affairs Bureau
*See* Land Management Bureau

**Internal Revenue Service**
RULES
Income taxes:
Qualified dividend income; time and manner of making election to treat as investment income, 47364–47365
PROPOSED RULES
Income taxes:
Qualified dividend income; time and manner of making election to treat as investment income; cross reference, 47395–47396
NOTICES
Agency information collection activities; proposals, submissions, and approvals; correction, 47485

**International Trade Administration**
NOTICES
Antidumping:
Barbed wire and barbless fencing wire from—
Argentina, 47404–47405
Barium chloride from—
China, 47405
Glycine from—
China, 47405–47407
Honey from—
China, 47407–47408
Pure magnesium from—
Canada, 47408–47409
Sebacic acid from—
China, 47409–47412
Softwood lumber products from—
Canada, 47413–47415
Sorbitol from—
France, 47415
Stainless steel plate in coils from—
Various countries, 47416–47417
Wooden bedroom furniture from—
China, 47417–47418
Antidumping and countervailing duties:
Five-year (sunset) reviews—
Initiation of reviews, 47404
Countervailing duties:
Stainless steel plate in coils from—
South Africa, 47418–47419

**International Trade Commission**
NOTICES
Import investigations:
Disk drives, components, and products containing same, 47460–47461
Softwood lumber from—
Canada, 47461

**Justice Department**
*See* Alcohol, Tobacco, Firearms, and Explosives Bureau
NOTICES
Pollution control; consent judgments:
Embassy Builders, Inc., et al., 47461–47462
Thorson, Peter, et al., 47462
Weyerhaeuser Co., 47462

**Land Management Bureau**
NOTICES
Survey plat filings:
Oregon and Washington, 47459–47460

**Legal Services Corporation**
NOTICES
Meetings; Sunshine Act, 47465

**Library of Congress**
*See* Copyright Office, Library of Congress

**National Highway Traffic Safety Administration**
NOTICES
Motor vehicle safety standards:
Exemption petitions, etc.—
Coupled Products, Inc., 47484–47485

**National Institutes of Health**
NOTICES
Agency information collection activities; proposals, submissions, and approvals, 47450–47451
Meetings:
National Cancer Institute, 47451
National Institute of Mental Health, 47451–47452
National Institute of Neurological Disorders and Stroke, 47453
National Institute on Alcohol Abuse and Alcoholism, 47452–47453

**National Oceanic and Atmospheric Administration**
RULES
Endangered Species Act:
Joint counterpart consultation regulations, 47731–47762

**Nuclear Regulatory Commission**
NOTICES
Environmental statements; availability, etc.:
FirstEnergy Nuclear Operating Co., 47469–47470
*Applications, hearings, determinations, etc.:*
Entergy Operations, Inc., 47465–47467
Florida Power & Light Co., 47467–47469

**Personnel Management Office**
RULES
Pay under General Schedule:
Locality-based comparability payments, 47353–47354

**Rural Utilities Service**
NOTICES
Environmental statements; notice of intent:
North Carolina Electric Membership Corp., 47401–47402

**Securities and Exchange Commission**
NOTICES
Investment Company Act of 1940:
Morgan Stanley All-Star Growth Fund et al., 47470–47473
Meetings; Sunshine Act, 47473
Self-regulatory organizations; proposed rule changes:
American Stock Exchange LLC, 47473–47474
New York Stock Exchange, Inc., 47474–47476
Options Clearing Corp., 47476–47477
Pacific Exchange, Inc., 47477–47479
Philadelphia Stock Exchange, Inc., 47479–47480

**Transportation Department**
*See* Federal Aviation Administration
*See* Federal Highway Administration
*See* Federal Motor Carrier Safety Administration
*See* National Highway Traffic Safety Administration
NOTICES
Aviation proceedings:
Agreements filed; weekly receipts, 47481
Certificates of public convenience and necessity and foreign air carrier permits; weekly applications, 47481

**Treasury Department**
*See* Internal Revenue Service
**NOTICES**
Agency information collection activities; proposals, submissions, and approvals, 47485

**Separate Parts In This Issue**

**Part II**
Health and Human Services Department, Centers for Medicare & Medicaid Services, 47487–47730

**Part III**
Commerce Department, National Oceanic and Atmospheric Administration; Interior Department, Fish and Wildlife Service, 47731–47762

**Reader Aids**
Consult the Reader Aids section at the end of this issue for phone numbers, online resources, finding aids, reminders, and notice of recently enacted public laws.

To subscribe to the Federal Register Table of Contents LISTSERV electronic mailing list, go to http://listserv.access.gpo.gov and select Online mailing list archives, FEDREGTOC-L, Join or leave the list (or change settings); then follow the instructions.

## CFR PARTS AFFECTED IN THIS ISSUE

A cumulative list of the parts affected this month can be found in the Reader Aids section at the end of this issue.


**5 CFR**
531 ..... 47353

**10 CFR**
**Proposed Rules:**
431 ..... 47486

**14 CFR**
23 ..... 47354
71 (2 documents) ..... 47357
73 ..... 47358
**Proposed Rules:**
39 (3 documents) ..... 47388, 47391, 47393

**21 CFR**
510 (2 documents) ..... 47360, 47361
522 (3 documents) ..... 47361, 47362
524 (2 documents) ..... 47361, 47363

**26 CFR**
1 ..... 47364
**Proposed Rules:**
1 ..... 47395

**37 CFR**
**Proposed Rules:**
202 ..... 47396

**40 CFR**
52 (3 documents) ..... 47365, 47366
81 ..... 47366
300 ..... 47377
**Proposed Rules:**
52 ..... 47399
81 ..... 47399

**42 CFR**
**Proposed Rules:**
405 ..... 47488
410 ..... 47488
411 ..... 47488
414 ..... 47488
418 ..... 47488
424 ..... 47488
484 ..... 47488
486 ..... 47488

**46 CFR**
71 ..... 47378
114 ..... 47378
115 ..... 47378
125 ..... 47378
126 ..... 47378
167 ..... 47378
169 ..... 47378
175 ..... 47378
176 ..... 47378

**47 CFR**
73 (2 documents) ..... 47385
**Proposed Rules:**
73 ..... 47399

**49 CFR**
375 ..... 47386

**50 CFR**
402 ..... 47732

# Rules and Regulations

Federal Register

Vol. 69, No. 150

Thursday, August 5, 2004

This section of the FEDERAL REGISTER contains regulatory documents having general applicability and legal effect, most of which are keyed to and codified in the Code of Federal Regulations, which is published under 50 titles pursuant to 44 U.S.C. 1510.

The Code of Federal Regulations is sold by the Superintendent of Documents. Prices of new books are listed in the first FEDERAL REGISTER issue of each week.

## OFFICE OF PERSONNEL MANAGEMENT

### 5 CFR Part 531

**RIN 3206–AK56**

### Locality-Based Comparability Payments

**AGENCY:** Office of Personnel Management.

**ACTION:** Interim rule with request for comments.

**SUMMARY:** The Office of Personnel Management is issuing interim regulations to provide that a locality rate of pay is considered basic pay for the purpose of computing danger pay allowances and post differentials for certain employees temporarily assigned to work in foreign areas for which the Department of State has established danger pay allowances. These regulations will aid agencies in responding to emergency, mission-critical staffing needs in support of the Global War on Terrorism and other international activities in imminently dangerous overseas work locations by increasing the danger pay allowance and post differential benefits for employees temporarily assigned to such locations.

**DATES:** *Effective Date:* August 5, 2004.

*Applicability Date:* These regulations apply on the first day of the first applicable pay period beginning on or after August 5, 2004.

*Comment Date:* Comments must be received on or before October 4, 2004.

**ADDRESSES:** Send or deliver comments to Donald J. Winstead, Deputy Associate Director for Pay and Performance Policy, Office of Personnel Management, Room 7H31, 1900 E Street, NW., Washington, DC 20415–8200; FAX: (202) 606–4264; or e-mail: *pay-performance-policy@opm.gov.*

**FOR FURTHER INFORMATION CONTACT:** Jeanne Jacobson, (202) 606–2858; FAX: (202) 606–0824; or e-mail: *pay-performance-policy@opm.gov.*

**SUPPLEMENTARY INFORMATION:** The Office of Personnel Management (OPM) is issuing interim regulations that amend 5 CFR 531.606(b) to provide that a locality rate of pay is considered basic pay for the purpose of computing danger pay allowances under 5 U.S.C. 5928 and post differentials under 5 U.S.C. 5925(a) for certain employees temporarily assigned to work in foreign areas for which the Department of State has established danger pay allowances. These regulations will aid agencies in responding to emergency, mission-critical staffing needs in imminently dangerous overseas work locations in support of the Global War on Terrorism and other international activities by increasing the danger pay allowance and post differential benefits for employees temporarily assigned to such locations.

### Overseas Danger Pay Allowances and Post Differentials

Under 5 U.S.C. 5928, the Department of State may establish a danger pay allowance for a foreign area on the basis of civil insurrection, civil war, terrorism, or wartime conditions in that area which threaten physical harm or imminent danger to the health or well-being of an employee. A danger pay allowance may not exceed 25 percent of an employee's rate of basic pay. Employees are entitled to receive a danger pay allowance if they work in an approved danger pay post for a minimum of 4 hours in one day (including while on detail or in a temporary duty travel status).

Under 5 U.S.C. 5925(a), the Department of State may establish a post differential for an overseas location based on conditions of environment that differ substantially from conditions of environment in the continental United States and warrant additional pay as a recruitment and retention incentive. A past differential may not exceed 25 percent of an employee's rate of basic pay. Employees working on extended detail or in a temporary duty travel status in an overseas location with an approved post differential are entitled to receive the post differential after working in a hardship post location for 42 days.

The allowance and differential rates established by the Department of State apply to all United States Government civilian employees overseas, regardless of agency affiliation. Additional information on danger pay allowances and post differentials may be obtained from the Department of State at *http://www.state.gov/m/a/als/.*

### Locality Rates of Pay

Locality rates of pay under 5 U.S.C. 5304 and 5 CFR part 531, subpart F, are authorized for employees whose official duty stations (as defined in 5 CFR 531.602) are located in one of the locality pay areas listed in 5 CFR 531.603, covering all locations in the 48 contiguous States and Washington, DC. Employees with official duty stations outside the 48 contiguous States are not entitled to locality pay. However, the official duty station of an employee who is temporarily assigned to work in a location outside the 48 contiguous States while on detail or in a temporary duty travel status generally remains the duty station of his or her permanent position of record as indicated on the most recent notification of personnel action. Such employees are entitled to receive the locality rate of pay associated with their official duty station while working overseas.

Under 5 U.S.C. 5304(c)(2), a locality rate of pay must be considered part of basic pay for purposes of retirement under 5 U.S.C. chapters 83 or 84, as applicable; life insurance under 5 U.S.C. chapter 87; premium pay under 5 U.S.C. chapter 55, subchapter V; and for such other purposes as may be expressly provided for by law or as OPM may prescribe by regulation. OPM regulations provide that a locality rate of pay is considered basic pay for purposes of severance pay under 5 CFR part 550, subpart G, and advances in pay under 5 CFR part 550, subpart B. (See 5 CFR 531.606(b).)

### Computing Danger Pay Allowances and Post Differentials Using Locality Rates of Pay

These interim regulations amend 5 CFR 531.606(b) to provide that a locality rate of pay is considered basic pay for the purpose of computing danger pay allowances under 5 U.S.C. 5928 and post differentials under 5 U.S.C. 5925(a) for employees temporarily assigned to work in a foreign area for which the Department of State has established a danger pay allowance. Covered employees must be temporarily assigned

to locations with an approved danger pay allowance (*e.g.*, via a detail or while in temporary duty travel status), have an official duty station that is located in a locality pay area specified in 5 CFR 531.603, and receive a locality rate of pay under 5 U.S.C. 5304. Using locality rates of pay to compute danger pay allowances and post differentials for employees who must work temporarily in imminently dangerous overseas duty locations will increase the size of these payments and enhance their benefit for affected employees. This, in turn, will help agencies better respond to critical staffing needs in certain overseas duty locations in support of the Global War on Terrorism and other important international activities.

Prior to the effective date of these regulations, a locality rate of pay under 5 U.S.C. 5304 and 5 CFR part 531, subpart F, cannot be considered part of an employee's basic pay for the purpose of computing any overseas allowance or differential, including those paid to employees detailed to or on official travel in a foreign area. Agencies must correct the payment of any danger pay allowance, post differential, or other overseas allowance or differential paid prior to the effective date of these regulations if it was computed using a locality rate of pay authorized under 5 U.S.C. 5304. An overpayment may be recovered under an agency's regulations for collection by offset from an indebted Government employee under 5 U.S.C. 5514 and 5 CFR part 550, subpart K, or through the appropriate provisions governing Federal debt collection if the individual is no longer a Federal employee. However, the head of an agency may waive an overpayment under 5 U.S.C. 5584, as appropriate.

### Waiver of Notice of Proposed Rulemaking and Delay in Effective Date

In order to give practical effect to these regulations at the earliest possible moment, I find that good cause exists to waive the general notice of proposed rulemaking pursuant to 5 U.S.C. 553(b)(3)(B). Also, I find that good cause exists for making this rule effective in less than 30 days. The delay in effective date is waived so that affected agencies and employees may benefit from the new provisions as quickly as possible. Increasing the danger pay allowance and post differential benefits for employees temporarily assigned to imminently dangerous overseas work locations will help agencies respond to emergency, mission-critical staffing needs in support of the Global War on Terrorism and other important international activities.

### E.O. 12866, Regulatory Review

The Office of Management and Budget has reviewed this rule in accordance with E.O. 12866.

### Regulatory Flexibility Act

I certify that these regulations will not have a significant economic impact on a substantial number of small entities because they will apply only to Federal agencies and employees.

### List of Subjects in 5 CFR Part 531

Government employees, Law enforcement officers, Wages.

Office of Personnel Management.

**Kay Coles James,**

*Director.*

■ Accordingly, OPM is amending 5 CFR part 531 as follows:

## PART 531—PAY UNDER THE GENERAL SCHEDULE

■ 1. The authority citation for part 531 continues to read as follows:

**Authority:** 5 U.S.C. 5115, 5307, and 5338; sec. 4 of Pub. L. 103–89, 107 Stat. 981; and E.O. 12748, 56 FR 4521, 3 CFR, 1991 Comp., p. 316; Subpart B also issued under 5 U.S.C. 5303(g), 5333, 5334(a), and 7701(b)(2); Subpart C also issued under 5 U.S.C. 5304, 5305, and 5553; sections 302 and 404 of Federal Employees Pay Comparability Act of 1990 (FEPCA), Pub. L. 101–509, 104 Stat. 1462 and 1466; and section 3(7) of Pub. L. 102–378, 106 Stat. 1356; Subpart D also issued under 5 U.S.C. 5335(g) and 7701(b)(2); Subpart E also issued under 5 U.S.C. 5336; Subpart F also issued under 5 U.S.C. 5304, 5305(g)(1), and 5553; and E.O. 12883, 58 FR 63281, 3 CFR, 1993 Comp., p. 682 and E.O. 1306, 63 FR 68151, 3 CFR, 1998 Comp., p. 224; Subpart G also issued under 5 U.S.C. 5304, 5305, and 5553; section 302 of the FEPCA, Pub. L. 101–509, 104 Stat. 1462; and E.O. 12786, 56 FR 67453, 3 CFR, 1991 Comp., p. 376.

## Subpart F—Locality-Based Comparability Payments

■ 2. In § 531.606, a new paragraph (b)(6) is added to read as follows:

### § 531.606 Administration of locality rates of pay.

* * * * *

(b) * * *

(6) Post differentials under 5 U.S.C. 5925(a) and danger pay allowances under 5 U.S.C. 5928 for an employee temporarily assigned to work in a foreign area for which the Department of State has established a danger pay allowance under 5 U.S.C. 5928, when the employee's official duty station is located in a locality pay area under § 531.603.

* * * * *

[FR Doc. 04–17842 Filed 8–4–04; 8:45 am]

BILLING CODE 6325–39–P

## DEPARTMENT OF TRANSPORTATION

## Federal Aviation Administration

## 14 CFR Part 23

**[Docket No. CE209, Special Condition 23–149–SC]**

## Special Conditions; Garmin AT, Inc., Piper PA–32; Protection of Electronic Flight Instrument Systems (EFIS) for High Intensity Radiated Fields (HIRF)

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Final special conditions; request for comments.

**SUMMARY:** These special conditions are issued to Garmin AT, Inc., 2345 Turner Road, Salem, OR 97302, for a Supplemental Type Certificate for the Piper PA–32. This airplane, as modified by Garmin AT, Inc., will have novel and unusual design features when compared to the state of technology envisaged in the applicable airworthiness standards. These novel and unusual design features include the installation of an electronic flight instrument system (EFIS) display, Model G–1000, manufactured by Garmin AT, Inc., for which the applicable regulations do not contain adequate or appropriate airworthiness standards for the protection of these systems from the effects of high intensity radiated fields (HIRF). These special conditions contain the additional safety standards that the Administrator considers necessary to establish a level of safety equivalent to the airworthiness standards applicable to this airplane.

**DATES:** The effective date of these special conditions is July 26, 2004. Comments must be received on or before September 7, 2004.

**ADDRESSES:** Comments may be mailed in duplicate to: Federal Aviation Administration, Regional Counsel, ACE–7, Attention: Rules Docket Clerk, Docket No. CE209, Room 506, 901 Locust, Kansas City, Missouri 64106. All comments must be marked: Docket No. CE209. Comments may be inspected in the Rules Docket weekdays, except Federal holidays, between 7:30 a.m. and 4 p.m.

**FOR FURTHER INFORMATION CONTACT:** Wes Ryan, Aerospace Engineer, Standards Office (ACE–110), Small Airplane

Directorate, Aircraft Certification Service, Federal Aviation Administration, 901 Locust, Room 301, Kansas City, Missouri 64106; telephone (816) 329–4127.

**SUPPLEMENTARY INFORMATION:** The FAA has determined that notice and opportunity for prior public comment hereon are impracticable because these procedures would significantly delay issuance of the design approval and thus delivery of the affected aircraft. In addition, the substance of these special conditions has been subject to the public comment process in several prior instances with no substantive comments received. The FAA, therefore, finds that good cause exists for making these special conditions effective upon issuance.

## Comments Invited

Interested persons are invited to submit such written data, views, or arguments, as they may desire. Communications should identify the regulatory docket or notice number and be submitted in duplicate to the address specified above. All communications received on or before the closing date for comments will be considered by the Administrator. The special conditions may be changed in light of the comments received. All comments received will be available in the Rules Docket for examination by interested persons, both before and after the closing date for comments. A report summarizing each substantive public contact with FAA personnel concerning this rulemaking will be filed in the docket. Commenters wishing the FAA to acknowledge receipt of their comments submitted in response to this notice must include a self-addressed, stamped postcard on which the following statement is made: ''Comments to Docket No. CE209.'' The postcard will be date stamped and returned to the commenter.

## Background

On January 5, 2004, Garmin AT, Inc., 2345 Turner Road, Salem, OR 97302, made an application to the FAA for a new Supplemental Type Certificate for the Piper PA–32. The PA–32 is currently approved under TC No. A3SO. The proposed modification incorporates a novel or unusual design feature, such as digital avionics consisting of an EFIS that is vulnerable to HIRF external to the airplane.

## Type Certification Basis

Under the provisions of 14 CFR part 21, § 21.101, Garmin AT, Inc. must show that the Piper PA–32 aircraft meets the original certification basis for the airplane, as listed on Type Data Sheet A3SO; the additional certification requirements added for the G1000 system, exemptions, if any; and the special conditions adopted by this rulemaking action.

## Discussion

If the Administrator finds that the applicable airworthiness standards do not contain adequate or appropriate safety standards because of novel or unusual design features of an airplane, special conditions are prescribed under the provisions of § 21.16.

Special conditions, as appropriate, as defined in § 11.19, are issued in accordance with § 11.38 after public notice and become part of the type certification basis in accordance with § 21.101.

Special conditions are initially applicable to the model for which they are issued. Should the applicant apply for a supplemental type certificate to modify any other model already included on the same type certificate to incorporate the same novel or unusual design feature, the special conditions would also apply to the other model under the provisions of § 21.101.

## Novel or Unusual Design Features

Garmin AT, Inc. plans to incorporate certain novel and unusual design features into the Piper PA–32 airplane for which the airworthiness standards do not contain adequate or appropriate safety standards for protection from the effects of HIRF. These features include EFIS, which are susceptible to the HIRF environment, that were not envisaged by the existing regulations for this type of airplane.

*Protection of Systems from High Intensity Radiated Fields (HIRF):* Recent advances in technology have given rise to the application in aircraft designs of advanced electrical and electronic systems that perform functions required for continued safe flight and landing. Due to the use of sensitive solid-state advanced components in analog and digital electronics circuits, these advanced systems are readily responsive to the transient effects of induced electrical current and voltage caused by the HIRF. The HIRF can degrade electronic systems performance by damaging components or upsetting system functions.

Furthermore, the HIRF environment has undergone a transformation that was not foreseen when the current requirements were developed. Higher energy levels are radiated from transmitters that are used for radar, radio, and television. Also, the number of transmitters has increased significantly. There is also uncertainty concerning the effectiveness of airframe shielding for HIRF. Furthermore, coupling to cockpit-installed equipment through the cockpit window apertures is undefined. The combined effect of the technological advances in airplane design and the changing environment has resulted in an increased level of vulnerability of electrical and electronic systems required for the continued safe flight and landing of the airplane. Effective measures against the effects of exposure to HIRF must be provided by the design and installation of these systems. The accepted maximum energy levels in which civilian airplane system installations must be capable of operating safely are based on surveys and analysis of existing radio frequency emitters. These special conditions require that the airplane be evaluated under these energy levels for the protection of the electronic system and its associated wiring harness. These external threat levels, which are lower than previous required values, are believed to represent the worst case to which an airplane would be exposed in the operating environment.

These special conditions require qualification of systems that perform critical functions, as installed in aircraft, to the defined HIRF environment in paragraph 1 or, as an option to a fixed value using laboratory tests, in paragraph 2, as follows: (1) The applicant may demonstrate that the operation and operational capability of the installed electrical and electronic systems that perform critical functions are not adversely affected when the aircraft is exposed to the HIRF environment defined below:

| Frequency | Field strength (volts per meter) | |
|---|---|---|
| | Peak | Average |
| 10 kHz–100 kHz | 50 | 50 |
| 100 KHz–500 kHz | 50 | 50 |

| Frequency | Field strength (volts per meter) | |
|---|---|---|
| | Peak | Average |
| 500 kHz–2 MHz | 50 | 50 |
| 2 MHz–30 MHz | 100 | 100 |
| 30 MHz–70 MHz | 50 | 50 |
| 70 MHz–100 MHz | 50 | 50 |
| 100 MHz–200 MHz | 100 | 100 |
| 200 MHz–400 MHz | 100 | 100 |
| 400 MHz–700 MHz | 700 | 50 |
| 700 MHz–1 GHz | 700 | 100 |
| 1 GHz–2GHz | 2000 | 200 |
| 2 GHz–4 GHz | 3000 | 200 |
| 4 GHz–6GHz | 3000 | 200 |
| 6 GHz–8GHz | 1000 | 200 |
| 8 GHz–12 GHz | 3000 | 300 |
| 12 GHz–18 GHz | 2000 | 200 |
| 18 GHz–40 GHz | 600 | 200 |

The field strengths are expressed in terms of peak root-mean-square (rms) values.

or,

(2) The applicant may demonstrate by a system test and analysis that the electrical and electronic systems that perform critical functions can withstand a minimum threat of 100 volts per meter, electrical field strength, from 10 kHz to 18 GHz. When using this test to show compliance with the HIRF requirements, no credit is given for signal attenuation due to installation.

A preliminary hazard analysis must be performed by the applicant for approval by the FAA to identify either electrical or electronic systems that perform critical functions. The term ''critical'' means those functions whose failure would contribute to, or cause, a failure condition that would prevent the continued safe flight and landing of the airplane. The systems identified by the hazard analysis that perform critical functions are candidates for the application of HIRF requirements. A system may perform both critical and non-critical functions. Primary electronic flight display systems, and their associated components, perform critical functions such as attitude, altitude, and airspeed indication. The HIRF requirements apply only to critical functions.

Compliance with HIRF requirements may be demonstrated by tests, analysis, models, similarity with existing systems, or any combination of these. Service experience alone is not acceptable since normal flight operations may not include an exposure to the HIRF environment. Reliance on a system with similar design features for redundancy as a means of protection against the effects of external HIRF is generally insufficient since all elements of a redundant system are likely to be exposed to the fields concurrently.

## Applicability

As discussed above, these special conditions are applicable to the Piper PA–32. Should Garmin AT, Inc. apply at a later date for a supplemental type certificate to modify any other model on the same type certificate to incorporate the same novel or unusual design feature, the special conditions would apply to that model as well under the provisions of § 21.101.

## Conclusion

This action affects only certain novel or unusual design features on one model of airplane. It is not a rule of general applicability and affects only the applicant who applied to the FAA for approval of these features on the airplane.

The substance of these special conditions has been subjected to the notice and comment period in several prior instances and has been derived without substantive change from those previously issued. It is unlikely that prior public comment would result in a significant change from the substance contained herein. For this reason, and because a delay would significantly affect the certification of the airplane, which is imminent, the FAA has determined that prior public notice and comment are unnecessary and impracticable, and good cause exists for adopting these special conditions upon issuance. The FAA is requesting comments to allow interested persons to submit views that may not have been submitted in response to the prior opportunities for comment described above.

## List of Subjects in 14 CFR Part 23

Aircraft, Aviation safety, Signs and symbols.

## Citation

■ The authority citation for these special conditions is as follows:

**Authority:** 49 U.S.C. 106(g), 40113 and 44701; 14 CFR 21.16 and 21.101; and 14 CFR 11.38 and 11.19.

## The Special Conditions

■ Accordingly, pursuant to the authority delegated to me by the Administrator, the following special conditions are issued as part of the type certification basis for the Piper PA–32 airplane modified by Garmin AT, Inc. to add a G1000 EFIS system.

1. *Protection of Electrical and Electronic Systems From High Intensity Radiated Fields (HIRF).* Each system that performs critical functions must be designed and installed to ensure that the operations, and operational capabilities of these systems to perform critical functions, are not adversely affected when the airplane is exposed to high intensity radiated electromagnetic fields external to the airplane.

2. For the purpose of these special conditions, the following definition applies: *Critical Functions:* Functions whose failure would contribute to, or cause, a failure condition that would prevent the continued safe flight and landing of the airplane.

Issued in Kansas City, Missouri, on July 26, 2004.

**Dorenda D. Baker,**

*Manager, Small Airplane Directorate, Aircraft Certification Service.*

[FR Doc. 04–17925 Filed 8–4–04; 8:45 am]

BILLING CODE 4910–13–P

## DEPARTMENT OF TRANSPORTATION

### Federal Aviation Administration

### 14 CFR Part 71

**[Docket No. FAA–2003–16029; Airspace Docket No. 03–ANM–08]**

### Amendment to Class E Airspace; La Junta, CO

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Final rule.

**SUMMARY:** This final rule modifies Class E airspace at La Junta, CO. Additional controlled airspace is required for the new Area Navigation (RNAV) Global Position System (GPS) Standard Instrument Approach Procedures (SIAPs) recently developed. This additional Class E airspace will promote the safety of instrument flight rules (IFR) aircraft executing these new procedures when transitioning to/from the en route environment.

**EFFECTIVE DATE:** 0901 UTC, October 28, 2004.

**FOR FURTHER INFORMATION CONTACT:** Ed Hawseker; Air Traffic Division, Federal Aviation Administration, 1601 Lind Avenue SW., Renton, Washington 98055–4056; telephone (425) 227–2527

**SUPPLEMENTARY INFORMATION:**

#### History

On November 6, 2003, the FAA issued a notice of proposed rule making (NPRM) in which it proposed to amend Federal Aviation Regulation 14 CFR Part 71 by modifying Class E airspace extending upward from 700 feet or more above the surface of the earth at La Junta, CO (68 FR page 62760). The NPRM proposed to increase the Class E airspace to accommodate IFR aircraft executing the new RNAV GPS SIAPs and IFR aircraft transitioning to/from the en route environment.

Interested parties were invited to participate in this rule making proceeding by submitting written comments on the proposal to the FAA. No comments were received. Class E airspace areas extending upward from 700 feet or more above the surface of the earth are published in paragraph 6005 of FAA Order 7400.9L dated September 02, 2003, and effective September 16, 2003, which is incorporated by reference in 14 CFR Part 71.1. The Class E airspace designations listed in this document will be published subsequently in that Order.

#### The Rule

This amendment to 14 CFR Part 71 will modify Class E airspace at La Junta, CO to accommodate IFR aircraft executing newly developed RNAV GPS SIAPs at La Junta Municipal Airport. Additional Class E airspace is necessary to provide adequate controlled airspace for the safety of IFR aircraft executing these new RNAV GPS SIAPs during the transition to/from the en route environment.

The FAA has determined that this regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. Therefore, this regulation: (1) Is not a ''significant regulatory action'' under Executive Order 12866; (2) is not a ''significant rule'' under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a Regulatory Evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this rule will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

#### List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

#### The Proposed Amendment

■ Accordingly, pursuant to the authority delegated to me, the Federal Aviation Administration amends 14 CFR Part 71 as follows:

### PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; AIRWAYS; ROUTES; AND REPORTING POINTS

■ 1. The authority citation for 14 CFR Part 71 continues to areas as follows:

**Authority:** 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959–1963 Comp., p. 389.

#### § 71.1 [Amended]

■ 2. The incorporation by reference in 14 CFR Part 71.1 of the Federal Aviation Administration Order 7400.9L, Airspace Designations and Reporting Points, dated September 2, 2003, and effective September 16, 2003, is amended as follows:

*Paragraph 6005 Class E airspace areas extending upward from 700 feet or more above the surface of the earth.*

* * * * *

**ANM CO E5 La Junta, CO (Revised)**

La Junta Municipal Airport, La Junta, CO
[Lat. 37°15′36″ N., Long 104°20′24″ W.]

That airspace extending upward from 700 feet above the surface of the earth bound by a line beginning at lat. 38°12′36″ n., long. 103°58′00″ W.; to lat. 38°10′24″ N., long. 103°22′24″ W.; to lat. 37°54′12″ N., long. 103°22′42″ W.; to lat. 37°54′05″ N., long. 103°58′25″ W.; thence to the point of origin; excluding that airspace within federal airways.

* * * * *

Issued in Seattle, Washington, on July 21, 2004.

**Danial T. Mawhorter,**

*Acting Area Director, Western En Route and Oceanic Operations.*

[FR Doc. 04–17829 Filed 8–4–04; 8:45 am]

BILLING CODE 4910–13–M

## DEPARTMENT OF TRANSPORTATION

### Federal Aviation Administration

### 14 CFR Part 71

**[Docket No. FAA–2004–18013; Airspace Docket No. 04–ACE–42]**

### Modification of Class E Airspace; Columbus, NE

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Direct final rule; request for comments; correction.

**SUMMARY:** This action corrects a direct final rule; request for comments that was published in the **Federal Register** on Friday, July 2, 2004, (69 FR 40310) [FR Doc. 04–15115]. It corrects an error in the legal description of the Class E airspace area extending upward from 700 feet above the surface at Columbus, NE.

**DATES:** This direct final rule is effective on 0901 UTC, September 30, 2004.

**FOR FURTHER INFORMATION CONTACT:** Brenda Mumper, Air Traffic Division, Airspace Branch, ACE–520A, DOT Regional Headquarters Building, Federal Aviation Administration, 901 Locust, Kansas City, MO 64106; telephone: (816) 329–2524.

**SUPPLEMENTARY INFORMATION:**

#### History

**Federal Register** Document 04–15115, published on Friday, July 2, 2004, (69 FR 40310) modified the Class E surface area and the Class E airspace area extending upward from 700 feet above the surface at Columbus, NE. The modification corrected discrepancies in the dimensions of controlled airspace for diverse departures from Columbus Municipal Airport by expanding the areas. The modification also corrected discrepancies in the Columbus Municipal Airport airport reference

point used in the legal descriptions, redefined extensions to the airspace areas and brought the legal descriptions of the Columbus, NE Class E airspace area into compliance with FAA Orders 7400.2E, Procedures for Handling Airspace Matters, and 8260.19C, Flight Procedures and Airspace. However, that portion of the legal description for the Class E airspace area extending upward from 700 fee above the surface defining the northwest extension was incorrect.

■ Accordingly, pursuant to the authority delegated to me, the legal description of Columbus, NE Class E airspace, as published in the **Federal Register** on Friday, July 2, 2004, (69 FR 40310) [FR Doc. 04–15115] is corrected as follows:

**§ 71.1 [Corrected]**

■ On page 40312, Column 1, first paragraph, third line from the bottom, change ''4.7-mile'' to read ''7.7-mile.''

Issued in Kansas City, MO, on July 13, 2004.

**Paul J. Sheridan,**

*Acting Manager, Air Traffic Division, Central Region.*

[FR Doc. 04–17828 Filed 8–4–04; 8:45 am]

**BILLING CODE 4910–13–M**

---

## DEPARTMENT OF TRANSPORTATION

## Federal Aviation Administration

## 14 CFR Part 73

**[Docket No. FAA–2003–13850; Airspace Docket No. 02–AEA–19]**

**RIN 2120–AA66**

## Establishment of Restricted Areas 5802C, D, and E; Fort Indiantown Gap, PA

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Final rule.

**SUMMARY:** This action establishes Restricted Areas 5802C, D, and E (R–5802C, D, and E), at Fort Indiantown Gap, PA. The FAA is taking this action to provide additional restricted airspace needed by the Department of Defense (DOD) to conduct realistic aircrew training and to maintain proficiency in modern tactics that are required for combat readiness.

**DATES:** Effective: 0901 UTC, September 30, 2004.

**FOR FURTHER INFORMATION CONTACT:** Paul Gallant, Airspace and Rules, Office of System Operations and Safety, Federal Aviation Administration, 800 Independence Avenue, SW., Washington, DC 20591; telephone: (202) 267–8783.

**SUPPLEMENTARY INFORMATION:**

### History

On August 14, 2003, the FAA published a notice in the **Federal Register** proposing to amend the time of designation and the using agency for R–5802A and B; and to establish R–5802C, D, and E, at Fort Indiantown Gap, PA (68 FR 48579). This restricted airspace is also known as the Bollen Range.

The notice proposed to establish R–5802C, extending from 500 feet above ground level (AGL) up to but not including 17,000 feet above mean sea level (MSL). R–5802C would consist primarily of that airspace currently designated as the Kiowa military operations area (MOA). Concurrent with the designation of R–5802C, the Kiowa MOA would be revoked through a separate non-rulemaking action. The FAA also proposed to establish R–5802D extending from 17,000 feet MSL to but not including flight level (FL) 220; and R–5802E extending from FL 220 to FL 250.

The notice further proposed to change the time of designation for the existing restricted areas, R–5802A and B, from the current ''February 15 through May 10 and September 1 through December 15, 0800–2300 local time on Saturdays and 0800–1200 local time on Sundays; May 11 through August 31, 0800–2400 local time on Saturdays and 0800–2000 local time on all other days; other times by NOTAM issued at least 48 hours in advance,'' to ''daily, sunrise to 2200;'' and to change the using agency from ''Commander, Fort Indiantown Gap, Annville, PA,'' to ''ANG, 193rd SOW, Det 1, Fort Indiantown Gap Military Reservation, PA.'' In addition, the FAA proposed to apply the revised time of designation and using agency to the proposed restricted areas R–5802C, D, and E. On August 22, 2003, the FAA published a correction in the **Federal Register** to correct a typographical error in one boundary coordinate of the proposed R–5803E (68 FR 50838).

Interested parties were invited to participate in this rulemaking effort by submitting written comments on the proposal. Comments were received from the Experimental Aircraft Association (EAA), the Aircraft Owners and Pilots Association (AOPA), and two individuals.

### Analysis of Comments

In response to the notice, the EAA did not oppose the proposed modifications, but commented that the FAA should make a graphic depiction of the proposed airspace available in an electronic format to make it easier for interested parties to review. The FAA currently provides ''hard copy'' graphics of special use airspace (SUA) proposals upon request and will explore options for making proposed SUA graphic depictions available via electronic means.

AOPA objected to the proposed increase in the restricted areas' time of designation stating that restricted area usage data do not indicate a need to increase the times of use. AOPA recommended that the currently published time of designation for R–5802A and B be retained for the Bollen Range airspace. In response to this comment, the Air National Guard (ANG) reevaluated its requirements and requested that the FAA not amend the time of designation for the restricted areas. Based on this request, the proposed change to the time of designation is hereby withdrawn. The time of designation currently published for R–5802A and B will remain unchanged and the same time period will be applied to R–5802C, D, and E.

The ANG also requested that the FAA not amend the name of the using agency for the Bollen Range restricted areas as proposed in the notice. Based on this request, the proposed change to the name of the using agency for the Bollen Range restricted areas is hereby withdrawn. The using agency for all Bollen Range restricted areas will remain ''Commander, Fort Indiantown Gap, Annville, PA.'' Consequently, R–5802A and B will not be modified by this action.

One commenter wrote that the notice did not provide a rationale for converting the Kiowa MOA to a restricted area. The FAA does not agree. As discussed in the notice, the FAA proposed these changes because the existing Bollen Range restricted areas are too small to permit essential aircrew training. For example, High Altitude Release Bomb (HARB) deliveries cannot be accomplished at the range because the existing restricted area ceiling (13,000 feet MSL) is too low to contain the required high altitude release bombing patterns. Further, the current restricted area lateral dimensions are too small to provide realistic training in other tactics such as covert lighting, night vision devices, and targeting laser systems. Since an MOA cannot be used for hazardous training activities, such as weapons delivery, use of target designation lasers, etc., these types of activities must be conducted in a restricted area. Therefore, the conversion of the Kiowa MOA to restricted airspace is necessary to provide sufficient SUA for realistic aircrew training at the Bollen Range.

Another commenter suggested that use of the restricted areas be limited to nighttime only because the stated justification for the proposal was based on ''recent combat experience'' wherein bombing was usually done at night. The FAA does not agree. The justification for expanding the airspace is only partly based on nighttime operations requirements. As discussed above, the purpose of the proposed expansion is to provide higher altitudes to contain HARB deliveries, and to provide sufficient lateral space for more realistic training in other tactics, including the use of target designation lasers, covert lighting, and night vision devices. Aircrew qualification and recurring proficiency training for HARB and other tactics requires both day and nighttime operations. In addition, there is a continuing requirement to use the range for ongoing day and night activities that have been conducted there for years.

AOPA and the other commenters opposed the restricted airspace expansion based on their belief that it would place unnecessary restrictions on general aviation operations, effectively eliminate general aviation aircraft overflights of this airspace, and disrupt and delay air traffic flowing into and out of the New York, Philadelphia, and Washington, DC areas. The FAA does not agree with these comments for the following reasons. The controlling agency (New York Air Route Traffic Control Center) negotiated modifications to the ANG's preliminary proposal to minimize air traffic disruptions and delay conflicts in the affected area. Air traffic flow in the area runs mainly to the north and east of both the existing and expanded Bollen Range SUA. Converting the Kiowa MOA to R–5802C will result in only a small lateral expansion of restricted airspace by approximately one, to one and one-half, nautical miles on the northwest side of the existing restricted area boundary. The expanded restricted airspace remains clear of all Federal airways in the vicinity of the range, and also remains clear of the boundary of the Harrisburg Terminal Radar Service Area (TRSA) located to the south of the range. Restricted areas R–5802A, B, C, and D, will encompass a relatively small area that is roughly 5 nautical miles by 7 nautical miles in size. Therefore, a minor flight path deviation would be required to avoid the airspace during periods when military activity precludes overflight of the range. Additionally, to minimize possible impact on nonparticipating aircraft operations that might result from the expansion of the range, the restricted areas will be subjected to ''joint-use'' procedures and will be scheduled only when needed for military activity. In consideration of the above, the FAA does not believe that these modifications will significantly affect aviation access in the vicinity of the Bollen Range.

Except for the above changes and editorial changes, this amendment is the same as that proposed in the notice.

**Statutory Authority**

The FAA Administrator has broad authority under Title 49 of the United States Code (49 U.S.C.) to regulate the use of the navigable airspace. In exercising that authority, the Administrator is required to give consideration to the requirements of national defense and commercial and general aviation, and the public right of freedom of transit through the navigable airspace (49 U.S.C. 40101). The Administrator is also empowered to develop plans and policy for the use of the navigable airspace and assign by regulation or order the use of the airspace necessary to ensure the safety of aircraft and the efficient use of airspace (49 U.S.C. 40103(b)). Additionally, the Administrator shall, in consultation with the Secretary of Defense, establish areas in the airspace the Administrator decides are necessary in the interest of national defense (49 U.S.C. 40103(b)(3)(A)).

**The Rule**

The FAA is amending Title 14 Code of Federal Regulations (14 CFR) part 73 (part 73) by establishing R–5802C, D, and E, at Fort Indiantown Gap, PA. Specifically, R–5802C will extend from 500 feet AGL to but not including 17,000 feet MSL and will be formed, in part, by converting the Kiowa MOA to restricted airspace. Concurrent with this action, the Kiowa MOA will be revoked. R–5802D will extend from 17,000 feet MSL to but not including FL 220, and R–5802E will extend from FL 220 to FL 250. The time of designation for the new restricted areas will be ''February 15 through May 10 and September 1 through December 15, 0800–2300 local time on Saturdays and 0800–1200 local time on Sundays; May 11 through August 31, 0800–2400 local time on Saturdays and 0800–2000 local time on all other days; other times by NOTAM issued at least 48 hours in advance.'' The using agency for the airspace will be the ''Commander, Fort Indiantown Gap, Annville, PA,'' and the Controlling Agency will be ''FAA, New York ARTCC.''

The ANG requested the FAA to take this action because additional restricted airspace is needed at the Bollen Range to contain HARB training, and to enable more realistic aircrew training in various other tactics, involving both high and low altitudes, and day and nighttime operations. In addition to the aircraft activities described above, portions of the Fort Indiantown Gap/Bollen Range restricted airspace will continue to be used for the various fixed-wing and helicopter aircraft operations, ground-based weapons firings, and other activities that are currently conducted at the range. The FAA has determined that this rulemaking action is ''necessary in the interest of national defense'' as required under 49 U.S.C. 40103(b)(3)(A).

Section 73.58 of part 73 of the Federal Aviation Regulations was republished in FAA Order 7400.8L dated October 7, 2003.

The FAA has determined that this regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. Therefore, this proposed regulation: (1) is not a ''significant regulatory action'' under Executive Order 12866; (2) is not a ''significant rule'' under Department of Transportation, (DOT) Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this rule, when promulgated, will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

**Environmental Review**

The Pennsylvania ANG conducted an environmental impact analysis of the proposal and determined that the proposed action qualifies for a categorical exclusion in accordance with applicable U.S. Air Force directives. The FAA reviewed the proponent's environmental analysis documentation and determined that this airspace action is not expected to cause any potentially significant environmental impacts and does not trigger any extraordinary circumstances that would warrant preparation of an environmental assessment. The FAA determined, therefore, that this action qualifies for categorical exclusion from further environmental analysis under the National Environmental Policy Act in accordance with FAA Order 1050.1E, ''Environmental Impacts: Policies and

Procedures,'' paragraphs 303d, 311d, and 312d.

**List of Subjects in 14 CFR Part 73**

Airspace, Navigation (air).

**Adoption of Amendment**

■ In consideration of the foregoing, the Federal Aviation Administration amends 14 CFR part 73 as follows:

## PART 73—SPECIAL USE AIRSPACE

■ 1. The authority citation for part 73 continues to read as follows:

**Authority:** 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959–1963 Comp., p. 389.

**§ 73.58 [Amended]**

■ 2. § 73.58 is amended as follows:

* * * * *

**R–5802C Fort Indiantown Gap, PA [New]**

*Boundaries.* Beginning at lat. 40°23′24″ N., long. 76°43′34″ W.; to lat. 40°25′06″ N., long. 76°44′47″ W.; to lat. 40°28′00″ N., long. 76°46′59″ W.; to lat. 40°29′42″ N., long. 76°42′59″ W.; to lat. 40°29′31″ N., long. 76°39′07″ W.; to lat. 40°28′31″ N., long. 76°36′21″ W.; to lat. 40°27′13″ N., long. 76°35′13″ W.; to lat. 40°26′18″ N., long. 76°36′40″ W.; thence to point of beginning.

*Designated altitudes.* 500 feet AGL to but not including 17,000 feet MSL.

*Time of designation.* February 15 through May 10 and September 1 through December 15, 0800–2400 local time on Saturdays and 0800–1200 local time on Sundays; May 11 through August 31, 0800–2400 local time on Saturdays and 0800–2000 local time on all other days; other times by NOTAM issued at least 48 hours in advance.

*Controlling agency.* FAA, New York ARTCC.

*Using agency.* Commander, Fort Indiantown Gap, Annville, PA.

**R–5802D Fort Indiantown Gap, PA [New]**

*Boundaries.* Beginning at lat. 40°23′24″ N., long. 76°43′34″ W.; to lat. 40°25′06″ N., long. 76°44′47″ W.; to lat. 40°28′00″ N., long. 76°46′59″ W.; to lat. 40°29′42″ N., long. 76°42′59″ W.; to lat. 40°29′31″ N., long. 76°39′07″ W.; to lat. 40°28′31″ N., long. 76°36′21″ W.; to lat. 40°27′13″ N., long. 76°35′13″ W.; to lat. 40°26′18″ N., long. 76°36′40″ W.; thence to point of beginning.

*Designated altitudes.* 17,000 feet MSL to but not including FL 220.

*Time of designation.* February 15 through May 10 and September 1 through December 15, 0800–2400 local time on Saturdays and 0800–1200 local time on Sundays; May 11 through August 31, 0800–2400 local time on Saturdays and 0800–2000 local time on all other days; other times by NOTAM issued at least 48 hours in advance.

*Controlling agency.* FAA, New York ARTCC.

*Using agency.* Commander, Fort Indiantown Gap, Annville, PA.

**R–5802E Fort Indiantown Gap, PA [New]**

*Boundaries.* Beginning at lat. 40°29′42″ N., long. 76°42′59″ W.; to lat. 40°29′31″ N., long. 76°39′07″ W.; to lat. 40°28′31″ N., long. 76°36′21″ W.; to lat. 40°27′13″ N., long. 76°35′13″ W.; to lat. 40°23′45″ N., long. 76°32′36″ W.; to lat. 40°22′50″ N., long. 76°34′03″ W.; to lat. 40°19′55″ N., long. 76°40′59″ W.; thence clockwise along the arc of a 4-nautical-mile radius circle centered at lat. 40°23′24″ N., long. 76°43′34″ W.; to lat. 40°21′48″ N., long. 76°48′18″ W.; to lat. 40°26′04″ N., long. 76°51′34″ W.; to lat. 40°28′00″ N., long. 76°46′59″ W.; thence to point of beginning.

*Designated altitudes.* FL 220 to FL 250.

*Time of designation.* February 15 through May 10 and September 1 through December 15, 0800–2400 local time on Saturdays and 0800–1200 local time on Sundays; May 11 through August 31, 0800–2400 local time on Saturdays and 0800–2000 local time on all other days; other times by NOTAM issued at least 48 hours in advance.

*Controlling agency.* FAA, New York ARTCC.

*Using agency.* Commander, Fort Indiantown Gap, Annville, PA.

* * * * *

Issued in Washington, DC, on July 30, 2004.

**Reginald C. Matthews,**

*Manager, Airspace and Rules.*

[FR Doc. 04–17928 Filed 8–4–04; 8:45 am]

BILLING CODE 4910–13–P

---

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Food and Drug Administration

## 21 CFR Part 510

## New Animal Drugs; Change of Sponsor's Address

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor's address for Hess & Clark, Inc., a wholly-owned company of the Neogen Corp.

**DATES:** This rule is effective August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** David R. Newkirk, Center for Veterinary Medicine (HFV–100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–6967, e-mail: *david.newkirk@fda.gov*.

**SUPPLEMENTARY INFORMATION:** Hess & Clark, Inc., Seventh and Orange Sts., Ashland, OH 44805, has informed FDA of a change of sponsor's address to 944 Nandino Blvd., Lexington, KY 40511. Accordingly, the agency is amending the regulations in 21 CFR 510.600(c) to reflect the change.

This rule does not meet the definition of ''rule'' in 5 U.S.C. 804(3)(A) because it is a rule of ''particular applicability.'' Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

**List of Subjects in 21 CFR Part 510**

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

## PART 510—NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

■ 2. Section 510.600 is amended in the table in paragraph (c)(1) by revising the entry for ''Hess & Clark, Inc.''; and in the table in paragraph (c)(2) by revising the entry for ''050749'' to read as follows:

**§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.**

* * * * *

(c) * * *

(1) * * *

| Firm name and address | Drug labeler code |
|---|---|
| * * * | * * |
| Hess & Clark, Inc., 944 Nandino Blvd., Lexington, KY 40511 | 050749 |
| * * * | * * |

(2) * * *

| Drug labeler code | Firm name and address |
|---|---|
| * * | * * * |
| 050749 ..... | Hess & Clark, Inc., 944 Nandino Blvd., Lexington, KY 40511 |
| * * | * * * |

Dated: June 23, 2004.

**Steven D. Vaughn,**

*Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.*

[FR Doc. 04–17893 Filed 8–4–04; 8:45 am]

BILLING CODE 4160–01–S

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**21 CFR Parts 510, 522, and 524**

## New Animal Drugs; Change of Sponsor

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for one new animal drug application (NADA) from Chemdex, Inc., to Sparhawk Laboratories, Inc., and one NADA and two abbreviated new animal drug applications (ANADAs) from Veterinary Laboratories, Inc., to Sparhawk Laboratories, Inc.

**DATES:** This rule is effective August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** David R. Newkirk, Center for Veterinary Medicine (HFV–100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–6967, e-mail: *david.newkirk@fda.gov*.

**SUPPLEMENTARY INFORMATION:** Chemdex, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215, has informed FDA that it has transferred ownership of, and all rights and interest in, the following approved NADA to Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215:

| Application No. | 21 CFR Section | Trade Name |
|---|---|---|
| NADA 138–255 | 522.1183 | Iron Hydrogenated Dextran Injection |

Veterinary Laboratories, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215, has informed FDA that it has transferred ownership of, and all rights and interest in, the following approved NADA and two approved ANADAs to Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215:

| Application No. | 21 CFR Section | Trade Name |
|---|---|---|
| NADA 138–657 | 524.1580b | Nitrofurazone Ointment |
| ANADA 200–315 | 522.1260 | Lincomycin Injection 25; Lincomycin Injection 100; Lincomycin Injection 300 |
| ANADA 200–324 | 522.540 | Dexamethasone Injection 2 milligrams/milliliters |

Accordingly, the agency is amending the regulations in 21 CFR 522.540, 522.1183, 522.1260, and 524.1580b to reflect the transfer of ownership.

Following these changes of sponsorship, Chemdex, Inc., and Veterinary Laboratories, Inc., are no longer the sponsor of an approved application. Accordingly, the agency is amending 21 CFR 510.600(c) to remove the entries for Chemdex, Inc., and Veterinary Laboratories, Inc.

This rule does not meet the definition of ''rule'' in 5 U.S.C. 804(3)(A) because it is a rule of ''particular applicability.'' Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

### List of Subjects

*21 CFR Part 510*

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

*21 CFR Parts 522 and 524*

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 522, and 524 are amended as follows:

## PART 510—NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

■ 2. Section 510.600 is amended in the table in paragraph (c)(1) by removing the entries for ''Chemdex, Inc.'' and ''Veterinary Laboratories, Inc.'' and by alphabetically adding an entry for ''Sparhawk Laboratories, Inc.''; and in the table in paragraph (c)(2) by removing the entries for ''017287'' and ''000857'' and by numerically adding an entry for ''058005'' to read as follows:

**§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.**

* * * * *

(c) * * *

(1) * * *

| Firm name and address | Drug labeler code |
|---|---|
| * * * | * * |
| Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215 | 058005 |
| * * * * | * |

(2) * * *

| Drug labeler code | Firm name and address |
|---|---|
| * * | * * * |
| 058005 | Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215 |
| * * | * * * |

## PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

■ 3. The authority citation for 21 CFR part 522 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

**§ 522.540 [Amended]**

■ 4. Section 522.540 is amended in paragraph (a)(2)(ii) by removing ''000857'' and by adding in its place ''058005''.

**§ 522.1183 [Amended]**

■ 5. Section 522.1183 is amended in paragraph (e)(1) by removing ''017287'' and by adding in its place ''058005''.

**§ 522.1260 [Amended]**

■ 6. Section 522.1260 is amended in paragraph (b)(2) by removing ''000857'' and by adding in its place ''058005''.

## PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

■ 7. The authority citation for 21 CFR part 524 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

■ 8. Section 524.1580b is amended by revising paragraph (b) to read as follows:

**§ 524.1580b Nitrofurazone ointment.**

* * * * *

(b) *Sponsor*. For use on dogs, cats, or horses, see Nos. 000010, 000069, 023851, 050749, 051259, 058005, and 061623 in § 510.600(c) of this chapter. For use on dogs and horses, see No. 017135 in § 510.600(c) of this chapter. For use on horses, see No. 017153 in § 510.600(c) of this chapter.

* * * * *

Dated: June 23, 2004.

**Steven D. Vaughn,**

*Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.*

[FR Doc. 04–17878 Filed 8–4–04; 8:45 am]

BILLING CODE 4160–01–S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### 21 CFR Part 522

### Implantation or Injectable Dosage Form New Animal Drugs; Ceftiofur

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of two supplemental new animal drug applications (NADAs) filed by Pharmacia & Upjohn Co. The supplemental NADAs provide for establishing a 4-day preslaughter withdrawal period in swine injected with either a solution made from ceftiofur sodium powder or with a ceftiofur hydrochloride suspension.

**DATES:** This rule is effective August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Joan C. Gotthardt, Center for Veterinary Medicine (HFV–130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–7571, e-mail: *joan.gotthardt@fda.gov*.

**SUPPLEMENTARY INFORMATION:** Pharmacia & Upjohn Co., 7000 Portage Rd., Kalamazoo, MI 49001–0199, filed supplements to NADA 140–338 for NAXCEL (ceftiofur sodium) Sterile Powder for Injection and to NADA 140–890 for EXCENEL RTU (ceftiofur hydrochloride) Sterile Suspension. The supplemental NADAs provide for establishing a 4-day preslaughter withdrawal period in swine injected with either product. The supplemental applications are approved as of June 18, 2004, and the regulations are amended in 21 CFR 522.313 and 522.314 to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), summaries of safety and effectiveness data and information submitted to support approval of these applications may be seen in the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that these actions are of a type that do not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required for either.

This rule does not meet the definition of ''rule'' in 5 U.S.C. 804(3)(A) because it is a rule of ''particular applicability.'' Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

**List of Subjects in 21 CFR Part 522**

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is amended as follows:

## PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 522 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

**§ 522.313 [Amended]**

■ 2. Section 522.313 is amended in paragraph (d)(2)(iii) by adding ''Treated swine must not be slaughtered for 4 days following the last treatment.'' as the last sentence.

**§ 522.314 [Amended]**

■ 3. Section 522.314 is amended in paragraph (d)(1)(iii) by adding ''Treated swine must not be slaughtered for 4 days following the last treatment.'' as the last sentence.

Dated: July 21, 2004.

**Steven D. Vaughn,**

*Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.*

[FR Doc. 04–17890 Filed 8–4–04; 8:45 am]

BILLING CODE 4160–01–S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### 21 CFR Part 522

### Implantation or Injectable Dosage Form New Animal Drugs; Romifidine

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Boehringer Ingelheim Vetmedica, Inc. The NADA provides for the veterinary prescription use of romifidine hydrochloride injectable solution in horses as a sedative and analgesic, and as a preanesthetic agent.

**DATES:** This rule is effective August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Melanie R. Berson, Center for Veterinary Medicine (HFV–110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–7543, e-mail: *mberson@cvm.fda.gov*.

**SUPPLEMENTARY INFORMATION:** Boehringer Ingelheim Vetmedica, Inc., 2621 North Belt Highway, St. Joseph, MO 64506–2002, filed NADA 141–229 that provides for the veterinary prescription use of SEDIVET (romifidine hydrochloride) 1% Injection as a sedative and analgesic to facilitate handling, clinical examinations, clinical procedures, and minor surgical procedures in adult horses. SEDIVET 1% Injection is also indicated as a preanesthetic to the induction of general anesthesia in adult horses. The NADA is approved as of June 3, 2004, and 21 CFR part 522 is amended by adding § 522.2076 to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application

may be seen in the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(i) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360b(c)(2)(F)(i)), this approval qualifies for 5 years of marketing exclusivity beginning .

The agency has determined under 21 CFR 25.33(d)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of ''rule'' in 5 U.S.C. 804(3)(A) because it is a rule of ''particular applicability.'' Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

**List of Subjects in 21 CFR Part 522**

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is amended as follows:

## PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 522 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

■ 2. Section 522.2076 is added to read as follows:

### § 522.2076 Romifidine.

(a) *Specifications*. Each milliliter of solution contains 10 milligrams (mg) romifidine hydrochloride.

(b) *Sponsor*. See No. 000010 in § 510.600(c) of this chapter.

(c) *Conditions of use in horses*—(1) *Amount*. 40 to 120 micrograms per kilogram of body weight (mcg/kg BW) intravenously for sedation and analgesia; 100 mcg/kg BW intravenously as a preanesthetic.

(2) *Indications for use*. For use as a sedative and analgesic to facilitate handling, clinical examinations, clinical procedures, and minor surgical procedures in adult horses; and for use as a preanesthetic prior to the induction of general anesthesia in adult horses.

(3) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for horses intended for human consumption

Dated: June 23, 2004.

**Stephen F. Sundlof,**

*Director, Center for Veterinary Medicine.*

[FR Doc. 04–17876 Filed 8–4–04; 8:45 am]

BILLING CODE 4160–01–S

---

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Food and Drug Administration

## 21 CFR Part 524

## Ophthalmic and Topical Dosage Form New Animal Drugs; Gentamicin Sulfate Ophthalmic Ointment

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Altana Inc. The ANADA provides for veterinary prescription use of gentamicin sulfate ophthalmic ointment on dogs and cats for topical treatment of conjunctivitis caused by susceptible bacteria.

**DATES:** This rule is effective August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Lonnie W. Luther, Center for Veterinary Medicine (HFV–104), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 301–827–8549, e-mail: *lonnie.luther@fda.gov*.

**SUPPLEMENTARY INFORMATION:** Altana Inc., 60 Baylis Rd., Melville, NY 11747, filed ANADA 200–273 for veterinary prescription use of VETRO–GEN (gentamicin sulfate) Veterinary Ophthalmic Ointment on dogs and cats for topical treatment of conjunctivitis caused by susceptible bacteria. Altana Inc.'s VETRO–GEN Veterinary Ophthalmic Ointment is approved as a generic copy of Schering-Plough Animal Health's GENTOCIN Ophthalmic Ointment, approved under NADA 98–989. The ANADA is approved as of June 8, 2004, and 21 CFR 524.1044c is amended to reflect the approval and a current format. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of ''rule'' in 5 U.S.C. 804(3)(A) because it is a rule of ''particular applicability.'' Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

**List of Subjects in 21 CFR Part 524**

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 524 is amended as follows:

## PART 524–OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 524 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

■ 2. Section 524.1044c is revised to read as follows:

### § 524.1044c Gentamicin sulfate ophthalmic ointment.

(a) *Specifications*. Each gram of ointment contains gentamicin sulfate equivalent to 3 milligrams of gentamicin.

(b) *Sponsors*. See Nos. 000061 and 025463 in § 510.600(c) of this chapter.

(c) *Conditions of use in dogs and cats*—(1) *Amount*. Apply approximately a 1/2-inch strip to the affected eye 2 to 4 times a day.

(2) *Indications for use*. For treatment of conjunctivitis caused by susceptible bacteria.

(3) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dated: June 23, 2004.

**Stephen F. Sundlof,**

*Director, Center for Veterinary Medicine.*

[FR Doc. 04–17891 Filed 8–4–04; 8:45 am]

BILLING CODE 4160–01–S

**DEPARTMENT OF THE TREASURY**

**Internal Revenue Service**

**26 CFR Part 1**

**[TD 9147]**

**RIN 1545–BD30**

## Time and Manner of Making Section 163(d)(4)(B) Election To Treat Qualified Dividend Income as Investment Income

**AGENCY:** Internal Revenue Service (IRS), Treasury.

**ACTION:** Temporary regulations.

**SUMMARY:** This document contains temporary regulations relating to an election that may be made by noncorporate taxpayers to treat qualified dividend income as investment income for purposes of calculating the deduction for investment interest. The regulations reflect changes to the law made by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The regulations affect taxpayers making the election under section 163(d)(4)(B) to treat qualified dividend income as investment income. The text of these temporary regulations also serves as the text of the proposed regulations set forth in the notice of proposed rulemaking on this subject in the Proposed Rules section in this issue of the **Federal Register**.

**DATES:** *Effective Date:* These regulations are effective August 5, 2004.

*Applicability Dates:* For dates of applicability, see § 1.163(d)–1T(d).

**FOR FURTHER INFORMATION CONTACT:** Amy Pfalzgraf, (202) 622–4950 (not a toll-free number).

**SUPPLEMENTARY INFORMATION:**

### Background and Explanation of Provisions

Section 163(d)(1) provides that the investment interest deduction for a noncorporate taxpayer for any taxable year is limited to the net investment income of the taxpayer for the taxable year. Section 163(d)(4)(A) defines ''net investment income'' as the excess of investment income over investment expenses. Section 163(d)(4)(B)(iii) provides that an electing taxpayer may take all or a portion of certain net capital gain attributable to dispositions of property held for investment into account as investment income. Section 1(h)(2) provides that any net capital gain taken into account as investment income is not eligible to be taxed at the capital gains rates.

Section 302(b) of the Jobs and Growth Tax Relief Reconciliation Act of 2003, (Pub. L. 108–27, 117 Stat. 762) (JGTRRA 2003), amended section 163(d)(4)(B) to provide that an electing taxpayer may take all or a portion of qualified dividend income (as defined in section 1(h)(11)(B)) into account as investment income. Section 302(a) of JGTRRA 2003 added new section 1(h)(11)(D) to provide that any qualified dividend income taken into account as investment income is not eligible to be taxed at the capital gains rates.

Section 1.163(d)–1 of the Income Tax Regulations provides rules regarding the time and manner for making the net capital gain election under section 163(d)(4)(B)(iii). These regulations amend § 1.163(d)–1 to provide that the rules regarding the time and manner for making the qualified dividend income election under section 163(d)(4)(B) are the same as the rules for making the net capital gain election under section 163(d)(4)(B)(iii).

### Special Analyses

It has been determined that this Treasury decision is not a significant regulatory action as defined in Executive Order 12866. Therefore, a regulatory assessment is not required. It also has been determined that section 553(b) of the Administrative Procedure Act (5 U.S.C. chapter 5) does not apply to these regulations. For application of the Regulatory Flexibility Act (5 U.S.C. chapter 6) please refer to the cross-reference notice of proposed rulemaking published elsewhere in this issue of the **Federal Register**. Pursuant to section 7805(f) of the Internal Revenue Code, these temporary regulations will be submitted to the Chief Counsel for Advocacy of the Small Business Administration for comment on its impact on small business.

### Drafting Information

The principal author of these regulations is Amy Pfalzgraf of the Office of Associate Chief Counsel (Income Tax & Accounting). However, other personnel from the IRS and Treasury Department participated in their development.

### List of Subjects in 26 CFR Part 1

Income taxes, Reporting and recordkeeping requirements.

### Amendments to the Regulations

■ Accordingly, 26 CFR part 1 is amended as follows:

## PART 1—INCOME TAXES

■ **Paragraph 1.** The authority citation for part 1 continues to read, in part, as follows:

**Authority:** 26 U.S.C. 7805 * * *

■ **Par. 2.** Section 1.163(d)–1 is revised to read as follows:

**§ 1.163(d)–1 Time and manner for making elections under the Omnibus Budget Reconciliation Act of 1993 and the Jobs and Growth Tax Relief Reconciliation Act of 2003.**

(a) [Reserved]. For further guidance, see § 1.163(d)–1T(a).

(b) [Reserved]. For further guidance, see § 1.163(d)–1T(b).

(c) [Reserved]. For further guidance, see § 1.163(d)–1T(c).

(d) [Reserved]. For further guidance, see § 1.163(d)–1T(d).

■ **Par. 3.** Section 1.163(d)–1T is added to read as follows:

**§ 1.163(d)–1T Time and manner for making elections under the Omnibus Budget Reconciliation Act of 1993 and the Jobs and Growth Tax Relief Reconciliation Act of 2003 (temporary).**

(a) *Description.* Section 163(d)(4)(B)(iii), as added by section 13206(d) of the Omnibus Budget Reconciliation Act of 1993 (Pub. L. 103–66, 107 Stat. 467), allows an electing taxpayer to take all or a portion of certain net capital gain attributable to dispositions of property held for investment into account as investment income. Section 163(d)(4)(B), as amended by section 302(b) of the Jobs and Growth Tax Relief Reconciliation Act of 2003 (Pub. L. 108–27, 117 Stat. 762), allows an electing taxpayer to take all or a portion of qualified dividend income, as defined in section 1(h)(11)(B), into account as investment income. As a consequence, the net capital gain and qualified dividend income taken into account as investment income under these elections are not eligible to be taxed at the capital gains rates. An election may be made for net capital gain recognized by noncorporate taxpayers during any taxable year beginning after December 31, 1992. An election may be made for qualified dividend income received by noncorporate taxpayers during any taxable year beginning after December 31, 2002, but before January 1, 2009.

(b) *Time and manner for making the elections.* The elections for net capital gain and qualified dividend income must be made on or before the due date (including extensions) of the income tax return for the taxable year in which the net capital gain is recognized or the qualified dividend income is received. The elections are to be made on Form 4952, ''Investment Interest Expense Deduction,'' in accordance with the form and its instructions.

(c) *Revocability of elections.* The elections described in this section are

revocable with the consent of the Commissioner.

(d) *Effective date.* The rules set forth in this section regarding the net capital gain election are effective December 12, 1996. The rules set forth in this section regarding the qualified dividend income election apply to any taxable year beginning after December 31, 2002, but before January 1, 2009.

**Nancy J. Jardini,**

*Acting Deputy Commissioner for Services and Enforcement.*

Approved: July 29, 2004.

**Gregory F. Jenner,**

*Acting Assistant Secretary of the Treasury.*

[FR Doc. 04–17796 Filed 8–4–04; 8:45 am]

**BILLING CODE 4830–01–P**

## ENVIRONMENTAL PROTECTION AGENCY

## 40 CFR Part 52

**[Docket No. WA–04–001; FRL–7792–5]**

## Approval and Promulgation of State Implementation Plans: State of Washington; Central Puget Sound Carbon Monoxide and Ozone Second 10-Year Maintenance Plans

**AGENCY:** Environmental Protection Agency (EPA).

**ACTION:** Final rule.

**SUMMARY:** In this action, the EPA is approving the Central Puget Sound carbon monoxide (CO) and Ozone Second 10-Year Maintenance Plans. Specifically EPA is approving Washington's demonstration that the Central Puget Sound area will maintain air quality standards for CO and ozone through the year 2016; a revised CO motor vehicle emissions budget for transportation conformity purposes using the MOBILE6.2 emissions model and latest growth and planning assumptions; updates and enhancements of state implementation plan (SIP) control measures and contingency measures; and identification of emissions associated with the Seattle Tacoma International Airport included in the area-wide emissions inventory through the maintenance period.

**DATES:** This final rule is effective on September 7, 2004.

**ADDRESSES:** EPA has established a docket for this action under Docket ID No. WA–04–001. Publicly available docket materials are available in hard copy at the EPA, Region 10, Office of Air, Waste and Toxics, 1200 Sixth Avenue, Seattle, WA. This Docket facility is open from 8:30–4, Monday through Friday, excluding legal holidays. The Docket telephone number is (206) 553–4273.

**FOR FURTHER INFORMATION CONTACT:** Connie L. Robinson, Office of Air, Waste and Toxics (OAQ–107), EPA Region 10, 1200 Sixth Avenue, Seattle, WA; telephone number: (206) 553–1086; fax number: (206) 553–0110; e-mail address: *robinson.connie@epa.gov.*

**SUPPLEMENTARY INFORMATION:** Throughout this document, wherever ''we,'' ''us,'' or ''our'' is used, we mean the EPA. Information is organized as follows:

I. Background
II. Public Comments on the Proposed Action
III. Final Action
IV. Statutory and Executive Order Reviews

### I. Background

On June 1, 2004, EPA published in the **Federal Register**, a proposal to approve the Central Puget Sound CO and Ozone second 10-year maintenance plans. A detailed description of our action was published in the **Federal Register** on June 1, 2004. The reader is referred to the proposed rulemaking (69 FR 30847, June 1, 2004) for details.

### II. Public Comments on the Proposed Action

EPA provided a 30-day review and comment period and solicited comments on our proposal published in the June 1, 2004, **Federal Register**. No comments were received for the proposed rulemaking. EPA is now taking final action on the SIP revision consistent with the published proposal.

### III. Final Action

In this action, the EPA is approving the Central Puget Sound CO and Ozone Second 10-Year Maintenance Plans. Specifically EPA is approving Washington's demonstration that the Central Puget Sound area will maintain air quality standards for CO and ozone through the year 2016; a revised CO motor vehicle emissions budget for transportation conformity purposes using the MOBILE6.2 emissions model and latest growth and planning assumptions; updates and enhancements of state implementation plan (SIP) control measures and contingency measures; and identification of emissions associated with the Seattle Tacoma International Airport included in the area-wide emissions inventory through the maintenance period. A Technical Support Document on file at the EPA Region 10 office contains a detailed analysis and rationale in support of the Central Puget Sound CO and Ozone Second 10-Year Maintenance Plans.

### IV. Statutory and Executive Order Reviews

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a ''significant regulatory action'' and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, ''Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use'' (66 FR 28355, May 22, 2001). This action merely approves state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule approves pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104–4).

This rule also does not have tribal implications because it will not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal government and Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000). This action also does not have federalism implications because it does not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999). This action merely approves a State rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 ''Protection of Children from Environmental Health Risks and Safety Risks'' (62 FR 19885, April 23, 1997), because it is not economically significant.

In reviewing SIP submissions, EPA's role is to approve State choices, provided that they meet the criteria of the Clean Air Act. In this context, in the

absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. This rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

The Congressional Review Act, 5 U.S.C. 801 *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the **Federal Register**. A major rule cannot take effect until 60 days after it is published in the **Federal Register**. This action is not a ''major rule'' as defined by 5 U.S.C. 804(2).

Under section 307(b)(1) of the Clean Air Act, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by October 4, 2004. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action may not be challenged later in proceedings to enforce its requirements. (*See* section 307(b)(2).)

**List of Subjects in 40 CFR Part 52**

Environmental protection, Air pollution control, Carbon monoxide, Incorporation by reference, Intergovernmental relations, Ozone, Reporting and recordkeeping requirements.

Dated: July 27, 2004.

**Ronald A. Kreizenbeck,**

*Acting Regional Administrator, Region 10.*

■ Part 52, chapter I, title 40 of the Code of Federal Regulations are amended as follows:

## PART 52—[AMENDED]

■ 1. The authority citation for part 52 continues to read as follows:

**Authority:** 42 U.S.C. 7401 *et seq.*

## Subpart WW—Washington

■ 2. Section 52.2470 is amended by adding paragraph (c)(83) to read as follows:

**§ 52.2470 Identification of plan.**

* * * * *

(c) * * *

(83) On December 17, 2003, the Washington Department of Ecology submitted carbon monoxide and ozone second 10-year maintenance plans. The State's maintenance plans, meet the requirements of the Clean Air Act.

(i) Incorporation by reference.

(A) Puget Sound Clean Air Agency, Regulation I, Section 8.06, Outdoor Burning Ozone Contingency Measure, as in effect December 19, 2002.

(B) Puget Sound Clean Air Agency, Regulation II, Section 2.09, Oxygenated Gasoline Carbon Monoxide Contingency Measures and Fee Schedule, as in effect December 19, 2002.

(C) Puget Sound Clean Air Agency, Regulation II, Section 2.10, Gasoline Station Ozone Contingency Measure, as in effect December 19, 2002.

■ 3. Amend § 52.2475 by adding paragraph (a)(3) to read as follows:

**§ 52.2475 Approval of plans.**

(a) * * *

(3) Central Puget Sound.

(i) EPA approves as a revision to the Washington State Implementation Plan, the Central Puget Sound Carbon Monoxide and Ozone Second 10-Year Maintenance Plans submitted by the State on December 17, 2003.

(ii) [Reserved]

* * * * *

[FR Doc. 04–17782 Filed 8–4–04; 8:45 am]

BILLING CODE 6560–50–P

---

## ENVIRONMENTAL PROTECTION AGENCY

## 40 CFR Part 52

**[PA217–4230a; FRL–7797–6]**

## Approval and Promulgation of Air Quality Implementation Plans; Pennsylvania; Withdrawal of Direct Final Rule

**AGENCY:** Environmental Protection Agency (EPA).

**ACTION:** Withdrawal of direct final rule.

**SUMMARY:** Due to adverse comments, EPA is withdrawing the direct final rule to amend Pennsylvania's ten-year plan to maintain the 1-hour ozone national ambient air quality standard (NAAQS) in the Pittsburgh-Beaver Valley ozone maintenance area (the Pittsburgh area). In the direct final rule published on July 1, 2004 (69 FR 39854), we stated that if we received adverse comment by August 2, 2004, the rule would be withdrawn and not take effect. EPA subsequently received adverse comments. EPA will address the comments received in a subsequent final action based upon the proposed action also published on July 1, 2004. EPA will not institute a second comment period on this action.

**EFFECTIVE DATE:** The Direct final rule is withdrawn as of August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Larry Budney, Energy, Radiation and Indoor Environment Branch, Mail code 3AP23, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; or by phone at (215) 814–2184.

**List of Subjects in 40 CFR Part 52**

Environmental protection, Air pollution control, Incorporation by reference, Nitrogen dioxide, Ozone, Reporting and recordkeeping requirements, Volatile organic compounds.

Dated: July 28, 2004.

**Donald S. Welsh,**

*Regional Administrator, Region III.*

■ Accordingly, the addition of § 52.2020(c)(226) is withdrawn as of August 5, 2004.

[FR Doc. 04–17781 Filed 8–4–04; 8:45 am]

BILLING CODE 6560–50–P

---

## ENVIRONMENTAL PROTECTION AGENCY

## 40 CFR Parts 52 and 81

**[CO-001–0076a, CO-001–0077a; FRL–7784–9]**

## Approval and Promulgation of Air Quality Implementation Plans; Colorado; Designation of Areas for Air Quality Planning Purposes, Lamar and Steamboat Springs

**AGENCY:** Environmental Protection Agency (EPA).

**ACTION:** Direct final rule.

**SUMMARY:** EPA is taking direct final action to approve a State Implementation Plan (SIP) revision submitted by the State of Colorado on July 31, 2002, for the purpose of redesignating the Lamar, Colorado and Steamboat Springs, Colorado areas from

nonattainment to attainment for particulate matter with an aerodynamic diameter less than or equal to a nominal 10 micrometers ($PM_{10}$) under the 1987 standards. The Governor's submittal, among other things, documents that the Lamar and Steamboat Springs areas have attained the $PM_{10}$ national ambient air quality standards (NAAQS), requests redesignation to attainment and includes a maintenance plan for each of the areas demonstrating maintenance of the $PM_{10}$ NAAQS for ten years. EPA is approving these redesignation requests and maintenance plans because Colorado has met the applicable requirements of the Clean Air Act (CAA), as amended. Upon the effective date of this approval, the Lamar and Steamboat Springs areas will be designated attainment for the $PM_{10}$ NAAQS. This action is being taken under sections 107, 110, and 175A of the Clean Air Act.

**DATES:** This rule is effective on October 4, 2004, without further notice, unless EPA receives adverse comment by September 7, 2004. If adverse comment is received, EPA will publish a timely withdrawal of the direct final rule in the **Federal Register** informing the public that the rule will not take effect.

**ADDRESSES:** Written comments may be mailed to Richard R. Long, Director, Air and Radiation Program, Mailcode 8P–AR, Environmental Protection Agency, Region VIII, 999 18th Street, Suite 300, Denver, CO 80202. Comments may also be submitted electronically, or through hand delivery/courier. Please follow the detailed instructions described in section (I)(B)(1)(i) through (iii) of the **SUPPLEMENTARY INFORMATION** section.

**FOR FURTHER INFORMATION CONTACT:** Libby Faulk, EPA, Region VIII, (303) 312–6083.

**SUPPLEMENTARY INFORMATION:** Throughout this document, wherever ''we,'' ''us,'' or ''our'' are used, we mean the Environmental Protection Agency (EPA).

**Table of Contents**

I. General Information
II. EPA's Final Action
A. What Action Is EPA Taking in This Direct Final Rule?
III. Summary of Redesignation Request and Maintenance Plan
A. What Requirements Must Be Followed for Redesignations to Attainment?
B. Do the Lamar and Steamboat Springs Redesignation Requests and Maintenance Plans Meet the CAA Requirements?
C. Have the Transportation Conformity Requirements Been Met?
D. Did Colorado Follow the Proper Procedures for Adopting This Action?
IV. Background
V. Consideration of CAA section 110(l)
VI. Statutory and Executive Order Reviews

## I. General Information

### *A. How Can I Get Copies of This Document and Other Related Information?*

1. *The Regional Office has established an official public rulemaking file available for inspection at the Regional Office.* EPA has established an official public rulemaking file for this action under CO–001–0076a, CO–001–0077a. The official public file consists of the documents specifically referenced in this action, any public comments received, and other information related to this action. Although a part of the official docket, the public rulemaking file does not include Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. The official public rulemaking file is the collection of materials that is available for public viewing at the Air and Radiation Program, EPA Region 8, 999 18th Street, Suite 300, Denver, CO. EPA requests that if at all possible, you contact the contact listed in the **FOR FURTHER INFORMATION CONTACT** section to schedule your inspection. You may view the public rulemaking file at the Regional Office Monday through Friday, 8 a.m. to 4 p.m., excluding federal holidays. Copies of the Incorporation by Reference material are also available at the Air and Radiation Docket and Information Center, U.S. Environmental Protection Agency, Room B–108 (Mail Code 6102T), 1301 Constitution Ave., NW., Washington, DC 20460.

2. *Copies of the State submittal are also available for public inspection during normal business hours, by appointment at the State Air Agency.* Copies of the State documents relevant to this action are also available for public inspection at the Colorado Department of Public Health and Environment, Air Pollution Control Division, 4300 Cherry Creek Drive South, Denver, Colorado 80246–1530.

3. Electronic Access. You may access this **Federal Register** document electronically through the Regulations.gov web site located at *http://www.regulations.gov* where you can find, review, and submit comments on Federal rules that have been published in the **Federal Register**, the Government's legal newspaper, and are open for comment.

For public commenters, it is important to note that EPA's policy is that public comments, whether submitted electronically or in paper, will be made available for public viewing at the EPA Regional Office, as EPA receives them and without change, unless the comment contains copyrighted material, CBI, or other information whose disclosure is restricted by statute. When EPA identifies a comment containing copyrighted material, EPA will provide a reference to that material in the version of the comment that is placed in the official public rulemaking file. The entire printed comment, including the copyrighted material, will be available at the Regional Office for public inspection.

### *B. How and to Whom Do I Submit Comments?*

You may submit comments electronically, by mail, or through hand delivery/courier. To ensure proper receipt by EPA, identify the appropriate rulemaking identification number by including the text ''Public comment on proposed rulemaking CO–001–0076a, CO–001–0077a'' in the subject line on the first page of your comment. Please ensure that your comments are submitted within the specified comment period. Comments received after the close of the comment period will be marked ''late.'' EPA is not required to consider these late comments.

1. Electronically. If you submit an electronic comment as prescribed below, EPA recommends that you include your name, mailing address, and an e-mail address or other contact information in the body of your comment. Also include this contact information on the outside of any disk or CD ROM you submit, and in any cover letter accompanying the disk or CD ROM. This ensures that you can be identified as the submitter of the comment and allows EPA to contact you in case EPA cannot read your comment due to technical difficulties or needs further information on the substance of your comment. EPA's policy is that EPA will not edit your comment, and any identifying or contact information provided in the body of a comment will be included as part of the comment that is placed in the official public docket. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, EPA may not be able to consider your comment.

i. E-mail. Comments may be sent by electronic mail (e-mail). Please send any comments to *long.richard@epa.gov* and *faulk.libby@epa.gov* and include the text ''Public comment on proposed rulemaking CO–001–0076a, CO–001–0077a'' in the subject line. EPA's e-mail system is not an ''anonymous access'' system. If you send an e-mail comment directly without going through

''Regulations.gov'' (see below), EPA's e-mail system will automatically capture your e-mail address. E-mail addresses that are automatically captured by EPA's e-mail system are included as part of the comment that is placed in the official public docket.

ii. Regulations.gov. Your use of Regulations.gov is an alternative method of submitting electronic comments to EPA. Go directly to Regulations.gov at *http://www.regulations.gov,* then click on the button ''TO SEARCH FOR REGULATIONS CLICK HERE,'' and select Environmental Protection Agency as the Agency name to search on. The list of current EPA actions available for comment will be listed. Please follow the online instructions for submitting comments. The system is an ''anonymous access'' system, which means EPA will not know your identity, e-mail address, or other contact information unless you provide it in the body of your comment.

iii. Disk or CD ROM. You may submit comments on a disk or CD ROM that you mail to the mailing address identified in Section 2, directly below. These electronic submissions will be accepted in WordPerfect, Word or ASCII file format. Avoid the use of special characters and any form of encryption.

2. By Mail. Send your comments to: Richard R. Long, Director, Air and Radiation Program, Mailcode 8P–AR, Environmental Protection Agency (EPA), Region 8, 999 18th Street, Suite 300, Denver, Colorado 80202–2466. Please include the text ''Public comment on proposed rulemaking CO–001–0076a, CO–001–0077a'' in the subject line on the first page of your comment.

3. By Hand Delivery or Courier. Deliver your comments to: Richard R. Long, Director, Air and Radiation Program, Mailcode 8P–AR, Environmental Protection Agency (EPA), Region 8, 999 18th Street, Suite 300, Denver, Colorado 80202–2466. Such deliveries are only accepted Monday through Friday, 8 a.m. to 4:55 p.m., excluding federal holidays.

### *C. How Should I Submit CBI to the Agency?*

Do not submit information that you consider to be CBI electronically to EPA. You may claim information that you submit to EPA as CBI by marking any part or all of that information as CBI (if you submit CBI on disk or CD ROM, mark the outside of the disk or CD ROM as CBI and then identify electronically within the disk or CD ROM the specific information that is CBI). Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2.

In addition to one complete version of the comment that includes any information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the official public regional rulemaking file. If you submit the copy that does not contain CBI on disk or CD ROM, mark the outside of the disk or CD ROM clearly that it does not contain CBI. Information not marked as CBI will be included in the public file and available for public inspection without prior notice. If you have any questions about CBI or the procedures for claiming CBI, please consult the person identified in the **FOR FURTHER INFORMATION CONTACT**

## II. EPA's Final Action

### *A. What Action Is EPA Taking in This Direct Final Rule?*

We are approving the Governor's submittal of July 31, 2002, that requests redesignation for the Lamar and Steamboat Springs nonattainment areas to attainment for the 1987 $PM_{10}$ standards. Included in Colorado's submittal are changes to the ''State Implementation Plan—Specific Regulations for Nonattainment—Attainment/Maintenance Areas (Local Areas)'' which we are approving, under section 110 of the CAA, into Colorado's SIP. We are also approving the maintenance plans for the Lamar and Steamboat Springs $PM_{10}$ nonattainment areas, which were submitted with Colorado's July 31, 2002 redesignation requests. We are approving these requests and maintenance plans because Colorado has adequately addressed all of the requirements of the CAA for redesignation to attainment applicable to the Lamar and Steamboat Springs $PM_{10}$ nonattainment areas. Upon the effective date of this action, the Lamar and Steamboat Springs areas' designation status under 40 CFR part 81 will be revised to attainment.

EPA is publishing this rule without prior proposal because the Agency views this as a noncontroversial amendment and anticipates no adverse comments. However, in the ''Proposed Rules'' section of today's **Federal Register** publication, EPA is publishing a separate document that will serve as the proposal to approve the SIP revision if adverse comments are filed. This rule will be effective October 4, 2004 without further notice unless the Agency receives adverse comments by September 7, 2004. If the EPA receives adverse comments, EPA will publish a timely withdrawal in the **Federal Register** informing the public that the rule will not take effect. EPA will address all public comments in a subsequent final rule based on the proposed rule. The EPA will not institute a second comment period on this action. Any parties interested in commenting must do so at this time. Please note that if EPA receives adverse comment on an amendment, paragraph, or section of this rule and if that provision may be severed from the remainder of the rule, EPA may adopt as final those provisions of the rule that are not the subject of an adverse comment.

## III. Summary of Redesignation Request and Maintenance Plan

### *A. What Requirements Must Be Followed for Redesignations to Attainment?*

In order for a nonattainment area to be redesignated to attainment, the following conditions in section 107(d)(3)(E) of the CAA must be met:

(i) We must determine that the area has attained the NAAQS;

(ii) The applicable implementation plan for the area must be fully approved under section 110(k) of the CAA;

(iii) We must determine that the improvement in air quality is due to permanent and enforceable reductions in emissions resulting from implementation of the applicable implementation plan and applicable Federal air pollutant control regulations and other permanent and enforceable reductions;

(iv) We must fully approve a maintenance plan for the area as meeting the requirements of CAA section 175A; and,

(v) The State containing such an area must meet all requirements applicable to the area under section 110 and part D of the CAA.

Our September 4, 1992 guidance entitled ''Procedures for Processing Requests to Redesignate Areas to Attainment'' outlines how to assess the adequacy of redesignation requests against the conditions listed above.

The following is a brief discussion of how Colorado's redesignation requests and maintenance plans meet the requirements of the CAA for redesignation of the Lamar and Steamboat Springs areas to attainment for $PM_{10}$.

*B. Do the Lamar and Steamboat Springs Redesignation Requests and Maintenance Plans Meet the CAA Requirements?*

i. Attainment of the $PM_{10}$ NAAQS

A state must demonstrate that an area has attained the $PM_{10}$ NAAQS through submittal of ambient air quality data from an ambient air monitoring network representing maximum $PM_{10}$ concentrations. The data, which must be quality assured and recorded in the Aerometric Information Retrieval System (AIRS), must show that the average annual number of expected exceedances for the area is less than or equal to 1.0, pursuant to 40 CFR 50.6. In making this showing, the three most recent years of complete air quality data must be used.

Colorado operates two $PM_{10}$ monitoring sites in the Lamar $PM_{10}$ nonattainment area. Colorado submitted ambient air quality data from the monitoring site which demonstrate that the area has attained the $PM_{10}$ NAAQS. These air quality data were quality-assured and placed in AIRS. There were three exceedances of the 24-hour $PM_{10}$ NAAQS recorded in the Lamar area between 1996 and 2000 due to high winds. Lamar has a Natural Events Action Plan (NEAP) that was approved by EPA on June 5, 1998 that addresses high wind events. The three exceedances between 1996 and 2000 were flagged in the AIRS database and were not included in the attainment demonstration because of Lamar's approved NEAP (see section III.B.iii. for additional information regarding Lamar's NEAP). EPA approved the flagging of the three exceedances in a letter to the State on July 3, 2001. The annual $PM_{10}$ NAAQS has never been exceeded in Lamar. The three most recent years of data for the area (2000—2002) are complete (*i.e.*, data are available for at least 75% of the scheduled $PM_{10}$ samples per quarter) with no recorded violations. We believe that Colorado has adequately demonstrated, through ambient air quality data, that the $PM_{10}$ NAAQS have been attained in the Lamar area.

Colorado also operates two $PM_{10}$ monitoring sites in the Steamboat Springs $PM_{10}$ nonattainment area. Colorado submitted ambient air quality data from both monitoring sites which demonstrate that the area has attained the $PM_{10}$ NAAQS. These air quality data were quality assured and placed in AIRS. Two exceedances of the 24-hour $PM_{10}$ NAAQS were measured in 1993 and 1996. However, the 3-year average of estimated exceedances remained below 1.0 (per year) (40 CFR 50.6) and therefore did not result in a violation of the 24-hour $PM_{10}$ NAAQS. The three most recent years of data for the area (2000–2002) are complete (*i.e.*, data are available for at least 75% of the scheduled $PM_{10}$ samples per quarter) with no recorded violations. The annual $PM_{10}$ NAAQS has never been exceeded in Steamboat Springs. We believe that Colorado has adequately demonstrated, through ambient air quality data, that the $PM_{10}$ NAAQS have been attained in the Steamboat Springs area.

ii. State Implementation Plan Approval

Those States containing initial moderate $PM_{10}$ nonattainment areas were required by the 1990 amendments to the CAA to submit a SIP by November 15, 1991 which demonstrated attainment of the $PM_{10}$ NAAQS by December 31, 1994. To approve a redesignation request, the SIP for the area must be fully approved under section 110(k) and must satisfy all requirements that apply to that area. The Lamar area was among the initial moderate $PM_{10}$ nonattainment areas. EPA fully approved the $PM_{10}$ SIP for Lamar on June 9, 1994 (59 FR 29732). The Steamboat Springs area was designated nonattainment for $PM_{10}$ on December 21, 1993 (58 FR 67334). EPA fully approved the $PM_{10}$ SIP for Steamboat Springs on December 31, 1997 (62 FR 68188). These $PM_{10}$ SIPs for Lamar and Steamboat Springs were approved as meeting the moderate $PM_{10}$ nonattainment plan requirements.

iii. Improvement in Air Quality Due to Permanent and Enforceable Measures

Section 107(d)(3(E)(iii) of the CAA provides that for an area to be redesignated to attainment, the Administrator must determine that the improvement in air quality is due to emission reductions which are permanent and enforceable. The Lamar $PM_{10}$ nonattainment area is a unique case in which no area-specific $PM_{10}$ control measures were needed to bring the area into attainment (or to ensure continued attainment). The primary source of $PM_{10}$ emissions in Lamar is blowing fugitive dust resulting from high wind events. Colorado's July 31, 2002 submittal did cite several State-wide regulations as being responsible for the improvement in air quality in Lamar as well as control measures implemented under the Lamar Natural Events Action Plan (NEAP) addressing $PM_{10}$ emissions as a result of blowing fugitive dust. EPA's Natural Events Policy (NEP) and the local measures Lamar implemented under the area's NEAP are discussed in more detail below. The State-wide regulations cited are the following: ''Emission Control Regulation for Particulates, Smoke, Carbon Monoxide and Sulfur Oxides'' (Regulation No. 1), ''Air Pollution Emission Notices, Construction Permits and Fees, Operating Permits and Including the Prevention of Significant Deterioration'' (Regulation No. 3), ''New Woodstoves and Woodburning Appliance Use During High Pollution Days'' (Regulation No. 4), ''Standards of Performance for New Stationary Sources'' (Regulation No. 6), and the ''Common Provisions Regulation.''

Recognizing that certain uncontrollable natural events, such as high winds, and wildfires, can have on the NAAQS, the EPA issued a Natural Events Policy (NEP) on May 30, 1996. The NEP sets forth procedures through the development of a Natural Events Action Plan (NEAP) for protecting public health in areas where the $PM_{10}$ standard may be violated due to these uncontrollable natural events. One of the requirements of the NEP is that Best Available Control Measures (BACM) must be implemented at contributing anthropogenic sources of dust in order for $PM_{10}$ exceedances to be treated as due to uncontrollable natural events. BACM for $PM_{10}$ are defined by EPA as techniques that achieve the maximum degree of emission reduction from a source as determined on a case-by-case basis considering technological and economic feasibility (59 FR 41998). An additional requirement of the NEP is that in order for an area to request redesignation of a nonattainment to attainment, the area must demonstrate that the area would be meeting the NAAQS but for the emissions caused by natural events.[1]

Over the past eight years, the monitors located at the Municipal Power Plant and Municipal Building in Lamar, Colorado experienced exceedances of the 24-hour NAAQS for $PM_{10}$. Each of these exceedances was associated with unusually high winds and blowing dust in the Lamar area. In response to Lamar's exceedances of the $PM_{10}$ NAAQS, the Colorado Department of Public Health and Environment's Air Pollution Control Division, in conjunction with the City of Lamar's Public Works Department, Parks and Recreation, and Prowers County Commissioners, the Natural Resources Conservation Services, the Burlington Northern Santa Fe Railroad, and other agencies developed a NEAP. The NEAP was presented to EPA in 1998. EPA subsequently approved the NEAP for

[1] This policy applies to emissions caused by natural events that have occurred since January 1, 1994.

Lamar as meeting all the requirements of the 1996 NEP. Since 1998, it is this plan that has assisted the area in addressing blowing dust due to uncontrollable winds. In the Lamar area the BACM that were implemented as part of the 1998 NEAP to address high wind events include wind breaks, controls at the East Lamar Landfill, vegetative cover at Escondido Park, soil stabilization along rail lines, installation of perennial grass over croplands, and the implementation of soil erosion conservation practices. In addition, the 1996 NEP requires that the State provide a five-year review of the NEAP, which was submitted to EPA in 2003 and subsequently approved. The five-year review of the NEAP for Lamar includes commitments for additional BACM control measures, including irrigation of tree groves established for wind breaks, additional litter control at the East Lamar Landfill, stabilization of the entrance road to Escondido Park, and the purchase and use of a regenerative air street sweeper. In addition to the BACM control measures, public education and notification procedures have been implemented as part of the NEAP for Lamar. Based on our approval of the 1998 Lamar NEAP and our subsequent approval of the 2003 Lamar NEAP's five-year review, EPA has concluded that, but for the emissions caused by natural events, the Lamar area has demonstrated attainment of the $PM_{10}$ NAAQS.

In addition to the local and State control measures discussed above, the Federal Motor Vehicle Emission Control Program has helped reduce $PM_{10}$ emissions in Lamar as older, higher emitting diesel vehicles are replaced with newer vehicles that meet tighter emission standards. Overall, despite growth in the Lamar nonattainment area (*e.g.*, in population and vehicle miles traveled), attainment of the $PM_{10}$ NAAQS has been demonstrated. We have evaluated the various control measures, in addition to the 2000 attainment year emission inventory and the projected emissions described below, and have concluded that the continued attainment of the $PM_{10}$ NAAQS in the Lamar area has resulted from emission reductions that are permanent and enforceable.

The primary sources of $PM_{10}$ emissions in the Steamboat Springs area are re-entrained road dust (from highways, paved roads, chip sealed roads, and unpaved roads) and woodburning. The permanent and enforceable control measures that brought the Steamboat Springs $PM_{10}$ nonattainment area into attainment and were approved by EPA into Colorado's SIP in 1997 are described in detail below.

The City of Steamboat Springs and Routt County adopted local ordinance and resolutions that limit the number and types of woodburning devices in new construction in the Steamboat Springs area. Installation of new solid fuel burning devices is limited to one approved device for any building. The Steamboat Springs area adopted these measures in the late 1980s and early 1990s and the measures were included in State regulation in 1993 (Section VIII.E. of the ''State Implementation Plan—Specific Regulations for Nonattainment—Attainment/Maintenance Areas (Local Areas)''). The rule was approved by EPA on December 31, 1997 (62 FR 68188).

The Steamboat Springs area adopted two street sanding control strategies for the nonattainment area. The first street sanding control strategy requires that any user that applies street sanding materials in the Steamboat Springs area must use materials containing less than two percent fines, except on U.S. Highway 40 from the junction of U.S. Highway 131 towards Rabbit Ears Pass. This strategy was included in State regulations in 1996 (Section VIII.B. of the ''State Implementation Plan—Specific Regulations for Nonattainment—Attainment/Maintenance Areas (Local Areas)). The second street sanding control strategy requires that the Colorado Department of Transportation (CDOT) reduce the amount of sand applied on U.S. Highways 40 and 131 in the Steamboat Springs area by 10 percent. This strategy was included in State regulation in 1996 (Section VIII.C. of the ''State Implementation Plan—Specific Regulations for Nonattainment—Attainment/Maintenance Areas (Local Areas)). Both the street sanding controls were approved by EPA on December 31, 1997 (62 FR 68188).

In addition, the Steamboat Springs area adopted street sweeping requirements for a defined section of Lincoln Avenue (Highway 40 in town). Street cleaning using vacuum sweepers or any other sweepers with equal efficiency must be performed four times within four days of the roadways becoming free and clear of snow and ice following each sanding deployment use. This strategy was included in State regulations in 1996 (Section VIII.D. of the ''State Implementation Plan—Specific Regulations for Nonattainment—Attainment/Maintenance Areas (Local Areas)). The rule was approved by EPA on December 31, 1997 (62 FR 68188).

In addition to the local control measures that have been adopted in the Steamboat Springs area, Colorado's July 31, 2002 submittal did cite several Statewide regulations that limit emissions from any new source that may locate in the Steamboat Springs area. These rules are: ''Air Pollution Emission Notices, Construction Permits and Fees, Operating Permits and Including the Prevention of Significant Deterioration'' (Regulation No. 3), ''Standards of Performance for New Stationary Sources'' (Regulation No. 6), and the ''Common Provisions Regulation.''

In addition to these State and Local control measures, the Federal Motor Vehicle Emission Control Program has helped reduce $PM_{10}$ emissions in Steamboat Springs as older, higher emitting diesel vehicles are replaced with newer vehicles that meet tighter emission standards. Overall, despite growth in the Steamboat Springs nonattainment area (*e.g.*, in population and vehicle miles traveled), attainment of the $PM_{10}$ NAAQS has been demonstrated. We have evaluated the various control measures, in addition to the 1999 attainment year emission inventory and the projected emissions described below, and have concluded that the continued attainment of the $PM_{10}$ NAAQS in the Steamboat Springs area has resulted from emission reductions that are permanent and enforceable.

iv. Fully Approved Maintenance Plan Under Section 175A of the CAA

Section 107(d)(3)(E) of the CAA requires that, for a nonattainment area to be redesignated to attainment, we must fully approve a maintenance plan which meets the requirements of section 175A of the CAA. The plan must demonstrate continued attainment of the relevant NAAQS in the area for at least 10 years after our approval of the redesignation. Eight years after our approval of a redesignation, Colorado must submit a revised maintenance plan demonstrating attainment for the 10 years following the initial 10 year period. The maintenance plan must also contain a contingency plan to ensure prompt correction of any violation of the NAAQS. (See sections 175A(b) and (d).) Our September 4, 1992 guidance outlines five core elements that are necessary to ensure maintenance of the relevant NAAQS in an area seeking redesignation from nonattainment to attainment. Those elements, as well as guidelines for subsequent maintenance plan revisions, are as follows:

a. Attainment Inventory

The maintenance plan should include an attainment emission inventory to identify the level of emissions in the area which is sufficient to attain the NAAQS. An emission inventory for Lamar was developed for the attainment year 2000 as well as the projection inventory for the year 2015. The emission inventory incorporates emission estimates for woodburning (fireplaces and wood stoves), restaurant and mobile exhaust emissions, highway, arterial and local re-entrained road dust emissions, and gravel road emissions. Summary emission figures from the 2000 attainment year inventory and the 2015 projected inventory for the Lamar area are provided in Tables 1, 2, and 3 below.

TABLE 1.—2000 AND 2015 $PM_{10}$ TOTAL EMISSION INVENTORY FOR ROAD DUST ACTIVITY IN POUNDS PER DAY FOR LAMAR CITY

| | Highway | Paved roads | | Unpaved roads |
|---|---|---|---|---|
| | | Arterial | Local | |
| 2000 | 2530 | 866 | 3195 | 24 |
| 2015 | 2792 | 993 | 3665 | 28 |

* Highway re-entrained road dust emissions for the year 2000 were developed using the latest traffic counts from Colorado Deparment of Transportation (CDOT) as well as revised emissions factors that incorporate the latest EPA methods for determining paved road emission and measured silt loadings from the area.

** Arterial and local street re-entrained emissions for 2000 were determined using VMT information contained in the 1993 SIP element (grown to 2000 by appropriate growth rates) as well as the latest EPA methods for determining paved road emissions and measured silt loadings form the area.

*** Gravel road emissions were developed using VMT information contained in the 1993 SIP element (grown to 2000 by appropriate growth rates) as well as EPA methods for determining gravel road emissions.

TABLE 2.—2000 AND 2015 $PM_{10}$ TOTAL EMISSION INVENTORY FOR VEHICLE EXHAUST, FIREPLACES, WOODSTOVES AND POINT SOURCES IN POUNDS PER DAY FOR LAMAR CITY

| | Vehicle exhaust | Fireplace | Woodstoves | Point sources |
|---|---|---|---|---|
| 2000 | 56 | 208 | 269 | 1271 |
| 2015 | 56 | 228 | 294 | 1281 |

* The woodburning emission estimates and mobile exhaust emissions for the year 1997 were taken from the 1993 SIP element that was approved by EPA on June 9, 1994 (59 FR 29732) and rolled forward to 2000. VMT was also adjusted using actual CDOT traffic counts.

TABLE 3.—2000 AND 2015 $PM_{10}$ TOTAL EMISSION INVENTORY FOR TILLING, WIND EROSION/FEEDLOT, GRAIN ELEVATORS, AND STORAGE PILES IN POUNDS PER DAY FOR LAMAR CITY

| | Tilling | Wind erosion/ feedlot | Grain elevators | Storage piles |
|---|---|---|---|---|
| 2000 | 28 | 4231 | 2 | 22 |
| 2015 | 28 | 4231 | 2 | 22 |

* The tilling, wind erosion, and the area's feedlot emissions were rolled forward from 2000 inventory levels as well as the storage piles emission inventory. The 2000 emissions are the same as the 1997 emissions documented in the 1994 Lamar SIP.

More detailed descriptions of the 2000 attainment year inventory and the 2015 projected inventory for the Lamar area are documented in the maintenance plan in Chapter 3, section B and in the Colorado technical support documentation. Colorado's submittal contains detailed emission inventory information that was prepared in accordance with EPA emission inventory guidance.[2] Following our review, we have determined that Colorado prepared an adequate attainment inventory for the Lamar area.

An emission inventory for Steamboat Springs was developed for the attainment year 1999 as well as the projection inventory for the 2005 and 2010 interim years and the 2015 maintenance year. The emission inventory incorporates the emission estimates for aircrafts, restaurants, stationary sources, woodburning, mobile exhaust, and re-entrained road dust emissions from paved and unpaved roads that are contained in the nonattainment area SIP element that was approved by EPA on December 31, 1997 (62 FR 68188). Aircraft emissions were determined by using EPA and Colorado's Air Pollution Control Division (APCD) developed emission factors and activity data provided by the City of Steamboat Springs. Restaurant emissions were developed using emission factors and survey data of activity in the Steamboat Springs area. Woodburning emissions were determined by using EPA and APCD developed emission factors and survey data of woodburning activity and practices in the Steamboat Springs area. Re-entrained dust from paved and unpaved roads were developed using APCD and CDOT vehicle miles traveled data and emission factors that were calculated using the EPA-approved formula, local silt loading data, and the application of credits from street sweeping and street sand reduction control measures. Mobil exhaust was determined using EPA's PART5 model. Stationary source emission in the Steamboat Springs area were

[2] EPA's current guidance on the preparation of $PM_{10}$ emission inventories includes, ''$PM_{10}$ Emission Inventory Requirements,'' September 1994, ''Emission Inventory Improvement Program Technical Report Series, Volumes I–VII,'' July 1997 and September 1999, ''Revised 1999 National Emission Inventory Preparation Plan,'' February 2001.

determined by calculating allowable emissions from three facilities in the area in existence in the mid-1990s. The Craig and Hayden power plants were modeled at allowable emissions for all years however these emissions were not included in the emission inventories because they are not located within the Steamboat Springs nonattainment—attainment/maintenance area and modeling domain. Summary emission figures from the 1999 attainment year inventory, the 2005 and 2010 interim years, and the 2015 projected inventory for the Steamboat Springs area are provided in Table 1 below.

TABLE 1.—1999, 2005, 2010 AND 2015 $PM_{10}$ TOTAL EMISSION INVENTORY IN POUNDS PER DAY FOR STEAMBOAT SPRINGS

| | $PM_{10}$ emissions (lbs./day) | | | |
|---|---|---|---|---|
| | 1999 | 2005 | 2010 | 2015 |
| Aircraft | 24 | 27 | 30 | 34 |
| Restaurant Grills | 99 | 114 | 127 | 143 |
| Vehicle Exhaust | 53 | 52 | 56 | 63 |
| Paved Roads | 9122 | 10059 | 11271 | 12630 |
| Unpaved Roads | 7519 | 7233 | 8104 | 9080 |
| Stationary Sources | 584 | 242 | 271 | 304 |
| Woodburning | 1057 | 1216 | 1353 | 1522 |

More detailed descriptions of the 1999 attainment year inventory, the 2005 and 2010 interim years, and the 2015 projected inventory for the Steamboat Springs area are documented in the maintenance plan in Chapter 3, section B and in the Colorado technical support documentation. Colorado's submittal contains detailed emission inventory information that was prepared in accordance with EPA emission inventory guidance.[3] Following our review, we have determined that Colorado prepared an adequate attainment inventory for the Steamboat Springs area.

b. Maintenance Demonstration

A state may generally demonstrate maintenance of the NAAQS by either showing that future emissions of a pollutant or its precursors will not exceed the level of the attainment inventory, or by modeling to show that the future mix of sources and emission rates will not cause a violation of the NAAQS. Colorado chose the chemical mass balance (CMB) modeling approach for the Lamar area and the dispersion modeling approach for the Steamboat Springs area.

The maintenance demonstration for the Lamar area uses the CMB roll-forward methodology, which is the same level of modeling used in the original attainment demonstration for the moderate $PM_{10}$ SIP for this area. The CMB receptor model data are used to identify the sources of emissions that influence $PM_{10}$ concentrations in the area. Colorado used the attainment inventory to further refine the CMB source identification and then apportion the design day concentration. The design day concentration was determined using EPA's ''Table look-up'' method. Based on the number of samples collected during a three year period from 1998—2000 (2026 samples total), the third highest concentration measured during that period is used as the design value. For the Lamar area, the design value is 137 $\mu g/m^3$. Colorado prepared a maintenance inventory for the year 2015 and rolled forward the design day concentration based on the changes that occurred in the emission inventory from the attainment year to the maintenance year. Based on this process, the Lamar 2015 maintenance concentration is 145.4 $\mu g/m^3$. Since this 2015 projection for Lamar is below the 24-hour $PM_{10}$ NAAQS of 150 $\mu g/m^3$, maintenance is demonstrated.

Although EPA would normally insist on some interim year projections between the attainment year and 2015, we have no reason to believe that total emissions for the Lamar area will be greater than the 2015 projections in any of the interim years. Colorado applied simple, environmentally conservative, growth rates to all source categories. Thus, total emissions in all years before 2015 in the Lamar area should be less than 2015 total emissions and no interim year projections are required.

Since no violation of the $PM_{10}$ annual NAAQS have ever occurred in the Lamar area and since the maintenance demonstration clearly shows maintenance of the 24-hour $PM_{10}$ NAAQS in this area through the year 2015, it is reasonable and adequate to assume that protection of the 24-hour standard will be sufficient to protect the annual standard as well. Thus, EPA believes Colorado has adequately demonstrated that the Lamar area will maintain the $PM_{10}$ NAAQS for at least the next ten years. Detailed information regarding the CMB modeling results and source apportionment can be found in Chapter 3, section C of the Lamar maintenance plan and in the technical support document.

The maintenance demonstration for the Steamboat Springs area relied on the dispersion modeling methodology, which is the same level of modeling used in the original attainment demonstration for the moderate $PM_{10}$ SIP for this area. Maintenance is demonstrated when the highest modeled values at each receptor on the modeling grid are below the 150 $\mu g/m^3$. The emission inventories for 2005, 2010, and 2015 were input into the dispersion model to obtain 2005, 2010, and 2015 projected $PM_{10}$ concentrations. The dispersion modeling for the Steamboat Springs $PM_{10}$ maintenance area demonstrates that in 2005 the highest concentration is 121 $\mu g/m^3$, in 2010 the highest concentration is 132 $\mu g/m^3$, and in 2015 the highest concentration is 146 $\mu g/m^3$ for the 24-hour $PM_{10}$ NAAQS.

Since no exceedances of the $PM_{10}$ annual NAAQS have ever occurred in the Steamboat Springs area and since the maintenance demonstration clearly shows maintenance of the 24-hour $PM_{10}$ NAAQS in this area through the year 2015, it is reasonable and adequate to assume that protection of the 24-hour standard will be sufficient to protect the annual standard as well. Thus, EPA believes Colorado has adequately demonstrated that the Steamboat

[3] EPA's current guidance on the preparation of $PM_{10}$ emission inventories includes, ''$PM_{10}$ Emission Inventory Requirements,'' September 1994, ''Emission Inventory Improvement Program Technical Report Series, Volumes I–VII,'' July 1997 and September 1999, ''Revised 1999 National Emission Inventory Preparation Plan,'' February 2001.

Springs area will maintain the $PM_{10}$ NAAQS for at least the next ten years. Detailed information regarding the dispersion modeling results and source apportionment can be found in Chapter 3, section C of the Steamboat Springs maintenance plan and in the technical support document.

c. Monitoring Network

Once a nonattainment area has been redesignated to attainment, the State must continue to operate an appropriate air quality monitoring network, in accordance with 40 CFR part 58, to verify the attainment status of the area. The maintenance plan should contain provisions for continued operation of air quality monitors that will provide such verification. Colorado operates two $PM_{10}$ monitoring sites in the Lamar area and two in the Steamboat Springs area. We approve these sites annually, and any future change would require discussion with, and approval from, us. In their July 31, 2002 submittal, Colorado committed to continue to operate these $PM_{10}$ monitoring stations in Lamar and Steamboat Springs, in accordance with 40 CFR part 58.

d. Verification of Continued Attainment

A state's maintenance plan submittal should indicate how it will track the progress of the maintenance plan. This is necessary due to the fact that the emission projections made for the maintenance demonstration depend on assumptions of point and area source growth. Colorado commits to operating both the Lamar and Steamboat Springs $PM_{10}$ monitoring network and analyze the $PM_{10}$ concentrations in accordance with 40 CFR part 58 to verify continued maintenance of the $PM_{10}$ NAAQS. In addition, Colorado commits to track the progress of both the Lamar and Steamboat Springs maintenance plans through a periodic review (every three years) of the assumptions made in the emissions inventories to verify continued maintenance of the $PE_{10}$ NAAQS in both areas. EPA relies on these commitments in approving the Lamar and Steamboat Springs maintenance plans.

e. Contingency Plan

Section 175A(d) of the CAA requires that a maintenance plan also include contingency provisions, as necessary, to promptly correct any violation of the NAAQS that occurs after redesignation of the area. For the purposes of section 175A, a state is not required to have fully adopted contingency measures that will take effect without further action by the State in order for the maintenance plan to be approved. However, the contingency plan is an enforceable part of the SIP and should ensure that contingency measures are adopted expeditiously when a violation of the NAAQS has occurred in a redesignated area. The plan should clearly identify the measures to be adopted, a schedule and procedure for adoption and implementation, and a specific time limit for action by the State. The State should also identify the specific indicators, or triggers, which will be used to determine when the contingency plan will be implemented.

Chapter 3, section H, of both the Lamar and Steamboat Springs maintenance plan contains the area's $PM_{10}$ contingency plan. Exceedances trigger one level of response and violations trigger another. If there's an exceedance, the Air Pollution Control Division (APCD) and the local government staff will develop appropriate contingency measures intended to prevent or correct a violation of the $PM_{10}$ standard for the $PM_{10}$ maintenance area. APCD and local government staff will consider relevant information, including information about historical exceedances, meteorological data, the most recent estimates of growth and emissions, and whether the exceedance might be attributed to an exceptional event. The Lamar and Steamboat Springs maintenance plans indicate that the State will generally notify EPA and local governments in the $PM_{10}$ maintenance area within 30 days of the exceedance, but no later than 45 days. The process for exceedances will be completed within six months of the exceedance notification.

If a violation of the $PM_{10}$ NAAQS has occurred, a public hearing process at the State and local level will begin. If the Colorado Air Quality Control Commission (AQCC) agrees that the implementation of local measures will prevent further exceedances or violations, the AQCC may endorse or approve of the local measures without adopting State requirements. If, however, the AQCC finds locally adopted contingency measures to be inadequate, the AQCC will adopt State enforceable measures as deemed necessary to prevent additional exceedances or violations. Contingency measures will be adopted and fully implemented within one year of the $PM_{10}$ NAAQS violation. Any State-enforceable measures will become part of the next revised maintenance plan, submitted to us for approval.

The Lamar $PM_{10}$ maintenance plan specifies the following as potential contingency measures for the Lamar area: street sweeping requirements; road paving requirements; street sand specifications; woodburning restrictions; use of alternative de-icers; re-establishing nonattainment new source review permitting requirements for stationary sources; [4] controls at existing stationary sources; transportation control measures designed to reduce vehicle miles traveled; or other emission control measures as deemed appropriate, considering various factors.

The Steamboat Springs $PM_{10}$ maintenance plan specifies the following as potential contingency measures for the Steamboat Springs area: reinstating the 10 percent street sand reduction requirement for State highways; increasing the Lincoln Avenue street sweeping frequency from two to four times after each sanding event; increased street sweeping requirements; road paving requirements; more stringent street sand specifications; voluntary or mandatory woodburning curtailment; bans on all woodburning; expanded, mandatory use of alternative de-icers; re-establishing nonattainment new source review permitting requirements for stationary sources; [3] transportation control measures designed to reduce vehicle miles traveled; or other emission control measures as deemed appropriate, considering various factors.

f. Subsequent Maintenance Plan Revisions

In accordance with section 175A(b) of the CAA, the State of Colorado is required to submit a revision to the maintenance plan eight years after the redesignation of the Lamar and Steamboat Springs areas to attainment for $PM_{10}$. This revision is to provide for maintenance of the NAAQS for an additional ten years following the first ten year period. Colorado committed, in the Lamar and Steamboat Springs redesignation requests, to submit a revised maintenance plan, for each area, to EPA eight years after the approval of the redesignation request and maintenance plan.

v. Meeting Applicable Requirements of Section 110 and Part D of the CAA

In order for an area to be redesignated to attainment, section 107(d)(3)(E) requires that it must have met all applicable requirements of section 110 and part D of the CAA. We interpret this

[4] The maintenance plan refers to ''Re-establishing new source review permitting requirement for stationary sources.'' Given that PSD permitting requirements will apply to the area after the effective date of this action, we interpret the maintenance plan's reference to mean ''nonattainment new source review.''

to mean that, for a redesignation request to be approved, the State must have met all requirements that applied to the subject area prior to, or at the time of, submitting a complete redesignation request. In our evaluation of a redesignation request, we don't need to consider other requirements of the CAA that became due after the date of the submission of a complete redesignation request.

a. Section 110 Requirements

Section 110(a)(2) contains general requirements for nonattainment plans. These requirements were met for Lamar with Colorado's May 7, 1993 submittal for the Lamar $PM_{10}$ nonattainment area. EPA fully approved the Lamar $PM_{10}$ SIP on June 9, 1994 (59 FR 29732). The section 110(a)(2) requirements were met for Steamboat Springs with Colorado's September 16, 1997 submittal for the Steamboat Springs $PM_{10}$ nonattainment area. EPA fully approved the Steamboat Springs $PM_{10}$ SIP on December 31, 1997 (62 FR 68188).

b. Part D Requirements

Before a $PM_{10}$ nonattainment area may be redesignated to attainment, the State must have fulfilled the applicable requirements of part D. Subpart 1 of part D establishes the general requirements applicable to all nonattainment areas, subpart 4 of part D establishes specific requirements applicable to $PM_{10}$ nonattainment areas.

The requirements of sections 172(c) and 189(a) regarding attainment of the $PM_{10}$ NAAQS, and the requirements of section 172(c) regarding reasonable further progress, imposition of Reasonably Available Control Measures (RACM), the adoption of contingency measures, and the submission of an emission inventory, have been satisfied through our June 9, 1994 (59 FR 29732) approval of the Lamar $PM_{10}$ SIP and our December 31, 1997 (62 FR 68188) approval of the Steamboat Springs $PM_{10}$ SIP.

Although EPA's regulations (see 40 CFR 51.396) require that states adopt transportation conformity provisions in their SIPs for areas designated nonattainment or subject to an EPA-approved maintenance plan, we have decided that a transportation conformity SIP is not an applicable requirement for purposes of evaluating a redesignation request under section 107(d) of the CAA. This decision is reflected in EPA's 1996 approval of the Boston carbon monoxide redesignation. (See 61 FR 2918, January 30, 1996.)

We approved the requirements of the part D new source review (NSR) permit program for the Lamar moderate $PM_{10}$ nonattainment area on August 18, 1994 (59 FR 42500) and for the Steamboat Springs moderate $PM_{10}$ nonattainment area on December 31, 1997 (62 FR 68188). Colorado's nonattainment area NSR permitting regulations were fully approved on September 19, 1994 (59 FR 47807). Once the Lamar and Steamboat Springs areas are redesignated to attainment, the prevention of significant deterioration (PSD) requirements of part C of the CAA will apply. Colorado's PSD regulations, which we approved as meeting all applicable Federal requirements, apply to any area designated as unclassifiable or attainment and, thus, will become fully effective in the Lamar and Steamboat Springs area upon redesignation of the area to attainment.

*C. Have the Transportation Conformity Requirements Been Met?*

Transportation conformity is required by section 176(c) of the CAA. Our conformity rule requires that transportation plans, programs and projects conform to SIPs and that transportation activities will not produce new air quality violations, worsen existing violations, or delay timely attainment of the NAAQS. On March 2, 1999, the United States Court of Appeals for the District of Columbia Circuit issued a decision in *Environmental Defense Fund* v. *the Environmental Protection Agency,* No. 97–1637, that we must make an affirmative determination that the submitted motor vehicle emission budgets contained in State Implementation Plans (SIPs) are adequate before they are used to determine the conformity of Transportation Plans or Transportation Improvement Programs. In response to the court decision, we make any submitted SIP revision containing an emission budget available for public comment and respond to these comments before announcing our adequacy determination. The criteria and process by which we determine whether a SIP's motor vehicle emission budgets are adequate for conformity purposes are outlined in 40 CFR 93.118(e)(4) and in the guidance ''Conformity Guidance on Implementation of March 2, 1999 Conformity Court Decision,'' dated May 14, 1999.

In the Lamar maintenance plan, Colorado established a new mobile source emissions budget of 7,534 lbs./day for the year 2015 and beyond. In the Steamboat Springs maintenance plan, Colorado established a new mobile source emissions budget of 21,773 lbs./day for the year 2015 and beyond. The new mobile source emissions budgets for both Lamar and Steamboat Springs are the total of the 2015 mobile source $PM_{10}$ emissions for each area and includes emissions from vehicle exhaust, highways, paved arterial and local roads, and gravel roads. EPA's approval of 7,534 lbs./day for Lamar and 21,773 lbs./day for Steamboat Springs as the budget for those areas means that these values must be used for conformity determinations for 2015 and beyond.

EPA sent a letter to the Colorado Air Pollution Control Division (APCD) on September 25, 2002 stating that the motor vehicle emission budgets that were submitted with the Lamar and Steamboat Springs $PM_{10}$ maintenance plan is adequate. This finding has also been announced on EPA's conformity Web site: *http://www.epa.gov/otaq/transp/conform/adequacy.htm.* We documented our adequacy determination for Lamar and Steamboat Springs in the **Federal Register** on October 28, 2002 (67 FR 65789). The budgets took effect on November 12, 2002 (15 days after our announcement in the **Federal Register**).

*D. Did Colorado Follow the Proper Procedures for Adopting This Action?*

The CAA requires States to observe certain procedural requirements in developing implementation plans and plan revisions for submission. Section 110(a)(2) of the CAA provides that each implementation plan submitted by a State must be adopted after reasonable notice and public hearing. Section 110(l) of the CAA similarly provides that each revision to an implementation plan submitted by a State under the CAA must be adopted by such State after reasonable notice and public hearing.

Colorado held a public hearing for the proposed rule changes on November 15, 2001. The rulemaking was adopted by the Air Quality Control Commission (AQCC) directly after the November 15, 2001 hearing and was formally submitted to EPA by the Governor on July 31, 2002. We have evaluated the Governor's submittal and have determined that Colorado met the requirements for reasonable notice and public hearing under section 110(a)(2) of the CAA.

## IV. Background

To implement our 1987 revisions to the particulate matter NAAQS, on August 7, 1987 (52 FR 29383), we categorized areas of the nation into three groups based on the likelihood that protection of the $PM_{10}$ NAAQS would require revisions of the existing SIP. We

identified Lamar as $PM_{10}$ ''Group I'' area of concern, *i.e.*, areas with a strong likelihood of violating the $PM_{10}$ NAAQS and requiring a substantial SIP revision and the Steamboat Springs area as a ''Group II'' area of concern, *i.e.*, areas where attainment of the NAAQS is uncertain and the SIP may require only slight adjustment.

The Lamar area was among several Group I $PM_{10}$ areas, all of which were designated and classified as moderate $PM_{10}$ nonattainment areas by operation of law upon enactment of the Clean Air Act Amendments of 1990 (November 15, 1990). See 56 FR 56694 at 56705–56706 (November 6, 1991). By November 15, 1991, States containing initial moderate $PM_{10}$ nonattainment areas were required to submit most elements of their $PM_{10}$ SIPs. (See sections 172(c), 188, and 189 of the CAA.) Some provisions, such as $PM_{10}$ contingency measures required by section 172(c)(9) of the CAA and nonattainment new source review (NSR) provisions, were due at later dates. In order for a nonattainment area to be redesignated to attainment, the above mentioned conditions in section 107(d)(3)(E) of the CAA must be met. EPA fully approved the $PM_{10}$ SIP for Lamar on June 9, 1994 (59 FR 29732).

Pursuant to sections 107(d)(4)(B) and 188(a) of the Act, areas previously identified as Group I (55 FR 45799, October 31, 1990) and other areas which had monitored violations of the $PM_{10}$ NAAQS prior to January 1, 1989 were, by operation of law upon enactment of the 1990 Clean Air Act Amendments (Public Law 101–549, 104 Stat. 2399), designated nonattainment and classified as moderate for $PM_{10}$. Formal codification in 40 CFR part 81 of those areas was announced in a **Federal Register** notice dated November 6, 1991 (56 FR 56694) (see also 57 FR 56762, November 30, 1992). All other areas of the country were designated unclassifiable for $PM_{10}$ by operation of law upon enactment of the 1990 Amendments (see section 107(d)(4)(B)(iii) of the Act). EPA redesignated and classified the Steamboat Springs area as a $PM_{10}$ moderate nonattainment area on December 21, 1993 (58 FR 67334) and fully approved the $PM_{10}$ SIP for Steamboat Springs on December 31, 1997 (62 FR 68188).

EPA promulgated new standards for $PM_{10}$ on September 18, 1997. Areas were to be designated under the new $PM_{10}$ standard by July 2000. On May 14, 1999, the United States Court of Appeals for the D.C. Circuit in *American Trucking Associations, Inc. et al.*, v. *United States Environmental Protection Agency* vacated the 1997 $PM_{10}$ standard. Because of the Court ruling, we are continuing to implement the pre-existing $PM_{10}$ standard, and are therefore approving redesignations to qualified $PM_{10}$ nonattainment areas. On July 31, 2002 the Governor of Colorado submitted a request to redesignate the Lamar and Steamboat Springs moderate $PM_{10}$ nonattainment areas to attainment (for the 1987 $PM_{10}$ NAAQS) and submitted maintenance plans for the areas.

## V. Consideration of CAA Section 110(l)

Section 110(l) of the CAA states that a SIP revision cannot be approved if the revision would interfere with any applicable requirement concerning attainment and reasonable further progress towards attainment of a NAAQS or any other applicable requirement of the CAA. As stated above, the Lamar and Steamboat Springs area has shown continuous attainment of the $PM_{10}$ NAAQS and has met the applicable Federal requirements for redesignation to attainment. The maintenance plan and associated SIP revisions will not interfere with attainment, reasonable further progress, or any other applicable requirement of the CAA.

## VI. Statutory and Executive Order Review

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a ''significant regulatory action'' and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, ''Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use'' (66 FR 28355, May 22, 2001). This action merely approves state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule approves pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104–4).

This rule also does not have tribal implications because it will not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000). This action also does not have Federalism implications because it does not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999). This action merely approves a state rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 ''Protection of Children from Environmental Health Risks and Safety Risks'' (62 FR 19885, April 23, 1997), because it is not economically significant.

In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. This rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

The Congressional Review Act, 5 U.S.C. 801 *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the **Federal Register**. A major rule cannot take effect until 60 days after it is published in the **Federal Register**. This action is not a ''major rule'' as defined by 5 U.S.C. 804(2).

Under section 307(b)(1) of the Clean Air Act, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by October 4, 2004. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action may not be challenged later in proceedings to enforce its requirements. (See section 307(b)(2).)

**List of Subjects**

*40 CFR Part 52*

Environmental protection, Air pollution control, Incorporation by reference, Intergovernmental relations, Particulate matter, Reporting and recordkeeping requirements.

*40 CFR Part 81*

Air pollution control.

Dated: June 28, 2004.

**Robert E. Roberts,**

*Regional Administrator, Region 8.*

■ 40 CFR parts 52 and 81, chapter I, title 40 are amended as follows:

## PART 52—[AMENDED]

■ 1. The authority citation for part 52 continues to read as follows:

**Authority:** 42 U.S.C. 7401 *et seq.*

## Subpart G—Colorado

■ 2. Section 52.320 is amended by adding paragraph (c)(101) to read as follows:

### § 52.320 Identification of plan.

* * * * *

(c) * * *

(101) On July 31, 2002, the State of Colorado submitted maintenance plans for the Lamar and Steamboat Springs $PM_{10}$ nonattainment areas and requested that these areas be redesignated to attainment for the $PM_{10}$ National Ambient Air Quality Standards. The redesignation requests and maintenance plans satisfy all applicable requirements of the Clean Air Act.

(i) Incorporation by Reference

(A) Colorado Air Quality Control Commission, ''State Implementation Plan—Specific Regulations for Nonattainment—Attainment/Maintenance Areas (Local Elements),'' 5 CCR 1001–20, revisions adopted November 15, 2001, effective December 30, 2001 as follows: Section IV, which is titled ''Lamar Attainment/Maintenance Area,'' and Section VIII., which is titled ''Steamboat Springs $PM_{10}$ Attainment/Maintenance Area'' and which supersedes and replaces all prior versions of Section IV and VIII.

(ii) Additional Material

(A) Colorado Department of Public Health and Environment, ''Natural Events Action Plan for High Wind Events, Lamar, Colorado,'' submitted to EPA on February 9, 1998 and subsequently approved by EPA, June 5, 1998 and Lamar's revised 2003 ''Natural Events Action Plan for High Wind Events, Lamar, Colorado,'' submitted to EPA on April 16, 2003 and subsequently approved by EPA, February 9, 2004.

■ 3. Section 52.332 is amended by adding paragraph (n) to read as follows:

### § 52.332 Control strategy: Particulate matter.

* * * * *

(n) On July 31, 2002, the State of Colorado submitted maintenance plans for the Lamar and Steamboat Springs $PM_{10}$ nonattainment areas and requested that these areas be redesignated to attainment for the $PM_{10}$ National Ambient Air Quality Standards. The redesignation requests and maintenance plans satisfy all applicable requirements of the Clean Air Act.

## PART 81—[AMENDED]

■ 1. The authority citation for part 81 continues to read as follows:

**Authority:** 42 U.S.C. 7401 *et seq.*

■ 2. In § 81.306, the table entitled ''Colorado-PM–10'' is amended by revising the entries under Prowers County for ''Lamar'' and under Routt County (part) for ''Steamboat Springs'' to read as follows:

### § 81.306 Colorado.

* * * * *

COLORADO—PM–10

| Designated Area | Designation | | Classification | |
|---|---|---|---|---|
| | Date | Type | Date | Type |
| * * | * | * | * | * |
| Prowers County: Lamar | October 4, 2004 | Attainment | | |
| * * | * | * | * | * |
| Routt County (part)—Steamboat Springs:<br>On the East—The Routt National Forest.<br>On the South—The southern border of sections 19, 10, 21, T4N, R84W of the 6th P.M. and the southern border of sections 23, 24, T4N, R85W of the 6th P.M.<br>On the West—Beginning at the southwestern corner of section 23, T4N, R85W of the 6th P.M. | October 4, 2004 | Attainment | | |

COLORADO—PM–10—Continued

| Designated Area | Designation | | Classification | |
|---|---|---|---|---|
| | Date | Type | Date | Type |
| North along the western border of sections 23, 14, 11, T4N, R85W. Thence, along the ridge which bisects sections 35, 36, 25, 24, 13, 14, 11, 12, 1, T5N, R85W, and sections 36, 25, 24, T6N, R85W. Thence heading northwest along the ridge which bisects sections 23, 15, 10, 9, 4, T6N, R85W of 6th P.M. Thence, heading northeast along the ridge which bisects sections 33, 34, 35, 36, 25, T7N, R85W and sections 30 and 10 of T7N, R84W. Thence, north along the N ½ of the western edge of section 19, to the NW corner of section 18, T7N, R84W. | | | | |
| On the North—The northern boundary of sections 16, 17, 18, T7N, R84W of 6th P.M. | | | | |
| * * | * | * | * | * |

* * * * *

[FR Doc. 04–17656 Filed 8–4–04; 8:45 am]

BILLING CODE 6560–50–P

## ENVIRONMENTAL PROTECTION AGENCY

### 40 CFR Part 300

**[FRL–7797–5]**

### National Oil and Hazardous Substances Pollution Contingency Plan; National Priorities List

**AGENCY:** Environmental Protection Agency.

**ACTION:** Notice of deletion for the Hooker (102nd Street) Superfund Site from the National Priorities List.

**SUMMARY:** The Environmental Protection Agency (EPA) Region II Office announces the deletion of the Hooker (102nd Street) Superfund Site from the National Priorities List (NPL). The Hooker (102nd Street) Site is located in the City of Niagara Falls, Niagara County, New York. The NPL is Appendix B to the National Oil and Hazardous Substances Pollution Contingency Plan (NCP), 40 CFR part 300, which the EPA promulgated pursuant to section 105 of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA), as amended. The EPA and New York State, through the Department of Environmental Conservation (NYSDEC) have determined that all appropriate response actions have been implemented and that no further response actions, other than operation, maintenance, and monitoring, are required. In addition, the EPA and the NYSDEC have determined that the remedial action taken at the Hooker (102nd Street) Site is protective of public health, welfare, and the environment.

**EFFECTIVE DATE:** August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Paul J. Olivo, Remedial Project Manager, U.S. Environmental Protection Agency, Region II, 290 Broadway, 20th Floor, New York, New York 10007–1866, (212) 637–4280.

**SUPPLEMENTARY INFORMATION:** To be deleted from the NPL is the Hooker (102nd Street) Superfund Site, City of Niagara Falls, Niagara County, New York.

A Notice of Intent-to-Delete for the Hooker (102nd Street) Site was published in the **Federal Register** on March 17, 2004 (69 FR 12604). The closing date for comments on the Notice of Intent-to-Delete was April 16, 2004. The EPA received no comments on the proposed deletion. The EPA identifies sites that appear to present a significant risk to public health, welfare, or the environment, and the EPA maintains the NPL as the list of those sites. As described in Sec. 300.425(e)(3) of the NCP, any site or portion thereof deleted from the NPL remains eligible for remedial actions in the unlikely event that conditions at the site warrant such action in the future. Deletion of a site from the NPL does not affect responsible party liability or impede agency efforts to recover costs associated with response efforts.

### List of Subjects in 40 CFR Part 300

Environmental protection, Air pollution controls, Chemicals, Hazardous substances, Hazardous waste, Intergovernmental relations, Penalties, Reporting and recordkeeping requirements, Superfund, Water pollution control, Water supply.

Dated: July 6, 2004.

**Walter Mugdan,**

*Acting Regional Administrator—Region II.*

■ For the reasons set out in the preamble, part 300, chapter I of title 40 of the Code of Federal Regulations, is amended as follows:

## PART 300—[AMENDED]

■ 1. The authority citation for Part 300 continues to read as follows:

**Authority:** 42 U.S.C. 9601–9675; 33 U.S.C. 1321(c)(2); E.O. 12777, 56 FR 54757, 3 CFR., 1991 Comp., p. 351; E.O. 12580, 52 FR 2923, 3 CFR, 1987 Comp., p. 193.

### Appendix B—[Amended]

■ 2. Table 1 of Appendix B to Part 300 is amended by removing ''Hooker (102nd Street), Niagara Falls, New York.''

[FR Doc. 04–17788 Filed 8–4–04; 8:45 am]

BILLING CODE 6560–50–P

**DEPARTMENT OF HOMELAND SECURITY**

**Coast Guard**

**46 CFR Parts 71, 114, 115, 125, 126, 167, 169, 175, and 176**

**[USCG–2000–6858]**

**RIN 1625–AA57**

# Alternate Hull Examinations Program for Certain Passenger Vessels, and Underwater Surveys for Nautical School, Offshore Supply, Passenger and Sailing School Vessels

**AGENCY:** Coast Guard, DHS.

**ACTION:** Final rule.

**SUMMARY:** The Coast Guard is establishing an alternative hull examination program for certain passenger vessels, and giving nautical school, offshore supply, passenger and sailing school vessels the option of having alternating drydock examinations with underwater surveys. It is also establishing examination processes, which give industry additional latitude in scheduling inspections and will create parity between passenger vessels and all other Coast Guard-inspected vessels.

**DATES:** This final rule is effective September 7, 2004.

**ADDRESSES:** Comments and material received from the public, as well as documents mentioned in this preamble as being available in the docket, are part of docket USCG–2000–6858 and are available for inspection or copying at the Docket Management Facility, U.S. Department of Transportation, room PL–401, 400 Seventh Street SW., Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. You may also find this docket on the Internet at *http://dms.dot.gov.* Anyone is able to search the electronic form of all comments received into any of our dockets by the name of the individual submitting the comment (or signing the comment, if submitted on behalf of an association, business, labor union, *etc.*). You may review DOT's complete Privacy Act Statement in the **Federal Register** published on April 11, 2000 (Volume 65, Number 70; Pages 19477–78) or you may visit *http://dms.dot.gov.*

**FOR FURTHER INFORMATION CONTACT:** If you have questions on this rule, call LCDR Martin Walker, Office of Compliance (G-MOC) Coast Guard, telephone 202–267–1047. If you have questions on viewing the docket, call Dorothy Beard, Chief, Dockets, Department of Transportation, telephone 202–366–5149.

**SUPPLEMENTARY INFORMATION:**

## Regulatory History

The project was originally part of a notice of proposed rulemaking (NPRM) entitled ''Frequency of Inspection, Alternate Hull Examination Program for Certain Passenger Vessels, and Underwater Surveys for Passenger, Nautical School, and Sailing School Vessels'' that was published on November 15, 1999, in the **Federal Register** [64 FR 62018]. A final rule, dealing only with ''Frequency of Inspection'' regulations, was published on February 9, 2000 [65 FR 6494], so that we could meet the International Convention for the Safety of Life at Sea, 1974 (SOLAS), and the International Convention on Load Lines compliance date of February 3, 2000. This allowed us to analyze the large number of comments on the Alternate Hull Examination and Underwater Survey portions of the NPRM independently from the comments addressing the ''Frequency of Inspections'' regulations.

On April 29, 2002, we published an interim rule with request for comments entitled ''Alternate Hull Examinations Program for Certain Passenger Vessels, and Underwater Surveys for Nautical School, Offshore Supply, Passenger and Sailing School Vessels'' in the **Federal Register** [67 FR 21062]. We received 51 comments on the interim rule.

## Background and Purpose

### *Alternative Hull Examination (AHE) Program*

Based on the results of an underwater survey demonstration performed in May 1997, the Coast Guard created a pilot program that allows owners or operators of qualified vessels to undergo an alternative hull examination process. This examination process includes an underwater survey and an internal structural examination along with annual condition assessments and scheduled preventative maintenance. The program allows owners and operators of qualified vessels to receive a credit hull exam of up to five years depending on the chosen method of hull examination.

### *Underwater Survey in Lieu of Drydocking (UWILD)*

Inspected U.S. passenger vessels, nautical school ships (public and civilian), off-shore supply vessels (OSVs) under 46 CFR chapter I, subchapter L, and sailing school vessels lacked the regulatory option of alternating drydock examinations with underwater surveys before the interim rule [67 FR 21062] was published in the **Federal Register** on April 29, 2002.

This rule, which adopts guidance from Navigation and Vessel Inspection Circular (NVIC) 1–89, allows owners or operators of U.S. passenger vessels, nautical school ships, OSVs, and sailing school vessels with steel or aluminum hulls the voluntary option of alternating underwater hull surveys with drydock examinations.

### *Discussion of Comments and Changes*

The Coast Guard received 51 comments in response to the interim rule with request for comment on the ''Alternate Hull Examination Program for Certain Passenger, and Underwater Surveys for Nautical School, Offshore Supply, Passenger and Sailing School Vessels'' published April 29, 2002, in the **Federal Register** [67 FR 21062]. All changes in this Final Rule have been made in response to comments. These changes are noted in the discussion of comments.

### *Public Meetings*

Three commenters requested public meetings be held to discuss various aspects of Alternative Hull Examinations (AHE). We extended the original comment period by publishing the interim rule, rather than a final rule. We further stated that if the public felt that a public meeting was still necessary, it should submit a comment explaining why there should be a meeting. The relatively low number of comments we received did not state compelling reasons to hold a public meeting. Therefore, we believe that the public has been afforded ample opportunity to comment and that a public meeting is unnecessary.

### *General*

One commenter said the frequency of internal exams of water ballast tanks is not mentioned in the interim rule. We disagree. The definition of ''internal structural exam'' includes ballast tanks, and § 71.50–3 discusses the intervals for conducting internal structural exams.

One commenter stated the phrase ''at alternate intervals'' should be deleted from the first sentence in § 71.50–5(c). We disagree. The wording was designed to be the same as found in existing Underwater Survey in Lieu of Drydocking (UWILD) regulations for other vessel types. Further, we believe that the meaning is clear when taken in context with the rest of the sentence, which discusses alternating underwater surveys and drydock exams.

One commenter stated it should be clarified in §§ 71.50–15, 115.620, and

176.620 that all four steps for entering or re-entering the AHE program are needed when only divers are used for the examinations. We agree and have changed the wording accordingly.

One commenter stated filing a report on underwater cleanliness prior to an exam would unnecessarily increase the expense of a survey. We agree, and have changed §§ 71.50–19(d), 115.630(d), and 176.630(d) accordingly.

Two commenters made suggestions in regard to wording. One commenter stated the phrase ''drydock extension'' in §§ 71.50–29(a), 115.655(d), and 176.655 should instead be ''drydock credit.'' We agree and have changed the wording.

One commenter said the impact on small businesses, a cost assessment, or potential takings were not discussed in the interim rule. We disagree. Both the interim rule and this final rule include sections on impacts to small businesses, costs, and potential takings. The Coast Guard stands by its analyses of these issues.

One commenter stated that the interim rule is overly prescriptive. We disagree. The interim rule contains a level of direction and detail that we believe is necessary to preserve vessel safety while maximizing owner flexibility in the inspection of vessels.

*Definition: Adequate Hull Protection System*

Three commenters suggested changes in the definition for ''adequate hull protection system'' in §§ 71.50–1, 114.400, and 175.400. Of those, two said the phrase ''sacrificial anodes'' should be used instead of the word ''zinc''. One commenter asked that the word ''magnesium'' be included in the definition. We agree, and have changed the definition to read ''sacrificial anodes'' versus ''zinc anodes''. This new definition will allow for the inclusion of zinc or magnesium anodes.

*Double Inspections*

Two commenters stated there is no need for inspections to be done by both the Coast Guard and the American Bureau of Shipping (ABS). We disagree. The delegation of Coast Guard inspection authority is outside the scope of this rulemaking.

*G–MOC Policy Letter 3–98*

Two commenters stated that the G–MOC Policy Letter 3–98 should be used as guidance in regard to hull marking instead of the language included in the interim rule. We agree and have changed §§ 71.50–27(a)(2), 115.650(a)(2), and 176.650(a)(2) to read similar to the policy letter.

*Hull Gauging*

Three commenters responded to the gauging of a vessel's hull. Of those, one stated multiple belts should be allowed as an alternative to five random shots per plate. We disagree. Belt gaugings are already required. The intent of the additional gaugings is to provide a greater probability of detecting thinning areas in the hull plating. We do not believe that gaugings taken 10 feet apart at the grid cables provide the same level of inspection as five readings per plate.

One commenter said there should be a minimum of five gaugings per plate, but that the third party examiner should be allowed to take the readings at any location. We disagree. The commenter said that some vessels do not have shell expansion diagrams, and that it is difficult to determine where to gauge these vessels. We acknowledge that spacing may not be easy, but believe that every effort should be made to spread the gaugings out as intended.

One commenter stated it is unclear in §§ 71.50–31(a), 115.660(a), and 176.660(a), who will do the audio gauging and conduct the internal exams for the annual hull condition assessment. We agree and have changed the wording to specify that vessel operators must do the audio gauging and conduct the internal exams during the hull condition assessment.

*Hull Inspections*

One commenter disagrees with the Coast Guard's assessment that there is a ''significant limitation'' in a diver's ability to inspect an entire hull. We disagree and believe that in anything other than ideal conditions, the diver will have some degree of difficulty seeing the surface, determining the exact location of a problem, and relaying it back to the third party examiner. The remotely operated vehicle (ROV) is able to overcome these difficulties to a greater degree.

*Inspection Intervals: Remotely Operated Vehicle (ROV) vs. Diver-only*

Six commenters questioned the difference in inspection intervals allowed for a predominately used ROV exam versus a diver-only exam. In addition, a Risk Based Decision Making (RBDM) study to assess the effectiveness of Policy Letter 3–98, Drydock Extensions For Certain Passenger Vessels, recommended that the interval be extended from 30 months to five years. Some commenters stated that a diver is required for a portion of the ROV exam and that often the divers find problems in the areas that are examined by the ROV. One commenter stated that certain vessels on clear inland lakes have participated in a locally managed program with good success using the five-year interval for several years.

We agree in part. With the technology currently available, we concur that divers must be used during a percentage of the exams, and that, under some specific circumstances, a diver-only exam may achieve a level comparable to that of an exam done predominately by a ROV. We, however, do not believe the diver-only exam is as comprehensive as a ROV exam. Furthermore, it is our belief that an inspection equivalent to a drydock exam may be attained using a combination of the two methods with the ROV covering at least 80 percent of the hull and the diver examining those areas that are inaccessible for the ROV.

This is one of the reasons the authorized credit for the ROV exam is five years and the diver-only exam is three years, but not more than five years between exams.

The difference in the intervals was also part of the interim rule's intent to allow the Officer in Charge, Marine Inspection (OCMI) to grant a larger time frame between exams depending on the results. It is also why the regulations allow the OCMI to waive the annual hull condition assessment in cases where the results of the UWILD indicate that it would be reasonable to do so.

We are adding a provision in §§ 71.50–29(d), 115.655(d), and 176.655(d) to allow the OCMI to waive the mid-period exam and, in effect, grant the full five years of credit to a vessel when it is examined under ideal conditions, and it is safe to do. Owners seeking a waiver must submit a request at least 60 days before each scheduled underwater exam.

One commenter said the word ''predominate'' is ambiguous in the definition for ''underwater survey portion conducted primarily by an approved underwater ROV'' in § 71.50–1. We disagree. The note to § 71.50–15 below the paragraph clearly states that the hull coverage for the ROV is at least 80 percent.

*OCMI Responsibilities*

Three commenters submitted views in regard to the OCMI's responsibilities. Of those, two stated individual OCMIs should make the final decision on eligibility requirements. We agree that the OCMI must make the final decision on eligibility. The interim rule granted the OCMI discretion to allow a vessel, which does not meet the eligibility requirements, to participate when ''it is safe and reasonable to do so,'' based on the vessel's history of safe operation.

One commenter stated OCMIs should make the decision on whether to require the preliminary exam. We disagree. The preliminary exam is necessary to ensure that the vessel is suitable for the program by surveying the underwater portion of the hull. This is not a requirement for a ROV exam, because we believe that an owner will take this step before contracting a ROV to perform the exam.

*Operating Limits*

One commenter stated the limitations of operating 0.5 miles from shore and in shallow water should be eliminated from the regulations. We disagree. The interim rule was targeted at this group of vessels because they operate in a benign environment. The OCMI has the latitude to allow other vessels that operate beyond 0.5 miles into the program if it is safe and reasonable to do so.

*Sea Valves*

Four commenters expressed views regarding sea valves. One commenter stated the requirements in §§ 71.50–25(a)(3) should be broadened to allow for equivalent methods of inspection and testing, especially for vessels operating in fresh water areas. We believe that the regulations should remain as written, and will address inspection procedures in a future NVIC.

One commenter said a clarification is needed that sea valves need to be examined only once every five years. We agree and are adding clarification to the regulations with regard to sea valve inspection intervals.

One commenter stated that large diameter sea valves pose a greater flooding risk and inspection should be allowed with the valves in place. We agree that there is a flooding risk when examining sea valves, which is why the passengers must be removed from the vessel if the OCMI deems it necessary. These regulations are consistent with, and reflect the existing standard in 46 CFR 61, required for a traditional drydock exam, as well as existing guidance in NVIC 1–89. We recognize, however, that it is common practice under certain circumstances, for the OCMI to accept Alternative inspection methods when dealing with large sea valves or unusual piping installations. Therefore, we have revised this section to allow the owner to propose alternatives to the OCMI. The OCMI may approve alternatives on a case-by-case basis, as is the practice already.

One commenter stated the OCMI should have the discretion to allow an alternative means of examining large sea valves. We agree, as stated above, the OCMI may approve alternatives on a case-by-case basis.

*Third Party Examiners*

Nine commenters responded in regard to third party examiners. Two commenters stated there is no need for third party examiners. We disagree. The third party examiner is required to direct the underwater portion of the survey, and may serve as a representative of the owner while the marine inspector conducts the internal exam of the vessel.

Three commenters stated third party examiners should be required to take part in the examinations regardless of the method. We disagree. The third party examiner must participate in diver-only exams and during the diver portion of a predominate ROV exam. We do not believe that the third party examiner needs to be present when the ROV is operating. The third party examiner's main function is interpreting the results obtained by the diver, whereas the ROV data is immediately and graphically available to the marine inspector.

Two commenters said third party examiners should be required to prepare reports from the examinations that include a recommendation of fitness for service. We agree. The written report is required by the regulations, and is the tool that the OCMI uses to evaluate the examination results. The third party examiner may make recommendations, provide assessments, and include opinions of the vessel's overall condition. It is, however, the marine inspector's responsibility to ensure that the exam has been conducted in accordance with the regulations, while it is the OCMI's responsibility to determine the vessel's suitability for continued service.

One commenter stated better qualifications are needed for third party examiners. We disagree. The general qualification a third party examiner must possess is defined in the rule. We did not include a specific qualification, which would prevent someone who otherwise meets the requirements from acting as a third party examiner, potentially creating a large onus for small entities. The rule's approach will allow vessel owners the opportunity to act as a third party examiner on their own vessel, if they are acceptable to the OCMI.

One commenter stated that third party examiners should allow a pre-survey conference call in lieu of an on-site meeting. We agree and are modifying §§ 71.50–23(c), 115.640(c), and 176.640(c) to allow teleconferences if agreed to by the OCMI in advance.

**Videotaping Tactile Exams**

Three commenters stated videotaping the tactile examinations of the hull is excessive. We disagree because this is the only record available to the OCMI of the extent, scope, and results of the underwater portion of the exam. The video and audio recording of the survey and the conditions will help the OCMI determine whether the annual condition assessments and mid-period exam may be waived.

**Regulatory Evaluation**

This rule is not a ''significant regulatory action'' under section 3(f) of Executive Order 12866, Regulatory Planning and Review, and does not require an assessment of potential costs and benefits under section 6(a)(3) of that Order. The Office of Management and Budget has not reviewed it under that Order. It is not ''significant'' under the regulatory policies and procedures of the Department of Homeland Security (DHS). A final Regulatory Evaluation under the regulatory policies and procedures of DHS is available in the docket as indicated under **ADDRESSES.** A summary of the Regulatory Evaluation follows:

**Alternative Hull Examination (AHE) Program**

Because the AHE Program is voluntary, no costs are associated with this component of the rulemaking. Each vessel owner is given the option to choose the most cost-effective hull examination process. We estimate that about 51 passenger vessels will take advantage of the increased flexibility of this rule.

**Underwater Survey in Lieu of Drydocking (UWILD) Program**

The UWILD Program will provide increased flexibility to owners and operators for hull inspections of U.S. passenger vessels, nautical school ships, sailing school vessels, and offshore supply vessels. This program allows an underwater survey instead of a drydock examination on every other interval for the described vessels, and is currently available to most other classes of inspected vessels.

There are no additional costs to the vessel owners or operators with this component of the rulemaking because the use of underwater survey is completely voluntary. We estimate that 6,224 vessels could take advantage of the increased flexibility of this rule.

**Small Entities**

Under the Regulatory Flexibility Act [5 U.S.C. 601–612], we considered whether this rule will have a significant

economic impact on a substantial number of small entities. The term ''small entities'' comprises small businesses, not-for-profit organizations that are independently owned and operated and are not dominant in their fields, and governmental jurisdictions with populations of less than 50,000.

The regulatory options in both the AHE and UWILD programs will make it more cost-efficient and beneficial for small entities by greatly decreasing the amount of time and resources associated with traditional drydock inspections. Additionally, because both programs are voluntary, it is expected that small entities will only participate when it is beneficial for them to do so.

Therefore, the Coast Guard certifies under 5 U.S.C. 605(b) that this final rule will not have a significant economic impact on a substantial number of small entities.

**Assistance for Small Entities**

Under section 213(a) of the Small Business Regulatory Enforcement Fairness Act of 1996 [Pub. L. 104–121], we offered to assist small entities in understanding the rule so that they could better evaluate its effects on them and participate in the rulemaking. The NPRM and the interim rule provided small businesses, organizations, or governmental jurisdictions a Coast Guard contact to ask questions concerning this rule's provisions or options for hull inspections.

Small businesses may send comments on the actions of Federal employees who enforce, or otherwise determine compliance with, Federal regulations to the Small Business and Agriculture Regulatory Enforcement Ombudsman and the Regional Small Business Regulatory Fairness Boards. The Ombudsman evaluates these actions annually and rates each agency's responsiveness to small business. If you wish to comment on actions by employees of the Coast Guard, call 1–888-REG-FAIR (1–888–734–3247).

**Collection of Information**

This rule calls for a new collection of information under the Paperwork Reduction Act of 1995 [44 U.S.C. 3501–3520]. We received no comments on the collection of information in our request for comments in the interim rule [67 FR 21062].

As required by 44 U.S.C. 3507(d), we submitted a copy of this rule to the Office of Management and Budget (OMB) for its review of the collection of information. OMB has approved the collection. The section numbers are (§§ ) 71.50–5(b), 71.50–23(b), 71.50–29(b), 71.50–31(b), 71.50–31(c), 71.50–31(d)(1), 115.615(b), 115.630, 115.640(b), 115.655(a), 115.655(b), 115.660(c), 115.660(d), 126.140(f), 126.140(g)(1), 126.140(g)(3), 167.15–33(b), 167.15–33(c), 169.230(b), 169.230(c), 176.615(b), 176.615(c), 176.630, 176.640(b), 176.655(a), 176.660(b), 176.660(c), and 176.660(d)(1), and the corresponding approval number from OMB is OMB Control Number 1625–0032, which expires on June 30, 2005. A notice announcing the effective date for this collection of information was published on August 28, 2002 [67 FR 55162].

**Federalism**

A rule has implications for federalism under Executive Order 13132, Federalism, if it has a substantial direct effect on State or local governments and would either preempt State law or impose a substantial direct cost of compliance on them.

It is well settled that States may not regulate in categories reserved for regulation by the Coast Guard. It is also well settled, now, that all of the categories covered in 46 U.S.C. 3306, 3703, 7101, and 8101 (design, construction, alteration, repair, maintenance, operation, equipping, personnel qualification, and manning of vessels), as well as the reporting of casualties and any other category in which Congress intended the Coast Guard to be the sole source of a vessel's obligations, are within the field foreclosed from regulation by the States. (See the decision of the Supreme Court in the consolidated cases of *United States* v. *Locke* and *Intertanko* v. *Locke*, 529 U.S. 89, 120 S.Ct. 1135 (March 6, 2000).)

This rule falls into the category of maintenance of vessels. Because the States may not regulate within this category, preemption under Executive Order 13132 is not an issue.

**Unfunded Mandates Reform Act**

The Unfunded Mandates Reform Act of 1995 [2 U.S.C. 1531–1538] requires Federal agencies to assess the effects of their discretionary regulatory actions. In particular, the Act addresses actions that may result in the expenditure by a State, local, or tribal government, in the aggregate, or by the private sector of $100,000,000 or more in any one year. Though this rule will not result in such an expenditure, we do discuss the effects of this rule elsewhere in this preamble.

**Taking of Private Property**

This rule will not effect a taking of private property or otherwise have taking implications under Executive Order 12630, Governmental Actions and Interference with Constitutionally Protected Property Rights.

**Civil Justice Reform**

This rule meets applicable standards in sections 3(a) and 3(b)(2) of Executive Order 12988, Civil Justice Reform, to minimize litigation, eliminate ambiguity, and reduce burden.

**Protection of Children**

We have analyzed this rule under Executive Order 13045, Protection of Children from Environmental Health Risks and Safety Risks. This rule is not an economically significant rule and does not create an environmental risk to health or risk to safety that may disproportionately affect children.

**Indian Tribal Governments**

This rule does not have tribal implications under Executive Order 13175, Consultation and Coordination with Indian Tribal Governments, because it does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes.

**Energy Effects**

We have analyzed this rule under Executive Order 13211, Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use. We have determined that it is not a ''significant energy action'' under that order because it is not a ''significant regulatory action'' under Executive Order 12866 and is not likely to have a significant adverse effect on the supply, distribution, or use of energy. It has not been designated by the Administrator of the Office of Information and Regulatory Affairs as a significant energy action. Therefore, it does not require a Statement of Energy Effects under Executive Order 13211.

**Environment**

We have considered the environmental impact of this rule and concluded that under section 6(a) of the ''Appendix to National Environmental Policy Act: Coast Guard Procedures for Categorical Exclusions, Notice of Final Agency Policy,'' [67 FR 48244 (July 23, 2002)], this rule is categorically excluded from further environmental documentation. This final rule deals exclusively with changing inspection intervals and providing voluntary dry-docking alternatives for certain passenger vessels. A ''Categorical Exclusion Determination'' is available in

the docket where indicated under **ADDRESSES.**

**List of Subjects**

*46 CFR Part 71*

Marine safety, Passenger vessels, Reporting and recordkeeping requirements.

*46 CFR Part 114*

Incorporation by reference, Marine safety, Passenger vessels, Reporting and recordkeeping requirements.

*46 CFR Part 115*

Fire prevention, Marine safety, Passenger vessels, Reporting and recordkeeping requirements.

*46 CFR Part 125*

Administrative practice and procedure, Cargo vessels, Hazardous materials transportation, Marine safety, Seamen.

*46 CFR Part 126*

Authority delegation, Hazardous materials transportation, Marine safety, Offshore supply vessels, Oil and gas exploration, Reporting and recordkeeping requirements, Vessels.

*46 CFR Part 167*

Fire prevention, Marine safety, Reporting and recordkeeping requirements, Schools, Seamen, Vessels.

*46 CFR Part 169*

Fire prevention, Marine safety, Reporting and recordkeeping requirements, Schools, Vessels.

*46 CFR Part 175*

Marine safety, Passenger vessels, Reporting and recordkeeping requirements.

*46 CFR Part 176*

Fire prevention, Marine safety, Passenger vessels, Reporting and recordkeeping requirements.

■ For the reasons discussed in the preamble, the interim rule amending 46 CFR parts 71, 114, 115, 125, 126, 167, 169, 175, and 176 which was published as 67 FR 21062 on April 29, 2002, is adopted as a final rule with the following changes:

## PART 71—INSPECTION AND CERTIFICATION

■ 1. Revise the authority citation for Part 71 to read as follows:

**Authority:** 33 U.S.C. 1321(j); 46 U.S.C. 2113, 3205, 3306, 3307; E.O. 12234, 45 FR 58801, 3 CFR, 1980 Comp., p. 277; E.O. 12777, 56 FR 54757, 3 CFR, 1991 Comp., p. 351; Department of Homeland Security Delegation No. 0170.

■ 2. In § 71.50–1, revise the definition for ''Adequate hull protection system'' to read as follows:

### § 71.50–1 Definitions relating to hull examinations.

* * * * *

*Adequate hull protection system* means a method of protecting the vessel's hull from corrosion. It includes, as a minimum, either hull coatings and a cathodic protection (CP) system consisting of sacrificial anodes, or an impressed current CP system.

* * * * *

■ 3. Revise § 71.50–15 and the Note to § 71.50–15 to read as follows:

### § 71.50–15 Description of the Alternative Hull Examination (AHE) Program for certain passenger vessels.

The Alternative Hull Examination (AHE) Program provides you with an alternative to a drydock examination by allowing your vessel's hull to be examined while it remains afloat. If completed using only divers, this program has four steps: the application process, the preliminary examination, the pre-survey meeting, and the hull examination. If the vessel is already participating in the program or if a remotely operated vehicle (ROV) is used during the program, the preliminary exam step may be omitted. Once you complete these steps, the Officer in Charge, Marine Inspection (OCMI), will evaluate the results and accept the examination as a credit hull exam if the vessel is in satisfactory condition. If only divers are used for the underwater survey portion of the examination process, you may receive credit for a period of time such that subsequent AHEs would be conducted at intervals of twice in every five years, with no more than three years between any two AHEs. The OCMI may waive an underwater survey in accordance with § 71.50–29(d) provided that the interval does not exceed five years between any two underwater surveys. If an underwater ROV is used as the predominate method to examine the vessel's underwater hull plating, you may receive credit up to five years. At the end of this period, you may apply for further participation under the AHE Program.

**Note to § 71.50–15:** The expected hull coverage when using an ROV must be at least 80 percent.

### § 71.50–19 [Amended]

■ 4. In § 71.50–19, in paragraph (d), following the word ''cleanliness'', add the words ''(if known)''.

■ 5. In § 71.50–23, add paragraph (c) to read as follows:

### § 71.50–23 Pre-survey meeting.

* * * * *

(c) The pre-survey meeting may be conducted by teleconference, if agreed to in advance by the OCMI.

### § 71.50–25 [Amended]

■ 6. In § 71.50–25, in paragraph (a)(3), following the words ''marine inspector'', add the words ''once every five years''.

■ 7. In § 71.50–27, revise paragraph (a)(2) to read as follows:

### § 71–50.27 Alternative Hull Examination (AHE) program options: Divers or underwater remotely operated vehicles (ROV).

* * * * *

(a) * * *

(2) Provide permanent hull markings, a temporary grid system of wires or cables spaced not more than 10 feet apart and tagged at one-foot intervals, or any other acoustic or electronic positioning system approved by the OCMI to identify the diver's location with respect to the hull, within one foot of accuracy;

* * * * *

■ 8. In § 71.50–29, revise paragraph (a) and add paragraph (d) to read as follows:

### § 71.50–29 Hull examination reports.

(a) If you use only divers for the underwater survey portion of the Alternative Hull Examination (AHE), you must provide the Officer in Charge, Marine Inspection (OCMI), with a written hull examination report. This report must include thickness gauging results, bearing clearances, a copy of the audio and video recordings, and any other information that will help the OCMI evaluate your vessel for a credit hull exam. The third party examiner must sign the report and confirm the validity of its contents.

* * * * *

(d) At least 60 days prior to each scheduled underwater exam, the owner may request a waiver from the OCMI if:

(1) A satisfactory exam has been completed within the last three years;

(2) The conditions during the last exam allowed at least 80 percent of the bottom surface to be viewed and recorded; and

(3) The results of the last exam indicated that an extended interval is safe and reasonable.

■ 9. In § 71.50–31, revise paragraphs (a) and (d)(1) to read as follows:

### § 71.50–31 Continued participation in the Alternative Hull Examination (AHE) Program.

(a) To continue to participate in the AHE Program, vessel operators must conduct an annual hull condition

assessment. At a minimum, vessel operators must conduct an internal examination and take random hull gaugings internally during the hull condition assessment, unless waived by the Officer in Charge, Marine Inspection (OCMI). If the annual hull assessment reveals significant damage or corrosion, where temporary repairs have been made, or where other critical areas of concern have been identified, the OCMI may require an expanded examination to include an underwater hull examination using divers. If an underwater examination is required, the examination must focus on areas at higher risk of damage or corrosion and must include a representative sampling of hull gaugings.

* * * * *

(d) * * *

(1) The owner may submit to the OCMI a plan for conducting the assessment, or a request for a waiver of this requirement, no fewer than 30 days before the scheduled assessment; and

* * * * *

## PART 114—GENERAL PROVISIONS

■ 10. Revise the authority citation for Part 114 to read as follows:

**Authority:** 46 U.S.C. 2103, 3306, 3703; Pub. L. 103–206, 107 Stat. 2439; 49 U.S.C. App. 1804; Department of Homeland Security Delegation No. 0170; § 114.900 also issued under 44 U.S.C. 3507.

■ 11. In § 114.400(b), revise the definition for ''Adequate hull protection system'' to read as follows:

### § 114.400 Definitions of terms used in this subchapter.

* * * * *

(b) * * *

*Adequate hull protection system* means a method of protecting the vessel's hull from corrosion. It includes, as a minimum, either hull coatings and a cathodic protection (CP) system consisting of sacrificial anodes, or an impressed current CP system.

* * * * *

## PART 115—INSPECTION AND CERTIFICATION

■ 12. Revise the authority citation for Part 115 to read as follows:

**Authority:** 33 U.S.C. 1321(j); 46 U.S.C. 2103, 3205, 3306, 3307; 49 U.S.C. App. 1804; E.O. 11735, 38 FR 21243, 3 CFR, 1971–1975 Comp., p. 743; E.O. 12234, 45 FR 58801, 3 CFR, 1980 Comp., p. 277; Department of Homeland Security Delegation No. 0170.

■ 13. Revise § 115.620 and add the Note to § 115.620 to read as follows:

### § 115.620 Description of the Alternative Hull Examination (AHE) Program for certain passenger vessels.

The Alternative Hull Examination (AHE) Program provides you with an alternative to a drydock examination by allowing your vessel's hull to be examined while it remains afloat. If completed using only divers, this program has four steps: the application process, the preliminary examination, the pre-survey meeting, and the hull examination. If the vessel is already participating in the program or if a remotely operated vehicle (ROV) is used during the program, the preliminary exam step may be omitted. Once you complete these steps, the Officer in Charge, Marine Inspection (OCMI), will evaluate the results and accept the examination as a credit hull exam if the vessel is in satisfactory condition. If only divers are used for the underwater survey portion of the examination process, you may receive credit for a period of time such that subsequent AHEs would be conducted at intervals of twice in every five years, with no more than three years between any two AHEs. The OCMI may waive an underwater survey in accordance with § 115.655(d) provided that the interval does not exceed five years between any two underwater surveys. If an underwater ROV is used as the predominate method to examine the vessel's underwater hull plating, you may receive credit up to five years. At the end of this period, you may apply for further participation under the AHE Program.

**Note to § 115.620:** The expected hull coverage when using an ROV must be at least 80 percent.

### § 115.630 [Amended]

■ 14. In § 115.630, in paragraph (d), following the word ''cleanliness'', add the words ''(if known)''.

■ 15. In § 115.640, add paragraph (c) to read as follows:

### § 115.640 Pre-survey meeting.

* * * * *

(c) The pre-survey meeting may be conducted by teleconference, if agreed to in advance by the OCMI.

### § 115.645 [Amended]

■ 16. In § 115.645, in paragraph (a)(3), following the words ''marine inspector'', add the words ''once every five years''.

■ 17. In § 115.650, revise paragraph (a)(2) to read as follows:

### § 115.650 Alternative Hull Examination (AHE) Program options: Divers or underwater ROV.

* * * * *

(a) * * *

(2) Provide permanent hull markings, a temporary grid system of wires or cables spaced not more than 10 feet apart and tagged at one-foot intervals, or any other acoustic or electronic positioning system approved by the OCMI to identify the diver's location with respect to the hull, within one foot of accuracy;

* * * * *

■ 18. In § 115.655, revise paragraph (a) and add paragraph (d) to read as follows:

### § 115.655 Hull examination reports.

(a) If you use only divers for the underwater survey portion of the Alternative Hull Examination (AHE), you must provide the Officer in Charge, Marine Inspection (OCMI), with a written hull examination report. This report must include thickness gauging results, bearing clearances, a copy of the audio and video recordings, and any other information that will help the OCMI evaluate your vessel for a credit hull exam. The third party examiner must sign the report and confirm the validity of its contents.

* * * * *

(d) At least 60 days prior to each scheduled underwater exam, the owner may request a waiver from the OCMI if:

(1) A satisfactory exam has been completed within the last three years;

(2) The conditions during the last exam allowed at least 80 percent of the bottom surface to be viewed and recorded; and

(3) The results of the last exam indicated that an extended interval is safe and reasonable.

■ 19. In § 115.660, revise paragraphs (a) and (d)(1) to read as follows:

### § 115.660 Continued participation in the Alternative Hull Examination (AHE) Program.

(a) To continue to participate in the AHE Program, vessel operators must conduct an annual hull condition assessment. At a minimum, vessel operators must conduct an internal examination and take random hull gaugings internally during the hull condition assessment, unless waived by the Officer in Charge, Marine Inspection (OCMI). If the annual hull assessment reveals significant damage or corrosion, where temporary repairs have been made, or where other critical areas of concern have been identified, the OCMI may require an expanded examination to include an underwater hull examination using divers. If an underwater examination is required, the examination must focus on areas at higher risk of damage or corrosion and

must include a representative sampling of hull gaugings.

* * * * *

(d) * * *

(1) The owner may submit to the OCMI a plan for conducting the assessment, or a request for a waiver of this requirement, no fewer than 30 days before the scheduled assessment; and

* * * * *

## PART 175—GENERAL PROVISIONS

■ 20. Revise the authority citation for Part 175 to read as follows:

**Authority:** 46 U.S.C. 2103, 3205, 3306, 3703; Pub. L. 103–206, 107 Stat. 2439; 49 U.S.C. App. 1804; Department of Homeland Security Delegation No. 0170; § 175.900 also issued under authority of 44 U.S.C. 3507.

■ 21. In § 175.400, revise the definition for ''Adequate hull protection system'' to read as follows:

### § 175.400 Definitions of terms used in this subchapter.

* * * * *

*Adequate hull protection system* means a method of protecting the vessel's hull from corrosion. It includes, as a minimum, either hull coatings and a cathodic protection (CP) system consisting of sacrificial anodes, or an impressed current CP system.

* * * * *

## PART 176—INSPECTION AND CERTIFICATION

■ 22. Revise the authority citation for Part 176 to read as follows:

**Authority:** 33 U.S.C. 1321(j); 46 U.S.C. 2103, 3205, 3306, 3307; 49 U.S.C. App. 1804; E.O. 11735, 38 FR 21243, 3 CFR, 1971–1975 Comp., p. 743; E.O. 12234, 45 FR 58801, 3 CFR, 1980 Comp., p. 277; Department of Homeland Security Delegation No. 0170.

■ 23. Revise § 176.620 and the Note to § 176.620 to read as follows:

### § 176.620 Description of the Alternative Hull Examination (AHE) Program for certain passenger vessels.

The Alternative Hull Examination (AHE) Program provides you with an alternative to a drydock examination by allowing your vessel's hull to be examined while it remains afloat. If completed using only divers, this program has four steps: the application process, the preliminary examination, the pre-survey meeting, and the hull examination. If the vessel is already participating in the program, or if a remotely operated vehicle (ROV) is used during the program, the preliminary exam step may be omitted. Once you complete these steps, the Officer in Charge, Marine Inspection (OCMI), will evaluate the results and accept the examination as a credit hull exam if the vessel is in satisfactory condition. If only divers are used for the underwater survey portion of the examination process, you may receive credit for a period of time such that subsequent AHEs would be conducted at intervals of twice in every five years, with no more than three years between any two AHEs. The OCMI may waive an underwater survey in accordance with § 176.655(d) provided that the interval does not exceed five years between any two underwater surveys. If an underwater ROV is used as the predominate method to examine the vessel's underwater hull plating, you may receive credit up to five years. At the end of this period, you may apply for further participation under the AHE Program.

**Note to § 176.620:** The expected hull coverage when using an ROV must be at least 80 percent.

### § 176.630 [Amended]

■ 24. In § 176.630, in paragraph (d), following the word ''cleanliness'', add the words ''(if known)''.

■ 25. In § 176.640, add paragraph (c) to read as follows:

### § 176.640 Pre-survey meeting.

* * * * *

(c) The pre-survey meeting may be conducted by teleconference, if agreed to in advance by the OCMI.

### § 176.645 [Amended]

■ 26. In § 176.645, in paragraph (a)(3), following the words ''marine inspector'', add the words ''once every five years''.

■ 27. In § 176.650, revise paragraph (a)(2) to read as follows:

### § 176.650 Alternative Hull Examination Program options: Divers or underwater ROV.

* * * * *

(a) * * *

(2) Provide permanent hull markings, a temporary grid system of wires or cables spaced not more than 10 feet apart and tagged at one-foot intervals, or any other acoustic or electronic positioning system approved by the OCMI to identify the diver's location with respect to the hull, within one foot of accuracy;

* * * * *

■ 28. In § 176.655, revise paragraph (a) and add paragraph (d) to read as follows:

### § 176.655 Hull examination reports.

(a) If you use only divers for the underwater survey portion of the Alternative Hull Examination (AHE), you must provide the Officer in Charge, Marine Inspection (OCMI), with a written hull examination report. This report must include thickness gauging results, bearing clearances, a copy of the audio and video recordings, and any other information that will help the OCMI evaluate your vessel for a credit hull exam. The third party examiner must sign the report and confirm the validity of its contents.

* * * * *

(d) At least 60 days prior to each scheduled underwater exam, the owner may request a waiver from the OCMI if:

(1) A satisfactory exam has been completed within the last three years;

(2) The conditions during the last exam allowed at least 80 percent of the bottom surface to be viewed and recorded; and

(3) The results of the last exam indicated that an extended interval is safe and reasonable.

■ 29. In § 176.660, revise paragraph (a) and (d)(1) to read as follows:

### § 176.660 Continued participation in the Alternative Hull Examination (AHE) Program.

(a) To continue to participate in the AHE Program, vessel operators must conduct an annual hull condition assessment. At a minimum, vessel operators must conduct an internal examination and take random hull gaugings internally during the hull condition assessment, unless waived by the Officer in Charge, Marine Inspection (OCMI). If the annual hull assessment reveals significant damage or corrosion, where temporary repairs have been made, or where other critical areas of concern have been identified, the OCMI may require an expanded examination to include an underwater hull examination using divers. If an underwater examination is required, the examination must focus on areas at higher risk of damage or corrosion and must include a representative sampling of hull gaugings.

* * * * *

(d) * * *

(1) The owner may submit to the OCMI a plan for conducting the assessment, or a request for a waiver of this requirement, no fewer than 30 days before the scheduled assessment; and

* * * * *

Dated: June 25, 2004.

**T.H. Gilmour,**

*Rear Admiral, U.S. Coast Guard, Assistant Commandant for Marine Safety, Security and Environmental Protection.*

[FR Doc. 04–17742 Filed 8–4–04; 8:45 am]

BILLING CODE 4910–15–P

## FEDERAL COMMUNICATIONS COMMISSION

### 47 CFR Part 73

**[DA 04–2299, MB Docket No. 04–32, RM–10851]**

### Digital Television Broadcast Service; Apalachicola, FL

**AGENCY:** Federal Communications Commission.

**ACTION:** Final rule.

**SUMMARY:** The Commission, at the request of Liberty County Educational, allots DTV channel 3 to Apalachicola, Florida, as the community's first local commercial television service. *See* 69 FR 9790, March 2, 2004. DTV channel 3 can be allotted to Apalachicola in compliance with the Sections 73.623(d) and 73.625(a) at reference coordinates 29–45–05 N. and 84–52–19 W. with a power of 45 and HAAT of 305 meters. With this action, this proceeding is terminated.

**DATES:** Effective September 13, 2004.

**FOR FURTHER INFORMATION CONTACT:** Pam Blumenthal, Media Bureau, (202) 418–1600.

**SUPPLEMENTARY INFORMATION:** This is a synopsis of the Commission's Report and Order, MB Docket No. 04–32, adopted July 23, 2004, and released July 30, 2004. The full text of this document is available for public inspection and copying during regular business hours in the FCC Reference Information Center, Portals II, 445 12th Street, SW., Room CY–A257, Washington, DC. This document may also be purchased from the Commission's duplicating contractor, Best Copy and Printing, Inc., 445 12th Street, SW., Room CY–B402, Washington, DC 20554, telephone 301–816–2820, facsimile 301–816–0169, or via e-mail *joshir@erols.com.*

This document does not contain (new or modified) information collection requirements subject to the Paperwork Reduction Act of 1995 (PRA), Public Law 104–13. In addition, therefore, it does not contain any new or modified ''information collection burden for small business concerns with fewer than 25 employees,'' pursuant to the Small Business Paperwork Relief Act of 2002, Public Law 107–198, *see* 44 U.S.C. 3506(c)(4).

The Commission will send a copy of this (Report & Order, *etc.*) in a report to be sent to Congress and the General Accounting Office pursuant to the Congressional Review Act, *see* 5 U.S.C. 801(a)(1)(A).

**List of Subjects in 47 CFR Part 73**

Digital television broadcasting, Television.

■ Part 73 of Title 47 of the Code of Federal Regulations is amended as follows:

### PART 73—[AMENDED]

■ 1. The authority citation for part 73 continues to read as follows:

**Authority:** 47 U.S.C. 154, 303, 334 and 336.

**§ 73.622 [Amended]**

■ 2. Section 73.622(b), the Table of Digital Television Allotments under Florida, is amended by adding Apalachicola, DTV channel 3.

Federal Communications Commission.

**Barbara A. Kreisman,**

*Chief, Video Division, Media Bureau.*

[FR Doc. 04–17904 Filed 8–4–04; 8:45 am]

BILLING CODE 6712–01–P

## FEDERAL COMMUNICATIONS COMMISSION

### 47 CFR Part 73

**[DA 04–2300]**

### Television Broadcast Service and Digital Television Broadcast Service; El Dorado, AR

**AGENCY:** Federal Communications Commission.

**ACTION:** Final rule.

**SUMMARY:** The Commission, on its own motion, editorially amends the Table of TV Allotments and the Digital Table of Allotments to specify the conversion from an analog to a DTV channel at El Dorado, Arkansas. This amendment is necessary to reflect the change that has be authorized in response to an application filed by Arkansas Educational Television Commission, permittee of Station KETZ–TV, channel *30+, now permittee of station KEDZ–DT authorized to operate on DTV channel *30 at El Dorado. This action is taken pursuant to the Memorandum Opinion and Order on Reconsideration of the Fifth Report and Order, 13 FCC Rcd 6860 (1998).

**DATES:** Effective August 13, 2004.

**FOR FURTHER INFORMATION CONTACT:** Pam Blumenthal, Media Bureau, (202) 418–1600.

**SUPPLEMENTARY INFORMATION:** This is a synopsis of the Commission's Report and Order, adopted July 23, 2004, and released July 30, 2004. The full text of this document is available for public inspection and copying during regular business hours in the FCC Reference Information Center, Portals II, 445 12th Street, SW., Room CY–A257, Washington, DC. This document may also be purchased from the Commission's duplicating contractor, Best Copy and Printing, Inc., 445 12th Street, SW., Room CY–B402, Washington, DC 20554, telephone 301–816–2820, facsimile 301–816–0169, or via e-mail *joshir@erols.com.*

This document does not contain [new or modified] information collection requirements subject to the Paperwork Reduction Act of 1995 (PRA), Public Law 104–13. In addition, therefore, it does not contain any new or modified ''information collection burden for small business concerns with fewer than 25 employees,'' pursuant to the Small Business Paperwork Relief Act of 2002, Public Law 107–198, *see* 44 U.S.C. 3506(c)(4).

The Commission will send a copy of this [Report & Order, *etc.*] in a report to be sent to Congress and the General Accounting Office pursuant to the Congressional Review Act, *see* 5 U.S.C. 801(a)(1)(A).

**List of Subjects in 47 CFR Part 73**

Digital television broadcasting, Television.

■ Part 73 of Title 47 of the Code of Federal Regulations is amended as follows:

### PART 73—[AMENDED]

■ 1. The authority citation for Part 73 continues to read as follows:

**Authority:** 47 U.S.C. 154, 303, 334 and 336.

**§ 73.606 [Amended]**

■ 2. Section 73.606(b), the Table of Television Allotments under Arkansas, is amended by removing TV channel *30+ at El Dorado.

**§ 73.622 [Amended]**

■ 3. Section 73.622(b), the Table of Digital Television Allotments under Arkansas, is amended by adding DTV channel *30 at El Dorado.

Federal Communications Commission.

**Barbara A. Kreisman,**

*Chief, Video Division, Media Bureau.*

[FR Doc. 04–17905 Filed 8–4–04; 8:45 am]

BILLING CODE 6712–01–P

**DEPARTMENT OF TRANSPORTATION**

**Federal Motor Carrier Safety Administration**

**49 CFR Part 375**

**[Docket No. FMCSA–97–2979]**

**RIN 2126–AA32**

## Transportation of Household Goods; Consumer Protection Regulations; Corrections

**AGENCY:** Federal Motor Carrier Safety Administration, DOT.

**ACTION:** Correcting amendments.

**SUMMARY:** The Federal Motor Carrier Safety Administration (FMCSA) published in the **Federal Register** of June 11, 2003, an interim final rule revising the requirements governing the interstate transportation of household goods (68 FR 35064). On March 5, 2004, at 69 FR 10570, we issued technical amendments to the interim final rule and its appendix, the consumer pamphlet *Your Rights and Responsibilities When You Move.* On April 2, 2004, we issued further technical amendments to the rule and appendix, and established a new compliance date of May 5, 2004, for the rule (69 FR 17313). In subpart E of the amended rule appendix, two paragraphs were not properly updated to reflect the technical changes relating to orders for service and bills of lading. In addition, four sections of the rule appendix published on June 11, 2003, and March 5, 2004, contained an erroneous statutory citation for the provision under which a person may seek judicial redress for alleged loss of or damage to household goods by a carrier. Finally, the introductory sentence to a list of requirements in subpart D of the appendix misstated the number of elements in the list. This document corrects the interim final rule by revising these sections of the appendix.

**DATES:** Effective on August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Mr. James Keenan, Office of Commercial Enforcement, (202) 385–2400, Federal Motor Carrier Safety Administration, Suite 600, 400 Virginia Avenue, SW., Washington, DC 20024.

**SUPPLEMENTARY INFORMATION:** On June 11, 2003, FMCSA published an interim final rule revising the requirements governing the interstate transportation of household goods (68 FR 35064). On March 5, 2004, we issued technical amendments to the interim final rule and its appendix—Appendix A to Part 375, the consumer pamphlet *Your Rights and Responsibilities When You Move* (69 FR 10570). On April 2, 2004, we issued further technical amendments to the rule and appendix, and established a new compliance date of May 5, 2004, for the rule (69 FR 17313).

In May 2004, attorneys for both Atlas World Group, Inc. and Wheaton Van Lines, Inc. contacted us concerning an incorrect statutory citation in four sections of Appendix A to Part 375. These sections of the consumer pamphlet advise individual shippers of their right to seek restitution for loss of or damage to their household goods by bringing a civil action against the mover. Ms. Marian Weilert Sauvey, General Counsel for Atlas World Group, informed us of the incorrect citation in electronic mail correspondence of May 6, 2004; Mr. James P. Reichert, General Counsel for Wheaton Van Lines, Inc., noted the error in a letter of May 10, 2004.

As Ms. Sauvey and Mr. Reichert stated, it is 49 U.S.C 14706, not section 14704, that establishes carrier liability for loss and damage and sets forth the minimum period for bringing a civil action against a carrier. Section 14704, in contrast, entitles a person to file a civil action against a carrier to enforce an order of the U.S. Department of Transportation or the Surface Transportation Board, or to seek redress for certain regulatory violations. We have corrected Appendix A to Part 375 by replacing each of the four occurrences of ''49 U.S.C. 14704'' with ''49 U.S.C. 14706.'' In the last of these revisions (the third paragraph of the section *Do I Have a Right To File a Claim To Recover Money for Property My Mover Lost or Damaged?* under subpart H of the appendix), we also made minor editorial changes to the last two sentences of the paragraph and combined the sentences. The revised sentence reads: ''You may also obtain the name of a process agent via the Internet by going to *http://www.fmcsa.dot.gov* and then clicking on Licensing and Insurance (L&I) section.''

In his letter, Mr. Reichert also brought to our attention certain language in subpart E of Appendix A that is not fully consistent with 49 CFR 375.501(h) and 375.505(e), as amended on March 5, 2004. The amended regulations make clear that household goods carriers have the option of placing the Surface Transportation Board's required released rates valuation statement, and any charges for optional valuation coverage, on either the order for service or the bill of lading. In contrast, subparagraph (10) of the section *Must My Mover Write Up an Order for Service?* and subparagraph (12) of *Must My Mover Write Up a Bill of Lading?* imply that the carrier must include the released rates valuation statement and any charges for valuation coverage on the order for service as well as on the bill of lading. We have corrected subparagraph (10) of *Must My Mover Write Up an Order for Service?* by adding to the first sentence an introductory clause clarifying that the order for service must include the released rates valuation statement and any valuation coverage charges *only* if the mover has not provided them on the bill of lading. Conversely, a new introductory clause in subparagraph (12) of *Must My Mover Write Up a Bill of Lading?* makes it clear that the bill of lading must include the released rates valuation statement and any valuation coverage charges *only* if these were not provided in the order for service. These corrections ensure that the information provided to consumers on the requirement for the released rates valuation statement is consistent with amended §§ 375.501(h) and 375.505(e).

Finally, we have corrected an error in the introductory sentence to a list of requirements in the section *Non-Binding Estimates* under subpart D of the appendix. The sentence described the list as containing 9 elements, when in fact it includes 10.

Section 375.213 requires movers to furnish the information in the rule appendix to prospective customers as the consumer pamphlet *Your Rights and Responsibilities When You Move.* For movers with Internet access, printing copies of the amended rule appendix need not be burdensome. The corrections have been incorporated in the electronic version Appendix A—*Your Rights and Responsibilities When You Move* posted on FMCSA's Web site at *http://www.fmcsa.dot.gov/,* where it can be downloaded and printed.

### List of Subjects in 49 CFR Part 375

Advertising, Arbitration, Consumer protection, Freight, Highways and roads, Insurance, Motor carriers, Moving of household goods, Reporting and recordkeeping requirements.

■ Accordingly, 49 CFR part 375 is corrected by making the following correcting amendments:

## PART 375—TRANSPORTATION OF HOUSEHOLD GOODS IN INTERSTATE COMMERCE; CONSUMER PROTECTION REGULATIONS

■ 1. The authority citation for part 375 continues to read as follows:

**Authority:** 5 U.S.C. 553; 49 U.S.C. 13301, 13704, 13707, 14104, 14706; and 49 CFR 1.73.

■ 2. In Appendix A to Part 375, amend subpart B by revising the third paragraph of the section *How Must My Mover Handle Complaints and Inquiries?* and revising the first paragraph of the section *Must My Mover Have an Arbitration Program?* to read as follows:

**Appendix A to Part 375—Your Rights and Responsibilities When You Move**

* * * * *

## Subpart B—Before Requesting Services From Any Mover

* * * * *

**How Must My Mover Handle Complaints and Inquiries?**

* * * * *

Interstate movers are also required to offer neutral arbitration as a means of resolving consumer loss or damage disputes involving loss of or damage to household goods. Your mover is required to provide you with information regarding its arbitration program. You have the right to pursue court action under 49 U.S.C. 14706 to seek judicial redress directly rather than participate in your mover's arbitration program.

* * * * *

**Must My Mover Have an Arbitration Program?**

Your mover must have an arbitration program for your use in resolving disputes concerning loss or damage to your household goods. You have the right not to participate in the arbitration program. You may pursue court action under 49 U.S.C. 14706 to seek judicial remedies directly. Your mover must establish and maintain an arbitration program with the following 11 minimum elements:

* * * * *

■ 3. In Appendix A to Part 375, amend subpart D by revising the fifth paragraph of the section *Non-Binding Estimates* to read as follows:

* * * * *

## Subpart D—Estimating Charges

* * * * *

**How Must My Mover Estimate Charges Under the Regulations?**

* * * * *

*Non-Binding Estimates*

* * * * *

Other requirements of non-binding estimates include the following 10 elements:

* * * * *

■ 4. In Appendix A to Part 375, amend subpart E by revising paragraph (10) of the section *Must My Mover Write Up an Order for Service?* and revising paragraph (12) of the section *Must My Mover Write Up a Bill of Lading?* to read as follows:

* * * * *

## Subpart E—Pickup of My Shipment of Household Goods

**Must My Mover Write Up an Order for Service?**

* * * * *

(10) If not provided in the bill of lading, the Surface Transportation Board's required released rates valuation statement, and the charges, if any, for optional valuation coverage. The STB's required released rates may be increased annually by your mover based on the U.S. Department of Commerce's Cost of Living Adjustment.

* * * * *

**Must My Mover Write Up a Bill of Lading?**

* * * * *

(12) If not provided in the order for service, the Surface Transportation Board's required released rates valuation statement, and the charges, if any, for optional valuation coverage. The Board's required released rates may be increased annually by your mover based on the U.S. Department of Commerce's Cost of Living Adjustment.

* * * * *

■ 5. In Appendix A to Part 375, amend subpart F by revising the eighth paragraph of the section *Must My Mover Transport the Shipment in a Timely Manner?* to read as follows:

* * * * *

## Subpart F—Transportation of My Shipment

**Must My Mover Transport the Shipment in a Timely Manner?**

* * * * *

If your mover fails to pick up and deliver your shipment on the date entered on the bill of lading and you have expenses you otherwise would not have had, you may be able to recover those expenses from your mover. This is what is called an inconvenience or delay claim. Should your mover refuse to honor such a claim and you continue to believe you are entitled to be paid damages, you may take your mover to court under 49 U.S.C. 14706. *The Federal Motor Carrier Safety Administration (FMCSA) has no authority to order your mover to pay such claims.*

* * * * *

■ 6. In Appendix A to Part 375, amend subpart H by revising the third paragraph of *Do I Have a Right To File a Claim To Recover Money for Property My Mover Lost or Damaged?* to read as follows:

* * * * *

## Subpart H—Collection of Charges

* * * * *

**Do I Have a Right To File a Claim To Recover Money for Property My Mover Lost or Damaged?**

* * * * *

While the Federal Government maintains regulations governing the processing of loss and damage claims (49 CFR part 370), it cannot resolve those claims. If you cannot settle a claim with the mover, you may file a civil action to recover your claim in court under 49 U.S.C. 14706. You may obtain the name and address of the mover's agent for service of legal process in your state by contacting the Federal Motor Carrier Safety Administration. You may also obtain the name of a process agent via the Internet by going to *http://www.fmcsa.dot.gov* and then clicking on Licensing and Insurance (L&I) section.

* * * * *

Issued on: July 30, 2004.

**Annette M. Sandberg,**

*Administrator.*

[FR Doc. 04–17931 Filed 8–4–04; 8:45 am]

BILLING CODE 4910–EX–P

# Proposed Rules

Federal Register
Vol. 69, No. 150
Thursday, August 5, 2004

This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rule making prior to the adoption of the final rules.

## DEPARTMENT OF TRANSPORTATION

### Federal Aviation Administration

### 14 CFR Part 39

**[Docket No. FAA–2004–18774; Directorate Identifier 2003–NM–212–AD]**

**RIN 2120–AA64**

## Airworthiness Directives; McDonnell Douglas Model DC–9–10, –20, –30, –40, and –50 Series Airplanes; and Model DC–9–81 (MD–81) and DC–9–82 (MD–82) Airplanes

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Notice of proposed rulemaking (NPRM).

**SUMMARY:** The FAA proposes to adopt a new airworthiness directive (AD) for certain McDonnell Douglas Model DC–9–10, –20, –30, –40, and –50 series airplanes; and Model DC–9–81 (MD–81) and DC–9–82 (MD–82) airplanes. This proposed AD would require repetitive detailed inspections of the upper and lower caps of the rear spar of the left and right wings, and corrective action if necessary. This proposed AD also provides an optional modification that would end the repetitive inspections. This proposed AD is prompted by reports of fatigue cracks in the upper and lower caps of the wing spar. We are proposing this AD to detect and correct fatigue cracking in the upper and lower caps of the rear spar of the left and right wings, which could result in structural failure of the wings.

**DATES:** We must receive comments on this proposed AD by September 20, 2004.

**ADDRESSES:** Use one of the following addresses to submit comments on this proposed AD.

- DOT Docket web site: Go to *http://dms.dot.gov* and follow the instructions for sending your comments electronically.
- Government-wide rulemaking web site: Go to *http://www.regulations.gov* and follow the instructions for sending your comments electronically.
- Mail: Docket Management Facility, U.S. Department of Transportation, 400 Seventh Street SW., Nassif Building, room PL–401, Washington, DC 20590.
- *By fax:* (202) 493–2251.
- Hand Delivery: room PL–401 on the plaza level of the Nassif Building, 400 Seventh Street SW., Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.

For the service information identified in this proposed AD, contact Boeing Commercial Airplanes, Long Beach Division, 3855 Lakewood Boulevard, Long Beach, California 90846, Attention: Data and Service Management, Dept. C1–L5A (D800–0024).

You can examine the contents of this AD docket on the Internet at *http://dms.dot.gov,* or at the Docket Management Facility, U.S. Department of Transportation, 400 Seventh Street SW., room PL–401, on the plaza level of the Nassif Building, Washington, DC.

**FOR FURTHER INFORMATION CONTACT:** Wahib Mina, Aerospace Engineer, Airframe Branch, ANM–120L, FAA, Los Angeles Aircraft Certification Office, 3960 Paramount Boulevard, Lakewood, California 90712–4137; telephone (562) 627–5324; fax (562) 627–5210.

**SUPPLEMENTARY INFORMATION:**

### Docket Management System (DMS)

The FAA has implemented new procedures for maintaining AD dockets electronically. As of May 17, 2004, new AD actions are posted on DMS and assigned a docket number. We track each action and assign a corresponding directorate identifier. The DMS AD docket number is in the form ''Docket No. FAA–2004–99999.'' The Transport Airplane Directorate identifier is in the form ''Directorate Identifier 2004-NM-999-AD.'' Each DMS AD docket also lists the directorate identifier (''Old Docket Number'') as a cross-reference for searching purposes.

### Comments Invited

We invite you to submit any written relevant data, views, or arguments regarding this proposed AD. Send your comments to an address listed under **ADDRESSES.** Include ''Docket No. FAA–2004–18774; Directorate Identifier 2003-NM-212-AD'' in the subject line of your comments. We specifically invite comments on the overall regulatory, economic, environmental, and energy aspects of the proposed AD. We will consider all comments submitted by the closing date and may amend the proposed AD in light of those comments.

We will post all comments we receive, without change, to *http://dms.dot.gov*, including any personal information you provide. We will also post a report summarizing each substantive verbal contact with FAA personnel concerning this proposed AD. Using the search function of that website, anyone can find and read the comments in any of our dockets, including the name of the individual who sent the comment (or signed the comment on behalf of an association, business, labor union, etc.). You may review DOT's complete Privacy Act Statement in the **Federal Register** published on April 11, 2000 (65 FR 19477–78), or you may visit *http://dms.dot.gov*.

We are reviewing the writing style we currently use in regulatory documents. We are interested in your comments on whether the style of this document is clear, and your suggestions to improve the clarity of our communications that affect you. You can get more information about plain language at *http://www.faa.gov/language* and *http://www.plainlanguage.gov*.

### Examining the Docket

You can examine the AD docket in person at the Docket Management Facility office between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The Docket Management Facility office (telephone (800) 647–5227) is located on the plaza level of the Nassif Building at the DOT street address stated in the **ADDRESSES** section. Comments will be available in the AD docket shortly after the DMS receives them.

### Discussion

We have received a report of cracks found in the lower cap of the rear spars of the left and right wing near station Xrs=267.000 during fatigue testing of fuselage number 3 on a McDonnell Douglas DC–9–14 airplane. Fuselage number 3 had accumulated 42,900 total flight hours and 66,504 total flight cycles before being removed from service for fatigue testing. An operator of McDonnell Douglas DC–9–30 series

airplanes also reported cracks found in the upper cap of the rear spar. In addition, several operators of McDonnell Douglas Model DC–9–81 (MD–81) and DC–9–82 (MD–82) airplanes reported cracks found in the upper and lower cap of the rear spar. Also, according to the manufacturer's analysis, for McDonnell Douglas Model DC–9–81 (MD–81) and DC–9–82 (MD–82) airplanes, fatigue cracking in the upper and lower caps of the rear spar of the wings at station Xrs=267.000 may initiate at about 15,000 total landing cycles as a result of loads introduced by the flap hinge fitting. Fatigue cracking in the upper and lower caps of the rear spar of the left and right wings, if not detected and corrected, could result in structural failure of the wings.

The subject area on certain Model DC–9–20, –40, and –50 series airplanes is almost identical to that on the affected Model DC–9–10 and –30 series airplanes and Model DC–9–81 (MD–81) and DC–9–82 (MD–82) airplanes. Therefore, those Model DC–9–20, –40, and –50 series airplanes may be subject to the unsafe condition revealed on the DC–9–10 and –30 series airplanes and Model DC–9–81 (MD–81) and DC–9–82 (MD–82) airplanes.

## Relevant Service Information

We have reviewed McDonnell Douglas DC–9 Service Bulletin 57–179, Revision 1, dated December 21, 1994. The service bulletin describes procedures for initial and repetitive detailed inspections of the upper and lower caps of the rear spar of the left and right wings at station Xrs=267.000 for cracks, and corrective action if necessary. The corrective action includes doing the permanent repair modification or the temporary repair modification of the upper and lower caps of the rear spar. The permanent repair modification extends the compliance time for the next repetitive detailed inspection. The temporary repair modification includes doing repetitive detailed, eddy current, and ultrasonic inspections for any crack progression or any new crack, and doing the permanent repair modification if any crack progression or any new crack is found.

The service bulletin also specifies that doing the crack preventative modification described in other service bulletins eliminates the need for the repetitive inspections.

McDonnell Douglas DC–9 Service Bulletin 57–160, dated December 7, 1987; MD–80 Service Bulletin 57–177, Revision 1, dated June 12, 1989; and MD–80 Service Bulletin 57–178, Revision 1, dated June 12, 1990; describe procedures for the crack preventative modification at station Xrs=267.000. The procedures include replacing/modifying the flap hinge fitting, brace fitting, and rear spar area, as applicable.

We have determined that doing the actions specified in McDonnell Douglas DC–9 Service Bulletin 57–179, Revision 1, dated December 21, 1994, will adequately address the unsafe condition.

## FAA's Determination and Requirements of the Proposed AD

We have evaluated all pertinent information and identified an unsafe condition that is likely to exist or develop on other airplanes of this same type design. Therefore, we are proposing this AD, which would require repetitive detailed inspections of the upper and lower caps of the rear spar of the left and right wings, and corrective action if necessary. The proposed AD would require you to use McDonnell Douglas DC–9 Service Bulletin 57–179, Revision 1, dated December 21, 1994, described previously to do these actions, except as discussed under ''Differences Between the Proposed AD and the Service Bulletin.''

## Differences Between the Proposed AD and the Service Bulletins

Operators should note that McDonnell Douglas DC–9 Service Bulletin 57–179, Revision 1, dated December 21, 1994, specifies that, if any crack progression or any new crack is found after the temporary repair, the permanent repair modification must be done within 3,000 landings. However, this proposed AD would require that if any crack progression or new crack is detected, repair must be done before further flight per a method approved by the FAA. This difference has been coordinated with the manufacturer.

In addition, McDonnell Douglas DC–9 Service Bulletin 57–160, dated December 7, 1987; MD-80 Service Bulletin 57–177, Revision 1, dated June 12, 1989; and MD-80 Service Bulletin 57–178, Revision 1, dated June 12, 1990; specify that operators may contact the manufacturer for specific modification information. However, this proposed AD would require operators to repair those conditions per a method approved by the FAA.

## Costs of Compliance

This proposed AD would affect about 583 airplanes of U.S. registry and 1,163 airplanes worldwide. The proposed inspection would take about 4 work hours per airplane, at an average labor rate of $65 per work hour. Based on these figures, the estimated cost of the proposed AD for U.S. operators is $151,580 or $260 per airplane, per inspection cycle.

## Regulatory Findings

We have determined that this proposed AD would not have federalism implications under Executive Order 13132. This proposed AD would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government.

For the reasons discussed above, I certify that the proposed regulation:

1. Is not a ''significant regulatory action'' under Executive Order 12866;

2. Is not a ''significant rule'' under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and

3. Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

We prepared a regulatory evaluation of the estimated costs to comply with this proposed AD. See the **ADDRESSES** section for a location to examine the regulatory evaluation.

## List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

## The Proposed Amendment

Accordingly, under the authority delegated to me by the Administrator, the FAA proposes to amend 14 CFR part 39 as follows:

## PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

**Authority:** 49 U.S.C. 106(g), 40113, 44701.

### § 39.13 [Amended]

2. The FAA amends § 39.13 by adding the following new airworthiness directive (AD):

**McDonnell Douglas:** Docket No. FAA-2004–18774; Directorate Identifier 2003-NM-212-AD.

**Comments Due Date**

(a) The Federal Aviation Administration (FAA) must receive comments on this AD action by September 20, 2004.

**Affected ADs**

(b) None.

**Applicability**

(c) This AD applies to the models listed in Table 1 of this AD, certificated in any category; as listed in McDonnell Douglas DC–

9 Service Bulletin 57–179, Revision 1, dated December 21, 1994.

---

Model DC–9–11, DC–9–12, DC–9–13, DC–9–14, DC–9–15, and DC–9–15F airplanes.
Model DC–9–21 airplanes.
Model DC–9–31, DC–9–32, DC–9–32 (VC–9C), DC–9–32F, DC–9–33F, DC–9–34, DC–9–34F, and DC–9–32F (C–9A, C–9B) airplanes.
Model DC–9–41 airplanes.
Model DC–9–51 airplanes.
Model DC–9–81 (MD–81), and DC–9–82 (MD–82) airplanes.

---

**Unsafe Condition**

(d) This AD was prompted by reports of fatigue cracks in the upper and lower caps of the wing spar. We are issuing this AD to detect and correct fatigue cracking in the upper and lower caps of the rear spar of the left and right wings, which could result in structural failure of the wings.

**Compliance**

(e) You are responsible for having the actions required by this AD performed within the compliance times specified, unless the actions have already been done.

**Service Bulletin Reference**

(f) Unless otherwise stated, the term ''service bulletin,'' as used in this AD, means McDonnell Douglas DC–9 Service Bulletin 57–179, Revision 1, dated December 21, 1994.

**Inspection of the Upper and Lower Caps of the Rear Spar**

(g) At the time specified in paragraph (g)(1) or (g)(2) of this AD, as applicable, do a detailed inspection of the upper and lower caps of the rear spar of the left and right wings at station Xrs=267.000 for cracks, in accordance with the Accomplishment Instructions of the service bulletin.

(1) For Group 1 airplanes identified in paragraph 1.A.(1) of the service bulletin: Inspect prior to the accumulation of 50,000 total landings or within 3,000 landings after the effective date of this AD, whichever occurs later.

(2) For Group 2 airplanes identified in paragraph 1.A.(1) of the service bulletin: Inspect prior to the accumulation of 20,000 total landings or within 3,000 landings after the effective date of this AD, whichever occurs later.

**Note 1:** For the purposes of this AD, a detailed inspection is ''An intensive visual examination of a specific structural area, system, installation, or assembly to detect damage, failure, or irregularity. Available lighting is normally supplemented with a direct source of good lighting at intensity deemed appropriate by the inspector. Inspection aids such as mirror, magnifying lenses, etc., may be used. Surface cleaning and elaborate access procedures may be required.''

**No Crack Detected: Repetitive Inspections**

(h) If no crack is detected during any detailed inspection required by paragraph (g) of this AD, repeat the inspection thereafter at intervals not to exceed 3,000 landings until the crack preventative modification specified in paragraph (m) of this AD is done.

**Any Crack Detected: Corrective Actions**

(i) If any crack is detected during any detailed inspection required by paragraph (g) of this AD, before further flight, do the actions in paragraph (j) of this AD, except as provided by paragraph (k) of this AD.

**Permanent Repair Modification**

(j) If required by paragraph (i) of this AD, do the permanent repair modification of the upper and lower caps of the rear spar; and at the times specified in paragraph (j)(1) or (j)(2) of this AD, as applicable, do the detailed inspection specified in paragraph (g) of this AD. Do the actions in accordance with the Accomplishment Instructions of the service bulletin.

(1) For Group 1 airplanes identified in paragraph 1.A.(1) of the service bulletin: Within 53,000 landings after accomplishing the permanent repair modification, do the detailed inspection. Repeat the detailed inspection thereafter at intervals not to exceed 3,000 landings until the crack preventative modification specified in paragraph (m) of this AD is done.

(2) For Group 2 airplanes identified in paragraph 1.A.(1) of the service bulletin: Within 33,000 landings after accomplishing the permanent repair modification, do the detailed inspection. Repeat the detailed inspection thereafter at intervals not to exceed 3,000 landings until the crack preventative modification specified in paragraph (m) of this AD is done.

**Optional Temporary Repair Modification for Certain Cracking**

(k) In lieu of the actions specified in paragraph (j) of this AD, for any crack that does not exceed the limits specified in the Accomplishment Instructions of the service bulletin: Before further flight, do the temporary repair modification of the upper and lower caps of the rear spar; and at the times specified in paragraphs (k)(1) and (k)(2) of this AD, do the detailed inspections specified in paragraphs (k)(1) and (k)(2) of this AD. Do the actions in accordance with the Accomplishment Instructions of the service bulletin.

(1) Within 1,500 landings after accomplishing the temporary repair modification, do a detailed inspection of the temporary repair for any new crack or crack progression and repeat the inspection thereafter at intervals not to exceed 1,500 landings until the permanent repair modification specified in paragraph (j) of this AD is done.

(2) Within 3,000 landings after accomplishing the temporary repair modification, do detailed, eddy current, and ultrasonic inspections of the temporary repair for any new crack or crack progression and repeat the inspections thereafter at intervals not to exceed 3,000 landings until the permanent repair modification specified in paragraph (j) of this AD is done.

(l) If any crack progression or new crack is detected during any inspection required by paragraph (k)(1) or (k)(2) of this AD, before further flight, repair per a method approved by the Manager, Los Angeles Aircraft Certification Office (ACO), FAA. For a repair method to be approved by the Manager, Los Angeles ACO, as required by this paragraph, the Manager's approval letter must specifically refer to this AD.

**Optional Terminating Crack Preventative Modification**

(m) Except as provided by paragraph (n) of this AD, accomplishment of the crack preventative modification in accordance with the applicable service bulletin listed in Table 2 of this AD ends the repetitive inspections required by this AD. If the applicable service bulletin specifies to contact the manufacturer for specific modification information: Repair per a method approved by the Manager, Los Angeles Aircraft Certification Office (ACO), FAA. For a repair method to be approved by the Manager, Los Angeles ACO, as required by this paragraph, the Manager's approval letter must specifically refer to this AD.

TABLE 2.—SERVICE BULLETINS FOR CRACK PREVENTATIVE MODIFICATION

| For Airplane Model— | Use McDonnell Douglas Service Bulletin— |
|---|---|
| Model DC–9–10, –20, –30, –40, and –50 series airplanes; and Model DC–9–81 (MD–81) and DC–9–82 (MD–82) airplanes. | DC–9 Service Bulletin 57–160, dated December 7, 1987. |
| Model DC–9–81 (MD–81),DC–9–82 (MD–82), and DC–9–83 (MD–83) airplanes. | MD–80 Service Bulletin 57–177, Revision 1, dated June 12, 1989. |
| Model DC–9–82 (MD–82), airplanes ..... | MD–80, Service Bulletin 57–178, Revision 1, dated June 12, 1990. |

(n) For airplanes on which the temporary repair modification specified in paragraph (k) of this AD has been done: Before or concurrently with the crack preventative modification specified in paragraph (m) of this AD, do the permanent repair modification specified in paragraph (j) of this AD.

**Alternative Methods of Compliance (AMOCs)**

(o) The Manager, Los Angeles ACO, FAA, has the authority to approve AMOCs for this AD, if requested in accordance with the procedures found in 14 CFR 39.19.

Issued in Renton, Washington, on July 29, 2004.

**Ali Bahrami,**

*Manager, Transport Airplane Directorate, Aircraft Certification Service.*

[FR Doc. 04–17859 Filed 8–4–04; 8:45 am]

BILLING CODE 4910–13–P

---

## DEPARTMENT OF TRANSPORTATION

## Federal Aviation Administration

## 14 CFR Part 39

**[Docket No. FAA–2004–18773; Directorate Identifier 2002–NM–312–AD]**

**RIN 2120–AA64**

## Airworthiness Directives; Airbus Model A320 Series Airplanes

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Notice of proposed rulemaking (NPRM).

**SUMMARY:** The FAA proposes to supersede an existing airworthiness directive (AD) for certain Airbus Model A320 series airplanes. That AD currently requires repetitive inspections to detect fatigue cracking in certain areas of the fuselage, and corrective action if necessary. That AD also provides for an optional terminating action for the repetitive inspections. This proposed AD would reduce the compliance threshold and repetitive intervals for the inspections required by the existing AD, and would reduce the allowable time for the optional terminating action. This proposed AD is prompted by a full-scale fatigue survey on the Model A320 fleet. We are proposing this AD to detect and correct fatigue cracking of the fuselage, which could result in reduced structural integrity of the airplane.

**DATES:** We must receive comments on this proposed AD by September 7, 2004.

**ADDRESSES:** Use one of the following addresses to submit comments on this proposed AD.

- DOT Docket Web site: Go to *http://dms.dot.gov* and follow the instructions for sending your comments electronically.
- Government-wide rulemaking Web site: Go to *http://www.regulations.gov* and follow the instructions for sending your comments electronically.
- Mail: Docket Management Facility; U.S. Department of Transportation, 400 Seventh Street SW., Nassif Building, room PL–401, Washington, DC 20590.
- *Fax:* (202) 493–2251.
- Hand Delivery: room PL–401 on the plaza level of the Nassif Building, 400 Seventh Street SW., Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.

You can get the service information identified in this proposed AD from Airbus, 1 Rond Point Maurice Bellonte, 31707 Blagnac Cedex, France.

You may examine the contents of this AD docket on the Internet at *http://dms.dot.gov*, or at the Docket Management Facility, U.S. Department of Transportation, 400 Seventh Street SW., room PL–401, on the plaza level of the Nassif Building, Washington, DC.

**FOR FURTHER INFORMATION CONTACT:** Dan Rodina, Aerospace Engineer, International Branch, ANM–116, FAA, Transport Airplane Directorate, 1601 Lind Avenue SW., Renton, Washington 98055–4056; telephone (425) 227–2125; fax (425) 227–1149.

**SUPPLEMENTARY INFORMATION:**

### Docket Management System (DMS)

The FAA has implemented new procedures for maintaining AD dockets electronically. As of May 17, 2004, new AD actions are posted on DMS and assigned a docket number. We track each action and assign a corresponding directorate identifier. The DMS AD docket number is in the form ''Docket No. FAA–2004–99999.'' The Transport Airplane Directorate identifier is in the form ''Directorate Identifier 2004–NM–999–AD.'' Each DMS AD docket also lists the directorate identifier (''Old Docket Number'') as a cross-reference for searching purposes.

### Comments Invited

We invite you to submit any written relevant data, views, or arguments regarding this proposed AD. Send your comments to an address listed under **ADDRESSES.** Include ''Docket No. FAA–2004–18773; Directorate Identifier 2002–NM–312–AD'' at the beginning of your comments. We specifically invite comments on the overall regulatory, economic, environmental, and energy aspects of the proposed AD. We will consider all comments received by the closing date and may amend the proposed AD in light of those comments.

We will post all comments we receive, without change, to *http://dms.dot.gov*, including any personal information you provide. We will also post a report summarizing each substantive verbal contact with FAA personnel concerning this proposed AD. Using the search function of our docket Web site, anyone can find and read the comments in any of our dockets, including the name of the individual who sent the comment (or signed the comment on behalf of an association, business, labor union, etc.). You may review the DOT's complete Privacy Act Statement in the **Federal Register** published on April 11, 2000 (65 FR 19477–78), or you may visit *http://dms.dot.gov*.

We are reviewing the writing style we currently use in regulatory documents. We are interested in your comments on whether the style of this document is clear, and your suggestions to improve the clarity of our communications that affect you. You can get more information about plain language at *http://www.faa.gov/language* and *http://www.plainlanguage.gov*.

### Examining the Docket

You may examine the AD docket in person at the Docket Management Facility office between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The Docket Management Facility office (telephone (800) 647–5227) is located on the plaza level of the Nassif Building at the DOT street address stated in the **ADDRESSES** section. Comments will be available in the AD docket shortly after the DMS receives them.

### Discussion

On December 30, 1998, we issued AD 99–01–19, amendment 39–10987 (64 FR 1114, January 11, 1999), for certain Airbus Model A320 series airplanes. That AD requires repetitive inspections to detect fatigue cracking in certain areas of the fuselage, and corrective action if necessary. That AD also provides for an optional terminating action for the repetitive inspections. That AD was prompted by issuance of mandatory continuing airworthiness information by a foreign civil airworthiness authority. We issued that AD to detect and correct fatigue cracking of the fuselage, which could result in reduced structural integrity of the airplane.

### Actions Since Existing AD Was Issued

Since we issued AD 99–01–19, the Direction Générale de l'Aviation Civile (DGAC), which is the airworthiness authority for France, advises that a full-scale fatigue survey on the Model A320 fleet revealed that the weight of fuel at landing and the average flight duration are higher than those defined for the analysis of fatigue-related tasks. This has led to an adjustment of the fatigue mission for the A320 fleet, in that the

DGAC has required shorter compliance thresholds and repetitive intervals for accomplishment of the inspections for fatigue cracking than those required by AD 99–01–19. Fatigue-related cracking in certain areas of the fuselage could result in reduced structural integrity of the airplane.

**Relevant Service Information**

Airbus has issued Service Bulletin A320–53–1032, Revision 02, dated December 5, 2001. The procedures specified in Revision 02 are essentially the same as those in Revision 01 of the service bulletin, which was referenced in the existing AD for accomplishment of the inspections and corrective action. However, Revision 02 has a change that recommends a reduction in the compliance threshold from 30,000 total flight cycles to 24,800 total flight cycles and in the repetitive intervals from 6,000 flight cycles to 4,900 flight cycles. Airbus also has issued Service Bulletin A320–53–1031, Revision 02, dated December 5, 2001. The procedures in Revision 02 are essentially the same as those in the original issue of the service bulletin, which was referenced in the existing AD for accomplishment of the optional terminating action. However, Revision 02 recommends a reduction in the compliance threshold from 20,000 flight cycles to 16,000 flight cycles.

We have determined that accomplishment of the actions specified in the revised service information will adequately address the unsafe condition. The DGAC mandated the service information and issued French airworthiness directive 2002–259(B), dated May 15, 2002, to ensure the continued airworthiness of these airplanes in France.

**FAA's Determination and Requirements of the Proposed AD**

This airplane model is manufactured in France and is type certificated for operation in the United States under the provisions of section 21.29 of the Federal Aviation Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. Pursuant to this bilateral airworthiness agreement, the DGAC has kept us informed of the situation described above. We have examined the DGACs findings, evaluated all pertinent information, and determined that AD action is necessary for airplanes of this type design that are certificated for operation in the United States.

Therefore, we are proposing this AD, to supersede AD 99–01–19 to continue to require repetitive inspections to detect fatigue cracking in certain areas of the fuselage, and corrective action if necessary. This proposed AD would also continue to provide for an optional terminating action for the repetitive inspections. This proposed AD would reduce the compliance threshold and repetitive intervals for the inspections required by the existing AD, and would reduce the allowable time for the optional terminating action. The proposed AD would require using the revised service information described previously to do these actions.

**Changes to Existing AD**

The number of affected airplanes has changed since we issued the existing AD; therefore, we have changed the Cost Impact section in this proposed AD to reflect the correct number of airplanes.

We have changed all references to a ''visual inspection'' in the existing AD to a ''detailed inspection'' in this action. Additionally, we have added a note to define that inspection.

**Revised Labor Rate**

We have reviewed the figures we have used over the past several years to calculate AD costs to operators. To account for various inflationary costs in the airline industry, we find it necessary to increase the labor rate used in these calculations from $60 per work hour to $65 per work hour. The cost information, below, reflects this increase in the hourly labor rate.

**Costs of Compliance**

This proposed AD would affect about 269 airplanes of U.S. registry.

The inspection that is required by AD 99–01–19 and retained in this proposed AD takes about 19 work hours per airplane, at an average labor rate of $65 per work hour. Based on these figures, the estimated cost of the currently required inspection is $1,235 per airplane.

The optional terminating action specified in Airbus Service Bulletin A320–53–1031, if done, would take about 1 work hour per fastener hole, at an average labor rate of $65 per work hour. The cost of required parts would be about $4,219 (for one modification kit). Based on these figures, the cost of the optional terminating action would be a minimum of $4,284 per airplane.

**Regulatory Findings**

We have determined that this proposed AD would not have federalism implications under Executive Order 13132. This proposed AD would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government.

For the reasons discussed above, I certify that the proposed regulation:

1. Is not a ''significant regulatory action'' under Executive Order 12866;

2. Is not a ''significant rule'' under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and

3. Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

We prepared a regulatory evaluation of the estimated costs to comply with this proposed AD. See the **ADDRESSES** section for a location to examine the regulatory evaluation.

**List of Subjects in 14 CFR Part 39**

Air transportation, Aircraft, Aviation safety, Safety.

**The Proposed Amendment**

Accordingly, under the authority delegated to me by the Administrator, the FAA proposes to amend 14 CFR part 39 as follows:

## PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

**Authority:** 49 U.S.C. 106(g), 40113, 44701.

**§ 39.13 [Amended]**

2. The FAA amends § 39.13 by removing amendment 39–10987 (64 FR 1114, January 11, 1999) and adding the following new airworthiness directive (AD):

**Airbus:** Docket No. FAA–2004–18773; Directorate Identifier 2002–NM–312–AD.

**Comments Due Date**

(a) The Federal Aviation Administration must receive comments on this AD action by September 7, 2004.

**Affected ADs**

(b) This AD supersedes AD 99–01–19, amendment 39–10987.

**Applicability**

(c) This AD applies to Airbus Model A320 A320–111, –211, –212, and –231 series airplanes on which Airbus Modification 21346 has not been done, certificated in any category.

**Unsafe Condition**

(d) This AD was prompted by a full-scale fatigue survey on the Model A320 fleet. We are issuing this AD to detect and correct fatigue cracking of the fuselage, which could result in reduced structural integrity of the airplane.

**Compliance**

(e) You are responsible for having the actions required by this AD performed within

the compliance times specified, unless the actions have already been done.

**Repetitive Inspections**

(f) At the applicable time specified in paragraph (f)(1) or (f)(2) of this AD: Do a detailed inspection to find cracking on the outboard flanges around the fastener holes of frames 38 through 41, between stringers 12 and 21, using Airbus Service Bulletin A320–53–1032, Revision 02, dated December 5, 2001. Accomplishment of the inspection required by this paragraph ends the requirements of AD 99–01–19.

(1) For airplanes on which the inspection specified in Airbus Service Bulletin A320–53–1032, Revision 01, dated January 15, 1998, or Revision 02, dated December 5, 2001; has been done as of the effective date of this AD: Do the next inspection within 4,900 flight cycles after accomplishment of the last inspection, or within 1,100 flight cycles after the effective date of this AD, whichever is later.

(2) For airplanes on which no inspection specified in Airbus Service Bulletin A320–53–1032, Revision 01, dated January 15, 1998, or Revision 02, dated December 5, 2001; has been done as of the effective date of this AD: Do the inspection at the earlier of the times specified in paragraphs (f)(1)(i) and (f)(1)(ii) of this AD.

(i) Before the accumulation of 30,000 total flight cycles.

(ii) Before the accumulation of 24,800 total flight cycles, or within 3,500 flight cycles after the effective date of this AD, whichever is later.

(g) If no crack is found during the inspection required by paragraph (f)(1) or (f)(2) of this AD: Repeat the inspection thereafter at intervals not to exceed 4,900 flight cycles.

**Note 1:** For the purposes of this AD, a detailed inspection is defined as: ''An intensive visual examination of a specific structural area, system, installation, or assembly to detect damage, failure, or irregularity. Available lighting is normally supplemented with a direct source of good lighting at intensity deemed appropriate by the inspector. Inspection aids such as mirror, magnifying lenses, etc., may be used. Surface cleaning and elaborate access procedures may be required.''

**Corrective Action**

(h) If any crack is found during any inspection required by paragraph (f) of this AD, before further flight, repair using Airbus Service Bulletin A320–53–1032, Revision 01, dated January 15, 1998, or Revision 02, dated December 5, 2001. Accomplishment of a repair using the service bulletin ends the repetitive inspection requirements for the area repaired. If any crack is found during any inspection required by this AD, and the service bulletin specifies to contact Airbus for appropriate action:

Before further flight, repair using a method approved by the Manager, International Branch, ANM–116, FAA, Transport Airplane Directorate.

**Optional Terminating Action**

(i) Accomplishment of Airbus Modification 21346 using Airbus Service Bulletin A320–53–1031, dated December 9, 1994, or Revision 02, dated December 5, 2001, constitutes terminating action for the repetitive inspection requirements of this AD.

(j) Accomplishment of the optional terminating action specified in AD 99–01–19 before the effective date of this AD, using Airbus Service Bulletin A320–53–1031, dated December 9, 1994, or Revision 02, dated December 5, 2001, is considered acceptable for compliance with paragraph (i) of this AD.

**Alternative Methods of Compliance (AMOCs)**

(k) The Manager, International Branch, ANM–116, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19.

**Related Information**

(l) French airworthiness directive 2002–259(B), dated May 15, 2002, also addresses the subject of this AD.

Issued in Renton, Washington, on July 29, 2004.

**Ali Bahrami,**

*Manager, Transport Airplane Directorate, Aircraft Certification Service.*

[FR Doc. 04–17857 Filed 8–4–04; 8:45 am]

BILLING CODE 4910–13–P

---

## DEPARTMENT OF TRANSPORTATION

## Federal Aviation Administration

## 14 CFR Part 39

**[Docket No. FAA–2004–18771; Directorate Identifier 2002–NM–313–AD]**

**RIN 2120–AA64**

## Airworthiness Directives; Airbus Model A320 Series Airplanes

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Notice of proposed rulemaking (NPRM).

**SUMMARY:** The FAA proposes to supersede an existing airworthiness directive (AD) for certain Airbus Model A320 series airplanes. That AD currently requires repetitive inspections to detect fatigue cracking in certain areas of the fuselage; and corrective action, if necessary. That AD also provides for an optional terminating action for the repetitive inspections. This proposed AD would reduce the compliance threshold and repetitive intervals for the inspections required by the existing AD and would add an allowable time for the optional terminating action. This proposed AD is prompted by a full-scale fatigue survey on the Model A320 fleet. We are proposing this AD to detect and correct fatigue cracking of the fuselage, which could result in reduced structural integrity of the airplane.

**DATES:** We must receive comments on this proposed AD by September 7, 2004.

**ADDRESSES:** Use one of the following addresses to submit comments on this proposed AD.

- DOT Docket Web site: Go to *http://dms.dot.gov* and follow the instructions for sending your comments electronically.
- Government-wide rulemaking web site: Go to *http://www.regulations.gov* and follow the instructions for sending your comments electronically.
- Mail: Docket Management Facility; U.S. Department of Transportation, 400 Seventh Street SW., Nassif Building, room PL–401, Washington, DC 20590.
- *Fax:* (202) 493–2251.
- Hand Delivery: room PL–401 on the plaza level of the Nassif Building, 400 Seventh Street SW., Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.

You can get the service information identified in this proposed AD from Airbus, 1 Rond Point Maurice Bellonte, 31707 Blagnac Cedex, France.

You may examine the contents of this AD docket on the Internet at *http://dms.dot.gov,* or at the Docket Management Facility, U.S. Department of Transportation, 400 Seventh Street SW., room PL–401, on the plaza level of the Nassif Building, Washington, DC.

**FOR FURTHER INFORMATION CONTACT:** Dan Rodina, Aerospace Engineer, International Branch, ANM–116, FAA, Transport Airplane Directorate, 1601 Lind Avenue SW., Renton, Washington 98055–4056; telephone (425) 227–2125; fax (425) 227–1149.

**SUPPLEMENTARY INFORMATION:**

### Docket Management System (DMS)

The FAA has implemented new procedures for maintaining AD dockets electronically. As of May 17, 2004, new AD actions are posted on DMS and assigned a docket number. We track each action and assign a corresponding directorate identifier. The DMS AD docket number is in the form ''Docket No. FAA–2004–99999.'' The Transport Airplane Directorate identifier is in the form ''Directorate Identifier 2004–NM–999–AD.'' Each DMS AD docket also lists the directorate identifier (''Old Docket Number'') as a cross-reference for searching purposes.

### Comments Invited

We invite you to submit any written relevant data, views, or arguments regarding this proposed AD. Send your comments to an address listed under **ADDRESSES.** Include ''Docket No. FAA–

2004–18771; Directorate Identifier 2002–NM–313–AD'' at the beginning of your comments. We specifically invite comments on the overall regulatory, economic, environmental, and energy aspects of the proposed AD. We will consider all comments received by the closing date and may amend the proposed AD in light of those comments.

We will post all comments we receive, without change, to *http://dms.dot.gov,* including any personal information you provide. We will also post a report summarizing each substantive verbal contact with FAA personnel concerning this proposed AD. Using the search function of our docket web site, anyone can find and read the comments in any of our dockets, including the name of the individual who sent the comment (or signed the comment on behalf of an association, business, labor union, etc.). You may review the DOT's complete Privacy Act Statement in the **Federal Register** published on April 11, 2000 (65 FR 19477–78), or you may visit *http://dms.dot.gov.*

We are reviewing the writing style we currently use in regulatory documents. We are interested in your comments on whether the style of this document is clear, and your suggestions to improve the clarity of our communications that affect you. You can get more information about plain language at *http://www.faa.gov/language* and *http://www.plainlanguage.gov.*

## Examining the Docket

You may examine the AD docket in person at the Docket Management Facility office between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The Docket Management Facility office (telephone (800) 647–5227) is located on the plaza level of the Nassif Building at the DOT street address stated in the **ADDRESSES** section. Comments will be available in the AD docket shortly after the DMS receives them.

## Discussion

On December 30, 1998, we issued AD 99–01–17, amendment 39–10985 (64 FR 1118, January 11, 1999), for certain Airbus Model A320 series airplanes. That AD requires repetitive inspections to detect fatigue cracking in certain areas of the fuselage; and corrective action, if necessary. That AD also provides for an optional terminating action for the repetitive inspections. That AD was prompted by issuance of mandatory continuing airworthiness information by a foreign civil airworthiness authority. We issued that AD to detect and correct fatigue cracking of the fuselage, which could result in reduced structural integrity of the airplane.

## Actions Since Existing AD Was Issued

Since we issued AD 99–01–17, the Direction Generale de l'Aviation Civile (DGAC), which is the airworthiness authority for France, advises that a full-scale fatigue survey on the Model A320 fleet revealed that the weight of fuel at landing and the average flight duration are higher than those defined for the analysis of fatigue-related tasks. This has led to an adjustment of the fatigue mission for the A320 fleet, in that the DGAC has required shorter compliance thresholds and repetitive intervals for accomplishment of the inspections for fatigue cracking than those required by AD 99–01–17. Fatigue-related cracking in certain areas of the fuselage could result in reduced structural integrity of the airplane.

## Relevant Service Information

Airbus has issued Service Bulletin A320–53–1034, Revision 02, dated December 4, 2001. The procedures specified in Revision 02 are essentially the same as those in the original issue of the service bulletin, which was referenced in the existing AD for accomplishment of the inspections and corrective action. However, Revision 02 has a change that recommends a reduction in the compliance threshold from 30,000 total flight cycles to 24,200 total flight cycles, and in the repetitive intervals from 6,000 flight cycles to 5,200 flight cycles. Airbus also has issued Service Bulletin A320–53–1033, Revision 04, dated December 4, 2001. The procedures in Revision 04 are essentially the same as those in Revision 03 of the service bulletin, which was referenced in the existing AD for accomplishment of the optional terminating action. However, Revision 04 adds an allowable time for the optional terminating action specified in the Revision 03, and contains editorial changes.

We have determined that accomplishment of the actions specified in the revised service information will adequately address the unsafe condition. The DGAC mandated the service information and issued French airworthiness directive 2002–260(B), dated May 15, 2002, to ensure the continued airworthiness of these airplanes in France.

## FAA's Determination and Requirements of the Proposed AD

This airplane model is manufactured in France and is type certificated for operation in the United States under the provisions of section 21.29 of the Federal Aviation Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. Pursuant to this bilateral airworthiness agreement, the DGAC has kept us informed of the situation described above. We have examined the DGACs findings, evaluated all pertinent information, and determined that AD action is necessary for airplanes of this type design that are certificated for operation in the United States.

Therefore, we are proposing this AD, to supersede AD 99–01–17 to continue to require repetitive inspections to detect fatigue cracking in certain areas of the fuselage, and corrective action if necessary. This proposed AD would also continue to provide for an optional terminating action for the repetitive inspections. This proposed AD would reduce the compliance threshold and repetitive intervals for the inspections required by the existing AD, and would add an allowable time for the optional terminating action. The proposed AD would require using the revised service information described previously to do these actions.

## Change to Existing AD

The number of affected airplanes has changed since we issued the existing AD; therefore, we have changed the Cost Impact section in this proposed AD to reflect the correct number of airplanes.

## Revised Labor Rate

We have reviewed the figures we have used over the past several years to calculate AD costs to operators. To account for various inflationary costs in the airline industry, we find it necessary to increase the labor rate used in these calculations from $60 per work hour to $65 per work hour. The cost information, below, reflects this increase in the hourly labor rate.

## Costs of Compliance

This proposed AD would affect about 269 airplanes of U.S. registry.

The ultrasonic inspection that is required by AD 99–01–17 and retained in this proposed AD takes about 6 work hours per airplane, at an average labor rate of $65 per work hour. Based on these figures, the estimated cost of the currently required ultrasonic inspection is $390 per airplane, per inspection cycle.

The optional terminating action specified in Airbus Service Bulletin A320–53–1033, if done, would take about 5 work hours to do, at an average labor rate of $65 per work hour. The cost of required parts would be about

$75 per airplane. Based on these figures, the cost impact of the optional terminating action would be $400 per airplane.

**Regulatory Findings**

We have determined that this proposed AD would not have federalism implications under Executive Order 13132. This proposed AD would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government.

For the reasons discussed above, I certify that the proposed regulation:

1. Is not a ''significant regulatory action'' under Executive Order 12866;

2. Is not a ''significant rule'' under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and

3. Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

We prepared a regulatory evaluation of the estimated costs to comply with this proposed AD. See the **ADDRESSES** section for a location to examine the regulatory evaluation.

**List of Subjects in 14 CFR Part 39**

Air transportation, Aircraft, Aviation safety, Safety.

**The Proposed Amendment**

Accordingly, under the authority delegated to me by the Administrator, the FAA proposes to amend 14 CFR part 39 as follows:

## PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

**Authority:** 49 U.S.C. 106(g), 40113, 44701.

**§ 39.13 [Amended]**

2. The FAA amends § 39.13 by removing amendment 39–10985 (64 FR 1118, January 11, 1999), and adding the following new airworthiness directive (AD):

**Airbus:** Docket No. FAA–2004–18771; Directorate Identifier 2002–NM–313–AD.

**Comments Due Date**

(a) The Federal Aviation Administration must receive comments on this AD action by September 7, 2004.

**Affected ADs**

(b) This AD supersedes AD 99–01–17, amendment 39–10985.

**Applicability**

(c) This AD applies to Airbus Model A320–111, –211, –212, and –231 series airplanes on which Airbus Modification 21202 has not been done, certificated in any category.

**Unsafe Condition**

(d) This AD was prompted by a full-scale fatigue survey on the Model A320 fleet. We are issuing this AD to detect and correct fatigue cracking of the fuselage, which could result in reduced structural integrity of the airplane.

**Compliance**

(e) You are responsible for having the actions required by this AD performed within the compliance times specified, unless the actions have already been done.

**Repetitive Inspections**

(f) At the applicable time specified in paragraph (f)(1) or (f)(2) of this AD: Do an ultrasonic inspection to detect cracking in the bottom panels of the keel beam (both left and right), in the area of the frame 46 and stringer 37 intersection at the pressure bulkhead, using Airbus Service Bulletin A320–53–1034, Revision 02, dated December 4, 2001. Thereafter, repeat the ultrasonic inspection at intervals not to exceed 5,200 flight cycles or 10,400 flight hours, whichever is first. Accomplishment of the inspection required by this paragraph ends the requirements of AD 99–01–17.

(1) For airplanes on which the inspection specified in Airbus Service Bulletin A320–53–1034, dated March 30, 1992; or Revision 02, dated December 4, 2001; has been done as of the effective date of this AD: Do the next inspection within 5,200 flight cycles after accomplishment of the last inspection, or within 800 flight cycles after the effective date of this AD, whichever is later.

(2) For airplanes on which no inspection specified in Airbus Service Bulletin A320–53–1034, dated March 30, 1992; or Revision 02, dated December 4, 2001; has been done as of the effective date of this AD: Do the inspection at the later of the times specified in paragraphs (f)(1)(i) and (f)(1)(ii) of this AD.

(i) Before the accumulation of 24,200 total flight cycles or 48,400 total flight hours, whichever is first.

(ii) Before the accumulation of 30,000 total flight cycles, or within 3,500 flight cycles after the effective date of this AD, whichever is first.

**Corrective Action**

(g) If any crack is found during any inspection required by paragraph (f) of this AD, before further flight, repair using Airbus Service Bulletin A320–53–1034, dated March 30, 1992; or Revision 02, dated December 4, 2001. Accomplishment of a repair using the service bulletin ends the repetitive inspection requirements for the area repaired. If any crack is found during any inspection required by this AD, and the service bulletin specifies to contact Airbus for appropriate action: Before further flight, repair using a method approved by the Manager, International Branch, ANM–116, FAA, Transport Airplane Directorate.

**Optional Terminating Action**

(h) Accomplishment of Airbus Modification 21202 using Airbus Service Bulletin A320–53–1033, Revision 03, dated July 4, 1994; or Revision 04, dated December 4, 2001, constitutes terminating action for the repetitive inspection requirements of this AD.

(i) Accomplishment of the optional terminating action specified in AD 99–01–17 before the effective date of this AD, using Airbus Service Bulletin A320–53–1033, Revision 03, dated July 4, 1994; or Revision 04, dated December 4, 2001, is considered acceptable for compliance with paragraph (h) of this AD.

**Alternative Methods of Compliance (AMOCs)**

(j) The Manager, International Branch, ANM–116, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19.

**Related Information**

(k) French airworthiness directive 2002–260(B), dated May 15, 2002, also addresses the subject of this AD.

Issued in Renton, Washington, on July 29, 2004.

**Ali Bahrami,**

*Manager, Transport Airplane Directorate, Aircraft Certification Service.*

[FR Doc. 04–17858 Filed 8–4–04; 8:45 am]

BILLING CODE 4910–13–P

## DEPARTMENT OF THE TREASURY

## Internal Revenue Service

## 26 CFR Part 1

**[REG–171386–03]**

**RIN 1545–BD16**

## Time and Manner of Making Section 163(d)(B) Election to Treat Qualified Dividend Income as Investment Income

**AGENCY:** Internal Revenue Service (IRS), Treasury.

**ACTION:** Notice of proposed rulemaking by cross-reference to temporary regulations.

**SUMMARY:** In the Rules and Regulations section of this issue of the **Federal Register**, the IRS is issuing temporary regulations relating to an election that may be made by noncorporate taxpayers to treat qualified dividend income as investment income for purposes of calculating the deduction for investment interest. The text of those temporary regulations also serves as the text of these proposed regulations.

**DATES:** Written or electronic comments and requests for a public hearing must be received by November 3, 2004.

**ADDRESSES:** Send submissions to: CC:PA:LPD:PR (REG–171386–03), room 5203, Internal Revenue Service, POB 7604, Ben Franklin Station, Washington, DC 20044. Alternatively, submissions may be hand-delivered Monday through Friday between the hours of 8 a.m. and 4 p.m. to: CC:PA:LPD:PR (REG–171386–03), Courier's Desk, Internal Revenue Service, 1111 Constitution Avenue, NW., Washington, DC. Taxpayers also may submit comments electronically to the IRS Internet site at *http://www.irs.gov/regs* or via the Federal eRulemaking Portal at *http://www.regulations.gov* (indicate IRS and REG–171386–03 or RIN 1545–BD16).

**FOR FURTHER INFORMATION CONTACT:** Concerning submission of comments or requesting a hearing, LaNita Van Dyke, (202) 622–7180; concerning the proposed regulations, Amy Pfalzgraf, (202) 622–4950 (not toll-free numbers).

**SUPPLEMENTARY INFORMATION:**

## Background and Explanation of Provisions

Temporary regulations in the Rules and Regulations section of this issue of the **Federal Register** amend the Income Tax Regulations (26 CFR part 1) relating to section 163(d)(4)(B) of the Internal Revenue Code. The temporary regulations provide rules regarding the time and manner for making an election under section 163(d)(4)(B) to treat qualified dividend income as investment income for purposes of calculating the deduction for investment interest. The text of the temporary regulations also serves as the text of these proposed regulations. The preamble to the temporary regulations explains the amendments.

## Special Analyses

It has been determined that this notice of proposed rulemaking is not a significant regulatory action as defined in Executive Order 12866. Therefore, a regulatory assessment is not required. It also has been determined that section 553(b) of the Administrative Procedure Act (5 U.S.C. chapter 5) does not apply to these regulations, and because the regulations do not impose a collection of information on small entities, the Regulatory Flexibility Act (5 U.S.C. chapter 6) does not apply. Pursuant to section 7805(f) of the Internal Revenue Code, this notice of proposed rulemaking will be submitted to the Chief Counsel for Advocacy of the Small Business Administration for comment on its impact on small business.

## Comments and Requests for a Public Hearing

Before these proposed regulations are adopted as final regulations, consideration will be given to any written comments (a signed original and eight (8) copies) or electronic comments that are submitted timely to the IRS. The IRS and Treasury Department request comments on the clarity of the proposed rules and how they can be made easier to understand. All comments will be available for public inspection and copying. A public hearing will be scheduled if requested in writing by any person that timely submits written comments. If a public hearing is scheduled, notice of the date, time, and place for the public hearing will be published in the **Federal Register**.

## Drafting Information

The principal author of these regulations is Amy Pfalzgraf of the Office of Associate Chief Counsel (Income Tax & Accounting). However, other personnel from the IRS and Treasury Department participated in their development.

## List of Subjects in 26 CFR Part 1

Income taxes, Reporting and recordkeeping requirements.

## Proposed Amendments to the Regulations

Accordingly, 26 CFR part 1 is proposed to be amended as follows:

## PART 1—INCOME TAXES

**Paragraph 1**. The authority citation for part 1 continues to read, in part, as follows:

**Authority:** 26 U.S.C. 7805 * * *

**Par. 2**. Section 1.163(d)–1 is revised to read as follows:

### § 1.163(d)–1 Time and manner for making elections under the Omnibus Budget Reconciliation Act of 1993 and the Jobs and Growth Tax Relief Reconciliation Act of 2003.

[The text of proposed paragraphs (a), (b), (c), and (d) is the same as the text of paragraphs (a), (b), (c), and (d) of § 1.163(d)–1T published elsewhere in this issue of the **Federal Register**.]

**Nancy J. Jardini,**

*Acting Deputy Commissioner for Services and Enforcement.*

[FR Doc. 04–17797 Filed 8–4–04; 8:45 am]

BILLING CODE 4830–01–P

## LIBRARY OF CONGRESS

## Copyright Office

## 37 CFR Part 202

**[Docket No. RM 2004–3]**

## Acquisition and Deposit of Unpublished Audio and Audiovisual Transmission Programs

**AGENCY:** Copyright Office, Library of Congress.

**ACTION:** Notice of proposed rulemaking.

**SUMMARY:** This notice is issued to inform the public that the Copyright Office of the Library of Congress is proposing to amend its regulations to permit the Library of Congress to record unpublished radio and other audio and audiovisual transmission programs. The Copyright Office regulations already provide for the Library of Congress to obtain copies of unpublished television transmission programs, either by recording fixations or by demanding copies in the form of a transfer, loan or sale at cost. This revised regulation makes similar provisions for audio transmission programs and includes transmission programs made available by radio broadcasts and by digital communications networks such as the Internet.

**DATES:** Comments are due by September 7, 2004.

**ADDRESSES:** If hand delivered by a private party, an original and five copies of any comment should be brought to: Room LM–401 of the James Madison Memorial Building and addressed as follows: Office of the General Counsel, U.S. Copyright Office, James Madison Memorial Building, Room LM–401, 101 Independence Avenue, SE., Washington, DC 20559–6000. If delivered by a commercial, non-government courier or messenger, an original and five copies of any comment must be delivered to the Congressional Courier Acceptance Site located at 2nd and D Streets, NE., between 8:30 a.m. and 4 p.m. The envelope should be addressed as follows: Copyright Office General Counsel, Room LM–403, James Madison Memorial Building, 101 Independence Avenue, SE., Washington, DC. If sent by mail, an original and five copies of any comment should be addressed to: Copyright GC/I&R, P.O. Box 70400, Southwest Station, Washington, DC 20024–0400. Comments may not be delivered by means of overnight delivery services such as Federal Express, United Parcel Service, etc., due to delays in processing receipt of such deliveries.

**FOR FURTHER INFORMATION CONTACT:** Charlotte Douglass, Principal Legal Advisor to the General Counsel, Office of the Copyright General Counsel, Telephone: (202) 707–8380; Fax: (202) 707–8366.

**SUPPLEMENTARY INFORMATION:** The collections of the Library of Congress serve as a repository of a vast number of works. The largest library in the world, the Library of Congress comprises more than 127 million items. In addition to acquiring works by purchase, gift and exchange, the Library acquires copies of works submitted to the Copyright Office for registration or mandatory deposit. 17 U.S.C. 408, 407. In fiscal year 2003, the incentives of voluntary copyright registration made nearly one million copies of works available to the Library of Congress for its collections. Of the 962,119 copies and phonorecords the Office transferred to the Library of Congress, 491,219 arrived under the mandatory deposit provisions of the copyright law. U.S. Copyright Office, *106th Annual Report of the Register of Copyrights 2003*, at 12 (2003). However, registration and mandatory deposit do not provide the Library with sufficient copies of certain types of works. For example, the Library does not predictably acquire a significant body of unpublished radio and television transmission programs.

Late in deliberations on the bill that became the 1976 Copyright Act, concern arose about whether mandatory deposit of only published works would be sufficient for the Library's collections, given that owners of publicly disseminated broadcasts were not obligated to deposit their works in the Library of Congress. The Register of Copyrights expressed that concern in the Second Supplementary Report, observing that transmission programs ''are disseminated widely to the public and reproductions of them should be maintained in an archive in the Library of Congress.* * *'' U.S. Copyright Office, *Second Supplementary Report of the Register of Copyrights on the General Revision of the U.S. Copyright Law*, Chapter XIII, at 15–16 (1975). On that basis, the report recommended that section 407 be amended ''to require deposit of copies or phonorecords of copyrighted transmission programs under appropriate conditions.'' *Id.* at 16. Thereafter, the copyright bill provided a basis for the Library of Congress to acquire copies and phonorecords of non-syndicated radio and television transmission programs without imposing any hardships on broadcasters. H.R. Rep. No. 94–1476, at 152 (1976). This was accomplished by giving the Library authority to record unpublished transmission programs in all cases where the copyright owner had made or authorized a fixation of the program. Additionally, the Copyright Office was given demand authority to obtain fixations of these programs by transfer, loan, or sale at cost. *Id.*

The copyright law defines a transmission program as a body of material that, as an aggregate, has been produced for the sole purpose of transmission to the public in sequence and as a unit. 17 U.S.C. 101. Under section 407(e), the Librarian of Congress may make a fixation of an unpublished transmission program that has been fixed and transmitted to the public in the United States. The Library may make the fixation directly from a transmission to the public, and may reproduce one copy or phonorecord from such fixation for archival purposes. 17 U.S.C. 407(e)(1). With respect to the registration of these programs, when copyright applications and fees are timely and properly submitted, the recorded or demanded fixations can be used as registration deposits.

In 1983, the Copyright Office promulgated regulations under section 407(e) to permit the Library to record unpublished television programs. 48 FR 37208 (Aug. 17, 1983). The amendment proposed today expands existing regulations for television to radio and other audio and audiovisual transmission programs. As is currently the case, the regulation establishes a presumption that noncommercial television programs are unpublished, while it provides a procedure for the copyright owner to overcome that presumption. Commercial television programs are not presumed to be unpublished under the existing regulation. However, consistent with the Library's acquisition experience through registration and deposit, this amendment presumes that both commercial and noncommercial radio transmission programs are unpublished. The presumption regarding radio transmission programs is based on empirical Office experience, factual information from surveys conducted in the Copyright Office and surveys of databases covering registered works. For example, a recent survey of the Performing Arts Section of the Examining Division in the Office revealed that all of the applications for registration of radio programs on hand during the two week period in question were for registration in unpublished form. The applications were for radio broadcasts of recent vintage, *e.g.*, opera broadcasts and contemporary programming of lighter genres as well as radio broadcasts from the 1940s and 1950s. The Office also conducted a survey of a broader group of radio programs registered over a longer period of time from an independent database covering registered works. Most of these radio programs were registered as unpublished works as well. On the basis of these surveys and other experience, it is appropriate in the context of this regulation to adopt the presumption of nonpublication of radio programs at the time of transmission, even though the publication status of the works may change at some later time.

A feature of the original regulation, which would be retained, is the cost-saving option that copyright owners may choose to register a copyright claim using the Library's recording as the deposit copy. The copyright owner need only submit, within 90 days of the Library's recording, a completed application for registration, and the appropriate fee, together with a notice to the Copyright Office that the Library's recording is to be used to satisfy the deposit requirement, to thereby save the cost of the deposit copy. In view of the significant number of programs the Library seeks to record, it will not be practical as a matter of course to provide specific advance notice to the copyright owner that the Library plans to record an unpublished radio program. Such action would constitute a major administrative burden for the Library. Should the copyright owner wish to register a claim using the Library's recording, the owner may obtain information about whether the Library has recorded a radio program by making a written request of the Chief, Motion Picture, Broadcasting and Recorded Sound Division at the Library of Congress.

When the regulation on off-the-air videotaping was originally promulgated more than two decades ago, the Office observed that it had not exhausted the authority conferred by section 407(e), particularly noting that the regulation had intentionally omitted radio transmissions. 47 FR 5259 (Feb. 4, 1982). In recognition of the great change in the world of communications over the last twenty years and to specifically acknowledge today's Internet age environment, the Office is updating the regulation to meet the new world of cultural communications by including audio transmission programs within its reach as well as Internet and other audiovisual transmission programs. This action is in keeping with Congress's intent to grant the Library broad authority to record unpublished transmission programs. 17 U.S.C. 407(e).

The legislative history of the 1976 Copyright Act recounts that

> The definition of ''transmit''—to communicate a performance or display ''by any device or process whereby images or sound[s] are received beyond the place from which they are sent''—is broad enough to include all conceivable forms and combinations of wired or wireless communications media, including but by no means limited to radio and television broadcasting as we know them. Each and every method by which the images or sounds comprising a performance or display are picked up and conveyed is a ''transmission'' * * *.

H.R. Report No. 94–1476, at 64 (1976). Congress's recognition in 1976 that transmission programs would not be confined to radio and television has been realized as the Internet has become a major medium for the transmission of programs, and the Library's collections will be enriched by including many programs now being transmitted on the Internet. By expanding the scope of works to include radio, Internet,[1] cable, satellite and other audiovisual transmissions to the public, the Register now proposes to further exercise her statutory authority to enable the Library of Congress to collect and preserve broad-based contemporary cultural materials from all kinds of unpublished transmission programs that represent the nation's rich heritage. *See also* Section 113, Transitional and Supplementary Provisions of the Copyright Act of 1976, Pub. L. No. 94–553, 90 Stat. 2541 (1976). With respect to television transmission programs, however, this amendment leaves the provisions of the original regulation essentially unchanged.

**List of Subjects in 37 CFR Part 202**

Copyright, Registration.

**Proposed Regulation**

In consideration of the foregoing, the Copyright Office proposes to amend part 202 of 37 CFR chapter II as follows:

## PART 202—REGISTRATION OF CLAIMS TO COPYRIGHT

1. The authority citation for part 202 continues to read as follows:

**Authority:** 17 U.S.C. 702, 407 and 408.

2. Section 202.22 is amended as follows:

a. by revising the section heading;

b. by revising paragraph (a);

c. by revising paragraph (b)(1);

d. in paragraph (b)(2), by removing ''by Pub. L. 94–553'';

e. by revising the heading of paragraph (c);

f. by revising paragraph (c)(1);

g. in paragraph (c)(2), by removing ''copied off-the-air'' and adding ''recorded'' in its place;

h. in paragraph (c)(3), by removing ''copy off-the-air'' and adding ''record'' in its place, by removing ''television'' before ''transmission program'', and by removing ''copying'' and adding ''recording'' in its place;

i. by revising paragraph (c)(4);

j. in paragraph (c)(5) introductory text, by removing ''off the air copying'' and adding ''recording'' in its place;

k. in paragraph (c)(5)(iii), by removing ''with notice of copyright'';

l. in paragraph (c)(6) introductory text, by removing ''off-the-air'' and by adding ''or phonorecord'' after ''copy'';

m. in paragraph (c)(7), by adding ''or phonorecord'' after ''copy'';

n. in paragraph (c)(8) introductory text, by adding ''television'' before ''transmission programs'', ''television'' before ''network stations'' and ''television'' before ''broadcasting station'';

o. in the heading for paragraph (d), by removing ''television'';

p. in paragraph (d)(1), by adding ''or phonorecord'' after ''copy'';

q. in paragraph (d)(3)(ii), by adding ''or phonorecord'' after ''copy'' each place it appears;

r. in paragraph (d)(3)(iv), by removing ''copies''' and adding ''of the copies or phonorecords'' after ''use'';

s. in paragraph (d)(3)(v), by removing ''(a) and (c)'';

t. in paragraph (d)(3)(vi), by adding '', or, in the case of an audio transmission program, a *compliance phonorecord*,'' after ''copy'';

u. in paragraph (d)(4), by adding ''or phonorecord'' after ''copy'' each place it appears;

v. in paragraph (d)(5), by adding ''and phonorecords'' after ''Copies'';

w. in paragraph (d)(6)(iii), by removing ''shall be granted'' and adding ''should be granted'' in its place;

x. in the heading of paragraph (e) and paragraph (e)(1), by adding ''and phonorecords'' after ''copies'' each place it appears, and by adding ''or phonorecord'' after ''copy'';

y. by revising paragraph (e)(2);

z. in paragraph (f)(1), by adding ''and phonorecords'' after ''Copies'';

aa. in paragraph (f)(1)(ii), by adding ''or phonorecord'' after ''copy'';

bb. in paragraph (f)(2), by adding ''and phonorecords'' after ''Copies'', and by adding ''or phonorecord'' after ''copy'' each place it appears; and

cc. in paragraph (g)(1), by adding '', or phonorecords'' after ''copies'', and by removing ''television'' and by adding ''audio or audiovisual'' in its place.

The additions and revisions to § 202.22 read as follows:

**§ 202.22 Acquisition and deposit of unpublished audio and audiovisual transmission programs.**

(a) *General*. This section prescribes rules pertaining to the acquisition of phonorecords and copies of unpublished audio and audiovisual transmission programs by the Library of Congress under section 407(e) of title 17 of the United States Code, as amended. It also prescribes rules pertaining to the use of such phonorecords and copies in the registration of claims to copyright, under section 408(b).

(b) * * *

(1) The terms *copies, fixed, phonorecords, publication*, and *transmission program* and their variant forms, have the meanings given to them in section 101 of title 17. The term *network station* has the meaning given it in section 111(f) of title 17. For the purpose of this section, the term *transmission* includes transmission via the Internet, cable, broadcasting, and satellite systems, and via any other existing or future devices or processes for the communication of a performance or display whereby images or sounds are received beyond the place from which they are sent.

* * * * *

(c) *Recording of transmission programs*. (1) Library of Congress employees, including Library of Congress contractors, acting under the general authority of the Librarian of Congress, may make a fixation of an unpublished audio or audiovisual transmission program directly from a transmission to the public in the United States, in accordance with subsections 407(e)(1) and (4) of title 17 of the United States Code. The choice of programs selected for fixation shall be based on the Library of Congress's acquisition policies in effect at the time of fixation. Specific notice of an intent to record a transmission program will ordinarily not be given. In general, the Library of Congress will seek to record a substantial portion of the television programming transmitted by noncommercial educational broadcast stations as defined in section 397 of title 47 of the United States Code, and will record selected programming transmitted by commercial television broadcast stations, both network and independent. The Library will also

[1] Within the scope of this regulation, Internet recording by the Library of Congress refers to the recording of transmission programs that are publicly performed, *i.e.,* ''streamed'' on the Internet. It does not refer to programs that are offered for download or otherwise available for reproduction, since such programs would likely be considered published.

record a selected portion of the radio programming transmitted by commercial and noncommercial broadcast stations. Additionally, the Library will record a selected portion of unpublished Internet, cable and satellite programming transmitted to the public in the United States.

* * * * * *

(4) The Library of Congress is entitled under this paragraph (c) to presume that a radio program transmitted to the public in the United States has been fixed but not published at the time of transmission, and that a television program transmitted to the public in the United States by a noncommercial educational broadcast station as defined in section 397 of title 47 of the United States Code has been fixed but not published.

(e) * * *

(2) All copies and phonorecords acquired or made under this section, except copies and phonorecords of transmission programs consisting of a regularly scheduled newscast or on-the-spot coverage of news events, shall be subject to the following restrictions concerning copying and access: in the case of television or other audiovisual transmission programs, copying and access are governed by Library of Congress Regulation 818–17, *Policies Governing the Use and Availability of Motion Pictures and Other Audiovisual Works in the Collections of the Library of Congress*, or its successors; in the case of audio transmission programs, copying and access are governed by Library of Congress Regulation 818–18.1, *Recorded Sound Listening and Duplication Services*, or its successors. Transmission programs consisting of regularly scheduled newscasts or on-the-spot coverage of news events are subject to the provisions of the ''American Television and Radio Archives Act,'' 2 U.S.C. 170, and such regulations as the Librarian of Congress shall prescribe.

* * * * *

Dated: August 2, 2004.

**David O. Carson,**

*General Counsel.*

[FR Doc. 04–17939 Filed 8–4–04; 8:45 am]

BILLING CODE 1410–30–P

## ENVIRONMENTAL PROTECTION AGENCY

### 40 CFR Parts 52 and 81

**[CO–001–0076a, CO–001–0077a; FRL–7785–1]**

### Approval and Promulgation of Air Quality Implementation Plans; Colorado; Designation of Areas for Air Quality Planning Purposes, Lamar and Steamboat Springs

**AGENCY:** Environmental Protection Agency (EPA).

**ACTION:** Proposed rule.

**SUMMARY:** EPA is taking direct final action to approve a State Implementation Plan (SIP) revision submitted by the State of Colorado on July 31, 2002, for the purpose of redesignating the Lamar, Colorado and Steamboat Springs, Colorado areas from nonattainment to attainment for particulate matter with an aerodynamic diameter less than or equal to a nominal 10 micrometers ($PM_{10}$) under the 1987 standards. The Governor's submittal, among other things, documents that the Lamar and Steamboat Springs areas have attained the $PM_{10}$ national ambient air quality standards (NAAQS), requests redesignation to attainment and includes a maintenance plan for each of the areas demonstrating maintenance of the $PM_{10}$ NAAQS for ten years. EPA is approving these redesignation requests and maintenance plans because Colorado has met the applicable requirements of the Clean Air Act (CAA), as amended. Upon the effective date of this approval, the Lamar and Steamboat Springs areas will be designated attainment for the $PM_{10}$ NAAQS. This action is being taken under sections 107, 110, and 175A of the Clean Air Act.

**DATES:** Written comments must be received in writing on or before September 7, 2004.

**ADDRESSES:** Written comments may be mailed to Richard R. Long, Director, Air and Radiation Program, Mailcode 8P–AR, Environmental Protection Agency (EPA), Region 8, 999 18th Street, Suite 300, Denver, Colorado 80202–2466. Comments may also be submitted electronically, or through hand delivery/courier. Please follow the detailed instructions (sections (I)(B)(1)(i) through (iii) of the **SUPPLEMENTARY INFORMATION** section) described in the direct final rule which is located in the Rules Section of this **Federal Register**. Copies of the documents relevant to this action are available for public inspection Monday through Friday, 8 a.m. to 4 p.m., excluding federal holidays, at the Air and Radiation Program, Environmental Protection Agency, Region 8, 999 18th Street, Suite 300, Denver, Colorado 80202–2466. Copies of the State documents relevant to this action are available for public inspection at the Colorado Department of Public Health and Environment, Air Pollution Control Division, 4300 Cherry Creek Drive South, Denver, Colorado 80222–1530.

**FOR FURTHER INFORMATION CONTACT:** Libby Faulk, EPA, Region VIII, 999 18th Street, Suite 300, Mailcode 8P–AR, Denver, Colorado, 80202, (303) 312–6083, e-mail *faulk.libby@epa.gov*.

**SUPPLEMENTARY INFORMATION:** See the information provided in the Direct Final action of the same title which is located in the Rules and Regulations section of this **Federal Register**.

**Authority:** 42 U.S.C. 7401 *et seq.*

Dated: June 28, 2004.

**Robert E. Roberts,**

*Regional Administrator, Region 8.*

[FR Doc. 04–17657 Filed 8–4–04; 8:45 am]

BILLING CODE 6560–50–P

## FEDERAL COMMUNICATIONS COMMISSION

### 47 CFR Part 73

**[DA 04–2298, MB Docket No. 04–283, RM–10965]**

### Digital Television Broadcast Service; Kalispell, MT

**AGENCY:** Federal Communications Commission.

**ACTION:** Proposed rule.

**SUMMARY:** The Commission requests comments on a petition filed by Montana State University proposing the allotment and reservation of DTV channel 46 for noncommercial educational use at Kalispell, Montana. DTV Channel *46 can be allotted to Kalispell at reference coordinates 48–00–48 N. and 114–21–55 W. with a power of 186, a height above average terrain HAAT of 830 meters. Since the community of Kalispell is located within 400 kilometers of the U.S.-Canadian border, concurrence from the Canadian government must be obtained for this allotment.

**DATES:** Comments must be filed on or before September 23, 2004, and reply comments on or before October 11, 2004.

**ADDRESSES:** The Commission permits the electronic filing of all pleadings and comments in proceeding involving petitions for rule making (except in

broadcast allotment proceedings). *See Electronic Filing of Documents in Rule Making Proceedings*. GC Docket No. 97–113 (rel. April 6, 1998). Filings by paper can be sent by hand or messenger delivery, by commercial overnight courier, or by first-class or overnight U.S. Postal Service mail. The Commission's contractor, Natek, Inc., will receive hand-delivered or messenger-delivered paper filings for the Commission's Secretary at 236 Massachusetts Avenue, NE., Suite 110, Washington, DC 20002. The filing hours at this location are 8 a.m. to 7 p.m. All hand deliveries must be held together with rubber bands or fasteners. Any envelopes must be disposed of before entering the building. Commercial overnight mail (other than U.S. Postal Service Express Mail and Priority Mail) must be sent to 9300 East Hampton Drive, Capitol Heights, MD 20743. U.S. Postal Service first-class mail, Express Mail, and Priority Mail should be addressed to 445 12th Street, SW., Washington, DC 20554. All filings must be addressed to the Commission's Secretary, Office of the Secretary, Federal Communications Commission, Washington, DC 20554. In addition to filing comments with the FCC, interested parties should serve the petitioner, or its counsel or consultant, as follows: Margaret L. Miller, Dow, Lohnes & Albertson, PLLC, 1200 New Hampshire Avenue, NW., Suite 800, Washington, DC 20036 (Counsel for Montana State University).

**FOR FURTHER INFORMATION CONTACT:** Pam Blumenthal, Media Bureau, (202) 418–1600.

**SUPPLEMENTARY INFORMATION:** This is a synopsis of the Commission's Notice of Proposed Rule Making, MB Docket No. 04–283, adopted July 23, 2004, and released July 30, 2004. The full text of this document is available for public inspection and copying during regular business hours in the FCC Reference Information Center, Portals II, 445 12th Street, SW., Room CY–A257, Washington, DC 20554. This document may also be purchased from the Commission's duplicating contractor, Best Copy and Printing, Inc., 445 12th Street, SW., Room CY–B402, Washington, DC 20554, telephone 301–816–2820, facsimile 301–816–0169, or via e-mail *joshir@erols.com*.

Provisions of the Regulatory Flexibility Act of 1980 do not apply to this proceeding.

This document does not contain proposed information collection(s) subject to the Paperwork Reduction Act of 1995 (PRA), Public Law 104–13. In addition, therefore, it does not contain any new or modified ''information collection burden for small business concerns with fewer than 25 employees,'' pursuant to the Small Business Paperwork Relief Act of 2002, Public Law 107–198, *see* 44 U.S.C. 3506(c)(4).

Members of the public should note that from the time a Notice of Proposed Rule Making is issued until the matter is no longer subject to Commission consideration or court review, all *ex parte* contacts are prohibited in Commission proceedings, such as this one, which involve channel allotments. *See* 47 CFR 1.1204(b) for rules governing permissible *ex parte* contacts.

For information regarding proper filing procedures for comments, *see* 47 CFR 1.415 and 1.420.

**List of Subjects in 47 CFR Part 73**

Digital television broadcasting, Television.

For the reasons discussed in the preamble, the Federal Communications Commission proposes to amend 47 CFR part 73 as follows:

## PART 73—RADIO BROADCAST SERVICES

1. The authority citation for part 73 continues to read as follows:

**Authority:** 47 U.S.C. 154, 303, 334 and 336.

**§ 73.622 [Amended]**

2. Section 73.622(b), the Table of Digital Television Allotments under Montana is amended by adding DTV channel *3 at Kalispell.

Federal Communications Commission.

**Barbara A. Kreisman,**

*Chief, Video Division, Media Bureau.*

[FR Doc. 04–17902 Filed 8–4–04; 8:45 am]

BILLING CODE 6712–01–P

# Notices

Federal Register

Vol. 69, No. 150

Thursday, August 5, 2004

This section of the FEDERAL REGISTER contains documents other than rules or proposed rules that are applicable to the public. Notices of hearings and investigations, committee meetings, agency decisions and rulings, delegations of authority, filing of petitions and applications and agency statements of organization and functions are examples of documents appearing in this section.

## DEPARTMENT OF AGRICULTURE

### Food Safety and Inspection Service

**[Docket No. 04–024N]**

### The National Advisory Committee on Meat and Poultry Inspection; Nominations for Membership

**AGENCY:** Food Safety and Inspection Service, USDA.

**ACTION:** Notice.

**SUMMARY:** This notice announces that the U.S. Department of Agriculture (USDA) is soliciting nominations for membership on the National Advisory Committee on Meat and Poultry Inspection (NACMPI). The full Committee consists of 16–18 members, and each person selected is expected to serve a 2-year term.

**DATES:** The names of the nominees and their typed curricula vitae or resumes must be postmarked no later than September 7, 2004. Applications are available on-line at *http://www.fsis.usda.gov/OPPDE/NACMPI/Nominations.htm.*

**ADDRESSES:** Nominations should be submitted to Dr. Barbara J. Masters, Acting Administrator, Food Safety and Inspection Service, USDA, Room 405-Aerospace Building, 1400 Independence Avenue, SW., Washington, DC 20250–3700.

**FOR FURTHER INFORMATION CONTACT:** Ms. Sonya L. West, Advisory Committee Specialist, Strategic Initiatives, Partnerships and Outreach Staff, FSIS, telephone (202) 690–1079; FAX (202) 690–6519; E-mail: *sonya.west@usda.fsis.gov.*

**SUPPLEMENTARY INFORMATION:** USDA is seeking nominees for membership on the National Advisory Committee on Meat and Poultry Inspection. The Committee provides advice and recommendations to the Secretary on the meat and poultry inspection programs, pursuant to sections 7(c), 24, 205, 301(a)(3), 301(a)(4), and 301(c) of the Federal Meat Inspection Act, 21 U.S.C. 607(c), 624, 645, 661(a)(3), 661(a)(4), and 661(c)) and the sections 5(a)(3), 5(a)(4), 5(c), 8(b), and 11(e) of the Poultry Products Inspection Act, 21 U.S.C. 454(a)(3), 454(a)(4), 454(c), 457(b), and 460(e)). Nominations for membership are being sought from persons representing producers; processors; exporters and importers of meat and poultry products; academia; Federal and State government officials; and consumers.

Appointments to the Committee will be made by the Secretary. To ensure that recommendations of the Committee take into account the needs of the diverse groups served by the Department, membership should include, to the extent practicable, persons with demonstrated ability to represent minorities, women, and persons with disabilities. It is anticipated that the Committee will meet at least twice annually.

#### Additional Public Notification

Public awareness of all segments of rulemaking and policy development is important. Consequently, in an effort to ensure that the public and in particular minorities, women, and persons with disabilities, are aware of this notice, FSIS will announce it on-line through the FSIS web page located at *http://www.fsis.usda.gov.*

FSIS also will make copies of this **Federal Register** publication available through the FSIS Constituent Update, which is used to provide information regarding FSIS policies, procedures, regulations, **Federal Register** notices, FSIS public meetings, recalls, and other types of information that could affect or would be of interest to our constituents and stakeholders. The update is communicated via Listserv, a free e-mail subscription service consisting of industry, trade, and farm groups, consumer interest groups, allied health professionals, scientific professionals, and other individuals who have requested to be included. The update also is available on the FSIS web page. Through Listserv and the web page, FSIS is able to provide information to a much broader, more diverse audience.

Done at Washington, DC on July 30, 2004.

**Barbara J. Masters,**

*Acting Administrator.*

[FR Doc. 04–17846 Filed 8–4–04; 8:45 am]

**BILLING CODE 3410–DM–P**

## DEPARTMENT OF AGRICULTURE

### Rural Utilities Service

### North Carolina Electric Membership Corporation; Notice of Intent

**AGENCY:** Rural Utilities Service, USDA.

**ACTION:** Notice of intent to hold public meetings and prepare an environmental assessment.

**SUMMARY:** Notice is hereby given that the Rural Utilities Service (RUS), an agency delivering the U.S. Department of Agriculture's Rural Development Utilities Programs, pursuant to the National Environmental Policy Act of 1969 (42 U.S.C. 4321 *et seq.*), the Council on Environmental Quality (CEQ) Regulations for Implementing NEPA (40 CFR parts 1500–1508), and RUS Environmental Policies and Procedures (7 CFR part 1794), proposes to prepare an Environmental Assessment (EA) related to possible financing assistance to North Carolina Electric Membership Corporation (NCEMC) to construct two, 300 megawatt simple cycle combustion turbines at two locations. Sites under consideration are located in Anson County, Person County, Richmond County, and Wake County, North Carolina.

*Meeting Information:* RUS will conduct public meetings in an open house format on August 23, 2004, from 6 p.m. until 9 p.m. at Cole Auditorium, 1042 West Hamlet Avenue, Hamlet, NC, on August 24, 2004, from 6 p.m. until 9 p.m. at Lilesville Elementary School, 121 Camden Street, Lilesville, NC, on September 7, 2004, from 6 p.m. until 9 p.m., at Person County Office Building Auditorium, 304 South Morgan Street, Roxboro, NC, and on September 9, 2004, from 6 p.m. until 9 p.m. at the Holly Springs Town Hall, 128 South Main Street, Holly Springs, NC. All interested parties are invited to attend the meetings.

**FOR FURTHER INFORMATION CONTACT:** Bob Quigel, Engineering and Environmental Staff, Rural Utilities Service, at (202) 720–0468, or *bob.quigel@usda.gov.* You

can also contact Jane Pritchard of North Carolina Electric Membership Corporation at 1–800–662–8835, extension 3104, or *jane.pritchard@ncemcs.com*.

**SUPPLEMENTARY INFORMATION:** North Carolina Electric Membership Corporation proposes to construct a natural gas fired electric generation plant at two of four potential sites. One site is in Anson County, North Carolina, located southwest of Blewett Falls Lake. Approximately one-half mile of natural gas pipeline will be constructed from the existing Sandhills pipeline to the plant site. No new electric transmission lines will be constructed at this site. The second site is located in Richmond County, North Carolina, just south of U.S. 74 and adjacent to the Progress Energy facility. Approximately one-half mile of natural gas pipeline and one-half mile of new electric transmission line would be associated with a plant at this site. The third site is located in Person County, North Carolina, approximately two miles southwest of Roxboro. Approximately 1,000 feet of natural gas pipeline and no new electric transmission line would be associated with a plant at this site. The fourth site is located in southwestern Wake County, North Carolina, on a parcel bounded by U.S. Highway One and Friendship Road. Approximately three miles of natural gas pipeline and 0.8 miles of new electric transmission line would be associated with a plant at this site.

The proposed projects will be composed of five or six Pratt & Whitney FT–8 Swift-Pac™ generation units operating in simple-cycle mode. The plants will use natural gas with low sulfur distillate fuel oil as backup fuel. It is the goal of North Carolina Electric Membership Corporation to have the facilities operational by mid to late 2007.

An alternative evaluation and site selection study for the project was prepared by North Carolina Electric Membership Corporation. The alternative evaluation and site selection study are available for public review at RUS in Room 2244 South Building, 1400 Independence Avenue, SW., Washington, DC, and at the headquarters of NCEMC located at 3400 Sumner Boulevard, Raleigh, North Carolina. This documents will also be available at the Hampton B. Allen Library, 120 South Greene Street, Wadesboro, North Carolina, (704) 694–5177, Pee Dee Electric Membership Corporation, Highway 52 South, Wadesboro, North Carolina, (704) 694–2114, at the Person County Library, 319 South Main Street, Roxboro, North Carolina, (336) 597–7881, at the Office of the County Manager, 304 South Morgan Street, Room 212, Roxboro, North Carolina, (336) 597–1720, at the Leath Memorial Library, 412 East Franklin Street, Rockingham, North Carolina, (910) 895–6337, Pee Dee Electric Membership Corporation, Rockingham District Office, U.S. 22 South & Midway Road, Rockingham, North Carolina, (910) 997–4441, at the Fuquay-Varina Library, 133 South Fuquay Avenue, Fuquay-Varina, North Carolina, (919) 557–2788, at the Eva H. Perry Library, 2100 Shepherd's Vineyard Drive, Apex, North Carolina, (919) 387–2100, and at the Office of the Town Clerk, Holly Springs Town Hall, 128 South Main Street, Holly Springs, North Carolina, (919) 557–3900.

Government agencies, private organizations, and the public are invited to participate in the planning and analysis of the proposed project. The purpose of the meetings is to describe the projects and alternatives under consideration, discuss the scope of environmental issues to be considered, answer questions, and accept oral and written comments. Written comments will be accepted for at least 30 days after the public scoping meeting.

From information provided in the alternative evaluation and site selection study, input that may be provided by government agencies, private organizations, and the public, NCEMC will prepare an environmental analysis to be submitted to RUS for review. RUS will use the environmental analysis to determine the significance of the impacts of the projects and may adopt it as its environmental assessment of the projects. RUS' environmental assessment of the projects would be available for review and comment for 30 days.

Should RUS determine, based on the environmental assessment of the project, that the impacts of the construction and operation of the plant would not have a significant environmental impact, it will prepare a finding of no significant impact. Public notification of a finding of no significant impact would be published in the **Federal Register** and in newspapers with a circulation in the project area.

Any final action by RUS related to the proposed project will be subject to, and contingent upon, compliance with environmental review requirements as prescribed by CEQ and RUS environmental policies and procedures.

Dated: July 30, 2004.

**Mark Plank,**

*Acting Director, Engineering and Environmental Staff.*

[FR Doc. 04–17847 Filed 8–4–04; 8:45 am]

**BILLING CODE 3410–15–P**

## DEPARTMENT OF COMMERCE

**[I.D. 080204A]**

## Submission for OMB Review; Comment Request

The Department of Commerce has submitted to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35).

*Agency:* National Oceanic and Atmospheric Administration (NOAA).

*Title:* South Pacific Tuna Act.

*Form Number(s):* None.

*OMB Approval Number:* 0648–0218.

*Type of Request:* Regular submission.

*Burden Hours:* 242.

*Number of Respondents:* 22.

*Average Hours Per Response:* 15 minutes each for license application form and VMS application form; 1 hour each for registration application form and catch report form; 30 minutes for unloading logsheet; and 2 hours for annual VMS maintenance.

*Needs and Uses:* NOAA collects license, registration, catch and unloading information from tuna vessels fishing within a large region of the Pacific Ocean governed by the ''Treaty on Fisheries Between the Governments of Certain Pacific Island States and the Government of the United States''. The information collected is needed to meet obligations under that Treaty.

*Affected Public:* Business or other for-profit organizations.

*Frequency:* On occasion, weekly, annually.

*Respondent's Obligation:* Mandatory.

*OMB Desk Officer:* David Rostker, (202) 395–3897.

Copies of the above information collection proposal can be obtained by calling or writing Diana Hynek, Departmental Paperwork Clearance Officer, (202) 482–0266, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW, Washington, DC 20230 (or via the *Internet at dHynek@doc.gov*).

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to David Rostker, OMB Desk Officer, FAX number 202–395–7285, or *David__Rostker@omb.eop.gov*.

Dated: July 29, 2004.

**Gwellnar Banks,**

*Management Analyst, Office of the Chief Information Officer.*

[FR Doc. 04–17895 Filed 8–4–04; 8:45 am]

BILLING CODE 3510–22–S

## DEPARTMENT OF COMMERCE

**[I.D. 080204B]**

### Submission for OMB Review; Comment Request

The Department of Commerce has submitted to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35).

*Agency:* National Oceanic and Atmospheric Administration (NOAA).

*Title:* Southwest Region Permit Family of Forms.

*Form Number(s):* None.

*OMB Approval Number:* 0648–0204.

*Type of Request:* Regular submission.

*Burden Hours:* 282.

*Number of Respondents:* 1,706.

*Average Hours Per Response:* Confirmation of records, 10 minutes; correction/fill in blanks, 20 minutes; and full new permit forms, 1 hour.

*Needs and Uses:* The owners of vessels that fish out of West Coast ports for highly migratory species such as tuna, billfish, and sharks would be required to obtain permits registered for use by specific fishing vessels with endorsements for the gear(s) to be used. The permits are necessary to ensure the ability to monitor the fisheries and determine the effects and effectiveness of the fishery management program. The permits also provide a basic tool to contact the persons who are active in the fisheries and have the major stake in the management of the fisheries. The National Marine Fisheries Service (NMFS) and the Pacific Fishery Management Council can keep permit holders informed of prospective management changes so they can advise about the potential impacts and implications of the changes. The permits also provide a basis for determining who should be providing information about their fishing activities so that fishery trends and conditions can be tracked for possible identification of problems as well as to evaluate the success of the management program. Finally, permit information may support effective enforcement of fishery conservation and management measures.

*Affected Public:* Business or other for-profit organizations.

*Frequency:* On occasion.

*Respondent's Obligation:* Mandatory.

*OMB Desk Officer:* David Rostker, (202) 395–3897.

Copies of the above information collection proposal can be obtained by calling or writing Diana Hynek, Departmental Paperwork Clearance Officer, (202) 482–0266, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW, Washington, DC 20230 (or via the Internet at *dHynek@doc.gov*).

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to David Rostker, OMB Desk Officer, FAX number 202–395–7285, or *David__Rostker@omb.eop.gov*.

Dated: July 29, 2004.

**Gwellnar Banks,**

*Management Analyst, Office of the Chief Information Officer.*

[FR Doc. 04–17896 Filed 8–4–04; 8:45 am]

BILLING CODE 3510–22–S

## DEPARTMENT OF COMMERCE

**[I.D. 080204C]**

### Submission for OMB Review; Comment Request

The Department of Commerce has submitted to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35).

*Agency:* National Oceanic and Atmospheric Administration (NOAA).

*Title:* Coast Pilot Report.

*Form Number(s):* NOAA Form 77–6.

*OMB Approval Number:* 0648–0007.

*Type of Request:* Regular submission.

*Burden Hours:* 50.

*Number of Respondents:* 100.

*Average Hours Per Response:* 30 minutes.

*Needs and Uses:* NOAA produces the U.S. Coast Pilot, a series of nine books that supplement marine nautical charts. The Coast Pilot contains information essential to navigators in U.S. coastal and intra-coastal waters but that cannot be shown graphically on paper nautical charts. The Coast Pilot Report form is offered to the public as a means for recommending changes to the publication.

*Affected Public:* Individuals or households.

*Frequency:* On occasion.

*Respondent's Obligation:* Voluntary.

*OMB Desk Officer:* David Rostker, (202) 395–3897.

Copies of the above information collection proposal can be obtained by calling or writing Diana Hynek, Departmental Paperwork Clearance Officer, (202) 482–0266, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW, Washington, DC 20230 (or via the Internet at *dHynek@doc.gov*).

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to David Rostker, OMB Desk Officer, FAX number (202) 395–7285, or *David__Rostker@omb.eop.gov*.

Dated: July 29, 2004.

**Gwellnar Banks,**

*Management Analyst, Office of the Chief Information Officer.*

[FR Doc. 04–17897 Filed 8–4–04; 8:45 am]

BILLING CODE 3510–JE–S

## DEPARTMENT OF COMMERCE

**[I.D. 080204D]**

### Submission for OMB Review; Comment Request

The Department of Commerce has submitted to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35).

*Agency:* National Oceanic and Atmospheric Administration (NOAA).

*Title:* Vessel Monitoring System Requirements in the Western Pacific Pelagic Longline Fishery.

*Form Number(s):* None.

*OMB Approval Number:* 0648–0441.

*Type of Request:* Regular submission.

*Burden Hours:* 399.

*Number of Respondents:* 164.

*Average Hours Per Response:* 1 second.

*Needs and Uses:* The commercial fishing vessels active in the Hawaii-based pelagic longline fishery must allow National Marine Fisheries Service (NMFS) to install vessel monitoring system (VMS) units on their vessel when directed to do so by NMFS enforcement personnel. The VMS units automatically send periodic reports on the position of the vessel. NMFS uses the reports to monitor the vessel's location and activities while enforcing longline fishing area closures. NMFS pays for the units and messaging.

*Affected Public:* Business or other for-profit organizations.

*Frequency:* Hourly.

*Respondent's Obligation:* Mandatory.

*OMB Desk Officer:* David Rostker, (202) 395–3897.

Copies of the above information collection proposal can be obtained by calling or writing Diana Hynek, Departmental Paperwork Clearance Officer, (202) 482–0266, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW, Washington, DC 20230 (or via the Internet at *dHynek@doc.gov*).

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to David Rostker, OMB Desk Officer, FAX number (202) 395–7285, or *David__Rostker@omb.eop.gov*.

Dated: July 29, 2004.

**Gwellnar Banks,**

*Management Analyst, Office of the Chief Information Officer.*

[FR Doc. 04–17898 Filed 8–4–04; 8:45 am]

**BILLING CODE 3510–22–S**

## DEPARTMENT OF COMMERCE

### International Trade Administration

**[A–351–605, A–423–808, A–475–822, A–580–831]**

### Frozen Concentrated Orange Juice From Brazil and Stainless Steel Plate in Coils From Belgium, Italy, and the Republic of Korea; Extension of Final Results of Expedited Sunset Reviews of Antidumping Duty Order

**AGENCY:** Import Administration, International Trade Administration, Department of Commerce.

**ACTION:** Notice of extension of time limit for final results of expedited sunset reviews: frozen concentrated orange juice from Brazil and stainless steel plate in coils from Belgium, Italy, and the Republic of Korea.

**SUMMARY:** The Department of Commerce (''the Department'') is extending the time limit for its final results in the expedited sunset review of the antidumping duty orders on frozen concentrated orange juice (''FCOJ'') from Brazil and stainless steel plate in coils (''SSPC'') from Belgium, Italy, and the Republic of Korea. As a result of this extension, the Department intends to issue final results of these sunset reviews on or about August 30, 2004.

**EFFECTIVE DATE:** August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Hilary E. Sadler, Esq., Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street & Constitution Avenue, NW., Washington, DC 20230; telephone: (202) 482–4340.

**Extension of Final Results**

On April 1, 2004, the Department initiated sunset reviews of the antidumping duty orders of FCOJ from Brazil and SSPC from Belgium, Italy, and Korea. *See Initiation of Five-Year (Sunset) Reviews*, 69 FR 17129 (April 1, 2004). In these proceedings, the Department determined that it would conduct expedited sunset reviews of these orders based on responses from the domestic and respondent interested parties to the notice of initiations. The Department's final results of these reviews were originally scheduled for July 30, 2004.

In accordance with section 751(c)(5)(C)(ii) of the Tariff Act of 1930, as amended (''the Act''), the Department may treat sunset reviews as extraordinarily complicated if the issues to be considered are complex. In these reviews, the Department is analyzing the magnitude of dumping margins likely to prevail for several companies from multiple countries and additional issues surrounding import volume. Because the Department has determined that these issues are complex according to 751(c)(5)(C)(ii) of the Act, we are extending the deadline for issuance of the final results. The Department intends to issue the final results on or about August 30, 2004 in accordance with section 751(c)(5)(B) of the Act.

Dated: July 30, 2004.

**Joseph A. Spetrini,**

*Acting Assistant Secretary for Import Administration.*

[FR Doc. 04–17920 Filed 8–4–04; 8:45 am]

**BILLING CODE 3510–DS–P**

## DEPARTMENT OF COMMERCE

### International Trade Administration

**[A–357–405]**

### Barbed Wire and Barbless Fencing Wire From Argentina; Expedited Sunset Review of Antidumping Duty Order; Final Results

**AGENCY:** Import Administration, International Trade Administration, Department of Commerce.

**ACTION:** Expedited sunset review of antidumping duty order on barbed wire and barbless fencing wire From Argentina; final results.

**SUMMARY:** On April 1, 2004, the Department of Commerce (''the Department'') initiated a sunset review of the antidumping duty order on barbed wire and barbless fencing wire (''barbed wire'') from Argentina. On the basis of the notice of intent to participate, and an adequate substantive response filed on behalf of the domestic interested parties and an inadequate response, *i.e.*, no response from respondent interested parties, the Department conducted an expedited (120-day) sunset review. As a result of this sunset review, the Department finds that revocation of the antidumping duty order would likely lead to continuation or recurrence of dumping at the levels listed below in the section entitled ''Final Results of Review.''

**DATES:** *Effective Date:* August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Martha V. Douthit, Office of Policy, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230; telephone: (202) 482–5050.

**SUPPLEMENTARY INFORMATION:**

**Background**

On April 1, 2004, the Department initiated a sunset review of the antidumping duty order on barbed wire from Argentina pursuant to section 751(c) of the Tariff Act of 1930, as amended (''the Act'').[1] The Department received Notice of Intent to Participate on behalf of Davis Wire Corporation, Keystone Steel & Wire Company, and Oklahoma Steel & Wire Company, Inc. (''domestic interested parties''), within the deadline specified in section 351.218(d)(1)(i) of the Department's regulations. The domestic interested parties claimed interested party status under section 771(9)(C) of the Act as U.S. producers of the subject merchandise. We received a complete response from the domestic interested parties within the 30-day deadline specified in the Department's regulations under section 351.218(d)(3)(i). However, we did not receive responses from any respondent interested parties as required in section 351.218(d)(3)(i) of the Departments regulations. As a result of receiving no responses from respondent interested parties, the Department conducted an expedited (120-day) sunset review of this order pursuant to section 751(c)(3)(B) of the Act and section 351.218(e)(1)(ii)(C)(2) of the Department's regulations.

The antidumping duty order remains in effect for all Argentine manufacturers, producers, and exporters of the subject merchandise.

**Scope of the Order**

The merchandise covered by this order is barbed wire and barbless

[1] *See Initiation of Five-Year (Sunset) Reviews*, 69 FR 17129 (April 1, 2004).

fencing wire from Argentina, which is currently classifiable under Harmonized Tariff Schedule (''HTS'') item number 7313.00.00. The HTS item numbers are provided for convenience and customs purposes. The written product description remains dispositive.

**Analysis of Comments Received**

All issues raised in this review are addressed in the ''Issues and Decision Memorandum'' (''Decision Memo'') from Ronald K. Lorentzen, Acting Director, Office of Policy, Import Administration, to Joseph A. Spetrini, Acting Assistant Secretary for Import Administration, dated July 30, 2004, which is hereby adopted by this notice. The issues discussed in the Decision Memo include the likelihood of continuation or recurrence of dumping and the magnitude of the margin likely to prevail if the order were revoked. Parties can find a complete discussion of all issues raised in this sunset review and the corresponding recommendations in this public memo, which is on file in room B–099 of the main Commerce Building.

In addition, a complete version of the Decision Memo can be accessed directly on the Web at *http://ia.ita.doc.gov/frn*, under the heading ''August 2004.'' The paper copy and electronic version of the Decision Memo are identical in content.

**Final Results of Review**

We determine that revocation of the antidumping duty order on barbed wire from Argentina would likely lead to continuation or recurrence of dumping at the following percentage weighted-average percentage margins:

| Manufacturers/exporters/producers | Weighted-average margin (percent) |
|---|---|
| Acindar Industria Argentina de Aceros, S.A. | 69.02 |
| All Others | 69.02 |

This notice also serves as the only reminder to parties subject to administrative protective orders (''APO'') of their responsibility concerning the return or destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305 of the Department's regulations. Timely notification of the return or destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.

We are issuing and publishing the results and notice in accordance with sections 751(c), 752, and 777(i)(1) of the Act.

Dated: July 30, 2004.

**Joseph A. Spetrini,**

*Acting Assistant Secretary for Import Administration.*

[FR Doc. 04–17922 Filed 8–4–04; 8:45 am]

BILLING CODE 3510–DS–P

---

## DEPARTMENT OF COMMERCE

### International Trade Administration

**[A–570–007]**

### Continuation of Antidumping Duty Order: Barium Chloride From The People's Republic of China

**AGENCY:** Import Administration, International Trade Administration, Department of Commerce.

**ACTION:** Notice of continuation of antidumping duty order: barium chloride from The People's Republic of China.

**SUMMARY:** The Department of Commerce (''the Department'') has determined that revocation of the antidumping duty order on barium chloride from The People's Republic of China (''PRC''), would be likely to lead to continuation or recurrence of dumping. Therefore the Department is publishing notice of the continuation of the antidumping duty order on barium chloride from the PRC.

**EFFECTIVE DATE:** August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Martha V. Douthit, Office of Policy, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Ave., NW., Washington, DC 20230; telephone: (202) 482–5050.

**SUPPLEMENTARY INFORMATION:**

**Background**

On February 2, 2004, the Department initiated and the International Trade Commission (''ITC'') instituted a sunset review of the antidumping duty order on barium chloride from The People's Republic of China (''PRC''), pursuant to section 751(c) of the Act.[1] As a result of its review, the Department found that revocation of the antidumping duty order would be likely to lead to continuation or recurrence of dumping and notified the ITC of the magnitude of the margins likely to prevail were the order to be revoked.[2] On July 23, 2004, the ITC determined pursuant to section 751(c) of the Act, that revocation of the antidumping duty order on barium chloride from the PRC would be likely to lead to continuation or recurrence of material injury to an industry in the United States within a reasonably foreseeable time.[3]

**Scope of the Order**

The merchandise covered by this order is barium chloride, a chemical compound having the formula $BaCl_2$ or $BaCl_2$–$2H_2$ 0, currently classifiable under item 2827.38.00 of the Harmonized Tariff Schedules (HTS). HTS items numbers are provided for convenience and customs purposes. The written descriptions remain dispositive.

**Determination**

As a result of the determinations by the Department and ITC that revocation of this antidumping duty order would be likely to lead to continuation or recurrence of dumping and material injury to an industry in the United States, pursuant to section 751(d)(2) of the Act, the Department hereby orders the continuation of the antidumping duty order on barium chloride from the PRC. The effective date of continuation of this order will be the date of publication in the **Federal Register** of this Notice of Continuation. Pursuant to sections 751(c)(2) and 751(c)(6) of the Act, the Department intends to initiate the next five-year review of this order not later than July 2009.

Dated: July 30, 2004.

**Joseph A. Spetrini,**

*Acting Assistant Secretary for Import Administration.*

[FR Doc. 04–17933 Filed 8–4–04; 8:45 am]

BILLING CODE 3510–DS–P

---

## DEPARTMENT OF COMMERCE

### International Trade Administration

**[Docket No. A–570–836]**

### Glycine From The People's Republic of China: Rescission of Antidumping Duty New Shipper Review of Hebei New Donghua Amino Acid Co., Ltd.

**AGENCY:** Import Administration, International Trade Administration, Department of Commerce.

**SUMMARY:** On May 6, 2003, the Department published the notice of initiation of the new shipper review of the antidumping duty order on glycine

[1] *See Initiation of Five-year (''Sunset'') Reviews,* 69 FR 50 (January 2, 2004).

[2] *See Barium Chloride From The People's Republic of China; Final Results of the Sunset Review of Antidumping Duty Order,* 69 FR 3171 (June 7, 2004).

[3] *See Barium Chloride From China,* 69 FR 44059 (July 23, 2004), and USITC Publication 3702 (July 2004) (*Second Review*), Investigation No. 731–TA–149.

from The People's Republic of China (PRC) covering the period March 1, 2002, through February 28, 2003. The new shipper review covered exports by Hebei New Donghua Amino Acid Co., Ltd. (New Donghua). *See Glycine from The People's Republic of China: Initiation of Antidumping New Shipper Review*, 68 FR 23962 (May 6, 2003) (*New Shipper Initiation*). For the reasons discussed below, we are rescinding the review of New Donghua.

**EFFECTIVE DATE:** August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Scot Fullerton or Matthew Renkey at (202) 482–1386 and (202) 482–2312, respectively; Office of AD/CVD Enforcement VII, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230.

**Background**

We issued the preliminary results of this new shipper review on February 24, 2004. *See Notice of Preliminary Results of Antidumping Duty New Shipper Review: Glycine from The People's Republic of China*, 69 FR 9804 (March 2, 2004) (*Preliminary Results*). Previously, on February 5, 2004, we sent New Donghua a third supplemental questionnaire, which also included a request for information from its U.S. importer. We received the response to the supplemental questionnaire on February 12, 2004. In the *Preliminary Results*, we noted that the response to the third supplemental questionnaire would be evaluated for the purposes of the final results of this review. In the memorandum entitled *Bona Fide Nature of the Sale in the New Shipper Review of Hebei New Donghua Amino Acid Co., Ltd.*, dated February 24, 2004, and accompanying the *Preliminary Results*, we stated that, although questions remained about New Donghua's sale, we preliminarily concluded that its sale was *bona fide*, and that we would continue to examine the issue.

On May 3, 2004, we sent New Donghua a fourth supplemental questionnaire, which again included a request for information from its U.S. importer. We received New Donghua's response to this supplemental questionnaire in two submissions, one dated May 13, 2004, and the other dated May 20, 2004. On May 20, 2004, the Department extended the due date for the final results to July 23, 2004. *See Notice of Extension of Time Limit of Final Results of New Shipper Review: Glycine from The People's Republic of China*, 69 FR 29922 (May 26, 2004) (*Final Extension Notice*). In the *Final Extension Notice*, one of the reasons stated for extending the final results was the issue of the *bona fide* nature of New Donghua's sale.

We received case briefs from petitions (Dow Chemical Company and Chattem Chemicals, Inc.) and New Donghua on June 17, 2004, and on June 22, 2004, both parties filed rebuttal briefs. On June 30, 2004, we sent a letter to New Donghua stating that we were rejecting its case brief on the basis that is contained new factual information. On July 16, 2004, after evaluating comments from New Donghua and petitioners on the rejection issue, we confirmed our decision to reject New Donghua's case brief. New Donghua re-filed its case brief, minus the new factual information, on July 19, 2004.

In addition to commenting on the *bona fide* nature of New Donghua's U.S. sale, parties' briefs also addressed several other issues: (1) Whether the Department should continue to apply partial adverse facts available (AFA) to New Donghua as it did in the *Preliminary Results*, (2) whether the Department should apply total AFA to New Donghua, (3) what the Department should use as the surrogate value for monochloroacetic acid, (4) what the Department should use as the surrogate for the financial ratios, and (5) whether or not to include foremen in New Donghua's labor factor calculation. Since, as discussed below, we are rescinding this review, we need not address the parties' comments on these issues.

**Scope of the Antidumping Duty Order**

The product covered by this antidumping duty order is glycine, which is a free-flowing crystalline material, like salt or sugar. Glycine is produced at varying levels of purity and is used as a sweetener/taste enhancer, a buffering agent, reabsorbable amino acid, chemical intermediate, and a metal complexing agent. Glycine is currently classifiable under subheading 2922.49.4020 of the Harmonized Tariff Schedule of the United States (HTSUS). This order covers glycine of all purity levels. Although the HTSUS subheading is provided for convenience and customs purposes, the written description of the scope of this order is dispositive.

**Rescission of Review**

The Department takes its responsibility to review the *bona fides* of new shipper sales very seriously. Therefore, we examine a number of factors, all of which may speak to the commercial realities surrounding the sale of subject merchandise. Our analysis of the *bona fides* of New Donghua's U.S. sale and our decision to rescind the new shipper review are based on the totality of the circumstances surrounding this single sale. Because much of the information necessary to our analysis of *bona fides* is business proprietary, we have addressed the *bona fide* issue and all of the parties' comments on *bona fides* in the *Memorandum from Gary Taverman to James J. Jochum; The Bona Fides Analysis for Hebei New Donghua Amino Acid Co., Ltd.'s Sale in the New Shipper Review of Glycine from The People's Republic of China* (*Rescission Memo*), issued concurrently with this notice. The Department has determined that the new shipper sale made by New Donghua was not *bona fide* because (1) the price for New Donghua's sale of glycine was not commercially reasonable when compared to the prices of other imports of glycine from the PRC and global market prices, (2) the quantity of New Donghua's glycine sale is low in comparison with other U.S. glycine imports from the PRC, and (3) the sale was not consistent with the normal business practices between a buyer and seller and was otherwise not commercially reasonable. *Id.* at 20–21. Taken as a whole, these facts lead the Department to conclude that the sale was not commercially reasonable or *bona fide*. As a result, we are rescinding this new shipper review.

**Call Deposit Requirements**

The Department will notify U.S. Customs and Border Protection (CBP) that bonding is no longer permitted to fulfill security requirements for shipments from New Donghua of glycine from the PRC entered, or withdrawn from warehouse, for consumption in the United States on or after the publication of this notice of rescission of antidumping duty new shipper review in the **Federal Register**. Further, effective upon publication of this notice for all shipments of the subject merchandise exported by New Donghua and entered, or withdrawn from warehouse, for consumption, the cash deposit rate will be the PRC-wide rate of 155.89 percent *ad valorem*.

**Assessment of Antidumping Duties**

The Department shall instruct CBP to assess antidumping duties on all appropriate entries. Since we are rescinding this antidumping duty new shipper review with respect to New Donghua, the PRC-wise rate of 155.89 percent in effect at the time of entry applies to all exports of glycine from the PRC by New Donghua entered or withdrawn from warehouse for

consumption during the period of review (March 1, 2002, through February 28, 2003). The Department will issue appropriate assessment instructions directly to CBP within 15 days of publication of this notice of rescission of antidumping duty new shipper review.

**Notification to Importers**

This notice also serves as a reminder to importers of their responsibility under § 351.402(f) of the Department regulations to file a certificate regarding the reimbursement of antidumping duties prior to liquidation of the relevant entries during this review period. Failure to comply with this requirement could result in the Secretary's presumption that reimbursement of antidumping duties occurred and the subsequent assessment of double antidumping duties.

This notice also serves as a reminder to parties subject to administrative protective orders (APO) of their responsibility concerning the disposition of proprietary information disclosed under APO in accordance with section 351.305(a)(3) of the Department regulations. Timely written notification of the return/destruction of APO material or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanctions.

We are issuing and publishing this determination and notice in accordance with sections 751(a)(2)(B) and 777(i)(1) of the Tariff Act of 1930, as amended.

Dated: July 23, 2004.

**Holly A. Kuga,**

*Acting Assistant Secretary for Import Administration.*

[FR Doc. 04–17917 Filed 8–4–04; 8:45 am]

BILLING CODE 3510–DS–M

---

## DEPARTMENT OF COMMERCE

### International Trade Administration

**[A–570–863]**

### Honey From The People's Republic of China: Initiation of New Shipper Antidumping Duty Review

**AGENCY:** Import Administration, International Trade Administration, Department of Commerce.

**EFFECTIVE DATE:** August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Steve Williams at (202) 482–4619 or Jim Nunno at (202) 482–0783, respectively; Antidumping and Countervailing Duty Enforcement Group III, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230.

**SUPPLEMENTARY INFORMATION:**

**Background**

The Department received a timely request from Foodworld International Club Limited (''Foodworld'') in accordance with 19 CFR 351.214 (c), for a new shipper review of the antidumping duty order on honey from The People's Republic of China (''PRC''), which has a December annual anniversary month and a June semiannual anniversary month. *See Notice of Amended Final Determination of Sales at Less Than Fair Value and Antidumping Duty Order; Honey from The People's Republic of China,* 66 FR 63670 (December 10, 2001). Foodworld identified itself as the exporter of honey produced by its producer Anhui Tianxin Bee Products Co., Ltd. (''Anhui Tianxin''). As required by 19 CFR 351.214(b)(2)(i), (ii), and (iii)(A), Foodworld and Anhui Tianxin Bee Products each certified that they did not export honey to the United States during the period of investigation (''POI''), and that they have never been affiliated with any exporter or producer which exported honey during the POI. Furthermore, each company has also certified that their export activities are not controlled by the central government of the PRC, satisfying the requirements of 19 CFR 351.214(b)(2)(iii)(B). Pursuant to the Department's regulations at 19 CFR 351.214(b)(2)(iv), Foodworld submitted documentation establishing the date on which the subject merchandise was first entered for consumption in the United States, the volume of that first shipment, and any subsequent shipment and the date of the first sale to an unaffiliated customer in the United States.

On July 13, 2004 and July 16, 2004 the Department issued pre-initiation supplemental questionnaires to Foodworld to clarify company information submitted in their requests to the Department for a new shipper review. In Foodworld's supplemental questionnaire response, dated July 21, Foodworld adequately responded to the Department's request for clarification on Customs documents attached to Foodworld's new shipper review request. Foodworld also provided state incorporation documents for the importer of record at the Department's request.

The Department conducted Customs database queries to determine whether Foodworld's shipment had officially entered the United States via assignment of an entry date in the Customs database by the U.S. Customs and Border Protection (CBP). In addition, the Department confirmed through research in PIERS and State incorporation records that Foodworld International and the importer of record appear to be bona fide companies.

**Scope**

The merchandise under review is honey from the PRC. The products covered are natural honey, artificial honey containing more than fifty percent natural honey by weight, preparations of natural honey containing more than fifty percent natural honey by weight, and flavored honey. The subject merchandise includes all grades and colors of honey whether in liquid, creamed, comb, cut comb, or chunk form, and whether packaged for retail or in bulk form. The merchandise under review is currently classifiable under item 0409.00.00, 1702.90.90, and 2106.90.99 of the Harmonized Tariff Schedule of the United States (HTSUS). Although the HTSUS subheading is provided for convenience and customs purposes, the written description of the merchandise under review is dispositive.

**Initiation of Review**

In accordance with section 751(a)(2)(B) of the Act, as amended, and 19 CFR 351.214(d)(1), and based on information on the record, we are initiating a new shipper review for Foodworld. *See Memoranda to the File through Edward C. Yang, ''New Shipper Review Initiation Checklist,''* dated July 30, 2004. We intend to issue the preliminary results of this review not later than 180 days after the date on which this review was initiated, and the final results of this review within 90 days after the date on which the preliminary results were issued.

Pursuant to 19 CFR 351.214(g)(1)(i)(A) of the Department's regulations, the period of review (''POR'') for a new shipper review initiated in the month immediately following the anniversary month will be the twelve-month period immediately preceding the anniversary month. Therefore, the POR for this new shipper review is:

| Antidumping duty proceeding | Period to be reviewed |
|---|---|
| Exporter: Foodworld International Club Limited.<br>Producer: Anhui Tianxin Bee Products Co., Ltd. | 12/01/03–05/31/04 |

It is the Department's usual practice in cases involving non-market economies

to require that a company seeking to establish eligibility for an antidumping duty rate separate from the country-wide rate to provide evidence of *de jure* and *de facto* absence of government control over the company's export activities. Accordingly, we will issue a questionnaire to Foodworld, including a separate rates section. The review will proceed if the responses provide sufficient indication that Foodworld is not subject to either *de jure* or *de facto* government control with respect to their exports of honey. However, if Foodworld does not demonstrate their eligibility for a separate rate, then it will be deemed not separate from other companies that exported during the POI and the new shipper review will be rescinded.

In accordance with section 751(a)(2)(B)(iii) of the Act and 19 CFR 351.214(e), we will instruct the CBP to allow, at the option of the importer, the posting, until the completion of the review, of a single entry bond or security in lieu of a cash deposit for certain entries of the merchandise exported by Foodworld. Specifically, since Foodworld has identified Anhui Tianxin as the producer of the subject merchandise for the sale under review, we will instruct CBP to limit the bonding option only to entries of merchandise from Foodworld that were produced by Anhui Tiaxin Bee Products.

Interested parties that need access to proprietary information in this new shipper review should submit applications for disclosure under administrative protective orders in accordance with 19 CFR 351.305 and 351.306.

This initiation and notice are in accordance with section 751(a) of the Act (19 U.S.C. 1675(a)) and 19 CFR 351.214(d).

Dated: July 30, 2004.

**Gary Taverman,**

*Acting Deputy Assistant Secretary for Import Administration, Group I.*

[FR Doc. 04–17934 Filed 8–4–04; 8:45 am]

**BILLING CODE 3510–DS–P**

## DEPARTMENT OF COMMERCE

### International Trade Administration

**[A–122–814]**

### Pure Magnesium From Canada: Final Results of 2002/2003 Antidumping Duty Administrative Review and Partial Rescission of Review

**AGENCY:** Import Administration, International Trade Administration, Department of Commerce.

**ACTION:** Notice of final results of administrative review and partial rescission of review.

**SUMMARY:** On April 16, 2004, the Department of Commerce published the preliminary results of the 2002/2003 administrative review of the antidumping duty order on pure magnesium from Canada with respect to Norsk Hydro Canada Inc. This review covers sales of pure magnesium from Canada to the United States during the period August 1, 2002, through July 31, 2003. We provided interested parties with an opportunity to comment on the preliminary results of this review, but received no comments. The final results do not differ from the preliminary results of this review, in which we found that the respondent made sales in the United States at prices not below normal value.

**DATES:** *Effective Date:* August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Scott Holland, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230; telephone: (202) 482–1279.

**SUPPLEMENTARY INFORMATION:**

#### Background

The Department of Commerce (''the Department'') published the preliminary results of this review on April 16, 2004 (*see Pure Magnesium from Canada; Preliminary Results of Antidumping Duty Administrative Review and Preliminary Partial Rescission of Review*, 69 FR 20597 (April 16, 2004) (*''Preliminary Results''*)).

We invited interested parties to comment on the preliminary results of this review. No comments were received.

#### Scope of the Order

The product covered by this order is pure magnesium. Pure unwrought magnesium contains at least 99.8 percent magnesium by weight and is sold in various slab and ingot forms and sizes. Granular and secondary magnesium are excluded from the scope currently classifiable under subheading 8104.11.0000 of the Harmonized Tariff Schedule (''HTS''). The HTS item number is provided for convenience and for customs purposes. The written description of the scope of the order remains dispositive.

#### Period of Review

The period of review (''POR'') is August 1, 2002, through July 31, 2003.

#### Partial Rescission

In accordance with 19 CFR 351.213(d)(3), and consistent with the *Preliminary Results*, we are rescinding this review with respect to Magnola Metallurgy Inc., which made no shipments of pure magnesium to the United States during this POR.

#### Fair Value Comparisons

To determine whether sales of pure magnesium from Canada to the United States were made at less than normal value (''NV''), we compared export price (''EP'') to NV. Our calculations followed the methodologies described in the *Preliminary Results*.

#### Currency Conversions

We made currency conversions in accordance with section 773A of the Tariff Act of 1930, as amended (''the Act'') in the same manner as in the *Preliminary Results*.

#### Final Results of the Review

We have determined that no changes to our analysis are warranted for purposes of these final results. As a result of this review, we determine that the following percentage weighted-average margin exists for the period August 1, 2002, through July 31, 2003:

| Manufacturer/exporter | Margin |
|---|---|
| Norsk Hydro Canada Inc. | 0.01 (*de minimis*) |

#### Assessment Rates

The Department shall determine, and U.S. Customs and Border Protection (''CBP'') shall assess, antidumping duties on all appropriate entries. In accordance with 19 CFR 351.212(b)(1), we have calculated importer (or customer)-specific assessment rates for merchandise subject to this review. To determine whether the duty assessment rates were *de minimis*, in accordance with the requirement set forth in 19 CFR 351.106(c)(2), we calculated importer (or customer)-specific *ad valorem* rates by aggregating the dumping margins calculated for all U.S. sales to that importer (or customer) and dividing this amount by the total value of the sales to that importer (or customer). Where an importer (or customer)-specific *ad valorem* rate was greater than *de minimis*, we calculated a per unit assessment rate by aggregating the dumping margins calculated for all U.S. sales to that importer (or customer) and dividing this amount by the total quantity sold to that importer (or customer).

Pending the final disposition of a NAFTA panel review, the Department

will not order the liquidation of entries of pure magnesium from Canada exported by NHCI on or after August 1, 2000, at this time.[1] Liquidation will occur following the final judgement in the NAFTA panel appeals process.

**Cash Deposit Requirements**

The following antidumping duty deposits will be required on all shipments of pure magnesium from Canada entered, or withdrawn from warehouse, for consumption, on or after the publication date of the final results of this administrative review, as provided by section 751(a)(1) of the Act: (1) No cash deposit rate will be required for NHCI because its weighted-average margin is *de minimis*, (*i.e.*, less than 0.5 percent); (2) for merchandise exported by manufacturers or exporters not covered in this review but covered in the original less-than-fair-value investigation or a previous review, the cash deposit rate will continue to be the most recent rate published in the final determination or final results for which the manufacturer or exporter received an individual rate; (3) if the exporter is not a firm covered in this review, the previous review, or the original investigation, but the manufacturer is, the cash deposit rate will be the rate established for the most recent period for the manufacturer of the merchandise; and (4) if neither the exporter nor the manufacturer is a firm covered in this or any previous reviews, the cash deposit rate will be 21 percent, the ''all others'' rate established in the less than fair value investigation. *See Pure Magnesium from Canada; Amendment of Final Determination of Sales At Less Than Fair Value and Order in Accordance With Decision on Remand*, 58 FR 62643 (November 29, 1993).

**Notification to Importers**

This notice serves as a final reminder to importers of their responsibility under 19 CFR 351.402(f)(2) to file a certificate regarding the reimbursement of antidumping duties prior to liquidation of the relevant entries during this review period. Failure to comply with this requirement could result in the Secretary's presumption that reimbursement of antidumping duties occurred and the subsequent assessment of doubled antidumping duties.

[1] *See* January 28, 2003, letter from the Department granting NHCI's October 23, 2002, request for the continuation of suspension of liquidation covering all unliquidated entries of subject merchandise exported by NHCI on or after August 1, 2000.

**Notification Regarding APOs**

This notice also serves as a reminder to parties subject to administrative protective orders (''APOs'') of their responsibility concerning the return or destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305, which continues to govern business proprietary information in this segment of the proceeding. Timely written notification of the return/destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.

We are issuing and publishing these results in accordance with sections 751(a)(1) and 777(i)(1) of the Act.

Dated: July 30, 2004.

**James J. Jochum,**

*Assistant Secretary for Import Administration.*

[FR Doc. 04–17919 Filed 8–4–04; 8:45 am]

BILLING CODE 3510–DS–P

---

## DEPARTMENT OF COMMERCE

### International Trade Administration

**[A–570–825]**

### Sebacic Acid From The People's Republic of China: Preliminary Results of Antidumping Duty Administrative Review and Notice of Partial Recision

**AGENCY:** Import Administration, International Trade Administration, Department of Commerce.

**SUMMARY:** The Department of Commerce is conducting an administrative review of the antidumping duty order on sebacic acid from The People's Republic of China (PRC) in response to a request by SST Materials, Inc. d/b/a Genesis Chemicals, Inc., a domestic producer of the subject merchandise. The period of review is July 1, 2002, through June 30, 2003. We have preliminarily determined that Guangdong Chemicals Import and Export Corporation (Guangdong) has sold subject merchandise at less than normal value. If these preliminary results are adopted in our final results of administrative review, we will instruct Customs and Border Protection (CBP) to assess antidumping duties on entries subject to this review by these exporters.

**DATES:** *Effective Date:* August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** John Conniff, AD/CVD Enforcement, Group II, Office 4, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230; telephone: (202) 482–1009.

**SUPPLEMENTARY INFORMATION:**

**Background**

On July 2, 2003, the Department of Commerce (the Department) published in the **Federal Register** a notice of ''Opportunity to Request an Administrative Review'' of the antidumping duty order on sebacic acid from the PRC covering the period July 1, 2002, through June 30, 2003. *See Antidumping or Countervailing Duty Order, Finding, or Suspended Investigation; Opportunity to Request Administrative Review,* 68 FR 50750 (July 2, 2003).

On July 31, 2003, in accordance with 19 CFR 351.213(b)(1), SST Materials, Inc. d/b/a Genesis Chemicals, Inc. (Genesis), a domestic producer of the subject merchandise, requested an administrative review of Tianjin Chemical Import and Export Corporation (Tianjin) and Guangdong.

On August 13, 2003, the Department issued antidumping questionnaires to Guangdong and Tianjin.[1] On August 20, 2003, Guangdong and Tianjin submitted a request that the Department decline to initiate the administrative review, because Genesis did not properly file its request. Specifically, Genesis did not serve its request for an administrative review on either Guangdong or Tianjin. On August 22, 2003, we afforded Genesis an opportunity to remedy the deficiencies in its filing. *See* memorandum from Michael Strollo to Louis Apple entitled ''Sebacic Acid from The People's Republic of China: Initiation of an Administrative Review,'' dated August 22, 2003; *see also* memorandum to the file from Patrick Connolly entitled ''Sebacic Acid from The People's Republic of China: Service of Request for Administrative Review on Respondents,'' dated August 25, 2003. On August 22, 2003, we published a notice of initiation of this administrative review. *See Initiation of Antidumping and Countervailing Duty Administrative Reviews and Requests for Revocation in*

[1] Section of A of the questionnaire requests general information concerning a company's corporate structure and business practices, the merchandise under this review that it sells, and the manner in which it sells that merchandise in all of its markets. Section B requests a complete listing of all home market sales, or, if the home market is not viable, of sales in the most appropriate third-country market (this section is not applicable to respondents in non-market economy (NME) cases). Section C requests a complete listing of U.S. sales. Section D requests information on the factors of production of the merchandise under investigation. Section E requests information on further manufacturing.

*Part,* 68 FR 50750 (Aug. 22, 2003). On August 26, 2003, Genesis submitted a letter to the Department certifying that it had remedied the procedural deficiencies in its original filing.

We received timely responses from Guangdong to sections A, C, and D of the initial antidumping questionnaire and associated supplemental questionnaires, and we received a timely certification from Tianjin that all of its exports of sebacic acid were manufactured by Hungshui Donfeng Chemical Co. (Hengshui), and thus were excluded from the antidumping duty order. For further information, *see* the *Tianjin/Hengshui: Partial Recision of Review* section below.

On March 15, 2004, the Department extended the time period for the preliminary results in this review. *See Sebacic Acid from The People's Republic of China: Extension of Time Limit for Preliminary Results in Antidumping Duty Administrative Review,* 69 FR 12127 (Mar. 15, 2004).

**Tianjin/Hengshui: Partial Recision of Review**

The Department previously revoked, in part, the antidumping duty order on sebacic acid from The PRC, with respect to Tianjin's sales of subject merchandise produced by Hengshui. *See Sebacic Acid From The People's Republic of China: Final Results of Antidumping Duty Administrative Review and Determination To Revoke Order in Part (Sebacic Acid Sixth Review Final)*, 67 FR 69719, 69720 (Nov. 19, 2002). As noted above, on August 13, 2003, the Department issued an antidumping questionnaire to Tianjin, and on September 29, 2003, Tianjin submitted a certification that all of its exports of sebacic acid were manufactured by Hengshui, and thus were excluded from the antidumping duty order. Therefore, in accordance with 19 CFR 351.213(d)(3) and consistent with our practice, we are rescinding this review of the antidumping duty order on sebacic acid from the PRC for the period of July 1, 2002, through June 30, 2003 with respect to subject merchandise exported to the United States by Tianjin.

On February 10, 2004, Genesis alleged that, subsequent to the revocation of the order, Tianjin resumed dumping sebacic acid in the United States with respect to its U.S. sales of sebacic acid produced by Hengshui. Accordingly, Genesis requested that the Department reinstate the antidumping duty order on exports of this merchandise. On February 17, 2004, Tianjin submitted a letter to the Department in which it argued that Genesis' request should be rejected because: (1) it is outside the scope of the 2002–2003 administrative review; and (2) it was untimely filed in that segment of the proceeding. Tianjin argued that Genesis' allegation should instead be considered in the context of a changed circumstances review, pursuant to 19 CFR 351.216.

On June 25, 2004, the Department initiated a changed circumstances review of the antidumping duty order on sebacic acid from the PRC to consider whether the Department should reinstate the order with respect to subject merchandise produced by Hengshui and exported to the United States by Tianjin. *See Sebacic Acid From The People's Republic of China: Notice of Initiation of Changed Circumstances Review,* 69 FR 39906 (July 1, 2004) (*Sebacic CCR Intitiation*). Accordingly, this issue will not be addressed in this administrative review.

**Scope of Review**

The products covered by this order are all grades of sebacic acid, a dicarboxylic acid with the formula $(CH2)_8(COOH)_2$, which include but are not limited to CP Grade (500ppm maximum ash, 25 maximum APHA color), Purified Grade (1000ppm maximum ash, 50 maximum APHA color), and Nylon Grade (500ppm maximum ash, 70 maximum ICV color). The principal difference between the grades is the quantity of ash and color. Sebacic acid contains a minimum of 85 percent dibasic acids of which the predominant species is the $C_{10}$ dibasic acid. Sebacic acid is sold generally as a free-flowing powder/flake. Sebacic acid has numerous industrial uses, including the production of nylon 6/10 (a polymer used for paintbrush and toothbrush bristles and paper machine felts), plasticizers, esters, automotive coolants, polyamides, polyester castings and films, inks and adhesives, lubricants, and polyurethane castings and coatings. Sebacic acid is currently classifiable under subheading 2917.13.00.30 of the *Harmonized Tariff Schedule of the United States* (HTSUS). Although the HTSUS subheading is provided for convenience and customs purposes, the written description of the scope of this proceeding is dispositive.

**Separate Rates**

It is the Department's policy to assign all exporters of the merchandise subject to review in non-market-economy (NME) countries a single rate, unless an exporter can demonstrate an absence of government control, both in law and in fact, with respect to its exports to the United States. To establish whether an exporter is sufficiently independent of government control to be entitled to a separate rate, the Department analyzes the exporter in light of the criteria established in the *Final Determination of Sales at Less Than Fair Value: Sparklers from The People's Republic of China,* 56 FR 20588 (May 6, 1991) (*Sparklers*), as amplified by *Final Determination of Sales at Less Than Fair Value: Silicon Carbide from The People's Republic of China,* 59 FR 22585 (May 2, 1994) (*Silicon Carbide*). Evidence supporting, though not requiring, a finding of *de jure* absence of government control over export activities includes: (1) An absence of restrictive stipulations associated with an individual exporter's business and export licenses; (2) any legislative enactments decentralizing control of companies; and (3) any other formal measures by the government decentralizing control of companies. With respect to evidence of a *de facto* absence of government control, the Department considers the following four factors: (1) Whether the respondent sets its own export prices independently from the government and other exporters; (2) whether the respondent can retain the proceeds from its export sales; (3) whether the respondent has the authority to negotiate and sign contracts; and (4) whether the respondent has autonomy from the government regarding the selection of management. *See Silicon Carbide*, 59 FR at 22587; *see also Sparklers*, 56 FR at 20589.

With respect to Guangdong, in our final results for the most recently completed review period (*i.e.*, July 1, 2000, through June 30, 2001), the Department determined there was both *de jure* and *de facto* absence of government control of this company's export activities and determined that it warranted a company-specific dumping margin. *See Sebacic Acid Sixth Review Final,* 67 FR 69719. For this review, Guangdong has responded to the Department's request for information regarding separate rates. We have found that the evidence on the record is consistent with the final results in the *Sebacic Acid Sixth Review Final* and continues to demonstrate an absence of both *de jure* and *de facto* government control with respect to its exports in accordance with the criteria identified in *Sparklers* and *Silicon Carbide.*

**Export Price**

We calculated export price (EP) in accordance with section 772(a) of the Tariff Act of 1930, as amended (the Act) because the subject merchandise was sold directly to the first unaffiliated purchaser in the United States prior to importation and constructed export

price methodology was not otherwise warranted. As appropriate, we calculated EP based on packed, free-on-board, PRC-port prices to unaffiliated purchasers in the United States. We deducted from the starting price amounts for foreign inland truck freight and foreign brokerage and handling. As these movement services were provided by NME suppliers, we valued them using surrogate values from Indian suppliers. For further discussion of our use of surrogate data in an NME proceeding, as well as the selection of India as the appropriate surrogate country, see the ''Normal Value'' section of this notice, below.

For foreign inland freight, we obtained publicly-available information which was published in the October 2002 through March 2003 editions of *Chemical Weekly.* For foreign brokerage and handling expenses, we used a publicly summarized version of the average value for brokerage and handling expenses reported in *Final Determination of Sales at Less Than Fair Value: Certain Hot-Rolled Carbon Steel Flat Products from India,* 67 FR 50406 (Oct. 3, 2001), and used in the 2000–2001 administrative review of freshwater crawfish tail meat from the PRC. *See* the memorandum to the file from Mathew Renkey and Adina Teodorescu dated September 30, 2002, and entitled ''Administrative Review of Freshwater Crawfish Tail Meat from The People's Republic of China: Factor Values Memorandum,'' the relevant portion of which we have placed on the record of this review, and which is on file in the Central Records Unit (CRU), Room B–099 of the main Commerce building. We inflated the per kilogram price (in rupees) to the POR using wholesale price index (WPI) data from the International Monetary Fund (IMF). For further discussion, see the memorandum to the file from Gregory Kalbaugh entitled ''Preliminary Valuation of Factors of Production for the Preliminary Results of the 2002–2003 Administrative Review of Sebacic Acid from The People's Republic of China,'' dated July 30, 2004 (*FOP Memo*), which is on the record of this review and is on file in the CRU.

**Normal Value**

*A. Surrogate Country*

Section 773(c)(4) of the Act requires the Department to value an NME producer's factors of production, to the extent possible, in one or more market economy countries that: (1) are at a level of economic development comparable to that of the NME country, and (2) are significant producers of comparable merchandise. *See* March 9, 2004, Surrogate Country Selection Memorandum from Ronald Lorentzen to Louis Apple entitled ''Administrative Review of Sebacic Acid from The People's Republic of China: Surrogate Country Selection,'' which is on the record of this review and is on file in the CRU.

For purposes of the most recent segment of this proceeding, we found that India is a producer of oxalic acid, a product comparable to sebacic acid. *See Sebacic Sixth Review.* For purposes of the preliminary results, we continue to find that India is a significant producer of oxalic acid. *See* the July 30, 2004, memorandum to the file from Greg Kalbaugh entitled ''Oxalic Acid Production in India During the Period of Review,'' which is on the record of this review and is on file in the CRU. Accordingly, as India is at a level of economic development comparable to that of the PRC, and a significant producer of a product comparable to the subject merchandise, we find that India fulfills both statutory requirements for use as a surrogate country and have continued to use India as the surrogate country in this administrative review. Accordingly, we have calculated NV using Indian values for the PRC producers' factors of production. We have obtained and relied upon publicly available information wherever possible.

*B. Factors of Production*

In accordance with 19 CFR 351.408(c)(1), the Department will normally use publicly available information to value factors of production. However, the Department's regulations also provide that where a producer purchases an input from a market economy supplier and pays for it in market economy currency, the Department employs the actual price paid for the input to the market economy supplier to calculate the factors-based NV. *Id.; see also Lasko Metal Products* v. *United States,* 43 F. 3d 1442, 1445–1446 (Fed. Cir. 1994).

In accordance with section 773(c) of the Act, we calculated NV based on factors of production reported by Guangdong for the POR. To calculate NV, the reported per-unit factor quantities were multiplied by publicly available Indian surrogate values. Factors of production include, but are not limited to: (1) Hours of labor required; (2) quantities of raw materials employed; (3) amounts of energy and other utilities consumed; and (4) representative capital cost, including depreciation. In examining surrogate values, we selected, where possible, the publicly available value which was: (1) An average non-export value; (2) representative of a range of prices within the POR or most contemporaneous with the POR; (3) product-specific; and (4) tax-exclusive. For a more detailed explanation of the methodology used in calculating various surrogate values, see the *FOP Memo.*

In selecting the surrogate values, we considered the quality, specificity, and contemporaneity of the data. Where appropriate, we adjusted surrogate values to reflect inflation up to the POR using the WPI published by the IMF. In accordance with this methodology, we valued the factors of production as follows:

To value caustic soda, cresol, phenol, sulfuric acid, and zinc oxide, we obtained information from the Indian publication *Chemical Weekly.* Where necessary, we adjusted the values reported in *Chemical Weekly* to exclude sales and excise taxes. To value activated carbon, inner polyethylene bags, woven plastic bags, jumbo plastic bags, and bag closing thread, we obtained import prices from the *Government of India's Department of Commerce Import/Export Data* for the period April 2002 through March 2003. To value steam coal, we obtained import prices from the *Monthly Statistics of the Foreign Trade of India (MSFTI),* and contained in the *World Trade Atlas* for the period April 2002 through March 2003.

Consistent with the methodology employed in *Sebacic Acid Sixth Review,* we have determined that fatty acid and glycerine are by-products. Because they are by-products, we subtracted the sales revenue of fatty acid and glycerine, from the estimated production costs of sebacic acid. This treatment of by-products is also consistent with generally accepted accounting principles. *See Cost Accounting: A Managerial Emphasis* (1991) at pages 539–544. To value fatty acid, we used data published in *Government of India's Department of Commerce Import/Export Data.* To value glycerine, we used data published in *Chemical Weekly.*

We also allocated a by-product credit for glycerine to the production cost for the co-product capryl alcohol. We deducted a by-product credit for glycerine from sebacic acid based on the ratio of the value of sebacic acid to the total value of both sebacic acid and capryl alcohol.

Consistent with the methodology employed in the previous administrative review, we have determined that capryl alcohol is a co-product and have allocated the factor inputs based on the relative surrogate

values for this product and sebacic acid. *See Sebacic Acid Sixth Review.* Additionally, we have used the production times necessary to complete each production stage of sebacic acid as a basis for allocating the amount of labor, energy usage, and factory overhead among the co-product(s). This treatment of co-products is consistent with generally accepted accounting principles. *See Cost Accounting: A Managerial Emphasis* (1991) at pages 528–533. To value capryl alcohol, we used data published in *Government of India's Department of Commerce Import/Export Data.*

To value electricity, we used data from the *International Energy Agency's Key World Energy Statistics 2003* report. For further discussion, *see* the *FOP Memo.*

We made adjustments to account for freight costs between the suppliers and the respective manufacturing facilities for each of the factors of production identified above. In accordance with our practice, for inputs for which we used cost-insurance-freight import values from India, we calculated a surrogate freight cost using the shorter of the reported distances either from the closest PRC ocean port to the factory or from the domestic supplier to the factory. *See Final Determination of Sales at Less Than Fair Value: Certain Cut-to-Length Carbon Steel Plate From The People's Republic of China,* 62 FR 61964, 61977 (Nov. 20, 1997); *see also Sigma Corp.* v. *United States,* 117 F.3d 1401, 1407–1408 (Fed. Cir. 1997).

For truck freight, we obtained publicly-available information which was published in the October 2002 through March 2003 editions of *Chemical Weekly. See* the *FOP Memo.* To value rail freight, we relied upon price quotes obtained from Indian rail freight companies in November 1999. These quotes were used in the investigation of bulk aspirin from the PRC and the 1999–2000 administrative review of tapered roller bearings from the PRC. *See Notice of Preliminary Determination of Sales at Less Than Fair Value: Bulk Aspirin From The People's Republic of China,* 65 FR 116, 119 (Jan. 3, 2000); and *Tapered Roller Bearings and Parts Thereof, Finished and Unfinished, From The People's Republic of China: Preliminary Results of 1999–2000 Administrative Review, Partial Rescission of Review, and Notice of Intent Not To Revoke Order in Part,* 66 FR 35937, 35941 (July 10, 2001). We averaged these quotes, then inflated this average to the POR using the WPI data published by IMF.

We valued labor based on a regression-based wage rate, in accordance with 19 CFR 351.408(c)(3). This information is available on the Department's Web site at *http://www.ia.ita.doc.gov/wages/01wages/01wages.html.*

To value factory overhead, selling, general, and administrative expenses, and profit, we obtained data from the *Reserve Bank of India Bulletin.*

**Preliminary Results of Review**

We preliminarily determine that the following margin exists for the period July 1, 2002, through June 30, 2003:

| Manufacturer/exporter | Margin (percent) |
|---|---|
| Guangdong Import and Export Corporation ..... | 1.73 |

The Department will disclose to parties the calculations performed in connection with these preliminary results within five days of the date of publication of this notice. Interested parties may request a hearing within 30 days of the publication. Any hearing, if requested, will be held 44 days after the publication of this notice, or the first workday thereafter. Interested parties may submit case briefs not later than 30 days after the date of publication of this notice. Rebuttal briefs, limited to issues raised in the case briefs, may be filed not later than 35 days after the date of publication of this notice. The Department will publish a notice of the final results of this administrative review, which will include the results of its analysis of issues raised in any such written briefs, within 120 days of the publication of these preliminary results.

The Department will determine and CBP shall assess antidumping duties on all appropriate entries. The Department will issue appropriate appraisement instructions directly to CBP upon completion of this review. The final results of this review shall be the basis for the assessment of antidumping duties on entries of merchandise covered by this review and for future deposits of estimated duties.

For assessment purposes, we do not have the information to calculate an estimated entered value. Accordingly, we have calculated importer-specific duty assessment rates for the merchandise by aggregating the dumping margins calculated for all U.S. sales and dividing this amount by the total quantity of those sales. To determine whether the duty assessment rates were *de minimis*, in accordance with the requirement set forth in 19 CFR 351.106(c)(2), we calculated importer-specific *ad valorem* ratios based on the EPs.

Furthermore, the following deposit requirements will be effective upon publication of the final results of this administrative review for all shipments of the subject merchandise entered, or withdrawn from warehouse, for consumption on or after the publication date, as provided by section 751(a)(1) of the Act: (1) The cash deposit rate for Guangdong will be that established in the final results of this administrative review; (2) for a company covered by the antidumping duty order, previously found to be entitled to a separate rate and for which no review was requested, the cash deposit rate will be the rate established in the most recent review of that company; (3) the cash deposit rate for all other PRC exporters (*i.e.*, all other exports except those of sebacic acid produced by Hengshui and exported by Tianjin) will be 243.40 percent, the PRC-wide rate established in the LTFV investigation; (4) the cash deposit rate for a non-PRC exporter of subject merchandise from the PRC will be the rate applicable to the PRC supplier of that exporter; and (5) as we have revoked the order, in part, with respect to sebacic acid produced by Hengshui and exported by Tianjin, no cash deposit is required for such merchandise. These requirements, when imposed, shall remain in effect until publication of the final results of the next administrative review.

**Notification of Interested Parties**

This notice serves as a preliminary reminder to importers of their responsibility under 19 CFR 351.402(f) to file a certificate regarding the reimbursement of antidumping duties prior to liquidation of the relevant entries during this review period. Failure to comply with this requirement could result in the Secretary's presumption that reimbursement of antidumping duties occurred and the subsequent assessment of double antidumping duties.

This administrative review is issued and published in accordance with sections 751(a)(1) and 777(i) of the Act.

Dated: July 29, 2004.

**Jeffrey A. May,**

*Acting Assistant Secretary for Import Administration.*

[FR Doc. 04–17936 Filed 8–4–04; 8:45 am]

BILLING CODE 3510–DS–P

## DEPARTMENT OF COMMERCE

### International Trade Administration

**[A–122–838]**

### Notice of Amended Initiation and Amended Preliminary Results of Antidumping Duty Administrative Review: Certain Softwood Lumber Products From Canada

**AGENCY:** Import Administration, International Trade Administration, Department of Commerce.

**ACTION:** Notice of amended initiation and amended preliminary results of antidumping duty administrative review.

**EFFECTIVE DATE:** August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Constance Handley or James Kemp, Office 5, AD/CVD Enforcement, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230; telephone: (202) 482–0631 or (202) 482–5346, respectively.

**SUMMARY:** The Department of Commerce is amending its notice of initiation of administrative review of the antidumping duty order on certain softwood lumber products from Canada, covering the period May 22, 2002, through April 30, 2003 (the POR) and its notice of preliminary results in the administrative review of the antidumping duty order on certain softwood lumber products from Canada for the POR. *See Notice of Initiation of Antidumping Duty Administrative Review,* 68 FR 39059, July 1, 2003 (*Initiation Notice*); and *Notice of Preliminary Results of Antidumping Duty Administrative Review and Postponement of Final Results: Certain Softwood Lumber Products From Canada,* 69 FR 33235, June 14, 2004 (*Preliminary Results*). Pursuant to this amendment, we are initiating a review on 22 additional companies. The review-specific average rate for respondents not selected for individual review as calculated in the *Preliminary Results* will be applicable to these companies.

**SUPPLEMENTARY INFORMATION:**

### Background

On May 1, 2003, the Department of Commerce (the Department) published a notice of opportunity to request the first administrative review of this order. *See Antidumping or Countervailing Duty Order, Finding, or Suspended Investigation; Opportunity to Request Administrative Review,* 68 FR 23281, May 1, 2003. On May 30, 2003, in accordance with 19 CFR 351.213(b), the petitioner [1] requested a review of producers/exporters of certain softwood lumber products. Also, between May 7, and June 2, 2003, Canadian producers requested a review on their own behalf or had a review of their company requested by a U.S. importer.

On July 1, 2003, the Department published a notice of initiation of administrative review of the antidumping duty order on certain softwood lumber products from Canada, covering the POR. *See Initiation Notice.*

On June 14, 2004, the Department published a notice of preliminary results of antidumping duty administrative on certain softwood lumber products from Canada, covering the POR. *See Preliminary Results.* Twenty-two companies for which a timely request for review had been received [2] were inadvertently omitted from the *Initiation Notice* and hence the *Preliminary Results.* To rectify this inaccuracy, the Department is issuing this notice of amended initiation and amended preliminary results of the antidumping duty administrative review to include the 22 previously omitted companies.

### Initiation of Review

We are initiating an administrative review of the antidumping duty order on Certain Softwood Lumber Products from Canada, covering the period May 22, 2002, through April 30, 2003 for the following companies. We intend to issue the final results of this review no later than December 13, 2004.

AFA Forest Products Inc.
Associated Cedar Products
Barry Maedel Woods & Timber
Deep Cove Forest Products
Ivis Wood Products
Lazy S Lumber
Louisiana Pacific Corporation
Mary's River Lumber
New West Lumber Ltd.
Quadra Wood Products Ltd.
Schols Cedar Products
Silvermere Forest Products Inc.
Standard Building Products Ltd.
Still Creek Forest Products Ltd.
Stuart Lake Marketing Company
Suncoast Lumber & Milling
Sundance Forest Industries
Taiga Forest Products
Teal-Jones Group
T.F. Specialty Sawmill
Western Cleanwood Preservers Ltd.
Western Wood Preservers Ltd.

### Scope of the Review

The products covered by this order are softwood lumber, flooring and siding (softwood lumber products). Softwood lumber products include all products classified under headings 4407.1000, 4409.1010, 4409.1090, and 4409.1020, respectively, of the Harmonized Tariff Schedule of the United States (HTSUS), and any softwood lumber, flooring and siding described below. These softwood lumber products include:

(1) coniferous wood, sawn or chipped lengthwise, sliced or peeled, whether or not planed, sanded or finger-jointed, of a thickness exceeding six millimeters;

(2) coniferous wood siding (including strips and friezes for parquet flooring, not assembled) continuously shaped (tongued, grooved, rabbeted, chamfered, v-jointed, beaded, molded, rounded or the like) along any of its edges or faces, whether or not planed, sanded or finger-jointed;

(3) other coniferous wood (including strips and friezes for parquet flooring, not assembled) continuously shaped (tongued, grooved, rabbeted, chamfered, v-jointed, beaded, molded, rounded or the like) along any of its edges or faces (other than wood moldings and wood dowel rods) whether or not planed, sanded or finger-jointed; and

(4) coniferous wood flooring (including strips and friezes for parquet flooring, not assembled) continuously shaped (tongued, grooved, rabbeted, chamfered, v-jointed, beaded, molded, rounded or the like) along any of its edges or faces, whether or not planed, sanded or finger-jointed.

Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the merchandise under review is dispositive.

Softwood lumber products excluded from the scope:

- Trusses and truss kits, properly classified under HTSUS 4418.90.
- I-joist beams.
- Assembled box spring frames.
- Pallets and pallet kits, properly classified under HTSUS 4415.20.
- Garage doors.
- Edge-glued wood, properly classified under HTSUS 4421.90.97.40 (formerly HTSUS 4421.90.98.40).
- Properly classified complete door frames.
- Properly classified complete window frames.

[1] The petitioner in this case is the Coalition for Fair Lumber Imports Executive Committee. We note that during the review, submissions have been made interchangeably by the petitioner itself and by the Coalition for Fair Lumber Imports, a domestic interested party. For ease of reference, we will use the term ''petitioner'' to refer to submissions by either, although we recognize that the Coalition for Fair Lumber Imports is not the actual petitioner.

[2] *See* letter from Joel R. Junker to the Department, dated May 28, 2003.

• Properly classified furniture.

Softwood lumber products excluded from the scope only if they meet certain requirements:

• *Stringers* (pallet components used for runners): if they have at least two notches on the side, positioned at equal distance from the center, to properly accommodate forklift blades, properly classified under HTSUS 4421.90.97.40 (formerly HTSUS 4421.90.98.40).

• *Box-spring frame kits:* if they contain the following wooden pieces—two side rails, two end (or top) rails and varying numbers of slats. The side rails and the end rails should be radius-cut at both ends. The kits should be individually packaged, they should contain the exact number of wooden components needed to make a particular box spring frame, with no further processing required. None of the components exceeds 1″ in actual thickness or 83″ in length.

• *Radius-cut box-spring-frame components,* not exceeding 1″ in actual thickness or 83″ in length, ready for assembly without further processing. The radius cuts must be present on both ends of the boards and must be substantial cuts so as to completely round one corner.

• *Fence pickets* requiring no further processing and properly classified under HTSUS 4421.90.70, 1″ or less in actual thickness, up to 8″ wide, 6′ or less in length, and have finials or decorative cuttings that clearly identify them as fence pickets. In the case of dog-eared fence pickets, the corners of the boards should be cut off so as to remove pieces of wood in the shape of isosceles right angle triangles with sides measuring ¾ inch or more.

• *U.S. origin lumber* shipped to Canada for minor processing and imported into the United States, is excluded from the scope of this order if the following conditions are met: (1) the processing occurring in Canada is limited to kiln-drying, planing to create smooth-to-size board, and sanding, and (2) if the importer establishes to Customs and Border Protection (CBP)'s satisfaction that the lumber is of U.S. origin.

• *Softwood lumber products contained in single family home packages or kits,*[3] regardless of tariff classification, are excluded from the scope of the orders if the following criteria are met:

(A) The imported home package or kit constitutes a full package of the number of wooden pieces specified in the plan, design or blueprint necessary to produce a home of at least 700 square feet produced to a specified plan, design or blueprint;

(B) The package or kit must contain all necessary internal and external doors and windows, nails, screws, glue, subfloor, sheathing, beams, posts, connectors and if included in purchase contract decking, trim, drywall and roof shingles specified in the plan, design or blueprint;

(C) Prior to importation, the package or kit must be sold to a retailer of complete home packages or kits pursuant to a valid purchase contract referencing the particular home design plan or blueprint, and signed by a customer not affiliated with the importer;

(D) The whole package must be imported under a single consolidated entry when permitted by CBP, whether or not on a single or multiple trucks, rail cars or other vehicles, which shall be on the same day except when the home is over 2,000 square feet;

(E) The following documentation must be included with the entry documents:

• a copy of the appropriate home design, plan, or blueprint matching the entry;

• a purchase contract from a retailer of home kits or packages signed by a customer not affiliated with the importer;

• a listing of inventory of all parts of the package or kit being entered that conforms to the home design package being entered;

• in the case of multiple shipments on the same contract, all items listed immediately above which are included in the present shipment shall be identified as well.

We have determined that the excluded products listed above are outside the scope of this order provided the specified conditions are met. Lumber products that CBP may classify as stringers, radius cut box-spring-frame components, and fence pickets, not conforming to the above requirements, as well as truss components, pallet components, and door and window frame parts, are covered under the scope of this order and may be classified under HTSUS subheadings 4418.90.40.90, 4421.90.70.40, and 4421.90.98.40. Due to changes in the 2002 HTSUS whereby subheading 4418.90.40.90 and 4421.90.98.40 were changed to 4418.90.45.90 and 4421.90.97.40, respectively, we are adding these subheadings as well.

In addition, this scope language has been further clarified to now specify that all softwood lumber products entered from Canada claiming non-subject status based on U.S. country of origin will be treated as non-subject U.S.-origin merchandise under the countervailing duty order, provided that these softwood lumber products meet the following condition: upon entry, the importer, exporter, Canadian processor and/or original U.S. producer establish to CBP's satisfaction that the softwood lumber entered and documented as U.S.-origin softwood lumber was first produced in the United States as a lumber product satisfying the physical parameters of the softwood lumber scope.[4] The presumption of non-subject status can, however, be rebutted by evidence demonstrating that the merchandise was substantially transformed in Canada.

**Amended Preliminary Results of Review**

In the preliminary results, the Department determined a preliminary weighted-average margin for those companies that requested, but were not selected for, individual review. As a result of this review, we preliminarily determine that the following review-specific weighted-average margin exists for the period covering the POR, for the following additional companies:

| Producer | Weighted-average margin (percentage) |
|---|---|
| AFA Forest Products Inc. | |
| Associated Cedar Products | |
| Barry Maedel Woods & Timber | |
| Deep Cove Forest Products | |
| Ivis Wood Products | |
| Lazy S Lumber | |
| Louisiana Pacific Corporation | |
| Mary's River Lumber | |
| New West Lumber Ltd. | |
| Quadra Wood Products Ltd. | |
| Schols Cedar Products | |
| Silvemere Forest Products Inc. | |
| Standard Building Products Ltd. | |
| Still Creek Forest Products Ltd. | |
| Stuart Lake Marketing Company | |
| Suncoast Lumber & Milling | |
| Sundance Forest Industries | |
| Taiga Forest Products | |
| Teal-Jones Group | |
| T.F. Specialty Sawmill | |

[3] To ensure administrability, we clarified the language of this exclusion to require an importer certification and to permit single or multiple entries on multiple days as well as instructing importers to retain and make available for inspection specific documentation in support of each entry.

[4] See the scope clarification message (3034202), dated February 3, 2003, to CBP, regarding treatment of U.S.-origin lumber on file in the Central Records Unit, Room B–099 of the main Commerce Building.

| Producer | Weighted-average margin (percentage) |
|---|---|
| Western Cleanwood Preservers Ltd. | |
| Western Wood Preservers Ltd | 3.98 |

**Assessment**

Upon completion of this administrative review, pursuant to 19 CFR 351.212(b), the Department will calculate an assessment rate on all appropriate entries. For the companies requesting a review, but not selected for examination and calculation of individual rates, we will calculate a weighted-average assessment rate based on all importer-specific assessment rates excluding any which are *de minimis* or margins determined entirely on adverse facts available. Where the assessment rate is above *de minimis*, we will instruct CBP to assess duties on all entries of subject merchandise by that importer.

**Cash Deposit Requirements**

The following deposit rate will be effective upon publication of the final results of this administrative review of all shipments of certain softwood lumber products from Canada entered, or withdrawn from warehouse, for consumption on or after the publication date, as provided by section 751(a)(1) of the Tariff Act of 1930 (the Act): (1) for the non-selected companies we will calculate a weighted-average cash deposit rate based on all the company-specific cash deposit rates, excluding *de minimis* margins or margins determined entirely on adverse facts available; (2) for previously reviewed or investigated companies not participating in this review, the cash deposit rate will continue to be the company-specific rate published for the most recent period; (3) if the exporter is not a firm covered in this review, a prior review, or the less-than-fair-value (LTFV) investigation, but the manufacturer is, the cash deposit rate will be the rate established for the most recent period for the manufacturer of the merchandise and; (4) if neither the exporter nor the manufacturer is a firm covered in this or any previous review conducted by the Department, the cash deposit rate will be 8.43 percent, the ''All Others'' rate established in the LTFV investigation. At this time the Department is considering instructing CBP to apply the cash deposit rate to the sum of the entered value, countervailing duties and antidumping duties when these items are deducted in determining entered value. These cash deposit requirements, when imposed, shall remain in effect until publication of the final results of the next administrative review.

This notice serves as a preliminary reminder to importers of their responsibility under 19 CFR 351.402(f) to file a certificate regarding the reimbursement of antidumping duties prior to liquidation of the relevant entities during this review period. Failure to comply with this requirement could result in the Secretary's presumption that reimbursement of antidumping duties occurred and the subsequent assessment of double antidumping duties.

This determination is issued and published in accordance with sections 751(a)(1) and 777(i)(1) of the Act.

Dated: July 29, 2004.

**James J. Jochum,**

*Assistant Secretary for Import Administration.*

[FR Doc. 04–17911 Filed 8–4–04; 8:45 am]

BILLING CODE 3510–DS–P

## DEPARTMENT OF COMMERCE

### International Trade Administration

**[A–427–001]**

### Continuation of Antidumping Duty Order: Sorbitol From France

**AGENCY:** Import Administration, International Trade Administration, Department of Commerce.

**ACTION:** Notice of continuation of antidumping duty order: Sorbitol from France.

**SUMMARY:** The Department of Commerce (''the Department'') has determined that revocation of the antidumping duty order on sorbitol from France, would be likely to lead to continuation or recurrence of dumping. Therefore, the Department is publishing notice of the continuation of the antidumping duty order on sorbitol from France.

**DATES:** *Effective Date:* August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** *Contact Information:* Hilary E. Sadler, Esq., Office of Policy, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Ave., NW., Washington, DC 20230; telephone: (202) 482–4340.

**SUPPLEMENTARY INFORMATION:**

**Background**

On February 2, 2004, the Department initiated and the Commission instituted a sunset review of the antidumping duty order on sorbitol from France, pursuant to section 751(c) of the Act.[1] As a result of its review, the Department found that revocation of the antidumping duty order would likely lead to continuation or recurrence of dumping and notified the International Trade Commission (''ITC'') of the magnitude of the margins likely to prevail were the order revoked.[2] On July 23, 2004, the ITC determined pursuant to section 751(c) of the Act, that revocation of the antidumping duty order on sorbitol from France would likely lead to continuation or recurrence of material injury to an industry in the United States within a reasonably foreseeable time.[3]

**Scope of the Order**

The merchandise covered by this order is crystalline sorbitol, a polyol produced by the hydrogenation of sugars (glucose), used in the production of sugarless gum, candy, groceries, and pharmaceuticals, currently classifiable under U.S. Harmonized Tariff Schedule item number 2905.44.00.

**Determination**

As a result of the determinations by the Department and ITC that revocation of this antidumping duty order would likely lead to continuation or recurrence of dumping and material injury to an industry in the United States, pursuant to section 751(d)(2) of the Act, the Department hereby orders the continuation of the antidumping duty order on sorbitol from France. The effective date of continuation of this order will be the date of publication in the **Federal Register** of this Notice of Continuation. Pursuant to sections 751(c)(2) and 751(c)(6) of the Act, the Department intends to initiate the next five-year review of this order not later than July 2009.

Dated: July 30, 2004.

**Joseph A. Spetrini,**

*Acting Assistant Secretary for Import Administration.*

[FR Doc. 04–17918 Filed 8–4–04; 8:45 am]

BILLING CODE 3510–DS–P

[1] *See Initiation of Five-year (''Sunset'') Reviews*, 69 FR 4921 (February 2, 2004).

[2] *See Sorbitol from France: Final Results of the Sunset Review of Antidumping Duty Order*, 69 FR 34652 (June 22, 2004).

[3] *See Sorbitol From France*, 69 FR 44061 (July 23, 2004), and USITC Publication 3702 (July 2004) (*Second Review*), Investigation No. 731–TA–149.

## DEPARTMENT OF COMMERCE

### International Trade Administration

**[A–122–830, A–583–830, A–791–805]**

## Stainless Steel Plate in Coils From Canada, South Africa and Taiwan; Notice of Expedited Sunset Review; Final Results

**AGENCY:** Import Administration, International Trade Administration, Department of Commerce.

**ACTION:** Notice of expedited sunset review on stainless steel plate in coils from Canada, South Africa, and Taiwan; final results.

**SUMMARY:** On April 1, 2004, the Department of Commerce (''the Department'') initiated a sunset review of the antidumping duty orders on stainless steel plate in coils (''SSPC'') from Canada, Taiwan, and South Africa pursuant to section 751(c) of the Tariff Act of 1930, as amended (''the Act''). On the basis of a notice of intent to participate and an adequate substantive response filed on behalf of domestic interested parties and inadequate response (in this case, no response) from respondent interested parties, the Department conducted an expedited (120-day) sunset review. As a result of this sunset review, the Department finds that revocation of the antidumping duty orders would likely lead to continuation or recurrence of dumping. The dumping margins are identified in the *Final Results of Review* section of this notice.

**DATES:** *Effective Date:* August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Martha V. Douthit, Office of Policy for Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street & Constitution Avenue, NW., Washington, DC 20230; telephone: (202) 482–5050.

**SUPPLEMENTARY INFORMATION:**

### Background

On April 1, 2004, the Department published the notice of initiation of the sunset reviews of the antidumping duty orders on SSPC from Canada, South Africa, and Taiwan.[1] On April 16, 2004, the Department received a Notice of Intent to Participate from Allegheny Ludlum Corp. (''Allegheny Ludlum''), North American Stainless (''NAS''),[2] and the United Steelworkers of America, AFL-CIO/CLC (USWA'')[3] collectively (''domestic interested parties''), within the deadline specified in section 315.218(d)(1)(i) of the Department's regulations. The domestic interested parties claimed interested party status under section 771(9)(C) and (D) of the Act, as U.S. producers of SSPC and certified union whose workers are engaged in the production of SSPC. On May 3, 2004, the Department received complete substantive responses from the domestic interested parties within the deadline specified in section 351.218(d)(3)(i) of the Department's regulations. We did not receive responses from any respondent interested parties to this proceeding. As a result, pursuant to section 751(c)(3)(B) of the Act and section 351.218(e)(1)(ii)(C)(2) of the Department's regulations, the Department determined to conduct expedited reviews of these orders.

### Scope of the Orders

The merchandise subject to these orders is stainless steel plate in coils. Stainless steel is an alloy steel containing, by weight, 1.2 percent or less of carbon and 10.5 percent or more of chromium, with or without other elements. The subject plate products are flat-rolled products, 254 mm or over in width and 4.75 mm or more in thickness, in coils, and annealed or otherwise heat treated and pickled or otherwise descaled. The subject plate may also be further processed (*e.g.*, cold-rolled, polished, *etc.*) provided that it maintains the specified dimensions of plate following such processing. Excluded from the scope of these orders are the following: (1) Plate not in coils, (2) plate that is not annealed or otherwise heat treated and pickled or otherwise descaled, (3) sheet and strip, and (4) flat bars. The merchandise subject to these orders is currently classifiable in the Harmonized Tariff Schedule of the United States (''HTSUS'') at subheadings: 7219.11.00.30, 7219.11.00.60, 7219.12.00.05, 7219.12.00.20, 7219.12.00.25, 7219.12.00.50, 7219.12.00.55, 7219.12.00.65, 7219.12.00.70, 7219.12.00.80, 7219.31.00.10, 7219.90.00.10, 7219.90.00.20, 7219.90.00.25, 7219.90.00.60, 7219.90.00.80, 7220.11.00.00, 7220.20.10.10, 7220.20.10.15, 7220.20.10.60, 7220.20.10.80, 7220.20.60.05, 7220.20.60.10, 7220.20.60.15, 7220.20.60.60, 7220.20.60.80, 7220.90.00.10, 7220.90.00.15, 7220.90.00.60, and 7220.90.00.80. Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the scope of the orders is dispositive.

### Analysis of Comments Received

All issues raised in these reviews are addressed in the ''Issues and Decision Memorandum'' (''Decision Memo'') from Ronald K. Lorentzen, Acting Director, Office of Policy, Import Administration, to Joseph A. Spetrini, Acting Assistant Secretary for Import Administration, dated July 30, 2004, which is hereby adopted by this notice. The issues discussed in the Decision Memo include the likelihood of continuation or recurrence of dumping and the magnitude of the margin likely to prevail if the order were to be revoked. Parties can find a complete discussion of all issues raised in these reviews and the corresponding recommendations in this public memorandum, which is on file in room B–099 of the main Commerce Building.

In addition, a complete version of the Decision Memo can be accessed directly on the Web at *http://ia.ita.doc.gov/frn,* under the heading ''August 2004.'' The paper copy and electronic version of the Decision Memorandum are identical in content.

### Final Results of Reviews

We determine that revocation of the antidumping duty orders on SSPC from Canada, South Africa, and Taiwan would likely lead to continuation or recurrence of dumping at the following percentage weighted-average percentage margins:

| Manufacturers/exporters/producers | Weighted average margin (percent) |
|---|---|
| *Canada* | |
| Atlas Stainless Steel | 15.35 |
| All Others | 11.10 |
| *South Africa* | |
| Columbus Stainless | 41.63 |
| All Others | 41.63 |
| *Taiwan* | |
| Yieh United Steel Corp. (YUSCO) | 8.02 |
| YUSCO/Ta Chen | 10.20 |
| All Others | 7.39 |

This notice also serves as the only reminder to parties subject to administrative protective orders (''APO'') of their responsibility concerning the return or destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305 of the Department's regulations. Timely notification of the return or

[1] *See Initiation of Five-Year (''Sunset'') Reviews*, 69 FR 17129 (April 1, 2004)(''*Initiation Notice*'').

[2] NAS is not supporting continuation of the antidumping duty order against South Africa in this proceeding.

[3] USWA is not supporting continuation of the antidumping duty order against Canada in this proceeding.

destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.

We are issuing and publishing the results and notice in accordance with sections 751(c), 752, and 777(i)(1) of the Act.

Dated: July 30, 2004.

**Joseph A. Spetrini,**

*Acting Assistant Secretary for Import Administration.*

[FR Doc. 04–17923 Filed 8–4–04; 8:45 am]

**BILLING CODE 3510–DS–P**

## DEPARTMENT OF COMMERCE

### International Trade Administration

**[A–570–890]**

### Notice of Amended Preliminary Antidumping Duty Determination of Sales at Less Than Fair Value: Wooden Bedroom Furniture From the People's Republic of China

**AGENCY:** Import Administration, International Trade Administration, Department of Commerce.

**DATES:** *Effective Date:* August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Catherine Bertrand or Robert Bolling, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230; telephone: (202) 482–3207, or 482–3434, respectively.

**SUPPLEMENTARY INFORMATION:**

#### Significant Ministerial Error

Pursuant to 19 CFR 351.224(g)(1) and (g)(2), the Department of Commerce (''Department'') is amending the preliminary determination of sales at less than fair value in the antidumping duty investigation of wooden bedroom furniture from the People's Republic of China (''PRC'') to reflect the correction of significant ministerial errors it made in the margin calculations regarding the following mandatory respondents: Rui Feng Woodwork Co., Ltd., Rui Feng Lumber Development Co., Ltd., and Dorbest Limited (collectively ''Dorbest Group''); Starcorp Furniture (Shanghai) Co., Ltd., Orin Furniture (Shanghai) Co., Ltd., and Shanghai Starcorp Furniture Co., Ltd. (collectively ''Starcorp''). A ministerial error is defined as an error in addition, subtraction, or other arithmetic function, clerical error resulting from inaccurate copying, duplication, or the like, and any other similar type of unintentional error which the Secretary considers ministerial. *See* 19 CFR 351.224(f). A significant ministerial error is defined as an error, the correction of which, singly or in combination with other errors, would result in (1) a change of at least five absolute percentage points in, but not less than 25 percent of, the weighted-average dumping margin calculated in the original (erroneous) preliminary determination or (2) a difference between a weighted-average dumping margin of zero or *de minimis* and a weighted-average dumping margin of greater than *de minimis* or vice versa. *See* 19 CFR 351.224(g). We are publishing this amendment to the preliminary determination pursuant to 19 CFR 351.224(e). As a result of this amended preliminary determination, we have revised the antidumping rates for the Dorbest Group, Starcorp, and Tech Lane. *See* discussion below.

Additionally, the Department is amending the preliminary determination of sales at less than fair value in the antidumping duty investigation of wooden bedroom furniture from the PRC to reflect the correction of ministerial errors it made regarding certain Section A respondents that have applied for a separate rate and provided information for the Department to consider for the preliminary determination but were denied a separate rate at the preliminary determination stage. Memorandum to Laurie Parkhill, Office Director, AD/CVD Enforcement, Antidumping Duty Investigation of Wooden Bedroom Furniture From the People's Republic of China: Analysis of Allegations of Ministerial Errors for Section A Respondents dated July 29, 2004.

#### Ministerial-Error Allegation

On June 24, 2004, the Department published its affirmative preliminary determination in this proceeding. *See Notice of Preliminary Determination of Sales at Less Than Fair Value and Postponement of Final Determination: Wooden Bedroom Furniture From the People's Republic of China,* 69 FR 35312 (June 24, 2004) (''*Preliminary Determination*'').

On June 29, 2004, the Department received timely allegations of ministerial errors in the *Preliminary Determination* from the American Furniture Manufacturers Committee for Legal Trade and its individual members and the Cabinet Makers, Millmen, and Industrial Carpenters Local 721, UBC Southern Council of Industrial Worker's Local Union 2305, United Steel Workers of American Local 193U, Carpenters Industrial Union Local 2093, and Teamsters, Chauffeurs, Warehousemen and Helper Local 991 (collectively ''Petitioners''), and the following respondents: Dongguan Lung Dong Furniture Co., Ltd., and Dongguan Dong He Furniture Co., Ltd. (collectively ''Dongguan Lung Dong''); the Dorbest Group; Lacquer Craft Manufacturing Company, Ltd. (''Lacquer Craft''); Markor International Furniture (Tianjin) Manufacture Co., Ltd. (''Markor Tianjin''); Shing Mark Enterprise Co., Ltd., Carven Industries Limited (BVI), Carven Industries Limited (HK), Dongguan Zhenxin Furniture Co., Ltd., and Dongguan Yongpeng Furniture Co., Ltd. (collectively ''Shing Mark''); and Starcorp. Additionally, Petitioners made a ministerial-error allegation with regard to Tech Lane Wood Mfg. and Kee Jia Wood Mfg. (collectively ''Tech Lane''). The Department has reviewed its preliminary calculations and agrees that some of the errors which the parties alleged are ministerial errors within the meaning of 19 CFR 351.224(f).

We agree with certain ministerial errors made with respect to the mandatory respondents. However, not all of the alleged ministerial errors for each mandatory respondent when taken in totality meet the definition of a ministerial error under 19 CFR 351.224. Due to the large number of mandatory respondents and the extraordinary number of alleged ministerial errors in this case we have summarized all comments in company-specific memoranda. For a complete listing of all comments, please see the individual memorandum for each mandatory respondent (*i.e.*, Dongguan Lung Dong, the Dorbest Group, Lacquer Craft, Markor Tianjin, Shing Mark, Starcorp, and Tech Lane), Memorandum to the Laurie Parkhill, Office Director, AD/CVD Enforcement, Antidumping Duty Investigation of Wooden Bedroom Furniture from the People's Republic of China: Analysis of Allegation of Ministerial Errors for (Company) (*i.e.*, Dongguan Lung Dong, the Dorbest Group, Lacquer Craft, Markor Tianjin, Shing Mark, Starcorp, or Tech Lane) dated July 29, 2004.[1]

On June 29, 2004, the Department received timely allegations of ministerial errors in the *Preliminary Determination* from twenty-nine section

[1] On July 29, 2004, the Department informed Tech Lane that it was not going to conduct verification of its sales and factors of production data, due to the fact Tech Lane did not provide financial statements covering reported subject merchandise and because Tech Lane did not provide the Department with a reconciliation of its sales made during the Period of Investigation (''POI'') to its financial statements. In light of the Department's decision to cancel verification, the Department notes that the amended rate for Tech Lane may change for purposes of the final determination.

A respondents. *See* Memorandum to the Laurie Parkhill, Office Director, Antidumping Duty Investigation of Wooden Bedroom Furniture from the People's Republic of China: Analysis of Allegations of Ministerial Errors for Section A Respondents dated July 29, 2004.

Additionally, on July 6, 2004, the Department received additional timely information from certain Section A Respondents. The Department will address these comments in the Final Determination. *See* Antidumping Duty Investigation of Wooden Bedroom Furniture from the People's Republic of China: Analysis of Consideration of Additional Information for Final Determination, dated July 29, 2004.

Further, the Department received several new Section A filings from companies requesting a separate rate after the preliminary determination. We have determined to return these filings because they were untimely. As the Department stated in the *Preliminary Determination,* all Section A filings had to be received by March 1, 2004. Therefore, these filings were untimely filed because the Department received them beyond the March 1, 2004, filing deadline.

The collection of bonds or cash deposits and suspension of liquidation will be revised accordingly and parties will be notified of this determination, in accordance with section 733 (d) and (f) of the Tariff Act of 1930, as amended, (the Act).

**Amended Preliminary Determination**

As a result of our correction of ministerial errors in the Preliminary Determination, we have determined that the following weighted-average dumping margins apply:

| Exporter and producer | Original preliminary margin (percent) | Amended preliminary margin (percent) |
|---|---|---|
| The Dorbest Group | 19.24 | 11.85 |
| Starcorp | 24.34 | 30.52 |
| Tech Lane | 9.36 | 29.72 |
| Alexandre International Corp | 198.08 | 10.92 |
| Art Heritage International, Ltd | 198.08 | 10.92 |
| Chuan Fa Furniture Factory | 198.08 | 10.92 |
| Clearwise Company Limited | 198.08 | 10.92 |
| COE, Ltd | 198.08 | 10.92 |
| Dongguan Chunsan Wood Products Co., Ltd | 198.08 | 10.92 |
| Dongguan Hero Way Woodwork Co., Ltd | 198.08 | 10.92 |
| Dongguan Da Zhong Woodwork Co., Ltd | 198.08 | 10.92 |
| Dongguan Sunrise Furniture Co | 198.08 | 10.92 |
| Dream Rooms Furniture (Shanghai) Co., Ltd | 198.08 | 10.92 |
| Foshan Guanqiu Furniture Co., Ltd | 198.08 | 10.92 |
| Gaomi Yatai Wooden Ware Co., Ltd | 198.08 | 10.92 |
| Green River Wood (Dongguan) Ltd | 198.08 | 10.92 |
| Kuan Lin Furniture (Dong Guan) Co., Ltd | 198.08 | 10.92 |
| Longrange Furniture Co., Ltd | 198.08 | 10.92 |
| Passwall Corporation | 198.08 | 10.92 |
| Prime Wood International Co., Ltd *et al* | 198.08 | 10.92 |
| Shenshen Xiande Furniture Factory | 198.08 | 10.92 |
| Tianjin Master Home Furniture | 198.08 | 10.92 |
| Yida Co., Ltd | 198.08 | 10.92 |

The PRC-wide rate has not been amended.

**International Trade Commission Notification**

In accordance with section 733(f) of the Act, we have notified the International Trade Commission (''ITC'') of our amended preliminary determination. If our final determination is affirmative, the ITC will determine before the later of 120 days after the date of the preliminary determination or 45 days after our final determination whether the domestic industry in the United States is materially injured, or threatened with material injury, by reason of imports, or sales (or the likelihood of sales) for importation, of the subject merchandise.

This determination is issued and published in accordance with sections 733(f) and 777(I)(1) of the Act and 19 CFR 351.224(e).

Dated: July 29, 2004.

**Jeffrey May,**

*Acting Assistant Secretary for Import Administration.*

[FR Doc. 04–17937 Filed 8–4–04; 8:45 am]

**BILLING CODE 3510–DS–P**

## DEPARTMENT OF COMMERCE

### International Trade Administration

**[C–791–806]**

### Stainless Steel Plate in Coils From South Africa; Final Results of Expedited Sunset Review

**AGENCY:** Import Administration, International Trade Administration, Department of Commerce.

**ACTION:** Notice of final results of the expedited sunset review of the countervailing duty order on stainless steel plate in coils from South Africa.

**SUMMARY:** On April 1, 2004, the Department of Commerce (''the Department'') initiated a sunset review of the countervailing duty order on stainless steel plate in coils (''SSPC'') from South Africa pursuant to section 751(c) of the Tariff Act of 1930, as amended (''the Act''). On the basis of a notice of intent to participate and an adequate substantive response filed on behalf of domestic interested parties and an inadequate response, *i.e.*, no response from respondent interested parties, the Department determined to conduct an expedited (120-day) sunset review. As a result of this sunset review, the Department finds that revocation of the countervailing duty order would be likely lead continuation or recurrence of a countervailable subsidy. The net countervailable subsidy and the nature of the subsidy are identified in the *Final Results of Review* section of this notice.

**FOR FURTHER INFORMATION CONTACT:** Martha V. Douthit, Office of Policy for

Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street & Constitution Avenue, NW., Washington, DC 20230; telephone: (202) 482–5050.

**EFFECTIVE DATE:** August 5, 2004.

**SUPPLEMENTARY INFORMATION:**

## Background

On April 1, 2004, the Department of Commerce (''the Department'') initiated a sunset review of the countervailing duty order on SSPC from South Africa pursuant to section 751(c) of the Act. *See Initiation of Five-Year (Sunset) Reviews,* 69 FR 17129 (April 1, 2004). On April 16, 2004, the Department received a Notice of Intent to Participate from Allegheny Ludlum Corporation (''Allegheny Ludlum''), North American Stainless (''NAS''), and the United Steelworkers of America, AFL–CIO–CLC (''USWA''), collectively (''domestic interested parties'') within the applicable deadline specified in section 351.218(d)(1)(i) of the Department's regulations. On May 3, 2004, we received a complete substantive response from domestic interested parties within the 30-day deadline specified in the Department's regulations. However, we did not receive responses from any respondent interested parties to this proceeding as required in section 351.218(d)(3)(i) of the Department's regulations. As a result of receiving no responses from respondent interested parties, the Department conducted an expedited (120-day) sunset review of this order pursuant to section 751(c)(3)(B) of the Act and section 351.218(e)(1)(ii)(C) of the Department's regulations.

## Scope of the Order

The merchandise subject to this countervailing duty order is stainless steel plate in coils. Stainless steel is an alloy steel containing, by weight, 1.2 percent or less of carbon and 10.5 percent or more of chromium, with or without other elements. The subject plate products are flat-rolled products, 254 mm or over in width and 4.75 mm or more in thickness, in coils, and annealed or otherwise heat treated and pickled or otherwise descaled. The subject plate may also be further processed (*e.g.*, cold-rolled, polished, etc.) provided that it maintains the specified dimensions of plate following such processing. Excluded from the scope of these orders are the following: (1) Plate not in coils, (2) plate that is not annealed or otherwise heat treated and pickled or otherwise descaled, (3) sheet and strip, and (4) flat bars. The merchandise subject to these orders is currently classifiable in the Harmonized Tariff Schedule of the United States (''HTSUS'') at subheadings: 7219.11.00.30, 7219.11.00.60, 7219.12.00.05, 7219.12.00.20, 7219.12.00.25, 7219.12.00.50, 7219.12.00.55, 7219.12.00.65, 7219.12.00.70, 7219.12.00.80, 7219.31.00.10, 7219.90.00.10, 7219.90.00.20, 7219.90.00.25, 7219.90.00.60, 7219.90.00.80, 7220.11.00.00, 7220.20.10.10, 7220.20.10.15, 7220.20.10.60, 7220.20.10.80, 7220.20.60.05, 7220.20.60.10, 7220.20.60.15, 7220.20.60.60, 7220.20.60.80, 7220.90.00.10, 7220.90.00.15, 7220.90.00.60, and 7220.90.00.80. Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the scope of the order is dispositive.

## Analysis of Comments Received

All issues raised in this case are addressed in the ''Issues and Decision Memorandum'' (''Decision Memo'') from Ronald K. Lorentzen, Acting Director, Office of Policy, Import Administration, to Joseph A. Spetrini, Acting Assistant Secretary for Import Administration, dated July 30, 2004, which is hereby adopted by this notice. The issues discussed in the Decision Memo include the likelihood of continuation or recurrence of subsidization and the magnitude of the margin likely to prevail if the order were revoked. Parties can find a complete discussion of all issues raised in this review and the corresponding recommendations in this public memorandum, which is on file in room B–099 of the main Commerce Building.

In addition, a complete version of the Decision Memo can be accessed directly on the Web at *http://ia.ita.doc.gov/frn,* under the heading ''August 2004.'' The paper copy and electronic version of the Decision Memo are identical in content.

## Final Results of Review

We determine that revocation of the countervailing duty order on SSPC from South Africa would likely lead to continuation or recurrence of subsidization at the following weighted-average percentage margins:

| Manufacturers/exporters/producers | Net countervailable subsidy margin (percent) |
|---|---|
| Columbus Stainless Steel Company (the operating unit of Columbus Joint Venture) | 3.95 |
| All Others | 3.95 |

This notice also serves as the only reminder to parties subject to administrative protective orders (''APO'') of their responsibility concerning the return or destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305 of the Department's regulations. Timely notification of the return or destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.

We are issuing and publishing the results and notice in accordance with sections 751(c), 752, and 777(i)(1) of the Act.

Dated: July 30, 2004.

**Joseph A. Spetrini,**

*Acting Assistant Secretary for Import Administration.*

[FR Doc. 04–17921 Filed 8–4–04; 8:45 am]

**BILLING CODE 3510–DS–P**

---

# COMMODITY FUTURES TRADING COMMISSION

## Agency Information Collection Activities: Notice of Intent To Renew Collection 3038–0022, Rules Pertaining to Contract Markets and Their Members

**AGENCY:** Commodity Futures Trading Commission.

**ACTION:** Notice.

**SUMMARY:** The Commodity Futures Trading Commission (CFTC) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (PRA), 44 U.S.C. 3501 *et seq.,* Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on Commission rules pertaining to contract markets and their members.

**DATES:** Comments must be submitted on or before October 4, 2004.

**ADDRESSES:** Comments may be mailed to David Van Wagner, Division of Market Oversight, U.S. Commodity Futures Trading Commission, 1155 21st Street, NW., Washington, DC 20581.

**FOR FURTHER INFORMATION CONTACT:** David Van Wagner at (202) 418–5481; FAX: (202) 418–5536; e-mail: *dvanwagner@cfctc.gov.*

**SUPPLEMENTARY INFORMATION:** Under the PRA, Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ''Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA, 44 U.S.C. 3506(c)(2)(A), requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, the CFTC is publishing notice of the proposed collection of information listed below.

With respect to the following collection of information, the CFTC invites comments on:

- Whether the proposed collection of information is necessary for the proper performance of the functions of the Commission, including whether the information will have a practical use;
- The accuracy of the Commission's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Ways to enhance the quality, usefulness, and clarity of the information to be collected; and
- Ways to minimize the burden of collection of information on those who are to respond, including through the use of appropriate automated electronic, mechanical, or other technology; *e.g.,* permitting electronic submission of responses.

**Rules Pertaining to Contract Markets and Their Members, OMB Control Number 3038–0022—Extension**

Rule 40.4 establishes a procedure for designated contract markets to submit certain rules concerning agricultural contracts to the Commission for prior approval. Rule 40.5 establishes a procedure for any registered entity (designated contract markets, registered derivatives transaction execution facilities and registered derivatives clearing organizations) to request that the Commission review and approve any rule or proposed rule or rule amendment. Rules 40.2 and 40.6 establishes procedures for designated contract markets and registered derivatives clearing organization to self-certify rules.

The Commission estimates the burden of this collection of information as follows:

ESTIMATED ANNUAL REPORTING BURDEN

| | Annual number of respondents | Frequency of response | Total annual responses | Hours per response | Total hours |
|---|---|---|---|---|---|
| 17 CFR | 11,006 | On occasion. | 13,118 | .83 | 749,031 |

There are no capital costs or operating and maintenance costs associated with this collection.

This estimate is based on the Commission's experience over the last three years.

Dated: July 30, 2004.

**Edward W. Colbert,**

*Deputy Secretary of the Commission.*

[FR Doc. 04–17880 Filed 8–4–04; 8:45 am]

**BILLING CODE 6351–01–M**

## CORPORATION FOR NATIONAL AND COMMUNITY SERVICE

### Approval of an Information Collection Currently Approved Through Emergency Clearance; Submission for OMB review; Comment request

**AGENCY:** Corporation for National and Community Service.

**ACTION:** Notice.

**SUMMARY:** The Corporation for National and Community Service (hereinafter the ''Corporation''), has submitted the two following public information collection requests (ICRs) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (Pub. L. 104–13), (44 U.S.C. Chapter 35). Copies of these individual ICRs (one for AmeriCorps and one for Learn and Serve America), with applicable supporting documentation, may be obtained by calling the Corporation for National and Community Service, LaMonica Shelton, (202) 606–5000, ext. 464 for the AmeriCorps collection and Kimberly Spring, ext. 543 for the Learn and Serve collection. Individuals who use a telecommunications device for the deaf (TTY–TDD) may call (202) 565–2799 between 8:30 a.m. and 5 p.m. Eastern time, Monday through Friday.

**ADDRESSES:** Comments may be submitted, identified by the title of the information collection activity, to the Office of Information and Regulatory Affairs, Attn: Ms. Katherine Astrich, OMB Desk Officer for the Corporation for National and Community Service, by any of the following two methods within 30 days from the date of this publication in the **Federal Register:**

(1) By fax to: (202) 395–6974, Attention: Ms. Katherine Astrich, OMB Desk Officer for the Corporation for National and Community Service; and

(2) Electronically by e-mail to: *Katherine_T._Astrich@omb.eop.gov.*

The initial 60-day **Federal Register** notice for Performance Measurement in AmeriCorps was published on January 21, 2004. The initial 60-day **Federal Register** notice for Learn and Serve America Program and Performance Reporting System was published on January 9, 2004. The comment period for these notices have elapsed, and the Corporation has since received emergency approval from OMB.

In direct response to the 60-day **Federal Register** Notice published on January 21, 2004, the Corporation for National and Community Service (the ''Corporation'') received two comments from the general public regarding the AmeriCorps surveys. In summary, the two comments reflected concerns and suggestions regarding (1) contacting potential survey respondents; (2) more clearly and appropriately identifying the survey respondents, survey requirements and sampling methodology to increase the level of responses and responsiveness; and (3) expanding some of the question types and indicators to capture a broader range of survey responses and to reflect the potential impacts of the AmeriCorps experience upon members and volunteers.

As a result of this feedback, we better modified questions to address the proper audiences and revised questions so that we can capture more information on the effects that volunteer service has upon members.

The Corporation received no comments from the general public regarding the Learn and Serve Program and Performance Reporting System as a

result of the 60-day **Federal Register** Notice published on January 9, 2004.

**SUPPLEMENTARY INFORMATION:** The OMB is particularly interested in comments which:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Corporation, including whether the information will have practical utility;
- Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Propose ways to enhance the quality, utility, and clarity of the information to be collected; and
- Propose ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.*, permitting electronic submissions of responses. Type of Review: Currently approved through emergency clearance. Agency: Corporation for National and Community Service. Title: (1) Performance Measurement in AmeriCorps: Surveys of Members, Organizations and End Beneficiaries; and (2) Learn and Serve America Program and Performance Reporting System.

*OMB Number:* 3045–0094(AmeriCorps) and 3045–0095(Learn and Serve).

*Frequency:* Annual.

*Affected Public:* Individuals and households, various small community and faith-based organizations, non-profits, state and local government and education institutions.

*Number of Respondents:* 6415 (3747 for AmeriCorps and 2668 for LSA).

*Estimated Time Per Respondent:* Ten minutes for AmeriCorps and one hour for LSA.

*Total Burden Hours:* 3172 hours (630 for AmeriCorps and 2542 for LSA).

*Total Burden Cost (capital/startup):* None.

*Total Annual Cost (operating/maintaining systems or purchasing services):* None.

*Description:* The Corporation is strongly committed to making its performance measurement and management systems more results oriented in order to strengthen the accountability and performance of its programs. As part of its effort to do so, there is a need to collect outcome information regarding the Corporation's AmeriCorps programs consisting of AmeriCorps*State and National, AmeriCorps*VISTA, and AmeriCorps*National Civilian Community Corps (NCCC). Information on program performance will be informed by a series of surveys, conducted electronically and by telephone, of a sample of AmeriCorps members, sub-grantee organizations that deliver services, and end-beneficiaries of the services provided by projects in which AmeriCorps sub-grantee organizations and AmeriCorps members are involved.

Learn and Serve has designed a Program Reporting and Performance Measurement form and a Customer Satisfaction Survey. The Program Reporting and Performance Measurement form is designed to collect information on (a) the characteristics of grantee and subgrantee organizations; (b) the scope and structure of service-learning activities in the funded organizations; (c) numbers of participants in service learning and hours of service provided; (d) institutional supports for service learning, and (e) program outcomes. There are three different versions of the form, corresponding to the three major funding streams under Learn and Serve America: K–12 school-based programs, Higher Education-based programs, and Community-Based programs. The Learn and Serve America Customer Satisfaction Survey will gather data on grantee satisfaction with the Learn and Serve program.

Dated: July 29, 2004.

**Robert Grimm,**

*Acting Director, Department of Research and Policy Development.*

[FR Doc. 04–17843 Filed 8–4–04; 8:45 am]

BILLING CODE 6050–$$–P

## DEPARTMENT OF DEFENSE

### Office of the Secretary

**[Transmittal No. 04–27]**

### 36(b)(1) Arms Sales Notification

**AGENCY:** Department of Defense, Defense Security Cooperation Agency.

**ACTION:** Notice.

**SUMMARY:** The Department of Defense is publishing the unclassified text of a section 36(b)(1) arms sales notification. This is published to fulfill the requirements of section 155 of Public Law 104–164 dated 21 July 1996.

**FOR FURTHER INFORMATION CONTACT:** Ms. J. Hurd, DSCA/OPS–ADMIN, (703) 604–6575.

The following is a copy of a letter to the Speaker of the House of Representatives, Transmittal 04–27 with attached transmittal, policy justification, and Sensitivity of Technology.

Dated: July 30, 2004.

**L. M. Bynum,**

*Alternate OSD Federal Register Liaison Officer, Department of Defense.*

BILLING CODE 5001–06–M

DEFENSE SECURITY COOPERATION AGENCY

WASHINGTON, DC 20301-2800

**23 July 2004**

**In reply refer to:**
**I-04/008407**

**The Honorable J. Dennis Hastert**
**Speaker of the House of Representatives**
**Washington, D.C. 20515-6501**

**Dear Mr. Speaker:**

**Pursuant to the reporting requirements of Section 36(b)(1) of the Arms Export Control Act, as amended, we are forwarding herewith Transmittal No. 04-27, concerning the Department of the Army's proposed Letter(s) of Offer and Acceptance to Canada for defense articles and services estimated to cost $83 million. Soon after this letter is delivered to your office, we plan to notify the news media.**

**Sincerely,**

**Edward W. Ross**
**Acting Director**

**Enclosures:**
1. **Transmittal No. 04-27**
2. **Policy Justification**
3. **Sensitivity of Technology**

**Same ltr to: House Committee on International Relations**
**Senate Committee on Foreign Relations**
**House Committee on Armed Services**
**Senate Committee on Armed Services**
**House Committee on Appropriations**
**Senate Committee on Appropriations**

**Transmittal No. 04-27**

**Notice of Proposed Issuance of Letter of Offer**
**Pursuant to Section 36(b)(1)**
**of the Arms Export Control Act, as amended**

(i) **Prospective Purchaser: Canada**

(ii) **Total Estimated Value:**

| | |
|---|---|
| Major Defense Equipment* | $33 million |
| Other | $50 million |
| TOTAL | $83 million |

(iii) **Description and Quantity or Quantities of Articles or Services under Consideration for Purchase: 19 Secure Mobile Anti-Jam Reliable Tactical Terminals (SMART-T) and 60 Single Channel Anti-Jam (SCAMP), modification kits, support equipment, spare and repair parts, supply support, personnel training and training equipment, publications and technical data, U.S. Government and contractor technical assistance and other related elements of logistics support.**

(iv) **Military Department: Army (ZUI)**

(v) **Prior Related Cases, if any: none**

(vi) **Sales Commission, Fee, etc., Paid, Offered, or Agreed to be Paid: none**

(vii) **Sensitivity of Technology Contained in the Defense Article or Defense Services Proposed to be Sold: See Annex attached**

(viii) **Date Report Delivered to Congress: 23 July 2004**

*** as defined in Section 47(6) of the Arms Export Control Act.**

## POLICY JUSTIFICATION

**Canada – Advanced Extremely High Frequency Terminals Program**

**The Government of Canada has requested a possible sale of 19 Secure Mobile Anti-Jam Reliable Tactical Terminals (SMART-T) and 60 Single Channel Anti-Jam (SCAMP), modification kits, support equipment, spare and repair parts, supply support, personnel training and training equipment, publications and technical data, U.S. Government and contractor technical assistance and other related elements of logistics support. The estimated cost is $83 million.**

**This proposed sale will contribute to the foreign policy and national security objectives of the United States by improving the military capabilities of Canada and further weapon system standardization and interoperability with U.S. forces.**

**Canada will mount the SMART-Ts on Canadian provided Light Support Vehicles Wheeled (LSVWs) which will be supplied as Government Furnished Equipment (GFE). The LSVWs will require modifications in order to mount the SMART-Ts to the LSVWs. This satellite terminal is also capable of stand-alone operation.**

**The proposed sale of this equipment and support will not affect the basic military balance in the region.**

**The principle contractors will be: Raytheon Incorporated in Marlborough, Massachusetts and Rockwll-Collins in Cedar Rapids, Iowa. There are no known offset agreements proposed in connection with this potential sale.**

**Implementation of this proposed sale will require the assignment of several U.S. Government representatives for two-week intervals twice annually to participate in training, program management and technical review. The specific requirements for the support in-country will be established during program definition between representatives of the United States Government and Canada.**

**There will be no adverse impact on U.S. defense readiness as a result of this proposed sale.**

**Transmittal No. 04-27**

**Notice of Proposed Issuance of Letter of Offer Pursuant to Section 36(b)(1) of the Arms Export Control Act**

**Annex**
**Item No. vii**

**(vii) Sensitivity of Technology:**

**1. The Secure Mobile Anti-Jam Reliable Tactical Terminal (SMART-T) is a low-cost High Mobility Multipurpose Wheeled Vehicle (HMMWV) mounted Enhanced High Frequency (EHF) satellite terminal which provides unattended, robust, worldwide, low probability of detection, jam resistant, multi-channel communications in support of the field commander. A typical application of the SMART-T is to provide range extension of the Mobile Subscriber Equipment (MSE) to units beyond line-of-sight, thus allowing communications support of widely dispersed forces.**

**2. The SMART-T and Single Channel Anti-Jam (SCAMP) is a Controlled Cryptographic Item (CCI) when it is unkeyed. It is classified Secret when keyed. There will be no transfer of classified data. The data, publications, and manuals are considered Unclassified.**

**3. The SCAMP terminal provides worldwide secure, jam-resistant, covert voice, data and imagery communications. Through its design and compact packaging, SCAMP offers communications for a wide range of applications, environments, platforms and users. The current SCAMP terminal operates at a low data rate of 75 bps up to 2400 bps with up to four full-duplex connections simultaneously. It is interoperable with Milstar and all satellites with EHF capability meeting the MIL-STD-1582 data link standards. The terminal is user-friendly and will automatically acquire the satellite and then establish, maintain and control communications links.**

**4. The SCAMP Advanced EHF enhancement also includes a new AEHF modem capable of transferring information at 128 kbps. A new AEHF synthesizer, new processor, software operating system, a new circuit cart assembly and a chassis change to add Ethernet connectors are also in the program.**

**5. If a technologically advanced adversary were to obtain knowledge of the specific hardware and software elements, the information could be used to develop countermeasures which might reduce weapon system effectiveness or be used in the development of a system with similar or advanced capabilities.**

**6. A determination has been made that Canada can provide substantially the same degree of protection for the sensitive technology being released as the U.S. Government. This sale is necessary in furtherance of the U.S. foreign policy and national security objectives outlined in the Policy Justification.**

[FR Doc. 04–17868 Filed 8–4–04; 8:45 am]
BILLING CODE 5001–06–C

## DEPARTMENT OF DEFENSE

### Office of the Secretary

**[Transmittal No. 04–13]**

### 36(b)(1) Arms Sales Notification

**AGENCY:** Department of Defense, Defense Security Cooperation Agency.

**ACTION:** Notice.

**SUMMARY:** The Department of Defense is publishing the unclassified text of a section 36(b)(1) arms sales notification. This is published to fulfill the requirements of section 155 of Public Law 104–164 dated 21 July 1996.

**FOR FURTHER INFORMATION CONTACT:** Ms. J. Hurd, DSCA/OPS–ADMIN, (703) 604–6575.

The following is a copy of a letter to the Speaker of the House of Representatives, Transmittal 04–13 with attached transmittal and policy justification.

Dated: July 30, 2004.

**L.M. Bynum,**

*Alternate OSD Federal Register Liaison Officer, Department of Defense.*

**BILLING CODE 5001–06–M**

DEFENSE SECURITY COOPERATION AGENCY

WASHINGTON, DC 20301-2800

**22 July 2004**

**In reply refer to:**
**I-04/006057**

**The Honorable J. Dennis Hastert**
**Speaker of the House of Representatives**
**Washington, D.C. 20515-6501**

**Dear Mr. Speaker:**

**Pursuant to the reporting requirements of Section 36(b)(1) of the Arms Export Control Act (AECA), as amended, we are forwarding herewith Transmittal No. 04-13 and under separate cover the classified offset certificate thereto. This Transmittal concerns the Department of the Air Force's proposed Letter(s) of Offer and Acceptance (LOA) to Sweden for defense articles and services estimated to cost $120 million. Soon after this letter is delivered to your office, we plan to notify the news media of the unclassified portion of this Transmittal.**

**Reporting of Offset Agreements in accordance with Section 36(b)(1)(C) of the AECA, as amended, requires a description of any offset agreement with respect to this proposed sale. Section 36(g) of the AECA, as amended, provides that reported information related to offset agreements be treated as confidential information in accordance with section 12(c) of the Export Administration Act of 1979 (50 U.S.C. App. 2411(c)). Information about offsets for this proposed sale is described in the enclosed confidential attachment.**

**Sincerely,**

Sincerely,

JEFFREY B. KOHLER
LIEUTENANT GENERAL, USAF
DIRECTOR

**Enclosures:**
**1. Transmittal No. 04-13**
**2. Policy Justification**

**Separate Cover:**
**Offset certificate**

**Same ltr to: House Committee on International Relations**
**Senate Committee on Foreign Relations**
**House Committee on Armed Services**
**Senate Committee on Armed Services**
**House Committee on Appropriations**
**Senate Committee on Appropriations**

**Transmittal No. 04-13**

**Notice of Proposed Issuance of Letter of Offer**
**Pursuant to Section 36(b)(1)**
**of the Arms Export Control Act, as amended**

(i) **Prospective Purchaser:** Sweden

(ii) **Total Estimated Value:**

| | |
|---|---|
| Major Defense Equipment* | $ 0 million |
| Other | $120 million |
| TOTAL | $120 million |

(iii) **Description and Quantity or Quantities of Articles or Services under Consideration for Purchase:** upgrade services for eight C-130H aircraft. The Avionics Modernization Program upgrade includes navigation, communications, LCD displays with a heads-up display, software development/ integration, associated support equipment, modification kits, spare and repair parts, test equipment, publications and technical documentation, personnel training and training equipment, U.S. Government and contractor engineering and logistics personnel services and other related elements of logistics support.

(iv) **Military Department:** Air Force (QAF)

(v) **Prior Related Cases, if any:** none

(vi) **Sales Commission, Fee, etc., Paid, Offered, or Agreed to be Paid:** none

(vii) **Sensitivity of Technology Contained in the Defense Article or Defense Services Proposed to be Sold:** none

(viii) **Date Report Delivered to Congress:** 22 July 2004

* as defined in Section 47(6) of the Arms Export Control Act.

## POLICY JUSTIFICATION

### Sweden – Avionics Modernization Program Upgrade of C-130H Aircraft

**The Government of Sweden has requested a possible sale of upgrade services for eight C-130H aircraft. The Avionics Modernization Program upgrade includes navigation, communications, LCD displays with a heads-up display, software development/integration, associated support equipment, modification kits, spare and repair parts, test equipment, publications and technical documentation, personnel training and training equipment, U.S. Government and contractor engineering and logistics personnel services and other related elements of logistics support. The estimated cost is $120 million.**

**This proposed sale will contribute to the foreign policy and national security of the United States by helping to improve the security of a friendly country which has been and continues to be an important force for political stability and economic progress in Europe.**

**This proposed sale would ensure the capability of performing all-weather, around the clock, combat delivery missions. The C-130H system requires upgrades to radar, navigation and communication systems, as well as the man-machine interface. Sweden will have no difficulty absorbing the upgraded aircraft into its armed forces.**

**The proposed sale of this equipment and support will not affect the basic military balance in the region.**

**The prime contractor will be the Boeing Company of Long Beach, California. One or more proposed offset agreements may be related to this proposed sale.**

**Implementation of this sale will not require the assignment of any additional U.S. Government personnel or contractor representatives to Sweden.**

**There will be no adverse impact on U.S. defense readiness as a result of this proposed sale.**

[FR Doc. 04–17869 Filed 8–4–04; 8:45 am]
BILLING CODE 5001–06–C

---

## DEPARTMENT OF DEFENSE

### Office of the Secretary

### Meeting of the Advisory Council on Dependents' Education

**AGENCY:** Department of Defense Education Activity (DoDEA), DoD.

**ACTION:** Open meeting notice.

**SUMMARY:** Pursuant to the Federal Advisory Committee Act, Appendix 2 of title 5, United States Code, Public Law 92–463, notice is hereby given that a meeting of the Advisory Council on Dependents' Education (ACDE) is scheduled to be held on September 24, 2004, from 8 a.m. to 5 p.m. The meeting will be held at the DoDEA headquarters building at 4040 North Fairfax Drive, Arlington, Virginia 22203. The purpose of the ACDE is to recommend to the Director, DoDEA, general policies for the operation of the Department of Defense Dependents Schools (DoDDS); to provide the Director with information about effective educational programs and practices that should be considered by DoDDS; and to perform other tasks as may be required by the Secretary of Defense. The meeting emphases will be the current operational qualities of DoDDS and the institutionalized school improvement processes, as well as other educational matters. For further information contact Mr. Jim Jarrard, at (703) 588–3121 or at *James.Jarrard@hq.dodea,edu.*

Dated: July 30. 2004.

**L.M. Bynum,**

*Alternate OSD Federal Register Liaison Officer, Department of Defense.*

[FR Doc. 04–17866 Filed 8–4–04; 8:45 am]
BILLING CODE 5001–06–M

## DEPARTMENT OF DEFENSE

### Department of the Army; Corps of Engineers

### Notice of Availability for the Final Environmental Impact Statement/ Environmental Impact Report for the Pier J South Marine Terminal Expansion Project, Los Angeles County, CA

**AGENCY:** Department of the Army—U.S. Army Corps of Engineers, DoD.

**ACTION:** Notice of availability.

**SUMMARY:** The U.S. Army Corps of Engineers, Los Angeles District (Regulatory Branch), in coordination with the Port of Long Beach, has completed a Final Environmental Impact Statement/Environmental Impact Report (EIS/EIR) for the Pier J South Marine Terminal Expansion project. The Port of Long Beach requires authorization pursuant to section 404 of the Clean Water Act and section 10 of the Rivers and Harbors Act for 115 acres

of landfill in three phases, dredging up to 10,000,000 cubic yards of sediment, construction of a new concrete pile-supported wharf, new terminal buildings and a new rail yard.

**FOR FURTHER INFORMATION CONTACT:** Questions or comments concerning the Final EIS/EIR should be directed to Dr. Aaron O. Allen, Senior Project Manager, Regulatory Branch, U.S. Army Corps of Engineers, P.O. Box 532711, Los Angeles, CA 90053–2325, (805) 585–2148.

**SUPPLEMENTARY INFORMATION:** None.

**David H. Turk,**

*Colonel, U.S. Army, Acting District Engineer.*

[FR Doc. 04–17836 Filed 8–4–04; 8:45 am]

**BILLING CODE 3716–KF–P**

## DEPARTMENT OF ENERGY

### Energy Information Administration

### Agency Information Collection Activities: Submission for OMB Review; Comment Request

**AGENCY:** Energy Information Administration (EIA), Department of Energy (DOE).

**ACTION:** Agency Information Collection Activities: Submission for OMB Review; comment request.

**SUMMARY:** The EIA has submitted the new survey form EIA–914, ''Monthly Natural Gas Production Report'' to the Office of Management and Budget (OMB) for review and a three-year approval under section 3507(h)(1) of the Paperwork Reduction Act of 1995 (Pub. L. 104–13) (44 U.S.C. 3501 *et seq.*)

**DATES:** Comments must be filed by September 7, 2004. If you anticipate that you will be submitting comments but find it difficult to do so within that period, you should contact the OMB Desk Officer for DOE listed below as soon as possible.

**ADDRESSES:** Send comments to OMB Desk Officer for DOE, Office of Information and Regulatory Affairs, Office of Management and Budget. To ensure receipt of the comments by the due date, submission by fax (202) 395–7285) is recommended. The mailing address is 726 Jackson Place, NW., Washington, DC 20503. (A copy of your comments should also be provided to EIA's Statistics and Methods Group at the address below.)

**FOR FURTHER INFORMATION CONTACT:** Requests for additional information should be directed to Herbert Miller. To ensure receipt of the comments by the due date, submission by fax (202) 287–1705) or e-mail (*herbert.miller@eia.doe.gov*) is recommended. The mailing address is Statistics and Methods Group (EI–70), Forrestal Building, U.S. Department of Energy, Washington, DC 20585–0670. Mr. Miller may be contacted by telephone at (202) 287–1711.

**SUPPLEMENTARY INFORMATION:** This section contains the following information about the energy information collection submitted to OMB for review: (1) The collection numbers and title; (2) the sponsor (*i.e.*, the Department of Energy component); (3) the current OMB docket number (if applicable); (4) the type of request (*i.e.*, new, revision, extension, or reinstatement); (5) response obligation (*i.e.*, mandatory, voluntary, or required to obtain or retain benefits); (6) a description of the need for and proposed use of the information; (7) a categorical description of the likely respondents; and (8) an estimate of the total annual reporting burden.

1. EIA–914, ''Monthly Natural Gas Production Report''.
2. Energy Information Administration.
3. OMB Number—Not applicable.
4. New.
5. Mandatory.
6. The purpose of the survey is to collect monthly data on the production of natural gas in seven geographical areas (Texas (including State offshore), Louisiana (including State offshore), Oklahoma, New Mexico, Wyoming, Federal Gulf of Mexico offshore and Other States (defined as all remaining states, except Alaska, in which the operator produced natural gas during the report month). Data will be used to monitor natural gas supplies. Survey respondents would be a sample of well operators.

Since EIA's main goal is to have timely overall production information, at this time the agency is not proposing to collect information on gas used for repressuring and reinjection, gas vented and flared, fuel used on the lease, or nonhydrocarbons removed on the lease, as proposed in the **Federal Register** on April 23, 2004, pp. 22019–22025. The proposed data collection would consist of (1) natural gas gross withdrawals (wet) and (2) natural gas lease production.

7. Business or other for-profit.
8. 15,517 hours.

Please refer to the supporting statement as well as the proposed forms and instructions for more information about the purpose, who must report, when to report, where to submit, the elements to be reported, detailed instructions, provisions for confidentiality, and uses (including possible nonstatistical uses) of the information. For instructions on obtaining materials, see the **FOR FURTHER INFORMATION CONTACT** section.

**Statutory Authority:** Section 3507(h)(1) of the Paperwork Reduction Act of 1995 (Pub. L. 104–13) (44 U.S.C. 3501 *et seq*).

Issued in Washington, DC, July 30, 2004.

**Jay H. Casselberry,**

*Agency Clearance Officer, Statistics and Methods Group, Energy Information Administration.*

[FR Doc. 04–17886 Filed 8–4–04; 8:45 am]

**BILLING CODE 6450–01–P**

## DEPARTMENT OF ENERGY

### Energy Information Administration

### Agency Information Collection Activities: Submission for OMB Review; Comment Request

**AGENCY:** Energy Information Administration (EIA), Department of Energy (DOE).

**ACTION:** Agency Information Collection Activities: Submission for OMB Review; comment request.

**SUMMARY:** The EIA has submitted the EIA–910, ''Monthly Natural Gas Marketers Report'', part of the Natural Gas Data Collection Program package to the Office of Management and Budget (OMB) for review and a three-year extension under section 3507(h)(1) of the Paperwork Reduction Act of 1995 (Pub. L. 104–13) (44 U.S.C. 3501 *et seq*).

**DATES:** Comments must be filed by September 7, 2004. If you anticipate that you will be submitting comments but find it difficult to do so within that period, you should contact the OMB Desk Officer for DOE listed below as soon as possible.

**ADDRESSES:** Send comments to OMB Desk Officer for DOE, Office of Information and Regulatory Affairs, Office of Management and Budget. To ensure receipt of the comments by the due date, submission by FAX (202–395–7285) is recommended. The mailing address is 726 Jackson Place, NW., Washington, DC 20503. (A copy of your comments should also be provided to EIA's Statistics and Methods Group at the address below.)

**FOR FURTHER INFORMATION CONTACT:** Requests for additional information should be directed to Herbert Miller. To ensure receipt of the comments by the due date, submission by FAX (202–287–1705) or e-mail (*herbert.miller@eia.doe.gov*) is recommended. The mailing address is Statistics and Methods Group (EI–70),

Forrestal Building, U.S. Department of Energy, Washington, DC 20585–0670. Mr. Miller may be contacted by telephone at (202) 287–1711.

**SUPPLEMENTARY INFORMATION:** This section contains the following information about the energy information collection submitted to OMB for review: (1) The collection numbers and title; (2) the sponsor (*i.e.*, the Department of Energy component); (3) the current OMB docket number (if applicable); (4) the type of request (*i.e.*, new, revision, extension, or reinstatement); (5) response obligation (*i.e.*, mandatory, voluntary, or required to obtain or retain benefits); (6) a description of the need for and proposed use of the information; (7) a categorical description of the likely respondents; and (8) an estimate of the total annual reporting burden.

1. EIA–176, 191, 857, 895, 910 and 912.

2. Energy Information Administration.

3 .OMB Number 1905–0175.

4. Revision.

5. Mandatory.

6. The Natural Gas Data Collection Program Package forms collect basic and detailed natural gas production, processing, transmission, storage, consumption, and price data. The data are published by the Energy Information Administration and are used by both public and private analysts. Respondents include natural gas pipeline companies, distributors, storage operators, processing plant operators, and State agencies.

With respect to its natural gas survey forms, the Energy Information Administration (EIA) is proposing to add seven States and the District of Columbia to the EIA–910, ''Monthly Natural Gas Marketers Report'' survey frame, which currently includes five States.

7. Business or other for profit.

8. 47,522 hours.

Please refer to the supporting statement as well as the proposed forms and instructions for more information about the purpose, who must report, when to report, where to submit, the elements to be reported, detailed instructions, provisions for confidentiality, and uses (including possible nonstatistical uses) of the information. For instructions on obtaining materials, see the **FOR FURTHER INFORMATION CONTACT** section.

**Statutory Authority:** Section 3507(h)(1) of the Paperwork Reduction Act of 1995 (Pub. L. 104–13)(44 U.S.C. 3501 et seq).

Issued in Washington, DC, July 30, 2004.

**Jay H. Casselberry,**

*Agency Clearance Officer, Statistics and Methods Group, Energy Information Administration.*

[FR Doc. 04–17887 Filed 8–4–04; 8:45 am]

**BILLING CODE 6450–01–P**

---

## DEPARTMENT OF ENERGY

## Federal Energy Regulatory Commission

**[Docket No. EC96–2–003, et al.]**

## Public Service Company of Colorado, et al.; Electric Rate and Corporate Filings

July 29, 2004.

The following filings have been made with the Commission. The filings are listed in ascending order within each docket classification.

### 1. Public Service Company of Colorado and Southwestern Public Service Company

[Docket Nos. EC96–2–003]

Take notice that on July 20, 2004, Public Service Company of Colorado (PSCo) and Southwestern Public Service Company (SPS) submitted for Commission review a supplemental market power analysis which addresses the effects of a transmission interconnection that PSCo and SPS are constructing between their systems.

*Comment Date:* 5 p.m. eastern time on September 17, 2004.

### 2. Allegheny Energy, Inc., Allegheny Energy Supply Company, LLC

[Docket No. EC04–130–000]

Take notice that on July 26, 2004, Allegheny Energy, Inc. (Allegheny) and Allegheny Energy Supply Company, LLC (AE Supply) (collectively, Applicants) filed an application for disposition of jurisdictional facilities under section 203 of the Federal Power Act. Applicants request Commission approval to sell to Buckeye Power Generating, LLC (BPG) a wholly-owned subsidiary of Buckeye Power, Inc., an Ohio non-profit corporation, certain jurisdictional assets. The applicants have requested privileged treatment of certain agreements submitted in support of the application.

*Comment Date:* 5 p.m. eastern time on August 16, 2004.

### 3. Pittsfield Generating Company, L.P.

[Docket No. EC04–136–000]

Take notice that on July 27, 2004, Pittsfield Generating Company, L.P. (Pittsfield) submitted an application pursuant to section 203 of the Federal Power Act for authorization of a disposition of jurisdictional facilities whereby Altresco, Inc. (Altresco) and Pittsfield Partners, Inc. (PPI) will transfer their respective limited partner interests in Pittsfield to SFG CLA Pittsfield, LLC (SFG) or its affiliated nominees and assignees. Pittsfield states that it is a public utility and exempt wholesale generator in Massachusetts, with a nominal capacity of 163 MW. Pittsfield requested privileged treatment of certain agreements pertaining to a settlement entered into by, among others, Pittsfield, SFG, Altresco, PPI, and General Electric Capital Corporation, pursuant to which the transfer of limited partner interests will occur.

*Comment Date:* 5 p.m. eastern time on August 17, 2004.

### 4. White Pine Copper Refinery, Inc., White Pine Electric Power, L.L.C.

[Docket Nos. EC04–137–000 and ER04–1047–000]

Take notice that on July 27, 2004, White Pine Copper Refinery, Inc. (White Pine Copper) and White Pine Electric Power, L.L.C. (White Pine Electric) (collectively, the Applicants), filed with the Federal Energy Regulatory Commission an application for authorization under sections 203 and 205 of the Federal Power Act to transfer, by a sale of assets for nominal amount, market based rate authority and certain jurisdictional facilities, to establish rate schedule and to cancel rate schedule. White Pine Copper seeks approval for an intra-corporate transfer of jurisdictional facility assets to White Pine Electric. The Applicant states that transfer of assets is related to White Pine Copper's concurrent disposition to White Pine Electric of three coal-fired steam-turbine generating units located in White Pine, MI, capable of delivering a total of 60 MW. Additionally, White Pine Electric seeks approval of its market-based rate tariff in order to make wholesale electric power and energy sales. Lastly, White Pine Copper seeks approval to cancel its market-based tariff, approved in Docket No. ER04–262–000, by letter order dated January 1, 2004.

*Comment Date:* 5 p.m. eastern time on August 17, 2004.

### 5. White Pine Electric Power, L.L.C.

[Docket No. EG04–87–000]

Take notice that on July 27, 2004, White Pine Electric Power, L.L.C. (White Pine), P.O. Box 695, 1 Willow Road, White Pine, MI 49971, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale

generator status pursuant to part 365 of the Commission's regulations and section 32(a)(1) of the Public Utility Holding Company Act of 1935. White Pine states that it is a limited liability company organized under the laws of Delaware that will be engaged directly and exclusively in the business of owning and/or operating eligible facilities in the United States and selling electric energy at wholesale. White Pine states that it proposes to operate three 20 MW coal-fired steam-turbines, in an electric generating facility located in White Pine, Michigan.

*Comment Date:* 5 p.m. eastern time on August 17, 2004.

**6. Public Service Company of Colorado**

[Docket No. ER03–971–005]

Take notice that, on July 26, 2004, Public Service Company of Colorado (PS Colorado) tendered for filing revised power sales agreements with Holy Cross Electric Association, Inc., Yampa Valley Electric Association, Inc., Grand Valley Rural Power Lines, Inc., the Town of Julesburg, Colorado, the City of Burlington, Colorado and the Town of Center, Colorado in compliance with the Commission's order issued February 27, 2004, in Docket No. ER03–971–000, *et al.* PS Colorado states that the revised agreements are a result of settlements between them and these wholesale customers.

PS Colorado states that copies of the filing were served on parties on the official service list in the above-captioned proceeding, as well as on the Colorado Public Utility Commission.

*Comment Date:* 5 p.m. eastern time on August 16, 2004.

**7. Sierra Pacific Resources Operating Companies**

[Docket No. ER03–1328–002]

Take notice that on July 26, 2004 Sierra Pacific Resources Operating Companies (SPR) submitted a refund report in compliance with the Commission's order issued July 8, 2004, in Docket No. ER03–1328–000, 108 FERC ¶ 61,023.

*Comment Date:* 5 p.m. eastern time on August 16, 2004.

**8. PacifiCorp**

[Docket No. ER04–767–002]

Take notice that on July 26, 2004, PacifiCorp, submitted a compliance filing pursuant to the Commission's order issued June 25, 2004, in Docket No. ER04–767–000, 107 FERC ¶ 61,318.

*Comment Date:* 5 p.m. eastern time on August 16, 2004.

**9. PJM Interconnection, L.L.C.**

[Docket No. ER04–1039–000]

Take notice that on July 23, 2004, PJM Interconnection, L.L.C. (PJM), submitted for filing an executed interconnection service agreement among PJM, National Institute of Health, and Potomac Electric Power Company designated as Original Service Agreement No. 1049 under PJM's FERC Electric Tariff Sixth Revised Volume No. 1. PJM requests an effective date of June 23, 2004.

PJM states that copies of this filing were served upon the parties to the agreement and the State regulatory commissions within the PJM region.

*Comment Date:* 5 p.m. eastern time on August 13, 2004.

**10. PJM Interconnection, L.L.C.**

[Docket No. ER04–1040–000]

Take notice that on July 23, 2004, PJM Interconnection, L.L.C. (PJM), submitted for filing an executed interim interconnection service agreement (ISA) among PJM, Calvert Cliffs Nuclear Power Plant, Inc. and Baltimore Gas and Electric Company designated Original Service Agreement No. 1050 under PJM's FERC Electric Tariff Sixth Revised Volume No. 1. PJM requests an effective date of June 23, 2004.

PJM states that copies of this filing were served upon the parties to the agreement and the State regulatory commissions within the PJM region.

*Comment Date:* 5 p.m. eastern time on August 13, 2004.

**11. NorthWestern Corporation**

[Docket No. ES04–43–000]

Take notice that on July 26, 2004, NorthWestern Corporation (NorthWestern) submitted an application pursuant to section 204 of the Federal Power Act seeking authorization to issue: (1) Debt comprised of a senior secured credit facility in an amount up to $250 million and senior secured notes in an amount up to $350 million, which, collectively, will be secured by up to $600 million of first mortgage bonds; and (2) up to 35.5 million shares of common stock. NorthWestern also requests a waiver from the Commission's competitive bidding and negotiated placement requirements at 18 CFR 34.2.

*Comment Date:* 5 p.m. eastern time on August 6, 2004.

**Standard Paragraph**

Any person desiring to intervene or to protest this filing must file in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214). Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a notice of intervention or motion to intervene, as appropriate. Such notices, motions, or protests must be filed on or before the comment date. Anyone filing a motion to intervene or protest must serve a copy of that document on the Applicant. On or before the comment date, it is not necessary to serve motions to intervene or protests on persons other than the Applicant.

The Commission encourages electronic submission of protests and interventions in lieu of paper using the ''Filing'' link at *http://www.ferc.gov*. Persons unable to file electronically should submit an original and 14 copies of the protest or intervention to the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426.

This filing is accessible on-line at *http://www.ferc.gov*, using the ''eLibrary'' link and is available for review in the Commission's Public Reference Room in Washington, DC. There is an ''eSubscription'' link on the Web site that enables subscribers to receive e-mail notification when a document is added to a subscribed docket(s). For assistance with any FERC Online service, please e-mail *FERCOnlineSupport@ferc.gov,* or call (866) 208-3676 (toll free). For TTY, call (202) 502–8659.

**Magalie R. Salas,**

*Secretary.*

[FR Doc. E4–1731 Filed 8–4–04; 8:45 am]

**BILLING CODE 6717–01–P**

## ENVIRONMENTAL PROTECTION AGENCY

**[OW–2004–0015, FRL–7798–1]**

## Agency Information Collection Activities: Proposed Collection; Comment Request; ''Clean Water Act State Revolving Fund Program,'' EPA ICR Number 1391.07, OMB Control Number 2040–0118

**AGENCY:** Environmental Protection Agency (EPA).

**ACTION:** Notice.

**SUMMARY:** In compliance with the Paperwork Reduction Act (44 U.S.C. 3501 *et seq.*), this document announces that EPA is planning to submit a continuing Information Collection Request (ICR) to the Office of Management and Budget (OMB). This is a request to renew an existing approved

collection. This ICR is scheduled to expire on 11/30/04. Before submitting the ICR to OMB for review and approval, EPA is soliciting comments on specific aspects of the proposed information collection as described below.

**DATES:** Comments must be submitted on or before October 4, 2004.

**ADDRESSES:** Submit your comments, referencing docket ID number OW–2004–0015, to EPA online using EDOCKET (our preferred method), by e-mail to *OW-DOCKET@EPA.gov*, or by mail to: EPA Docket Center, Environmental Protection Agency, [Office of Water Docket, Mail Code–4101T, 1200 Pennsylvania Ave., NW., Washington, DC 20460.

**FOR FURTHER INFORMATION CONTACT:** Clifford Yee, Office of Wastewater Management, Mail Code, 4204M, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: 202–564–0598; fax number: 202–501–2403; e-mail address: *yee.clifford@EPA.gov*.

**SUPPLEMENTARY INFORMATION:** EPA has established a public docket for this ICR under Docket ID number OW–2004–0015, which is available for public viewing at the Water Docket in the EPA Docket Center (EPA/DC), EPA West, Room B102, 1301 Constitution Ave., NW., Washington, DC. The EPA Docket Center Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Reading Room is (202) 566–1744, and the telephone number for the Water Docket is (202) 566–2426. An electronic version of the public docket is available through EPA Dockets (EDOCKET) at *http://www.epa.gov/edocket.* Use EDOCKET to obtain a copy of the draft collection of information, submit or view public comments, access the index listing of the contents of the public docket, and to access those documents in the public docket that are available electronically. Once in the system, select ''search,'' then key in the docket ID number identified above.

Any comments related to this ICR should be submitted to EPA within 60 days of this notice. EPA's policy is that public comments, whether submitted electronically or in paper, will be made available for public viewing in EDOCKET as EPA receives them and without change, unless the comment contains copyrighted material, CBI, or other information whose public disclosure is restricted by statute. When EPA identifies a comment containing copyrighted material, EPA will provide a reference to that material in the version of the comment that is placed in EDOCKET. The entire printed comment, including the copyrighted material, will be available in the public docket. Although identified as an item in the official docket, information claimed as CBI, or whose disclosure is otherwise restricted by statute, is not included in the official public docket, and will not be available for public viewing in EDOCKET. For further information about the electronic docket, *see* EPA's **Federal Register** notice describing the electronic docket at 67 FR 38102 (May 31, 2002), or go to *http://www.epa.gov./edocket.*

*Affected entities:* Entities potentially affected by this action are State and Local Government officials.

*Title:* Clean Water Act State Revolving Fund Program (OMB Control No. 2040–0118; EPA ICR No. 1391.06) expiring 11/30/04.

*Abstract:* The Clean Water Act, as amended by ''The Water Quality Act of 1987'' (U.S.C. 1381–1387 *et seq.*), created a Title VI which authorizes grants to States for the establishment of State Water Pollution Control Revolving Funds (SRFs). The information collection activities will occur primarily at the program level through the State ''Intended Use Plan'' and ''Annual Report''. The information is needed annually to implement section 606 of the Clean Water Act (CWA).

The 1987 Act declares that water pollution control revolving funds shall be administered by an instrumentality of the State subject to the requirements of the act. This means that each State has a general responsibility for administering its revolving fund and must take on certain specific responsibilities in carrying out its administrative duties. The information collection activities will occur primarily at the program level through the State Intended Use Plan and Annual Report. The information is needed annually to implement section 606 of the Clean Water Act (CWA). The Act requires the information to ensure national accountability, adequate public comment and review, fiscal integrity and consistent management directed to achieve environmental benefits and results. The individual information collections are: (1) Capitalization Grant Application and Agreement/State Intended Use Plan, (2) Annual Report, (3) State Annual Audit, and (4) Application for SRF Financial Assistance.

(1) *Capitalization Grant Application and Agreement/State Intended Use Plan:* The State will prepare a Capitalization Grant application that includes an Intended Use Plan (IUP) outlining in detail how it will use all the funds available to the fund. The grant agreement contains or incorporates by reference the IUP, application materials, payment schedule, and required assurances. The bulk of the information is provided in the IUP, the legal agreement which commits the State and EPA to execute their responsibilities under the Act.

(2) *Annual Report:* The State must agree to complete and submit an annual Report that indicates how the State has met the goals and objectives of the previous fiscal year as stated in the IUP and grant agreement. The report provides information on loan recipients, loan amounts, loan terms, project categories, and similar data on other forms of assistance. The report describes the extent to which the existing SRF financial operating policies, alone or in combination with other State financial assistance programs, will provide for the long term fiscal health of the Fund and carry out other provisions specified in the grant operating agreement.

(3) *Annual Audit:* Most States have agreed to conduct or have conducted a separate financial audit of the Capitalization Grant which will provide opinions on the financial statements, and a report on the internal controls and compliance with program requirements. The remaining States will be covered by audits conducted under the requirements of the Single Audit Act and by EPA's Office of Inspector General.

(4) *Application for SRF Financial Assistance:* Local communities and other eligible entities have to prepare and submit applications for SRF assistance to their respective State Agency which manages the SRF program. The State reviews the completed loan applications, and verifies that the proposed projects will comply with applicable Federal and State requirements.

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control numbers for EPA's regulations in 40 CFR are listed in 40 CFR part 9.

The EPA would like to solicit comments to:

(i) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility;

(ii) Evaluate the accuracy of the Agency's estimate of the burden of the proposed collection of information,

including the validity of the methodology and assumptions used;

(iii) Enhance the quality, utility, and clarity of the information to be collected; and

(iv) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.*, permitting electronic submission of responses.

Burden Statement: The information collection will involve about an estimated 2,805 respondents per year, with about 2,754 average annual responses per year. The time required for the responses will vary depending on the respondent, but the total average annual number of hours requested is estimated to be about 339,405 hours. The total average annual respondent (State and Local) cost is estimated to be about $6,830,850.

Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, or disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; develop, acquire, install, and utilize technology and systems for the purposes of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; adjust the existing ways to comply with any previously applicable instructions and requirements; train personnel to be able to respond to a collection of information; search data sources; complete and review the collection of information; and transmit or otherwise disclose the information.

Dated: July 29, 2004.

**Jane Moore,**

*Deputy Director, Office of Wastewater Management.*

[FR Doc. 04–17883 Filed 8–4–04; 8:45 am]

**BILLING CODE 6560–50–P**

## ENVIRONMENTAL PROTECTION AGENCY

**[FRL–7797–2]**

## Local Resource Centers to Assist Public Entities Develop Environmental Management Systems (EMS)

**AGENCY:** Environmental Protection Agency.

**ACTION:** Notice and request for public comment.

**SUMMARY:** This Notice requests public comments on the efforts of the United States Environmental Protection Agency (EPA) to promote the adoption of environmental management systems (EMS) by local governments and other public entities through the establishment of EMS Local Resource Centers. EPA is seeking comments particularly from not-for-profit organizations interested in providing technical assistance to public entities that are considering adopting EMSs for their operations.

The EPA, through a cooperative agreement with the Global Environment and Technology Foundation (GETF), is interested in providing financial and technical assistance for up to three additional not-for-profit organizations who would then work with various public entities, primarily local governments, that are interested in developing EMSs. The financial and technical assistance provided to these not-for-profit organizations could include help with developing business plans, providing relevant EMS materials to facilitate each organization's existing EMS assistance activities, train-the-trainer sessions on ways to address the needs of public agencies, and other marketing services. Each not-for-profit organization would also gain increased attention, and recognition of the key role they can play in meeting the growing needs of public agencies wishing to adopt EMSs through a Web site managed by GETF at *www.peercenter.net*, and other means.

This Notice is soliciting comments from not-for-profit organizations interested in becoming part of an existing program involving seven organizations around the country. These EMS Local Resource Centers, which were first designated in 2002, are now working with public agencies around the country to educate and assist them to develop EMSs. A list of these Local Resource Centers and more information about their services can be found at *www.peercenter.net*. EPA, in cooperation with the Global Environment and Technology Foundation (GETF), is now interested in receiving comments and information from additional not-for-profit organizations that would be interested in serving as a Local Resource Center and providing EMS assistance to public entities. EPA is particularly interested in receiving comment from organizations located in areas of the country not now served by an existing EMS Local Resource Center in EPA Regions VII, VIII, and IX. Region VII includes the States of Missouri, Kansas, Nebraska, and Iowa. Region VIII includes the States of Colorado, Utah, Montana, Wyoming, North Dakota, and South Dakota. Region IX includes the States of California, Arizona, Nevada, Hawaii, and the U.S. Territories of Guam and Northern Mariana Islands.

**DATES:** Responses to this Notice, identified by docket identification (ID) number OW–2004–0018, must be received on or before September 7, 2004.

**ADDRESSES:** Comments may be submitted electronically, by mail, or through hand delivery/courier. Follow the instructions as provided in Section I of the **SUPPLEMENTARY INFORMATION**.

In addition, a copy of the comments should also be submitted to Nick Martin, Global Environment and Technology Foundation (GETF), 2900 South Quincy Street, Suite 410, Arlington, Virginia 22206, (703) 379–2713, Ext. 290, *nmartin@getf.org*.

**FOR FURTHER INFORMATION CONTACT:** Jim Horne, U.S. EPA, Office of Water, by phone at (202 564–0571, or by e-mail at *horne.james@epa. gov*.

**SUPPLEMENTARY INFORMATION:**

### I. General Information

*A. How Can I Get Copies of This Notice and Other Related Information?*

1. *Docket:* EPA has established an official public docket for this Notice under Docket ID No. OW–2004–0018. The official public docket consists of the documents specifically referenced in this Notice, any public comments received, and other information related to this action. Documents in the official public docket are listed in the index list in EPA's electronic public docket and comments system, EDOCKET. Documents may be available either electronically or in hard copy. Hard copy documents may be viewed at the Water Docket in the EPA Docket Center (EPA/DC), EPA West, Room B–102, 1301 Constitution Avenue, NW., Washington, DC. The EPA Docket Center Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Public Reading Room is (202) 566–1744, and the telephone number for the Water Docket is (202) 566–2426.

2. *Electronic Access:* Your may access this **Federal Register** document electronically through the EPA Internet under the **Federal Register** listings at *http://www.epa.gov/fedregstr/*. An electronic version of the public docket is available through EDOCKET. You may use EDOCKET at *http://www.epa.gov.edocket/* to view public comments, access the index listing of the contents of the official public docket, and access those documents in

the public docket that are available electronically. Once in the system, select ''search,'' then key in the appropriate docket identification number referenced above.

Certain types of information will not be placed in EDOCKET. Information claimed as Confidential Business Information (CBI) and other information whose disclosure is restricted by statute, and which is not included in the official public docket, will not be available for public viewing in EPA's electronic public docket. EPA's policy is that copyrighted material will not be placed in EPA's electronic public docket, but will be available only in printed, paper form in the official public docket. Publicly available docket materials that are not available electronically may be viewed at the docket facility identified in Section I.A.

For public commenters, it is important to note that EPA's policy is that public comments, whether submitted electronically or in paper, will be made available for public viewing in EPA's electronic public docket as EPA receives them and without change, unless the comment contains copyrighted material, confidential business information (CBI), or other information whose disclosure is restricted in statute. When EPA identifies a comment containing copyrighted material, EPA will provide a reference to that material in the version of the comment that is placed in EPA's electronic public docket. The entire printed comment, including the copyrighted material, will be available in the public docket.

Public comments submitted on computer disks that are mailed or delivered to the docket will be transferred to EPA's electronic public docket. Public comments that are mailed or delivered to the Docket will be scanned and placed in EPA's electronic public docket. Where practical, physical objects will be photographed, and the photograph will be placed in EPA's electronic pubic docket along with a brief description written by the docket staff.

*B. How and to Whom Do I Submit Comments?*

You may submit comments electronically, by mail, or through hand delivery/courier. To ensure proper receipt by EPA, identify the appropriate docket identification number in the subject line on the first page of your comments. The docket identification number for this Notice is OW–2004–0018. Please ensure that your comments are submitted within the specified comment period. Comments received after the close of the comment period will be marked ''late''. EPA is not required to consider these late comments.

1. *Electronically*. If you submit an electronic copy as prescribed below, EPA recommends that you include your name, mailing address, and an e-mail address or other contact information in the body of your comment. Also, include this contact information on the outside of any disk or CD ROM you submit, and in any cover letter accompanying the disk or CD ROM. This ensures you can be identified as the submitter of the comment and allows EPA to contact you in the case EPA cannot read your comment due to technical difficulties or needs further information on the substance of your comment. EPA's policy is that EPA will not edit your comment, and identifying or contact information provided in the body of the comment will be included as part of the comment that is placed in the official public docket, and made available in EPA's electronic public docket. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, EPA may not be able to consider your comment.

i. *EDOCKET*. Your use of EPA's electronic public docket to submit comments electronically is EPA's preferred method for receiving comments. Go directly to EDOCKET at *http://www.epa.gov/edocket*, and follow the online instructions for submitting comments. Once in the system, select ''search'' and then key in the Docket ID No. OW–2002–0018. The system is an ''anonymous access'' system, which means EPA will not know your identify, e-mail address, or other contact information unless you provide it in the body of your comment.

ii. *E-mail*. Comments may be sent by electronic mail to *OW-Docket@epa.gov*, Attention Docket ID Number OW–2004–0018. In contrast to EPA's electronic public docket, EPA's e-mail system is not an ''anonymous access'' system. If you send e-mail comments directly to the docket without going through EPA's electronic public docket, EPA's e-mail system automatically captures your e-mail address. E-mail addresses that are automatically captured in EPA's e-mail system are included as part of the comment that is placed in the official public docket, and made available in EPA's electronic public docket.

iii. *Disk or CD ROM*. You may also submit comments on a disk or CD ROM that you mail to the mailing address identified in Unit I.A.1. These electronic submissions will be accepted in WordPerfect or ASCII file format. Please avoid the use of special characters and any form of encryption.

2. *By Mail*. Send your comments to: Water Docket, Environmental Protection Agency, Mailcode: 4101T, 1200 Pennsylvania Ave., NW., Washington, DC, 20460.

*Attention*: Docket ID No. OW–2004–0018.

Finally, please provide an additional copy of your submission to: Nick Martin, Global Environment and Technology Foundation (GETF), 2900 South Quincy Street, Suite 410, Arlington, Virginia 22206, *nmartin@getf.org*.

3. *By Hand Delivery or Courier*. Deliver your comments to: Public Reading Room, Room B–102, Attention Docket ID No. OW–2004–0018, EPA West Building, 1301 Constitution Ave., NW., Washington, DC 20004. Such deliveries are only accepted during the Docket's normal hours of operation as identified in Unit I.A.1.

Regardless of the method you choose, please provide the name of a person in your organization that EPA may contact, along with that person's mailing address, phone number, and E-mail address. This information is needed for EPA to selectively follow up with commenters, as explained in the Section V. of this Notice.

## II. Background

Public entities, including local governments and local authorities, are responsible for managing and maintaining large-scale physical plants. These may include power systems, wastewater treatment operations, water systems, and roadways. Local authorities are also responsible for managing solid and hazardous waste. As the front line implementers of environmental programs, they protect the health and safety of hundreds of millions of citizens. Faced with shrinking resources and aging infrastructure, public entities must manage their operations in a more efficient manner, at lower cost, and with less environmental impact. EMSs are an important emerging tool to help public entities do this.

EMSs follow Stewart and Deming's plan, do, check and act systems methodology and can be implemented by organizations of all sizes and types. They provide a set of problem identification and problem-solving tools that can be implemented in an organization in many different ways, depending on its activities and needs. Based on the organization's core values, business goals, and environmental commitments, employees examine their environmental footprint and the

procedures they use to manage environmental issues. They incorporate strong operational controls and environmental responsibilities into existing job descriptions and work instructions. They set measurable objectives and targets, monitor, measure, and evaluate progress, find and fix environmental problems as they occur, and provide top management with a feedback loop to assess progress and make appropriate changes to the management system. The various elements of the EMS work together to provide opportunities to continually improve management of environmental impacts both in regulated areas and in areas that are not regulated (*e.g.,* odor, water or electricity use, and growth management).

Key elements of the EMS include:

- An environmental policy statement endorsed and actively promoted by senior management;
- A planning process that identifies the organization's environmental impacts and integrates their management into the organization's regular business and operations decisions;
- An organizational structure that places environmental responsibilities directly with employees in operational functions that deal with significant environmental impacts;
- An implementation process that stresses training, communication, operational controls, and reaching measurable goals—all oriented toward reducing risks of significant environmental impacts and continually improving environmental management;
- Measurement and auditing procedures that focus on finding and fixing problems and reducing the chances of their recurring; and,
- Periodic top management review of the EMS to ensure continual improvement.

Since 1996, the most commonly used framework for an EMS is the ISO 14001 Environmental Management Standard developed by the International Organization for Standardization (ISO). The ISO was established in 1947 with the mission of developing voluntary technical standards to promote international trade in goods and services.

For the last several years the EPA has been promoting the adoption of EMSs to help public entities, particularly local governments, improve their environmental performance beyond compliance, prevent pollution, promote greater environmental stewardship across the workforce, and improve their overall efficiency. EPA has issued an overall EMS Position Statement and is using EMSs in a wide variety of voluntary programs. More information about EPA's position on EMSs can be found at *www.epa.gov/ems.*

The EPA's Office of Water (OW) has played a leadership role in bringing EMS capacity to local governments. This leadership has continued and expanded to include other Headquarters and Regional Offices. Since 1997, through a cooperative agreement with GETF, OW has supported three EMS initiatives helping local governments test the applicability and benefits of an EMS on environmental performance, compliance, pollution prevention, and stakeholder involvement in government operations. In total, 32 local governments have participated in developing and implementing their own EMSs through these two initiatives.

The agencies participating in these three initiatives have realized a wide range of benefits including improved environmental performance and compliance, reduced operational costs, increased recycling, improved relations with their communities and regulatory agencies, and improved operational controls and internal communication. More information about these projects and the specific benefits the participating agencies have seen can be found at *www.peercenter.net.*

## III. The National Public Entity EMS Resource Center: The Peer Center

The EMS initiatives described above have helped to demonstrate the relevance of EMSs in the public sector and established a solid basis for expanding EMS adoption for public agencies, especially local governments. The strong enthusiasm and tangible environmental results demonstrated through these initiatives suggest substantial long-term benefits from EMS implementation and ensure the parallel development of sustainable management practices in both the private and public sectors. Public entity EMS implementation has sparked interest from government leaders around the world. Building on the successes of these efforts, EPA, through a cooperative agreement with GETF, launched the National Public Entity Environmental Management System Resource Center—the National PEER Center in 2002.

The PEER Center's goals are three-fold:

- To promote the understanding and adoption of EMSs by public entities;
- To facilitate peer-to-peer exchange of information and experiences and build awareness of EMSs as a tool to improve environmental performance; and
- To build regional EMS competence and technical assistance capacity through EMS Local Resource Centers.

The PEER Center consists of two major components: A national clearinghouse and seven EMS Local Resource Centers.

### *National Clearinghouse of EMS Information*

The National PEER Center Clearinghouse is currently in place (*www.peercenter.net*) and link users to a national database of key resources such as sample EMS documentation, local and state EMS programs in place, EMS service providers, detailed descriptions of the EMS implementation phases, trainers, mentors and course providers, as well as training materials, web links, contact information, and case studies. The Clearinghouse also serves to clarify the elements of environmental management systems and programs. It provides case studies, reports, implementation guidance, and other information to help public entities understand EMSs, their potential benefits, and ways to develop them for various operations.

### *EMS Local Resource Centers*

Critical to the effectiveness and success of the PEER Center are seven existing EMS Local Resource Centers (LRCs) that advance the use of EMSs in public entities. Building on individual EMS skills and competencies, and leveraging the successes and skills of the other LRCs and the National PEER Center, each LRC serves as a high-quality EMS resource center for the public entities in their area. The LRCs facilitate information transfer, provided training, and government-to-government mentoring in order to maximize public entities' time and resource investment in EMS implementation. The joint efforts of the National PEER Center and the LRCs are helping an increasing number of public entities, particularly local governments, that develop EMSs for various operations. More information about each Center can be found at *www.peercenter.net.*

Activities that the existing Centers are currently providing include:

- Leveraging their existing EMS expertise to provided training, technical assistance, tools and materials that will facilitate EMS implementation on the public sector;
- Using their data, information, resources and key contacts to encourage EMS information transfer and facilitate government-to-government mentoring;
- Leading regular and frequent outreach activities to increase awareness and understanding of EMS applicability

among public entities in their local/regional area;

• Collecting data and information and preparing case studies about EMS implementation in public entities and assisting in the dissemination of this information across public organizations;

• Facilitating information transfer between the PEER Center Clearinghouse and other Local Resource Centers to ensure access to the most current data, information, tools, keys to success, and lessons learned; and

• Facilitating EMS workshops and conferences in their local/regional area

Based on the experiences of these existing Centers, EPA is interested in receiving feedback from other not-for-profit organizations that are already providing some degree of EMS services in their respective areas, and may now wish to become a Local Resource Center. EPA is especially interested in hearing from organizations in areas of the country not now served by an existing Center, primarily in EPA Regions VII, VIII, and IX. Any additional Local Resource Center will be expected to offer a menu of EMS services, including: EMS training, technical expertise, field-tested tools, information, speakers/mentors, workshops and conferences, outreach, and EMS implementation assistance.

## IV. Benefits of Becoming a Local Resource Center

Each Local Resource Center will receive, at no cost, extensive start-up support, including a full catalogue of EMS implementation tools from GETF and materials that have already been field-tested and used in the public sector, including:

• National attention, visibility, and partnership opportunities from EPA, GETF, and other partners and stakeholders;

• Assistance in developing a business plan, and business development materials;

• An extensive suite of field-tested, high-quality and successful materials for public entities: training techniques, implementation strategies, document samples, outreach and presentation toolkits;

• Regular train-the-trainer work sessions on EMS implementation in public sector organizations with other LRCs and national partners;

• An extensive database of national mentors and experts with hands-on experience to assist in local/regional EMS outreach and implementation;

• Support services and mentoring from existing public entities that are implementing an EMS; and

• Assistance with marketing services and opportunities.

## V. Opportunity To Provide Comment For consideration as an EMS Local Resource Center

Based on the information provided above, EPA is interested in receiving public comment from not-for-profit organizations that may wish to serve as an EMS Local Resource Center, especially organizations located in areas not now served by an existing Center, primarily in EPA Regions VII, VIII, and IX. Based on these comments up to three additional not-for-profit organizations could participate with the other Centers and provide high quality EMS assistance to public entities, especially local governments. Providing comment based on this Notice does not guarantee that the organization will participate.

When reviewing comments, EPA considers a number of factors.

The most important of these include: (1) A clear understanding of EMSs, (2) demonstrated experience and delivery mechanisms in providing EMS services to various organizations, (3) commitment by the organization's top management to the goals of the PEER Center initiative, (4) adequate staffing to support both start up and ongoing activities, (5) a willingness to proactively reach out to public entities in their area, (6) strong web literacy and functionality, and (7) a willingness and ability to share data and other information with other Local Resource centers and the PEER Clearinghouse.

Organizations are also encouraged to provide a more general statement outlining why they are interested in becoming a Local Resource Center and describing how their participation could benefit the program as a whole. Finally, organizations are encouraged to provide a letter from top management accompanying their comments that includes the name and contact information of the individual that would represent your organization on possible follow up calls with GETF.

Following the receipt of this feedback, staff from GETF may schedule follow up calls, as appropriate, with each applicant's management and appropriate staff at a mutually convenient time and will consult with EPA. Following this, staff from GETF will begin work with each new Local Resource Center to develop business plans, materials, processes, marketing strategies, information transfer, data collection, etc.

Dated: July 29, 2004.

**Jane S. Moore,**

*Acting Director, Office of Wastewater Management.*

[FR Doc. 04–17789 Filed 8–4–04; 8:45 am]

BILLING CODE 6560–50–M

---

## ENVIRONMENTAL PROTECTION AGENCY

**[OPP–2004–0201; FRL–7369–5]**

## Fenvalerate; Cancellation Order

**AGENCY:** Environmental Protection Agency (EPA).

**ACTION:** Notice.

**SUMMARY:** In accordance with section 6(f)(1) of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), as amended, on December 23, 2003, the Agency issued a Cancellation Order announcing its approval of the requests submitted by Sumitomo Chemical Company, Limited and Bayer Environmental Science to voluntarily cancel the registrations for all of their products containing 4-chloro-alpha-(1-methylethyl)benzeneacetic acid, cyano(3-phenoxyphenyl)methyl ester (fenvalerate). Any distribution, sale or use of the products subject to this cancellation order is only permitted in accordance with the terms of the existing stocks provisions of this cancellation order.

**FOR FURTHER INFORMATION CONTACT:** Wilhelmena Livingston; Special Review and Reregistration Division (7508C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Avenue, NW., Washington, DC 20460–0001; telephone number: (703) 308–8025; fax number: (703) 308–8041; e-mail address: *livingston.wilhelmena@epa.gov.*

**SUPPLEMENTARY INFORMATION:**

## I. General Information

### *A. Does this Action Apply to Me?*

This action is directed to the public in general. Although this action may be of particular interest to persons who produce or use pesticides, the Agency has not attempted to describe all the specific entities that may be affected by this action. If you have any questions regarding the information in this notice, consult the person listed under **FOR FURTHER INFORMATION CONTACT.**

### *B. How Can I Get Copies of This Document and Other Related Information?*

1. *Docket.* EPA has established an official public docket for this action under docket identification (ID) number

OPP–2004–0201. The official public docket consists of the documents specifically referenced in this action, any public comments received and other information related to this action. Although a part of the official docket, the public docket does not include Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. The official public docket is the collection of materials that is available for public viewing at the Public Information and Records Integrity Branch (PIRIB), Room 119, Crystal Mall #2, 1801 S. Bell St., Arlington, VA 22202–4501. This docket facility is open from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The docket telephone number is (703) 305–5805.

2. *Electronic access.* You may access this **Federal Register** document electronically through the EPA Internet under the ''**Federal Register**'' listings at *http://www.epa.gov/fedrgstr/.*

An electronic version of the public docket is available through EPA's electronic public docket and comment system, EPA Dockets. You may use EPA Dockets at *http://www.epa.gov/edocket/* to submit or view public comments, access the index listing of the contents of the official public docket, access those documents in the public docket that are available electronically. Although not all docket materials may be available electronically, you may still access any of the publicly available docket materials through the docket facility identified in Unit I.B.1. Once in the system, select ''search,'' then key in the appropriate docket ID number.

## II. What Action is the Agency Taking?

This notice announces that EPA approved the Cancellation Order requests from Sumitomo Chemical Company, Limited and Bayer Environmental Science to cancel the registrations of three pesticide products registered under section 3 of the FIFRA. These three registrations constitute all registrations held by Sumitomo Chemical Company, Limited and Bayer Environmental Science of products containing 4-chloro-alpha-(1-methylethyl)benzeneacetic acid, cyano(3-phenoxyphenyl)methyl ester (fenvalerate).

On March 27, 2003, Sumitomo Chemical Company, Limited, and on April 1, 2003, Bayer Environmental Science submitted a letter to the Agency requesting voluntary cancellation of their fenvalerate technical registrations. This order follows up a **Federal Register** Notice of July 11, 2003 (68 FR 41343) (FRL–7315–5), announcing receipt of written requests from Sumitomo and Bayer to voluntarily cancel their fenvalerate product registrations. Sumitomo and Bayer also requested that the Administrator waive the 180–day waiting period under FIFRA section 6(f)(1)(C)(ii). Fenvalerate is a synthetic pyrethroid insecticide which is used to control insects and related organisms, molluscs, fouling organisms and miscellaneous invertebrates on agricultural, pet care, domestic home and garden (domestic), and commercial/industrial/food and non-food/mosquito abatement (commercial) sites.

No comments were received during the 30–day comment period, so therefore, EPA has decided to accept the voluntary cancellation requests. Accordingly, on December 23, 2003, the Agency issued an order canceling the three registrations identified in Table 1.

TABLE 1.—APPROVED REGISTRATION CANCELLATIONS

| Registration No. | Product Name | Chemical Name |
|---|---|---|
| 432–766 | Technical Fenvalerate Insecticide | Fenvalerate |
| 1432–767 | Gold Crest Tribute Termiticide/Insecticide | Fenvalerate |
| 10308–13 | Technical Sumicidin Insecticide | Fenvalerate |

Table 2 of this unit includes the name and address of record for the registrants of the products in Table 1 of this unit.

TABLE 2.—REGISTRANTS REQUESTING VOLUNTARY CANCELLATION

| EPA Company No. | Company Name and Address |
|---|---|
| 432 | Bayer Environmental Science<br>95 Chestnut Ridge Road<br>Montvale, NJ 07645 |
| 10308 | Sumitomo Chemical Company, Limited<br>5–33 Kitahama 4-Chome, Chuo-ku<br>Osaka, 541, Japan |

## III. Cancellation Order

Pursuant to section 6(f) of FIFRA, EPA hereby approved the requested cancellations of fenvalerate product registrations identified in Table 1 of this notice. Accordingly, the Agency ordered that the fenvalerate product registrations identified in Table 1 were hereby canceled as of December 23, 2003.

## IV. What is the Agency's Authority for Taking this Action?

Section (6)(f)(1) of FIFRA provides that a registrant of a pesticide product may at any time request that any of its pesticide registrations be canceled. FIFRA further provides that before acting on the request, EPA must publish a notice of receipt of any such request in the **Federal Register.** Thereafter, the Administrator may approve such a request.

## V. What Comments did the Agency Receive?

EPA did not receive any comments on the voluntary cancellation requests for the fenvalerate products during the comment period.

## VI. Provisions for Disposition of Existing Stocks

For purposes of this Cancellation Order, the term ''existing stocks'' is defined, pursuant to EPA's existing stocks policy (56 FR 29362, June 26, 1991), as those stocks of a registered pesticide product which are currently in the United States and which have been packaged, labeled and released for shipment prior to the effective date of the cancellation. The existing stocks provisions of the Cancellation Order are as follows:

The orders affecting these requested cancellations permit a registrant to sell or distribute existing stocks for 1 year after the date the cancellation was requested. Sumitomo Chemical Company, Limited was not able to sell or distribute exiting stocks after March 27, 2004, and Bayer Environmental Science was not able to sell or distribute exiting stocks after April 1, 2004, which marks 1 year after the date the cancellation was requested. The product

may be sold, distributed, and used by others until existing stocks have been exhausted, provided that such sale and use comply with the EPA-approved label and labeling of the effective product.

**List of Subjects**

Environmental protection, Pesticides and pests.

Dated: July 26, 2004.

**Debra Edwards,**

*Director, Special Review and Reregistration Division, Office of Pesticide Programs.*

[FR Doc. 04–17881 Filed 8–4–04; 8:45 am]

BILLING CODE 6560–50–S

## ENVIRONMENTAL PROTECTION AGENCY

**[FRL–7797–9]**

### Clean Water Act Section 303(d): Final Agency Action on 2 Total Maximum Daily Loads (TMDLs)

**AGENCY:** Environmental Protection Agency (EPA).

**ACTION:** Notice of availability.

**SUMMARY:** This notice announces final agency action on 2 TMDLs prepared by EPA Region 6 for waters listed in Louisiana's Barataria river basin, under section 303(d) of the Clean Water Act (CWA). Documents from the administrative record file for the 2 TMDLs, including TMDL calculations and responses to comments, may be viewed at *http://www.epa.gov/region6/water/tmdl.htm.* The administrative record file may be examined by calling or writing Ms. Ellen Caldwell at the following address. Please contact Ms. Caldwell to schedule an inspection.

**FOR FURTHER INFORMATION CONTACT:** Ellen Caldwell, Environmental Protection Specialist, Water Quality Protection Division, U.S. EPA Region 6, 1445 Ross Avenue, Dallas, TX 75202–2733, telephone (214) 665–7513.

**SUPPLEMENTARY INFORMATION:** In 1996, two Louisiana environmental groups, the Sierra Club and Louisiana Environmental Action Network (plaintiffs), filed a lawsuit in Federal Court against the EPA, styled *Sierra Club, et al.* v. *Clifford et al.*, No. 96–0527, (E.D. La.). Among other claims, plaintiffs alleged that EPA failed to establish Louisiana TMDLs in a timely manner.

By this notice EPA is taking final agency action on the following 2 TMDLs for waters located within the Barataria river basin:

| Subsegment | Waterbody name | Pollutant |
|---|---|---|
| 020401 | Bayou Lafourche—Donaldville to Intracoastal Waterway at Larose | Fecal Coliform. |
| 020701 | Bayou Segnette—origin to Bayou Villars | Fecal Coliform. |

EPA requested the public to provide EPA with any significant data or information that may impact the 2 TMDLs in 69 FR 5985–5986 (February 9, 2004). The comments received and EPA's response to comments may be found at *http://www.epa.gov/region6/water/tmdl.htm.*

Dated: July 27, 2004.

**James R. Brown,**

*Acting Director, Water Quality Protection Division, Region 6.*

[FR Doc. 04–17892 Filed 8–4–04; 8:45 am]

BILLING CODE 6560–50–P

## EXPORT-IMPORT BANK

### Economic Impact Policy

This notice is to inform the public that the Export-Import Bank of the United States has received an application to finance the export of approximately $500 million in U.S. semiconductor manufacturing equipment to dedicated foundries in China. The U.S. exports will enable the dedicated foundries to produce 60,000 300-mm wafers per month across advanced process technology nodes. Available information indicates that some of this new production will be exported from China and consumed globally. Interested parties may submit comments on this transaction by e-mail to *economic.impact@exim.gov* or by mail to 811 Vermont Avenue, NW., Room 1238, Washington, DC 20571, within 14 days of the date this notice appears in the **Federal Register**.

**Helene S. Walsh,**

*Director, Policy Oversight and Review.*

[FR Doc. 04–17870 Filed 8–4–04; 8:45 am]

BILLING CODE 6690–01–P

## FEDERAL ELECTION COMMISSION

### Sunshine Act Meeting Notice

**DATE & TIME:** *Tuesday, August 10, 2004, at 10 a.m.*

**PLACE:** 999 E Street, NW., Washington, DC.

**STATUS:** This meeting will be closed to the public.

**ITEMS TO BE DISCUSSED:**

Compliance matters pursuant to 2 U.S.C. 437g.

Audits conducted pursuant to 2 U.S.C. 437g, 438(b), and Title 26, U.S.C.

Matters concerning participation in civil actions or proceedings or arbitration.

Internal personnel rules and procedures or matters affecting a particular employee.

**DATE & TIME:** *Thursday, August 12, 2004 at 10 a.m.*

**PLACE:** 999 E Street, NW., Washington, DC (ninth floor).

**STATUS:** This meeting will be open to the public.

**ITEMS TO BE DISCUSSED:**

Correction and Approval of Minutes.

Advisory Opinion 2004–21: Give to USA, Inc. by Matthew L. Ginsberg, Chief Executive Officer, On Time Systems, Inc.

Advisory Opinion 2004–23: U.S. Oncology, Inc. Good Government Committee (''USON–GGC'') by counsel, Thomas J. Spulak.

Advisory Opinion 2004–24: NGP Software, Inc. by Nathaniel Pearlman, President.

Advisory Opinion 2004–25: Senator Jon Corzien by counsel, Marc E. Elias.

Routine Administrative Matters.

**PERSON TO CONTACT FOR INFORMATION:** Mr. Robert Biersack, Acting Press Officer, Telephone: (202) 694–1220.

**Mary W. Dove,**

*Secretary of the Commission.*

[FR Doc. 04–18078 Filed 8–3–04; 3:16 am]

BILLING CODE 6715–01–M

## FEDERAL RESERVE SYSTEM

### Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part

225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at *www.ffiec.gov/nic/*.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 30, 2004.

**A. Federal Reserve Bank of San Francisco** (Tracy Basinger, Director, Regional and Community Bank Group) 101 Market Street, San Francisco, California 94105–1579:

*1. Affinity Bank Holdings, Inc.*, Ventura, California; to become a bank holding company by acquiring 100 percent of the voting shares of Affinity Bank, Ventura, California.

Board of Governors of the Federal Reserve System, August 2, 2004.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. 04–17940 Filed 8–4–04; 8:45 am]

**BILLING CODE 6210–01–S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

### Funding Opportunity Title: Safe and Bright Futures for Children Initiative

**ANNOUNCEMENT TYPE:** Initial.

**CFDA NUMBER:** 93.990.

**DATES:** Applications are due no later than September 9, 2004.

**SUMMARY:** This notice announces the availability of fiscal year (FY) 2004 grant funds for the Safe and Bright Futures for Children Initiative—a program to diminish the damaging effects of domestic violence on children and adolescents and to stop the cycles of abuse and intentional injury. Approximately $2.2 million in funding is available on a competitive basis for a maximum of up to 30 grants for Phase One of the Safe and Bright Futures for Children Initiative. Phase One consists of 2 years strategic planning (as outlined in Application and Submission Information—Section IV). It is expected that the first year award will begin on or about September 30, 2004 and will be for a 12-month budget period. The second year award will require a non-competing continuation application and be made on or about September 30, 2005, depending on grantee performance and availability of funds and be for a 12-month budget period. Each grantee will be funded approximately $ 75,000 each year of the 2-year project period. Applicants must demonstrate direct experience with domestic violence prevention or show ability to partner with relevant domestic violence prevention community agencies. Phase Two—Safe and Bright Futures for Children Implementation Grants—will be competitively awarded, under a separate announcement, to approximately 8 of the Phase One planning grantees in FY 2006. It is anticipated that approximately $500,000 a year for each of the three years, depending on availability of funds, will be awarded. Implementation plans, as developed in the planning years would be submitted as a competing application for objective competitive peer review; implementation (continuation) funding will be contingent on peer review approval, score, and award preferences criteria.

### I. Funding Opportunity Description

The Office of Public Health and Science (OPHS) of the Department of Health and Human Services (DHHS) announces the availability of funds for FY 2004 and requests applications for grants for Phase One of the Safe and Bright Futures for Children Initiative—a program to diminish the damaging effects of domestic violence on children and adolescents and to stop the cycles of abuse and intentional injury.

The OPHS is under the direction of the Assistant Secretary for Health (ASH), who serves as the Senior Advisor on public health and science issues to the Secretary of the Department of Health and Human Services. The Office serves as the focal point for leadership and coordination across the Department in public health and science, provides direction to program offices within OPHS; and provides advice and counsel on public health and science issues to the Secretary.

The prosperity of our nation rests upon the health of our children. Accordingly, securing a bright future must begin with ensuring the health and safety of our children. Of the many threats to their well being, one of the most devastating is the trauma experienced by witnessing parent conflict and the violation of safety and security in the home. Domestic violence is also a generational problem that perpetuates a dangerous cycle of both abusers and victims of abuse. As such, it is important to recognize that the primacy of safety first for children relies on providing safety and assistance to the non-abusing parent or primary caregiver, in ending violence in the home. Providing safety and preventive or intervention services to the non-abusing caregiver(s) and teaching children and adolescents by example that it is unacceptable to resolve the problems of life by violent means is essential for their well-being.

Too often children who reside in homes where domestic violence occurs are not identified; when they are, they do not receive the necessary and appropriate help, either related to the trauma surrounding the precipitating event or with regard to long term follow-up and follow-through needs. The systems of support for battered parents/caregivers and the systems of accountability for those perpetrating interpersonal violence are often not well geared for addressing the developmental, social, emotional, or behavioral needs of children or adolescents. New promising approaches for working with children exposed to violence and their parents/caregivers are emerging. This initiative seeks to encourage communities to plan for, develop, implement and sustain a coordinated system of prevention, intervention, treatment, and follow-through services for children who have witnessed or been exposed to domestic violence and their families.

The Safe and Bright Futures for Children Initiative is a multi-agency collaboration within the DHHS which builds on the President's existing efforts to combat violence against women and families. Resources will be competitively available to support the implementation of projects that will become models of community prevention and intervention for children/adolescent who are witnesses of or those exposed to domestic

violence. The initiative will support coordination of services, necessary expansion or enhancement of services at the community or regional level which are age-appropriate, culturally- and linguistically-appropriate. The initiative will build on community assets and strengthen collaborations between local government, and community- and/or faith-based programs that can prevent or intervene, identify, assess, treat, and provide follow-up services to the target population. It is anticipated and intended that proceeds from the ''Stop Family Violence'' semi postal stamp, released in 2003, will be used for this initiative in fiscal years 2006–2009.

In order to produce the coordinated system and service enhancement design, grantees will be required to accomplish tasks based on strategic planning that targets specific child/adolescent service outcomes which are community specific and appropriate for the population to be served. This initiative and planning phase also provides a vehicle for communities to integrate existing Federal programs focused on this population. (Applicants are directed to *http://harvester.census.gov/CFFR/index.html* to identity existing Federal programs in their areas).

This DHHS-sponsored Safe and Bright Futures for Children Initiative is announced in concert with a related activity being undertaken by the Department of Justice (DOJ) which also supports the President's domestic violence prevention efforts. The DOJ will award grants to 12 communities for the creation of Family Justice Centers to provide medical care, counseling, law enforcement, social services, employment assistance, and housing assistance together in one location. To the extent applicable, communities that receive a Safe and Bright Futures for Children grant, will be required to demonstrate linkage with a DOJ-sponsored Family Justice Center either as a planning partner or during the implementation phase of this initiative.

*Program Statutes*

Sections 1701–1704 of the Public Health Service (PHS) Act authorize the Secretary to undertake and support, through improved planning and implementation of tested models and evaluation of results, effective and efficient programs respecting health information and health promotion, preventive health services, and the education in the appropriate use of health care. Additional applicable program authorities of the Department of Health and Human Services relevant to the implementation of this activity include: Sections 301 (general authority), 392(b), 393 (relating to violence prevention) and 501(d) (relating to substance abuse prevention and treatment and mental health services) of the PHS Act. Title V of the Social Security Act (relating to maternal and child health) is also applicable.

## II. Award Information

*Funding Instrument Type:* Grant.

*Anticipated Total Funding:* $2,200,000.00.

*Anticipated Number of Awards:* Up to 30.

*Amount of Individual Awards:* Up to $75,000.00.

*Project Period for Award:* 24 months.

*Anticipated Start Date:* September 30, 2004.

## III. Eligibility Information

*1. Eligible Applicants*

To qualify for funding, an applicant must be a public or private non-profit entity, including but not limited to child/adolescent-serving local government agency, community-based or faith-based entity or organization located in a State or U.S. Territory, or Federally recognized Tribe or Tribal Organization. States may only apply on behalf of a coalition of entities for a State-defined community to develop or enhance a community system. Since this initiative is intended to be a community effort with focus on diminishing the impact of domestic violence, it is required that a primary partner be from the domain of service providers in a community that engage in domestic violence prevention or intervention services. Other organizations that are experienced in the areas of injury/violence prevention, protection, safety, identification, assessment and treatment of children and adolescents who have witnessed or been exposed to domestic violence and in working with victims and perpetrators, mental health providers with expertise in trauma-related services are encouraged to be included as partners.

*2. Cost Sharing or Matching*

None.

*3. Other*

Applicants are required to have a Dun and Bradstreet Data Universal Numbering System (DUNS) number to apply for a grant or Cooperative Agreement from the Federal Government. The DUNS number is a nine digit identification number, which uniquely identifies business entities. Obtaining a DUNS number is easy and there is no charge. To obtain a DUNS number, access either the web site: *https://www/dnb.com/product/eupdate/requestOptions.html* or call 1–866–705–5711. Be sure to click on the link that reads, ''DUNS Number Only'' at the right hand bottom corner of the screen to access the free registration page. Please note that registration via the web site may take up to 30 business days to complete.

## IV. Application and Submission Information

*1. Address To Request Application Package*

Application kits are available from and shall be submitted to the Department of Health and Human Services, Office of Public Health and Science, Office of Grants Management, 1101 Wootton Parkway, Suite 550, Rockville, MD 20853. Send the original and 2 copies of the complete application to this address. Application kits may also be obtained by calling the Office of Grants Management, (301) 594–0758 between the hours of 8 a.m. and 5 p.m. EST. For Further Programmatic Information Contact: Woodie Kessel, M.D., M.P.H., *wkessel@osophs.dhhs.gov,* 202–401–6295.

*2. Content and Form of Application Submission*

For this grant, applications must be submitted on the Form PHS–5161–1 (Revised 07/00) and in the manner prescribed in the application kit. An applicant is advised to pay close attention to the specific program guidelines and general instructions provided in the kit.

Applicants are required to submit an original application signed by an individual authorized to act for the applicant agency or organization and to assume for the organization the obligations imposed by the terms and conditions of the grant award. Applicants are required to submit an original application and two copies. Applications are limited to 25 double-spaced pages, not including appendices and be in 12-point font. Appendices may include curriculum vitae and other evidence of organizational capabilities.

Applications must include a one-page abstract of the proposed project. The abstract will be used to provide reviewers with an overview of the application, and will form the basis for the application summary in grants management documents.

It is the practice of the Office of Disease Prevention and Health Promotion (ODPHP), in the Office of Public Health and Science, to maintain a summary of grants and to post this information on the ODPHP web site.

The abstract will be used as the basis for this posting and for other requests for summary information regarding funded grants.

Grantees under this program will implement a strategic planning and design process that yields a realistic coordinated service system model with service enhancements. The strategic plan will guide implementation, monitoring, and evaluation of ongoing modifications which will result from feedback and influence future system development. Applicants must address each of the areas below and in similar sequence in the application:

Understanding of Methodologies for planning a continuous and coordinated system of identification, protection, and care for children and adolescents, including those with special needs, who witness or are exposed to domestic violence. Specifically, the applicant must address how it will:

(a) Establish an inclusive and participatory format that ensures engagement in and acceptance of the planning process and specific outcome expectations by key community stakeholders, including but not limited to: *e.g.*, domestic violence prevention and service providers and advocates, family members/caregivers, children and adolescents; community- and faith-based organizations; child protective services; schools; law enforcement/judicial system representatives, including Tribal courts where applicable; public and/or private practitioners from child welfare, health and behavioral health, schools; and agencies providing job training/placement and housing services. Applicants may utilize and build on an existing community/provider partnership or coalition. Where this is case, applicant must describe how the partnership will be expanded to include the required service providers (*i.e.*, domestic violence prevention/intervention services) and address the requirements of this initiative. The applicant also must document its experience and success with planning of coordinated programs.

(b) Design an approach to assessing need and organizing a coordinated system of intervention and care for children, adolescents and their families, including children with special needs and the non-abusing primary caregiver(s), that includes mental health services such as child trauma services or victim counseling, child/adolescent/family counseling; protection and safety; health care services; substance abuse prevention and treatment services; and supportive and/or ancillary services (*e.g.*, legal advocacy, transportation), important to meeting the comprehensive needs of the target population. In designing the approach to assess needs and coordinate services, attention should given to the cultural diversity and corresponding issues within the community, as well as developmental or social concerns for the target population, *e.g.*, age, gender, sexual orientation, language, socio-economic status.

(c) Identify the evaluation parameters (as designated by the community) and outcome measures that will be used to determine the level of success of the implemented service system model (such as ranking priorities from among topics like access to services, rate of emergency department use, school success and connectedness, enhancing resilience, juvenile justice involvement, family stability, change in service capacity, and cost offsets) and its level of functioning (such as ranking priorities from topics such as client/community/staff satisfaction, identification and severity of diagnosis, financial stability). Note that both outcome and process evaluations should be considered in the planning effort. Identified evaluation processes should be evidenced-based and rely on current research, to the extent possible.

(d) Describe how the collaboration will support non-offending parents (or primary caregivers) in seeking greater safety for their children and themselves as a step in the process of ameliorating the effects of domestic violence on children.

(e) Develop a resource strategy, including cost offsets from other systems, that creates a realistic framework for implementation and shows how community agencies/stakeholders will obtain and invest various resources, both public and private, into the integrated services system model with a goal of financial sustainability.

(f) To the extent applicable, identify and demonstrate collaboration and linkages with other related DHHS and Federal initiatives or programs in the applicant's community that address prevention, early intervention and treatment for children who are exposed to or witness domestic violence and their families, and how these programs will be incorporated into the planning process; how they will be involved with implementation; and their role with maintaining the established integrated model of coordinated care. (See *http://harvester.census.gov/CFFR/index.html* to access a listing of Federally-supported programs in a community).

The applicant should describe how the following dimensions will be addressed in the planning process:

(a) Governance and executive leadership.

(b) Coordination of organizational structures and staff; configurations of staff.

(c) Operations and management; accountability.

(d) Facilities and equipment; materials and supplies.

(e) Financing and allocation of resources; blending of funds and resources; fiscal management; fiscal sustainability.

(f) Legal and regulatory issues, including confidentiality and safety issues for the target population and non-offending parents or primary caregivers.

(g) Involvement and interactions among diverse disciplines; human resources development and management; organizational culture and work climate; relationships with external care providers.

(h) Education, training and supervision of clinicians, administrators, social workers, teachers, and support staff; needs of health professions students and professionals-in-training.

(i) Information systems and medical record keeping including confidentiality of client/family information.

(j) Quality assessment and strategies for improvement, evaluation (process and outcomes), and performance results.

(k) On-going strategic planning for future development and growth; flexibility and ability to accommodate a changing environment should also be addressed.

Understanding the issues of the target population and community as an essential part of planning for a coordinated services system model. Applicant will describe a vision of the existing and enhanced services for the target population based on the service needs and outcome expectations of the target community and describe the challenges, in terms of both opportunities and barriers, related to designing a coordinated system, filling service gaps, and sustaining a coordinated system, across the various child/adolescent-serving agencies which address the target population, including but not limited to: Police, emergency rooms, child welfare, family and juvenile court judges, child protective services, domestic abuse shelters, schools, and health and mental health service providers.

Organization Capabilities/Resources Management Plan

The applicant will demonstrate that it has the capacity to engage the relevant local agency stakeholders in the planning process. Application will address:

(a) Experience with similar planning activities and experience with the target population of children, adolescents, and their families/caregivers;

(b) Experience of proposed leadership, including past endeavors that involved relationships with multiple stakeholders;

(c) Commitment to developing and sustaining working relationships among key stakeholders, with the goal of designing and ultimately implementing a coordinated services program. The demonstration of explicit leadership commitment to this collaborative project will be established through jointly signed letters from the applicant organization with the directors of each participating agency/organization. Each letter should state: (a) Which organization/agency/program will be responsible for the grant award (that is, serve as the grantee and assume fiscal and managerial responsibility for the funding); (b) how planning and leadership will be organized; (c) commitment to full engagement in the planning process, and if selected for Phase Two of this initiative, full commitment to the future implementation of the developed integrated services system that was produced from the planning process. These letters should be contained in the Appendix, ''Letters of Agreement.''

(d) Description of its organizational structure in relation to: sponsoring organizations, designated planning and support personnel, the target community, and specifically with regard to leading the planning in terms of: (1) Time frames for performance; (2) resources proposed for each task (*e.g.*, staffing, consultants, collaborating agencies, facilities, equipment, information systems, and (3) a staffing/management plan.

(e) How proposed planning activities will be monitored and tracked.

(f) Description of contingency efforts that might be undertaken to implement the plan in part or as a whole if implementation funding is not available.

Experience of Key Personnel

Applicant will describe qualifications and experience of the designated planning director and other key personnel as well as the qualifications and experience of staff from the partnering organizations, agencies and programs, consultants, and subcontractors. Resumes and/or curricula vitae should be included in Appendices.

Budget

Applicant will submit a detailed budget on form SF–424a with complete budget justification for each line item in the budget categories of the application. See Form PHS–5161–1 (Revised 7/00). Budget should reflect appropriate costs of up to $150,000.00 for the entire 2 year planning process. Submit year 1 and year 2 budgets separately.

Budget must reflect costs travel costs for up to 2 key personnel to attend one 2-day meeting in Washington, DC at mid-project period.

*3. Submission Dates and Times*

To receive consideration, applications must be received by the Office of Public Health and Science, Office of Grants Management by 5 p.m. EDT on September 9, 2004. Applications received after the exact date and time specified for receipt will not be accepted. The application due date requirement specified in this announcement supercedes the instruction in the PHS 5161–1. Applications submitted by facsimile transmission (FAX) or any other electronic format will not be accepted. Applications which do not meet the deadline or format requirements, specified under Content and Form of Application Submission, will not be accepted for review and will be returned to the applicant unread.

*4. Intergovernmental Reivew*

Applicants under this announcement are not subject to the requirements of Executive Order 12372, ''Intergovernmental Review of Federal Programs.''

*5. Funding Restrictions*

Funds cannot be used for construction or renovation, to purchase or lease vehicles or vans, to purchase a facility to house project staff or carry out project activities, or to substitute new activities and expenditures for current ones. The allowability, allocability, reasonableness, and necessity of direct and indirect costs that may be charged to OPHS grants are outlined in the following documents: OMB Circular A–21 (Institutions of Higher education); OMB Circular A–87 (State and Local Governments); OMB Circular A–122 (Non-Profit Organizations); and 45 CFR Part 74, Appendix E (Hospitals). Copies of the Office of Management and Budget (OMB) Circulars are available on the internet at *http://www.whitehouse.gov/omb/grants/grants_circulars.html*.

*6. Submission Requirements*

Applications must be submitted to the U.S. Department of Health and Human Services, Office of Public Health and Science, Officer of Grants Management, 1101 Wootton Parkway, Suite 550, Rockville, Maryland, 20852; (301) 594–0758. Attention: Ms. Karen Campbell.

**V. Application Review Information**

*1. Criteria*

Each application will be evaluated individually against the following criteria by a panel of independent reviewers appointed by OPHS. Before the review panel convenes, each application will be screened for applicant organization eligibility, as well as to make sure the application contains all the essential elements. Applications received from ineligible organizations and applications received after the deadline will be withdrawn from further consideration. Applications that do not conform to the requirements of this program announcement will not be accepted for review and will be returned to the applicant. Applications sent via facsimile or electronic mail will not be accepted for review. Applicants that meet the requirements of this program announcement will be notified by the Office of Grants Management. A panel of at least three reviewers will use the evaluation criteria listed below to determine the strengths and weaknesses of each application, provide comments and assign numerical scores. Applicants should address each criterion in the project application. The point value (summing up to 100) indicated the maximum numerical weight each criterion will be accorded in the review process.

Criterion 1: Planning Methodology (30 Points)

The extent to which the applicant understands the methodologies for planning and designing an effective, organized and coordinated system of comprehensive services for children and adolescents, including those with special needs, who witness or are exposed to domestic violence, and their families.

That applicant has demonstrated an inclusive and participatory process which involves the key community stakeholders, and includes a local provider(s) of domestic violence prevention and intervention services as a primary partner.

If applicable, the appropriateness of using an existing partnership or

coalition, its potential for successfully planning a coordinated system of services, as evidenced by documented experience and success with previous strategic planning, and how required service providers, not already a part of the existing partnership or coalition will be included. This includes linkage or collaboration with other related DHHS and Federal initiatives that address prevention, early intervention and treatment for children who are exposed to or witness domestic violence and their families and how they will be incorporated into the planning process, involved with implementation, maintaining the proposed model of care.

Appropriateness of Proposed Governance Structure

The extent to which the proposed planning process will determine need and guide development of a coordinated services system that includes the required and supportive services to meet the comprehensive needs of the target population and with attention to age, development stages, racial/ethnic, cultural, language, gender, sexual orientation, socio-economic status and other community-specific issues identified in the proposed service model design.

The extent to which applicant describes a process for developing an evaluation (of success) and reasonable outcome expectations and measures that the stakeholders will likely adopt and which define the proposed evaluation measures of the expected outcomes. Note that both outcome and process evaluations are to be a part of the planning effort.

The adequacy and appropriateness of the proposed activities to develop a resource strategy which is likely to create a realistic framework for implementation and shows how community agencies/stakeholders will obtain and invest various resources, both public and private, into the coordinated services system model with a goal of financial sustainability.

The extent to which the methodology is appropriate to the applicant's community (will be able to address any problems and barriers associated with the community's current system for children and adolescents and their families) and can be relied upon to yield a clear description of a proposed system.

The extent to which the proposed methodology accommodates a process for assessing the cost of the current and proposed services, including cost offsets from other systems.

Criterion 2: Organization Capabilities/ Resource/Management Plan (25 Points).

The extent of applicant's previous experiences in designing integrated systems and/or integrated services models; those that have involved multiple stakeholders, especially with the organizations, agencies, and programs designated as partners to this activity.

Stability of applicant organizational in terms of structure and history, including its relationships to the partnering organizations, among proposed personnel, with the target community, and its ability to obtain and sustain interagency coordination, collaboration and resources. The applicant should affirm the commitment of each collaborating and cooperating agency and describe the intended roles that each agency will play in planning.

Applicant should describe its plan for monitoring and tracking planning activities.

Feasibility of contingency efforts that might be undertaken to implement the plan in part or as a whole if implementation funding is not available.

Criterion 3: Qualifications and Experience of Key Personnel (20 Points)

Qualification and experience of key personnel: Planning director; designated personnel from partnering organizations, agencies and programs; consultants and subcontractors, with domestic violence prevention/ intervention programs and activities, especially those for children and adolescents who have been exposed to or witnessed domestic violence and their families.

Criterion 4: Management Plan (15 Points)

Feasibility and appropriateness of the planning process in terms of: (a) Time frames, (b) adequacy and availability of resources (*e.g.*, personnel, consultants, contractors, collaborating agencies, facilities, equipment, information technology resources), and (c) staffing plan, including how the primary staff reflect the target community.

Criterion 5: Budget (10 Points)

Appropriateness of budget and the justification in relation to the proposed activities.

Reasonableness of costs and other necessary details to facilitate the determination of cost allowability and the relevance of these costs to the proposed planning process.

Inclusion of appropriate travel costs for up to 2 key personnel to attend one 2-day meeting in Washington, DC at mid-project period.

*2. Review and Selection Process*

Each application submitted to the OPHS Office of Grants management will be screened to determine whether it was received by the closing date and time.

The results of a competitive review are a primary factor of the applications and, in light of the results of the competitive review, will recommend applications for funding to the ASH. The ASH reserves the option of discussing applications with other funding sources when this is in the interest of the Federal government. The ASH may also solicit and consider comments from Public Health Services Regional Office staff and others within DHHS in making funding decision. Final grant award decisions will be made by the ASH. The ASH will fund those projects which will, in his/her judgement, best promote the purposes of this program, within the limits of funds available for such projects.

Award Decision Preferences

Final funding decisions for OPHS grants are the responsibility of the Assistant Secretary for Health (ASH). In considering approved applications for funding, preferences may be exercised for groups of applications. Selection preference will be given to the approved applications, under this initiative, based on the following:

Availability of funds.

Evidence of non-supplantation of funds.

Evidence of commitment by the identified stakeholders through letters of commitment which include the defined roles and responsibilities during the planning period.

Evidence of formal coordination/ collaboration with a Federal and/or non-Federal organization that has the recognized capacity to provide resources to support/assist in this project. Specifically, and to the extent applicable, linkage with a DOJ supported Family Justice Center.

Equitable distribution of awards in terms of geography, project size, and rural/urban locality; including location of current HHS grantees.

## VI. Award Administration Information

*1. Award Notices*

The OPHS does not release information about individual applications during the review process. When final decisions have been made, successful applicants will be notified by letter of the outcome of the final funding decisions. The official document

notifying an applicant that a project has been approved for funding is the Notice of Grant Award (NGA), signed by the OPHS Grants Management Officer, which sets forth the amount of funds granted, the terms and conditions of the award, the effective date of the grant, the budget period for which initial support will be given, and the total project period for which support is contemplated. The OPHS will notify an organization in writing when its application will not be funded. Every effort will be made to notify all unsuccessful applicants as soon as possible after final decisions are made.

*2. Administrative and National Policy Requirements*

In accepting this award, the grantee stipulates that the award and any activities thereunder are subject to all provisions in 45 CFR parts 74 (non-governmental) and 92 (governmental) currently in effect or implemented during the period of the grant.

The Buy American Act of 1933, as amended (41 U.S.C. 10a–10d), requires that Government agencies give priority to domestic products when making purchasing decisions. Therefore, to the greatest extent practicable, all equipment and products purchased with grant funds should be American-made.

A Notice providing information and guidance regarding the ''Government-wide Implementation of the President's Welfare-to-Work Initiative for Federal Grant Programs'' was published in the **Federal Register** on May 16, 1997. This initiative was designated to facilitate and encourage grantees and their subrecipients to hire welfare recipients and to provide additional needed training and/or mentoring as needed. The text of the Notice is available electronically on the OMB homepage at *http://www.whitehouse.gov/omb*.

The HHS Appropriations Act requires that when issuing statements, press releases, requests for proposals, bid solicitations, and other documents describing projects or programs funded in whole or in part with Federal money, grantees shall clearly state the percentage and dollar amount of the total costs of the program or project which will be financed with Federal money and the percentage and dollar amount of the total costs of the project or program that will be financed by non-governmental sources.

Provision of Smoke-free Workplace and Non-Use of Tobacco Products by Recipients of PHS Grants

The PHS strongly encourages all grant recipients to provide a smoke-free workplace and to promote the non-use of all tobacco products. In addition, Public Law 103–227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children.

*3. Reporting*

A successful applicant under this notice will submit: (1) Semi-annual progress reports; (2) a final progress report in the form of the Plan; and (3) a Financial Status Report in the format established in accordance with the provisions of the general regulations which apply under ''Monitoring and Reporting Program Performance,'' 45 CFR 74.51–74.52, with the exception of State and local governments to which 45 CFR part 92, Subpart C reporting requirements apply. Applicants must submit all required reports in a timely manner, in recommended formats (to be provided) and submit a final report on the project, including any information on evaluation results, at the completion of the project period. Agencies receiving $500,000 or more in total Federal funds are required to undergo an annual audit as described in OMB Circular A–133, ''Audits of States, Local Governments, and Non-Profit Organizations.''

Public Health System Reporting Requirements

This program is subject to Public Health System reporting Requirements. Under these requirements, a community-based nongovernmental applicant must prepare and submit a Public Health System Impact Statement (PHSIS). The PHSIS is intended to provide information to State and local health officials to keep them apprised of proposed health services grant applications submitted by community-based organizations within their jurisdictions.

Community-based nongovernmental applicants are required to submit, no later than the Federal due date for receipt of the application, the following information to the head of the appropriate State and local health agencies in the area(s) to be impacted: (a) A Copy of the face page of the applications (SF 424), and (b) a summary of the project (PHSIS), not to exceed one page, which provides: (1) a description of the population to be served, (2) a summary of the services to be provided, and (3) a description of the coordination planned with the appropriate State or local health agencies. Copies of the letters forwarding the PHSIS to these authorities must be contained in the application materials submitted to the Office of Public Health and Science.

## VII. Agency Contacts

Grants Management Office Contact: Karen Campbell, Department of Health and Human Services, Office of Public Health and Science, OPHS Grants Management Office, 1101 Wootton Parkway, Suite 550, Rockville, Maryland, 20852. E-mail: *Kcampbell@osophs.dhhs.gov*; telephone: 301–594–0758. Program Office Contact: Woodie Kessel, Department of Health and Human Services, Office of Public Health and Science, Office of Disease Prevention and Health Promotion, Room 738–G Hubert H. Humphrey Building, 200 Independence Ave., SW., Washington, DC, 20201. E-mail: *wkessel@osophs.dhhs.gov*; telephone: 202–401–6295.

Dated: July 30, 2004.

**Cristina V. Beato,**

*Acting Assistant Secretary for Health, Office of Public Health and Science.*

[FR Doc. 04–17835 Filed 8–4–04; 8:45 am]

BILLING CODE 4150–32–P

---

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

**[Program Announcement 04259]**

### Improving the Effectiveness of the Diagnosis and Treatment of Tuberculosis and Multi-Drug Resistant Tuberculosis in the Philippines; Notice of Intent To Fund Single Eligibility Award

## A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the intent to fund fiscal year (FY) 2004 funds for a cooperative agreement program to support and ensure the implementation of tuberculosis (TB) control activities that are designed to develop, establish, and coordinate systems and procedures to address the obstacles to achieving control of TB and multi-drug resistant tuberculosis (MDR–TB) in metropolitan Manila, the Philippines. The Catalog of Federal Domestic Assistance number for this program is 93.116.

## B. Eligible Applicant

Assistance will be provided only to the Tropical Disease Foundation, Inc. (TDF) located in Manila, the Philippines. No other applications will be solicited.

The TDF is the only qualified organization that has the technical and administrative capacity to conduct the specific set of activities requested to support CDC TB and MDR–TB prevention and control activities in the Philippines under this cooperative agreement because:

1. The TDF is uniquely positioned, in terms of legal authority, ability, track record, infrastructure and credibility in the Philippines to develop and support TB and MDR–TB control activities in both public and non-governmental organization sites throughout the country.
2. The TDF has already established a framework and mechanisms to develop and implement TB and MDR–TB treatment and control activities in the Philippines, enabling it to immediately become engaged in the activities listed in this announcement.
3. The TDF has demonstrated its ability to coordinate and implement TB treatment and control activities including MDR–TB and TB/HIV co-infection within the country.
4. The TDF has a unique and unparalleled relationship with the Makati Medical Center (MMC), the Department of Health (DOH), NTP, the Tropical Disease Foundation (TDF), and the Philippines Coalition Against Tuberculosis (PhilCAT), based on a rich history of collaboration.
5. The TDF Directly Observed Treatment Short Course (DOTS) Clinic has been in existence since February 1999, in response to the need for public-private partnership in the management of TB patients in the Philippines. The clinic is a collaboration between the TDF and MMC.
6. The TDF was approved as the first pilot project worldwide to undertake DOTS-Plus by the Green Light Committee (GLC), a subgroup of the Scientific Working Group on Multi-Drug Resistant Tuberculosis of the WHO. The MMC DOTS-Plus clinic is the only facility in the Philippines providing treatment to MDR–TB patients.
7. The TDF has the ability to collect information, train staff and advocate for policy based on the experiences learned implementing DOTS-Plus activities.
8. The specific services that the TDF will deliver are directly associated with, and compliment, other ongoing CDC prevention strategies and activities in the Philippines.

### C. Funding

Approximately $110,000 is available in FY 2004 to fund this award. It is expected that the award will begin on or before September 1, 2004, and will be made for a 12-month budget period within a project period of up to five years. Funding estimates may change.

### D. Where To Obtain Additional Information

For general comments or questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341–4146, Telephone: (770) 488–2700.

For program technical assistance, contact: Dr. Charles Wells, Project Officer, Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road Mailstop E–10, Atlanta, Georgia 30333, Telephone: (404) 639–8485, E-mail: *cwells@cdc.gov*.

For budget assistance, contact: Steward Nichols, Grants Management Specialist, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, Georgia 30341, Telephone: (770) 488–2788, E-mail: *SNichols1@cdc.gov*.

Dated: July 29, 2004.

**William P. Nichols,**

*Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention.*

[FR Doc. 04–17860 Filed 8–4–04; 8:45 am]

**BILLING CODE 4163–18–P**

---

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### National Center for Health Statistics, Board of Scientific Counselors

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) announces the following committee meeting.

*Name:* Board of Scientific Counselors (BSC).

*Times and Dates:* 2 p.m.–5:30 p.m., September 9, 2004. 8:30 a.m.–2:00 p.m., September 10, 2004.

*Place:* NCHS Headquarters, 3311 Toledo Road, Hyattsville, Maryland 20782.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

*Purpose:* This committee is charged with providing advice and making recommendations to the Secretary; the Director, CDC; and Director, NCHS, regarding the scientific and technical program goals and objectives, strategies, and priorities of NCHS.

*Matters To Be Discussed:* The agenda will include welcome remarks by the Director, NCHS; introductions of members and key NCHS staff; scientific presentations and discussions; and an open session for comments from the public. Requests to make an oral presentation should be submitted in writing to the contact person listed below by close of business, August 25, 2004. All requests to make oral comments should contain the name, address, telephone number, and organizational affiliation of the presenter. Written comments should not exceed five single-spaced typed pages in length and should be received by the contact person listed below by close of business, August 25, 2004.

Agenda items are subject to change as priorities dictate.

**FOR FURTHER INFORMATION CONTACT:** Robert Weinzimer, Executive Secretary, NCHS, 3311 Toledo Road, Room 7108, Hyattsville, Maryland 20782, telephone (301) 458–4565, fax (301) 458–4021.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: July 28, 2004.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 04–17855 Filed 8–4–04; 8:45 am]

**BILLING CODE 4163–18–P**

---

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Medicare & Medicaid Services

**[CMS–1275–N]**

### Medicare Program; Meeting of the Advisory Panel on Ambulatory Payment Classification Groups—September 1, 2, and 3, 2004

**AGENCY:** Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (DHHS).

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with section 10(a) of the Federal Advisory Committee Act (FACA)(5 U.S.C. Appendix 2), this notice announces the second biannual meeting of the Advisory Panel on Ambulatory Payment Classification (APC) Groups (the Panel) for 2004.

The purpose of the Panel is to review the APC groups and their associated weights and to advise the Secretary, DHHS, (the Secretary) and the Administrator, CMS, (the Administrator) concerning the clinical integrity of the APC groups and their associated weights. The Secretary and the Administrator consider the Panel's advice as CMS prepares its annual updates of the hospital Outpatient Prospective Payment System (OPPS) through rulemaking.

**DATES:** The second biannual meeting for 2004 is scheduled for the following dates and times: Wednesday, September 1, 2004, 1 p.m.–5 p.m. (e.d.t.); Thursday, September 2, 2004, 8 a.m.–5 p.m. (e.d.t.); Friday, September 3, 2004, 8 a.m.–12 noon (e.d.t.).

*Deadlines:*

*Deadline for Hardcopy and Electronic Comments or Suggested Agenda Topics—*

- 5 p.m. (e.d.t.), Wednesday, August 18, 2004.

*Deadline for Hardcopy and Electronic Presentations—*

- 5 p.m. (e.d.t.), Wednesday, August 18, 2004.

*Deadline for Attendance Registration—*

- 5 p.m. (e.d.t.), Monday, August 23, 2004.

*Deadline for Special Accommodations—*

- 5 p.m. (e.d.t.), Monday, August 23, 2004.

**Submittal of Materials to the Designated Federal Officer (DFO)**

Because of staffing and resource limitations, we cannot accept written comments/presentations by facsimile (FAX), nor can we print written comments/presentations received electronically for dissemination at the meeting.

Only hardcopy comments and presentations will be accepted for placement in the meeting booklets.

We are also requiring electronic versions of the written comments and presentations (in addition to the hardcopies) for the Panel's review prior to the meeting.

Therefore, *you must send BOTH electronic and hardcopy versions of your presentations and written comments by the prescribed deadlines.* (Electronic transmission must be sent to the e-mail address, and hardcopies must be mailed to the DFO, as shown below.)

**ADDRESSES:** The meeting will be held in the Multipurpose Room, 1st Floor, at the CMS Central Office, 7500 Security Boulevard, Baltimore, Maryland 21244–1850.

**FOR FURTHER INFORMATION CONTACT:** For inquiries regarding the meeting; meeting registration; and hardcopy submissions of oral presentations, agenda items, and comments, please use the following:

*Mailing Address:* Shirl Ackerman-Ross, DFO, CMS, CMM, HAPG, DOC, 7500 Security Boulevard, Mail Stop C4–05–17, Baltimore, MD 21244–1850. Phone number—(410) 786–4474. E-mail address—*APCPanel@cms.hhs.gov*. Public Affairs Office Phone Number—(202) 690–6145.

News media representatives should contact our Public Affairs Office at this phone number.

*Advisory Committees' Information Lines:* The CMS Advisory Committees' Information Line is 1–877–449–5659 (toll free) and (410) 786–9379 (local).

*Web Sites:* For additional information on the APC meeting agenda topics and/or updates to the Panel's activities, please search our Internet Web site at: *http://www.cms.hhs.gov/faca/apc/default.asp*.

To obtain Charter copies, search our Internet Web site at *http://www.cms.hhs.gov/faca*, or e-mail the DFO at: *APCPanel@cms.hhs.gov*.

**SUPPLEMENTARY INFORMATION:**

**I. Background**

The Secretary, DHHS, is required by section 1833(t)(9)(A) of the Social Security Act (the Act), as amended by section 201(h)(1)(B) and redesignated by section 202(a)(2) of the Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act (BBRA) of 1999 (Pub. L. 106–113), to establish and consult with an expert, outside advisory panel on APC groups. The Panel meets up to three times annually to review the APC groups and to provide technical advice to the Secretary and the Administrator concerning the clinical integrity of the groups and their associated weights. We will consider the technical advice provided by the Panel as we prepare the proposed rule that proposes changes to the OPPS for the next calendar year.

The Panel may consist of up to 15 representatives who are full-time employees (not consultants) of Medicare providers, which are subject to the OPPS, and a Chair/Acting Chair. Panel members must have technical expertise that will enable them to fully participate in the Panel's work. The Administrator selected the Panel membership based upon either self-nominations or nominations submitted by providers or interested organizations. The Panel presently consists of the following members and an Acting Chair: Edith Hambrick, M.D., J.D.; Acting Chair, Marilyn Bedell, M.S., R.N., O.C.N.; Albert Brooks Einstein, Jr., M.D.; Robert E. Henkin, M.D.; Lee H. Hilborne, M.D., M.P.H. Stephen T. House, M.D.; Kathleen Kinslow, C.R.N.A., Ed.D.; Mike Metro, R.N., B.S.; Sandra J. Metzler, M.B.A., R.H.I.A., C.P.H.Q.*; Gerald V. Naccarelli, M.D.; Frank G. Opelka, M.D., F.A.C.S.; Beverly K. Philip, M.D.; Lou Ann Schraffenberger, M.B.A., R.H.I.A., C.C.S.–P*; Lynn R. Tomascik, R.N., M.S.N., C.N.A.A.; Timothy Gene Tyler, Pharm.D.; William Van Decker, M.D. (*New member as of April 1, 2004).

**II. Agenda**

The agenda for the September 2004 meeting will provide for discussion and comment on the following topics as designated in the Panel's Charter:

- Reconfiguration of APCs (for example, splitting of APCs, moving Healthcare Common Procedure Coding System HCPCS) codes from one APC to another and moving HCPCS codes from new technology APCs to clinical APCs).
- Evaluation of APC weights.
- Packaging devices and drug costs into APCs: methodology, effect on APCs, and need for reconfiguring APCs based upon device and drug packaging.
- Removal of procedures from the inpatient list for payment under the OPPS.
- Use of single and multiple procedure claims data.
- Packaging of HCPCS codes.
- Other technical issues concerning APC structure.

**III. Written Comments and Suggested Agenda Topics**

The DFO must receive the electronic and hardcopy written comments and suggested agenda topics by 5 p.m. (e.d.t.), Wednesday, August 18, 2004.

Additionally, the written comments and suggested agenda topics must fall within the subject categories listed above that are outlined in the Panel's Charter.

**IV. Oral Presentations**

Individuals or organizations wishing to make 5-minute oral presentations must contact the DFO. The DFO must receive the electronic and hardcopy presentations by 5 p.m. (e.d.t.), on Wednesday, August 18, 2004, in order to be scheduled.

The number of oral presentations may be limited by the time available. Oral presentations must not exceed 5 minutes in length.

The Acting Chair may further limit time allowed for presentations due to the number of oral presentations scheduled, if necessary.

**V. Presenter and Presentation Criteria**

The additional criteria below must be supplied to the DFO by the August 18 deadline (along with hardcopies of presentations).

- Required personal information regarding presenter(s):
- Name of presenter(s),
- Title(s),
- Organizational affiliation,
- Address,
- E-mail address, and
- Telephone number(s).

All presentations must contain, at a minimum, the following supporting information and data:

- Financial relationship(s) of presenter(s), if any, with any company whose products, services, or procedures that are under consideration;
- Physicians' Current Procedural Terminology (CPT) codes involved;
- APC(s) affected;
- Description of the issue(s);
- Clinical description of the service under discussion (with comparison to other services within the APC);
- Recommendations and rationale for change;
- Expected outcome of change; and
- Potential consequences of not making the change(s).

Form CMS–20017, Presenter/Presentation Information Checklist.

To assist presenters in meeting the above criteria, Form CMS–20017, which identifies the specific standard for Panel presentations, can be found on our Internet Web site at: *http://www.cms.hhs.gov/forms/cms20017.pdf.*

**VI. Oral Comments**

In addition to formal oral presentations, there will be opportunity during the meeting for public oral comments that will be limited to 1 minute for each individual and a total of 5 minutes per organization.

**VII. Meeting Attendance**

The meeting is open to the public; however, attendance is limited to space available. Attendance will be determined on a first-come, first-served basis.

Persons wishing to attend this meeting, which is located on Federal property, must call or e-mail the Panel DFO to register in advance no later than 5 p.m. (e.d.t.), Monday, August 23, 2004.

The following information must be e-mailed or telephoned to the DFO by the date and time above:

- Name(s) of attendee(s),
- Title(s),
- Organization,
- E-mail address(es), and
- Telephone number(s).

**VIII. Security, Building, and Parking Guidelines**

Persons attending the meeting must present photographic identification to the Federal Protective Service or Guard Service personnel before they will be allowed to enter the building.

*Individuals who are not registered in advance will not be permitted to enter the building, and will be unable to attend the meeting.* The public may not enter the Central Office (CO) complex earlier than 30 to 45 minutes prior to when the meeting convenes each day. For example, entrance into CO on Day 1 (Wednesday, September 1) would not be until 12:15 p.m., at the earliest, for the 1 p.m. meeting. Likewise, entrance into CO on Days 2 and 3 would not be until 7:15 a.m., at the earliest, for the 8 a.m. meetings.

All visitors must be escorted in areas other than the lower-lobby and first floor levels in CO building.

Parking permits and instructions are issued upon arrival by the guards at the main entrance on Security Boulevard.

**IX. Special Accommodations**

Individuals requiring sign-language interpretation or other special accommodations must send a request for these services to the DFO by 5 p.m. (e.d.t.), Monday, August 23, 2004.

**Authority:** Section 1833(t) of the Act (42 U.S.C. 1395l(t), as amended by section 201(h) of the BBRA of 1999 (Pub. L. 106–113). The Panel is governed by the provisions of Pub. L. 92–463, as amended (5 U.S.C. Appendix 2).

(Catalog of Federal Domestic Assistance Program No. 93.773, Medicare—Hospital Insurance; and Program No. 93.774, Medicare—Supplementary Medical Insurance Program.)

Dated: July 8, 2004.

**Mark B. McClellan,**

*Administrator, Centers for Medicare & Medicaid Services.*

[FR Doc. 04–17992 Filed 8–4–04; 8:45 am]

BILLING CODE 4120–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

### Grant to Center for Economic Progress of Chicago, IL; Office of Family Assistance

**AGENCY:** Office of Family Assistance, ACF, DHHS.

**ACTION:** Grant award announcement.

**SUMMARY:** Notice is hereby given that an award is being made to the Center for Economic Progress of Chicago, IL in the amount of $50,000 to provide outreach on the Earned Income Tax Credit to TANF recipients and other low income individuals. After the appropriate reviews, it has been determined that this unsolicited proposal qualifies for funding.

The goal of the Center for Economic Progress is to increase access to tax credits and asset building opportunities for low and moderate income individuals, families and communities. The Center serves hundreds of thousands of low income taxpayers each tax filing season, and has developed critical knowledge and understanding of the experiences of the taxpayers and the barriers they face accessing the EITC and other low income tax credits.

The Center for Economic Progress is the only organization in the country that has a statewide contract with a State TANF Agency to provide EITC outreach to TANF recipients. They have distinguished itself as a Chicago, statewide and national leader through its innovative programs, partnerships with community organizations, corporate allies, and government agencies. The Center for Economic Progress is uniquely qualified to conduct this project because of its many successes in EITC outreach.

The period of this funding will extend through September 30, 2004.

**FOR FURTHER INFORMATION CONTACT:** Paul Maiers, Office of Family Assistance, Administration for Children and Families, 370 L'Enfant Promenade, SW., Washington, DC 20447, Telephone: 202–401–5438.

Dated: July 27, 2004.

**Andrew S. Bush,**

*Director, Office of Family Assistance.*

[FR Doc. 04–17889 Filed 8–4–04; 8:45 am]

BILLING CODE 4184–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 2003D–0383]**

### Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Recommended Glossary and Educational Outreach to Support Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (the PRA).

**DATES:** Fax written comments on the collection of information by September 7, 2004.

**ADDRESSES:** OMB is still experiencing significant delays in the regular mail, including first class and express mail, and messenger deliveries are not being accepted. To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: Fumie Yokota, Desk Officer for FDA, FAX: 202–395–6974.

**FOR FURTHER INFORMATION CONTACT:** Peggy Robbins, Office of Management Programs (HFA 250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1223.

**SUPPLEMENTARY INFORMATION:** In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

**Recommended Glossary and Educational Outreach to Support Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use**

This document provides guidance on the voluntary use of selected symbols in place of text to convey some of the information required for in vitro diagnostic devices (IVDs) intended for professional use under § 809.10 (21 CFR 809.10) (FDA's labeling requirements for IVDs) and parts 610 and 660 (21 CFR parts 610 and 660) (FDA's labeling requirements for biologics (including IVDs)) that are licensed under the Public Health Service Act. Use of these symbols will not result in a new collection of information but is a means of fulfilling underlying labeling requirements that are subject to OMB clearance. Under section 502(c) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 352), a drug or device is misbranded

> If any word, statement, or other information required by or under authority of this Act to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.

This guidance document recommends that a glossary of terms accompany each IVD to define the symbols used on that device's labels and/or labeling. Furthermore, this guidance recommends an educational outreach effort to enhance the understanding of newly introduced symbols. Both the glossary and the educational outreach help to ensure that IVD users will have enough general familiarity with the symbols, as well as quick reference materials available, to be likely to understand the symbols used in IVD labeling, further ensuring that such labeling satisfies the requirements of section 502(c) of the act.

*Respondents*: The likely respondents are IVD manufacturers who plan to use the selected symbols in place of text on the labels and/or labeling of their IVDs.

In the **Federal Register** of October 28, 2003 (68 FR 61449), FDA published a 60-day notice requesting public comment on the information collection provisions. FDA received one comment regarding information collection from a manufacturer. This comment stated ''We believe no additional educational outreach is needed for the symbols contained within the draft guidance document. A user comprehension study was conducted showing acceptance of these symbols and an explanation is provided in the glossary.'' FDA disagrees with this comment. The educational outreach will enhance the understanding of the newly introduced symbols among the intended audience.

FDA estimates the burden for this collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN[1]

| Activity | No. of Respondents | Annual Frequency per Responses | Total Annual Responses | Hours per Response | Total Hours |
|---|---|---|---|---|---|
| Glossary | 1,742 | 1 | 1,742 | 4 | 6,9681 |
| Educational outreach | 1,742 | 1 | 1,742 | 16 | 27,872 |
| Total | | | | | 34,840 |

[1] There are no capital costs or operating and maintenance costs associated with this collection of information.
[2] One-time burden.

The glossary and educational outreach activities would be carried out by domestic and foreign IVD manufacturers. The Center for Devices and Radiological Health Information Retrieval System's Registration and Listing Information database provided the number of IVD manufacturers as 1,742; 1,206 are domestic IVD manufacturers and 536 are foreign manufacturers. Consequently, FDA has based its burden estimate on the maximum possible number of manufacturers choosing to implement the use of symbols in labeling. The number of hours per response for the glossary and educational outreach activities were derived from consultation with a trade association and FDA personnel. The 4-hour estimate for a glossary is based on the average time necessary for a manufacturer to modify the glossary, as shown in the draft guidance, for the specific symbols used in labels or labeling for the IVDs they manufacture. The 16-hour estimate for educational outreach includes activities manufacturers will use to educate the various professional users of IVDs about the meaning of the IVD symbols. This estimate is based on FDA 's expectation that IVD manufacturers will jointly sponsor many educational outreach activities.

The draft guidance document also refers to labeling requirements, annual reporting requirements, and other information collections established under existing regulations. The collections of information described in section III of the guidance that result from § 809.10 were approved under OMB control number 0910–0485. The collections of information described in

section III of the guidance that result from §§ 610.60, 610.61, and 610.62 were approved under OMB control number 0910–0338. In accordance with section 3506(c)(2)(A) of the PRA, a 60-day notice soliciting public comment on the collections of information described in section III of the guidance that result from part 660 (§§ 660.2, 660.28, 660.35, 660.45, and 660.55) published in the **Federal Register** of July 22, 2003 (68 FR 43359). The collections of information described in section X of the guidance, regarding annual reports, were approved under OMB control numbers 0910–0231 and 0910–0315. The collections of information described in section X of the guidance, regarding adverse event reporting, were approved under OMB control numbers 0910–0437 and 0910–0291.

Dated: July 27, 2004.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

[FR Doc. 04–17879 Filed 8–4–04; 8:45 am]

BILLING CODE 4160–01–S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 2004N–0246]**

### Agency Emergency Processing Under Office of Management and Budget Review; Experimental Study of Petitioned Health Claims on Glucosamine and Chondroitin Sulfate; Withdrawal

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; withdrawal.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing a notice that published in the **Federal Register** of June 3, 2004 (69 FR 31395).

**DATES:** This notice is withdrawn on August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** May D. Nelson, Center for Food Safety and Applied Nutrition (HFS–024), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301–436–1722.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of June 3, 2004, FDA published a notice informing interested parties that the proposed collection of information entitled ''Experimental Study of Petitioned Health Claims on Glucosamine and Chondroitin Sulfate'' had been submitted to the Office of Management and Budget (OMB) for emergency processing under section 3507(j) of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507(j) and 5 CFR 1320.13). The notice contains a number of errors. In addition, we are reevaluating the design and objective of the study. Therefore, we are withdrawing both the notice itself and the request for OMB approval of the proposed collection of information.

Dated: July 29, 2004.

**William K. Hubbard,**

*Associate Commissioner for Policy and Planning.*

[FR Doc. 04–17877 Filed 8–4–04; 8:45 am]

BILLING CODE 4160–01–S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### Proposed Data Collection; Comment Request; California Health Interview Survey 2005

**SUMMARY:** In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the National Institute of Health (NIH), National Cancer Institute (NCI) will public periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

*Proposed Collection: Title:* California Health Interview Survey (CHIS) 2005 Cancer Control Module (CCM). *Type of Information Collection Request:* New. *Need and Use of Information Collection:* The NCI has sponsored two Cancer Control Modules to the California Health Interview Survey (CHIS), and will be sponsoring a third to be administered in 2005.

The CHIS is a telephone survey designed to provide population-based, standardized health-related data to assess California's progress in meeting Healthy People 2010 objectives for the nation and the state. The CHIS sample is designed to provide statistically reliable estimates statewide, for California counties, and for California's ethnically and racially diverse population. Initiated by the UCLA Center for Health Policy Research, the California Department of Health Services, and the California Public Health Institutes, the survey is funded by a number of public and private sources. It was first administered in 2001 to 55,428 adults and subsequently in 2003 to 42,043 adults. These adults are a representative sample of California's non-institutional population living in households.

CHIS 2005, the third bi-annual survey, is planned for administration to 55,000 adult Californians. The cancer control module, which is similar to that administered in CHIS 2001 and CHIS 2003, will allow NCI to examine trends in breast cancer screening and diagnosis, as well as to study other cancer-related topics, such as, diet, physical activity and obesity.

Because California is the most populous and the most racially and ethnically diverse state in the nation, the CHIS 2005 sample will yield adequate numbers of respondents in key ethnic and racial groups, including African Americans, Latinos, Asians, and American Indian/Alaska Natives. The Latino group will include large numbers of Mexican-origin, Central Americans, South Americans, and other Latino subgroups; the Asian group will include large numbers of respondents in the Chinese, Filipino, Japanese, Vietnamese, and Korean subgroups. NCI will compare the CHIS and National Health Interview Survey (NHIS) data in order to conduct comparative analyses and better estimate cancer risk factors and screening among racial/ethnic minority populations. The CHIS sample size also permits NCI to create estimates for ethnic subdomains of the population, for which NHIS has insufficient numbers for analysis.

*Frequency of Response:* One-time. *Affected public:* Individuals or households. *Types of Respondents:* U.S. adults (persons 18 years of age and older). The annual reporting burden is as follows.

TABLE A.—ANNUALIZED BURDEN ESTIMATES FOR CHIS 2005 DATA COLLECTION

| Data collection | Estimated number of respondents | Frequency of response | Average time per response | Annual hour burden |
|---|---|---|---|---|
| Adult Core | 55,000 | 1 | .42 | 23,100 |
| CCTM | 55,000 | 1 | .08 | 4,400 |

TABLE A.—ANNUALIZED BURDEN ESTIMATES FOR CHIS 2005 DATA COLLECTION—Continued

| Data collection | Estimated number of respondents | Frequency of response | Average time per response | Annual hour burden |
|---|---|---|---|---|
| Totals | | | | 27,500 |

There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

*Request for Comments:* Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed performance of the functions of the agency, including whether the information shall have practical utility; (2) the accuracy of the agency's estimate of the burden of the proposed collection of information including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

**FOR FURTHER INFORMATION CONTACT:** To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Nancy Breen, Ph.D., Project Officer, National Cancer Institute, EPN 4005, 6130 Executive Boulevard MSC 7344. Bethesda, Maryland 20852–7344, or call non-toll free number (301) 496–8500 or FAX your request, including your address to *breenn@mail.nih.gov*.

**DATES:** Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of this publication.

Dated: July 21, 2004.

**Rachelle Ragland-Greene,**

*NCI Project Clearance Liaison.*

[FR Doc. 04–17958 Filed 8–3–04; 1:53 pm]

BILLING CODE 4140–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Review of Administrative Supplement Applications for Disseminating Evidence-Based Intervention Research Products.

*Date:* August 12, 2004.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* 6130 Executive Blvd., Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Cynthia Vinson, MPA, Program Analyst, National Cancer Institute, Division of Cancer Control and Population Sciences, 6130 Executive Blvd, Room 7046, Bethesda, MD 20892, (301) 594–5906.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: July 29, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04–17909 Filed 8–4–04; 8:45 am]

BILLING CODE 4140–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Mental Health Special Emphasis Panel, Technologies for Clinical Assessment.

*Date:* August 25, 2004.

*Time:* 1 p.m. to 3 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call).

*Contact Person:* Mark Czarnolewski, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6153, MSC 9608, Bethesda, MD 20892–9608, (301) 402–8152, *mczarnol@mail.nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: July 29, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04–17908 Filed 8–4–04; 8:45 am]

BILLING CODE 4140–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Mental Health Special Emphasis Panel, Flexible Decision Support Systems.

*Date:* August 13, 2004.

*Time:* 4 p.m. to 6 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

*Contact Person:* Christopher S. Sarampote, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6148, MSC 9608, Bethesda, MD 20892–9608, (301) 443–1959, *csarampo@mail.nih.gov.*

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: July 29, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04–17910 Filed 8–4–04; 8:45 am]

BILLING CODE 4140–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel, ZAA1 HH (27)—Review of U18 Grant Applications.

*Date:* August 12, 2004.

*Time:* 2 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 5635 Fishers Lane, Room 3033, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Jeffrey I. Toward, PhD, Scientific Review Administrator, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, Extramural Project Review Branch, OSA, 5635 Fishers Lane, Bethesda, MD 20892–9304, (301) 435–5337, *jtoward@mail.nih.gov.*

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel, ZAA1 HH (25)—Review of R25 Applications.

*Date:* August 13, 2004.

*Time:* 1 p.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, NIAAA/Fishers Building, 5635 Fishers Lane, Room 3033, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Jeffrey I. Toward, PhD, Scientific Review Administrator, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, Extramural Project Review Branch, OSA, 5635 Fishers Lane, Bethesda, MD 20892–9304, (301) 435–5337, *jtoward@mail.nih.gov.*

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants, National Institutes of Health, HHS)

Dated: July 29, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04–17912 Filed 8–4–04; 8:45 am]

BILLING CODE 4140–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Alcohol Abuse and Alcoholism Initial Review Group, Health Services Research Review Subcommittee, AA–2 Initial Review Group Meeting.

*Date:* October 21, 2004.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Select Bethesda, 8120 Wisconsin Ave, Bethesda, MD 20814.

*Contact Person:* Dorita Sewell, PhD, Scientific Review Administrator, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, Office of Extramural Research, 5635 Fishers Lane, Bethesda, MD 20892–9304, (301) 443–2890, *dsewell@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants, National Institutes of Health, HHS)

Dated: July 29, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04–17913 Filed 8–4–04; 8:45 am]

BILLING CODE 4140–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel, ZAA1 HH (50)—Review of SBIR Phase II Proposal.

*Date:* August 23, 2004.

*Time:* 10 a.m. to 11 a.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institutes of Health, NIAAA/Fisher's Building, 5635 Fishers Lane, Room 3033, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Jeffrey I. Toward, PhD, Scientific Review Administrator, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, Extramural Project Review Branch, OSA, 5635 Fishers Lane, Bethesda, MD 20892–9304, (301) 435–5337, *jtoward@mail.nih.gov*.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants, National Institutes of Health, HHS)

Dated: July 29, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04–17914 Filed 8–4–04; 8:45 am]

BILLING CODE 4140–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Neurological Disorders and Stroke Special Emphasis Panel, SNRP Review.

*Date:* August 2–3, 2004.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Marriott Plaza San Antonio, 555 South Alamo Street, San Antonio, TX 78205.

*Contact Person:* Phillip F. Wiethorn, Scientific Review Administrator, DHHS/NIH/NINDS/DER/SRB, 6001 Executive Boulevard; MSC 9529, Neuroscience Center; Room 3203, Bethesda, MD 20892–9529, (301) 496–5388, *wiethorp@ninds.nih.gov*.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: July 29, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04–17915 Filed 8–4–04; 8:45 am]

BILLING CODE 4140–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Neurological Disorders and Stroke Special Emphasis Panel, Parkinson's Disease.

*Date:* August 9, 2004.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Katherine Woodbury, PhD, Scientific Review Administrator, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd, Suite 3208, MSC 9529, Bethesda, MD 20892–9529, (301) 496–5980, *kw47o@nih.gov*.

This notice is being published less than 15 days prior to the meeting due to the timing limitations impsoed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: July 29, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04–17916 Filed 8–4–04; 8:45 am]

BILLING CODE 4140–01–M

## DEPARTMENT OF HOMELAND SECURITY

**[USCG–2001–10486]**

### Approval of Ballast Water Treatment Systems

**AGENCY:** Coast Guard, DHS.

**ACTION:** Notice with request for comments.

**SUMMARY:** The Coast Guard seeks consultation with all interested and affected parties in establishing a program to approve ballast water treatment systems. The intent of this program is to ensure that ballast water treatment systems approved for use on-board vessels will meet the ballast water discharge standard the Coast Guard will be implementing in the near future to prevent the introduction and spread of nonindigenous species via ballast water discharges, as authorized by the Nonindigenous Aquatic Nuisance Prevention and Control Act and the National Invasive Species Act.

**DATES:** Comments and related material must reach the Docket Management Facility on or before December 3, 2004.

**ADDRESSES:** To make sure your comments and related material are not entered more than once in the docket, please submit them by only one of the following means:

(1) By mail to the Docket Management Facility (USCG–2001–10486), U.S. Department of Transportation, room PL–401, 400 Seventh Street, SW., Washington, DC 20590–0001.

(2) By delivery to room PL–401 on the Plaza level of the Nassif Building, 400 Seventh Street, SW., Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The telephone number is (202) 366–9329.

(3) By fax to the Docket Management Facility at (202) 493–2251.

(4) Electronically through the Web site for the Docket Management System at *http://dms.dot.gov*.

In choosing among these means, please give due regard to the recent difficulties and delays associated with the delivery of mail through the U.S. Postal Service to Federal facilities. Delivery methods 2–4 of those listed above are the preferred methods because security measures taken by the U.S. Postal Service and Coast Guard mail reception facilities may seriously damage or render unreadable comments sent via regular mail.

The Docket Management Facility maintains the public docket for this rulemaking. Comments and material received from the public, as well as documents mentioned in this notice as being available in the docket, will become part of this docket and will be available for inspection or copying at room PL–401 on the Plaza level of the Nassif Building, 400 Seventh Street, SW., Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. You may also find this docket at the following Web site address: *http://dms.dot.gov*.

Electronic forms of all comments received into any of our dockets can be searched by the name of the individual submitting the comment (or signing the comment, if submitted on behalf of an association, business, labor unit, etc) and is open to the public without restriction. You may review the Department of Transportation's complete Privacy Act Statement in the **Federal Register** published on April 11, 2000 (65 FR 19477–78), or you may visit *http://dms.dot.gov*.

**FOR FURTHER INFORMATION CONTACT:** For information concerning this notice, call Mr. Bivan Patnaik, Project Manager, Environmental Standards Division, U.S. Coast Guard, telephone (202) 267–0995 or via e-mail *bpatnaik@comdt.uscg.mil*. If you have any questions on viewing or submitting material to the docket, call Ms. Andrea M. Jenkins, Program Manager, Docket Operations, Department of Transportation, telephone (202) 366–0271.

**SUPPLEMENTARY INFORMATION:**

## Request for Comments

The Coast Guard encourages interested persons to submit written data, views, or comments. Persons submitting comments should please include their name and address and identify the docket number (USCG–2001–10486). You may submit your comments and material by mail, hand delivery, fax, or electronic means to the Docket Management Facility at the address under **ADDRESSES**; but please submit your comments and material by only one means. If you submit them by mail or hand delivery, submit them in an unbound format, no larger than 8½ by 11 inches, suitable for copying and electronic filing. If you submit them by mail and would like to know they were received, please enclose a stamped, self-addressed postcard or envelope.

## Background and Purpose

The Nonindigenous Aquatic Nuisance Prevention and Control Act of 1990, as reauthorized and amended by the National Invasive Species Act of 1996, authorizes the Coast Guard to approve alternative ballast water management methods in lieu of ballast water exchange to prevent the introduction and spread of nonindigenous species (NIS) in U.S. waters via ballast water discharge. The Coast Guard will use information gathered from this notice to develop a comprehensive approval program to ensure ballast water treatment systems meet the ballast water discharge standard regulations, which we intend to promulgate in the near future. Commenters should note that the approval program will have to accommodate many different technologies as ballast water treatment options, as well as different types of vessels, and the costs associated with establishing this program. Commenters should also consider that treated ballast water may be sampled for the life of the treatment system as part of compliance measures to enforce ballast water discharge standards. In addition, commenters should be aware that the Environmental Protection Agency's Environmental Technology Verification Program (*http://www.epa.gov/etv/*), an independent technology evaluation program could be used in conjunction with our approval program. If commenters believe that an approval program is not warranted, comments on alternative programs and their associated costs would be beneficial.

The development of an approval program presents a complex challenge for the Coast Guard. We currently approve some equipment as a result of only land-based testing. The public should comment on if this is an adequate approach for approving ballast water treatment systems or should approval of these systems involve shipboard testing. The public should comment on appropriate water quality conditions, whether or not testing should include testing from both fresh water and salt water sources, and other environmental conditions that treatment systems should be subjected to as part of the approval program. The development of this program will require close collaboration between government agencies, the scientific community, water treatment experts, the shipping industry, and a wide range of stakeholders.

## Public Meetings

At this time, the Coast Guard is looking into holding a public meeting, and the various types of venues for the meeting. You may submit requests and/or comments for a public meeting to the Docket Management Facility at the address under **ADDRESSES** explaining why one would be beneficial. If we determine that one would aid the development of this program, we will hold one at a time and place announced by a later notice in the **Federal Register**.

Dated: July 29, 2004.

**Joseph J. Angelo,**

*Director of Standards, Marine Safety, Security & Environmental Protection.*

[FR Doc. 04–17827 Filed 8–4–04; 8:45 am]

BILLING CODE 4910–15–P

## DEPARTMENT OF HOMELAND SECURITY

### Coast Guard

**[COTP Port Arthur–04–011]**

### Notice and Request for Comments; Letter of Recommendation, LNG Cameron Parish, LA

**AGENCY:** Coast Guard, DHS.

**ACTION:** Notice and request for public comment.

**SUMMARY:** The U.S. Coast Guard Captain of the Port (COTP), Port Arthur, is preparing a letter of recommendation as to the suitability of the Sabine Pass Channel waterway for liquefied natural gas (LNG) marine traffic. The COTP is looking for comments and related material pertaining specifically to the Maritime Operation, Waterways Management, and Port Security aspects of the proposed LNG Facility.

**DATES:** Comments and related material pertaining specifically to the Maritime Operation, Waterways Management, and Port Security aspects of the proposed LNG Facility must reach the Coast Guard on or before September 7, 2004.

**ADDRESSES:** You may mail comments and related material to: Commanding Officer, U.S. Coast Guard Marine Safety Office, 2875 Jimmy Johnson Blvd., Port Arthur, TX 77640, ATTN: Waterways Management Branch.

You may send comments and related material by fax to: U.S. Coast Guard Marine Safety Office (MSO) Port Arthur Attention: Waterways Management Branch (409) 723–6534. U.S. Coast Guard MSO Port Arthur maintains a file for this notice. Comments and material received from the public during the comment period will become part of this file and will be available for inspection or copying at U.S. Coast Guard MSO Port Arthur, Waterways Management Branch, between the hours of 7:30 a.m. to 4 p.m., Monday through Friday, excluding Federal holidays.

**FOR FURTHER INFORMATION CONTACT:** Lieutenant (Junior Grade) Jennifer Hnatow at U.S. Coast Guard MSO Port Arthur, (409) 723–6501.

**SUPPLEMENTARY INFORMATION:**

#### Request for Comments

We encourage you to participate by submitting comments and related material pertaining specifically to the Maritime Operation, Waterways Management, and Port Security aspects of the proposed LNG Facility. If you do so, please include your name and address, identify the docket number [COTP Port Arthur–04–011], indicate the specific section of this document to which each comment applies, and give the reason for each comment. Please submit all comments and related material in an unbound format, no larger than 8½ by 11 inches, suitable for copying and electronic filing. For a returned receipt, please enclose a stamped, self-addressed postcard or envelope. We will consider all comments and material received during the comment period. The recommendation made by this office may be affected by comments received.

#### Public Meeting

We do not now plan to hold public meetings. But you may submit a request for meetings by writing to Commanding Officer, U.S. Coast Guard MSO Port Arthur at the address under **ADDRESSES** explaining why they would be beneficial. If we determine that public meetings would benefit the recommendation process, we will hold them at a time and place announced by a later notice in the **Federal Register**.

The Federal Energy Regulatory Commission (FERC) is responsible for authorizing the siting and construction of onshore LNG facilities under Section 3 of the Natural Gas Act (NGA) (15 U.S.C. 717 *et seq.*). FERC also authorizes the construction and operation of interstate natural gas pipelines that may be associated with the LNG facilities under section 7 of the NGA. The FERC conducts environmental, safety, and security reviews of LNG plants and related pipeline facilities, and as the lead Federal Agency prepares the overall National Environmental Policy Act (NEPA) documentation (18 CFR part 380). As required by NEPA, FERC will issue a Draft Environmental Impact Statement (DEIS) for review and comment by the public. After issuing the DEIS for this proposed LNG facility and pipeline project, FERC will hold a public meeting. The date, time, and location of this meeting will be published on FERC's Web site, *http://www.ferc.gov*, under Docket Nos. CP04–47–000, CP04–38–000, CP04–39–000, and CP04–40–000.

#### Background and Purpose

In accordance with the requirements in 33 CFR 127.009, the U.S. Coast Guard COTP Port Arthur, is preparing a letter of recommendation as to the suitability of the Sabine Pass Channel waterway for liquefied natural gas (LNG) marine traffic. The letter of recommendation is in response to a Letter of Intent to operate a LNG facility in Cameron Parish, LA. This facility would consist of an LNG import terminal and storage facilities and approximately 16 miles of 42-inch-diameter pipeline in Cameron Parish. The Letter of Intent is available in the docket where indicated under **ADDRESSES**.

Sabine Pass LNG, L.P. and Cheniere Sabine Pass Pipeline Company (collectively referred to as Cheniere Sabine) propose to build a new LNG import, storage, and vaporization terminal in a rural part of Cameron Parish, Louisiana, across the Sabine Pass Channel from Sabine Pass, Texas; and a natural gas pipeline to transfer up to 2.6 billion cubic feet per day of imported natural gas. Cheniere Sabine has acquired 568 acres of land, formerly used for dredge spoil placement by the U.S. Army Corps of Engineers, for the proposed LNG terminal facility. The LNG import terminal would import, store, and vaporize an average of approximately 2,600 million standard cubic feet per day (MMscfd) of LNG, with an installed capacity of 2,880 MMscfd, for supply to U.S. natural gas markets. Cheniere Sabine seeks authority to construct and operate the following new facilities:

1. A new marine basin connected to the Sabine Pass Channel that would include a ship maneuvering area and two protected berths to unload up to 300 LNG ships per year with a ship capacity ranging up to 250,000 cubic meters ($m^3$) of LNG;
2. Two 30-inch-diameter stainless steel insulated LNG transfer lines to transfer the LNG from the berth facilities to the LNG storage tanks;
3. Three all-metal, double-walled, single containment, top-entry LNG storage tanks, each with a nominal working volume of approximately 160,000 $m^3$ and each with secondary containment dikes to contain 110 percent of the gross tank volume;
4. Sixteen high-pressure submerged combustion LNG vaporizers with a capacity of approximately 180 MMscfd each, as well as other associated vaporization equipment, including pumps, boil-off gas compressors, instrumentation, and safety systems;
5. Ancillary utilities, buildings, and service facilities, including hazard detection and fire response systems;
6. Approximately 16 miles of 42-inch-diameter natural gas pipeline extending from the LNG import terminal to an interconnection with four existing pipelines at Johnson's Bayou;
7. Three metering stations, one at the LNG terminal site, one at an interconnection with Natural Gas Pipeline Company of America, and one at the interconnection with the existing pipelines at Johnson's Bayou; and
8. Associated pipeline facilities including a pig launcher receiver

facility, and three mainline valves, and one side valve.

Construction of the LNG terminal facilities would take approximately 3 years, and the pipeline would take approximately 4 to 6 months. Cheniere Sabine proposes to place the project in service before the 2007 winter heating season.

In preparation for issuance of the letter of recommendation, the COTP will consider all information submitted by the owner or operator under the requirements of 33 CFR 127.007, as well as comments received from the public.

### Additional Information

Additional information can be found in the Federal Energy Regulatory Commission Document entitled ''Notice of Intent To Prepare an Environmental Impact Statement for the Proposed Sabine Pass LNG and Pipeline Project and Request for Comments on Environmental Issues and Notice of Public Scoping Meeting and Site Visit'', Docket Nos. CP04–47–000, CP04–38–000, CP04–39–000, and CP04–40–000 dated February 20, 2004, which is available for download at *http://www.ferc.gov*.

Dated: July 15, 2004.

**Sharon K. Richey,**

*Captain, U.S. Coast Guard, Captain of the Port, Port Arthur.*

[FR Doc. 04–17826 Filed 8–4–04; 8:45 am]

**BILLING CODE 4910–15–P**

---

## DEPARTMENT OF THE INTERIOR

## Bureau of Indian Affairs

## Notice of Intent To Prepare a Supplemental Programmatic Environmental Impact Statement for the Proposed Navajo Ten-Year Forest Management Plan, Navajo Nation, Arizona/New Mexico

**AGENCY:** Bureau of Indian Affairs, Interior.

**ACTION:** Notice.

**SUMMARY:** This notice advises the public that the Bureau of Indian Affairs (BIA) as lead agency, with the Navajo Nation as cooperating agency, intends to prepare a Supplemental Programmatic Environmental Impact Statement (SPEIS) for the proposed Navajo Nation Ten-Year Forest Management Plan. The purpose of the proposed action is to pursue forest management in a manner that is both environmentally sound and economically beneficial to the Navajo Nation.

**DATES:** Written comments must arrive by September 7, 2004.

**ADDRESSES:** You may mail written comments to Mr. Jonathan Martin, Regional Forester, Bureau of Indian Affairs, Navajo Regional Office, P.O. Box 1060, Gallup, New Mexico 87305.

**FOR FURTHER INFORMATION CONTACT:** Jonathan Martin, (928) 729–7228.

**SUPPLEMENTARY INFORMATION:** The proposed action is to adopt a ten-year forest management plan for the Navajo Forest. The Navajo Forest lies in the Chuska Mountains and Defiance Plateau areas of the Navajo Nation, along the Arizona-New Mexico border. The forest area encompasses nearly 600,000 acres.

A Final Programmatic Environmental Impact Statement (FPEIS) for the proposed action was originally issued in April 2002. The Environmental Protection Agency published a Notice of Availability of the FPEIS and the BIA published a Supplemental Notice in the **Federal Register** on April 14, 2002 (65 FR 20156 and 20197, respectively). The BIA and the Navajo Nation then deliberated for 2½ years to select an alternative for the Record of Decision on the proposed action, but because of questions about the adequacy of the FPEIS subsequently raised by Department of the Interior legal staff, no Record of Decision was issued. Instead, the BIA has decided to prepare a SPEIS to address the issues raised by the legal staff, plus any relevant information that has become available or circumstances that have changed over the 4 years since the FPEIS was issued.

The original FPEIS included five alternatives, as follows: (1) Even-aged and uneven-aged management for timber harvesting with Special Management Areas (SMAs) protecting critical wildlife habitat and vital watersheds (preferred); (2) even-aged management with SMAs; (3) uneven-aged management without SMAs; (4) no commercial harvesting; and (5) no action, which would continue current harvest levels with even-aged management and without SMAs. Areas of environmental concern addressed in the FPEIS included timber and other forest resources, biological, water and cultural resources, air quality and socio-economics. The SPEIS will further elaborate on alternatives considered, but eliminated from detailed study, such as homesites, grazing and range conditions, distribution and condition of riparian systems, wildlife occurrence and habitat, water quality and cumulative impacts.

### Public Comment Availability

Comments, including names and addresses of respondents, will be available for public review at the mailing address shown in the **ADDRESSES** section, during regular business hours, 8 a.m. to 4:30 p.m., Monday through Friday, except holidays. Individual respondents may request confidentiality. If you wish us to withhold your name and/or address from public review or from disclosure under the Freedom of Information Act, you must state this prominently at the beginning of your written comment. Such requests will be honored to the extent allowed by law. We will not, however, consider anonymous comments. All submissions from organizations or businesses, and from individuals identifying themselves as representatives or officials of organizations or businesses, will be made available for public inspection in their entirety.

### Authority

This notice is published in accordance with section 1503.1 of the Council on Environmental Quality Regulations (40 CFR parts 1500 through 1508) implementing the procedural requirements of the National Environmental Policy Act of 1969, as amended (42 U.S.C. 4321 *et seq.*), and the Department of the Interior Manual (516 DM 1–6), and is in the exercise of authority delegated to the Assistant Secretary—Indian Affairs by 209 DM 8.

Dated: July 28, 2004.

**David W. Anderson,**

*Assistant Secretary—Indian Affairs.*

[FR Doc. 04–17841 Filed 8–4–04; 8:45 am]

**BILLING CODE 4310–W7–P**

---

## DEPARTMENT OF THE INTERIOR

## Bureau of Indian Affairs

## Seneca Nation Sale and Consumption of Alcoholic Beverages

**AGENCY:** Bureau of Indian Affairs, Interior.

**ACTION:** Notice.

**SUMMARY:** This notice publishes the Seneca Nation Liquor Control Code. The Code regulates and controls the possession, sale and consumption of liquor on the Seneca Nation. The land is located on trust land and this Code allows for the possession and sale of alcoholic beverages on the Seneca Nation and will increase the ability of the tribal government to control the Nation's liquor distribution and possession, and at the same time will provide an important source of revenue for the continued operation and strengthening of the tribal government and the delivery of tribal services.

**EFFECTIVE DATE:** This Code is effective on August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Harold Spears, Eastern Regional Office, Division of Tribal Government, 711 Stewarts Ferry Pike, Nashville, Tennessee 37214, Telephone (615) 467–2953 or Ralph Gonzales, Office of Tribal Services, 1951 Constitution Avenue, NW., MS–320–SIB, Washington, DC 20240; Telephone (202) 513–7629.

**SUPPLEMENTARY INFORMATION:** Pursuant to the Act of August 15, 1953, Public Law 83–277, 67 Stat. 586, 18 U.S.C. 1161, as interpreted by the Supreme Court in *Rice* v. *Rehner,* 463 U.S. 713 (1983), the Secretary of the Interior shall certify and publish in the **Federal Register** notice of adopted liquor ordinances for the purpose of regulating liquor transactions in Indian country. The Seneca Nation adopted its Code, CN:R–04–10–04–19 on April 10, 2004.

The purpose of this Code is to govern the sale, possession and distribution of alcohol on the Seneca Nation.

This notice is published in accordance with the authority delegated by the Secretary of the Interior to the Assistant Secretary—Indian Affairs.

I certify that this Liquor Ordinance, a Legislative Code of the Seneca Nation, was duly adopted by the Seneca Nation Tribal Council on March 15, 2004.

**David W. Anderson,**

*Assistant Secretary—Indian Affairs.*

The Seneca Nation Liquor Control Code, CN:R–04–10–04–19 reads as follows:

**Adopted by Seneca Nation Tribal Council by Resolution CN:R–04–10–04–19 (April 10, 2004)**

*Seneca Nation of Indians Alcoholic Beverage Control Code*

**Section 1—Title**

This Code shall be known as the ''Seneca Nation of Indians Alcoholic Beverage Control Code.''

**Section 2—Authority and Purpose**

The authority for this Code and its adoption by the Council of the Seneca Nation of Indians (''Nation Council'') is found in Article XIII of the Constitution of the Seneca Nation of Indians of 1848, as amended, and in the Act of August 15, 1953, Public Law 83–277, 18 U.S.C. 1161.

Pursuant to the inherent sovereignty of the Nation and in the exercise of the Nation's powers for the purpose of protecting the welfare, health, peace, morals and safety of Nation members, the Nation adopts this Code for the purpose of regulating and controlling the possession, sale and consumption of alcoholic beverages within the boundaries of the Seneca Nation Territory. This Code is enacted in conformity with the Nation's concurrent jurisdiction with the State of New York over alcoholic beverage regulation within the Seneca Nation Territory pursuant to the Act of August 15, 1953, Public Law 83–277, 18 U.S.C. 1161.

**Section 3—Relation to Other Seneca Nation Regulations**

Nation Council resolution CN: R–11–16–02–17, duly adopted by the Nation Council on November 16, 2002, is hereby repealed and replaced. Any and all prior ordinances, resolutions, regulations or other form of control of the Nation, whether written or unwritten, which authorize, prohibit, or deal with the sale of alcohol are hereby repealed and have no further force and effect. No Nation ordinance or regulation shall be applied in a manner inconsistent with the provisions of this Code.

**Section 4—Application of This Code to Seneca Nation Territory**

The Seneca Nation lands to which this Code applies is the Indian Country that is subject to the jurisdiction of the Nation, including those lands acquired by the Nation in restricted fee status pursuant to the Seneca Nation Land Claims Settlement Act of 1990, 25 U.S.C. 1774f(c). For the purposes of this Code only, all lands to which this Code applies shall be referred to herein as the ''Seneca Nation Territory.''

**Section 5—Conformity With State Law and This Ordinance**

The possession, sale and consumption of alcoholic beverages within the Seneca Nation Territory shall be lawful provided that such possession is in conformity with both this Ordinance and the laws of the State of New York pursuant to 18 U.S.C. 1161.

**Section 6—Definitions**

To the extent that definitions are consistent with Nation and federal law, terms used herein shall have the same meaning as defined in New York Consolidated Laws, Chapter 3–B (Alcoholic Beverage Control Law) and in Title 9, Subtitle B, Chapter I of the New York Regulations (Rules of the New York State Liquor Authority).

(a) ''Alcohol'' shall mean ethyl alcohol, hydrated oxide of ethyl or spirit of wine from whatever source or by whatever process produced.

(b) ''Alcoholic beverage'' shall mean any liquid suitable for human consumption, which contains one-half of one percent or more of alcohol by volume.

(c) ''Beer'' shall mean and include any fermented beverages of any name or description, manufactured from malt, wholly or in part, or from any substitute therefore.

(d) ''Distilled spirits'' shall mean any alcoholic beverage that is not beer, wine, sparkling wine or alcohol.

(e) ''Liquor'' shall mean and include any and all distilled or rectified spirits, brandy, whiskey, rum, gin, cordials or similar distilled alcoholic beverages, including all dilutions and mixtures of one or more of the foregoing.

(f) ''Minor'' shall mean any person under age twenty-one (21) years of age.

(g) ''Nation Council'' shall mean the duly elected governing body of the Seneca Nation of Indians.

(h) ''Nation Enterprise,'' for purposes of this Code only, shall mean those corporations chartered by the Nation and authorized to conduct Class II or III gaming and related commercial activities within Seneca Nation Territory pursuant to the Nation's Gaming Compact with New York State and that is licensed by the Nation Council after paying the appropriate fee set forth by the Nation Council by Resolution at not less than two hundred ($200.00) Dollars and not more than Five Thousand ($5,000) Dollars annually.

(i) ''Possession or possessing'' shall mean over one's person, vehicle or other property and includes constructive possession through control without regard to ownership.

(j) ''Purchase'' shall mean the exchange, barter, traffic, receipt, with or without consideration in any form.

(k) ''Sale'' shall mean the exchange, barter, traffic, donation, with or without consideration, in addition to the selling, supplying or distribution by any means, by any person to any person.

(l) ''State'' means the State of New York.

(m) ''Transport'' shall mean the introduction of alcoholic beverage onto the Seneca Nation Territory by any means of conveyance for the purpose of sale, or distribution, to any licensed dealer.

**Section 7—Powers of Enforcement**

(a) The Nation Council, or other designee as authorized by the Nation Council by Resolution, has primary regulatory authority over the subject matter of this Code. The Nation Council, or its duly authorized designee, shall have the following powers and duties:

(b) To establish, publish and enforce rules and regulations governing the sale of alcoholic beverages within Seneca

Nation Territory. Such rules and regulations shall be in conformity with the rules and regulations of the State of New York and shall be approved by the Nation Council prior to taking effect;

(c) To employ managers, accountants, security personnel, inspectors, and other such persons as may be reasonably necessary to ensure adequate enforcement of this Code;

(d) To issue licenses permitting the sale of alcoholic beverages within Seneca Nation Territory;

(e) To hold hearings on violations of this Code or for the issuance or revocation of licenses hereunder;

(f) To bring suit to enforce this Code as necessary;

(g) To determine penalties for violations of this Code;

(h) To make such reports as may be required;

(i) To collect fees levied or set in relation to this Code and keep accurate records, books and accounts; and

(j) To exercise such other powers as is necessary and appropriate to fulfill the purposes of this Code.

(2) The Marshals, the Seneca Nation Conservation officers, and the officers of the Seneca Nation Law Enforcement Department are authorized to enforce this Code within the Seneca Nation Territory. Such officials are authorized to confiscate and preserve evidence of all alcoholic beverages sold, introduced for purposes of sale, or possessed in violation of this Code within the Seneca Nation Territory.

**Section 8—Conditions Regarding Sales of Alcoholic Beverages Within Seneca Nation Territory**

(a) License Required. The sale and introduction for purposes of sale of alcoholic beverages shall be unlawful within the Seneca Nation Territory unless pursuant to an alcoholic beverage license issued by the Nation Council or its duly authorized designee. Any person who is not licensed pursuant to this Code who sells, or introduces for sale, alcoholic beverages within the Seneca Nation Territory, whether in the original container or not, shall be guilty of a violation of this Code and shall be subject to a fine under this Code.

(b) Unlawful Possession. The possession and consumption of alcoholic beverages shall be unlawful on the public lands of the Seneca Nation Territory, including public highways, bridges, Nation property, parking lots, driveways and surrounding Nation Buildings. Any person who possesses or consumes alcoholic beverages in violation of this provision shall be guilty of a violation of this Code and shall be subject to a fine under this Code.

(c) Possession by minors. It shall be unlawful for any person under the age of twenty-one to possess or consume alcoholic beverages, or for any person to give alcoholic beverages to any person under the age of twenty-one, within the Seneca Nation Territory. Any person in violation of this provision shall be guilty of a violation of this Code and shall be subject to a fine under this Code.

(d) Sale to minors. It shall be unlawful for any person to maintain a premises within the Seneca Nation Territory where alcoholic beverages are consumed, possessed or served to any person under the age of twenty-one. Any person in violation of this provision shall be guilty of a violation of this Code and shall be subject to a fine under this Code.

**Section 9—Violations of the Code Within Seneca Nation Territory**

(a) The Nation may bring an action in the Peacemakers' Court against any person for violation of the provisions of this Code within Seneca Nation Territory. The action shall be initiated by the filing of a written complaint with the court of the tribal prosecutor, sworn to by a person having personal knowledge of the charged violation, or by a Marshal or Seneca Nation Law Enforcement officer having personal knowledge of the charged violation. The complaint shall set forth the essential facts charging that named individual has violated the Code. Such action, including any appeal which is taken from the decision of the Peacemakers' Court, shall be governed by the Seneca Nation of Indians Peacemakers' Court and surrogate's court civil procedure rules.

(b) Any person found to have violated the Code shall pay a fine of:

(1) No more than $5000 and no less than $0 for a Section 8(a) violation, plus court costs.

(2) No more than $5000 and no less than $0 for a Section 8(b) violation, plus court costs.

(3) No more than $5000 and no less than $0 for a Section 8(c) violation, plus court costs.

(4) No more than $5000 and no less than $0 for a Section 8(d) violation, plus court costs.

In addition to the penalty described for such violation, all alcoholic beverages confiscated from any person found to have violated this Code shall be destroyed.

(c) In lieu of imposing a fine pursuant to subsection (b) above, the Peacemakers' Court may employ the procedure provided in section 4–102(a), (b) of the Seneca Nation of Indians Peacemakers' Court and surrogate's court civil procedure rules.

(d) Any person found to have violated this Code who is charged with a second subsequent violation may be referred to any other jurisdiction which the Peacemakers' Court determines has concurrent jurisdiction over the charge.

(e) In addition to other remedies, the Peacemakers' Court may enjoin any person in violation of this Code.

**Section 10—Licensing**

(1) License Requirements. No license shall be issued under this Code except upon a sworn application filed with the Nation Council, or its duly authorized designee, containing a full and complete showing of the following:

(a) Satisfactory proof that the applicant is duly licensed by the State of New York to sell alcoholic beverages.

(b) Satisfactory completion of a background investigation including but not limited to a determination that the applicant is of good character and reputation and that the applicant is financially responsible.

(c) The description and location of the premises in which the alcoholic beverages are to be sold and proof that the applicant is entitled to use such premises for such purposes for the duration of the time period of the license.

(d) Agreement by the applicant to accept and abide by all conditions of the license as established by the Nation Council.

(e) Payment of a fee established by the Nation Council.

(f) Satisfactory proof that neither the applicant, nor the applicant's spouse, nor any principal owner, officer, shareholder, or director of the applicant, has ever been convicted of a felony or a crime of moral turpitude as defined by the laws of the State of New York.

**Section 11—Processing Applications for Tribal Alcoholic Beverages License**

The Nation Council will consider the merits of applications for alcoholic beverages licenses based on the following factors:

(1) whether the requirements of Section 10 have been met; and

(2) whether granting the license is in the best interests of the Nation.

No member of the Nation Council shall be a part of the decision making process of an application submitted by a Nation Council member or any person in the immediate family of a Nation Council member.

**Section 12—Temporary Permits**

The Nation Council may grant a temporary permit for the sale of alcoholic beverages, in any form, for a period not to exceed 3 days to any persons applying for the same in connection with a tribal or community activity, provided that the conditions prescribed in Sections 8 of this Code shall be observed by the permittee. Each permit issued shall specify the types of alcoholic beverages to be sold, the time, date and location permitted. A fee, as set by the Nation Council, will be assessed on temporary permits.

**Section 13—Conditions of the Tribal License**

(1) Any license issued under this Code shall be subject to such reasonable conditions, as the Nation Council shall fix, including, but not limited to the following:

(a) The license shall be for a term not to exceed 2 years.

(b) The licensee shall at all times maintain an orderly, clean, and neat establishment, both inside and outside the licensed premises.

(c) The licensed premises shall be open to inspection by duly authorized tribal officials at all times during regular business hours.

(d) Alcoholic beverages shall be sold, served, disposed of, delivered or given to any person, and consumed on the licensed premises in conformity with the hours and days prescribed by the laws of the State, and in accordance with the hours fixed by the Nation Council.

(e) All acts and transactions under authority of a alcoholic beverages license shall be in conformity with State and Federal law, and shall be in accordance with this Code and any license issued pursuant to this Code.

(f) No person under the age permitted under the laws of the State (21 years) shall be sold, served, delivered, given, or allowed to consume alcoholic beverages.

(g) There shall be no discrimination in the operations under the license by reason of race, color, or creed.

**Section 14—License not a Property Right**

Notwithstanding any other provision of this Code, a alcoholic beverages license is a mere permit for a fixed duration of time. An alcoholic beverages license shall not be deemed a property right or vested right of any kind, nor shall the granting of a alcoholic beverages license give rise to a presumption of legal entitlement to the granting of such license for a subsequent time period.

**Section 15—Assignment or Transfer**

No license issued under this Code shall be assigned or transferred without the written approval of the Nation Council expressed in a formal resolution.

**Section 16—Inspection Rights**

The premises upon which alcoholic beverages is sold or distributed shall be open to inspection by the Nation Council or its authorized designee during all hours of operation for the purposes of ascertaining compliance with this Code.

**Section 17—Sovereign Immunity Preserved**

Nothing in this Code is intended nor shall be construed as a waiver of sovereign immunity by the Nation. No officer, manager or employee of any Nation Enterprise shall be authorized nor shall attempt to waive the sovereign immunity of the Nation.

**Section 18—Disclaimer**

Nothing in this Code shall be construed to authorize or require the criminal trial and punishment of non-Indians by the Nation except to the extent allowed by an applicable present or future Act of Congress or any applicable laws.

**Section 19—Regulations**

The Nation Council shall have the exclusive authority to adopt and enforce the rules and regulations to implement this Code on the Seneca Nation Territory and to further the purposes of this Code. Such rules and regulations shall have the force of law upon promulgation by Nation Council Resolution.

**Section 20—Severability**

If any clause, part or section of this Code shall be adjudged as invalid, such judgment shall not affect or invalidate the remainder of the ordinance but shall be confined in its operation to the clause, part or section directly involved in the controversy in which such judgment was rendered.

**Section 21—Effective Date**

This Code shall be effective upon the date that the Secretary of Interior certifies this Code and it is published in the **Federal Register**.

**Section 22—Duration**

The duration of this Code shall be perpetual until repealed or amended by Nation Council Resolution.

[FR Doc. 04–17856 Filed 8–4–04; 8:45 am]

BILLING CODE 4310–4J–P

## DEPARTMENT OF THE INTERIOR

### Bureau of Indian Affairs

### Indian Gaming

**AGENCY:** Bureau of Indian Affairs, Interior.

**ACTION:** Notice of approved Tribal—State Compact.

**SUMMARY:** This notice publishes an approved Class III Gaming Compact between the Mescalero Apache Tribe and the State of New Mexico. Under the Indian Gaming Regulatory Act of 1988, the Secretary of the Interior is required to publish notice in the **Federal Register** approved Tribal-State compacts for the purpose of engaging in Class III gaming activities on Indian lands.

**EFFECTIVE DATE:** August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** George T. Skibine, Director, Office of Indian Gaming Management, Office of the Deputy Assistant Secretary—Policy and Economic Development, Washington, DC 20240, (202) 219–4066.

**SUPPLEMENTARY INFORMATION:** Under Section 11 of the Indian Gaming Regulatory Act of 1988 (IGRA) Public Law 100–497, 25 U.S.C. 2710, the Secretary of the Interior shall publish in the **Federal Register** notice of approved Tribal—State compacts for the purpose of engaging in Class III gaming activities on Indian lands.

The Principal Deputy Assistant Secretary—Indian Affairs, Department of the Interior, through her delegated authority, is publishing notice that the Tribal—State Compact between the Mescalero Apache Tribe and the State of New Mexico is now in effect.

Dated: July 22, 2004.

**Aurene M. Martin,**

*Principal Deputy Assistant Secretary—Indian Affairs.*

[FR Doc. 04–17882 Filed 8–4–04; 8:45 am]

BILLING CODE 4310–4N–P

## DEPARTMENT OF THE INTERIOR

### Bureau of Land Management

**[OR–957–00–1420–BJ: GP04–0231]**

### Filing of Plats of Survey: Oregon/Washington

**AGENCY:** Bureau of Land Management, Interior.

**ACTION:** Notice.

**SUMMARY:** The plats of survey of the following described lands were officially filed in the Oregon State Office, Portland, Oregon, on July 1, 2004.

**Willamette Meridian**

*Oregon*

T. 38 S., R. 4 W., accepted March 23, 2004
T. 20 S., R. 29 E., accepted March 23, 2004
T. 12 S., R. 3 E., accepted April 2, 2004
T. 1 N., R. 34 E., accepted April 2, 2004
T. 25 S., R. 5 W., accepted April 9, 2004
T. 30 S., R. 9 W., accepted May 6, 2004
T. 16 S., R. 6 W., accepted May 6, 2004

*Washington*

Tps. 21 & 22 N., R. 13 W., accepted March 23, 2004
T. 16 N., R. 20 E., accepted March 23, 2004
T. 22 N., R. 4 W., accepted April 9, 2004
T. 21 N., R. 4 W., accepted April 9, 2004

A copy of the plats may be obtained from the Public Room at the Oregon State Office, Bureau of Land Management, 333 SW. 1st Avenue, Portland, Oregon 97204, upon required payment. A person or party who wishes to protest against a survey must file a notice that they wish to protest. (at the above address) with the State Director, Bureau of Land Management, Portland, Oregon.

For further information contact: Chief, Branch of Geographic Sciences, Bureau of Land Management, (333 SW. 1st Avenue) P.O. Box 2965, Portland, Oregon 97208.

Dated: July 22, 2004.

**Sherrie L. Reid,**

*Acting Chief, Branch of Realty and Records Services.*

[FR Doc. 04–17845 Filed 8–4–04; 8:45 am]

**BILLING CODE 4310–33–P**

## INTERNATIONAL TRADE COMMISSION

**[Investigation No. 337–TA–516]**

## In the Matter of Certain Disc Drives, Components Thereof, and Products Containing Same; Notice of Investigation

**AGENCY:** U.S. International Trade Commission.

**ACTION:** Institution of investigation pursuant to 19 U.S.C. 1337.

**SUMMARY:** Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on July 2, 2004 under section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, on behalf of Seagate Technology, LLC. Letters supplementing the complaint were filed on July 21 and 26, 2004. The complaint, as supplemented, alleges violations of section 337 in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain disc drives, components thereof, and products containing same by reason of infringement of claims 1–4 of U.S. Patent No. 5,452,159, claims 1 and 5–7 of U.S. Patent No. 5,596,461, claims 1, 5–22, and 28–48 of U.S. Patent No. 5,600,506, claims 1, 6, 7 and 10–13 of U.S. Patent No. 6,146,754, claims 1–4, 15–17, and 19–22 of U.S. Patent No. 6,324,054, claims 5–7, 9, 11, 12, 14, and 15 of U.S. Patent No. 6,545,845, and claims 1, 2, 4–6, 9–15, and 17–20 of U.S. Patent No. 6,744,606. The complaint further alleges that there exists an industry in the United States as required by subsection (a)(2) of section 337.

The complainant requests that the Commission institute an investigation and, after the investigation, issue a permanent exclusion order and a permanent cease and desist order.

**ADDRESSES:** The complaint and supplemental letters, except for any confidential information contained therein, are available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street, SW., Room 112, Washington, DC 20436, telephone (202) 205–2000. Hearing-impaired individuals are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at (202) 205–2000. General information concerning the Commission may also be obtained by accessing its internet server at *http://www.usitc.gov*. The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at *http://edis.usitc.gov*.

**FOR FURTHER INFORMATION CONTACT:** Thomas S. Fusco, Esq., Office of Unfair Import Investigations, U.S. International Trade Commission, telephone (202) 205–2571.

**Authority:** The authority for institution of this investigation is contained in section 337 of the Tariff Act of 1930, as amended, and in section 210.10 of the Commission's Rules of Practice and Procedure, 19 CFR 210.10 (2004).

*Scope of Investigation:* Having considered the complaint, the U.S. International Trade Commission, on July 29, 2004 *ordered that*—

(1) Pursuant to subsection (b) of section 337 of the Tariff Act of 1930, as amended, an investigation be instituted to determine whether there is a violation of subsection (a)(1)(B) of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain disc drives, components thereof, or products containing same by reason of infringement of one or more of claims 1–4 of U.S. Patent No. 5,452,159, claims 1 and 5–7 of U.S. Patent No. 5,596,461, claims 1, 5–22, and 28–48 of U.S. Patent No. 5,600,506, claims 1, 6, 7, and 10–13 of U.S. Patent No. 6,146,754, claims 1–4, 15–17, and 19–22 of U.S. Patent No. 6,324,054, claims 5–7, 9, 11, 12, 14, and 15 of U.S. Patent No. 6,545,845, and claims 1, 2, 4–6, 9–15, and 17–20 of U.S. Patent No. 6,744,606, and whether an industry in the United States exists as required by subsection (a)(2) of section 337.

(2) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served:

(a) The complainant is—Seagate Technology, LLC, 920 Disc Drive, Scotts Valley, California 95066.

(b) The respondent is the following company alleged to be in violation of Section 337 and upon which the complaint is to be served—Cornice, Inc., 1951 South Fordham Street, Suite 105, Longmont, Colorado 80503.

(c) Thomas S. Fusco, Office of Unfair Import Investigations, U.S. International Trade Commission, 500 E Street, SW., Room 401–E, Washington, DC 20436, who shall be the Commission investigative attorney, party to this investigation; and

(3) For the investigation so instituted, the Honorable Sidney Harris is designated as the presiding administrative law judge.

A response to the complaint and the notice of investigation must be submitted by the named respondent in accordance with § 210.13 of the Commission's Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(d) and 210.13(a), such response will be considered by the Commission if received no later than 20 days after the date of service by the Commission of the complaint and notice of investigation. Extensions of time for submitting a response to the complaint will not be granted unless good cause therefor is shown.

Failure of the respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter both an initial

determination and a final determination containing such findings, and may result in the issuance of a limited exclusion order or a cease and desist order or both directed against the respondent.

Issued: August 2, 2004.

By order of the Commission.

**Marilyn R. Abbott,**

*Secretary to the Commission.*

[FR Doc. 04–17899 Filed 8–4–04; 8:45 am]

**BILLING CODE 7020–02–P**

## INTERNATIONAL TRADE COMMISSION

**[Investigations Nos. 701–TA–414 and 731–TA–928 (Section 129 Consistency Determination)]**

### Softwood Lumber From Canada

**AGENCY:** United States International Trade Commission.

**ACTION:** Institution of a proceeding under section 129(a)(4) of the Uruguay Round Agreements Act (URAA) (19 U.S.C. 3538(a)(4)).

**SUMMARY:** The Commission hereby gives notice that it has instituted this proceeding following receipt on July 27, 2004, of a request from the United States Trade Representative (USTR) for a determination under section 129(a)(4) of the URAA that would render the Commission's action in connection with Investigations Nos. 701–TA–414 and 731–TA–928 not inconsistent with the findings of the dispute settlement panel of the World Trade Organization (WTO) in its report entitled, ''United States—Investigation of the International Trade Commission in Softwood Lumber From Canada,'' WT/DS277/R. A schedule for this proceeding will be established and announced at a later date. For further information concerning the conduct of this proceeding and rules of general application, consult the Commission's Rules of Practice and Procedure, part 201, subparts A through E (19 CFR part 201), and part 207, subpart A (19 CFR part 207).

**EFFECTIVE DATE:** August 5, 2004.

**FOR FURTHER INFORMATION CONTACT:** Jim McClure (202–205–3191), Office of Investigations, or Robin L. Turner (202–205–3103), Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436. Hearing-impaired persons can obtain information on this matter by contacting the Commission's TDD terminal on 202–205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its Internet server (*http://www.usitc.gov*). The public record of investigations Nos. 701–TA–414 and 731–TA–928 may be viewed on the Commission's electronic docket (EDIS) at *http://edis.usitc.gov.*

**SUPPLEMENTARY INFORMATION:** *Background.* On May 16, 2002, the Commission determined that an industry in the United States is threatened with material injury by reason of imports from Canada of softwood lumber found to be subsidized and sold in the United States at less than fair value (LTFV) (investigations Nos. 701–TA–414 and 731–TA–928, *Softwood Lumber from Canada,* USITC Pub. 3509 (May 2002). The Government of Canada subsequently requested review under the WTO *Understanding on Rules and Procedures Governing the Settlement of Disputes.* A WTO dispute settlement panel issued its final report, and found, inter alia, that action by the Commission in connection with its *Softwood Lumber* investigations under Title VII of the Tariff Act of 1930, ITC Investigations Nos. 701–TA–414 and 731–TA–928, is not in conformity with the obligations of the United States under the WTO *Agreement on Implementation of Article VI of the General Agreement on Tariffs and Trade 1994* and the WTO *Agreement on Subsidies and Countervailing Measures.* The panel's findings in this regard are set out in paragraphs 7.87 to 7.96 and 7.122 of the panel report. Its conclusions based on these findings are set out in paragraphs 8.1 and 8.2 of the report. The panel report was adopted by the WTO Dispute Settlement Body on April 26, 2004. The USTR transmitted his request for this determination following receipt from the Commission on July 14, 2004, of an advisory report under section 129(a)(1) stating that the Commission has concluded that Title VII of the Tariff Act of 1930 permits it to take steps in connection with its action in *Softwood Lumber from Canada,* Investigations Nos. 701–TA–414 and 731–TA–928, that would render its action in that proceeding not inconsistent with the findings of the dispute settlement panel.

*Participation in the investigation and public service list.* Only those persons who were interested parties to the original investigations (*i.e.*, persons listed on the Commission Secretary's service list) may participate in this proceeding. Such persons wishing to participate in this proceeding as parties must file an entry of appearance with the Secretary to the Commission, as provided in § 201.11 of the Commission's rules, no later than 21 days after publication of this notice in the **Federal Register**. The Secretary will maintain a public service list containing the names and addresses of all persons, or their representatives, who are parties to this proceeding.

*Limited disclosure of business proprietary information (BPI) under an administrative protective order (APO) and APO service list.* Pursuant to § 207.7(a) of the Commission's rules, the Secretary will make BPI submitted in this proceeding available to authorized applicants under the APO issued in this proceeding, provided that the application is made no later than 21 days after publication of this notice in the **Federal Register**. Authorized applicants must represent interested parties, as defined in 19 U.S.C. 1677(9), who are parties to this proceeding. Parties that received BPI under the APO in the original investigations that are also subject to the APO in the related NAFTA proceeding must file a new application to receive any information obtained and released during this proceeding. Pursuant to § 207.7(a) of the Commission's rules, the Secretary will make BPI gathered in the original investigations and in this proceeding available to additional authorized applicants, that are not subject to the APO in the related NAFTA proceeding (*i.e.*, returned or destroyed all BPI received under the APO in the original investigations) or not covered under the original APO, provided that an application is made in this proceeding. A separate service list will be maintained by the Secretary for those parties authorized to receive BPI under the APO.

Issued: July 30, 2004.

By order of the Commission.

**Marilyn R. Abbott,**

*Secretary to the Commission.*

[FR Doc. 04–17865 Filed 8–4–04; 8:45 am]

**BILLING CODE 7020–02–P**

## DEPARTMENT OF JUSTICE

### Notice of Lodging Proposed Consent Decree

In accordance with Departmental Policy, 28 CFR 50.7, notice is hereby given that a proposed consent decree in *United States and the State of Illinois* v. *Embassy Builders, Inc. and Randall Stevenson,* Case No. 03 C 6723, was lodged with the United States District Court for the Northern District of Illinois

on July 22, 2004. This proposed Consent Decree concerns a complaint filed by the United States against the Defendants pursuant to section 301(a) of the Clean Water Act (''CWA''), 33 U.S.C. 1311(a), to obtain injunctive relief from and impose civil penalties against the Defendants for filing wetlands on their property without a permit.

The proposed Consent Decree requires the defendants to pay $106,250 to a wetland restoration fund as mitigation for the wetlands that were filled without a U.S. Army Corps of Engineers permit. The Consent Decree also requires payment of a civil penalty.

The Department of Justice will accept written comments relating to this proposed Consent Decree for thirty (30) days from the date of publication of this notice. Please address comments to Kurt Lindland, Assistant United States Attorney, United States Attorney's Office, 5th Floor, 219 S. Dearborn Street, Chicago, Illinois 60604 and refer to *United States and the State of Illinois* v. *Embassy Builders, Inc. and Randall Stevenson,* Case No. 03 C 6723, including the USAO # 2003V01248.

The proposed Consent Decree may be examined at the Clerk's Office, United States District Court for the Northern District of Illinois, 219 S. Dearborn Street, Chicago, Illinois. In addition, the proposed Consent Decree may be viewed on the World Wide Web at *http://www.usdoj.gov/enrd/open.html.*

**Kurt N. Lindland,**

*Assistant United States Attorney.*

[FR Doc. 04–17833 Filed 8–4–04; 8:45 am]

**BILLING CODE 4410–15–M**

## DEPARTMENT OF JUSTICE

### Notice of Lodging Proposed Consent Decree

In accordance with Departmental Policy, 28 CFR 50.7, notice is hereby given that a proposed Consent Decree in *United States* v. *Peter Thorson, et al.*, Case No. 03–C–0074–C (W.D. Wisc.) was lodged with the United States District Court for the Western District of Wisconsin on July 27, 2004.

This proposed Consent Decree concerns a complaint filed by the United States against Peter Thorson, Managed Investments, Inc., and Construction Management, Inc., and Gerke Excavating, Inc., pursuant to sections 301 and 404 of the Clean Water Act, to obtain injunctive relief from and impose civil penalties against the Defendants for violating the Clean Water Act by discharging pollutants without a permit into waters of the United States. The proposed Consent Decree resolves the allegations against Peter Thorson, Managed Investments, Inc., and Construction Management, Inc. by requiring these Defendants to restore the impacted areas and to pay a civil penalty.

The Department of Justice will accept written comments relating to this proposed Consent Decree for thirty (30) days from the date of publication of this Notice. Please address comments to Leslie K. Herje, Assistant U.S. Attorney, PO Box 1585, Madison, Wisconsin 53701–1585 and refer to *United States* v. *Peter Thorson, et al.*, Case No. 03–C–0074–C.

The proposed Consent Decree may be examined at the Clerk's Office, United States District Court for the Western District of Wisconsin, 120 North Henry Street, Room 320, Madison, Wisconsin 53701–0432. In addition, the proposed Consent Decree may be viewed at *http://www.usdoj.gov/enrd/open.html.*

**Leslie K. Herje,**

*Assistant United States Attorney, Chief, Civil Division, Madison, Wisconsin.*

[FR Doc. 04–17832 Filed 8–4–04; 8:45 am]

**BILLING CODE 4410–15–M**

## DEPARTMENT OF JUSTICE

### Notice of Lodging of Consent Decree Under the Clean Air Act

Under 28 CFR 50.7, notice is hereby given that on July 22, 2004, a proposed consent decree (''consent decree'') in *United States* v. *Weyerhaeuser Company*, Civil Action No. 04–211 Erie, was lodged with the United States District Court for the Western District of Pennsylvania. This consent decree resolves claims against Weyerhaeuser Company for violations of the Clean Air Act.

In this action the United States sought penalties and injunctive relief for: Failure to obtain a prevention of significant deterioration permit for two power boilers, as required by the Pennsylvania State Implementation Plan; failure to obtain an operating permit including best available control technology (BACT), as required by the state implementation plan; and failure to comply with federal new source performance standards.

Under the terms of the consent decree, Weyerhaeuser agrees to install wet gas scrubbers to control sulfur dioxide emissions, to operate them in accordance with the terms in the consent decree and to pay a civil penalty of $900,000 ($675,000 to the United States and $225,000 to Pennsylvania).

The Department of Justice will receive for a period of thirty (30) days from the date of this publication comments relating to the consent decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, P.O. Box 7611, U.S. Department of Justice, Washington, D.C. 20044–7611, and should refer to *United States* v. *Weyerhaeuser Company*, Civil Action No. 04–211 Erie, D.J. Ref. 90–5–2–1–2186/1.

The consent decree may be examined at the Office of the United States Attorney, 700 Grant Street, Suite 400 Pittsburgh, PA 15219, and at U.S. EPA Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103–2029. A copy of the consent decree may also be examined on the following Department of Justice Web site, *http://www.usdoj.gov/enrd/open.html.* A copy of the consent decree may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611 or by faxing or e-mailing a request to Tonia Fleetwood (*tonia.fleetwood@usdoj.gov*), fax no. (202) 514–0097, phone confirmation number (202) 514–1547. In requesting a copy of the consent decree, please enclose a check in the amount of $7.00 (25 cents per page reproduction cost) payable to the U.S. Treasury.

**Robert Brook,**

*Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.*

[FR Doc. 04–17834 Filed 8–4–04; 8:45 am]

**BILLING CODE 4410–15–M**

## DEPARTMENT OF JUSTICE

### Bureau of Alcohol, Tobacco, Firearms, and Explosives

### Agency Information Collection Activities: Proposed Collection; Comments Requested

**ACTION:** 30-Day notice of information collection under review: Extension of a Currently Approved Collection Request for Disposition of Offense

The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed

information collection was previously published in the **Federal Register** Volume 69, Number 88, on page 25415 on May 6, 2004, allowing for a 60-day comment period.

The purpose of this notice is to allow for an additional 30 days for public comment until September 7, 2004. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to The Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted to OMB via facsimile to (202) 395–5806.

Request written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

(1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.*, permitting electronic submission of responses.

**Overview of This Information Collection**

(1) *Type of Information Collection:* Extension of a currently approved collection.

(2) *Title of the Form/Collection:* Request for Disposition of Offense.

(3) *Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:* Form Number: ATF F 5020.29. Bureau of Alcohol, Tobacco, Firearms and Explosives.

(4) *Affected public who will be asked or required to respond, as well as a brief abstract:* Primary: Individuals or households. Other: Business or other for-profit. Abstract: The form is used if an applicant applies for a license or permit and has an arrest record charged with a violation of Federal or State law and there is no record present of the disposition of the case(s), ATF F 5020.29 is sent to the custodian of records to ascertain the disposition of case.

(5) *An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* There will be an estimated 50 respondents, who will complete the form within approximately 30 minutes.

(6) *An estimate of the total burden (in hours) associated with the collection:* There are an estimated 25 total burden hours associated with this collection.

If additional information is required contact: Brenda E. Dyer, Clearance Officer, United States Department of Justice, Policy and Planning Staff, Justice Management Division, Suite 1600, Patrick Henry Building, 601 D Street, NW., Washington 20530.

Dated: July 30, 2004.

**Brenda E. Dyer,**

*Clearance Officer, United States Department of Justice.*

[FR Doc. 04–17837 Filed 8–4–04; 8:45 am]

**BILLING CODE 4410–FY–M**

---

## DEPARTMENT OF JUSTICE

### Bureau of Alcohol, Tobacco, Firearms, and Explosives

### Agency Information Collection Activities: Proposed Collection; Comments Requested

**ACTION:** 30-Day Notice of Information Collection Under Review: Application for Tax-Exempt Transfer of Firearm and Registration to Special Occupational Taxpayer.

The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the **Federal Register** Volume 69, Number 101, on page 29755 on May 25, 2004, allowing for a 60 day comment period.

The purpose of this notice is to allow for an additional 30 days for public comment until September 7, 2004. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to The Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted to OMB via facsimile to (202) 395–5806.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

—Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

—Enhance the quality, utility, and clarity of the information to be collected; and

—Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.*, permitting electronic submission of responses.

**Overview of This Information Collection**

(1) *Type of Information Collection:* Extension of a currently approved collection.

(2) *Title of the Form/Collection:* Application for Tax-Exempt Transfer of Firearm and Registration to Special Occupational Taxpayer.

(3) *Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection: Form Number:* ATF F 3 (5320.3). Bureau of Alcohol, Tobacco, Firearms and Explosives.

(4) *Affected public who will be asked or required to respond, as well as a brief abstract:* Primary: Business or other for-profit. Other: none. Abstract: The form is submitted and approved by ATF prior to the transfer of a National Firearms Act weapon from one Special Occupational tax paying Federal firearms licensee to another special

taxpaying licensee. The form is required whenever such a transfer is to be made.

(5) *An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* There will be an estimated 2,521 respondents, who will complete the form within approximately 30 minutes.

(6) *An estimate of the total burden (in hours) associated with the collection:* There are an estimated 11,850 total burden hours associated with this collection.

If additional information is required contact: Brenda E. Dyer, Clearance Officer, United States Department of Justice, Policy and Planning Staff, Justice Management Division, Suite 1600, Patrick Henry Building, 601 D Street NW., Washington, DC 20530.

Dated: July 29, 2004.

**Brenda E. Dyer,**

*Clearance Officer, Department of Justice.*

[FR Doc. 04–17838 Filed 8–4–04; 8:45 am]

BILLING CODE 4410–FY–P

## DEPARTMENT OF JUSTICE

### Bureau of Alcohol, Tobacco, Firearms, and Explosives

### Agency Information Collection Activities: Proposed Collection; Comments Requested

**ACTION:** 30-Day Notice of Information Collection Under Review: Application for an Amended Federal Firearms License.

The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the **Federal Register** Volume 69, Number 102, on page 29978 on May 26, 2004, allowing for a 60-day comment period.

The purpose of this notice is to allow for an additional 30 days for public comment until September 7, 2004. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted to OMB via facsimile to (202) 395–5806.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

—Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

—Enhance the quality, utility, and clarity of the information to be collected; and

—Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.*, permitting electronic submission of responses.

Overview of this Information Collection

(1) *Type of Information Collection:* Extension of a currently approved collection.

(2) *Title of the Form/Collection:* Application for an Amended Federal Firearms License.

(3) *Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:* Form Number: ATF F 5300.38. Bureau of Alcohol, Tobacco, Firearms and Explosives.

(4) *Affected public who will be asked or required to respond, as well as a brief abstract:* Primary: Business or other for-profit. Other: Individual or households. Abstract: The form is used when a Federal firearms license makes application to change the location of the firearms business premises. The applicant must certify that the proposed new business premises will be in compliance with State and local law for that location.

(5) *An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* There will be an estimated 18,000 respondents, who will complete the form within approximately 1 hour and 15 minutes.

(6) *An estimate of the total burden (in hours) associated with the collection:* There are an estimated 22,500 total burden hours associated with this collection.

If additional information is required contact: Brenda E. Dyer, Clearance Officer, United States Department of Justice, Policy and Planning Staff, Justice Management Division, Suite 1600, Patrick Henry Building, 601 D Street NW., Washington, DC 20530.

Dated: July 30, 2004.

**Brenda E. Dyer,**

*Clearance Officer, Department of Justice.*

[FR Doc. 04–17839 Filed 8–4–04; 8:45 am]

BILLING CODE 4410–FY–P

## DEPARTMENT OF JUSTICE

### Bureau of Alcohol, Tobacco, Firearms, and Explosives

### Agency Information Collection Activities: Proposed Collection; Comments Requested

**ACTION:** 30-day notice of information collection under review: Implementation of Pub. L. 103–322, the Violent Crime Control and Law Enforcement Act of 1994.

The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the **Federal Register** volume 69, number 90, on page 25922 on May 10, 2004, allowing for a 60 day comment period.

The purpose of this notice is to allow for an additional 30 days for public comment until September 7, 2004. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted to OMB via facsimile to (202) 395–5806.

Written comments and suggestions from the public and affected agencies

concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility,

—Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used,

—Enhance the quality, utility, and clarity of the information to be collected, and

—Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.*, permitting electronic submission of responses.

Overview of this Information Collection

(1) *Type of Information Collection:* Extension of a currently approved collection.

(2) *Title of the Form/Collection:* Implementation of Pub. L. 103–322, The Violent Crime Control and Law Enforcement Act of 1994.

(3) *Agency Form Number, if Any, and the Applicable Component of the Department of Justice Sponsoring the Collection: Form Number:* None. Bureau of Alcohol, Tobacco, Firearms and Explosives.

(4) *Affected Public Who Will Be Asked or Required to Respond, as well as a Brief Abstract: Primary:* Business or other for-profit. *Other:* none. Abstract: The Violent Crime Control and Law Enforcement Act of 1994 restricts the manufacture, transfer, and possession of certain semiautomatic assault weapons and large capacity ammunition feeding devices. Federal firearms licensees may transfer these weapons to law enforcement agencies and law enforcement officers with proper documentation. This documentation is necessary for ATF to ensure compliance with the law and to prevent the introduction of semiautomatic assault weapons into commercial channels.

(5) *An Estimate of the Total Number of Respondents and the Amount of Time Estimated for an Average Respondent To Respond:* It is estimated that 2,107,000 respondents will provide the necessary documentation and maintain records for a total of 2 hours and 50 minutes.

(6) *An Estimate of the Total Burden (in Hours) Associated with the Collection:* There are an estimated 458,940 total burden hours associated with this collection.

**FOR FURTHER INFORMATION CONTACT:** Brenda E. Dyer, Clearance Officer, United States Department of Justice, Policy and Planning Staff, Justice Management Division, Suite 1600, Patrick Henry Building, 601 D Street, NW., Washington, DC 20530.

Dated: July 30, 2004.

**Brenda E. Dyer,**

*Clearance Officer, United States Department of Justice.*

[FR Doc. 04–17840 Filed 8–4–04; 8:45 am]

**BILLING CODE 4410–FY–P**

## LEGAL SERVICES CORPORATION

### Sunshine Act Meeting of the Board of Directors

**TIME AND DATE:** The Board of Directors of the Legal Services Corporation will meet August 12, 2004, from 9 a.m., until conclusion of the Board's agenda.

**LOCATION:** The Melrose Hotel, 2430 Pennsylvania Avenue, NW., Washington, DC 20037.

**STATUS OF MEETING:** Closed. The meeting will be closed pursuant to a vote of the Board of Directors to hold an executive session. At the closed session, the Board will interview finalists for the position of Inspector General of the Legal Services Corporation and consider the qualifications of these individuals, options available for compensating the Inspector General as well as further steps to be taken in connection with the selection and hiring of that individual. The closing is authorized by 5 U.S.C. 552b(c)(6) and LSC's corresponding regulation 45 CFR 1622.5(e). A copy of the General Counsel's Certification that the closing is authorized by law will be available upon request.

**MATTERS TO BE CONSIDERED:** Closed Session

1. Approval of agenda.
2. Interview finalists for the position of Inspector General.
3. Review and discuss qualifications of the finalists interviewed.
4. Consider and act on options available to compensate the Inspector General.
5. Consider and act on further steps to be taken in connection with the selection and hiring of an Inspector General.
6. Consider and act on adjournment of meeting.

**CONTACT PERSON FOR INFORMATION:** Patricia Batie, Manager of Board Operations, at (202) 295–1500.

*Special Needs:* Upon request, meeting notices will be made available in alternate formats to accommodate visual and hearing impairments. Individuals who have a disability and need an accommodation to attend the meeting may notify Patricia Batie, at (202) 295–1500.

Dated: August 3, 2004.

**Victor M. Fortuno,**

*Vice President for Legal Affairs, General Counsel & Corporate Secretary.*

[FR Doc. 04–18033 Filed 8–3–04; 1:45 pm]

**BILLING CODE 7050–01–P**

## NUCLEAR REGULATORY COMMISSION

**[Docket No. 50–382]**

### Entergy Operations, Inc., Waterford Steam Electric Station, Unit No. 3; Exemption

**1.0 Background**

Entergy Operations, Inc. (Entergy or the licensee) is the holder of Facility Operating License No. NPF–38 which authorizes operation of Waterford Steam Electric Station, Unit 3 (Waterford 3). The license provides, among other things, that the facility is subject to all rules, regulations, and orders of the U.S. Nuclear Regulatory Commission (NRC or the Commission) now or hereafter in effect. The facility consists of a pressurized water reactor located in St. Charles Parish, Louisiana.

**2.0 Request/Action**

Pursuant to title 10 of the Code of Federal Regulations (10 CFR) section 50.12, ''Specific Exemptions,'' Entergy, in a letter dated April 30, 2004, as supplemented by letter dated June 8, 2004, requested an exemption to 10 CFR 50.46, ''Acceptance Criteria for Emergency Core Cooling Systems for Light-Water Nuclear Power Reactors'', and Appendix K to 10 CFR part 50, ''ECCS Evaluation Models.'' The regulation in 10 CFR 50.46 contains acceptance criteria for the emergency core cooling system (ECCS) for reactors fueled with zircaloy or ZIRLO™ cladding. Appendix K to 10 CFR part 50 requires that the Baker-Just equation be used to predict the rates of energy release, hydrogen concentration, and cladding oxidation from the metal-water reaction. This exemption request relates solely to the specific types of cladding material specified in these regulations. As written, the regulations presume the use of zircaloy or ZIRLO™ fuel rod

cladding. Thus, an exemption from the requirements of 10 CFR 50.46 and Appendix K to 10 CFR part 50 is needed to irradiate lead test assemblies (LTAs) comprised of a developmental alloy (Optimized ZIRLO™) at Waterford 3.

## 3.0 Discussion

### *3.1 Material Evaluation*

#### 3.1.1 Fuel Mechanical Design

Tin is a solid solution strengthener and α-phase stabilizer present entirely in the base α-phase zirconium crystalline structure. Potential impacts of a reduced tin content on material properties include: (1) A reduced tensile strength; (2) an increased thermal creep rate; (3) an increased irradiation growth rate; (4) a reduced $\alpha \rightarrow \alpha+\beta$ phase transition temperature; and (5) an improved corrosion resistance. The stated reduction in tin content of Optimized ZIRLO™ will not affect the size, shape, or distribution of any second-phase or inter-metallic precipitates nor the overall microstructure of this developmental zirconium alloy. With a consistent microstructure, Optimized ZIRLO™ will exhibit many material characteristics similar to those of the licensed ZIRLO™.

In response to a Request for Additional Information (RAI), Entergy provided details of the planned post-irradiation examinations of the LTAs. Measured parameters include rod profilometry, rod wear, assembly and rod growth, assembly bow, grid cell dimensions, and oxide thickness. As a result of these post-irradiation examinations, any negative aspects of the low tin alloy's performance, including the potential impacts of a reduced tin content identified above, will be identified and resolved. Furthermore, significant deviations from model predictions will be reconciled.

The fuel rod burnup and fuel duty experienced by the LTAs in Waterford 3 will remain well within the operating experience base and applicable licensed limits for ZIRLO™.

Utilizing currently-approved fuel performance and fuel mechanical design models and methods, Entergy and Westinghouse Electric Corporation (Westinghouse) will perform cycle-specific reload evaluations to ensure that the LTAs satisfy design criteria.

Based upon LTA irradiation experience of similar low tin versions of ZIRLO™, expected performance due to similar material properties, and an extensive LTA post-irradiation examination program aimed at qualifying model predictions, the NRC staff finds the LTA mechanical design acceptable for Waterford 3.

#### 3.1.2 Core Physics and Safety Analysis

The Waterford 3 exemption request relates solely to the specific types of cladding material specified in the regulations. Due to similar material properties, any impact of Optimized ZIRLO™ on the safety analysis models and methods is expected to be minimal. Utilizing currently-approved core physics, core thermal-hydraulics, and non-loss-of-coolant accident (LOCA) safety analysis models and methods, Entergy and Westinghouse will perform cycle-specific reload evaluations to ensure that the LTAs satisfy design criteria.

Fuel management guidelines will require that LTAs be placed in non-limiting core locations. In response to an RAI, Entergy described how power-peaking margins would be used to ensure that LTAs will not be limiting.

Based upon the use of approved models and methods, expected material performance, and the placement of LTAs in non-limiting core locations, the NRC staff finds that the irradiation of up to four LTAs in Waterford 3 will not result in unsafe operation or violation of specified acceptable fuel design limits. Furthermore, in the event of a design-basis accident, these LTAs will not promote consequences beyond those currently analyzed. Based upon results of metal-water reaction tests and ring-compression tests, which ensure the applicability of ECCS models and acceptance criteria and the use of approved LOCA models to ensure that the LTAs satisfy 10 CFR 50.46 acceptance criteria, the NRC staff considers the LTAs acceptable for use at Waterford 3 as proposed by Entergy.

### *3.2 Regulatory Evaluation*

Pursuant to 10 CFR 50.12, the Commission may, upon application by any interested person or upon its own initiative, grant exemptions from the requirements of 10 CFR Part 50 if: (1) The exemptions are authorized by law, will not present an undue risk to public health or safety, and are consistent with the common defense and security; and (2) special circumstances are present.

#### 3.2.1 10 CFR 50.46

The underlying purpose of 10 CFR 50.46 is to establish acceptance criteria for ECCS performance. The applicability of the ECCS acceptance criteria has been demonstrated by Westinghouse. Ring-compression tests performed by Westinghouse on Optimized ZIRLO™ (documented in Appendix B of Addendum 1 to WCAP–12610–P–A) demonstrate an acceptable retention of ductility up to 10 CFR 50.46 limits of 2200 °F and 17 percent Equivalent Cladding Reacted.

Utilizing currently approved LOCA models and methods, Westinghouse will perform cycle-specific reload evaluations to ensure that the LTAs satisfy 10 CFR 50.46 acceptance criteria. Therefore, granting the proposed exemption will not defeat the underlying purpose of 10 CFR 50.46.

#### 3.2.2 10 CFR Part 50, Appendix K

Paragraph I.A.5 of Appendix K to 10 CFR part 50 states that the rates of energy, hydrogen concentration, and cladding oxidation from the metal-water reaction shall be calculated using the Baker-Just equation. Since the Baker-Just equation presumes the use of zircaloy clad fuel, strict application of the rule would not permit use of the equation for the LTA cladding for determining acceptable fuel performance. Metal-water reaction tests performed by Westinghouse on Optimized ZIRLO™ (documented in Appendix B of Addendum 1 to WCAP–12610–P–A) demonstrate conservative reaction rates relative to the Baker-Just equation. Therefore, granting the proposed exemption will not defeat the underlying purpose of Appendix K, Paragraph I.A.5.

#### 3.2.3 Special Circumstances

In summary, the NRC staff reviewed the licensee's request of proposed exemption to allow up to four LTAs containing fuel rods fabricated with Optimized ZIRLO™. Based on the NRC staff's evaluation, as set forth above, the NRC staff considers that granting the proposed exemption will not defeat the underlying purpose of 10 CFR 50.46 or Appendix K to 10 CFR Part 50. Accordingly, special circumstances, are present pursuant to 10 CFR 50.12(a)(2)(ii).

#### 3.2.4 Other Standards in 10 CFR 50.12

The staff examined the rest of the licensee's rationale to support the exemption request, and concluded that the use of Optimized ZIRLO™ would satisfy 10 CFR 50.12(a) as follows:

(1) The requested exemption is authorized by law:

No law precludes the activities covered by this exemption request. The Commission, based on technical reasons set forth in rulemaking records, specified the specific cladding materials identified in 10 CFR 50.46 and 10 CFR part 50, Appendix K. Cladding materials are not specified by statute.

(2) The requested exemption does not present an undue risk to the public

health and safety as stated by the licensee:

The LTA reload evaluation will ensure that these acceptance criteria [in the Commission's regulations] are met following the insertion of LTAs containing Optimized ZIRLO™ material. Fuel assemblies using Optimized ZIRLO™ cladding will be evaluated using NRC-approved analytical methods and plant specific models to address the changes in the cladding material properties. The safety analysis for Waterford 3 is supported by the applicable Technical Specifications. The Waterford 3 reload cores containing Optimized ZIRLO™ cladding are required to be operated in accordance with the operating limits specified in the Technical Specifications. The LTAs utilizing Optimized ZIRLO™ cladding will be placed in non-limiting core locations. Thus, the granting of this exemption request will not pose an undue risk to public health and safety.

The NRC staff has evaluated these considerations as set forth in Section 3.1 of this exemption. For the reasons set forth in that section, the NRC staff concludes that Optimized ZIRLO™ may be used as a cladding material for no more than four LTAs to be placed in non-limiting core locations during Waterford 3's next refueling outage, and that an exemption from the requirements of 10 CFR 50.46 and 10 CFR part 50, Appendix K does not pose an undue risk to the public health and safety.

(3) The requested exemption will not endanger the common defense and security:

The common defense and security are not affected and, therefore, not endangered by this exemption.

### 4.0 Conclusion

Accordingly, the Commission has determined that, pursuant to 10 CFR 50.12(a), the Exemption is authorized by law, will not present an undue risk to the public health and safety, and is consistent with the common defense and security. Also, special circumstances are present. Therefore, the Commission hereby grants Entergy an exemption from the requirements of 10 CFR 50.46 and 10 CFR part 50, Appendix K, to allow the use of Optimized ZIRLO™ as a cladding material in four LTAs in the capacity described in their April 30, 2004, submittal, as supplemented by letter dated June 8, 2004, up to a lead rod average burnup of 60,000 MWD/MTU.

Pursuant to 10 CFR 51.32, the Commission has determined that the granting of this exemption will not have a significant effect on the quality of the human environment (69 FR 31848 dated June 7, 2004).

This exemption is effective upon issuance.

Dated in Rockville, Maryland, this 28th day of July, 2004.

For the Nuclear Regulatory Commission.

**James E. Lyons,**

*Deputy Director, Division of Licensing Project Management, Office of Nuclear Reactor Regulation.*

[FR Doc. 04–17853 Filed 8–4–04; 8:45 am]

**BILLING CODE 7590–01–P**

---

## NUCLEAR REGULATORY COMMISSION

**[Docket No. 50–251]**

## Florida Power and Light Co.; Notice of Consideration of Issuance of Amendment to Facility Operating License, Proposed No Significant Hazards Consideration Determination, and Opportunity for a Hearing

The U.S. Nuclear Regulatory Commission (the Commission) is considering issuance of an amendment to Facility Operating License No. DPR–41, issued to Florida Power and Light (the licensee), for operation of the Turkey Point Unit 4 located in Miami-Dade County.

The proposed amendment would revise Technical Specifications (TSs) 3/4.1.3.1, 3/4.1.3.2 and 3/4.1.3.5 to allow the use of an alternate method of determining rod position for the control rod F–8 with the rod position indicator, until repairs can be conducted at the next outage which is scheduled for spring 2005.

The reason for the exigency is due to the unanticipated failure of the Turkey Point Unit 4 Analog Rod Position Indication for control rod F–8 in Shutdown Bank B, which was last declared inoperable on July 26, 2004, at 8:47 a.m. Additionally, there is a concern regarding excessive wear due to exercising the movable incore detectors every 8 hours (90 times per month) to comply with the compensatory actions required by the current Action Statement a. of TS 3.1.3.2.

Before issuance of the proposed license amendment, the Commission will have made findings required by the Atomic Energy Act of 1954, as amended (the Act) and the Commission's regulations.

Pursuant to 10 CFR 50.91(a)(6) for amendments to be granted under exigent circumstances, the NRC staff must determine that the amendment request involves no significant hazards consideration. Under the Commission's regulations in 10 CFR 50.92, this means that operation of the facility in accordance with the proposed amendment would not (1) involve a significant increase in the probability or consequences of an accident previously evaluated; or (2) create the possibility of a new or different kind of accident from any accident previously evaluated; or (3) involve a significant reduction in a margin of safety. As required by 10 CFR 50.91(a), the licensee has provided its analysis of the issue of no significant hazards consideration, which is presented below:

1. Will operation of the facility in accordance with this proposed change involve a significant increase in the probability or consequences of an accident previously evaluated?

No. The proposed change provides an alternative method for verifying rod position of one shutdown rod. The proposed change meets the intent of the current specification in that it ensures verification of position of the control rod once every eight (8) hours. The proposed change provides only an alternative method of monitoring shutdown rod position and does not change the assumption or results of any previously evaluated accident.

Therefore, operation of the facility in accordance with the proposed amendment would not involve a significant increase in the probability or consequences of an accident previously evaluated.

2. Will operation of the facility in accordance with this proposed change create the possibility of a new or different kind of accident from any accident previously evaluated?

No. As described above, the proposed change provides only an alternative method of determining the position of one shutdown rod. No new accident initiators are introduced by the proposed alternative manner of performing rod position verification. The proposed change does not affect the reactor protection system or the reactor control system. Hence, no new failure modes are created that would cause a new or different kind of accident from any accident previously evaluated.

Therefore, operation of the facility in accordance with the proposed amendments would not create the possibility of a new or different kind of accident from any previously evaluated.

3. Will operation of the facility in accordance with this proposed change involve a significant reduction in a margin of safety?

No. The bases of Specification 3.1.3.2 state that the operability of the rod position indicators is required to determine control rod positions and thereby ensure compliance with the control rod alignment and insertion limits. The proposed change does not alter the requirement to determine rod position but provides an alternative method for determining the position of the affected rod. As a result, the initial conditions of the accident analysis are preserved and the consequences of previously analyzed accidents are unaffected.

Therefore, operation of the facility in accordance with the proposed amendments

would not involve a significant reduction in the margin of safety.

The NRC staff has reviewed the licensee's analysis and, based on this review, it appears that the three standards of 10 CFR 50.92(c) are satisfied. Therefore, the NRC staff proposes to determine that the amendment request involves no significant hazards consideration.

The Commission is seeking public comments on this proposed determination. Any comments received within 14 days after the date of publication of this notice will be considered in making any final determination.

Normally, the Commission will not issue the amendment until the expiration of the 14-day notice period. However, should circumstances change during the notice period, such that failure to act in a timely way would result, for example, in derating or shutdown of the facility, the Commission may issue the license amendment before the expiration of the 14-day notice period, provided that its final determination is that the amendment involves no significant hazards consideration. The final determination will consider all public and State comments received. Should the Commission take this action, it will publish in the **Federal Register** a notice of issuance. The Commission expects that the need to take this action will occur very infrequently.

Written comments may be submitted by mail to the Chief, Rules and Directives Branch, Division of Administrative Services, Office of Administration, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001, and should cite the publication date and page number of this **Federal Register** notice. Written comments may also be delivered to Room 6D59, Two White Flint North, 11545 Rockville Pike, Rockville, Maryland, from 7:30 a.m. to 4:15 p.m. Federal workdays. Documents may be examined, and/or copied for a fee, at the NRC's Public Document Room, located at One White Flint North, 11555 Rockville Pike (first floor), Rockville, Maryland.

The filing of requests for hearing and petitions for leave to intervene is discussed below.

Within 60 days after the date of publication of this notice, the licensee may file a request for a hearing with respect to issuance of the amendment to the subject facility operating license and any person whose interest may be affected by this proceeding and who wishes to participate as a party in the proceeding must file a written request for a hearing and a petition for leave to intervene. Requests for a hearing and a petition for leave to intervene shall be filed in accordance with the Commission's ''Rules of Practice for Domestic Licensing Proceedings'' in 10 CFR part 2. Interested persons should consult a current copy of 10 CFR 2.309, which is available at the Commission's PDR, located at One White Flint North, Public File Area 01F21, 11555 Rockville Pike (first floor), Rockville, Maryland. Publicly available records will be accessible from the Agencywide Documents Access and Management System's (ADAMS) Public Electronic Reading Room on the Internet at the NRC Web site, *http://www.nrc.gov/reading-rm/doc-collections/cfr/*. If a request for a hearing or petition for leave to intervene is filed by the above date, the Commission or a presiding officer designated by the Commission or by the Chief Administrative Judge of the Atomic Safety and Licensing Board Panel, will rule on the request and/or petition; and the Secretary or the Chief Administrative Judge of the Atomic Safety and Licensing Board will issue a notice of a hearing or an appropriate order.

As required by 10 CFR 2.309, a petition for leave to intervene shall set forth with particularity the interest of the petitioner in the proceeding, and how that interest may be affected by the results of the proceeding. The petition should specifically explain the reasons why intervention should be permitted with particular reference to the following general requirements: (1) The name, address and telephone number of the requestor or petitioner; (2) the nature of the requestor's/petitioner's right under the Act to be made a party to the proceeding; (3) the nature and extent of the requestor's/petitioner's property, financial, or other interest in the proceeding; and (4) the possible effect of any decision or order which may be entered in the proceeding on the requestor's/petitioner's interest. The petition must also identify the specific contentions which the petitioner/requestor seeks to have litigated at the proceeding.

Each contention must consist of a specific statement of the issue of law or fact to be raised or controverted. In addition, the petitioner/requestor shall provide a brief explanation of the bases for the contention and a concise statement of the alleged facts or expert opinion which support the contention and on which the petitioner intends to rely in proving the contention at the hearing. The petitioner/requestor must also provide references to those specific sources and documents of which the petitioner/requestor is aware and on which the petitioner/requestor intends to rely to establish those facts or expert opinion. The petitioner/requestor must provide sufficient information to show that a genuine dispute exists with the applicant on a material issue of law or fact. Contentions shall be limited to matters within the scope of the amendment under consideration. The contention must be one which, if proven, would entitle the petitioner/requestor to relief. A petitioner/requestor who fails to satisfy these requirements with respect to at least one contention will not be permitted to participate as a party.

Those permitted to intervene become parties to the proceeding, subject to any limitations in the order granting leave to intervene, and have the opportunity to participate fully in the conduct of the hearing.

If a hearing is requested, the Commission will make a final determination on the issue of no significant hazards consideration. The final determination will serve to decide when the hearing is held. If the final determination is that the amendment request involves no significant hazards consideration, the Commission may issue the amendment and make it immediately effective, notwithstanding the request for a hearing. Any hearing held would take place after issuance of the amendment. If the final determination is that the amendment request involves a significant hazards consideration, any hearing held would take place before the issuance of any amendment.

Nontimely requests and/or petitions and contentions will not be entertained absent a determination by the Commission or the presiding officer of the Atomic Safety and Licensing Board that the petition, request and/or the contentions should be granted based on a balancing of the factors specified in 10 CFR 2.309(a)(1)(i)–(viii).

A request for a hearing or a petition for leave to intervene must be filed by: (1) First class mail addressed to the Office of the Secretary of the Commission, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001, Attention: Rulemaking and Adjudications Staff; (2) courier, express mail, and expedited delivery services: Office of the Secretary, Sixteenth Floor, One White Flint North, 11555 Rockville Pike, Rockville, Maryland 20852, Attention: Rulemaking and Adjudications Staff; (3) e-mail addressed to the Office of the Secretary, U.S. Nuclear Regulatory Commission, *HEARINGDOCKET@NRC.GOV;* or (4) facsimile transmission addressed to the

Office of the Secretary, U.S. Nuclear Regulatory Commission, Washington, DC, Attention: Rulemakings and Adjudications Staff at (301) 415–1101, verification number is (301) 415–1966. A copy of the request for hearing and petition for leave to intervene should also be sent to the Office of the General Counsel, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001, and it is requested that copies be transmitted either by means of facsimile transmission to 301–415–3725 or by e-mail to *OGCMailCenter@nrc.gov.* A copy of the request for hearing and petition for leave to intervene should also be sent to M. S. Ross, Managing Attorney, Florida Power & Light Company, P.O. Box 14000, Juno Beach, FL 33408–0420, attorney for the licensee.

For further details with respect to this action, see the application for amendment dated July 28, 2004, which is available for public inspection at the Commission's Public Document Room (PDR), located at One White Flint North, Public File Area O1 F21, 11555 Rockville Pike (first floor), Rockville, Maryland. Publicly available records will be accessible electronically from the Agencywide Documents Access and Management System's (ADAMS) Public Electronic Reading Room on the Internet at the NRC Web site *http://www.nrc.gov/reading-rm/adams.html.* Persons who do not have access to ADAMS or who encounter problems in accessing the documents located in ADAMS, should contact the NRC PDR Reference staff by telephone at 1–800–397–4209, 301–415–4737, or by e-mail to *pdr@nrc.gov.*

Dated at Rockville, Maryland, this 30th day of July 2004.

For the Nuclear Regulatory Commission.

**Eva A. Brown,**

*Project Manager, Section 2, Project Directorate II, Division of Licensing Project Management, Office of Nuclear Reactor Regulation.*

[FR Doc. 04–17854 Filed 8–4–04; 8:45 am]

**BILLING CODE 7590–01–P**

---

## NUCLEAR REGULATORY COMMISSION

**[Docket No. 50–346]**

## FirstEnergy Nuclear Operating Company, Davis-Besse Nuclear Power Station, Environmental Assessment and Finding of No Significant Impact

The U.S. Nuclear Regulatory Commission (NRC) is considering amending an exemption from (1) Title 10 of the Code of Federal Regulations (10 CFR) part 50, Appendix K, section I.D.1, which requires that accident evaluations use the combination of emergency core cooling system (ECCS) subsystems assumed to be operative ''after the most damaging single failure of ECCS equipment has taken place;'' and (2) requirements of 50.46(a)(1)(ii), for Facility Operating License No. NPF–3, issued to FirstEnergy Nuclear Operating Company (FENOC or the licensee), for operation of the Davis-Besse Nuclear Power Station (DBNPS), located in Ottawa County, Ohio. Therefore, as required by 10 CFR 51.21, the NRC is issuing this environmental assessment and finding of no significant impact.

### Environmental Assessment

*Identification of the Proposed Action*

The original exemption issued on May 5, 2000, exempted the licensee from the single-failure requirement for the two systems for preventing boric acid precipitation during the long-term cooling phase following a loss-of-coolant accident (LOCA). Additionally, the action exempted the licensee from the calculation requirements of 50.46(b)(5) and Appendix K, section I.A.4 for the second or backup system for preventing boric acid precipitation. The proposed action would amend the existing exemption by approving a new system to prevent boric acid precipitation. This new system would become the primary system and the current primary system would become the backup system. The current backup system would no longer be credited as part of the licensing basis, although it would remain as a third option procedurally. As such, the part of the existing exemption related to the calculation requirements of 50.46(b)(5) and Appendix K, section I.A.4 would be removed from the exemption as it only applied to the current backup system and is no longer needed.

The proposed action is in accordance with the licensee's application dated February 13, 2004.

*The Need for the Proposed Action*

The proposed action provides a new active means of preventing boric acid precipitation within the reactor vessel core region following a LOCA. The new system has fewer vulnerabilities and meets calculation requirements without an exemption, unlike the system to be removed from the licensing basis.

*Environmental Impacts of the Proposed Action*

The NRC has completed its evaluation of the proposed action and concludes that the proposed amended exemption would continue to satisfy the underlying purpose of 10 CFR 50.46 and 10 CFR part 50, Appendix K. Additionally, the proposed action does not involve radioactive wastes, release of radioactive material into the atmosphere, solid radioactive waste, or liquid effluents released to the environment.

The DBNPS systems were evaluated in the Final Environmental Statement (FES) dated October 1975 (NUREG 75/097). The proposed amended exemption will not involve any change in the waste treatment systems described in the FES.

The proposed action will not significantly increase the probability or consequences of accidents. No changes are being made in the types of effluents that may be released off site. There is no significant increase in the amount of any effluent released off site. There is no significant increase in occupational or public radiation exposure. Therefore, there are no significant radiological environmental impacts associated with the proposed action.

With regard to potential non-radiological impacts, the proposed action does not have a potential to affect any historic sites. It does not affect non-radiological plant effluents and has no other environmental impact. Therefore, there are no significant non-radiological environmental impacts associated with the proposed action.

Accordingly, the NRC concludes that there are no significant environmental impacts associated with the proposed action.

*Environmental Impacts of the Alternatives to the Proposed Action*

As an alternative to the proposed action, the staff considered denial of the proposed action (*i.e.*, the ''no-action'' alternative). Denial of the application would result in no change in current environmental impacts. The environmental impacts of the proposed action and the alternative action are similar.

*Alternative Use of Resources*

The action does not involve the use of any different resources than those previously considered in the Final Environmental Statement for DBNPS, NUREG 75/097, dated October 1975.

*Agencies and Persons Consulted*

On May 25, 2004, the staff consulted with the Ohio State official, C. O'Claire of the Ohio Emergency Management Agency, regarding the environmental impact of the proposed action. The State official had no comments.

**Finding of No Significant Impact**

On the basis of the environmental assessment, the NRC concludes that the proposed action will not have a significant effect on the quality of the human environment. Accordingly, the NRC has determined not to prepare an environmental impact statement for the proposed action.

For further details with respect to the proposed action, see the licensee's letter dated February 13, 2004 (ADAMS ML040490242), and the existing exemption approved by NRC letter dated May 5, 2000 (ADAMS ML003712264). Documents may be examined, and/or copied for a fee, at the NRC's Public Document Room (PDR), located at One White Flint North, 11555 Rockville Pike (first floor), Rockville, Maryland. Publicly available records will be accessible electronically from the Agencywide Documents Access and Management System (ADAMS) Public Electronic Reading Room on the NRC Web site, *http://www.nrc.gov/reading-rm/adams.html.* Persons who do not have access to ADAMS or who encounter problems in accessing the documents located in ADAMS, should contact the NRC PDR Reference staff by telephone at 1–800–397–4209 or 301–415–4737, or send an e-mail to *pdr@nrc.gov.*

Dated in Rockville, Maryland, this 29th day of July, 2004.

For the Nuclear Regulatory Commission.

**Jon B. Hopkins,**

*Senior Project Manager, Project Directorate III, Section 2, Division of Licensing Project Management, Office of Nuclear Reactor Regulation.*

[FR Doc. 04–17852 Filed 8–4–04; 8:45 am]

**BILLING CODE 7590–01–P**

## SECURITIES AND EXCHANGE COMMISSION

**[Release No. IC–26522]**

## Notice of Applications for Deregistration Under Section 8(f) of the Investment Company Act of 1940

July 30, 2004.

The following is a notice of applications for deregistration under section 8(f) of the Investment Company Act of 1940 for the month of July, 2004. A copy of each application may be obtained for a fee at the SEC's Public Reference Branch, 450 Fifth St., NW., Washington, DC 20549–0102 (tel. 202–942–8090). An order granting each application will be issued unless the SEC orders a hearing. Interested persons may request a hearing on any application by writing to the SEC's Secretary at the address below and serving the relevant applicant with a copy of the request, personally or by mail. Hearing requests should be received by the SEC by 5:30 p.m. on August 24, 2004, and should be accompanied by proof of service on the applicant, in the form of an affidavit or, for lawyers, a certificate of service. Hearing requests should state the nature of the writer's interest, the reason for the request, and the issues contested. Persons who wish to be notified of a hearing may request notification by writing to the Secretary, SEC, 450 Fifth Street, NW., Washington, DC 20549–0609. For Further Information Contact: Diane L. Titus at (202) 942–0564, SEC, Division of Investment Management, Office of Investment Company Regulation, 450 Fifth Street, NW., Washington, DC 20549–0504.

**Morgan Stanley All-Star Growth Fund**

[File No. 811–10173]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On October 3, 2003, applicant transferred its assets to Morgan Stanley American Opportunities Fund, based on net asset value. Applicant incurred expenses of approximately $444,429 in connection with the reorganization.

*Filing Dates:* The application was filed on May 25, 2004 and amended on July 13, 2004.

*Applicant's Address:* Morgan Stanley Investment Advisors Inc., 1221 Avenue of the Americas, New York, NY 10020.

**Morgan Stanley Next Generation Trust**

[File No. 811–9441]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On December 19, 2003, applicant transferred its asset to Morgan Stanley Developing Growth Securities Trust, based on net asset value. Applicant incurred expenses of approximately $157,694 in connection with the reorganization.

*Filing Dates:* The application was filed on May 25, 2004, and amended on July 13, 2004.

*Applicant's Address:* Morgan Stanley Investment Advisors Inc., 1221 Avenue of the Americas, New York, NY 10020.

**Morgan Stanley High Income Advantage Trust, Morgan Stanley High Income Advantage Trust II, Morgan Stanley High Income Advantage Trust III**

[File No. 811–5337], [File No. 811–5612], [File No. 811–5700]

*Summary:* Each applicant, a closed-end investment company, seeks an order declaring that it has ceased to be an investment company. On December 13, 2002, each applicant transferred its assets to Morgan Stanley High Yield Securities Inc., based on net asset value. Applicants incurred expenses of approximately $148,108, $146,728 and $142,175, respectively, in connection with the reorganizations.

*Filing Dates:* The applications were filed on May 25, 2004 and amended on July 13, 2004.

*Applicants' Address:* Morgan Stanley Investment Advisors Inc., 1221 Avenue of the Americas, New York, NY 10020.

**Active Assets Premier Money Trust**

[File No. 811–9711]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On March 28, 2002, applicant made a liquidating distribution to its shareholders, based on net asset value. Applicant incurred expenses of approximately $20,000 in connection with the liquidation.

*Filing Dates:* The application was filed on May 25, 2004, and amended on July 13, 2004.

*Applicant's Address:* Morgan Stanley Investment Advisors Inc., 1221 Avenue of the Americas, New York, NY 10020.

**Iowa Schools Joint Investment Trust**

[File No. 811–7698]

*Summary:* Applicant is a common law trust organized and operated as a diversified, open-end management investment company that has two series. Applicant was established under Iowa law (the ''Iowa Code'') pursuant to Iowa Code chapter 28E and section 279.29, which authorize Iowa schools to jointly invest their funds pursuant to a joint investment agreement.

In 1993, applicant voluntarily registered under the Act. Applicant now states that it has experienced burdensome costs in operating in accordance with the requirements of the Act and seeks an order declaring that it has ceased to be an investment company. Applicant will rely on section 2(b) of the Act to remain exempt from the registration requirements of the Act. Applicant states that it is exempt under section 2(b) of the Act because it is an instrumentality of the State of Iowa.

*Filing Date:* The application was filed on July 12, 2004.

*Applicant's Address:* 665 Locust, PO Box 897, Des Moines, IA 50304–0897.

**Fidelity Capital Investment Plans, Fidelity Trend Investment Plans, Salem Investment PFAS Fidelity Magellan Fund**

[File No. 811–990], [File No. 811–1269], [File No. 811–1469]

*Summary:* Each applicant, a unit investment trust, seeks an order declaring that it has ceased to be an investment company. On May 20, 2003, each applicant made a liquidating distribution to its shareholders, based on net asset value. Applicants incurred no expenses in connection with the liquidations.

*Filing Dates:* The applications were filed on May 3, 2004, and amended on June 22, 2004.

*Applicants' Address:* 82 Devonshire St., Boston, MA 02109.

**The Kaufmann Fund, Inc.**

[File No. 811–1586]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On April 23, 2004, applicant transferred its assets to Federated Kaufmann Fund, a series of Federated Equity Funds, based on net asset value. Expenses of $2,339,411 incurred in connection with the reorganization were paid by Edgemont Asset Management Corporation, applicant's investment adviser, and Federated Equity Funds.

*Filing Dates:* The application was filed on April 13, 2004, and amended on July 6, 2004.

*Applicant's Address:* 140 East 45 St., 43rd Floor, New York, NY 10017.

**FBR Fund for Government Investors, FBR American Gas Index Fund, Inc., FBR Family of Funds**

[File No. 811–2539], [File No. 811–5702], [File No. 811–7665]

*Summary:* Each applicant seeks an order declaring that it has ceased to be an investment company. On February 27, 2004, each applicant transferred its assets to corresponding series of The FBR Funds, based on net asset value. Expenses of $47,158, $73,437 and $317,664, respectively, incurred in connection with the reorganizations were paid by FBR National Trust Company, applicants' administrator, and its affiliates.

*Filing Dates:* The applications were filed on June 2, 2004, and amended on July 1, 2004.

*Applicants' Address:* 1001 Nineteenth St. N., Arlington, VA 22209.

**Liberty Investment Grade Bond Fund (Formerly Colonial Investment Grade Interval Trust)**

[File No. 811–9701]

*Summary:* Applicant, a closed-end investment company, seeks an order declaring that it has ceased to be an investment company. On September 19, 2000, applicant made a liquidating distribution to its shareholders, based on net asset value. Applicant incurred no expenses in connection with the liquidation.

*Filing Dates:* The application was filed on April 12, 2004, and amended on June 24, 2004.

*Applicant's Address:* One Financial Center, Boston, MA 02111.

**Liberty Funds Trust IX (Formerly LAMCO Trust I)**

[File No. 811–9095]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On February 7, 2001, applicant transferred its assets to Liberty Growth & Income Fund, a series of Liberty Funds Trust VI, based on net asset value. Expenses of $49,368 incurred in connection with the reorganization were paid by applicant and Liberty Financial Companies, Inc., the parent company of applicant's investment adviser.

*Filing Dates:* The application was filed on April 12, 2004, and amended on June 24, 2004.

*Applicant's Address:* One Financial Center, Boston, MA 02111.

**Liberty Stein Roe Funds Institutional Trust (Formerly Stein Roe Institutional Trust)**

[File No. 811–7823]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On October 30, 1998, applicant made a liquidating distribution to its shareholders, based on net asset value. Applicant incurred no expenses in connection with the liquidation.

*Filing Dates:* The application was filed on April 12, 2004, and amended on June 24, 2004.

*Applicant's Address:* One Financial Center, Boston, MA 02111.

**Liberty Funds Trust VIII (Formerly LFC Utilities Trust)**

[File No. 811–6393]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On February 26, 1999, applicant made a liquidating distribution to its shareholders, based on net asset value. Applicant incurred no expenses in connection with the liquidation.

*Filing Dates:* The application was filed on April 12, 2004, and amended on June 24, 2004.

*Applicant's Address:* One Financial Center, Boston, MA 02111.

**D. L. Babson Tax-Free Income Fund, Inc., Babson Enterprise Fund, Inc., Babson Value Fund, Inc., Shadow Stock Fund, Inc., Babson Enterprise Fund II, Inc., Great Hall Investment Funds, Inc., RBC Funds, Inc., J&B Funds**

[File No. 811–2948], [File No. 811–3823], [File No. 811–4114], [File No. 811–5218], [File No. 811–6252], [File No. 811–6340], [File No. 811–8384], [File No. 811–10039]

*Summary:* Each applicant seeks an order declaring that it has ceased to be an investment company. On April 16, 2004, each applicant transferred its assets to a corresponding series of Tamarack Funds Trust, based on net asset value. Expenses of $35,931, $76,877, $92,948, $52,983, $43,697, $2,406,972, $227,223 and $94,837, respectively, incurred in connection with the reorganizations were paid by Voyageur Asset Management Inc., applicants' investment adviser.

*Filing Date:* The applications were filed on June 24, 2004.

*Applicants' Address:* 100 South Fifth St., Suite 2300, Minneapolis, MN 55402.

**D. L. Babson Money Market Fund, Inc.**

[File No. 811–2963]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On April 16, 2004, applicant transferred its assets to Great Hall Prime Money Market Fund, a series of Great Hall Investment Funds, Inc., based on net asset value. Expenses of $38,229 incurred in connection with the reorganization were paid by applicant's investment adviser, Voyageur Asset Management Inc.

*Filing Date:* The application was filed on June 24, 2004.

*Applicant's Address:* 100 South Fifth St., Suite 2300, Minneapolis, MN 55402.

**D. L. Babson Bond Trust, David L. Babson Growth Fund, Inc.**

[File No. 811–495], [File No. 811–901]

*Summary:* Each applicant seeks an order declaring that it has ceased to be an investment company. On April 16, 2004, each applicant transferred its assets to corresponding series of RBC Funds, Inc., based on net asset value. Expenses of $78,867 and $63,112, respectively, incurred in connection with the reorganizations were paid by Voyageur Asset Management Inc., applicants' investment adviser.

*Filing Date:* The applications were filed on June 24, 2004.

*Applicants' Address:* 100 South Fifth St., Suite 2300, Minneapolis, MN 55402.

**South Dakota Tax-Free Fund, Inc.**

[File No. 811–8124]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On June 25, 2004, applicant made a liquidating distribution to its shareholders, based on net asset value. Applicant incurred no expenses in connection with the liquidation.

*Filing Date:* The application was filed on July 19, 2004.

*Applicant's Address:* 1 Main St. N., Minot, ND 58703.

**UC Investment Trust**

[File No. 811–8701]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On April 30, 2004, applicant made a liquidating distribution to its shareholders, based on net asset value. Expenses of $53,136 incurred in connection with the liquidation were paid by applicant's investment adviser, United Management Company, LLC.

*Filing Date:* The application was filed on June 30, 2004.

*Applicant's Address:* 135 Merchant St., Suite 230, Cincinnati, OH 45246.

**PIC Growth Portfolio, PIC Small Cap Portfolio and PIC Mid Cap Portfolio**

[File No. 811–6496, File No. 811–8060, File No. 811–8593]

*Summary:* Each applicant seeks an order declaring that it has ceased to be an investment company. On December 22, 2003, each applicant made a liquidating distribution to its shareholders, based on net asset value. Applicants incurred no expenses in connection with the liquidations.

*Filing Date:* The applications were filed on July 13, 2004.

*Applicants' Address:* 300 N. Lake Ave., Pasadena, CA 91101.

**PIC Investment Trust**

[File No. 811–6498]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On December 22, 2003, applicant transferred its assets to Advisors Series Trust, based on net asset value. Applicant incurred no expenses in connection with the reorganization.

*Filing Date:* The application was filed on July 13, 2004.

*Applicant's Address:* 300 N. Lake Ave., Pasadena, CA 91101.

**UBS Redwood Fund, L.L.C.**

[File No. 811–10077]

*Summary:* Applicant, a closed-end investment company, seeks an order declaring that it has ceased to be an investment company. On June 22, 2004, applicant made a liquidating distribution to its shareholders, based on net asset value. Expenses of $43,900 incurred in connection with the liquidation were paid by PFPC Inc., applicant's administrator.

*Filing Date:* The application was filed on June 30, 2004.

*Applicant's Address:* c/o UBS Financial Services, Inc., 1285 Avenue of the Americas, New York, NY 10019.

**The Munder Funds, Inc.**

[File No. 811–7346]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On October 30, 2003, applicant transferred its assets to Munder Series Trust, based on net asset value. Expenses of $40,004 incurred in connection with the reorganization were paid by applicant.

*Filing Date:* The application was filed on June 23, 2004.

*Applicant's Address:* 480 Pierce St., Birmingham, MI 48009.

**The Bear Stearns Funds**

[File No. 811–8798]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On April 30, 2004, each series of applicant transferred its assets to a corresponding series of four investment companies managed by The Dreyfus Corporation, Dreyfus Premier Manager Funds I, Dreyfus Growth & Value Funds, Inc., The Dreyfus/Laurel Funds Trust and Dreyfus Premier Fixed Income Funds, based on net asset value. Expenses of $1,610,806 incurred in connection with the reorganization were paid by Bear Stearns Asset Management Inc., applicant's investment adviser, and The Dreyfus Corporation, investment adviser to the acquiring funds.

*Filing Date:* The application was filed on June 18, 2004.

*Applicant's Address:* 383 Madison Ave., New York, NY 10179.

**Select Asset Fund III**

[File No. 811–10081]

*Summary:* Applicant, a closed-end investment company, seeks an order declaring that it has ceased to be an investment company. On May 14, 2004, applicant made a liquidating distribution to its sole common shareholder, based on net asset value. Applicant's auction market preferred stock and floating rate notes were redeemed in accordance with their terms prior to the liquidation. Expenses of $14,309 incurred in connection with the liquidation were paid by applicant.

*Filing Date:* The application was filed on June 22, 2004.

*Applicant's Address:* c/o James A. McIntosh, President, 3945 Ridgmaar Sq., Ann Arbor, MI 48105.

**First Penn-Pacific Variable Life Insurance Separate Account**

[File No. 811–9827]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. Applicant abandoned its intention to operate before it received any assets. Applicant has never made a public offering of its securities and does not propose to make a public offering or engage in any business activity other than that necessary to wind up its affairs.

*Filing Dates:* The application was filed on March 11, 2002 and amended on June 30, 2004.

*Applicant's Address:* 1300 South Clinton Street, Fort Wayne, IN 46802.

**Pan-American Assurance Company Variable Life Separate Account**

[File No. 811–10295]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. Applicant requests deregistration based on abandonment of registration. At the time of filing, Applicant had no shareholders or contractholders.

*Filing Date:* The application was filed on June 7, 2004.

*Applicant's Address:* 601 Poydras Street, Suite 2600, New Orleans, LA 70130.

**LSA Variable Series Trust**

[File No. 811–9379]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. Shareholders approved the merger of applicant's fund on March 26, 2004, and applicant distributed its assets on April 30, 2004. The funds surviving the merger are AIM V.I. Basic Value Fund, a series of AIM Variable Insurance Funds, OPCAP Balanced Portfolio, a series of PIMCO Advisors VIT, Janus Aspen Capital Appreciation Portfolio, a series of Janus Aspen Series, Salomon Brothers Variable Investors Fund, a series of Salmon Brother Variable Series Inc., Aggressive Growth Portfolio, a series of Van Kampen Life Investment Trust, and UIF Equity Growth Portfolio and UIF U.S. Mid Cap Value Portfolio, series of The Universal Institutional Funds, Inc.

LSA Asset Management LLC (the Adviser to the fund), its affiliates, and the advisers of the acquiring funds (AIM Capital Management, Inc., OPCAP Advisers LLC, Morgan Stanley Asset Management, Inc. doing business as Van Kampen, Van Kampen Asset Management, Inc., Salomon Brothers Asset Management, Inc. and Janus Capital Management LLC) paid the $525,061 incurred in connection with the merger.

*Filing Date:* The application was filed on June 15, 2004.

*Applicant's Address:* 3100 Sanders Road, Northbrook, IL 60062.

**American United Life Pooled Equity Fund B**

[File No. 811–1571]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On March 31, 2004, Applicant made a distribution to its shareholders based on net asset value, and pro rata based on share ownership. AUL American Unit Trust is the name of the fund surviving the merger. American United Life Insurance Company paid the expenses incurred in connection with the merger, in the amount of $75,750.

*Filing Dates:* The application was filed on May 6, 2004, and amended on June 7, 2004.

*Applicant's Address:* One American Square, Indianapolis, IN 46282.

**AAL Variable Product Series Fund, Inc.**

[File No. 811–8662]

*Summary:* Applicant seeks an order declaring that it has ceased to be an investment company. On April 30, 2004, applicant made a liquidating distribution to its shareholders based on net asset value. Applicant incurred no expenses in connection with the liquidation.

*Filing Dates:* The application was filed on May 20, 2004 and amended and restated on July 21, 2004 and July 27, 2004.

*Applicant's Address:* 625 Fourth Avenue South, Minneapolis, MN 55415.

For the Commission, by the Division of Investment Management, pursuant to delegated authority.

**Margaret H. McFarland,**

*Deputy Secretary.*

[FR Doc. 04–17848 Filed 8–4–04; 8:45 am]

BILLING CODE 8010–01–P

## SECURITIES AND EXCHANGE COMMISSION

### Sunshine Act Meeting

Notice is hereby given, pursuant to the provisions of the Government in the Sunshine Act, Public Law 94–409, that the Securities and Exchange Commission will hold the following meeting during the week of August 9, 2004:

A Closed Meeting will be held on Thursday, August 12, 2004, at 2 p.m.

Commissioners, Counsel to the Commissioners, the Secretary to the Commission, and recording secretaries will attend the Closed Meeting. Certain staff members who have an interest in the matters may also be present.

The General Counsel of the Commission, or his designee, has certified that, in his opinion, one or more of the exemptions set forth in 5 U.S.C. 552b(c)(3), (5), (7), (9)(B), and (10) and 17 CFR 200.402(a)(3), (5), (7), 9(ii) and (10), permit consideration of the scheduled matters at the Closed Meeting.

Commissioner Campos, as duty officer, voted to consider the items listed for the closed meeting in a closed session.

The subject matter of the Closed Meeting scheduled for Thursday, August 12, 2004, will be:

Formal orders of investigations;

Institution and settlement of injunctive actions;

Institution and settlement of administrative proceedings of an enforcement nature; and

Litigation matter.

At times, changes in Commission priorities require alterations in the scheduling of meeting items. For further information and to ascertain what, if any, matters have been added, deleted or postponed, please contact:

The Office of the Secretary at (202) 942–7070.

Dated: August 3, 2004.

**Jonathan G. Katz,**

*Secretary.*

[FR Doc. 04–17993 Filed 8–3–04; 11:30 am]

BILLING CODE 8010–01–P

## SECURITIES AND EXCHANGE COMMISSION

**[Release No. 34–50116; File No. SR–Amex–2004–54]**

### Self-Regulatory Organizations; Notice of Filing and Order Granting Accelerated Approval of Proposed Rule Change by American Stock Exchange LLC Relating to the Extension of the Linkage Fee Pilot Program

July 29, 2004.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934,[1] and Rule 19b–4 thereunder,[2] notice is hereby given that on July 15, 2004, the American Stock Exchange LLC (''Amex'' or ''Exchange'') filed with the Securities and Exchange Commission (''Commission'') the proposed rule change as described in Items I and II below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons and is approving the proposed rule change on an accelerated basis.

**I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change**

The Exchange proposes to extend for one (1) year until July 31, 2005, the current pilot program regarding transaction fees for trades executed through the intermarket options linkage (''Linkage'') on the Exchange.

The text of the proposed rule change is available at the Office of the Secretary, Amex, and at the Commission's Public Reference Room.

**II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change**

In its filing with the Commission, the Exchange included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item III below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.

[1] 15 U.S.C. 78s(b)(1).

[2] 17 CFR 240.19b–4.

*A. Self-Regulatory Organization's Statement of the Purpose of, and the Statutory Basis for, the Proposed Rule Change*

1. Purpose

Amex is proposing to extend for one (1) year until July 31, 2005, the current pilot program establishing Exchange fees for Principal Orders (''P Orders'') and Principal Acting as Agent Orders (''P/A Orders'') executed through Linkage. The fees in connection with the pilot program are scheduled to expire on July 31, 2004.[3] The Exchange represents that these are the same fees charged to specialists and registered option traders (''ROTs'') for transactions executed on the Exchange.

As was the case in the original pilot program and subsequent extension, the Exchange believes that the existing fees currently charged to Exchange specialists and ROTs should also apply to executions resulting from Linkage Orders sent to the Exchange.

Based on the experience to date, the Exchange believes that an extension of the pilot program for one (1) year until July 31, 2005 is appropriate.

2. Statutory Basis

The Exchange believes that proposed rule change is consistent with Section 6(b)(4) of the Act[4] regarding the equitable allocation of reasonable dues, fees and other charges among exchange members and other persons using exchange facilities.

*B. Self-Regulatory Organization's Statement on Burden on Competition*

The Exchange believes that the proposed rule change will impose no burden on competition.

*C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others*

No written comments were solicited or received with respect to the proposed rule change.

## III. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:

*Electronic comments:*

- Use the Commission's Internet comment form (*http://www.sec.gov/rules/sro.shtml*); or
- Send an e-mail to *rule-comments@sec.gov*. Please include File Number SR–Amex–2004–54 on the subject line.

*Paper comments:*

- Send paper comments in triplicate to Jonathan G. Katz, Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609.

All submissions should refer to File Number SR–Amex–2004–54. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's Internet Web site (*http://www.sec.gov/rules/sro.shtml*). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Section, 450 Fifth Street, NW., Washington, DC 20549. Copies of such filing also will be available for inspection and copying at the principal offices of Amex. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All submissions should refer to File Number SR–Amex–2004–54 and should be submitted on or before August 26, 2004.

## IV. Commission's Findings and Order Granting Accelerated Approval of Proposed Rule Change

After careful consideration, the Commission finds that the proposed rule change is consistent with the requirements of the Act and the rules and regulations thereunder, applicable to a national securities exchange,[5] and, in particular, with the requirements of Section 6(b) of the Act[6] and the rules and regulations thereunder. The Commission finds that the proposed rule change is consistent with Section 6(b)(4) of the Act,[7] which requires that the rules of the Exchange provide for the equitable allocation or reasonable dues, fees and other charges among its members and other persons using its facilities. The Commission believes that the extension of the Linkage fee pilot until July 31, 2005 will give the Exchange and the Commission further opportunity to evaluate whether such fees are appropriate.

The Commission finds good cause, pursuant to Section 19(b)(2) of the Act,[8] for approving the proposed rule change prior to the thirtieth day after the date of publication of the notice of the filing thereof in the **Federal Register**. The Commission believes that granting accelerated approval will preserve the Exchange's existing pilot program for Linkage fees without interruption as Amex and the Commission further consider the appropriateness of Linkage fees.

## V. Conclusion

It is therefore ordered, pursuant to Section 19(b)(2) of the Act[9] that the proposed rule change (SR–Amex–2004–54) is hereby approved on an accelerated basis for a pilot period to expire on July 31, 2005.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.[10]

**J. Lynn Taylor,**

*Assistant Secretary.*

[FR Doc. 04–17850 Filed 8–4–04; 8:45 am]

**BILLING CODE 8010–01–P**

[3] See Securities Exchange Act Release No. 49145 (January 29, 2004), 69 FR 5619 (February 5, 2004).

[4] 15 U.S.C. 78f(b)(4).

[5] In approving this rule, the Commission notes that it has considered its impact on efficiency, competition and capital formation. 15 U.S.C. 78c(f).

[6] 15 U.S.C. 78f(b).

[7] 15 U.S.C. 78f(b)(4).

[8] 15 U.S.C. 78s(b)(2).

[9] *Id.*

[10] 17 CFR 200.30–3(a)(12).

---

## SECURITIES AND EXCHANGE COMMISSION

**[Release No. 34–50123; File No. SR–NYSE–2004–40]**

## Self-Regulatory Organizations; Notice of Filing and Immediate Effectiveness of Proposed Rule Change by the New York Stock Exchange, Inc. Relating to Its Original Financial Listing Standards Pilot Program

July 29, 2004.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (''Act'')[1] and Rule 19b–4 thereunder,[2] notice is hereby given that on July 15, 2004, the New York Stock Exchange, Inc. (''NYSE'' or ''Exchange'') filed with the Securities and Exchange Commission (''Commission'') the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange.

[1] 15 U.S.C. 78s(b)(10.

[2] 17 CFR 240.19b–4.

The proposed rule change has been filed by the NYSE as a ''non-controversial'' rule change pursuant to Rule 19b–4(f)(6) under the Act.[3] The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

## I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The Exchange seeks to extend its original financial listing standards pilot program (the ''Pilot Program'')[4] until the earlier of October 31, 2004, or such date as the Commission may approve file Number SR–NYSE–2004–20,[5] which seeks permanent approval of the Pilot Program. The Pilot Program established revised financial standards applicable to the listing of equity securities on the Exchange. The Pilot Program is currently in effect for a six-month period ending on July 30, 2004.

## II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

On January 29, 2004, the Commission granted accelerated approval of the Pilot Program on a six-month pilot basis through July 30, 2004.[6] Two comments were received in response to File Number SR–NYSE–2004–43.[7] The NYSE thereafter filed File Number SR–NYSE–2004–15 on March 16, 2004 for immediate effectiveness,[8] which suspended portions of the original Pilot Program regarding minimum numerical continued listing set forth in Section 802.01B of the NYSE's Listed Company Manual. In File Number SR–NYSE–2004–15, the Exchange noted its intention to publish the requirements of the original Pilot Program regarding minimum numerical continued listing standards set forth Section 801.01B for public comment on a non-accelerated timeframe. SR–NYSE–2004–15 did not, however, affect the Pilot Program with respect to original listing standards set forth in Sections 101.01C and 103.01B of the NYSE's Listed Company Manual or the Pilot Program's non-substantive change to the language of Section 801.01C.

On April 4, 2004, the Exchange filed File Number SR–NYSE–2004–20, which seeks permanent approval for the Pilot Program currently in effect with respect to the Exchange's original minimum listing standards, and approval of the continued minimum listing standards as originally proposed in File Number SR–NYSE–2003–43. File Number SR–NYSE–2004–20 was published in the **Federal Register** on July 2, 2004.[9] The Exchange believes it is appropriate to extend the amended Pilot Program until the earlier of October 31, 2004, or such date as the Commission may approve File Number SR–NYSE–2004–20.

2. Statutory Basis

The Exchange believes that the proposed rule change is consistent with Section 6(b)(5) of the Act[10] because it is designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to remove impediments to and perfect the mechanism of a free and open market and a national market system, and, in general, to protect investors and the public interest.

*B. Self-Regulatory Organization's Statement on Burden on Competition*

The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.

*C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others*

Written comments were neither solicited nor received with respect to the proposed rule change.

## III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Because the foregoing proposed rule change (1) does not significantly affect the protection of investors or the public interest; (2) does not impose any significant burden on competition; and (3) by its terms, does not become operative until 30 days from the date on which it was filed, or such shorter time as the Commission may designate if consistent with the protection of investors and the public interest, and the exchange provided the Commission with written notice of its intent to file the proposed rule change at least five business days prior to the date of filing of the proposed rule change, or such shorter time as designated by the Commission, it has become effective pursuant to Section 19(b)(3)(A) of the Act[11] and Rule 19b–4(f)(6) thereunder.[12] At any time within 60 days of the filing of this proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

Although Rule 19b–4(f)(6) under the Act[13] requires that an Exchange submit a notice of its intent to file at least five business days prior to the filing date, the Commission waived this requirement at the Exchange's request in view of the fact that the proposed rule change seeks to continue the existing Pilot Program. The NYSE has also requested that the Commission waive the 30-day operative delay. The Commission believes waiving the 30-day operative delay is consistent with the protection of investors and the public interest. Waiver of the operative date will allow the Exchange's Pilot Program to continue without any interruption in service to issuers and investors. For these reasons, the Commission designates the proposal to be effective and operative upon filing with the Commission.[14]

## IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:

*Electronic comments:*

- Use the Commission's Internet comment form (*http:///www.sec.gov/rules/sro.shtml*); or
- Send an e-mail to *rule-comments@sec.gov.* Please include File Number SR–NYSE–2004–40 on the subject line.

*Paper comments:*

- Send paper comments in triplicate to Jonathan G. Katz, Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC

[3] 17 CFR 240.19b–4(f)(6).

[4] *See* Securities Exchange Act Release No. 49154 (January 29, 2004), 69 FR 5633 (February 5, 2004) (approving File No. SR–NYSE–2004–43).

[5] *See* Securities Exchange Act Release No. 49917 (June 25, 2004), 69 FR 40439 (July 2, 2004).

[6] *See* Securities Exchange Act Release No. 49154 (January 29, 2004), 69 FR 5633 (February 5, 2004) approving File No. SR–NYSE–2004–43.

[7] *See* Letters to Jonathan G. Katz, Secretary, Commission, form W. Randy Eaddy, Kilpatrick Stockton LLP, dated March 11, 2004, and Kenneth A. Hoogstra, von Briesen & Roper, s.c., dated February 25, 2004.

[8] *See* Securities Exchange Act Release No. 49443 (March 18, 2004), 69 FR 13929 (March 24, 2004).

[9] *See* Securities Exchange Act Release No. 49917 (June 24, 2004), 69 FR 40439.

[10] 15 U.S.C. 78f(b)(5).

[11] 15 U.S.C. 78s(b)(3)(A).

[12] 17 CFR 240.19b–4(f)(6).

[13] *Id.*

[14] For purposes only of accelerating the operative date of this proposal, the Commission has considered the proposed rule's impact on efficiency, competition, and capital formation. 15 U.S.C. 78c(f).

20549–0609. All submissions should refer to File Number SR–NYSE–2004–40. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's Internet Web site (*http://www.sec.gov/rules/sro.shtml*). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Section, 450 Fifth Street, NW., Washington, DC 20549. Copies of such filing also will be available for inspection and copying at the principal office of NYSE. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All submissions should refer to File Number SR–NYSE–2004–40 and should be submitted on or before August 26, 2004.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.[15]

**Margaret H. McFarland,**

*Deputy Secretary.*

[FR Doc. 04–17873 Filed 8–4–04; 8:45 am]

**BILLING CODE 8010–01–M**

---

## SECURITIES AND EXCHANGE COMMISSION

**[Release No. 34–50120; File No. SR–OCC–2004–09]**

## Self-Regulatory Organizations; the Options Clearing Corporation; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change Relating to Eligible Securities for OCC's Stock/Loan Hedge Program

July 29, 2004.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (''Act''),[1] notice is hereby given that on June 1, 2004, the Options Clearing Corporation (''OCC'') filed with the Securities and Exchange Commission (''Commission'') the proposed rule change as described in Items I, II, and III below, which items have been prepared primarily by OCC. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

### I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The purpose of the proposed rule change is to amend the eligibility requirements for securities that may be the subject of stock loan/borrow transactions cleared through OCC's Stock Loan/Hedge Program (''Hedge Program'').

### II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, OCC included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. OCC has prepared summaries, set forth in sections (A), (B), and (C) below, of the most significant aspects of such statements.[2]

*(A) Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change*

In 2002 OCC proposed an additional eligibility criterion for equity securities that may be loaned in the Hedge Program. Specifically, OCC proposed that a loaned security be an underlying security for options unless (1) the loan was accepted by OCC prior to the implementation of the new requirement or (2) the security was deliverable upon the exercise of an outstanding option.[3] OCC's intention in adding this requirement was to more closely align the Hedge Program with its intended objective of recognizing intermarket hedges between a clearing member's equity and options positions.

OCC, with the Commission's consent, deferred implementing this new standard pending completion of system enhancements by DTC and Loanet which would permit DTC and Loanet to confirm that the securities loaned in a transaction meet OCC's criteria in order to confirm that the transaction was eligible for clearance at OCC.[4] These system enhancements have been scheduled for implementation in June 2004.

During the deferment period, OCC took the opportunity to reassess its eligibility criteria as approved by the Commission, and OCC determined that the criteria would preclude the lending of shares of certain exchange-traded funds (''ETFs''). There are a number of ETFs that track indexes underlying OCC-issued options but that are not themselves underlying securities for options. These ETFs are often used as hedges against the related index options. Without a change in the eligibility criteria, OCC would have to disqualify such ETFs from being loaned in the Hedge Program. OCC believes that excluding such ETFs would be inconsistent with the purpose of the Hedge Program, which is to give recognition to intermarket hedges between equity and options positions.[5] Accordingly, OCC is making this technical change to its securities eligibility criteria to permit loans of an ETF that tracks an index underlying an outstanding index option whether or not the ETF itself is an underlying security for options.

OCC believes that the proposed changes to its rules are consistent with the purpose and requirements of Section 17A of the Securities and Exchange Act of 1934, because it is designed to promote the prompt and accurate clearance and settlement of securities transactions, foster cooperation and coordination with persons engaged in the clearance and settlement of securities transactions, remove impediments to the mechanisms of a national system for the prompt and accurate clearance and settlement of securities transactions, and assure the safeguarding of securities and funds in the custody or control of OCC.

*(B) Self-Regulatory Organization's Statement on Burden on Competition*

OCC does not believe that the proposed rule change would impose any burden on competition.

---

[15] 17 CFR 200.30–3(a)(12).

[1] 15 U.S.C. 78s(b)(1).

[2] The Commission has modified parts of these statements.

[3] The existing criteria required that a security loaned in the Hedge Program be an equity security eligible for deposit at DTC and that OCC had not terminated all loans with respect to that security. These requirements are still in effect.

[4] Loanet is a service bureau used by broker dealers, including OCC clearing members, involved in stock loan transactions. Clearing members, either on their own or through Loanet, enter into stock loan transactions via DTC systems and through use of a special code designate the stock loan transactions as eligible for clearance at OCC.

[5] Five such ETFs account for nearly $673 million in loans outstanding in the Hedge Program as of May 2004.

*(C) Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others*

Written comments were not and are not intended to be solicited with respect to the proposed rule change, and none has been received.

**III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action**

The foregoing rule change has become effective pursuant to Section 19(b)(3)(A)(iii) of the Act [6] and Rule 19b–4(f)(4) [7] promulgated thereunder because the proposal effects a change in an existing service of OCC that (A) does not adversely affect the safeguarding of securities or funds in the custody or control of OCC or for which it is responsible and (B) does not significantly affect the respective rights or obligations of OCC or persons using the service. At any time within sixty days of the filing of the proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

**IV. Solicitation of Comments**

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:

*Electronic comments:*

- Use the Commission's Internet comment form (*http://www.sec.gov/rules/sro.shtml*) or
- Send an e-mail to *rule-comments@sec.gov*. Please include File Number SR–OCC–2004–09 on the subject line.

*Paper comments:*

- Send paper comments in triplicate to Jonathan G. Katz, Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609.

All submissions should refer to File Number SR–OCC–2004–09. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's Internet Web site (*http://www.sec.gov/rules/sro.shtml*). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Section, 450 Fifth Street, NW., Washington, DC 20549. Copies of such filing also will be available for inspection and copying at the principal office of OCC and on OCC's Web site at *www.optionsclearing.com*. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All submissions should refer to File Number SR–OCC–2004–09 and should be submitted on or before August 26, 2004.

For the Commission by the Division of Market Regulation, pursuant to delegated authority.[8]

**Margaret H. McFarland,**

*Deputy Secretary.*

[FR Doc. 04–17849 Filed 8–4–04; 8:45 am]

BILLING CODE 8010–01–P

[6] 15 U.S.C. 78s(b)(3)(A)(iii).

[7] 17 CFR 240.19b–4(f)(4).

[8] 17 CFR 200.30–3(a)(12).

## SECURITIES AND EXCHANGE COMMISSION

**[Release No. 34–50126; File No. SR–PCX–2004–45]**

## Self-Regulatory Organizations; Pacific Exchange, Inc.; Notice of Filing of Proposed Rule Change and Amendment No. 1 To Amend the PCX Sanctioning Guidelines To Enforce Compliance With the Exchange's FOCUS Reports Filing Requirements

July 30, 2004.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (''Act''),[1] and Rule 19b–4 thereunder,[2] notice is hereby given that on May 17, 2004, the Pacific Exchange, Inc. (''PCX'' or ''Exchange'') filed with the Securities and Exchange Commission (''Commission'') the proposed rule change as described in Items I, II and III below, which Items have been prepared by the PCX. The Exchange filed an amendment to the proposed rule change on July 1, 2004.[3] The Commission is publishing this notice to solicit comments on the proposed rule change, as amended, from interested persons.

[1] 15 U.S.C. 78s(b)(1).

[2] 17 CFR 240.19b–4.

**I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change**

The PCX proposes to amend the PCX sanctioning guidelines in order to effectively enforce compliance with the Exchange's Financial and Operational Combined Uniform Single (''FOCUS'') Reports filing requirements. The text of the proposed rule change is below. Proposed new language is in italics.

Rule 10.16

Pacific Exchange Sanctioning Guidelines

(a)–(e)—No change.

*(f) Specific Sanctioning Guidelines for Recordkeeping and Financial Requirements Rules.*

*(1) Financial Reports ''PCX Rule 4.11(b)(1).*

*(A) Principal Considerations in Determining Sanctions.*

*(i) See list of Principal Considerations applicable to all violations as set forth in PCX Rule 10.16(d).*

*(B) Monetary Sanctions.*

*(i) First Disciplinary Action Fine of $1,000 to $5,000.*

*(ii) Second Disciplinary Action Fine of $2,000 to $10,000.*

*(iii) Subsequent Disciplinary Action Fine of $3,000 to $50,000.*

*(iv) To determine if an action is the first disciplinary action, consider disciplinary actions with respect to violative conduct that occurred within the two years prior to the misconduct at issue. As indicated in the General Principles, as set forth in PCX Rule 10.16(b), recent acts of similar misconduct may be considered to be aggravating factors.*

*(C) Suspension, Expulsion, or Other Sanctions. For the first disciplinary action, consider a letter of caution to the named party. In egregious cases, consider suspending the named party with respect to any or all activities or functions for up to two years. In particularly egregious cases involving a pattern of misconduct, consider expelling the OTP Holder or OTP Firm, withdrawing approval of the responsible approved person, and/or permanently barring a named party from employment or association with any OTP Holder or OTP Firm.*

* * * * *

[3] The July 1, 2004 amendment (''Amendment No. 1'') replaced the original filing in its entirety.

## II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for its proposal and discussed any comments it received regarding the proposal. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in Sections A, B and C below, of the most significant aspects of such statements.

*A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change*

1. Purpose

The Exchange proposes to amend the PCX sanctioning guidelines in order to effectively enforce compliance with the Exchange's FOCUS Reports filing requirements.[4]

Currently, PCX Rule 10.16 sets forth the general principles applicable to all sanction determinations, principal considerations in determining sanctions, and specific sanctioning guidelines for options order handling rules. The sanctioning guidelines are used by various PCX bodies that adjudicate disciplinary actions, including the Ethics and Business Conduct Committee (''EBCC''), the PCX Board of Directors, and the PCX Surveillance and Enforcement Departments, to determine appropriate remedial sanctions.

With the instant proposed rule change, the PCX proposes to establish specific sanctioning guidelines relating to disciplinary actions initiated as a result of late filings of FOCUS Reports. Currently, late filings of FOCUS Reports are handled by the assessment of late charges. While a specific late charge schedule is provided, Exchange staff also has the flexibility to refer repeated or aggravated failure to file such reports, or failure to file such reports, to the Enforcement Department. For example, Exchange staff may refer a failure to file FOCUS Reports after the first, second, or third occurrence, depending on the circumstances. Exchange staff has the responsibility to determine whether the circumstances involved are aggravated or repeated enough to warrant such failure to file FOCUS Reports to be taken out of the late charge schedule for disciplinary action. In other words, Exchange staff may refer such failures to the Enforcement Department without exhausting the late charge schedule set forth in PCX Rule 4.11(b)(1), if the circumstances warrant such action.[5]

The PCX believes the proposed guidelines will assist the Exchange in determining appropriate remedial sanctions for violation(s) of FOCUS Report filing rules. The PCX also believes the guidelines will work to promote consistency and uniformity as each Exchange Department will use the same form and parameters set forth in the guidelines with respect to violation(s) of FOCUS Report filing. The fine amounts will differ depending on the number of disciplinary actions that have been brought by the PCX against the particular OTP Holder or OTP Firm and the Exchange will have a range of fines as well as non-monetary sanctions that could be assessed against offending OTP Holders or OTP Firms.

The PCX proposes the following monetary sanctions for disciplinary actions brought for violations of PCX Rule 4.11(b)(1):[6]

1st Disciplinary Action—$1,000.00 to $5,000.00;

2nd Disciplinary Action—$2,000.00 to $10,000.00; and

Subsequent Disciplinary Actions-$3,000.00 to $50,000.00.

The proposed guidelines would also allow for non-monetary sanctions such as suspension, expulsion, or other sanctions in egregious cases. The Exchange believes that the proposed fine levels will help to deter violations of its FOCUS Report filing rules. These guidelines are not intended to be absolute, and sanctions may be imposed that fall outside the ranges recommended.

2. Statutory Basis

The Exchange believes that the proposed rule change is consistent with Section 6(b)[7] of the Act, in general, and furthers the objectives of Section 6(b)(5),[8] in particular, because it is designed to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in facilitating transactions in securities, to remove impediments to and perfect the mechanism of a free and open market, and to protect investors and the public interest.

*B. Self-Regulatory Organization's Statement on Burden on Competition*

The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.

*C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others*

Written comments on the proposed rule change were neither solicited nor received.

## III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within 35 days of the date of publication of this notice in the **Federal Register** or within such longer period (i) as the Commission may designate up to 90 days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which the PCX consents, the Commission will:

(A) By order approve the proposed rule change, or

(B) Institute proceedings to determine whether the proposed rule change should be disapproved.

## IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:

*Electronic comments:*

- Use the Commission's Internet comment form (*http://www.sec.gov/rules/sro.shtml*); or
- Send an e-mail to *rule-comments@sec.gov.* Please include File Number SR–PCX–2004–45 on the subject line.

*Paper comments:*

[4] *See* PCX Rule 4.11(b)(1). OTP Holders who fail to file such FOCUS Reports in a timely manner are subject to late filing charges. For a first occurrence, an OTP Holder who is 1–30 days late in filing the FOCUS Reports will be charged $100 per day (capped at $500); for 31–60 days, the charge is $750; and for 61–90 days, the charge is $1000. For a second occurrence, an OTP Holder who is 1–30 days late will be charged $100 per day (capped at $1000); for 31–60 days, the charge is $1500; and for 61–90 days, the charge is $2000. For a third occurrence, an OTP Holder who is 1–30 days late will be charged $2000; for 31–60 days, the charge is $2500; and for 61–90 days, the charge is $3000. The PCX recently increased the late charges for late filings of FOCUS Reports. *See* Securities Exchange Act Release No. 49756 (May 21, 2004), 69 FR 30972 (June 1, 2004) (SR–PCX–2004–27).

[5] The late charge schedule set forth in PCX Rule 4.11(b)(1) is independent of the monetary sanctions set forth in proposed PCX Rule 10.16(f)(1)(B). Thus, whether an OTP Holder is subject to a first, second or subsequent disciplinary action, is independent of how many occurrences of late filings the OTP Holder incurred pursuant to PCX Rule 4.11(b)(1).

[6] The recommended range of fines is intended to correspond to the late filing charges set forth in PCX Rule 4.11(b)(1) yet be diverse so as to provide Exchange staff with the discretion to fine an OTP Holder at either end of the range depending on the circumstances.

[7] 15 U.S.C. 78f(b).

[8] 15 U.S.C. 78f(b)(5).

• Send paper comments in triplicate to Jonathan G. Katz, Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609.

All submissions should refer to File Number SR–PCX–2004–45. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's Internet Web site (*http://www.sec.gov/rules/sro.shtml*). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Section, 450 Fifth Street, NW., Washington, DC 20549. Copies of such filing also will be available for inspection and copying at the principal office of the PCX. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All submissions should refer to File Number SR–PCX–2004–45 and should be submitted on or before August 26, 2004.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.[9]

**Margaret H. McFarland,**

*Deputy Secretary.*

[FR Doc. 04–17872 Filed 8–4–04; 8:45 am]

**BILLING CODE 8010–01–P**

[9] 17 CFR 200.30–3(a)(12).

## SECURITIES AND EXCHANGE COMMISSION

**[Release No. 34–50125; File No. SR–Phlx–2004–44]**

## Self-Regulatory Organizations; Notice of Filing and Order Granting Accelerated Approval of Proposed Rule Change and Amendment No. 1 Thereto by the Philadelphia Stock Exchange, Inc. Relating to Linkage Fee Pilot Program

July 30, 2004.

Pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 (''Act''),[1] and Rule 19b–4 thereunder,[2] notice is hereby given that on July 9, 2004, the Philadelphia Stock Exchange, Inc. (''Phlx'' or ''Exchange'') filed with the Securities and Exchange Commission (''Commission'') the proposed rule change as described in Items I and II below, which Items have been prepared by the Exchange. On July 27, 2004, Phlx filed Amendment No. 1 to the proposed rule change.[3] The Commission is publishing this notice to solicit comments on the proposed rule change, as amended, from interested persons and is approving the proposed rule change, as amended, on an accelerated basis.

### I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The Exchange proposes to amend its schedule of dues, fees and charges to adopt new charges applicable to Principal (''P'') Orders sent via the Intermarket Options Linkage (''Linkage'') under the Plan for the Purpose of Creating and Operating an Options Intermarket Linkage (''Plan'').[4]

The Exchange intends to implement this fee on a pilot basis, ending July 31, 2005, for transactions settling on or after the first day following the Commission's approval of the proposal.[5]

The proposed fee schedule is available at the principal office of the Exchange and at the Commission's Public Reference Room.

### II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for the Proposed Rule Change

In its filing with the Commission, Phlx included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item III below. Phlx has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.

*A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change*

1. Purpose

The purpose of the proposed rule change is to raise revenue for the Exchange by charging Exchange members for transactions involving inbound P Orders sent by such members via the Linkage pursuant to the Plan.[6]

Currently, the Exchange's schedule of dues, fees and charges includes the following charges applicable to Linkage P Orders on a pilot basis (''pilot''),[7] scheduled to expire on July 31, 2004:

Up to 2,000 contracts—$.35 per contract.

Between 2,001 and 3,000 contracts—$.25 per contract (for all contracts).

Residual above 3,000 contracts—$.20 per contract above 3,000 contracts (with the first 3,000 contracts charged $.25 per contract).

The Exchange has represented that its fees applicable to Linkage P Orders are consistent with other fees charged by the Exchange for non-Linkage Orders for the proprietary account(s) of off-floor

[1] 15 U.S.C. 78s(b)(1).

[2] 17 CFR 240.19b–4.

[3] *See* letter from Richard S. Rudolph, Counsel, Phlx, to Jennifer Colihan, Special Counsel, Commission, dated July 27, 2004 (''Amendment No. 1''). In Amendment No. 1, the Exchange proposes to make technical corrections to the Summary of Equity Option Charges of the Exchange's schedule of dues, fees, and charges, originally submitted as Exhibit 2 to the proposed rule change.

[4] *See* Securities Exchange Act Release Nos. 43086 (July 28, 2000), 65 FR 48023 (August 4, 2000); 43573 (November 16, 2000), 65 FR 70851 (November 28, 2000) (order approving Phlx as participant in the Plan); and 44482 (June 27, 2001), 66 FR 35470 (July 5, 2001) (amendment conforming the Plan to the requirements of the Act Rule 11Ac1–7).

[5] For example, if the Commission approves the proposal on July 31, 2004, the Exchange intends to implement this fee for transactions settling on or after August 1, 2004.

[6] Under section 2(16) of the Plan and Exchange Rule 1083(k), which tracks the language of the Plan, a ''Linkage Order'' means an Immediate or Cancel order routed through the Linkage as permitted under the Plan. There are three types of Linkage Orders:

(i) ''Principal Acting as Agent (''P/A'') Order,'' which is an order for the principal account of a specialist (or equivalent entity on another Participant Exchange that is authorized to represent Public Customer orders), reflecting the terms of a related unexecuted Public Customer order for which the specialist is acting as agent;

(ii) ''Principal (''P'') Order,'' which is an order for the principal account of an Eligible Market Maker and is not a P/A Order; and

(iii) ''Satisfaction Order,'' which is an order sent through the Linkage to notify a member of another Participant Exchange of a Trade-Through and to seek satisfaction of the liability arising from that Trade-Through.

The Exchange will not assess any charges for P/A Orders and Satisfaction Orders.

[7] The Commission originally approved the pilot on May 30, 2003. *See* Securities Exchange Act Release No. 47953, 68 FR 34027 (June 6, 2003) (SR–Phlx–2003–16). This pilot expired on January 31, 2004. On January 30, 2004, the Commission approved the Exchange's proposal to extend the pilot through July 31, 2004. See Securities Exchange Act Release No. 49163, 69 FR 5885 (February 6, 2004) (SR–Phlx–2003–89).

broker-dealers[8] delivered to the Exchange.[9]

However, since the implementation of the pilot, the Exchange has amended its fees applicable to non-Linkage off-floor broker-dealer orders sent to the Exchange via AUTOM, the Exchange's electronic order delivery, routing, execution and reporting system.[10] Specifically, AUTOM-delivered non-Linkage off-floor broker-dealer orders are now charged $.45 per contract for all contracts executed.[11] The proposed amendment to the Exchange's fee schedule would impose the same $.45 per contract charge on Linkage participants who send P Orders to the Exchange on a pilot basis through July 31, 2005.[12] The Exchange will not charge fees for other types of Linkage Orders.[13]

2. Statutory Basis

The Exchange believes that its proposal to amend its schedule of dues, fees and charges is consistent with section 6(b) of the Act[14] in general, and furthers the objectives of section 6(b)(4) of the Act[15] in particular, in that it is an equitable allocation of reasonable dues, fees, and other charges among Exchange members who avail themselves of the Linkage, consistent with other fees charged by the Exchange for non-Linkage Orders.

*B. Self-Regulatory Organization's Statement on Burden on Competition*

The Exchange does not believe that the proposed rule change will impose any inappropriate burden on competition.

*C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others*

No written comments were either solicited or received.

## III. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:

*Electronic comments:*

- Use the Commission's Internet comment form (*http://www.sec.gov/rules/sro.shtml*); or
- Send an e-mail to *rule-comments@sec.gov*. Please include File Number SR–Phlx–2004–44 on the subject line.

*Paper comments:*

- Send paper comments in triplicate to Jonathan G. Katz, Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609.

All submissions should refer to File Number SR–Phlx–2004–44. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's Internet Web site (*http://www.sec.gov/rules/sro.shtml*). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Section, 450 Fifth Street, NW., Washington, DC 20549. Copies of such filing also will be available for inspection and copying at the principal offices of the Exchange. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All submissions should refer to File Number SR–Phlx–2004–44 and should be submitted on or before August 26, 2004.

## IV. Commission's Findings and Order Granting Accelerated Approval of Proposed Rule Change

After careful consideration, the Commission finds that the proposed rule change is consistent with the requirements of the Act and the rules and regulations thereunder, applicable to a national securities exchange,[16] and, in particular, with the requirements of section 6(b) of the Act[17] and the rules and regulations thereunder. The Commission finds that the proposed rule change, as amended, is consistent with section 6(b)(4) of the Act,[18] which requires that the rules of the Exchange provide for the equitable allocation or reasonable dues, fees and other charges among its members and other persons using its facilities. The Commission believes that approving the amended Linkage fee pilot to adopt new charges applicable to P Orders until July 31, 2005 will give the Exchange and the Commission further opportunity to evaluate whether such fees are appropriate.

The Commission finds good cause, pursuant to section 19(b)(2) of the Act,[19] for approving the proposed rule change, as amended, prior to the thirtieth day after the date of publication of the notice of the filing thereof in the **Federal Register**. The Commission believes that granting accelerated approval will preserve the Exchange's pilot program for Linkage fees without interruption as Phlx and the Commission further consider the appropriateness of Linkage fees.

## V. Conclusion

*It is therefore ordered*, pursuant to section 19(b)(2) of the Act[20] that the proposed rule change, as amended, (SR–Phlx–2004–44) is hereby approved on an accelerated basis for a pilot period to expire on July 31, 2005.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.[21]

**Margaret H. McFarland,**

*Deputy Secretary.*

[FR Doc. 04–17871 Filed 8–4–04; 8:45 am]

**BILLING CODE 8010–01–P**

[8] The term ''off-floor broker-dealer'' is defined as a broker-dealer that delivers orders from off the floor of the Exchange for the proprietary account(s) of such broker-dealer, including a market maker located on an exchange or trading floor other than the Exchange's trading floor who elects to deliver orders via AUTOM for the proprietary account(s) of such market maker. *See* Exchange Rule 1080(b)(i)(C).

[9] *See supra* note 6.

[10] *See* Securities Exchange Act Release No. 49751 (May 21, 2004), 69 FR 30735 (May 28, 2004) (SR–Phlx–2004–25).

[11] Previously, these orders were charged under the $.35/$.25/$.20 schedule listed above.

[12] The Exchange represents that Linkage Orders are delivered to the Exchange via AUTOM. Telephone conversation between Richard S. Rudolph, Counsel, Phlx, and Jennifer Colihan, Special Counsel, and Molly M. Kim, Attorney, Division of Market Regulation, Commission, on July 22, 2004.

[13] *See supra* note 5.

[14] 15 U.S.C. 78f(b).

[15] 15 U.S.C. 78f(b)(4).

[16] In approving this rule, the Commission notes that it has considered its impact on efficiency, competition and capital formation. 15 U.S.C. 78c(f).

[17] 15 U.S.C. 78f(b).

[18] 15 U.S.C. 78f(b)(4).

[19] 15 U.S.C. 78s(b)(2).

[20] *Id.*

[21] 17 CFR 200.30–3(a)(12).

## DEPARTMENT OF TRANSPORTATION

### Office of the Secretary

### Aviation Proceedings, Agreements Filed the Week Ending July 16, 2004

The following Agreements were filed with the Department of Transportation under the provisions of 49 U.S.C. 412 and 414. Answers may be filed within 21 days after the filing of the application.

*Docket Number:* OST–2004–18622.
*Date Filed:* July 13, 2004.
*Parties:* Members of the International Air Transport Association.
*Subject:* PTC23 AFR–TC3 0231 dated 13 July 2004, Mail Vote 396—Resolution 010n, TC23 Africa-TC3 Special Passenger Amending Resolution from Libya to TC3 r1–r11, Intended effective date: 1 August 2004.

*Docket Number:* OST–2004–18652.
*Date Filed:* July 14, 2004.
*Parties:* Members of the International Air Transport Association.
*Subject:* CAC/32/Meet/006/2004 dated 28 June, 2004, Finally Adopted Resolutions 801/801a(III)801c/801r/801rr/ 803/805/807/809/813/823, Intended effective date: 1 October 2004.

*Docket Number:* OST–2004–18658.
*Date Filed:* July 16, 2004.
*Parties:* Members of the International Air Transport Association.
*Subject:* PTC123 0288 dated 16 July 2004, Mail Vote 397—Resolution 010o TC123 Special Passenger Amending Resolution from Brazil to TC3 r1, Intended effective date: 15 August 2004.

**Andrea M. Jenkins,**
*Program Manager, Docket Operations, Federal Register Liaison.*

[FR Doc. 04–17929 Filed 8–4–04; 8:45 am]

BILLING CODE 4910–62–P

## DEPARTMENT OF TRANSPORTATION

### Office of the Secretary

### Notice of Applications for Certificates of Public Convenience and Necessity and Foreign Air Carrier Permits Filed Under Subpart B (Formerly Subpart Q) During the Week Ending July 16, 2004

The following Applications for Certificates of Public Convenience and Necessity and Foreign Air Carrier Permits were filed under Subpart B (formerly Subpart Q) of the Department of Transportation's Procedural Regulations (*See* 14 CFR 301.201 *et. seq.*). The due date for Answers, Conforming Applications, or Motions to Modify Scope are set forth below for each application. Following the Answer period DOT may process the application by expedited procedures. Such procedures may consist of the adoption of a show-cause order, a tentative order, or in appropriate cases a final order without further proceedings.

*Docket Number:* OST–2004–18615–1.
*Date Filed:* July 12, 2004.
*Due Date for Answers, Conforming Applications, or Motion To Modify Scope:* August 2, 2004.
*Description:* Application of America West Airlines, Inc., requesting a new or amended certificate of public convenience and necessity to engage in scheduled foreign air transportation of persons, property, and mail from points in the United States and intermediate points to a point or points in Jordan and beyond.

*Docket Number:* OST–2004–18638–1.
*Date Filed:* July 13, 2004.
*Due Date for Answers, Conforming Applications, or Motion To Modify Scope:* August 3, 2004.
*Description:* Application of Chautauqua Airlines, Inc., requesting a certificate of public convenience and necessity authorizing it to engage in scheduled interstate air transportation of persons, property and mail.

*Docket Number:* OST–2004–18639–1.
*Date Filed:* July 13, 2004.
*Due Date for Answers, Conforming Applications, or Motion To Modify Scope:* August 3, 2004.
*Description:* Application of TNT Airways S.A., requesting a foreign air carrier permit to engage in scheduled foreign air transportation of property and mail from points behind Belgium via Belgium and intermediate points to a point or points in the United States and beyond, and all-cargo charters.

**Andrea M. Jenkins,**
*Program Manager, Docket Operations, Federal Register Liaison.*

[FR Doc. 04–17930 Filed 8–4–04; 8:45 am]

BILLING CODE 4910–62–P

## DEPARTMENT OF TRANSPORTATION

### Federal Aviation Administration

### Proposed Advisory Circular (AC) 65–26C, Charles Taylor ''Master Mechanic'' Award

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Notice of availability of proposed AC, and request for comments.

**SUMMARY:** This notice announces the availability of and requests comments on a proposed AC that provides guidance on eligibility, application, and selection for the Charles Taylor ''Master Mechanic'' Award.

**DATES:** Submit comments on or before September 4, 2004.

**ADDRESSES:** Send all comments on the proposed AC to William O'Brien, Aircraft Maintenance Division (AFS–300), Federal Aviation Administration, Independence Ave., SW., Washington, DC 20591; facsimile (202) 267–5115; e-mail *william.o'brien@faa.gov.*

**FOR FURTHER INFORMATION CONTACT:** William O'Brien, AFS–300, at the address, facsimile or e-mail listed above, or by telephone at (202) 267–3796.

**SUPPLEMENTARY INFORMATION:**

#### Comments Invited

The proposed AC 65–26C is available on the FAA's Regulatory Guidance Library Web site at *http://www.airweb.faa.gov/rgl,* under the Draft Advisory Circulars link. Interested persons are invited to comment on the proposed AC by submitting written data, views, or arguments as they may desire. Please identify AC 65–26C, Charles Taylor ''Master Mechanic'' Award, and submit comments, either hardcopy or electronic, to the appropriate address listed above. Comments may be inspected at the above address between 9 a.m. and 4 p.m. weekdays, except Federal holidays.

Issued in Washington, DC, on July 29, 2004.

**John M. Allen,**
*Deputy Director, Flight Standards Service.*

[FR Doc. 04–17924 Filed 8–4–04; 8:45 am]

BILLING CODE 4910–13–M

## DEPARTMENT OF TRANSPORTATION

### Federal Aviation Administration

### Public Notice of Availability of Finding of No Significant Impact (FONSI)/ Record of Decision (ROD) for Capital Improvement Projects, Dane County Regional Airport, Madison, WI

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Notice of availability.

**SUMMARY:** The Federal Aviation Administration (FAA) is giving notice that a FONSI/ROD has been issued addressing anticipated environmental impacts expected to occur from a decision to proceed with capital improvement projects at Dane County Regional Airport, Madison, WI.

**FOR FURTHER INFORMATION CONTACT:** Mr. Daniel J. Millenacker, Federal Aviation Administration, Airports District Office, 6020 28th Avenue South, Room 102,

Minneapolis, MN 55450–2706. Telephone Number (612) 713–4359/Fax Number (612) 713–4364.

**SUPPLEMENTARY INFORMATION:** This Notice is provided per 40 CFR 1506.6 notifying the public that a FONSI/ROD has been issued by the FAA identifying anticipated environmental impacts from a decision to proceed with airport capital improvement projects. Projects are intended to enhance compliance with Federal airport safety design standards including runway safety area, object free area, approach surfaces, and marking and lighting. The preferred alternative results in the following work items: relocation of a segment of rail line to the northwest from its current location; relocation of County Highway ''CV'' and Messerschmidt Road; relocation of the West Branch of Starkweather Creek; relocation of the airport perimeter road and perimeter fence; and extension of Runway 13/31 by 570 feet.

The FONSI/ROD is available for public examination from August 9, through August 23, 2004, at the following locations: Lakeview Branch of the Madison Public Library, 2845 N. Sherman Ave., Madison, WI; Office of Dane County Clerk, 210 Martin Luther King Blvd., Madison, WI 53703; Dane County Regional Airport, Office of Director, 4000 International Lane, Madison, WI; Town of Burke, Town Clerk, 5365 Reiner Rd, Madison, WI; DOT Transportation District 1, 2101 Wright Street, Madison, WI; Bureau of Aeronautics, 4802 Sheboygan Avenue, Room 701, Madison, Wisconsin; and FAA Airports District Office, 6020 28th Ave., So., Room 102, Minneapolis, MN.

Issued in Minneapolis, MN, on July 19, 2004.

**Robert Huber,**

*Manager, Minneapolis Airports District Office, FAA, Great Lakes Region.*

[FR Doc. 04–17831 Filed 8–4–04; 8:45 am]

**BILLING CODE 4910–13–M**

---

## DEPARTMENT OF TRANSPORTATION

### Federal Aviation Administration

### Notice of Intent To Rule on Application To Impose and Use the Revenue From a Passenger Facility Charge (PFC) at Key West International Airport, Key West, FL

**AGENCY:** Federal Aviation Administration (FAA), DOT

**ACTION:** Notice of intent to rule on application.

**SUMMARY:** The FAA proposes to rule and invites public comment on the application to impose and use the revenue from a PFC at Key West International Airport under the provisions of the Aviation Safety and Capacity Expansion Act of 1990 (Title IX of the Omnibus Budget Reconciliation Act of 1990) (Public Law 101–508) and part 158 of the Federal Aviation Regulations (14 CFR part 158).

**DATES:** Comments must be received on or before September 7, 2004.

**ADDRESSES:** Comments on this application may be mailed or delivered in triplicate to the FAA at the following address: Orlando Airports District Office, 5950 Hazeltine National Drive, Suite 400, Orlando, Florida 32822.

In addition, one copy of any comments submitted to the FAA must be mailed or delivered to Peter Horton, Director of Airports of the Monroe County Board of County Commissioners at the following address: Key West International Airport, 3491 S. Roosevelt Boulevard, Key West, Florida 33040.

Air carriers and foreign air carriers may submit copies of written comments previously provided to the Monroe County Board of County Commissioners under section 158.23 of part 158.

**FOR FURTHER INFORMATION CONTACT:** Susan Moore, Program Manager, Orlando Airports District Office, 5950 Hazeltine National Drive, Suite 400, Orlando FL 32822, (407) 812–6331, extension 120. The application may be reviewed in person at this same location.

**SUPPLEMENTARY INFORMATION:** The FAA proposes to rule and invites public comment on the application to impose and use the revenue from a PFC at key West International Airport under the provisions of the Aviation Safety and Capacity Expansion Act of 1990 (Title IX of the Omnibus Budget Reconciliation Act of 1990) (Public Law 101–508) and part 158 of the Federal Aviation Regulations (14 CFR part 158).

On July 23, 2004, the FAA determined that the application to impose and use the revenue from a PFC submitted by Monroe County Board of County Commissioners was substantially complete within the requirements of section 158.25 of part 158. The FAA will approve or disapprove the application, in whole or in part, no later than November 12, 2004.

The following is a brief overview of the application.

*PFC Application No.:* 04–08–C–00–EYW.

*Level of the proposed PFC:* $4.50.

*Proposed charge effective date:* February 1, 2005.

*Proposed charge expiration date:* July 1, 2005.

*Total estimated net PFC revenue:* $425,250.

*Brief description of proposed project(s):* PFC Application; Noise Mitigation, Phase 4 (50 homes, Design and Construction); Noise Contour Update #5; Safety Area Runway 9/2736, Phase 2 (Construction); New Terminal Development (Construction); Rehabilitate Existing Terminal (Customs Building); Rehabilitate Taxiway Pavement; New Terminal Development (Design and Permitting); Wildlife Study; Acquire Pavement Sweeper; Acquire Land for Runway 27 Protection Zone; Sealcoat and Mark Ramps; Environmental Mitigation-Mosquito Ditches; Install Perimeter Fencing; Rehabilitate Terminal Canopy (at Florida Keys Marathon Airport, MTH); Install (31) and Relocate (4) Taxiway Guidance Signs (MTH); Install Taxiway D and E Medium Intensity Lighting (MTH); Update Airport Layout Plan (MTH).

*Class or classes of air carriers which the public agency has requested not be required to collect PFCs:* Commercial Air Carriers with less than one percent (1%) of total passenger enplanements.

Any person may inspect the application in person at the FAA office listed above under **FOR FURTHER INFORMATION CONTACT**.

In addition, any person may, upon request, inspect the application, notice and other documents germane to the application in person at the Monroe County Board of County Commissioners.

Issued in Orlando, Florida, on July 30, 2004.

**Matthew J. Thys,**

*Acting Manager, Orlando Airports District Office, Southern Region.*

[FR Doc. 04–17926 Filed 8–4–04; 8:45 am]

**BILLING CODE 4910–13–M**

---

## DEPARTMENT OF TRANSPORTATION

### Federal Aviation Administration

### Notice of Intent To Rule on Application 04–06–U–00–GJT) To Use a Passenger Facility Charge (PFC) at the Walker Field Airport, Submitted by the Walker Field Airport Authority, Grand Junction, CO

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Notice of intent to rule on application.

**SUMMARY:** The FAA proposes to rule and invites public comment on the application to use PFC revenue at the Walker Field Airport under the

provisions of 49 U.S.C. 40117 and part 158 of the Federal Aviation Regulations (14 CFR part 158).

**DATES:** Comments must be received on or before September 7, 2004.

**ADDRESSES:** Comments on this application may be mailed or delivered in triplicate to the FAA at the following address: Craig A. Sparks, Manager; Denver Airports District Office, DEN–ADO; Federal Aviation Administration; 26805 E. 68th Avenue, Suite 224; Denver, Colorado 80249–6361.

In addition, one copy of any comments submitted to the FAA must be mailed or delivered to Ms. Corinne C. Nystrom, Airport Manager, at the following address: Walker Field Airport Authority, 2828 Walker Field Drive, Suite 301, Grand Junction, Colorado 81506.

Air Carriers and foreign air carriers may submit copies of written comments previously provided to the Walker Field Airport Authority, under § 158.23 of part 158.

**FOR FURTHER INFORMATION CONTACT:** Mr. Chris Schaffer, (303) 342–1258; Denver Airports District Office, DEN–ADO; Federal Aviation Administration; 26805 E. 68th Avenue, Suite 224; Denver, Colorado 80249–6361. The application may be reviewed in person at this same location.

**SUPPLEMENTARY INFORMATION:** The FAA proposes to rule and invites public comment on the application (04–06–U–00–GJT) to use a PFC at the Walker Field Airport, under the provisions of 49 U.S.C. 40117 and part 158 of the Federal Aviation Regulations (14 CFR part 158).

On July 23, 2004, the FAA determined that the application to use a PFC submitted by the Walker Field Airport Authority, Grand Junction, Colorado, was substantially complete within the requirements of § 158.25 of part 158. The FAA will approve or disapprove the application, in whole or in part, no later than October 29, 2004.

The following is a brief overview of the application.

*Level of the proposed PFC:* $3.00.

*Proposed charge effective date:* November 1, 2004.

*Proposed charge expiration date:* September 1, 2006.

*Brief description of proposed project:* Air carrier ramp expansion.

*Class or classes of air carriers which the public agency has requested not be required to collect PFC's:* None.

Any person may inspect the application in person at the FAA office listed above under **FOR FURTHER INFORMATION CONTACT** and at the FAA Regional Airports Office located at: Federal Aviation Administration, Northwest Mountain Region, Airports Division, ANM–600, 1601 Lind Avenue, SW., Suite 315, Renton, WA 98055–4056.

In addition, any person may, upon request, inspect the application, notice and other documents germane to the application in person at the Walker Field Airport.

Issued in Renton, Washington, on July 23, 2004.

**David A. Field,**

*Manager, Planning, Programming and Capacity Branch, Northwest Mountain Region.*

[FR Doc. 04–17830 Filed 8–4–04; 8:45 am]

**BILLING CODE 4910–13–M**

---

## DEPARTMENT OF TRANSPORTATION

### Federal Highway Administration

### Environmental Impact Statement: Cache County, Utah

**AGENCY:** Federal Highway Administration (FHWA), DOT.

**ACTION:** Notice of intent.

**SUMMARY:** The FHWA is issuing this notice to advise the public that an environmental impact statement will be prepared for a proposed highway project in Cache County, Utah.

**FOR FURTHER INFORMATION CONTACT:** Jeffrey Berna, Environmental Specialist, Federal Highway Administration, 2520 West 4700 South, Suite 9A, Salt Lake City, Utah 84118, Telephone: (801) 963–0078 ext, 235; or Brad Humphreys, Utah Department of Transportation, Region 1, 166 West Southwell Road, Ogden, Utah 84404–4194, telephone: (801) 620–1684.

**SUPPLEMENTARY INFORMATION:** The FHWA, in cooperation with the Utah Department of Transportation (UDOT) and the City of Logan, Utah, will prepare an environmental impact statement (EIS) on a proposal to develop a new transportation corridor of approximately 1.2 miles between 300 South Street in the City of Logan to 100 North/Providence Lane in the City of Providence, Utah. The proposed new transportation corridor would consist of a new collector road built within an 80–foot right-of-way (ROW). The proposed transportation corridor would provide a transportation link between the City of Logan and the rapidly growing commercial and residential area of Providence, facilitating the economic expansion and residential development of south Logan and north Providence on the east side of Main Street. This purpose is consistent with the City of Logan and the City of Providence general plans.

The proposed new transportation corridor with a collector road within an 80–foot ROW is included in the current Long-Range Plan and the Transportation Improvement Plan for the Logan Urbanized Area (LUA). The Cache Metropolitan Planning Organization's (CMPO) Long-Range Plan and the Transportation Improvement Plan for the Logan Urbanized Area (LUA). The Cache Metropolitan Planning Organization's (CMPO) Long-Range Plan has identified the proposed new collector road on approximately 100 East Street as one of the highest priorities in preserving and improving transportation mobility within the LUA.

Alternatives under consideration include (1) taking no action, (2) using transportation system management strategies that would provide for transportation efficiency within the existing transportation network, and (3) constructing the new collector road on one of several alignments. These alignments could require widening existing roadways in south Logan, and would also require entirely new ROW for large segments of the alignments. Design variations of grade and alignment will be incorporated into, and analyzed with, the various build alternatives.

Information letters describing the proposed action and soliciting comments on the proposed project will be sent to appropriate Federal, State and local agencies, as well as to private organizations and individuals who have previously expressed, or that are expected to be interested, in the proposed project. An initial public scoping meeting will be held in the City of Logan during late August or September 2004. Notice of additional public meetings to present information and solicit comments relative to alternatives for consideration and possible impacts will be given as the proposed project proceeds. Upon release of the draft EIS for public and agency review and comment, public notice will be given of the time and place for a public hearing to be held to receive comments. The draft EIS will be available for public and agency review and comment for no less than two weeks prior to the public hearing.

To ensure that the full range of issues related to this proposed action are addressed and all significant issues are identified, comments and suggestions are invited from all interested parties. Comments or questions concerning this proposed action and the EIS should be directed to the FHWA or UDOT at the addresses provided above.

(Catalog of Federal Domestic Assistance Program Number 20.205, Highway Research, Planning and Construction. The regulations impending Executive Order 12372 regarding intergovernmental consultation on Federal programs and activities apply to this program)

Issued on: July 30, 2004.

**Jeffrey Berna,**

*Environmental Specialist, Salt Lake City, Utah.*

[FR Doc. 04–17863 Filed 8–4–04; 8:45 am]

**BILLING CODE 4910–22–M**

## DEPARTMENT OF TRANSPORTATION

### National Highway Traffic Safety Administration

**[Docket No. NHTSA–2004–18755; Notice 1]**

### Coupled Products, Inc., Receipt of Petition for Decision of Inconsequential Noncompliance

Coupled Products, Inc. (Coupled Products) has determined that certain hydraulic brake hose assemblies that it produced do not comply with S5.3.4 of 49 CFR 571.106, Federal Motor Vehicle Safety Standard (FMVSS) No. 106, ''Brake hoses.'' Coupled Products has filed an appropriate report pursuant to 49 CFR part 573, ''Defect and Noncompliance Reports.''

Pursuant to 49 U.S.C. 30118(d) and 30120(h), Coupled Products has petitioned for an exemption from the notification and remedy requirements of 49 U.S.C. chapter 301 on the basis that this noncompliance is inconsequential to motor vehicle safety.

This notice of receipt of Coupled Product's petition is published under 49 U.S.C. 30118 and 30120 and does not represent any agency decision or other exercise of judgment concerning the merits of the petition.

A total of approximately 24,622 brake hose assemblies, consisting of 3,092 assemblies bearing Part Number 5478 and 21,530 assemblies bearing Part Number 5480 are affected. S5.3.4 of FMVSS No. 106, tensile strength, requires that ''a hydraulic brake hose assembly shall withstand a pull of 325 pounds without separation of the hose from its end fittings.'' The potentially affected hoses were manufactured using a ''straight cup'' procedure rather than the appropriate ''step cup'' procedure. Compliance testing by the petitioner of eight sample hose assemblies from two separate manufacturing lots of these hoses revealed that seven of the eight samples experienced hose separation from the end fittings at from 224 to 317 pounds.

Coupled Products believes that the noncompliance is inconsequential to motor vehicle safety and that no corrective action is warranted. Coupled Products states that these hoses were shipped exclusively to EZ Loader, a manufacturer of boat trailers, the sole customer of the affected hoses. Coupled Products states:

> Both Part Numbers 5478 and 5480 are utilized in specific boat trailer applications of a single trailer manufacturer. * * * [T]he routing and placement of the hoses on the particular boat trailers involved, and the shielded nature of the end fittings on those trailers are such that a linear, end-to-end ''straight pull'' on the hose assembly, such as that specified in the FMVSS No. 106 tensile strength test procedure, is unlikely to occur in real-world use. Because of the manner in which these hose assemblies are installed, rather than a ''straight pull,'' it is more likely that the free length of the hose itself could be entangled or caught on a piece of road debris or other obstruction, resulting in a ''side pull'' on the assembly. With this potential in mind, [Coupled Products] conducted a side pull tensile test on a sample of the subject brake hose assemblies to simulate the possible effect of a side pull on the integrity of the assembly. This was accomplished by creating special mounting fixtures and apparatus to the standard testing equipment. * * * The ''side pull'' test results show that the tensile load achieved prior to the ends separating from the hose exceeded 530 pounds in each of the five samples tested—well in excess of the 325 pound requirement.

Coupled Products further states:

> We believe that it is likely that in order for such a [side] pull to occur, the debris or obstacle in question would need to be of such size and/or weight that its encounter with the trailer would result in significant structural impact and thus have immediate effect on the operation of the trailer. While we have not been able to devise a test that would verify this theory, we believe that this is a realistic scenario. As a result, it seems likely that the trailer would likely incur an operational impact even before the possible loss of braking capability resulting from hose assembly failure.
>
> The axles used in the trailers in question are stationary. Unlike sliding axles that are used in some trailers, the axles used in these trailers are in a fixed location. Consequently, the possibility that the sliding movement of the axle might result in unintended pull on the hose is remote. * * *
>
> Because the braking system on the trailer is independent of the towing vehicle's braking system, any failure of the hose assembly due to excessive tensile force—unlikely as that may be—will not result in a loss of braking capability of the towing vehicle. Thus, in the unlikely event of separation, the driver would still retain full braking capability of the towing vehicle and would be able to stop the vehicle (although additional stopping distance may be required depending on the type of vehicle being used).

Coupled Products states that in other cases NHTSA determined that a FMVSS No. 106 noncompliance is inconsequential where, because of the specific vehicle application involved, the hose assembly would not be subject to the type of forces specified in the standard. Coupled Product says:

> *See, e.g.*, General Motors Grant of Petition * * * 57 FR 1511 (January 14, 1992) (granting petition with respect to adhesion test noncompliance because, among other reasons, the ''end use of the hoses was such that they were subject to pressure, not vacuum applications''), and Mitsubishi Motors America Grant of Petition * * * 57 FR 45868 (October 5, 1992) (same).

Coupled Products states it cannot estimate the percentage of the affected population that may be noncompliant, but the test results indicate that it is likely to be less than 100 percent. Coupled Products indicates that the problem has been corrected.

Interested persons are invited to submit written data, views, and arguments on the petition described above. Comments must refer to the docket and notice number cited at the beginning of this notice and be submitted by any of the following methods. Mail: Docket Management Facility, U.S. Department of Transportation, Nassif Building, Room PL–401, 400 Seventh Street, SW., Washington, DC 20590–0001. Hand Delivery: Room PL–401 on the plaza level of the Nassif Building, 400 Seventh Street, SW., Washington, DC. It is requested, but not required, that two copies of the comments be provided. The Docket Section is open on weekdays from 10 a.m. to 5 p.m. except Federal holidays. Comments may be submitted electronically by logging onto the Docket Management System Web site at *http://dms.dot.gov.* Click on ''Help'' to obtain instructions for filing the document electronically. Comments may be faxed to 1–202–493–2251, or may be submitted to the Federal eRulemaking Portal: go to *http://www.regulations.gov.* Follow the online instructions for submitting comments.

The petition, supporting materials, and all comments received before the close of business on the closing date indicated below will be filed and will be considered. All comments and supporting materials received after the closing date will also be filed and will be considered to the extent possible. When the petition is granted or denied, notice of the decision will be published in the **Federal Register** pursuant to the authority indicated below.

*Comment closing date:* September 7, 2004.

(Authority: 49 U.S.C. 30118, 30120: delegations of authority at CFR 1.50 and 501.8.)

Issued on: August 2, 2004.

**Kenneth N. Weinstein,**

*Associate Administrator for Enforcement.*

[FR Doc. 04–17932 Filed 8–4–04; 8:45 am]

BILLING CODE 4910–59–P

## DEPARTMENT OF THE TREASURY

### Submission for OMB Review; Comment Request

July 29, 2004.

The Department of Treasury has submitted the following public information collection requirement(s) to OMB for review and clearance under the Paperwork Reduction Act of 1995, Public Law 104–13. Copies of the submission(s) may be obtained by calling the Treasury Bureau Clearance Officer listed. Comments regarding this information collection should be addressed to the OMB reviewer listed and to the Treasury Department Clearance Officer, Department of the Treasury, Room 11000, 1750 Pennsylvania Avenue, NW., Washington, DC 20220.

**DATES:** Written comments should be received on or before September 7, 2004 to be assured of consideration.

**Internal Revenue Service (IRS)**

*OMB Number:* 1545–0070.

*Regulation Project Number:* PS–163–84 Final.

*Type of Review:* Extension.

*Title:* Treatment of Transactions Between Partners and Partnerships.

*Description:* Section 707(a)(2) provides that if there is a transfer of money or property by a partner to a partnership, the transfer will be treated, in certain situations, as a disguised sale between the partner and the partnership. The regulations provide that the partner or the partnership should disclose the transfers and certain attendant facts in some situations.

*Respondents:* Business of other for-profit.

*Estimated Number of Respondents:* 7,500.

*Estimated Burden Hours Respondent:* 20 minutes.

*Frequency of response:* Annually.

*Estimated Total Reporting Burden:* 2,500 hours.

*Clearance Officer:* Glenn P. Kirkland (202) 622–3428, Internal Revenue Service, Room 6411–03, 1111 Constitution Avenue, NW., Washington, DC 20224.

*OMB Reviewer:* Joseph F. Lackey, Jr. (202) 395–7316, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503.

**Lois K. Holland,**

*Treasury PRA Clearance Officer.*

[FR Doc. 04–17888 Filed 8–4–04; 8:45 am]

BILLING CODE 4830–01–P

## DEPARTMENT OF THE TREASURY

### Internal Revenue Service

### Proposed Collection; Comment Request for Form 8847; Correction

**AGENCY:** Internal Revenue Service (IRS), Treasury.

**ACTION:** Correction to notice and request for comments.

**SUMMARY:** This document corrects a notice and request for comments that was published in the **Federal Register** on Monday, July 26, 2004 (66 FR 44567). This notice relates to the Department of the Treasury's invitation to the general public and other Federal agencies to submit public comments on proposed and/or continuing information collections.

**FOR FURTHER INFORMATION CONTACT:** Allan Hopkins, (202) 622–6665 (not a toll-free number).

**SUPPLEMENTARY INFORMATION:**

**Background**

The notice and request for comments that is the subject of this correction is required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506(c)(2)(A)).

**Need for Correction**

As published, the notice and request for comments contains an error that may prove to be misleading and is in need of clarification.

**Correction of Publication**

Accordingly, the notice and request for comments which was the subject of FR Doc. 04–16968, is corrected as follows:

On page 44567, column 2, under the caption **SUPPLEMENTARY INFORMATION:**, the paragraph ''Current Actions:'' is corrected to read as follows: ''Old lines 8b through 8i were collapsed into new line 8b. Lines 8j through 8m were renumbered lines 8c through 8f. IRS made this change to reduce taxpayer burden. Most filers do not have any of the credits on old lines b through i, thus the change reduces the number of lines they must consider to one''.

**LaNita Van Dyke,**

*Acting Chief, Publications and Regulations Branch, Legal Processing Division, Associate Chief Counsel, (Procedures and Administration).*

[FR Doc. 04–17903 Filed 8–4–04; 8:45 am]

BILLING CODE 4830–01–P

# Corrections

Federal Register

Vol. 69, No. 150

Thursday, August 5, 2004

This section of the FEDERAL REGISTER contains editorial corrections of previously published Presidential, Rule, Proposed Rule, and Notice documents. These corrections are prepared by the Office of the Federal Register. Agency prepared corrections are issued as signed documents and appear in the appropriate document categories elsewhere in the issue.

## DEPARTMENT OF ENERGY

### Office of Energy Efficiency and Renewable Energy

### 10 CFR Part 431

**[Docket No. EE–RM/STD–01–375]**

**RIN 1904–AB09**

### Energy Conservation Program for Commercial and Industrial Equipment: Energy Conservation Standards for Commercial Unitary Air Conditioners and Heat Pumps

*Correction*

In proposed rule document 04–16575 beginning on page 45460 in the issue of Thursday, July 29, 2004, make the following correction:

On page 45465, in the table, in the column ''Equipment type'', in the final entry, the phrase, ''(Cooling Mode)'' should read, ''(Heating Mode).''

[FR Doc. C4–16575 Filed 8–4–04; 8:45 am]

BILLING CODE 1505–01–D

## DEPARTMENT OF TRANSPORTATION

### Federal Aviation Administration

### Commercial Space Transportation; Waiver of Liquid Propellant Storage and Handling Requirements for Operation of a Launch Site at the Mojave Airport in CA

*Correction*

In notice document 04–15551 beginning on page 41327 in the issue of Thursday, July 8, 2004 make the following correction:

On page 41328, in the second column, in the first full paragraph, in the last line, ''1,000 feet'' should read ''100 feet''.

[FR Doc. C4–15551 Filed 8–4–04; 8:45 am]

BILLING CODE 1505–01–D

Federal Register

Thursday,
August 5, 2004

# Part II

# Department of Health and Human Services

## Centers for Medicare and Medicaid Services

## 42 CFR Parts 405, 410, 411, et al.

## Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2005; Proposed Rule

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Medicare & Medicaid Services**

**42 CFR Parts 405, 410, 411, 414, 418, 424, 484, and 486**

**[CMS–1429–P]**

**RIN 0938–AM90**

## Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2005

**AGENCY:** Centers for Medicare & Medicaid Services (CMS), HHS.

**ACTION:** Proposed rule.

**SUMMARY:** This proposed rule would refine the resource-based practice expense relative value units (RVUs) and make other changes to Medicare Part B payment policy. The proposed policy changes concern: supplemental survey data for practice expense, updated geographic practice cost indices for physician work and practice expense, updated malpractice RVUs, revised requirements for supervision of therapy assistants, revised payment rules for low osmolar contrast media, changes to payment policies for physicians and practitioners managing dialysis patients, clarification of care plan oversight requirements, revised requirements for supervision of diagnostic psychological testing services, clarifications to the policies affecting therapy services, revised requirements for assignment of Medicare claims, addition to the list of telehealth services, and several coding issues.

We are proposing these changes to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services. We solicit comments on these proposed policy changes.

This proposed rule also addresses the following provisions of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA): coverage of an initial preventive physical examination; coverage of cardiovascular screening blood tests; coverage of diabetes screening tests; incentive payment improvements for physicians in shortage areas; payment for covered outpatient drugs and biologicals; payment for renal dialysis services; coverage of routine costs associated with certain clinical trials of category A devices as defined by the Food and Drug Administration; hospice consultation service; indexing the Part B deductible to inflation; extension of coverage of intravenous immune globulin (IVIG) for the treatment in the home of primary immune deficiency diseases; revisions to reassignment provisions; clinical conditions for payment of covered items of durable medical equipment; and payment for diagnostic mammograms.

In addition, we discuss physicians' services associated with drug administration services and payment for set-up of portable x-ray equipment.

**DATES:** To be assured consideration, comments must be received at one of the addresses provided below, no later than 5 p.m. on September 24, 2004.

**ADDRESSES:** In commenting, please refer to file code CMS–1429–P. Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission.

You may submit comments in one of three ways (no duplicates, please):

1. *Electronically.* You may submit electronic comments on specific issues in this regulation to *http://www.cms.hhs.gov/regulations/ecomments.* (Attachments should be in Microsoft Word, WordPerfect, or Excel; however, we prefer Microsoft Word.)

2. *By mail.* You may mail written comments (one original and two copies) to the following address ONLY:

Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–1429–P, P.O. Box 8012, Baltimore, MD 21244–8012.

Please allow sufficient time for mailed comments to be received before the close of the comment period.

3. *By hand or courier.* If you prefer, you may deliver (by hand or courier) your written comments (one original and two copies) before the close of the comment period to one of the following addresses. If you intend to deliver your comments to the Baltimore address, please call telephone number (410) 786–7197 in advance to schedule your arrival with one of our staff members.

Room 445–G, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201; or 7500 Security Boulevard, Baltimore, MD 21244–1850.

(Because access to the interior of the HHH Building is not readily available to persons without Federal Government identification, commenters are encouraged to leave their comments in the CMS drop slots located in the main lobby of the building. A stamp-in clock is available for persons wishing to retain a proof of filing by stamping in and retaining an extra copy of the comments being filed.)

Comments mailed to the addresses indicated as appropriate for hand or courier delivery may be delayed and received after the comment period.

*Submission of comments on paperwork requirements.* You may submit comments on this document's paperwork requirements by mailing your comments to the addresses provided at the end of the ''Collection of Information Requirements'' section in this document.

For information on viewing public comments, see the beginning of the **SUPPLEMENTARY INFORMATION** section.

**FOR FURTHER INFORMATION CONTACT:**

Pam West (410) 786–2302 (for issues related to Practice Expense, Respiratory Therapy Coding, and Therapy Supervision).

Rick Ensor (410) 786–5617 (for issues related to Geographic Practice Cost Index (GPCI) and malpractice RVUs).

Craig Dobyski (410) 786–4584 (for issues related to list of telehealth services or payments for physicians and practitioners managing dialysis patients).

Bill Larson or Tiffany Sanders (410) 786–7176 (for issues related to coverage of an initial preventive physical examination).

Cathleen Scally (410) 786–5714 (for issues related to payment of an initial preventive physical examination).

Joyce Eng (410) 786–7176 (for issues related to coverage of cardiovascular screening tests).

Betty Shaw (410) 786–7176 (for issues related to coverage of diabetes screening tests).

Anita Greenberg (410) 786–0548 (for issues related to payment of cardiovascular and diabetes screening tests).

David Worgo (410) 786–5919, (for issues related to incentive payment improvements for physicians practicing in shortage areas).

Angela Mason or Jennifer Fan (410) 786–0548 (for issues related to payment for covered outpatient drugs and biologicals).

David Walczak (410) 786–4475 (for issues related to reassignment provisions).

Henry Richter (410) 786–4562 (for issues related to payments for ESRD facilities).

Steve Berkowitz (410) 786–7176 (for issues related to coverage of routine costs associated with certain clinical trials of category A devices).

Terri Deutsch (410) 786–9462 (for issues related to hospice consultation services).

Karen Daily (410) 786–7176 (for issues related to clinical conditions for payment of covered items of durable medical equipment).

Dorothy Shannon (410) 786–3396 (for issues related to outpatient therapy services performed ''incident to'' physicians' services).
Roberta Epps (410) 786–5919 (for issues related to low osmolar contrast media or supervision of diagnostic psychological testing services).
Gail Addis (410) 786–4522 (for issues related to care plan oversight).
Diane Milstead (410) 786–3355 or Gaysha Brooks (410) 786–9649 (for all other issues).

**SUPPLEMENTARY INFORMATION:**

*Submitting Comments:* We welcome comments from the public on all issues set forth in this rule to assist us in fully considering issues and developing policies. You can assist us by referencing the file code CMS–1429-P and the specific ''issue identifier'' that precedes the section on which you choose to comment.

*Inspection of Public Comments:* Comments received timely will be available for public inspection as they are processed, generally beginning approximately 3 weeks after publication of a document, at the headquarters of the Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Baltimore, Maryland 21244, Monday through Friday of each week from 8:30 a.m. to 4 p.m. To schedule an appointment to view public comments, phone (410) 786–7197.

*Copies:* To order copies of the **Federal Register** containing this document, send your request to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250–7954. Specify the date of the issue requested and enclose a check or money order payable to the Superintendent of Documents, or enclose your Visa or Master Card number and expiration date. Credit card orders can also be placed by calling the order desk at (202) 512–1800 (or toll-free at 1–888–293–6498) or by faxing to (202) 512–2250. The cost for each copy is $10. As an alternative, you can view and photocopy the **Federal Register** document at most libraries designated as Federal Depository Libraries and at many other public and academic libraries throughout the country that receive the **Federal Register**.

This **Federal Register** document is also available from the **Federal Register** online database through *GPO Access*, a service of the U.S. Government Printing Office. The web site address is: *http://www.access.gpo.gov/nara/index.html*.

Information on the physician fee schedule can be found on the CMS homepage. You can access this data by using the following directions:

1. Go to the CMS homepage (*http://www.cms.hhs.gov*).
2. Place your cursor over the word ''Professionals'' in the blue area near the top of the page. Select ''physicians'' from the drop-down menu.
3. Under ''Policies/Regulations'' select ''Physician Fee Schedule.''

To assist readers in referencing sections contained in this preamble, we are providing the following table of contents. Some of the issues discussed in this preamble affect the payment policies but do not require changes to the regulations in the Code of Federal Regulations. Information on the regulation's impact appears throughout the preamble and is not exclusively in section VII.

**Table of Contents**

I. Background
A. Legislative History
B. Published Changes to the Fee Schedule
II. Provisions of the Proposed Regulation Related to the Physician Fee Schedule
A. Resource-Based Practice Expense Relative Value Units (RVUs)
B. Geographic Practice Cost Indices (GPCIs)
C. Malpractice Work RVUs
D. Coding Issues
III. Provisions Related to the Medicare Modernization Act of 2003
A. Section 611—Preventive Physical Examination
B. Section 613—Diabetes Screening
C. Section 612—Cardiovascular Screening
D. Section 413—Incentive Payment for Physician Scarcity
E. Section 303—Payment for Covered Outpatient Drugs and Biologicals
F. Section 952—Revision to Reassignment Provisions
G. Section 642—Extension of Coverage of IVIG for the Treatment in the Home of Primary Immune Deficiency Diseases
H. Section 623—Payment for Renal Dialysis Services
I. Section 731—Coverage of Routine Costs for Category A Clinical Trials
J. Section 629—Part B Deductible
K. Section 512—Hospice Consultation Service
L. Section 302—Clinical Conditions for Coverage of Durable Medical Equipment (DME)
M. Section 614—Payment for Certain Mammography Services
N. Section 305—Payment for Inhalation Drugs
IV. Other Issues
A. Provisions Related to Therapy Services
1. Outpatient Therapy Services Performed ''Incident to'' Physicians'' Services
2. Supervision Requirements for Therapy Assistants in Private Practice
3. Other Technical Revisions
B. Low Osmolar Contrast Media
C. Payments for Physicians and Practitioners Managing Dialysis Patients
D. Technical Revision—§ 411.404
E. Supervision of Clinical Psychological Testing
F. Care Plan Oversight
G. Assignment of Medicare Claims—Payment to the Supplier
V. Collection of Information Requirements
VI. Response to Comments
VII. Regulatory Impact Analysis
Addendum A—Explanation and Use of Addendum B.
Addendum B—2005 Relative Value Units and Related Information Used in Determining Medicare Payments for 2005.
Addendum C—Codes for Which We Received PEAC Recommendations on Practice Expense Direct Cost Inputs.
Addendum D—Proposed Changes to Practice Expense Equipment Description and Pricing.
Addendum E—Revised 2005 Office Rental Index Versus Current Office Rental Index by 2004 Fee Schedule Area
Addendum F—Current Geographic Practice Cost Indices by Medicare Carrier and Locality
Addendum G—Proposed 2005 Geographic Practice Cost Indices by Medicare Carrier and Locality
Addendum H—Proposed 2006 Geographic Practice Cost Indices by Medicare Carrier and Locality
Addendum I—Comparison of Current 2004 Geographic Adjustment Factors (GAFs) to Proposed 2005 GAFS
Addendum J—Comparison of Current 2004 GAFs to Proposed 2006 GAFs

In addition, because of the many organizations and terms to which we refer by acronym in this proposed rule, we are listing these acronyms and their corresponding terms in alphabetical order below:

ACC American College of Cardiology
ACR American College of Radiology
AMA American Medical Association
APA American Psychological Association
ASP Average Sales Price
ATA American Telemedicine Association
BBA Balanced Budget Act of 1997
BBRA Balanced Budget Refinement Act of 1999
BIPA Benefits Improvement and Protection Act of 2000
BLS Bureau of Labor Statistics
CAH Critical Access Hospital
CF Conversion factor
CFR Code of Federal Regulations
CMS Centers for Medicare & Medicaid Services
CNS Clinical Nurse Specialist
CPT [Physicians'] Current Procedural Terminology [4th Edition, 2002, copyrighted by the American Medical Association]
CPEP Clinical Practice Expert Panel
CY Calendar Year
E/M Evaluation and management
ESRD End-Stage Renal Disease
FMR Fair market rental
FY Fiscal Year
GAF Geographic adjustment factor
GPCI Geographic practice cost index
HCPCS Healthcare Common Procedure Coding System
HHA Home health agency
HHS [Department of] Health and Human Services

HOCM High osmolar contrast media
HPSA Health Professional Shortage Area
HRSA Health Resources and Services Administration
IDTFs Independent Diagnostic Testing Facilities
IPPS Inpatient prospective payment system
IOM Internet Only Manual
ISO Insurance Services Office
LOCM Low osmolar contrast media
MCM Medicare Carrier Manual
MCP Monthly Capitation Payment
MedPAC Medicare Payment Advisory Commission
MEI Medicare Economic Index
MGMA Medical Group Management Association
MMA Medicare Prescription Drug, Improvement, and Modernization Act of 2003
MPFS Medicare Physician Fee Schedule
MSA Metropolitan Statistical Area
NAMCS National Ambulatory Medical Care Survey
NP Nurse Practitioner
OBRA Omnibus Budget Reconciliation Act
OMB Office of Management and Budget
OPPS Outpatient prospective payment system
PA Physician Assistant
PC Professional component
PCF Patient compensation fund
PEAC Practice Expense Advisory Committee
PET Positron Emission Tomography
PHSA Public Health Services Act
PPS Prospective payment system
PSA Physician Scarcity Area
RN Registered Nurse
RUC [AMA's Specialty Society] Relative [Value] Update Committee
RUCA Rural-Urban Commuting Area
RVU Relative value unit
SCHIP State Child Health Insurance Program
SGR Sustainable growth rate
SLP Speech language pathology
SMS [AMA's] Socioeconomic Monitoring System
TC Technical component
USPSTF U.S. Preventive Services Task Force

## I. Background

### *A. Legislative History*

Since January 1, 1992, Medicare has paid for physicians' services under section 1848 of the Social Security Act (the Act), ''Payment for Physicians' Services.'' The Act requires that payments under the fee schedule be based on national uniform relative value units (RVUs) based on the resources used in furnishing a service. Section 1848(c) of the Act requires that national RVUs be established for physician work, practice expense, and malpractice expense. Section 1848(c)(2)(B)(ii)(II) of the Act provides that adjustments in RVUs may not cause total physician fee schedule payments to differ by more than $20 million from what they would have been had the adjustments not been made. If adjustments to RVUs cause expenditures to change by more than $20 million, we must make adjustments to ensure that they do not increase or decrease by more than $20 million.

### *B. Published Changes to the Fee Schedule*

The July 2000 and August 2003 proposed rules ((65 FR 44177) and (68 FR 49030), respectively), include a summary of the final physician fee schedule rules published through February 2003.

In the November 7, 2003 final rule, we refined the resource-based practice expense RVUs and made other changes to Medicare Part B payment policy. The specific policy changes concerned: The Medicare Economic Index; practice expense for professional component services; definition of diabetes for diabetes self-management training; supplemental survey data for practice expense; geographic practice cost indices; and several coding issues. In addition, this rule updated the codes subject to the physician self-referral prohibition. We also made revisions to the sustainable growth rate, the anesthesia conversion factor and finalized the CY 2003 interim RVUs and issued interim RVUs for new and revised procedure codes for CY 2004.

As required by the statute, we announced that the physician fee schedule update for CY 2004 would be −4.5 percent; the initial estimate of the sustainable growth rate for CY 2004 was 7.4 percent; and the conversion factor for CY 2004 was $35.1339.

Subsequent to the November 7, 2003 final rule, the Congress enacted the MMA (Pub. L. 108–17). On January 7, 2004, an interim final rule was published to implement provisions of the MMA applicable in 2004 to Medicare payment for covered drugs and physician fee schedule services. These provisions included—

- Revising the current payment methodology for Part B covered drugs and biologicals that are not paid on a cost or prospective payment basis;
- Making changes to Medicare payment for furnishing or administering drugs and biologicals;
- Revising the geographic practice cost indices;
- Changing the physician fee schedule conversion factor. The 2004 physician fee schedule conversion factor is $37.3374; and
- Extending the ''opt-out'' provisions of section 1802(b)(5)(3) of the Act to dentists, podiatrists, and optometrists.

The information contained in the January 7, 2004 interim final rule concerning payment under the physician fee schedule superceded information contained in the November 7, 2003 final rule to the extent that the two are inconsistent.

## II. Provisions of the Proposed Rule

This proposed rule would affect the regulations set forth at Part 405, Federal Health Insurance for the Aged and Disabled; Part 410, Supplementary Medical Insurance (SMI) Benefits; Part 411, Exclusions from Medicare and Limitations on Medicare Payment; Part 414, Payment for Part B Medical and Other Health Services; Part 418, Hospice Care; Part 424, Conditions for Medicare Payment; Part 484, Home Health Services; and Part 486, Conditions for Coverage of Specialized Services Furnished by Suppliers.

### *A. Resource-Based Practice Expense Relative Value Units*

[If you choose to comment on issues in this section, please include the caption ''Practice Expense'' at the beginning of your comments.]

#### 1. Resource-Based Practice Expense Legislation

Section 121 of the Social Security Act Amendments of 1994 (Pub. L. 103–432), enacted on October 31, 1994, amended section 1848(c)(2)(C)(ii) of the Social Security Act and required us to develop a methodology for a resource-based system for determining practice expense RVUs for each physician's service beginning in 1998. Until that time, physicians' practice expenses were established based on historical allowed charges.

In developing the methodology, we were to consider the staff, equipment, and supplies used in providing medical and surgical services in various settings. The legislation specifically required that, in implementing the new system of practice expense RVUs, we apply the same budget-neutrality provisions that we apply to other adjustments under the physician fee schedule.

Section 4505(a) of the Balanced Budget Act of 1997 (BBA) (Pub. L. 105–33), enacted on August 5, 1997, amended section 1848(c)(2)(C)(ii) of the Act and delayed the effective date of the resource-based practice expense RVU system until January 1, 1999. In addition, section 4505(b) of the BBA provided for a 4-year transition period from charge-based practice expense RVUs to resource-based RVUs.

Further legislation affecting resource-based practice expense RVUs was included in the Medicare, Medicaid and State Child Health Insurance Program (SCHIP) Balanced Budget Refinement Act of 1999 (BBRA) (Pub. L. 106–113)

enacted on November 29, 1999. Section 212 of the BBRA amended section 1848(c)(2)(C)(ii) of the Act by directing us to establish a process under which we accept and use, to the maximum extent practicable and consistent with sound data practices, data collected or developed by entities and organizations. These data would supplement the data we normally collect in determining the practice expense component of the physician fee schedule for payments in CY 2001 and CY 2002. (The 1999 and 2003 final rules (64 FR 59380 and 68 FR 63196, respectively, extended the period during which we would accept supplemental data.)

2. Current Methodology for Computing the Practice Expense Relative Value Unit System

In the November 2, 1998 final rule (63 FR 58910), effective with services furnished on or after January 1, 1999, we established at 42 CFR 414.22(b)(5) a new methodology for computing resource-based practice expense RVUs that used the two significant sources of actual practice expense data we have available—the Clinical Practice Expert Panel (CPEP) data and the American Medical Association's (AMA) Socioeconomic Monitoring System (SMS) data. The CPEP data were collected from panels of physicians, practice administrators, and nonphysicians (for example registered nurses) nominated by physician specialty societies and other groups. The CPEP panels identified the direct inputs required for each physician service in both the office setting and out-of-office setting. The AMA's SMS data provided aggregate specialty-specific information on hours worked and practice expenses. The methodology was based on an assumption that current aggregate specialty practice costs are a reasonable way to establish initial estimates of relative resource costs for physicians' services across specialties. The methodology allocated these aggregate specialty practice costs to specific procedures and, thus, can be seen as a ''top-down'' approach.

Also in the November 2, 1998 final rule, in response to comments, we discussed the establishment of the Practice Expense Advisory Committee (PEAC) of the AMA's Specialty Society Relative Value Update Committee (RUC), which would review code-specific CPEP data during the refinement period. This committee would include representatives from all major specialty societies and would make recommendations to us on suggested changes to the CPEP data.

As directed by the BBRA, we also established a process (*see* 65 FR 65380) under which we would accept and use, to the maximum extent practicable and consistent with sound data practices, data collected by entities and organizations to supplement the data we normally collect in determining the practice expense component of the physician fee schedule.

a. Major Steps

A brief discussion of the major steps involved in the determination of the practice expense RVUs follows. (Please see the November 1, 2001 final rule (66 FR 55249) for a more detailed explanation of the top-down methodology.)

- *Step 1*—Determine the specialty specific practice expense per hour of physician direct patient care. We used the AMA's SMS survey of actual aggregate cost data by specialty to determine the practice expenses per hour for each specialty. We calculated the practice expenses per hour for the specialty by dividing the aggregate practice expenses for the specialty by the total number of hours spent in patient care activities.
- *Step 2*—Create a specialty-specific practice expense pool of practice expense costs for treating Medicare patients. To calculate the total number of hours spent treating Medicare patients for each specialty, we used the physician time assigned to each procedure code and the Medicare utilization data. The primary sources for the physician time data were surveys submitted to the AMA's RUC and surveys done by Harvard for the establishment of the work RVUs. We then multiplied the physician time assigned per procedure code by the number of times that code was billed by each specialty, and summed the products for each code, by specialty, to get the total physician hours spent treating Medicare patients for that specialty. We then calculated the specialty specific practice expense pools by multiplying the specialty practice expenses per hour (from step 1) by the total Medicare physician hours for the specialty.
- *Step 3*—Allocate the specialty specific practice expense pool to the specific services (procedure codes) performed by each specialty. For each specialty, we divided the practice expense pool into two groups based on whether direct or indirect costs were involved and used a different allocation basis for each group.

(i) Direct costs—For direct costs (which include clinical labor, medical supplies, and medical equipment), we used the procedure-specific CPEP data on the staff time, supplies, and equipment as the allocation basis. For the separate practice expense pool for services without physician work RVUs, we have used, on an interim basis, 1998 practice expense RVUs to allocate the direct cost pools.

(ii) Indirect costs—To allocate the cost pools for indirect costs, including administrative labor, office expenses, and all other expenses, we used the total direct costs, or the 1998 practice expense RVUs, in combination with the physician fee schedule work RVUs. We converted the work RVUs to dollars using the Medicare CF (expressed in 1995 dollars for consistency with the SMS survey years).

- *Step 4*—The direct and indirect costs are then added together to attain the practice expense for each procedure, by specialty. For procedures performed by more than one specialty, the final practice expense allocation was a weighted average of practice expense allocations for the specialties that perform the procedure, based on the frequency with which each specialty performs the procedure on Medicare patients.

b. Other Methodological Issues

i. Nonphysician Work Pool

As an interim measure, until we could further analyze the effect of the top-down methodology on the Medicare payment for services with physician work RVUs equal to zero (including the technical components of radiology services and other diagnostic tests), we created a separate practice expense pool. We first used the average clinical staff time from the CPEP data and the ''all physicians'' practice expense per hour to create the pool. In the December 2002 final rule, we changed this policy and now use the total clinical staff time and the weighted average specialty–specific practice expense per hour for specialties with services in this pool. In the next step, we used the adjusted 1998 practice expense RVUs to allocate this pool to each service. Also, for all radiology services that are assigned physician work RVUs, we used the adjusted 1998 practice expense RVUs for radiology services as an interim measure to allocate the direct practice expense cost pool for radiology.

A specialty society may request that its services be removed from the nonphysician workpool. We have removed services from the nonphysician work pool if the requesting specialty predominates utilization of the service.

ii. Crosswalks for Specialties Without Practice Expense Survey Data

Since many specialties identified in our claims data did not correspond exactly to the specialties included in the SMS survey data, it was necessary to crosswalk these specialties to the most appropriate SMS specialty.

iii. Physical Therapy Services

Because we believe that most physical therapy services furnished in physicians' offices are performed by physical therapists, we crosswalked all utilization for therapy services in the CPT 97000 series to the physical and occupational therapy practice expense pool.

3. Practice Expense Proposals for Calendar Year 2005

a. Supplemental Practice Expense Surveys

i. Survey Criteria and Submission Dates

As required by the BBRA, we established criteria to evaluate survey data collected by organizations to supplement the SMS survey data normally used in the calculation of the practice expense component of the physician fee schedule. By regulation (see 68 FR 63200), we provided that, beginning this year, supplemental survey data must be submitted by March 1 to be considered for use in computing practice expense RVUs for the following year. This allows us to publish our decisions regarding survey data in the proposed rule and provides the opportunity for public comment on these results before implementation.

To continue to ensure the maximum opportunity for specialties to submit supplemental practice expense data, we extended until 2005 the period that we would accept survey data that meet the criteria set forth in the November 2000 final rule. We will no longer accept supplemental practice expense data after that point. The deadline for submission of supplemental data to be considered in CY 2006 is March 1, 2005.

ii. Survey by the College of American Pathologists (CAP)

In the June 28, 2002 **Federal Register** (67 FR 43849), we proposed a technical change to the practice expense methodology that calculated the technical component as the difference between the global and professional component RVUs for services not included in the nonphysician work pool. In the December 31, 2002 final rule (67 FR 79979), we established a 1-year moratorium on the technical change for pathology services to allow CAP to do a survey of independent laboratories. Consistent with last year's rules, CAP submitted its supplemental survey by August 1, 2003 for use in determining the 2004 practice expense RVUs. Our contractor, The Lewin Group, evaluated the data and recommended that we accept the survey to supplement the data on PE. However, because we changed the survey deadline to March 1, CAP requested that we delay incorporation of the survey data until this year's proposed rule. CAP also requested that we extend the moratorium on calculating the technical component as the difference between the global and professional component RVUs for pathology services for one additional year to allow us to evaluate in a proposed rule the combined effects of the use of the new survey data along with other proposed technical changes. In the November 7, 2003 final rule, in response to the CAP comment, we agreed to extend the moratorium by an additional year. In this proposed rule, we propose to incorporate the CAP survey data into the practice expense methodology and to end the moratorium on calculating the technical component as the difference between the global and professional component RVUs for pathology services. We propose to use the following practice expense per hour figures for specialty 69—Independent Laboratory.

TABLE 1.—PRACTICE EXPENSE PER HOUR FIGURES FOR SPECIALTY 69—INDEPENDENT LABORATORY

| Specialty | Clinical staff | Admin. staff | Office expense | Medical supplies | Medical equipment | Other | Total |
|---|---|---|---|---|---|---|---|
| Independent Laboratory | $39.7 | $37.5 | $40.1 | $19.3 | $11.1 | $16.1 | $163.8 |

iii. Submission of Supplemental Surveys

We received surveys from the American College of Cardiology (ACC), the American College of Radiology (ACR), and the American Society for Therapeutic Radiation Oncology (ASTRO). Our contractor, The Lewin Group, evaluated the data and made recommendations to us regarding use of the data in a report on May 26, 2004. We have made The Lewin Group report available on the CMS Web site at *http://www.cms.hhs.gov/physicians/pfs/*. The Lewin Group is recommending that we accept the data from ACC and ACR but indicated that the survey from ASTRO does not meet the precision criteria we have established for supplemental surveys. As a result, The Lewin Group is not recommending that we use the ASTRO survey results at this time. We agree with this recommendation and are proposing not using the ASTRO survey data at this time.

Many of the procedures that are performed by radiology, cardiology, and radiation oncology are affected by the nonphysician work pool calculations. We created the nonphysician work pool as an interim measure because of a concern that the top-down methodology was having a large adverse impact on payment for services that do not have physician work RVUs. As we stated in the December 31, 2002 final rule (67 FR 79979), we believe a relatively low practice expense per hour explains the adverse impact on diagnostic and other services that would occur from eliminating the nonphysician work pool. The ACR, ACC, and ASTRO began undertaking surveys in 2003 following our analysis of options for eliminating the nonphysician work pool in the December 31, 2002 final rule. CMS' interest is in using the supplemental survey data to eliminate the nonphysician work pool and use a single methodology to establish payments for all physician fee schedule services.

We appreciate the efforts of these three specialties to undertake surveys and assist CMS in finding a permanent resolution of issues related to the nonphysician work pool. While the radiology survey data do meet the criteria we have established for use of supplemental surveys, the ACR has written to us asking that we not use the data until we have a stable and global solution that is workable for all specialties that are currently paid using the nonphysician work pool. The ACC also requested that we use the supplemental survey for services that are in the cardiology pool. However, ACC also indicated if CMS determines that it would only be appropriate to use the survey data if cardiology services are removed from the nonphysician work pool or if the nonphysician work pool

is eliminated, we should delay using the data until the issues involved can be discussed further.

At this time, we are not proposing to eliminate the nonphysician work pool or to remove selected radiology and cardiology codes from it. Since our interest is in using supplemental data in conjunction with pricing all services under the top-down methodology, we agree with the request from ACR to delay use of its supplemental survey until issues related to the nonphysician work pool can be addressed. Furthermore, we believe the high practice expense per hour for cardiology from the supplemental survey results from the inclusion of practices that do very high cost office-based cardiology services. Because the RVUs for these office-based cardiology services are currently determined using the nonphysician work pool methodology, we believe the ACC supplemental survey data should only be used in conjunction with removing cardiology services from the nonphysician work pool. For this reason, we are also delaying use of the ACC survey data as we continue to analyze elimination of the nonphysician work pool in conjunction with using supplemental survey data. As we complete our analysis, we look forward to working with the medical community to find a permanent resolution of this issue.

b. Practice Expense Advisory Committee (PEAC) Recommendations on CPEP Inputs for 2005

Since 1999, the PEAC, an advisory committee of the RUC, has been providing us with recommendations for refining the direct practice expense inputs (clinical staff, supplies, and equipment) for existing CPT codes. As we did last year, we are including our proposals regarding the PEAC recommendations in the proposed rule, to enable specialty groups to assess the impact of the proposed changes on their services and to make comments on them before the final rule.

These PEAC recommendations are the result of meetings held in March and August 2003 and January and March 2004, and account for over 2,200 codes from many specialties. (A list of these codes can be found in Addendum C.)

The PEAC held its last meeting in March 2004, and these are the last recommendations we will be receiving from the committee. The AMA established the PEAC to assist the RUC in refining the direct input data used in calculating the practice expense RVUs for established codes. Since its inception, the PEAC has provided recommendations on over 7,600 codes, which leaves only a few hundred physician fee schedule codes that we believe are still unrefined. The PEAC has also recommended standard times for many clinical staff activities and has established several supply and equipment packages that can be applied across wide ranges of codes. This has helped us ensure that the CPEP inputs have been assigned equitably across procedures performed by different specialties. The work of the PEAC has, therefore, contributed greatly to the refinement of the practice expense inputs, and we appreciate the 5 years of hard work by the specialty societies and the AMA that helped make the PEAC so successful. Future practice expense issues, including the refinement of the remaining codes not addressed by the PEAC, will be handled by the RUC. We anticipate the RUC will formulate the specific process at a future meeting, possibly as soon as October 2004. If possible, additional information on this process will be included in the final fee schedule rule.

We have reviewed the PEAC-submitted recommendations and propose to adopt nearly all of them. We have worked with the PEAC staff to correct any typographical errors and to make certain that the recommendations are in line with previously accepted standards. In addition, in order to prevent rank order anomalies, we reviewed those codes that are currently unrefined or that were refined early in the PEAC process to apply some of the major PEAC-agreed standards. For the unrefined 10-day global services, we are proposing to substitute for the original CPEP times the PEAC-agreed standard post-service office visit clinical staff times used for all 90-day and refined 10-day global services. We also are proposing to eliminate the discharge management clinical staff time from all but the 10 and 90-day global codes, substituting one post-service phone call if not already in the earlier data. Lastly, we are proposing to delete any extra clinical staff time for post-visit phone calls because that time is already included in the time allotted for the visits.

The complete PEAC recommendations and the revised practice expense database can be found on our web site. (See the ''Supplementary Information'' section of this proposed rule for directions on accessing our website.)

We disagree with the PEAC recommendation for clinical labor time for CPT 99183, Hyperbaric oxygen (HBO) therapy. During last year's rulemaking, we assigned, on an interim basis, 135 minutes of total clinical labor. The PEAC however, recommended 42 minutes of total clinical labor time, which allows for 20 minutes for the HBO chamber treatment (intra) time. We believe that 90 minutes is a more appropriate estimation of the clinical staff time actually needed for the intra time because, according to our data, a typical HBO treatment session billed under the outpatient prospective payment system is 90 minutes and the clinical staff is in constant attendance. Therefore, we are proposing a total clinical labor time of 112 minutes for this service.

The PEAC recommendations for CPT codes 91011 and 91052 included a supply input for methacholine chloride as the injected stimulant for these two services. In discussions with representatives from the gastroenterology specialty subsequent to receipt of the PEAC recommendations, we learned this is incorrect, since an injected form of methacholine chloride is not currently available. For CPT 91011, esophageal motility study, we are proposing to include edrophonium, 1 ml, as the drug typically used in this procedure. For CPT 91052, gastric analysis study, we were unable to identify the single drug that is most typically used with this procedure. We have added the edrophonium to the list of supplies where we need information from the specialty in order to price appropriately (see Table 3). We are also requesting that commenters, particularly the specialty organizations, provide us with information on the drug that is most typically used for CPT 91052, including drug dosage and price, so that it can be included in the practice expense database.

In last year's final rule, we indicated that we would not go forward with the 2003 PEAC recommendations on eight E/M codes for nursing home services, CPT codes 99301 through 99316 and on two E/M codes for home visits, CPT codes 99348 and 99350, to allow the PEAC to reconsider the clinical staff time for these codes based on the specific input from the representatives of the nursing home and home visit specialties. This year's PEAC recommendations for the E/M nursing home services included the views of the long-term care physicians and represent an overall decrease in clinical labor inputs for these codes. However, the home care physicians subsequently withdrew these codes from further PEAC consideration, which leaves the 2003 PEAC recommendation for these services unchanged. Therefore, we are proposing to adopt the direct practice expense input recommendations from

the March 2003 PEAC meeting for CPT codes 99348 and 99350.

c. Repricing of Clinical Practice Expense Inputs—Equipment

We use the practice expense inputs (the clinical staff, supplies, and equipment assigned to each procedure) to allocate the specialty-specific practice expense cost pools to the procedures performed by each specialty. The costs of the original equipment inputs assigned by the CPEP panels were determined in 1997 by our contractor, Abt Associates, based primarily on list prices from equipment suppliers. Subsequent to the CPEP panels, equipment has also been added to the CPEP data, with the costs of the inputs provided by the relevant specialty society. We only include equipment with costs equal to or exceeding $500 in our practice expense database because the cost per use for equipment costing less than $500 would be negligible. We also considered the useful life of the equipment in establishing an equipment cost per minute of use. This was discussed in our proposed rule published June 18, 1997 (62 FR 33164). The primary source of this information was the ''Estimated Useful Lives of Depreciable Hospital Assets'' (1993 edition) from the American Hospital Association (AHA).

We proposed updates and revisions to the clinical staff salary data and supply inputs and finalized these in the rules published November 1, 2001 (66 FR 55255) and November 7, 2003 (68 FR 63196), respectively. We also indicated that, in future rulemaking, we would be proposing updates to the equipment inputs that are used in the CPEP database.

We contracted with a consultant to assist us in obtaining the current price for each equipment item in our CPEP database. The consultant has been able to determine the current prices for most of the equipment inputs and, to ensure that accurate information was obtained, has submitted documentation from vendor catalogs or websites for nearly 600 equipment items.

Our contractor also clarified the specific composition of each of the various packaged and standardized rooms or ophthalmology ''lanes'' currently identified in the equipment practice expense database (for example, ''mammography room'' or ''exam lane''). We are proposing to delete the current ''room'' designation for the radiopharmaceutical receiving area and, in its place, list separately the equipment necessary for each procedure as individual line items because there does not appear to be a standard configuration for such a room across the nuclear medicine codes.

Although individual equipment items valued under $500 are not included in the equipment database, we do include instrument packs or surgical trays that are maintained, stored, and used as a unit, where the aggregate cost of individual items equals or exceeds $500. We have adopted the PEAC recommendation based on consensus among specialties to establish two generic instrument packages rather than list a myriad of different packages for each specialty. The basic instrument pack, assigned a value of $500, includes instrument aggregate costs ranging from $500 to $1,499. The medium pack was assigned $1,500, for instrument packages priced at or above $1,500. We are proposing to replace all surgical packs and trays in the practice expense database with the appropriate standardized packs described above.

Our consultant worked closely with the specialty societies to obtain accurate information to identify equipment and applicable prices. The useful life for each equipment item has also been reviewed and updated as necessary. This update is primarily based on the AHA's ''Estimated Useful Lives of Depreciable Hospital Assets'' (1998 edition) by direct association with a listed item in the publication or by crosswalking from a reasonably similar item. We understand that AHA will publish updated guidelines this summer, and we plan to reflect any updates in our final rule.

Addendum D lists the proposed new prices for equipment items, instrument packs, and rooms/lanes, as well as new descriptions when needed. A more detailed spreadsheet can be found on our website, *http://www.cms.hhs.gov/physicians/pfs.* This spreadsheet contains additional information regarding the sources used to price each equipment item.

Additionally, there are specific equipment items for which a source has not yet been identified or for which pricing information has not yet been found and documented. These are included in Table 2 below. In this table, we have identified the equipment code (if assigned), the existing description for the equipment item and current price, the procedures or specialties associated with the item, as well as the proposed new description and standardized life for the equipment's use, where this could be identified. We have also identified equipment for deletion from the database, such as equipment items less than $500 and items that have become obsolete. We are requesting that commenters, particularly the relevant specialty groups, provide us with the needed pricing information, including appropriate documentation. Whenever possible, commenters should provide multiple sources of documentation so that a typical price can be determined. If we are not able to obtain any verified pricing information for an item, we may eliminate it from the database.

TABLE 2.—EQUIPMENT ITEMS NEEDING SPECIALTY INPUT FOR PRICING AND PROPOSED DELETIONS

| Code | 2005 description | Price | Primary specialties associated with item | *CPT code(s) associated with item | Status of item |
|---|---|---|---|---|---|
| | Ambulatory blood pressure monitor. | 3,000.00 | Cardiology | 93784, 93786, 93788 | See Note A. |
| | Biofeedback equipment | | Psychology | 90875 | See Note A. |
| | CAD processor unit (mammography). | 210,000.00 | Radiology | 76082, 76083, 76085 | See Note A (Need system components). |
| E53005 | Camera system, cardiac, nuclear. | 675,000.00 | Anesthesia, IM, cardiology | 78414 | See Note A. |
| E53026 | Collimator, cardiofocal set | 29,990.00 | Radiology | 78206, 78607, 78647, 78803, 78807. | See Note A. |
| E71013 | Computer and VDT and software. | 9,000.00 | Ophthalmology, optometry | 92060, 92065 | See Notes A and C. |
| | Computer software, MR/PET/CT fusion. | 60,000.00 | Radiation oncology | 77301 | See Note A. |
| E51022 | Computer system, record and verify. | 60,000.00 | Radiation oncology | 77418 | See Note A. |

TABLE 2.—EQUIPMENT ITEMS NEEDING SPECIALTY INPUT FOR PRICING AND PROPOSED DELETIONS—Continued

| Code | 2005 description | Price | Primary specialties associated with item | *CPT code(s) associated with item | Status of item |
|---|---|---|---|---|---|
| E51050 | Computer workstation, 3D teletherapy treatment planning. | 221,500.00 | Radiation oncology | 77300, 77305, 77310, 77315, 77321, 77331. | See Note A. |
| | Computer workstation, MRA post processing. | | Radiology | 71555, 72159, 72198, 73225, 73725, 74185. | See Note A. |
| | Computer, server | | Radiation oncology | 77301 | See Note A. (Need system components). |
| | Cortical bipolar-biphasic stimulating equipment. | | Neurosurgery, neurology | 95961, 95962 | See Note A. |
| | CPAP/BiPAP remote clinical unit. | | Pulmonary disease, neurology. | 95811 | See Note A. |
| | Cryo-thermal unit | | Anesthesia | 64620 | See Notes A and C. |
| E53034 | Densitometry unit, whole body, DPA. | 65,000.00 | Radiology | 78351 | See Notes A and C. |
| E53032 | Densitometry unit, whole body, SPA. | 22,500.00 | Radiology | 78350 | See Notes A and C. |
| E53036 | Detector (Probe) | 14,000.00 | Radiology, cardiology | 78455 | See Notes A and C. |
| | Dialysis access flow monitor. | 10,000.00 | Nephrology | 90940 | See Note A. |
| | Diathermy, microwave | | Anesthesia, GP, podiatry | 97020 | See Notes A and C. |
| | DNA image analyzer (ACIS). | 200,000.00 | Lab, pathology | 88358, 88361 | See Note A. |
| | Drill, ophthalmology | | Ophthalmology | 65125 | See Note A. |
| E55035 | ECG signal averaging system. | 8,250.00 | Cardiology, IM | 93278 | See Note A. |
| | EEG monitor, digital, portable. | | 95953 | Neurology | See Note A. |
| E54008 | EEG recorder, ambulatory | 6,940.00 | Neurology | 95950 | See Note A. |
| E54009 | EEG review station, ambulatory. | 44,950.00 | Neurology | 95950 | See Note A. |
| | Electroconvulsive therapy machine. | | Psychiatry | 90870 | See Note A. |
| | Electromagnetic therapy machine. | 25,000.00 | Physical therapy | G0329 | See Note A. |
| E54012 | EMG botox | 1,500.00 | Critical care, pulmonary, ophthalmology. | 92265 | See Note A. |
| E52002 | Fetal monitor *software* | 35,000.00 | Ob-gyn, radiology | 76818, 76819 | See Note A. |
| | Film alternator (motorized film viewbox). | 27,500.00 | Radiology | 329 codes | See Note B. |
| | Generator, constant current. | 950.00 | Neurology, NP | 95923 | See Note A. |
| E51072 | HDR Afterload System, Nucletron—Oldelft. | 375,000.00 | Radiation oncology | 77781–84 | See Note A. |
| | Hyperbaric chamber | 125,000.00 | FP, IM, EM | 99183 | See Note A. |
| | Hyperthermia system, ultrasound, external. | 360,000.00 | Radiation oncology | 77600 | See Note A. |
| | Hyperthermia system, ultrasound, intracavitary. | 250,000.00 | Radiation oncology | 77620 | See Note A. |
| | Hysteroscopy ablation system. | 19,500.00 | Ob-gyn | 58563 | See Note A. |
| E13652 | image analyzer (CAS system). | 92,000.00 | Pathology, neurology | 88355, 88356 | See Note A. |
| | IMRT physics tools | 55,485.00 | Radiation oncology | 77301, 77418 | See Note A. |
| E91008 | IVAC Injection Automatic Pump. | 2,500.00 | Radiology | 78206, 78607, 78647, 78803, 78807. | See Note A. |
| | Mammography reporting software. | | Radiology | 76090, 76091, 76092 | See Note A. |
| E12002 | Neurobehavioral status instrument-average. | 717.00 | Psychology, IM | 96115, 96117 | See Note A. |
| | Orthovoltage radiotherapy system. | 140,000.00 | Radiation oncology | 77401 | See Note A. |
| | OSHA ventilated hood | 5,000.00 | Radiation oncology | 77334 | See Note B. |
| E91011 | Plasma pheresis machine w/UV light source. | 37,900.00 | Radiology, dermatology | 36481, 36510, 36522 | See Note A. |
| E55013 | Programmer, pacemaker | 10,000.00 | Cardiology, cardiothoracic surgery, general surgery. | 33200–01, 33206–08, 33212–18, 33220, 33222, 33240, 33245–46, 33249, 33282. | See Note A. |

TABLE 2.—EQUIPMENT ITEMS NEEDING SPECIALTY INPUT FOR PRICING AND PROPOSED DELETIONS—Continued

| Code | 2005 description | Price | Primary specialties associated with item | *CPT code(s) associated with item | Status of item |
|---|---|---|---|---|---|
| | Pulse oxymetry recording *software* (prolonged monitoring). | 3,660.00 | Pulmonary disease, IM | 94762 | See Note A. |
| | Radiation treatment vault | 550,670.00 | Radiation oncology | 774XX | See Note B. |
| | Radiation virtual simulation system. | | Radiation oncology | 77280, 77285, 77290, 77402–16. | See Note A. |
| | Remote monitoring service (neurodiagnostics). | 9,500.00 | Neurology | 95955 | See Note A. |
| E54010 | Review master | 23,500.00 | Pulmonary disease, neurology. | 95805, 95807–11, 95816, 95822, 95955–56. | See Note A. |
| E51004 | Room, basic radiology | 150,000.00 | Radiology | 103 codes | See Note A. |
| E51016 | Room, mammography | 130,000.00 | Radiology | 19030, 19290–91, 19295, 76086–92, 76096. | See Note A. |
| E51005 | Room, radiographic-fluoroscopic. | 475,000.00 | | 123 codes | See Note A. |
| | Source, 10 Ci Ir 192 | 22,000.00 | Radiation oncology | 77781–84 | See Note A. |
| | Strontium-90 applicator | 8,599.00 | Radiation oncology | 77789 | See Note A. |
| | Table, cystoscopy | | urology | 52204–24, 52265-75 52310–17, 52327–32. | See Note A. |
| E52001 | Ultrasound color doppler, transducers and vaginal probe. | 155,000.00 | Ob-gyn | 59070, 59074, 76818–19. | See Note A. |
| E52007 | Ultrasound, echocardiography digital acquisition (Novo Microsonics, TomTec). | 29,900.00 | Ob-gyn, cardiology, pediatrics. | 76825–28, 93303-12, 93314, 93320, 93325, 93350. | See Note A. |
| | Vacuum cart | | Anesthesia | 64620 | See Notes A and C. |
| E13635 | Video camera | 1,000.00 | Radiation oncology | 77418 | See Note A. |
| | Water chiller (radiation treatment). | 28,000.00 | Radiation oncology | 77402–16 | See Note B. |
| E51076 | Well counter | | Radiology | 78160–72, 78282 | See Note A. |

*CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

**Notes:**

A. Additional information required. Need detailed description (including system components as specified), source, and current pricing information.

B. Proposed deletion as indirect expense.

C. Item may no longer be available.

In addition to reviewing and updating the cost information for equipment items in the database, our contractor also recommended the following revisions to provide uniformity and consistency in the CPEP equipment database. All of the following recommendations are noted in Addendum D:

*Assignment of equipment categories.* In the original CPEP data, a number was assigned to each item of equipment. The contractor has recommended that each equipment item also be assigned a ''category'' to allow for easier identification and sorting of items. We agree and are proposing that equipment be assigned to one of the following six categories: documentation, laboratory, scopes, radiology, furniture, rooms-lanes, and other equipment.

These categories could also be used to establish a new numbering system for equipment that would more clearly identify them for practice expense purposes. We would assign a letter to each category and use this in conjunction with a number (000 through 999) to identify each item of equipment. This would enable specialty groups to identify more easily whether an item of equipment has already been included in the practice expense database and would help avoid duplication of references to the same item of equipment under different descriptions. If we proceed in the final rule with this proposed method for categorizing equipment, we will assign new identifying numbers to each equipment input item and these will be available on our website.

*Consolidation/standardization of item descriptions.*

When items appear to be duplicative, we are proposing to combine the items. For example, for two cervical endoscopy procedures, our contractor identified that the price of the LEEP system includes a smoke evacuation system but that system is also listed separately. We propose to merge these two line items and reflect both prices in the price of the LEEP system. All proposed changes are specifically referenced in Addendum D.

We welcome any comments on the proposed pricing and all other proposed revisions. To help us evaluate the information provided, comments should include documentation from more than one source, where available, such as information from a vendor catalog or website or from a current invoice.

d. Miscellaneous Practice Expense Issues

i. Pricing for Seldinger Needle

We received comments from a specialty organization on our November 7, 2003 rule stating that the $72.90 price assigned to the Seldinger needle, which is used in certain radiological procedures, is too high. The organization estimated that the cost is actually closer to $7.00; however, documentation was not provided to

support this price estimate. Our contractor was able to confirm pricing information from two sources, including a price of $3.50 from a hospital supplier and a price of $6.85 from a cardiology supplier. Based on this pricing variability, we are proposing to average the two prices of this supply item to reflect a cost of $5.175. If a commenter disagrees with this proposed change in price, the comment should provide documentation to support the recommended price, as well as the specific type of needle that is most commonly used.

ii. Hysteroscopic Endometrial Ablation

We received requests from a manufacturer and physicians to price CPT code 56853, Hysteroscopy with endometrial ablation, in the office setting so that physicians providing this service in the nonfacility setting could receive an appropriate payment. (This service is currently valued only in the facility setting.) We have worked with the specialty society, the American College of Obstetricians and Gynecologists, to identify the required resources based on the typical practice. We propose to assign on an interim basis, the following direct practice expense inputs in the nonfacility setting for this service.

- *Clinical Staff:* RN/LPN/MTA—72 minutes (18 pre-service and 54 service)
- *Supplies:* PEAC multispecialty visit supply package, Post-op incision care kit, pelvic exam package, irrigation tubing, sterile impervious gown, surgical cap, shoe cover, surgical mask with face shield, 3x3 sterile gauze (20), cotton tip applicator, cotton balls (4), irrigation 0.9 percent sodium chloride 500–1000ml(3), maxi-pad, mini-pad, 3-pack betadine swab (4), Monsel's solution (10ml), lidocaine jelly (1000ml), disposable speculum, spinal needle, 18–24g needle, 20 ml syringe, bupivicaine 0.25 percent (10ml), 1 percent xylocaine (20ml), cidex (10ml), Polaroid film–type 667 (2), endosheath, and hysteroscopic ablation device kit.
- *Equipment:* power table, fiberoptic exam light, endoscopic-rigid hysteroscope, endoscopy video system, and hysteroscopic ablation system.

We will request that the RUC review these inputs along with inputs of other codes still in need of refinement. iii. Photopheresis

We received a request from a supplier to review the direct practice expense inputs currently in our database for the photopheresis service, CPT code 36522. These inputs are based on the original CPEP panel recommendations and the supplier does not believe they are reflective of the resources now being used. This service was not reviewed by the PEAC during the refinement process, and we agree that the direct inputs need to be revised for this service. We propose to assign, on an interim basis, the following nonfacility practice expense inputs, and we will request that the RUC review them as part of the practice expense refinement process.

- *Clinical Staff:* RN—223 minutes (treatment is for approximately 4 hours)
- *Supplies:* multispecialty visit supply package, photopheresis procedural kit, blood filter (filter iv set), IV blood administration set, 0.9 percent irrigation sodium chloride 500–1000 ml (2), heparin 1,000 units-ml (10), povidone solution-betadine, methoxsalen (UVADEX) sterile solution-10 ml vial, 1 percent-2 percent lidocaine-xylocaine, paper surgical tape (12), 2x3 underpad (chux), nonsterile drapesheet 40 inches x 60 inches, nonsterile Kling bandage, bandage strip, 3x3 sterile gauze, 4x4 sterile gauze, alcohol swab pad (3), impervious staff gown, 19–25 g butterfly needle, 14–24g angiocatheter, 18–27 g needle, 20 ml syringe, 10–12 ml syringe, 1 ml syringe, 22–26 g syringe needle-3 ml.
- *Equipment:* plasma pheresis machine with ultraviolet light source, medical recliner.

iv. Pricing of New Supply Items

As part of last year's rulemaking process, we reviewed and updated the prices for supply items in our practice expense database. During subsequent meetings of both the PEAC and the RUC, supply items were added that were not included in the supply pricing update. The following table, Proposed Practice Expense Supply Item Additions for 2005, lists these additional supply items and the proposed associated prices that we will use in the practice expense calculation.

TABLE 3.—PROPOSED PRACTICE EXPENSE SUPPLY ITEM ADDITIONS FOR 2004

| Supply description | Unit price * | Unit | * CPT code(s) associated with item | Supply category |
|---|---|---|---|---|
| Acrylic tray-base material | 1.775 | oz | 21421, 21452 | Lab. |
| Adapter, luer lock | 1.249 | Item | 36515 | Hypodermic, IV. |
| Adapter, spike (for syringe) | 4.558 | Item | 36515 | Hypodermic, IV. |
| Adhesive, conductive (silver, liquid) | 3.000 | gm | 88349 | Lab. |
| Adhesive, cyanoacrylate (2ml uou).doc. | 28.988 | Item | 65286 | Pharmacy, Rx. |
| Airway adapter | 12.500 | Item | 94770 | Accessory, Procedure. |
| Albuterol inhal soln (3ml vial) | 0.436 | Item | 95070 | Pharmacy, Rx. |
| Alcohol ethyl 100% | 0.028 | ml | 88348 | Lab. |
| Applicator, cotton-tipped, sterile, 6in | 0.056 | Item | 127 codes | Wound Care, Dressings. |
| Applicator, wood, 6.5in | 0.008 | Item | 99348–49 | Lab. |
| Bag system, 1000ml (for angiography waste fluids). | 8.925 | Item | 93501, 93505–10 | Accessory, Procedure. |
| Balanced salt soln (BSS) (15ml uou) | 1.600 | Item | 59 codes | Pharmacy, Rx. |
| Battery, AA | 0.450 | Item | 95250 | Office Supply, Grocery. |
| Blade, surgical, super-sharp | 4.167 | Item | 14 codes | Cutters, Closures, Cautery. |
| Blade, urethrotome | 85.030 | Item | 52270 | Cutters, Closures, Cautery. |
| Blood collection tube holder | 0.163 | Item | 78110–11, 78120–22, 78130, 78191, 78725. | Hypodermic, IV. |
| Blood collection tube needle | 0.142 | Item | 36514–16, 78110–11, 78120–22, 78130, 78191, 78725. | Hypodermic, IV. |
| Blood pressure recording form, average. | 0.310 | Item | 93784, 93786, 93788 | Office Supply, Grocery. |
| Brush, protected airway specimen | 13.000 | Item | 31623, 31717 | Accessory, Procedure. |
| Bur, surgical, sterile (drill) | 4.792 | Item | 28289 | Accessory, Procedure. |
| Canned air (Dust-Off) | 1.021 | oz | 88348 | Office Supply, Grocery. |
| Cannula, anterior chamber, 18–27g | 2.688 | Item | 65815, 66020, 66030, 66250 | Accessory, Procedure. |

TABLE 3.—PROPOSED PRACTICE EXPENSE SUPPLY ITEM ADDITIONS FOR 2004—Continued

| Supply description | Unit price * | Unit | * CPT code(s) associated with item | Supply category |
|---|---|---|---|---|
| Catheter percutaneous fastener (Percu-Stay). | 12.745 | Item | 32201, 44901, 47525, 47530, 48511, 49021, 49041, 49061, 49423, 49424, 50021, 58823. | Accessory, Procedure. |
| Catheter, (Glide) | 62.000 | Item | 36218, 36248 | Accessory, Procedure. |
| Catheter, (SIM2F1) | 17.000 | Item | 36011–15, 36215–17, 36245–47 | Accessory, Procedure. |
| Catheter, angiographic | 16.200 | Item | 93508, 93510, 93526 | Hypodermic, IV. |
| Catheter, balloon inflation device | 24.900 | Item | 35470–76 | Accessory, Procedure. |
| Catheter, balloon ureteral (Dowd) | 65.000 | Item | 52330 | Accessory, Procedure. |
| Catheter, balloon, low profile PTA | 431.500 | Item | 35470, 35471, 35474 | Accessory, Procedure. |
| Catheter, balloon, PTA | 243.500 | Item | 35472–73, 35475–76 | Accessory, Procedure. |
| Catheter, curved | 17.775 | Item | 36218 | Accessory, Produce. |
| Catheter, hyperthermia, closed-end | | Item | 77600–20 | Hypodermic, IV. |
| Catheter, hyperthermia, open-end | | Item | 77600 | Hypodermic, IV. |
| Catheter, microcatheter (selective 3rd order). | 337.880 | Item | 36217, 36247 | Accessory, Procedure. |
| Catheter, Swan Ganz | 65.000 | Item | 93501, 93526 | Accessory, Procedure. |
| Catheter, ureteral, acorn tip | 9.550 | Item | 52007, 52010, 52327, 52330 | Accessory, Procedure. |
| Clamp, circumcision | 7.500 | Item | 54150 | Cutters, Closures, Cautery. |
| Collagen, dermal implant (2.5ml uou) (Contigen). | 317.000 | Item | 52327, 52330 | Pharmacy, Rx. |
| Conformer, sterile, acrylic | 20.000 | Item | 68340 | Accessory, Procedure. |
| Contact lens (hard) care kit | 7.950 | Item | 92325–26 | Pharmacy, NonRx. |
| Contact lens (hard) extra strength cleaning solution. | 0.158 | ml | 92325–26 | Pharmacy, NonRx. |
| Contact lends (RGP) polishing soln (Silo2 Care). | 0.077 | ml | 92325 | Pharmacy, NonRx. |
| Container, 2000ml, transfer pack | 7.120 | Item | 36515 | Accessory, Procedure. |
| Container, 600ml, transfer pack | 3.360 | Item | 36515 | Accessory Procedure. |
| Cotton balls, sterile | 0.022 | Item | 115 codes | Wound Care, Dressings. |
| Cup, sterile, 12–16 oz | 0.760 | Item | 32201, 44901, 48511, 49021, 49041, 49061, 50021, 58823, 93501, 93505, 93508, 93510, 93526. | Lab. |
| Cup, sterile, 8 oz | 0.542 | Item | 32201, 44901, 48511, 49021, 49041, 49061, 50021, 58823. | Lab. |
| Cuvette, whole blood oximeter | 115.000 | Item | 93501, 93526 | Hypodermic, IV. |
| Diamond knife cleaning rod | 1.000 | Item | 99348 | Lab. |
| Drainage catheter, all purpose | 88.430 | Item | 44901, 47525, 47530, 48511, 49021, 49041, 49061, 49423, 50021, 50398, 58823. | Accessory, Procedure. |
| Drainage catheter, chest | 88.890 | Item | 32201 | Accessory, Procedure. |
| Drainage pouch, nephrostomy-biliary | 13.250 | Item | 32201, 44901, 47525, 47530, 48511, 49021, 49041, 49061, 49423, 50021, 50398, 58823. | Accessory, Procedure. |
| Drape, sterile, incise, ophthalmic | 4,900 | | 67025, 67028, 67110, 67120 | Gown, Drape. |
| Drape, sterile, split-sheet | 10,243 | Item | 212 codes | Gown, Drape. |
| Drape, sterile, table 44 in x 76 in | 5.250 | Item | 93501–10, 93526 | Gown, Drape. |
| Electrode, Bugbee | 115.000 | Item | 52204, 52214, 52224, 52265, 52275, 55200, 55250. | Accessory, Procedure. |
| Electrode, EEG (single) | 1.638 | Item | 95961, 95816 | Accessory, Procedure. |
| Electrode, EGG (single) | 2.917 | Item | 91132, 95925–27, 95930 | Accessory, Procedure. |
| Endoscopic deflecting brush | 73.500 | Item | 52007 | Accessory, Procedure. |
| Film, x-ray, laser print | 1.437 | Item | 146 codes | Office Supply, Grocery. |
| Floxin 0.3% otic soln | 2.354 | ml | 69145, 69620 | Pharmacy, Rx. |
| Forceps, endomyocardial biopsy | 250.000 | Item | 93505 | Accessory, Procedure. |
| Forceps, Kelly | 2.335 | Item | 93501–10, 93526 | Accessory, Procedure. |
| Gas, nitrogen | 2.708 | cu ft | 88348–49 | Lab. |
| Glass knife boat | 0.200 | Item | 88348 | Lab. |
| Grid storage box (holds 50 grids) | 3.750 | Item | 88348 | Lab. |
| Guidewire bowl w-lid, sterile | 3.000 | Item | 93501–10, 93526 | Accessory, Procedure. |
| Guidewire, cerebral (Bentson) | 14.500 | Item | 36011–15, 36215–17, 36245–47 | Accessory, Procedure. |
| Guidewire, low profile (SpartaCore) | 101.250 | Item | 35470–71, 35474 | Accessory, Procedure. |
| Guidewire, steerable (Hi-Torque) | 90.000 | Item | 35470–76, 37203 | Accessory, Procedure. |
| Guidewire, steerable (Transcend) | 180.000 | Item | 36217, 32647 | Accessory, Procedure. |
| Guidewire, torque | 41.000 | Item | 35470–76 | Accessory, Procedure. |
| Heparin 5,000 units-mi inj | 0.509 | ml | 36514–15 | Pharmacy, Rx. |
| Hyaluronic acid viscoelastic inj (Amvisc, 0.5ml uou. | 61.000 | Item | 65286, 65815, 66250 | Pharmacy, Rx. |
| Hysteroscope ablation device | 1,146.000 | Item | 58563 | Accessory, Procedure. |
| Jessner's soln | 0.240 | ml | 15788–89, 15792–93 | Pharmacy, Rx. |
| Kenalog 40 inj | 1.830 | ml | 31830 | Pharmacy, Rx. |

TABLE 3.—PROPOSED PRACTICE EXPENSE SUPPLY ITEM ADDITIONS FOR 2004—Continued

| Supply description | Unit price * | Unit | * CPT code(s) associated with item | Supply category |
|---|---|---|---|---|
| Kit, AccuStick II Introducer system with RO Marker. | 82.620 | Kit | 26 codes | Kit, Pack, Tray. |
| Kit, apheresis treatment | 140.000 | Kit | 36515 | Kit, Pack, Tray. |
| Kit, barium enema | 9.466 | Kit | 75270, 74283 | Kit, Pack, Tray. |
| Kit, BCR/ABL DNA probe | 42.650 | Kit | 88365 | Kit, Pack, Tray. |
| Kit, slit catheter (for compartment pressure monitor). | 73.750 | Kit | 20950 | Kit, Pack, Tray. |
| Kit, vasotomy | | Kit | 55200, 55250 | Kit, Pack, Tray. |
| Lacrimal duct stent-tube set | 74.000 | Item | 68815 | Accessory, Procedure. |
| Lead citrate | 0.510 | gm | 88348 | Lab. |
| Manifold (for angiography) | 6.682 | Item | 93501, 93508, 93510, 93526 | Accessory, procedure. |
| Marker, gold, for radiosurgery-radiotherapy. | 29.667 | Item | 77761–63 | Accessory, Procedure. |
| Mask, CPR (RespAide) | 16.950 | Item | 92950 | Accessory, Procedure. |
| Methoxsalen, sterile solution (UVADEX), 10ml vial. | 49.500 | ml | 36522 | Pharmacy, Rx. |
| Microsponge, cellulose (10 pack uou). | 3.620 | Item | 22 codes | Wound Care, Dressings. |
| Mount, carbon spectro-pure (for SEM). | 0.500 | Item | 88349 | Lab. |
| Nasal tip, olive | 0.340 | Item | 92512 | Accessory, Procedure. |
| Nebulizer medication cup | 0.140 | Item | 95070 | Accessory, Procedure. |
| Needle, arterial, percutaneous | 3.150 | Item | 93501, 93505, 93508, 93510, 93526 | Hypodermic, IV. |
| Needle, bone biopsy | 65.000 | Item | 20225 | Hypodermic, IV. |
| Needle, flexi, hyperthermia | 12.000 | Item | 77600–20 | Hypodermic, IV. |
| Needle, micropigmentation (tattoo) | 12.000 | Item | 11920–21 | Hypodermic, IV. |
| Needle, OSHA compliant (SafetyGlide). | 0.454 | Item | 37 codes | Hypodermic, IV. |
| Needle, retrobulbar (Atkinson) | 1.825 | Item | 67120, 67141 | Hypodermic, IV. |
| Omnipaque 350mg (125ml uou) | 29.530 | Item | 93508, 93510, 93526 | Pharmacy, Rx. |
| Omnipaque 350mg (50ml uou) | 12.498 | Item | 42550, 70370 | Pharmacy, Rx. |
| Osmometer sample tip and cleaner | 0.534 | Item | 88348 | Lab. |
| Osmometer std, 50 mOsm-kg, 2ml amp. | 17.000 | ml | 88348 | Lab. |
| Osmometer std, 850 mOsm-kg, 2ml amp. | 17.000 | ml | 88348 | Lab. |
| Pack, drapes, ortho, large | 40.646 | Pack | 102 codes | Kit, Pack, Tray. |
| Pack, drapes, ortho, small | 1.128 | Pack | 37 codes | Kit, Pack, Tray. |
| Pack, ophthalmology visit (w-dilation) | 1.997 | Pack | 65272–73, 65280–85, 65290, 65810–015, 65855–60, 66130, 66625–35, 67031, 68130. | Kit, Pack, Tray. |
| Pack, protective, ortho, large | 9.182 | Pack | 99 codes | Kit, Pack, Tray. |
| Pack, protective, ortho, small | 4.441 | Pack | 38 codes | Kit, Pack, Tray. |
| Paper, weighing (glassine) | 0.021 | Item | 88348 | Lab. |
| Phenol, liquified, USP | 0.135 | ml | 15788–93 | Pharmacy, Rx. |
| Photo-Flo soln | 0.021 | ml | 88348 | Office Supply, Grocery. |
| Pipette bulb | 0.271 | Item | 88348–49 | Lab. |
| Pipette 9inch | 0.054 | Item | 88348–89 | Lab. |
| Plasma antibody adsorption column (Prosorba). | 1,150.000 | Item | 36515 | Accessory, Procedure. |
| Plasma LDL adsorption column (Liposorber). | 1,300.000 | Item | 36516 | Accessory, Procedure. |
| Plasma leukocyte filter | 49.719 | Item | 36515 | Accessory, Procedure. |
| Plasma separator (Liposorber) | 100.000 | Item | 36516 | Accessory, Procedure. |
| Plate, surgical, mini-compression, 4 hole. | 226.000 | Item | 21208 | Accessory, Procedure. |
| Plate, surgical, mini-i, 16mm | 147.000 | Item | 21210 | Accessory, Procedure. |
| Plate, surgical, reconstruction, left, 5 x 16 hole. | 719.000 | Item | 21125–27, 21215 | Accessory, Procedure. |
| Plate, surgical, reconstruction, template, 5 x 16 hole. | 50.000 | Item | 21125–27, 21215 | Accessory, Procedure. |
| Plate, surgical, rigid comminuted fracture. | 389,000 | item | 21461, 21462 | Accessory, Procedure. |
| Plate, surgical, rigid comminuted fracture, template. | 29.000 | Item | 21461, 21462 | Accessory, Procedure. |
| Pressure bag | | Item | 93501, 93508–10, 93526 | Hypodermic, IV. |
| Prosthesis, voice button (Blom-Singer). | 48.000 | Item | 31611 | Accessory, Procedure. |
| Scalpel, safety, surgical, with blade (#10–20). | 2.143 | Item | 54150, 54160, 54162 | Cutters, Closures, Cautery. |
| Screw, surgical, auto-drive, 2.0mm x 4mm. | 37.000 | Item | 2120 | Accessory, Procedure. |

TABLE 3.—PROPOSED PRACTICE EXPENSE SUPPLY ITEM ADDITIONS FOR 2004—Continued

| Supply description | Unit price * | Unit | * CPT code(s) associated with item | Supply category |
|---|---|---|---|---|
| Screw, surgical, Carroll-Girard, 9cm x 3.75in. | 92.000 | Item | 21401 | Accessory, Procedure. |
| Screw, surgical, lag, 2.4mm x 26mm | 66.000 | Item | 21461–62 | Accessory, Procedure. |
| Screw, surgical, locking, 2.4mm x 16mm. | 74.000 | Item | 21127, 21208, 21215 | Accessory, Procedure. |
| Screw, surgical, self-tapping, 1.5–2.0 mm. | 27.000 | Item | 21100, 21452 | Accessory, Procedure. |
| Screw, surgical, standard, 2.4mm x 14mm. | 42.000 | Item | 21125 | Accessory, Procedure. |
| Screw, surgical, standard, 2.7mm x 12mm. | 47.000 | Item | 21125–27, 21208, 21215, 21461–62 | Accessory, Procedure. |
| Sea salt | 0.004 | gm | 15810–11 | Office Supply, Grocery. |
| Sensor, manometry | 25.000 | Item | 91010–12, 91122 | Accessory, Procedure. |
| Sheath, peel away | 68.990 | Item | 47530 | Accessory, Procedure. |
| Skin refrigerant-anesthetic spray (Frigiderm). | 5.000 | oz | 15780–86, 15788–93 | Pharmacy, Rx. |
| Sodium acetate | 0.064 | gm | 88348 | Lab. |
| Sodium barbital | 0.315 | gm | 88348 | Lab. |
| Specimen block storage box | 0.625 | Item | 88348 | Lab. |
| Splint, finger (metal-foam) | 1.655 | Item | 26700–05, 26720–25, 26740–42, 26750–55, 26770–75. | Wound Care, Dressings. |
| Sucrose, reagent | 0.037 | gm | 88348 | Lab. |
| Suture device for vessel closure (Perclose A–T). | 225.000 | Item | 35470–75 | Accessory, Procedure. |
| Suture, monocryl, 3–0 to 6–0, p, ps | 9.887 | Item | 15050, 15200, 15220, 15240, 15260 | Cutters, Closures, Cautery. |
| Suture, nylon, 8–0 to 9–0 | 15.320 | Item | 65270–72, 65275, 65420–26, 66130, 66250, 68115–30, 68320, 68330, 68340, 68360. | Cutters, Closures, Cautery. |
| Suture, plain, gut, 2–0 to 6–0 | 4.262 | Item | 41872 | Cutters, Closures, Cautery. |
| Suture, polyester, 0 to 3–0 (Mersilene). | 3.895 | Item | 40840–45 | Cutters, Closures, Cautery. |
| Suture, vicryl, 7–0 | 21.773 | Item | 67120 | Cutters, Closures, Cautery. |
| Syringe 12ml, coronary control | 7.000 | Item | 93508–10, 93526 | Hypodermic, IV. |
| Syringe filter | 2.040 | Item | 88348 | Hypodermic, IV. |
| Tape, foam, elastic, 2in (Microfoam) | 0.003 | Inch | 21120–23, 21315, 21355–56, 31820–25. | Wound Care, Dressings. |
| Toluidine Blue O (for microscopy) | 0.580 | gm | 88348 | Lab. |
| Towel clamp, plastic | 0.556 | Item | 93501–10, 93526 | Accessory, Procedure. |
| Tracheostomy collar-neckband | 3.235 | Item | 31580–84, 31588, 31610 | Wound Care, Dressings. |
| Tracheostomy dressing | 3.240 | Item | 31580–84, 31588, 31610 | Wound Care, Dressings. |
| Tracheostomy tube | 20.934 | Item | 31370–82, 31580–84, 31588, 31610, 31613–14, 31750, 41140, 41145. | Accessory, Procedure. |
| Transducer, pressure monitoring (for angiography). | 9.520 | Item | 93501, 93508, 93510, 93526 | Accessory, Procedure. |
| Tray, bronchogram | | Tray | 31708 | Kit, Pack, Tray. |
| Tray, central line dressing change | 2.430 | Tray | 36514–16 | Kit, Pack, Tray. |
| Tray, circumcision | 25.173 | Tray | 54150, 54160–62 | Kit, Pack, Tray. |
| Tray, surgical skin prep, sterile | 6.765 | Tray | 134 codes | Kit, Pack, Tray. |
| Trichloroacetic acid 90% (sat soln) | 0.855 | ml | 46900 | Pharmacy, Rx. |
| Tubing set (Liposorber) | 50.000 | Item | 36516 | Hypodermic, IV. |
| Tubing set, blood warmer | 7.396 | Item | 36514–16 | Hypodermic, IV. |
| Tubing set, plasma exchange | 173.333 | Item | 36514 | Hypodermic, IV. |
| Tubing set, plasma transfer | 1.680 | Item | 36515 | Hypodermic, IV. |
| Tubing set, Y-type blood recipient | 5.750 | Item | 36515 | Hypodermic, IV. |
| Tubing, pressure injection line (angiography). | 3.170 | Item | 93508, 93510, 93526 | Accessory, Procedure. |
| Tubing, sterile, connecting (fluid administration). | 1.950 | Item | 93510, 93526 | Accessory, Procedure. |
| Tubing, sterile, non-vented (fluid administration). | | Item | 93501, 93508, 93510, 93526 | Accessory, Procedure. |
| Tubing, suction, non-latex (2ft) with Frazier tip (1). | 7.557 | Item | 99 codes | Accessory, Procedure. |
| Underpad 2ft x 2ft (lab bench) | 0.377 | Item | 88348–49 | Lab. |
| Vial, specimen-sample, 4ml | 0.550 | Item | 88348–49 | Lab. |
| Wax sheet | 0.285 | Item | 88348 | Lab. |

* CPT codes and descriptions only are copyright.
2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

We have identified certain supply items for which we were unable to verify the pricing information (see Table 4, Supply Items Needing Specialty Input for Pricing). Therefore, we are requesting commenters, particularly specialty organizations, to provide pricing information on items in this table along with documentation to support the recommended price. In addition, we are seeking information on the specific contents of the listed kits, so that we do not duplicate any supply items.

TABLE 4.—SUPPLY ITEMS NEEDING SPECIALTY INPUT FOR PRICING

| Code | 2005 Description | Unit | Unit price | Primary specialties associated with item | *CPT code(s) associated with item | Status of item |
|---|---|---|---|---|---|---|
| SL008 | Antibodies—detection | Slide | 30.90 | Lab, pathology | 88365 | See Note A. |
| | Blood pressure recording form, average. | Item | 0.31 | Cardiology | 93784, 93786, 93788 | See Note A. |
| | Catheter, hyperthermia, closed-end. | Item | | Radiation oncology | 77600–20 | See Note A. |
| | Catheter, hyperthermia, open-end. | Item | | Radiation oncology | 77600 | See Note A. |
| | Edrophonium | ml | 4.67 | Gastroenterology | 91011 | See Note A |
| | Hysteroscope, ablation device. | Item | 1,146.00 | Ob-gyn | 58563 | See Note A |
| | Kit, BCR/ABL DNA probe | Kit | 42.65 | Pathology | 88365 | See Note A. |
| SA013 | Kit, detection | Slide | 8.50 | Pathology, neurology | 88355, 88356 | See Note A. |
| SA024 | Kit, photopheresis procedure. | Kit | 809.00 | Dermatology, ob-gyn | 36522 | See Note A. |
| | Kit, vasotomy | Kit | | Urology | 55200, 55250 | See Note A. |
| | Methoxsalen, sterile solution (UVADEX) 10 ml vial. | ml | 49.50 | Dermatology, radiation oncology. | 36522 | See Note A. |
| | Pressure bag | Item | | Cardiology | 93501, 93508, 93510, 93526. | See Note A. |
| SL114 | Primary antibodies | Slide | 3.52 | Pathology, neurology | 88355, 88356, 88358 | See Note A. |
| | Tray, bronchogram | Tray | | Pulmonary disease | 31708 | See Note A. |
| | Tubing, sterile, non-vented (fluid administration). | Item | | Cardiology | 93501, 93508, 93510, 93526. | See Note A. |

*CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
**Note A.** Additional information required. Need detailed description (including kit contents), source, and current pricing information.

v. Addition of Supply Item to CPT 88365, Tissue In Situ Hybridization

We received a request from a pathology society to add a DNA probe to the CPEP database for CPT 88365, tissue in situ hybridization. The society specified that 1.5 DNA probes are typically used in this service and the cost of one probe is $42.65. Documentation supporting this price was also provided. We are proposing to add, on an interim basis, this supply to the practice expense database with the understanding that the inclusion of the item will be subject to forthcoming RUC review.

vi. Ophthalmology Equipment

In the CPEP equipment data for many of the ophthalmology procedures, there is a duplication of time assigned to the screening lane and exam lane. In a majority of these identified procedures, the same timeframe was assigned to both the screening and exam lanes. While some of the procedures had not been refined by the PEAC, others were refined early on in the PEAC process before the PEAC agreed to assign only one equipment lane to each procedure because a patient can be in only one room at a time. In cases where both the screening and exam lanes are included, we are proposing to adjust the lane assignment by defaulting to the exam lane and, thus, we will delete the screening lane from these procedures. For all of the above services where a lane change was made, time values were assigned to the exam lane in accordance with our established standard procedure. We are asking commenters, in particular, organizations representing ophthalmology, to review these proposed changes and submit specific comments on the appropriateness of the exam lane default.

vii. Other Practice Expense Issues

Parathyroid Imaging, CPT 78070

We received comments from the RUC and the specialty society representing nuclear medicine that the practice expenses for CPT 78070, parathyroid imaging, which is valued in the nonphysician work pool, are too low. Because this procedure involves multiple imaging sessions, the organizations have requested that a different crosswalk of charge-based RVUs be used to more appropriately value the practice expenses involved with CPT 78070. We agree and are proposing to crosswalk the charge-based RVUs from CPT 78306, whole body imaging, to this procedure.

*B. Geographic Practice Cost Indices (GPCIs)*

[If you choose to comment on issues in this section, please include the caption ''GPCI'' at the beginning of your comments.]

1. Background

The Social Security Act (the Act) requires that payments vary among physician fee schedule areas according to the extent that resource costs vary as measured by the Geographic Practice Cost Indices (GPCIs). In general, the fee schedule areas that existed under the prior reasonable charge system were retained under the physician fee schedule from calendar years 1992 to 1996. We implemented a comprehensive revision in the physician fee schedule payment areas (localities) in 1997, reducing the number of localities from 210 to 89. A detailed discussion of physician fee schedule areas can be found in the July 2, 1996 proposed rule (61 FR 34615) and the November 22, 1996 final rule (61 FR 59494).

We are required by section 1848(e)(1)(A) of the Act to develop separate GPCIs to measure resource cost differences among localities compared to the national average for each of the three fee schedule components. While requiring that the practice expense and malpractice GPCIs reflect the full relative cost differences, section 1848(e)(1)(A)(iii) of the Act requires that the physician work GPCIs reflect only one-quarter of the relative cost differences compared to the national average.

Section 1848(e)(1)(C) of the Act requires us to review and, if necessary, to adjust the GPCIs at least every 3 years. This section of the Act also requires us to phase-in the adjustment over 2 years and implement only one-half of any adjustment if more than 1 year has elapsed since the last GPCI revision. The GPCIs were first implemented in 1992. The first review and revision was implemented in 1995, the second review was implemented in 1998, and the third review was implemented in 2001. This constitutes the fourth review of the work and practice expense GPCIs.

The malpractice GPCIs were reviewed and revised as part of the November 7, 2003 (68 FR 63196) physician fee schedule final rule. At the time of the publication of the November 2003 final rule, the U.S. Census data upon which the work and practice expense GPCIs are based were not yet available.

Section 412 of MMA amends section 1848(e)(1) of the Act and establishes a floor of 1.0 for the work GPCI for any locality where the GPCI would otherwise fall below 1.0. This 1.0 work GPCI floor will be used for purposes of payment for services furnished on or after January 1, 2004 and before January 1, 2007. In addition, section 602 of MMA further amended section 1848(e)(1) of the Act for purposes of payment for services furnished in Alaska under the physician fee schedule on or after January 1, 2004 and before January 1, 2006, and sets the work, practice expense, and malpractice expense GPCIs at 1.67 if any GPCI would otherwise be less than 1.67.

Based on these MMA provisions, we revised the addenda published in the November 7, 2003 final rule (68 FR 63196) that reflected both the transitional 2004 and 2005 malpractice GPCIs, as well as the work and practice expense GPCIs that were not updated (Addendum D and Addendum E, respectively) in an interim final rule with comment period entitled, ''Changes to Medicare Payment for Drugs and Physician Fee Schedule Payments for Calendar Year 2004,'' published January 7, 2004 (69 FR 1084). Due to the MMA provisions, no locality in these revised addenda has a work GPCI of less than 1.00. Additionally, the work, practice expense, and malpractice GPCIs for Alaska are set at 1.67.

We are proposing to revise the work and practice expense GPCIs beginning in 2005 based on updated U.S. Census data and Department of Housing and Urban Development fair market rent data.

2. Development of the Geographic Practice Cost Indices

The GPCIs were developed by a joint effort of the Urban Institute and the Center for Health Economics Research under contract to us. Indices were developed that measured the relative physician resource cost differences among areas compared to the national average in a ''market basket'' of goods. The market basket consists of the resources involved with operating a private medical practice. The resource inputs are—

- Physician work or net income (used to construct the physician work GPCI);
- Employee wages, office rents, medical equipment, supplies, and other miscellaneous expenses used to comprise the practice expense GPCI; and
- Professional liability insurance premiums (used to construct the malpractice GPCI).

The resource inputs and their respective weights for the resource costs associated with the work, practice expense, and malpractice expense associated with providing a physician service, were obtained from the 2003 AMA Physician Socioeconomic Characteristics publication (2003 Patient Care Physician Survey data) which measures physicians' earnings and overall practice expenses for 2000.

The weights for the 2004 GPCIs, as well as the proposed 2005 through 2007 GPCI revisions, are from the 2003 AMA survey and were used in the Medicare Economic Index (MEI) revision discussed in the November 2003 physician fee schedule final rule (68 FR 63245). Table 5 below shows the weights of the resource inputs, as defined by the MEI, those used for the original GPCIs, as well as the weights for the first, second, and third GPCI revisions. The MEI weights associated with the first and second GPCI updates (1995–2000 GPCIs) were not revised. In addition, the MEI weights for the proposed fourth GPCI revision are also shown.

TABLE 5.—HISTORICAL VIEW OF MEI WEIGHTS

| Input component | Percentage of practice cost indices | | | |
|---|---|---|---|---|
| | 1992–1994 GPCIs | 1995–2000 GPCIs | 2001–2003 GPCIs | 2004–2006 GPCI |
| Physician Work | 54.2 | 54.2 | 54.5 | 52.5 |
| Practice Expense | 40.2 | 41.0 | 42.3 | 43.7 |
| Employee Wages | 15.7 | 16.3 | 16.8 | 18.7 |
| Rent | 11.1 | 10.3 | 11.6 | 12.2 |
| Miscellaneous | 13.4 | 14.4 | 13.9 | 12.8 |
| Malpractice | 5.6 | 4.8 | 3.2 | 3.9 |
| Total | 100.0 | 100.0 | 100.0 | 100.0 |

a. Work Geographic Practice Cost Indices

As in previous GPCI updates, the median hourly earnings component is based on a 20 percent sample of U.S. Census data from workers in seven professional occupations. The actual reported earnings of physicians were not used to establish the GPCIs because Medicare payments (which are based on the GPCIs) are in part determinants of the earnings. Including physician wages in the physician work GPCI could, in effect, make the index dependent upon Medicare payments. Based upon analysis performed by Health Economics Research, we believe that in the majority of instances, the earnings of physicians will vary among areas to the same degree that the earnings of other professionals vary.

Data from the 2000 decennial U.S. Census by county of seven professional occupations (architecture and engineering; computer, mathematical, and natural sciences; social scientist, social workers, lawyers; education, library, training; registered nurses; pharmacists; writers, artists, editors) were utilized in the development of the proposed work GPCIs.

TABLE 6.—SPECIFIC OCCUPATION CATEGORIES USED IN DEVELOPMENT OF PHYSICIAN WORK GPCI

| Categories | Census 2000 occupation code |
|---|---|
| Architecture and Engineering | 130–156 |
| Computer, Mathematical, and Natural Sciences | 100–124<br>160–176 |
| Social Scientists, Social Workers, Lawyers | 180–215 |
| Education, Training, and Library | 220–255 |
| Registered Nurses | 313 |
| Pharmacists | 305 |
| Writers, Artists, and Editors | 260–296 |

The Census Bureau has very specific criteria that tabulations must meet in order to be released to the public. To maximize the accuracy and availability of the data collection, the nonphysician professional wage data were aggregated into three geographic area categories:

1. By Individual Counties—The tabulations were requested for each county in a Consolidated Metropolitan Statistical Area (CMSA).

2. By Metropolitan Statistical Area (MSA)—The tabulations were requested by MSA for all counties that fall within an MSA.

3. By Rest of State—The tabulations were requested by rest of State for counties that are not in a CMSA or MSA.

The nonphysician professional wage data were subsequently assigned to each respective county within the MSA or Rest of State aggregations (or, in the case of CMSAs, the data were already at the county level), and a median wage by county was calculated for each occupational category. These median wages were then weighted by the total RVUs associated with a given county to ultimately arrive at locality-specific work GPCIs. This geographic aggregation of Census data is the same methodology that was utilized in previous updates to the GPCIs.

The work GPCIs reflect one-fourth of the relative cost differences, as required by statute, with the exception of those areas where MMA requires that the GPCI be set at no lower than 1.00 and that the Alaska GPCIs be set at 1.67.

b. Practice Expense GPCIs

As in the past, we are proposing that the practice expense GPCI would be comprised of several factors that represent the major expenses incurred in operating a physician practice. The factors and the data sources we propose to use are detailed below. The impact of each individual factor on the calculation of the practice expense GPCI is based on the relative weight for that factor consistent with the calculation of the MEI.

*Employee Wage Indices*—The employee wage index is based on special tabulations of 2000 census data, which are generated from the Long Form Questionnaire. These special tabulations provided by the Census Bureau are designed to capture the median wage by county of the professional labor force. The Employee Wage Index uses the median wages of four labor categories that are most commonly present in a physician's private practice (administrative support, registered nurses, licensed practical nurses, and health technicians). Median wages for these occupations were provided by the U.S. Census Bureau using the same set of geographic aggregation rules discussed previously in the physician work GPCI section.

TABLE 7.—SPECIFIC OCCUPATIONS USED IN CREATING EMPLOYEE WAGE INDEX UPDATE

| Categories | Census 2000 occupation code |
|---|---|
| Administrative Support | 500–593 |
| Registered Nurses | 313 |
| Licensed Practical Nurses | 350 |
| Health Technicians | 330, 332, 341, 351–354, 365 |

*Office Rent Indices*— Since no national data are readily available for physician office rents, some proxy must be used for this portion of the practice expense index. To construct the practice expense GPCIs, we need data that are widely and consistently available across all fee schedule areas. Although we searched for alternative commercial rental data that were both widely and consistently available across all fee schedule areas, we were unable to identify any reliable sources of commercial rental data.

As with the current practice expense GPCIs, the Department of Housing and Urban Development (HUD) Fair Market Rental (FMR) data for the residential rents were again used as the proxy for physician office rents. The proposed 2005 through 2007 practice expense GPCIs reflect the final fiscal year 2004 HUD FMR data. See Addendum E for a more detailed illustration of the actual office rent indices.

We believe that the FMR data remain the best available source for constructing the office rent index. The FMR data are available for all areas, are updated annually, and retain consistency from area-to-area and from year-to-year. Additionally, physicians frequently locate their offices in areas that are residential, rather than commercial, in nature. Residential rates may, in fact, be a better measure of the differences among areas in the physician office market than a general commercial rental index. In developing FMRs for metropolitan areas, HUD assumes that all counties within an MSA have the same rent. However, we believe that the rents in the New York City MSA vary too widely and propose that the FMR for this metropolitan area should be adjusted to account for this variation. For the New York City MSA, we used median gross rent from the 2000 Census to adjust the individual rents within counties in this MSA.

A reduction in an area's rent index does not necessarily mean that rents have gone down in that area since the last GPCI update. Since the GPCIs measure area costs compared to the national average, a decrease in an area's rent index means that that area's rental costs are lower relative to the national average rental costs. Addendum E illustrates the changes in the rental index based upon the new FMR data.

*Medical Equipment, Supplies, and other Miscellaneous Expenses*—The GPCIs assume that items such as medical equipment and supplies have a national market and that input prices do not vary among geographic areas. We were again unable to find any data sources that demonstrated price differences by geographic areas. As mentioned in previous updates, some price differences might exist, but these differences are more likely to be based on volume discounts rather than on geographic areas. The medical equipment, supplies, and miscellaneous expense portion of the practice expense geographic index will continue to be 1.000 for all areas in the proposed GPCIs, except for Alaska which will have an overall practice expense GPCI set at 1.67 for 2004 and 2005.

c. Malpractice Expense GPCIs

The malpractice GPCIs were reviewed and revised as part of the November 7, 2003 (68 FR 63196) physician fee schedule final rule. Please refer to that

final rule for a detailed discussion of the update to the malpractice GPCIs.

4. Calculation and Effect of the Proposed 2005 Through 2007 Work and Practice Expense GPCIs

All three of the indices for a specific fee schedule locality are based on the indices for the individual counties within the respective fee schedule localities. As has been done in the past, fee schedule RVUs would again be used to weight the county indices (to reflect volumes of services within counties) when mapping to fee schedule areas and in constructing the national average indices. However, we propose to use more recent data, 2002 versus 1998 RVUs, in the county, locality, and national mapping in the proposed GPCIs. The payment effect associated with the use of these revised RVUs would generally be negligible, in most cases resulting in changes at the third decimal point, if at all.

Fee schedule payments are the product of the RVUs, the GPCIs, and the conversion factor. Updating the GPCIs changes the relative position of fee schedule areas compared to the national average. Since the changes represented by the proposed GPCIs could result in total payments either greater than or less than what would have been paid if the GPCIs were not updated, it would be necessary to apply scaling factors to the proposed GPCIs to ensure budget neutrality (prior to applying the provisions of MMA that change the work GPCIs to a minimum of 1.0 and increase the Alaska GPCIs to 1.67 because these provisions are exempted from budget neutrality). We determined that the proposed work and practice expense GPCIs would have resulted in slightly higher total national payments. Since the law requires that each individual component of the fee schedule—work, practice expense, and malpractice expense—is separately adjusted by its respective GPCI, we propose to scale each of the GPCIs separately. To ensure budget neutrality prior to applying the MMA provisions, it would be necessary to—

- Decrease the proposed work GPCI by 0.9965;
- Decrease the proposed practice expense GPCI by 0.9930; and
- Increase the malpractice GPCIs that were published in the November 7, 2003 final rule by 1.0021.

As all geographic payment areas would receive the same percentage adjustments, the adjustments do not change the new relative positions among areas indicated by the proposed GPCIs. After the appropriate scaling factors are applied, the MMA provision setting a 1.0 floor would be applied to all work GPCIs falling below 1.0. Additionally, the GPCIs for Alaska would all be set to 1.67 in accordance with MMA.

The locality specific effect of these proposed revisions to the work and practice expense GPCIs, as well as the revisions to the malpractice GPCIs published in the November 7, 2003 final rule, and the MMA provisions enacted December 8, 2003, are shown in Addendum F through Addendum H. Addendum F reflects the current GPCIs that were effective on January 1, 2004. Addendum F can be utilized as a baseline for purposes of comparison to the proposed GPCIs. Addendum H illustrates the proposed fully implemented 2006 GPCIs. Addendum G illustrates the proposed transitional 2005 GPCIs, which are one-half of the effect of the proposed fully implemented GPCI revisions as required by section 1848(e)(1)(C) of the Act.

Because the three GPCIs have different weights, the overall effect of the proposed changes cannot be achieved by summing the individual effects of the revisions on the work, practice expense, and malpractice expense GPCIs. The overall effect of all three revised GPCI components on an area can be estimated by a comparison of the area's geographic adjustment factors (GAFs). The GAF for a specific payment area is the weighted composite of the three separate components. The GAF illustrates an estimate of the general effect on total payments across a specific fee schedule locality. The effects on individual physicians would vary depending on each physician's mix and volume of services.

To illustrate a comparison of the overall effect of the current and proposed GPCIs, Addendum J contains a comparison of the current 2004 GAFs to the proposed fully-implemented 2006 GAFs. Addendum I contains a comparison of the proposed transitional GAFs (2005) to the current 2004 GAFs. Both Addenda I and J are sorted in descending order of change. As Addendum J shows, no fee schedule area would experience a total decrease in its respective GAF by more than 3.5 percent, or increase by more than 7 percent, if the proposed GPCI revisions are fully implemented in 2006. The majority of payment areas would change by considerably less than these amounts. Nearly 75 percent of payment areas would change by less than 2 percent with the majority of these payment areas changing by less than 1 percent. Consequently, as illustrated by Addendum I, no fee schedule area would experience a total decrease in its respective GAF of more than 1.6 percent, or an increase of more than 3.5 percent, in the transition year (2005).

The GPCIs measure relative cost differences among payment areas compared to the national average. The national average cost is represented by a value of about 1.000. A proposed GPCI revision showing a decrease from the current value does not necessarily mean that absolute costs in a payment area have decreased, only that the average costs of a payment area have decreased as compared to the national average costs.

5. Payment Localities

In the August 15, 2003 proposed rule, we requested comments on the composition of the current 89 Medicare physician payment localities to which the GPCIs are applied. In the November 7, 2003 final rule, we indicated that we received comments from various parties requesting that specific counties be removed from their current locality. We further indicated that we are continuing to examine alternatives for reconfiguring the current locality structure.

While we have considered alternatives, we have not yet been able to come up with a policy and criteria that would satisfactorily apply to all situations. Any policy that we would propose would have to apply to all States and payment localities. For example, if we were to establish a policy that if adjacent county geographic indices exceeded a threshold amount, the lower county could be moved to the higher county or a separate locality could be created, that approach would cause redistributions within a State.

Locality changes are budget-neutral with respect to the aggregate amount of Medicare money in a State. That is, reconfigurations of localities within a State do not result in any more Medicare money for the State in the aggregate, but only redistributions of money within a State. Since there will be both winners and losers in any locality reconfiguration, the State medical associations should be the impetus behind these changes. Since 1996, we have moved to Statewide areas in several States after receiving resolutions from State medical societies including support from physicians in losing areas, and after going through Notice and Comment rulemaking. The support of State medical associations has been the basis for previous changes to Statewide areas, and continues to be equally important in our consideration of other future locality changes.

*C. Malpractice Relative Value Units (RVUs)*

[If you choose to comment on issues in this section, please include the caption ''Malpractice RVUs'' at the beginning of your comments.]

1. History of Relative Value Unit System

Section 1848(c)(2)(C) of the Act requires that each service paid under the physician fee schedule be comprised of three components: work, practice expense, and malpractice.

From 1992 to 1999, malpractice RVUs were charge-based, using weighted specialty-specific malpractice expense percentages and 1991 average allowed charges. Malpractice RVUs for new codes after 1991 were extrapolated from similar existing codes or as a percentage of the corresponding work RVU. Section 4505(f) of the BBA required us to implement resource-based malpractice RVUs for services furnished beginning in 2000. With the implementation of resource-based malpractice RVUs in 2000 and the full implementation of resource-based practice expense RVUs in 2002, all physician fee schedule RVUs were resource-based, eliminating the last vestiges of charged-based payment.

2. Proposed Methodology for the Revision of Resource-based Malpractice RVUs

The methodology used in calculating the proposed resource-based malpractice RVUs is the same methodology that was used in the initial development of resource-based RVUs, the only difference being the use of more current data. The proposed resource-based malpractice expense RVUs are based upon:

- Actual 2001 and 2002 malpractice premium data;
- Projected 2003 premium data; and
- 2002 Medicare payment data on allowed services and charges.

As was done in the initial development of resource-based malpractice expense RVUs in the November 2, 1999 final rule, we are proposing to revise resource-based malpractice expense RVUs using specialty-specific malpractice premium data because they represent the actual malpractice expense to the physician. In addition, malpractice premium data are widely available. We propose to use actual 2001 and 2002 malpractice premium data and projected 2003 malpractice premium data for three reasons:

- These are the most current data available.
- These data capture the highly publicized and most recent trends in the specialty-specific costs of professional liability insurance.
- These are the same malpractice premium data that were utilized in the development of revised malpractice GPCIs in the November 7, 2003 final rule.

We were unable to obtain a nationally representative sample of 2003 malpractice premium data for two reasons: (1) The premium data that we collected from the private insurance companies had to ''match'' the market share data that were provided by the respective State Departments of Insurance. Because none of the State Departments of Insurance had 2003 market share information at the time of this data collection, 2003 premium data were not usable; and (2) the majority of private insurers were not amicable to releasing premium data to us. In the majority of instances, the private insurance companies would release their premium data only to the State Departments of Insurance.

Discussions with the industry lead us to conclude that the primary determinants of malpractice liability costs remain physician specialty, level of surgical involvement, and the physician's malpractice history. Malpractice premium data were collected for the top 20 Medicare physician specialties measured by total payments. Premiums were for a $1 million/$3 million mature claims-made policy (a policy covering claims made, rather than services provided during the policy term). We attempted to collect premium data from all 50 States, Washington, DC, and Puerto Rico. Data were collected from commercial and physician-owned insurers and from joint underwriting associations (JUAs). A JUA is a State government-administered risk pooling insurance arrangement in areas where commercial insurers have left the market. Adjustments were made to reflect mandatory patient compensation funds (PCFs) (funds to pay for any claim beyond the statutory amount, thereby limiting an individual physician's liability in cases of a large suit) surcharges in States where PCF participation is mandatory. The premium data collected represent at least 50 percent of physician malpractice premiums paid in each State.

For 2001, we were able to collect premium data from 48 States (for purposes of this discussion, State counts include Washington, DC and Puerto Rico). We were unable to obtain premium data from Kentucky, New Hampshire, New Mexico, and Washington DC. To calculate a proxy for the malpractice premium data for these four areas in 2001, we began with the most current malpractice premium data collected for these areas, 1996 through 1998 (the last premium data collection that was undertaken). An average premium price was calculated (using 1996 through 1998 data) for all States except Kentucky, New Hampshire, New Mexico, and Washington, DC. Similarly, an average premium price was calculated for the 1999 through 2001 period for all States except Kentucky, New Hampshire, New Mexico, and Washington, DC. The percentage change in these premium prices was calculated as the percent difference between the 1999 to 2001 calculated average premium price and the 1996 to 1998 calculated average premium price. This percentage change was then applied to the weighted average 1996 to 1998 malpractice premium price for these four areas to arrive at a comparable 1999 to 2001 average premium price.

For 2002, we were able to obtain malpractice premium data from 33 States. Many State Departments of Insurance had not yet obtained premium data from the primary insurers within their State at the time of this data collection. For those States for which we were unable to obtain malpractice premium data, we calculated a national average rate of growth for 2002 and applied this national rate of growth to the weighted average premium for 2001 to obtain an average premium for 2002 for each county for which we were unable to obtain malpractice premium data for 2002.

We projected premium values for 2003 based on the average of historical year-to-year changes for each locality (when locality level data were available) or by State (when only Statewide premium data projections were available). First, we calculated the percentage changes in the premiums from the 1999 through 2000, 2000 through 2001, and 2001 through 2002 periods for each payment locality. Next, we calculated the geometric mean of these three percentages and applied the mean to the 2002 premium to obtain the forecasted 2003 malpractice premium. We used the geometric mean to calculate the forecasted 2003 premium data because the geometric mean is commonly used to derive the mean of a series of values that represent rates of change. Because the geometric mean is based on the logarithmic scale, it is less impacted by outlying data.

Malpractice insurers generally use five-digit codes developed by the Insurance Services Office (ISO), an advisory body serving property and casualty insurers, to classify physician

specialties into different risk classes for premium rating purposes. ISO codes classify physicians not only by specialty, but in many cases also by whether or not the specialty performs surgical procedures. A given specialty could thus have two ISO codes, one for use in rating a member of that specialty who performs surgical procedures and another for rating a member who does not perform surgery. Medicare uses its own system of specialty classification for payment and data purposes. It was therefore necessary to map Medicare specialties to ISO codes and insurer risk classes. Different insurers, while using ISO codes, have their own risk class categories. To ensure consistency, we used the risk classes of St. Paul Companies, one of the oldest and largest malpractice insurers. Table 8 crosswalks Medicare specialties to ISO codes and to the St. Paul risk classes used.

TABLE 8.—CROSSWALK OF MEDICARE SPECIALTIES TO IOS CODES AND TO THE ST. PAUL RISK CLASSES USED

| Medicare code | Medicare description | ISO code | | Risk class | | St. Paul's description |
|---|---|---|---|---|---|---|
| | | Surgery | Other | Surgery | Other | |
| 1 | General practice | 80117 | 80420 | 4 | 1 | Family/Gen. Practitioners—No Obstetrical. |
| 2 | General surgery | 80143 | 80143 | 5 | 5 | Surgery, General. |
| 3 | Allergy/Immunology | 80254 | 80254 | 1A | 1A | Allergy. |
| 4 | Otolaryngology | 80159 | 80265 | 3 | 1 | Otarhinolaryngology. |
| 5 | Anesthesiology | 80151 | 80151 | 5A | 5A | Anesthesiology. |
| 6 | Cardiology | 80281 | 80255 | 2 | 1 | Cardiovascular Disease. |
| 7 | Dermatology | 80472 | 80256 | 5 | 1A | Dermatology. |
| 8 | Family practice | 80117 | 80420 | 4 | 1 | Family/Gen. Practitioners—No Obstetrical. |
| 10 | Gastroenterology | 80104 | 80241 | 3 | 1 | Gastroenterology. |
| 11 | Internal medicine | 80284 | 80257 | 2 | 1 | Internal medicine. |
| 13 | Neurology | 80288 | 80261 | 2 | 2 | Neurology. |
| 14 | Neurosurgery | 80152 | 80152 | 8 | 8 | Surgery, Neurology. |
| 16 | Obstetrics/Gynecology | 80167 | 80244 | 4 | 1 | Gynecology. |
| 18 | Ophthalmology | 80114 | 80263 | 2 | 1 | Ophthalmology. |
| 20 | Orthopedic surgery | 80501 | 80501 | 5 | 5 | Surgery, Orthopedic—excluding Spinal Surgery. |
| 20 | Orthopedic surgery | 80154 | 80154 | 6 | 6 | Surgery, Orthopedic—including Spinal Surgery. |
| 22 | Pathology | 80292 | 80266 | 2 | 1A | Pathology. |
| 24 | Plastic and reconstructive surgery | 80156 | 80156 | 5 | 5 | Surgery, Plastic. |
| 25 | Physical medicine and rehab | 80235 | 80235 | 1 | 1 | Physical medicine and rehab. |
| 26 | Psychiatry* | 80492, 80431 | 80249 | 2 | 1A | Psychiatry. |
| 28 | Colorectal surgery | 80115 | 80115 | 3 | 3 | Surgery, Colon and Rectal. |
| 29 | Pulmonary Disease | 80269 | 80269 | 1 | 1 | Pulmonary Disease. |
| 30 | Diagnostic radiology ** | 80280 | 80253 | 2 | 2 | Radiology. |
| 33 | Thoracic surgery | 80144 | 80144 | 6 | 6 | Surgery, Thoracic. |
| 34 | Urology | 80145 | 80145 | 2 | 2 | Surgery, Urological. |
| 36 | Nuclear medicine | 80262 | 80262 | 1 | 1 | Nuclear medicine. |
| 37 | Pediatric medicine | 80293 | 80267 | 2 | 1 | Pediatrics. |
| 38 | Geriatric medicine*** | 80276 | 80243 | 2 | 1 | Geriatrics. |
| 39 | Nephrology*** | 80287 | 80260 | 2 | 1 | Nephrology. |
| 40 | Hand surgery | 80169 | 80169 | 5 | 5 | Surgery, Hand. |
| 44 | Infectious disease | 80279 | 80246 | 2 | 1 | Infectious disease. |
| 46 | Endocrinology*** | 80272 | 80238 | 2 | 1 | Endocrinology. |
| 65 | Physical therapist (independent) | 80235 | 80235 | 1 | 1 | Physical medicine and rehab. |
| 66 | Rheumatology | 80252 | 80252 | 1 | 1 | Rheumatology. |
| 67 | Occupational therapist (independent) | 80235 | 80235 | 1 | 1 | Occupational Medicine. |
| 77 | Vascular surgery | 80146 | 80146 | 6 | 6 | Surgery, Vascular. |
| 78 | Cardiac surgery | 80141 | 80141 | 6 | 6 | Surgery, Cardiac. |
| 82 | Hematology | 80278 | 80245 | 2 | 1 | Hematology. |
| 83 | Hematology/oncology | 80473 | 80473 | 1 | 1 | Oncology. |
| 84 | Preventive medicine | 80231 | 80231 | 1 | 1 | General Preventive Medicine. |
| 92 | Radiation Oncology**** | 80425 | 80425 | 2 | 2 | Radiation Therapy. |
| 93 | Emergency medicine | 80157 | 80102 | 5 | 4 | Emergency Medicine. |
| 98 | Gynecologist/oncologist | 80167 | 80244 | 4 | 1 | Gynecology. |

**Note:** For specialties with multiple risk classifications depending on the level of surgical involvement, the highest level of surgery for each specialty was selected for the ''surgery'' ISO and risk class; and the lowest level of surgery was selected for the ''nonsurgery'' ISO and risk class.

**Note:** If a specialty has only one risk classification, the same classification was used for both surgery and nonsurgery.

* The ISO codes for surgery for Psychiatry represents Psychiatry—shock therapy.

** St. Paul's is the only one of the five companies that has a ''major invasive'' procedures ISO Code for Radiology; therefore, the ''minor invasive procedures'' ISO Code is being used as the highest level of surgery.

*** St. Paul's is the only one of the five companies that has a ''major surgery'' ISO Code for Geriatrics, Nephrology, and Endocrinology; therefore, the minor surgery'' ISO Code is being used as the highest level of surgery.

**** Medical Protective's Description was used, as St. Paul's does not provide specific medical malpractice insurance for Radiation Therapy.

Some physician specialties, nonphysician practitioners, and other entities (for example, independent diagnostic testing facilities) paid under the physician fee schedule could not be assigned an ISO code. We crosswalked these specialties to similar physician specialties assigned an ISO code and a risk class. The unassigned specialties and the specialty to which they were assigned are shown in Table 9.

TABLE 9.—CROSSWALK OF SPECIALTIES TO SIMILAR PHYSICIAN SPECIALTIES ASSIGNED AN ISO CODE AND A RISK CLASS

| Medicare code | Unassigned Medicare specialty | Crosswalk specialty |
|---|---|---|
| 12 | Osteopathic Manipulative Therapy | Family Practice. |
| 32 | Anesthesiologist Assistant | Anesthesiology. |
| 35 | Chiropractic | Physical medicine and rehab. |
| 41 | Optometry | Ophthalmology. |
| 43 | Certified Registered Nurse Assistant | All Physicians. |
| 47 | Physiological Laboratory (independent) | All Physicians. |
| 48 | Podiatry | All Physicians. |
| 50 | Nurse Practitioner | All Physicians. |
| 62 | Psychologist | Psychiatry. |
| 68 | Clinical Psychologist | Psychiatry. |
| 69 | Clinical Laboratory | All Physicians. |
| 70 | Multi-Specialty Clinic or Group Practice | All Physicians. |
| 74 | Radiation Therapy Center | Radiation Oncology. |
| 76 | Peripheral Vascular Disease | Vascular Surgery. |
| 79 | Addiction Medicine | Psychiatry. |
| 80 | Licensed Clinical Social Worker | Psychiatry. |
| 81 | Critical Care (Intensivists) | All Physicians. |
| 85 | Maxillofacial Surgery | Plastic Surgery. |
| 86 | Neuropsychiatry | Psychiatry. |
| 89 | Certified Clinical Nurse Specialist | All Physicians. |
| 90 | Medical Oncology | Internal Medicine. |
| 91 | Surgical Oncology | General Surgery. |
| 94 | Interventional Radiology | Radiology. |
| 96 | Optician | Ophthalmology. |
| 97 | Physician Assistant | All Physicians. |

In the development of the proposed resource-based malpractice RVU methodology, we considered two malpractice premium-based alternatives for resource-based malpractice RVUs, the dominant specialty approach and the specialty-weighted approach.

**Dominant Specialty Approach**

The dominant specialty approach bases the malpractice RVUs upon the risk factor of only the dominant specialty performing a given service as long as the dominant specialty accounted for at least 51 percent of the total utilization for a given service. When 51 percent of the total utilization does not comprise the dominant specialty, this approach uses a modified specialty-weighted approach. In this modified specialty-weighted approach, two or more specialties are collectively defined as the dominant specialty. Starting with the specialty with the largest percentage of allowed services, the modified specialty-weighted approach successively adds the next highest specialty in terms of percentage of allowed services until a 50 percent threshold is achieved. The next step is to sum the risk factors of those specialties (weighted by utilization) in order to achieve at least 50 percent of the total utilization of a given service and then use the factors in the calculation of the final malpractice RVU.

The dominant specialty approach produces modest increases for some specialties and modest decreases for other specialties. The largest increase for any given specialty, over the specialty-weighted approach, is less than 1.5 percent of total RVUs, while the largest decrease for any given specialty is less than 0.5 percent of total RVUs.

**Specialty-Weighted Approach**

The approach that we adopted in the November 1999 final rule and are proposing to use in this proposed rule, bases the final malpractice RVUs upon a weighted average of the risk factors of all specialties performing a given service. The specialty-weighted approach ensures that all specialties performing a given service are accounted for in the calculation of the final malpractice RVU. Our proposed methodology is as follows:

(1) *Compute a national average premium for each specialty.* Insurance rating area malpractice premiums for each specialty were mapped to the county level. The specialty premium for each county is then multiplied by the total county RVUs (as defined by Medicare claims data), which had been divided by the malpractice GPCI applicable to each county to standardize the relative values for geographic variations. If the malpractice RVUs were not normalized for geographic variation, the locality cost differences (as reflected by the GPCIs) would be counted twice. The product of the malpractice premiums and standardized RVUs is then summed across specialties for each county. This calculation is then divided by the total RVUs for all counties, for each specialty, to yield a national average premium for each specialty.

Table 10 shows the national average premiums for the years 1999 through 2003 for the 20 specialties for which we collected premium data. As stated previously, we used an average of the 3 most current years, 2001 to projected 2003 malpractice premiums, in our calculation of the proposed malpractice RVUs.

TABLE 10.—NATIONAL AVERAGE PREMIUMS FOR THE YEARS 1999 THROUGH 2003 FOR THE 20 SPECIALTIES FOR WHICH WE COLLECTED PREMIUM DATA

| ISO | Specialty | 2001 average | 2002 average | 2003 average | 1996–1998 average | 2001–2003 average [1] | Annual trend [2] (percent) | Specialty MGPCI [3] | Normalized 2001–2003 premium [4] | Risk factor [5] |
|---|---|---|---|---|---|---|---|---|---|---|
| 80269 | Pulmonary disease | 12,574 | 13,456 | 14,541 | 9,508 | 13,524 | 7.30 | 1.027 | 13,168 | 2.14 |
| 80280 | Diagnostic radiology | 15,807 | 16,783 | 17,997 | 12,372 | 16,862 | 6.39 | 0.997 | 16,913 | 2.75 |
| 80284 | Internal medicine | 14,395 | 15,714 | 16,985 | 11,836 | 15,698 | 5.81 | 1.028 | 15,270 | 2.48 |
| 80274 | Gastroenterology | 14,347 | 15,398 | 16,643 | 11,745 | 15,463 | 5.65 | 1.017 | 15,204 | 2.47 |
| 80143 | General surgery | 33,163 | 36,004 | 39,059 | 27,825 | 36,075 | 5.33 | 0.957 | 37,696 | 6.13 |
| 80423 | General practice | 13,325 | 14,479 | 15,731 | 11,234 | 14,512 | 5.25 | 0.943 | 15,389 | 2.50 |
| 80288 | Neurology | 16,206 | 17,330 | 18,629 | 13,726 | 17,388 | 4.84 | 1.032 | 16,849 | 2.74 |
| 80114 | Ophthalmology | 13,064 | 14,103 | 15,317 | 11,209 | 14,161 | 4.79 | 0.997 | 14,204 | 2.31 |
| 80152 | Neurosurgery | 64,724 | 70,125 | 76,060 | 57,701 | 70,303 | 4.03 | 0.952 | 73,848 | 12.00 |
| 80281 | Cardiology | 14,798 | 15,836 | 17,085 | 13,204 | 15,906 | 3.79 | 1.021 | 15,579 | 2.53 |
| 80145 | Urology | 18,701 | 20,253 | 21,931 | 16,958 | 20,295 | 3.66 | 0.999 | 20,315 | 3.30 |
| 80159 | Otolaryngology | 21,720 | 23,127 | 24,794 | 19,990 | 23,214 | 3.04 | 0.997 | 23,284 | 3.78 |
| 80154 | Orthopedic w/spinal | 40,384 | 43,758 | 47,321 | 38,584 | 43,821 | 2.58 | 0.955 | 45,886 | 7.46 |
| 80144 | Thoracic surgery | 39,538 | 43,200 | 47,249 | 38,812 | 43,329 | 2.23 | 1.020 | 42,479 | 6.91 |
| 80282 | Dermatology | 11,046 | 11,549 | 12,375 | 10,650 | 11,657 | 1.82 | 1.020 | 11,428 | 1.86 |
| 80260 | Nephrology [6] | 8,408 | 9,290 | 10,142 | n/a | 9,280 | n/a | 0.999 | 9,289 | 1.51 |
| 80146 | Vascular surgery | 39,391 | 42,660 | 46,211 | n/a | 42,754 | n/a | 1.014 | 42,164 | 6.85 |
| 80141 | Cardiac surgery | 37,802 | 40,498 | 43,722 | n/a | 40,674 | n/a | 0.921 | 44,163 | 7.18 |
| 80425 | Radiation oncology | 13,800 | 14,755 | 15,976 | n/a | 14,844 | n/a | 0.995 | 14,918 | 2.43 |
| 80102 | Emergency medicine | 20,671 | 22,672 | 24,733 | n/a | 22,692 | n/a | 0.974 | 23,298 | 3.79 |

[1] A simple average of figures for 2001, 2002, and 2003.
[2] Percent annualized average growth rate between 1996–1998 and 2001–2003.
[3] An average of locality malpractice GPCIs using specialty-specific malpractice RVUs as weights.
[4] 2001–2003 premium divided by specialty MGPCI.
[5] (Normalized 2001–2003 Premium, .9289) × 1.51.
[6] Nephrology is set to 1.51 to be consistent with the risk factor taken from the rating manuals. n/a signifies that the premium data were not available.

(2) *Calculate a risk factor for each specialty.* Differences among specialties in malpractice premiums are a direct reflection of the malpractice risk associated with the services performed by a given specialty. The relative differences in national average premiums between various specialties can be expressed as a specialty risk factor. These risk factors are an index calculated by dividing the national average premium for each specialty by the national average premium for the specialty with the lowest average premium, nephrology. Table 11 shows the risk factors, surgical and nonsurgical, by specialty.

TABLE 11.—RISK FACTORS, SURGICAL AND NONSURGICAL, BY SPECIALTY

| Medicare code | Medicare description | Nonsurgical risk factor | Surgical risk factor |
|---|---|---|---|
| 01 | General practice | 1.79 | 4.26 |
| 02 | General surgery | 6.13 | 6.13 |
| 03 | Allergy/Immunology | 1.00 | 1.00 |
| 04 | Otolaryngology | 1.45 | 3.78 |
| 05 | Anesthesiology | 2.84 | 2.84 |
| 06 | Cardiology | 1.45 | 2.53 |
| 07 | Dermatology | 1.00 | 3.90 |
| 08 | Family practice | 1.79 | 4.26 |
| 10 | Gastroenterology | 2.05 | 3.49 |
| 11 | Internal medicine | 2.05 | 2.48 |
| 12 | Osteopathic Manipulative Therapy | 1.79 | 4.26 |
| 13 | Neurology | 2.52 | 2.74 |
| 14 | Neurosurgery | 12.00 | 12.00 |
| 16 | Obstetrics/Gynecology | 2.15 | 5.63 |
| 18 | Ophthalmology | 1.24 | 2.31 |
| 20 | Orthopedic surgery w/o Spinal | 8.06 | 8.06 |
| 20 | Orthopedic surgery with Spinal | 7.46 | 7.46 |
| 22 | Pathology | 1.72 | 2.09 |
| 24 | Plastic Surgery | 6.92 | 6.92 |
| 25 | Physical Med & Rehab | 1.26 | 1.26 |
| 26 | Psychiatry | 1.11 | 3.08 |
| 28 | Colorectal surgery | 4.08 | 4.08 |
| 29 | Pulmonary disease | 2.14 | 2.14 |
| 30 | Diagnostic radiology | 2.07 | 2.75 |
| 32 | Anesthesiologist Assistant | 2.84 | 2.84 |
| 33 | Thoracic surgery | 6.91 | 6.91 |
| 34 | Urology | 3.30 | 3.30 |
| 35 | Chiropractic | 1.26 | 1.26 |
| 36 | Nuclear medicine | 1.66 | 1.66 |
| 37 | Pediatric medicine | 1.76 | 2.42 |
| 38 | Geriatric medicine | 1.35 | 2.17 |
| 39 | Nephrology | 1.51 | 1.96 |

TABLE 11.—RISK FACTORS, SURGICAL AND NONSURGICAL, BY SPECIALTY—Continued

| Medicare code | Medicare description | Nonsurgical risk factor | Surgical risk factor |
|---|---|---|---|
| 40 | Hand surgery | 4.71 | 4.71 |
| 41 | Optometry | 1.24 | 2.31 |
| 43 | Certified Registered Nurse Assistant | 3.04 | 3.71 |
| 44 | Infectious disease | 1.55 | 2.09 |
| 46 | Endocrinology | 2.03 | 2.09 |
| 47 | Physiological Laboratory (independent) | 3.04 | 3.71 |
| 48 | Podiatry | 3.04 | 3.71 |
| 50 | Nurse Practitioner | 3.04 | 3.71 |
| 62 | Psychologist | 1.11 | 3.08 |
| 65 | Physical therapist (independent) | 1.26 | 1.26 |
| 66 | Rheumatology | 2.11 | 2.11 |
| 67 | Occupational therapist | 1.11 | 1.11 |
| 68 | Clinical Psychologist | 1.11 | 3.08 |
| 69 | Clinical Laboratory | 3.04 | 3.71 |
| 70 | Multi-Specialty Clinic or Group Practice | 3.04 | 3.71 |
| 74 | Radiation Therapy Center | 2.43 | 2.43 |
| 76 | Peripheral Vascular Disease | 6.85 | 6.85 |
| 77 | Vascular surgery | 6.85 | 6.85 |
| 78 | Cardiac surgery | 7.18 | 7.18 |
| 79 | Addiction Medicine | 1.11 | 3.08 |
| 80 | Licensed Clinical Social Worker | 1.11 | 3.08 |
| 81 | Critical Care (Intensivists) | 3.04 | 3.71 |
| 82 | Hematology | 1.77 | 2.26 |
| 83 | Hematology/oncology | 2.05 | 2.11 |
| 84 | Preventive medicine | 1.26 | 1.26 |
| 85 | Maxillofacial Surgery | 6.92 | 6.92 |
| 86 | Neuropsychiatry | 1.11 | 3.08 |
| 89 | Certified Clinical Nurse Specialist | 3.04 | 3.71 |
| 90 | Medical Oncology | 2.05 | 2.48 |
| 91 | Surgical Oncology | 6.13 | 6.13 |
| 92 | *Radiation oncology/therapy | 2.43 | 2.43 |
| 93 | Emergency medicine | 3.79 | 4.55 |
| 94 | Interventional Radiology | 2.07 | 2.75 |
| 96 | Optician | 1.24 | 2.31 |
| 97 | Physician Assistant | 3.04 | 3.71 |
| 98 | Gynecologist/oncologist | 2.15 | 5.63 |

**Note:** If a specialty has only one risk classification, the same classification was used for both surgery and nonsurgery.
**Note:** For specialties with multiple risk classifications depending on the level of surgical involvement, the highest level of surgery was selected for surgery risk factor and the lowest level of surgery was selected for nonsurgery risk factor.

(3) *Calculate malpractice RVUs for each code.* Resource-based malpractice RVUs were calculated for each procedure. The first step was to identify the percentage of services performed by each specialty for each respective procedure code. This percentage was then multiplied by each respective specialty's risk factor as calculated in Step 2. The products for all specialties for the procedure were then summed, yielding a specialty-weighted malpractice RVU reflecting the weighted malpractice costs across all specialties for that procedure. This number was then multiplied by the procedure's work RVUs to account for differences in risk-of-service. Since we were unable to find an acceptable source of data to be used in determining risk-of-service, work RVUs were used. We would welcome any suggestions for alternative data sources to be used in determining risk-of-service.

As mentioned above, certain specialties may have more than one ISO rating class and risk factor. The surgical risk factor for a specialty was used for surgical services and the nonsurgical risk factor for evaluation and management services. Also, for obstetrics/gynecology, the lower gynecology risk factor was used for all codes except those obviously surgical services, in which case the higher, surgical risk factor was used.

Certain codes have no physician work RVUs. The overwhelming majority of these codes are the technical components (TCs) of diagnostic tests, such as x-rays and cardiac catheterization, which have a distinctly separate technical component (the taking of an x-ray by a technician) and professional component (the interpretation of the x-ray by a physician). Examples of other codes with no work RVUs are audiology tests and injections. These services are usually furnished by nonphysicians, in this example, audiologists and nurses, respectively. In many cases, the nonphysician or entity furnishing the TC is distinct and separate from the physician ordering and interpreting the test. We believe it is appropriate for the malpractice RVUs assigned to TCs to be based on the malpractice costs of the nonphysician or entity, not the professional liability of the physician.

Our proposed methodology, however, would result in zero malpractice RVUs for codes with no physician work, since we propose the use of physician work RVUs to adjust for risk-of-service. We believe that zero malpractice RVUs would be inappropriate because nonphysician health practitioners and entities such as independent diagnostic testing facilities (IDTFs) also have malpractice liability and carry malpractice insurance. Therefore, we are proposing to retain the current charge-based malpractice RVUs for all services with zero work RVUs. We are open to comments and suggestions for constructing resource-based malpractice RVUs for codes with no physician work.

(4) *Rescale for budget neutrality.* The law requires that changes to fee schedule RVUs be budget neutral. The current resource-based malpractice RVUs and the proposed resource-based malpractice RVUs were constructed using entirely different malpractice premium data. Thus, the last step is to adjust for budget neutrality by rescaling the proposed malpractice RVUs so that the total proposed resource-based malpractice RVUs equal the total current resource-based malpractice RVUs. The proposed resource-based malpractice RVUs for each procedure were multiplied by the frequency count for that procedure to determine the total resource-based malpractice RVUs for each procedure. This was summed for all procedures to determine the total fee schedule proposed resource-based malpractice RVUs. This was compared to the total current resource-based malpractice RVUs, using the same calculation and cases. The total current and proposed malpractice RVUs were equal, and therefore budget neutral. Thus, no adjustments were needed to ensure that expenditures remained constant for the malpractice RVU portion of the physician fee schedule payment.

The proposed resource-based malpractice RVUs are shown in Addendum B. These values have been adjusted for budget neutrality on the basis of the most recent available data. The values do not reflect the final budget-neutrality adjustment, which we will make in the final rule based upon the more current Medicare claims data. We do not believe, however, that the values will change significantly as a result of the final budget-neutrality adjustment.

Because of the differences in the sizes of the three fee schedule components, implementation of the proposed resource-based malpractice RVUs will have a smaller payment effect than the previous implementation of resource-based practice expense RVUs. On average, work represents about 52.5 percent of the total payment for a procedure, practice expense about 43.6 percent of the total payment, and malpractice expense about 3.9 percent of the total payment. Thus, a 20 percent change in practice expense or work RVUs would yield a change in payment of about 8 to 11 percent. In contrast, a corresponding 20 percent change in malpractice values would yield a change in payment of only about 0.6 percent. Estimates of the effects on payment by specialty and selected high-volume procedures can be found in the impact section of this rule.

We are requesting comments on our proposed methodology and resource-based malpractice RVUs.

*D. Coding Issues*

1. Change in Global Period for CPT Code 77427, Radiation Treatment Management, Five Treatments

[If you choose to comment on issues in this section, please include the caption ''CODING-GLOBAL PERIOD'' at the beginning of your comments.]

This code was included in the November 2, 1999 physician fee schedule final rule and was effective for services beginning January 1, 2000. In that rule, and subsequent rules, we have applied a global indicator of ''xxx'' to this code, meaning that the global concept does not apply. It has been brought to our attention that this global indicator is incorrect. The global indicator should be 090 since the RUC valuation of this service reflected a global period of 90 days and we accepted this valuation. Therefore, we would correct the global indicator for this service to reflect a global period of 90 days (090).

2. Requests for Adding Services to the List of Medicare Telehealth Services

[If you choose to comment on issues in this section, please include the caption ''CODING—TELEHEALTH'' at the beginning of your comments.]

a. Background

Section 1834(m) of the Act defines telehealth services as professional consultations, office and other outpatient visits, and office psychiatry services identified as of July 1, 2000 by CPT codes 99241 through 99275, 99201 through 99215, 90804 through 90809, and 90862. In addition, the statute required us to establish a process for adding services to or deleting services from the list of telehealth services on an annual basis. In the CY 2003 final rule, we established a process for adding or deleting services to the list of Medicare telehealth services. This process provides the public an opportunity on an ongoing basis to submit requests for adding a service. For more information on submitting a request for addition to the list of Medicare telehealth services, visit our Web site at www.cms.hhs.gov/physicians/telehealth.

b. Submitted Requests for Addition to the List of Telehealth Services

Requests for adding services to the list of Medicare telehealth services must be submitted and received no later than December 31st of each calendar year to be considered for the next proposed rule. For example, requests submitted in CY 2003 are considered for the CY 2005 proposed rule.

We received the following public requests for addition in CY 2003: Inpatient hospital care, emergency department visits, hospital observation services, inpatient psychotherapy, monthly management of patients with end-stage renal disease (ESRD), speech and audiologist services, case management, and care plan oversight.

Requests for additions submitted in CY 2003 are discussed below.

*Inpatient hospital care, emergency department visits, hospital observation services, and inpatient psychotherapy*

The American Telemedicine Association (ATA) and an individual practitioner submitted a request to add initial and subsequent inpatient hospital care as represented by CPT codes 99221 through 99223 and 99231 through 99233; hospital observation services (CPT codes 99217, 99218 through 99220); and individual psychotherapy furnished in an inpatient, partial hospitalization, or residential care facility setting (as defined by CPT codes 90816 through 90822). The requestors argue that the addition of hospital observation services, inpatient hospital care, and inpatient psychotherapy will reduce transfers from remote facilities to tertiary care facilities, decrease length of stay, improve diagnostic accuracy, plan of care strategies and patient outcomes, and also stabilize local health care systems. The requestors emphasize that adding individual psychotherapy in the inpatient and partial hospitalization setting is crucial for providing access to mental health services for the rural population. Additionally, the requestors believe that no current Medicare telehealth service can be billed when a patient is in observation status or is admitted as an inpatient. They also noted that the current psychiatry services paid for as telehealth services are not appropriate for mental health patients in the hospital, partial hospital, or residential facility settings.

The University of Kansas Medical Center requested that we add emergency department visits as defined by CPT codes 99281 through 99285 as telehealth services. The requestor stated that, for many rural hospitals, the attending physician in emergency cases is a local primary care or family physician who may not have sufficient experience with the complexities of emergent care. The requestor believes that adding emergency department visits will provide quicker access to an expert trauma or emergency physician and that the time saved could be life-saving for the patient.

CMS Review

As discussed in the June 28, 2002 **Federal Register** (67 FR 43862), we assign requests to one of two categories for review. Category 1 is comprised of services, which are similar in nature to an office or other outpatient visit, consultation, or office psychiatry. We review category 1 services to ensure that the roles of, and interaction among, the patient, physician, or practitioner at the distant site and telepresenter (if necessary) are similar to the current telehealth services.

Category 2 services would include services that are not similar to an office or other outpatient visit, consultation, or office psychiatry. Because of the potential acuity of the patient in the hospital setting, we consider inpatient hospital care, emergency department visits, hospital observation services, and inpatient psychotherapy to fall into the second category of requests. As discussed on our website, for category 2 services, requestors must provide evidence indicating that the use of a telecommunications system produces similar diagnostic findings or therapeutic interventions as would face-to-face delivery of the same service.

For inpatient hospital care, hospital observation services, and inpatient psychotherapy, the requestors did not submit evidence indicating that the use of a telecommunications system does not affect the diagnosis or treatment plan as compared to the face-to-face delivery of the service. The requestors instead submitted various studies and articles regarding: the psychiatric diagnostic interview examination; school-based pediatric acute care to children; child and adolescent psychotherapy in clinics and schools; the use of telehealth technology to simplify case management and prior authorization; consultation on neurology cases; and nursing care to reduce hospitalization for heart failure.

These data are not directly relevant to the services that the requesters wanted to have added. They do not address whether the use of a telecommunications system produces similar diagnoses or therapeutic interventions by physicians or practitioners, as would the face-to-face delivery of inpatient hospital care, hospital observation services, and inpatient psychotherapy. With respect to emergency department visits, the requestor submitted a comparison study between emergency department telemedicine and face-to-face emergency department visits. However, this study did not take into account complex emergent care. Study participants were pre-selected based on cases with limited clinical intervention, for example, animal bites with no skin laceration or puncture wounds, insect bites without evidence of wheezing or airway compromise, sore throat, first degree burns—less than 5 percent, and nonurgent medical problems requiring a referral.

In the absence of sufficient, well-designed comparison studies showing that the use of a telecommunications system produces similar diagnoses or therapeutic interventions as would the face-to-face delivery of the requested services, we are proposing not to add these services to the list of telehealth services.

We believe that the current list of Medicare telehealth services is appropriate for hospital inpatients, emergency room cases, and patients designated as observation status. If guidance or advice is needed in these settings, a consultation could be requested from an appropriate source.

End Stage Renal Disease—Monthly Management of Patients on Dialysis

The ATA and an individual practitioner submitted a request that we add the monthly management of patients on dialysis, as represented by HCPCS codes G0308 through G0319, to the list of Medicare telehealth services. Under these codes, Medicare pays an increased monthly capitated payment amount for additional visits during the month (up to four). The requestors noted the shortage of nephrologists and the difficulty they have in visiting face-to-face with all patients on dialysis. Additionally, the requestors stated that many States, including Alaska, Hawaii, Montana, and Wisconsin, have remote community-based dialysis centers with underserved populations located a considerable distance from a nephrologist. To address this issue, consultations and patient care conferences are currently being provided using a telecommunications system to manage patients on dialysis located in communities that do not have a nephrologist, including communities in Texas, where dialysis consultations and assessments using telecommunications are paid under the State's Medicaid program. Given the claims of a shortage of nephrologists and the new face-to-face visit requirements for physicians managing patients on dialysis, the requestors believe that permitting the management of dialysis patients through telehealth services is crucial.

CMS Review

The MCP G codes represent a range of services provided during a month, including a complete assessment of the patient and subsequent visits to monitor the patient's condition. We believe the types of services provided as part of the subsequent visits included in the codes are similar to the office and other outpatient visits currently on the list of Medicare telehealth services. Therefore, we believe these services would meet the criteria set forth in Category 1 of the process for adding services described above. However, we do not believe the complete assessment aspect of the MCP G codes is similar to existing telehealth services. For example, one aspect of a complete assessment would involve examination of the vascular access site. This is a specific clinical examination that is not similar to other services on the list.

Therefore, we consider the request for addition of the complete assessment to the list of telehealth services to be a Category 2 request, requiring comparative analyses. In submitting their requests for addition to the list of Medicare telehealth services, the requestors included summaries of many studies related to renal dialysis patient monitoring. However, we do not believe the requestor provided comparative analyses illustrating that the use of a telecommunications system is an adequate substitute for the clinical examination of the vascular access site. We do not believe that the use of a telecommunications system is an adequate method for conducting a complete assessment of the ESRD beneficiary. We believe that a clinical examination of the vascular access site can be adequately performed only with a face-to-face, ''hands on'' examination of the patient.

However, we do believe the subsequent visits meet the criteria for approving a Category 1 request. That is, we believe the roles and interactions between the patient and the physician (or practitioner) are similar to those of office and other outpatient visits currently on the telehealth list. This presents a unique scenario, wherein a portion of the services represented by the MCP G codes are eligible to add to the list, but one service (the complete assessment) is not. To address this issue, we propose to add the ESRD-related services with 2 or 3 visits per month and ESRD-related services with 4 or more visits per month as described by G0308, G0309, G0311, G0312, G0314, G0315, G0317, G0318 to the list of Medicare telehealth services. However, the complete assessment of the ESRD

beneficiary would not be permitted through the use of a telecommunications system. A comprehensive visit including a clinical examination of the vascular access site must be furnished face-to-face ''hands on'' by a physician, clinical nurse specialist, nurse practitioner, or physician's assistant. An interactive telecommunications system may be used for providing additional visits required under the 2-to-3 visit MCP and the 4-or-more visit MCP.

As noted previously, the MCP G codes are unique in that they reflect the ongoing care provided to ESRD patients by the physician or practitioner, on a monthly basis. These codes also reflect a range of services, from a monthly comprehensive assessment to monitoring the patient's overall condition and addressing individual issues and concerns as they arise during the month. We believe these codes are distinguishable from other codes by the scope of services and the ongoing nature of the services provided. Therefore, we believe that it would be appropriate to permit the use of a telecommunications system for providing some of the visits required under the ESRD MCP and to add these codes to the list of Medicare telehealth services.

The MCP physician, for example, the physician or practitioner who provided the complete assessment, and other practitioners within the same group practice or employed by the same employer/entity, may furnish ESRD-related visits through a telecommunications system. However, the physician or practitioner who performs the complete assessment and establishes the plan of care should bill for the MCP in any given month.

*Clinical Criteria*—The complete assessment visit must be conducted face-to-face. For subsequent visits, the physician or practitioner at the distant site is required, at a minimum, to use an interactive audio and video telecommunications system that allows the physician or practitioner to provide medical management services for a maintenance dialysis beneficiary. For example, an ESRD visit conducted via telecommunications system must permit the physician or practitioner at the distant site to perform an assessment of whether the dialysis is working effectively and whether the patient is tolerating the procedure well (physiologically and psychologically). During this assessment, the physician or practitioner at the distant site must be able to determine whether alteration in any aspect of the beneficiary's prescription is indicated, due to such changes as the estimate of the patient's dry weight.

*Clarification on originating sites*—The statute currently defines a telehealth originating site as a physician's or practitioner's office, hospital, critical access hospital, rural health clinic, or Federally-qualified health center. ESRD facilities are not originating sites (dialysis facilities are not defined in the statute as originating sites). Subsequent visits (other than the comprehensive assessment) in any of the statutorily-covered settings could be provided via telecommunications equipment, including a physician's satellite office within a dialysis center. Adding dialysis facilities to the list of Medicare telehealth originating sites would require a legislative change.

Speech and Audiologist Services

The American Speech-Language Hearing Association (ASHA) requested that we add 36 audiology services (CPT code range 92541 through 92596) and 30 speech language pathology (SLP) services (CPT code range 31575 through 97703) to the list of Medicare telehealth services. The ASHA believes the cognitive nature of these services makes them well-suited for telehealth and noted several telehealth programs that have been successful at providing SLP and audiology services. For example, existing telehealth networks were cited as successfully providing diagnosis, treatment, and management recommendations for patients with speech language and hearing disorders.

CMS Review

Speech language pathologists and audiologists are not permitted under current law to provide and receive payment for Medicare telehealth services at the distant site. The statute permits only a physician, as defined by section 1861(r) of the Act or a practitioner as described in section 1842(b)(18)(C) of the Act (clinical nurse specialist, nurse practitioner, physician assistant, nurse midwife, clinical psychologist, and clinical social worker), to furnish Medicare telehealth services. We are exploring this issue as part of a report to Congress (required by section 223(d) of BIPA) on additional sites and settings, geographic areas, and practitioners that may be reimbursed for the provision of telehealth services. At this time, we are not adding speech and audiology services to the list of Medicare telehealth services.

Case Management and Care Plan Oversight (Team Conferences and Physician Supervision)

Two requests were submitted asking that we add medical team conferences as identified by CPT codes 99361 and 99362 and physician supervision (CPT codes 99374 and 99375) as telehealth services. Requestors stated that for these services, the use of a telecommunications system provides interdisciplinary medical teams serving remote underserved populations better access to the clinical expertise and decision making of specialty physicians. The requestors note that the current list of Medicare telehealth services, for example, consultations or office visits, cannot be used for case management and care plan oversight services because the patient is not typically present.

CMS Review

Medical team conferences and monthly physician supervision are already covered Medicare services and do not require a face-to-face encounter with the beneficiary. Under the Medicare program, the use of a telecommunications system in furnishing a telehealth service is a substitution for the face-to-face requirements of a service. Since medical team conferences and monthly physician supervision do not require a face-to-face encounter with the patient, we cannot add these services to the list of Medicare telehealth services.

Review Summary

For the reasons stated above, we propose to add ESRD-related services as described by G0308, G0309, G0311, G0312, G0314, G0315, G0317 and G0318 to the list of Medicare telehealth services.

Moreover, we would add the term ''ESRD-related visits'' to the definition of Medicare telehealth services at CFR 410.78 and 414.65 as appropriate.

We do not propose to add any additional services discussed above to the list of Medicare telehealth services for CY 2005.

3. National Pricing of G0238 and G0239 Respiratory Therapy Service Codes

[If you choose to comment on issues in this section, please include the caption ''CODING—RESPIRATORY THERAPY'' at the beginning of your comments.]

In the 2001 final rule, we created three G codes for respiratory therapy services: G0237 *Therapeutic procedures to increase strength or endurance of respiratory muscles, face-to-face, one-on-one, each 15 minutes (includes monitoring),* G0238 *Therapeutic procedures to improve*

*respiratory function, other than ones described by G0237, one-on-one, face-to-face, per 15 minutes (includes monitoring)* and G0239 *Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes monitoring).*

We assigned RVUs to one of the codes (G0237), and indicated that the other two codes (G0238 and G0239) would be carrier-priced. Since the services represented by these codes are frequently being performed in comprehensive outpatient rehabilitation facilities, and paid under the physician fee schedule through fiscal intermediaries, there has been some uncertainty surrounding the payment for the carrier-priced services. We believe assigning RVUs to G0238 and G0239 would alleviate some of this uncertainty. Since these services are typically performed by respiratory therapists, no physician work was assigned to G0237, and we are not proposing work RVUs for either G0238 or G0239.

Therefore, we are proposing to value these services using the nonphysician workpool.

We propose practice expense RVUS for G0238 equal to those for G0237. While these codes represent two different types of activities (G0237 involves therapeutic procedures specifically targeted at improving the strength and endurance of respiratory muscles such as pursed-lip breathing, diaphragmatic breathing, and paced breathing, and G0238 involves other activities such as teaching patients strategies for performing tasks with less respiratory effort and the performance of graded activity programs to increase endurance and strength of upper and lower extremities), we believe that the practice expense involved is substantially the same for both services and thus, propose to crosswalk the practice expense RVUs for G0237 to G0238.

G0239 represents situations in which two or more individuals are receiving services simultaneously (such as those described above in G0237 or G0238) during the same time period. Although the practitioner must be in constant attendance, he or she need not be providing one-on-one patient contact. For G0239, we believe a typical group session to be 30 minutes in length and to consist of 3 patients. Therefore, for the practice expense RVUs for G0239, we will use the practice expense RVUs of G0237 reduced by one-third to account for the fact that the service is being provided to more than one patient simultaneously and each patient in a group can be billed for the services of G0239.

We also propose a malpractice RVU of 0.02, the malpractice RVU assigned to G0237, for these two G codes.

4. Bone Marrow Aspiration and Biopsy Through the Same Incision on the Same Date of Service

[If you choose to comment on issues in this section, please include the caption ''CODING—BONE MARROW ASPIRATION'' at the beginning of your comments.]

In the physician fee schedule final rule published on June 28, 2002 (67 FR 43864), we proposed creation of a new G-code that reflects a bone marrow biopsy and aspiration procedure performed on the same date, at the same encounter, through the same incision. While some commenters were supportive of this proposal, other commenters felt that creation of a G-code was unnecessary and that any concerns with respect to payment could be addressed through application of the multiple procedure payment rules. In a final rule published on December 31, 2002 (67 FR 79992), we agreed that the code should go through the CPT process and did not make our proposal final.

To date, CPT has not addressed the issue. Therefore, we are proposing to create a G-code for this service in 2005. We believe that there is minimal incremental work associated with performing the second procedure through the same incision during a single encounter and are proposing an add-on G-code to reflect the additional physician work and practice expense. As we had stated in our previous proposal, if the two procedures, aspiration and biopsy, are performed at *different* sites (for example, contralateral iliac crests, sternum/iliac crest or two separate incisions on the same iliac crest), the –59 modifier, which denotes a distinct procedural service, would be appropriate to use and Medicare's multiple procedure rules would apply. In this instance, the CPT codes for aspiration and biopsy would each be used.

**G0XX1: Bone Marrow Aspiration Performed With Bone Marrow Biopsy Through Same Incision on Same Date of Service, Add-On**

The code would be used when a bone marrow aspiration and a bone marrow biopsy are performed on the same day through a single incision. The physician would use the CPT code for bone marrow biopsy (38221) and G0XX1 for the second procedure (*bone marrow aspiration*).

Based on our estimation that the time associated with this G-code is approximately 5 minutes and based on a comparison to CPT code 38220 which has 34 minutes of intraservice time and a work RVU of 1.08 work, we are proposing 0.16 work RVUs for this proposed G-code. The proposed malpractice RVUs are 0.04 which are the current malpractice RVUS assigned to CPT code 38220. We are proposing the following practice expense inputs:

—Clinical staff time: Registered nurse—5 minutes
Lab technician—2 minutes
—Equipment: Exam table

We are also proposing a ZZZ global period for this add-on code since this code is related to another service and is included in the global period of the other service.

5. Q Code for the Set-Up of Portable X-Ray Equipment

The Q-code for the set-up of portable x-ray equipment, Q0092, is currently paid under the physician fee schedule and is assigned an RVU of 0.33. In 2004, this produces a national payment of $12.32. This set-up code encompasses only a portion of the resources required to provide a portable x-ray service to patients. In 2003, portable x-ray suppliers received total Medicare payments of approximately $208 million. More than half of these payments (approximately $116 million) were for portable x-ray transportation (codes R0070 and R0075). The portable x-ray set-up code (Q0092) generated approximately $19 million in payments. The remainder of the Medicare payments for portable x-ray services (approximately $73 million) were for the actual x-ray services themselves.

Between 2002 and 2004, the Medicare carriers increased the average amount paid for portable x-ray transportation across the country from about $89 to $112, an increase of about 25 percent (transportation is carrier-priced). Nonetheless, the Conference Report accompanying the Consolidated Appropriations Bill, HR 2673 (Pub. L. 108–199, enacted January 23, 2004), urged the Secretary to review and update the RVUs for Q0092 utilizing existing data.

In 2002, the National Association of Portable X-ray Providers had requested that we use their cost data to develop practice expense RVUs for the physician fee schedule services they provide. We asked the Lewin Group to evaluate the data using the same standards of review applied to other specialty survey data. The Lewin Group found that the data as presented were not adequately detailed

to calculate a practice expense per hour based on the current practice expense methodology. Therefore, we did not use the data. However, in response to ongoing requests from the portable x-ray industry that we reexamine payments for this code, we have reevaluated this code.

This code is currently priced in the nonphysician work pool. Removing this code from the nonphysician work pool has an overall negative impact on payments to portable x-ray suppliers (as a result of decreases to radiology codes that remain in the nonphysician work pool) and has a negative impact on many of the codes remaining in the nonphysician workpool. An alternative to national pricing of portable x-ray set-up would be to require Medicare carriers to develop local pricing as they do currently for portable x-ray transportation. In 2002, we received a comment from a supplier of portable x-rays stating that the practice costs associated with set-up of portable x-ray equipment are not included in the Socioeconomic Monitoring System (SMS) and that there are sufficient differences among geographic regions in the performance of this procedure that warrant reclassifying this service as carrier-priced. We are interested in public comments on whether we should pursue national pricing for portable x-ray set-up outside of the nonphysician work pool or local carrier pricing for 2005 or whether we should continue to price the service in the nonphysician workpool.

6. Venous Mapping for Hemodialysis

We are proposing to create a new G-code (G0XX3: *Venous mapping for hemodialysis access placement* (Service to be performed by operating surgeon for preoperative venous mapping prior to creation of a hemodialysis access conduit using an autogenous graft). Autogenous grafts have longer patency rates, a lower incidence of infection and greater durability than prosthetic grafts. Use of autogenous grafts can also result in a decrease in hospitalizations and morbidity related to vascular access complications. Creation of this G-code will enable us to distinguish between CPT code 93971 (*Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study*) and G0XX3. This new code will allow us to track use of venous mapping for quality improvement purposes.

This G code would only be billed by the operating surgeon in conjunction with the following CPT codes: 36819, 36821, 36825, and 36832. Because CPT code 93971 and the new G-code would be used to describe a similar service, we would propose that we not permit payment for CPT code 93971 when this G-code is billed, unless code 93971 were being performed for a separately identifiable clinical indication in a different anatomic region.

The physician work, practice expense and professional liability expense for this new G code would be the same as those for CPT code 93971. Thus, we propose to crosswalk the RVUs for the new G-code from those of CPT code 93971. We would also assign this new G-code a global period of ''XXX'', which means that the global concept does not apply.

## III. Provisions of the Medicare Modernization Act of 2003

### *A. Section 611—Initial Preventive Physical Examination*

[If you choose to comment on issues in this section, please include the caption ''Section 611'' at the beginning of your comments.]

1. Coverage of Initial Preventive Physical Examinations

Section 611 of the MMA provides for coverage under Part B of an initial preventive physical examination for new beneficiaries, effective for services furnished on or after January 1, 2005, subject to certain eligibility and other limitations.

Previously, Medicare law had not allowed for payment for routine physical examinations or checkups. Section 1862(a)(7) of the Act states that routine physical checkups are excluded services. This exclusion is described in § 411.15(a) (Particular services excluded from coverage). In addition, we have interpreted section 1862(a)(1)(A) of the Act to exclude coverage for preventive physical examinations. This section provides that items and services must be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member as stated in § 411.15(k). Since preventive services are not provided for diagnosis or treatment of illness, injury, or malformation, we determined that these services are not reasonable and necessary within the meaning of the statute.

To conform the regulations to the MMA, we are specifying an exception to the list of examples of routine physical examinations excluded from coverage in § 411.15(a)(1) and § 411.15(k)(11) for initial preventive physical examinations that meet the eligibility limitation and the conditions for coverage that we are specifying under § 410.16—Initial Preventive Physical Examinations.

Coverage of initial preventive physical examinations is provided under Medicare Part B only. The MMA permits payment for one initial preventive physical examination within the first 6 months after the effective date of the beneficiary's first Part B coverage period, but only if that coverage period begins on or after January 1, 2005.

We are proposing to add § 410.16(b), Condition for Coverage of Initial Preventive Physical Examinations, and § 410.16(c), Limitation on Coverage of Initial Preventive Physical Examinations, to provide for coverage of the various initial preventive physical examination services specified in the statute.

We are proposing to define several terms, as described specifically in § 410.16, that would be used in implementing the statutory provisions, including definitions of the following terms—

(1) Eligible beneficiary;

(2) An initial preventive physical examination;

(3) Medical history;

(4) Physician;

(5) Qualified nonphysician practitioner.

(6) Social history;

(7) Review of the individual's functional ability and level of safety;

Section 611 of the MMA defines an ''initial preventive physical examination'' to mean physicians' and certain qualified nonphysician practitioners' services consisting of—

(1) A physical examination (including measurement of height, weight, blood pressure, and an electrocardiogram, but excluding clinical laboratory tests) with the goal of health promotion and disease detection; and

(2) Education, counseling, and referral with respect to screening and other covered preventive benefits separately authorized under Medicare Part B.

Specifically, section 611(b) of the MMA provides that the education, counseling, and referral of the individual by the physician or other qualified nonphysician practitioner should be with respect to the following statutory screening and other preventive services authorized under Medicare Part B:

(1) Pneumococcal, influenza, and hepatitis B vaccine and their administration.

(2) Screening mammography.

(3) Screening pap smear and screening pelvic exam services.

(4) Prostate cancer screening services.

(5) Colorectal cancer screening tests.

(6) Diabetes outpatient self-management training services;

(7) Bone mass measurements.

(8) Screening for glaucoma.

(9) Medical nutrition therapy services for individuals with diabetes or renal disease.

(10) Cardiovascular screening blood tests.

(11) Diabetes screening tests.

Based on the language of the statute, our review of the medical literature, current clinical practice guidelines, and United States Preventive Services Task Force recommendations, we are proposing to interpret the term, ''initial preventive physical examination,'' for purposes of this new benefit to include all of the following:

(1) Review of the individual's comprehensive medical and social history, as those terms are defined in paragraph (a) of proposed § 410.16.

(2) Review of the individual's potential (risk factors) for depression (including past experiences with depression or other mood disorders) based on the use of an appropriate screening instrument which the physician or other qualified nonphysician practitioner may select from various available standardized screening tests for this purpose, unless the appropriate screening instrument is defined through the national coverage determination (NCD) process.

(3) Review of the individual's functional ability and level of safety, as described in paragraph (a) of proposed § 410.16, (that is, at a minimum, a review of the following areas: hearing impairment, activities of daily living, falls risk, and home safety), based on the use of an appropriate screening instrument, which the physician or other qualified nonphysician practitioner may select from various available standardized screening tests for this purpose, unless the appropriate screening instrument is further defined through the NCD process.

(4) An examination to include measurement of the individual's height, weight, blood pressure, a visual acuity screen, and other factors as deemed appropriate by the physician or qualified nonphysician practitioner, based on the individual's comprehensive medical and social history and current clinical standards.

(5) Performance and interpretation of an electrocardiogram.

(6) Education, counseling, and referral, as appropriate, based on the results of the previous five elements of the initial preventive physical examination.

(7) Education, counseling, and referral, including a written plan provided to the individual for obtaining the appropriate screening and other preventive services, which are separately covered under Medicare Part B benefits; that is, pneumococcal, influenza, and hepatitis B vaccines and their administration, screening mammography, screening pap smear and screening pelvic exams, prostate cancer screening tests, diabetes outpatient self-management training services, bone mass measurements, screening for glaucoma, medical nutrition therapy services, cardiovascular screening blood tests, and diabetes screening tests.

We are requesting public comments on the definition of the term ''initial preventive physical examination.'' For example, we have chosen not to define the term, ''appropriate screening instrument,'' for screening individuals for depression, functional ability, and level of safety, as specified in the proposed rule, because we anticipate that the examining physician or qualified nonphysician practitioner will want to use the test of his or her choice, based on current clinical practice guidelines. We believe that any standardized screening test for depression, functional ability, and level of safety recognized by the American Academy of Family Physicians, the American College of Physicians-American Society of Internal Medicine, the American College of Preventive Medicine, the American Geriatrics Society, the American Psychiatric Association, or the United States Preventive Services Task Force, or other recognized medical professional group, would be acceptable for purposes of meeting the ''appropriate screening instrument'' provision. We ask that commenters making specific recommendations on this or any related issue provide documentation from the medical literature, current clinical practice guidelines, or the United States Preventive Services Task Force recommendations.

We recognize that the NCD process could be used to define more specifically the type or types of appropriate screening instruments for depression, functional ability, or level of safety and propose to include in § 410.16(a) in elements (2) and (3) of the definition of an initial preventive physical examination a reference that would allow us to define these screening instruments more specifically through the national coverage determination (''NCD'') process. The NCD process would include an opportunity for public comment on the medical and scientific issues related to the coverage of the new tests that may be brought to our attention in the future. Use of an NCD to establish a change in the scope of benefits is authorized by section 1871(a)(2) of the Act.

2. Payment for Initial Preventive Physical Examination

There is no current CPT code that contains the specific elements included in the initial preventive examination. Therefore, we are proposing to establish the following new HCPCS code, G0XX2, *Initial preventive physical examination,* to be used for billing for the initial preventive examination. As required by the statute, this code includes an electrocardiogram, but does not include the other previously mentioned preventive services that are currently separately covered and paid under the Medicare Part B screening benefits. When these other preventive services are performed, they should be identified using the existing appropriate codes.

a. Basis for Payment

Payment for this new HCPCS code will be based on the following:

1. *Work RVUs*—We are proposing a work value of 1.51 RVUs for G0XX2. This value is based on our determination that this new service has equivalent resources and work intensity to those contained in CPT E/M code 99203, *new patient, office or other outpatient visit,* and CPT code 93000 *electrocardiogram, complete.* CPT code 99203 has a work RVU of 1.34 and requires a detailed history, detailed examination, and medical decision making of low complexity, which we believe to be representative of the elements contained in the initial preventive health examination. CPT code 93000, which is for a routine ECG with the interpretation and report, has a work RVU of 0.17.

2. *Malpractice RVUs*—For the malpractice component of G0XX2, we are proposing malpractice RVUs of 0.13 in the nonfacility setting based on the malpractice RVUs currently assigned to CPT code 99203 (0.10) and CPT code 93000 (0.03). In the facility setting, we are proposing malpractice RVUs of 0.11 based on the current malpractice RVUs assigned to CPT code 99203 (0.10) and 93010 (an EKG interpretation with a value of 0.01).

3. *Practice Expense RVUs*—For the practice expense component of G0XX2, we are proposing practice expense RVUs of 1.65 in the nonfacility setting based on the practice RVUs assigned to CPT code 99203 (1.14) and CPT code 93000 (0.51). In the facility setting, we are proposing practice expense RVUs of 0.54 based on the practice RVUs assigned to CPT code 99203 (0.48) and 93010 (0.06).

b. Evaluation and Management (E/M) Service

Since some of the components for a medically necessary E/M visit are reflected in this new HCPCS code, we are also proposing, when it is appropriate, to allow a medically necessary E/M service no greater than a level 2 to be reported at the same visit as the initial preventive physical examination. That portion of the visit must be medically necessary to treat the patient's illness or injury or to improve the function of a malformed body member and should be reported with modifier –25. The physician or qualified nonphysician practitioner could also bill for the screening and other preventive services currently covered and paid by Medicare Part B under separate provisions of section 1861 of the Act, if provided during this initial preventive physical examination.

c. Coinsurance and Part B Deductible

MMA did not make any provision for the waiver of the Medicare coinsurance and Part B deductible for the initial preventive physical examination. Payment for this service would be applied to the required deductible, which is $110 for CY 2005, if the deductible has not been met, and the usual coinsurance provisions would apply.

*B. Section 613—Diabetes Screening Tests*

[If you choose to comment on issues in this section, please include the caption ''Section 613'' at the beginning of your comments.]

Section 613 of the MMA adds section 1861(yy) to the Act and mandates coverage of diabetes screening tests.

The term ''diabetes screening tests'' is defined in section 613 as testing furnished to an individual at risk for diabetes including a fasting plasma glucose test and such other tests, and modifications to tests, as the Secretary determines appropriate, in consultation with appropriate organizations. In compliance with this directive, we consulted with the American Diabetes Association, the American Association of Clinical Endocrinologists, and the National Institute for Diabetes and Digestive and Kidney Diseases.

1. Coverage

We are proposing in § 410.18 that Medicare cover—

- A fasting plasma glucose test; and
- Post-glucose challenge tests; either an oral glucose tolerance test with a glucose challenge of 75 grams of glucose for nonpregnant adults, or a 2-hour post-glucose challenge test alone.

We would not include a random serum or plasma glucose for persons with symptoms of uncontrolled diabetes such as excessive thirst or frequent urination in this benefit because it is already covered as a diagnostic service. This language is not intended to exclude other post-glucose challenge tests that may be developed in the future, including panels that may be created to include new diabetes and lipid screening tests. We also would include language that would allow Medicare to cover other diabetes screening tests, subject to a NCD process. We are requesting comments regarding the specific tests, definitions, and eligibility criteria. The comments that we receive will also be used to create the list of billing codes for covered tests and diagnosis codes that would be published in instructions for Medicare contractors.

The statutory provision describes an ''individual at risk for diabetes'' as having any of the following risk factors:

1. Hypertension.
2. Dyslipidemia.
3. Obesity, defined as a body mass index greater than or equal to 30 kg/m2.
4. Previous identification of an elevated impaired fasting glucose.
5. Previous identification of impaired glucose tolerance.
6. A risk factor consisting of at least two of the following characteristics:

(a) Overweight, defined as a body mass index greater than 25 kg/m2, but less than 30.

(b) A family history of diabetes.

(c) A history of gestational diabetes mellitus or delivery of a baby weighing greater than 9 pounds.

(d) 65 years of age or older.

The statutory language directs the Secretary to establish standards regarding the frequency of diabetes screening tests that will be covered and limits the frequency to no more than twice within the 12-month period following the date of the most recent diabetes screening test of that individual.

We are proposing that Medicare beneficiaries diagnosed with ''pre-diabetes'' be eligible for the maximum frequency allowed by the statute, that is, 2 screening tests per 12 month period. We propose to define ''pre-diabetes'' as a previous fasting glucose level of 100–125 mg/dL, or a 2-hour post-glucose challenge of 140–199 mg/dL. This definition of ''pre-diabetes'' was developed with the assistance of the American Association of Clinical Endocrinologists and complements the definition of diabetes that we published November 7, 2003 (68 FR 63195). We are specifically asking for comments regarding our new definition of ''pre-diabetes.'' We are also requesting suggestions for the definition of ''a family history of diabetes.''

For individuals not meeting the ''pre-diabetes'' criteria, we are proposing that one diabetes screening test be covered per individual per year.

2. Payment

We are proposing to pay for the screening diabetes tests at the same amounts paid for these tests when performed to diagnose an individual with signs and symptoms of diabetes. We would pay for these tests under the clinical laboratory fee schedule. We propose to pay for these tests under CPT code 82947 Glucose; quantitative, blood (except reagent strip) and CPT code 82951 Glucose; tolerance test (GTT), three specimens (includes glucose). To indicate that the purpose of the test is for diabetes screening, we would require that the laboratory include a screening diagnosis code in the diagnosis section of the claim. We propose V77.1 Special screening for diabetes mellitus as the applicable ICD–9—CM code for this purpose. Because laboratories are required and accustomed to submitting diagnosis codes when requesting payment for testing, we believe including a screening diagnosis code is appropriate for this benefit.

*C. Section 612—Cardiovascular Screening Blood Tests*

[If you choose to comment on issues in this section, please include the caption ''Section 612'' at the beginning of your comments.]

Section 612 of the MMA provides for Medicare coverage of cardiovascular screening blood tests for the early detection of cardiovascular disease or abnormalities associated with an elevated risk for that disease effective on or after January 1, 2005.

1. Coverage

The Act requires coverage of tests for cholesterol and other lipid or trigylcerides levels for this purpose. It also authorizes the Secretary to approve coverage of other screening tests for other indications associated with cardiovascular disease or an elevated risk for that disease, including indications measured by noninvasive testing, if the United States Preventive Services Task Force (USPSTF) recommended a blood test for that indication.

We invited comments about the types of tests from the American College of Physicians/ American Society of Internal Medicine, the American College of Cardiology, American Academy of

Family Physicians, American Heart Association, College of American Pathologists, American Society for Clinical Laboratory Science, American Society for Clinical Pathologists, American Association for Clinical Chemistry, and the American Clinical Laboratory Association. Comments were received from the American Heart Association, American Academy of Family Physicians, the American Association for Clinical Chemistry, American Society for Clinical Laboratory Science, the National Kidney Foundation, and the Vascular Disease Foundation, regarding the coverage of a number of cardiovascular screening tests in addition to the required blood lipid tests; for example, high sensitivity C-Reactive Protein (CRP), homocysteine, or Beta Naturetic Protein (BNP), electrocardiograms, Doppler and noninvasive vascular tests, and a skin reflectance test.

We also reviewed the following 2001 recommendations of the USPSTF regarding screening for lipid disorders that are associated with cardiovascular disease:

a. Clinicians should routinely screen men aged 35 years and older and women aged 45 years and older for lipid disorders and treat abnormal lipids in people who are at increased risk.

b. Clinicians should routinely screen younger adults (men aged 20 to 35 and women aged 20 to 45) for lipid disorders if they have other risk factors for coronary heart disease.

c. No recommendation was made for or against routine screening for lipid disorders in younger adults (men aged 20 to 35 or women aged 20 to 45) in the absence of known risk factors for coronary heart disease.

d. Screening for lipid disorders should include measurement of total cholesterol (TC) and high-density lipoprotein cholesterol (HDL–C).

e. Evidence is insufficient to recommend for or against trigylcerides measurement as a part of routine screening for lipid disorders.

Based on the statutory language and our review of the scientific literature, expert opinion, and the USPSTF recommendations, we are proposing coverage of the following three screening blood tests for conditions associated with cardiovascular disease:

(1) A total cholesterol test.

(2) A cholesterol test for high density lipoproteins.

(3) A triglycerides test.

These tests should be performed as part of a panel and should be done after a 12-hour fast. We are also proposing coverage of each of these tests once every 5 years. The statute provides that the Secretary shall establish frequency standards for the coverage of cardiovascular screening blood tests, provided the frequency is no more often than once every 2 years. However, the scientific literature shows that cholesterol levels are fairly stable and do not fluctuate drastically for those older than age 65. The USPSTF clinical considerations indicate that, while screening may be appropriate in older people, repeated screening is less important because lipid levels are less likely to increase after age 65. Under the USPSTF recommendations, routine measurement of total cholesterol and HDL cholesterol every 5 years is recommended by the National Cholesterol Education program Adult Treatment Panel II (ATP II), sponsored by the National Institutes of Health, and endorsed by the American Heart Association. In addition, the most recent Report of the Adult Treatment Panel (ATP III) includes similar recommendations. In all adults aged 20 years or older, a fasting lipoprotein profile (total cholesterol, LDL cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride) should be obtained once every 5 years. Since the LDL cholesterol can be calculated, the remaining tests, which are part of the lipid panel, are the tests we are proposing for coverage under this new benefit at a 5-year screening interval. We do not believe the evidence justifies or the statute allows for coverage of other cardiovascular screening blood tests at this time.

To facilitate our consideration of future coverage of other new types of cardiovascular screening blood tests, we have decided to add a provision to this proposed regulation that, in addition to the specific cardiovascular screening blood tests proposed for coverage in this proposed rule, would provide that other types of these tests may be covered under this new screening benefit, if we determine that this is appropriate through a National Coverage Determination (NCD). This provision would allow us to conduct a more timely assessment of other new types of cardiovascular screening blood tests that may have been approved for marketing by the Food and Drug Administration and recommended by the USPSTF than is possible under the standard rulemaking process. We intend to use the NCD process, which includes an opportunity for public comments, for evaluating the medical and scientific issues relating to the coverage of additional tests that may be brought to our attention in the future. Use of an NCD to establish a change in the scope of benefits is authorized by section 1871(a)(2) of the Act. These proposed coverage requirements are set forth in new section § 410.17.

2. Payment

Section 612 of the MMA provides for Medicare coverage of cardiovascular screening blood tests for the early detection of cardiovascular disease or abnormalities associated with an elevated risk for cardiovascular disease. The coverage is effective on or after January 1, 2005. We are proposing to pay for the screening cardiovascular disease tests at the same amounts paid for these tests when they are performed to diagnose an individual with signs and symptoms of cardiovascular disease. Medicare would pay for the tests under the clinical laboratory fee schedule. We propose to use the following CPT codes:

- 82465 Cholesterol, serum or whole blood, total.
- 83718 Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol).
- 84478 Triglycerides.
- 80061 Lipid Panel.

To indicate that the purpose of the test is for cardiovascular screening, we propose that the laboratory include in the diagnosis section of the claim the diagnosis code that provides the highest degree of accuracy and completeness in describing the diagnosis. We propose that the applicable ICD–9–CM codes for cardiovascular screening blood tests be selected from the following:

- V81.0 Special screening for ischemic heart disease.
- V81.1 Special screening for Hypertension.
- V81.2 Special screening for other and unspecified cardiovascular conditions.

Because laboratories are required and accustomed to submitting diagnosis codes when requesting payment for testing, we believe including a screening diagnosis code for this purpose will not be unduly burdensome to them.

*D. Section 413—Physician Scarcity Areas and Health Professional Shortage Areas Incentive Payments*

[If you choose to comment on issues in this section, please include the caption "Section 413'' at the beginning of your comments.]

1. Background

Section 4043 of the Omnibus Budget Reconciliation Act (OBRA) of 1987 added section 1833(m) to the Act to provide incentive payments to physicians who furnish services to

Medicare beneficiaries in Health Professional Shortage Areas (HPSAs). Under section 1833(m) of the Act, a 5 percent payment was added, beginning January 1, 1989, to the amounts otherwise payable under the physician fee schedule to doctors who furnish covered services to Medicare patients in designated HPSAs. Section 6102 of OBRA 1989 further amended section 1833 of the Act to raise the amount of this incentive payment from 5 percent to 10 percent for services furnished after December 31, 1990. The OBRA 1989 amendment also increased eligible service areas to include both rural and urban HPSAs. The Congress established the HPSA incentive payments as incentives to attract new physicians to medically underserved communities and to encourage physicians in those areas to remain there.

Eligibility for receiving the 10 percent incentive payment is based on whether the specific location at which the service is furnished is within an area that is designated (under section 332(a)(1)(A) of the Public Health Service Act (PHS)) as a HPSA. The Health Resources and Services Administration of the Department of Health and Human Services (HRSA) is responsible for designating shortage areas. HRSA designates several types of HPSAs. Some HPSAs are areas with shortages of primary care physicians, dentists, or psychiatrists. These shortage designations are referred to as geographic-based HPSAs. Also, there are HPSA designations based on underserved populations within an area, which are referred to as population-based HPSAs.

Section 1833(m) of the Act provides incentive payments for physicians who furnish services in areas designated as HPSAs under section 332(a)(1)(A) of the PHS Act. These include all three types of geographic-based HPSAs (primary medical care, dental, and mental health). Consequently, physicians, including psychiatrists, furnishing services in a primary medical care HPSA are eligible to receive bonus payments. Medicare HPSA bonus payments apply to all physicians who perform covered services within a primary medical care HPSA, regardless of specialty. In addition, psychiatrists furnishing services in mental health HPSAs are eligible to receive incentive payments. We do not recognize dental HPSAs for the Medicare HPSA payment program because Medicare does not cover general dental services for its beneficiaries.

Since the inception of the Medicare HPSA incentive payment program, physicians have been responsible for indicating their eligibility for the incentive payment on the Medicare billing form. To facilitate the verification of eligibility, physicians have been notified by their Medicare carriers when changes (withdrawals, revisions, or replacements) occur in HPSA designations. Using this information from carriers, physicians have been required to verify their eligibility and correctly code their Medicare claims using modifiers (QB for rural HPSAs and QU for urban HPSAs) to receive incentive payments.

2. New Legislation

a. Physician Scarcity Areas

Section 413(a) of the MMA, provides a new 5 percent incentive payment to physicians furnishing services in physician scarcity areas. The MMA adds a new section 1833(u) of the Act which provides for paying primary care physicians furnishing services in a primary care scarcity county and specialty physicians furnishing services in a specialist care scarcity county, an additional amount equal to 5 percent of the amount paid for these services. Eligible physicians furnishing services in an area qualified as a physician scarcity area (PSA) and HPSA would be entitled to receive both incentive payments, that is, a 15 percent bonus payment. Eligibility for receiving both incentive payments is time limited (January 1, 2005 to January 1, 2008) because the 5 percent PSA bonus is scheduled to sunset on December 31, 2007.

The Congress created the new 5 percent incentive payment program to make it easier to recruit and retain both primary and specialist care physicians for furnishing services to Medicare beneficiaries in PSAs.

The two measures of physician scarcity are defined by the statute as follows:

1. The primary care scarcity areas are determined by the ratio of primary care physicians to Medicare beneficiaries.

2. The specialist care scarcity areas are determined by the ratio of specialty care physicians to Medicare beneficiaries.

i. Primary Care

Consistent with section 1833(u) of the Act, we would identify eligible primary care scarcity counties by ranking each county by its ratio of primary care physicians to Medicare beneficiaries. From the list of primary care scarcity counties, only those counties with the lowest primary care ratios that represent 20 percent of the total number of Medicare beneficiaries residing in the counties will be considered eligible for the 5 percent incentive payment. For calculating the ratios, section 1833(u)(6) of the Act, as added by the MMA, defines a primary care physician as a general practitioner, family practice practitioner, general internist, obstetrician, or gynecologist. All other physicians will be considered specialists for purposes of the 5 percent incentive payment. Section 1833(u) of the Act, as added by the MMA, specifically defines ''physician'' as one described in section 1861(r)(1) of the Act. This statutory provision does not include dentists, podiatrists, optometrists, and chiropractors.

ii. Specialist Care

To identify eligible specialist care scarcity areas, we would rank each county by its ratio of specialty physicians to Medicare beneficiaries. From the list of specialist care scarcity counties, only those counties with the lowest ratios that represent 20 percent of the total number of Medicare beneficiaries residing in the counties will be considered eligible for the 5 percent incentive payment.

iii. The Goldsmith Modification

For purposes of counties identified as having a shortage of primary care or specialty care physicians, section 1833(u)(5) of the Act also requires that, to the extent feasible, we treat a rural census tract of a metropolitan statistical area (as determined under the most recent modification of the Goldsmith Modification) as an equivalent area. The Goldsmith modification evolved from an outreach grant program sponsored by the Office of Rural Health Policy of HRSA. This program was created to establish an operational definition of rural populations lacking easy access to health services in Large Area Metropolitan Counties (LAMCs). Dr. Harold F. Goldsmith and his associates created a methodology for identifying rural census tracts located within a large metropolitan county of at least 1,225 square miles. Using a combination of data on population density and commuting patterns, census tracts were identified as being so isolated by distance or physical features that they are more rural than urban in character.

iv. Rural-Urban Commuting Area

The original Goldsmith Modification was developed using data from the 1980 census. In order to more accurately reflect current demographic and geographic characteristics of the nation, the Office of Rural Health Policy, in partnership with the Department of Agriculture's Economic Research

Service and the University of Washington, developed the Rural-Urban Commuting Area codes (RUCAs). Rather than being limited to LAMCs, RUCAs use urbanization, population density, and daily commuting data to categorize every census tract in the country. RUCAs are the updated version of the Goldsmith Modification and are used to identify rural census tracts in all metropolitan counties.

Once all the full county PSAs are determined, we would identify, consistent with section 1833(u)(4)(C)of the Act, eligible PSAs by their 5-digit zip code area for the purpose of automatically providing the 5 percent incentive payment to eligible physicians. The zip code of the place of service is the only data element reported on the Medicare claim form that would allow automation. For zip codes that cross county boundaries, the statute specifically requires the use of the dominant county of the postal zip code (as determined by the U.S. Postal Service) if the Secretary uses the 5-digit postal zip code to identify areas eligible to receive the 5 percent payment. The statute also requires us to publish a list of eligible areas as part of the proposed and final physician fee schedule rules for the years for which PSAs are identified or revised and to post a list of PSAs on the CMS Website. Lastly, the statute provides no administrative or judicial review under sections 1869 or 1878 of the Act or otherwise, regarding the identification of a county or area, the assignment of a specialty of any physician, the assignment of a physician to a county, or the assignment of a postal ZIP Code to a county or other area.

b. Improvement to Medicare HPSA Incentive Payment Program

In addition to the creation of the 5 percent PSA incentive payment, section 413 of MMA amended section 1833(m) of the Act to mandate that we automate payment of the 10 percent HPSA incentive payment to eligible physicians for full county HPSAs without a requirement for the physician to identify the HPSA involved. When automation is not feasible, consistent with section 1833(m) of the Act as amended by section 413(b) of MMA, we plan to post a list of HPSAs on our website. When automation is not feasible, the billing of modifiers would still be required.

The statute provides for no administrative or judicial review of the identification of a county or area, the assignment of the individual physician's specialty, the assignment of a physician to a county or the assignment of a zip code to a county or area.

3. Provisions Related to Physician Scarcity Areas and HPSA Incentive Payment Program

a. Determination of Physician Scarcity Areas

As the statute prescribes, PSAs for primary care would be determined by the ratio of primary care physicians to the Medicare beneficiaries residing in that county or area. A primary care physician is defined by statute as a general practitioner, family practice practitioner, general internist, obstetrician, or gynecologist. The physician definition for determining primary care PSAs will be based on HRSA's physician designations for primary medical care HPSAs, which include all of the above physicians. In other words, the PSA definition for primary care will be identical to HRSA's, except for pediatricians. Furthermore, the statute provides that the primary care ratio include only primary care doctors in the active practice of medicine. Physicians whose practice is exclusively for the Federal Government or who provide only administrative services would not be included in the physician tally. PSAs for specialty care would be determined by the ratio of physicians who are not primary care physicians to the Medicare beneficiaries residing in that county or area. The specialist care PSA ratio would include all physicians other than primary care physicians as defined in the statute. To the extent feasible, we also plan to include rural census tracts of metropolitan statistical areas (as determined under the most recent modification of the Goldsmith Modification), as identified at the zip code level, with sufficiently low physician-to-Medicare population ratios as equivalent to qualified full county scarcity areas. The calculation of physician scarcity ratios is being made by the North Carolina Rural Research and Policy Analysis Center using the most current Medicare beneficiary and physician data available. At this time, the North Carolina Rural Research and Policy Analysis Center can only determine physician scarcity for Goldsmith areas at the zip code level due to the fact that Medicare beneficiary data is currently unavailable at the census tract level.

As previously discussed, section 1833(u) of the Act requires the automation of incentive payments for all PSAs, which we can only achieve by assigning zip codes to eligible areas. We propose the identification of qualified PSAs by zip code for automatic payment as follows:

- For zip codes that fall within a full county PSA, the bonus would be paid automatically.
- For full county PSAs, the dominant county of the 5-digit zip code, as determined by the U.S. Postal Service, would be used when the zip code area is not entirely located within the county. In some cases, a service may be provided in a county that is considered to be a PSA, but the zip code is not considered to be dominant for that area, which would not permit automation of the bonus payment. In order to receive the bonus for those areas, physicians would need to include a new physician scarcity modifier on the claim. We plan to establish and implement the new modifier through the Medicare Claims Processing Manual.
- For partial county PSAs (Goldsmith Modification), all zip code areas that are entirely located within the qualified Goldsmith area and all zip code areas that are partially located within a qualified Goldsmith area as long as the majority (51 percent) of the population located within the zip code area resides in the qualified Goldsmith area would be able to receive automatic payment.

Due to the complex nature of processing available physician and Medicare beneficiary data into a usable format to identify counties and areas with the lowest ratios, we cannot make available a list of PSAs within this proposed rule. We are working closely with HRSA and its contractors to publish these lists in the physician fee schedule final rule.

b. Incentive Payments for Physician Scarcity Areas

Similar to the Medicare HPSA bonus payment program, eligibility for receiving the 5 percent bonus payment would be based on whether the specific location at which the service is furnished is within an area that is designated as a PSA. Furthermore, the statute requires us to restrict eligibility for receiving the incentive payments for physicians' services furnished within primary care PSAs to general practitioners, family practice practitioners, general internists, obstetricians, or gynecologists. Also prescribed by statute, dentists, podiatrists, optometrists, and chiropractors are not eligible to receive incentive payments for PSAs. Section 1833(u) of the Act specifically defines a physician as one described in section 1861(r)(1) of the Act, which does not include dentists, podiatrists, optometrists, and chiropractors.

To conform our regulations to the statute, we are proposing to add § 414.66 to provide a 5 percent incentive payment to eligible physicians furnishing covered services in eligible PSAs. We propose to add § 414.66(a)(1) to specify that primary care physicians furnishing services in primary care PSAs are entitled to an additional 5 percent incentive payment above the amount paid under the physician fee schedule for their professional services furnished on or after January 1, 2005, and before January 1, 2008. The new incentive payment would apply to the professional services performed by physicians, including evaluation and management, surgery, consultation, and home, office and institutional visits. The technical component of physicians' services is not eligible because this component is not included in the definition of physicians' services at section 1861(q) of the Act as applied by the MMA. We are also proposing to add § 414.66(b) to specify that physicians, other than primary care physicians, dentists, podiatrists, optometrists, and chiropractors, furnishing services in specialist care PSAs are entitled to an additional 5 percent payment above the amount paid under the physician fee schedule for their professional services furnished on or after January 1, 2005, and before January 1, 2008.

c. Improvement to Medicare HPSA Incentive Payment Program

As of January 1, 2005, most physicians eligible for the 10 percent HPSA incentive payment would no longer be required to determine whether their service areas are eligible for incentive payments and to modify their claims to receive those payments. The MMA requires us to automate bonus payments for physicians' services furnished in full county HPSAs.

Automation of full county HPSA incentive payments involves the same issues of automation as PSA incentive payments: the zip code of the place of service is the only data element reported on the claim form that would allow automation. Similarly, zip codes need to be cross-walked to full county HPSAs. The statute allows use of the same method of automation of incentive payments for full county HPSAs as for full county PSAs. We are proposing the identification of HPSAs by zip code for automatic payment as follows:

- For zip codes that fall entirely within a full or partial county HPSA, the bonus would be paid automatically.
- When the zip code area is not entirely located within the full county HPSA, only the dominant county of the 5-digit zip code as determined by the U.S. Postal Service would be used for automatically paying the HPSA incentive payment.
- For all other zip code areas that are not entirely, but are to some extent, located within a designated HPSA (full county or partial), we would require physicians furnishing services in these areas to bill for the incentive payments by using the appropriate modifier on their Medicare claims. We propose to post on our website, prior to January 1, 2005, a list of zip codes that fully fall within a designated HPSA and a list of zip codes that partially fall within a designated HPSA, so that physicians can determine whether they would need to bill using a modifier.

Determination of zip codes eligible for automatic HPSA bonus payment would be made on an annual basis, and there would not be any mid-year updates. We would effectuate mid-year revisions made to designations by HRSA the following year for automatic bonus payment purposes.

d. Medicare HPSA Incentive Payments

The Medicare HPSA Incentive Payment program, which the Congress established under OBRA 1987, was implemented through the Medicare Claims Processing Manual. This proposed rule would create § 414.67 to conform the regulations to the law, as amended by OBRA 1987 and 1989.

We propose in § 414.67 to provide a 10 percent incentive payment to eligible physicians furnishing covered services in eligible HPSAs. Section 414.67(a) would specify that physicians, regardless of specialty, furnishing services in a primary medical care HPSA are entitled to a 10 percent incentive payment above the amount paid for their professional services under the physician fee schedule. We would also create § 414.67(c) to specify that psychiatrists furnishing services in a mental health HPSA are entitled to a 10 percent incentive payment above the amount paid for their professional services under the physician fee schedule. Psychiatrists furnishing services in mental health HPSAs that do not overlap with primary care HPSAs are the only physicians eligible to receive the 10 percent incentive payment in those areas. In other words, these stand-alone mental health HPSAs are eligible areas for psychiatrists only to receive incentive payments.

*E. Section 303—Payment Reform for Covered Outpatient Drugs and Biologicals*

[If you choose to comment on issues in this section, please include the caption ''Section 303'' at the beginning of your comments.]

1. Average Sales Price (ASP) Payment Methodology

a. Background

Medicare Part B covers a limited number of prescription drugs and biologicals. For the purposes of this proposed rule, the term ''drugs'' will hereafter refer to both drugs and biologicals. Medicare Part B covered drugs generally fall into the following three categories:

- Drugs furnished incident to a physician's service.
- Durable medical equipment (DME) drugs.
- Drugs specifically covered by statute (for example, immunosuppressive drugs).

Section 303(c) of the MMA revises the payment methodology for Part B covered drugs that are not paid on a cost or prospective payment basis. In particular, section 303(c) of the MMA amends Title XVIII of the Act by adding section 1847A. Beginning in 2005, section 1847A of the Act establishes a new ASP drug payment system. In 2005, almost all Medicare Part B drugs not paid on a cost or prospective payment basis will be paid under this system.

The new ASP drug payment system is based on data submitted to us quarterly by manufacturers. For calendar quarters beginning on or after January 1, 2004, the statute requires manufacturers to report their ASP data to us for almost all Medicare Part B drugs not paid on a cost or prospective payment basis. Manufacturers' submissions are due to us not later than 30 days after the last day of each calendar quarter.

For further information on the submission of manufacturers' ASP data, see the interim final rule titled ''Manufacturer Submission of Manufacturer's Average Sales Price (ASP) Data for Medicare Part B Drugs and Biologicals' published in the **Federal Register** on April 6, 2004 (69 FR 17935). It is accessible on the CMS Web site at *http://www.cms.hhs.gov/providers/drugs/default.asp.*

The methodology for developing Medicare drug payment allowances based on the manufacturer's submitted ASP data is described in this proposed rule and reflected in proposed revisions to the regulations at § 405.517 and new Subpart K in part 414.

b. Provisions of the Proposed Rule

i. The ASP Methodology

Beginning in 2005, section 1847A of the Act establishes an ASP payment system for certain drugs and biologicals

not paid on a cost or prospective payment basis furnished on or after January 1, 2005. The most notable exceptions are described below in sections III.E.1.c through III.E.1.e.

ii. Calculation of ASP

As described in section 1847A(b)(3)(A) of the Act for multiple source drugs and section 1847A(b)(4)(A) for single source drugs, the ASP for all drug products included within the same billing and payment code [or HCPCS code] is the volume-weighted average of the manufacturer's average sales prices reported to us across all the NDCs assigned to the HCPCS code. Specifically, section 1847A(b)(3)(A) of the Act and section 1847A(b)(4)(A) of the Act require that this amount be determined by—

- Computing the sum of the products (for each National Drug Code assigned to those drug products) of the manufacturer's average sales price and the total number of units sold; and
- Dividing that sum by the sum of the total number of units sold for all NDCs assigned to those drug products.

Note that in the following discussions, the term ''manufacturer's ASP'' refers to the ASP data submitted to us by manufacturers at the NDC level and the term ''ASP'' used in isolation refers to the weighted average sales price for all drug products included within the HCPCS [billing and payment] code.

Section 1847A(b)(5) of the Act requires that the ASP be determined without regard to any special packaging, labeling, or identifiers on the dosage form or product or package.

iii. Medicare Payment Allowances for Multiple Source Drugs

Section 1847A(b)(1)(A) of the Act requires that the Medicare payment allowance for a multiple source drug included within the same HCPCS code be equal to 106 percent of the ASP for the HCPCS code. This payment allowance is subject to applicable deductible and coinsurance. The payment limit is also subject to the two limitations described below in section III.E.1.b.v of this preamble concerning widely available market prices and average manufacturer prices in the Medicaid drug rebate program. As described in section 1847A(e) of the Act, the payment limit may also be adjusted in response to a public health emergency under section 319 of the Public Health Service Act in which there is a documented inability to access drugs and a concomitant increase in the price of the drug which is not reflected in the manufacturer's average sales price.

iv. Medicare Payment Allowances for Single Source Drugs

Section 1847A(b)(1)(B) of the Act requires that the Medicare payment allowance for a single source drug HCPCS code be equal to the lesser of 106 percent of the average sales price for the HCPCS code or 106 percent of the wholesale acquisition cost of the HCPCS code. This payment allowance is subject to applicable deductible and coinsurance. The payment limit is also subject to the two limitations described below in section III.E.1.b.v concerning widely available market prices and average manufacturer prices in the Medicaid drug rebate program. As described in section 1847A(e) of the Act, the payment limit may also be adjusted in response to a public health emergency under section 319 of the Public Health Service Act.

It has been brought to our attention that some physicians have concerns about their ability to purchase drugs at the Medicare payment amount of 106 percent of the ASP as these physicians believe that they are small purchasers of the Medicare Part B drugs subject to this proposed rule and do not have access to the average discounts. It is our understanding that many physicians are members of purchasing groups, which do obtain discounts on drugs. We encourage physicians to consider participating in such groups in order to achieve advantageous prices. We are interested in comments regarding the extent to which physicians can become members of such buying groups and the possible effects of doing so.

v. Limitations on ASP

Section 1847A(d)(1) of the Act states that ''The Inspector General of the Department of Health and Human Services shall conduct studies, which may include surveys, to determine the widely available market prices of drugs and biologicals to which this section applies, as the Inspector General, in consultation with the Secretary, determines to be appropriate.'' Section 1847A(d)(2) of the Act states that ''Based upon such studies and other data for drugs and biologicals, the Inspector General shall compare the average sales price under this section for drugs and biologicals with—

- The widely available market price for such drugs and biologicals (if any); and
- The average manufacturer price (as determined under section 1927(k)(1)) for such drugs and biologicals.''

Section 1847A(d)(3) of the Act states that ''The Secretary may disregard the average sales price for a drug or biological that exceeds the widely available market price or the average manufacturer price for such drug or biological by the applicable threshold percentage (as defined in subparagraph (B)).'' Section 1847A(d)(3)(B) states that ''the term 'applicable threshold percentage' means—

- In 2005, in the case of an average sales price for a drug or biological that exceeds widely available market price or the average manufacturer price, 5 percent; and
- In 2006 and subsequent years, the percentage applied under this subparagraph subject to such adjustment as the Secretary may specify for the widely available market price or the average manufacturer price, or both.''

Section 1847A(d)(3)(C) of the Act states that ''If the Inspector General finds that the average sales price for a drug or biological exceeds such widely available market price or average manufacturer price for such drug or biological by the applicable threshold percentage, the Inspector General shall inform the Secretary (at such times as the Secretary may specify to carry out this subparagraph) and the Secretary shall, effective as of the next quarter, substitute for the amount of payment otherwise determined under this section for such drug or biological the lesser of—

- The widely available market price for the drug or biological (if any); or
- 103 percent of the average manufacturer price (as determined under section 1927(k)(1)) for the drug or biological.''

vi. Payment Methodology in Cases Where the Average Sales Price During the First Quarter of Sales Is Unavailable

Section 1847A(c)(4) of the Act states that ''In the case of a drug or biological during an initial period (not to exceed a full calendar quarter) in which data on the prices for sales for the drug or biological is not sufficiently available from the manufacturer to compute an average sales price for the drug or biological, the Secretary may determine the amount payable under this section for the drug or biological based on—

- The wholesale acquisition cost; or
- The methodologies in effect under this part on November 1, 2003, to determine payment amounts for drugs or biologicals.''

c. Payment for Influenza, Pneumococcal, and Hepatitis B Vaccines

Section 1841(o)(1)(A)(iv) of the Act requires that influenza, pneumococcal, and hepatitis B vaccines described in subparagraph (A) or (B) of section 1861(s)(10) of the Act be paid based on 95 percent of the average wholesale price (AWP) of the drug. These AWP payments, which will be updated quarterly, have not been revised by the ASP provisions.

d. Payment for Drugs Furnished During 2005 in Connection With the Furnishing of Renal Dialysis Services if Separately Billed by Renal Dialysis Facilities.

Section 1881(b)(13)(A)(ii) of the Act indicates that payment for a drug furnished during 2005 in connection with the furnishing of renal dialysis services, if separately billed by renal dialysis facilities, will be based on the acquisition cost of the drug as determined by the Inspector General (IG) report to the Secretary required by section 623(c) of the MMA or, insofar as the IG has not determined the acquisition cost with respect to a drug, the Secretary shall determine the payment amount for the drug. In the report, ''Medicare Reimbursement for Existing End-Stage Renal Disease Drugs,'' the IG found that, on average, in 2003 the four largest chains had drug acquisition costs that were 6 percent lower than the ASP of 10 of the top drugs, including erythropoietin. A sample of the remaining independent facilities had acquisition costs that were 4 percent above the ASP. Based on this information, the overall weighted average drug acquisition cost for renal dialysis facilities is 3 percent lower than the ASP. Therefore, payment for a drug or biological furnished during 2005 in connection with renal dialysis services and separately billed by renal dialysis facilities will be based on the ASP of the drug minus 3 percent. This will be updated quarterly based on the ASP reported to us by drug manufacturers.

e. Payment for Infusion Drugs Furnished Through an Item of DME

In 2005, section 1841(o)(1)(D)(i) of the Act requires an infusion drug furnished through an item of DME covered under section 1861(n) of the Act be paid 95 percent of the average wholesale price for that drug in effect on October 1, 2003.

2. Provisions for Appropriate Reporting and Billing for Physicians' Services Associated With the Administration of Covered Outpatient Drugs

Section 1848(c)(2)(J) of the Act (as added by section 303(a) of the MMA) requires the Secretary to promptly evaluate existing drug administration codes for physicians' services to ensure accurate reporting and billing for those services, taking into account levels of complexity of the administration and resource consumption. According to section 1848(c)(2)(B)(iv) of the Act (also as amended by section 303(a) of the MMA), any changes in expenditures in 2005 or 2006 resulting from this review are exempt from the budget neutrality requirement of section 1848(c)(2)(B)(ii) of the Act. The statute further indicates that the Secretary shall use existing processes for the consideration of coding changes and, to the extent changes are made, shall use those processes to establish relative values for those services. The Secretary is also required to consult with physician specialties affected by the provisions that change Medicare payments for drugs and drug administration.

In the January 7, 2004 interim final rule with comment (69 FR 1094), we indicated that the Physicians Regulatory Issues Team (PRIT) will review Medicare payment policy for drug administration and that we plan to consult with the AMA's CPT Editorial Panel and physician specialties affected by changes in payment for drugs and drug administration. We requested that the CPT Editorial Panel review all codes related to the administration of drugs and consider whether any revisions or additional codes are needed. At its February 2004 meeting, the CPT Editorial Panel established a workgroup, with representatives from affected specialties, to make recommendations on drug administration coding to the full Panel. In addition, the workgroup will be reviewing issues related to drug administration that were identified in the public comments on the January 7, 2004 Physician Fee Schedule rule. These comments raised the following two major issues:

1. Can the current coding distinction between chemotherapy and nonchemotherapy infusions allow for recognition of the resources needed to administer drugs with high toxicity or potential for serious side effects for diagnoses other than cancer? If not, are code revisions or new codes needed?

2. Does the current coding for chemotherapy administration capture all the support services provided by oncology practices for chemotherapy patients? If not, are code revisions or new codes such as a cancer management code needed?

There were also a number of specific comments on individual codes raised by some specialties such as urology and ophthalmology. On June 21, 2004, the workgroup held a public meeting to receive input and comments about drug administration code changes under consideration. The workgroup is expected to report to the full CPT Editorial Panel on all these issues at its August 2004 meeting. Once we review the CPT Editorial Panel's work on this issue, we will consider whether it is necessary for us to make coding changes effective January 1, 2005 through the use of G codes, since the 2005 CPT book will already have been published. While the CPT Editorial Panel's work on this issue is important to us, we finally determine coding policy for Medicare; we also would welcome public comments on these issues. We would also welcome comments concerning any alternative methods of allocating practice expenses to the drug administration codes. (*See* section II.A.2. of this proposed rule for a discussion of allocation of practice expenses.) If coding changes are to be made for next year, we would announce them in the physician fee schedule final rule effective January 1, 2005.

We also plan to analyze any shift or change in utilization patterns once the payment changes for drugs and drug administration required by MMA go into effect. While we do not believe the changes will result in access problems, we plan to continue studying this issue. We also note that the MMA requires the Medicare Payment Advisory Commission (MedPAC) to study items and services furnished by oncologists and drug administration services furnished by other specialties.

3. Blood Clotting Factor—Section 303(e)(1)—Items and Services Relating to Furnishing of Blood Clotting Factors

For clotting factors furnished on or after January 1, 2005, we propose to establish a separate payment of $0.05 per unit to hemophilia treatment centers and homecare companies for the items and services associated with the furnishing of blood clotting factor.

Section 303(e)(1) of the MMA requires the Secretary, after review of the January 2003 report to the Congress by the Comptroller General of the United States, to establish a separate payment to hemophilia treatment centers and homecare companies for the items and services associated with the furnishing of blood clotting factor. In the proposed rule, Payment Reform for Part B Drugs

(68 FR 50440), published in the **Federal Register** on August 20, 2003, we indicated that we are proposing to create a payment of $0.05 per unit of clotting factor provided to Medicare beneficiaries by hemophilia treatment centers and homecare companies to appropriately pay for the administrative costs associated with furnishing the clotting factor. We did not propose the creation of separate payment for furnishing the clotting factor for individuals or entities other than hemophilia treatment centers and homecare companies.

We received comments from hemophilia organizations and specialty pharmacy providers of blood clotting factor. Most comments questioned our position to create a separate payment of $0.05 per unit, stating that this amount would jeopardize the ability of these facilities to adequately supply the clotting factor. Commenters were concerned that the $0.05 amount was too low and would cause many entities to discontinue providing the clotting factors and severely impact beneficiaries' access to clotting factor.

Based on a review of the General Accounting Office (GAO) report and data received from various clotting factor providers, we believe a separate payment amount of $0.05 per unit would cover the administrative costs associated with supplying the clotting factor. As outlined in the MMA, any separate payment amount established may include the mixing and delivery of factors, including special inventory management and storage requirements, as well as ancillary supplies and patient training necessary for the self-administration of these factors. The MMA states that, in determining the separate payment, the total amount of payments and these separate payments shall not exceed the total amount of payments that would have been made for the factors if the amendments in section 303 of the MMA had not been enacted. As indicated in the GAO report, ''[w]hen Medicare's payment for clotting factor more closely reflects acquisition costs, we recommend that the Administrator establish a separate payment for providers based on the costs of delivering clotting factor to Medicare beneficiaries. Effective January 1, 2005, payment for blood clotting factors will more closely reflect acquisition costs as payment will be based on the average sales price as reported by drug manufacturers plus 6 percent.''

Therefore, in the absence of additional data, we believe that a separate payment amount of $0.05 per unit for the cost of delivering clotting factor is an appropriate amount beginning CY 2005 and we are proposing revisions to § 410.63 to reflect this amount. However, we are also seeking updated data and comments on the GAO report, as well as information on the fixed and variable costs of furnishing clotting factor. We recognize that there may be alternatives to a fee, which varies entirely based on the number of units of clotting factor furnished. We will closely examine all data and information submitted in order to make a final determination with respect to the appropriateness of the $0.05 per unit amount. That information will enable us to effectively determine the appropriateness of the $0.05 per unit amount.

4. Supplying Fee

Section 1842(o)(6) of the Act, as added by section 303(e)(2) of the MMA, requires the Secretary to pay a supplying fee (less applicable deductible and coinsurance) to pharmacies for certain Medicare Part B drugs and biologicals, as determined appropriate by the Secretary. The types of Medicare Part B drugs and biologicals eligible for a supplying fee are immunosuppressive drugs described in section 1861(s)(2)(J) of the Act, oral anticancer chemotherapeutic drugs described in section 1861(s)(2)(Q) of the Act, and oral anti-emetic drugs used as part of an anticancer chemotherapeutic regimen described in section 1861(s)(2)(T) of the Act. As discussed in the interim final rule published on January 7, 2004 (69 FR 1084), we considered this fee to be bundled into the current payment for these drugs for 2004 where payment is based on the Average Wholesale Price (AWP).

We propose to establish a separately billable supplying fee, effective January 1, 2005, when Medicare implements a different payment system for these drugs. We believe that a separately billable supplying fee of $10 per prescription is an appropriate level, beginning CY 2005. We received data suggesting various amounts for the supplying fee. Retail chain pharmacies suggested a supplying fee of $12 to $15 per prescription. These pharmacies stated that on average it cost between $10 to $12 to dispense a prescription to a Medicare beneficiary. However, when supplying immunosuppressive and oral anti-cancer drugs to Medicare beneficiaries, they argued that costs increase due to factors such as coordination of benefits activities. The specialty pharmacies that exclusively or largely furnish immunosuppressive drugs submitted data indicating that they believe a supplying fee of $44 (weighted average) to $56 (unweighted average) was appropriate. Pharmacies have pointed to the additional Medicare billing requirements as additional costs they had to incur, in the form of extra staff and time required to fulfill the billing requirements. We believe that a supplying fee of $10 per prescription is appropriate, especially when combined with the savings the pharmacy will experience with the clarification and elimination of the billing and shipping requirements, as described below.

We point out that if we were to establish a supplying fee of $44, then we expect that Medicare would be spending more money in 2005 on the supplying fees and immunosuppressive drugs than Medicare would have paid for immunosuppressive drugs in 2005 under the former system at 95 percent of AWP, when the supplying fee was bundled into payment for the drug.

Our goal is to assure that each beneficiary who needs covered oral drugs has access to those medications. We seek comments about the appropriateness of our proposed supplying fee amount as well as the components of a supplying fee that would assure beneficiary access to oral drugs. We believe that a supplying fee is intended to cover a pharmacy's activities to get oral drugs to beneficiaries. We seek data and information on the additional services these pharmacies provide to Medicare beneficiaries, the extent to which oral drugs can be furnished without these additional services and the extent to which such services are covered under Medicare. We seek comment about whether the supplying fee should be somewhat higher during the initial month following a Medicare beneficiary's transplant to the extent that additional resources are required for example, due to more frequent changes in prescriptions for immunosuppressive drugs.

5. Billing Requirements

We propose to clarify or eliminate the following billing requirements in an effort to reduce a pharmacy's costs of supplying covered immunosuppressive and oral drugs to Medicare beneficiaries:

• *Original signed order*. We wish to clarify Medicare's policy regarding the necessity of an original signed order prior to the filling of a prescription. According to the Medicare Program Integrity Manual (section 5.1 of Chapter 5), which addresses the ordering requirement for durable medical equipment, prosthetics, orthotics and supplies (DMEPOS), including drugs, most DMEPOS items can be dispensed

based on a verbal order from a physician. A written order must be obtained before submitting a claim, but that written order may be faxed, photocopied, electronic, or pen and ink. The order for the drug must specify the name of the drug, the concentration (if applicable), the dosage, and the frequency of administration. We hope that clarification of this requirement would reduce a pharmacy's costs of supplying covered immunosuppressive and oral drugs to Medicare beneficiaries to the extent that pharmacies are currently applying an original signed prescription requirement.

• *Assignment of Benefits Form.* Currently, pharmacies must obtain a completed Assignment of Benefits form in order to receive payment from Medicare. Other payors do not impose this requirement. This requirement increases a pharmacy's cost of supplying covered drugs to Medicare beneficiaries. Section 1842(o)(3) of the Act requires that payment for drugs under Part B of Medicare can only be made on an assignment related basis. However, § 424.55(a) implies that if a beneficiary does not sign an assignment of benefits form, then Medicare will not make payment to the supplier. It has been pointed out that this requirement increases costs to suppliers that are not reimbursed by Medicare. We believe that it is not necessary for an assignment of benefit form to be filled out for drugs covered under Part B since payment for them can only be made on an assignment-related basis. We propose to eliminate use of the Assignment of Benefits form for Part B covered oral drugs as a means of reducing a pharmacy's costs of supplying such drugs to Medicare beneficiaries. (Additional discussion on assignment of Medicare claims is in section IV.G of this preamble.)

• *DMERC Information Form (DIF).* The DIF is a form created by the DMERC Medical Directors that contains information regarding the dates of the beneficiary's transplant and other diagnosis information. Pharmacies must have a completed DIF in order to receive payment. This requirement increases a pharmacy's cost of supplying covered drugs to Medicare beneficiaries. The DIF is a one-time requirement that was established to facilitate implementation of the immunosuppressive drug benefit when Medicare covered the drugs for different periods of time to distinguish between transplant and non-transplant uses for immunosuppressive drugs. Since section 1861(s)(2)(J) of the Act no longer imposes limits on the period of time for coverage of immunosuppressive drugs, we believe that the information on transplant diagnosis can be captured through other means (for example, diagnosis codes on the Part B claim form). In light of this statutory revision, we have had discussions with the DMERCs about their elimination of the use of this form when billing DMERC drugs. The DMERCs plan to eliminate the use of this form effective October 1, 2004. We believe that a pharmacy's costs of supplying Part B covered oral drugs to Medicare beneficiaries would be reduced with this change.

6. Shipping Time Frame

It has been suggested that Medicare guidelines for refill prescriptions allowed too short of a window between shipping the next month's prescription and the end of the current month. It has been argued that, as a result, a pharmacy ''effectively'' had to ship the product to a beneficiary using an overnight delivery service.

As indicated in section III.N of this preamble, on January 2, 2004, we revised the guidelines (effective February 2, 2004) regarding the time frame for subsequent deliveries of refills of DMEPOS products to occur no sooner than ''approximately 5 days prior to the end of the usage for the current product'' (see section 4.26.1 of Chapter 4—Benefit Integrity of the Medicare Program Integrity Manual). This change allows shipping of refills on ''approximately'' the 25th day of the month in the case of a month's supply. We emphasize the word ''approximately'; while we believe that normal ground service shipping would allow delivery in 5 days, if there were circumstances where ground service could not occur in 5 days, the guideline would still be met if the shipment occurs in 6 or 7 days. (''Days'' refers to business days or shipping days applicable to the shipper, that is, a 6-day week in the case of the U.S. Postal Service.) We believe that this change eliminates the need for suppliers to use overnight shipping methods and allows shipping of drugs by less expensive ground service.

*F. Section 952—Revisions to Reassignment Provisions—Section 952 of the MMA*

[If you choose to comment on issues in this section, please include the caption ''Section 952'' at the beginning of your comments.]

Section 1842(b)(6) of the Act requires that payment may only be made to the physician or other person who furnished a service, or to the beneficiary for whom services were furnished, unless certain specified exceptions are met. Prior to the enactment of section 952 of the MMA, Medicare did not permit the reassignment of payments for services provided by an independent contractor physician or nonphysician practitioner unless the services were performed on the premises of the facility or health care delivery system that submitted the bill. Therefore, if the services were furnished offsite, reassignment was prohibited (see section 1842(b)(6)(A)(ii) of the Act).

Section 1842(b)(6)(A)(ii) of the Act, as amended by section 952 of the MMA, allows a physician or nonphysician practitioner to reassign payment for Medicare-covered services, regardless of the site of service, as long as there is a contractual arrangement between the physician and nonphysician practitioner and the entity through which the entity submits the bill for those services. Thus, the services may be provided on or off the premises of the entity receiving the reassigned payments. The MMA Conference Agreement states that entities that retain independent contractors may enroll in the Medicare program. We note that the expanded exception created by section 952 applies to those situations when an entity seeks to obtain the medical services of a physician or nonphysician practitioner.

Section 952 states that reassignment is permissible if the contractual arrangement between the entity that submits the bill for the service and the physician or nonphysician practitioner who performs the service ''meets such program integrity and other safeguards as the Secretary may determine to be appropriate.'' The Conference Agreement supports appropriate program integrity efforts for entities with independent contractors that bill the Medicare program, including joint and several liability (that is, both the entity accepting reassignment and the physician or nonphysician practitioner providing a service are both liable for any Medicare overpayments). The Conference Agreement also recommends that physician or nonphysician practitioners have unrestricted access to the billings submitted on their behalf by entities with which they contract. We incorporated these recommended safeguards in a change to the Medicare Manual, implementing section 952 of the MMA that was published on February 27, 2004. We are proposing to revise § 424.71 and § 424.80 to reflect these safeguards, as well as the expanded exception established by section 952.

Given the myriad relationships and financial arrangements potentially permitted by section 952, the purpose of

joint and several liability is to encourage both parties to the contractual arrangement to exercise oversight of billings submitted to the Medicare program by holding them each fully accountable. Since physician or nonphysician practitioners will be subject to liability for claims that are submitted to the Medicare program by entities to which they have reassigned payments, it follows that a physician or nonphysician practitioners should have access to the billings submitted on their behalf.

We note that section 952 of the MMA revises only the statutory reassignment exceptions relevant to services provided in facilities and clinics (section 1842(b)(6)(A)(ii) of the Act). Arrangements involving reassignment must not violate any other applicable Medicare laws or regulations governing billing or claims submission, including, but not limited to, those regarding ''incident to'' services, payment for purchased diagnostic tests, and payment for purchased test interpretations.

In addition, physician group practices should be mindful that compliance with the in-office ancillary services exception to the physician self-referral prohibition requires that a physician who is engaged by a group practice on an independent contractor basis must provide services to the group practice's patients in the group's facilities. As noted in the Phase I physician self-referral final rule (66 FR 887), ''[w]e consider an independent contractor physician to be ''in the group practice'' if (1) he or she has a contractual arrangement to provide services to the group's patients in the group practice's facilities, (2) the contract contains compensation terms that are the same as those that apply to group members under section 1877(h)(4)(iv) of the Act or the contract fits in the personal services exception, and (3) the contract complies with the reassignment rules * * *.'' See also 66 FR 886. This test is codified at § 411.351 in the definition of ''physician in the group practice.''

We are aware that the changes in the reassignment rules based on section 952 of the MMA may create new fraud and abuse vulnerabilities, which may not become apparent until the program has experience with the new contractual arrangements addressed in section 952 of the MMA. Parties should be mindful that contractual arrangements involving reassignment may not be used to camouflage inappropriate fee-splitting arrangements or payments for referrals. We are soliciting public comment on potential program vulnerabilities and on possible additional program integrity safeguards to guard against such vulnerabilities. We intend to monitor reassignment arrangements for potential program abuse.

*G. Section 642—Extension of Coverage of IVIG for the Treatment of Primary Immune Deficiency Diseases in the Home*

[If you choose to comment on issues in this section, please include the caption ''Section 642'' at the beginning of your comments.]

Beginning for dates of service on or after January 1, 2004, Medicare pays for intravenous immune globulin administered in the home. This benefit is for the drug and not for the items or services related to the administration of the drug when administered in the home, if deemed medically appropriate. Manual instructions implementing this MMA provision have been issued and can be found at *http://www.cms.hhs.gov/manuals/pm_trans/R6BP.pdf* and *http://www.cms.hhs.gov/manuals/pm_trans/R74CP.pdf.* We are also proposing to revise § 410.10 to address this statutory change.

*H. Section 623—Payment for Renal Dialysis Services*

[If you choose to comment on issues in this section, please include the caption ''Section 623'' at the beginning of your comments.]

1. Background

We are proposing changes affecting payments to ESRD facilities that result from enactment of the MMA and would be effective January 1, 2005. Section 1881(b) of the Act, as amended by section 623 of the MMA, directed the Secretary to revise the current composite rate payment system. The statute has several major provisions that require the development of revised composite payment rates, as follows:

- An update of 1.6 percent.
- An add-on to the composite rate for the difference between current payments for separately billable drugs and biologicals and payments based on the revised drug pricing methodology using acquisition costs.
- Case-mix adjustments for a limited number of patient characteristics.
- Application of a budget neutrality adjustment. The statute also allows the Secretary to adjust the payment rates by a geographic index as the Secretary determines to be appropriate which would be phased-in over a multiyear period.

By January 1, 2005, we plan to implement the proposed revisions affecting the composite payment rate which would include the following:

- An increase of 1.6 percent to the basic composite payment rate.
- Proposed revisions to the pricing of separately billable drugs and biologicals.
- A drug add-on to the composite rate to reflect the difference between current payments for separately billable drugs and biologicals, and payment based on the revised drug pricing methodology using acquisition costs.

We propose to implement the patient characteristics adjustments and the related budget neutrality adjustments by April 1, 2005. (*See* detailed discussion later in this section.)

2. Legislative History

Section 2991 of the Social Security Amendments of 1972 (Pub. L. 92–603), established Medicare's End Stage Renal Disease (ESRD) Program. This law extended Medicare coverage to individuals who have permanent kidney failure, require either dialysis or transplantation, and meet certain other eligibility requirements. The End Stage Renal Disease Program Amendments of 1978 (Pub. L. 95–292) added section 1881(b)(2)(B) to title XVIII of the Act.

That legislation provided for the establishment of a prospective reimbursement methodology for the payment of dialysis treatments provided by renal dialysis facilities. Further changes to the ESRD payment system were made by section 2145 of Pub. L. 97–35, which amended section 1881 of the Act, requiring the development of a prospective reimbursement system for outpatient maintenance dialysis that promotes home dialysis. The payment system required either the reimbursement of home dialysis and in-facility dialysis under ''composite'' rates, or the use of some other more efficient method determined to promote home dialysis more effectively.

On February 12, 1982, we published a proposed rule on reimbursement for outpatient maintenance dialysis services (47 FR 6556) and we published the final rule on May 13, 1983 (48 FR 21254). This regulation implemented section 1881 of the Act, as amended by section 2145 of Pub. L. 97–35, and provided that each ESRD facility will receive a fixed composite payment rate per dialysis treatment, adjusted for geographic differences in area wage levels. Payment for in-facility and home dialysis treatments was established using a composite payment rate reflecting the costs of both modalities. Separate composite payment rates were established for hospital-based and independent dialysis facilities. The regulation also included a process under which facilities could obtain exceptions

to their composite payment rates under specified circumstances.

The average composite payment rate per treatment, effective on August 1, 1983, was $123 for independent ESRD facilities and $127 for hospital-based facilities. The composite rate was designed to provide payment for a package of goods and services needed to furnish dialysis treatments that included certain routinely provided drugs, laboratory tests, supplies, and equipment. Unless specifically included in the composite payment rate, other injectable drugs and laboratory tests medically necessary for the care of the dialysis patient are separately billable.

Prior to January 1, 2004, drugs not paid on a cost or prospective payment basis were paid based on the lower of the actual charge or 95 percent of the AWP (section 1842(o)(1) of the Act, as added by section 4556 of the BBA of 1997 (Pub. L. 105–33)). Sections 303 through 305 of the MMA make revisions to payment methodology for Part B covered drugs that are not paid on a cost or prospective payment basis. For CY 2004, the MMA provides that drugs not paid on a cost or prospective payment basis will be paid at 85 percent of the AWP determined as of April 1, 2003. However, there are several exceptions to this general rule, including payment of ESRD drugs and biologicals. In CY 2004, drugs and biologicals furnished in connection with the furnishing of renal dialysis services if separately billed by renal dialysis facilities are paid at 95 percent of AWP. We note that hospital-based ESRD facilities are paid reasonable costs for separately billable drugs, except for Erythropoietin/Epoietin (EPO).

EPO is an anti-anemia drug administered to certain patients with ESRD. Medicare Part B pays for EPO and its administration if it is furnished by an approved ESRD facility as part of an outpatient dialysis service or by a supplier of home dialysis equipment and supplies to ESRD patients in their homes as part of home dialysis services. Most dialysis is furnished to ESRD patients on an outpatient basis or is self-administered in the home.

Section 1881(b)(11) of the Act expressly excludes payment for EPO furnished to ESRD patients from the composite rate for dialysis services. The costs of EPO are, therefore, billed separately by an ESRD facility or by a supplier of home dialysis equipment and supplies and are paid in addition to the facility's composite rate. Any EPO-related costs, such as the cost of its administration or overhead costs associated with its storage, however, are subsumed in the facility's composite rate.

Section 413.174(f)(3) requires that we prospectively determine the EPO amount pursuant to section 1881(b)(11)(B)(ii) of the Act. Section 4201(c) of the Omnibus Budget Reconciliation Act of 1990 (OBRA 90) (Pub. L. 101–508), however, amended section 1881(b)(11) of the Act to establish a new EPO payment methodology. OBRA 90 directed, effective January 1, 1991, that payment for EPO furnished to ESRD patients by Medicare-approved dialysis facilities or suppliers of home dialysis equipment and supplies for home use be made on a per-unit basis. OBRA 90 also established a maximum payment amount of $11 per 1,000 unit doses rounded to the nearest 100 units. Subsequently, section 13556(a)(2) of OBRA 93 was enacted, which further amended section 1881(11)(b)(B)(ii) of the Act to reduce the maximum payment level to $10 per 1,000 units effective January 1, 1994. Although we have the authority to revise the rate, we continue to pay at the rate of $10 per 1,000 units.

Section 9335(a) of Pub. L. 99–509 required the Secretary to reduce the initially established composite payment rates by $2.00 per treatment effective October 1, 1986. This reduction was partially reversed as a result of the enactment of section 4201(a)(2) of Pub. L. 101–508, which increased the composite payment rates in effect as of September 30, 1990 by $1.00 per treatment, but effectively froze the methodology for their calculation, including the data and definitions used, as of that date. Section 222 of Pub. L. 106–113, provided for a 1.2 percent increase to the payment rates effective January 1, 2000, and also provided for another 1.2 percent increase effective January 1, 2001. Section 422(a)(1) of Pub. L. 106–554, raised the amount of the January 1, 2001 payment increase by another 1.2 percent for a total increase of 2.4 percent effective January 1, 2001.

Section 422 of Pub. L. 106–554 also directed the Secretary to develop a Prospective Payment System (PPS) that expanded the bundle of routine services reflected in the composite rate to include separately billable laboratory tests and drugs ''to the maximum extent feasible''. In addition, section 422(a) of Pub. L. 106–554 prohibited the granting of new composite rate payment exceptions for services furnished after December 31, 2000. Because a bundled ESRD payment system must be periodically updated, section 422(b) of Pub. L. 106–554 also required the development of an ESRD market basket to account for changes in price inflation, with discretionary consideration of other factors known to affect costs. Section 422(c) of Pub. L. 106–554 mandated the submission of a report to the Congress on the bundled payment system and ESRD market basket.

On May 12, 2003, the Secretary submitted the required report to the Congress. The report explained the major issues that must be addressed before a bundled ESRD PPS can be implemented, presented an ESRD composite rate market basket, and discussed the results from the first phase of our sponsored research to develop a bundled payment system. The report presented the following three major findings that are relevant to our efforts to revise the composite rate payment system:

- Current data sources are adequate for proceeding to develop a bundled ESRD PPS.
- Case-mix may be an important variable for risk adjusting payments, based on preliminary analysis.
- Current data provide a sound basis for monitoring patient outcomes in a revised ESRD payment system.

3. Summary of Section 623 of MMA

The following provisions in section 623 of the MMA, effective January 1, 2005, affect the composite payment rate methodology, as well as the pricing methodology for separately billable drugs and biologicals furnished by ESRD facilities:

a. *Section 623(a)*—The last sentence of section 1881(b)(7) of the Act, as amended by MMA, provides for an increase in the current composite payment rate of 1.6 percent.

b. *Section 623(d)(1)*—Section 1881(b)(13) of the Act, as added by MMA section 623(d)(1), provides for a revision to the current AWP pricing of separately billable drugs and biologicals; payment will be based on acquisition costs as determined by the OIG's study mandated under section 623(c) of the MMA. Insofar, as the OIG has not determined the acquisition costs, with respect to a drug or biological, the Secretary shall determine the payment amount for such drug or biological.

c. *Section 623(d)(1)*—Section 1881(b)(12) of the Act, as added by MMA section 623(d)(1), also requires the establishment of a basic case-mix adjusted composite payment rate that applies certain adjustments to the composite payment rate as follows:

- Adjustments for a limited number of patient characteristics.
- An adjustment that reflects the difference between current payments for

separately billed drugs and biologicals and the revised pricing based on acquisition costs or other method as determined by the Secretary.

- A geographic adjustment, if the Secretary determines such an adjustment is appropriate with the possibility of a phase-in.
- A budget neutrality adjustment, so that aggregate payments under the basic case-mix adjusted composite payment rates for 2005 equal the aggregate payments that would have been made for the same period if section 1881(b)(12) of the Act did not apply.

4. Provisions of the Proposed Rule

a. Composite Rate Increase

The current composite payment rates applicable to urban and rural hospital-based and independent ESRD facilities were effective January 1, 2002. The current wage-adjusted rates for each urban and rural area were published in Tables III and IV of Program Memorandum A–01–19 issued February 1, 2001 and are applicable through the end of 2004. Section 623(a)(3) of the MMA requires that the composite rates in effect on December 31, 2004 be increased by 1.6 percent. We are publishing revised wage-adjusted composite rates that reflect the statutorily required 1.6 percent increase. Those rates are set forth in Tables I and II at the end of this section. These tables reflect the updated hospital-based and independent facility composite rate of $132.40 and $128.35, respectively, adjusted by the current wage index. The rates will be effective January 1, 2005. The rates shown in the tables do not include any of the basic case-mix adjustments required under section 623 of the MMA.

b. Revised Pricing Methodology for Separately Billable Drugs and Biologicals Furnished by ESRD Facilities

Section 623(d) of the MMA requires the Secretary to establish a basic case-mix adjusted PPS for dialysis services that are furnished beginning on January 1, 2005 by providers of services and renal dialysis facilities to individuals in a facility and to individuals at home. This system will include services comprising the composite rate as well as the difference between payment amounts for separately billed drugs and biologicals (including erythropoietin) furnished by ESRD facilities and acquisition costs of such drugs and biologicals as determined by the OIG reports from the studies mandated by section 623(c) of the MMA.

For 2004, the payment amounts for separately billed drugs and biologicals (other than erythropoietin) furnished by ESRD facilities are determined by 95 percent of AWP. For 2005, the payment amounts for separately billed drugs and biologicals (including erythropoietin) furnished by ESRD facilities are described in section III.E of the NRPM. Insofar as the acquisition cost has not been determined by the OIG, then the Secretary shall determine the payment amount of the drug and biological.

For 2005 and subsequent years, the payment amounts for separately billed drugs and biologicals (including erythropoietin) furnished by ESRD facilities will be the acquisition cost or the amount that is derived from the ASP methodology in section 1847A of the Act, as the Secretary may specify.

See section III.E.1.d. of this proposed rule for further explanation of payment for separately billable drugs and biologicals furnished by renal dialysis facilities.

c. Composite Rate Adjustment to Account for Changes in Pricing of Separately Billable Drugs and Biologicals

Section 1881(b)(12) of the Act, as added by section 623(d) of the MMA, contains two provisions that specify how the drug add-on adjustment is to be handled in the revised ESRD payment system. First, subparagraph (B)(ii) of such section requires an adjustment to the composite payment rates to account for the difference between payment amounts for separately billed drugs (including erythropoietin) under the current payment system and acquisition costs as determined by the OIG. Second, subparagraph (E)(i) requires that the drug add-on adjustment be budget-neutral, that is, that it be designed to result in the same aggregate amount of expenditures as would have been made without the statutory policy change.

We need to determine the composite rate adjustment for drug add-on amount that simultaneously deals with both statutory requirements. That is, the aggregate amount of the composite rate adjustment for drug add-on amount needs to equal the aggregate amount of the drug spread (the difference between drug payments under the old system and acquisition costs).

In order to ensure that we satisfy both constraints, it is necessary to consider the proposed drug pricing in developing the adjustment to the composite rates. As discussed in section III.E.1.d. of this proposed rule, we are proposing to pay for separately billable ESRD drugs using ASP minus 3 percent based on the average relationship of acquisition costs to average sales prices from the drug manufacturers as outlined in the OIG report. We have developed the proposed drug add-on adjustment using the ASP minus 3 percent drug prices. Section 2 below discusses the details of the calculation of the drug add-on adjustment. An alternative approach would be to use the 2003 acquisition prices from the OIG report, calculate the aggregate difference between such prices and payments for drugs under the AWP system, update this difference to 2005 and then apply the budget neutrality adjustment. Because the same budget-neutrality adjustment would be used in both calculations, we believe that the drug add-on adjustment for the drug spread would be the same with both approaches. Therefore, we are proposing to use the ASP minus 3 percent prices as the basis for developing the drug add-on adjustment to the composite rate.

1. Options for Applying the Drug Add-On Adjustment to the Composite Payment Rate

Currently, separately billable ESRD drugs are paid differently to hospital-based and independent ESRD facilities. EPO is currently the only drug for which payment is uniform across ESRD facilities; EPO is paid at the current rate of $10 per 1000 units. All other separately billed ESRD drugs provided by independent ESRD facilities are currently paid 95 percent of AWP prices. However, hospital based ESRD facilities are paid their reasonable cost for the other separately billed drugs they provide. Because they are paid on cost, hospital-based facilities have not made the profits from drug payment that independent facilities have enjoyed.

The statutory language describing the add-on adjustment to the composite rate does not specifically differentiate between hospital-based and independent facility composite rate adjustments. However, the drug add-on provision is included with the other provisions related to the basic case-mix adjusted composite rate system; thus, it could be argued that the drug add-on provision was intended to address ESRD industry concerns about the inadequacy of the composite payment rate. We believe these concerns apply equally to hospital-based facilities and independent facilities. Therefore, we are proposing a single adjustment to the composite payment rates for both hospital based and independent facilities.

An alternative option would be to develop a separate adjustment for hospital-based facilities for EPO and one for independent facilities for all of their separately billed drugs. The IG's report provided the acquisition costs we are

using; it did not provide different acquisition costs for hospital-based and independent facilities. We believe that it would not be appropriate for us to use these data to create two separate adjustments. The following discussion outlines the development of the drug add-on adjustment under both options—a single factor and separate factors.

2. Computation of Drug Add-On Adjustment to the ESRD Composite Payment Rate

i. Data

To develop the drug add-on adjustment we used historical total aggregate payments for separately billed ESRD drugs for half of 2000 and all of 2001 and 2002. For EPO, these payments were broken down according to type of ESRD facility (hospital-based versus independent). We also used the number of dialysis treatments performed by these two types of facilities over the same period.

ii. ASP Minus 3 Percent

We updated the ASP minus 3 percent prices, for the first quarter of 2004, to represent 2005 prices. We used the projected annual price growth factor for National Health Expenditure prescription drugs of 3.39 percent.

TABLE 12

| Drugs | First quarter 2004 average sales price first minus 3 percent | Quarter 2005 average sales price minus 3 percent |
|---|---|---|
| Epogen | $8.74 | $9.04 |
| Calcitriol | 0.66 | 0.68 |
| Doxercalciferol | 2.55 | 2.64 |
| Iron_dextran | 9.22 | 9.54 |
| Iron_sucrose | 0.34 | 0.35 |
| Levocarnitine | 7.15 | 7.39 |
| Paricalcitol | 3.86 | 3.99 |
| Sodium_ferric_glut | 4.15 | 4.29 |
| Alteplase, Recombinant | 27.74 | 28.68 |
| Vancomycin | 3.40 | 3.52 |

iii. Current Medicare Reimbursement

We updated the first quarter 2004 Medicare payment amounts (95 percent of AWP), based on the January 2004 Single Drug Pricer, for drugs other than EPO, to estimate 2005 payment amounts by using an estimated AWP growth of 3 percent. These growth factors are based on historical trends of AWPs. We did not increase the price for Epogen since payment was maintained at $10.00 per thousand units prior to MMA.

TABLE 13

| Drugs | Current medicare reimbursement prices for 2005 |
|---|---|
| Epogen | $10.00 |
| Calcitriol | 1.42 |
| Doxercalciferol | 5.67 |
| Iron_dextran | 18.45 |
| Iron_sucrose | 0.68 |
| Levocarnitine | 35.23 |
| Paricalcitol | 5.49 |
| Sodium_ferric_glut | 8.42 |
| Alteplase, Recombinant | 37.80 |
| Vancomycin | 7.24 |

iv. Dialysis Treatments

We updated the number of dialysis treatments by actuarial projected growth in the number of ESRD beneficiaries. Since Medicare covers a maximum of three treatments per week, utilization growth is limited, and therefore any increase in the number of treatments should be due to enrollment. In 2005, we project there will be a total of 36.5 million treatments performed (5.1 million treatments will be performed by hospital-based facilities and 31.4 million treatments by independent facilities).

v. Drug Payments

We updated the total aggregate Epogen drug payments for each hospital-based and independent facilities using historical trend factors. For 2003 through 2005, the 2002 payment level was increased each year by trend factors of 2.8 percent for hospital-based facilities and by 9.4 percent for independent facilities.

Using drug growth factors for drugs paid for by Medicare Part B carriers, which were calculated from historical data, we updated the aggregate spending for separately billable drugs, other than EPO, for independent facilities. We used 24.7 percent for 2003, 23.3 percent for 2004, and 21.4 percent for 2005 as factors because historical growth of ESRD drugs is similar to that for drugs paid for by Part B carriers. These factors are projected to approach the level of National Health Expenditure prescription drug growth. For 2005, we estimate that spending will reach $185 million for Epogen provided in hospital-based facilities, and $2,664 million for drugs provided in independent facilities ($1,568 million for Epogen and $1,096 million for other drugs).

vi. Add-On Calculation and Budget Neutrality

For each of the ten drugs, we calculated the percent by which ASP minus 3 percent prices are projected to be less than reimbursement amounts under the current system for 2005. For Epogen, this amount is 10 percent. We applied this 10 percent figure to the total aggregate drug payments for Epogen in hospital-based facilities, resulting in a difference of $18 million. We then calculated a weighted average of the percentages by which ASP minus 3 percent would be below current Medicare reimbursement prices for the top 10 ESRD drugs. We weighted these percentages by using the 2002 Medicare reimbursement values contained in the OIG report for the ten drugs. This procedure resulted in a weighted average of 19 percent. Since these ten drugs represented 98 percent of drugs payments, we applied the weighted average to 100 percent or all of aggregate drug spending projections for independent facilities, producing a projected difference of $516 million.

Combining the 2005 figures of $18 million and $516 million, for a total of $534 million and then distributing this over a total projected 36.5 million treatments would result in a single add-on to the per treatment composite rate

of 11.3 percent. By making this adjustment to the composite rate, we estimate that the aggregate payments to ESRD facilities would be budget neutral with respect to drug payments.

Alternatively, we could produce separate drug add-on adjustments for hospital-based and independent facilities using the same methodology. Under this option, we could distribute the $18 million difference in EPO payments to hospital-based facilities based on data projecting 5.1 million treatments resulting in a hospital-based facility drug add-on adjustment of 2.7 percent. We would distribute the $516 million difference in drug payments (including EPO) to independent facilities using projected treatments of 31.4 million, resulting in a drug add-on adjustment of 12.8 percent for independent facilities.

Drug prices used in the computation of the proposed drug add-on adjustment to the ESRD composite payment rate, may be revised based on later data and will be reflected in the final rule.

3. Composite Rate Effect of Proposed Drug Add-On Adjustment

We used a single drug add-on adjustment for both hospital-based and independent ESRD facilities, the proposed adjustment to the composite rate would be 1.113. Separate adjustments would provide a 1.128 adjustment for independent facilities and 1.027 for hospital-based facilities. The following table illustrates the effect on the composite payment rates under the two potential drug add-on options. (Case-mix budget neutrality adjustments are not reflected in this table).

TABLE 14

| Facility type | CY 2005 base rate | Separate add-on | Single add-on |
|---|---|---|---|
| Independent | $128.35 | $144.78 | $142.85 |
| Hospital Based | 132.41 | 135.99 | 147.37 |

Under the single add-on, the proportionately higher rate for hospital-based facilities would be consistent with section 1881(b)(7) which requires that our payment methods differentiate between hospital-based facilities and others. Separate add-on adjustments would result in a significantly higher composite payment rate for independent facilities, than hospital-based facilities, that is, $8.79 higher per treatment.

d. Patient Characteristic Adjustments

1. Statutory Authority

The current ESRD composite payment rates do not adjust for variation in patient characteristics or case mix. Section 1881(b)(12)(A) of the Act, as added by section 623(d)(1) of the MMA, requires that the outpatient dialysis services included in the composite rate be case-mix adjusted. Specifically, the statute states that "The Secretary shall establish a basic case-mix adjusted prospective payment system for dialysis services furnished by providers of services and renal dialysis facilities in a year to individuals in a facility and to individuals at home. The case-mix under the system would be for a limited number of patient characteristics.'' In the following sections, we describe the development of the methodology for the proposed patient characteristic case-mix adjusters required under the MMA.

2. Background

Case-mix measures utilizing patient characteristics have been used in a number of prospective payment systems. Use of a case-mix measure permits targeting of greater payments to facilities that treat more costly resource-intensive patients. However, the legislative mandate to establish a case-mix adjustment for services included in the composite rate based on a limited number of patient characteristics presents a unique challenge.

The composite rate represents payment for a fixed bundle of routine services provided to ESRD patients as part of a dialysis treatment. Generally, the items and services needed to provide a dialysis treatment do not vary significantly across patients. Moreover, the bills for composite payment rate services furnished to ESRD patients, which are generally submitted monthly, do not identify the specific items and services provided on a case-by-case basis. In addition, the Medicare cost reports identify only aggregate costs for composite rate services at the facility level. Therefore, any case-mix adjustment based on patient characteristics obtained from the bills for outpatient ESRD services and applied to the composite rate will reflect only variation in composite rate costs at the facility level.

Earlier research by Hirth (1999) and Dor (1992) found that if case-mix adjustments applied only to composite rate items and services the adjustments played a limited role in predicting variation in costs per treatment because case-mix and dialysis treatment patterns are very similar across facilities. However, more recent analyses conducted under our contract with the University of Michigan, Kidney, Epidemiology and Cost Center (KECC) found that patient level case-mix adjustment would be more relevant in a bundled payment system that includes both composite rate and separately billable items and services. KECC's research studies relied on an extensive set of variables to define patient case-mix. These variables included patient characteristics, a large number of specific comorbidities and clinical measures (including primary diagnosis) and other (non-Medicare) insurance coverage, as well as the duration of ESRD. We relied on linear regression analyses used in the studies to assess the relationship of patient characteristics and comorbidity measures to per session cost and Medicare payments to facilities. These studies relied on data from our administrative files.

We are continuing and expanding the research project in support of the development of a fully bundled case-mix adjusted system. We are continuing to explore alternative models and options with more detailed analysis of patient characteristics as part of the legislatively mandated report to the Congress in the fall of 2005.

Despite the difficulty in developing a patient characteristic case-mix adjustment, we were able to develop case-mix adjustment factors for a limited number of patient characteristics, consistent with the legislative mandate. As expected, these adjusters are only modest predictors of variation in average costs for composite services. In developing the proposed patient characteristic adjustments, we used our available administrative data. Because facilities do not list individual composite rate items and services on the dialysis bill, billing data do not identify resources used by each patient. In

addition, facilities can underreport or not report comorbid conditions. Therefore, these bills are not useful for deriving average facility input costs. Since there are not any current requirements to list comorbid conditions on the dialysis bill, we used a combination of data sources to determine co-morbidities for ESRD patients on maintenance dialysis. These include the Medicare claims history file as well as the CMS Form 2728 (ESRD Medical Evidence Report) which provides information on the cause of ESRD and lists 20 possible co-morbidities present at the onset of a patient's ESRD. The Form 2728 is completed only at the initiation of dialysis treatment. It is not updated to reflect more recent medical conditions.

Nonetheless, we found selected variables from the Form 2728 to be valid predictors of cost per treatment for the proposed case-mix adjustment, and the Form 2728 was also useful in developing our proposed case-mix adjustments. As discussed below, the Form 2728 variables were supplemented by additional information we obtained from billing records.

3. Development of the Proposed Adjustments for Patient Characteristics

We are proposing a methodology to establish a basic case-mix adjusted composite rate system using a limited number of patient characteristic variables developed from existing our administrative files. We analyzed a number of patient level variables including age, gender, alcohol and drug dependence, inability to ambulate/transfer, current smoker, number of years since ESRD onset, weight, height, mean BUN, and mean creatinine clearance, as well as a number of comorbidities.

As a means to estimate how average cost variations among facilities are influenced by selected patient characteristics, extensive analyses were performed to develop a proposed ''basic case-mix adjusted PPS, for a limited number of patient characteristics,'' as specified in the statute. We analyzed the average cost per dialysis session (including both hemodialysis and Method I peritoneal dialysis converted to equivalent 3 times per week hemodialysis sessions) from national data gathered for the years 2000, 2001, and 2002.

A stepwise regression was used to select a limited set of variables that were predictive of average facility cost per treatment. We used data pooled over a three-year period because we found the regression coefficients to reflect a consistent pattern over three years. We used data pooled over a three-year period to minimize the potential for volatility in the regressive coefficients. The analysis controlled for selected variables that influence facility costs, but are not case-mix related. These variables included wage index, the natural log of the number of dialysis sessions provided annually by the facility, type of facility, chain affiliation, and percentage of patients with urea reduction ratio (URR) as a measure of dialysis dose equal to or greater than 65 percent. The proposed model is based not only on the predictive power of these measures, but also upon objectivity (for example, discrete variables: age/gender), clinical plausibility, and practicality (that is, availability) of data collection. The variables used were assessed for their clinical plausibility by clinicians from the University of Michigan and CMS. Physicians assessed a proposed list to determine relationship of the proposed comorbidities to ESRD patients, and clinical practice/patterns.

In addition to exploring a number of potential case-mix variables, we examined two methods, that is, linear and log linear models of the composite rate costs. We selected the log linear model in order to yield patient specific case-mix adjustments which can be multiplied by a dialysis facility's otherwise applicable composite rate payment. In this proposed rule, we provide a detailed example of the calculation of the proposed case-mix adjusted composite rate payments.

4. Proposed Patient Characteristic Adjustments

As discussed in the background section above, the basic case-mix system is constrained by the composite rate and the data available for these adjustments. While we analyzed a number of variables, four patient characteristic variables were found to be modest predictors of cost variation among ESRD facilities. These patient characteristic variables include gender, age, and two comorbidities (AIDs and PVD) (See table 3 for specific ICD 9 codes for these comorbidities). Each of the gender categories was also divided into three age categories so that one adjustment factor could be developed to encompass both gender and age. The proposed patient characteristic adjustments are discussed below.

i. Gender and Age

We are proposing adjustments for both gender and age. We found that gender and age were strong predictors of facility cost variations. In addition, data on gender and age are readily available, and are objective measures. After examining a number of options for age, we are proposing under 65, 65–79, and over 80 as the three categories for age. We attempted to develop a case-mix adjuster specific to the under 18 age group. However, the population in that age group that was included in the data used to develop the case-mix adjustments was too small, and was generally concentrated in a very small number of facilities.

While we recognize that pediatric patients are more costly to treat, those patients are generally treated in specialized pediatric facilities. As provided in MMA, those facilities can request adjustments to their composite payment rates through the exceptions process. This process will enable pediatric facilities to obtain payments that specifically recognize the higher cost associated with treating these patients. In developing the age adjustments, data for those patients were grouped into the under 65 age category. We note that adjustments for both gender and age are consistent with the MA risk adjustment models for ESRD patients.

ii. Proposed Comorbidity Adjustments

As discussed above, the effect of the costs of dialysis for a number of conditions were analyzed. These included several comorbidities that did not have a statistically significant relationship to facility costs. In other cases, the lack of data precluded inclusion of a comorbid condition in the proposed patient characteristic adjustments. That is, we are unable to propose any adjustments based on data that cannot be routinely reported, (for example, some data elements that are reported only on the Form 2728). For the reasons discussed above, the Form 2728 is not an appropriate source of information since it is not updated after a patient enters the ESRD program. Two variables not currently available on the Medicare bill are weight and height. Weight and height are used to compute a patient's body mass index (BMI). Our analysis indicates that patients with extremely low or high BMI are costly to treat. Since BMI is directly related to a patient's dialysis prescription, we believe this factor could be an important measure of resource consumption related to the composite payment rate. We also believe that the length of time a patient is dialyzed could directly affect composite rate costs. We are currently exploring the feasibility of developing a mechanism to collect these data on the ESRD bill. In addition, we are soliciting comments on other data elements that could be added to the bill

that could be relevant predictors of composite rate costs.

We also examined whether having cancer was predictive of higher resource used. We examined all cancers reported within the last 3 to 10 years as reported on our claims history file or the Form 2728. While a patient's history of cancer was associated with higher costs, we found this measure to be too broad to be clinically meaningful. We will continue to evaluate this condition as a potential variable for refinement purposes. As ESRD facilities begin reporting patient comorbidities, we expect that we will be in a better position to identify the specific cancer diagnoses that may be related to increased composite rate costs.

We also explored whether diabetes as a comorbidity is predictive of high resource use. We found that the predictive power of diabetes was dependent on whether PVD was part of the model. PVD was always statistically significant, when accounted for, while most measures of diabetes were not strongly associated with facility costs. Therefore, we are proposing a case-mix adjustment for PVD diagnoses. We believe this adjustment appropriately addresses the higher costs associated with sicker diabetic patients. We note that about 73 percent of diabetes patients included in our data also had PVD. Another comorbid condition that was found to be a significant predictor of facility cost is AIDs. This diagnosis is currently coded as part of the claims data.

Another Form 2728 variable we examined was the presence of a substance (alcohol and drugs) dependence diagnosis. While the presence of substance abuse was found to be predictive of higher facility level costs, we are not proposing an adjustment for this comorbidity at this time since the substance abuse diagnosis is underreported on the claims. We are soliciting comments on the variables included in the proposed patient characteristic adjustment as well as recommendations for the inclusion of other potential variables that may affect the costs of dialysis.

In summary, we are proposing to use a limited number of patient characteristics that do explain variation in reported costs for composite rate services consistent with the legislative requirement. The proposed adjustment factors are as follows:

TABLE 15

| | | |
|---|---|---|
| Female | age <65 years | 1.11 |
| | age 65–79 years | 1.00 |
| | age >79 years | 1.16 |
| Male | age <65 years | 1.21 |
| | age 65–79 years | 1.17 |
| | age >79 years | 1.23 |
| AIDS | | 1.15 |
| PVD | | 1.07 |

While the magnitude of some of the patient specific case-mix adjustments appears to be significant, facility variation in the case-mix is limited. This is because of the overall similarity of the distribution of patients among the eight case-mix classification categories across facility classification groups. This is reflected by the average case-mix adjustment based on 2002 data for the various types of ESRD facilities shown in the table below.

TABLE 16

| Facility type | Average case mix adjustment |
|---|---|
| All | 1.1919 |
| Independent | 1.1917 |
| Hospital Based | 1.1936 |
| Urban | 1.1931 |
| Rural | 1.1865 |
| Small (<5k treatments/yr.) | 1.1911 |
| Medium (5–10k treatments/yr.) | 1.1910 |
| Large (>10k treatments/yr.) | 1.1924 |
| Non-profit | 1.1924 |
| For-profit | 1.1918 |

As illustrated from this table, regardless of the type of provider, the average case-mix adjustments for patient characteristics do not vary significantly. We are continuing research to develop a more fully bundled proposed model that is not constrained by the existing composite rate. We will continue to study the predictive value of comorbidities and facility and patient level variables as part of the ongoing research. In addition, we are aware that by limiting the number of variables for the patient characteristics adjustment applicable to the composite payment rate, we are limiting the predictive power of the model. We are planning to consider additional variables to refine and update the proposed patient characteristics. Once we have implemented this basic case-mix system, we will continue to analyze comorbidities (on the reported claims file) and will consider expanding the list of variables used in the patient classification adjustment. In addition, we will be working with our fiscal intermediaries to improve the reporting of comorbidities on claims.

5. Technical Description of Model Used To Develop the Proposed Patient Characteristic Adjustments

Both facility and patient level variables were used for the development of the proposed case-mix adjustment. Facility costs are based on Medicare allowable costs reported by facilities for dialysis and related services for which they are reimbursed through the composite rate. The sources of the cost data are the Medicare Independent Renal Dialysis Facility Cost Reports (Form CMS 265–94) and the Medicare Hospital Cost Reports (Form CMS 2552–96). We used the most current set of facility cost reports available (cost reports updated through December 2003 and made publicly available in March 2004).

All cost reports spanning any part of calendar years 2000, 2001 or 2002 were included in the development of the case mix adjusters. While for most facilities, especially independent facilities, a single cost report encompasses the entire calendar year; data for some facilities, most notably those whose reporting period spans two calendar years (for example, October through September rather than January through December) were pro-rated to calculate the average treatment cost during a calendar year. The resulting numbers of cost reports used in the analyses are shown in the table below by facility type and year. Note that currently there are fewer cost reports available for analysis in 2002 because many facilities have not yet submitted cost reports for that year. The final version of this regulation will contain the most recent data available.

TABLE 17

| | 2000 | 2001 | 2002 |
|---|---|---|---|
| Independent facilities | 3,027 | 3,034 | 2,508 |
| Hospital-based facilities | 477 | 466 | 456 |

The average treatment cost per dialysis session for each facility was calculated by dividing the total reported cost for dialysis and related services by the total number of dialysis treatments. The source of the reported cost for independent facilities was Worksheet B from Form CMS 265–94 and, for hospital-based facilities, Worksheet I–2 (Form CMS 2552–96). The source for the total number of dialysis treatments for independent facilities was worksheet Form CMS265–94 and, for hospital-based facilities, worksheet I–4 (Form CMS 2552–96). Note that, for CMS Form 2552–96 and CMS Form 265–94, values

in the fields for renal dialysis and home program dialysis were used in the cost and treatment calculations. For the CMS Form 265–94 and the CMS Form 2552–96 (Worksheet C, and worksheet I–4, respectively) values in the field home program CAPD and home program CCPD were stated in terms of patient weeks, rather than the number of treatments. These cells were multiplied by three to make them comparable to the number of hemodialysis sessions per week. The method used was consistent with the research (Dor, Held, Pauley 1992, Hirth, *et.al.*, 1999, Griffiths, *et.al.*, 1994, and Ozgen and Ozcan, 2002).

This method created an average Medicare allowable cost per dialysis treatment for each facility year of observation. Using the facility's Medicare billing number, cost report data were linked to claims data. For some facilities more than one billing number appears on claims and a list of correspondence among billing was used to link the claims to the cost report facility identifiers. This linkage was somewhat ambiguous for hospital facilities with satellite centers.

Patient level data was obtained from the Medicare claims data, and the Medical Evidence Form (CMS 2728). ESRD patients were identified using the Renal Beneficiary and Utilization System (REBUS), Medical Evidence and Master Patient File Records. Dialysis-related services (for example, the number of dialysis sessions) were identified for ESRD patients by Billing source (72x: renal dialysis facility bills), revenue center codes and the Healthcare Common Procedure Coding System (HCPCS).

6. Study Sample

Regression models for the average cost per session were used to estimate the typical cost per session. The average cost per session can be influenced by facilities with exceptional costs or with exceptional case-mix measures. To insure that the sample would characterize the patterns across the majority of facilities rather than being influenced by a few exceptional, non-representative facilities, the following facilities were excluded:

- Facilities with missing data from the cost reports or claims data. Twelve percent of the facilities lacked reported data.
- Facilities with high or low average costs.
- Facilities with exceptions.
- Facilities with extremely high or low proportions of patients with relevant medical cormorbidities.
- Small facilities.

Facilities with high or low average costs were determined based upon their composite rate. Facilities, having values for the log of the ratio of average costs to the composite rate of less than minus 0.5 or greater than 1.0 were excluded. This excluded less than 1 percent of facilities. Some facilities, that is, those with extremely high or low values based on selected patient characteristics (for example, percent of patients having a specific comorbidities such as AIDs, HIV, or alcohol and drug dependence) and selected facility characteristics (for example, facility size or URR). As with average costs, facilities with extreme variables did not represent the normal distribution of patient characteristics across facilities. This excluded 1.6 percent of the facilities. In addition, we excluded small facilities with less than 20 full patient years of dialysis during the year because it was difficult to assess the relationship between case-mix and facility costs based on the experience of a small number of patients. Facilities treating a small number of patients represented approximately 6.9 percent of the total facilities.

The sample excluded facilities with exceptional reimbursement levels. These included facilities with exceptions, facilities with higher than average payments, for example, with $3.00 or greater than the predicted composite rate payments. We excluded facilities based on our list of exceptions granted from November 1993 to July 2001. Some facilities were not included within the sample because their average payments were greater than the calculated (predicted) composite rate for the individual facility. While for the majority of the facilities, average composite rate payments were exactly as predicted, for some facilities, the payments were $3.00 greater than the predicted rate. These facilities were excluded because they were likely to be facilities with errors in reporting or facilities with exceptions. Of all of the facilities in the sample, 7.5 of the facilities were excluded from the sample.

7. Developing Case-Mix Measures at Each Facility Based on Patient-Specific Data

Facility-level case-mix measures were defined using certain demographic and comorbidity indicators for the Medicare dialysis patients in each facility for CYs 2000 to 2002. In aggregating patient data by facility, case-mix measures for each patient were weighted by the number of hemodialysis-equivalent dialysis sessions received in each facility. This process gives approximately 12 times as much weight to the characteristics of patients receiving a full year of dialysis care at a particular facility as compared to a patient receiving only one month of care at that facility. The resulting facility-level case-mix measures reflect how case-mix is distributed across individual treatments provided in the facility for Medicare dialysis patients. The number of dialysis sessions for each patient in each facility was obtained from Medicare outpatient institutional dialysis claims. The number of peritoneal dialysis patient days reported on each claim was multiplied by 3/7 to yield the number of hemodialysis-equivalent dialysis sessions provided during the time period covered by each claim. (For additional information see Phase I KECC Report, dated August 2002, p. 43).

8. Statistical Models

We explored a number of statistical methods to model the relationship between composite rate costs and patient/facility characteristics. We explored both linear and log-linear ordinary least squares regression models for each year from 2000 to 2002 to predict the natural log of the ratio of each facility's composite rate costs divided by that facility's composite payment rate (without regard to exception payments).

i. Choice of Estimation Method

We are proposing to use the log linear model in the methodology explained below in order to yield an easily administered case-mix adjuster which can be multiplied by the patient's otherwise applicable composite payment rate. This case-mix adjustment system also controls for selected variables.

We used the cost to payment ratio (that is, the natural log of the ratio of reported costs compared to the composite rate calculated for each facility) as the dependent variable in the models. The analysis that supports our decision is described in detailed below. In order to determine how reimbursement levels could be adjusted to reflect the costs of treating different patients, estimates of how the cost of providing dialysis services (that is, the composite rate) varies according to the patient characteristics (for example, age gender and comorbidities) were completed. Because the reported cost per treatment for each facility, in part, reflects the level of reimbursement (for example, Medicare payments) that the facility received, the measure of facility costs used is defined as the ratio relative to the current standard reimbursement level for each facility. For the purposes

of these analyses, the standard Medicare reimbursement payments for composite rate services (excluding those facilities with payment exceptions) were used. These currently vary across facilities based on the application of the area wage index used to develop the patient characteristics adjustment. This wage index (that is, labor costs) was used to account for regional differences in labor costs, and includes an adjustment for hospital based versus independent facility status.

As we have indicated, the costs of treatment varies from the composite rate payment for a number of reasons, including differences in the patient case-mix. The ratio of average reported costs at each facility were compared with the calculated composite rate payment in order to measure any variation in costs (that is, facility costs) from the composite rate. This cost to payment ratio measures the extent to which costs at a facility are higher or lower than the payment that would be expected based on their labor costs and facility type. Regression analysis was used to determine the extent to which the ratio varied with the average case-mix for each facility.

The analysis indicated that a log transformation of this cost to payment ratio was less skewed and a better fit (that is, the predicted variables were closer to the actual values using the log transformation).

ii. Control Variables

Apart from patient clinical and demographic characteristics, the proposed model also controls for selected other variables. These selected control variables include the wage index, the natural log of facility size (number of annual treatments), hospital-based/independent status, chain affiliation, and percent of patients with urea reduction ratios (URRs) greater than or equal to 65 percent. These control variables were included in the proposed model in order to account for the separate effect of facility variables and one readily available outcome variable on composite rate costs. These control variables were included in order to reduce potential distortion in the patient specific case-mix adjustors attributable to facility characteristics. We included the wage index to account for differences among facilities in area wage levels. We used facility size as a control factor because larger facilities, on average, have lower per treatment costs than smaller facilities. The hospital-based/independent classification was used because hospital based providers tend to have higher self-reported costs. Chain ownership is included in the model to account for differences among chains due to reporting conventions, as well as reflect similarities among facilities within chains. The URR was included as a control variable to account for a quality of care outcome measure at each facility, thereby mitigating any potential bias between composite rate costs and quality of care on the model's coefficients.

iii. The Log-Linear Model for Facility Costs

We identified a limited number of comorbidities that are strong predictors of composite rate costs and developed an estimated adjustment factor for each of these comorbidities. In order to yield an adjustor that can be multiplied with the composite rate payment, the model was used to estimate the facility's reported composite rate costs per treatment, divided by the composite payment rate calculated for each facility. The resulting ratio was modeled using case-mix and control variables. Analysis indicated that a log transformation of this ratio was less skewed and was better fit by the model (that is, predicted values were closer to actual values using the log transformation, especially for high cost facilities).

For facility j, the case-mix is measured by a vector of values, denoted by $X_j$. These values include both control variables and case-mix measures. The log of the ratio of cost per session ($C_j$) to composite rate ($R_j$) is denoted by $Y_j=\log(C_j/R_j)$. The multiple observations for three years are not indicated explicitly. The model equation is $Y_j = X_j \beta + \varepsilon_j$, where $\beta$ is the vector of coefficients for the predictor variables and $\varepsilon_j$ is an error term. This model is equivalent to the following model for cost for patient i, with a vector of individual characteristics $X_{ij}$, at facility j: $C_{ij} = R_j\, e^{X_{ij}\beta}$.

9. Identifying Factors for Case-Mix Adjustment

An evaluation of individual case-mix factors as potential risk adjusters was performed using several criteria to explain variation in facility costs. Consideration was also given to the validity of these potential case adjustors to costs based on clinical judgment, the stability of this relationship over time, the objectivity and accuracy of the data used to compute the factors, the reliability of information reported by different providers, and the feasibility of including them as risk adjusters.

Case-mix factors that explained statistically significant variation in facility costs were identified based on a regression model that used a stepwise selection method. Unless otherwise specified, case-mix measures represent the fraction of dialysis sessions in each facility that were provided to patients having the relevant characteristic or comorbidity. Case-mix measures that were considered for selection in the model included age/gender groups (ages <65, 65–79 and 80+ years, separately for females and males), less than one year of treatment for ESRD, average weight among adult dialysis patients (ages≥20), low body mass index among adult dialysis patients (BMI<18.5 kg/m$^2$) and the presence of individual comorbidities that were previously described that were developed from a combination of data from the Medicare claims history file and the CMS Form 2728.

10. Using the Model To Apply a Patient-Specific Case-Mix Adjustment to the Composite Rate

The regression coefficients that are estimated using facility cost model we discuss above can be used to apply a patient-specific case mix adjustment to the composite rate. This is accomplished by re-transforming the estimated coefficients to obtain relative factors for case mix adjustment. Based on a facility level cost model, where $X_n$ is the proportion of patients in a facility having a specific characteristic (for example, a specific comorbidity), a one unit change in $X_n$ can be used to characterize the difference between having and not having a specific patient characteristic. The coefficient for $X_n$,$\beta_n$, then estimates the change in the dependent variable (the natural log of the ratio of average composite rate costs to the composite rate) corresponding to whether or not a patient has that characteristic. The estimated coefficients can be re-transformed as $e^{X_{in}\beta tv}$ to obtain relative factors for n=1 to N case-mix measures included in the model.

The relative factors can then be applied multiplicatively to the composite rate in order to derive a case mix adjusted composite rate. Since these relative factors were all estimated to have values of 1.00 or greater, an adjustment to the composite rate based on these factors would necessarily lead to higher payments by Medicare. However, the MMA provision requires that the modification to the composite rate payment system be budget neutral. For the purpose of this example only, a budget neutrality factor that is less than 1.00 must, therefore, also be applied, with the same factor being applied to all patients and all facilities.

For patient i in facility j, a case-mix adjusted composite rate, $AR_{ij}$ is

calculated as a function of the current composite rate, $R_{ij}$, the estimated budget neutrality factor, N (to be determined), and an overall relative factor for case mix adjustment, $A_{ij}$, where $AR_{ij} = R_j * N * A_{ij}$, $R_j = (\rho B_j W_j + (1-\rho)B_j)$, and $A_{ij} = e^{X_{ij}\beta}$.

In the above equations, ρ is the fraction of costs attributed to labor and therefore subject to an adjustment for geographic differences in wages, 1-ρ is the fraction of costs attributed to non-labor inputs, $B_j$ is the base rate for facility j, $W_j$ is the CMS/BLS wage index for facility j (with 0.9 and 1.3 representing the minimum and maximum values for $W_j$, respectively), $X_{ij}$ is a vector of case-mix measures for patient i at facility j, and B is the vector of coefficients estimated by the regression model. Parameters $P_j$ and $B_j$ vary according to whether facilities are independent or hospital-based and may also vary over time, while $W_j$ is determined either by the MSA in which each facility is located or by the state location for facilities not in an MSA.

As suggested by the equations above, the coefficients estimated by the cost model can be used to derive an aggregate relative adjustment factor for each patient ($A_{ij}$) based on their individual characteristics ($X_i$). By applying this factor in a multiplicative fashion to the composite rate, it is also being applied multiplicatively to the wage index, so that the dollar effect of the case-mix adjustment also varies across facilities according to regional differences in labor costs. That is, the case-mix adjustment will be larger in magnitude for facilities that face relatively high labor costs. This is appropriate if we expect the higher level of care that may be necessary for certain types of patients, such as those with PVD, to require additional staff time or more highly trained staff in locales with differential wage levels. An overall relative case-mix adjustment factor for patient i, $A_i$, can be calculated based on the model as $A_i = e^{X_i\beta} = e^{X_{1i}\beta_1 + X_{2i}\beta_2 + + X_{pi}\beta_p}$.

However, since this is equivalent to $A_i = e^{X_i\square} = e^{X_{1i}\square_1} * e^{X_{2i}\square_2} * \ldots * e^{X_{ni}\square_n}$, the overall relative case-mix adjustment factor, or patient multiplier, can be calculated by multiplying together the relative adjustment factors for each case-mix measure. For every n=1 to p, $X_{pi}$ corresponds to a 1 if that characteristic is present and a 0 if that characteristic is not present. For any characteristic that is not present, $X_{pi}=0$ and $e^{X_{pi}\square_p}=1$, such that the equation can be simplified by including only those terms that are relevant for each patient. For characteristics that are present, $X_{pi}=1$, and the equation can be further simplified by dropping $X_{pi}$.

Where the individual factors for case-mix adjustment are age/gender, PVD and AIDS, the equation used to calculate the relative factor for case mix adjustment can then be expressed as $A_i = e^{\beta} = e^{\beta AS} * e^{\beta PVD} * e^{\beta AIDS}$ where $e^{\beta AS}$ is the relative factor for the appropriate age and sex category (one of six age/sex groups), $e^{\beta PVD}$ is the relative factor for the relevant PVD category (whether PVD is present or absent) and $e^{\beta AIDS}$ is the relative factor for the appropriate AIDS category (whether AIDS is present or absent).

11. Example

To illustrate, the proposed adjustment factors in section 4. above were used to derive a case-mix multiplier for a 7-year old male who has been diagnosed with PVD, but not AIDS. Using the proposed adjustment factors that correspond to males between the ages of 65 and 79 years and the presence of PVD, the overall case-mix multiplier for this patient is calculated as $A = e^{Xb} = e^{\beta AS} * e^{\beta PVD} = 1.17 \times 1.07 = 1.2519$.

A detailed example of the computation of the adjusted composite payment rate that includes the patient characteristics adjustments, as well as the applicable adjustments related to the ESRD drug payment revisions and budget neutrality, is provided later in this section I. below.

e. Geographic Index

Section 623(d)(1) of the MMA provides that the Secretary shall adjust the payment rates under this section by a geographic index as the Secretary determines to be appropriate. This section also specifies that, if the Secretary revises the current geographic adjustments applied to the composite payment rate, the revised adjustments must be phased in over a period of time. The current geographic adjustment (wage index) is a blend of two wage indexes, one based on hospital wage data collected by us from fiscal year 1986 and the other developed from 1980 hospital wage and employment data from the Bureau of Labor Statistics (BLS). The hospital and BLS proportions of the blended wage index are 40 percent and 60 percent. The actual wage index values and MSA/non-MSA designations currently used in connection with the composite rates were published in the August 15, 1986 **Federal Register** (51 FR 29412–29417). For the reasons discussed below, we have decided not to propose any changes to the current wage index adjustments at this time.

On June 6, 2003, OMB issued Bulletin 03–04 that announced new MSAs and two new sets of statistical areas, Micropolitan Statistical Areas and Combined Statistical Areas (CSAs). We recognize that the new OMB definitions will have implications for the various payment systems we administer that reflect payment distinctions based on geographic location. Any changes adopted will not only result in payment redistributions among ESRD facilities, but will also affect hospitals, home health agencies, skilled nursing facilities, and rehabilitation providers.

Therefore, it is essential that we evaluate any proposals to revise the area definitions and assess the impact of changes in geographical areas on those payment systems that incorporate adjusters for area wage levels among urban and rural locations.

Although the MMA gives the Secretary discretion to revise the outdated wage indexes used in the composite rates, we believe that we should take no action to replace them with revised measures pending completion of our assessments.

Therefore, we are proposing to take no action at this time to revise the current set of composite rate wage indexes and the urban and rural definitions used to develop them. Once revisions to the urban and rural definitions are adopted, we may be in a better position to propose revisions to the geographic adjustments applied to the case-mix adjusted composite payment rates.

For purposes of applying the required geographic adjustments to the case-mix adjusted composite rate payment system, we are proposing to continue using the wage index values and urban and rural designations that are currently applied to the composite payment rates.

Section 1881(b)(12)(E)(i) of the Act, as added by section 623(d)(1) of the MMA, requires that the basic case-mix adjusted composite rate system be designed to result in the same aggregate amount of expenditure for such services, as estimated by the Secretary, as would have been made for 2005 if that paragraph did not apply. Therefore, the drug add-on adjustment and the patient characteristics case-mix adjustment required by section 623(d)(1) of the MMA must result in the same aggregate expenditures for 2005 as if these adjustments were not made.

With respect to the drug payment add-on adjustment the total estimated difference between the current drug payment based on 95 percent of AWP and the payment amount generated from payment based on ASP minus 3 percent is reflected in the proposed adjustment which is designed so that aggregate

payments are budget neutral. (See section H.4.c.2. of this proposed rule for more detailed explanation of drug add-on adjustment).

In order to account for the payment effect related to the case-mix adjustment, we standardized the composite rate by dividing the rate by the average case-mix modifier of 1.1919. (See section 4.ii Proposed Cormorbidity Adjustments). The resulting adjustment to the composite rate is .8390. However, we were not able to simulate the case-mix effects from the ESRD billing file because comorbidities are generally not included on the ESRD bill. (See section H.3. of this proposed rule for the discussion of the data issues.) We propose to refine our adjustments for case-mix once we have more complete data on the ESRD bill.

*F. Payment Exceptions and the Revised Composite Payment Rates*

Before the enactment of BIPA, an ESRD facility could apply for and receive prospective adjustments or exceptions to its otherwise applicable composite payment rate under specified circumstances. Section 1881(b)(7) of the Act and § 413.182 contain the statutory and regulatory authorities for the provision of exceptions to the composite payment rates. Section 422(a)(2) of BIPA prohibited the granting of new exceptions to the composite payment rates on or after December 31, 2000, except under very limited circumstances, which expired July 1, 2001. That prohibition remains in effect, with one exception. Section 623(b) of the MMA amended section 422(a)(2) of BIPA to afford pediatric facilities the opportunity to seek exceptions provided they did not have an exception rate in effect as of October 1, 2002. The statute defines a pediatric facility as a renal facility, 50 percent of whose patients are under age 18. On April 1, 2004, we opened an exception window for pediatric facilities. The exception window closes September 27, 2004.

Section 422(a)(2)(C) of BIPA provided that any ESRD composite rate exception in effect on December 31, 2000 would continue as long as the exception rate exceeds the applicable composite payment rate. The MMA did not revise that provision. Comparisons of a provider's exception rate and the standard composite payment rate are straightforward, because each payment rate was applied on a facility specific basis, without any adjustments for case-mix. However, in this proposed rule, we are proposing revised composite payment rates that are case-mix adjusted. The wage adjusted composite payment rates listed for each urban and rural area noted in Tables I and II at the end of this section, although applied on a per treatment basis, are subject to case mix adjustments in accordance with section 623(d)(1) of the MMA. The proposed methodology for applying patient characteristic adjusters applicable to each treatment will determine the case-mix adjustment which will vary for each patient. Thus, an ESRD facility's average composite rate per treatment will depend on its unique case mix.

Our policy was not to increase any ESRD facility's exception rate when there has been a congressionally mandated update to the ESRD composite payment rates. When computing an exception amount, we take into consideration the ESRD facility's patient population and the higher costs relating to the patient mix. Since ESRD facilities can maintain their current exception rates, we would expect them to compare the exception rate to the basic case-mix adjusted composite rate to determine the best payment rate for their facility. We are proposing to allow each dialysis facility the option of continuing to be paid at its exception rate or at the basic case-mix adjusted composite rate (which includes all the MMA 623 payment adjustments). If the facility retains its exception rate, it would not be subject to any of the adjustments specified in section 623 of the MMA. Whether a provider's exception rate in effect on December 31, 2000 will exceed its average case-mix adjusted composite payment rate is impossible for us to accurately determine. We believe that projections as to whether an ESRD facility's exception rate per treatment will exceed its average case-mix adjusted composite rate per treatment are best left to the entities affected. Therefore, we are proposing that each ESRD facility with composite rate exceptions currently in effect, and each pediatric ESRD facility granted an exception, must notify its fiscal intermediary in writing if it wishes to withdraw its exception and be subject to the basic case-mix adjusted composite payment rate methodology set forth in this notice.

We are proposing to allow an ESRD facility to notify its fiscal intermediary at any time if it wishes to give up its exception rate. Once a facility has notified its fiscal intermediary of its election to give up its exception rate, it would lose that exception rate, regardless of basis or amount, and be subject to the proposed case-mix adjusted composite payment rates beginning 30 days after the intermediary's receipt of the facility's notification letter. Facilities with exception rates will be required to notify their fiscal intermediaries only if they wish to forego their exceptions. ESRD facilities electing to retain their exceptions do not need to notify their intermediaries. ESRD facilities without exceptions, of course, will be subject to the composite payment rates determined using the basic case-mix methodology described in this notice beginning January 1, 2005.

*G. Summary of Composite Rate Revisions and Proposed Implementation*

As set forth in this proposed rule, we will increase the ESRD composite payment rates by 1.6 percent effective January 1, 2005 in accordance with section 623(a) of the MMA. Also, the composite payment rates will be increased to reflect revisions to the drug pricing methodology for separately billable drugs, as discussed in section H.4.b. of this proposed rule. That increase represents the spread or difference between the payment amounts for separately billable drugs and biologicals and their acquisition costs based on the OIG's May 2004 report to the Secretary. The development and computation of the drug add-on adjustment are described in section H.4.c of this proposed rule. We have also proposed a basic case-mix methodology for adjusting the composite payment rates based on a limited number of patient characteristics, as prescribed in section 623(d) of the MMA. The development and application of the case-mix adjusters are explained in section H.4.d.4 of this proposed rule. The MMA requires that the basic case-mix adjusted composite payment rates be effective for services furnished beginning January 1, 2005. Despite the law's specificity with respect to effective date, the systems and operational changes necessary to apply the case-mix adjusters cannot be completed in time for a prospective January 1, 2005 effective date.

The 1.6 percent statutory increase and 11.3 drug add-on for independent and hospital-based facilities for separately billable drugs will be applied to the composite rates for all ESRD facilities beginning January 1, 2005. However, the computation of the case mix adjusters depends on age, sex, and specific comorbidities which must be obtained from the bills for each ESRD facility. Therefore, the combination of case-mix adjusters used to increase a provider's otherwise applicable composite payment rate depends on a provider's unique patient profile and is facility-specific. The correct computation of these facility-specific case-mix adjusters will require numerous programming,

systems, billing, and instructional changes by us, fiscal intermediaries, and system maintainers. In addition, providers and their fiscal intermediaries will require education and training not only on the basic features of the new ESRD PPS, but also on the proper reporting of patient and clinical information on the bills, essential for an accurate case mix adjustment in connection with each patient's claims.

Given these requirements, the lead time necessary for systems changes, and the anticipated time necessary for providers and their fiscal intermediaries to familiarize themselves with and correctly apply the basic case-mix adjustments, we are proposing an April 1, 2005 effective date.

As an alternative to an April 1, 2005 effective date for the patient characteristic case mix adjustments, we considered two options for an April 1, 2005 prospective implementation date that would effectively comply with the MMA's January 1, 2005 effective date. Under the first option, we would implement the patient characteristic adjustments on April 1, 2005 and reprocess bills and adjust payments to January 1, 2005. Under this option, the budget neutrality adjustment related to the patient characteristic factors would not be applied to the composite rate until bills are reprocessed.

The second option that we considered was to make payment to facilities starting January 1, 2005, at the budget neutralized composite rate, until the systems changes for the case-mix adjustment can be implemented, April 1, 2005. Payment at this rate would avoid overpayments, and thus, the need to recoup moneys that may occur when we retroactively process the claims for case-mix adjustments on April 1, 2005. Under this option, facilities would receive approximately 16 percent less than they would otherwise be entitled to on January 1, 2005.

We rejected both of these alternatives. Both options require the reprocessing and adjustment of bills for the first quarter of 2005. In addition, because of the likelihood of payment error due to the complexity of the process and costly implementation and potential disruption of payment to ESRD facilities, we believe that these options are problematic. Given that the expected impact of the patient characteristic adjustments on ESRD facility payments will, for the most part, be minimal, we believe that applying the adjustments prospectively from April 1, 2005 provides a smoother transition to the new payment methodology.

Finally, this notice provides for a budget neutrality reduction of .8390 percent to the case-mix adjusted composite payment rates. Our budget neutrality methodology is explained in section H.4.f. of this proposed rule. Because section 623(d) of the MMA requires that budget neutrality be applied in the context of implementing the case-mix adjusted composite rate payment system, we are proposing that the effective date of the budget neutrality adjustment should also be April 1, 2005. If we applied the budget neutrality adjustment in January, rather than when the case-mix adjustment is applied in April, the result would be that all the composite rates would go down.

We are specifically soliciting comments on these options of the proposed rule. However, the 1.6 percent statutory increase to the composite payment rates, and the drug add-on for separately billable drugs, will be effective January 1, 2005, as these adjustments are easily implemented prospectively.

## IV. Example of Payment Calculation Under the Proposed Case-Mix Adjusted Composite Rate System

The following example presents 2 patients dialyzing at Neighbor Dialysis, an independent facility in Baltimore, MD. Patient #1, John Smith, is a 71-year old male who has been diagnosed with PVD and AIDS. Patient #2, Jane Doe, is a 59-year old female who has been diagnosed with PVD.

Calculation of Basic Composite Rate for Neighbor Dialysis

Wage adjusted Composite Rate for independent facilities in Baltimore, Md. (Table I): $134.93

Wage adjusted Composite Rate increased by proposed drug add-on adjustment ($134.93 x 1.113): $150.18

Adjusted Facility Composite Rate after budget neutrality (150.18 x .8490): $126.00

Calculation of Case-mix Adjusted Payments

Patient #1—John Smith:

Male age 65–79 years: 1.17

AIDS: 1.15

PVD: 1.07

Case-mix adjusted rate for John Smith ($126.00 x 1.17 x 1.15 x 1.07): $181.40

Patient #2—Jane Doe:

Female age < 65 years: 1.11

PVD: 1.07

Case-mix adjusted rate for Jane Doe ($126.00 x 1.11 x 1.07): $149.65

TABLE 18.—COMPOSITE PAYMENT RATES EFFECTIVE JANUARY 1, 2005

[For urban renal facilities]

| MSA code | Name of MSA | State | Hospital | Independent |
|---|---|---|---|---|
| 0040 | ABILENE | TX | 127.58 | 123.18 |
| 0060 | AGUADILLA | PR | 127.57 | 123.18 |
| 0080 | AKRON | OH | 137.39 | 133.68 |
| 0120 | ALBANY | GA | 127.57 | 123.18 |
| 0160 | ALBANY-SCHENECTADY-TROY | NY | 129.93 | 125.70 |
| 0200 | ALBUQUERQUE | NM | 135.60 | 131.77 |
| 0220 | ALEXANDRIA | LA | 129.70 | 125.46 |
| 0240 | ALLENTOWN-BETHLEHEM | PA-NJ | 134.75 | 130.87 |
| 0280 | ALTOONA | PA | 133.79 | 129.84 |
| 0320 | AMARILLO | TX | 130.03 | 125.80 |
| 0360 | ANAHEIM-SANTA ANA | CA | 145.72 | 142.64 |
| 0380 | ANCHORAGE | AK | 146.35 | 146.35 |
| 0400 | ANDERSON | IN | 131.74 | 127.63 |
| 0405 | ANDERSON | SC | 127.57 | 123.18 |
| 0440 | ANN ARBOR | MI | 145.80 | 142.71 |
| 0450 | ANNISTON | AL | 127.57 | 123.18 |
| 0460 | APPLETON-OSHKOSH-NEENAH | WI | 132.60 | 128.56 |
| 0470 | ARECIBO | PR | 127.57 | 123.18 |
| 0480 | ASHEVILLE | NC | 130.57 | 126.39 |
| 0500 | ATHENS | GA | 127.57 | 123.18 |

TABLE 18.—COMPOSITE PAYMENT RATES EFFECTIVE JANUARY 1, 2005—Continued

[For urban renal facilities]

| MSA code | Name of MSA | State | Hospital | Independent |
|---|---|---|---|---|
| 0520 | ATLANTA | GA | 130.07 | 125.84 |
| 0560 | ATLANTIC CITY | NJ | 134.72 | 130.82 |
| 0600 | AUGUSTA | GA-SC | 130.08 | 125.85 |
| 0620 | AURORA-ELGIN | IL | 140.21 | 136.70 |
| 0640 | AUSTIN | TX | 135.14 | 131.29 |
| 0680 | BAKERSFIELD | CA | 141.64 | 138.25 |
| 0720 | BALTIMORE | MD | 138.55 | 134.93 |
| 0733 | BANGOR | ME | 129.34 | 125.09 |
| 0760 | BATON ROUGE | LA | 131.80 | 127.71 |
| 0780 | BATTLE CREEK | MI | 134.05 | 130.11 |
| 0840 | BEAUMONT-PORT ARTHUR | TX | 130.85 | 126.67 |
| 0845 | BEAVER COUNTY | PA | 138.52 | 134.89 |
| 0860 | BELLINGHAM | WA | 132.87 | 128.85 |
| 0870 | BENTON HARBOR | MI | 127.57 | 123.18 |
| 0875 | BERGEN-PASSAIC | NJ | 142.22 | 140.71 |
| 0880 | BILLINGS | MT | 132.16 | 128.08 |
| 0920 | BILOXI-GULFPORT | MS | 127.57 | 123.18 |
| 0960 | BINGHAMTON | NY | 130.00 | 125.77 |
| 1000 | BIRMINGHAM | AL | 131.83 | 127.73 |
| 1010 | BISMARCK | ND | 130.64 | 126.47 |
| 1020 | BLOOMINGTON | IN | 129.78 | 125.54 |
| 1040 | BLOOMINGTON-NORMAL | IL | 129.69 | 125.45 |
| 1080 | BOISE CITY | ID | 135.23 | 131.39 |
| 1123 | BOSTON-SALEM-BROCKTON | MA | 139.45 | 135.89 |
| 1125 | BOULDER-LONGMONT | CO | 140.62 | 137.15 |
| 1140 | BRADENTON | FL | 128.79 | 124.47 |
| 1145 | BRAZORIA | TX | 134.02 | 130.08 |
| 1150 | BREMERTON | WA | 129.14 | 124.87 |
| 1163 | BRIDGEPORT-NORWALK-DANBURY | CT | 141.49 | 138.08 |
| 1240 | BROWNSVILLE-HARLINGEN | TX | 129.79 | 125.56 |
| 1260 | BRYAN-COLLEGE STATION | TX | 128.68 | 124.37 |
| 1280 | BUFFALO | NY | 133.55 | 129.59 |
| 1300 | BURLINGTON | NC | 127.57 | 123.18 |
| 1303 | BURLINGTON | VT | 131.37 | 127.24 |
| 1310 | CAGUAS | PR | 127.57 | 123.18 |
| 1320 | CANTON | OH | 131.51 | 127.40 |
| 1350 | CASPER | WY | 136.29 | 132.52 |
| 1360 | CEDAR RAPIDS | IA | 131.05 | 126.92 |
| 1400 | CHAMPAIGN-URBANA-RANTOUL | IL | 133.39 | 129.39 |
| 1440 | CHARLESTON | SC | 131.44 | 127.33 |
| 1480 | CHARLESTON | WVA | 135.86 | 132.06 |
| 1520 | CHARLOTTE-ROCK HILL | NC-SC | 129.79 | 125.57 |
| 1540 | CHARLOTTESVILLE | VA | 133.15 | 129.15 |
| 1560 | CHATTANOOGA | TN-GA | 132.45 | 128.39 |
| 1580 | CHEYENNE | WY | 131.21 | 127.06 |
| 1600 | CHICAGO | IL | 142.79 | 139.48 |
| 1620 | CHICO | CA | 139.53 | 135.98 |
| 1640 | CINCINNATI | OH-KY-IN | 137.22 | 133.50 |
| 1660 | CLARKSVILLE-HOPKINSVILLE | TN-KY | 127.57 | 123.18 |
| 1680 | CLEVELAND | OH | 141.66 | 138.27 |
| 11720 | COLORADO SPRINGS | CO | 135.83 | 132.03 |
| 1740 | COLUMBIA | MO | 140.08 | 136.56 |
| 1760 | COLUMBIA | SC | 130.43 | 126.24 |
| 1800 | COLUMBUS | GA-AL | 128.15 | 123.79 |
| 1840 | COLUMBUS | OH | 134.12 | 130.19 |
| 1880 | CORPUS CHRISTI | TX | 131.52 | 127.41 |
| 1900 | CUMBERLAND | MD-WVA | 128.22 | 123.87 |
| 1920 | DALLAS | TX | 134.47 | 130.56 |
| 1950 | DANVILLE | VA | 127.57 | 123.18 |
| 1960 | DAVENPORT-MOLINE | IA-IL | 133.12 | 129.11 |
| 2000 | DAYTON-SPRINGFIELD | OH | 137.82 | 134.14 |
| 2020 | DAYTONA BEACH | FL | 127.85 | 123.47 |
| 2030 | DECATUR | AL | 127.57 | 123.18 |
| 2040 | DECATUR | IL | 131.69 | 127.57 |
| 2080 | DENVER | CO | 143.60 | 140.35 |
| 2120 | DES MOINES | IA | 135.21 | 131.36 |
| 2160 | DETROIT | MI | 143.03 | 139.73 |
| 2180 | DOTHAN | AL | 127.57 | 123.18 |
| 2200 | DUBUQUE | IA | 132.63 | 128.61 |
| 2240 | DULUTH | MN-WI | 130.10 | 125.88 |
| 2290 | EAU CLAIRE | WI | 128.84 | 124.53 |

TABLE 18.—COMPOSITE PAYMENT RATES EFFECTIVE JANUARY 1, 2005—Continued

[For urban renal facilities]

| MSA code | Name of MSA | State | Hospital | Independent |
|---|---|---|---|---|
| 2320 | EL PASO | TX | 128.41 | 124.08 |
| 2330 | ELKHART-GOSHEN | IN | 129.30 | 125.01 |
| 2335 | ELMIRA | NY | 132.63 | 128.60 |
| 2340 | ENID | OK | 129.51 | 125.24 |
| 2360 | ERIE | PA | 131.82 | 127.74 |
| 2400 | EUGENE-SPRINGFIELD | OR | 133.37 | 129.37 |
| 2440 | EVANSVILLE | IN-KY | 134.10 | 130.16 |
| 2520 | FARGO-MOORHEAD | ND-MN | 133.83 | 129.88 |
| 2560 | FAYETTEVILLE | NC | 127.57 | 123.18 |
| 2580 | FAYETTEVILLE-SPRINGDALE | AR | 127.57 | 123.18 |
| 2640 | FLINT | MI | 141.83 | 138.45 |
| 2650 | FLORENCE | AL | 127.57 | 123.18 |
| 2655 | FLORENCE | SC | 127.57 | 123.18 |
| 2670 | FORT COLLINS-LOVELAND | CO | 131.49 | 127.38 |
| 2680 | FT LAUDERDALE-POMPANO BEACH | FL | 137.23 | 133.51 |
| 2700 | FORT MYERS-CAPE CORAL | FL | 129.73 | 125.49 |
| 2710 | FORT PIERCE | FL | 130.09 | 125.87 |
| 2720 | FORT SMITH | AR-OK | 128.97 | 124.67 |
| 2750 | FORT WALTON BEACH | FL | 127.57 | 123.18 |
| 2760 | FORT WAYNE | IN | 129.32 | 125.05 |
| 2800 | FORT WORTH-ARLINGTON | TX | 133.06 | 129.04 |
| 2840 | FRESNO | CA | 142.09 | 138.72 |
| 2880 | GADSDEN | AL | 128.48 | 124.17 |
| 2900 | GAINESVILLE | FL | 130.25 | 126.06 |
| 2920 | GALVESTON-TEXAS CITY | TX | 137.86 | 134.20 |
| 2960 | GARY-HAMMOND | IN | 138.47 | 134.85 |
| 2975 | GLENS FALLS | NY | 128.98 | 124.68 |
| 2985 | GRAND FORKS | ND | 129.26 | 124.98 |
| 3000 | GRAND RAPIDS | MI | 133.41 | 129.44 |
| 3040 | GREAT FALLS | MT | 132.09 | 128.01 |
| 3060 | GREELEY | CO | 134.34 | 130.43 |
| 3080 | GREEN BAY | WI | 133.34 | 129.33 |
| 3120 | GREENSBORO-WINSTON SALEM-HIGH PT | NC | 129.67 | 125.42 |
| 3160 | GREENVILLE-SPARTANBURG | SC | 130.15 | 125.95 |
| 3180 | HAGERSTOWN | MD | 132.79 | 128.78 |
| 3200 | HAMILTON-MIDDLETOWN | OH | 134.87 | 130.98 |
| 3240 | HARRISBURG-LEBANON-CARLISLE | PA | 133.92 | 129.97 |
| 3283 | HARTFORD-NEW BRITAIN-BRISTOL | CT | 140.38 | 136.90 |
| 3290 | HICKORY | NC | 127.57 | 123.18 |
| 3320 | HONOLULU | HI | 141.73 | 138.34 |
| 3350 | HOUMA-THIBODAUX | LA | 128.02 | 123.66 |
| 3360 | HOUSTON | TX | 137.24 | 133.53 |
| 3400 | HUNTINGTON-ASHLAND | WVA-KY-OH | 130.11 | 125.88 |
| 3440 | HUNTSVILLE | AL | 127.57 | 123.18 |
| 3480 | INDIANAPOLIS | IN | 135.16 | 131.30 |
| 3500 | IOWA CITY | IA | 143.23 | 140.37 |
| 3520 | JACKSON | MI | 134.43 | 130.53 |
| 3560 | JACKSON | MS | 128.82 | 124.51 |
| 3580 | JACKSON | TN | 127.57 | 123.18 |
| 3600 | JACKSONVILLE | FL | 130.77 | 126.58 |
| 3605 | JACKSONVILLE | NC | 127.75 | 123.37 |
| 3620 | JANESVILLE-BELOIT | WI | 128.39 | 124.05 |
| 3640 | JERSEY CITY | NJ | 138.46 | 134.84 |
| 3660 | JOHNSON CITY-BRISTOL | TN-VA | 127.57 | 123.18 |
| 3680 | JOHNSTOWN | PA | 133.36 | 129.36 |
| 3690 | JOLIET | IL | 140.66 | 137.19 |
| 3710 | JOPLIN | MO | 127.97 | 123.61 |
| 3720 | KALAMAZOO | MI | 143.25 | 139.98 |
| 3740 | KANKAKEE | IL | 130.84 | 126.66 |
| 3760 | KANSAS CITY | MO-KS | 133.22 | 129.21 |
| 3800 | KENOSHA | WI | 137.39 | 133.69 |
| 3810 | KILLEEN-TEMPLE | TX | 128.12 | 123.75 |
| 3840 | KNOXVILLE | TN | 127.83 | 123.45 |
| 3850 | KOKOMO | IN | 132.39 | 128.34 |
| 3870 | LA CROSSE | WI | 131.00 | 126.87 |
| 3880 | LAFAYETTE | LA | 132.84 | 128.83 |
| 3920 | LAFAYETTE | IN | 128.65 | 124.33 |
| 3960 | LAKE CHARLES | LA | 130.17 | 125.97 |
| 3965 | LAKE COUNTY | IL | 141.41 | 137.98 |
| 3980 | LAKELAND-WINTER HAVEN | FL | 127.57 | 123.18 |
| 4000 | LANCASTER | PA | 135.38 | 131.54 |

TABLE 18.—COMPOSITE PAYMENT RATES EFFECTIVE JANUARY 1, 2005—Continued

[For urban renal facilities]

| MSA code | Name of MSA | State | Hospital | Independent |
|---|---|---|---|---|
| 4040 | LANSING-EAST LANSING | MI | 135.98 | 132.18 |
| 4080 | LAREDO | TX | 127.57 | 123.18 |
| 4100 | LAS CRUCES | NM | 127.57 | 123.18 |
| 4120 | LAS VEGAS | NV | 141.01 | 137.58 |
| 4150 | LAWRENCE | KS | 131.82 | 127.73 |
| 4200 | LAWTON | OK | 130.27 | 126.08 |
| 4243 | LEWISTON-AUBURN | ME | 128.39 | 124.06 |
| 4280 | LEXINGTON-FAYETTE | KY | 130.21 | 126.01 |
| 4320 | LIMA | OH | 133.29 | 129.29 |
| 4360 | LINCOLN | NE | 129.96 | 125.72 |
| 4400 | LITTLE ROCK-N LITTLE ROCK | AR | 135.96 | 132.17 |
| 4420 | LONGVIEW-MARSHALL | TX | 127.57 | 123.18 |
| 4440 | LORAIN-ELYRIA | OH | 134.22 | 130.30 |
| 4480 | LOS ANGELES-LONG BEACH | CA | 146.35 | 145.02 |
| 4520 | LOUISVILLE | KY-IN | 134.40 | 130.50 |
| 4600 | LUBBOCK | TX | 129.87 | 125.63 |
| 4640 | LYNCHBURG | VA | 128.00 | 123.63 |
| 4680 | MACON-WARNER ROBINS | GA | 129.46 | 125.19 |
| 4720 | MADISON | WI | 135.45 | 131.63 |
| 4763 | MANCHESTER-NASHUA | NH | 131.20 | 127.04 |
| 4800 | MANSFIELD | OH | 130.40 | 126.20 |
| 4840 | MAYAGUEZ | PR | 127.57 | 123.18 |
| 4880 | MCALLEN-EDINBURG-MISSION | TX | 127.57 | 123.18 |
| 4890 | MEDFORD | OR | 133.00 | 128.99 |
| 4900 | MELBOURNE-TITUSVILLE | FL | 130.19 | 125.99 |
| 4920 | MEMPHIS | TN-AR-MS | 135.10 | 131.23 |
| 4940 | MERCED | CA | 138.45 | 134.83 |
| 5000 | MIAMI-HIALEAH | FL | 138.47 | 134.85 |
| 5015 | MIDDLESEX-HUNTERDON | NJ | 134.87 | 130.99 |
| 5040 | MIDLAND | TX | 135.10 | 131.24 |
| 5080 | MILWAUKEE | WI | 136.75 | 133.02 |
| 5120 | MINNEAPOLIS-ST PAUL | MN-WI | 136.11 | 132.33 |
| 5160 | MOBILE | AL | 129.00 | 124.70 |
| 5170 | MODESTO | CA | 138.05 | 134.41 |
| 5190 | MONMOUTH-OCEAN | NJ | 133.08 | 129.06 |
| 5200 | MONROE | LA | 129.18 | 124.90 |
| 5240 | MONTGOMERY | AL | 130.14 | 125.92 |
| 5280 | MUNCIE | IN | 131.36 | 127.22 |
| 5320 | MUSKEGON | MI | 131.68 | 127.57 |
| 5345 | NAPLES | FL | 130.55 | 126.35 |
| 5360 | NASHVILLE | TN | 132.71 | 128.70 |
| 5380 | NASSAU-SUFFOLK | NY | 146.35 | 144.35 |
| 5403 | NEW BEDFORD-FALL RIVER-ATTELBORO | MA | 131.79 | 127.70 |
| 5483 | NEW HAVEN-WATERBURY-MERIDEN | CT | 137.50 | 133.80 |
| 5523 | NEW LONDON-NORWICH | CT | 137.24 | 133.52 |
| 5560 | NEW ORLEANS | LA | 130.68 | 126.50 |
| 5600 | NEW YORK | NY | 146.35 | 146.35 |
| 5640 | NEWARK | NJ | 141.09 | 137.67 |
| 5700 | NIAGARA FALLS | NY | 130.31 | 126.11 |
| 5720 | NORFOLK-NEWPORT NEWS | VA | 129.67 | 125.42 |
| 5775 | OAKLAND | CA | 146.35 | 145.92 |
| 5790 | OCALA | FL | 128.79 | 124.48 |
| 5800 | ODESSA | TX | 129.63 | 125.38 |
| 5880 | OKLAHOMA CITY | OK | 134.67 | 130.78 |
| 5910 | OLYMPIA | WA | 135.49 | 131.66 |
| 5920 | OMAHA | NE-IA | 132.99 | 128.98 |
| 5950 | ORANGE COUNTY | NY | 132.46 | 128.39 |
| 5960 | ORLANDO | FL | 132.46 | 128.39 |
| 5990 | OWENSBORO | KY | 127.57 | 123.18 |
| 6000 | OXNARD-VENTURA | CA | 146.28 | 145.05 |
| 6015 | PANAMA CITY | FL | 127.57 | 123.18 |
| 6020 | PARKERSBURG-MARIETTA | WVA-OH | 130.89 | 126.73 |
| 6025 | PASCAGOULA | MS | 135.50 | 131.67 |
| 6080 | PENSACOLA | FL | 128.26 | 123.91 |
| 6120 | PEORIA | IL | 136.83 | 133.10 |
| 6160 | PHILADELPHIA | PA-NJ | 141.48 | 138.07 |
| 6200 | PHOENIX | AZ | 137.96 | 134.32 |
| 6240 | PINE BLUFF | AR | 127.57 | 123.18 |
| 6280 | PITTSBURGH | PA | 138.69 | 135.09 |
| 6323 | PITTSFIELD | MA | 133.87 | 129.91 |
| 6360 | PONCE | PR | 127.57 | 123.18 |

TABLE 18.—COMPOSITE PAYMENT RATES EFFECTIVE JANUARY 1, 2005—Continued

[For urban renal facilities]

| MSA code | Name of MSA | State | Hospital | Independent |
|---|---|---|---|---|
| 6403 | PORTLAND | ME | 132.96 | 128.94 |
| 6440 | PORTLAND | OR | 139.91 | 136.40 |
| 6453 | PORTSMOUTH-DOVER-ROCHESTER | NH-ME | 128.29 | 123.95 |
| 6460 | POUGHKEEPSIE | NY | 135.84 | 132.03 |
| 6483 | PROVIDENCE-PAWTUCKET-WOONSOCKET | RI | 134.58 | 130.69 |
| 6520 | PROVO-OREM | UT | 130.42 | 126.22 |
| 6560 | PUEBLO | CO | 137.23 | 133.52 |
| 6600 | RACINE | WI | 129.52 | 125.26 |
| 6640 | RALEIGH-DURHAM | NC | 132.93 | 128.90 |
| 6660 | RAPID CITY | SD | 128.78 | 124.47 |
| 6680 | READING | PA | 133.16 | 129.15 |
| 6690 | REDDING | CA | 138.98 | 135.39 |
| 6720 | RENO | NV | 144.32 | 142.52 |
| 6740 | RICHLAND-KENNEWICK | WA | 131.96 | 127.89 |
| 6760 | RICHMOND-PETERSBURG | VA | 129.76 | 125.53 |
| 6780 | RIVERSIDE-SAN BERNARDINO | CA | 143.65 | 140.40 |
| 6800 | ROANOKE | VA | 130.33 | 126.13 |
| 6820 | ROCHESTER | MN | 134.23 | 130.31 |
| 6840 | ROCHESTER | NY | 134.50 | 130.60 |
| 6880 | ROCKFORD | IL | 136.62 | 132.85 |
| 6920 | SACRAMENTO | CA | 144.16 | 141.12 |
| 6960 | SAGINAW-BAY CITY-MIDLAND | MI | 138.22 | 134.57 |
| 6980 | ST CLOUD | MN | 129.55 | 125.29 |
| 7000 | ST JOSEPH | MO | 132.19 | 128.12 |
| 7040 | ST LOUIS | MO-IL | 135.07 | 131.21 |
| 7080 | SALEM | OR | 136.70 | 132.96 |
| 7120 | SALINAS-SEASIDE-MONTEREY | CA | 144.09 | 140.88 |
| 7160 | SALT LAKE CITY-OGDEN | UT | 131.27 | 127.13 |
| 7200 | SAN ANGELO | TX | 127.57 | 123.18 |
| 7240 | SAN ANTONIO | TX | 129.30 | 125.03 |
| 7320 | SAN DIEGO | CA | 144.75 | 142.04 |
| 7360 | SAN FRANCISCO | CA | 146.35 | 145.92 |
| 7400 | SAN JOSE | CA | 146.35 | 145.68 |
| 7440 | SAN JUAN | PR | 127.57 | 123.18 |
| 7480 | SANTA BARBARA-LOMPOC | CA | 139.14 | 135.58 |
| 7485 | SANTA CRUZ | CA | 140.64 | 137.18 |
| 7490 | SANTA FE | NM | 129.81 | 125.59 |
| 7500 | SANTA ROSA-PETALUMA | CA | 146.35 | 145.59 |
| 7510 | SARASOTA | FL | 131.98 | 127.90 |
| 7520 | SAVANNAH | GA | 129.72 | 125.48 |
| 7560 | SCRANTON-WILKES BARRE | PA | 133.66 | 129.70 |
| 7600 | SEATTLE | WA | 136.87 | 133.14 |
| 7610 | SHARON | PA | 132.08 | 128.00 |
| 7620 | SHEBOYGAN | WI | 129.28 | 125.01 |
| 7640 | SHERMAN-DENISON | TX | 127.57 | 123.18 |
| 7680 | SHREVEPORT | LA | 133.23 | 129.23 |
| 7720 | SIOUX CITY | IA-NE | 132.47 | 128.40 |
| 7760 | SIOUX FALLS | SD | 130.62 | 126.44 |
| 7800 | SOUTH BEND-MISHAWAKA | IN | 130.13 | 125.92 |
| 7840 | SPOKANE | WA | 138.38 | 134.75 |
| 7880 | SPRINGFIELD | IL | 137.27 | 133.56 |
| 7920 | SPRINGFIELD | MO | 129.48 | 125.21 |
| 8003 | SPRINGFIELD | MA | 133.39 | 129.39 |
| 8050 | STATE COLLEGE | PA | 137.91 | 134.25 |
| 8080 | STEUBENVILLE-WEIRTON | OH-WVA | 131.46 | 127.35 |
| 8120 | STOCKTON | CA | 146.35 | 145.06 |
| 8160 | SYRACUSE | NY | 141.36 | 139.77 |
| 8200 | TACOMA | WA | 136.53 | 132.76 |
| 8240 | TALLAHASSE | FL | 129.91 | 125.67 |
| 8280 | TAMPA-ST PETERSBURG-CLEARWATER | FL | 132.27 | 128.21 |
| 8320 | TERRE HAUTE | IN | 127.57 | 123.18 |
| 8360 | TEXARKANA | TX-AR | 135.59 | 131.75 |
| 8400 | TOLEDO | OH | 140.91 | 137.45 |
| 8440 | TOPEKA | KS | 135.89 | 132.10 |
| 8480 | TRENTON | NJ | 135.66 | 131.82 |
| 8520 | TUCSON | AZ | 134.02 | 130.07 |
| 8560 | TULSA | OK | 133.31 | 129.30 |
| 8600 | TUSCALOOSA | AL | 133.86 | 129.91 |
| 8640 | TYLER | TX | 132.17 | 128.09 |
| 8680 | UTICA-ROME | NY | 130.41 | 126.22 |
| 8720 | VALLEJO-FAIRFIELD-NAPA | CA | 146.35 | 146.18 |

TABLE 18.—COMPOSITE PAYMENT RATES EFFECTIVE JANUARY 1, 2005—Continued

[For urban renal facilities]

| MSA code | Name of MSA | State | Hospital | Independent |
|---|---|---|---|---|
| 8725 | VANCOUVER | WA | 139.12 | 135.53 |
| 8750 | VICTORIA | TX | 127.57 | 123.18 |
| 8760 | VINELAND-MILLVILLE-BRIDGETON | NJ | 132.48 | 128.41 |
| 8780 | VISALIA-PORTERVILLE | CA | 142.02 | 140.48 |
| 8800 | WACO | TX | 127.81 | 123.43 |
| 8840 | WASHINGTON | DC-MD-VA | 141.74 | 138.35 |
| 8920 | WATERLOO-CEDAR FALLS | IA | 129.50 | 125.24 |
| 8940 | WAUSAU | WI | 130.90 | 126.74 |
| 8960 | WEST PALM & DELRAY BEACH | FL | 131.84 | 127.75 |
| 9000 | WHEELING | WVA-OH | 131.83 | 127.74 |
| 9040 | WICHITA | KS | 136.67 | 132.93 |
| 9080 | WICHITA FALLS | TX | 127.57 | 123.18 |
| 9140 | WILLIAMSPORT | PA | 130.24 | 126.04 |
| 9160 | WILMINGTON | DE-NJ-MD | 136.71 | 132.97 |
| 9200 | WILMINGTON | NC | 128.74 | 124.42 |
| 9243 | WORCESTER-LEOMINSTER | MA | 132.43 | 128.37 |
| 9260 | YAKIMA | WA | 132.24 | 128.18 |
| 9280 | YORK | PA | 132.45 | 128.39 |
| 9320 | YOUNGSTOWN-WARREN | OH | 137.25 | 133.54 |
| 9340 | YUBA CITY | CA | 137.02 | 133.29 |

TABLE 19.—COMPOSITE PAYMENT RATES EFFECTIVE JANUARY 1, 2005

[For rural renal facilities]

| MSA Code | Name of MSA | State | Hospital | Independent |
|---|---|---|---|---|
| AL | ALABAMA | AL | 127.57 | 123.18 |
| AK | ALASKA | AK | 146.35 | 146.35 |
| AZ | ARIZONA | AZ | 128.68 | 124.35 |
| AR | ARKANSAS | AR | 127.57 | 123.18 |
| CA | CALIFORNIA | CA | 137.00 | 133.27 |
| CO | COLORADO | CO | 128.21 | 123.86 |
| CT | CONNECTICUT | CT | 136.02 | 132.22 |
| DE | DELAWARE | DE | 128.76 | 124.44 |
| FL | FLORIDA | FL | 127.75 | 123.37 |
| GA | GEORGIA | GA | 127.57 | 123.18 |
| HI | HAWAII | HI | 140.40 | 136.92 |
| ID | IDAHO | ID | 127.83 | 123.45 |
| IL | ILLINOIS | IL | 127.57 | 123.18 |
| IN | INDIANA | IN | 127.57 | 123.18 |
| IA | IOWA | IA | 127.57 | 123.18 |
| KS | KANSAS | KS | 127.57 | 123.18 |
| KY | KENTUCKY | KY | 127.57 | 123.18 |
| LA | LOUISIANA | LA | 127.57 | 123.18 |
| ME | MAINE | ME | 127.57 | 123.18 |
| MD | MARYLAND | MD | 130.27 | 126.08 |
| MA | MASSACHUSETTS | MA | 135.99 | 132.19 |
| MI | MICHIGAN | MI | 132.98 | 128.97 |
| MN | MINNESOTA | MN | 127.57 | 123.18 |
| MS | MISSISSIPPI | MS | 127.57 | 123.18 |
| MO | MISSOURI | MO | 127.57 | 123.18 |
| MT | MONTANA | MT | 127.87 | 123.50 |
| NE | NEBRASKA | NE | 127.57 | 123.18 |
| NV | NEVADA | NV | 133.20 | 129.20 |
| NH | NEW HAMPSHIRE | NH | 132.24 | 128.18 |
| NM | NEW MEXICO | NM | 128.68 | 124.36 |
| NY | NEW YORK | NY | 127.78 | 123.40 |
| NC | NORTH CAROLINA | NC | 127.57 | 123.18 |
| ND | NORTH DAKOTA | ND | 127.70 | 123.31 |
| OH | OHIO | OH | 128.66 | 124.34 |
| OK | OKLAHOMA | OK | 127.57 | 123.18 |
| OR | OREGON | OR | 132.66 | 128.64 |
| PA | PENNSYLVANIA | PA | 132.54 | 128.48 |
| PR | PUERTO RICO | PR | 127.57 | 123.18 |
| RI | RHODE ISLAND | RI | 130.86 | 126.69 |
| SC | SOUTH CAROLINA | SC | 127.57 | 123.18 |
| SD | SOUTH DAKOTA | SD | 127.57 | 123.18 |
| TN | TENNESSEE | TN | 127.57 | 123.18 |
| TX | TEXAS | TX | 127.57 | 123.18 |

TABLE 19.—COMPOSITE PAYMENT RATES EFFECTIVE JANUARY 1, 2005—Continued

[For rural renal facilities]

| MSA Code | Name of MSA | State | Hospital | Independent |
|---|---|---|---|---|
| UT | UTAH | UT | 128.56 | 124.24 |
| VT | VERMONT | VT | 127.57 | 123.18 |
| VA | VIRGINIA | VA | 127.57 | 123.18 |
| WA | WASHINGTON | WA | 131.35 | 127.21 |
| WV | WEST VIRGINIA | WV | 128.43 | 124.09 |
| WI | WISCONSIN | WI | 127.57 | 123.18 |
| WY | WYOMING | WY | 131.29 | 127.15 |

TABLE 20.—COMORBIDITIES

| | |
|---|---|
| *AIDS* | |
| 042 | Human immunodeficiency disease |
| *Peripheral vascular disease* | |
| 0400 | Gas gangrene |
| 4151 | Pulmonary embolism and infarction |
| 41511 | Pulmonary embolism and infarction, iatrogenic pulmonary embolism and infarction |
| 440 | Atherosclerosis |
| 4400 | Atherosclerosis of aorta |
| 4401 | Atherosclerosis of renal artery |
| 4402 | Atherosclerosis of native arteries of the extremities |
| 44020 | Atherosclerosis of native arteries of the extremities, unspecified |
| 44021 | Atherosclerosis of native arteries of the extremities, with intermittent claudication |
| 44022 | Atherosclerosis of native arteries of the extremities, with rest pain |
| 44023 | Atherosclerosis of the extremities with ulceration |
| 44024 | Atherosclerosis of the extremities with gangrene |
| 44029 | Atherosclerosis of native arteries of the extremities, with ulceration |
| 4403 | Atherosclerosis of bypass graft of the extremities |
| 44030 | Atherosclerosis of bypass graft of the extremities of unspecified graft |
| 44031 | Atherosclerosis of bypass graft of the extremities of autologous vein bypass graft |
| 44032 | Atherosclerosis of bypass graft of the extremities of nonautologous biological bypass graft |
| 441 | Aortic aneurysm and dissection |
| 4410 | Aortic aneurysm and dissection, dissection of aorta |
| 44100 | Aortic aneurysm and dissection, dissection of aorta, unspecified site |
| 44101 | Aortic aneurysm and dissection, dissection of aorta, thoracic |
| 44102 | Aortic aneurysm and dissection, dissection of aorta, abdominal |
| 44103 | Aortic aneurysm and dissection, dissection of aorta, thoracoabdominal |
| 4411 | Thoracic aneurysm, ruptured |
| 4412 | Thoracic aneurysm without mention of rupture |
| 4413 | Abdominal aneurysm, ruptured |
| 4414 | Abdominal aneurysm without mention of rupture |
| 4415 | Aortic aneurysm of unspecified site, ruptured |
| 4416 | Thoracoabdominal aneurysm, ruptured |
| 4417 | Thoracoabdominal aneurysm without mention of rupture |
| 4419 | Aortic aneurysm and dissection of unspecified site without mention of rupture |
| 442 | Other aneurysm |
| 4420 | Other aneurysm of artery of upper extremity |
| 4421 | Other aneurysm of renal artery |
| 4422 | Other aneurysm of iliac artery |
| 4423 | Other aneurysm of artery of lower extremity |
| 4428 | Other aneurysm of other specified artery |
| 44281 | Other aneurysm of other specified artery, artery of neck |
| 44282 | Other aneurysm of other specified artery, subclavian artery |
| 44283 | Other aneurysm of other specified artery, splenic artery |
| 44284 | Other aneurysm of other specified artery, other visceral artery |
| 44289 | Other aneurysm of other specified artery, other |
| 4429 | Other aneurysm of unspecified site |
| 443 | Other peripheral vascular disease |
| 4430 | Other peripheral vascular disease, Raynaud's syndrome |
| 4431 | Other peripheral vascular disease, thromboangiitis obliterans [Buerger's disease] |
| 4432 | Other peripherovascular diseases, other arterial dissection |
| 44321 | Other peripherovascular diseases, other arterial dissection, dissection of carotid artery |
| 44322 | Other peripherovascular diseases, other arterial dissection, dissection of iliac artery |
| 44323 | Other peripherovascular diseases, other arterial dissection, dissection of renal artery |
| 44324 | Other peripherovascular diseases, other arterial dissection, dissection of vertebral artery |
| 44329 | Other peripherovascular diseases, other arterial dissection, dissection of other artery |
| 4438 | Other peripheral vascular disease, other specified peripheral vascular disease |
| 44381 | Other peripheral vascular disease, other specified peripheral vascular disease, peripheral angiopathy in diseases classified elsewhere |
| 44389 | Other peripheral vascular disease, other specified peripheral vascular disease, other |
| 4439 | Peripheral vascular disease, unspecified |

TABLE 20.—COMORBIDITIES

| | |
|---|---|
| 444 | Arterial embolism and thrombosis |
| 4440 | Arterial embolism and thrombosis, of abdominal aorta |
| 4441 | Arterial embolism and thrombosis, of thoracic aorta |
| 4442 | Arterial embolism and thrombosis, of arteries of the extremities |
| 44421 | Arterial embolism and thrombosis, of arteries of the extremities, upper extremity |
| 44422 | Arterial embolism and thrombosis, of arteries of the extremities, lower extremity |
| 4448 | Arterial embolism and thrombosis, of other specified artery |
| 44481 | Arterial embolism and thrombosis, of other specified artery, upper extremity |
| 44489 | Arterial embolism and thrombosis, of other specified artery, lower extremity |
| 449 | Arterial embolism and thrombosis, of unspecified artery |
| 4450 | Atheroembolism, of extremities |
| 44501 | Atheroembolism, of extremities, upper extremity |
| 44502 | Atheroembolism, of extremities, lower extremity |
| 446 | Polyarteritis nodosa and allied conditions |
| 4460 | Polyarteritis nodosa and allied conditions, polyarteritis nodosa |
| 451 | Phlebitis and thrombophlebitis |
| 4510 | Phlebitis and thrombophlebitis of superficial vessels of lower extremities |
| 4511 | Phlebitis and thrombophlebitis, of deep vessels of lower extremities |
| 45111 | Phlebitis and thrombophlebitis, of deep vessels of lower extremities, femoral vein |
| 45119 | Phlebitis and thrombophlebitis, of deep vessels of lower extremities, other |
| 4512 | Phlebitis and thrombophlebitis, of lower extremities, unspecified |
| 45181 | Phlebitis and thrombophlebitis, of other sites, iliac vein |
| 45182 | Phlebitis and thrombophlebitis, of other sites, of superficial veins of upper extremities |
| 45183 | Phlebitis and thrombophlebitis, of other sites, of deep veins of upper extremities |
| 45184 | Phlebitis and thrombophlebitis, of upper extremities, unspecified |
| 45189 | Phlebitis and thrombophlebitis, other |
| 4519 | Phlebitis and thrombophlebitis, unspecified |
| 453 | Other venous embolism and thrombosis |
| 4530 | Other venous embolism and thrombosis, Budd-Chiari syndrome |
| 4531 | Other venous embolism and thrombosis, Thrombophlebitis migrans |
| 4532 | Other venous embolism and thrombosis of vena cava |
| 4533 | Other venous embolism and thrombosis of renal vein |
| 4538 | Other venous embolism and thrombosis of other specified sites |
| 4539 | Other venous embolism and thrombosis of unspecified site |

*I. Section 731(b)—Coverage for Routine Costs of Category A Clinical Trials*

[If you choose to comment on issues in this section, please include the caption ''Section 731(b)'' at the beginning of your comments.]

Section 1862(m) of the Act, as added by Section 731(b) of the MMA, prohibits the Secretary from excluding payment for the routine costs of care furnished to a Medicare beneficiary participating in a clinical trial of a Category A device based on a determination that such care is not ''reasonable and necessary'' under section 1862(a)(1). In effect, this section authorizes Medicare to cover the routine costs of clinical trials involving Category A devices. Category A (experimental/investigational) devices are defined in § 405.201 as innovative medical devices about which the Food and Drug Administration (FDA) has major questions about safety and effectiveness.

For a trial to qualify for payment of routine costs, it must meet certain criteria established by the Secretary to ensure that the trial conforms to appropriate scientific and ethical standards. Current criteria are established in the National Coverage Determination Manual (CMS Pub. 100–3, Manual section 310.1).

In addition, the MMA established additional criteria for trials initiated before January 1, 2010 to ensure that the devices involved in these trials be intended for use in the diagnosis, monitoring, or treatment of an immediately life-threatening disease or condition. Guidelines for determining if a device meets this requirement will be defined through the NCD process.

Section 411.15(o) currently precludes Medicare payment for Category A devices. We would not revise this section because the MMA does not require Medicare to pay for the cost of the Category A device (as opposed to the cost of routine care associated with the trial of a Category A device).

We are proposing changes to § 405.207. As currently written, this section precludes coverage of services related to a noncovered device. Since the Category A device is noncovered, we would amend this section to allow coverage of routine care services related to a noncovered Category A device. In addition, we propose language to cross-reference § 405.201 concerning coverage of Category B (nonexperimental/investigational) devices. We would not be changing coverage of Category B devices, but providing consistency by placing information on Category A and Category B devices in the same section.

*J. Section 629—Part B Deductible*

[If you choose to comment on issues in this section, please include the caption ''Section 629'' at the beginning of your comments.]

Section 629 of the MMA provides for regular updates to the Medicare Part B deductible in consideration of inflationary changes in the nation's economy. Since 1991, the Medicare Part B deductible has been $100 per year. The MMA stipulates that the Medicare Part B deductible will be $110 for calendar year 2005, and, for a subsequent year, the deductible will be the previous year's deductible increased by the annual percentage increase in the monthly actuarial rate under section 1839(a)(1) of the Act, ending with that subsequent year (rounded to the nearest dollar). Section 1839(a)(1) of the Act requires the Secretary of Health and Human Services to calculate the monthly actuarial rate for Medicare enrollees age 65 and over.

We propose to update § 410.160(f), ''Amount of the Part B annual deductible,'' to conform to the MMA and to reflect that the Medicare Part B deductible is $100 for calendar years

1991 through 2004. Finally, we plan to publish an annual notification in the **Federal Register**, announcing each upcoming year's Part B deductible. This notification for the Part B deductible will be included as part of the annual notice we currently publish announcing Medicare's Part B premiums and actuarial rates.

*K. Section 512—Hospice Consultation*

[If you choose to comment on issues in this section, please include the caption ''Section 512'' at the beginning of your comments.]

1. Coverage of Hospice Consultation Services

Effective January 1, 2005, section 512 of the MMA provides for payment to be made to a hospice for specified services furnished by a physician who is either the medical director of or employee of a hospice agency. Payment will be made on behalf of a beneficiary who is terminally ill (which is defined as having a prognosis of 6 months or less if the disease or illness runs its normal course), has not made a hospice election, and has not previously received the pre-election hospice services specified in section 1812(a)(1)(5) of the Act as added by section 512 of the MMA. These services comprise an evaluation of an individual's need for pain and symptom management, counseling the individual regarding hospice and other care options, and may include advising the individual regarding advanced care planning.

The decision to elect hospice services is a personal choice and is generally a decision made between the individual and his or her physician (probably the physician making the terminal diagnosis). Therefore, we believe that most individuals will seek this type of service from their own physician. Thus, we do not expect that the services of a hospice physician would be necessary for all individuals who elect hospice. However, a beneficiary, or his/her physician may seek the expertise of a hospice medical director or physician employee of a hospice to assure that a beneficiary's end-of-life options for care and pain management are discussed and evaluated.

Currently, beneficiaries are able to receive this evaluation, pain management, counseling, and advice through other Medicare benefits. For example, physicians, typically those who determine the beneficiary's terminal diagnoses, can provide for these evaluation and management services as well as for pain and symptom management under the physician fee schedule. Beneficiaries may also obtain assistance with decisions pertaining to end-of life issues through discharge planning in hospitals and through services of social workers, case managers, and other health care professionals. To the extent that beneficiaries have already received Medicare-covered evaluation and counseling with respect to end-of-life care, the hospice evaluation and counseling would seem duplicative. We intend to monitor data regarding these services to assess whether Medicare is paying for duplicative services.

We are proposing to cover the services described above for a terminally ill beneficiary, at the request of the beneficiary or the beneficiary's physician. The service would, in accordance with the statute, be available on a one-time basis to a beneficiary who has not elected or previously used the hospice benefit, but who might benefit from evaluation and counseling with a hospice physician regarding the beneficiary's decision-making process or to provide recommendations for pain and symptom management. Since the beneficiary or his/her physician decides to obtain this service from the hospice medical director or physician employee, the evaluation and counseling service may not be initiated by the hospice, that is, the entity receiving payment for the service.

The statute specifies that payment will be made to the hospice when the physician providing the service is an employee physician or medical director of a hospice. Therefore, other hospice personnel, such as nurse practitioners, nurses, or social workers, cannot furnish the services. The statute requires the physicians to be employed by a hospice; therefore, the service cannot be furnished by a physician under contractual arrangements with the hospice or by the beneficiary's physician, if that physician is not an employee of the hospice. Moreover, if the beneficiary's physician is also the medical director or physician employee of a hospice, that physician already possesses the expertise necessary to furnish end-of-life evaluation, management, and counseling services and is providing these services to the beneficiary and is receiving payment for these services through the use of evaluation and management (E&M) codes.

In the event that the individual's physician initiates the request for services of the hospice medical director or physician, we would expect that appropriate documentation guidelines would be followed. The request or referral would be in writing, and the hospice medical director or employee physician would be expected to provide a written note on the patient's medical chart. The hospice employee physician providing these services would be required to maintain a written record of this service. If the beneficiary initiates the services, we would expect that the hospice agency would maintain a written record of the service and that communication between the hospice medical director or physician and the beneficiary's physician would occur, with the beneficiary's permission, to the extent necessary to ensure continuity of care.

We propose to add new § 418.205 and § 418.304(d) to implement section 512 of the MMA.

2. Payment for Hospice Consultation Services

Section 512(b) of the MMA amends section 1414(i) of the Act and establishes payment for this service at an amount ''equal to an amount established for an office or other outpatient visit for evaluation and management associated with presenting problems of moderate severity and requiring medical decision-making of low complexity under the physician fee schedule, other than the portion of such amount attributable to the practice expense component.'' No existing CPT or HCPCS code specifically represents these services. We are proposing to establish a new HCPCS code, G0xx4 *Hospice—evaluation and counseling services, pre-election*. The hospice would use this HCPCS code to submit claims to the Regional Home Health Intermediary (RHHI) for payment for these services. Utilization of this code would allow us to provide payment for this service as well as enable us to monitor the frequency with which the code is used and to assess whether the code is used appropriately. Payments by hospices to physicians or others in a position to refer patients for services furnished under this provision may implicate the Federal anti-kickback statute.

In accordance with the statute, we are proposing that the payment amount for this service would be based on the work and malpractice expense RVUs for CPT code 99203 multiplied by the CF (1.34 Work RVU + 0.10 Malpractice RVU)* (CF). This CPT code for an office or outpatient visit for the evaluation and management of a new patient represents a detailed history, detailed examination and medical decision making of low complexity, which, we believe, is quite similar to the components of this new service provided by a medical director or physician employed by the hospice

agency. Assuming that there are no changes in RVUs for CPT code 99203 and that the CY 2005 update to the physician fee schedule is the 1.5 percent specified in the MMA, the national payment amount for this service would be $54.57 for this service (1.44 * 37.8975).

*L. Section 302—Clinical Conditions for Coverage of Durable Medical Equipment (DME)*

[If you choose to comment on issues in this section, please include the caption ''Section 302'' at the beginning of your comments.]

1. Legislative Requirement

Section 1832(a)(1)(E) of the Act, as added by section 302(a)(2) of the MMA, requires the Secretary to establish clinical conditions for payment of covered items of durable medical equipment (DME). The law requires the Secretary to establish types or classes of covered items that require a face-to-face examination of the individual by a physician or practitioner and also require a prescription for these items.

Covered items of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) have already been divided into classes of covered items, as established by the local medical review policies (LMRP) and local coverage determinations (LCD) issued by the durable medical equipment regional carriers (DMERCs). For example, the contractors have developed policies on long term home oxygen therapy, canes, crutches, wheelchairs, hospital beds, urological supplies, spinal orthoses, surgical dressing, and enteral and parenteral nutrition therapy. These and other policies for each of the four DMERCs are entered into the Medicare Coverage Database at *http://www.cms.hhs.gov/coverage*.

These policies are developed based on clinical evidence and after discussion with clinical experts in the area. There are already a number of local coverage determinations and national coverage determinations that outline the clinical conditions for which these items are covered. These determinations outline the conditions for coverage, payment, and the documentation or testing necessary to establish medical necessity. We propose to continue developing these clinical conditions of coverage through the local and national coverage determination process.

We are also proposing to expand the requirement for clinical conditions of coverage to medical supplies, appliances and devices defined in 42 CFR 410.36. These are commonly referred to as prosthetics, orthotics and supplies (POS). We believe items of POS require the same level of medical intervention and skill as DME. As with DME, there are already a number of local and national coverage determinations outlining appropriate clinical conditions for coverage and propose to continue this process.

From a clinical perspective, we believe that it is appropriate for beneficiaries requiring DMEPOS to be under the care of a physician and for DMEPOS orders to occur in the context of routine clinical care. We believe it is good clinical practice for the beneficiary to be seen by the physician for their medical condition and the physician to decide whether or not an item of DMEPOS is appropriate during the face-to-face examination of the beneficiary. Since we expect a beneficiary to be seen by their physician for a specific medical condition, we do not believe that a requirement for a face-to-face examination for initial orders and at the time of the prescription renewals for items of continued need (those DMEPOS items where an order is good for only a certain period of time and requires a follow-up examination by the physician) would place a burden on the physician or beneficiary, as it would be part of a necessary examination. We believe this to be the current practice in most cases.

Our goal is to encourage quality care, to mitigate any proliferation of use of these products and ensure that only patients that need items of DMEPOS receive them. To comply with the requirements of section 302(a)(2) of the MMA and to enhance quality and reduce fraud, we would establish basic requirements that apply to all items of durable medical equipment, prosthetics, orthotics, and supplies. We have identified a proliferation of use for some items of DMEPOS and we believe that engaging the physician or practitioner early in the process of ordering DMEPOS will assist us in mitigating any unnecessary proliferation of use.

This regulation proposes to make a face-to-face exam by the physician to determine the medical necessity and ordering an item of DMEPOS an explicit requirement for all initial orders of DMEPOS and at the time of prescription renewal for all DMEPOS continued need items. However, we seek specific comments about whether specific items of DMEPOS should be exempt from the face-to-face examination requirement.

In order for us to verify the medical necessity for an item, the prescribing physician's or practitioner's records must document the need at the time the physician or practitioner examines the beneficiary. For example, a letter to the supplier or to us dated months after the date the examination was conducted and the order was written would not be sufficient verification.

2. Provisions Related to DMEPOS

To implement the provisions of the MMA, we would—

- Establish a requirement for a face-to-face examination by a physician, physician assistant (PA), clinical nurse specialist (CNS), or nurse practitioner (NP), as they are defined in the Act (the prescribing physician or practitioner) to determine the medical necessity of durable medical equipment, orthotics and prosthetics.
- Require that the prescribing physician or practitioner be independent from the DMEPOS supplier and may not be a contractor or an employee of the supplier.
- Establish a requirement that the face-to-face examination should be for the purpose of evaluating and treating the patient's medical condition and not for the sole purpose of obtaining the prescribing physician's or practitioner's order for the DMEPOS. We expect the prescribing physician or practitioner to conduct a sufficient examination of the patient's medical condition to ascertain the appropriate overall treatment plan and to order the DMEPOS as only one aspect of that treatment plan.
- Require an order prior to delivery for all items of durable medical equipment, prosthetics, or orthotics.
- Require that the order be dated and signed within 30 days after the face-to-face examination and include verification of the examination. We are soliciting comments on the appropriate verification process.
- Require the prescribing physician or practitioner to maintain appropriate and timely documentation in the medical records that support the need for all DMEPOS ordered.
- Provide that we would promulgate through contractor instructions other criteria required for payment, such as for prescription renewal requirements, repair, minor revisions and replacement. We are interested in comments on whether the Agency should establish national renewal requirements or permit contractor discretion.
- Provide that we would promulgate through the national coverage determination process or through the local coverage determination process additional clinical conditions for items of DMEPOS.

We propose to revise language in § 410.36 and § 410.38 to implement section 302(a)(2) of the MMA.

*M. Section 614—Payment for Certain Mammography Services*

[If you choose to comment on issues in this section, please include the caption ''Section 614'' at the beginning of your comments.]

Medicare covers an annual screening mammogram for all beneficiaries who are women age 40 and older, and one baseline mammogram for beneficiaries who are women age 35 through 39. Medicare also covers medically necessary diagnostic mammograms. Payment for screening mammography, regardless of setting, is paid under the physician fee schedule, but diagnostic mammography performed in the hospital outpatient department is currently paid under the hospital outpatient prospective payment system (OPPS).

Section 614 of the MMA amended section 1833(t)(1)(B)(iv) of the Act to exclude payment for screening and diagnostic mammograms from the OPPS. In the OPPS proposed rule, we will discuss our proposal for payment for diagnostic mammograms using the payments established under the physician fee schedule. This proposal will parallel the current practice used for the payment of screening mammography services provided in the OPPS setting and will be effective January 1, 2005.

*N. Section 305—Payment for Inhalation Drugs*

[If you choose to comment on issues in this section, please include the caption ''Section 305'' at the beginning of your comments.]

1. Background

Lung diseases such as chronic obstructive pulmonary disease (COPD) affect large numbers of Medicare beneficiaries. COPD is the fourth largest cause of death in America behind heart disease, certain cancers, and stroke. We hope to reduce the number of new COPD cases by educating Americans about the disease, its causes, and ways to prevent it. We hope to improve the lives of Medicare beneficiaries and improve beneficiary access to treatment for those who already suffer from these conditions.

Depending on an individual's age and health, a number of steps can be taken to treat or prevent this. Because approximately 85 percent of those with COPD are smokers, the first step to avoid the disease is to stop smoking. Smoking has been linked to a large number of health problems and is a leading cause of cancer and pulmonary disease. The Department of Health and Human Services (HHS) has been actively encouraging Americans to quit smoking through its smoking cessation initiatives. Americans who quit smoking will enjoy longer, healthier lives and avoid diseases such as COPD.

We have also recently approved services to address the needs of Americans suffering from COPD, including lung-volume reduction surgery, which, performed in more serious cases, removes the diseased lung tissue, allowing the rest of the lung to function better. Specifically, effective January 1, 2004, Medicare expanded coverage of lung volume reduction surgery to include patients, who are not high-risk surgical patients, who either have severe, upper-lobe emphysema, or have severe, non-upper-lobe emphysema with low exercise capacity.

A number of drugs are available to treat the persons with asthma or who develop COPD. These include agents, often inhaled, that expand the bronchial tubes, allowing the patient to breathe more freely. Access to these drugs for Medicare beneficiaries has been expanded by the MMA.

Nebulizers and metered dose inhalers (MDIs) are two different delivery methods to administer inhalation drugs to a beneficiary. A nebulizer works by aerosolizing liquefied inhalation drugs so that the medication can be more easily inhaled into the lungs. For about 10 to 30 minutes, a beneficiary breathes the mist via compressor tubing hooked up to the nebulizer. An MDI consists of a canister of pressurized medication that is propelled directly into the airways of the lungs when a beneficiary presses on the inhaler and breathes in through the mouth, thereby allowing the medicine to take effect quickly.

Medicare Part B currently pays for nebulizers and inhalation drugs. However, Medicare Part B does not cover MDIs and, therefore, does not pay for inhalation drugs delivered by an MDI. An MDI is considered to be an item of disposable medical equipment (for which there is no current Part B benefit category) while a nebulizer is considered to be an item of DME.

The Part D drug benefit improves beneficiary access to inhalation therapy by covering MDIs (including the inhalation drugs they furnish) beginning January 1, 2006. In addition, the prescription drug discount card began offering discounts on MDIs effective June 1, 2004.

Since Medicare currently covers inhalation drugs provided through nebulizers, but not alternative forms of inhalation therapy, there are strong financial incentives toward use of the former compared to alternatives. Our review of the literature over the past decade did not find that bronchodilators delivered via nebulizers were more effective than bronchodilators delivered via metered dose inhalers.

Since one delivery method is not clinically superior to the other, when Medicare covers both methods of delivery of inhalation therapy, the decision to prescribe one over the other will be made by the physician and beneficiary based on beneficiary needs and preferences consistent with applicable standards of medical practice. It would not be unlikely for many beneficiaries to choose the convenience of MDIs over nebulizers once the Medicare coverage imbalance is removed in 2006. Since MDIs are less expensive, very portable, and easier to use, it is likely there will be a substantial shift of Medicare beneficiaries from nebulizers to MDIs beginning in 2006, even absent the Medicare payment changes for nebulizers and inhalation drugs in 2005.

2. What Medicare Part B Currently Covers

Medicare Part B currently covers and pays for five separate items related to nebulizers. All of the items are subject to the standard Part B deductible and coinsurance.

a. Nebulizers

Medicare Part B currently covers the rental of nebulizers. Nebulizers are in the ''capped rental'' category of DME for payment purposes. Payment is made on a monthly basis during the period of medical need. Medicare pays 10 percent of the payment amount during the first three months and 7.5 percent during the next 12 months. Section 1834(a) of the Act specifies that the payment amount is equal to the amount paid for purchase of the nebulizer in 1986, indexed to current levels by the cumulative DME update factor specified in this subsection. Thus, Medicare will pay up to a cumulative total of 120 percent of the payment amount for 15 months of renting a nebulizer.

If the beneficiary needs a nebulizer for more than 15 months, and continues to rent it, Medicare makes no further payment for the equipment because the equipment has already been paid for. Medicare does continue to pay for maintenance and servicing of the nebulizer, as well as the inhalation drugs, but the supplier retains title to the equipment.

During the 10th month of continuous rental of a nebulizer, the supplier is required to offer the beneficiary a purchase option, and if the beneficiary accepts the offer and exercises the

purchase option, the supplier transfers title to the nebulizer in the 13th month. In this case, Medicare would make its final monthly rental payment in the 13th month, and the title then would transfer to the beneficiary. About 3 percent of beneficiaries exercise the purchase option.

In 2003, the average Medicare monthly rental payment for nebulizers was $19.07 for the first three months and $14.30 for the fourth through fifteenth month. Thus, Medicare would pay $228.81 for a nebulizer if the beneficiary's period of medical need were 15 months. There are various types of nebulizers (compressor, ultrasonic, portable, disposable) and nebulizer accessories (breathing circuits, air filters, tubing extensions, mouthpieces, spare battery packs, DC adapters) available. Internet prices for compressor nebulizers range from $50 to $100, and prices for portable nebulizers range from $100 to $200, depending on the specific features of the nebulizer. The Medicare payment amount includes payment for delivery of the equipment. (Shipping costs for nebulizers available for purchase on the Internet range from free shipping up to $25).

b. Maintenance and Servicing of Nebulizers

Medicare Part B makes an additional separate payment to the supplier for maintenance and servicing of the equipment (for parts and labor not covered by the supplier's or manufacturer's warranty). For nebulizers that are not purchased, but are used for more than 21 months, the servicing fee covers six-month periods beginning after the 21st month of use. As required by section 1834(a)(7) of the Act, Medicare's payment for maintenance and servicing is equal to the lesser of a reasonable and necessary maintenance and servicing fee, or 10 percent of the total purchase price of the equipment. For nebulizers that are purchased, Medicare may make a payment to the supplier for any necessary maintenance and servicing that is performed.

In 2003, the average service fee for nebulizers was $19.07 per six-month period. Other than routine cleaning of the unit (that is, cleaning and changing filters, cleaning and disinfecting nebulizers, tubing, and mouthpieces), very little maintenance is required to maintain a nebulizer's peak performance. There is usually no scheduled maintenance for the nebulizer. Medicare pays for the usual frequency for replacement of accessories. Maintenance kits and replacement parts are available through online suppliers for approximately $5 to $15.

c. Inhalation Drugs

Medicare Part B pays for drugs that the nebulizer furnishes to a beneficiary. Unlike nebulizers, inhalation drugs are not an explicit benefit covered by statute. However, there was an administrative decision made early in the program's history to cover inhalation drugs as a supply so that the nebulizer could work. Without the inhalation drugs, the nebulizer would not be effective for a beneficiary.

The two most common inhalation drugs used by beneficiaries are albuterol sulfate (a beta-adrenergic bronchodilator) and ipratropium bromide (an anticholinergic bronchodilator). A beneficiary may use one or the other of these inhalation drugs, and they are frequently prescribed together. Both albuterol sulfate and ipratropium bromide are manufactured in powder form, but are generally liquefied and furnished to beneficiaries in liquid form for use in a nebulizer. The beneficiary may use a solution of one drug, or a combination of both drugs, in addition to saline if necessary, with the nebulizer. The beneficiary may mix the solution, or the supplier may furnish the drug in a pre-mixed form (either commercially pre-mixed or pharmacy compounded). The shelf life of these drugs is at least 18 to 24 months, and they do not require any special storage arrangements such as refrigeration.

Medicare also pays for other inhalation drugs, such as budesonide (an inhaled corticosteroid), which are used in conjunction with albuterol sulfate and ipratropium bromide. These drugs can also be administered using a nebulizer or an MDI.

d. Dispensing Fee

Medicare has paid a monthly $5 dispensing fee for each covered inhalation drug or combination of drugs used in a nebulizer. The dispensing fee is paid for each drug dispensed, not the number of unit dose vials provided to the beneficiaries. Additionally, if two or more drugs are combined in single unit dose vials, only one dispensing fee will be paid per drug combination per month. A dispensing fee for saline is not separately billable or payable. Inhalation drugs are the only drugs for which Medicare Part B currently pays a separate dispensing fee.

e. Beneficiary Training.

In 2003, CPT code 94664 was revised to include beneficiary training by a physician or physician's staff regarding use of a nebulizer, MDI, aerosol generator, or intermittent positive pressure breathing (IPPB) machine. The narrative terminology for the code currently is—Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB machine.'' The 2004 Medicare physician fee schedule payment for this service is $13.44. This service has no physician work relative value units reflecting that the training is typically performed by physician office staff. In 2004, this service has 0.32 practice expense relative value units (RVUs) and 0.04 malpractice RVUs. Additionally, the supplier of the nebulizer, under § 424.57(c)(12), must ''document that it or another qualified party has at an appropriate time, provided beneficiaries with necessary information and instructions on how to use Medicare covered-items safely and effectively.'' Beneficiary training by a physician or physician's staff regarding use of a nebulizer would meet the definition of ''another qualified party'' for purposes of this supplier requirement.

3. Medicare Spending for Nebulizers and Inhalation Drugs

In 2003, Medicare spent about $1.6 billion for nebulizers and inhalation drugs. This amount includes—

(a) About $130 million for nebulizers (both rental and purchase) and nebulizer related accessories and supplies;

(b) About $13 million for servicing/maintenance fees;

(c) About $1.3 billion for albuterol sulfate and ipratropium bromide and another $120 million for other inhalation drugs for a total of approximately $1.4 billion. (This represents about 88 percent of Medicare spending for inhalation therapy.);

(d) About $35.5 million for 7.1 million dispensing fees; and

(e) About $4.5 million for beneficiary training under CPT code 94664 (though this figure also includes training for other items as well as nebulizers).

Medicare spending for inhalation drugs has grown rapidly. Preliminary data indicate that between 2001 and 2003, Medicare spending increased by 77 percent for albuterol sulfate and ipratropium bromide.

4. Inspector General and General Accounting Office Studies

The HHS IG issued 10 reports between February 1996 and January 2004 about Medicare payments for albuterol sulfate and ipratropium bromide in excess of acquisition costs. In a report issued in September 2001,

the General Accounting Office (GAO) also concluded that Medicare payment for these drugs was in excess of acquisition costs.

Table 1 of the Interim Final Rule regarding Changes to Medicare Payment for Drugs and Physician Fee Schedule Payments for Calendar Year 2004, published in the January 7, 2004 **Federal Register** (69 FR 1084), showed that the acquisition cost (averaging IG and GAO results) was 34 percent of the Average Wholesale Price (AWP) for ipratropium bromide and 17 percent for albuterol sulfate. Prior to 2004, Medicare paid 95 percent of the AWP for each of these drugs and beneficiary coinsurance was 20 percent of the Medicare payment amount. In the case of albuterol sulfate, the beneficiary coinsurance was more than the actual acquisition cost for the drug. During 2004, Medicare payment is 80 percent of the AWP for each of these drugs. Beginning with 2005, Medicare payment will be 106 percent of the Average Sales Price (ASP).

The IG report issued in January 2004 again concluded that Medicare payments were far in excess of acquisition costs for both albuterol sulfate and ipratropium bromide. The IG found that the Medicare 2004 payment (and payment in prior years) was a multiple of the actual acquisition costs for both drugs based on a comparison to the median price that the drug was available through wholesalers/distributors and group purchasing organizations (GPOs) and comparison to the manufacturer-reported Wholesale Acquisition Cost (WAC).

5. Inhalation Drug Spread

In 2003, ipratropium bromide and albuterol sulfate were the third and seventh largest drugs in terms of Medicare spending for carrier paid drugs. The differences between Medicare's payment amount and acquisition costs (that is, spread) for albuterol sulfate and ipratropium bromide are among the largest spreads for drugs studied by the IG and GAO. Based on the actual acquisition costs determined by IG and GAO studies, in 2003, Medicare paid an estimated nearly $900 million in excess of acquisition costs for albuterol sulfate and ipratropium bromide.

The IG and GAO findings of large differences between Medicare payment amounts and acquisition costs for inhalation drugs provided the foundation for Congressional enactment of section 305 of the MMA. This section of the MMA sets Medicare payment for inhalation drugs at 106 percent of the ASP. (The Congressional Budget Office's November 20, 2003 pricing of the MMA estimated section 305 as having savings of $4.2 billion over 10 years.)

Suppliers argue that inhalation drug spread has allowed them to fund activities related to care for beneficiaries with asthma or COPD that otherwise do not have a Medicare Part B benefit category. These other activities may include the following:

- Respiratory therapists on staff or in networks available on-call for home visits or telephone consultations.
- On-call pharmacists.
- Monthly calls to schedule medication refills.
- Continuous education on disease states, including monthly follow-ups.
- 24-hour support lines.
- On-call and/or monthly home delivery of medication and supplies.
- Quality improvement programs.

6. Nebulizers vs. MDIs

Medicare Part B currently covers only one type of inhalation therapy, nebulizers and inhalation drugs. Although Medicare Part B does not cover MDIs and the inhalation drugs they furnish, the new Part D benefit beginning in 2006 will cover these alternative hand-held inhalation therapy devices (MDIs). In addition, the discount card and $600 transitional assistance payment for low-income beneficiaries will help seniors buy inhalers in 2004 and 2005, helping to bridge the gap until 2006 when coverage begins.

MDIs are the quickest and easiest way to take inhalation medication for most asthmatics and patients with COPD. The medication is propelled directly into the lungs, allowing it to take effect more quickly, and with fewer medication side effects. An MDI contains a specific number of ''metered inhalations,'' and is made to deliver the prescribed amount of medication for the labeled number of doses (typically 200 doses, which is 8 doses per day for 25 days). Inhalation accessory devices, such as holding chambers and spacers, are used to improve the direction and deposition of medication delivered by MDIs, making it easier for beneficiaries to use an MDI and making the MDI more effective in delivering the medicine to the lungs.

Since Medicare currently covers nebulizers and inhalation drugs, but not alternative forms of inhalation therapy, there are strong financial incentives toward use of the former compared to alternatives. Our review of the literature over the past decade, including two meta-analyses and over two dozen individual studies applicable to adults, did not find that bronchodilators delivered via nebulizer were more effective than when delivered via metered dose inhaler.

Since one delivery method is not clinically superior to the other, when Medicare covers both methods of delivery of inhalation therapy, the decision to prescribe one over the other will be made by the physician and beneficiary based on beneficiary needs and preferences consistent with applicable standards of medical practice. It would not be unlikely for many beneficiaries to choose the convenience of MDIs over nebulizers once the Medicare coverage imbalance is removed in 2006. Since MDIs are less expensive, very portable, and easier to use, it is likely there will be a substantial shift of Medicare beneficiaries from nebulizers to MDIs beginning in 2006, even absent the Medicare payment changes for nebulizers and inhalation drugs in 2005.

Some claim that beneficiaries cannot use MDIs because they do not have the dexterity to use them. Use of an MDI requires proper inhalation techniques in order to receive the full benefit possible from the amount of medication included in each dose. Spacers and holding chambers extend the mouthpiece of the inhaler and increase the air volume into which the medication is atomized, allowing more time for the patient to breathe the medication and avoid misdirecting the medication onto the soft tissues inside the mouth where it will have little effect on lung function.

A nebulizer may also require a certain level of dexterity (that is, operating, maintaining, and cleaning the nebulizer correctly). There may also be beneficiaries who do not have the dexterity to use either an MDI or nebulizer, which would require the availability of alternative therapies, such as an IPPB machine to aid in the delivery of aerosol medication by increasing the depth of breathing more than the patient alone can achieve.

7. Payments Beginning in 2005 Including Provisions of the Proposed Rule

Our goal is to assure that each beneficiary who needs inhalation therapy has access to the most appropriate medication and delivery method. We expect that the combined changes to cover MDIs, adjust payments for inhalation drugs, and provide for an appropriate dispensing fee will improve beneficiary access and choice. We seek comments about an appropriate amount for a dispensing fee that would assure beneficiary access to inhalation medications provided through nebulizers.

We believe that a dispensing fee is intended to cover a pharmacy's activities to get inhalation drugs to beneficiaries. We seek data and information on the additional services these pharmacies provide to Medicare beneficiaries, the extent to which inhalation drugs can be furnished without these additional services and the extent to which such services are covered under Medicare. We are concerned about significant shifts in beneficiary access to inhalation therapy prior to implementation of the Part D drug benefit in light of the reduction in Medicare payment for inhalation drugs beginning in 2005, and also seek comments about whether the dispensing fee should include a somewhat higher, transitional payment.

Below we discuss, changes in payment for inhalation drugs and nebulizers beginning in 2005.

a. Nebulizers

Section 1834(a)(21) of the Act, as amended by section 302(c)(2) of the MMA, requires a reduction in Medicare payment, beginning with 2005, for specified items of DME, including nebulizers paid under code E0570. The reduction is the difference in payment amounts under Medicare and the median Federal Employees Health Benefits (FEHB) plan, as identified in IG testimony before the Senate Committee of Appropriations on June 12, 2002. Other codes for nebulizers and related equipment are not affected by the payment reduction.

b. Maintenance and Servicing of Nebulizers

Since the maintenance and servicing fee is equal to the first month's rental payment, the maintenance and servicing fee for nebulizers will also be reduced in 2005.

c. Inhalation Drugs

As discussed in the ASP payment section of this proposed rule, for the first quarter of 2005, the Medicare payment at ASP plus 6 percent is estimated to be $0.04 per milligram for albuterol sulfate and $0.30 per milligram for ipratropium bromide. While these figures represent estimated reductions from 2004 payment levels of about 90 percent, they are not necessarily the actual payment amounts for the first quarter of 2005. The actual payment amounts will be based on ASP's calculated from the manufacturer ASP to be submitted for the third quarter of 2004.

Both albuterol sulfate and ipratropium bromide are generic drugs that have multiple manufacturers. Since these ASPs are average figures across all manufacturers, a pharmacy should be able to acquire albuterol sulfate and ipratropium bromide at these prices. Moreover, to the extent there is price variation among manufacturers, there will be some manufacturers with lower prices than others. In this case, a pharmacy might be able to obtain albuterol sulfate and ipratropium bromide at a price below the average.

The Medicare payment amount includes a 6 percent add-on. Assuming that ASP remains constant between the first and third quarters of 2004, the 6 percent add-on would be about $1.00 for a typical month's supply of 450 milligrams of albuterol sulfate and about $3.00 for a 90-day supply. Similarly, the 6 percent add-on would be about $1.60 for a typical month's supply of 93 milligrams of ipratropium bromide and about $4.80 for a 90-day supply. Because albuterol sulfate and ipratropium bromide are often prescribed together, Medicare payment at 106 percent of ASP would include, as additional payments above the acquisition cost of the drugs, a total payment to the supplier of about $2.60 for a 30-day supply and about $7.80 for a 90-day supply of both drugs.

d. Dispensing Fee

Given the overall reduction in payment for inhalation drugs, we are concerned about beneficiary access to these drugs. Because shipping, handling, compounding, and other pharmacy activities would usually exceed the 6 percent payment above the drug acquisition cost, we believe that it is appropriate for Medicare to continue to pay a separate dispensing fee to pharmacies that furnish inhalation drugs to beneficiaries.

We propose to establish a separate dispensing fee for inhalation drugs. This separate dispensing fee will be in addition to the difference between the supplier's acquisition cost and the Medicare payment for the drug. For example, if a supplier is acquiring albuterol and ipratropium bromide for the average sales price, the supplier would receive a separate dispensing fee amount plus their acquisition cost plus $7.80 for a 90-day supply. The $7.80 is the amount included in the payment for the drug itself since Medicare pays 6 percent above the average sales price.

As noted above, Medicare has paid a $5 monthly dispensing fee for each covered inhalation drug or combination of drugs used in a nebulizer. Dispensing fees are paid by Medicaid and private insurers; we seek information about these dispensing fees for inhalation drugs and their applicability to Medicare. In addition, we seek comments about an appropriate dispensing fee amount to cover the shipping, handling, compounding, and other pharmacy activities required to get these inhalation medications to Medicare beneficiaries. We seek data and information that explains the direct labor and non-labor costs as well as indirect costs of overhead for these pharmacy activities as they relate to dispensing of inhalation drugs.

Consideration of dispensing fees needs to be viewed in the context of several important changes and clarifications in Medicare policy and billing requirements.

First, we are proposing to allow a prescription for inhalation drugs covering a 90-day period to be written by a physician and filled by a pharmacy. Current guidelines are that a pharmacy generally should not fill a prescription for inhalation drugs for more than a month's supply for a beneficiary. We believe that this requirement needs revision in the case of inhalation drugs for two key reasons. Most beneficiaries who use inhalation drugs use them for extended periods of time and often use them for the rest of their lives. In addition, we understand that many inhalation drugs are delivered to a beneficiary through the mail. We understand that a mail-order prescription drug model works well for a 90-day prescription. We believe that there will be significant savings in shipping for a 90-day prescription rather than a monthly prescription.

We would expect that reasonableness would govern filling a monthly vs. a 90-day prescription with a physician writing and a pharmacy filling a monthly or a 90-day prescription depending on the circumstances of the beneficiary. For example, it would be reasonable to expect that the first time a beneficiary receives a prescription for a nebulizer and inhalation drugs that the prescription would be for a month. Similarly, it would be reasonable to expect that refill prescriptions for beneficiaries would be for a 90-day period. Carriers would continue to assess claims for dispensed quantities greater than what would be reasonable based on usual dosing guidelines. We would expect that the bulk of prescriptions would be for 90-day periods.

Second, we recently revised the guidelines regarding the time frame for delivery of refills of DMEPOS products to occur no sooner than ''approximately 5 days prior to the end of the usage for the current product''. As previously noted, inhalation drugs are often furnished to a beneficiary by mail. It has

been suggested that Medicare guidelines for refill prescriptions allowed too short of a window between shipping the next month's prescription and the end of the current month. It was argued that as a result, a pharmacy ''effectively'' had to ship the product to a beneficiary using an overnight delivery service.

On January 2, 2004, we revised the guidelines (effective February 2, 2004) regarding the time frame for subsequent deliveries of refills of DMEPOS products to occur no sooner than ''approximately 5 days prior to the end of the usage for the current product'' (see section 4.26.1 of Chapter 4—Benefit Integrity of the Medicare Program Integrity Manual). This change allows shipping of inhalation drugs on ''approximately'' the 25th day of the month in the case of a month's supply, and on ''approximately'' the 85th day in the case of a 90-day supply. We emphasize the word ''approximately''; while we believe that normal ground service shipping would allow delivery in 5 days, if there were circumstances where ground service could not occur in 5 days, the guideline would still be met if the shipment occurs in 6 or 7 days. (''Days'' refers to business days or shipping days applicable to the shipper, that is, a 6 day week in the case of the U.S. Postal Service.). We believe that this change eliminates the need for suppliers to use overnight shipping methods and allows shipping of inhalation drugs by less expensive ground service.

Third, we understand that some pharmacies believe that Medicare has a requirement that a pharmacy must obtain an original signed prescription before each prescription is dispensed. The Program Integrity Manual (section 5.1 of Chapter 5) addresses the ordering requirement for DMEPOS items. The Manual indicates that most DMEPOS items, including drugs, can be dispensed based on a verbal order from a physician. The Manual further indicates that a written order must be obtained before submitting a claim, but that such written order may be faxed, photocopied, electronic or pen and ink. The order for inhalation drugs must specify the name of the drug, the concentration (if applicable), dosage, and frequency of administration. We hope that clarification of this requirement would reduce a pharmacy's costs of supplying covered inhalation drugs to Medicare beneficiaries to the extent that pharmacies are currently applying an original signed prescription requirement.

Fourth, Medicare regulations (§ 424.57) specify the requirements a DMEPOS supplier must meet in order to receive payment for a Medicare covered item. Section 424.57(c)(12) contains the proof of delivery requirement and indicates that a ''supplier must be responsible for the delivery of Medicare covered items to beneficiaries and maintain proof of delivery.'' We recently revised the Program Integrity Manual (section 4.26 of Chapter 4) to address proof of delivery requirements for suppliers. As discussed in the Manual, the burden of proving delivery is left to the supplier. The Manual provides examples of the types of proof that are reasonable and acceptable, but it does not provide an all-inclusive list. Other acceptable proof-of-delivery methods may exist and may be employed by suppliers. This documentation is normally only requested by the contractor when a complaint is received that the item was not provided or received. The documentation is necessary to investigate the allegation. We believe that the current provisions on proof of delivery are adequate and appropriate for inhalation drugs.

Fifth, in section IV.H (Assignment of Medicare Claims—Payment to the Supplier) of this proposed rule, we propose to change current regulations at § 424.55 to eliminate the requirement that beneficiaries assign claims to suppliers in situations where suppliers are required by section 1842(o)(3) of the Act to accept assignment. This change would eliminate the need for suppliers to have a signed Assignment of Benefits (AOB) form from a beneficiary in order for Medicare to make payment. Because such section of the Act requires Medicare to make payment for drugs only on an assigned basis, this change would eliminate a billing requirement for drugs, including inhalation drugs. We believe that this change would reduce a pharmacy's costs of supplying covered inhalation drugs to Medicare beneficiaries to the extent that pharmacies are requiring a signed AOB form before submitting a claim.

We believe that the amount of dispensing fee needs to be considered in conjunction with—

(1) Our proposal to allow 90-day prescriptions;

(2) Our recent revision to allow the next month's refill prescription to be shipped approximately 5 business days prior to the end of usage for the product, that is, to allow shipping on the 25th of the month for a month's supply, and shipping or 85th day in the case of a 90-day period;

(3) Our policy clarification regarding signed original orders before a prescription is filled;

(4) Our proof of delivery requirement revisions; and

(5) Our proposed change regarding the Assignment of Benefits form.

e. Beneficiary Training

Medicare Part B will continue to pay for beneficiary training by a physician's staff regarding use of a nebulizer, MDI, aerosol generator, or IPPB machine. Section 424.57(c)(12) specifies that ''The supplier must document that it or another qualified party has at an appropriate time, provided beneficiaries with necessary information and instructions on how to use Medicare covered-items safely and effectively.'' Beneficiary training by a physician or physician's staff regarding use of a nebulizer would meet the definition of ''another qualified party'' for purposes of this supplier requirement.

## IV. Other Issues

### *A. Proposals Related to Therapy Services*

1. Outpatient Therapy Services Performed ''Incident To'' Physicians' Services

[If you choose to comment on issues in this section, please include the caption ''Therapy—Incident To'' at the beginning of your comments.]

In last year's proposed rule, we requested comments on clarifying that the personnel qualifications of therapists in home health settings at § 484.4 apply consistently to all therapy settings, including the offices of physical and occupational therapists, physicians, and nonphysician practitioners. We received comments from therapists, physicians, nontherapist health care providers and their representative organizations. After consideration of all comments, we now propose to revise 42 CFR 410.26, 410.59, 410.60 and 410.62 to reflect that physical therapy, occupational therapy, and speech-language pathology services provided incident to a physician's professional services are subject to certain limitations as described at section 1862(a)(20) of the Act.

Regulations in 42 CFR 485.705 specify that, in almost all settings, outpatient rehabilitative therapy services, (physical therapy (PT), occupational therapy (OT), or speech-language pathology (SLP)) can be furnished only by the following individuals meeting the qualifications in § 484.4: physical therapists, occupational therapists, appropriately supervised physical therapist assistants, appropriately supervised occupational therapy assistants, and speech-language pathologists. Some States permit licensed physicians, physician assistants, clinical nurse specialists, and nurse practitioners to furnish PT, OT,

and SLP services also. Therapy services, and those who provide therapy services, must also meet the standards and conditions as specified in Medicare manuals.

Section 1862(a)(20) of the Act permits payment for therapy services furnished incident to a physician's professional services only if the practitioner meets the standards and conditions that would apply to such therapy services if they were furnished by a therapist, with the exception of the licensing requirement. We are proposing to amend the regulations to include the statutory requirement that only individuals meeting the existing qualification and training standards for therapists (with the exception of licensure) consistent with § 484.4 qualify to provide therapy services incident to physicians' services.

Section 1862(a)(20) of the Act refers only to PT, OT, and SLP services and not to any other type of therapy or service. This section applies to services of the type described in section 1861(p), 1861(g) and 1861(ll) of the Act; it does not, for example, apply to therapy provided by qualified clinical psychologists. This section also does not apply to services that are not covered either as therapy or as evaluation and management services provided incident to a physician or nonphysician practitioner such as recreational therapy, relaxation therapy, athletic training, exercise physiology, kinesiology, or massage therapy services.

2. Qualification Standards and Supervision Requirements in Therapy Private Practice Settings

[If you choose to comment on issues in this section, please include the caption ''Therapy Standards and Requirements'' at the beginning of your comments.]

Section 1861(p) includes services furnished to individuals by physical and occupational therapists meeting licensing and other standards prescribed by the Secretary if the services meet the necessary conditions for standards for health and safety. These services include those furnished in the therapist's office or the individual's home. By regulation, we have defined therapists under this provision as physical or occupational therapists in private practice (PTPPs and OTPPs).

Under Medicare Part B, outpatient therapy services, including physical and occupational therapy services, are generally covered when reasonable and necessary and when provided by physical and occupational therapists meeting the qualifications set forth at § 484.4. Services provided by qualified therapy assistants, including physical therapist assistants (PTAs) and occupational therapy assistants (OTAs), may also be covered by Medicare when furnished under the specified level of therapist supervision that is required for the setting in which the services are provided (institutions and private practice therapist offices). For PTPPs and OTPPs, the regulations specify that the PT or OT meets only State licensure or certification standards and do not currently refer to the professional qualification requirements at § 484.4.

Since 1999, when therapy services are provided by PTAs and OTAs in the PT or OT private practice setting, the services must be personally supervised by the PTPP or OTPP. In response to a requirement to report to Congress on State standards for supervision of PTAs, CMS contracted with the Urban Institute. The Urban Institute found that no State has the strict, full-time ''personal'' supervision requirement, for any setting, that Medicare places on PTAs in PTPPs (the report only examined PTAs, which are more heavily regulated than OTAs). The Urban Institute study found that only 7 States require any ''personal'' PTA supervision by the PT, and all 7 required this level of supervision only periodically, every 14, 30 or 60 days. The remaining States and Washington, DC all have less stringent PTA supervision requirements, including: 7 States and Washington, DC require full-time on-site supervision, which corresponds to Medicare's direct supervision level; 16 States require the equivalent of Medicare's general supervision level, which does not require the PT to be on site, but requires the PT to be in contact via telecommunication; and another 16 States have rules for periodic on-site PT visits. Most States permit a supervision level similar to the Medicare ''general'' supervision requirement for physical therapy services delivered in institutional settings. To provide a consistent therapy assistant supervision policy, we are proposing to revise the regulations at 410.59 and 410.60 to require direct supervision of PTAs and OTAs when therapy services are provided by PTs or OTs in private practice. This proposed change would no longer require the personal presence of the PTPP or OTPP when their PTAs or OTAs provide services in the private practice setting. We are particularly interested in receiving comments regarding the proposed PTA supervision change, from personal to direct, for the private practice setting as whether or not it will have implications for the quality of services provided, or for Medicare spending, either through increased capacity to provide these services, or, alternatively, in the event that the Congress again extends the moratorium on the implementation of the limits on Medicare reimbursement for therapy services imposed by the Balanced Budget Act of 1997.

Currently, the OTPP or PTPP regulations at § 410.59(c) and § 410.60(c) do not reference qualification requirements for therapy assistants, or other staff, working for PTs and OTs in private practices. These qualification requirements were removed during 1998 rulemaking—when the coverage conditions requiring survey and certification, at § 486 Subpart D, for independently practicing PTs and OTs were replaced with a simplified carrier enrollment process for PTPPs and OTPPs. In our 1998 rule, at 63 FR 58868, we deleted the references at § 410.59 and § 410.60 to the requirements at § 484.4 for PTs and OTs in private practice. At that time, the qualifications for the staff of the PTPP and OTPP, including PTAs and OTAs, were inadvertently removed because the coverage conditions at § 486 Subpart D were no longer applicable. In order to provide a consistent policy regarding requirements for therapists and therapy assistants, we are proposing to restore the qualifications by adding at § 410.59 and § 410.60 the cross-reference to the qualifications at § 484.4 for privately practicing therapists and their therapy assistants.

3. Other Technical Revisions

[If you choose to comment on issues in this section, please include the caption ''Therapy Technical Revisions'' at the beginning of your comments.]

We are making technical corrections to § 410.62 to refer consistently to speech-language pathology in this section (currently the terms ''speech pathology'' and ''speech-language pathology'' are used interchangeably) and are revising § 410.62(a)(2)(iii) to appropriately reference § 410.61 (the current reference is to § 410.63).

We are also removing subpart D, Conditions for Coverage: Outpatient Physical Therapy Services Furnished by Physical Therapists, from part 486. Our November 1998 rule (63 FR 58868) discussed replacing this subpart with a simplified carrier enrollment process for physical or occupational therapists in private practice; however, the conforming regulatory change to remove Subpart D was never made.

In addition, we are making a technical change at § 484.4 to correct the title ''physical therapy assistant'' to ''physical therapist assistant.''

We are also amending § 410.59(e) and § 410.60(e) to include a reference to the 2-year moratorium on the therapy caps established by section 624 of the MMA.

*B. Low Osmolar Contrast Media*

[If you choose to comment on issues in this section, please include the caption ''LOW OSMOLAR CONTRAST MEDIA'' at the beginning of your comments.]

Contrast media are used to enhance the images produced by various types of diagnostic radiological procedures. High osmolar contrast media (HOCM), initially developed for use with these procedures, was relatively inexpensive and payment for HOCM is subsumed in the payment for the technical component of these procedures. When the more expensive low osmolar contrast media (LOCM) were developed, estimates showed that if *all* radiologic studies requiring contrast media were to use LOCM, the costs to the Medicare program would have been substantial. At that time, there were no definitive studies showing that the benefits of using LOCM justified the very high additional costs.

When the Medicare physician fee schedule was established, findings of studies of patients receiving both types of contrast media had been published, and the American College of Radiology (ACR) had adopted criteria for the use of LOCM. We determined that the older, less expensive contrast media (HOCM) could be used safely in a large percentage of the Medicare population. However, we also decided that separate payment for LOCM should be made for patients with certain medical characteristics. We adopted the ACR criteria, with some modification, as the basis for a policy that separate payments be made for the use of LOCM in radiological procedures for patients meeting certain criteria. These criteria were established at § 414.38. Specifically, separate payment is made for all intrathecal, intravenous, and intra-arterial injections of LOCM, when it is used for nonhospital patients who have one or more of the following five medical conditions—

- A history of previous adverse reactions to contrast media, with the exception of a sensation of heat, flushing, or a single episode of nausea or vomiting;
- A history of asthma or allergy;
- Significant cardiac dysfunction, including recent or imminent cardiac decompensation, severe arrhythmias, unstable angina pectoris, recent myocardial infarction, and pulmonary hypertension;
- Generalized debilitation;
- Sickle cell disease.

Under these conditions, we pay for LOCM, utilizing HCPCS codes A4644 through A4646. The payment amount for LOCM is calculated according to the rules applicable to drugs provided incident to a physician's service. The amount is reduced by 8 percent to account for the allowance for contrast media already included in the technical component of the service.

ACR has requested that we allow further separate payment for LOCM by either expanding or eliminating the conditions. According to ACR, use of LOCM has become the standard in most radiology practices and benefits both physicians and patients. The benefits of uniform use of LOCM would include—

- The reduction of patient discomfort arising when HOCM is used instead of LOCM; and
- A reduction in physician resources now required to screen for high-risk patients.

The price differential between HOCM and LOCM is also decreasing. Universal use of LOCM, along with declining prices, will result in an efficient, and safer alternative to HOCM.

We are proposing to revise the regulations at § 414.38 to eliminate the restrictive criteria for the payment of LOCM. This proposal would make Medicare payment for LOCM consistent across settings. Before January 1, 2003, the criteria in § 414.38 were also used to determine payment in the hospital setting. However, as instructed in our Program Memorandum A–02–120, issued November 22, 2002, hospitals that are subject to the outpatient prospective payment system (OPPS) no longer use these criteria. Instead, payment for both ionic and non-ionic contrast media (including LOCM) is packaged into the APC payment for the procedure. Under OPPS there is no longer a payment difference between LOCM and other contrast materials.

Effective January 1, 2005, payment for LOCM would be made on the basis of the average sales price plus six percent in accordance with the standard methodology for drug pricing established by the MMA. However, because the technical portions of radiology services are currently valued in the nonphysician workpool and the CPEP inputs for these services are not used in calculating payment, we will continue to reduce payment for LOCM by eight percent to avoid any duplicate payment for contrast media.

*C. Payments for Physicians and Practitioners Managing Patients on Dialysis*

[If you choose to comment on issues in this section, please include the caption ''MANAGING PATIENTS ON DIALYSIS'' at the beginning of your comments.]

1. ESRD-Related Services Provided to Patients in Observation Settings

In response to comments received on billing procedures when the patient is hospitalized during the month, we stated in the November 7, 2003 **Federal Register** (68 FR 63220) that the physician may bill the code that reflects the number of visits during the month on days when the patient was not in the hospital (either admitted as an inpatient or in observation status). (We refer to Medicare's payment amount below as the monthly capitation payment or MCP and the patient's normal attending physician for ESRD-related services as the MCP physician).

In comments on the August 15, 2003 proposed rule, the Renal Physicians Association (RPA) indicated that the observation area is not an uncommon setting for outpatient face-to-face encounters to occur and the observation area should be an approved site-of-service for physician-dialysis patient encounters that count toward the MCP visit total. We indicated in the final rule, however, that observation services would not be counted as a visit under the MCP, but would be paid separately. Prior to this, long-standing Medicare policy had subsumed ESRD-related observation visits within the MCP.

Upon further review of this issue, we now agree with RPA's comment and propose that ESRD-related visits provided to patients by the MCP physician in an observation setting would be counted as visits for purposes of billing the MCP codes.

2. Payment for Outpatient ESRD-Related Services for Partial Month Scenarios

Since changing our payments for managing patients on dialysis, we have received a number of comments from the nephrology community requesting guidance on billing for outpatient ESRD-related services provided to transient patients and in partial month scenarios where the comprehensive visit may not have been furnished: for example, when the patient is hospitalized during the month, or receives a kidney transplant before the monthly comprehensive visit is furnished. To address this issue, we propose to change the description of the G codes for ESRD-related home dialysis services, less than full month, as

identified by G0324 through G0327. The new descriptor would include other partial month scenarios, in addition to patients dialyzing at home. The proposed descriptors for G0324 through G0327 are as follows:

''G0324: End stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients under two years of age.''

''G0325: End stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients between two and eleven years of age.''

''G0326: End stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients between twelve and nineteen years of age.''

''G0327: End stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients twenty years of age and over.''

The G codes G0324 through G0327 would be used to bill for outpatient ESRD-related services provided in the following scenarios:

- Transient patients—Patients traveling away from home (less than full month);
- Home Dialysis Patients (less than full month);
- Partial month where there was one or more face-to-face visits without the comprehensive visit and either the patient was hospitalized before a complete assessment was furnished, dialysis stopped due to death, or the patient had a transplant.

We believe that modifying the definition of the per diem G codes (as identified by G0324 through G0327) would provide a consistent way to bill for these partial month scenarios. However, this proposed change to the descriptions of G0324 through G0327 is intended to accommodate unusual circumstances when the outpatient ESRD-related services would not be paid for under the MCP. Use of these per diem codes would be limited to the scenarios listed above. Physicians who have an on-going formal agreement with the MCP physician to provide cursory visits during the month (for example ''rounding physicians'') may not use the per diem codes.

**Clarification on Billing for Transient Patients**

For transient patients who are away from their home dialysis site, and at another site for fewer than 30 consecutive days, the revised per diem G codes (G0324 through G0327) would be billed by the physician or practitioner responsible for the transient patient's ESRD-related care. Only the physician or practitioner responsible for the traveling ESRD patient's care would be permitted to bill for ESRD-related services using the per diem G codes (G0324 through G0327).

If the transient patient is under the care of a physician or practitioner other than his or her regular MCP physician for a complete month, the physician or practitioner responsible for the transient patient's ESRD-related care cannot bill using the per diem codes. In this case the transient physician or practitioner treating the patient must furnish a complete assessment and bill for ESRD-related services under the MCP.

We are currently evaluating the criteria for defining a transient patient and welcome comments on when a patient should be considered transient.

*D. Technical Revision*

[If you choose to comment on issues in this section, please include the caption ''TECHNICAL REVISION'' at the beginning of your comments.]

In § 411.404, Medicare noncoverage of all obesity-related services is used as an example. Since we are currently revising this coverage policy, we are proposing to omit this example.

*E. Diagnostic Psychological Tests*

[If you choose to comment on issues in this section, please include the caption ''DIAGNOSTIC PSYCHOLOGICAL TESTS'' at the beginning of your comments.]

All diagnostic tests covered under section 1861(s)(3) of the Act and payable under the physician fee schedule must be furnished under the appropriate level of supervision by a physician as defined in section 1861(r) of the Act. Additionally, the physician or nonphysician practitioner who is treating the patient must order all diagnostic tests in order for these tests to be considered reasonable and necessary. These tests must be furnished under at least a general level of physician supervision, that is, the test is furnished under the physician's overall direction and control, but the physician's presence is not required during the performance of the procedure.

However, certain diagnostic tests require either direct or personal supervision. Direct supervision in the office setting means the physician must be present in the office suite and immediately available to furnish assistance and direction throughout the performance of the procedure. It does not mean that the physician must be present in the room when the procedure is performed. Personal supervision means the physician must be in attendance in the room during the performance of the procedure. Physician supervision at the specified level is required throughout the performance of the test. Services furnished without the required level of supervision are not reasonable and necessary, and Medicare payment is precluded.

Section 410.32(b)(2)(iii) does permit an exception to these physician supervision level requirements for clinical psychologists and independently practicing psychologists (who are not clinical psychologists) to personally perform diagnostic psychological testing services without physician supervision. However, diagnostic psychological tests performed by anyone other than a clinical psychologist or independently practicing psychologist must be provided under the general supervision of a physician as defined above. Accordingly, clinical psychologists and independently practicing psychologists have not been permitted to supervise others in the administration of diagnostic psychological tests.

In § 410.71(d), we require a clinical psychologist who furnishes diagnostic, assessment, preventive, and therapeutic services directly to individuals to hold a doctoral degree in psychology and to be licensed or certified, on the basis of the doctoral degree in psychology, by the State in which he or she practices. Program instructions define an independently practicing psychologist as an individual who is not a clinical psychologist and practices independently of an institution, agency, or physician's office. Examples include, but are not limited to, educational psychologists and counseling psychologists. Any psychologist who is licensed or certified to practice psychology in the State or jurisdiction where he or she is furnishing services may qualify as an independent psychologist. It is our understanding that all States, the District of Columbia, and Puerto Rico license psychologists, but that some trust territories do not. In the jurisdictions that do not issue licenses, an independently practicing psychologist may be any practicing psychologist.

The American Psychological Association (APA) requested that we re-evaluate our regulations regarding clinical psychologists' supervision of diagnostic psychological tests. The APA also provided additional information concerning provision of these services.

According to the APA, clinical psychologists generally have seven years of graduate education in the study of human behavior and are highly trained in the selection, administration,

and interpretation of psychological tests. In addition, according to our payment data, the majority of health care practitioners, other than physicians, performing psychological and neuropsychological testing services under the central nervous system codes (CPT codes 96100 through 96117) are psychologists. We agree that clinical psychologists possess core knowledge in test measurement and development, psychometric theory, specialized psychological assessment techniques, statistics, and the psychology of behavior that uniquely qualifies them to direct test selection and interpret test data.

Therefore, we are proposing to change the supervision requirements regarding who can supervise diagnostic psychological testing services.

Having ancillary staff supervised by clinical psychologists would enable these practitioners with a higher level of expertise to oversee psychological testing. It could also potentially relieve burdens on physicians and healthcare facilities.

Additionally, in rural areas, we anticipate that permitting psychologists to supervise diagnostic psychological testing services would reduce delays in testing, diagnosis, and treatment that could result from the unavailability of physicians to supervise the tests.

We propose that the appropriate level of supervision of diagnostic psychological tests by clinical psychologists be general supervision, the level required of physicians supervising the same services.

We are proposing to revise the regulations at § 410.32(b)(2)(iii) to permit clinical psychologists to supervise the performance of diagnostic psychological and neuropsychological testing services. This proposal extends solely to clinical psychologists, and it does not include independently practicing psychologists.

*F. Care Plan Oversight*

[If you choose to comment on issues in this section, please include the caption ''CARE PLAN OVERSIGHT'' at the beginning of your comments.]

Care Plan Oversight (CPO) refers to the supervision of patients under Medicare-covered home health or hospice care requiring complex multi-disciplinary care modalities, including regular development and review of plans of care. In the December 8, 1994 physician fee schedule final rule (59 FR 63423), we established separate payment for CPO when performed by physicians. The Balanced Budget Act (BBA) of 1997 extended to nonphysician practitioners (NPPs) the right to receive payment for Medicare physicians' services that fall within their scope of practice under State law. In the November 1, 2000 final rule (65 FR 65407), we created HCPCS codes G0181 and G0182 for reporting home health and hospice CPO, respectively. We also clarified in that rule that services of NPPs, practicing within the scope of State law applicable to their services, could be billed as CPO services.

To certify a patient for home health services, a physician must review the patient records and sign the plan of care. Our policy has been that the physician who bills for CPO must be the same physician who signs the plan of care and that, according to the statute, (sections 1814(a)(2)(C) and 1835(a)(2)(A) of the Act), only a physician can sign the plan of care for home health services. The effect of these two provisions, both of which were in place prior to the BBA of 1997, created a problem with respect to an NPP billing for CPO in the home health setting.

We propose to revise § 414.39 to clarify that NPPs can perform home health CPO even though they cannot certify a patient for home health services and sign the plan of care. However, we are also proposing the conditions under which NPP services may be billed for CPO; we established these conditions in consultation with our contractor medical directors and CMS medical staff. In general, the proposed conditions are meant to ensure that the NPP has seen and examined the patient and that the appropriate and established relationship exists between the physician who certifies the patient for home health services and the NPP who will provide the home health CPO.

*G. Assignment of Medicare Claims—Payment to the Supplier*

[If you choose to comment on issues in this section, please include the caption ''Assignment'' at the beginning of your comments.]

Current regulations require the beneficiary (or the person authorized to request payment on the beneficiary's behalf) to assign a claim to the supplier for an assignment to be effective. Over time, however, the Act has been amended in various sections to require suppliers, in some instances, to accept assignment for a Medicare covered service regardless of whether or not the beneficiary actually assigns the claim to the supplier. (This would include situations in which services are furnished by a participating physician or supplier.) In these instances, the requirement in our current regulations at § 424.55(a) that the beneficiary assign the claim to the supplier is now unnecessary. Therefore, we are proposing to create an exception to the general rule in § 424.55(a). New § 424.55(c) would eliminate the requirement that beneficiaries assign claims to suppliers in situations where suppliers are required by statute to accept assignment.

We believe the creation of this exception to the requirement for beneficiaries to assign benefits in situations where benefits can by statute only be paid on an assigned basis will reduce the paperwork burden on beneficiaries and suppliers.

## V. Collection of Information Requirements

Under the Paperwork Reduction Act of 1995 (PRA), we are required to provide 60-day notice in the **Federal Register** and solicit public comment before a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. In order to fairly evaluate whether OMB should approve an information collection, section 3506(c)(2)(A) of the PRA requires that we solicit comment on the following issues:

- The need for the information collection and its usefulness in carrying out the proper functions of our agency.
- The accuracy of our estimate of the information collection burden.
- The quality, utility, and clarity of the information to be collected.
- Recommendations to minimize the information collection burden on the affected public, including automated collection techniques.

Section 410.16 requires the furnishing of education, counseling, and referral services as part of an initial preventive physical examination, a written plan for obtaining the appropriate screening and other preventive services which are also covered as separate Medicare B Part services.

The burden associated with this requirement is the time required of the physician or practitioner to provide beneficiaries with education, counseling, and referral services and to develop and provide a written plan for obtaining screening and other preventive services.

While these requirements are subject to the PRA, we believe the burden associated with these requirements to be reasonable and customary business practice; therefore, the burden for this collection requirement is exempt under 5 CFR 1320.3(b)(2)&(3).

Section 411.404 requires that written notice must be given to a beneficiary, or someone acting on his or her behalf, that

the services were not covered because they did not meet Medicare coverage guidelines.

Although this section is subject to the PRA, the burden associated with this requirement is currently captured and accounted for in two currently approved information collections under OMB numbers 0938–0566 and 0938–0781.

Sections 410.36 and 410.38 require that the physician must document in the medical records the need for the prosthetic, orthotic, durable medical equipment, and/or supplies being ordered.

While these information collection requirements are subject to the PRA, the burden associated with them is exempt as defined in 5 CFR 1320.3(b)(2).

If you comment on these information collection and recordkeeping requirements, please mail copies directly to the following:

Centers for Medicare & Medicaid Services, Office of Strategic Operations and Regulatory Affairs, Attn: Melissa Musotto (CMS–1429–P), Room C5–13–28, 7500 Security Boulevard, Baltimore, MD 21244–1850; and Office of Information and Regulatory Affairs, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503, Attn: Christopher Martin, CMS Desk Officer (CMS–1429–P), *Christopher_Martin@omb.eop.gov.* FAX (202) 395–6974.

## VI. Response to Comments

Because of the large number of public comments we normally receive on **Federal Register** documents, we are not able to acknowledge or respond to them individually. We will consider all comments we receive by the date and time specified in the **DATES** section of this preamble, and, when we proceed with a subsequent document, we will respond to the comments in the preamble to that document.

## VII. Regulatory Impact Analysis

[If you choose to comment on issues in this section, please include the caption ''IMPACT'' at the beginning of your comments.]

We have examined the impact of this rule as required by Executive Order 12866 (September 1993, Regulatory Planning and Review), the Regulatory Flexibility Act (RFA) (September 16, 1980 Pub. L. 96–354), section 1102(b) of the Social Security Act, the Unfunded Mandates Reform Act of 1995 (Pub.L. 104–4), and Executive Order 13132.

Executive Order 12866 (as amended by Executive Order 13258, which merely reassigns responsibilities of duties) directs agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). A regulatory impact analysis must be prepared for proposed rules with economically significant effects (that is, a proposed rule that would have an annual effect on the economy of $100 million or more in any 1 year, or would adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, or tribal governments or communities). As indicated in more detail below, we estimate that the physician fee schedule provisions included in this proposed rule will redistribute more than $100 million in 1 year. We are also estimating that the combined effect of several provisions of the MMA implemented in this proposed rule will increase spending by more than $100 million. Other MMA provisions implemented in this proposed rule are estimated to reduce spending by more than $100 million. We are considering this proposed rule to be economically significant because its provisions are estimated to result in an increase, decrease or aggregate redistribution of Medicare spending that will exceed $100 million. Therefore, this proposed rule is a major rule and we have prepared a regulatory impact analysis.

The RFA requires that we analyze regulatory options for small businesses and other entities. We prepare a regulatory flexibility analysis unless we certify that a rule would not have a significant economic impact on a substantial number of small entities. The analysis must include a justification concerning the reason action is being taken, the kinds and number of small entities the rule affects, and an explanation of any meaningful options that achieve the objectives with less significant adverse economic impact on the small entities.

Section 1102(b) of the Act requires us to prepare a regulatory impact analysis for any proposed rule that may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 603 of the RFA. For purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside a Metropolitan Statistical Area and has fewer than 100 beds. We have determined that this proposed rule would have minimal impact on small hospitals located in rural areas. Of 431 hospital-based ESRD facilities located in rural areas, only 40 are affiliated with hospitals with fewer than 100 beds.

For purposes of the RFA, physicians, nonphysician practitioners, and suppliers are considered small businesses if they generate revenues of $6 million or less. Approximately 95 percent of physicians are considered to be small entities. There are about 875,000 physicians, other practitioners and medical suppliers that receive Medicare payment under the physician fee schedule. There are in excess of 20,000 physicians and other practitioners that receive Medicare payment for drugs. (As noted previously in this proposed rule and described further below, we are proposing significant changes to the payments for drugs.) These physicians are concentrated in the specialties of oncology, urology, and rheumatology. Of the physicians in these specialties, approximately 40 percent are in oncology and 45 percent in urology.

For purposes of the RFA, approximately 98 percent of suppliers of durable medical equipment (DME) and prosthetic devices are considered small businesses according to the Small Business Administration's (SBA) size standards. We estimate that 106,000 entities bill Medicare for durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) each year. Total annual estimated Medicare revenues for DME suppliers exceed approximately $4.0 billion. Of this amount, approximately $1.6 billion are for DME drugs.

In addition, most ESRD facilities are considered small entities, either based on nonprofit status, or by having revenues of $29 million or less in any year. We consider a substantial number of entities to be affected if the proposed rule is estimated to impact more than 5 percent of the total number of small entities. Based on our analysis of the 697 nonprofit ESRD facilities considered small entities in accordance with the above definitions, we estimate that the combined impact of the proposed changes to payment for renal dialysis services included in this rule would have a 1.6 percent increase in payments relative to current composite rate payments.

The analysis and discussion provided in this section, as well as elsewhere in this proposed rule, complies with the RFA requirements. Section 202 of the Unfunded Mandates Reform Act of 1995 also requires that agencies assess anticipated costs and benefits before issuing any rule that may result in expenditures in any year by State, local,

or tribal governments, in the aggregate, or by the private sector, of $110 million. Medicare beneficiaries are considered to be part of the private sector for this purpose. The net impact of the provisions of this rule, including those related to the MMA, are estimated to result in a savings to beneficiaries of nearly $270 million for FY 2005. The specific effects of the provisions being implemented in this proposed rule are explained in greater detail below.

We have examined this proposed rule in accordance with Executive Order 13132 and have determined that this regulation would not have any significant impact on the rights, roles, or responsibilities of State, local, or tribal governments.

We have prepared the following analysis, which, together with the information provided in the rest of this preamble, meets all assessment requirements. It explains the rationale for and purposes of the rule; details the costs and benefits of the rule; analyzes alternatives; and presents the measures we propose to use to minimize the burden on small entities. As indicated elsewhere in this proposed rule, we propose to refine resource-based practice expense RVUs and make a variety of other changes to our regulations, payments, or payment policy to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services. We are also proposing several changes resulting from the MMA, including changes to Medicare payment rates for outpatient drugs, changes to the payment for renal dialysis services, creating new preventive health care benefits and creating incentive payment program improvements for physician scarcity.

We are providing information for each of the policy changes in the relevant sections of this proposed rule. We are unaware of any relevant Federal rules that duplicate, overlap or conflict with this proposed rule. The relevant sections of this proposed rule contain a description of significant alternatives if applicable.

*A. Resource-Based Practice Expense and Malpractice Relative Value Units*

Under section 1848(c)(2) of the Act, adjustments to RVUs may not cause the amount of expenditures to differ by more than $20 million from the amount of expenditures that would have resulted without such adjustments. We are proposing several changes that would result in a change in expenditures that would exceed $20 million if we made no offsetting adjustments to either the conversion factor or RVUs.

With respect to practice expense, our policy has been to meet the budget-neutrality requirements in the statute by incorporating a rescaling adjustment in the practice expense methodologies. That is, we estimate the aggregate number of practice expense RVUs that will be paid under current and proposed policy in CY 2005. We apply a uniform adjustment factor to make the aggregate number of proposed practice expense RVUs equal the number estimated that would be paid under current policy.

Table 21 shows the specialty level impact on payment of changes being proposed for CY 2005. Our estimates of changes in Medicare revenues for physician fee schedule services compare payment rates for 2005 with payment rates for 2004 using 2003 Medicare utilization for both years. We are using 2003 Medicare claims processed and paid through June 30, 2004 that we estimate are 96.7 complete and have adjusted the figures to reflect a full year of data. Thus, because we are using a single year of utilization, the estimated changes in revenues reflect payment changes only between 2004 and 2005. To the extent that there are year-to-year changes in the volume and mix of services provided by physicians, the actual impact on total Medicare revenues will be different than those shown here. The payment impacts reflect averages for each specialty based on Medicare utilization. The payment impact for an individual physician would be different from the average, based on the mix of services the physician provides. The average change in total revenues would be less than the impact displayed here because physicians furnish services to both Medicare and non-Medicare patients and specialties may receive substantial Medicare revenues for services that are not paid under the physician fee schedule. For instance, independent laboratories receive approximately 80 percent of their Medicare revenues from clinical laboratory services that are not paid under the physician fee schedule. The table shows only the payment impact on physician fee schedule services.

We modeled the impact of changes to the practice expense methodology and illustrated the effect in table 21 below. The column labeled ''Practice Expense RVU Refinements'' shows the effect of the refinements we are making to the practice expense methodology for 2005. For instance, we are incorporating refined practice expense inputs recommended by the PEAC into the methodology as well as updating the prices of medical equipment. We are also adding 2003 utilization data for codes that did not exist in the 1997 through 2002 period.

In general, updating the methodology with 2003 utilization data has little or no impact on total payments to a specialty but the practice expense values for specific services may change. In general, the largest changes to a practice expense RVU will occur when a code was established after 2002 and we did not have any Medicare utilization data to determine the specialty that performs the service. In these cases, we either assigned the code to a specialty cost pool based on the specialty most likely to do the service or we used the ''all physician'' scaling factors to determine the code's practice expense RVUs. While we are trying to minimize instability in the practice expense RVUs for new services by assigning the specialty that is most likely to perform the service when we have no utilization data, the addition of utilization to the methodology may still result in some change to the practice expense RVUs during the first few years a code is in existence.

The practice expense refinements will reduce payments to audiologists by approximately 4 percent. Virtually all of the reduction in payment is due to the refinement of procedure code 92547. We accepted the PEAC recommendation to reduce the clinical staff time of the audiologist involved in this add-on service from 71 minutes to 1 minute. The refinement of clinical staff and equipment resulted in a reduction from 1.15 to 0.08 practice expense RVUs producing the nearly 4 percent reduction in payments shown in table 21.

Payments to vascular surgeons will increase approximately 3 percent as a result of the refinements. The increase in payment is attributed to the repricing of medical equipment used in performing noninvasive vascular diagnostic tests that will increase the practice expense RVUs for procedure codes 93880, 93923, 93925, 93970 and other codes in that family. The estimated 2 percent increase in payment from the practice expense refinements for interventional radiology is primarily due to the establishment of nonfacility pricing for procedure codes 35470 to 35476. The 3 percent increase in payment to oral and maxillofacial surgeons is largely attributed to the refinement of medical supplies for procedure codes 21210 and 21215. The 1 percent decrease in payment to nurse practitioners and geriatricians is attributed to the refinement of the nonfacility practice expense RVUs for

nursing facility visits (procedure codes 99301 through 99316). As stated in the November 7, 2003 **Federal Register** (68 FR 63204), the changes to the nonfacility practice expense RVUs for these codes were delayed by 1 year to allow the PEAC to reconsider its earlier recommendation to us to reflect input from representatives of specialties that provide these services in nursing homes. The PEAC reconsidered its recommendations with input from these specialties. Our acceptance of the PEAC recommendations is resulting in a decrease in the nonfacility practice expense RVUs for the nursing facility visit codes.

The column labeled ''Survey Data'' shows the impact on payment from using the supplemental practice expense survey from the College of American Pathologists (CAP). Using this survey together with making the technical component practice expense RVUs equal to the difference between the global and professional component practice expense RVUs and the other practice expense refinements will increase payments to pathologists by approximately 2 percent and independent laboratories by more than 6 percent. As we indicated above, independent laboratories receive approximately 20 percent of their total Medicare revenues from physician fee schedule services. The remaining 80 percent of their Medicare revenues are from clinical diagnostic laboratory services that will be unchanged by use of the CAP survey data. Thus, total Medicare revenues to independent laboratories as a result of using the CAP survey will increase by slightly more than 1 percent (or 20 percent of the 6 percent increase in physician fee schedule revenues). There will be little or no impact on all other specialties from use of the CAP survey.

The column labeled ''Total'' in Table 21 below shows the payment impact by specialty of all the changes described above. If we change any of these proposals following our consideration of comments, these figures may change.

TABLE 21.—IMPACT OF PRACTICE EXPENSE RVU CHANGES ON TOTAL MEDICARE ALLOWED CHARGES BY PHYSICIAN, PRACTITIONER AND SUPPLIER SUBCATEGORY

| Specialty | Medicare allowed charges ($ in millions) | Practice expense RVU refinements (percent) | Survey data (percent) | Total (percent) |
|---|---|---|---|---|
| Physicians: | | | | |
| ALLERGY/IMMUNOLOGY | 161 | −1 | 0 | −1 |
| ANESTHESIOLOGY | 1,416 | 0 | 0 | 0 |
| CARDIAC SURGERY | 359 | 0 | 0 | 0 |
| CARDIOLOGY | 6,583 | 0 | 0 | 0 |
| COLON AND RECTAL SURGERY | 111 | 0 | 0 | 0 |
| CRITICAL CARE | 130 | 0 | 0 | 0 |
| DERMATOLOGY | 1,870 | 0 | 0 | 0 |
| EMERGENCY MEDICINE | 1,672 | 0 | 0 | 0 |
| ENDOCRINOLOGY | 280 | 0 | 0 | 0 |
| FAMILY PRACTICE | 4,448 | 0 | 0 | 0 |
| GASTROENTEROLOGY | 1,636 | 0 | 0 | 0 |
| GENERAL PRACTICE | 998 | 0 | 0 | 0 |
| GENERAL SURGERY | 2,258 | 0 | 0 | 0 |
| GERIATRICS | 117 | −1 | 0 | −1 |
| HAND SURGERY | 57 | 1 | 0 | 1 |
| HEMATOLOGY/ONCOLOGY | 1,753 | 0 | 0 | 0 |
| INFECTIOUS DISEASE | 401 | 0 | 0 | 0 |
| INTERNAL MEDICINE | 8,846 | 0 | 0 | 0 |
| INTERVENTIONAL RADIOLOGY | 190 | 2 | 0 | 2 |
| NEPHROLOGY | 1,248 | 1 | 0 | 1 |
| NEUROLOGY | 1,200 | 0 | 0 | 0 |
| NEUROSURGERY | 490 | 0 | 0 | 0 |
| NUCLEAR MEDICINE | 85 | 0 | 0 | 0 |
| OBSTETRICS/GYNECOLOGY | 582 | 0 | 0 | 0 |
| OPHTHALMOLOGY | 4,583 | −1 | 0 | −1 |
| ORTHOPEDIC SURGERY | 2,902 | 0 | 0 | 0 |
| OTOLARNGOLOGY | 815 | 0 | 0 | 0 |
| PATHOLOGY | 869 | −1 | 3 | 2 |
| PEDIATRICS | 59 | −1 | 0 | −1 |
| PHYSICAL MEDICINE | 677 | 0 | 0 | 0 |
| PLASTIC SURGERY | 281 | 0 | 0 | 0 |
| PSYCHIATRY | 1,093 | 0 | 0 | 0 |
| PULMONARY DISEASE | 1,446 | 0 | 0 | 0 |
| RADIATION ONCOLOGY | 1,164 | 0 | 0 | 0 |
| RADIOLOGY | 4,690 | 0 | 0 | 0 |
| RHEUMATOLOGY | 413 | 0 | 0 | 0 |
| THORACIC SURGERY | 463 | 0 | 0 | 0 |
| UROLOGY | 1,699 | 0 | 0 | 0 |
| VASCULAR SURGERY | 487 | 3 | 0 | 3 |
| Practitioners: | | | | |
| AUDIOLOGIST | 28 | −4 | 0 | −4 |
| CHIROPRACTOR | 656 | 0 | 0 | 0 |
| CLINICAL PSYCHOLOGIST | 490 | 0 | 0 | 0 |
| CLINICAL SOCIAL WORKER | 313 | 0 | 0 | 0 |
| NURSE ANESTHETIST | 481 | 0 | 0 | 0 |

TABLE 21.—IMPACT OF PRACTICE EXPENSE RVU CHANGES ON TOTAL MEDICARE ALLOWED CHARGES BY PHYSICIAN, PRACTITIONER AND SUPPLIER SUBCATEGORY—Continued

| Specialty | Medicare allowed charges ($ in millions) | Practice expense RVU refinements (percent) | Survey data (percent) | Total (percent) |
|---|---|---|---|---|
| NURSE PRACTITIONER | 552 | −1 | 0 | −1 |
| OPTOMETRY | 664 | 0 | 0 | 0 |
| ORAL/MAXILLOFACIAL SURGERY | 36 | 3 | 0 | 3 |
| PHYSICAL/OCCUPATIONAL THERAPY | 990 | −1 | 0 | −1 |
| PHYSICIAN ASSISTANT | 410 | 0 | 0 | 0 |
| PODIATRY | 1,383 | 0 | 0 | 0 |
| Suppliers: | | | | |
| DIAGNOSTIC TESTING FACILITY | 876 | 1 | 0 | 1 |
| INDEPENDENT LABORATORY | 530 | 0 | 6 | 6 |
| PORTABLE X-RAY SUPPLIER | 91 | 0 | 0 | 0 |
| Other: | | | | |
| ALL OTHER | 93 | 0 | 2 | 2 |
| ALL PHYSICIAN FEE SCHEDULE | 66,395 | 0 | 0 | 0 |

As discussed in Section II.C of this rule, we are proposing changes to the malpractice RVUs based on more current malpractice premium data. As anticipated from past revisions to the malpractice RVUs, use of more current malpractice premium data results in minimal proposed impacts on the specialty level payments. See Table 22, ''Specialty Impact of Malpractice RVUs Revisions'', for a breakdown of the impacts of these revisions on individual specialties. Of the 54 specialties shown, 15 specialties (representing a total of 40 percent of Medicare allowed charges) experience no estimated change. Total Medicare payments for an additional 32 specialties are estimated to increase or decrease between 0.1 percent and 0.5 percent. We estimate that 7 specialties will experience a total payment increase or decrease of more than 0.5 percent as a result of the malpractice RVU changes. If we change any of these proposals following our consideration of comments, these figures may change.

TABLE 22.—SPECIALTY IMPACT OF MALPRACTICE RVU REVISIONS

| Specialty | Allowed charges [1] | Percent of total charges | Percent change [2] |
|---|---|---|---|
| DERMATOLOGY | 1,870,318,730 | 2.8 | 0.7 |
| PLASTIC SURGERY | 280,508,065 | 0.4 | 0.6 |
| ORAL/MAXILLOFACIAL SURGERY | 35,598,814 | 0.1 | 0.6 |
| COLON AND RECTAL SURGERY | 110,683,908 | 0.2 | 0.6 |
| GASTROENTEROLOGY | 1,635,616,057 | 2.5 | 0.5 |
| GENERAL SURGERY | 2,257,836,035 | 3.4 | 0.5 |
| CRITICAL CARE | 130,256,300 | 0.2 | 0.5 |
| INFECTIOUS DISEASE | 395,195,230 | 0.6 | 0.4 |
| GERIATRICS | 116,547,182 | 0.2 | 0.3 |
| PSYCHIATRY | 1,092,801,668 | 1.7 | 0.3 |
| PULMONARY DISEASE | 1,445,180,432 | 2.2 | 0.3 |
| NURSE PRACTITIONER | 549,723,060 | 0.8 | 0.2 |
| PATHOLOGY | 868,617,850 | 1.3 | 0.2 |
| NEUROLOGY | 1,199,069,489 | 1.8 | 0.2 |
| PHYSICAL MEDICINE | 676,516,230 | 1.0 | 0.2 |
| INDEPENDENT LABORATORY | 529,571,661 | 0.8 | 0.2 |
| OPTOMETRY | 664,163,601 | 1.0 | 0.2 |
| NEPHROLOGY | 1,247,164,211 | 1.9 | 0.1 |
| VASCULAR SURGERY | 486,263,563 | 0.7 | 0.1 |
| OBSTETRICS/GYNECOLOGY | 578,322,768 | 0.9 | 0.1 |
| INTERNAL MEDICINE | 8,821,789,552 | 13.4 | 0.1 |
| ENDOCRINOLOGY | 279,359,088 | 0.4 | 0.1 |
| ANESTHESIOLOGY | 1,415,251,017 | 2.1 | 0.0 |
| HEMATOLOGY/ONCOLOGY | 1,553,937,401 | 2.4 | 0.0 |
| CARDIOLOGY | 6,580,625,617 | 10.0 | 0.0 |
| OPHTHALMOLOGY | 4,583,221,470 | 7.0 | 0.0 |
| NURSE ANESTHETIST | 481,060,016 | 0.7 | 0.0 |
| THORACIC SURGERY | 463,428,857 | 0.7 | 0.0 |
| RADIATION ONCOLOGY | 1,162,754,357 | 1.8 | 0.0 |
| ALL OTHER | 92,826,859 | 0.1 | 0.0 |
| CLINICAL SOCIAL WORKER | 313,327,455 | 0.5 | 0.0 |
| GENERAL PRACTICE | 995,188,403 | 1.5 | 0.0 |
| UROLOGY | 1,689,047,785 | 2.6 | 0.0 |
| INTERVENTIONAL RADIOLOGY | 189,980,663 | 0.3 | 0.0 |
| EMERGENCY MEDICINE | 1,671,773,516 | 2.5 | 0.0 |
| FAMILY PRACTICE | 4,442,795,644 | 6.7 | 0.0 |
| DIAGNOSTIC TESTING FACILITY | 876,242,174 | 1.3 | 0.0 |

TABLE 22.—SPECIALTY IMPACT OF MALPRACTICE RVU REVISIONS—Continued

| Specialty | Allowed charges [1] | Percent of total charges | Percent change [2] |
|---|---|---|---|
| PHYSICIANS ASSISTANT | 409,700,298 | 0.6 | -0.1 |
| PEDIATRICS | 58,880,964 | 0.1 | -0.1 |
| AUDIOLOGIST | 27,930,180 | 0.0 | -0.1 |
| CLINICAL PSYCHOLOGIST | 490,006,176 | 0.7 | -0.1 |
| CARDIAC SURGERY | 359,324,850 | 0.5 | -0.1 |
| PORTABLE X-RAY SUPPLIER | 91,026,934 | 0.1 | -0.1 |
| HAND SURGERY | 56,595,222 | 0.1 | -0.1 |
| OTOLARNGOLOGY | 814,914,443 | 1.2 | -0.1 |
| RHEUMATOLOGY | 405,622,764 | 0.6 | -0.1 |
| NUCLEAR MEDICINE | 85,239,821 | 0.1 | -0.1 |
| CHIROPRACTOR | 656,312,519 | 1.0 | -0.2 |
| RADIOLOGY | 4,689,652,801 | 7.1 | -0.3 |
| PODIATRY | 1,382,552,109 | 2.1 | -0.4 |
| ORTHOPEDIC SURGERY | 2,902,084,841 | 4.4 | -0.4 |
| NEUROSURGERY | 489,366,546 | 0.7 | -0.6 |
| ALLERGY/IMMUNOLOGY | 160,728,139 | 0.2 | -0.9 |
| PHYSICAL/OCCUPATIONAL THERAPY | 990,284,755 | 1.5 | -1.3 |

[1] 2003 Allowed Charges
[2] Percent change based upon percent change in total payment.

Section 1848(d) and (f) of the Act requires the Secretary to set the physician fee schedule update under the sustainable growth rate (SGR) system. For 2004 and 2005, the statute requires the update to be no less than 1.5 percent. We believe it is highly likely that the statutory formula in section 1848(d)(4) will produce an update of less than 1.5 percent for 2005. Therefore, we estimate that the physician fee schedule update for 2005 will be 1.5 percent. We are currently forecasting payment reductions under the SGR system for 2006 and later years. As in the past, we will include a complete discussion of our methodology for calculating the SGR in the final rule.

Table 23 below shows the estimated change in average payments by specialty resulting from changes to the practice expense and malpractice RVUs and the 2005 physician fee schedule update. (Please note that the table does not include the specialties of Hematology/Oncology, Urology, Rheumatology and Obstetrics/Gynecology. There are unique issues related to drug administration that will further affect these specialties that are presented in detail below).

TABLE 23.—IMPACT OF PRACTICE EXPENSE AND MALPRACTICE RVU CHANGES AND PHYSICIAN FEE SCHEDULE UPDATE ON TOTAL MEDICARE ALLOWED CHARGES BY PHYSICIAN, PRACTITIONER AND SUPPLIER SUBCATEGORY

| Speciality | Medicare allowed charges ($ in Millions) | Practice expenses & malpractice RVU changes (percent) | Physician fee schedule update (percent) | Total (percent) |
|---|---|---|---|---|
| Physicians: | | | | |
| ALLERGY/IMMUNOLOGY | 161 | −2 | 1.5 | 0 |
| ANESTHESIOLOGY | 1,416 | 0 | 1.5 | 2 |
| CARDIAC SURGERY | 359 | 0 | 1.5 | 1 |
| CARDIOLOGY | 6,583 | 0 | 1.5 | 2 |
| COLON AND RECTAL SURGERY | 111 | 1 | 1.5 | 2 |
| CRITICAL CARE | 130 | 0 | 1.5 | 2 |
| DERMATOLOGY | 1,870 | 1 | 1.5 | 3 |
| EMERGENCY MEDICINE | 1,672 | 0 | 1.5 | 2 |
| ENDOCRINOLOGY | 280 | 0 | 1.5 | 2 |
| FAMILY PRACTICE | 4,448 | 0 | 1.5 | 1 |
| GASTROENTEROLOGY | 1,636 | 0 | 1.5 | 2 |
| GENERAL PRACTICE | 998 | 0 | 1.5 | 1 |
| GENERAL SURGERY | 2,258 | 1 | 1.5 | 2 |
| GERIATRICS | 117 | −1 | 1.5 | 1 |
| HAND SURGERY | 57 | 0 | 1.5 | 2 |
| INFECTIOUS DISEASE | 401 | 0 | 1.5 | 2 |
| INTERNAL MEDICINE | 8,846 | 0 | 1.5 | 1 |
| INTERVENTIONAL RADIOLOGY | 190 | 2 | 1.5 | 4 |
| NEPHROLOGY | 1,248 | 1 | 1.5 | 2 |
| NEUROLOGY | 1,200 | 0 | 1.5 | 2 |
| NEUROSURGERY | 490 | −1 | 1.5 | 1 |
| NUCLEAR MEDICINE | 85 | 0 | 1.5 | 1 |
| OPHTHALMOLOGY | 4,583 | −1 | 1.5 | 0 |
| ORTHOPEDIC SURGERY | 2,902 | 0 | 1.5 | 1 |
| OTOLARNGOLOGY | 815 | 0 | 1.5 | 2 |
| PATHOLOGY | 869 | 2 | 1.5 | 4 |

TABLE 23.—IMPACT OF PRACTICE EXPENSE AND MALPRACTICE RVU CHANGES AND PHYSICIAN FEE SCHEDULE UPDATE ON TOTAL MEDICARE ALLOWED CHARGES BY PHYSICIAN, PRACTITIONER AND SUPPLIER SUBCATEGORY—Continued

| Speciality | Medicare allowed charges ($ in Millions) | Practice expenses & malpractice RVU changes (percent) | Physician fee schedule update (percent) | Total (percent) |
|---|---|---|---|---|
| PEDIATRICS | 59 | −1 | 1.5 | 1 |
| PHYSICAL MEDICINE | 677 | 0 | 1.5 | 2 |
| PLASTIC SURGERY | 281 | 1 | 1.5 | 2 |
| PSYCHIATRY | 1,093 | 0 | 1.5 | 2 |
| PULMONARY DISEASE | 1,446 | 0 | 1.5 | 2 |
| RADIATION ONCOLOGY | 1,164 | 0 | 1.5 | 1 |
| RADIOLOGY | 4,690 | 0 | 1.5 | 1 |
| THORACIC SURGERY | 463 | 0 | 1.5 | 2 |
| VASCULAR SURGERY | 487 | 3 | 1.5 | 4 |
| Practitioners: | | | | |
| AUDIOLOGIST | 28 | −4 | 1.5 | −2 |
| CHIROPRACTOR | 656 | −1 | 1.5 | 1 |
| CLINICAL PSYCHOLOGIST | 490 | 0 | 1.5 | 1 |
| CLINICAL SOCIAL WORKER | 313 | 0 | 1.5 | 1 |
| NURSE ANESTHETIST | 481 | 0 | 1.5 | 2 |
| NURSE PRACTITIONER | 552 | −1 | 1.5 | 0 |
| OPTOMETRY | 664 | 0 | 1.5 | 1 |
| ORAL/MAXILLOFACIAL SURGERY | 36 | 4 | 1.5 | 5 |
| PHYSICAL/OCCUPATIONAL THERAPY | 990 | −2 | 1.5 | −1 |
| PHYSICIAN ASSISTANT | 410 | 0 | 1.5 | 1 |
| PODIATRY | 1,383 | −1 | 1.5 | 1 |
| Suppliers: | | | | |
| DIAGNOSTIC TESTING FACILITY | 876 | 1 | 1.5 | 3 |
| INDEPENDENT LABORATORY | 530 | 6 | 1.5 | 8 |
| PORTABLE X-RAY SUPPLIER | 91 | 0 | 1.5 | 1 |
| Other: | | | | |
| ALL OTHER | 93 | 2 | 1.5 | 3 |
| ALL PHYSICIAN FEE SCHEDULE | 66,395 | 0 | 1.5 | 2 |

Table 24 shows the impact on payments for selected high-volume procedures of all of the changes previously discussed. We selected these procedures because they are the most commonly provided procedures by a broad spectrum of physician specialties, or they are of particular interest to the physician community (for example, the preventive office visit, G0XX2). This table shows the combined impact of the change in the practice expense and malpractice RVUs and the estimated physician fee schedule update on total payment for the procedure. There are separate columns that show the change in the facility rates and the nonfacility rates. For an explanation of facility and nonfacility practice expense refer to § 414.22(b)(5)(i). The table shows the estimated change in payment rates based on provisions of this proposed rule and the estimated physician fee schedule update. If we change any of the provisions following the consideration of public comments, these figures may change.

TABLE 24.—IMPACT OF PROPOSED RULE AND PHYSICIAN FEE SCHEDULE UPDATE ON MEDICARE PAYMENT FOR SELECTED PROCEDURES

| CODE | MOD | Description | Non-facility | | | Facility | | |
|---|---|---|---|---|---|---|---|---|
| | | | Old | New | Percent change | Old | New | Percent change |
| 11721 | | Debride nail, 6 or more | $ 38.08 | $ 38.28 | 1 | $ 29.87 | $ 29.94 | 0 |
| 17000 | | Destroy benign/premlg lesion | 60.49 | 61.39 | 1 | 35.84 | 45.48 | 27 |
| 27130 | | Total hip arthroplasty | N/A | N/A | N/A | 1,370.28 | 1,382.50 | 1 |
| 27236 | | Treat thigh fracture | N/A | N/A | N/A | 1,088.01 | 1,103.20 | 1 |
| 27244 | | Treat thigh fracture | N/A | N/A | N/A | 1,115.27 | 1,133.51 | 2 |
| 27447 | | Total knee arthroplasty | N/A | N/A | N/A | 1,475.95 | 1,492.02 | 1 |
| 33533 | | CABG, arterial, single | N/A | N/A | N/A | 1,882.18 | 1,905.49 | 1 |
| 35301 | | Rechanneling of artery | N/A | N/A | N/A | 1,114.89 | 1,122.90 | 1 |
| 43239 | | Upper GI endoscopy, biopsy | 321.85 | 336.15 | 4 | 159.43 | 162.58 | 2 |
| 45385 | | Lesion removal colonoscopy | 497.71 | 514.65 | 3 | 288.24 | 293.71 | 2 |
| 66821 | | After cataract laser surgery | 240.83 | 237.62 | −1 | 237.09 | 230.80 | −3 |
| 66984 | | Cataract surg w/iol, 1 stage | N/A | N/A | N/A | 684.39 | 683.67 | 0 |
| 67210 | | Treatment of retinal lesion | 577.98 | 599.92 | 4 | 560.81 | 573.01 | 2 |
| 71010 | 26 | Chest x-ray | 9.33 | 9.47 | 2 | 9.33 | 9.47 | 2 |
| 71020 | 26 | Chest x-ray | 11.20 | 11.37 | 2 | 11.20 | 11.37 | 2 |
| 76091 | 26 | Mammogram, both breasts | 96.33 | 97.40 | 1 | N/A | N/A | N/A |
| 76091 | | Mammogram, both breasts | 44.80 | 45.10 | 1 | 44.80 | 45.10 | 1 |

TABLE 24.—IMPACT OF PROPOSED RULE AND PHYSICIAN FEE SCHEDULE UPDATE ON MEDICARE PAYMENT FOR SELECTED PROCEDURES—Continued

| CODE | MOD | Description | Non-facility | | | Facility | | |
|---|---|---|---|---|---|---|---|---|
| | | | Old | New | Percent change | Old | New | Percent change |
| 76092 | 26 | Mammogram, screening | 84.76 | 85.27 | 1 | N/A | N/A | N/A |
| 76092 | | Mammogram, screening | 36.22 | 36.38 | 0 | 36.22 | 36.38 | 0 |
| 77427 | | Radiation tx management, x5 | 169.14 | 172.05 | 2 | 169.14 | 172.05 | 2 |
| 78465 | 26 | Heart image (3d), multiple | 76.17 | 77.31 | 1 | 76.17 | 77.31 | 1 |
| 88305 | 26 | Tissue exam by pathologist | 41.44 | 42.07 | 2 | 41.44 | 42.07 | 2 |
| 90801 | | Psy dx interview | 150.84 | 153.48 | 2 | 142.26 | 144.39 | 1 |
| 90806 | | Psytx, off, 45–50 min | 97.45 | 98.91 | 1 | 93.72 | 95.12 | 1 |
| 90807 | | Psytx, off, 45–50 min w/e&m | 103.80 | 104.98 | 1 | 101.18 | 102.32 | 1 |
| 90862 | | Medication management | 51.15 | 52.30 | 2 | 48.17 | 49.27 | 2 |
| 90935 | | Hemodialysis, one evaluation | N/A | N/A | N/A | 72.06 | 73.14 | 1 |
| 92004 | | Eye exam, new patient | 126.57 | 129.61 | 2 | 89.24 | 90.58 | 2 |
| 92012 | | Eye exam established pat | 63.47 | 65.18 | 3 | 36.22 | 37.14 | 3 |
| 92014 | | Eye exam & treatment | 93.34 | 96.26 | 3 | 58.99 | 60.64 | 3 |
| 92980 | | Insert intracoronary stent | N/A | N/A | N/A | 812.09 | 829.58 | 2 |
| 92982 | | Coronary artery dilation | N/A | N/A | N/A | 602.63 | 615.83 | 2 |
| 93000 | | Electrocardiogram, complete | 26.51 | 26.91 | 2 | N/A | N/A | N/A |
| 93010 | | Electrocardiogram report | 8.96 | 9.10 | 2 | 8.96 | 9.10 | 2 |
| 93015 | | Cardiovascular stress test | 106.78 | 108.01 | 1 | N/A | N/A | N/A |
| 93307 | 26 | Echo exam of heart | 49.29 | 49.27 | 0 | 49.29 | 49.27 | 0 |
| 93510 | 26 | Left heart catheterization | 252.77 | 257.32 | 2 | 252.77 | 257.32 | 2 |
| 98941 | | Chiropractic manipulation | 36.22 | 36.76 | 1 | 31.74 | 31.83 | 0 |
| 99203 | | Office/outpatient visit, new | 95.96 | 97.40 | 2 | 71.69 | 72.38 | 1 |
| 99204 | | Office/outpatient visit, new | 135.53 | 137.57 | 2 | 105.66 | 107.25 | 2 |
| 99205 | | Office/outpatient visit, new | 172.13 | 174.71 | 1 | 140.39 | 142.49 | 1 |
| 99211 | | Office/outpatient visit, est | 21.28 | 21.98 | 3 | 8.96 | 9.10 | 2 |
| 99212 | | Office/outpatient visit, est | 37.71 | 38.66 | 3 | 23.52 | 24.25 | 3 |
| 99213 | | Office/outpatient visit, est | 52.65 | 53.06 | 1 | 35.47 | 35.24 | −1 |
| 99214 | | Office/outpatient visit, est | 82.14 | 83.00 | 1 | 57.87 | 58.74 | 2 |
| 99215 | | Office/outpatient visit, est | 119.11 | 121.27 | 2 | 93.34 | 95.12 | 2 |
| 99221 | | Initial hospital care | N/A | N/A | N/A | 66.83 | 68.22 | 2 |
| 99222 | | Initial hospital care | N/A | N/A | N/A | 111.27 | 112.93 | 1 |
| 99223 | | Initial hospital care | N/A | N/A | N/A | 154.95 | 157.27 | 1 |
| 99231 | | Subsequent hospital care | N/A | N/A | N/A | 33.23 | 34.11 | 3 |
| 99232 | | Subsequent hospital care | N/A | N/A | N/A | 54.89 | 56.09 | 2 |
| 99233 | | Subsequent hospital care | N/A | N/A | N/A | 78.04 | 79.58 | 2 |
| 99236 | | Observ/hosp same date | N/A | N/A | N/A | 226.26 | 223.60 | −1 |
| 99238 | | Hospital discharge day | N/A | N/A | N/A | 69.82 | 70.87 | 2 |
| 99239 | | Hospital discharge day | N/A | N/A | N/A | 95.21 | 91.71 | −4 |
| 99241 | | Office consultation | 50.03 | 50.40 | 1 | 33.98 | 34.49 | 2 |
| 99242 | | Office consultation | 91.48 | 92.47 | 1 | 69.45 | 70.11 | 1 |
| 99243 | | Office consultation | 120.60 | 122.79 | 2 | 92.22 | 93.99 | 2 |
| 99244 | | Office consultation | 170.63 | 172.81 | 1 | 136.65 | 138.70 | 2 |
| 99245 | | Office consultation | 220.29 | 224.35 | 2 | 181.09 | 184.56 | 2 |
| 99251 | | Initial inpatient consult | N/A | N/A | N/A | 35.84 | 36.00 | 0 |
| 99252 | | Initial inpatient consult | N/A | N/A | N/A | 71.69 | 72.76 | 1 |
| 99253 | | Initial inpatient consult | N/A | N/A | N/A | 97.45 | 98.91 | 1 |
| 99254 | | Initial inpatient consult | N/A | N/A | N/A | 140.39 | 142.12 | 1 |
| 99255 | | Initial inpatient consult | N/A | N/A | N/A | 193.03 | 195.55 | 1 |
| 99261 | | Follow-up inpatient consult | N/A | N/A | N/A | 22.40 | 22.36 | 0 |
| 99262 | | Follow-up inpatient consult | N/A | N/A | N/A | 44.80 | 45.48 | 2 |
| 99263 | | Follow-up inpatient consult | N/A | N/A | N/A | 66.09 | 67.46 | 2 |
| 99282 | | Emergency dept visit | N/A | N/A | N/A | 27.63 | 27.67 | 0 |
| 99283 | | Emergency dept visit | N/A | N/A | N/A | 61.61 | 62.15 | 1 |
| 99284 | | Emergency dept visit | N/A | N/A | N/A | 95.58 | 7.02 | 2 |
| 99285 | | Emergency dept visit | N/A | N/A | N/A | 149.72 | 151.97 | 2 |
| 99291 | | Critical care, first hour | 242.69 | 257.32 | 6 | 203.12 | 207.68 | 2 |
| 99292 | | Critical care, add'l 30 min | 107.91 | 114.45 | 6 | 101.56 | 103.84 | 2 |
| 99301 | | Nursing facility care | 71.69 | 66.32 | −7 | 61.61 | 66.32 | 8 |
| 99302 | | Nursing facility care | 97.82 | 87.92 | −10 | 82.52 | 87.92 | 7 |
| 99303 | | Nursing facility care | 120.97 | 108.39 | −10 | 102.68 | 108.39 | 6 |
| 99311 | | Nursing fac care, subseq | 40.70 | 34.49 | −15 | 30.62 | 34.49 | 13 |
| 99312 | | Nursing fac care, subseq | 63.10 | 56.85 | −10 | 51.53 | 56.85 | 10 |
| 99313 | | Nursing fac care, subseq | 86.25 | 79.96 | −7 | 72.43 | 79.96 | 10 |
| 99348 | | Home visit, est patient | 75.42 | 72.01 | −5 | N/A | N/A | N/A |
| 99350 | | Home visit, est patient | 169.89 | 165.23 | −3 | N/A | N/A | N/A |
| G0317 | | ESRDrelsvc 4+/mo;20+yr | 303.18 | 307.73 | 2 | 303.18 | 307.73 | 2 |
| G0318 | | ESRDrelsvc 2–3/mo;20+yr | 252.40 | 256.19 | 2 | 252.40 | 256.19 | 2 |
| G0319 | | ESRDrelsvc 1/mo;20+yr | 201.62 | 204.65 | 2 | 201.62 | 204.65 | 2 |

TABLE 24.—IMPACT OF PROPOSED RULE AND PHYSICIAN FEE SCHEDULE UPDATE ON MEDICARE PAYMENT FOR SELECTED PROCEDURES—Continued

| CODE | MOD | Description | Non-facility | | | Facility | | |
|---|---|---|---|---|---|---|---|---|
| | | | Old | New | Percent change | Old | New | Percent change |
| G0XX2 ..... | ..... | Preventive Office Visit ..... | N/A | 124.30 | N/A | N/A | 82.24 | N/A |

Section 303(a)(1) of the MMA amended section 1848(c)(2) of the Act to require increased work and practice expense RVUs for drug administration services. Section 303(a)(4) of the MMA required an additional temporary increase in payment to specific drug administration services (procedure codes 90780 through 90788, 96400, 96408 through 96425, 96520, and 96530) of 32 percent for 2004 and 3 percent for 2005. Table 25 shows the payment amounts for selected high-volume drug administration CPT codes from 2002 to 2006 including the effect of the transition adjustment of 32 percent required for 2004 and 3 percent for 2005 and 0 percent for 2006. The amounts shown in the table include the effect of the 1.5 percent update for 2004 and 2005. The 2006 payment amount shown in the table reflects the 2005 conversion factor because the 2006 physician fee schedule update is currently unknown.

With the exception of procedure code 96412 declining by 17 percent (which occurred because resource-based pricing replaced the use of charge-based RVUs when the services were removed from the nonphysician work pool), the MMA permanently increases payment for all of these services from a low of 17 percent for procedure code 90781 to 321 percent for procedure code 90782. The volume-weighted average permanent increase in payment among these drug administration services is approximately 105 percent (109 percent for oncologists and 94 percent for other physicians). Including the effect of the transition makes the volume-weighted increase in payment for these codes more than 170 percent from 2003 to 2004 and 110 percent from 2003 to 2005. The payment amount for procedure code 96400 in 2002 was $5.07. Payment for this code increased substantially to $37.52 in 2003 when, at the request of the American Urological Association (see 67 FR 79981 published on December 31, 2002), we removed this code from the nonphysician work pool. Including the effect of the additional changes required by MMA, we expect payment for this code to be $49.65 by 2006. Thus, the payment increase for procedure code 96400 between 2002 and 2006 is 879 percent. As indicated earlier, we are continuing to consider coding and RVU changes for drug administration services for 2005 based on the results of the CPT review and our consideration of public comments. If we change any of the RVUs for these codes as a result of CPT's review or the consideration of public comments, these figures may change.

TABLE 25.—IMPACT OF PROPOSED RULE AND PHYSICIAN FEE SCHEDULE UPDATE ON MEDICARE PAYMENT FOR SELECTED DRUG ADMINISTRATION SERVICES

| Code Description | Non-facility payment | | | | | | |
|---|---|---|---|---|---|---|---|
| | 2002 Payment | 2003 Payment | 2004 Payment | 2005 Payment * w/Current PE RVUs | 2006 Payment * w/Current PE RVUs | Percent change 2003 to 2006 | Percent change 2002 to 2006 |
| 90780 IV infusion therapy, 1 hour ..... | $40.54 | $42.67 | $117.79 | $92.90 | $90.20 | 111 | 122 |
| 90781 IV infusion, additional hour ..... | 20.27 | 21.70 | 33.02 | 26.15 | 25.39 | 17 | 25 |
| 90782 Injection, sc/im ..... | 3.98 | 4.41 | 24.64 | 19.13 | 18.57 | 321 | 367 |
| 96400 Chemotherapy, sc/im ..... | 5.07 | 37.52 | 64.07 | 51.14 | 49.65 | 32 | 879 |
| 96408 Chemotherapy, push technique .... | 35.11 | 37.52 | 154.76 | 122.96 | 119.38 | 218 | 240 |
| 96410 Chemotherapy,infusion method .... | 55.75 | 59.22 | 217.35 | 171.75 | 166.75 | 182 | 199 |
| 96412 Chemo, infuse method add-on ..... | 41.63 | 44.14 | 48.30 | 37.86 | 36.76 | –17 | –12 |

* Payment amounts reflect the current practice expense RVUs and a 1.5 percent update for 2005. The 2006 update is currently unknown. The payment amounts for 2006 were calculated using the 2005 conversion factor. If we were to make further revisions to the practice expense RVUs following the consideration of public comments and/or the CPT coding process, the payment amounts will be different.

Table 26 below shows the impact of the drug and physician fee schedule changes for selected specialties that receive a significant portion of their total Medicare revenues from drugs. Table 27 shows the combined payment impact of the drug and physician fee schedule payment changes on combined Medicare revenues. The first column ("Estimated Medicare Drug Revenues") shows estimated 2004 Medicare Drug Revenues using 2003 utilization adjusted for drug payment changes required in 2004 by the MMA. The next column ("% Change Medicare Drug Revenues") shows the payment impact of the adoption of the average sales price plus 6 percent (ASP+6) drug payment methodology in 2005 relative to 2004 on specialty drug payments. The payment impacts are based on ASP submissions from the 1st quarter of 2004. The ASP prices that will be used to determine payment in 2005 will begin with the 3rd quarter 2004 ASP submission and will be updated quarterly. To model the impact illustrated, we assumed an average increase in ASP prices of 3.39 percent (the national health expenditure prescription drug price growth factor) from the 1st quarter 2004 submission to the prices that will be used to determine 2005 payments. Table xxxxxxx follows table xxxxxx and shows the drug prices we used to determine the payment impact. The drug payment impacts are based on those high volume drugs where we have validated the ASP price submission that represent the following percentages of 2003 drug payments: 72 percent for Hematology/Oncology, 94

percent for Urology, 97 percent for Rheumatology and 73 percent for Obstetrics/Gynecology. For drugs in which we did not complete our validation of the ASP submission before completing the proposed rule, we used the average payment change for other drugs provided by the specialty unless a special circumstance applied. (that is, for Hematology/Oncology and Obstetrics/Gynecology, we calculated the average reduction in payment for drugs excluding J9265, J2430, and J9390, three drugs having an unusually large reduction in payment as a result of coming off patent. We do not believe these reductions will be typical of other drugs furnished by oncologists and obstetrician/gynecologists).

Our estimates of changes in Medicare revenues for drugs and physician fee schedule services compare payment rates for 2005 with payment rates for 2004 using 2003 Medicare utilization for both years. We are using 2003 Medicare claims processed and paid through June 30, 2004 that we estimate are 96.7 complete and have adjusted the figures to reflect a full year of data. Thus, because we are using a single year of utilization, the estimated changes in revenues reflect payment changes only between 2004 and 2005. To the extent that there are year-to-year changes in the volume and mix of drugs and physician fee schedule services provided by physicians, the actual impact on total Medicare revenues will be different than those shown here.

Assuming no change in utilization, we estimate that Medicare drug revenues for oncologists would decline by less than 8 percent as a result of policies adopted in this proposed rule. Oncologists administer a number of drugs that are changing in payments by different amounts. For instance, oncologists' highest Medicare revenue drug, Q0136 (EPOGEN; PROCRIT), would decline in payment by 7 percent while its second highest revenue drug, J9310 (RITUXAN), would increase in payment by 7 percent. Three drugs supplied by oncologists, J9265 (ONXOL TAXOL), J2430 (PAMIDRONATE DISODIUM), and J9390 (NAVELBINE), are coming off patent and their price would decline respectively by 81 percent, 71 percent, and 12 percent. The 2004 Medicare payment amounts for these three drugs respectively were equal to 81, 85 and 81 percent of the April 1, 2003 average wholesale price levels that applied or did not decrease proportionally after the drugs came off patent. These three drugs are estimated to account for only 7 percent of oncologists adjusted 2004 Medicare drug revenues but contribute more than 5 percent of the approximate 8 percent total reduction in Medicare drug revenues that oncologists would experience as a result of adopting the ASP+6 payment methodology. While Medicare revenues to oncologists would decline from the reductions in payment for these three drugs, the cost to acquire these drugs has already declined. Thus, Medicare's payment, as with all other drugs experiencing payment changes, will be much closer to the cost the physician pays to acquire the drug.

Adoption of ASP+6 prices would reduce Medicare drug revenues for urologists by approximately 36 percent. This large reduction can be attributed to a 35 percent reduction in payment for two drugs: J9202 (ZOLADEX) and J9217 (LUPRON DEPOT–PED). While we estimate an even larger reduction in the ASP+6 price for J9217, our payment impact assumes that nearly all Medicare carriers are using the ''least costly alternative'' pricing and paying code J9217 at the J9202 price.

We estimate a 6 percent reduction in Medicare drug revenues for rheumatology. Nearly all of this reduction can be attributed to a 6 percent reduction in Medicare payment for J1745 (REMICADE).

We estimate less than an 18 percent decrease in Medicare drug revenues for obstetrics/gynecology. However, much of this revenue reduction can be attributed to an 81 percent reduction in payment for J9265 (ONXOL TAXOL) coming off patent. Even though this one drug is estimated to account for only 16 percent of obstetrics/gynecology adjusted 2004 Medicare drug revenues, it contributes 13 percent of the approximate 18 percent total reduction in Medicare drug revenues that obstetrics/gynecologists would experience as a result of adopting the ASP+6 payment methodology. As explained above, while Medicare revenues to obstetrics/gynecology would decline as a result of the price reduction for this code, Medicare's payment will be much closer to the price physicians pay to acquire the drug. We are estimating an average approximate reduction of 6 percent across other drugs supplied by obstetrics/gynecology.

The remaining columns of Table 26 show the potential impact on physician fee schedule services of changes being contemplated for 2005 for the specialties shown. The column labeled ''Practice Expense and Malpractice RVU Changes'' show the combined impact of the changes previously illustrated for these specialties in Tables 21 and 22. The column labeled ''Drug Administration Payment Changes'' shows a range of potential physician fee schedule impacts for 2005. The left side of this column shows the impact of the changes required in payment by section 303(a)(4) of the MMA (that is, the change in the transition payment from 2004 to 2005) if we were to make no further changes to the payments or codes for drug administration services. However, because we are considering further changes to the payments or codes for drug administration once the AMA's CPT Panel review of this issue is complete, the right hand side of the column labeled ''Drug Administration Payment Changes'' reflects the amount that physician fee schedule payments would have to increase to make the net reduction across all Medicare revenues for these specialties equal to 2 percent. The next column shows the physician fee schedule update of 1.5 percent and the final column labeled ''Total Physician Fee Schedule'' Changes'' shows the combined effect of all of the changes previously described. The left hand side of the column shows the combined effect of (1) the practice expense and malpractice RVU changes, (2) the maximum reduction in payment that could occur if we made no further changes to payments for drug administration and (3) the physician fee schedule update. The right hand side of the column shows the combined effect of (1) the practice expense and malpractice RVU changes, (2) the amount physician fee schedule revenues would have to increase to make the reduction in total revenues equal to 2 percent and (3) the physician fee schedule update.

If we made no further changes to drug administration, physician fee schedule revenues would decline by 9 percent for oncology, be unchanged for urology and rheumatology, and increase by 1 percent for obstetrics/gynecology. Physician fee schedule revenues would have to increase by 12 percent for oncology, 19 percent for urology, 2 percent for rheumatology and 1 percent for obstetrics/gynecology for total revenues to these specialties to decline by 2 percent from adoption of the ASP+6 percent drug payment methodology.

Table 27 shows the combined impact of changes we are making to Medicare drug and physician fee schedule payments for the same specialties shown in table 26. The column labeled ''% of Total Medicare Revenues from Drugs'' shows the proportion of total Medicare revenues received from drugs, while the next column shows the payment impact from adoption of the ASP+6 drug payment methodology. The following columns show the proportion of total Medicare revenues received

from physician fee schedule services and the payment impact from physician fee schedule changes. All of the payment impacts are the same as those shown in Table 26. We note that these impacts and percentages represent averages for each specialty or supplier. The percentages and impacts for any individual physician are dependent on the mix of drugs and physician fee schedule services they provide to Medicare beneficiaries. These tables are intended to illustrate, assuming constant utilization, the combined impact of payment changes from 2004 to 2005 across all of the services that these specialties perform using the most recent data available to us. Thus, the last 3 columns show combined Medicare revenues from all sources and the combined Medicare payment impact from the earlier described changes being proposed or considered for 2005.

For example, as indicated in the Table 27, we estimate that approximately 70 percent of total 2004 Medicare revenues for oncologists are attributed to drugs. We estimate that Medicare revenues from drugs will decline by approximately 8 percent for oncology as a result of policies adopted in this proposed rule. Physician fee schedule services account for approximately 28 percent of oncology's 2004 Medicare revenues. If we made no other changes to the RVUs or codes for drug administration services and if there is no change in the utilization of services, we estimate that physician fee schedule payments to oncology would decline by approximately 9 percent from 2004 to 2005. In this scenario, combined Medicare payments to oncology would decline approximately 8 percent. However, if we were to make further changes to physician fee schedule payments so they increased by 12 percent, we estimate the combined revenue reduction to oncology would be 2 percent.

We estimate that urology receives approximately 37 percent of their 2004 total revenues from drugs and 60 percent from physician fee schedule services. Because urology and other physician specialties receive a smaller share of their total Medicare revenues from drug administration services than oncology, they are less affected than oncology by the reduction in the drug administration transition payment percentage from 32 to 3 percent from 2004 to 2005. If we made no other changes to the RVUs or codes for drug administration services, we estimate that physician fee schedule revenues for urologists would increase by approximately 1 percent from 2004 to 2005. (While the reduction in payment for drug administration alone would slightly reduce urologists' physician fee schedule revenues, we estimate that any reduction would be offset by the physician fee schedule update). In this scenario, combined Medicare payments to urologists would decline approximately 13 percent. However, if we were to make further changes to physician fee schedule payments so that they increased by 19 percent, we estimate the combined revenue reduction to urology would be 2 percent.

Rheumatology revenues from drugs are estimated to account for approximately 46 percent of their total revenues and would decline approximately 6 percent from adoption of the ASP+6 drug payment methodology. If we made no other changes to the RVUs or codes for drug administration services, we estimate that physician fee schedule revenues would be either unchanged or decline slightly in the aggregate and estimate a reduction in total Medicare revenues to rheumatology of approximately 3 percent. However, if we were to make further changes to physician fee schedule payments so they increased by 2 percent, we estimate the combined revenue reduction to rheumatologists would be 2 percent.

Medicare drug revenues represent 13 percent of total Medicare revenues for obstetrics/gynecology while physician fee schedule revenues account for 85 percent. We estimate that Medicare drug revenues for obstetrics/gynecology would decline by 18 percent and physician fee schedule revenues would increase 1 percent if we make no further changes to the RVUs or codes for drug administration services. In this scenario, obstetrics/gynecology's combined Medicare revenues would decline by 2 percent. Any change to the drug administration codes that increases their payments would make the net revenue reduction equal to or less than 2 percent for obstetrics/gynecology.

TABLE 26.—IMPACT OF DRUG AND PHYSICIAN FEE SCHEDULE PAYMENT CHANGES ON TOTAL MEDICARE ALLOWED CHARGES FOR SELECTED SPECIALTIES

| Specialty | Drugs | | | Physician fee schedule | | | |
|---|---|---|---|---|---|---|---|
| | Estimated medicare drug revenues ($ in millions) | Percent change medicare drug revenues | Medicare allowed charges ($ in millions) | Practice expense & malpractice RVU changes (percent) | Drug administration payment changes | Physician fee schedule update (percent) | Total physician fee schedule changes |
| HEMATOLOGY/ONCOLOGY | $4,363 | −8 | $1,753 | 0 | −10 to 10 | 1.5 | −9% to 12% |
| UROLOGY | 1,061 | −36 | 1,699 | 0 | −1% to 17% | 1.5 | 0% to 19% |
| RHEUMATOLOGY | 373 | −6 | 413 | 0 | −2% to 0% | 1.5 | 0% to 2% |
| OBSTETRICS/GYNECOLOGY | 88 | −18 | 582 | 0 | −1% to −1% | 1.5 | 1% to 1% |

The amounts shown on the left-hand side of the column labeled "Drug Administration Payment Changes" offset a part of the increase these specialties received in 2004 as shown in the January 7, 2004 **Federal Register** (69 FR 1100). We estimate the 2003–2005 increase in physician fee schedule payments to these specialties (before application of the physician fee schedule update) to be 28 percent for oncology, 2 percent for obstetrics/gynecology, 4 percent for rheumatology and 2 percent for urology. Urology received an additional 2 percent increase in total physician fee schedule payments (again, before application of the update) from 2002 to 2003 (see 67 FR 80035–80036 published on December 31, 2002) as a result of the large increase in payment for CPT code 96400 making the 2002–2005 payment increase exceed 4 percent.

TABLE 27.—COMBINED PAYMENT IMPACT DRUG AND PHYSICIAN FEE SCHEDULE PAYMENT CHANGES FOR SELECTED SPECIALTIES

| Specialty | Drugs | | Physician fee schedule | | All revenues | |
|---|---|---|---|---|---|---|
| | Percent of total medicare revenues from drugs | Percent change medicare drug revenues | Percent of total medicare revenues from fee schedule | Percent change physician fee schedule revenues | Combined medicare revenues all sources ($ in millions) | Combined percent change all medicare revenues |
| HEMATOLOGY/ONCOLOGY. | 70 | −8 | 28 | −9% to 12% .... | $6,251 | −8% to −2% |
| UROLOGY ..... | 37 | −36 | 60 | 0% to 19% ..... | 2,842 | −13% to −2% |
| RHEUMATOLOGY ..... | 46 | −6 | 51 | 0% to 2% ..... | 818 | −3% to −2% |
| OBSTETRICS/GYNECOLOGY. | 13 | −18 | 85 | 1% to 1% ..... | 684 | −2% to −2% |

The above tables show those specialties that receive significant revenues from drugs and physician fee schedule services that could be further affected by the review of drug administration coding currently undertaken by the CPT Editorial Panel and any changes we may make after further consideration of this effort and public comments.

Although infectious disease physicians do receive significant revenues from drugs and drug administration, we are not showing them in this table because we have validated only drug payment data accounting for 27 percent of their allowed charges for drugs. Based on these data, we estimate an 11 percent reduction in their Medicare drug payments that account for approximately 6 percent of their total Medicare revenues. If total drug payment were to decline by 11 percent, we estimate that net revenues to infectious disease physicians will remain unchanged, absent any further changes in drug and drug administration coding. We are not showing DME and Other Medical Suppliers in the above table because they do not receive significant revenues for physician fee schedule services and will be unaffected by any further changes made to drug administration coding or RVUs because they do not bill for these services. However, they do receive a substantial portion of their total Medicare revenues from drugs that are affected by the change to ASP+6 pricing. For DME/Other Medical Suppliers, 40 and 60 percent of Medicare revenues respectively are received from drugs and DME fee schedule services. These suppliers would receive an approximate reduction of 70 percent in their Medicare drug revenues from the adoption of ASP+6 drug prices due to the large reduction in payment for two high volume inhalation drugs (J7619 and J7644). These impacts will be reduced somewhat by the dispensing fee we are proposing for inhalation drugs. We estimate the total reduction in payment across all of the services provided by DME suppliers as a result of provisions of this proposed rule would be approximately 28 percent.

TABLE 28.—DRUG PRICING TABLE USED FOR PAYMENT IMPACTS

| Code | Short description | Trade name | CY 2004 Pay allowance limit | Estimated CY 2005 allowance limit 6%) | Percent change |
|---|---|---|---|---|---|
| J0152 ..... | Adenosine injection ..... | ADENOSCAN ..... | $66.56 | $69.78 | 5% |
| J0585 ..... | Botulinum toxin a per unit ..... | BOTOX ..... | 4.43 | 4.69 | 6 |
| J0880 ..... | Darbepoetin alfa injection ..... | ARANESP ..... | 21.20 | 18.10 | −15 |
| J1441 ..... | Filgrastim 480 mcg injection ..... | NEUPOGEN ..... | 267.79 | 267.04 | 0 |
| J1745 ..... | Infliximab injection ..... | REMICADE ..... | 58.79 | 53.32 | −9 |
| J2430 ..... | Pamidronate disodium/30 MG ..... | AREDIA, PAMIDRONATE DISODIUM, ... | 237.88 | 67.27 | −72 |
| J2505 ..... | Injection, pegfilgrastim 6mg ..... | NEULASTA ..... | 2,507.50 | 2,260.77 | −10 |
| J2792 ..... | Rho(D) immune globulin h, sd ..... | WINRHO ..... | 18.39 | 13.04 | −29 |
| J3395 ..... | Verteporfin injection ..... | VISUDYNE ..... | 1,404.26 | 1,368.79 | −3 |
| J3487 ..... | Zoledronic acid ..... | ZOMETA ..... | 194.54 | 202.50 | 4 |
| J7192 ..... | Factor viii recombinant ..... | KOGENATE, HELIXATE, RECOMBINATE, REFACTO, BIOCLATE,. | 1.29 | 0.92 | −29 |
| J7317 ..... | Sodium hyaluronate injection ..... | HYALGAN, SUPARTZ, ORTHOVISC ..... | 124.11 | 110.07 | −11 |
| J7320 ..... | Hylan G-F 20 injection ..... | SYNVISC ..... | 204.03 | 188.88 | −7 |
| J7507 ..... | Tacrolimus oral per 1 MG ..... | PROGRAF ..... | 3.13 | 3.19 | 2 |
| J7517 ..... | Mycophenolate mofetil oral ..... | CELLCEPT ..... | 2.55 | 2.54 | 0 |
| J7619 ..... | Albuterol inh sol u d ..... | PROVENTIL, ALBUTEROL SULFATE, VENTOLIN. | 0.39 | 0.04 | −89 |
| J7626 ..... | Budesonide inhalation sol ..... | PULMICORT ..... | 4.04 | 3.91 | −3 |
| J7644 ..... | Ipratropium brom inh sol u d ..... | IPRATROPIUM BROMIDE ..... | 2.82 | 0.30 | −89 |
| J9045 ..... | Carboplatin injection ..... | PARAPLATIN ..... | 137.54 | 131.77 | −4 |
| J9170 ..... | Docetaxel ..... | TAXOTERE ..... | 301.40 | 287.59 | −5 |
| J9201 ..... | Gemcitabine HCl ..... | GEMZAR ..... | 111.33 | 107.46 | −3 |
| J9202 ..... | Goserelin acetate implant ..... | ZOLADEX ..... | 375.99 | 234.28 | −38 |
| J9206 ..... | Irinotecan injection ..... | CAMPTOSAR ..... | 130.24 | 123.86 | −5 |
| J9217* ..... | Leuprolide acetate suspnsion ..... | LUPRON DEPOT, ELIGARD, LUPRON DEPOT-PED. | 500.58 | 234.28 | −53 |

TABLE 28.—DRUG PRICING TABLE USED FOR PAYMENT IMPACTS—Continued

| Code | Short description | Trade name | CY 2004 Pay allowance limit | Estimated CY 2005 allowance limit 6%) | Percent change |
|---|---|---|---|---|---|
| J9219 | Leuprolide acetate implant | VIADUR | 4,831.40 | 2,190.71 | −55 |
| J9265 | Paclitaxel injection | TAXOL, ONXOL, NOV-ONXOL | 138.28 | 25.84 | −81 |
| J9310 | Rituximab cancer treatment | RITUXAN | 427.28 | 438.38 | 3 |
| J9350 | Topotecan | HYCAMTIN | 706.17 | 731.46 | 4 |
| J9355 | Trastuzumab | HERCEPTIN | 52.01 | 50.84 | −2 |
| J9390 | Vinorelbine tartrate/10 mg | NAVELBINE | 76.19 | 64.67 | −15 |
| Q0136 | Non esrd epoetin alpha inj | PROCRIT | 11.62 | 10.37 | −11 |
| **Unlisted | | ALOXI | 307.80 | 202.51 | −34 |

*The figures here for J9217 reflect the ASP prices submitted by the drug manufacturer. However, we assumed that Medicare carriers are applying "least costly alternative" pricing and are using the J9202 price for J9217.

**Aloxi is the brand name for an antiemetic that is paid in 2004 at 95% of AWP using an unlisted code because the drug was approved by the FDA in the fall of 2003. Even though we do not have a code or volume for this drug from 2003 like we do for the other drugs shown in the table, we are showing it here because it is the highest growth injectable antiemetic drug currently on the market.

*B. Geographic Practice Cost Indices*

As discussed in section II.B, in this rule, we are proposing changes to the work and practice expense GPCIs based on new census data. The resulting geographic redistributions would not result in an overall increase in the current geographic adjustment indices by more than 3.5 percent or a decrease by more than 1.6 percent for any given locality in 2005. These geographic redistributions would not result in an overall increase in the current geographic adjustment indices by more than 7 percent or a decrease by more than 3.5 percent for any given locality in 2006. Addenda E and F illustrate the locality specific overall impact of this proposal. The GAF, as displayed in addenda E and F is a weighted composite index of the individual proposed revisions to the work, practice expense, and malpractice expense GPCIs, respectively. The malpractice GPCI was updated as part of the November 7, 2003 final rule, and the MMA provisions were addressed in the final rule published on January 7, 2004.

*C. Coding Issues*

1. Revisions to Global Period

In section II.D.1, we are proposing a change in the global period for procedure code 77427, *Radiation treatment management, five treatments* from a global indicator of "xxx" (meaning that the global concept does not apply) to "090" (meaning that there is a 90-day global period). We are not changing any of the RVUs for procedure code 77427 because this service was valued to reflect a global period of 90 days. The implication of this change is that any visit services provided in the 90-day global period that are related to procedure code 77427 will no longer be paid separately. We reviewed Medicare data and found that physicians rarely bill for services during the 90-day period following the date-of-service for procedure code 77427. Therefore, we believe this proposal will have little effect on Medicare program expenditures and our payments to physicians.

2. Additions to the List of Medicare Telehealth Services

In section II.D.2, we are proposing to add end stage renal disease (ESRD) services, as represented by HCPCS codes G0308, G0309, G0311, G0312, G0314, G0315, G0317, G03178 to the list of telehealth services. We believe that this change will have little effect on Medicare expenditures.

3. National Pricing of G0238/G0239 (Respiratory Therapy Service Codes)

As discussed earlier in the preamble, we are proposing to use the nonphysician workpool to value two respiratory therapy service codes (G0238 and G0239) that are currently carrier priced. We believe that this proposed change will eliminate the uncertainty surrounding payment of these codes when performed in comprehensive outpatient rehabilitation facilities that are paid under the physician fee schedule through fiscal intermediaries. We do not anticipate that nationally pricing these services would have a significant impact on Medicare expenditures.

4. New HCPCS Code for Bone Marrow Aspiration

We are proposing a new HCPCS code for instances when a bone marrow aspiration and a bone marrow biopsy are performed on the same day through a single incision. Currently, we do not allow payment for both of these procedures on the same day. While this coding change will allow for a small additional payment for the second procedure performed through a single incision on the same day, we anticipate that the costs will be insignificant.

5. New HCPCS Code for Venous Mapping

As stated earlier in the preamble, we are proposing a new HCPCS code for venous mapping for hemodialysis access placement. The primary reason for this new code is to enable us to track the use of venous mapping for quality improvement purposes. Since pricing for this service is not changing, there will be no impact on Medicare expenditures.

*D. MMA Provisions*

1. Section 611—Preventive Physical Examination

As discussed earlier in this preamble, the MMA authorizes coverage of an initial preventive physical examination effective January 1, 2005, subject to certain eligibility and other limitations. We estimate that this new benefit will result in an increase in Medicare expenditures. These new payments will be made to physicians and other practitioners who provide these examinations and for any medically necessary follow-up tests, counseling, or treatment that may be required as a result of the coverage of these examinations. The impact of this provision is shown in the following table.

TABLE 29.—MEDICARE COST ESTIMATES FOR MMA PROVISION 611

(in millions)

| MMA provision | FY 2005 | FY 2006 | FY 2007 | FY 2008 | FY 2009 |
|---|---|---|---|---|---|
| Sec. 611 | 65 | 75 | 75 | 75 | 75 |

2. Section 613—Diabetes Screening

Section 613 of the MMA adds subsection (yy) to section 1861 of the Social Security Act and mandates coverage of diabetes screening tests, effective on or after January 1, 2005. We estimate that this change in coverage for certain beneficiaries will result in an increase in Medicare payments. These payments will be made to physicians' office laboratories and other laboratory suppliers who perform these tests as a result of the increased frequency of coverage of these tests. The impact of this provision is shown in Table 30 that follows.

3. Section 612—Cardiovascular Screening

Section 612 of the MMA provides for Medicare coverage for cholesterol and other lipid or triglyceride levels of cardiovascular screening blood tests for the early detection of abnormalities associated with an elevated risk for such diseases effective on or after January 1, 2005. We estimate that this change in coverage for certain beneficiaries will result in an increase in Medicare payments. These payments will be made to physician office laboratories and other laboratory suppliers who perform these tests as a result of the increased frequency of coverage of these tests. Increased Medicare program expenditures for this provision are shown in Table 30 below.

TABLE 30.—MEDICARE COST ESTIMATES FOR MMA PROVISIONS 612 AND 613

(in millions)

| MMA provision | FY 2005 | FY 2006 | FY 2007 | FY 2008 | FY 2009 |
|---|---|---|---|---|---|
| Sec. 612 Cholesterol and Blood Lipid | 50 | 80 | 90 | 90 | 100 |
| Sec. 613 Diabetes Screening. | 20 | 40 | 50 | 60 | 80 |

4. Section 413—Incentive Payment for Physician Scarcity

a. Physician Scarcity Areas

Section 413(a) of the MMA provides a new 5-percent incentive payment to physicians who furnish services in physician scarcity areas. The MMA provides for paying primary care physicians furnishing services in a primary care scarcity area, and specialty physicians furnishing services in a specialist care scarcity county, an additional amount equal to 5 percent of the amount paid for their professional services under the fee schedule from January 1, 2005 to December 31, 2007. We estimate that this new incentive payment for physician services will result in an increase in Medicare payments that are shown in Table 31.

b. Improvement to Medicare HPSA Incentive Payment Program

Section 413(b) of the MMA amended section 1833(m) of the Act to mandate that we automate payment of the 10 percent HPSA incentive payment to eligible physicians. Since the inception of the HPSA incentive payment program, physicians have been required to determine their eligibility and correctly code their Medicare claims using modifiers. We estimate that this change to the HPSA incentive payment program to provide for automation of payment will result in an increase in Medicare payments because many eligible physicians are not applying for bonuses due to the burden of verifying eligibility. The impact of this provision is shown in Table 31.

TABLE 31.—MEDICARE COST ESTIMATES FOR MMA PROVISIONS

(in millions)

| MMA provision | FY 2005 | FY 2006 | FY 2007 | FY 2008 | FY 2009 |
|---|---|---|---|---|---|
| Sec. 413(a) Physician Scarcity Areas | 30 | 50 | 50 | 20 | 0 |
| Sec. 413(b) Improvement to HPSA | 20 | 30 | 30 | 30 | 30 |

5. Sections 303–304—Payment for Covered Outpatient Drugs and Biologicals and Section 305—Payment for Inhalation Drugs

Sections 303 and 304 of the MMA make changes to Medicare payment for covered outpatient drugs and biologicals and changes to the administration of those drugs. Section 305 makes changes to payment for inhalation drugs. We implemented provisions of sections 303 through 305 changing payments in 2004 for drugs and their administration in the January 7, 2004 **Federal Register** (69 FR 1084). In this proposed rule, we are making further changes to Medicare's payment for drugs and drug administration for 2005 required by sections 303 through 305 of the MMA. We estimate that adoption of the ASP+6 payment methodology will result in Medicare savings for FY 2005 of $180 million for section 303 of the MMA, $140 million for section 304 of the MMA, and $210 million for section 305 of the MMA. If we were to make no further changes to the coding or payment for drug administration services, we estimate Medicare savings of $90 million for section 303 of the MMA and $40 million for section 304 of the MMA. In addition, we are also proposing to pay a supplying fee of $10 per Medicare Part B oral drug prescription. We estimate this proposal will increase Medicare expenditures by $52 million from FY 2005 through FY 2009, assuming an average of two prescriptions per month. We are also

proposing to pay a furnishing fee of $0.05 per unit off clotting factor. This proposal is estimated to cost $13 million from FY 2005 through FY 2009.

6. Section 952—Reassignment

The reassignment provisions discussed in section III.F is currently estimated to have no significant impact on Medicare expenditures.

7. Section 623—Payment for Renal Dialysis Services

a. Effects on the Medicare Program (Budgetary Effect)

Because the proposed basic case mix adjusted composite payment rate and the revised payment for ESRD drugs must be budget neutral in accordance with section 623(d)(1) of the MMA, except for the statutorily required 1.6 percent increase set forth in section 623(a), we estimate that there would be no budgetary impact for the Medicare program beyond this increase. The impact of this provision (net of beneficiary liability) is shown in the following table.

TABLE 32.—MEDICARE COST ESTIMATES FOR MMA PROVISION 623

(in millions)

| MMA provision | FY 2005 | FY 2006 | FY 2007 | FY 2008 | FY 2009 |
|---|---|---|---|---|---|
| Section 623 | 40 | 50 | 50 | 60 | 60 |

b. Impact on ESRD Providers

In order to understand the impact of the proposed changes affecting payments to ESRD facilities that result from enactment of the MMA on different categories of ESRD facilities, it is necessary to compare estimated payments under the current payment system (current payments) to estimated payments under the proposed revisions to the composite rate payment system as set forth in this proposed rule (proposed payments). To estimate the impact among various classes of ESRD facilities, it is imperative that the estimates of current payments and proposed payments contain similar inputs. Therefore, we simulated proposed payments only for those ESRD facilities for which we are able to calculate both current payment and proposed payment.

Due to data limitations, we are unable estimate current and proposed payments for 592 facilities that bill for ESRD drugs. Of these 592 facilities, 174 are hospital based and 418 are independent. Therefore, 29 percent of hospital-based facilities and 11 percent of independent facilities are not shown in the impact table. ESRD providers were grouped into the categories based on characteristics provided in the Online Survey and Certification and Reporting (OSCAR) file and the most recent cost report data from HCRIS. We also used the December 2003 update of CY 2003 Standard Analytical File (SAF) claims as a basis for Medicare dialysis treatments and separately billable drugs and biologicals. While the December 2003 update of the 2003 SAF file is not complete, we wanted to use the most recent data available, and plan to use an updated version of the 2003 SAF file for the final rule.

TABLE 33.—IMPACT OF MMA SECTION 623 PAYMENTS TO HOSPITAL BASED AND INDEPENDENT ESRD FACILITIES (INCLUDES DRUG AND COMPOSITE RATE PAYMENTS)

[Percent change in total payments to ESRD facilities (both program and beneficiaries)]

| | Number of facilities | Number of dialysis treatments (in millions) | Effect of changes in drug payments 1/ | Effect of 1.6% composite rate update on total payments 2/ | Effect of case mix 3/ | Overall effect 4/ |
|---|---|---|---|---|---|---|
| All | 3,671 | 29.2 | 0.0 | 1.0 | 0.0 | 1.0 |
| Independent | 3,240 | 26.1 | −0.6 | 1.0 | −0.0 | 0.4 |
| Hospital Based | 431 | 3.1 | 5.7 | 1.1 | 0.1 | 7.0 |
| Size: | | | | | | |
| Small <5000 treatment per year | 1,313 | 4.0 | −0.6 | 1.0 | −0.1 | 0.3 |
| Medium 5000–10000 treatments per yr | 1,414 | 10.2 | −0.7 | 1.0 | −0.1 | 0.2 |
| Large > 10000 treatments per year | 944 | 15.0 | 0.6 | 1.0 | 0.0 | 1.7 |
| Type of Ownership: | | | | | | |
| Not-for-profit | 697 | 5.2 | 2.9 | 1.1 | 0.0 | 4.1 |
| For-profit | 2,710 | 21.9 | −0.6 | 1.0 | −0.0 | 0.4 |
| Other | 264 | 2.1 | −0.1 | 1.0 | 0.0 | 1.0 |
| Urban | 2,701 | 23.6 | 0.1 | 1.0 | 0.1 | 1.2 |
| Rural | 970 | 5.6 | −0.5 | 1.0 | −0.5 | −0.0 |
| Region: | | | | | | |
| New England | 125 | 1.2 | 1.3 | 1.1 | 0.1 | 2.4 |
| Middle Atlantic | 475 | 4.0 | 0.5 | 1.0 | 0.9 | 2.4 |
| East North Central | 540 | 4.5 | 0.4 | 1.0 | −0.1 | 1.3 |
| West North Central | 255 | 1.7 | 1.4 | 1.1 | −0.5 | 2.0 |
| South Atlantic | 886 | 6.9 | −1.0 | 1.0 | 0.0 | 0.0 |
| East South Central | 309 | 2.2 | −1.0 | 1.0 | −0.7 | −0.7 |
| West South Central | 522 | 4.1 | −1.0 | 1.0 | −0.2 | −0.1 |
| Mountain | 194 | 1.3 | 0.6 | 1.1 | −0.5 | 1.1 |
| Pacific | 339 | 3.0 | 1.4 | 1.1 | −0.2 | 2.3 |

TABLE 33.—IMPACT OF MMA SECTION 623 PAYMENTS TO HOSPITAL BASED AND INDEPENDENT ESRD FACILITIES (INCLUDES DRUG AND COMPOSITE RATE PAYMENTS)—Continued

[Percent change in total payments to ESRD facilities (both program and beneficiaries)]

| | Number of facilities | Number of dialysis treatments (in millions) | Effect of changes in drug payments 1/ | Effect of 1.6% composite rate update on total payments 2/ | Effect of case mix 3/ | Overall effect 4/ |
|---|---|---|---|---|---|---|
| Puerto Rico | 26 | 0.4 | 0.8 | 1.0 | 1.4 | 3.3 |

[1] This column shows the effect of the changes in drug payments to ESRD providers. These include changes in payment for separately billable drugs and the 11.3% drug add-on.

[2] This column shows the effect of the 1.6% update to the composite rate on total payments to ESRD providers. Note that ESRD providers receive an average of 36% of their total revenues from separately billable drugs which results in an average net increase of 1.0%.

[3] This column shows impact of case-mix adjustments only.

[4] This column shows percent change between the proposed and current payments to ESRD facilities. The proposed payments includes the 1.6% increase, the 11.3% drug add-on, and the case-mix adjustments times treatments plus proposed payment for separately billable drugs. The current payment to ESRD facilities includes the current composite rate times treatments plus current drug payments for separately billable drugs.

Table 33 shows the impact of MMA Section 623 on hospital based and independent facilities. We have included both composite rate payments as well as payments for separately billable drugs and biologicals because both are effected by Section 623. The first column of Table 33 identifies the type of ESRD provider, the second column indicates the number of ESRD facilities for each type, and the third column indicates the number of dialysis treatments.

The fourth column shows the effect of the changes in drug payments to ESRD providers. The overall effect of changes in drug payments is budget-neutral as required by MMA. The drug add-on adjustment is designed to result in the same aggregate amount of expenditures as would have been made without the statutory policy change.

Current payments for drugs represent 2005 Medicare reimbursement using 95 percent of AWP prices for the top ten drugs. Medicare spending for drugs other than EPO is estimated using 2004 AWP prices updated by a 3 percent inflation factor times actual drug utilization from 2003 claims. EPO is priced $10 per 1000 units (EPO units are estimated using payments because the units field on bills represents the number of EPO administrations rather than the number EPO units). Spending under the proposed change is 2004 ASP minus 3 percent for the top ten drugs plus 3.39 percent inflation factor times actual drug utilization from 2003 claims.

Proposed payment for drugs under MMA also includes the 11.3 percent drug add-on to the composite rate. This amount is computed by multiplying the composite rate for each provider (with the 1.6 percent increase) times dialysis treatments from 2003 claims. Column 4 is computed by comparing spending under the proposed payment for drugs including the 11.3 percent drug add-on amount to spending under current payments for drugs. In order to make column 4 comparable with rest of Table 33, current composite rate payments to ESRD facilities were included in both current and proposed spending calculations.

Column 5 shows the effect of the 1.6 percent increase to the composite rate on total payments to ESRD providers. While all ESRD providers will get a 1.6 percent increase to their composite rate, this table shows the net effect of this increase on ESRD providers total Medicare revenues (both drug and composite rate payments combined), and therefore does not show a 1.6 percent increase.

On average, ESRD providers receive an average of 36 percent of their total revenues from separately billable drugs and 64 percent of their total revenues from composite rate payment. Since the 1.6 percent increase is applied to the 64 percent portion of their total Medicare revenues, the 1.6 percent composite rate increase is also arithmetically equal to a 1.0 percent increase in ESRD providers' total Medicare revenues. Column 5 is computed by combining proposed payment for drugs (including the 11.3 percent drug add-on amount) with: (1) Current composite rate times dialysis treatments from 2003 claims or (2) composite rate with 1.6 percent increase times dialysis treatments from 2003 claims. The difference between these two combinations is the net effect of the 1.6 percent increase on total payments to ESRD providers. In order to isolate the effect of the 1.6 percent increase, the computation in Column 5 assumes that drug payments to ESRD providers remain constant.

Column 6 shows the impact of the case-mix adjustments as described in section H.4.d of this proposed rule. Because MMA requires this adjustment be budget-neutral in the aggregate, there is no overall impact to the ESRD providers as a whole. While the case-mix adjustment will have an impact within the various provider types, Column 6 shows that the effect between provider groupings is minimal. Column 6 is computed as the difference between proposed payments to ESRD providers with the case-mix adjustments compared to payments to providers without the case-mix adjustments. As described in section H.4.f, we standardized the composite rate to meet the MMA requirement that payment be budget-neutral with respect to aggregate payments. Therefore, there is no change for ESRD providers in aggregate. We note that when applying the case-mix adjustments, we did so at the summary level as shown in Table 33.

Column 7 shows the overall effect of all changes in drug and composite rate payments to ESRD providers. The overall effect measured as the difference between proposed payment with all MMA changes as proposed in this rule and current payment. Proposed payment is computed by multiplying the composite rate for each provider (with both 1.6 percent increase and the 11.3 percent add-on) times dialysis treatments from 2003 claims times the appropriate case-mix adjustment by provider category. In addition, proposed payment includes payments for separately billable drugs under the revised pricing methodology as described in section III–E–Section 303–Payment Reform for Outpatient Drugs and Biologicals, Subsection 1.d. Current payment is the current composite rate for each provider times dialysis treatments from 2003 claims plus current drug payments for separately billable drugs.

The overall impact to ESRD providers in aggregate is 1.0 percent. Among the three separately shown effects, the effect

of changes in drug payments has the most variation among provider type and contributes most to the overall effect. Separately billable ESRD drugs are paid differently to hospital-based and independent ESRD providers. As discussed in section H.4.c, we are proposing a single drug add-on to the composite rates for both hospital based and independent facilities. The 7.0 percent increase in payments to hospital-based providers is largely due to the proposed single drug add-on to the composite rate. Many hospital based providers are not-for-profit, which may explain the larger than average increase in payments.

8. Section 731—Coverage of Routine Costs for Category A Clinical Trials

The coverage of routine costs associated with certain Category A clinical trials as discussed in MMA section 731(b) has no significant impact on Medicare expenditures.

9. Section 629—Part B Deductible

As explained earlier in the preamble, section 629 of the MMA provides for annual updates to the Medicare Part B deductible. The MMA stipulates that the Medicare Part B deductible will be $110 for calendar year 2005, and, for subsequent years, the deductible will be the previous year's deductible increased by the annual percentage increase in the monthly actuarial rate under section 1839(a)(1) of the Act, ending with that subsequent year (rounded to the nearest dollar). We note that while this MMA provision results in a savings to the Medicare program, it also increases beneficiary costs by an equal amount.

TABLE 34.—ESTIMATED MEDICARE SAVINGS FOR MMA PROVISION 629

[in millions]

| MMA provision | FY 2005 | FY 2006 | FY 2007 | FY 2008 | FY 2009 |
|---|---|---|---|---|---|
| Sec. 629 | 110 | 290 | 440 | 590 | 770 |

10. Section 512—Hospice Consultation Service

As explained in section III.K, effective January 1, 2005, section 512 of the MMA provides for payment to be made to a hospice for specified services furnished by a physician who is either the medical director of, or an employee of, a hospice agency. We estimate that this MMA provision will increase Medicare expenditures by $10 million per year beginning in 2005.

11. Section 302—Clinical Conditions for Coverage of Durable Medical Equipment (DME)

As explained earlier in the preamble, to comply with the requirements of section 302 of the MMA and to enhance quality and reduce fraud, we are proposing to establish basic requirements that apply to all items of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS). The impact to the Medicare program will be to improve quality of care because we are involving the physician early in the process when determining the medical necessity for items of DMEPOS. The physician community has stated that they are often asked to order an item of DMEPOS for their patient when they do not think the item is reasonable and necessary. We believe these requirements will result in no costs or savings to Medicare because if any additional spending from more physician visits occur it will be offset by savings from Medicare paying for less DMEPOS. However, we expect to continue evaluating this issue.

*E. Other Issues*

1. Outpatient Therapy Services Performed ''Incident to'' Physicians'' Services

As discussed in section IV.A, we are proposing to amend the regulations to include the statutory requirement that only individuals meeting the existing qualification and training standards for therapists (with the exception of licensure) consistent with § 484.4 qualify to provide therapy services incident to physicians' services. We believe that while this will have little impact on Medicare expenditures, it will assist in ensuring the quality of services provided to beneficiaries.

2. Supervision Requirements for Therapy Assistants in Private Practice

As discussed earlier in section IV.A.2, we are proposing to revise the regulations at § 410.59 and § 410.60 to replace a requirement to provide personal supervision and instead require direct supervision of physical therapist assistants and occupational therapy assistants when therapy services are provided by physical therapists or occupational therapists in private practice. This proposed policy change would provide beneficiaries access to medically necessary therapy services, under a physician-certified plan of care. We believe that this change would result in a 5 percent increase in therapy billing in therapy private practice settings with an estimated cost of $9 million for FY 2005. Projected costs for FY 2006 are $17 million while each subsequent year would only increase by $1 million each year, assuming the therapy caps are applied.

3. Low Osmolar Contrast Media

As discussed earlier in the preamble, we are proposing to revise the regulations at § 414.38 to eliminate the restrictive criteria for the payment of LOCM. This proposal will make payment for LOCM consistent across Medicare payment systems. By identifying contrast-enhanced procedures that most commonly use LOCM, the typical ranges of LOCM amounts used by modality, and the cost ranges for LOCM in the marketplace, we estimate program costs as shown in the following table:

TABLE 35

| Regulatory Provision | FY 2005 | FY 2006 | FY 2007 | FY 2008 | FY 2009 |
|---|---|---|---|---|---|
| LOCM | 20 | 30 | 30 | 30 | 30 |

4. Payments for Physicians and Practitioners Managing Patients on Dialysis

We believe that the proposals with respect to ESRD-related services furnished to patients in observation settings and payment for outpatient ESRD-related services for partial month scenarios discussed earlier in section 1V. E. provide clarification of current policy surrounding these issues. We do not believe these proposals would have a significant impact on Medicare expenditures.

5. Supervision of Clinical Psychological Testing

We are proposing to change the supervision requirements regarding who can supervise diagnostic psychological testing services. As previously discussed, having ancillary staff supervised by clinical psychologists would enable these practitioners with a higher level of expertise to oversee psychological testing and potentially relieve burdens on physicians and healthcare facilities.

Additionally, in rural areas, we anticipate that permitting psychologists to supervise diagnostic psychological testing services would reduce delays in testing, diagnosis, and treatment that could result from the unavailability of physicians to supervise the tests. We believe that this proposal will have little impact on Medicare expenditures.

6. Care Plan Oversight

As discussed in section IV.G, we are proposing to revise § 414.39 to clarify that NPPs can perform home health care plan oversight even though they cannot certify a patient for home health services and sign the plan of care. We do not expect that this proposal would have an impact on Medicare expenditures, since it is only clarifying that an NPP or a physician can provide care plan oversight for home health care.

7. Assignment of Medicare Claims

The proposed changes with respect to assignment of Medicare claims are currently estimated to have no significant impact on Medicare expenditures. However, as stated earlier in this preamble at section IV.H, we believe the proposed changes will reduce the paperwork burden on beneficiaries and suppliers.

*F. Alternatives Considered*

This proposed rule contains a range of policies, including proposals related to specific MMA provisions. The preamble provides descriptions of the statutory provisions that are addressed, identifies those policies when discretion has been exercised and presents rationale for our decisions and, when possible, alternatives that were considered.

The following is a discussion of additional points on the proposed changes required by section 302 of the MMA involving ordering items of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS).

In developing the proposed changes to implement section 302 of the MMA, we did consider establishing ''the face-to-face requirement,'' and ''the order prior to delivery'' requirement only for specific items of DMEPOS for which there has been an identified proliferation of use. However, we believe it is important that the physician or nonphysician practitioner determine the medical need for all items of DME. It is good clinical practice for beneficiaries to be seen by the physician for their medical condition and at that time the physician will decide whether an item of DME is appropriate. It is our intent to make Medicare more consistent with private payers in that beneficiaries be seen by their physician for their medical condition, who then makes a diagnosis and orders any supplies needed to address their needs. Since we expect beneficiaries to be seen by their doctor for a specific medical condition, we do not believe that this would place a burden on the physician, as it would be part of a necessary examination.

We also note that in establishing these proposed requirements we do make exceptions for items of continued need, such as, glucose test strips or support surfaces. Once the physician has initially established the need, we do not require additional visits or additional documentation.

*G. Impact on Beneficiaries*

There are a number of changes made in this proposed rule that would have an effect on beneficiaries. In general, we believe these changes will improve beneficiary access to services that are currently covered or will expand the Medicare benefit package to include new services. As explained in more detail below, the MMA or regulatory provisions may increase beneficiary liability in some cases. Any changes in aggregate beneficiary liability from a particular provision will be a function of the coinsurance (20 percent if applicable for the particular provision after the beneficiary has met the deductible) and the effect of the aggregate cost (savings) of the provision on the calculation of the Medicare Part B premium rate (generally 25 percent of the provision's cost or savings). Taking into account the MMA and regulatory provisions of this proposed rule, we estimate beneficiary savings in FY 2005 of $270 million. This figure could be less if we make further changes to Medicare's drug administration payments.

The MMA provisions that expand Medicare benefits include: section 611, adding a preventive office visit for newly eligible Medicare beneficiaries; section 612 providing coverage of cardiovascular screening blood tests; and section 613, providing coverage for diabetes screening tests for Medicare beneficiaries at risk for diabetes. While the preventive office visit for newly eligible Medicare beneficiaries is subject to deductible and coinsurance, we believe Medicare beneficiaries will continue to benefit from expanded coverage for this service. We believe many beneficiaries have supplemental insurance coverage or Medicaid that pays the Medicare deductible on their behalf and there will be no immediate additional out-of-pocket cost. Further, even if a beneficiary pays nearly all of the costs of this new benefit, the preventive office visit will substitute for another service a beneficiary may need to meet the annual deductible and the beneficiary will receive more covered benefits at little additional cost. There are no out-of-pocket costs to the beneficiary for the cardiovascular screening blood tests and diabetes screening tests.

Other proposals in this rule related to the MMA will also impact beneficiary liability, with the most significant related to indexing of the part B deductible (section 629 of the MMA) and the drug administration payment changes (sections 303 and 305 of the MMA). Indexing of the Part B deductible will result in an estimated cost to beneficiaries of $110 million in 2005. MMA provisions that improve administration of the 10 percent HPSA bonus and provide an additional 5 percent bonus payment to physicians in Medicare scarcity areas will have no impact on beneficiary liability because the bonus payments are applied to the amount Medicare pays the physician net of beneficiary liability. These provisions will also improve access for Medicare beneficiaries by increasing payments to physicians in areas that traditionally have had a low ratio of physicians to population.

The implementation of MMA provisions related to drugs and drug administration will reduce Medicare beneficiary liability for Medicare covered services. We estimate that implementation of sections 303 through 305 of the MMA will reduce Medicare

beneficiary liability for drugs by $360 million in FY 2005. If we were to make no further changes to Medicare's payments for drug administration, we estimate additional savings to Medicare beneficiaries of $120 million in FY 2005. Provisions of this proposed rule that increase the supplying fee for immunosuppressive drugs and the furnishing fee for the clotting factor are estimated to increase beneficiary liability by $36 million and $10 million respectively, from FY 2005 through FY 2009.

We do not believe that the drug and drug administration payment changes required by the MMA are intended to lessen beneficiary access to care. By reducing beneficiary liability, we believe it is likely that beneficiary access to care will be improved. As indicated earlier, without any further change in payment for drug administration, the MMA increased payment for drug administration by more than 105 percent from 2003 to 2005 while making payment for drugs at 6 percent more than their average sales price. Nevertheless, we acknowledge that there is a concern among physicians and others that the large changes in Medicare's payments may affect their ability or willingness to continue making drugs and related services available.

As indicated above, we are considering making further changes to Medicare payment for drug administration based on the results of CPT's review of this issue or in response to public comment. Further, we are gathering Medicare utilization for drugs and drug administration beginning in 2002 and plan to analyze shifts or changes in utilization patterns as the information becomes available to us once the payment changes required by the MMA go into effect. While we do not believe the payment changes for drugs and drug administration will result in access problems, we plan to continue studying this issue. We also note that the MMA requires the Medicare Payment Advisory Commission (MedPAC) to study related issues. Specifically, section 303(a)(5) of the MMA requires MedPAC to study items and services furnished by oncologists and drug administration services furnished by other specialists. Similarly, section 305(b) requires the General Accounting Office to study the adequacy of Medicare payments for inhalation therapy.

We are also undertaking several changes using our administrative authority that will affect Medicare beneficiaries. Our proposal to remove restrictions that limit Medicare payment for use of low osmolar contrast material to specific indications would update Medicare's payment policy to be consistent with the standard practice of medicine and will improve the quality of care for beneficiaries.

We believe early involvement of the physician in determining the medical necessity for items of DMEPOS will assist in improving the accuracy of Medicare program payments and the quality of care. In addition, it will also reduce out-of-pocket costs for unnecessary DMEPOS that may have otherwise been provided to Medicare beneficiaries.

In accordance with the provisions of Executive Order 12866, this regulation was reviewed by the Office of Management and Budget.

**List of Subjects**

*42 CFR Part 405*

Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medical devices, Medicare, Reporting and recordkeeping requirements, Rural areas, X-rays

*42 CFR Part 410*

Health facilities, Health professions, Kidney diseases, Laboratories, Medicare, Reporting and recordkeeping requirements, Rural areas, X-rays

*42 CFR Part 411*

Kidney diseases, Medicare, Reporting and recordkeeping requirements

*42 CFR Part 414*

Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medicare, Reporting and recordkeeping requirements

*42 CFR Part 418*

Health facilities, Hospice care, Medicare, Reporting and recordkeeping requirements

*42 CFR Part 424*

Emergency medical services, Health facilities, Health professions, Medicare, Reporting and recordkeeping requirements

*42 CFR Part 484*

Health facilities, Health professions, Medicare, Reporting and recordkeeping requirements

*42 CFR Part 486*

Grant programs-health, Health facilities, Medicare, Reporting and recordkeeping requirements, X-rays

For the reasons set forth in the preamble, the Centers for Medicare & Medicaid Services proposes to amend 42 CFR chapter IV as follows:

## PART 405—FEDERAL HEALTH INSURANCE FOR THE AGED AND DISABLED

1. The authority citation for part 405 continues to read as follows:

**Authority:** Secs. 1102, 1861, 1862(a), 1871, 1874, 1881, and 1886(k) of the Social Security Act (42 U.S.C. 1302, 1395x, 1395y(a), 1395hh, 1395kk, 1395rr, and 1395ww(k)), and sec. 353 of the Public Health Service Act (42 U.S.C. 263a).

2. Section 405.207 is amended by revising paragraph (b) to read as follows:

### § 405.207 Services related to a noncovered device.

* * * * *

(b) *When payment is made.* Medicare payment may be made for—

(1) Covered services to treat a condition or complication that arises due to the use of a noncovered device or a noncovered device-related service; or

(2) Routine care services related to experimental/investigational (Category A) devices as defined in § 405.201(b); and furnished in conjunction with an FDA-approved clinical trial. The trial must meet criteria established through the national coverage determination process; and if the trial is initiated before January 1, 2010, the device must be determined as intended for use in the diagnosis, monitoring or treatment of an immediate life-threatening disease or condition.

(3) Routine care services related to a non-experimental/investigational (Category B) device defined in § 405.201(b) that is furnished in conjunction with an FDA-approved clinical trial.

3. Section 405.517 is amended by adding a new paragraph (a)(3) to read as follows:

### § 405.517 Payment for drugs and biologicals that are not paid on a cost or prospective payment basis.

(a) *Applicability.* * * *

(3) *Payment for drugs and biologicals on or after January 1, 2005.* Effective January 1, 2005, payment for drugs and biologicals that are not paid on a cost or prospective payment basis are paid in accordance with part 414, subpart K of this chapter.

## PART 410—SUPPLEMENTARY MEDICAL INSURANCE (SMI) BENEFITS

4. The authority citation for part 410 continues to read as follows:

**Authority:** Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

5. Section 410.10 is amended by adding new paragraph (y) to read as follows:

**§ 410.10 Medical and other health services: Included services.**

* * * * *

(y) Intravenous immune globulin administered in the home for the treatment of primary immune deficiency diseases.

6. Section 410.16 is added to read as follows:

**§ 410.16 Initial preventive physical examination: Conditions for and limitations on coverage.**

(a) *Definitions.* As used in this section, the following definitions apply—

*Eligible beneficiary* means individuals who receive their initial preventive physical examinations within 6 months after the effective date of their first Medicare Part B coverage period, but only if their first Part B coverage period begins on or after January 1, 2005.

*Initial preventive physical examination* means all of the following services furnished to an individual by a physician or other qualified nonphysician practitioner with the goal of health promotion and disease detection:

(1) Review of the individual's comprehensive medical and social history.

(2) Review of the individual's potential (risk factors) for depression, including past experiences with depression or other mood disorders, based on the use of an appropriate screening instrument, which the physician or other qualified nonphysician practitioner may select unless the appropriate screening instrument is further defined through a national coverage determination.

(3) Review of the individual's functional ability, and level of safety, based on the use of an appropriate screening instrument, which the physician or other qualified nonphysician practitioner may select unless the appropriate screening instrument is defined through a national coverage determination.

(4) An examination to include measurement of the individual's height, weight, blood pressure, a visual acuity screen, and other factors as deemed appropriate, based on the individual's medical and social history, and current clinical standards.

(5) Performance and interpretation of an electrocardiogram.

(6) Education, counseling, and referral, as deemed appropriate by the physician or qualified nonphysician practitioner, based on the results of the review and evaluation services described in this section.

(7) Education, counseling, and referral, including a written plan provided to the individual for obtaining the appropriate screening and other preventive services for the individual that are covered as separate Medicare Part B benefits as described in section 1861(s)(10), section 1861(jj), section 1861(nn), section 1861(oo), section 1861(pp), section 1861(qq)(1), section 1861(rr), section 1861(uu), section 1861(vv), section 1861(xx)(1), and section 1861(yy) of the Social Security Act (the Act).

*Medical history* is defined to include, at a minimum, the following:

(1) Past medical and surgical history, including experiences with illnesses, hospital stays, operations, allergies, injuries and treatments.

(2) Current medications and supplements, including calcium and vitamins.

(3) Family history, including a review of medical events in the patient's family, including diseases that may be hereditary or place the individual at risk.

*Physician* for purposes of this provision means a doctor of medicine or osteopathy (as defined in section 1861(r)(1) of the Act).

*Qualified nonphysician practitioner* for purposes of this provision means a physician assistant, nurse practitioner, or clinical nurse specialist (as authorized under section 1861(s)(2)(K)(i) and section 1861(s)(2)(K)(ii) of the Act and defined in section 1861(aa)(5) of the Act, or in regulations at § 410.74, § 410.75, and § 410.76).

*Review of the individual's functional ability and level of safety.* Review of the individual's functional ability and level of safety must include, at a minimum, a review of the following areas:

(1) Hearing impairment.

(2) Activities of daily living.

(3) Falls risk.

(4) Home safety.

*Social history* is defined to include, at a minimum, the following:

(1) History of alcohol, tobacco, and illicit drug use.

(2) Work and travel history.

(3) Diet.

(4) Social activities.

(5) Physical activities.

(b) *Condition for coverage of an initial preventive physical examination.* Medicare Part B pays for an initial preventive physical examination provided to an eligible beneficiary, as described in paragraph (a) of this section, if it is furnished by a physician or other qualified nonphysician practitioner, as defined in paragraphs (a) of this section.

(c) *Limitations on coverage of initial preventive physical examinations.* Payment may not be made for an initial preventive physical preventive examination that is performed for an individual who is not an eligible beneficiary as described in paragraph (a) of this section.

7. A new § 410.17 is added to read as follows:

**§ 410.17 Cardiovascular disease screening tests.**

(a) *Definition.* For purposes of this subpart, the following definition applies:

*Cardiovascular screening blood test* means:

(1) A lipid panel consisting of a total cholesterol, HDL cholesterol, and triglyceride. The test is performed after a 12-hour fasting period.

(2) Other blood tests, previously recommended by the U.S. Preventive Services Task Force (USPSTF), as determined by the Secretary through a national coverage determination process.

(3) Other non-invasive tests, for indications that have a blood test recommended by the USPSTF, as determined by the Secretary through a national coverage determination process.

(b) *General conditions of coverage.* Medicare Part B covers cardiovascular disease screening tests when ordered by the physician who is treating the beneficiary (see § 410.32(a)) for the purpose of early detection of cardiovascular disease in individuals without apparent signs or symptoms of cardiovascular disease.

(c) *Limitation on coverage of cardiovascular screening tests.* Payment may be made for cardiovascular screening tests performed for an asymptomatic individual only if the individual has not had the screening tests paid for by Medicare during the preceding 59 months following the month in which the last cardiovascular screening tests were performed.

8. A new § 410.18 is added to read as follows:

**§ 410.18 Diabetes screening tests.**

(a) *Definitions.* For purposes of this section, the following definitions apply:

*Diabetes* means diabetes mellitus, a condition of abnormal glucose metabolism diagnosed using the following criteria: a fasting blood sugar

greater than or equal to 126 mg/dL on two different occasions; a 2-hour post-glucose challenge greater than or equal to 200 mg/dL on two different occasions; or a random glucose test over 200 mg/dL for a person with symptoms of uncontrolled diabetes.

*Pre-diabetes* means a condition of abnormal glucose metabolism diagnosed using the following criteria: a fasting glucose level of 100–125 mg/dL, or a 2-hour post-glucose challenge of 140–199 mg/dL. The term pre-diabetes includes the following conditions:

(1) Impaired fasting glucose.

(2) Impaired glucose tolerance.

(b) *General conditions of coverage.* Medicare Part B covers diabetes screening tests after a referral from a physician or qualified nonphysician practitioner to an individual at risk for diabetes for the purpose of early detection of diabetes.

(c) *Types of tests covered.* The following tests are covered if all other conditions of this subpart are met:

(1) Fasting plasma glucose test.

(2) Post-glucose challenges including, but not limited to, an oral glucose tolerance test with a glucose challenge of 75 grams of glucose for non-pregnant adults, a 2-hour post glucose challenge test alone.

(3) Other tests as determined by the Secretary through a national coverage determination.

(d) *Amount of testing covered.* Medicare covers the following for individuals:

(1) Diagnosed with pre-diabetes Medicare, two screening tests per calendar year.

(2) Previously tested who were not diagnosed with pre-diabetes, or who have never been tested before, one screening test per year.

(e) *Eligible risk factors.* Individuals with the following risk factors are eligible to receive the benefit:

(1) Hypertension.

(2) Dyslipidemia.

(3) Obesity, defined as a body mass index greater than or equal to 30 kg/m2.

(4) Prior identification of impaired fasting glucose or glucose intolerance.

(5) Any two of the following characteristics:

(i) Overweight, defined as body mass index greater than 25, but less than 30, kg/m2.

(ii) A family history of diabetes.

(iii) 65 years of age or older.

(iv) A history of birthing a baby weighing more than 9 pounds.

(f) *Individuals not covered.* For individuals previously diagnosed as diabetic, no coverage.

9. Section 410.26 is amended by revising paragraph (c) to read as follows:

**§ 410.26 Services and supplies incident to a physician's professional services: Conditions.**

* * * * *

(c) *Limitations.* (1) Drugs and biologicals are also subject to the limitations specified in § 410.29.

(2) Physical therapy, occupational therapy and speech-language pathology services provided incident to a physician's professional services are subject to the provisions established in § 410.59(a)(3)(iii), § 410.60(a)(3)(iii), and § 410.62(a)(3)(ii).

10. Section 410.32 is amended by revising paragraph (b)(2)(iii) to read as follows:

**§ 410.32 Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions.**

* * * * *

(b) * * *

(2) * * *

(iii) Diagnostic psychological testing services when—

(A) Personally furnished by a clinical psychologist or an independently practicing psychologist as defined in program instructions; or

(B) Furnished under the general supervision of a physician or a clinical psychologist.

* * * * *

11. Section 410.36 is amended by—

A. Revising the section heading.

B. Adding to paragraph (a), the paragraph heading ''Condition for coverage medical supplies, appliances, and devices.''

C. Revising paragraph (b).

D. Adding new paragraphs (c) and (d).

The additions and revisions read as follows:

**§ 410.36 Medical supplies, appliances, and devices: Conditions for and limitations on coverage.**

(a) *Conditions for coverage of medical supplies, appliances, and medical devices.* * * *

(b) *Conditions for coverage.* Medicare Part B pays for the medical supplies, appliances, and devices listed in paragraph (a) of this section when:

(1) The medical supplies, appliances, and devices are ordered by a physician, physician assistant, clinical nurse specialist, or nurse practitioner as defined in the Act.

(2) The physician or prescribing practitioner—

(i) Conducts a face-to-face examination to determine the medical necessity for medical supplies, appliances, and devices.

(ii) Conducts the face-to-face examination only for the initial order and at the time of the prescription renewal for items of continued need, such as glucose testing supplies.

(iii) Is independent from the DME supplier and may not be an employee or contractor of the supplier.

(3) A written order is completed and signed before delivery of these medical supplies, appliances, and devices to the beneficiary.

(4) The physician's or prescribing practitioner's order is dated and signed within 30 days after the face-to-face examination and the beneficiary's medical record includes verification of the face-to-face examination.

(5) The physician or prescribing practitioner documents in the beneficiary's medical record the need for the medical supplies, appliances, and devices being ordered.

(6) CMS may determine other criteria, such as prescription renewal requirements, repairs, minor revisions and replacement, through contractor instructions.

(c) *Limitation.* Medicare does not pay for a face-to-face examination for the sole purpose of the beneficiary's obtaining the physician or prescribing practitioner's order for the medical supplies, appliances, and devices.

(d) *Clinical conditions for coverage.* Clinical conditions for coverage, other than those set forth in paragraph (b) of this section, of medical supplies, appliances, and devices are determined through the national or local coverage determination process.

12. Section 410.38 is amended by—

A. Revising paragraph (g).

B. Adding paragraphs (h) and (i).

The revision and additions read as follows:

**§ 410.38 Durable medical equipment: Scope and conditions.**

* * * * *

(g) *Conditions for coverage.* (1) Medicare Part B pays for durable medical equipment ordered by a physician, physician assistant, clinical nurse specialist, or nurse practitioner, as defined in the Act.

(2) The physician or prescribing practitioner must—

(i) Conduct a face-to-face examination to determine the medical necessity of each item of durable medical equipment.

(ii) Conduct the face-to-face examination for the initial order and at the time of the prescription renewal for items of continued need, such as infusion pumps or hospital beds.

(iii) Be independent from the DME supplier and cannot be an employee or contractor of the supplier.

(3) A written order must be completed and signed before delivery of any

durable medical equipment to the beneficiary.

(4) The physician's or prescribing practitioner's order must be dated and signed within 30 days after the face-to-face examination and the beneficiary's medical record must include verification of the face-to-face examination.

(5) The physician or prescribing practitioner must document in the beneficiary's medical record the need for the durable medical equipment being ordered.

(6) CMS may determine other additional payment criteria, such as prescription renewal requirements, repairs, minor revisions and replacement, through contractor instructions.

(h) *Limitation.* Medicare does not pay for a face-to-face examination for the sole purpose of the beneficiary's obtaining the physician's or prescribing practitioner's order for the durable medical equipment.

(i) *Clinical conditions for coverage.* Clinical conditions for coverage, not defined in paragraph (g) of this section, of durable medical equipment are determined through the national or local coverage determination process.

13. Section 410.59 is amended by—

A. Revising paragraph (a) introductory text and paragraph (a)(3)(ii).

B. Adding new paragraph (a)(3)(iii).

C. Revising paragraph (b) heading.

C. Revising paragraph (c)(2).

D. Adding new paragraph (e)(1)(iii).

The additions and revisions read as follows:

**§ 410.59 Outpatient occupational therapy services: Conditions.**

(a) *Basic rule.* Except as specified in paragraph (a)(3)(iii) of this section, Medicare Part B pays for outpatient occupational therapy services only if they are furnished by an individual meeting the qualifications in § 484.4 for an occupational therapist or by an appropriately supervised occupational therapy assistant who meets the following conditions: * * *

(3) * * *

(ii) By, or under the direct supervision of, an occupational therapist in private practice as described in paragraph (c) of this section; or

(iii) By, or incident to the service of, a physician, physician assistant, clinical nurse specialist, or nurse practitioner when those professionals may perform occupational therapy services within the scope of their State practice. When an occupational therapy service is provided incident to the service of a physician, physician assistant, clinical nurse specialist, or nurse practitioner, the service and the person who furnishes the service must meet the standards and conditions that apply to occupational therapy and occupational therapists, except that a license to practice occupational therapy in the State is not required.

(b) *Conditions for coverage of outpatient therapy services furnished to certain inpatients of a hospital or a CAH or SNF.* * * *

* * * * *

(c) *Special provisions for services furnished by occupational therapists in private practice.* * * *

(2) *Supervision of occupational therapy services.* Occupational therapy services are performed by, or under the direct supervision of, an occupational therapist in private practice. All services not performed personally by the therapist must be performed by employees of the practice, directly supervised by the therapist, and included in the fee for the therapist's services.

* * * * *

(e) *Annual limitation on incurred expenses.*

(1) * * *

(iii) The limitation is not applied for services furnished from December 8, 2003 through December 31, 2005.

* * * * *

14. Section 410.60 is amended by—

A. Revising paragraph (a) introductory text.

B. Revising paragraph (a)(3)(ii).

C. Adding new paragraph (a)(3)(iii).

D. Revising paragraph (b) heading.

E. Revising paragraph (c)(2).

F. Adding new paragraph (e)(1)(iii).

The additions and revisions read as follows:

**§ 410.60 Outpatient physical therapy services: Conditions.**

(a) *Basic rule.* Except as specified in paragraph (a)(3)(iii) of this section, Medicare Part B pays for outpatient physical therapy services only if they are furnished by an individual meeting the qualifications in § 484.4 for a physical therapist or by an appropriately supervised physical therapist assistant who meets the following conditions:

* * * * *

(3) * * *

(ii) By or under the direct supervision of a physical therapist in private practice as described in paragraph (c) of this section; or

(iii) By, or incident to, the service of a physician, physician assistant, clinical nurse specialist, or nurse practitioner when those professionals may perform physical therapy services within the scope of their State practice. When a physical therapy service is provided incident to the service of a physician, physician's assistant, clinical nurse specialist, or nurse practitioner, the service and person who furnishes the service must meet the standards and conditions that apply to physical therapy and physical therapists, except that a license to practice physical therapy in the State is not required.

(b) *Condition for coverage of outpatient physical therapy services furnished to certain inpatients of a hospital or a CAH or SNF.* * * *

(c) Special provisions for services furnished by physical therapists in private practice. * * *

(2) *Supervision of physical therapy services.* Physical therapy services are performed by, or under the direct supervision of, a physical therapist in private practice. All services not performed personally by the therapist must be performed by employees of the practice, directly supervised by the therapist, and included in the fee for the therapist's services.

* * * * *

(e) *Annual limitation on incurred expenses.*

(1) * * *

(iii) The limitation is not applied for services furnished from December 8, 2003 through December 31, 2005.

* * * * *

15. Section 410.62 is amended by—

A. Revising paragraph (a) introductory text and (a)(2)(i), (a)(2)(iii) and (a)(3).

B. Revising paragraphs (b) and (c).

The revisions read as follows:

**§ 410.62 Outpatient speech-language pathology services: Conditions and exclusions.**

(a) *Basic rule.* Except as specified in paragraph (a)(3)(ii) of this section, Medicare Part B pays for outpatient speech-language pathology services only if they are furnished by an individual who meets the qualifications for a speech-language pathologist in § 484.4 of this chapter if they meet the following conditions: * * *

(2) * * *

(i) Is established by a physician or, effective January 1, 1982, by either a physician or the speech-language pathologist who provides the services to the particular individual;

(ii) * * *

(iii) Meets the requirements of § 410.61.

(3) They are furnished—

(i) By a provider as defined in § 489.2 of this chapter, or by others under arrangements with, and under the supervision of, a provider; or

(ii) By, or incident to, the service of a physician, physician assistant, clinical

nurse specialist, or nurse practitioner when those professionals may perform speech-language pathology services within the scope of their State practice. When a speech-language pathology service is provided incident to the services of a physician, physician's assistant, clinical nurse specialist, or nurse practitioner, the service and the person who furnishes the service must meet the standards and conditions that apply to speech-language pathology and speech-language pathologists, except that a license to practice speech-language pathology services in the State is not required.

(b) *Condition for coverage of outpatient speech-language pathology services to certain inpatients of a hospital, CAH, or SNF.* Medicare Part B pays for outpatient speech-language pathology services furnished to an inpatient of a hospital, CAH, or SNF who requires the services but has exhausted or is otherwise ineligible for benefit days under Medicare Part A.

(c) *Excluded services.* No service is included as an outpatient speech-language pathology service if it is not included as an inpatient hospital service if furnished to a hospital or CAH inpatient.

* * * * *

16. Section 410.63 is amended by—

A. Revising paragraph (b) section heading.

B. Adding a new paragraph (c).

The revision and addition reads as follows:

**§ 410.63 Hepatitis vaccine and blood clotting factors: Conditions.**

(b) *Blood clotting factors: Conditions.*

* * *

(c) *Blood clotting factors: Separate payment.* Effective January 1, 2005, Medicare pays hemophilia treatment centers and homecare companies that furnish blood clotting factor a separate payment of $0.05 per unit for the items and services associated with the furnishing of the blood clotting factor. These items and services include the mixing and delivery of factors, including special inventory management and storage requirements, as well as ancillary supplies and patient training necessary for the self-administration of these factors.

17. Section 410.78 is amended by—

A. Revising paragraph (a)(4).

B. Revising paragraph (b) introductory text.

The revisions read as follows:

**§ 410.78 Telehealth services.**

(a) * * *

(4) *Originating site* means the location of an eligible Medicare beneficiary at the time the service being furnished via a telecommunications system occurs. For asynchronous store and forward telecommunications technologies, the only originating sites are Federal telemedicine demonstration programs conducted in Alaska or Hawaii.

(b) *General rule.* Medicare Part B pays for office and other outpatient visits, professional consultation, psychiatric diagnostic interview examination, individual psychotherapy, monthly end stage renal disease (ESRD) related evaluation and management services and pharmacologic management furnished by an interactive telecommunications system if the following conditions are met:

* * * * *

18. Section 410.160 is amended by revising paragraph (f) to read as follows:

**§ 410.160 Part B annual deductible.**

* * * * *

(f) *Amount of the Part B annual deductible.* (1) Beginning with expenses for services furnished during calendar year 2006, and for all succeeding years, the annual deductible is the previous year's deductible plus the annual percentage increase in the monthly actuarial rate for Medicare enrollees age 65 and over, rounded to the nearest dollar.

(2) For 2005, the deductible is $110.

(3) From 1991 through 2004, the deductible was $100.

(4) From 1982 through 1990, the deductible was $75.

(5) From 1973 through 1981, the deductible was $60.

(6) From 1966 through 1972, the deductible was $50.

* * * * *

## PART 411—EXCLUSIONS FROM MEDICARE AND LIMITATIONS ON MEDICARE PAYMENT

19. The authority citation for part 411 continues to read as follows:

**Authority:** Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

20. Section 411.15 is amended by—

A. Revising paragraph (a)(1).

B. Adding paragraph (k)(11).

The revision and addition read as follows:

**§ 411.15 Particular services excluded from coverage.**

* * * * *

(a) * * *

(1) Examinations performed for a purpose other than treatment or diagnosis of a specific illness, symptoms, complaint, or injury, except for screening mammography, colorectal cancer screening tests, screening pelvic exams, prostate cancer screening tests, glaucoma screening exams, or initial preventive physical examinations that meet the criteria specified in paragraphs (k)(6) through (k)(11) of this section.

* * * * *

(k) * * *

(11) In the case of initial preventive physical examinations, with the goal of health promotion and disease prevention, subject to the conditions and limitations specified in § 410.16 of this chapter.

* * * * *

21. Section 411.404 is amended by revising paragraph (b) to read as follows:

**§ 411.404 Criteria for determining that a beneficiary knew that services were excluded from coverage as custodial care or as not reasonable and necessary.**

* * * * *

(b) *Written notice.* Written notice is given to the beneficiary, or to someone acting on his or her behalf, that the services were not covered because they did not meet Medicare coverage guidelines. A notice concerning similar or reasonably comparable services furnished on a previous occasion also meets this criterion. After a beneficiary is notified that there is no Medicare payment for a service that is not covered by Medicare, he or she is presumed to know that there is no Medicare payment for any form of subsequent treatment for the non-covered condition.

* * * * *

## PART 414—PAYMENT FOR PART B MEDICAL AND OTHER HEALTH SERVICES.

22. The authority citation for part 414 continues to read as follows:

**Authority:** Secs. 1102, 1871, and 1881(b)(1) of the Social Security Act (42 U.S.C. 1302, 1395hh, and 1395rr(b)(1)).

**§ 414.38 [Removed]**

23. Section 414.38 is removed.

24. Section 414.39 is amended by—

A. Revising paragraph (a).

B. Adding paragraph (c).

The revision and addition read as follows:

**§ 414.39 Special rules for payment of care plan oversight.**

(a) *General.* Except as specified in paragraphs (b) and (c) of this section, payment for care plan oversight is included in the payment for visits and other services under the physician fee schedule. For purposes of this section a nonphysician practitioner (NPP) is a nurse practitioner, clinical nurse specialist or physician assistant.

* * * * *

(c) *Special rules for payment of care plan oversight provided by nonphysician practitioners for beneficiaries who receive HHA services covered by Medicare.* (1) An NPP can perform physician care plan oversight without certifying a patient for home health services (only a physician can certify a patient for home health care) if the relationship with the physician who signs the plan of care meets one of the following conditions:

(i) The physician and NPP are part of the same group practice;

(ii) If the NPP is a nurse practitioner or clinical nurse specialist, the physician signing the plan of care also has a collaborative agreement with the NPP;

(iii) If the NPP is a physician assistant, the physician signing the plan of care is also the physician who provides general supervision of physician assistant services for the practice; or

(iv) The physician signing the plan of care provides regular ongoing care under the same plan of care as does the NPP billing for care plan oversight.

(2) Payment may be made for care plan oversight services furnished by an NPP when:

(i) The NPP providing the care plan oversight has seen and examined the patient;

(ii) The NPP providing care plan oversight is not functioning as a consultant whose participation is limited to a single medical condition rather than multi-disciplinary coordination of care; or

(iii) The NPP providing care plan oversight integrates his or her care with that of the physician who signed the plan of care.

25. Section 414.65 is amended by revising paragraph (a)(1) to read as follows:

**§ 414.65 Payment for telehealth services.**

(a) * * *

(1) The Medicare payment amount for office or other outpatient visits, consultation, individual psychotherapy, psychiatric diagnostic interview examination, monthly end stage renal disease (ESRD) related evaluation and management services and pharmacologic management furnished via an interactive telecommunications system is equal to the current fee schedule amount applicable for the service of the physician or practitioner.

* * * * *

26. Section 414.66 is added to read as follows:

**§ 414.66 Incentive payments for physicians scarcity areas.**

(a) *Definition.* As used in this section, the following definition applies—

*Primary care physician* is defined as a general practitioner, family practice practitioner, general internist, obstetrician or gynecologist.

(b) Physicians' services furnished to a beneficiary in a Physician Scarcity Area (PSA) for primary or specialist care are eligible for a 5 percent incentive payment.

(c) Primary care physicians furnishing services in primary care PSAs are entitled to an additional 5 percent incentive payment above the amount paid under the physician fee schedule for their professional services furnished on or after January 1, 2005 and before January 1, 2008.

(d) Physicians (other than dentists, podiatrists, optometrists, chiropractors, and those identified in paragraph (a) of this section) furnishing services in specialist care PSAs are entitled to an additional 5 percent payment above the amount paid under the physician fee schedule for their professional services furnished on or after January 1, 2005 and before January 1, 2008.

27. Section 414.67 is added to read as follows:

**§ 414.67 Incentive payments for Health Professional Shortage Areas.**

(a) Physicians' services furnished to a beneficiary in a geographic-based Health Professional Shortage Area (HPSA) are eligible for a 10 percent incentive payment.

(b) Physicians furnishing services in a geographic-based primary medical care HPSA are entitled to a 10 percent incentive payment above the amount paid for their professional services under the physician fee schedule.

(c) Psychiatrists furnishing services in a mental health HPSA are entitled to a 10 percent incentive payment above the amount paid for their professional services under the physician fee schedule. (The only physicians eligible to receive the 10 percent incentive payment in mental health HPSAs that do not overlap with primary care HPSAs are psychiatrists.)

28. Part 414 is amended by adding a new subpart K to read as follows:

**Subpart K—Payment for Drugs and Biologicals in 2005**

Sec.
414.900 Basis.
414.902 Definitions.
414.904 Basis of Payment.

## Subpart K—Payment for Drugs and Biologicals in 2005

**§ 414.900 Basis.**

(a) This subpart implements section 1842(o) of the Social Security Act by specifying the methodology for determining the payment allowance limit for drugs and biologicals covered under Medicare Part B that are not paid on a cost or prospective payment system basis.

(b) Examples of drugs that are subject to the requirements specified in this subpart are:

(1) Drugs furnished incident to a physician's service; durable medical equipment (DME) drugs.

(2) Separately billable drugs at independent dialysis facilities not under the ESRD composite rate.

(3) Statutorily covered drugs, for example—

(i) Influenza

(ii) Pneumococcal and hepatitis vaccines.

(iii) Antigens.

(iv) Hemophilia blood clotting factor.

(v) Immunosuppressive drugs.

(vi) Certain oral anti-cancer drugs.

**§ 414.902 Definitions.**

As used in this subpart, unless the context indicates otherwise—

*Drug* means both drugs and biologicals.

*Manufacturer's average sales price* means the price calculated and reported by a manufacturer under part 414, subpart J of this chapter.

*Multiple source drug* means a drug described by section 1847A(c)(6)(C) of the Act.

*Single source drug* means a drug described by section 1847A(c)(6)(D) of the Act.

*Unit* is defined as in part 414, subpart J of this chapter.

*Wholesale acquisition cost (WAC)* means the price described by section 1847A(c)(6)(B) of the Act.

**§ 414.904 Basis of payment.**

(a) *Method of payment.* Payment for a drug for calendar year 2005 is based on the lesser of—

(1) The actual charge on the claim for program benefits; or

(2) 106 percent of the average sales price, subject to the applicable limitations specified in paragraph (d) of this section or subject to the exceptions described in paragraph (e) of this section.

(b) *Multiple source drugs.* (1) *Average sales prices.* The average sales price for all drug products included within the same multiple source drug billing and payment code is the volume-weighted

average of the manufacturers' average sales prices for those drug products.

(2) *Calculation of the average sales price.* The average sales price is determined by—

(i) Computing the sum of the products (for each National Drug Code assigned to the drug products) of the manufacturer's average sales price and the total number of units sold; and

(ii) Dividing that sum by the sum of the total number of units sold for all NDCs assigned to the drug products.

(c) *Single source drugs.* (1) *Average sales price.* The average sales price is the volume-weighted average of the manufacturers' average sales prices for all National Drug Codes assigned to the drug or biological product.

(2) *Calculation of the average sales price.* The average sales price is determined by computing—

(i) The sum of the products (for each National Drug Code assigned to the drug product) of the manufacturer's average sales price and the total number of units sold; and

(ii) Dividing that sum by the sum of the total number of units sold for all NDCs assigned to the drug product.

(d) *Limitations on the average sales price.* (1) *Wholesale acquisition cost for a single source drug.* The payment limit for a single source drug product is the lesser of 106 percent of the average sales price for the product or 106 percent of the wholesale acquisition cost for the product.

(2) *Payment limit for a drug furnished to an end-stage renal disease patient.* The payment for a drug furnished to an end-stage renal disease patient that is separately billed by an end stage renal disease facility, including erythropoietin, cannot exceed 97 percent of the average sales price.

(3) *Widely available market price and average manufacturer price.* If the Inspector General finds that the average sales price exceeds the widely available market price or the average manufacturer price by 5 percent or more in calendar year 2005, the payment limit in the quarter following the transmittal of this information to the Secretary is the lesser of the widely available market price or 103 percent of the average manufacturer price.

(e) *Exceptions to the average sales price.* (1) *Vaccines.* The payment limits for hepatitis B vaccine furnished to individuals at high or intermediate risk of contracting hepatitis B (as determined by the Secretary), pneumococcal vaccine, and influenza vaccine and are calculated using 95 percent of the average wholesale price.

(2) *Infusion drugs furnished through a covered item of durable medical equipment.* The payment limit for an infusion drug furnished through a covered item of durable medical equipment is calculated using 95 percent of the average wholesale price in effect on October 1, 2003 and is not updated in 2005.

(3) *Blood and blood products.* In the case of blood and blood products (other than blood clotting factors), the payment limits are determined in the same manner as the payment limits were determined on October 1, 2003.

(4) *Payment limit in a case where the average sales price during the first quarter of sales is unavailable.* In the case of a drug during an initial period (not to exceed a full calendar quarter) in which data on the prices for sales of the drug are not sufficiently available from the manufacturer to compute an average sales price for the drug, the payment limit is based on the wholesale acquisition cost or the applicable Medicare Part B drug payment methodology in effect on November 1, 2003.

(f) Except as otherwise specified (see paragraph (e)(2)of this section) for infusion drugs, the payment limits are updated quarterly.

(g) The payment limit is computed without regard to any special packaging, labeling, or identifiers on the dosage form or product or package.

(h) The payment amount is subject to applicable deductible and coinsurance.

## PART 418—HOSPICE CARE

29. The authority citation for part 418 continues to read as follows:

**Authority:** Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

30. Section 418.205 is added to read as follows:

### § 418.205 Special requirements for hospice pre-election evaluation and counseling services.

(a) *Definition.* For purposes of this section, the following definition applies:

*Terminal illness* is defined as having a prognosis of 6 months or less if the disease or illness runs its normal course.

(b) *Effective date for payment and requirements.* Effective January 1, 2005, payment for hospice pre-election evaluation and counseling services as specified in § 418.304(d) may be made to a hospice agency on behalf of a Medicare beneficiary who is terminally ill if the requirements of this section are met.

(1) *The beneficiary:* (i) Is certified as having a terminal illness.

(ii) Has not made a hospice election.

(iii) Has not previously received hospice pre-election evaluation and consultation services specified under this section.

(2) *Services provided.* The hospice pre-election services include—(i) An evaluation of an individual's need for pain and symptom management;

(ii) Counseling regarding hospice and other care options; and

(iii) May include advising the individual regarding advanced care planning.

(3) *Provider of pre-election hospice services.* (i) The physician furnishing these services must be an employee or medical director of the hospice billing for this service.

(ii) The services cannot be furnished by other hospice personnel, such as but not limited to nurse practitioners, nurses, or social workers, physicians under contractual arrangements with the hospice or by the beneficiary's physician, if that physician is not an employee of the hospice.

(iii) If the beneficiary's physician is also the medical director or a physician employee of the hospice, the attending physician is not required to request or provide this service because that physician already possesses the expertise necessary to furnish end-of-life evaluation and management, and counseling services.

(4) *Documentation.* (i) If the individual's physician initiates the request for services of the hospice medical director or physician, appropriate documentation is required.

(ii) The request or referral must be in writing, and the hospice medical director or physician employee is expected to provide a written note on the patient's medical record.

(iii) The hospice agency employing the physician providing these services is required to maintain a written record of the services rendered.

(iv) If the services are initiated by the beneficiary, the hospice agency is required to maintain a record of the services and that communication between the hospice medical director or physician and the beneficiary's physician occurs, with the beneficiary's permission, to the extent necessary to ensure continuity of care.

31. Section 418.304 is amended by adding paragraph (d) to read as follows.

### § 418.304 Payment for physician services.

* * * * *

(d) *Payment for hospice evaluation and counseling services—pre-election.* The intermediary makes payment for these services established in § 418.205 to the hospice. As directed by the statute, payment for this service is set at an amount established for an office or other outpatient visit for evaluation and

management associated with presenting problems of moderate severity and requiring medical decision-making of low complexity under the physician fee schedule, other than the portion of such amount attributable to the practice expense component. Payment for this pre-election service is not calculated towards the hospice cap amount.

## PART 424—CONDITIONS FOR MEDICARE PAYMENT

32. The authority citation for part 424 continues to read as follows:

**Authority:** Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

33. Section 424.55 is amended by adding new paragraph (c) to read as follows:

### § 424.55 Payment to the supplier.

* * * * *

(c) *Exception.* In situations when payment under the Act can only be made on an assignment-related basis or when payment is for services furnished by a participating physician or supplier, the beneficiary (or the person authorized to request payment on the beneficiary's behalf) is not required to assign the claim to the supplier in order for an assignment to be effective.

34. Section 424.71 is amended as follows:

A. The definition of ''Health care delivery system or system'' is removed.

B. The definition of the term ''Entity'' is added in alphabetical order.

The addition reads as follows:

### § 424.71 Definitions.

* * * * *

*Entity* means a person, group, or facility that is enrolled in the Medicare program.

* * * * *

35. Section 424.80 is amended by—

A. Revising paragraph (b)(2).

B. Removing paragraph (b)(3).

C. Redesignating paragraphs (b)(4) through (6) as paragraphs (b) (3) through (5), respectively.

D. Revising paragraph (c).

E. Adding a new paragraph (d).

The revisions and addition read as follows:

### § 424.80 Prohibition of reassignment of claims by suppliers.

* * * * *

(b) * * *

(1) * * *

(2) *Payment to an entity under a contractual arrangement.* Medicare may pay an entity enrolled in the Medicare program if there is a contractual arrangement between the entity and the supplier under which the entity bills for the supplier's services, subject to the provisions of paragraph (d) of this section.

* * * * *

(c) *Rules applicable to an employer or entity.* An employer or entity that may receive payment under paragraph (b)(1) or (b)(2) of this section is considered the supplier of those services for purposes of subparts C, D, and E of this part, subject to the provisions of paragraph (d) of this section.

(d) *Reassignment to an entity under a contractual arrangement: Conditions and limitations.* (1) *Liability of the parties.* An entity enrolled in the Medicare program that receives payment under a contractual arrangement under paragraph (b)(2) of this section and the supplier that otherwise receives payment are jointly and severally responsible for any Medicare overpayment to that entity.

(2) *Access to records.* The supplier furnishing the service has unrestricted access to claims submitted by an entity for services provided by that supplier.

## PART 484–HOME HEALTH SERVICES

36. The authority citation for part 484 continues to read as follows:

**Authority:** Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395(hh).

### § 484.4 [Amended]

37. In § 484.4 in the definition of physical therapy assistant the term ''physical therapy assistant'' is removed and the term ''physical therapist assistant'' is added in its place wherever it appears.

## PART 486—CONDITIONS FOR COVERAGE OF SPECIALIZED SERVICES FURNISHED BY SUPPLIERS

38. The authority citation for part 486 continues to read as follows:

**Authority:** Sections 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

### Subpart D [Removed and Reserved]

39. Part 486 subpart D, consisting of § 486.150 through § 486.163, is removed and reserved.

(Catalog of Federal Domestic Assistance Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: July 13, 2004.

**Mark B. McClellan,**

*Administrator, Centers for Medicare & Medicaid Services.*

Approved: July 23, 2004.

**Tommy G. Thompson,**

*Secretary.*

**Note:** These addenda will not appear in the Code of Federal Regulations.

### Addendum A—Explanation and Use of Addenda B

The addenda on the following pages provide various data pertaining to the Medicare fee schedule for physicians' services furnished in 2005. Addendum B contains the RVUs for work, non-facility practice expense, facility practice expense, and malpractice expense, and other information for all services included in the physician fee schedule.

In previous years, we have listed many services in Addendum B that are not paid under the physician fee schedule. To avoid publishing as many pages of codes for these services, we are not including clinical laboratory codes and most alpha-numeric codes (Healthcare Common Procedure Coding System (HCPCS) codes not included in CPT) in Addendum B.

### Addendum B—2005 Relative Value Units and Related Information Used in Determining Medicare Payments for 2005

This addendum contains the following information for each CPT code and alphanumeric HCPCS code, except for alphanumeric codes beginning with B (enteral and parenteral therapy), E (durable medical equipment), K (temporary codes for nonphysicians' services or items), or L (orthotics), and codes for anesthesiology.

1. *CPT/HCPCS code.* This is the CPT or alphanumeric HCPCS number for the service. Alphanumeric HCPCS codes are included at the end of this addendum.

2. *Modifier.* A modifier is shown if there is a technical component (modifier TC) and a professional component (PC) (modifier –26) for the service. If there is a PC and a TC for the service, Addendum B contains three entries for the code: One for the global values (both professional and technical); one for modifier –26 (PC); and one for modifier TC. The global service is not designated by a modifier, and physicians must bill using the code without a modifier if the physician furnishes both the PC and the TC of the service.

Modifier –53 is shown for a discontinued procedure. There will be RVUs for the code (CPT code 45378) with this modifier.

3. *Status indicator.* This indicator shows whether the CPT/HCPCS code is in the physician fee schedule and whether it is separately payable if the service is covered.

A = Active code. These codes are separately payable under the fee schedule if covered. There will be RVUs for codes with this status. The presence of an ''A'' indicator does not mean that Medicare has made a national decision regarding the coverage of the service. Carriers remain responsible for coverage decisions in the absence of a national Medicare policy.

B = Bundled code. Payment for covered services is always bundled into payment for other services not specified. If RVUs are shown, they are not used for Medicare payment. If these services are covered, payment for them is subsumed by the payment for the services to which they are incident. (An example is a telephone call from a hospital nurse regarding care of a patient.)

C = Carrier-priced code. Carriers will establish RVUs and payment amounts for these services, generally on a case-by-case basis following review of documentation, such as an operative report.

D = Deleted code. These codes are deleted effective with the beginning of the calendar year.

E = Excluded from physician fee schedule by regulation. These codes are for items or services that we chose to exclude from the physician fee schedule payment by regulation. No RVUs are shown, and no payment may be made under the physician fee schedule for these codes. Payment for them, if they are covered, continues under reasonable charge or other payment procedures.

F = Deleted/discontinued codes. Code not subject to a 90-day grace period.

G = Code not valid for Medicare purposes. Medicare does not recognize codes assigned this status. Medicare uses another code for reporting of, and payment for, these services.

H = Deleted modifier. Either the TC or PC component shown for the code has been deleted, and the deleted component is shown in the data base with the H status indicator. (Code subject to a 90-day grace period.)

I = Not valid for Medicare purposes. Medicare uses another code for the reporting of, and the payment for these services. (Code NOT subject to a 90-day grace period.)

N = Noncovered service. These codes are noncovered services. Medicare payment may not be made for these codes. If RVUs are shown, they are not used for Medicare payment.

P = Bundled or excluded code. There are no RVUs for these services. No separate payment should be made for them under the physician fee schedule.

—If the item or service is covered as incident to a physician's service and is furnished on the same day as a physician's service, payment for it is bundled into the payment for the physician's service to which it is incident (an example is an elastic bandage furnished by a physician incident to a physician's service).

—If the item or service is covered as other than incident to a physician's service, it is excluded from the physician fee schedule (for example, colostomy supplies) and is paid under the other payment provisions of the Act.

R = Restricted coverage. Special coverage instructions apply. If the service is covered and no RVUs are shown, it is carrier-priced.

T = Injections. There are RVUs for these services, but they are only paid if there are no other services payable under the physician fee schedule billed on the same date by the same provider. If any other services payable under the physician fee schedule are billed on the same date by the same provider, these services are bundled into the service(s) for which payment is made.

X = Exclusion by law. These codes represent an item or service that is not within the definition of ''physicians' services'' for physician fee schedule payment purposes. No RVUs are shown for these codes, and no payment may be made under the physician fee schedule. (Examples are ambulance services and clinical diagnostic laboratory services.)

4. *Description of code.* This is an abbreviated version of the narrative description of the code.

5. *Physician work RVUs.* These are the RVUs for the physician work for this service in 2005. Codes that are not used for Medicare payment are identified with a ''+.''

6. *Facility practice expense RVUs.* These are the fully implemented resource-based practice expense RVUs for facility settings.

7. *Non-facility practice expense RVUs.* These are the fully implemented resource-based practice expense RVUs for non-facility settings.

8. *Malpractice expense RVUs.* These are the RVUs for the malpractice expense for the service for 2005.

9. *Facility total.* This is the sum of the work, fully implemented facility practice expense, and malpractice expense RVUs.

10. *Non-facility total.* This is the sum of the work, fully implemented non-facility practice expense, and malpractice expense RVUs.

11. *Global period.* This indicator shows the number of days in the global period for the code (0, 10, or 90 days). An explanation of the alpha codes follows:

MMM = The code describes a service furnished in uncomplicated maternity cases including antepartum care, delivery, and postpartum care. The usual global surgical concept does not apply. *See* the 1999 Physicians' Current Procedural Terminology for specific definitions.

XXX = The global concept does not apply.

YYY = The global period is to be set by the carrier (for example, unlisted surgery codes).

ZZZ = Code related to another service that is always included in the global period of the other service. (**Note:** Physician work and practice expense are associated with intra service time and in some instances the post service time.)

## ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 10021 | | A | Fna w/o image | 1.27 | 2.16 | 0.54 | 0.11 | 3.54 | 1.92 | XXX |
| 10022 | | A | Fna w/image | 1.27 | 2.55 | 0.42 | 0.08 | 3.90 | 1.77 | XXX |
| 10040 | | A | Acne surgery | 1.18 | 1.01 | 0.79 | 0.10 | 2.29 | 2.07 | 010 |
| 10060 | | A | Drainage of skin abscess | 1.17 | 1.21 | 0.94 | 0.10 | 2.48 | 2.21 | 010 |
| 10061 | | A | Drainage of skin abscess | 2.40 | 1.82 | 1.50 | 0.21 | 4.43 | 4.11 | 010 |
| 10080 | | A | Drainage of pilonidal cyst | 1.17 | 3.12 | 1.12 | 0.11 | 4.40 | 2.40 | 010 |
| 10081 | | A | Drainage of pilonidal cyst | 2.45 | 4.10 | 1.51 | 0.26 | 6.81 | 4.22 | 010 |
| 10120 | | A | Remove foreign body | 1.22 | 2.19 | 0.99 | 0.11 | 3.52 | 2.32 | 010 |
| 10121 | | A | Remove foreign body | 2.69 | 3.53 | 1.79 | 0.30 | 6.52 | 4.78 | 010 |
| 10140 | | A | Drainage of hematoma/fluid | 1.53 | 1.77 | 1.29 | 0.15 | 3.45 | 2.97 | 010 |
| 10160 | | A | Puncture drainage of lesion | 1.20 | 1.61 | 1.09 | 0.12 | 2.93 | 2.41 | 010 |
| 10180 | | A | Complex drainage, wound | 2.25 | 3.00 | 1.98 | 0.32 | 5.57 | 4.55 | 010 |
| 11000 | | A | Debride infected skin | 0.60 | 0.58 | 0.21 | 0.05 | 1.23 | 0.86 | 000 |
| 11001 | | A | Debride infected skin add-on | 0.30 | 0.23 | 0.11 | 0.02 | 0.55 | 0.43 | ZZZ |
| 11010 | | A | Debride skin, fx | 4.19 | 6.89 | 2.62 | 0.59 | 11.67 | 7.40 | 010 |
| 11011 | | A | Debride skin/muscle, fx | 4.94 | 8.19 | 2.33 | 0.69 | 13.82 | 7.96 | 000 |
| 11012 | | A | Debride skin/muscle/bone, fx | 6.87 | 12.09 | 3.83 | 1.11 | 20.07 | 11.81 | 000 |
| 11040 | | A | Debride skin, partial | 0.50 | 0.52 | 0.21 | 0.04 | 1.06 | 0.75 | 000 |
| 11041 | | A | Debride skin, full | 0.82 | 0.66 | 0.33 | 0.07 | 1.55 | 1.22 | 000 |
| 11042 | | A | Debride skin/tissue | 1.12 | 0.97 | 0.44 | 0.11 | 2.20 | 1.67 | 000 |
| 11043 | | A | Debride tissue/muscle | 2.38 | 3.40 | 2.59 | 0.27 | 6.05 | 5.24 | 010 |
| 11044 | | A | Debride tissue/muscle/bone | 3.06 | 4.47 | 3.75 | 0.38 | 7.91 | 7.19 | 010 |
| 11055 | | R | Trim skin lesion | 0.43 | 0.56 | 0.17 | 0.03 | 1.02 | 0.63 | 000 |
| 11056 | | R | Trim skin lesions, 2 to 4 | 0.61 | 0.63 | 0.23 | 0.05 | 1.29 | 0.89 | 000 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 11057 | | R | Trim skin lesions, over 4 | 0.79 | 0.74 | 0.30 | 0.06 | 1.59 | 1.15 | 000 |
| 11100 | | A | Biopsy, skin lesion | 0.81 | 1.25 | 0.36 | 0.07 | 2.13 | 1.24 | 000 |
| 11101 | | A | Biopsy, skin add-on | 0.41 | 0.33 | 0.19 | 0.03 | 0.77 | 0.63 | ZZZ |
| 11200 | | A | Removal of skin tags | 0.77 | 1.05 | 0.76 | 0.07 | 1.89 | 1.60 | 010 |
| 11201 | | A | Remove skin tags add-on | 0.29 | 0.16 | 0.12 | 0.03 | 0.48 | 0.44 | ZZZ |
| 11300 | | A | Shave skin lesion | 0.51 | 0.99 | 0.21 | 0.04 | 1.54 | 0.76 | 000 |
| 11301 | | A | Shave skin lesion | 0.85 | 1.11 | 0.38 | 0.07 | 2.03 | 1.30 | 000 |
| 11302 | | A | Shave skin lesion | 1.05 | 1.30 | 0.46 | 0.09 | 2.44 | 1.60 | 000 |
| 11303 | | A | Shave skin lesion | 1.24 | 1.58 | 0.52 | 0.11 | 2.93 | 1.87 | 000 |
| 11305 | | A | Shave skin lesion | 0.67 | 0.84 | 0.27 | 0.06 | 1.57 | 1.00 | 000 |
| 11306 | | A | Shave skin lesion | 0.99 | 1.10 | 0.42 | 0.08 | 2.17 | 1.49 | 000 |
| 11307 | | A | Shave skin lesion | 1.14 | 1.29 | 0.49 | 0.10 | 2.53 | 1.73 | 000 |
| 11308 | | A | Shave skin lesion | 1.41 | 1.45 | 0.59 | 0.12 | 2.98 | 2.12 | 000 |
| 11310 | | A | Shave skin lesion | 0.73 | 1.12 | 0.32 | 0.07 | 1.92 | 1.12 | 000 |
| 11311 | | A | Shave skin lesion | 1.05 | 1.23 | 0.49 | 0.09 | 2.37 | 1.63 | 000 |
| 11312 | | A | Shave skin lesion | 1.20 | 1.42 | 0.55 | 0.11 | 2.73 | 1.86 | 000 |
| 11313 | | A | Shave skin lesion | 1.62 | 1.79 | 0.72 | 0.15 | 3.56 | 2.49 | 000 |
| 11400 | | A | Exc tr-ext b9+marg 0.5 < cm | 0.85 | 2.00 | 0.88 | 0.09 | 2.94 | 1.82 | 010 |
| 11401 | | A | Exc tr-ext b9+marg 0.6-1 cm | 1.23 | 2.06 | 1.02 | 0.13 | 3.42 | 2.38 | 010 |
| 11402 | | A | Exc tr-ext b9+marg 1.1-2 cm | 1.51 | 2.23 | 1.08 | 0.17 | 3.91 | 2.76 | 010 |
| 11403 | | A | Exc tr-ext b9+marg 2.1-3 cm | 1.79 | 2.40 | 1.32 | 0.21 | 4.40 | 3.32 | 010 |
| 11404 | | A | Exc tr-ext b9+marg 3.1-4 cm | 2.06 | 2.71 | 1.40 | 0.25 | 5.02 | 3.71 | 010 |
| 11406 | | A | Exc tr-ext b9+marg > 4.0 cm | 2.76 | 3.07 | 1.66 | 0.33 | 6.16 | 4.75 | 010 |
| 11420 | | A | Exc h-f-nk-sp b9+marg 0.5 < | 0.98 | 1.76 | 0.93 | 0.10 | 2.84 | 2.01 | 010 |
| 11421 | | A | Exc h-f-nk-sp b9+marg 0.6-1 | 1.42 | 2.06 | 1.11 | 0.15 | 3.63 | 2.68 | 010 |
| 11422 | | A | Exc h-f-nk-sp b9+marg 1.1-2 | 1.63 | 2.25 | 1.34 | 0.18 | 4.06 | 3.15 | 010 |
| 11423 | | A | Exc h-f-nk-sp b9+marg 2.1-3 | 2.01 | 2.58 | 1.45 | 0.23 | 4.82 | 3.69 | 010 |
| 11424 | | A | Exc h-f-nk-sp b9+marg 3.1-4 | 2.43 | 2.80 | 1.60 | 0.28 | 5.51 | 4.31 | 010 |
| 11426 | | A | Exc h-f-nk-sp b9+marg > 4 cm | 3.77 | 3.49 | 2.10 | 0.44 | 7.70 | 6.31 | 010 |
| 11440 | | A | Exc face-mm b9+marg 0.5 < cm | 1.06 | 2.21 | 1.31 | 0.10 | 3.37 | 2.47 | 010 |
| 11441 | | A | Exc face-mm b9+marg 0.6-1 cm | 1.48 | 2.34 | 1.49 | 0.16 | 3.98 | 3.13 | 010 |
| 11442 | | A | Exc face-mm b9+marg 1.1-2 cm | 1.72 | 2.54 | 1.57 | 0.20 | 4.46 | 3.49 | 010 |
| 11443 | | A | Exc face-mm b9+marg 2.1-3 cm | 2.29 | 2.92 | 1.81 | 0.26 | 5.47 | 4.36 | 010 |
| 11444 | | A | Exc face-mm b9+marg 3.1-4 cm | 3.14 | 3.47 | 2.17 | 0.35 | 6.96 | 5.66 | 010 |
| 11446 | | A | Exc face-mm b9+marg > 4 cm | 4.48 | 4.04 | 2.76 | 0.47 | 8.99 | 7.71 | 010 |
| 11450 | | A | Removal, sweat gland lesion | 2.73 | 5.06 | 2.02 | 0.35 | 8.14 | 5.10 | 090 |
| 11451 | | A | Removal, sweat gland lesion | 3.94 | 6.64 | 2.54 | 0.52 | 11.10 | 7.00 | 090 |
| 11462 | | A | Removal, sweat gland lesion | 2.51 | 5.14 | 2.01 | 0.31 | 7.96 | 4.83 | 090 |
| 11463 | | A | Removal, sweat gland lesion | 3.94 | 6.85 | 2.68 | 0.51 | 11.30 | 7.13 | 090 |
| 11470 | | A | Removal, sweat gland lesion | 3.25 | 5.09 | 2.26 | 0.38 | 8.72 | 5.89 | 090 |
| 11471 | | A | Removal, sweat gland lesion | 4.40 | 6.74 | 2.76 | 0.54 | 11.68 | 7.70 | 090 |
| 11600 | | A | Exc tr-ext mlg+marg 0.5 < cm | 1.31 | 2.64 | 0.97 | 0.13 | 4.08 | 2.41 | 010 |
| 11601 | | A | Exc tr-ext mlg+marg 0.6-1 cm | 1.80 | 2.70 | 1.22 | 0.18 | 4.68 | 3.20 | 010 |
| 11602 | | A | Exc tr-ext mlg+marg 1.1-2 cm | 1.95 | 2.83 | 1.26 | 0.20 | 4.98 | 3.41 | 010 |
| 11603 | | A | Exc tr-ext mlg+marg 2.1-3 cm | 2.19 | 3.07 | 1.33 | 0.24 | 5.50 | 3.76 | 010 |
| 11604 | | A | Exc tr-ext mlg+marg 3.1-4 cm | 2.40 | 3.38 | 1.39 | 0.28 | 6.06 | 4.07 | 010 |
| 11606 | | A | Exc tr-ext mlg+marg > 4 cm | 3.42 | 4.06 | 1.73 | 0.40 | 7.88 | 5.55 | 010 |
| 11620 | | A | Exc h-f-nk-sp mlg+marg 0.5 < | 1.19 | 2.60 | 0.95 | 0.13 | 3.92 | 2.27 | 010 |
| 11621 | | A | Exc h-f-nk-sp mlg+marg 0.6-1 | 1.76 | 2.70 | 1.24 | 0.19 | 4.65 | 3.19 | 010 |
| 11622 | | A | Exc h-f-nk-sp mlg+marg 1.1-2 | 2.09 | 2.97 | 1.38 | 0.23 | 5.29 | 3.70 | 010 |
| 11623 | | A | Exc h-f-nk-sp mlg+marg 2.1-3 | 2.61 | 3.33 | 1.58 | 0.31 | 6.25 | 4.50 | 010 |
| 11624 | | A | Exc h-f-nk-sp mlg+marg 3.1-4 | 3.06 | 3.74 | 1.77 | 0.38 | 7.18 | 5.21 | 010 |
| 11626 | | A | Exc h-f-nk-sp mlg+mar > 4 cm | 4.29 | 4.64 | 2.38 | 0.50 | 9.43 | 7.17 | 010 |
| 11640 | | A | Exc face-mm malig+marg 0.5 < | 1.35 | 2.66 | 1.11 | 0.15 | 4.16 | 2.61 | 010 |
| 11641 | | A | Exc face-mm malig+marg 0.6-1 | 2.16 | 3.02 | 1.52 | 0.24 | 5.42 | 3.92 | 010 |
| 11642 | | A | Exc face-mm malig+marg 1.1-2 | 2.59 | 3.40 | 1.71 | 0.30 | 6.29 | 4.60 | 010 |
| 11643 | | A | Exc face-mm malig+marg 2.1-3 | 3.10 | 3.80 | 1.95 | 0.37 | 7.27 | 5.42 | 010 |
| 11644 | | A | Exc face-mm malig+marg 3.1-4 | 4.02 | 4.67 | 2.44 | 0.49 | 9.18 | 6.95 | 010 |
| 11646 | | A | Exc face-mm mlg+marg > 4 cm | 5.94 | 5.74 | 3.46 | 0.67 | 12.35 | 10.07 | 010 |
| 11719 | | R | Trim nail(s) | 0.17 | 0.25 | 0.07 | 0.01 | 0.43 | 0.25 | 000 |
| 11720 | | A | Debride nail, 1-5 | 0.32 | 0.34 | 0.12 | 0.03 | 0.69 | 0.47 | 000 |
| 11721 | | A | Debride nail, 6 or more | 0.54 | 0.43 | 0.21 | 0.04 | 1.01 | 0.79 | 000 |
| 11730 | | A | Removal of nail plate | 1.13 | 1.03 | 0.43 | 0.09 | 2.25 | 1.65 | 000 |
| 11732 | | A | Remove nail plate, add-on | 0.57 | 0.44 | 0.22 | 0.05 | 1.06 | 0.84 | ZZZ |
| 11740 | | A | Drain blood from under nail | 0.37 | 0.56 | 0.36 | 0.03 | 0.96 | 0.76 | 000 |
| 11750 | | A | Removal of nail bed | 1.86 | 2.16 | 1.75 | 0.15 | 4.17 | 3.76 | 010 |
| 11752 | | A | Remove nail bed/finger tip | 2.67 | 2.99 | 2.99 | 0.28 | 5.94 | 5.94 | 010 |
| 11755 | | A | Biopsy, nail unit | 1.31 | 1.57 | 0.77 | 0.11 | 2.99 | 2.19 | 000 |
| 11760 | | A | Repair of nail bed | 1.58 | 2.63 | 1.79 | 0.18 | 4.39 | 3.55 | 010 |
| 11762 | | A | Reconstruction of nail bed | 2.89 | 2.88 | 2.34 | 0.27 | 6.04 | 5.50 | 010 |
| 11765 | | A | Excision of nail fold, toe | 0.69 | 1.78 | 0.76 | 0.06 | 2.53 | 1.51 | 010 |
| 11770 | | A | Removal of pilonidal lesion | 2.61 | 3.50 | 1.50 | 0.32 | 6.43 | 4.43 | 010 |
| 11771 | | A | Removal of pilonidal lesion | 5.73 | 5.66 | 3.31 | 0.72 | 12.11 | 9.76 | 090 |
| 11772 | | A | Removal of pilonidal lesion | 6.97 | 7.54 | 5.08 | 0.88 | 15.39 | 12.93 | 090 |
| 11900 | | A | Injection into skin lesions | 0.52 | 0.65 | 0.21 | 0.04 | 1.21 | 0.77 | 000 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 11901 | | A | Added skin lesions injection | 0.80 | 0.66 | 0.35 | 0.07 | 1.53 | 1.22 | 000 |
| 11920 | | R | Correct skin color defects | 1.61 | 3.69 | 1.09 | 0.22 | 5.52 | 2.92 | 000 |
| 11921 | | R | Correct skin color defects | 1.93 | 3.95 | 1.27 | 0.28 | 6.16 | 3.48 | 000 |
| 11922 | | R | Correct skin color defects | 0.49 | 1.13 | 0.25 | 0.07 | 1.69 | 0.81 | ZZZ |
| 11950 | | R | Therapy for contour defects | 0.84 | 1.14 | 0.39 | 0.09 | 2.07 | 1.32 | 000 |
| 11951 | | R | Therapy for contour defects | 1.19 | 1.49 | 0.51 | 0.15 | 2.83 | 1.85 | 000 |
| 11952 | | R | Therapy for contour defects | 1.69 | 1.85 | 0.68 | 0.24 | 3.78 | 2.61 | 000 |
| 11954 | | R | Therapy for contour defects | 1.85 | 2.43 | 0.90 | 0.17 | 4.45 | 2.92 | 000 |
| 11960 | | A | Insert tissue expander(s) | 9.07 | NA | 10.37 | 1.23 | NA | 20.67 | 090 |
| 11970 | | A | Replace tissue expander | 7.05 | NA | 6.12 | 1.04 | NA | 14.21 | 090 |
| 11971 | | A | Remove tissue expander(s) | 2.13 | 9.13 | 3.78 | 0.30 | 11.56 | 6.21 | 090 |
| 11976 | | R | Removal of contraceptive cap | 1.78 | 1.73 | 0.68 | 0.20 | 3.71 | 2.66 | 000 |
| 11980 | | A | Implant hormone pellet(s) | 1.48 | 1.08 | 0.54 | 0.13 | 2.69 | 2.15 | 000 |
| 11981 | | A | Insert drug implant device | 1.48 | 1.70 | 0.68 | 0.11 | 3.29 | 2.27 | XXX |
| 11982 | | A | Remove drug implant device | 1.78 | 1.94 | 0.83 | 0.18 | 3.90 | 2.79 | XXX |
| 11983 | | A | Remove/insert drug implant | 3.30 | 2.28 | 1.46 | 0.24 | 5.82 | 5.00 | XXX |
| 12001 | | A | Repair superficial wound(s) | 1.70 | 2.00 | 0.78 | 0.15 | 3.85 | 2.63 | 010 |
| 12002 | | A | Repair superficial wound(s) | 1.86 | 2.06 | 0.91 | 0.17 | 4.09 | 2.94 | 010 |
| 12004 | | A | Repair superficial wound(s) | 2.24 | 2.35 | 1.02 | 0.21 | 4.80 | 3.47 | 010 |
| 12005 | | A | Repair superficial wound(s) | 2.86 | 2.85 | 1.21 | 0.27 | 5.98 | 4.34 | 010 |
| 12006 | | A | Repair superficial wound(s) | 3.66 | 3.42 | 1.52 | 0.37 | 7.45 | 5.55 | 010 |
| 12007 | | A | Repair superficial wound(s) | 4.11 | 3.86 | 1.82 | 0.44 | 8.41 | 6.37 | 010 |
| 12011 | | A | Repair superficial wound(s) | 1.76 | 2.15 | 0.79 | 0.16 | 4.07 | 2.71 | 010 |
| 12013 | | A | Repair superficial wound(s) | 1.99 | 2.30 | 0.95 | 0.18 | 4.47 | 3.12 | 010 |
| 12014 | | A | Repair superficial wound(s) | 2.46 | 2.59 | 1.07 | 0.22 | 5.27 | 3.75 | 010 |
| 12015 | | A | Repair superficial wound(s) | 3.19 | 3.16 | 1.26 | 0.29 | 6.64 | 4.74 | 010 |
| 12016 | | A | Repair superficial wound(s) | 3.92 | 3.59 | 1.53 | 0.37 | 7.88 | 5.82 | 010 |
| 12017 | | A | Repair superficial wound(s) | 4.70 | NA | 1.89 | 0.48 | NA | 7.07 | 010 |
| 12018 | | A | Repair superficial wound(s) | 5.52 | NA | 2.25 | 0.58 | NA | 8.35 | 010 |
| 12020 | | A | Closure of split wound | 2.62 | 3.84 | 1.92 | 0.30 | 6.76 | 4.84 | 010 |
| 12021 | | A | Closure of split wound | 1.84 | 1.83 | 1.42 | 0.23 | 3.90 | 3.49 | 010 |
| 12031 | | A | Layer closure of wound(s) | 2.15 | 2.28 | 0.96 | 0.22 | 4.65 | 3.33 | 010 |
| 12032 | | A | Layer closure of wound(s) | 2.47 | 3.85 | 1.81 | 0.24 | 6.56 | 4.52 | 010 |
| 12034 | | A | Layer closure of wound(s) | 2.92 | 3.20 | 1.46 | 0.31 | 6.43 | 4.69 | 010 |
| 12035 | | A | Layer closure of wound(s) | 3.42 | 5.22 | 2.16 | 0.39 | 9.03 | 5.97 | 010 |
| 12036 | | A | Layer closure of wound(s) | 4.04 | 5.59 | 2.55 | 0.52 | 10.15 | 7.11 | 010 |
| 12037 | | A | Layer closure of wound(s) | 4.66 | 6.13 | 2.96 | 0.61 | 11.40 | 8.23 | 010 |
| 12041 | | A | Layer closure of wound(s) | 2.37 | 2.54 | 1.13 | 0.24 | 5.15 | 3.74 | 010 |
| 12042 | | A | Layer closure of wound(s) | 2.74 | 3.27 | 1.47 | 0.26 | 6.27 | 4.47 | 010 |
| 12044 | | A | Layer closure of wound(s) | 3.14 | 3.23 | 1.61 | 0.32 | 6.69 | 5.07 | 010 |
| 12045 | | A | Layer closure of wound(s) | 3.63 | 5.30 | 2.28 | 0.41 | 9.34 | 6.32 | 010 |
| 12046 | | A | Layer closure of wound(s) | 4.24 | 6.55 | 2.75 | 0.49 | 11.28 | 7.48 | 010 |
| 12047 | | A | Layer closure of wound(s) | 4.64 | 6.39 | 3.08 | 0.57 | 11.60 | 8.29 | 010 |
| 12051 | | A | Layer closure of wound(s) | 2.47 | 3.27 | 1.45 | 0.25 | 5.99 | 4.17 | 010 |
| 12052 | | A | Layer closure of wound(s) | 2.77 | 3.22 | 1.44 | 0.26 | 6.25 | 4.47 | 010 |
| 12053 | | A | Layer closure of wound(s) | 3.12 | 3.24 | 1.54 | 0.30 | 6.66 | 4.96 | 010 |
| 12054 | | A | Layer closure of wound(s) | 3.45 | 3.56 | 1.64 | 0.34 | 7.35 | 5.43 | 010 |
| 12055 | | A | Layer closure of wound(s) | 4.42 | 4.49 | 2.12 | 0.46 | 9.37 | 7.00 | 010 |
| 12056 | | A | Layer closure of wound(s) | 5.23 | 6.76 | 3.05 | 0.53 | 12.52 | 8.81 | 010 |
| 12057 | | A | Layer closure of wound(s) | 5.95 | 6.16 | 3.75 | 0.64 | 12.75 | 10.34 | 010 |
| 13100 | | A | Repair of wound or lesion | 3.12 | 4.05 | 2.30 | 0.33 | 7.50 | 5.75 | 010 |
| 13101 | | A | Repair of wound or lesion | 3.91 | 4.66 | 2.68 | 0.40 | 8.97 | 6.99 | 010 |
| 13102 | | A | Repair wound/lesion add-on | 1.24 | 1.17 | 0.57 | 0.15 | 2.56 | 1.96 | ZZZ |
| 13120 | | A | Repair of wound or lesion | 3.30 | 4.14 | 2.35 | 0.35 | 7.79 | 6.00 | 010 |
| 13121 | | A | Repair of wound or lesion | 4.32 | 4.85 | 2.79 | 0.43 | 9.60 | 7.54 | 010 |
| 13122 | | A | Repair wound/lesion add-on | 1.44 | 1.51 | 0.63 | 0.18 | 3.13 | 2.25 | ZZZ |
| 13131 | | A | Repair of wound or lesion | 3.78 | 4.36 | 2.68 | 0.39 | 8.53 | 6.85 | 010 |
| 13132 | | A | Repair of wound or lesion | 5.94 | 5.58 | 3.80 | 0.56 | 12.08 | 10.30 | 010 |
| 13133 | | A | Repair wound/lesion add-on | 2.19 | 1.66 | 1.03 | 0.24 | 4.09 | 3.46 | ZZZ |
| 13150 | | A | Repair of wound or lesion | 3.80 | 4.87 | 2.76 | 0.41 | 9.08 | 6.97 | 010 |
| 13151 | | A | Repair of wound or lesion | 4.44 | 4.80 | 3.14 | 0.45 | 9.69 | 8.03 | 010 |
| 13152 | | A | Repair of wound or lesion | 6.32 | 6.03 | 4.03 | 0.62 | 12.97 | 10.97 | 010 |
| 13153 | | A | Repair wound/lesion add-on | 2.38 | 1.93 | 1.14 | 0.28 | 4.59 | 3.80 | ZZZ |
| 13160 | | A | Late closure of wound | 10.46 | NA | 7.15 | 1.48 | NA | 19.09 | 090 |
| 14000 | | A | Skin tissue rearrangement | 5.88 | 7.82 | 5.43 | 0.70 | 14.40 | 12.01 | 090 |
| 14001 | | A | Skin tissue rearrangement | 8.46 | 9.39 | 7.03 | 1.00 | 18.85 | 16.49 | 090 |
| 14020 | | A | Skin tissue rearrangement | 6.58 | 8.58 | 6.48 | 0.77 | 15.93 | 13.83 | 090 |
| 14021 | | A | Skin tissue rearrangement | 10.04 | 9.96 | 8.23 | 1.10 | 21.10 | 19.37 | 090 |
| 14040 | | A | Skin tissue rearrangement | 7.86 | 8.78 | 7.16 | 0.83 | 17.47 | 15.85 | 090 |
| 14041 | | A | Skin tissue rearrangement | 11.47 | 10.58 | 8.64 | 1.13 | 23.18 | 21.24 | 090 |
| 14060 | | A | Skin tissue rearrangement | 8.49 | 8.78 | 7.41 | 0.88 | 18.15 | 16.78 | 090 |
| 14061 | | A | Skin tissue rearrangement | 12.27 | 11.59 | 9.46 | 1.20 | 25.06 | 22.93 | 090 |
| 14300 | | A | Skin tissue rearrangement | 11.74 | 11.11 | 9.13 | 1.40 | 24.25 | 22.27 | 090 |
| 14350 | | A | Skin tissue rearrangement | 9.60 | NA | 7.14 | 1.22 | NA | 17.96 | 090 |
| 15000 | | A | Skin graft | 3.99 | 3.79 | 2.18 | 0.47 | 8.25 | 6.64 | 000 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 15001 | | A | Skin graft add-on | 1.00 | 1.35 | 0.41 | 0.13 | 2.48 | 1.54 | ZZZ |
| 15050 | | A | Skin pinch graft | 4.29 | 6.92 | 5.11 | 0.55 | 11.76 | 9.95 | 090 |
| 15100 | | A | Skin split graft | 9.04 | 12.55 | 7.82 | 1.24 | 22.83 | 18.10 | 090 |
| 15101 | | A | Skin split graft add-on | 1.72 | 3.72 | 1.17 | 0.24 | 5.68 | 3.13 | ZZZ |
| 15120 | | A | Skin split graft | 9.82 | 10.72 | 7.79 | 1.19 | 21.73 | 18.80 | 090 |
| 15121 | | A | Skin split graft add-on | 2.67 | 4.49 | 1.84 | 0.36 | 7.52 | 4.87 | ZZZ |
| 15200 | | A | Skin full graft | 8.02 | 9.41 | 6.19 | 1.02 | 18.45 | 15.23 | 090 |
| 15201 | | A | Skin full graft add-on | 1.32 | 2.56 | 0.62 | 0.18 | 4.06 | 2.12 | ZZZ |
| 15220 | | A | Skin full graft | 7.86 | 9.18 | 6.67 | 0.97 | 18.01 | 15.50 | 090 |
| 15221 | | A | Skin full graft add-on | 1.19 | 2.31 | 0.56 | 0.17 | 3.67 | 1.92 | ZZZ |
| 15240 | | A | Skin full graft | 9.03 | 10.20 | 7.94 | 1.08 | 20.31 | 18.05 | 090 |
| 15241 | | A | Skin full graft add-on | 1.86 | 2.44 | 0.91 | 0.24 | 4.54 | 3.01 | ZZZ |
| 15260 | | A | Skin full graft | 10.04 | 10.21 | 8.57 | 0.97 | 21.22 | 19.58 | 090 |
| 15261 | | A | Skin full graft add-on | 2.23 | 2.68 | 1.40 | 0.26 | 5.17 | 3.89 | ZZZ |
| 15342 | | A | Cultured skin graft, 25 cm | 1.00 | 1.86 | 0.55 | 0.10 | 2.96 | 1.65 | 010 |
| 15343 | | A | Culture skn graft addl 25 cm | 0.25 | 0.09 | 0.09 | 0.03 | 0.37 | 0.37 | ZZZ |
| 15350 | | A | Skin homograft | 3.99 | 6.44 | 3.84 | 0.48 | 10.91 | 8.31 | 090 |
| 15351 | | A | Skin homograft add-on | 1.00 | 0.36 | 0.36 | 0.14 | 1.50 | 1.50 | ZZZ |
| 15400 | | A | Skin heterograft | 3.99 | 4.01 | 4.01 | 0.39 | 8.39 | 8.39 | 090 |
| 15401 | | A | Skin heterograft add-on | 1.00 | 1.89 | 0.44 | 0.12 | 3.01 | 1.56 | ZZZ |
| 15570 | | A | Form skin pedicle flap | 9.20 | 11.30 | 6.75 | 1.30 | 21.80 | 17.25 | 090 |
| 15572 | | A | Form skin pedicle flap | 9.26 | 9.49 | 6.44 | 1.29 | 20.04 | 16.99 | 090 |
| 15574 | | A | Form skin pedicle flap | 9.87 | 10.67 | 7.77 | 1.22 | 21.76 | 18.86 | 090 |
| 15576 | | A | Form skin pedicle flap | 8.68 | 9.75 | 6.87 | 0.95 | 19.38 | 16.50 | 090 |
| 15600 | | A | Skin graft | 1.91 | 7.61 | 3.06 | 0.27 | 9.79 | 5.24 | 090 |
| 15610 | | A | Skin graft | 2.42 | 4.74 | 3.42 | 0.33 | 7.49 | 6.17 | 090 |
| 15620 | | A | Skin graft | 2.94 | 7.76 | 3.87 | 0.36 | 11.06 | 7.17 | 090 |
| 15630 | | A | Skin graft | 3.27 | 7.03 | 4.14 | 0.38 | 10.68 | 7.79 | 090 |
| 15650 | | A | Transfer skin pedicle flap | 3.96 | 7.14 | 4.20 | 0.49 | 11.59 | 8.65 | 090 |
| 15732 | | A | Muscle-skin graft, head/neck | 17.81 | 18.03 | 12.20 | 1.98 | 37.82 | 31.99 | 090 |
| 15734 | | A | Muscle-skin graft, trunk | 17.76 | 18.12 | 12.36 | 2.52 | 38.40 | 32.64 | 090 |
| 15736 | | A | Muscle-skin graft, arm | 16.25 | 18.14 | 11.20 | 2.38 | 36.77 | 29.83 | 090 |
| 15738 | | A | Muscle-skin graft, leg | 17.89 | 17.91 | 11.70 | 2.58 | 38.38 | 32.17 | 090 |
| 15740 | | A | Island pedicle flap graft | 10.23 | 10.14 | 8.25 | 1.01 | 21.38 | 19.49 | 090 |
| 15750 | | A | Neurovascular pedicle graft | 11.39 | NA | 9.02 | 1.51 | NA | 21.92 | 090 |
| 15756 | | A | Free myo/skin flap microvasc | 35.18 | NA | 20.52 | 4.51 | NA | 60.21 | 090 |
| 15757 | | A | Free skin flap, microvasc | 35.18 | NA | 21.55 | 4.05 | NA | 60.78 | 090 |
| 15758 | | A | Free fascial flap, microvasc | 35.05 | NA | 21.53 | 3.91 | NA | 60.49 | 090 |
| 15760 | | A | Composite skin graft | 8.73 | 10.02 | 7.25 | 0.94 | 19.69 | 16.92 | 090 |
| 15770 | | A | Derma-fat-fascia graft | 7.51 | NA | 6.67 | 1.01 | NA | 15.19 | 090 |
| 15775 | | R | Hair transplant punch grafts | 3.95 | 2.97 | 1.30 | 0.52 | 7.44 | 5.77 | 000 |
| 15776 | | R | Hair transplant punch grafts | 5.53 | 5.33 | 2.80 | 0.72 | 11.58 | 9.05 | 000 |
| 15780 | | A | Abrasion treatment of skin | 7.28 | 11.57 | 8.24 | 0.75 | 19.60 | 16.27 | 090 |
| 15781 | | A | Abrasion treatment of skin | 4.84 | 6.91 | 5.36 | 0.47 | 12.22 | 10.67 | 090 |
| 15782 | | A | Abrasion treatment of skin | 4.31 | 9.92 | 6.56 | 0.35 | 14.58 | 11.22 | 090 |
| 15783 | | A | Abrasion treatment of skin | 4.28 | 6.87 | 4.18 | 0.42 | 11.57 | 8.88 | 090 |
| 15786 | | A | Abrasion, lesion, single | 2.03 | 3.35 | 1.32 | 0.18 | 5.56 | 3.53 | 010 |
| 15787 | | A | Abrasion, lesions, add-on | 0.33 | 1.10 | 0.16 | 0.03 | 1.46 | 0.52 | ZZZ |
| 15788 | | R | Chemical peel, face, epiderm | 2.09 | 6.72 | 3.08 | 0.19 | 9.00 | 5.36 | 090 |
| 15789 | | R | Chemical peel, face, dermal | 4.91 | 8.09 | 4.82 | 0.43 | 13.43 | 10.16 | 090 |
| 15792 | | R | Chemical peel, nonfacial | 1.86 | 7.11 | 4.45 | 0.17 | 9.14 | 6.48 | 090 |
| 15793 | | A | Chemical peel, nonfacial | 3.73 | 6.29 | 4.39 | 0.32 | 10.34 | 8.44 | 090 |
| 15810 | | A | Salabrasion | 4.73 | NA | 3.90 | 0.34 | NA | 8.97 | 090 |
| 15811 | | A | Salabrasion | 5.38 | 5.47 | 4.76 | 0.80 | 11.65 | 10.94 | 090 |
| 15819 | | A | Plastic surgery, neck | 9.37 | NA | 7.17 | 0.91 | NA | 17.45 | 090 |
| 15820 | | A | Revision of lower eyelid | 5.14 | 6.93 | 5.52 | 0.48 | 12.55 | 11.14 | 090 |
| 15821 | | A | Revision of lower eyelid | 5.71 | 7.32 | 5.68 | 0.46 | 13.49 | 11.85 | 090 |
| 15822 | | A | Revision of upper eyelid | 4.44 | 5.82 | 4.47 | 0.39 | 10.65 | 9.30 | 090 |
| 15823 | | A | Revision of upper eyelid | 7.04 | 7.84 | 6.40 | 0.50 | 15.38 | 13.94 | 090 |
| 15831 | | A | Excise excessive skin tissue | 12.38 | NA | 8.15 | 1.69 | NA | 22.22 | 090 |
| 15832 | | A | Excise excessive skin tissue | 11.57 | NA | 8.33 | 1.63 | NA | 21.53 | 090 |
| 15833 | | A | Excise excessive skin tissue | 10.62 | NA | 8.20 | 1.48 | NA | 20.30 | 090 |
| 15834 | | A | Excise excessive skin tissue | 10.83 | NA | 7.68 | 1.60 | NA | 20.11 | 090 |
| 15835 | | A | Excise excessive skin tissue | 11.65 | NA | 7.53 | 1.63 | NA | 20.81 | 090 |
| 15836 | | A | Excise excessive skin tissue | 9.33 | NA | 6.77 | 1.31 | NA | 17.41 | 090 |
| 15837 | | A | Excise excessive skin tissue | 8.42 | 8.63 | 7.36 | 1.19 | 18.24 | 16.97 | 090 |
| 15838 | | A | Excise excessive skin tissue | 7.12 | NA | 6.05 | 0.63 | NA | 13.80 | 090 |
| 15839 | | A | Excise excessive skin tissue | 9.37 | 8.87 | 6.39 | 1.15 | 19.39 | 16.91 | 090 |
| 15840 | | A | Graft for face nerve palsy | 13.24 | NA | 9.96 | 1.39 | NA | 24.59 | 090 |
| 15841 | | A | Graft for face nerve palsy | 23.23 | NA | 14.98 | 2.79 | NA | 41.00 | 090 |
| 15842 | | A | Flap for face nerve palsy | 37.90 | NA | 22.88 | 2.91 | NA | 63.69 | 090 |
| 15845 | | A | Skin and muscle repair, face | 12.55 | NA | 9.29 | 0.86 | NA | 22.70 | 090 |
| 15850 | | B | Removal of sutures | 0.78 | 1.57 | 0.29 | 0.05 | 2.40 | 1.12 | XXX |
| 15851 | | A | Removal of sutures | 0.86 | 1.70 | 0.31 | 0.06 | 2.62 | 1.23 | 000 |
| 15852 | | A | Dressing change not for burn | 0.86 | 1.87 | 0.33 | 0.09 | 2.82 | 1.28 | 000 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 15860 | | A | Test for blood flow in graft | 1.95 | 0.83 | 0.78 | 0.25 | 3.03 | 2.98 | 000 |
| 15920 | | A | Removal of tail bone ulcer | 7.94 | NA | 5.55 | 0.97 | NA | 14.46 | 090 |
| 15922 | | A | Removal of tail bone ulcer | 9.89 | NA | 7.20 | 1.41 | NA | 18.50 | 090 |
| 15931 | | A | Remove sacrum pressure sore | 9.23 | NA | 5.68 | 1.23 | NA | 16.14 | 090 |
| 15933 | | A | Remove sacrum pressure sore | 10.83 | NA | 7.84 | 1.48 | NA | 20.15 | 090 |
| 15934 | | A | Remove sacrum pressure sore | 12.67 | NA | 8.03 | 1.76 | NA | 22.46 | 090 |
| 15935 | | A | Remove sacrum pressure sore | 14.55 | NA | 10.31 | 2.06 | NA | 26.92 | 090 |
| 15936 | | A | Remove sacrum pressure sore | 12.36 | NA | 8.21 | 1.74 | NA | 22.31 | 090 |
| 15937 | | A | Remove sacrum pressure sore | 14.19 | NA | 9.80 | 2.01 | NA | 26.00 | 090 |
| 15940 | | A | Remove hip pressure sore | 9.33 | NA | 6.17 | 1.30 | NA | 16.80 | 090 |
| 15941 | | A | Remove hip pressure sore | 11.41 | NA | 9.43 | 1.63 | NA | 22.47 | 090 |
| 15944 | | A | Remove hip pressure sore | 11.44 | NA | 8.59 | 1.63 | NA | 21.66 | 090 |
| 15945 | | A | Remove hip pressure sore | 12.67 | NA | 9.63 | 1.80 | NA | 24.10 | 090 |
| 15946 | | A | Remove hip pressure sore | 21.54 | NA | 14.34 | 3.09 | NA | 38.97 | 090 |
| 15950 | | A | Remove thigh pressure sore | 7.53 | NA | 5.41 | 1.02 | NA | 13.96 | 090 |
| 15951 | | A | Remove thigh pressure sore | 10.70 | NA | 7.85 | 1.48 | NA | 20.03 | 090 |
| 15952 | | A | Remove thigh pressure sore | 11.37 | NA | 7.74 | 1.58 | NA | 20.69 | 090 |
| 15953 | | A | Remove thigh pressure sore | 12.61 | NA | 8.97 | 1.83 | NA | 23.41 | 090 |
| 15956 | | A | Remove thigh pressure sore | 15.50 | NA | 10.75 | 2.18 | NA | 28.43 | 090 |
| 15958 | | A | Remove thigh pressure sore | 15.46 | NA | 11.02 | 2.17 | NA | 28.65 | 090 |
| 16000 | | A | Initial treatment of burn(s) | 0.89 | 0.87 | 0.26 | 0.08 | 1.84 | 1.23 | 000 |
| 16010 | | A | Treatment of burn(s) | 0.87 | 0.66 | 0.63 | 0.08 | 1.61 | 1.58 | 000 |
| 16015 | | A | Treatment of burn(s) | 2.35 | NA | 1.15 | 0.30 | NA | 3.80 | 000 |
| 16020 | | A | Treatment of burn(s) | 0.80 | 1.31 | 0.59 | 0.08 | 2.19 | 1.47 | 000 |
| 16025 | | A | Treatment of burn(s) | 1.85 | 1.77 | 0.96 | 0.19 | 3.81 | 3.00 | 000 |
| 16030 | | A | Treatment of burn(s) | 2.08 | 2.18 | 1.12 | 0.22 | 4.48 | 3.42 | 000 |
| 16035 | | A | Incision of burn scab, initi | 3.74 | NA | 1.58 | 0.42 | NA | 5.74 | 090 |
| 16036 | | A | Escharotomy; add-l incision | 1.50 | NA | 0.60 | 0.20 | NA | 2.30 | ZZZ |
| 17000 | | A | Destroy benign/premlg lesion | 0.60 | 0.97 | 0.55 | 0.05 | 1.62 | 1.20 | 010 |
| 17003 | | A | Destroy lesions, 2-14 | 0.15 | 0.11 | 0.07 | 0.01 | 0.27 | 0.23 | ZZZ |
| 17004 | | A | Destroy lesions, 15 or more | 2.79 | 2.30 | 1.59 | 0.23 | 5.32 | 4.61 | 010 |
| 17106 | | A | Destruction of skin lesions | 4.58 | 4.58 | 3.33 | 0.44 | 9.60 | 8.35 | 090 |
| 17107 | | A | Destruction of skin lesions | 9.15 | 7.17 | 5.43 | 0.87 | 17.19 | 15.45 | 090 |
| 17108 | | A | Destruction of skin lesions | 13.18 | 9.25 | 7.64 | 1.33 | 23.76 | 22.15 | 090 |
| 17110 | | A | Destruct lesion, 1-14 | 0.65 | 1.63 | 0.71 | 0.05 | 2.33 | 1.41 | 010 |
| 17111 | | A | Destruct lesion, 15 or more | 0.92 | 1.68 | 0.81 | 0.08 | 2.68 | 1.81 | 010 |
| 17250 | | A | Chemical cautery, tissue | 0.50 | 1.22 | 0.34 | 0.05 | 1.77 | 0.89 | 000 |
| 17260 | | A | Destruction of skin lesions | 0.91 | 1.28 | 0.68 | 0.08 | 2.27 | 1.67 | 010 |
| 17261 | | A | Destruction of skin lesions | 1.17 | 1.61 | 0.83 | 0.10 | 2.88 | 2.10 | 010 |
| 17262 | | A | Destruction of skin lesions | 1.58 | 1.88 | 1.02 | 0.13 | 3.59 | 2.73 | 010 |
| 17263 | | A | Destruction of skin lesions | 1.79 | 2.05 | 1.09 | 0.15 | 3.99 | 3.03 | 010 |
| 17264 | | A | Destruction of skin lesions | 1.94 | 2.22 | 1.12 | 0.16 | 4.32 | 3.22 | 010 |
| 17266 | | A | Destruction of skin lesions | 2.34 | 2.50 | 1.22 | 0.20 | 5.04 | 3.76 | 010 |
| 17270 | | A | Destruction of skin lesions | 1.32 | 1.70 | 0.87 | 0.11 | 3.13 | 2.30 | 010 |
| 17271 | | A | Destruction of skin lesions | 1.49 | 1.77 | 0.98 | 0.13 | 3.39 | 2.60 | 010 |
| 17272 | | A | Destruction of skin lesions | 1.77 | 1.99 | 1.11 | 0.15 | 3.91 | 3.03 | 010 |
| 17273 | | A | Destruction of skin lesions | 2.05 | 2.20 | 1.21 | 0.17 | 4.42 | 3.43 | 010 |
| 17274 | | A | Destruction of skin lesions | 2.59 | 2.56 | 1.44 | 0.22 | 5.37 | 4.25 | 010 |
| 17276 | | A | Destruction of skin lesions | 3.20 | 2.94 | 1.68 | 0.29 | 6.43 | 5.17 | 010 |
| 17280 | | A | Destruction of skin lesions | 1.17 | 1.61 | 0.81 | 0.10 | 2.88 | 2.08 | 010 |
| 17281 | | A | Destruction of skin lesions | 1.72 | 1.90 | 1.09 | 0.15 | 3.77 | 2.96 | 010 |
| 17282 | | A | Destruction of skin lesions | 2.04 | 2.15 | 1.24 | 0.17 | 4.36 | 3.45 | 010 |
| 17283 | | A | Destruction of skin lesions | 2.64 | 2.54 | 1.49 | 0.22 | 5.40 | 4.35 | 010 |
| 17284 | | A | Destruction of skin lesions | 3.21 | 2.92 | 1.74 | 0.28 | 6.41 | 5.23 | 010 |
| 17286 | | A | Destruction of skin lesions | 4.43 | 3.67 | 2.43 | 0.41 | 8.51 | 7.27 | 010 |
| 17304 | | A | 1 stage mohs, up to 5 spec | 7.59 | 8.22 | 3.55 | 0.64 | 16.45 | 11.78 | 000 |
| 17305 | | A | 2 stage mohs, up to 5 spec | 2.85 | 3.88 | 1.34 | 0.24 | 6.97 | 4.43 | 000 |
| 17306 | | A | 3 stage mohs, up to 5 spec | 2.85 | 3.90 | 1.35 | 0.24 | 6.99 | 4.44 | 000 |
| 17307 | | A | Mohs addl stage up to 5 spec | 2.85 | 2.63 | 1.36 | 0.24 | 5.72 | 4.45 | 000 |
| 17310 | | A | Mohs any stage > 5 spec each | 0.95 | 1.62 | 0.46 | 0.09 | 2.66 | 1.50 | ZZZ |
| 17340 | | A | Cryotherapy of skin | 0.76 | 0.37 | 0.36 | 0.06 | 1.19 | 1.18 | 010 |
| 17360 | | A | Skin peel therapy | 1.43 | 1.44 | 0.87 | 0.12 | 2.99 | 2.42 | 010 |
| 19000 | | A | Drainage of breast lesion | 0.84 | 1.98 | 0.31 | 0.08 | 2.90 | 1.23 | 000 |
| 19001 | | A | Drain breast lesion add-on | 0.42 | 0.25 | 0.14 | 0.04 | 0.71 | 0.60 | ZZZ |
| 19020 | | A | Incision of breast lesion | 3.56 | 6.36 | 2.68 | 0.45 | 10.37 | 6.69 | 090 |
| 19030 | | A | Injection for breast x-ray | 1.53 | 2.88 | 0.50 | 0.09 | 4.50 | 2.12 | 000 |
| 19100 | | A | Bx breast percut w/o image | 1.27 | 2.08 | 0.42 | 0.15 | 3.50 | 1.84 | 000 |
| 19101 | | A | Biopsy of breast, open | 3.18 | 4.51 | 1.91 | 0.36 | 8.05 | 5.45 | 010 |
| 19102 | | A | Bx breast percut w/image | 2.00 | 3.83 | 0.66 | 0.15 | 5.98 | 2.81 | 000 |
| 19103 | | A | Bx breast percut w/device | 3.69 | 11.53 | 1.23 | 0.30 | 15.52 | 5.22 | 000 |
| 19110 | | A | Nipple exploration | 4.29 | 5.82 | 2.87 | 0.56 | 10.67 | 7.72 | 090 |
| 19112 | | A | Excise breast duct fistula | 3.66 | 6.11 | 2.69 | 0.48 | 10.25 | 6.83 | 090 |
| 19120 | | A | Removal of breast lesion | 5.55 | 4.55 | 3.06 | 0.72 | 10.82 | 9.33 | 090 |
| 19125 | | A | Excision, breast lesion | 6.05 | 4.79 | 3.28 | 0.79 | 11.63 | 10.12 | 090 |
| 19126 | | A | Excision, addl breast lesion | 2.93 | NA | 1.00 | 0.38 | NA | 4.31 | ZZZ |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 19140 | | A | Removal of breast tissue | 5.13 | 7.18 | 3.41 | 0.69 | 13.00 | 9.23 | 090 |
| 19160 | | A | Removal of breast tissue | 5.98 | NA | 3.43 | 0.78 | NA | 10.19 | 090 |
| 19162 | | A | Remove breast tissue, nodes | 13.51 | NA | 6.34 | 1.74 | NA | 21.59 | 090 |
| 19180 | | A | Removal of breast | 8.79 | NA | 5.03 | 1.14 | NA | 14.96 | 090 |
| 19182 | | A | Removal of breast | 7.72 | NA | 4.77 | 1.03 | NA | 13.52 | 090 |
| 19200 | | A | Removal of breast | 15.47 | NA | 7.98 | 1.82 | NA | 25.27 | 090 |
| 19220 | | A | Removal of breast | 15.70 | NA | 8.25 | 1.97 | NA | 25.92 | 090 |
| 19240 | | A | Removal of breast | 15.98 | NA | 8.23 | 2.06 | NA | 26.27 | 090 |
| 19260 | | A | Removal of chest wall lesion | 15.42 | NA | 11.17 | 2.01 | NA | 28.60 | 090 |
| 19271 | | A | Revision of chest wall | 18.87 | NA | 17.99 | 2.51 | NA | 39.37 | 090 |
| 19272 | | A | Extensive chest wall surgery | 21.52 | NA | 18.97 | 3.01 | NA | 43.50 | 090 |
| 19290 | | A | Place needle wire, breast | 1.27 | 2.89 | 0.42 | 0.08 | 4.24 | 1.77 | 000 |
| 19291 | | A | Place needle wire, breast | 0.63 | 1.22 | 0.21 | 0.04 | 1.89 | 0.88 | ZZZ |
| 19295 | | A | Place breast clip, percut | 0.00 | 2.70 | NA | 0.01 | 2.71 | NA | ZZZ |
| 19316 | | A | Suspension of breast | 10.67 | NA | 7.52 | 1.60 | NA | 19.79 | 090 |
| 19318 | | A | Reduction of large breast | 15.60 | NA | 11.12 | 2.79 | NA | 29.51 | 090 |
| 19324 | | A | Enlarge breast | 5.84 | NA | 4.87 | 0.84 | NA | 11.55 | 090 |
| 19325 | | A | Enlarge breast with implant | 8.44 | NA | 6.53 | 1.28 | NA | 16.25 | 090 |
| 19328 | | A | Removal of breast implant | 5.67 | NA | 5.02 | 0.89 | NA | 11.58 | 090 |
| 19330 | | A | Removal of implant material | 7.58 | NA | 6.02 | 1.24 | NA | 14.84 | 090 |
| 19340 | | A | Immediate breast prosthesis | 6.32 | NA | 3.10 | 1.03 | NA | 10.45 | ZZZ |
| 19342 | | A | Delayed breast prosthesis | 11.18 | NA | 8.89 | 1.77 | NA | 21.84 | 090 |
| 19350 | | A | Breast reconstruction | 8.91 | 13.79 | 7.15 | 1.38 | 24.08 | 17.44 | 090 |
| 19355 | | A | Correct inverted nipple(s) | 7.56 | 10.25 | 4.70 | 1.07 | 18.88 | 13.33 | 090 |
| 19357 | | A | Breast reconstruction | 18.13 | NA | 13.76 | 2.79 | NA | 34.68 | 090 |
| 19361 | | A | Breast reconstruction | 19.23 | NA | 11.71 | 2.84 | NA | 33.78 | 090 |
| 19364 | | A | Breast reconstruction | 40.94 | NA | 23.49 | 5.85 | NA | 70.28 | 090 |
| 19366 | | A | Breast reconstruction | 21.25 | NA | 11.16 | 3.07 | NA | 35.48 | 090 |
| 19367 | | A | Breast reconstruction | 25.69 | NA | 16.45 | 3.84 | NA | 45.98 | 090 |
| 19368 | | A | Breast reconstruction | 32.37 | NA | 20.12 | 4.63 | NA | 57.12 | 090 |
| 19369 | | A | Breast reconstruction | 29.78 | NA | 19.66 | 4.29 | NA | 53.73 | 090 |
| 19370 | | A | Surgery of breast capsule | 8.04 | NA | 6.87 | 1.27 | NA | 16.18 | 090 |
| 19371 | | A | Removal of breast capsule | 9.34 | NA | 7.79 | 1.65 | NA | 18.78 | 090 |
| 19380 | | A | Revise breast reconstruction | 9.13 | NA | 7.67 | 1.42 | NA | 18.22 | 090 |
| 19396 | | A | Design custom breast implant | 2.17 | 1.08 | 0.99 | 0.26 | 3.51 | 3.42 | 000 |
| 20000 | | A | Incision of abscess | 2.12 | 2.70 | 1.73 | 0.19 | 5.01 | 4.04 | 010 |
| 20005 | | A | Incision of deep abscess | 3.41 | 3.50 | 2.25 | 0.41 | 7.32 | 6.07 | 010 |
| 20100 | | A | Explore wound, neck | 10.06 | NA | 4.46 | 1.19 | NA | 15.71 | 010 |
| 20101 | | A | Explore wound, chest | 3.22 | 5.94 | 1.62 | 0.41 | 9.57 | 5.25 | 010 |
| 20102 | | A | Explore wound, abdomen | 3.93 | 7.50 | 1.91 | 0.50 | 11.93 | 6.34 | 010 |
| 20103 | | A | Explore wound, extremity | 5.29 | 8.60 | 3.39 | 0.70 | 14.59 | 9.38 | 010 |
| 20150 | | A | Excise epiphyseal bar | 13.67 | NA | 7.04 | 1.43 | NA | 22.14 | 090 |
| 20200 | | A | Muscle biopsy | 1.46 | 3.05 | 0.75 | 0.22 | 4.73 | 2.43 | 000 |
| 20205 | | A | Deep muscle biopsy | 2.35 | 4.07 | 1.19 | 0.31 | 6.73 | 3.85 | 000 |
| 20206 | | A | Needle biopsy, muscle | 0.99 | 6.63 | 0.63 | 0.07 | 7.69 | 1.69 | 000 |
| 20220 | | A | Bone biopsy, trocar/needle | 1.27 | 4.89 | 0.80 | 0.09 | 6.25 | 2.16 | 000 |
| 20225 | | A | Bone biopsy, trocar/needle | 1.87 | 26.72 | 1.13 | 0.18 | 28.77 | 3.18 | 000 |
| 20240 | | A | Bone biopsy, excisional | 3.23 | NA | 2.56 | 0.41 | NA | 6.20 | 010 |
| 20245 | | A | Bone biopsy, excisional | 7.77 | NA | 6.59 | 1.19 | NA | 15.55 | 010 |
| 20250 | | A | Open bone biopsy | 5.02 | NA | 3.50 | 0.91 | NA | 9.43 | 010 |
| 20251 | | A | Open bone biopsy | 5.55 | NA | 4.15 | 1.05 | NA | 10.75 | 010 |
| 20500 | | A | Injection of sinus tract | 1.23 | 2.27 | 1.53 | 0.10 | 3.60 | 2.86 | 010 |
| 20501 | | A | Inject sinus tract for x-ray | 0.76 | 2.98 | 0.25 | 0.05 | 3.79 | 1.06 | 000 |
| 20520 | | A | Removal of foreign body | 1.85 | 2.93 | 1.77 | 0.20 | 4.98 | 3.82 | 010 |
| 20525 | | A | Removal of foreign body | 3.49 | 9.14 | 2.62 | 0.47 | 13.10 | 6.58 | 010 |
| 20526 | | A | Ther injection, carp tunnel | 0.94 | 0.97 | 0.51 | 0.10 | 2.01 | 1.55 | 000 |
| 20550 | | A | Inj tendon sheath/ligament | 0.75 | 0.71 | 0.23 | 0.08 | 1.54 | 1.06 | 000 |
| 20551 | | A | Inj tendon origin/insertion | 0.75 | 0.69 | 0.33 | 0.08 | 1.52 | 1.16 | 000 |
| 20552 | | A | Inj trigger point, 1/2 muscl | 0.66 | 0.72 | 0.20 | 0.07 | 1.45 | 0.93 | 000 |
| 20553 | | A | Inject trigger points, =/> 3 | 0.75 | 0.82 | 0.22 | 0.05 | 1.62 | 1.02 | 000 |
| 20600 | | A | Drain/inject, joint/bursa | 0.66 | 0.65 | 0.35 | 0.06 | 1.37 | 1.07 | 000 |
| 20605 | | A | Drain/inject, joint/bursa | 0.68 | 0.76 | 0.36 | 0.07 | 1.51 | 1.11 | 000 |
| 20610 | | A | Drain/inject, joint/bursa | 0.79 | 0.95 | 0.42 | 0.10 | 1.84 | 1.31 | 000 |
| 20612 | | A | Aspirate/inj ganglion cyst | 0.70 | 0.71 | 0.36 | 0.07 | 1.48 | 1.13 | 000 |
| 20615 | | A | Treatment of bone cyst | 2.28 | 3.53 | 1.84 | 0.19 | 6.00 | 4.31 | 010 |
| 20650 | | A | Insert and remove bone pin | 2.23 | 2.36 | 1.55 | 0.25 | 4.84 | 4.03 | 010 |
| 20660 | | A | Apply, rem fixation device | 2.51 | 3.05 | 1.61 | 0.54 | 6.10 | 4.66 | 000 |
| 20661 | | A | Application of head brace | 4.88 | NA | 5.06 | 1.11 | NA | 11.05 | 090 |
| 20662 | | A | Application of pelvis brace | 6.06 | NA | 5.58 | 0.53 | NA | 12.17 | 090 |
| 20663 | | A | Application of thigh brace | 5.42 | NA | 4.89 | 0.33 | NA | 10.64 | 090 |
| 20664 | | A | Halo brace application | 8.05 | NA | 7.15 | 1.68 | NA | 16.88 | 090 |
| 20665 | | A | Removal of fixation device | 1.31 | 2.21 | 1.35 | 0.19 | 3.71 | 2.85 | 010 |
| 20670 | | A | Removal of support implant | 1.74 | 11.52 | 2.09 | 0.26 | 13.52 | 4.09 | 010 |
| 20680 | | A | Removal of support implant | 3.34 | 8.77 | 3.71 | 0.52 | 12.63 | 7.57 | 090 |
| 20690 | | A | Apply bone fixation device | 3.51 | NA | 2.54 | 0.58 | NA | 6.63 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 20692 | | A | Apply bone fixation device | 6.40 | NA | 3.77 | 0.99 | NA | 11.16 | 090 |
| 20693 | | A | Adjust bone fixation device | 5.85 | NA | 5.73 | 0.98 | NA | 12.56 | 090 |
| 20694 | | A | Remove bone fixation device | 4.15 | 7.13 | 4.04 | 0.69 | 11.97 | 8.88 | 090 |
| 20802 | | A | Replantation, arm, complete | 41.09 | NA | 21.49 | 4.51 | NA | 67.09 | 090 |
| 20805 | | A | Replant forearm, complete | 49.93 | NA | 35.25 | 4.64 | NA | 89.82 | 090 |
| 20808 | | A | Replantation hand, complete | 61.56 | NA | 43.10 | 5.37 | NA | 110.03 | 090 |
| 20816 | | A | Replantation digit, complete | 30.89 | NA | 38.46 | 4.37 | NA | 73.72 | 090 |
| 20822 | | A | Replantation digit, complete | 25.55 | NA | 35.14 | 3.46 | NA | 64.15 | 090 |
| 20824 | | A | Replantation thumb, complete | 30.89 | NA | 37.30 | 4.15 | NA | 72.34 | 090 |
| 20827 | | A | Replantation thumb, complete | 26.37 | NA | 37.15 | 3.73 | NA | 67.25 | 090 |
| 20838 | | A | Replantation foot, complete | 41.35 | NA | 22.78 | 10.71 | NA | 74.84 | 090 |
| 20900 | | A | Removal of bone for graft | 5.57 | 8.44 | 5.66 | 0.85 | 14.86 | 12.08 | 090 |
| 20902 | | A | Removal of bone for graft | 7.54 | NA | 7.06 | 1.21 | NA | 15.81 | 090 |
| 20910 | | A | Remove cartilage for graft | 5.33 | NA | 5.26 | 0.66 | NA | 11.25 | 090 |
| 20912 | | A | Remove cartilage for graft | 6.34 | NA | 6.15 | 0.70 | NA | 13.19 | 090 |
| 20920 | | A | Removal of fascia for graft | 5.30 | NA | 4.40 | 0.58 | NA | 10.28 | 090 |
| 20922 | | A | Removal of fascia for graft | 6.60 | 7.54 | 4.87 | 0.68 | 14.82 | 12.15 | 090 |
| 20924 | | A | Removal of tendon for graft | 6.47 | NA | 6.06 | 0.97 | NA | 13.50 | 090 |
| 20926 | | A | Removal of tissue for graft | 5.52 | NA | 4.99 | 0.81 | NA | 11.32 | 090 |
| 20931 | | A | Spinal bone allograft | 1.81 | NA | 0.93 | 0.42 | NA | 3.16 | ZZZ |
| 20937 | | A | Spinal bone autograft | 2.79 | NA | 1.45 | 0.49 | NA | 4.73 | ZZZ |
| 20938 | | A | Spinal bone autograft | 3.02 | NA | 1.55 | 0.57 | NA | 5.14 | ZZZ |
| 20950 | | A | Fluid pressure, muscle | 1.26 | 6.83 | 0.99 | 0.19 | 8.28 | 2.44 | 000 |
| 20955 | | A | Fibula bone graft, microvasc | 39.15 | NA | 25.19 | 4.72 | NA | 69.06 | 090 |
| 20956 | | A | Iliac bone graft, microvasc | 39.21 | NA | 25.05 | 7.16 | NA | 71.42 | 090 |
| 20957 | | A | Mt bone graft, microvasc | 40.59 | NA | 19.21 | 4.32 | NA | 64.12 | 090 |
| 20962 | | A | Other bone graft, microvasc | 39.21 | NA | 26.71 | 6.19 | NA | 72.11 | 090 |
| 20969 | | A | Bone/skin graft, microvasc | 43.85 | NA | 27.63 | 4.68 | NA | 76.16 | 090 |
| 20970 | | A | Bone/skin graft, iliac crest | 43.00 | NA | 25.97 | 6.77 | NA | 75.74 | 090 |
| 20972 | | A | Bone/skin graft, metatarsal | 42.93 | NA | 20.56 | 3.44 | NA | 66.93 | 090 |
| 20973 | | A | Bone/skin graft, great toe | 45.69 | NA | 25.46 | 5.61 | NA | 76.76 | 090 |
| 20974 | | A | Electrical bone stimulation | 0.62 | 0.69 | 0.54 | 0.10 | 1.41 | 1.26 | 000 |
| 20975 | | A | Electrical bone stimulation | 2.60 | NA | 1.71 | 0.46 | NA | 4.77 | 000 |
| 20979 | | A | Us bone stimulation | 0.62 | 0.80 | 0.33 | 0.09 | 1.51 | 1.04 | 000 |
| 20982 | | A | Ablate, bone tumor(s) perq | 7.27 | 109.89 | 2.97 | 0.69 | 117.85 | 10.93 | 000 |
| 21010 | | A | Incision of jaw joint | 10.12 | NA | 7.14 | 1.02 | NA | 18.28 | 090 |
| 21015 | | A | Resection of facial tumor | 5.28 | NA | 5.43 | 0.70 | NA | 11.41 | 090 |
| 21025 | | A | Excision of bone, lower jaw | 10.04 | 12.22 | 9.35 | 1.30 | 23.56 | 20.69 | 090 |
| 21026 | | A | Excision of facial bone(s) | 4.84 | 7.85 | 6.31 | 0.63 | 13.32 | 11.78 | 090 |
| 21029 | | A | Contour of face bone lesion | 7.70 | 9.34 | 6.99 | 0.90 | 17.94 | 15.59 | 090 |
| 21030 | | A | Excise max/zygoma b9 tumor | 4.49 | 6.32 | 5.03 | 0.86 | 11.67 | 10.38 | 090 |
| 21031 | | A | Remove exostosis, mandible | 3.24 | 5.16 | 3.62 | 0.47 | 8.87 | 7.33 | 090 |
| 21032 | | A | Remove exostosis, maxilla | 3.24 | 5.34 | 3.51 | 0.46 | 9.04 | 7.21 | 090 |
| 21034 | | A | Excise max/zygoma mlg tumor | 16.15 | 15.88 | 12.63 | 1.74 | 33.77 | 30.52 | 090 |
| 21040 | | A | Excise mandible lesion | 4.49 | 6.38 | 4.72 | 0.57 | 11.44 | 9.78 | 090 |
| 21044 | | A | Removal of jaw bone lesion | 11.84 | NA | 9.37 | 1.10 | NA | 22.31 | 090 |
| 21045 | | A | Extensive jaw surgery | 16.15 | NA | 12.34 | 1.57 | NA | 30.06 | 090 |
| 21046 | | A | Remove mandible cyst complex | 12.98 | NA | 11.86 | 0.88 | NA | 25.72 | 090 |
| 21047 | | A | Excise lwr jaw cyst w/repair | 18.72 | NA | 13.42 | 0.88 | NA | 33.02 | 090 |
| 21048 | | A | Remove maxilla cyst complex | 13.48 | NA | 12.08 | 0.88 | NA | 26.44 | 090 |
| 21049 | | A | Excis uppr jaw cyst w/repair | 17.97 | NA | 13.00 | 0.88 | NA | 31.85 | 090 |
| 21050 | | A | Removal of jaw joint | 10.75 | NA | 9.43 | 1.36 | NA | 21.54 | 090 |
| 21060 | | A | Remove jaw joint cartilage | 10.21 | NA | 8.60 | 1.51 | NA | 20.32 | 090 |
| 21070 | | A | Remove coronoid process | 8.19 | NA | 7.10 | 1.16 | NA | 16.45 | 090 |
| 21076 | | A | Prepare face/oral prosthesis | 13.40 | 12.34 | 9.99 | 1.91 | 27.65 | 25.30 | 010 |
| 21077 | | A | Prepare face/oral prosthesis | 33.70 | 31.27 | 25.96 | 5.03 | 70.00 | 64.69 | 090 |
| 21079 | | A | Prepare face/oral prosthesis | 22.31 | 21.46 | 17.12 | 3.09 | 46.86 | 42.52 | 090 |
| 21080 | | A | Prepare face/oral prosthesis | 25.06 | 24.45 | 19.33 | 3.68 | 53.19 | 48.07 | 090 |
| 21081 | | A | Prepare face/oral prosthesis | 22.85 | 22.26 | 17.45 | 3.10 | 48.21 | 43.40 | 090 |
| 21082 | | A | Prepare face/oral prosthesis | 20.84 | 19.30 | 15.69 | 2.95 | 43.09 | 39.48 | 090 |
| 21083 | | A | Prepare face/oral prosthesis | 19.27 | 18.76 | 14.41 | 2.55 | 40.58 | 36.23 | 090 |
| 21084 | | A | Prepare face/oral prosthesis | 22.48 | 22.40 | 17.67 | 2.28 | 47.16 | 42.43 | 090 |
| 21085 | | A | Prepare face/oral prosthesis | 8.99 | 8.27 | 6.77 | 1.17 | 18.43 | 16.93 | 010 |
| 21086 | | A | Prepare face/oral prosthesis | 24.88 | 23.73 | 19.39 | 3.19 | 51.80 | 47.46 | 090 |
| 21087 | | A | Prepare face/oral prosthesis | 24.88 | 23.23 | 19.14 | 3.58 | 51.69 | 47.60 | 090 |
| 21100 | | A | Maxillofacial fixation | 4.21 | 11.59 | 4.76 | 0.35 | 16.15 | 9.32 | 090 |
| 21110 | | A | Interdental fixation | 5.20 | 9.57 | 8.35 | 0.62 | 15.39 | 14.17 | 090 |
| 21116 | | A | Injection, jaw joint x-ray | 0.81 | 4.36 | 0.33 | 0.06 | 5.23 | 1.20 | 000 |
| 21120 | | A | Reconstruction of chin | 4.92 | 10.62 | 7.48 | 0.49 | 16.03 | 12.89 | 090 |
| 21121 | | A | Reconstruction of chin | 7.63 | 9.73 | 7.81 | 0.93 | 18.29 | 16.37 | 090 |
| 21122 | | A | Reconstruction of chin | 8.51 | NA | 8.62 | 0.98 | NA | 18.11 | 090 |
| 21123 | | A | Reconstruction of chin | 11.14 | NA | 10.78 | 0.91 | NA | 22.83 | 090 |
| 21125 | | A | Augmentation, lower jaw bone | 10.60 | 55.70 | 8.31 | 0.76 | 67.06 | 19.67 | 090 |
| 21127 | | A | Augmentation, lower jaw bone | 11.10 | 42.76 | 9.44 | 1.66 | 55.52 | 22.20 | 090 |
| 21137 | | A | Reduction of forehead | 9.81 | NA | 7.71 | 1.13 | NA | 18.65 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 21138 | | A | Reduction of forehead | 12.17 | NA | 9.50 | 0.61 | NA | 22.28 | 090 |
| 21139 | | A | Reduction of forehead | 14.59 | NA | 11.04 | 1.68 | NA | 27.31 | 090 |
| 21141 | | A | Reconstruct midface, lefort | 18.07 | NA | 13.75 | 2.41 | NA | 34.23 | 090 |
| 21142 | | A | Reconstruct midface, lefort | 18.78 | NA | 12.94 | 2.26 | NA | 33.98 | 090 |
| 21143 | | A | Reconstruct midface, lefort | 19.55 | NA | 14.30 | 1.09 | NA | 34.94 | 090 |
| 21145 | | A | Reconstruct midface, lefort | 19.91 | NA | 14.02 | 2.58 | NA | 36.51 | 090 |
| 21146 | | A | Reconstruct midface, lefort | 20.68 | NA | 15.44 | 3.09 | NA | 39.21 | 090 |
| 21147 | | A | Reconstruct midface, lefort | 21.74 | NA | 15.13 | 1.83 | NA | 38.70 | 090 |
| 21150 | | A | Reconstruct midface, lefort | 25.20 | NA | 16.75 | 3.04 | NA | 44.99 | 090 |
| 21151 | | A | Reconstruct midface, lefort | 28.26 | NA | 22.88 | 4.22 | NA | 55.36 | 090 |
| 21154 | | A | Reconstruct midface, lefort | 30.47 | NA | 23.07 | 4.55 | NA | 58.09 | 090 |
| 21155 | | A | Reconstruct midface, lefort | 34.40 | NA | 23.85 | 6.61 | NA | 64.86 | 090 |
| 21159 | | A | Reconstruct midface, lefort | 42.32 | NA | 29.02 | 6.31 | NA | 77.65 | 090 |
| 21160 | | A | Reconstruct midface, lefort | 46.37 | NA | 27.46 | 4.91 | NA | 78.74 | 090 |
| 21172 | | A | Reconstruct orbit/forehead | 27.76 | NA | 14.01 | 2.83 | NA | 44.60 | 090 |
| 21175 | | A | Reconstruct orbit/forehead | 33.12 | NA | 18.18 | 3.43 | NA | 54.73 | 090 |
| 21179 | | A | Reconstruct entire forehead | 22.22 | NA | 14.72 | 3.24 | NA | 40.18 | 090 |
| 21180 | | A | Reconstruct entire forehead | 25.15 | NA | 15.92 | 3.08 | NA | 44.15 | 090 |
| 21181 | | A | Contour cranial bone lesion | 9.89 | NA | 7.78 | 1.37 | NA | 19.04 | 090 |
| 21182 | | A | Reconstruct cranial bone | 32.14 | NA | 19.47 | 3.42 | NA | 55.03 | 090 |
| 21183 | | A | Reconstruct cranial bone | 35.26 | NA | 21.18 | 3.51 | NA | 59.95 | 090 |
| 21184 | | A | Reconstruct cranial bone | 38.18 | NA | 22.37 | 6.84 | NA | 67.39 | 090 |
| 21188 | | A | Reconstruction of midface | 22.43 | NA | 18.83 | 2.97 | NA | 44.23 | 090 |
| 21193 | | A | Reconst lwr jaw w/o graft | 17.12 | NA | 12.84 | 2.10 | NA | 32.06 | 090 |
| 21194 | | A | Reconst lwr jaw w/graft | 19.81 | NA | 13.91 | 2.11 | NA | 35.83 | 090 |
| 21195 | | A | Reconst lwr jaw w/o fixation | 17.21 | NA | 14.79 | 1.22 | NA | 33.22 | 090 |
| 21196 | | A | Reconst lwr jaw w/fixation | 18.88 | NA | 15.66 | 2.03 | NA | 36.57 | 090 |
| 21198 | | A | Reconstr lwr jaw segment | 14.14 | NA | 12.69 | 1.41 | NA | 28.24 | 090 |
| 21199 | | A | Reconstr lwr jaw w/advance | 15.98 | NA | 9.15 | 1.39 | NA | 26.52 | 090 |
| 21206 | | A | Reconstruct upper jaw bone | 14.08 | NA | 12.62 | 1.78 | NA | 28.48 | 090 |
| 21208 | | A | Augmentation of facial bones | 10.21 | 22.32 | 9.56 | 1.11 | 33.64 | 20.88 | 090 |
| 21209 | | A | Reduction of facial bones | 6.71 | 10.78 | 8.06 | 0.90 | 18.39 | 15.67 | 090 |
| 21210 | | A | Face bone graft | 10.21 | 24.84 | 9.33 | 1.37 | 36.42 | 20.91 | 090 |
| 21215 | | A | Lower jaw bone graft | 10.75 | 41.85 | 9.35 | 1.51 | 54.11 | 21.61 | 090 |
| 21230 | | A | Rib cartilage graft | 10.75 | NA | 8.46 | 1.20 | NA | 20.41 | 090 |
| 21235 | | A | Ear cartilage graft | 6.71 | 9.83 | 6.40 | 0.68 | 17.22 | 13.79 | 090 |
| 21240 | | A | Reconstruction of jaw joint | 14.03 | NA | 12.17 | 2.28 | NA | 28.48 | 090 |
| 21242 | | A | Reconstruction of jaw joint | 12.93 | NA | 11.66 | 2.29 | NA | 26.88 | 090 |
| 21243 | | A | Reconstruction of jaw joint | 20.76 | NA | 17.37 | 3.05 | NA | 41.18 | 090 |
| 21244 | | A | Reconstruction of lower jaw | 11.84 | NA | 12.07 | 1.24 | NA | 25.15 | 090 |
| 21245 | | A | Reconstruction of jaw | 11.84 | 14.35 | 9.83 | 1.12 | 27.31 | 22.79 | 090 |
| 21246 | | A | Reconstruction of jaw | 12.45 | NA | 9.03 | 1.24 | NA | 22.72 | 090 |
| 21247 | | A | Reconstruct lower jaw bone | 22.60 | NA | 17.43 | 3.23 | NA | 43.26 | 090 |
| 21248 | | A | Reconstruction of jaw | 11.46 | 12.11 | 9.38 | 1.67 | 25.24 | 22.51 | 090 |
| 21249 | | A | Reconstruction of jaw | 17.49 | 16.70 | 12.67 | 2.02 | 36.21 | 32.18 | 090 |
| 21255 | | A | Reconstruct lower jaw bone | 16.69 | NA | 16.15 | 2.57 | NA | 35.41 | 090 |
| 21256 | | A | Reconstruction of orbit | 16.17 | NA | 12.03 | 1.36 | NA | 29.56 | 090 |
| 21260 | | A | Revise eye sockets | 16.50 | NA | 12.75 | 0.98 | NA | 30.23 | 090 |
| 21261 | | A | Revise eye sockets | 31.44 | NA | 24.21 | 3.09 | NA | 58.74 | 090 |
| 21263 | | A | Revise eye sockets | 28.38 | NA | 19.17 | 2.61 | NA | 50.16 | 090 |
| 21267 | | A | Revise eye sockets | 18.87 | NA | 19.72 | 1.64 | NA | 40.23 | 090 |
| 21268 | | A | Revise eye sockets | 24.44 | NA | 20.22 | 2.43 | NA | 47.09 | 090 |
| 21270 | | A | Augmentation, cheek bone | 10.21 | 11.66 | 7.24 | 1.04 | 22.91 | 18.49 | 090 |
| 21275 | | A | Revision, orbitofacial bones | 11.22 | NA | 8.63 | 1.29 | NA | 21.14 | 090 |
| 21280 | | A | Revision of eyelid | 6.02 | NA | 5.95 | 0.46 | NA | 12.43 | 090 |
| 21282 | | A | Revision of eyelid | 3.48 | NA | 4.58 | 0.27 | NA | 8.33 | 090 |
| 21295 | | A | Revision of jaw muscle/bone | 1.53 | NA | 2.54 | 0.15 | NA | 4.22 | 090 |
| 21296 | | A | Revision of jaw muscle/bone | 4.24 | NA | 4.90 | 0.35 | NA | 9.49 | 090 |
| 21300 | | A | Treatment of skull fracture | 0.72 | 2.39 | 0.26 | 0.11 | 3.22 | 1.09 | 000 |
| 21310 | | A | Treatment of nose fracture | 0.58 | 2.30 | 0.15 | 0.05 | 2.93 | 0.78 | 000 |
| 21315 | | A | Treatment of nose fracture | 1.51 | 4.23 | 1.88 | 0.14 | 5.88 | 3.53 | 010 |
| 21320 | | A | Treatment of nose fracture | 1.85 | 3.91 | 1.62 | 0.18 | 5.94 | 3.65 | 010 |
| 21325 | | A | Treatment of nose fracture | 3.76 | NA | 8.61 | 0.34 | NA | 12.71 | 090 |
| 21330 | | A | Treatment of nose fracture | 5.37 | NA | 9.64 | 0.61 | NA | 15.62 | 090 |
| 21335 | | A | Treatment of nose fracture | 8.60 | NA | 9.60 | 0.75 | NA | 18.95 | 090 |
| 21336 | | A | Treat nasal septal fracture | 5.71 | NA | 9.57 | 0.56 | NA | 15.84 | 090 |
| 21337 | | A | Treat nasal septal fracture | 2.70 | 6.49 | 3.56 | 0.27 | 9.46 | 6.53 | 090 |
| 21338 | | A | Treat nasoethmoid fracture | 6.45 | NA | 13.90 | 0.75 | NA | 21.10 | 090 |
| 21339 | | A | Treat nasoethmoid fracture | 8.08 | NA | 13.77 | 0.92 | NA | 22.77 | 090 |
| 21340 | | A | Treatment of nose fracture | 10.75 | NA | 8.59 | 0.97 | NA | 20.31 | 090 |
| 21343 | | A | Treatment of sinus fracture | 12.93 | NA | 15.39 | 1.67 | NA | 29.99 | 090 |
| 21344 | | A | Treatment of sinus fracture | 19.69 | NA | 16.42 | 2.45 | NA | 38.56 | 090 |
| 21345 | | A | Treat nose/jaw fracture | 8.15 | 9.84 | 7.16 | 1.11 | 19.10 | 16.42 | 090 |
| 21346 | | A | Treat nose/jaw fracture | 10.59 | NA | 12.18 | 1.22 | NA | 23.99 | 090 |
| 21347 | | A | Treat nose/jaw fracture | 12.67 | NA | 16.03 | 1.57 | NA | 30.27 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 21348 | | A | Treat nose/jaw fracture | 16.66 | NA | 11.21 | 1.62 | NA | 29.49 | 090 |
| 21355 | | A | Treat cheek bone fracture | 3.76 | 6.24 | 3.49 | 0.28 | 10.28 | 7.53 | 010 |
| 21356 | | A | Treat cheek bone fracture | 4.14 | 7.10 | 4.53 | 0.47 | 11.71 | 9.14 | 010 |
| 21360 | | A | Treat cheek bone fracture | 6.45 | NA | 5.92 | 0.71 | NA | 13.08 | 090 |
| 21365 | | A | Treat cheek bone fracture | 14.93 | NA | 10.79 | 1.72 | NA | 27.44 | 090 |
| 21366 | | A | Treat cheek bone fracture | 17.74 | NA | 11.52 | 1.90 | NA | 31.16 | 090 |
| 21385 | | A | Treat eye socket fracture | 9.15 | NA | 8.27 | 0.83 | NA | 18.25 | 090 |
| 21386 | | A | Treat eye socket fracture | 9.15 | NA | 7.06 | 1.04 | NA | 17.25 | 090 |
| 21387 | | A | Treat eye socket fracture | 9.69 | NA | 8.93 | 0.96 | NA | 19.58 | 090 |
| 21390 | | A | Treat eye socket fracture | 10.11 | NA | 7.91 | 0.92 | NA | 18.94 | 090 |
| 21395 | | A | Treat eye socket fracture | 12.66 | NA | 9.21 | 1.60 | NA | 23.47 | 090 |
| 21400 | | A | Treat eye socket fracture | 1.40 | 2.64 | 1.90 | 0.14 | 4.18 | 3.44 | 090 |
| 21401 | | A | Treat eye socket fracture | 3.26 | 8.05 | 3.49 | 0.27 | 11.58 | 7.02 | 090 |
| 21406 | | A | Treat eye socket fracture | 7.00 | NA | 6.26 | 0.82 | NA | 14.08 | 090 |
| 21407 | | A | Treat eye socket fracture | 8.60 | NA | 7.05 | 0.94 | NA | 16.59 | 090 |
| 21408 | | A | Treat eye socket fracture | 12.36 | NA | 9.10 | 1.39 | NA | 22.85 | 090 |
| 21421 | | A | Treat mouth roof fracture | 5.13 | 9.33 | 8.31 | 0.61 | 15.07 | 14.05 | 090 |
| 21422 | | A | Treat mouth roof fracture | 8.31 | NA | 8.06 | 0.97 | NA | 17.34 | 090 |
| 21423 | | A | Treat mouth roof fracture | 10.38 | NA | 9.30 | 1.20 | NA | 20.88 | 090 |
| 21431 | | A | Treat craniofacial fracture | 7.04 | NA | 9.51 | 1.05 | NA | 17.60 | 090 |
| 21432 | | A | Treat craniofacial fracture | 8.60 | NA | 8.05 | 0.87 | NA | 17.52 | 090 |
| 21433 | | A | Treat craniofacial fracture | 25.31 | NA | 16.66 | 3.07 | NA | 45.04 | 090 |
| 21435 | | A | Treat craniofacial fracture | 17.22 | NA | 12.82 | 2.81 | NA | 32.85 | 090 |
| 21436 | | A | Treat craniofacial fracture | 28.00 | NA | 18.25 | 3.23 | NA | 49.48 | 090 |
| 21440 | | A | Treat dental ridge fracture | 2.70 | 7.10 | 6.16 | 0.35 | 10.15 | 9.21 | 090 |
| 21445 | | A | Treat dental ridge fracture | 5.37 | 9.73 | 8.36 | 0.68 | 15.78 | 14.41 | 090 |
| 21450 | | A | Treat lower jaw fracture | 2.97 | 7.38 | 6.92 | 0.37 | 10.72 | 10.26 | 090 |
| 21451 | | A | Treat lower jaw fracture | 4.86 | 9.34 | 8.40 | 0.65 | 14.85 | 13.91 | 090 |
| 21452 | | A | Treat lower jaw fracture | 1.98 | 13.11 | 4.61 | 0.20 | 15.29 | 6.79 | 090 |
| 21453 | | A | Treat lower jaw fracture | 5.53 | 10.73 | 10.71 | 0.71 | 16.97 | 16.95 | 090 |
| 21454 | | A | Treat lower jaw fracture | 6.45 | NA | 6.50 | 0.76 | NA | 13.71 | 090 |
| 21461 | | A | Treat lower jaw fracture | 8.08 | 24.43 | 12.64 | 0.95 | 33.46 | 21.67 | 090 |
| 21462 | | A | Treat lower jaw fracture | 9.78 | 27.59 | 12.69 | 0.94 | 38.31 | 23.41 | 090 |
| 21465 | | A | Treat lower jaw fracture | 11.89 | NA | 9.99 | 1.63 | NA | 23.51 | 090 |
| 21470 | | A | Treat lower jaw fracture | 15.32 | NA | 12.18 | 1.97 | NA | 29.47 | 090 |
| 21480 | | A | Reset dislocated jaw | 0.61 | 1.77 | 0.19 | 0.06 | 2.44 | 0.86 | 000 |
| 21485 | | A | Reset dislocated jaw | 3.98 | 8.22 | 7.67 | 0.49 | 12.69 | 12.14 | 090 |
| 21490 | | A | Repair dislocated jaw | 11.84 | NA | 9.84 | 1.79 | NA | 23.47 | 090 |
| 21493 | | A | Treat hyoid bone fracture | 1.27 | NA | 0.55 | 0.07 | NA | 1.89 | 090 |
| 21494 | | A | Treat hyoid bone fracture | 6.27 | NA | 3.53 | 0.53 | NA | 10.33 | 090 |
| 21495 | | A | Treat hyoid bone fracture | 5.68 | NA | 8.41 | 0.46 | NA | 14.55 | 090 |
| 21497 | | A | Interdental wiring | 3.85 | 8.44 | 7.63 | 0.44 | 12.73 | 11.92 | 090 |
| 21501 | | A | Drain neck/chest lesion | 3.80 | 6.47 | 3.83 | 0.45 | 10.72 | 8.08 | 090 |
| 21502 | | A | Drain chest lesion | 7.11 | NA | 5.67 | 0.93 | NA | 13.71 | 090 |
| 21510 | | A | Drainage of bone lesion | 5.73 | NA | 5.70 | 0.79 | NA | 12.22 | 090 |
| 21550 | | A | Biopsy of neck/chest | 2.06 | 3.59 | 1.72 | 0.19 | 5.84 | 3.97 | 010 |
| 21555 | | A | Remove lesion, neck/chest | 4.34 | 5.53 | 3.20 | 0.54 | 10.41 | 8.08 | 090 |
| 21556 | | A | Remove lesion, neck/chest | 5.56 | NA | 4.08 | 0.66 | NA | 10.30 | 090 |
| 21557 | | A | Remove tumor, neck/chest | 8.87 | NA | 5.41 | 1.09 | NA | 15.37 | 090 |
| 21600 | | A | Partial removal of rib | 6.88 | NA | 5.77 | 0.95 | NA | 13.60 | 090 |
| 21610 | | A | Partial removal of rib | 14.59 | NA | 9.11 | 2.49 | NA | 26.19 | 090 |
| 21615 | | A | Removal of rib | 9.86 | NA | 6.70 | 1.39 | NA | 17.95 | 090 |
| 21616 | | A | Removal of rib and nerves | 12.02 | NA | 8.04 | 1.72 | NA | 21.78 | 090 |
| 21620 | | A | Partial removal of sternum | 6.78 | NA | 6.03 | 0.93 | NA | 13.74 | 090 |
| 21627 | | A | Sternal debridement | 6.80 | NA | 6.43 | 0.95 | NA | 14.18 | 090 |
| 21630 | | A | Extensive sternum surgery | 17.35 | NA | 11.89 | 2.45 | NA | 31.69 | 090 |
| 21632 | | A | Extensive sternum surgery | 18.11 | NA | 11.13 | 2.45 | NA | 31.69 | 090 |
| 21685 | | A | Hyoid myotomy & suspension | 12.98 | NA | 9.96 | 1.05 | NA | 23.99 | 090 |
| 21700 | | A | Revision of neck muscle | 6.18 | NA | 4.44 | 0.72 | NA | 11.34 | 090 |
| 21705 | | A | Revision of neck muscle/rib | 9.59 | NA | 5.60 | 1.21 | NA | 16.40 | 090 |
| 21720 | | A | Revision of neck muscle | 5.67 | 2.45 | 2.45 | 0.86 | 8.98 | 8.98 | 090 |
| 21725 | | A | Revision of neck muscle | 6.98 | NA | 5.63 | 0.78 | NA | 13.39 | 090 |
| 21740 | | A | Reconstruction of sternum | 16.48 | NA | 8.56 | 2.06 | NA | 27.10 | 090 |
| 21750 | | A | Repair of sternum separation | 10.75 | NA | 6.11 | 1.44 | NA | 18.30 | 090 |
| 21800 | | A | Treatment of rib fracture | 0.96 | NA | 1.37 | 0.09 | NA | 2.42 | 090 |
| 21805 | | A | Treatment of rib fracture | 2.75 | NA | 3.38 | 0.35 | NA | 6.48 | 090 |
| 21810 | | A | Treatment of rib fracture(s) | 6.85 | NA | 5.01 | 0.93 | NA | 12.79 | 090 |
| 21820 | | A | Treat sternum fracture | 1.28 | 1.84 | 1.79 | 0.15 | 3.27 | 3.22 | 090 |
| 21825 | | A | Treat sternum fracture | 7.40 | NA | 6.68 | 0.99 | NA | 15.07 | 090 |
| 21920 | | A | Biopsy soft tissue of back | 2.06 | 3.29 | 1.48 | 0.20 | 5.55 | 3.74 | 010 |
| 21925 | | A | Biopsy soft tissue of back | 4.48 | 5.20 | 3.24 | 0.59 | 10.27 | 8.31 | 090 |
| 21930 | | A | Remove lesion, back or flank | 4.99 | 5.73 | 3.40 | 0.63 | 11.35 | 9.02 | 090 |
| 21935 | | A | Remove tumor, back | 17.93 | NA | 10.24 | 2.46 | NA | 30.63 | 090 |
| 22100 | | A | Remove part of neck vertebra | 9.72 | NA | 7.73 | 1.68 | NA | 19.13 | 090 |
| 22101 | | A | Remove part, thorax vertebra | 9.80 | NA | 7.99 | 1.80 | NA | 19.59 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 22102 | | A | Remove part, lumbar vertebra | 9.80 | NA | 8.25 | 1.57 | NA | 19.62 | 090 |
| 22103 | | A | Remove extra spine segment | 2.34 | NA | 1.21 | 0.39 | NA | 3.94 | ZZZ |
| 22110 | | A | Remove part of neck vertebra | 12.72 | NA | 9.38 | 2.24 | NA | 24.34 | 090 |
| 22112 | | A | Remove part, thorax vertebra | 12.79 | NA | 9.46 | 1.92 | NA | 24.17 | 090 |
| 22114 | | A | Remove part, lumbar vertebra | 12.79 | NA | 9.45 | 2.13 | NA | 24.37 | 090 |
| 22116 | | A | Remove extra spine segment | 2.32 | NA | 1.16 | 0.41 | NA | 3.89 | ZZZ |
| 22210 | | A | Revision of neck spine | 23.78 | NA | 15.63 | 4.60 | NA | 44.01 | 090 |
| 22212 | | A | Revision of thorax spine | 19.39 | NA | 13.45 | 3.12 | NA | 35.96 | 090 |
| 22214 | | A | Revision of lumbar spine | 19.42 | NA | 13.98 | 3.10 | NA | 36.50 | 090 |
| 22216 | | A | Revise, extra spine segment | 6.03 | NA | 3.12 | 1.05 | NA | 10.20 | ZZZ |
| 22220 | | A | Revision of neck spine | 21.34 | NA | 13.87 | 3.43 | NA | 38.64 | 090 |
| 22222 | | A | Revision of thorax spine | 21.49 | NA | 11.74 | 3.46 | NA | 36.69 | 090 |
| 22224 | | A | Revision of lumbar spine | 21.49 | NA | 14.40 | 3.63 | NA | 39.52 | 090 |
| 22226 | | A | Revise, extra spine segment | 6.03 | NA | 3.08 | 1.05 | NA | 10.16 | ZZZ |
| 22305 | | A | Treat spine process fracture | 2.05 | 2.31 | 1.92 | 0.33 | 4.69 | 4.30 | 090 |
| 22310 | | A | Treat spine fracture | 2.61 | 2.79 | 2.34 | 0.42 | 5.82 | 5.37 | 090 |
| 22315 | | A | Treat spine fracture | 8.83 | 9.68 | 7.32 | 1.60 | 20.11 | 17.75 | 090 |
| 22318 | | A | Treat odontoid fx w/o graft | 21.47 | NA | 13.56 | 4.70 | NA | 39.73 | 090 |
| 22319 | | A | Treat odontoid fx w/graft | 23.96 | NA | 14.97 | 5.38 | NA | 44.31 | 090 |
| 22325 | | A | Treat spine fracture | 18.27 | NA | 12.26 | 3.18 | NA | 33.71 | 090 |
| 22326 | | A | Treat neck spine fracture | 19.56 | NA | 12.93 | 3.85 | NA | 36.34 | 090 |
| 22327 | | A | Treat thorax spine fracture | 19.17 | NA | 12.55 | 3.21 | NA | 34.93 | 090 |
| 22328 | | A | Treat each add spine fx | 4.60 | NA | 2.26 | 0.78 | NA | 7.64 | ZZZ |
| 22505 | | A | Manipulation of spine | 1.87 | NA | 0.94 | 0.30 | NA | 3.11 | 010 |
| 22520 | | A | Percut vertebroplasty thor | 8.90 | 99.93 | 5.09 | 1.43 | 110.26 | 15.42 | 010 |
| 22521 | | A | Percut vertebroplasty lumb | 8.33 | 90.95 | 4.94 | 1.34 | 100.62 | 14.61 | 010 |
| 22522 | | A | Percut vertebroplasty add-l | 4.30 | NA | 1.67 | 0.69 | NA | 6.66 | ZZZ |
| 22532 | | A | Lat thorax spine fusion | 23.96 | NA | 14.84 | 3.78 | NA | 42.58 | 090 |
| 22533 | | A | Lat lumbar spine fusion | 23.09 | NA | 13.60 | 2.80 | NA | 39.49 | 090 |
| 22534 | | A | Lat thor/lumb, add-l seg | 5.99 | NA | 3.03 | 1.04 | NA | 10.06 | ZZZ |
| 22548 | | A | Neck spine fusion | 25.78 | NA | 15.79 | 5.15 | NA | 46.72 | 090 |
| 22554 | | A | Neck spine fusion | 18.59 | NA | 12.33 | 3.73 | NA | 34.65 | 090 |
| 22556 | | A | Thorax spine fusion | 23.42 | NA | 14.72 | 3.78 | NA | 41.92 | 090 |
| 22558 | | A | Lumbar spine fusion | 22.25 | NA | 13.28 | 2.80 | NA | 38.33 | 090 |
| 22585 | | A | Additional spinal fusion | 5.52 | NA | 2.79 | 1.04 | NA | 9.35 | ZZZ |
| 22590 | | A | Spine & skull spinal fusion | 20.48 | NA | 13.31 | 4.31 | NA | 38.10 | 090 |
| 22595 | | A | Neck spinal fusion | 19.36 | NA | 12.82 | 3.88 | NA | 36.06 | 090 |
| 22600 | | A | Neck spine fusion | 16.12 | NA | 11.18 | 3.24 | NA | 30.54 | 090 |
| 22610 | | A | Thorax spine fusion | 16.00 | NA | 11.40 | 2.95 | NA | 30.35 | 090 |
| 22612 | | A | Lumbar spine fusion | 20.97 | NA | 14.18 | 3.55 | NA | 38.70 | 090 |
| 22614 | | A | Spine fusion, extra segment | 6.43 | NA | 3.35 | 1.14 | NA | 10.92 | ZZZ |
| 22630 | | A | Lumbar spine fusion | 20.81 | NA | 13.59 | 3.86 | NA | 38.26 | 090 |
| 22632 | | A | Spine fusion, extra segment | 5.22 | NA | 2.66 | 0.98 | NA | 8.86 | ZZZ |
| 22800 | | A | Fusion of spine | 18.22 | NA | 12.74 | 3.04 | NA | 34.00 | 090 |
| 22802 | | A | Fusion of spine | 30.83 | NA | 19.55 | 5.01 | NA | 55.39 | 090 |
| 22804 | | A | Fusion of spine | 36.22 | NA | 22.65 | 5.68 | NA | 64.55 | 090 |
| 22808 | | A | Fusion of spine | 26.23 | NA | 16.28 | 4.55 | NA | 47.06 | 090 |
| 22810 | | A | Fusion of spine | 30.22 | NA | 18.33 | 4.43 | NA | 52.98 | 090 |
| 22812 | | A | Fusion of spine | 32.65 | NA | 20.03 | 4.55 | NA | 57.23 | 090 |
| 22818 | | A | Kyphectomy, 1-2 segments | 31.78 | NA | 18.85 | 6.00 | NA | 56.63 | 090 |
| 22819 | | A | Kyphectomy, 3 or more | 36.39 | NA | 20.03 | 5.64 | NA | 62.06 | 090 |
| 22830 | | A | Exploration of spinal fusion | 10.83 | NA | 7.95 | 1.89 | NA | 20.67 | 090 |
| 22840 | | A | Insert spine fixation device | 12.52 | NA | 6.48 | 2.19 | NA | 21.19 | ZZZ |
| 22842 | | A | Insert spine fixation device | 12.56 | NA | 6.49 | 2.21 | NA | 21.26 | ZZZ |
| 22843 | | A | Insert spine fixation device | 13.44 | NA | 6.59 | 2.37 | NA | 22.40 | ZZZ |
| 22844 | | A | Insert spine fixation device | 16.42 | NA | 8.73 | 2.63 | NA | 27.78 | ZZZ |
| 22845 | | A | Insert spine fixation device | 11.94 | NA | 6.06 | 2.39 | NA | 20.39 | ZZZ |
| 22846 | | A | Insert spine fixation device | 12.40 | NA | 6.32 | 2.47 | NA | 21.19 | ZZZ |
| 22847 | | A | Insert spine fixation device | 13.78 | NA | 7.01 | 2.37 | NA | 23.16 | ZZZ |
| 22848 | | A | Insert pelv fixation device | 5.99 | NA | 3.18 | 0.96 | NA | 10.13 | ZZZ |
| 22849 | | A | Reinsert spinal fixation | 18.48 | NA | 11.86 | 3.14 | NA | 33.48 | 090 |
| 22850 | | A | Remove spine fixation device | 9.51 | NA | 7.11 | 1.61 | NA | 18.23 | 090 |
| 22851 | | A | Apply spine prosth device | 6.70 | NA | 3.35 | 1.23 | NA | 11.28 | ZZZ |
| 22852 | | A | Remove spine fixation device | 9.00 | NA | 6.90 | 1.52 | NA | 17.42 | 090 |
| 22855 | | A | Remove spine fixation device | 15.11 | NA | 9.79 | 2.90 | NA | 27.80 | 090 |
| 22900 | | A | Remove abdominal wall lesion | 5.79 | NA | 3.25 | 0.74 | NA | 9.78 | 090 |
| 23000 | | A | Removal of calcium deposits | 4.35 | 8.62 | 4.42 | 0.59 | 13.56 | 9.36 | 090 |
| 23020 | | A | Release shoulder joint | 8.92 | NA | 7.79 | 1.43 | NA | 18.14 | 090 |
| 23030 | | A | Drain shoulder lesion | 3.42 | 7.42 | 2.90 | 0.53 | 11.37 | 6.85 | 010 |
| 23031 | | A | Drain shoulder bursa | 2.74 | 7.91 | 2.72 | 0.44 | 11.09 | 5.90 | 010 |
| 23035 | | A | Drain shoulder bone lesion | 8.60 | NA | 8.72 | 1.38 | NA | 18.70 | 090 |
| 23040 | | A | Exploratory shoulder surgery | 9.19 | NA | 8.09 | 1.50 | NA | 18.78 | 090 |
| 23044 | | A | Exploratory shoulder surgery | 7.11 | NA | 6.71 | 1.19 | NA | 15.01 | 090 |
| 23065 | | A | Biopsy shoulder tissues | 2.27 | 2.48 | 1.62 | 0.24 | 4.99 | 4.13 | 010 |
| 23066 | | A | Biopsy shoulder tissues | 4.15 | 7.70 | 3.98 | 0.62 | 12.47 | 8.75 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 23075 | | A | Removal of shoulder lesion | 2.39 | 3.68 | 1.78 | 0.33 | 6.40 | 4.50 | 010 |
| 23076 | | A | Removal of shoulder lesion | 7.62 | NA | 5.86 | 1.11 | NA | 14.59 | 090 |
| 23077 | | A | Remove tumor of shoulder | 16.07 | NA | 10.90 | 2.27 | NA | 29.24 | 090 |
| 23100 | | A | Biopsy of shoulder joint | 6.02 | NA | 5.89 | 0.96 | NA | 12.87 | 090 |
| 23101 | | A | Shoulder joint surgery | 5.57 | NA | 5.58 | 0.91 | NA | 12.06 | 090 |
| 23105 | | A | Remove shoulder joint lining | 8.22 | NA | 7.39 | 1.32 | NA | 16.93 | 090 |
| 23106 | | A | Incision of collarbone joint | 5.95 | NA | 5.94 | 0.83 | NA | 12.72 | 090 |
| 23107 | | A | Explore treat shoulder joint | 8.61 | NA | 7.60 | 1.40 | NA | 17.61 | 090 |
| 23120 | | A | Partial removal, collar bone | 7.10 | NA | 6.69 | 1.13 | NA | 14.92 | 090 |
| 23125 | | A | Removal of collar bone | 9.38 | NA | 7.81 | 1.45 | NA | 18.64 | 090 |
| 23130 | | A | Remove shoulder bone, part | 7.54 | NA | 7.33 | 1.27 | NA | 16.14 | 090 |
| 23140 | | A | Removal of bone lesion | 6.88 | NA | 5.50 | 0.99 | NA | 13.37 | 090 |
| 23145 | | A | Removal of bone lesion | 9.08 | NA | 7.79 | 1.42 | NA | 18.29 | 090 |
| 23146 | | A | Removal of bone lesion | 7.82 | NA | 7.38 | 1.13 | NA | 16.33 | 090 |
| 23150 | | A | Removal of humerus lesion | 8.47 | NA | 7.15 | 1.24 | NA | 16.86 | 090 |
| 23155 | | A | Removal of humerus lesion | 10.33 | NA | 8.68 | 1.48 | NA | 20.49 | 090 |
| 23156 | | A | Removal of humerus lesion | 8.67 | NA | 7.60 | 1.36 | NA | 17.63 | 090 |
| 23170 | | A | Remove collar bone lesion | 6.85 | NA | 6.54 | 1.10 | NA | 14.49 | 090 |
| 23172 | | A | Remove shoulder blade lesion | 6.89 | NA | 6.63 | 0.95 | NA | 14.47 | 090 |
| 23174 | | A | Remove humerus lesion | 9.50 | NA | 8.63 | 1.56 | NA | 19.69 | 090 |
| 23180 | | A | Remove collar bone lesion | 8.52 | NA | 9.43 | 1.47 | NA | 19.42 | 090 |
| 23182 | | A | Remove shoulder blade lesion | 8.14 | NA | 9.09 | 1.26 | NA | 18.49 | 090 |
| 23184 | | A | Remove humerus lesion | 9.37 | NA | 9.78 | 1.50 | NA | 20.65 | 090 |
| 23190 | | A | Partial removal of scapula | 7.23 | NA | 6.38 | 1.18 | NA | 14.79 | 090 |
| 23195 | | A | Removal of head of humerus | 9.80 | NA | 7.95 | 1.18 | NA | 18.93 | 090 |
| 23200 | | A | Removal of collar bone | 12.06 | NA | 9.14 | 1.69 | NA | 22.89 | 090 |
| 23210 | | A | Removal of shoulder blade | 12.47 | NA | 9.49 | 2.01 | NA | 23.97 | 090 |
| 23220 | | A | Partial removal of humerus | 14.54 | NA | 11.12 | 2.50 | NA | 28.16 | 090 |
| 23221 | | A | Partial removal of humerus | 17.71 | NA | 12.01 | 2.33 | NA | 32.05 | 090 |
| 23222 | | A | Partial removal of humerus | 23.88 | NA | 16.10 | 3.90 | NA | 43.88 | 090 |
| 23330 | | A | Remove shoulder foreign body | 1.85 | 3.75 | 1.88 | 0.24 | 5.84 | 3.97 | 010 |
| 23331 | | A | Remove shoulder foreign body | 7.37 | NA | 7.01 | 1.14 | NA | 15.52 | 090 |
| 23332 | | A | Remove shoulder foreign body | 11.60 | NA | 9.53 | 1.85 | NA | 22.98 | 090 |
| 23350 | | A | Injection for shoulder x-ray | 1.00 | 3.52 | 0.33 | 0.06 | 4.58 | 1.39 | 000 |
| 23395 | | A | Muscle transfer,shoulder/arm | 16.82 | NA | 12.97 | 2.56 | NA | 32.35 | 090 |
| 23397 | | A | Muscle transfers | 16.11 | NA | 11.57 | 2.62 | NA | 30.30 | 090 |
| 23400 | | A | Fixation of shoulder blade | 13.52 | NA | 10.38 | 2.07 | NA | 25.97 | 090 |
| 23405 | | A | Incision of tendon & muscle | 8.36 | NA | 7.15 | 1.29 | NA | 16.80 | 090 |
| 23406 | | A | Incise tendon(s) & muscle(s) | 10.77 | NA | 8.60 | 1.72 | NA | 21.09 | 090 |
| 23410 | | A | Repair rotator cuff, acute | 12.43 | NA | 9.61 | 1.95 | NA | 23.99 | 090 |
| 23412 | | A | Repair rotator cuff, chronic | 13.29 | NA | 10.10 | 2.08 | NA | 25.47 | 090 |
| 23415 | | A | Release of shoulder ligament | 9.96 | NA | 8.15 | 1.70 | NA | 19.81 | 090 |
| 23420 | | A | Repair of shoulder | 13.28 | NA | 11.06 | 2.10 | NA | 26.44 | 090 |
| 23430 | | A | Repair biceps tendon | 9.97 | NA | 8.32 | 1.57 | NA | 19.86 | 090 |
| 23440 | | A | Remove/transplant tendon | 10.46 | NA | 8.49 | 1.63 | NA | 20.58 | 090 |
| 23450 | | A | Repair shoulder capsule | 13.38 | NA | 10.06 | 2.12 | NA | 25.56 | 090 |
| 23455 | | A | Repair shoulder capsule | 14.35 | NA | 10.65 | 2.26 | NA | 27.26 | 090 |
| 23460 | | A | Repair shoulder capsule | 15.35 | NA | 11.58 | 2.43 | NA | 29.36 | 090 |
| 23462 | | A | Repair shoulder capsule | 15.28 | NA | 10.97 | 2.42 | NA | 28.67 | 090 |
| 23465 | | A | Repair shoulder capsule | 15.83 | NA | 11.52 | 2.51 | NA | 29.86 | 090 |
| 23466 | | A | Repair shoulder capsule | 14.20 | NA | 11.53 | 2.25 | NA | 27.98 | 090 |
| 23470 | | A | Reconstruct shoulder joint | 17.12 | NA | 12.23 | 2.70 | NA | 32.05 | 090 |
| 23472 | | A | Reconstruct shoulder joint | 21.07 | NA | 14.38 | 3.29 | NA | 38.74 | 090 |
| 23480 | | A | Revision of collar bone | 11.16 | NA | 8.98 | 1.89 | NA | 22.03 | 090 |
| 23485 | | A | Revision of collar bone | 13.41 | NA | 10.10 | 2.12 | NA | 25.63 | 090 |
| 23490 | | A | Reinforce clavicle | 11.84 | NA | 9.04 | 1.44 | NA | 22.32 | 090 |
| 23491 | | A | Reinforce shoulder bones | 14.19 | NA | 10.91 | 2.29 | NA | 27.39 | 090 |
| 23500 | | A | Treat clavicle fracture | 2.08 | 2.87 | 2.54 | 0.29 | 5.24 | 4.91 | 090 |
| 23505 | | A | Treat clavicle fracture | 3.68 | 4.41 | 3.85 | 0.58 | 8.67 | 8.11 | 090 |
| 23515 | | A | Treat clavicle fracture | 7.40 | NA | 6.70 | 1.16 | NA | 15.26 | 090 |
| 23520 | | A | Treat clavicle dislocation | 2.16 | 2.86 | 2.75 | 0.32 | 5.34 | 5.23 | 090 |
| 23525 | | A | Treat clavicle dislocation | 3.59 | 4.57 | 3.96 | 0.42 | 8.58 | 7.97 | 090 |
| 23530 | | A | Treat clavicle dislocation | 7.30 | NA | 6.12 | 1.21 | NA | 14.63 | 090 |
| 23532 | | A | Treat clavicle dislocation | 8.00 | NA | 7.11 | 1.17 | NA | 16.28 | 090 |
| 23540 | | A | Treat clavicle dislocation | 2.23 | 2.87 | 2.41 | 0.27 | 5.37 | 4.91 | 090 |
| 23545 | | A | Treat clavicle dislocation | 3.25 | 4.20 | 3.39 | 0.42 | 7.87 | 7.06 | 090 |
| 23550 | | A | Treat clavicle dislocation | 7.23 | NA | 6.55 | 1.14 | NA | 14.92 | 090 |
| 23552 | | A | Treat clavicle dislocation | 8.44 | NA | 7.46 | 1.27 | NA | 17.17 | 090 |
| 23570 | | A | Treat shoulder blade fx | 2.23 | 3.01 | 2.90 | 0.35 | 5.59 | 5.48 | 090 |
| 23575 | | A | Treat shoulder blade fx | 4.05 | 4.88 | 4.32 | 0.66 | 9.59 | 9.03 | 090 |
| 23585 | | A | Treat scapula fracture | 8.95 | NA | 7.80 | 1.44 | NA | 18.19 | 090 |
| 23600 | | A | Treat humerus fracture | 2.93 | 4.54 | 3.57 | 0.46 | 7.93 | 6.96 | 090 |
| 23605 | | A | Treat humerus fracture | 4.86 | 6.14 | 5.11 | 0.81 | 11.81 | 10.78 | 090 |
| 23615 | | A | Treat humerus fracture | 9.34 | NA | 8.97 | 1.51 | NA | 19.82 | 090 |
| 23616 | | A | Treat humerus fracture | 21.24 | NA | 14.28 | 3.37 | NA | 38.89 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 23620 | | A | Treat humerus fracture | 2.40 | 3.61 | 3.00 | 0.38 | 6.39 | 5.78 | 090 |
| 23625 | | A | Treat humerus fracture | 3.92 | 4.93 | 4.28 | 0.64 | 9.49 | 8.84 | 090 |
| 23630 | | A | Treat humerus fracture | 7.34 | NA | 6.77 | 1.18 | NA | 15.29 | 090 |
| 23650 | | A | Treat shoulder dislocation | 3.38 | 3.80 | 2.81 | 0.30 | 7.48 | 6.49 | 090 |
| 23655 | | A | Treat shoulder dislocation | 4.56 | NA | 4.24 | 0.62 | NA | 9.42 | 090 |
| 23660 | | A | Treat shoulder dislocation | 7.48 | NA | 6.53 | 1.22 | NA | 15.23 | 090 |
| 23665 | | A | Treat dislocation/fracture | 4.46 | 5.33 | 4.72 | 0.70 | 10.49 | 9.88 | 090 |
| 23670 | | A | Treat dislocation/fracture | 7.89 | NA | 7.00 | 1.25 | NA | 16.14 | 090 |
| 23675 | | A | Treat dislocation/fracture | 6.04 | 6.83 | 5.82 | 0.97 | 13.84 | 12.83 | 090 |
| 23680 | | A | Treat dislocation/fracture | 10.04 | NA | 8.27 | 1.61 | NA | 19.92 | 090 |
| 23700 | | A | Fixation of shoulder | 2.52 | NA | 2.17 | 0.43 | NA | 5.12 | 010 |
| 23800 | | A | Fusion of shoulder joint | 14.14 | NA | 10.68 | 2.34 | NA | 27.16 | 090 |
| 23802 | | A | Fusion of shoulder joint | 16.58 | NA | 10.41 | 2.45 | NA | 29.44 | 090 |
| 23900 | | A | Amputation of arm & girdle | 19.69 | NA | 12.03 | 3.04 | NA | 34.76 | 090 |
| 23920 | | A | Amputation at shoulder joint | 14.59 | NA | 10.26 | 2.21 | NA | 27.06 | 090 |
| 23921 | | A | Amputation follow-up surgery | 5.48 | NA | 5.09 | 0.90 | NA | 11.47 | 090 |
| 23930 | | A | Drainage of arm lesion | 2.94 | 6.36 | 2.31 | 0.41 | 9.71 | 5.66 | 010 |
| 23931 | | A | Drainage of arm bursa | 1.79 | 5.93 | 2.17 | 0.26 | 7.98 | 4.22 | 010 |
| 23935 | | A | Drain arm/elbow bone lesion | 6.08 | NA | 6.43 | 0.98 | NA | 13.49 | 090 |
| 24000 | | A | Exploratory elbow surgery | 5.81 | NA | 5.50 | 0.93 | NA | 12.24 | 090 |
| 24006 | | A | Release elbow joint | 9.30 | NA | 7.85 | 1.48 | NA | 18.63 | 090 |
| 24065 | | A | Biopsy arm/elbow soft tissue | 2.08 | 3.22 | 1.75 | 0.22 | 5.52 | 4.05 | 010 |
| 24066 | | A | Biopsy arm/elbow soft tissue | 5.20 | 8.95 | 4.14 | 0.77 | 14.92 | 10.11 | 090 |
| 24075 | | A | Remove arm/elbow lesion | 3.91 | 7.37 | 3.41 | 0.54 | 11.82 | 7.86 | 090 |
| 24076 | | A | Remove arm/elbow lesion | 6.29 | NA | 5.17 | 0.91 | NA | 12.37 | 090 |
| 24077 | | A | Remove tumor of arm/elbow | 11.74 | NA | 8.85 | 1.67 | NA | 22.26 | 090 |
| 24100 | | A | Biopsy elbow joint lining | 4.92 | NA | 4.64 | 0.78 | NA | 10.34 | 090 |
| 24101 | | A | Explore/treat elbow joint | 6.12 | NA | 6.02 | 1.01 | NA | 13.15 | 090 |
| 24102 | | A | Remove elbow joint lining | 8.02 | NA | 6.97 | 1.27 | NA | 16.26 | 090 |
| 24105 | | A | Removal of elbow bursa | 3.60 | NA | 4.50 | 0.60 | NA | 8.70 | 090 |
| 24110 | | A | Remove humerus lesion | 7.38 | NA | 6.93 | 1.21 | NA | 15.52 | 090 |
| 24115 | | A | Remove/graft bone lesion | 9.62 | NA | 7.54 | 1.36 | NA | 18.52 | 090 |
| 24116 | | A | Remove/graft bone lesion | 11.79 | NA | 9.31 | 2.05 | NA | 23.15 | 090 |
| 24120 | | A | Remove elbow lesion | 6.64 | NA | 6.02 | 1.07 | NA | 13.73 | 090 |
| 24125 | | A | Remove/graft bone lesion | 7.88 | NA | 6.27 | 0.73 | NA | 14.88 | 090 |
| 24126 | | A | Remove/graft bone lesion | 8.30 | NA | 7.10 | 1.13 | NA | 16.53 | 090 |
| 24130 | | A | Removal of head of radius | 6.24 | NA | 6.11 | 1.03 | NA | 13.38 | 090 |
| 24134 | | A | Removal of arm bone lesion | 9.72 | NA | 9.38 | 1.52 | NA | 20.62 | 090 |
| 24136 | | A | Remove radius bone lesion | 7.98 | NA | 7.41 | 1.29 | NA | 16.68 | 090 |
| 24138 | | A | Remove elbow bone lesion | 8.04 | NA | 7.86 | 1.29 | NA | 17.19 | 090 |
| 24140 | | A | Partial removal of arm bone | 9.17 | NA | 9.76 | 1.45 | NA | 20.38 | 090 |
| 24145 | | A | Partial removal of radius | 7.57 | NA | 8.27 | 1.22 | NA | 17.06 | 090 |
| 24147 | | A | Partial removal of elbow | 7.53 | NA | 8.80 | 1.26 | NA | 17.59 | 090 |
| 24149 | | A | Radical resection of elbow | 14.18 | NA | 11.65 | 2.23 | NA | 28.06 | 090 |
| 24150 | | A | Extensive humerus surgery | 13.25 | NA | 10.35 | 2.15 | NA | 25.75 | 090 |
| 24151 | | A | Extensive humerus surgery | 15.56 | NA | 11.94 | 1.27 | NA | 28.77 | 090 |
| 24152 | | A | Extensive radius surgery | 10.04 | NA | 7.99 | 1.01 | NA | 19.04 | 090 |
| 24153 | | A | Extensive radius surgery | 11.52 | NA | 5.74 | 0.70 | NA | 17.96 | 090 |
| 24155 | | A | Removal of elbow joint | 11.71 | NA | 8.51 | 1.82 | NA | 22.04 | 090 |
| 24160 | | A | Remove elbow joint implant | 7.82 | NA | 6.88 | 1.26 | NA | 15.96 | 090 |
| 24164 | | A | Remove radius head implant | 6.22 | NA | 5.76 | 1.01 | NA | 12.99 | 090 |
| 24200 | | A | Removal of arm foreign body | 1.76 | 3.45 | 1.63 | 0.19 | 5.40 | 3.58 | 010 |
| 24201 | | A | Removal of arm foreign body | 4.55 | 9.85 | 4.23 | 0.68 | 15.08 | 9.46 | 090 |
| 24220 | | A | Injection for elbow x-ray | 1.31 | 3.71 | 0.44 | 0.08 | 5.10 | 1.83 | 000 |
| 24300 | | A | Manipulate elbow w/anesth | 3.74 | NA | 5.62 | 0.63 | NA | 9.99 | 090 |
| 24301 | | A | Muscle/tendon transfer | 10.18 | NA | 8.32 | 1.64 | NA | 20.14 | 090 |
| 24305 | | A | Arm tendon lengthening | 7.44 | NA | 6.83 | 1.13 | NA | 15.40 | 090 |
| 24310 | | A | Revision of arm tendon | 5.97 | NA | 5.91 | 0.91 | NA | 12.79 | 090 |
| 24320 | | A | Repair of arm tendon | 10.54 | NA | 7.93 | 1.72 | NA | 20.19 | 090 |
| 24330 | | A | Revision of arm muscles | 9.59 | NA | 8.02 | 1.51 | NA | 19.12 | 090 |
| 24331 | | A | Revision of arm muscles | 10.63 | NA | 8.75 | 1.33 | NA | 20.71 | 090 |
| 24332 | | A | Tenolysis, triceps | 7.44 | NA | 6.70 | 1.19 | NA | 15.33 | 090 |
| 24340 | | A | Repair of biceps tendon | 7.88 | NA | 7.07 | 1.27 | NA | 16.22 | 090 |
| 24341 | | A | Repair arm tendon/muscle | 7.89 | NA | 7.97 | 1.26 | NA | 17.12 | 090 |
| 24342 | | A | Repair of ruptured tendon | 10.60 | NA | 8.61 | 1.69 | NA | 20.90 | 090 |
| 24343 | | A | Repr elbow lat ligmnt w/tiss | 8.64 | NA | 8.07 | 1.39 | NA | 18.10 | 090 |
| 24344 | | A | Reconstruct elbow lat ligmnt | 13.98 | NA | 11.43 | 2.25 | NA | 27.66 | 090 |
| 24345 | | A | Repr elbw med ligmnt w/tissu | 8.64 | NA | 7.95 | 1.40 | NA | 17.99 | 090 |
| 24346 | | A | Reconstruct elbow med ligmnt | 13.98 | NA | 11.25 | 2.04 | NA | 27.27 | 090 |
| 24350 | | A | Repair of tennis elbow | 5.24 | NA | 5.68 | 0.86 | NA | 11.78 | 090 |
| 24351 | | A | Repair of tennis elbow | 5.90 | NA | 6.02 | 0.98 | NA | 12.90 | 090 |
| 24352 | | A | Repair of tennis elbow | 6.42 | NA | 6.28 | 1.09 | NA | 13.79 | 090 |
| 24354 | | A | Repair of tennis elbow | 6.47 | NA | 6.24 | 1.11 | NA | 13.82 | 090 |
| 24356 | | A | Revision of tennis elbow | 6.67 | NA | 6.42 | 1.08 | NA | 14.17 | 090 |
| 24360 | | A | Reconstruct elbow joint | 12.32 | NA | 9.46 | 1.92 | NA | 23.70 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 24361 | | A | Reconstruct elbow joint | 14.06 | NA | 10.56 | 2.10 | NA | 26.72 | 090 |
| 24362 | | A | Reconstruct elbow joint | 14.97 | NA | 10.04 | 2.30 | NA | 27.31 | 090 |
| 24363 | | A | Replace elbow joint | 18.46 | NA | 13.69 | 2.84 | NA | 34.99 | 090 |
| 24365 | | A | Reconstruct head of radius | 8.38 | NA | 7.19 | 1.39 | NA | 16.96 | 090 |
| 24366 | | A | Reconstruct head of radius | 9.12 | NA | 7.53 | 1.47 | NA | 18.12 | 090 |
| 24400 | | A | Revision of humerus | 11.04 | NA | 9.14 | 1.82 | NA | 22.00 | 090 |
| 24410 | | A | Revision of humerus | 14.80 | NA | 10.60 | 2.57 | NA | 27.97 | 090 |
| 24420 | | A | Revision of humerus | 13.42 | NA | 10.90 | 2.07 | NA | 26.39 | 090 |
| 24430 | | A | Repair of humerus | 12.79 | NA | 9.97 | 2.04 | NA | 24.80 | 090 |
| 24435 | | A | Repair humerus with graft | 13.15 | NA | 11.12 | 2.10 | NA | 26.37 | 090 |
| 24470 | | A | Revision of elbow joint | 8.73 | NA | 7.80 | 0.77 | NA | 17.30 | 090 |
| 24495 | | A | Decompression of forearm | 8.11 | NA | 8.94 | 1.18 | NA | 18.23 | 090 |
| 24498 | | A | Reinforce humerus | 11.90 | NA | 9.50 | 1.93 | NA | 23.33 | 090 |
| 24500 | | A | Treat humerus fracture | 3.21 | 4.86 | 3.71 | 0.48 | 8.55 | 7.40 | 090 |
| 24505 | | A | Treat humerus fracture | 5.16 | 6.59 | 5.39 | 0.86 | 12.61 | 11.41 | 090 |
| 24515 | | A | Treat humerus fracture | 11.63 | NA | 9.55 | 1.88 | NA | 23.06 | 090 |
| 24516 | | A | Treat humerus fracture | 11.63 | NA | 9.31 | 1.88 | NA | 22.82 | 090 |
| 24530 | | A | Treat humerus fracture | 3.49 | 5.20 | 4.05 | 0.55 | 9.24 | 8.09 | 090 |
| 24535 | | A | Treat humerus fracture | 6.86 | 7.83 | 6.62 | 1.16 | 15.85 | 14.64 | 090 |
| 24538 | | A | Treat humerus fracture | 9.42 | NA | 8.89 | 1.51 | NA | 19.82 | 090 |
| 24545 | | A | Treat humerus fracture | 10.44 | NA | 8.60 | 1.70 | NA | 20.74 | 090 |
| 24546 | | A | Treat humerus fracture | 15.67 | NA | 11.50 | 2.52 | NA | 29.69 | 090 |
| 24560 | | A | Treat humerus fracture | 2.80 | 4.49 | 3.22 | 0.39 | 7.68 | 6.41 | 090 |
| 24565 | | A | Treat humerus fracture | 5.55 | 6.62 | 5.52 | 0.94 | 13.11 | 12.01 | 090 |
| 24566 | | A | Treat humerus fracture | 7.78 | NA | 8.34 | 1.33 | NA | 17.45 | 090 |
| 24575 | | A | Treat humerus fracture | 10.64 | NA | 8.44 | 1.70 | NA | 20.78 | 090 |
| 24576 | | A | Treat humerus fracture | 2.86 | 4.77 | 3.73 | 0.42 | 8.05 | 7.01 | 090 |
| 24577 | | A | Treat humerus fracture | 5.78 | 6.92 | 5.83 | 0.97 | 13.67 | 12.58 | 090 |
| 24579 | | A | Treat humerus fracture | 11.58 | NA | 9.02 | 1.89 | NA | 22.49 | 090 |
| 24582 | | A | Treat humerus fracture | 8.54 | NA | 9.26 | 1.48 | NA | 19.28 | 090 |
| 24586 | | A | Treat elbow fracture | 15.19 | NA | 11.26 | 2.45 | NA | 28.90 | 090 |
| 24587 | | A | Treat elbow fracture | 15.14 | NA | 11.05 | 2.23 | NA | 28.42 | 090 |
| 24600 | | A | Treat elbow dislocation | 4.22 | 4.86 | 3.53 | 0.47 | 9.55 | 8.22 | 090 |
| 24605 | | A | Treat elbow dislocation | 5.41 | NA | 5.41 | 0.87 | NA | 11.69 | 090 |
| 24615 | | A | Treat elbow dislocation | 9.41 | NA | 7.87 | 1.53 | NA | 18.81 | 090 |
| 24620 | | A | Treat elbow fracture | 6.97 | NA | 6.27 | 1.07 | NA | 14.31 | 090 |
| 24635 | | A | Treat elbow fracture | 13.17 | NA | 14.21 | 2.17 | NA | 29.55 | 090 |
| 24640 | | A | Treat elbow dislocation | 1.20 | 1.85 | 0.81 | 0.13 | 3.18 | 2.14 | 010 |
| 24650 | | A | Treat radius fracture | 2.16 | 3.79 | 2.78 | 0.33 | 6.28 | 5.27 | 090 |
| 24655 | | A | Treat radius fracture | 4.39 | 5.95 | 4.80 | 0.70 | 11.04 | 9.89 | 090 |
| 24665 | | A | Treat radius fracture | 8.13 | NA | 7.69 | 1.35 | NA | 17.17 | 090 |
| 24666 | | A | Treat radius fracture | 9.48 | NA | 8.25 | 1.55 | NA | 19.28 | 090 |
| 24670 | | A | Treat ulnar fracture | 2.54 | 4.11 | 3.09 | 0.38 | 7.03 | 6.01 | 090 |
| 24675 | | A | Treat ulnar fracture | 4.71 | 6.00 | 4.97 | 0.77 | 11.48 | 10.45 | 090 |
| 24685 | | A | Treat ulnar fracture | 8.79 | NA | 7.72 | 1.43 | NA | 17.94 | 090 |
| 24800 | | A | Fusion of elbow joint | 11.18 | NA | 8.87 | 1.63 | NA | 21.68 | 090 |
| 24802 | | A | Fusion/graft of elbow joint | 13.67 | NA | 10.49 | 2.16 | NA | 26.32 | 090 |
| 24900 | | A | Amputation of upper arm | 9.59 | NA | 7.49 | 1.44 | NA | 18.52 | 090 |
| 24920 | | A | Amputation of upper arm | 9.53 | NA | 7.71 | 1.48 | NA | 18.72 | 090 |
| 24925 | | A | Amputation follow-up surgery | 7.06 | NA | 6.44 | 1.12 | NA | 14.62 | 090 |
| 24930 | | A | Amputation follow-up surgery | 10.23 | NA | 7.66 | 1.53 | NA | 19.42 | 090 |
| 24931 | | A | Amputate upper arm & implant | 12.70 | NA | 6.10 | 1.88 | NA | 20.68 | 090 |
| 24935 | | A | Revision of amputation | 15.54 | NA | 8.40 | 2.05 | NA | 25.99 | 090 |
| 25000 | | A | Incision of tendon sheath | 3.37 | NA | 6.96 | 0.53 | NA | 10.86 | 090 |
| 25001 | | A | Incise flexor carpi radialis | 3.37 | NA | 4.16 | 0.52 | NA | 8.05 | 090 |
| 25020 | | A | Decompress forearm 1 space | 5.91 | NA | 9.84 | 0.95 | NA | 16.70 | 090 |
| 25023 | | A | Decompress forearm 1 space | 12.94 | NA | 15.33 | 1.91 | NA | 30.18 | 090 |
| 25024 | | A | Decompress forearm 2 spaces | 9.49 | NA | 7.51 | 1.10 | NA | 18.10 | 090 |
| 25025 | | A | Decompress forearm 2 spaces | 16.52 | NA | 9.99 | 1.79 | NA | 28.30 | 090 |
| 25028 | | A | Drainage of forearm lesion | 5.24 | NA | 8.40 | 0.78 | NA | 14.42 | 090 |
| 25031 | | A | Drainage of forearm bursa | 4.13 | NA | 8.21 | 0.63 | NA | 12.97 | 090 |
| 25035 | | A | Treat forearm bone lesion | 7.35 | NA | 13.88 | 1.21 | NA | 22.44 | 090 |
| 25040 | | A | Explore/treat wrist joint | 7.17 | NA | 7.40 | 1.15 | NA | 15.72 | 090 |
| 25065 | | A | Biopsy forearm soft tissues | 1.99 | 3.23 | 1.90 | 0.20 | 5.42 | 4.09 | 010 |
| 25066 | | A | Biopsy forearm soft tissues | 4.12 | NA | 7.18 | 0.62 | NA | 11.92 | 090 |
| 25075 | | A | Removel forearm lesion subcu | 3.73 | NA | 6.06 | 0.52 | NA | 10.31 | 090 |
| 25076 | | A | Removel forearm lesion deep | 4.91 | NA | 9.83 | 0.74 | NA | 15.48 | 090 |
| 25077 | | A | Remove tumor, forearm/wrist | 9.75 | NA | 12.53 | 1.38 | NA | 23.66 | 090 |
| 25085 | | A | Incision of wrist capsule | 5.49 | NA | 7.40 | 0.84 | NA | 13.73 | 090 |
| 25100 | | A | Biopsy of wrist joint | 3.89 | NA | 5.49 | 0.58 | NA | 9.96 | 090 |
| 25101 | | A | Explore/treat wrist joint | 4.68 | NA | 6.06 | 0.51 | NA | 11.25 | 090 |
| 25105 | | A | Remove wrist joint lining | 5.84 | NA | 7.58 | 0.91 | NA | 14.33 | 090 |
| 25107 | | A | Remove wrist joint cartilage | 6.42 | NA | 8.54 | 0.97 | NA | 15.93 | 090 |
| 25110 | | A | Remove wrist tendon lesion | 3.91 | NA | 7.20 | 0.60 | NA | 11.71 | 090 |
| 25111 | | A | Remove wrist tendon lesion | 3.38 | NA | 4.89 | 0.52 | NA | 8.79 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 25112 | | A | Reremove wrist tendon lesion | 4.52 | NA | 5.49 | 0.70 | NA | 10.71 | 090 |
| 25115 | | A | Remove wrist/forearm lesion | 8.81 | NA | 14.32 | 1.31 | NA | 24.44 | 090 |
| 25116 | | A | Remove wrist/forearm lesion | 7.10 | NA | 13.40 | 1.08 | NA | 21.58 | 090 |
| 25118 | | A | Excise wrist tendon sheath | 4.36 | NA | 5.97 | 0.68 | NA | 11.01 | 090 |
| 25119 | | A | Partial removal of ulna | 6.03 | NA | 7.86 | 0.90 | NA | 14.79 | 090 |
| 25120 | | A | Removal of forearm lesion | 6.09 | NA | 12.28 | 0.99 | NA | 19.36 | 090 |
| 25125 | | A | Remove/graft forearm lesion | 7.47 | NA | 13.08 | 1.14 | NA | 21.69 | 090 |
| 25126 | | A | Remove/graft forearm lesion | 7.54 | NA | 13.15 | 1.16 | NA | 21.85 | 090 |
| 25130 | | A | Removal of wrist lesion | 5.25 | NA | 6.61 | 0.81 | NA | 12.67 | 090 |
| 25135 | | A | Remove & graft wrist lesion | 6.88 | NA | 7.64 | 0.93 | NA | 15.45 | 090 |
| 25136 | | A | Remove & graft wrist lesion | 5.96 | NA | 6.77 | 0.89 | NA | 13.62 | 090 |
| 25145 | | A | Remove forearm bone lesion | 6.36 | NA | 12.33 | 0.91 | NA | 19.60 | 090 |
| 25150 | | A | Partial removal of ulna | 7.08 | NA | 8.50 | 1.11 | NA | 16.69 | 090 |
| 25151 | | A | Partial removal of radius | 7.38 | NA | 12.93 | 1.12 | NA | 21.43 | 090 |
| 25170 | | A | Extensive forearm surgery | 11.07 | NA | 15.29 | 1.69 | NA | 28.05 | 090 |
| 25210 | | A | Removal of wrist bone | 5.94 | NA | 7.00 | 0.87 | NA | 13.81 | 090 |
| 25215 | | A | Removal of wrist bones | 7.88 | NA | 9.00 | 1.20 | NA | 18.08 | 090 |
| 25230 | | A | Partial removal of radius | 5.22 | NA | 6.31 | 0.78 | NA | 12.31 | 090 |
| 25240 | | A | Partial removal of ulna | 5.16 | NA | 7.18 | 0.80 | NA | 13.14 | 090 |
| 25246 | | A | Injection for wrist x-ray | 1.45 | 3.48 | 0.48 | 0.09 | 5.02 | 2.02 | 000 |
| 25248 | | A | Remove forearm foreign body | 5.13 | NA | 8.64 | 0.70 | NA | 14.47 | 090 |
| 25250 | | A | Removal of wrist prosthesis | 6.59 | NA | 6.09 | 0.95 | NA | 13.63 | 090 |
| 25251 | | A | Removal of wrist prosthesis | 9.56 | NA | 7.91 | 1.27 | NA | 18.74 | 090 |
| 25259 | | A | Manipulate wrist w/anesthes | 3.74 | NA | 5.62 | 0.62 | NA | 9.98 | 090 |
| 25260 | | A | Repair forearm tendon/muscle | 7.79 | NA | 13.77 | 1.17 | NA | 22.73 | 090 |
| 25263 | | A | Repair forearm tendon/muscle | 7.81 | NA | 13.67 | 1.11 | NA | 22.59 | 090 |
| 25265 | | A | Repair forearm tendon/muscle | 9.87 | NA | 14.56 | 1.36 | NA | 25.79 | 090 |
| 25270 | | A | Repair forearm tendon/muscle | 5.99 | NA | 12.45 | 0.92 | NA | 19.36 | 090 |
| 25272 | | A | Repair forearm tendon/muscle | 7.03 | NA | 13.15 | 1.10 | NA | 21.28 | 090 |
| 25274 | | A | Repair forearm tendon/muscle | 8.74 | NA | 13.88 | 1.28 | NA | 23.90 | 090 |
| 25275 | | A | Repair forearm tendon sheath | 8.49 | NA | 7.49 | 1.19 | NA | 17.17 | 090 |
| 25280 | | A | Revise wrist/forearm tendon | 7.21 | NA | 12.88 | 1.07 | NA | 21.16 | 090 |
| 25290 | | A | Incise wrist/forearm tendon | 5.28 | NA | 15.12 | 0.81 | NA | 21.21 | 090 |
| 25295 | | A | Release wrist/forearm tendon | 6.54 | NA | 12.45 | 0.95 | NA | 19.94 | 090 |
| 25300 | | A | Fusion of tendons at wrist | 8.79 | NA | 8.61 | 1.15 | NA | 18.55 | 090 |
| 25301 | | A | Fusion of tendons at wrist | 8.39 | NA | 8.26 | 1.24 | NA | 17.89 | 090 |
| 25310 | | A | Transplant forearm tendon | 8.13 | NA | 13.29 | 1.17 | NA | 22.59 | 090 |
| 25312 | | A | Transplant forearm tendon | 9.56 | NA | 14.17 | 1.37 | NA | 25.10 | 090 |
| 25315 | | A | Revise palsy hand tendon(s) | 10.18 | NA | 14.74 | 1.52 | NA | 26.44 | 090 |
| 25316 | | A | Revise palsy hand tendon(s) | 12.31 | NA | 16.51 | 2.07 | NA | 30.89 | 090 |
| 25320 | | A | Repair/revise wrist joint | 10.75 | NA | 11.40 | 1.58 | NA | 23.73 | 090 |
| 25332 | | A | Revise wrist joint | 11.39 | NA | 9.15 | 1.72 | NA | 22.26 | 090 |
| 25335 | | A | Realignment of hand | 12.86 | NA | 11.80 | 2.00 | NA | 26.66 | 090 |
| 25337 | | A | Reconstruct ulna/radioulnar | 10.15 | NA | 11.24 | 1.57 | NA | 22.96 | 090 |
| 25350 | | A | Revision of radius | 8.77 | NA | 14.12 | 1.36 | NA | 24.25 | 090 |
| 25355 | | A | Revision of radius | 10.15 | NA | 14.74 | 1.39 | NA | 26.28 | 090 |
| 25360 | | A | Revision of ulna | 8.42 | NA | 14.01 | 1.36 | NA | 23.79 | 090 |
| 25365 | | A | Revise radius & ulna | 12.38 | NA | 15.77 | 2.03 | NA | 30.18 | 090 |
| 25370 | | A | Revise radius or ulna | 13.34 | NA | 16.19 | 2.27 | NA | 31.80 | 090 |
| 25375 | | A | Revise radius & ulna | 13.02 | NA | 16.55 | 2.22 | NA | 31.79 | 090 |
| 25390 | | A | Shorten radius or ulna | 10.38 | NA | 14.74 | 1.55 | NA | 26.67 | 090 |
| 25391 | | A | Lengthen radius or ulna | 13.63 | NA | 16.70 | 2.17 | NA | 32.50 | 090 |
| 25392 | | A | Shorten radius & ulna | 13.93 | NA | 16.09 | 2.15 | NA | 32.17 | 090 |
| 25393 | | A | Lengthen radius & ulna | 15.85 | NA | 17.71 | 2.76 | NA | 36.32 | 090 |
| 25394 | | A | Repair carpal bone, shorten | 10.38 | NA | 8.05 | 1.31 | NA | 19.74 | 090 |
| 25400 | | A | Repair radius or ulna | 10.90 | NA | 15.32 | 1.73 | NA | 27.95 | 090 |
| 25405 | | A | Repair/graft radius or ulna | 14.36 | NA | 17.42 | 2.27 | NA | 34.05 | 090 |
| 25415 | | A | Repair radius & ulna | 13.33 | NA | 16.64 | 2.07 | NA | 32.04 | 090 |
| 25420 | | A | Repair/graft radius & ulna | 16.31 | NA | 18.41 | 2.58 | NA | 37.30 | 090 |
| 25425 | | A | Repair/graft radius or ulna | 13.19 | NA | 21.64 | 1.91 | NA | 36.74 | 090 |
| 25426 | | A | Repair/graft radius & ulna | 15.80 | NA | 16.70 | 1.39 | NA | 33.89 | 090 |
| 25430 | | A | Vasc graft into carpal bone | 9.24 | NA | 7.21 | 1.25 | NA | 17.70 | 090 |
| 25431 | | A | Repair nonunion carpal bone | 10.42 | NA | 8.33 | 1.69 | NA | 20.44 | 090 |
| 25440 | | A | Repair/graft wrist bone | 10.42 | NA | 9.51 | 1.50 | NA | 21.43 | 090 |
| 25441 | | A | Reconstruct wrist joint | 12.88 | NA | 9.98 | 2.06 | NA | 24.92 | 090 |
| 25442 | | A | Reconstruct wrist joint | 10.83 | NA | 8.86 | 1.51 | NA | 21.20 | 090 |
| 25443 | | A | Reconstruct wrist joint | 10.37 | NA | 8.75 | 1.66 | NA | 20.78 | 090 |
| 25444 | | A | Reconstruct wrist joint | 11.13 | NA | 9.01 | 1.53 | NA | 21.67 | 090 |
| 25445 | | A | Reconstruct wrist joint | 9.68 | NA | 7.97 | 1.52 | NA | 19.17 | 090 |
| 25446 | | A | Wrist replacement | 16.53 | NA | 11.90 | 2.43 | NA | 30.86 | 090 |
| 25447 | | A | Repair wrist joint(s) | 10.35 | NA | 8.63 | 1.53 | NA | 20.51 | 090 |
| 25449 | | A | Remove wrist joint implant | 14.47 | NA | 10.64 | 2.08 | NA | 27.19 | 090 |
| 25450 | | A | Revision of wrist joint | 7.86 | NA | 10.31 | 1.22 | NA | 19.39 | 090 |
| 25455 | | A | Revision of wrist joint | 9.48 | NA | 11.25 | 1.21 | NA | 21.94 | 090 |
| 25490 | | A | Reinforce radius | 9.53 | NA | 13.89 | 1.38 | NA | 24.80 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 25491 | | A | Reinforce ulna | 9.95 | NA | 14.66 | 1.52 | NA | 26.13 | 090 |
| 25492 | | A | Reinforce radius and ulna | 12.31 | NA | 15.43 | 2.14 | NA | 29.88 | 090 |
| 25500 | | A | Treat fracture of radius | 2.45 | 3.59 | 2.74 | 0.33 | 6.37 | 5.52 | 090 |
| 25505 | | A | Treat fracture of radius | 5.20 | 6.54 | 5.43 | 0.82 | 12.56 | 11.45 | 090 |
| 25515 | | A | Treat fracture of radius | 9.17 | NA | 7.65 | 1.47 | NA | 18.29 | 090 |
| 25520 | | A | Treat fracture of radius | 6.25 | 6.86 | 6.06 | 1.02 | 14.13 | 13.33 | 090 |
| 25525 | | A | Treat fracture of radius | 12.22 | NA | 10.16 | 1.97 | NA | 24.35 | 090 |
| 25526 | | A | Treat fracture of radius | 12.96 | NA | 13.63 | 2.04 | NA | 28.63 | 090 |
| 25530 | | A | Treat fracture of ulna | 2.09 | 3.77 | 2.88 | 0.32 | 6.18 | 5.29 | 090 |
| 25535 | | A | Treat fracture of ulna | 5.13 | 6.02 | 5.29 | 0.83 | 11.98 | 11.25 | 090 |
| 25545 | | A | Treat fracture of ulna | 8.89 | NA | 7.85 | 1.43 | NA | 18.17 | 090 |
| 25560 | | A | Treat fracture radius & ulna | 2.44 | 3.71 | 2.64 | 0.33 | 6.48 | 5.41 | 090 |
| 25565 | | A | Treat fracture radius & ulna | 5.62 | 6.70 | 5.43 | 0.90 | 13.22 | 11.95 | 090 |
| 25574 | | A | Treat fracture radius & ulna | 7.00 | NA | 7.37 | 1.14 | NA | 15.51 | 090 |
| 25575 | | A | Treat fracture radius/ulna | 10.43 | NA | 9.66 | 1.67 | NA | 21.76 | 090 |
| 25600 | | A | Treat fracture radius/ulna | 2.63 | 4.09 | 2.99 | 0.39 | 7.11 | 6.01 | 090 |
| 25605 | | A | Treat fracture radius/ulna | 5.80 | 7.22 | 6.21 | 0.96 | 13.98 | 12.97 | 090 |
| 25611 | | A | Treat fracture radius/ulna | 7.76 | NA | 9.11 | 1.32 | NA | 18.19 | 090 |
| 25620 | | A | Treat fracture radius/ulna | 8.54 | NA | 7.47 | 1.35 | NA | 17.36 | 090 |
| 25622 | | A | Treat wrist bone fracture | 2.61 | 4.27 | 3.13 | 0.39 | 7.27 | 6.13 | 090 |
| 25624 | | A | Treat wrist bone fracture | 4.52 | 6.30 | 5.08 | 0.72 | 11.54 | 10.32 | 090 |
| 25628 | | A | Treat wrist bone fracture | 8.42 | NA | 8.04 | 1.30 | NA | 17.76 | 090 |
| 25630 | | A | Treat wrist bone fracture | 2.88 | 4.19 | 2.97 | 0.43 | 7.50 | 6.28 | 090 |
| 25635 | | A | Treat wrist bone fracture | 4.38 | 5.94 | 3.93 | 0.65 | 10.97 | 8.96 | 090 |
| 25645 | | A | Treat wrist bone fracture | 7.24 | NA | 6.99 | 1.12 | NA | 15.35 | 090 |
| 25650 | | A | Treat wrist bone fracture | 3.05 | 4.31 | 3.21 | 0.41 | 7.77 | 6.67 | 090 |
| 25651 | | A | Pin ulnar styloid fracture | 5.35 | NA | 5.42 | 0.73 | NA | 11.50 | 090 |
| 25652 | | A | Treat fracture ulnar styloid | 7.59 | NA | 6.94 | 1.19 | NA | 15.72 | 090 |
| 25660 | | A | Treat wrist dislocation | 4.75 | NA | 4.76 | 0.64 | NA | 10.15 | 090 |
| 25670 | | A | Treat wrist dislocation | 7.91 | NA | 7.27 | 1.23 | NA | 16.41 | 090 |
| 25671 | | A | Pin radioulnar dislocation | 5.99 | NA | 6.07 | 0.93 | NA | 12.99 | 090 |
| 25675 | | A | Treat wrist dislocation | 4.66 | 5.67 | 4.67 | 0.61 | 10.94 | 9.94 | 090 |
| 25676 | | A | Treat wrist dislocation | 8.03 | NA | 7.53 | 1.34 | NA | 16.90 | 090 |
| 25680 | | A | Treat wrist fracture | 5.98 | NA | 4.85 | 0.73 | NA | 11.56 | 090 |
| 25685 | | A | Treat wrist fracture | 9.77 | NA | 8.05 | 1.53 | NA | 19.35 | 090 |
| 25690 | | A | Treat wrist dislocation | 5.49 | NA | 5.57 | 0.89 | NA | 11.95 | 090 |
| 25695 | | A | Treat wrist dislocation | 8.33 | NA | 7.38 | 1.32 | NA | 17.03 | 090 |
| 25800 | | A | Fusion of wrist joint | 9.75 | NA | 9.20 | 1.31 | NA | 20.26 | 090 |
| 25805 | | A | Fusion/graft of wrist joint | 11.26 | NA | 10.35 | 1.79 | NA | 23.40 | 090 |
| 25810 | | A | Fusion/graft of wrist joint | 10.55 | NA | 10.01 | 1.60 | NA | 22.16 | 090 |
| 25820 | | A | Fusion of hand bones | 7.44 | NA | 7.99 | 1.11 | NA | 16.54 | 090 |
| 25825 | | A | Fuse hand bones with graft | 9.26 | NA | 9.34 | 1.34 | NA | 19.94 | 090 |
| 25830 | | A | Fusion, radioulnar jnt/ulna | 10.04 | NA | 14.57 | 1.39 | NA | 26.00 | 090 |
| 25900 | | A | Amputation of forearm | 9.00 | NA | 12.73 | 1.36 | NA | 23.09 | 090 |
| 25905 | | A | Amputation of forearm | 9.11 | NA | 12.65 | 1.28 | NA | 23.04 | 090 |
| 25907 | | A | Amputation follow-up surgery | 7.79 | NA | 12.07 | 1.20 | NA | 21.06 | 090 |
| 25909 | | A | Amputation follow-up surgery | 8.95 | NA | 12.60 | 1.21 | NA | 22.76 | 090 |
| 25915 | | A | Amputation of forearm | 17.05 | NA | 19.33 | 1.13 | NA | 37.51 | 090 |
| 25920 | | A | Amputate hand at wrist | 8.67 | NA | 8.07 | 1.33 | NA | 18.07 | 090 |
| 25922 | | A | Amputate hand at wrist | 7.41 | NA | 7.30 | 1.29 | NA | 16.00 | 090 |
| 25924 | | A | Amputation follow-up surgery | 8.45 | NA | 8.31 | 1.47 | NA | 18.23 | 090 |
| 25927 | | A | Amputation of hand | 8.79 | NA | 12.00 | 1.34 | NA | 22.13 | 090 |
| 25929 | | A | Amputation follow-up surgery | 7.58 | NA | 6.15 | 1.27 | NA | 15.00 | 090 |
| 25931 | | A | Amputation follow-up surgery | 7.80 | NA | 11.93 | 1.04 | NA | 20.77 | 090 |
| 26010 | | A | Drainage of finger abscess | 1.54 | 5.60 | 1.64 | 0.17 | 7.31 | 3.35 | 010 |
| 26011 | | A | Drainage of finger abscess | 2.19 | 8.81 | 2.32 | 0.32 | 11.32 | 4.83 | 010 |
| 26020 | | A | Drain hand tendon sheath | 4.66 | NA | 5.73 | 0.72 | NA | 11.11 | 090 |
| 26025 | | A | Drainage of palm bursa | 4.81 | NA | 5.52 | 0.74 | NA | 11.07 | 090 |
| 26030 | | A | Drainage of palm bursa(s) | 5.92 | NA | 6.16 | 0.92 | NA | 13.00 | 090 |
| 26034 | | A | Treat hand bone lesion | 6.22 | NA | 6.34 | 0.97 | NA | 13.53 | 090 |
| 26035 | | A | Decompress fingers/hand | 9.50 | NA | 8.28 | 1.40 | NA | 19.18 | 090 |
| 26037 | | A | Decompress fingers/hand | 7.24 | NA | 6.74 | 1.09 | NA | 15.07 | 090 |
| 26040 | | A | Release palm contracture | 3.33 | NA | 4.04 | 0.54 | NA | 7.91 | 090 |
| 26045 | | A | Release palm contracture | 5.55 | NA | 5.63 | 0.93 | NA | 12.11 | 090 |
| 26055 | | A | Incise finger tendon sheath | 2.69 | 14.17 | 3.93 | 0.43 | 17.29 | 7.05 | 090 |
| 26060 | | A | Incision of finger tendon | 2.81 | NA | 3.50 | 0.44 | NA | 6.75 | 090 |
| 26070 | | A | Explore/treat hand joint | 3.68 | NA | 3.38 | 0.47 | NA | 7.53 | 090 |
| 26075 | | A | Explore/treat finger joint | 3.78 | NA | 3.79 | 0.52 | NA | 8.09 | 090 |
| 26080 | | A | Explore/treat finger joint | 4.23 | NA | 4.85 | 0.65 | NA | 9.73 | 090 |
| 26100 | | A | Biopsy hand joint lining | 3.66 | NA | 4.13 | 0.54 | NA | 8.33 | 090 |
| 26105 | | A | Biopsy finger joint lining | 3.70 | NA | 4.22 | 0.58 | NA | 8.50 | 090 |
| 26110 | | A | Biopsy finger joint lining | 3.52 | NA | 4.03 | 0.53 | NA | 8.08 | 090 |
| 26115 | | A | Removel hand lesion subcut | 3.85 | 13.01 | 4.76 | 0.59 | 17.45 | 9.20 | 090 |
| 26116 | | A | Removel hand lesion, deep | 5.52 | NA | 5.99 | 0.82 | NA | 12.33 | 090 |
| 26117 | | A | Remove tumor, hand/finger | 8.54 | NA | 7.05 | 1.24 | NA | 16.83 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 26121 | | A | Release palm contracture | 7.53 | NA | 6.95 | 1.17 | NA | 15.65 | 090 |
| 26123 | | A | Release palm contracture | 9.28 | NA | 8.85 | 1.42 | NA | 19.55 | 090 |
| 26125 | | A | Release palm contracture | 4.60 | NA | 2.44 | 0.70 | NA | 7.74 | ZZZ |
| 26130 | | A | Remove wrist joint lining | 5.41 | NA | 5.33 | 0.97 | NA | 11.71 | 090 |
| 26135 | | A | Revise finger joint, each | 6.95 | NA | 6.45 | 1.01 | NA | 14.41 | 090 |
| 26140 | | A | Revise finger joint, each | 6.16 | NA | 6.03 | 0.92 | NA | 13.11 | 090 |
| 26145 | | A | Tendon excision, palm/finger | 6.31 | NA | 6.04 | 0.98 | NA | 13.33 | 090 |
| 26160 | | A | Remove tendon sheath lesion | 3.15 | 12.36 | 4.12 | 0.48 | 15.99 | 7.75 | 090 |
| 26170 | | A | Removal of palm tendon, each | 4.76 | NA | 4.93 | 0.71 | NA | 10.40 | 090 |
| 26180 | | A | Removal of finger tendon | 5.17 | NA | 5.40 | 0.81 | NA | 11.38 | 090 |
| 26185 | | A | Remove finger bone | 5.24 | NA | 6.02 | 0.72 | NA | 11.98 | 090 |
| 26200 | | A | Remove hand bone lesion | 5.50 | NA | 5.35 | 0.87 | NA | 11.72 | 090 |
| 26205 | | A | Remove/graft bone lesion | 7.69 | NA | 6.88 | 1.20 | NA | 15.77 | 090 |
| 26210 | | A | Removal of finger lesion | 5.14 | NA | 5.41 | 0.79 | NA | 11.34 | 090 |
| 26215 | | A | Remove/graft finger lesion | 7.09 | NA | 6.30 | 1.10 | NA | 14.49 | 090 |
| 26230 | | A | Partial removal of hand bone | 6.32 | NA | 5.90 | 0.95 | NA | 13.17 | 090 |
| 26235 | | A | Partial removal, finger bone | 6.18 | NA | 5.80 | 0.93 | NA | 12.91 | 090 |
| 26236 | | A | Partial removal, finger bone | 5.31 | NA | 5.32 | 0.80 | NA | 11.43 | 090 |
| 26250 | | A | Extensive hand surgery | 7.54 | NA | 6.42 | 1.21 | NA | 15.17 | 090 |
| 26255 | | A | Extensive hand surgery | 12.41 | NA | 9.38 | 1.47 | NA | 23.26 | 090 |
| 26260 | | A | Extensive finger surgery | 7.02 | NA | 6.17 | 1.05 | NA | 14.24 | 090 |
| 26261 | | A | Extensive finger surgery | 9.08 | NA | 6.20 | 1.29 | NA | 16.57 | 090 |
| 26262 | | A | Partial removal of finger | 5.66 | NA | 5.32 | 0.85 | NA | 11.83 | 090 |
| 26320 | | A | Removal of implant from hand | 3.97 | NA | 4.31 | 0.59 | NA | 8.87 | 090 |
| 26340 | | A | Manipulate finger w/anesth | 2.50 | NA | 4.87 | 0.39 | NA | 7.76 | 090 |
| 26350 | | A | Repair finger/hand tendon | 5.98 | NA | 15.28 | 0.85 | NA | 22.11 | 090 |
| 26352 | | A | Repair/graft hand tendon | 7.67 | NA | 15.84 | 1.19 | NA | 24.70 | 090 |
| 26356 | | A | Repair finger/hand tendon | 8.06 | NA | 18.75 | 1.22 | NA | 28.03 | 090 |
| 26357 | | A | Repair finger/hand tendon | 8.57 | NA | 16.30 | 1.33 | NA | 26.20 | 090 |
| 26358 | | A | Repair/graft hand tendon | 9.13 | NA | 17.19 | 1.34 | NA | 27.66 | 090 |
| 26370 | | A | Repair finger/hand tendon | 7.10 | NA | 15.70 | 1.09 | NA | 23.89 | 090 |
| 26372 | | A | Repair/graft hand tendon | 8.75 | NA | 17.07 | 1.27 | NA | 27.09 | 090 |
| 26373 | | A | Repair finger/hand tendon | 8.15 | NA | 16.64 | 1.30 | NA | 26.09 | 090 |
| 26390 | | A | Revise hand/finger tendon | 9.18 | NA | 13.77 | 1.35 | NA | 24.30 | 090 |
| 26392 | | A | Repair/graft hand tendon | 10.24 | NA | 17.43 | 1.49 | NA | 29.16 | 090 |
| 26410 | | A | Repair hand tendon | 4.62 | NA | 12.40 | 0.72 | NA | 17.74 | 090 |
| 26412 | | A | Repair/graft hand tendon | 6.30 | NA | 13.72 | 0.98 | NA | 21.00 | 090 |
| 26415 | | A | Excision, hand/finger tendon | 8.33 | NA | 12.22 | 1.06 | NA | 21.61 | 090 |
| 26416 | | A | Graft hand or finger tendon | 9.36 | NA | 15.03 | 1.18 | NA | 25.57 | 090 |
| 26418 | | A | Repair finger tendon | 4.24 | NA | 12.78 | 0.65 | NA | 17.67 | 090 |
| 26420 | | A | Repair/graft finger tendon | 6.76 | NA | 14.05 | 1.05 | NA | 21.86 | 090 |
| 26426 | | A | Repair finger/hand tendon | 6.14 | NA | 13.57 | 0.96 | NA | 20.67 | 090 |
| 26428 | | A | Repair/graft finger tendon | 7.20 | NA | 14.32 | 1.10 | NA | 22.62 | 090 |
| 26432 | | A | Repair finger tendon | 4.01 | NA | 10.55 | 0.62 | NA | 15.18 | 090 |
| 26433 | | A | Repair finger tendon | 4.55 | NA | 11.22 | 0.70 | NA | 16.47 | 090 |
| 26434 | | A | Repair/graft finger tendon | 6.08 | NA | 11.92 | 0.88 | NA | 18.88 | 090 |
| 26437 | | A | Realignment of tendons | 5.81 | NA | 11.84 | 0.89 | NA | 18.54 | 090 |
| 26440 | | A | Release palm/finger tendon | 5.01 | NA | 13.94 | 0.76 | NA | 19.71 | 090 |
| 26442 | | A | Release palm & finger tendon | 8.15 | NA | 16.43 | 1.16 | NA | 25.74 | 090 |
| 26445 | | A | Release hand/finger tendon | 4.30 | NA | 13.70 | 0.66 | NA | 18.66 | 090 |
| 26449 | | A | Release forearm/hand tendon | 6.99 | NA | 16.21 | 1.03 | NA | 24.23 | 090 |
| 26450 | | A | Incision of palm tendon | 3.66 | NA | 7.53 | 0.58 | NA | 11.77 | 090 |
| 26455 | | A | Incision of finger tendon | 3.63 | NA | 7.46 | 0.55 | NA | 11.64 | 090 |
| 26460 | | A | Incise hand/finger tendon | 3.45 | NA | 7.28 | 0.51 | NA | 11.24 | 090 |
| 26471 | | A | Fusion of finger tendons | 5.72 | NA | 11.52 | 0.88 | NA | 18.12 | 090 |
| 26474 | | A | Fusion of finger tendons | 5.31 | NA | 11.69 | 0.74 | NA | 17.74 | 090 |
| 26476 | | A | Tendon lengthening | 5.17 | NA | 11.23 | 0.79 | NA | 17.19 | 090 |
| 26477 | | A | Tendon shortening | 5.14 | NA | 11.40 | 0.77 | NA | 17.31 | 090 |
| 26478 | | A | Lengthening of hand tendon | 5.79 | NA | 12.09 | 0.94 | NA | 18.82 | 090 |
| 26479 | | A | Shortening of hand tendon | 5.73 | NA | 11.94 | 0.90 | NA | 18.57 | 090 |
| 26480 | | A | Transplant hand tendon | 6.68 | NA | 15.43 | 1.00 | NA | 23.11 | 090 |
| 26483 | | A | Transplant/graft hand tendon | 8.28 | NA | 15.89 | 1.22 | NA | 25.39 | 090 |
| 26485 | | A | Transplant palm tendon | 7.69 | NA | 15.77 | 1.09 | NA | 24.55 | 090 |
| 26489 | | A | Transplant/graft palm tendon | 9.54 | NA | 12.39 | 1.18 | NA | 23.11 | 090 |
| 26490 | | A | Revise thumb tendon | 8.40 | NA | 13.04 | 1.17 | NA | 22.61 | 090 |
| 26492 | | A | Tendon transfer with graft | 9.61 | NA | 13.84 | 1.39 | NA | 24.84 | 090 |
| 26494 | | A | Hand tendon/muscle transfer | 8.46 | NA | 13.47 | 1.21 | NA | 23.14 | 090 |
| 26496 | | A | Revise thumb tendon | 9.58 | NA | 13.47 | 1.38 | NA | 24.43 | 090 |
| 26497 | | A | Finger tendon transfer | 9.56 | NA | 13.82 | 1.46 | NA | 24.84 | 090 |
| 26498 | | A | Finger tendon transfer | 13.98 | NA | 16.40 | 1.95 | NA | 32.33 | 090 |
| 26499 | | A | Revision of finger | 8.97 | NA | 13.40 | 1.30 | NA | 23.67 | 090 |
| 26500 | | A | Hand tendon reconstruction | 5.95 | NA | 11.98 | 0.89 | NA | 18.82 | 090 |
| 26502 | | A | Hand tendon reconstruction | 7.13 | NA | 12.45 | 1.03 | NA | 20.61 | 090 |
| 26504 | | A | Hand tendon reconstruction | 7.46 | NA | 12.85 | 1.18 | NA | 21.49 | 090 |
| 26508 | | A | Release thumb contracture | 6.00 | NA | 11.97 | 0.94 | NA | 18.91 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 26510 | | A | Thumb tendon transfer | 5.42 | NA | 11.65 | 0.77 | NA | 17.84 | 090 |
| 26516 | | A | Fusion of knuckle joint | 7.14 | NA | 12.50 | 1.04 | NA | 20.68 | 090 |
| 26517 | | A | Fusion of knuckle joints | 8.82 | NA | 13.82 | 1.49 | NA | 24.13 | 090 |
| 26518 | | A | Fusion of knuckle joints | 9.01 | NA | 13.63 | 1.52 | NA | 24.16 | 090 |
| 26520 | | A | Release knuckle contracture | 5.29 | NA | 14.38 | 0.80 | NA | 20.47 | 090 |
| 26525 | | A | Release finger contracture | 5.32 | NA | 14.49 | 0.81 | NA | 20.62 | 090 |
| 26530 | | A | Revise knuckle joint | 6.68 | NA | 6.13 | 1.03 | NA | 13.84 | 090 |
| 26531 | | A | Revise knuckle with implant | 7.90 | NA | 7.10 | 1.15 | NA | 16.15 | 090 |
| 26535 | | A | Revise finger joint | 5.23 | NA | 3.74 | 0.58 | NA | 9.55 | 090 |
| 26536 | | A | Revise/implant finger joint | 6.36 | NA | 9.63 | 0.89 | NA | 16.88 | 090 |
| 26540 | | A | Repair hand joint | 6.42 | NA | 12.22 | 0.97 | NA | 19.61 | 090 |
| 26541 | | A | Repair hand joint with graft | 8.61 | NA | 13.69 | 1.23 | NA | 23.53 | 090 |
| 26542 | | A | Repair hand joint with graft | 6.77 | NA | 12.25 | 0.98 | NA | 20.00 | 090 |
| 26545 | | A | Reconstruct finger joint | 6.91 | NA | 12.66 | 1.01 | NA | 20.58 | 090 |
| 26546 | | A | Repair nonunion hand | 8.91 | NA | 15.14 | 1.33 | NA | 25.38 | 090 |
| 26548 | | A | Reconstruct finger joint | 8.02 | NA | 13.25 | 1.16 | NA | 22.43 | 090 |
| 26550 | | A | Construct thumb replacement | 21.21 | NA | 18.11 | 2.98 | NA | 42.30 | 090 |
| 26551 | | A | Great toe-hand transfer | 46.51 | NA | 33.36 | 5.65 | NA | 85.52 | 090 |
| 26553 | | A | Single transfer, toe-hand | 46.20 | NA | 22.83 | 3.49 | NA | 72.52 | 090 |
| 26554 | | A | Double transfer, toe-hand | 54.87 | NA | 37.75 | 9.36 | NA | 101.98 | 090 |
| 26555 | | A | Positional change of finger | 16.61 | NA | 18.47 | 2.26 | NA | 37.34 | 090 |
| 26556 | | A | Toe joint transfer | 47.19 | NA | 33.81 | 8.04 | NA | 89.04 | 090 |
| 26560 | | A | Repair of web finger | 5.37 | NA | 10.18 | 0.76 | NA | 16.31 | 090 |
| 26561 | | A | Repair of web finger | 10.90 | NA | 12.81 | 1.53 | NA | 25.24 | 090 |
| 26562 | | A | Repair of web finger | 14.98 | NA | 17.46 | 1.18 | NA | 33.62 | 090 |
| 26565 | | A | Correct metacarpal flaw | 6.73 | NA | 12.32 | 0.96 | NA | 20.01 | 090 |
| 26567 | | A | Correct finger deformity | 6.81 | NA | 12.25 | 1.02 | NA | 20.08 | 090 |
| 26568 | | A | Lengthen metacarpal/finger | 9.07 | NA | 15.87 | 1.34 | NA | 26.28 | 090 |
| 26580 | | A | Repair hand deformity | 18.15 | NA | 14.01 | 1.88 | NA | 34.04 | 090 |
| 26587 | | A | Reconstruct extra finger | 14.03 | NA | 9.06 | 1.46 | NA | 24.55 | 090 |
| 26590 | | A | Repair finger deformity | 17.93 | NA | 14.31 | 1.62 | NA | 33.86 | 090 |
| 26591 | | A | Repair muscles of hand | 3.25 | NA | 10.31 | 0.49 | NA | 14.05 | 090 |
| 26593 | | A | Release muscles of hand | 5.30 | NA | 11.38 | 0.77 | NA | 17.45 | 090 |
| 26596 | | A | Excision constricting tissue | 8.94 | NA | 9.00 | 1.38 | NA | 19.32 | 090 |
| 26600 | | A | Treat metacarpal fracture | 1.96 | 3.61 | 2.68 | 0.29 | 5.86 | 4.93 | 090 |
| 26605 | | A | Treat metacarpal fracture | 2.85 | 4.56 | 3.65 | 0.45 | 7.86 | 6.95 | 090 |
| 26607 | | A | Treat metacarpal fracture | 5.35 | NA | 6.38 | 0.84 | NA | 12.57 | 090 |
| 26608 | | A | Treat metacarpal fracture | 5.35 | NA | 6.54 | 0.88 | NA | 12.77 | 090 |
| 26615 | | A | Treat metacarpal fracture | 5.32 | NA | 5.73 | 0.85 | NA | 11.90 | 090 |
| 26641 | | A | Treat thumb dislocation | 3.93 | 4.60 | 3.58 | 0.43 | 8.96 | 7.94 | 090 |
| 26645 | | A | Treat thumb fracture | 4.40 | 5.18 | 4.20 | 0.62 | 10.20 | 9.22 | 090 |
| 26650 | | A | Treat thumb fracture | 5.71 | NA | 6.95 | 0.94 | NA | 13.60 | 090 |
| 26665 | | A | Treat thumb fracture | 7.59 | NA | 6.99 | 1.19 | NA | 15.77 | 090 |
| 26670 | | A | Treat hand dislocation | 3.68 | 4.29 | 2.99 | 0.39 | 8.36 | 7.06 | 090 |
| 26675 | | A | Treat hand dislocation | 4.63 | 5.48 | 4.48 | 0.72 | 10.83 | 9.83 | 090 |
| 26676 | | A | Pin hand dislocation | 5.51 | NA | 6.99 | 0.88 | NA | 13.38 | 090 |
| 26685 | | A | Treat hand dislocation | 6.97 | NA | 6.44 | 1.05 | NA | 14.46 | 090 |
| 26686 | | A | Treat hand dislocation | 7.93 | NA | 7.21 | 1.21 | NA | 16.35 | 090 |
| 26700 | | A | Treat knuckle dislocation | 3.68 | 3.79 | 2.91 | 0.34 | 7.81 | 6.93 | 090 |
| 26705 | | A | Treat knuckle dislocation | 4.18 | 5.35 | 4.31 | 0.61 | 10.14 | 9.10 | 090 |
| 26706 | | A | Pin knuckle dislocation | 5.11 | NA | 5.27 | 0.77 | NA | 11.15 | 090 |
| 26715 | | A | Treat knuckle dislocation | 5.73 | NA | 5.91 | 0.89 | NA | 12.53 | 090 |
| 26720 | | A | Treat finger fracture, each | 1.66 | 2.79 | 2.09 | 0.22 | 4.67 | 3.97 | 090 |
| 26725 | | A | Treat finger fracture, each | 3.33 | 4.77 | 3.51 | 0.50 | 8.60 | 7.34 | 090 |
| 26727 | | A | Treat finger fracture, each | 5.22 | NA | 6.60 | 0.84 | NA | 12.66 | 090 |
| 26735 | | A | Treat finger fracture, each | 5.97 | NA | 6.06 | 0.94 | NA | 12.97 | 090 |
| 26740 | | A | Treat finger fracture, each | 1.94 | 3.14 | 2.71 | 0.30 | 5.38 | 4.95 | 090 |
| 26742 | | A | Treat finger fracture, each | 3.84 | 4.99 | 3.89 | 0.56 | 9.39 | 8.29 | 090 |
| 26746 | | A | Treat finger fracture, each | 5.80 | NA | 6.12 | 0.91 | NA | 12.83 | 090 |
| 26750 | | A | Treat finger fracture, each | 1.70 | 2.49 | 2.05 | 0.20 | 4.39 | 3.95 | 090 |
| 26755 | | A | Treat finger fracture, each | 3.10 | 4.43 | 3.02 | 0.41 | 7.94 | 6.53 | 090 |
| 26756 | | A | Pin finger fracture, each | 4.38 | NA | 6.23 | 0.69 | NA | 11.30 | 090 |
| 26765 | | A | Treat finger fracture, each | 4.16 | NA | 4.96 | 0.62 | NA | 9.74 | 090 |
| 26770 | | A | Treat finger dislocation | 3.02 | 3.46 | 2.46 | 0.27 | 6.75 | 5.75 | 090 |
| 26775 | | A | Treat finger dislocation | 3.70 | 5.20 | 3.84 | 0.49 | 9.39 | 8.03 | 090 |
| 26776 | | A | Pin finger dislocation | 4.79 | NA | 6.40 | 0.73 | NA | 11.92 | 090 |
| 26785 | | A | Treat finger dislocation | 4.20 | NA | 4.99 | 0.67 | NA | 9.86 | 090 |
| 26820 | | A | Thumb fusion with graft | 8.25 | NA | 13.49 | 1.36 | NA | 23.10 | 090 |
| 26841 | | A | Fusion of thumb | 7.12 | NA | 13.39 | 1.17 | NA | 21.68 | 090 |
| 26842 | | A | Thumb fusion with graft | 8.23 | NA | 13.57 | 1.24 | NA | 23.04 | 090 |
| 26843 | | A | Fusion of hand joint | 7.60 | NA | 12.53 | 1.21 | NA | 21.34 | 090 |
| 26844 | | A | Fusion/graft of hand joint | 8.72 | NA | 13.55 | 1.29 | NA | 23.56 | 090 |
| 26850 | | A | Fusion of knuckle | 6.96 | NA | 12.41 | 1.05 | NA | 20.42 | 090 |
| 26852 | | A | Fusion of knuckle with graft | 8.45 | NA | 13.14 | 1.23 | NA | 22.82 | 090 |
| 26860 | | A | Fusion of finger joint | 4.68 | NA | 11.42 | 0.73 | NA | 16.83 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 26861 | | A | Fusion of finger jnt, add-on | 1.74 | NA | 0.93 | 0.24 | NA | 2.91 | ZZZ |
| 26862 | | A | Fusion/graft of finger joint | 7.36 | NA | 12.63 | 1.05 | NA | 21.04 | 090 |
| 26863 | | A | Fuse/graft added joint | 3.89 | NA | 2.10 | 0.56 | NA | 6.55 | ZZZ |
| 26910 | | A | Amputate metacarpal bone | 7.59 | NA | 11.57 | 1.13 | NA | 20.29 | 090 |
| 26951 | | A | Amputation of finger/thumb | 4.58 | NA | 10.48 | 0.70 | NA | 15.76 | 090 |
| 26952 | | A | Amputation of finger/thumb | 6.30 | NA | 12.05 | 0.94 | NA | 19.29 | 090 |
| 26990 | | A | Drainage of pelvis lesion | 7.47 | NA | 7.75 | 1.18 | NA | 16.40 | 090 |
| 26991 | | A | Drainage of pelvis bursa | 6.67 | 11.17 | 5.43 | 1.07 | 18.91 | 13.17 | 090 |
| 26992 | | A | Drainage of bone lesion | 13.00 | NA | 11.06 | 2.06 | NA | 26.12 | 090 |
| 27000 | | A | Incision of hip tendon | 5.61 | NA | 5.46 | 0.96 | NA | 12.03 | 090 |
| 27001 | | A | Incision of hip tendon | 6.93 | NA | 6.33 | 1.16 | NA | 14.42 | 090 |
| 27003 | | A | Incision of hip tendon | 7.33 | NA | 6.74 | 1.18 | NA | 15.25 | 090 |
| 27005 | | A | Incision of hip tendon | 9.65 | NA | 8.04 | 1.58 | NA | 19.27 | 090 |
| 27006 | | A | Incision of hip tendons | 9.67 | NA | 8.21 | 1.56 | NA | 19.44 | 090 |
| 27025 | | A | Incision of hip/thigh fascia | 11.14 | NA | 8.75 | 1.75 | NA | 21.64 | 090 |
| 27030 | | A | Drainage of hip joint | 12.99 | NA | 9.85 | 2.10 | NA | 24.94 | 090 |
| 27033 | | A | Exploration of hip joint | 13.37 | NA | 10.12 | 2.20 | NA | 25.69 | 090 |
| 27035 | | A | Denervation of hip joint | 16.66 | NA | 12.61 | 2.43 | NA | 31.70 | 090 |
| 27036 | | A | Excision of hip joint/muscle | 12.86 | NA | 10.28 | 2.11 | NA | 25.25 | 090 |
| 27040 | | A | Biopsy of soft tissues | 2.87 | 5.25 | 2.01 | 0.30 | 8.42 | 5.18 | 010 |
| 27041 | | A | Biopsy of soft tissues | 9.88 | NA | 6.79 | 1.30 | NA | 17.97 | 090 |
| 27047 | | A | Remove hip/pelvis lesion | 7.44 | 7.14 | 4.78 | 1.00 | 15.58 | 13.22 | 090 |
| 27048 | | A | Remove hip/pelvis lesion | 6.24 | NA | 5.12 | 0.89 | NA | 12.25 | 090 |
| 27049 | | A | Remove tumor, hip/pelvis | 13.64 | NA | 8.93 | 1.95 | NA | 24.52 | 090 |
| 27050 | | A | Biopsy of sacroiliac joint | 4.35 | NA | 4.64 | 0.66 | NA | 9.65 | 090 |
| 27052 | | A | Biopsy of hip joint | 6.22 | NA | 6.09 | 0.98 | NA | 13.29 | 090 |
| 27054 | | A | Removal of hip joint lining | 8.53 | NA | 7.59 | 1.35 | NA | 17.47 | 090 |
| 27060 | | A | Removal of ischial bursa | 5.42 | NA | 4.94 | 0.78 | NA | 11.14 | 090 |
| 27062 | | A | Remove femur lesion/bursa | 5.36 | NA | 5.40 | 0.91 | NA | 11.67 | 090 |
| 27065 | | A | Removal of hip bone lesion | 5.89 | NA | 5.71 | 0.90 | NA | 12.50 | 090 |
| 27066 | | A | Removal of hip bone lesion | 10.31 | NA | 8.73 | 1.60 | NA | 20.64 | 090 |
| 27067 | | A | Remove/graft hip bone lesion | 13.81 | NA | 10.92 | 2.25 | NA | 26.98 | 090 |
| 27070 | | A | Partial removal of hip bone | 10.70 | NA | 9.98 | 1.67 | NA | 22.35 | 090 |
| 27071 | | A | Partial removal of hip bone | 11.44 | NA | 10.98 | 1.82 | NA | 24.24 | 090 |
| 27075 | | A | Extensive hip surgery | 34.95 | NA | 19.82 | 5.16 | NA | 59.93 | 090 |
| 27076 | | A | Extensive hip surgery | 22.09 | NA | 15.05 | 3.43 | NA | 40.57 | 090 |
| 27077 | | A | Extensive hip surgery | 39.94 | NA | 23.29 | 5.61 | NA | 68.84 | 090 |
| 27078 | | A | Extensive hip surgery | 13.42 | NA | 10.70 | 2.12 | NA | 26.24 | 090 |
| 27079 | | A | Extensive hip surgery | 13.73 | NA | 10.31 | 2.00 | NA | 26.04 | 090 |
| 27080 | | A | Removal of tail bone | 6.38 | NA | 5.17 | 0.92 | NA | 12.47 | 090 |
| 27086 | | A | Remove hip foreign body | 1.87 | 4.57 | 1.82 | 0.22 | 6.66 | 3.91 | 010 |
| 27087 | | A | Remove hip foreign body | 8.53 | NA | 6.85 | 1.29 | NA | 16.67 | 090 |
| 27090 | | A | Removal of hip prosthesis | 11.13 | NA | 8.76 | 1.81 | NA | 21.70 | 090 |
| 27091 | | A | Removal of hip prosthesis | 22.11 | NA | 13.97 | 3.49 | NA | 39.57 | 090 |
| 27093 | | A | Injection for hip x-ray | 1.30 | 4.50 | 0.48 | 0.12 | 5.92 | 1.90 | 000 |
| 27095 | | A | Injection for hip x-ray | 1.50 | 5.81 | 0.52 | 0.13 | 7.44 | 2.15 | 000 |
| 27096 | | A | Inject sacroiliac joint | 1.40 | 3.95 | 0.33 | 0.10 | 5.45 | 1.83 | 000 |
| 27097 | | A | Revision of hip tendon | 8.79 | NA | 6.63 | 1.49 | NA | 16.91 | 090 |
| 27098 | | A | Transfer tendon to pelvis | 8.82 | NA | 7.26 | 0.91 | NA | 16.99 | 090 |
| 27100 | | A | Transfer of abdominal muscle | 11.06 | NA | 8.97 | 1.76 | NA | 21.79 | 090 |
| 27105 | | A | Transfer of spinal muscle | 11.75 | NA | 9.41 | 1.32 | NA | 22.48 | 090 |
| 27110 | | A | Transfer of iliopsoas muscle | 13.24 | NA | 9.48 | 1.82 | NA | 24.54 | 090 |
| 27111 | | A | Transfer of iliopsoas muscle | 12.13 | NA | 9.36 | 2.11 | NA | 23.60 | 090 |
| 27120 | | A | Reconstruction of hip socket | 17.98 | NA | 11.83 | 2.73 | NA | 32.54 | 090 |
| 27122 | | A | Reconstruction of hip socket | 14.96 | NA | 11.02 | 2.42 | NA | 28.40 | 090 |
| 27125 | | A | Partial hip replacement | 14.67 | NA | 10.60 | 2.32 | NA | 27.59 | 090 |
| 27130 | | A | Total hip arthroplasty | 20.09 | NA | 13.28 | 3.11 | NA | 36.48 | 090 |
| 27132 | | A | Total hip arthroplasty | 23.27 | NA | 15.60 | 3.64 | NA | 42.51 | 090 |
| 27134 | | A | Revise hip joint replacement | 28.48 | NA | 17.76 | 4.44 | NA | 50.68 | 090 |
| 27137 | | A | Revise hip joint replacement | 21.14 | NA | 13.90 | 3.35 | NA | 38.39 | 090 |
| 27138 | | A | Revise hip joint replacement | 22.14 | NA | 14.37 | 3.51 | NA | 40.02 | 090 |
| 27140 | | A | Transplant femur ridge | 12.22 | NA | 9.61 | 1.97 | NA | 23.80 | 090 |
| 27146 | | A | Incision of hip bone | 17.40 | NA | 12.49 | 2.61 | NA | 32.50 | 090 |
| 27147 | | A | Revision of hip bone | 20.55 | NA | 13.51 | 2.80 | NA | 36.86 | 090 |
| 27151 | | A | Incision of hip bones | 22.48 | NA | 8.26 | 3.57 | NA | 34.31 | 090 |
| 27156 | | A | Revision of hip bones | 24.59 | NA | 16.32 | 3.52 | NA | 44.43 | 090 |
| 27158 | | A | Revision of pelvis | 19.71 | NA | 11.30 | 3.14 | NA | 34.15 | 090 |
| 27161 | | A | Incision of neck of femur | 16.68 | NA | 12.29 | 2.77 | NA | 31.74 | 090 |
| 27165 | | A | Incision/fixation of femur | 17.88 | NA | 13.07 | 2.82 | NA | 33.77 | 090 |
| 27170 | | A | Repair/graft femur head/neck | 16.05 | NA | 11.49 | 2.56 | NA | 30.10 | 090 |
| 27175 | | A | Treat slipped epiphysis | 8.45 | NA | 6.75 | 1.47 | NA | 16.67 | 090 |
| 27176 | | A | Treat slipped epiphysis | 12.03 | NA | 9.14 | 2.00 | NA | 23.17 | 090 |
| 27177 | | A | Treat slipped epiphysis | 15.06 | NA | 10.99 | 2.49 | NA | 28.54 | 090 |
| 27178 | | A | Treat slipped epiphysis | 11.97 | NA | 8.53 | 2.08 | NA | 22.58 | 090 |
| 27179 | | A | Revise head/neck of femur | 12.96 | NA | 10.09 | 2.25 | NA | 25.30 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 27181 | | A | Treat slipped epiphysis | 14.66 | NA | 10.31 | 2.28 | NA | 27.25 | 090 |
| 27185 | | A | Revision of femur epiphysis | 9.17 | NA | 7.78 | 1.59 | NA | 18.54 | 090 |
| 27187 | | A | Reinforce hip bones | 13.52 | NA | 10.55 | 2.16 | NA | 26.23 | 090 |
| 27193 | | A | Treat pelvic ring fracture | 5.55 | 5.32 | 5.17 | 0.93 | 11.80 | 11.65 | 090 |
| 27194 | | A | Treat pelvic ring fracture | 9.64 | NA | 7.64 | 1.62 | NA | 18.90 | 090 |
| 27200 | | A | Treat tail bone fracture | 1.84 | 2.23 | 2.17 | 0.26 | 4.33 | 4.27 | 090 |
| 27202 | | A | Treat tail bone fracture | 7.03 | NA | 17.13 | 0.93 | NA | 25.09 | 090 |
| 27215 | | A | Treat pelvic fracture(s) | 10.03 | NA | 7.30 | 1.78 | NA | 19.11 | 090 |
| 27216 | | A | Treat pelvic ring fracture | 15.17 | NA | 9.91 | 2.49 | NA | 27.57 | 090 |
| 27217 | | A | Treat pelvic ring fracture | 14.09 | NA | 10.34 | 2.23 | NA | 26.66 | 090 |
| 27218 | | A | Treat pelvic ring fracture | 20.12 | NA | 11.62 | 3.23 | NA | 34.97 | 090 |
| 27220 | | A | Treat hip socket fracture | 6.17 | 5.71 | 5.62 | 1.05 | 12.93 | 12.84 | 090 |
| 27222 | | A | Treat hip socket fracture | 12.68 | NA | 10.04 | 2.17 | NA | 24.89 | 090 |
| 27226 | | A | Treat hip wall fracture | 14.89 | NA | 8.03 | 2.46 | NA | 25.38 | 090 |
| 27227 | | A | Treat hip fracture(s) | 23.41 | NA | 15.53 | 3.73 | NA | 42.67 | 090 |
| 27228 | | A | Treat hip fracture(s) | 27.12 | NA | 17.75 | 4.44 | NA | 49.31 | 090 |
| 27230 | | A | Treat thigh fracture | 5.49 | 5.51 | 5.11 | 0.90 | 11.90 | 11.50 | 090 |
| 27232 | | A | Treat thigh fracture | 10.66 | NA | 7.34 | 1.78 | NA | 19.78 | 090 |
| 27235 | | A | Treat thigh fracture | 12.14 | NA | 9.57 | 2.08 | NA | 23.79 | 090 |
| 27236 | | A | Treat thigh fracture | 15.58 | NA | 11.04 | 2.49 | NA | 29.11 | 090 |
| 27238 | | A | Treat thigh fracture | 5.51 | NA | 5.27 | 0.86 | NA | 11.64 | 090 |
| 27240 | | A | Treat thigh fracture | 12.48 | NA | 9.58 | 2.06 | NA | 24.12 | 090 |
| 27244 | | A | Treat thigh fracture | 15.92 | NA | 11.42 | 2.57 | NA | 29.91 | 090 |
| 27245 | | A | Treat thigh fracture | 20.28 | NA | 13.85 | 3.24 | NA | 37.37 | 090 |
| 27246 | | A | Treat thigh fracture | 4.70 | 4.45 | 4.42 | 0.80 | 9.95 | 9.92 | 090 |
| 27248 | | A | Treat thigh fracture | 10.43 | NA | 8.35 | 1.68 | NA | 20.46 | 090 |
| 27250 | | A | Treat hip dislocation | 6.94 | NA | 4.75 | 0.61 | NA | 12.30 | 090 |
| 27252 | | A | Treat hip dislocation | 10.37 | NA | 7.53 | 1.58 | NA | 19.48 | 090 |
| 27253 | | A | Treat hip dislocation | 12.90 | NA | 9.89 | 1.91 | NA | 24.70 | 090 |
| 27254 | | A | Treat hip dislocation | 18.23 | NA | 12.17 | 2.97 | NA | 33.37 | 090 |
| 27256 | | A | Treat hip dislocation | 4.11 | 3.52 | 2.09 | 0.43 | 8.06 | 6.63 | 010 |
| 27257 | | A | Treat hip dislocation | 5.21 | NA | 2.82 | 0.67 | NA | 8.70 | 010 |
| 27258 | | A | Treat hip dislocation | 15.41 | NA | 11.10 | 2.51 | NA | 29.02 | 090 |
| 27259 | | A | Treat hip dislocation | 21.52 | NA | 14.33 | 3.35 | NA | 39.20 | 090 |
| 27265 | | A | Treat hip dislocation | 5.04 | NA | 4.91 | 0.64 | NA | 10.59 | 090 |
| 27266 | | A | Treat hip dislocation | 7.48 | NA | 6.46 | 1.26 | NA | 15.20 | 090 |
| 27275 | | A | Manipulation of hip joint | 2.27 | NA | 2.10 | 0.38 | NA | 4.75 | 010 |
| 27280 | | A | Fusion of sacroiliac joint | 13.37 | NA | 10.55 | 2.21 | NA | 26.13 | 090 |
| 27282 | | A | Fusion of pubic bones | 11.32 | NA | 8.34 | 1.26 | NA | 20.92 | 090 |
| 27284 | | A | Fusion of hip joint | 23.41 | NA | 15.00 | 3.26 | NA | 41.67 | 090 |
| 27286 | | A | Fusion of hip joint | 23.41 | NA | 16.02 | 3.54 | NA | 42.97 | 090 |
| 27290 | | A | Amputation of leg at hip | 23.25 | NA | 14.33 | 3.33 | NA | 40.91 | 090 |
| 27295 | | A | Amputation of leg at hip | 18.62 | NA | 11.64 | 2.77 | NA | 33.03 | 090 |
| 27301 | | A | Drain thigh/knee lesion | 6.48 | 10.12 | 5.14 | 1.00 | 17.60 | 12.62 | 090 |
| 27303 | | A | Drainage of bone lesion | 8.27 | NA | 7.54 | 1.35 | NA | 17.16 | 090 |
| 27305 | | A | Incise thigh tendon & fascia | 5.91 | NA | 5.50 | 0.92 | NA | 12.33 | 090 |
| 27306 | | A | Incision of thigh tendon | 4.61 | NA | 4.97 | 0.79 | NA | 10.37 | 090 |
| 27307 | | A | Incision of thigh tendons | 5.79 | NA | 5.69 | 1.01 | NA | 12.49 | 090 |
| 27310 | | A | Exploration of knee joint | 9.26 | NA | 7.75 | 1.51 | NA | 18.52 | 090 |
| 27315 | | A | Partial removal, thigh nerve | 6.96 | NA | 4.91 | 1.21 | NA | 13.08 | 090 |
| 27320 | | A | Partial removal, thigh nerve | 6.29 | NA | 5.19 | 0.94 | NA | 12.42 | 090 |
| 27323 | | A | Biopsy, thigh soft tissues | 2.28 | 3.52 | 1.88 | 0.27 | 6.07 | 4.43 | 010 |
| 27324 | | A | Biopsy, thigh soft tissues | 4.89 | NA | 4.45 | 0.73 | NA | 10.07 | 090 |
| 27327 | | A | Removal of thigh lesion | 4.46 | 6.01 | 3.73 | 0.63 | 11.10 | 8.82 | 090 |
| 27328 | | A | Removal of thigh lesion | 5.56 | NA | 4.65 | 0.83 | NA | 11.04 | 090 |
| 27329 | | A | Remove tumor, thigh/knee | 14.12 | NA | 9.68 | 2.05 | NA | 25.85 | 090 |
| 27330 | | A | Biopsy, knee joint lining | 4.96 | NA | 4.72 | 0.85 | NA | 10.53 | 090 |
| 27331 | | A | Explore/treat knee joint | 5.87 | NA | 5.68 | 0.95 | NA | 12.50 | 090 |
| 27332 | | A | Removal of knee cartilage | 8.26 | NA | 7.26 | 1.38 | NA | 16.90 | 090 |
| 27333 | | A | Removal of knee cartilage | 7.29 | NA | 6.81 | 1.17 | NA | 15.27 | 090 |
| 27334 | | A | Remove knee joint lining | 8.69 | NA | 7.58 | 1.41 | NA | 17.68 | 090 |
| 27335 | | A | Remove knee joint lining | 9.99 | NA | 8.39 | 1.61 | NA | 19.99 | 090 |
| 27340 | | A | Removal of kneecap bursa | 4.17 | NA | 4.69 | 0.71 | NA | 9.57 | 090 |
| 27345 | | A | Removal of knee cyst | 5.91 | NA | 5.77 | 0.95 | NA | 12.63 | 090 |
| 27347 | | A | Remove knee cyst | 5.77 | NA | 5.58 | 0.94 | NA | 12.29 | 090 |
| 27350 | | A | Removal of kneecap | 8.16 | NA | 7.38 | 1.31 | NA | 16.85 | 090 |
| 27355 | | A | Remove femur lesion | 7.64 | NA | 7.03 | 1.20 | NA | 15.87 | 090 |
| 27356 | | A | Remove femur lesion/graft | 9.47 | NA | 8.11 | 1.58 | NA | 19.16 | 090 |
| 27357 | | A | Remove femur lesion/graft | 10.51 | NA | 8.94 | 1.81 | NA | 21.26 | 090 |
| 27358 | | A | Remove femur lesion/fixation | 4.73 | NA | 2.52 | 0.76 | NA | 8.01 | ZZZ |
| 27360 | | A | Partial removal, leg bone(s) | 10.48 | NA | 10.15 | 1.68 | NA | 22.31 | 090 |
| 27365 | | A | Extensive leg surgery | 16.25 | NA | 11.89 | 2.70 | NA | 30.84 | 090 |
| 27370 | | A | Injection for knee x-ray | 0.96 | 3.76 | 0.32 | 0.07 | 4.79 | 1.35 | 000 |
| 27372 | | A | Removal of foreign body | 5.06 | 10.10 | 4.69 | 0.77 | 15.93 | 10.52 | 090 |
| 27380 | | A | Repair of kneecap tendon | 7.15 | NA | 7.37 | 1.16 | NA | 15.68 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 27381 | | A | Repair/graft kneecap tendon | 10.32 | NA | 9.17 | 1.63 | NA | 21.12 | 090 |
| 27385 | | A | Repair of thigh muscle | 7.75 | NA | 7.71 | 1.27 | NA | 16.73 | 090 |
| 27386 | | A | Repair/graft of thigh muscle | 10.54 | NA | 9.61 | 1.69 | NA | 21.84 | 090 |
| 27390 | | A | Incision of thigh tendon | 5.32 | NA | 5.43 | 0.84 | NA | 11.59 | 090 |
| 27391 | | A | Incision of thigh tendons | 7.19 | NA | 6.83 | 1.19 | NA | 15.21 | 090 |
| 27392 | | A | Incision of thigh tendons | 9.19 | NA | 7.94 | 1.52 | NA | 18.65 | 090 |
| 27393 | | A | Lengthening of thigh tendon | 6.38 | NA | 6.04 | 0.98 | NA | 13.40 | 090 |
| 27394 | | A | Lengthening of thigh tendons | 8.49 | NA | 7.49 | 1.37 | NA | 17.35 | 090 |
| 27395 | | A | Lengthening of thigh tendons | 11.71 | NA | 9.63 | 1.80 | NA | 23.14 | 090 |
| 27396 | | A | Transplant of thigh tendon | 7.85 | NA | 7.29 | 1.13 | NA | 16.27 | 090 |
| 27397 | | A | Transplants of thigh tendons | 11.26 | NA | 9.27 | 1.50 | NA | 22.03 | 090 |
| 27400 | | A | Revise thigh muscles/tendons | 9.01 | NA | 7.52 | 1.47 | NA | 18.00 | 090 |
| 27403 | | A | Repair of knee cartilage | 8.32 | NA | 7.33 | 1.34 | NA | 16.99 | 090 |
| 27405 | | A | Repair of knee ligament | 8.64 | NA | 7.66 | 1.41 | NA | 17.71 | 090 |
| 27407 | | A | Repair of knee ligament | 10.26 | NA | 8.48 | 1.65 | NA | 20.39 | 090 |
| 27409 | | A | Repair of knee ligaments | 12.88 | NA | 10.10 | 2.18 | NA | 25.16 | 090 |
| 27418 | | A | Repair degenerated kneecap | 10.83 | NA | 9.05 | 1.70 | NA | 21.58 | 090 |
| 27420 | | A | Revision of unstable kneecap | 9.82 | NA | 8.25 | 1.55 | NA | 19.62 | 090 |
| 27422 | | A | Revision of unstable kneecap | 9.77 | NA | 8.25 | 1.55 | NA | 19.57 | 090 |
| 27424 | | A | Revision/removal of kneecap | 9.80 | NA | 8.22 | 1.54 | NA | 19.56 | 090 |
| 27425 | | A | Lat retinacular release open | 5.21 | NA | 5.67 | 0.89 | NA | 11.77 | 090 |
| 27427 | | A | Reconstruction, knee | 9.35 | NA | 7.95 | 1.47 | NA | 18.77 | 090 |
| 27428 | | A | Reconstruction, knee | 13.98 | NA | 11.37 | 2.30 | NA | 27.65 | 090 |
| 27429 | | A | Reconstruction, knee | 15.50 | NA | 12.61 | 2.61 | NA | 30.72 | 090 |
| 27430 | | A | Revision of thigh muscles | 9.66 | NA | 8.15 | 1.53 | NA | 19.34 | 090 |
| 27435 | | A | Incision of knee joint | 9.48 | NA | 8.59 | 1.45 | NA | 19.52 | 090 |
| 27437 | | A | Revise kneecap | 8.45 | NA | 7.23 | 1.51 | NA | 17.19 | 090 |
| 27438 | | A | Revise kneecap with implant | 11.21 | NA | 8.52 | 1.80 | NA | 21.53 | 090 |
| 27440 | | A | Revision of knee joint | 10.41 | NA | 6.01 | 1.56 | NA | 17.98 | 090 |
| 27441 | | A | Revision of knee joint | 10.80 | NA | 6.71 | 1.66 | NA | 19.17 | 090 |
| 27442 | | A | Revision of knee joint | 11.87 | NA | 8.90 | 1.86 | NA | 22.63 | 090 |
| 27443 | | A | Revision of knee joint | 10.91 | NA | 8.70 | 1.67 | NA | 21.28 | 090 |
| 27445 | | A | Revision of knee joint | 17.65 | NA | 12.32 | 2.80 | NA | 32.77 | 090 |
| 27446 | | A | Revision of knee joint | 15.82 | NA | 11.25 | 2.44 | NA | 29.51 | 090 |
| 27447 | | A | Total knee arthroplasty | 21.45 | NA | 14.57 | 3.35 | NA | 39.37 | 090 |
| 27448 | | A | Incision of thigh | 11.04 | NA | 8.86 | 1.67 | NA | 21.57 | 090 |
| 27450 | | A | Incision of thigh | 13.96 | NA | 10.81 | 2.26 | NA | 27.03 | 090 |
| 27454 | | A | Realignment of thigh bone | 17.53 | NA | 12.73 | 2.84 | NA | 33.10 | 090 |
| 27455 | | A | Realignment of knee | 12.80 | NA | 10.02 | 2.06 | NA | 24.88 | 090 |
| 27457 | | A | Realignment of knee | 13.43 | NA | 10.06 | 2.21 | NA | 25.70 | 090 |
| 27465 | | A | Shortening of thigh bone | 13.85 | NA | 10.55 | 2.31 | NA | 26.71 | 090 |
| 27466 | | A | Lengthening of thigh bone | 16.31 | NA | 12.12 | 2.57 | NA | 31.00 | 090 |
| 27468 | | A | Shorten/lengthen thighs | 18.94 | NA | 12.62 | 2.90 | NA | 34.46 | 090 |
| 27470 | | A | Repair of thigh | 16.05 | NA | 12.08 | 2.57 | NA | 30.70 | 090 |
| 27472 | | A | Repair/graft of thigh | 17.69 | NA | 12.96 | 2.85 | NA | 33.50 | 090 |
| 27475 | | A | Surgery to stop leg growth | 8.63 | NA | 7.40 | 1.50 | NA | 17.53 | 090 |
| 27477 | | A | Surgery to stop leg growth | 9.84 | NA | 7.90 | 1.72 | NA | 19.46 | 090 |
| 27479 | | A | Surgery to stop leg growth | 12.78 | NA | 10.03 | 2.22 | NA | 25.03 | 090 |
| 27485 | | A | Surgery to stop leg growth | 8.83 | NA | 7.56 | 1.71 | NA | 18.10 | 090 |
| 27486 | | A | Revise/replace knee joint | 19.24 | NA | 13.46 | 2.99 | NA | 35.69 | 090 |
| 27487 | | A | Revise/replace knee joint | 25.23 | NA | 16.52 | 3.90 | NA | 45.65 | 090 |
| 27488 | | A | Removal of knee prosthesis | 15.72 | NA | 11.68 | 2.49 | NA | 29.89 | 090 |
| 27495 | | A | Reinforce thigh | 15.53 | NA | 11.71 | 2.52 | NA | 29.76 | 090 |
| 27496 | | A | Decompression of thigh/knee | 6.10 | NA | 5.85 | 0.96 | NA | 12.91 | 090 |
| 27497 | | A | Decompression of thigh/knee | 7.16 | NA | 5.77 | 1.00 | NA | 13.93 | 090 |
| 27498 | | A | Decompression of thigh/knee | 7.98 | NA | 6.16 | 1.27 | NA | 15.41 | 090 |
| 27499 | | A | Decompression of thigh/knee | 8.99 | NA | 7.12 | 1.32 | NA | 17.43 | 090 |
| 27500 | | A | Treatment of thigh fracture | 5.91 | 6.11 | 4.99 | 0.95 | 12.97 | 11.85 | 090 |
| 27501 | | A | Treatment of thigh fracture | 5.91 | 6.02 | 5.38 | 1.01 | 12.94 | 12.30 | 090 |
| 27502 | | A | Treatment of thigh fracture | 10.56 | NA | 8.35 | 1.73 | NA | 20.64 | 090 |
| 27503 | | A | Treatment of thigh fracture | 10.56 | NA | 8.52 | 1.80 | NA | 20.88 | 090 |
| 27506 | | A | Treatment of thigh fracture | 17.42 | NA | 12.93 | 2.83 | NA | 33.18 | 090 |
| 27507 | | A | Treatment of thigh fracture | 13.97 | NA | 10.04 | 2.24 | NA | 26.25 | 090 |
| 27508 | | A | Treatment of thigh fracture | 5.82 | 6.45 | 5.48 | 0.95 | 13.22 | 12.25 | 090 |
| 27509 | | A | Treatment of thigh fracture | 7.70 | NA | 8.03 | 1.30 | NA | 17.03 | 090 |
| 27510 | | A | Treatment of thigh fracture | 9.12 | NA | 7.34 | 1.54 | NA | 18.00 | 090 |
| 27511 | | A | Treatment of thigh fracture | 13.62 | NA | 11.29 | 2.20 | NA | 27.11 | 090 |
| 27513 | | A | Treatment of thigh fracture | 17.89 | NA | 13.95 | 2.91 | NA | 34.75 | 090 |
| 27514 | | A | Treatment of thigh fracture | 17.27 | NA | 13.42 | 2.76 | NA | 33.45 | 090 |
| 27516 | | A | Treat thigh fx growth plate | 5.36 | 6.35 | 5.51 | 0.89 | 12.60 | 11.76 | 090 |
| 27517 | | A | Treat thigh fx growth plate | 8.77 | NA | 7.44 | 1.28 | NA | 17.49 | 090 |
| 27519 | | A | Treat thigh fx growth plate | 15.00 | NA | 11.71 | 2.42 | NA | 29.13 | 090 |
| 27520 | | A | Treat kneecap fracture | 2.86 | 4.54 | 3.46 | 0.44 | 7.84 | 6.76 | 090 |
| 27524 | | A | Treat kneecap fracture | 9.99 | NA | 8.31 | 1.62 | NA | 19.92 | 090 |
| 27530 | | A | Treat knee fracture | 3.77 | 5.31 | 4.43 | 0.62 | 9.70 | 8.82 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 27532 | | A | Treat knee fracture | 7.29 | 7.35 | 6.45 | 1.25 | 15.89 | 14.99 | 090 |
| 27535 | | A | Treat knee fracture | 11.48 | NA | 10.20 | 1.78 | NA | 23.46 | 090 |
| 27536 | | A | Treat knee fracture | 15.63 | NA | 11.67 | 2.56 | NA | 29.86 | 090 |
| 27538 | | A | Treat knee fracture(s) | 4.86 | 6.13 | 5.20 | 0.81 | 11.80 | 10.87 | 090 |
| 27540 | | A | Treat knee fracture | 13.08 | NA | 9.60 | 2.11 | NA | 24.79 | 090 |
| 27550 | | A | Treat knee dislocation | 5.75 | 6.02 | 4.96 | 0.73 | 12.50 | 11.44 | 090 |
| 27552 | | A | Treat knee dislocation | 7.89 | NA | 7.08 | 1.34 | NA | 16.31 | 090 |
| 27556 | | A | Treat knee dislocation | 14.39 | NA | 11.79 | 2.32 | NA | 28.50 | 090 |
| 27557 | | A | Treat knee dislocation | 16.74 | NA | 13.25 | 2.83 | NA | 32.82 | 090 |
| 27558 | | A | Treat knee dislocation | 17.69 | NA | 13.18 | 2.82 | NA | 33.69 | 090 |
| 27560 | | A | Treat kneecap dislocation | 3.81 | 4.84 | 3.24 | 0.39 | 9.04 | 7.44 | 090 |
| 27562 | | A | Treat kneecap dislocation | 5.78 | NA | 4.88 | 0.75 | NA | 11.41 | 090 |
| 27566 | | A | Treat kneecap dislocation | 12.21 | NA | 9.41 | 2.03 | NA | 23.65 | 090 |
| 27570 | | A | Fixation of knee joint | 1.74 | NA | 1.77 | 0.30 | NA | 3.81 | 010 |
| 27580 | | A | Fusion of knee | 19.34 | NA | 14.85 | 3.09 | NA | 37.28 | 090 |
| 27590 | | A | Amputate leg at thigh | 12.01 | NA | 7.08 | 1.68 | NA | 20.77 | 090 |
| 27591 | | A | Amputate leg at thigh | 12.66 | NA | 9.04 | 1.95 | NA | 23.65 | 090 |
| 27592 | | A | Amputate leg at thigh | 10.00 | NA | 6.61 | 1.41 | NA | 18.02 | 090 |
| 27594 | | A | Amputation follow-up surgery | 6.91 | NA | 5.49 | 1.02 | NA | 13.42 | 090 |
| 27596 | | A | Amputation follow-up surgery | 10.58 | NA | 7.27 | 1.55 | NA | 19.40 | 090 |
| 27598 | | A | Amputate lower leg at knee | 10.51 | NA | 7.40 | 1.48 | NA | 19.39 | 090 |
| 27600 | | A | Decompression of lower leg | 5.64 | NA | 4.76 | 0.84 | NA | 11.24 | 090 |
| 27601 | | A | Decompression of lower leg | 5.63 | NA | 5.09 | 0.86 | NA | 11.58 | 090 |
| 27602 | | A | Decompression of lower leg | 7.34 | NA | 5.32 | 1.06 | NA | 13.72 | 090 |
| 27603 | | A | Drain lower leg lesion | 4.93 | 7.53 | 4.17 | 0.71 | 13.17 | 9.81 | 090 |
| 27604 | | A | Drain lower leg bursa | 4.46 | 6.10 | 3.96 | 0.67 | 11.23 | 9.09 | 090 |
| 27605 | | A | Incision of achilles tendon | 2.87 | 7.67 | 2.32 | 0.36 | 10.90 | 5.55 | 010 |
| 27606 | | A | Incision of achilles tendon | 4.13 | NA | 3.36 | 0.66 | NA | 8.15 | 010 |
| 27607 | | A | Treat lower leg bone lesion | 7.96 | NA | 6.89 | 1.25 | NA | 16.10 | 090 |
| 27610 | | A | Explore/treat ankle joint | 8.33 | NA | 7.28 | 1.34 | NA | 16.95 | 090 |
| 27612 | | A | Exploration of ankle joint | 7.32 | NA | 6.31 | 0.97 | NA | 14.60 | 090 |
| 27613 | | A | Biopsy lower leg soft tissue | 2.17 | 3.24 | 1.80 | 0.22 | 5.63 | 4.19 | 010 |
| 27614 | | A | Biopsy lower leg soft tissue | 5.65 | 7.15 | 4.44 | 0.75 | 13.55 | 10.84 | 090 |
| 27615 | | A | Remove tumor, lower leg | 12.54 | NA | 10.73 | 1.75 | NA | 25.02 | 090 |
| 27618 | | A | Remove lower leg lesion | 5.08 | 6.03 | 4.00 | 0.68 | 11.79 | 9.76 | 090 |
| 27619 | | A | Remove lower leg lesion | 8.39 | 9.53 | 5.95 | 1.16 | 19.08 | 15.50 | 090 |
| 27620 | | A | Explore/treat ankle joint | 5.97 | NA | 5.68 | 0.87 | NA | 12.52 | 090 |
| 27625 | | A | Remove ankle joint lining | 8.29 | NA | 6.75 | 1.14 | NA | 16.18 | 090 |
| 27626 | | A | Remove ankle joint lining | 8.90 | NA | 7.21 | 1.33 | NA | 17.44 | 090 |
| 27630 | | A | Removal of tendon lesion | 4.79 | 7.60 | 4.38 | 0.67 | 13.06 | 9.84 | 090 |
| 27635 | | A | Remove lower leg bone lesion | 7.77 | NA | 7.09 | 1.25 | NA | 16.11 | 090 |
| 27637 | | A | Remove/graft leg bone lesion | 9.84 | NA | 8.61 | 1.61 | NA | 20.06 | 090 |
| 27638 | | A | Remove/graft leg bone lesion | 10.55 | NA | 8.63 | 1.70 | NA | 20.88 | 090 |
| 27640 | | A | Partial removal of tibia | 11.35 | NA | 11.05 | 1.78 | NA | 24.18 | 090 |
| 27641 | | A | Partial removal of fibula | 9.23 | NA | 9.03 | 1.39 | NA | 19.65 | 090 |
| 27645 | | A | Extensive lower leg surgery | 14.15 | NA | 12.52 | 2.12 | NA | 28.79 | 090 |
| 27646 | | A | Extensive lower leg surgery | 12.64 | NA | 11.52 | 1.83 | NA | 25.99 | 090 |
| 27647 | | A | Extensive ankle/heel surgery | 12.22 | NA | 8.03 | 1.23 | NA | 21.48 | 090 |
| 27648 | | A | Injection for ankle x-ray | 0.96 | 3.57 | 0.33 | 0.07 | 4.60 | 1.36 | 000 |
| 27650 | | A | Repair achilles tendon | 9.68 | NA | 7.69 | 1.44 | NA | 18.81 | 090 |
| 27652 | | A | Repair/graft achilles tendon | 10.31 | NA | 8.20 | 1.51 | NA | 20.02 | 090 |
| 27654 | | A | Repair of achilles tendon | 10.00 | NA | 7.43 | 1.32 | NA | 18.75 | 090 |
| 27656 | | A | Repair leg fascia defect | 4.56 | 8.58 | 3.78 | 0.62 | 13.76 | 8.96 | 090 |
| 27658 | | A | Repair of leg tendon, each | 4.97 | NA | 4.56 | 0.70 | NA | 10.23 | 090 |
| 27659 | | A | Repair of leg tendon, each | 6.80 | NA | 5.64 | 0.97 | NA | 13.41 | 090 |
| 27664 | | A | Repair of leg tendon, each | 4.58 | NA | 4.55 | 0.68 | NA | 9.81 | 090 |
| 27665 | | A | Repair of leg tendon, each | 5.39 | NA | 4.97 | 0.82 | NA | 11.18 | 090 |
| 27675 | | A | Repair lower leg tendons | 7.17 | NA | 5.97 | 0.94 | NA | 14.08 | 090 |
| 27676 | | A | Repair lower leg tendons | 8.41 | NA | 6.96 | 0.91 | NA | 16.28 | 090 |
| 27680 | | A | Release of lower leg tendon | 5.73 | NA | 5.37 | 0.87 | NA | 11.97 | 090 |
| 27681 | | A | Release of lower leg tendons | 6.81 | NA | 6.15 | 1.06 | NA | 14.02 | 090 |
| 27685 | | A | Revision of lower leg tendon | 6.49 | 7.29 | 5.46 | 0.82 | 14.60 | 12.77 | 090 |
| 27686 | | A | Revise lower leg tendons | 7.45 | NA | 6.48 | 1.21 | NA | 15.14 | 090 |
| 27687 | | A | Revision of calf tendon | 6.23 | NA | 5.62 | 0.89 | NA | 12.74 | 090 |
| 27690 | | A | Revise lower leg tendon | 8.70 | NA | 6.65 | 1.16 | NA | 16.51 | 090 |
| 27691 | | A | Revise lower leg tendon | 9.95 | NA | 8.02 | 1.46 | NA | 19.43 | 090 |
| 27692 | | A | Revise additional leg tendon | 1.87 | NA | 0.92 | 0.28 | NA | 3.07 | ZZZ |
| 27695 | | A | Repair of ankle ligament | 6.50 | NA | 6.14 | 1.01 | NA | 13.65 | 090 |
| 27696 | | A | Repair of ankle ligaments | 8.26 | NA | 6.71 | 1.10 | NA | 16.07 | 090 |
| 27698 | | A | Repair of ankle ligament | 9.35 | NA | 7.16 | 1.29 | NA | 17.80 | 090 |
| 27700 | | A | Revision of ankle joint | 9.28 | NA | 5.67 | 1.03 | NA | 15.98 | 090 |
| 27702 | | A | Reconstruct ankle joint | 13.65 | NA | 10.44 | 2.15 | NA | 26.24 | 090 |
| 27703 | | A | Reconstruction, ankle joint | 15.85 | NA | 11.21 | 2.48 | NA | 29.54 | 090 |
| 27704 | | A | Removal of ankle implant | 7.61 | NA | 5.59 | 1.22 | NA | 14.42 | 090 |
| 27705 | | A | Incision of tibia | 10.36 | NA | 8.45 | 1.60 | NA | 20.41 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 27707 | | A | Incision of fibula | 4.36 | NA | 5.24 | 0.74 | NA | 10.34 | 090 |
| 27709 | | A | Incision of tibia & fibula | 9.94 | NA | 8.39 | 1.54 | NA | 19.87 | 090 |
| 27712 | | A | Realignment of lower leg | 14.23 | NA | 10.97 | 2.22 | NA | 27.42 | 090 |
| 27715 | | A | Revision of lower leg | 14.37 | NA | 11.09 | 2.38 | NA | 27.84 | 090 |
| 27720 | | A | Repair of tibia | 11.77 | NA | 9.71 | 1.90 | NA | 23.38 | 090 |
| 27722 | | A | Repair/graft of tibia | 11.80 | NA | 9.46 | 1.94 | NA | 23.20 | 090 |
| 27724 | | A | Repair/graft of tibia | 18.17 | NA | 12.68 | 2.93 | NA | 33.78 | 090 |
| 27725 | | A | Repair of lower leg | 15.57 | NA | 12.18 | 2.53 | NA | 30.28 | 090 |
| 27727 | | A | Repair of lower leg | 13.99 | NA | 10.68 | 2.22 | NA | 26.89 | 090 |
| 27730 | | A | Repair of tibia epiphysis | 7.40 | NA | 6.42 | 1.29 | NA | 15.11 | 090 |
| 27732 | | A | Repair of fibula epiphysis | 5.31 | NA | 4.93 | 0.57 | NA | 10.81 | 090 |
| 27734 | | A | Repair lower leg epiphyses | 8.47 | NA | 6.61 | 0.68 | NA | 15.76 | 090 |
| 27740 | | A | Repair of leg epiphyses | 9.29 | NA | 7.98 | 1.58 | NA | 18.85 | 090 |
| 27742 | | A | Repair of leg epiphyses | 10.28 | 3.88 | 3.88 | 0.68 | 14.84 | 14.84 | 090 |
| 27745 | | A | Reinforce tibia | 10.05 | NA | 8.44 | 1.70 | NA | 20.19 | 090 |
| 27750 | | A | Treatment of tibia fracture | 3.19 | 4.76 | 3.86 | 0.51 | 8.46 | 7.56 | 090 |
| 27752 | | A | Treatment of tibia fracture | 5.83 | 6.64 | 5.66 | 0.99 | 13.46 | 12.48 | 090 |
| 27756 | | A | Treatment of tibia fracture | 6.77 | NA | 6.79 | 1.09 | NA | 14.65 | 090 |
| 27758 | | A | Treatment of tibia fracture | 11.65 | NA | 9.41 | 1.82 | NA | 22.88 | 090 |
| 27759 | | A | Treatment of tibia fracture | 13.74 | NA | 10.54 | 2.23 | NA | 26.51 | 090 |
| 27760 | | A | Treatment of ankle fracture | 3.01 | 4.68 | 3.62 | 0.44 | 8.13 | 7.07 | 090 |
| 27762 | | A | Treatment of ankle fracture | 5.24 | 6.33 | 5.27 | 0.80 | 12.37 | 11.31 | 090 |
| 27766 | | A | Treatment of ankle fracture | 8.35 | NA | 7.36 | 1.41 | NA | 17.12 | 090 |
| 27780 | | A | Treatment of fibula fracture | 2.65 | 4.19 | 3.24 | 0.39 | 7.23 | 6.28 | 090 |
| 27781 | | A | Treatment of fibula fracture | 4.39 | 5.49 | 4.64 | 0.71 | 10.59 | 9.74 | 090 |
| 27784 | | A | Treatment of fibula fracture | 7.10 | NA | 6.65 | 1.18 | NA | 14.93 | 090 |
| 27786 | | A | Treatment of ankle fracture | 2.84 | 4.46 | 3.36 | 0.43 | 7.73 | 6.63 | 090 |
| 27788 | | A | Treatment of ankle fracture | 4.44 | 5.63 | 4.65 | 0.71 | 10.78 | 9.80 | 090 |
| 27792 | | A | Treatment of ankle fracture | 7.65 | NA | 7.10 | 1.28 | NA | 16.03 | 090 |
| 27808 | | A | Treatment of ankle fracture | 2.83 | 4.80 | 3.71 | 0.44 | 8.07 | 6.98 | 090 |
| 27810 | | A | Treatment of ankle fracture | 5.12 | 6.23 | 5.15 | 0.81 | 12.16 | 11.08 | 090 |
| 27814 | | A | Treatment of ankle fracture | 10.66 | NA | 8.75 | 1.71 | NA | 21.12 | 090 |
| 27816 | | A | Treatment of ankle fracture | 2.89 | 4.39 | 3.43 | 0.41 | 7.69 | 6.73 | 090 |
| 27818 | | A | Treatment of ankle fracture | 5.49 | 6.37 | 5.17 | 0.80 | 12.66 | 11.46 | 090 |
| 27822 | | A | Treatment of ankle fracture | 10.98 | NA | 10.80 | 1.79 | NA | 23.57 | 090 |
| 27823 | | A | Treatment of ankle fracture | 12.98 | NA | 11.64 | 2.11 | NA | 26.73 | 090 |
| 27824 | | A | Treat lower leg fracture | 2.89 | 4.59 | 3.57 | 0.44 | 7.92 | 6.90 | 090 |
| 27825 | | A | Treat lower leg fracture | 6.18 | 6.59 | 5.37 | 1.00 | 13.77 | 12.55 | 090 |
| 27826 | | A | Treat lower leg fracture | 8.53 | NA | 9.01 | 1.36 | NA | 18.90 | 090 |
| 27827 | | A | Treat lower leg fracture | 14.04 | NA | 12.90 | 2.31 | NA | 29.25 | 090 |
| 27828 | | A | Treat lower leg fracture | 16.21 | NA | 14.06 | 2.65 | NA | 32.92 | 090 |
| 27829 | | A | Treat lower leg joint | 5.48 | NA | 6.92 | 0.89 | NA | 13.29 | 090 |
| 27830 | | A | Treat lower leg dislocation | 3.78 | 4.41 | 3.87 | 0.49 | 8.68 | 8.14 | 090 |
| 27831 | | A | Treat lower leg dislocation | 4.55 | NA | 4.58 | 0.75 | NA | 9.88 | 090 |
| 27832 | | A | Treat lower leg dislocation | 6.48 | NA | 6.36 | 1.07 | NA | 13.91 | 090 |
| 27840 | | A | Treat ankle dislocation | 4.57 | NA | 3.91 | 0.45 | NA | 8.93 | 090 |
| 27842 | | A | Treat ankle dislocation | 6.20 | NA | 5.18 | 0.92 | NA | 12.30 | 090 |
| 27846 | | A | Treat ankle dislocation | 9.78 | NA | 8.12 | 1.61 | NA | 19.51 | 090 |
| 27848 | | A | Treat ankle dislocation | 11.18 | NA | 9.84 | 1.74 | NA | 22.76 | 090 |
| 27860 | | A | Fixation of ankle joint | 2.34 | NA | 1.98 | 0.37 | NA | 4.69 | 010 |
| 27870 | | A | Fusion of ankle joint, open | 13.89 | NA | 10.75 | 2.04 | NA | 26.68 | 090 |
| 27871 | | A | Fusion of tibiofibular joint | 9.16 | NA | 7.85 | 1.47 | NA | 18.48 | 090 |
| 27880 | | A | Amputation of lower leg | 11.83 | NA | 7.48 | 1.67 | NA | 20.98 | 090 |
| 27881 | | A | Amputation of lower leg | 12.32 | NA | 9.16 | 1.89 | NA | 23.37 | 090 |
| 27882 | | A | Amputation of lower leg | 8.93 | NA | 6.90 | 1.26 | NA | 17.09 | 090 |
| 27884 | | A | Amputation follow-up surgery | 8.20 | NA | 6.15 | 1.21 | NA | 15.56 | 090 |
| 27886 | | A | Amputation follow-up surgery | 9.31 | NA | 6.89 | 1.38 | NA | 17.58 | 090 |
| 27888 | | A | Amputation of foot at ankle | 9.66 | NA | 7.76 | 1.43 | NA | 18.85 | 090 |
| 27889 | | A | Amputation of foot at ankle | 9.97 | NA | 6.76 | 1.40 | NA | 18.13 | 090 |
| 27892 | | A | Decompression of leg | 7.38 | NA | 5.92 | 1.01 | NA | 14.31 | 090 |
| 27893 | | A | Decompression of leg | 7.34 | NA | 5.83 | 1.08 | NA | 14.25 | 090 |
| 27894 | | A | Decompression of leg | 10.47 | NA | 8.01 | 1.58 | NA | 20.06 | 090 |
| 28001 | | A | Drainage of bursa of foot | 2.73 | 2.98 | 1.95 | 0.23 | 5.94 | 4.91 | 010 |
| 28002 | | A | Treatment of foot infection | 4.61 | 4.99 | 3.76 | 0.51 | 10.11 | 8.88 | 010 |
| 28003 | | A | Treatment of foot infection | 8.40 | 6.24 | 5.22 | 0.93 | 15.57 | 14.55 | 090 |
| 28005 | | A | Treat foot bone lesion | 8.67 | NA | 6.57 | 0.95 | NA | 16.19 | 090 |
| 28008 | | A | Incision of foot fascia | 4.44 | 4.56 | 3.21 | 0.43 | 9.43 | 8.08 | 090 |
| 28010 | | A | Incision of toe tendon | 2.84 | 2.38 | 2.38 | 0.27 | 5.49 | 5.49 | 090 |
| 28011 | | A | Incision of toe tendons | 4.13 | NA | 3.30 | 0.47 | NA | 7.90 | 090 |
| 28020 | | A | Exploration of foot joint | 5.00 | 6.03 | 4.13 | 0.64 | 11.67 | 9.77 | 090 |
| 28022 | | A | Exploration of foot joint | 4.66 | 5.20 | 3.85 | 0.49 | 10.35 | 9.00 | 090 |
| 28024 | | A | Exploration of toe joint | 4.37 | 5.22 | 3.92 | 0.43 | 10.02 | 8.72 | 090 |
| 28030 | | A | Removal of foot nerve | 6.14 | NA | 3.61 | 0.55 | NA | 10.30 | 090 |
| 28035 | | A | Decompression of tibia nerve | 5.08 | 5.85 | 4.09 | 0.57 | 11.50 | 9.74 | 090 |
| 28043 | | A | Excision of foot lesion | 3.53 | 3.82 | 3.17 | 0.37 | 7.72 | 7.07 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 28045 | | A | Excision of foot lesion | 4.71 | 5.38 | 3.60 | 0.49 | 10.58 | 8.80 | 090 |
| 28046 | | A | Resection of tumor, foot | 10.16 | 8.76 | 6.47 | 1.17 | 20.09 | 17.80 | 090 |
| 28050 | | A | Biopsy of foot joint lining | 4.24 | 4.89 | 3.59 | 0.55 | 9.68 | 8.38 | 090 |
| 28052 | | A | Biopsy of foot joint lining | 3.93 | 4.92 | 3.43 | 0.42 | 9.27 | 7.78 | 090 |
| 28054 | | A | Biopsy of toe joint lining | 3.44 | 4.73 | 3.22 | 0.34 | 8.51 | 7.00 | 090 |
| 28060 | | A | Partial removal, foot fascia | 5.22 | 5.47 | 3.87 | 0.53 | 11.22 | 9.62 | 090 |
| 28062 | | A | Removal of foot fascia | 6.51 | 6.53 | 4.01 | 0.61 | 13.65 | 11.13 | 090 |
| 28070 | | A | Removal of foot joint lining | 5.09 | 5.22 | 3.81 | 0.56 | 10.87 | 9.46 | 090 |
| 28072 | | A | Removal of foot joint lining | 4.57 | 5.53 | 4.29 | 0.63 | 10.73 | 9.49 | 090 |
| 28080 | | A | Removal of foot lesion | 3.57 | 5.12 | 3.68 | 0.35 | 9.04 | 7.60 | 090 |
| 28086 | | A | Excise foot tendon sheath | 4.77 | 7.98 | 4.68 | 0.69 | 13.44 | 10.14 | 090 |
| 28088 | | A | Excise foot tendon sheath | 3.85 | 5.76 | 3.89 | 0.51 | 10.12 | 8.25 | 090 |
| 28090 | | A | Removal of foot lesion | 4.40 | 5.15 | 3.44 | 0.46 | 10.01 | 8.30 | 090 |
| 28092 | | A | Removal of toe lesions | 3.63 | 5.22 | 3.52 | 0.40 | 9.25 | 7.55 | 090 |
| 28100 | | A | Removal of ankle/heel lesion | 5.65 | 7.98 | 4.69 | 0.70 | 14.33 | 11.04 | 090 |
| 28102 | | A | Remove/graft foot lesion | 7.72 | NA | 6.24 | 0.88 | NA | 14.84 | 090 |
| 28103 | | A | Remove/graft foot lesion | 6.49 | NA | 4.61 | 0.70 | NA | 11.80 | 090 |
| 28104 | | A | Removal of foot lesion | 5.11 | 5.49 | 3.92 | 0.56 | 11.16 | 9.59 | 090 |
| 28106 | | A | Remove/graft foot lesion | 7.15 | NA | 4.75 | 0.64 | NA | 12.54 | 090 |
| 28107 | | A | Remove/graft foot lesion | 5.55 | 6.54 | 4.20 | 0.54 | 12.63 | 10.29 | 090 |
| 28108 | | A | Removal of toe lesions | 4.15 | 4.59 | 3.25 | 0.37 | 9.11 | 7.77 | 090 |
| 28110 | | A | Part removal of metatarsal | 4.07 | 5.22 | 3.22 | 0.41 | 9.70 | 7.70 | 090 |
| 28111 | | A | Part removal of metatarsal | 5.00 | 6.28 | 3.65 | 0.55 | 11.83 | 9.20 | 090 |
| 28112 | | A | Part removal of metatarsal | 4.48 | 5.80 | 3.56 | 0.51 | 10.79 | 8.55 | 090 |
| 28113 | | A | Part removal of metatarsal | 4.78 | 6.07 | 4.32 | 0.49 | 11.34 | 9.59 | 090 |
| 28114 | | A | Removal of metatarsal heads | 9.78 | 11.63 | 8.37 | 1.23 | 22.64 | 19.38 | 090 |
| 28116 | | A | Revision of foot | 7.74 | 6.80 | 5.17 | 0.83 | 15.37 | 13.74 | 090 |
| 28118 | | A | Removal of heel bone | 5.95 | 6.25 | 4.34 | 0.69 | 12.89 | 10.98 | 090 |
| 28119 | | A | Removal of heel spur | 5.38 | 5.43 | 3.72 | 0.52 | 11.33 | 9.62 | 090 |
| 28120 | | A | Part removal of ankle/heel | 5.39 | 7.30 | 4.41 | 0.66 | 13.35 | 10.46 | 090 |
| 28122 | | A | Partial removal of foot bone | 7.28 | 6.84 | 5.26 | 0.76 | 14.88 | 13.30 | 090 |
| 28124 | | A | Partial removal of toe | 4.80 | 5.00 | 3.65 | 0.42 | 10.22 | 8.87 | 090 |
| 28126 | | A | Partial removal of toe | 3.51 | 4.21 | 2.99 | 0.32 | 8.04 | 6.82 | 090 |
| 28130 | | A | Removal of ankle bone | 8.10 | NA | 6.92 | 1.12 | NA | 16.14 | 090 |
| 28140 | | A | Removal of metatarsal | 6.90 | 7.22 | 4.76 | 0.79 | 14.91 | 12.45 | 090 |
| 28150 | | A | Removal of toe | 4.08 | 4.84 | 3.28 | 0.41 | 9.33 | 7.77 | 090 |
| 28153 | | A | Partial removal of toe | 3.65 | 4.31 | 2.68 | 0.34 | 8.30 | 6.67 | 090 |
| 28160 | | A | Partial removal of toe | 3.73 | 4.57 | 3.33 | 0.37 | 8.67 | 7.43 | 090 |
| 28171 | | A | Extensive foot surgery | 9.59 | NA | 5.86 | 0.83 | NA | 16.28 | 090 |
| 28173 | | A | Extensive foot surgery | 8.79 | 7.59 | 5.19 | 0.85 | 17.23 | 14.83 | 090 |
| 28175 | | A | Extensive foot surgery | 6.04 | 5.70 | 3.70 | 0.53 | 12.27 | 10.27 | 090 |
| 28190 | | A | Removal of foot foreign body | 1.96 | 3.40 | 1.49 | 0.17 | 5.53 | 3.62 | 010 |
| 28192 | | A | Removal of foot foreign body | 4.63 | 5.49 | 3.64 | 0.46 | 10.58 | 8.73 | 090 |
| 28193 | | A | Removal of foot foreign body | 5.72 | 5.61 | 3.93 | 0.56 | 11.89 | 10.21 | 090 |
| 28200 | | A | Repair of foot tendon | 4.59 | 5.10 | 3.55 | 0.48 | 10.17 | 8.62 | 090 |
| 28202 | | A | Repair/graft of foot tendon | 6.83 | 7.40 | 4.49 | 0.64 | 14.87 | 11.96 | 090 |
| 28208 | | A | Repair of foot tendon | 4.36 | 4.82 | 3.30 | 0.42 | 9.60 | 8.08 | 090 |
| 28210 | | A | Repair/graft of foot tendon | 6.34 | 6.22 | 4.02 | 0.64 | 13.20 | 11.00 | 090 |
| 28220 | | A | Release of foot tendon | 4.52 | 4.67 | 3.42 | 0.40 | 9.59 | 8.34 | 090 |
| 28222 | | A | Release of foot tendons | 5.61 | 5.24 | 4.12 | 0.49 | 11.34 | 10.22 | 090 |
| 28225 | | A | Release of foot tendon | 3.65 | 4.28 | 2.90 | 0.33 | 8.26 | 6.88 | 090 |
| 28226 | | A | Release of foot tendons | 4.52 | 4.80 | 3.74 | 0.45 | 9.77 | 8.71 | 090 |
| 28230 | | A | Incision of foot tendon(s) | 4.23 | 4.67 | 3.66 | 0.42 | 9.32 | 8.31 | 090 |
| 28232 | | A | Incision of toe tendon | 3.38 | 4.53 | 3.31 | 0.34 | 8.25 | 7.03 | 090 |
| 28234 | | A | Incision of foot tendon | 3.36 | 4.68 | 3.35 | 0.34 | 8.38 | 7.05 | 090 |
| 28238 | | A | Revision of foot tendon | 7.72 | 7.25 | 4.93 | 0.81 | 15.78 | 13.46 | 090 |
| 28240 | | A | Release of big toe | 4.35 | 4.64 | 3.48 | 0.45 | 9.44 | 8.28 | 090 |
| 28250 | | A | Revision of foot fascia | 5.91 | 5.63 | 4.13 | 0.68 | 12.22 | 10.72 | 090 |
| 28260 | | A | Release of midfoot joint | 7.95 | 6.34 | 4.99 | 0.92 | 15.21 | 13.86 | 090 |
| 28261 | | A | Revision of foot tendon | 11.71 | 8.62 | 7.29 | 1.12 | 21.45 | 20.12 | 090 |
| 28262 | | A | Revision of foot and ankle | 15.81 | 13.56 | 10.90 | 2.43 | 31.80 | 29.14 | 090 |
| 28264 | | A | Release of midfoot joint | 10.33 | 7.74 | 7.28 | 1.28 | 19.35 | 18.89 | 090 |
| 28270 | | A | Release of foot contracture | 4.75 | 4.89 | 3.73 | 0.46 | 10.10 | 8.94 | 090 |
| 28272 | | A | Release of toe joint, each | 3.79 | 4.18 | 2.85 | 0.31 | 8.28 | 6.95 | 090 |
| 28280 | | A | Fusion of toes | 5.18 | 6.25 | 4.48 | 0.63 | 12.06 | 10.29 | 090 |
| 28285 | | A | Repair of hammertoe | 4.58 | 4.87 | 3.42 | 0.44 | 9.89 | 8.44 | 090 |
| 28286 | | A | Repair of hammertoe | 4.55 | 4.79 | 3.25 | 0.41 | 9.75 | 8.21 | 090 |
| 28288 | | A | Partial removal of foot bone | 4.73 | 5.94 | 4.88 | 0.53 | 11.20 | 10.14 | 090 |
| 28289 | | A | Repair hallux rigidus | 7.03 | 7.98 | 5.75 | 0.87 | 15.88 | 13.65 | 090 |
| 28290 | | A | Correction of bunion | 5.65 | 6.26 | 4.72 | 0.69 | 12.60 | 11.06 | 090 |
| 28292 | | A | Correction of bunion | 7.03 | 7.48 | 5.54 | 0.67 | 15.18 | 13.24 | 090 |
| 28293 | | A | Correction of bunion | 9.14 | 10.63 | 6.10 | 0.79 | 20.56 | 16.03 | 090 |
| 28294 | | A | Correction of bunion | 8.55 | 7.45 | 4.72 | 0.81 | 16.81 | 14.08 | 090 |
| 28296 | | A | Correction of bunion | 9.17 | 8.16 | 5.41 | 0.88 | 18.21 | 15.46 | 090 |
| 28297 | | A | Correction of bunion | 9.17 | 8.95 | 6.25 | 1.08 | 19.20 | 16.50 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 28298 | | A | Correction of bunion | 7.93 | 7.23 | 5.00 | 0.80 | 15.96 | 13.73 | 090 |
| 28299 | | A | Correction of bunion | 10.56 | 8.77 | 6.06 | 1.01 | 20.34 | 17.63 | 090 |
| 28300 | | A | Incision of heel bone | 9.53 | NA | 7.02 | 1.36 | NA | 17.91 | 090 |
| 28302 | | A | Incision of ankle bone | 9.54 | NA | 6.88 | 1.59 | NA | 18.01 | 090 |
| 28304 | | A | Incision of midfoot bones | 9.15 | 8.37 | 5.93 | 1.05 | 18.57 | 16.13 | 090 |
| 28305 | | A | Incise/graft midfoot bones | 10.48 | 4.63 | 4.63 | 0.87 | 15.98 | 15.98 | 090 |
| 28306 | | A | Incision of metatarsal | 5.85 | 7.37 | 4.41 | 0.69 | 13.91 | 10.95 | 090 |
| 28307 | | A | Incision of metatarsal | 6.32 | 11.75 | 5.49 | 0.82 | 18.89 | 12.63 | 090 |
| 28308 | | A | Incision of metatarsal | 5.28 | 6.27 | 3.90 | 0.53 | 12.08 | 9.71 | 090 |
| 28309 | | A | Incision of metatarsals | 12.76 | NA | 8.22 | 1.70 | NA | 22.68 | 090 |
| 28310 | | A | Revision of big toe | 5.42 | 6.48 | 4.13 | 0.53 | 12.43 | 10.08 | 090 |
| 28312 | | A | Revision of toe | 4.54 | 6.21 | 4.28 | 0.51 | 11.26 | 9.33 | 090 |
| 28313 | | A | Repair deformity of toe | 5.00 | 6.67 | 5.64 | 0.63 | 12.30 | 11.27 | 090 |
| 28315 | | A | Removal of sesamoid bone | 4.85 | 6.03 | 3.80 | 0.46 | 11.34 | 9.11 | 090 |
| 28320 | | A | Repair of foot bones | 9.17 | NA | 6.93 | 1.27 | NA | 17.37 | 090 |
| 28322 | | A | Repair of metatarsals | 8.33 | 10.27 | 6.50 | 1.16 | 19.76 | 15.99 | 090 |
| 28340 | | A | Resect enlarged toe tissue | 6.97 | 7.26 | 4.56 | 0.58 | 14.81 | 12.11 | 090 |
| 28341 | | A | Resect enlarged toe | 8.40 | 7.45 | 5.10 | 0.72 | 16.57 | 14.22 | 090 |
| 28344 | | A | Repair extra toe(s) | 4.25 | 6.93 | 3.86 | 0.51 | 11.69 | 8.62 | 090 |
| 28345 | | A | Repair webbed toe(s) | 5.91 | 7.19 | 4.97 | 0.54 | 13.64 | 11.42 | 090 |
| 28360 | | A | Reconstruct cleft foot | 13.32 | NA | 10.75 | 1.90 | NA | 25.97 | 090 |
| 28400 | | A | Treatment of heel fracture | 2.16 | 3.63 | 3.06 | 0.32 | 6.11 | 5.54 | 090 |
| 28405 | | A | Treatment of heel fracture | 4.56 | 4.83 | 4.61 | 0.71 | 10.10 | 9.88 | 090 |
| 28406 | | A | Treatment of heel fracture | 6.30 | NA | 6.98 | 1.03 | NA | 14.31 | 090 |
| 28415 | | A | Treat heel fracture | 15.95 | NA | 13.42 | 2.44 | NA | 31.81 | 090 |
| 28420 | | A | Treat/graft heel fracture | 16.62 | NA | 13.08 | 2.65 | NA | 32.35 | 090 |
| 28430 | | A | Treatment of ankle fracture | 2.09 | 3.39 | 2.58 | 0.29 | 5.77 | 4.96 | 090 |
| 28435 | | A | Treatment of ankle fracture | 3.39 | 3.90 | 3.74 | 0.48 | 7.77 | 7.61 | 090 |
| 28436 | | A | Treatment of ankle fracture | 4.70 | NA | 6.10 | 0.76 | NA | 11.56 | 090 |
| 28445 | | A | Treat ankle fracture | 15.60 | NA | 11.26 | 2.40 | NA | 29.26 | 090 |
| 28450 | | A | Treat midfoot fracture, each | 1.90 | 3.11 | 2.50 | 0.25 | 5.26 | 4.65 | 090 |
| 28455 | | A | Treat midfoot fracture, each | 3.09 | 3.43 | 3.43 | 0.41 | 6.93 | 6.93 | 090 |
| 28456 | | A | Treat midfoot fracture | 2.68 | NA | 4.38 | 0.43 | NA | 7.49 | 090 |
| 28465 | | A | Treat midfoot fracture, each | 7.00 | NA | 6.48 | 0.97 | NA | 14.45 | 090 |
| 28470 | | A | Treat metatarsal fracture | 1.99 | 3.12 | 2.46 | 0.27 | 5.38 | 4.72 | 090 |
| 28475 | | A | Treat metatarsal fracture | 2.97 | 3.33 | 3.21 | 0.38 | 6.68 | 6.56 | 090 |
| 28476 | | A | Treat metatarsal fracture | 3.37 | NA | 5.18 | 0.51 | NA | 9.06 | 090 |
| 28485 | | A | Treat metatarsal fracture | 5.70 | NA | 5.67 | 0.72 | NA | 12.09 | 090 |
| 28490 | | A | Treat big toe fracture | 1.09 | 2.01 | 1.67 | 0.12 | 3.22 | 2.88 | 090 |
| 28495 | | A | Treat big toe fracture | 1.58 | 2.18 | 2.08 | 0.16 | 3.92 | 3.82 | 090 |
| 28496 | | A | Treat big toe fracture | 2.33 | 9.78 | 3.77 | 0.31 | 12.42 | 6.41 | 090 |
| 28505 | | A | Treat big toe fracture | 3.80 | 9.77 | 4.81 | 0.49 | 14.06 | 9.10 | 090 |
| 28510 | | A | Treatment of toe fracture | 1.09 | 1.53 | 1.53 | 0.11 | 2.73 | 2.73 | 090 |
| 28515 | | A | Treatment of toe fracture | 1.46 | 1.89 | 1.89 | 0.14 | 3.49 | 3.49 | 090 |
| 28525 | | A | Treat toe fracture | 3.32 | 9.36 | 4.36 | 0.41 | 13.09 | 8.09 | 090 |
| 28530 | | A | Treat sesamoid bone fracture | 1.06 | 1.45 | 1.45 | 0.10 | 2.61 | 2.61 | 090 |
| 28531 | | A | Treat sesamoid bone fracture | 2.35 | 8.98 | 2.61 | 0.23 | 11.56 | 5.19 | 090 |
| 28540 | | A | Treat foot dislocation | 2.04 | 2.41 | 2.41 | 0.19 | 4.64 | 4.64 | 090 |
| 28545 | | A | Treat foot dislocation | 2.45 | 2.35 | 2.35 | 0.36 | 5.16 | 5.16 | 090 |
| 28546 | | A | Treat foot dislocation | 3.20 | 8.03 | 5.00 | 0.41 | 11.64 | 8.61 | 090 |
| 28555 | | A | Repair foot dislocation | 6.29 | 11.58 | 6.67 | 0.90 | 18.77 | 13.86 | 090 |
| 28570 | | A | Treat foot dislocation | 1.66 | 2.42 | 2.34 | 0.20 | 4.28 | 4.20 | 090 |
| 28575 | | A | Treat foot dislocation | 3.31 | 3.74 | 3.74 | 0.56 | 7.61 | 7.61 | 090 |
| 28576 | | A | Treat foot dislocation | 4.16 | 10.32 | 5.68 | 0.59 | 15.07 | 10.43 | 090 |
| 28585 | | A | Repair foot dislocation | 7.98 | 8.27 | 6.65 | 1.01 | 17.26 | 15.64 | 090 |
| 28600 | | A | Treat foot dislocation | 1.89 | 2.82 | 2.69 | 0.24 | 4.95 | 4.82 | 090 |
| 28605 | | A | Treat foot dislocation | 2.71 | 3.14 | 3.14 | 0.39 | 6.24 | 6.24 | 090 |
| 28606 | | A | Treat foot dislocation | 4.89 | 15.93 | 6.18 | 0.78 | 21.60 | 11.85 | 090 |
| 28615 | | A | Repair foot dislocation | 7.76 | NA | 8.16 | 1.21 | NA | 17.13 | 090 |
| 28630 | | A | Treat toe dislocation | 1.70 | 1.57 | 1.01 | 0.17 | 3.44 | 2.88 | 010 |
| 28635 | | A | Treat toe dislocation | 1.91 | 2.02 | 1.53 | 0.19 | 4.12 | 3.63 | 010 |
| 28636 | | A | Treat toe dislocation | 2.77 | 3.87 | 2.62 | 0.38 | 7.02 | 5.77 | 010 |
| 28645 | | A | Repair toe dislocation | 4.21 | 5.81 | 3.59 | 0.44 | 10.46 | 8.24 | 090 |
| 28660 | | A | Treat toe dislocation | 1.23 | 1.26 | 0.81 | 0.12 | 2.61 | 2.16 | 010 |
| 28665 | | A | Treat toe dislocation | 1.92 | NA | 1.43 | 0.22 | NA | 3.57 | 010 |
| 28666 | | A | Treat toe dislocation | 2.66 | 5.90 | 2.57 | 0.38 | 8.94 | 5.61 | 010 |
| 28675 | | A | Repair of toe dislocation | 2.92 | 8.85 | 3.88 | 0.40 | 12.17 | 7.20 | 090 |
| 28705 | | A | Fusion of foot bones | 18.77 | NA | 12.65 | 2.77 | NA | 34.19 | 090 |
| 28715 | | A | Fusion of foot bones | 13.08 | NA | 9.98 | 1.93 | NA | 24.99 | 090 |
| 28725 | | A | Fusion of foot bones | 11.59 | NA | 8.50 | 1.66 | NA | 21.75 | 090 |
| 28730 | | A | Fusion of foot bones | 10.74 | NA | 8.71 | 1.44 | NA | 20.89 | 090 |
| 28735 | | A | Fusion of foot bones | 10.83 | NA | 8.08 | 1.44 | NA | 20.35 | 090 |
| 28737 | | A | Revision of foot bones | 9.63 | NA | 7.07 | 1.12 | NA | 17.82 | 090 |
| 28740 | | A | Fusion of foot bones | 8.01 | 11.72 | 6.66 | 1.03 | 20.76 | 15.70 | 090 |
| 28750 | | A | Fusion of big toe joint | 7.29 | 13.06 | 6.84 | 1.04 | 21.39 | 15.17 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 28755 | | A | Fusion of big toe joint | 4.73 | 7.02 | 4.04 | 0.52 | 12.27 | 9.29 | 090 |
| 28760 | | A | Fusion of big toe joint | 7.74 | 8.24 | 5.81 | 0.81 | 16.79 | 14.36 | 090 |
| 28800 | | A | Amputation of midfoot | 8.20 | NA | 6.12 | 1.04 | NA | 15.36 | 090 |
| 28805 | | A | Amputation thru metatarsal | 8.38 | NA | 5.93 | 1.10 | NA | 15.41 | 090 |
| 28810 | | A | Amputation toe & metatarsal | 6.20 | NA | 4.78 | 0.81 | NA | 11.79 | 090 |
| 28820 | | A | Amputation of toe | 4.40 | 8.56 | 4.15 | 0.55 | 13.51 | 9.10 | 090 |
| 28825 | | A | Partial amputation of toe | 3.58 | 8.01 | 3.87 | 0.44 | 12.03 | 7.89 | 090 |
| 29000 | | A | Application of body cast | 2.25 | 3.00 | 1.73 | 0.47 | 5.72 | 4.45 | 000 |
| 29010 | | A | Application of body cast | 2.06 | 3.29 | 1.77 | 0.36 | 5.71 | 4.19 | 000 |
| 29015 | | A | Application of body cast | 2.41 | 2.97 | 1.60 | 0.26 | 5.64 | 4.27 | 000 |
| 29020 | | A | Application of body cast | 2.11 | 3.19 | 1.42 | 0.21 | 5.51 | 3.74 | 000 |
| 29025 | | A | Application of body cast | 2.40 | 3.19 | 1.84 | 0.44 | 6.03 | 4.68 | 000 |
| 29035 | | A | Application of body cast | 1.77 | 3.61 | 1.58 | 0.29 | 5.67 | 3.64 | 000 |
| 29040 | | A | Application of body cast | 2.22 | 2.49 | 1.52 | 0.18 | 4.89 | 3.92 | 000 |
| 29044 | | A | Application of body cast | 2.12 | 3.97 | 1.90 | 0.37 | 6.46 | 4.39 | 000 |
| 29046 | | A | Application of body cast | 2.41 | 3.27 | 2.08 | 0.40 | 6.08 | 4.89 | 000 |
| 29049 | | A | Application of figure eight | 0.89 | 1.30 | 0.53 | 0.11 | 2.30 | 1.53 | 000 |
| 29055 | | A | Application of shoulder cast | 1.78 | 2.98 | 1.47 | 0.28 | 5.04 | 3.53 | 000 |
| 29058 | | A | Application of shoulder cast | 1.31 | 1.56 | 0.73 | 0.16 | 3.03 | 2.20 | 000 |
| 29065 | | A | Application of long arm cast | 0.87 | 1.32 | 0.75 | 0.14 | 2.33 | 1.76 | 000 |
| 29075 | | A | Application of forearm cast | 0.77 | 1.26 | 0.68 | 0.12 | 2.15 | 1.57 | 000 |
| 29085 | | A | Apply hand/wrist cast | 0.87 | 1.28 | 0.63 | 0.13 | 2.28 | 1.63 | 000 |
| 29086 | | A | Apply finger cast | 0.62 | 0.96 | 0.50 | 0.08 | 1.66 | 1.20 | 000 |
| 29105 | | A | Apply long arm splint | 0.87 | 1.23 | 0.51 | 0.12 | 2.22 | 1.50 | 000 |
| 29125 | | A | Apply forearm splint | 0.59 | 1.02 | 0.39 | 0.07 | 1.68 | 1.05 | 000 |
| 29126 | | A | Apply forearm splint | 0.77 | 1.21 | 0.46 | 0.06 | 2.04 | 1.29 | 000 |
| 29130 | | A | Application of finger splint | 0.50 | 0.47 | 0.17 | 0.06 | 1.03 | 0.73 | 000 |
| 29131 | | A | Application of finger splint | 0.55 | 0.74 | 0.24 | 0.03 | 1.32 | 0.82 | 000 |
| 29200 | | A | Strapping of chest | 0.65 | 0.73 | 0.35 | 0.05 | 1.43 | 1.05 | 000 |
| 29220 | | A | Strapping of low back | 0.64 | 0.73 | 0.39 | 0.05 | 1.42 | 1.08 | 000 |
| 29240 | | A | Strapping of shoulder | 0.71 | 0.86 | 0.37 | 0.06 | 1.63 | 1.14 | 000 |
| 29260 | | A | Strapping of elbow or wrist | 0.55 | 0.75 | 0.33 | 0.05 | 1.35 | 0.93 | 000 |
| 29280 | | A | Strapping of hand or finger | 0.51 | 0.81 | 0.33 | 0.03 | 1.35 | 0.87 | 000 |
| 29305 | | A | Application of hip cast | 2.03 | 3.34 | 1.76 | 0.33 | 5.70 | 4.12 | 000 |
| 29325 | | A | Application of hip casts | 2.32 | 3.52 | 1.95 | 0.39 | 6.23 | 4.66 | 000 |
| 29345 | | A | Application of long leg cast | 1.40 | 1.76 | 1.06 | 0.23 | 3.39 | 2.69 | 000 |
| 29355 | | A | Application of long leg cast | 1.53 | 1.71 | 1.12 | 0.24 | 3.48 | 2.89 | 000 |
| 29358 | | A | Apply long leg cast brace | 1.43 | 2.06 | 1.09 | 0.23 | 3.72 | 2.75 | 000 |
| 29365 | | A | Application of long leg cast | 1.18 | 1.65 | 0.95 | 0.20 | 3.03 | 2.33 | 000 |
| 29405 | | A | Apply short leg cast | 0.86 | 1.22 | 0.71 | 0.13 | 2.21 | 1.70 | 000 |
| 29425 | | A | Apply short leg cast | 1.01 | 1.23 | 0.74 | 0.13 | 2.37 | 1.88 | 000 |
| 29435 | | A | Apply short leg cast | 1.18 | 1.55 | 0.92 | 0.19 | 2.92 | 2.29 | 000 |
| 29440 | | A | Addition of walker to cast | 0.57 | 0.69 | 0.27 | 0.08 | 1.34 | 0.92 | 000 |
| 29445 | | A | Apply rigid leg cast | 1.78 | 1.80 | 0.96 | 0.24 | 3.82 | 2.98 | 000 |
| 29450 | | A | Application of leg cast | 2.08 | 1.47 | 1.10 | 0.19 | 3.74 | 3.37 | 000 |
| 29505 | | A | Application, long leg splint | 0.69 | 1.18 | 0.46 | 0.07 | 1.94 | 1.22 | 000 |
| 29515 | | A | Application lower leg splint | 0.73 | 0.87 | 0.47 | 0.08 | 1.68 | 1.28 | 000 |
| 29520 | | A | Strapping of hip | 0.54 | 0.87 | 0.47 | 0.02 | 1.43 | 1.03 | 000 |
| 29530 | | A | Strapping of knee | 0.57 | 0.79 | 0.33 | 0.05 | 1.41 | 0.95 | 000 |
| 29540 | | A | Strapping of ankle and/or ft | 0.51 | 0.42 | 0.31 | 0.04 | 0.97 | 0.86 | 000 |
| 29550 | | A | Strapping of toes | 0.47 | 0.42 | 0.28 | 0.04 | 0.93 | 0.79 | 000 |
| 29580 | | A | Application of paste boot | 0.57 | 0.65 | 0.36 | 0.06 | 1.28 | 0.99 | 000 |
| 29590 | | A | Application of foot splint | 0.76 | 0.51 | 0.29 | 0.06 | 1.33 | 1.11 | 000 |
| 29700 | | A | Removal/revision of cast | 0.57 | 0.89 | 0.28 | 0.07 | 1.53 | 0.92 | 000 |
| 29705 | | A | Removal/revision of cast | 0.76 | 0.82 | 0.38 | 0.11 | 1.69 | 1.25 | 000 |
| 29710 | | A | Removal/revision of cast | 1.34 | 1.53 | 0.70 | 0.20 | 3.07 | 2.24 | 000 |
| 29715 | | A | Removal/revision of cast | 0.94 | 1.17 | 0.40 | 0.13 | 2.24 | 1.47 | 000 |
| 29720 | | A | Repair of body cast | 0.68 | 1.16 | 0.39 | 0.11 | 1.95 | 1.18 | 000 |
| 29730 | | A | Windowing of cast | 0.75 | 0.81 | 0.35 | 0.11 | 1.67 | 1.21 | 000 |
| 29740 | | A | Wedging of cast | 1.12 | 1.15 | 0.49 | 0.16 | 2.43 | 1.77 | 000 |
| 29750 | | A | Wedging of clubfoot cast | 1.26 | 1.06 | 0.58 | 0.19 | 2.51 | 2.03 | 000 |
| 29800 | | A | Jaw arthroscopy/surgery | 6.42 | NA | 7.06 | 0.99 | NA | 14.47 | 090 |
| 29804 | | A | Jaw arthroscopy/surgery | 8.13 | NA | 7.84 | 1.30 | NA | 17.27 | 090 |
| 29805 | | A | Shoulder arthroscopy, dx | 5.88 | NA | 5.84 | 1.01 | NA | 12.73 | 090 |
| 29806 | | A | Shoulder arthroscopy/surgery | 14.35 | NA | 11.08 | 2.42 | NA | 27.85 | 090 |
| 29807 | | A | Shoulder arthroscopy/surgery | 13.88 | NA | 10.91 | 2.35 | NA | 27.14 | 090 |
| 29819 | | A | Shoulder arthroscopy/surgery | 7.61 | NA | 6.77 | 1.26 | NA | 15.64 | 090 |
| 29820 | | A | Shoulder arthroscopy/surgery | 7.06 | NA | 6.21 | 1.17 | NA | 14.44 | 090 |
| 29821 | | A | Shoulder arthroscopy/surgery | 7.71 | NA | 6.79 | 1.24 | NA | 15.74 | 090 |
| 29822 | | A | Shoulder arthroscopy/surgery | 7.42 | NA | 6.67 | 1.20 | NA | 15.29 | 090 |
| 29823 | | A | Shoulder arthroscopy/surgery | 8.16 | NA | 7.21 | 1.30 | NA | 16.67 | 090 |
| 29824 | | A | Shoulder arthroscopy/surgery | 8.24 | NA | 7.47 | 1.30 | NA | 17.01 | 090 |
| 29825 | | A | Shoulder arthroscopy/surgery | 7.61 | NA | 6.75 | 1.12 | NA | 15.48 | 090 |
| 29826 | | A | Shoulder arthroscopy/surgery | 8.98 | NA | 7.52 | 1.42 | NA | 17.92 | 090 |
| 29827 | | A | Arthroscop rotator cuff repr | 15.34 | NA | 11.52 | 2.08 | NA | 28.94 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 29830 | | A | Elbow arthroscopy | 5.75 | NA | 5.33 | 0.87 | NA | 11.95 | 090 |
| 29834 | | A | Elbow arthroscopy/surgery | 6.27 | NA | 5.82 | 1.02 | NA | 13.11 | 090 |
| 29835 | | A | Elbow arthroscopy/surgery | 6.47 | NA | 5.87 | 1.12 | NA | 13.46 | 090 |
| 29836 | | A | Elbow arthroscopy/surgery | 7.54 | NA | 6.77 | 1.08 | NA | 15.39 | 090 |
| 29837 | | A | Elbow arthroscopy/surgery | 6.86 | NA | 6.12 | 1.11 | NA | 14.09 | 090 |
| 29838 | | A | Elbow arthroscopy/surgery | 7.70 | NA | 6.87 | 1.23 | NA | 15.80 | 090 |
| 29840 | | A | Wrist arthroscopy | 5.53 | NA | 5.31 | 0.82 | NA | 11.66 | 090 |
| 29843 | | A | Wrist arthroscopy/surgery | 6.00 | NA | 5.62 | 0.90 | NA | 12.52 | 090 |
| 29844 | | A | Wrist arthroscopy/surgery | 6.36 | NA | 5.81 | 0.99 | NA | 13.16 | 090 |
| 29845 | | A | Wrist arthroscopy/surgery | 7.51 | NA | 6.47 | 0.99 | NA | 14.97 | 090 |
| 29846 | | A | Wrist arthroscopy/surgery | 6.74 | NA | 6.04 | 1.04 | NA | 13.82 | 090 |
| 29847 | | A | Wrist arthroscopy/surgery | 7.07 | NA | 6.18 | 1.07 | NA | 14.32 | 090 |
| 29848 | | A | Wrist endoscopy/surgery | 5.43 | NA | 5.59 | 0.87 | NA | 11.89 | 090 |
| 29850 | | A | Knee arthroscopy/surgery | 8.18 | NA | 5.06 | 0.84 | NA | 14.08 | 090 |
| 29851 | | A | Knee arthroscopy/surgery | 13.08 | NA | 9.78 | 2.04 | NA | 24.90 | 090 |
| 29855 | | A | Tibial arthroscopy/surgery | 10.60 | NA | 8.75 | 1.71 | NA | 21.06 | 090 |
| 29856 | | A | Tibial arthroscopy/surgery | 14.12 | NA | 10.65 | 2.46 | NA | 27.23 | 090 |
| 29860 | | A | Hip arthroscopy, dx | 8.04 | NA | 6.94 | 1.23 | NA | 16.21 | 090 |
| 29861 | | A | Hip arthroscopy/surgery | 9.14 | NA | 7.34 | 1.45 | NA | 17.93 | 090 |
| 29862 | | A | Hip arthroscopy/surgery | 9.89 | NA | 8.55 | 1.62 | NA | 20.06 | 090 |
| 29863 | | A | Hip arthroscopy/surgery | 9.89 | NA | 8.49 | 1.56 | NA | 19.94 | 090 |
| 29870 | | A | Knee arthroscopy, dx | 5.06 | NA | 4.88 | 0.85 | NA | 10.79 | 090 |
| 29871 | | A | Knee arthroscopy/drainage | 6.54 | NA | 5.86 | 1.12 | NA | 13.52 | 090 |
| 29873 | | A | Knee arthroscopy/surgery | 5.99 | NA | 6.57 | 0.89 | NA | 13.45 | 090 |
| 29874 | | A | Knee arthroscopy/surgery | 7.04 | NA | 6.06 | 1.10 | NA | 14.20 | 090 |
| 29875 | | A | Knee arthroscopy/surgery | 6.30 | NA | 5.84 | 1.05 | NA | 13.19 | 090 |
| 29876 | | A | Knee arthroscopy/surgery | 7.91 | NA | 7.01 | 1.36 | NA | 16.28 | 090 |
| 29877 | | A | Knee arthroscopy/surgery | 7.34 | NA | 6.73 | 1.25 | NA | 15.32 | 090 |
| 29879 | | A | Knee arthroscopy/surgery | 8.03 | NA | 7.10 | 1.36 | NA | 16.49 | 090 |
| 29880 | | A | Knee arthroscopy/surgery | 8.49 | NA | 7.35 | 1.43 | NA | 17.27 | 090 |
| 29881 | | A | Knee arthroscopy/surgery | 7.75 | NA | 6.95 | 1.31 | NA | 16.01 | 090 |
| 29882 | | A | Knee arthroscopy/surgery | 8.64 | NA | 7.23 | 1.48 | NA | 17.35 | 090 |
| 29883 | | A | Knee arthroscopy/surgery | 11.03 | NA | 9.04 | 1.88 | NA | 21.95 | 090 |
| 29884 | | A | Knee arthroscopy/surgery | 7.32 | NA | 6.68 | 1.21 | NA | 15.21 | 090 |
| 29885 | | A | Knee arthroscopy/surgery | 9.08 | NA | 7.95 | 1.48 | NA | 18.51 | 090 |
| 29886 | | A | Knee arthroscopy/surgery | 7.53 | NA | 6.83 | 1.29 | NA | 15.65 | 090 |
| 29887 | | A | Knee arthroscopy/surgery | 9.03 | NA | 7.92 | 1.51 | NA | 18.46 | 090 |
| 29888 | | A | Knee arthroscopy/surgery | 13.88 | NA | 10.18 | 2.22 | NA | 26.28 | 090 |
| 29889 | | A | Knee arthroscopy/surgery | 15.98 | NA | 12.41 | 2.67 | NA | 31.06 | 090 |
| 29891 | | A | Ankle arthroscopy/surgery | 8.39 | NA | 7.50 | 1.28 | NA | 17.17 | 090 |
| 29892 | | A | Ankle arthroscopy/surgery | 8.99 | NA | 7.72 | 1.16 | NA | 17.87 | 090 |
| 29893 | | A | Scope, plantar fasciotomy | 5.21 | 6.27 | 3.98 | 0.45 | 11.93 | 9.64 | 090 |
| 29894 | | A | Ankle arthroscopy/surgery | 7.20 | NA | 5.46 | 0.99 | NA | 13.65 | 090 |
| 29895 | | A | Ankle arthroscopy/surgery | 6.98 | NA | 5.46 | 0.96 | NA | 13.40 | 090 |
| 29897 | | A | Ankle arthroscopy/surgery | 7.17 | NA | 5.87 | 1.10 | NA | 14.14 | 090 |
| 29898 | | A | Ankle arthroscopy/surgery | 8.31 | NA | 6.18 | 1.11 | NA | 15.60 | 090 |
| 29899 | | A | Ankle arthroscopy/surgery | 13.89 | NA | 10.55 | 2.04 | NA | 26.48 | 090 |
| 29900 | | A | Mcp joint arthroscopy, dx | 5.41 | NA | 5.81 | 0.87 | NA | 12.09 | 090 |
| 29901 | | A | Mcp joint arthroscopy, surg | 6.12 | NA | 6.20 | 0.97 | NA | 13.29 | 090 |
| 29902 | | A | Mcp joint arthroscopy, surg | 6.69 | NA | 6.46 | 0.84 | NA | 13.99 | 090 |
| 30000 | | A | Drainage of nose lesion | 1.43 | 4.09 | 1.40 | 0.12 | 5.64 | 2.95 | 010 |
| 30020 | | A | Drainage of nose lesion | 1.43 | 3.28 | 1.47 | 0.12 | 4.83 | 3.02 | 010 |
| 30100 | | A | Intranasal biopsy | 0.94 | 1.97 | 0.82 | 0.08 | 2.99 | 1.84 | 000 |
| 30110 | | A | Removal of nose polyp(s) | 1.63 | 3.24 | 1.57 | 0.14 | 5.01 | 3.34 | 010 |
| 30115 | | A | Removal of nose polyp(s) | 4.34 | NA | 5.76 | 0.42 | NA | 10.52 | 090 |
| 30117 | | A | Removal of intranasal lesion | 3.16 | 13.13 | 4.62 | 0.26 | 16.55 | 8.04 | 090 |
| 30118 | | A | Removal of intranasal lesion | 9.68 | NA | 9.19 | 0.82 | NA | 19.69 | 090 |
| 30120 | | A | Revision of nose | 5.26 | 6.48 | 5.99 | 0.56 | 12.30 | 11.81 | 090 |
| 30124 | | A | Removal of nose lesion | 3.10 | NA | 3.62 | 0.30 | NA | 7.02 | 090 |
| 30125 | | A | Removal of nose lesion | 7.15 | NA | 8.32 | 0.58 | NA | 16.05 | 090 |
| 30130 | | A | Removal of turbinate bones | 3.37 | NA | 5.58 | 0.32 | NA | 9.27 | 090 |
| 30140 | | A | Removal of turbinate bones | 3.42 | NA | 6.19 | 0.36 | NA | 9.97 | 090 |
| 30150 | | A | Partial removal of nose | 9.13 | NA | 10.99 | 0.91 | NA | 21.03 | 090 |
| 30160 | | A | Removal of nose | 9.57 | NA | 10.19 | 0.87 | NA | 20.63 | 090 |
| 30200 | | A | Injection treatment of nose | 0.78 | 1.62 | 0.74 | 0.06 | 2.46 | 1.58 | 000 |
| 30210 | | A | Nasal sinus therapy | 1.08 | 2.10 | 1.31 | 0.09 | 3.27 | 2.48 | 010 |
| 30220 | | A | Insert nasal septal button | 1.54 | 4.23 | 1.53 | 0.12 | 5.89 | 3.19 | 010 |
| 30300 | | A | Remove nasal foreign body | 1.04 | 4.64 | 1.93 | 0.08 | 5.76 | 3.05 | 010 |
| 30310 | | A | Remove nasal foreign body | 1.96 | NA | 3.09 | 0.17 | NA | 5.22 | 010 |
| 30320 | | A | Remove nasal foreign body | 4.51 | NA | 7.03 | 0.37 | NA | 11.91 | 090 |
| 30400 | | R | Reconstruction of nose | 9.82 | NA | 15.46 | 1.02 | NA | 26.30 | 090 |
| 30410 | | R | Reconstruction of nose | 12.96 | NA | 18.32 | 1.47 | NA | 32.75 | 090 |
| 30420 | | R | Reconstruction of nose | 15.86 | NA | 17.87 | 1.48 | NA | 35.21 | 090 |
| 30430 | | R | Revision of nose | 7.20 | NA | 15.95 | 0.79 | NA | 23.94 | 090 |
| 30435 | | R | Revision of nose | 11.69 | NA | 19.28 | 1.33 | NA | 32.30 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 30450 | | R | Revision of nose | 18.62 | NA | 21.82 | 1.89 | NA | 42.33 | 090 |
| 30460 | | A | Revision of nose | 9.95 | NA | 9.94 | 0.91 | NA | 20.80 | 090 |
| 30462 | | A | Revision of nose | 19.54 | NA | 20.20 | 1.90 | NA | 41.64 | 090 |
| 30465 | | A | Repair nasal stenosis | 11.62 | NA | 11.99 | 1.10 | NA | 24.71 | 090 |
| 30520 | | A | Repair of nasal septum | 5.69 | NA | 6.65 | 0.47 | NA | 12.81 | 090 |
| 30540 | | A | Repair nasal defect | 7.74 | NA | 9.29 | 0.64 | NA | 17.67 | 090 |
| 30545 | | A | Repair nasal defect | 11.36 | NA | 11.87 | 0.81 | NA | 24.04 | 090 |
| 30560 | | A | Release of nasal adhesions | 1.26 | 4.78 | 2.13 | 0.10 | 6.14 | 3.49 | 010 |
| 30580 | | A | Repair upper jaw fistula | 6.68 | 7.76 | 5.78 | 0.87 | 15.31 | 13.33 | 090 |
| 30600 | | A | Repair mouth/nose fistula | 6.01 | 7.53 | 5.02 | 0.61 | 14.15 | 11.64 | 090 |
| 30620 | | A | Intranasal reconstruction | 5.96 | NA | 8.81 | 0.56 | NA | 15.33 | 090 |
| 30630 | | A | Repair nasal septum defect | 7.11 | NA | 7.94 | 0.61 | NA | 15.66 | 090 |
| 30801 | | A | Cauterization, inner nose | 1.09 | 4.14 | 1.93 | 0.09 | 5.32 | 3.11 | 010 |
| 30802 | | A | Cauterization, inner nose | 2.03 | 4.61 | 2.35 | 0.17 | 6.81 | 4.55 | 010 |
| 30901 | | A | Control of nosebleed | 1.21 | 1.36 | 0.32 | 0.11 | 2.68 | 1.64 | 000 |
| 30903 | | A | Control of nosebleed | 1.54 | 2.71 | 0.50 | 0.13 | 4.38 | 2.17 | 000 |
| 30905 | | A | Control of nosebleed | 1.97 | 3.51 | 0.76 | 0.17 | 5.65 | 2.90 | 000 |
| 30906 | | A | Repeat control of nosebleed | 2.45 | 3.89 | 1.20 | 0.20 | 6.54 | 3.85 | 000 |
| 30915 | | A | Ligation, nasal sinus artery | 7.19 | NA | 6.69 | 0.60 | NA | 14.48 | 090 |
| 30920 | | A | Ligation, upper jaw artery | 9.82 | NA | 8.96 | 0.80 | NA | 19.58 | 090 |
| 30930 | | A | Therapy, fracture of nose | 1.26 | NA | 1.62 | 0.12 | NA | 3.00 | 010 |
| 31000 | | A | Irrigation, maxillary sinus | 1.15 | 2.85 | 1.40 | 0.10 | 4.10 | 2.65 | 010 |
| 31002 | | A | Irrigation, sphenoid sinus | 1.91 | NA | 3.26 | 0.16 | NA | 5.33 | 010 |
| 31020 | | A | Exploration, maxillary sinus | 2.94 | 8.54 | 5.18 | 0.28 | 11.76 | 8.40 | 090 |
| 31030 | | A | Exploration, maxillary sinus | 5.91 | 11.51 | 6.66 | 0.58 | 18.00 | 13.15 | 090 |
| 31032 | | A | Explore sinus, remove polyps | 6.56 | NA | 7.22 | 0.61 | NA | 14.39 | 090 |
| 31040 | | A | Exploration behind upper jaw | 9.41 | NA | 9.85 | 0.90 | NA | 20.16 | 090 |
| 31050 | | A | Exploration, sphenoid sinus | 5.27 | NA | 6.35 | 0.57 | NA | 12.19 | 090 |
| 31051 | | A | Sphenoid sinus surgery | 7.10 | NA | 8.24 | 0.69 | NA | 16.03 | 090 |
| 31070 | | A | Exploration of frontal sinus | 4.27 | NA | 5.93 | 0.39 | NA | 10.59 | 090 |
| 31075 | | A | Exploration of frontal sinus | 9.15 | NA | 9.72 | 0.80 | NA | 19.67 | 090 |
| 31080 | | A | Removal of frontal sinus | 11.40 | NA | 13.54 | 1.36 | NA | 26.30 | 090 |
| 31081 | | A | Removal of frontal sinus | 12.73 | NA | 13.99 | 2.47 | NA | 29.19 | 090 |
| 31084 | | A | Removal of frontal sinus | 13.49 | NA | 13.50 | 1.23 | NA | 28.22 | 090 |
| 31085 | | A | Removal of frontal sinus | 14.18 | NA | 13.94 | 1.74 | NA | 29.86 | 090 |
| 31086 | | A | Removal of frontal sinus | 12.84 | NA | 13.26 | 1.11 | NA | 27.21 | 090 |
| 31087 | | A | Removal of frontal sinus | 13.08 | NA | 12.51 | 1.28 | NA | 26.87 | 090 |
| 31090 | | A | Exploration of sinuses | 9.52 | NA | 12.54 | 0.94 | NA | 23.00 | 090 |
| 31200 | | A | Removal of ethmoid sinus | 4.96 | NA | 9.24 | 0.31 | NA | 14.51 | 090 |
| 31201 | | A | Removal of ethmoid sinus | 8.36 | NA | 9.16 | 0.82 | NA | 18.34 | 090 |
| 31205 | | A | Removal of ethmoid sinus | 10.22 | NA | 11.89 | 0.73 | NA | 22.84 | 090 |
| 31225 | | A | Removal of upper jaw | 19.20 | NA | 17.81 | 1.69 | NA | 38.70 | 090 |
| 31230 | | A | Removal of upper jaw | 21.91 | NA | 19.35 | 1.89 | NA | 43.15 | 090 |
| 31231 | | A | Nasal endoscopy, dx | 1.10 | 3.38 | 0.88 | 0.09 | 4.57 | 2.07 | 000 |
| 31233 | | A | Nasal/sinus endoscopy, dx | 2.18 | 4.31 | 1.47 | 0.19 | 6.68 | 3.84 | 000 |
| 31235 | | A | Nasal/sinus endoscopy, dx | 2.64 | 4.91 | 1.72 | 0.27 | 7.82 | 4.63 | 000 |
| 31237 | | A | Nasal/sinus endoscopy, surg | 2.98 | 5.19 | 1.88 | 0.28 | 8.45 | 5.14 | 000 |
| 31238 | | A | Nasal/sinus endoscopy, surg | 3.26 | 5.23 | 2.08 | 0.27 | 8.76 | 5.61 | 000 |
| 31239 | | A | Nasal/sinus endoscopy, surg | 8.69 | NA | 8.01 | 0.62 | NA | 17.32 | 010 |
| 31240 | | A | Nasal/sinus endoscopy, surg | 2.61 | NA | 1.73 | 0.25 | NA | 4.59 | 000 |
| 31254 | | A | Revision of ethmoid sinus | 4.64 | NA | 2.84 | 0.46 | NA | 7.94 | 000 |
| 31255 | | A | Removal of ethmoid sinus | 6.95 | NA | 4.10 | 0.74 | NA | 11.79 | 000 |
| 31256 | | A | Exploration maxillary sinus | 3.29 | NA | 2.11 | 0.34 | NA | 5.74 | 000 |
| 31267 | | A | Endoscopy, maxillary sinus | 5.45 | NA | 3.29 | 0.56 | NA | 9.30 | 000 |
| 31276 | | A | Sinus endoscopy, surgical | 8.84 | NA | 5.11 | 0.92 | NA | 14.87 | 000 |
| 31287 | | A | Nasal/sinus endoscopy, surg | 3.91 | NA | 2.45 | 0.40 | NA | 6.76 | 000 |
| 31288 | | A | Nasal/sinus endoscopy, surg | 4.57 | NA | 2.80 | 0.47 | NA | 7.84 | 000 |
| 31290 | | A | Nasal/sinus endoscopy, surg | 17.21 | NA | 12.04 | 1.41 | NA | 30.66 | 010 |
| 31291 | | A | Nasal/sinus endoscopy, surg | 18.16 | NA | 12.46 | 1.74 | NA | 32.36 | 010 |
| 31292 | | A | Nasal/sinus endoscopy, surg | 14.74 | NA | 10.60 | 1.27 | NA | 26.61 | 010 |
| 31293 | | A | Nasal/sinus endoscopy, surg | 16.19 | NA | 11.37 | 1.17 | NA | 28.73 | 010 |
| 31294 | | A | Nasal/sinus endoscopy, surg | 19.03 | NA | 12.86 | 1.42 | NA | 33.31 | 010 |
| 31300 | | A | Removal of larynx lesion | 14.27 | NA | 14.99 | 1.21 | NA | 30.47 | 090 |
| 31320 | | A | Diagnostic incision, larynx | 5.25 | NA | 10.34 | 0.46 | NA | 16.05 | 090 |
| 31360 | | A | Removal of larynx | 17.05 | NA | 16.72 | 1.44 | NA | 35.21 | 090 |
| 31365 | | A | Removal of larynx | 24.12 | NA | 20.35 | 2.03 | NA | 46.50 | 090 |
| 31367 | | A | Partial removal of larynx | 21.83 | NA | 21.88 | 1.81 | NA | 45.52 | 090 |
| 31368 | | A | Partial removal of larynx | 27.05 | NA | 25.47 | 2.26 | NA | 54.78 | 090 |
| 31370 | | A | Partial removal of larynx | 21.35 | NA | 22.26 | 1.77 | NA | 45.38 | 090 |
| 31375 | | A | Partial removal of larynx | 20.18 | NA | 20.41 | 1.65 | NA | 42.24 | 090 |
| 31380 | | A | Partial removal of larynx | 20.18 | NA | 20.60 | 1.64 | NA | 42.42 | 090 |
| 31382 | | A | Partial removal of larynx | 20.49 | NA | 21.61 | 1.72 | NA | 43.82 | 090 |
| 31390 | | A | Removal of larynx & pharynx | 27.49 | NA | 24.37 | 2.32 | NA | 54.18 | 090 |
| 31395 | | A | Reconstruct larynx & pharynx | 31.04 | NA | 28.28 | 2.61 | NA | 61.93 | 090 |
| 31400 | | A | Revision of larynx | 10.29 | NA | 13.80 | 0.84 | NA | 24.93 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 31420 | | A | Removal of epiglottis | 10.20 | NA | 9.54 | 0.83 | NA | 20.57 | 090 |
| 31500 | | A | Insert emergency airway | 2.33 | NA | 0.55 | 0.18 | NA | 3.06 | 000 |
| 31502 | | A | Change of windpipe airway | 0.65 | 0.31 | 0.28 | 0.05 | 1.01 | 0.98 | 000 |
| 31505 | | A | Diagnostic laryngoscopy | 0.61 | 1.45 | 0.62 | 0.05 | 2.11 | 1.28 | 000 |
| 31510 | | A | Laryngoscopy with biopsy | 1.92 | 3.32 | 1.25 | 0.17 | 5.41 | 3.34 | 000 |
| 31511 | | A | Remove foreign body, larynx | 2.16 | 3.12 | 1.06 | 0.19 | 5.47 | 3.41 | 000 |
| 31512 | | A | Removal of larynx lesion | 2.07 | 3.20 | 1.36 | 0.17 | 5.44 | 3.60 | 000 |
| 31513 | | A | Injection into vocal cord | 2.10 | NA | 1.46 | 0.17 | NA | 3.73 | 000 |
| 31515 | | A | Laryngoscopy for aspiration | 1.80 | 3.63 | 1.07 | 0.14 | 5.57 | 3.01 | 000 |
| 31520 | | A | Diagnostic laryngoscopy | 2.56 | NA | 1.56 | 0.20 | NA | 4.32 | 000 |
| 31525 | | A | Diagnostic laryngoscopy | 2.63 | 3.65 | 1.66 | 0.22 | 6.50 | 4.51 | 000 |
| 31526 | | A | Diagnostic laryngoscopy | 2.57 | NA | 1.71 | 0.21 | NA | 4.49 | 000 |
| 31527 | | A | Laryngoscopy for treatment | 3.27 | NA | 1.87 | 0.27 | NA | 5.41 | 000 |
| 31528 | | A | Laryngoscopy and dilation | 2.37 | NA | 1.46 | 0.20 | NA | 4.03 | 000 |
| 31529 | | A | Laryngoscopy and dilation | 2.68 | NA | 1.71 | 0.22 | NA | 4.61 | 000 |
| 31530 | | A | Operative laryngoscopy | 3.38 | NA | 1.95 | 0.29 | NA | 5.62 | 000 |
| 31531 | | A | Operative laryngoscopy | 3.58 | NA | 2.27 | 0.29 | NA | 6.14 | 000 |
| 31535 | | A | Operative laryngoscopy | 3.16 | NA | 1.99 | 0.26 | NA | 5.41 | 000 |
| 31536 | | A | Operative laryngoscopy | 3.55 | NA | 2.24 | 0.29 | NA | 6.08 | 000 |
| 31540 | | A | Operative laryngoscopy | 4.12 | NA | 2.54 | 0.34 | NA | 7.00 | 000 |
| 31541 | | A | Operative laryngoscopy | 4.52 | NA | 2.77 | 0.37 | NA | 7.66 | 000 |
| 31560 | | A | Operative laryngoscopy | 5.45 | NA | 3.15 | 0.44 | NA | 9.04 | 000 |
| 31561 | | A | Operative laryngoscopy | 5.99 | NA | 3.36 | 0.40 | NA | 9.75 | 000 |
| 31570 | | A | Laryngoscopy with injection | 3.86 | 5.67 | 2.38 | 0.31 | 9.84 | 6.55 | 000 |
| 31571 | | A | Laryngoscopy with injection | 4.26 | NA | 2.59 | 0.35 | NA | 7.20 | 000 |
| 31575 | | A | Diagnostic laryngoscopy | 1.10 | 1.90 | 0.89 | 0.09 | 3.09 | 2.08 | 000 |
| 31576 | | A | Laryngoscopy with biopsy | 1.97 | 3.66 | 1.29 | 0.15 | 5.78 | 3.41 | 000 |
| 31577 | | A | Remove foreign body, larynx | 2.47 | 3.76 | 1.53 | 0.20 | 6.43 | 4.20 | 000 |
| 31578 | | A | Removal of larynx lesion | 2.84 | 4.28 | 1.52 | 0.23 | 7.35 | 4.59 | 000 |
| 31579 | | A | Diagnostic laryngoscopy | 2.26 | 3.78 | 1.48 | 0.19 | 6.23 | 3.93 | 000 |
| 31580 | | A | Revision of larynx | 12.36 | NA | 15.92 | 1.00 | NA | 29.28 | 090 |
| 31582 | | A | Revision of larynx | 21.59 | NA | 25.84 | 1.76 | NA | 49.19 | 090 |
| 31584 | | A | Treat larynx fracture | 19.61 | NA | 18.15 | 1.57 | NA | 39.33 | 090 |
| 31585 | | A | Treat larynx fracture | 4.63 | NA | 6.70 | 0.49 | NA | 11.82 | 090 |
| 31586 | | A | Treat larynx fracture | 8.02 | NA | 10.86 | 0.65 | NA | 19.53 | 090 |
| 31587 | | A | Revision of larynx | 11.97 | NA | 9.26 | 0.99 | NA | 22.22 | 090 |
| 31588 | | A | Revision of larynx | 13.09 | NA | 13.60 | 1.05 | NA | 27.74 | 090 |
| 31590 | | A | Reinnervate larynx | 6.96 | NA | 15.54 | 0.85 | NA | 23.35 | 090 |
| 31595 | | A | Larynx nerve surgery | 8.33 | NA | 10.58 | 0.79 | NA | 19.70 | 090 |
| 31600 | | A | Incision of windpipe | 7.17 | NA | 3.18 | 0.80 | NA | 11.15 | 000 |
| 31601 | | A | Incision of windpipe | 4.44 | NA | 2.39 | 0.47 | NA | 7.30 | 000 |
| 31603 | | A | Incision of windpipe | 4.14 | NA | 1.71 | 0.45 | NA | 6.30 | 000 |
| 31605 | | A | Incision of windpipe | 3.57 | NA | 1.18 | 0.39 | NA | 5.14 | 000 |
| 31610 | | A | Incision of windpipe | 8.75 | NA | 8.27 | 0.80 | NA | 17.82 | 090 |
| 31611 | | A | Surgery/speech prosthesis | 5.63 | NA | 6.11 | 0.47 | NA | 12.21 | 090 |
| 31612 | | A | Puncture/clear windpipe | 0.91 | 1.10 | 0.35 | 0.08 | 2.09 | 1.34 | 000 |
| 31613 | | A | Repair windpipe opening | 4.58 | NA | 5.99 | 0.45 | NA | 11.02 | 090 |
| 31614 | | A | Repair windpipe opening | 7.11 | NA | 8.71 | 0.62 | NA | 16.44 | 090 |
| 31615 | | A | Visualization of windpipe | 2.09 | 2.59 | 1.20 | 0.16 | 4.84 | 3.45 | 000 |
| 31622 | | A | Dx bronchoscope/wash | 2.78 | 5.71 | 1.06 | 0.19 | 8.68 | 4.03 | 000 |
| 31623 | | A | Dx bronchoscope/brush | 2.88 | 6.51 | 1.05 | 0.16 | 9.55 | 4.09 | 000 |
| 31624 | | A | Dx bronchoscope/lavage | 2.88 | 5.85 | 1.05 | 0.16 | 8.89 | 4.09 | 000 |
| 31625 | | A | Bronchoscopy w/biopsy(s) | 3.36 | 5.91 | 1.21 | 0.20 | 9.47 | 4.77 | 000 |
| 31628 | | A | Bronchoscopy/lung bx, each | 3.80 | 6.13 | 1.30 | 0.19 | 10.12 | 5.29 | 000 |
| 31629 | | A | Bronchoscopy/needle bx, each | 4.09 | 13.50 | 1.40 | 0.17 | 17.76 | 5.66 | 000 |
| 31630 | | A | Bronchoscopy dilate/fx repr | 3.81 | NA | 1.70 | 0.35 | NA | 5.86 | 000 |
| 31631 | | A | Bronchoscopy, dilate w/stent | 4.36 | NA | 1.74 | 0.37 | NA | 6.47 | 000 |
| 31632 | | A | Bronchoscopy/lung bx, add-l | 1.03 | 0.83 | 0.31 | 0.19 | 2.05 | 1.53 | ZZZ |
| 31633 | | A | Bronchoscopy/needle bx add-l | 1.32 | 0.93 | 0.40 | 0.17 | 2.42 | 1.89 | ZZZ |
| 31635 | | A | Bronchoscopy w/fb removal | 3.67 | 6.17 | 1.43 | 0.27 | 10.11 | 5.37 | 000 |
| 31640 | | A | Bronchoscopy w/tumor excise | 4.93 | NA | 2.07 | 0.44 | NA | 7.44 | 000 |
| 31641 | | A | Bronchoscopy, treat blockage | 5.02 | NA | 1.88 | 0.37 | NA | 7.27 | 000 |
| 31643 | | A | Diag bronchoscope/catheter | 3.49 | NA | 1.23 | 0.20 | NA | 4.92 | 000 |
| 31645 | | A | Bronchoscopy, clear airways | 3.16 | 5.21 | 1.13 | 0.18 | 8.55 | 4.47 | 000 |
| 31646 | | A | Bronchoscopy, reclear airway | 2.72 | 4.93 | 1.00 | 0.16 | 7.81 | 3.88 | 000 |
| 31656 | | A | Bronchoscopy, inj for x-ray | 2.17 | 6.44 | 0.83 | 0.13 | 8.74 | 3.13 | 000 |
| 31700 | | A | Insertion of airway catheter | 1.34 | 2.17 | 0.69 | 0.08 | 3.59 | 2.11 | 000 |
| 31708 | | A | Instill airway contrast dye | 1.41 | 2.12 | 0.46 | 0.07 | 3.60 | 1.94 | 000 |
| 31710 | | A | Insertion of airway catheter | 1.30 | NA | 0.41 | 0.09 | NA | 1.80 | 000 |
| 31715 | | A | Injection for bronchus x-ray | 1.11 | NA | 0.34 | 0.07 | NA | 1.52 | 000 |
| 31717 | | A | Bronchial brush biopsy | 2.12 | 8.66 | 0.79 | 0.10 | 10.88 | 3.01 | 000 |
| 31720 | | A | Clearance of airways | 1.06 | 0.33 | 0.33 | 0.08 | 1.47 | 1.47 | 000 |
| 31725 | | A | Clearance of airways | 1.96 | 0.65 | 0.58 | 0.13 | 2.74 | 2.67 | 000 |
| 31730 | | A | Intro, windpipe wire/tube | 2.85 | 2.20 | 0.99 | 0.22 | 5.27 | 4.06 | 000 |
| 31750 | | A | Repair of windpipe | 13.00 | NA | 17.58 | 1.14 | NA | 31.72 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 31755 | | A | Repair of windpipe | 15.91 | NA | 24.51 | 1.41 | NA | 41.83 | 090 |
| 31760 | | A | Repair of windpipe | 22.32 | NA | 10.76 | 3.08 | NA | 36.16 | 090 |
| 31766 | | A | Reconstruction of windpipe | 30.38 | NA | 13.67 | 4.53 | NA | 48.58 | 090 |
| 31770 | | A | Repair/graft of bronchus | 22.48 | NA | 10.28 | 2.76 | NA | 35.52 | 090 |
| 31775 | | A | Reconstruct bronchus | 23.50 | NA | 11.82 | 3.06 | NA | 38.38 | 090 |
| 31780 | | A | Reconstruct windpipe | 17.69 | NA | 11.07 | 1.72 | NA | 30.48 | 090 |
| 31781 | | A | Reconstruct windpipe | 23.49 | NA | 12.15 | 2.51 | NA | 38.15 | 090 |
| 31785 | | A | Remove windpipe lesion | 17.20 | NA | 10.20 | 1.54 | NA | 28.94 | 090 |
| 31786 | | A | Remove windpipe lesion | 23.94 | NA | 13.12 | 3.33 | NA | 40.39 | 090 |
| 31800 | | A | Repair of windpipe injury | 7.42 | NA | 9.29 | 0.76 | NA | 17.47 | 090 |
| 31805 | | A | Repair of windpipe injury | 13.11 | NA | 7.25 | 1.78 | NA | 22.14 | 090 |
| 31820 | | A | Closure of windpipe lesion | 4.48 | 5.66 | 3.65 | 0.40 | 10.54 | 8.53 | 090 |
| 31825 | | A | Repair of windpipe defect | 6.80 | 7.66 | 5.37 | 0.58 | 15.04 | 12.75 | 090 |
| 31830 | | A | Revise windpipe scar | 4.49 | 5.76 | 3.98 | 0.43 | 10.68 | 8.90 | 090 |
| 32000 | | A | Drainage of chest | 1.54 | 3.10 | 0.48 | 0.09 | 4.73 | 2.11 | 000 |
| 32002 | | A | Treatment of collapsed lung | 2.19 | 3.24 | 1.06 | 0.13 | 5.56 | 3.38 | 000 |
| 32005 | | A | Treat lung lining chemically | 2.19 | 6.50 | 0.70 | 0.22 | 8.91 | 3.11 | 000 |
| 32020 | | A | Insertion of chest tube | 3.97 | NA | 1.35 | 0.42 | NA | 5.74 | 000 |
| 32035 | | A | Exploration of chest | 8.66 | NA | 5.88 | 1.18 | NA | 15.72 | 090 |
| 32036 | | A | Exploration of chest | 9.67 | NA | 6.46 | 1.32 | NA | 17.45 | 090 |
| 32095 | | A | Biopsy through chest wall | 8.35 | NA | 5.38 | 1.10 | NA | 14.83 | 090 |
| 32100 | | A | Exploration/biopsy of chest | 15.22 | NA | 7.84 | 2.03 | NA | 25.09 | 090 |
| 32110 | | A | Explore/repair chest | 22.97 | NA | 10.74 | 3.01 | NA | 36.72 | 090 |
| 32120 | | A | Re-exploration of chest | 11.52 | NA | 7.10 | 1.54 | NA | 20.16 | 090 |
| 32124 | | A | Explore chest free adhesions | 12.70 | NA | 7.23 | 1.77 | NA | 21.70 | 090 |
| 32140 | | A | Removal of lung lesion(s) | 13.91 | NA | 7.70 | 1.88 | NA | 23.49 | 090 |
| 32141 | | A | Remove/treat lung lesions | 13.98 | NA | 7.57 | 1.86 | NA | 23.41 | 090 |
| 32150 | | A | Removal of lung lesion(s) | 14.13 | NA | 7.63 | 1.88 | NA | 23.64 | 090 |
| 32151 | | A | Remove lung foreign body | 14.19 | NA | 8.03 | 1.61 | NA | 23.83 | 090 |
| 32160 | | A | Open chest heart massage | 9.29 | NA | 5.28 | 1.20 | NA | 15.77 | 090 |
| 32200 | | A | Drain, open, lung lesion | 15.27 | NA | 8.62 | 1.25 | NA | 25.14 | 090 |
| 32201 | | A | Drain, percut, lung lesion | 3.99 | 21.04 | 1.30 | 0.24 | 25.27 | 5.53 | 000 |
| 32215 | | A | Treat chest lining | 11.31 | NA | 6.92 | 1.50 | NA | 19.73 | 090 |
| 32220 | | A | Release of lung | 23.96 | NA | 12.96 | 3.20 | NA | 40.12 | 090 |
| 32225 | | A | Partial release of lung | 13.94 | NA | 7.68 | 1.86 | NA | 23.48 | 090 |
| 32310 | | A | Removal of chest lining | 13.42 | NA | 7.41 | 1.77 | NA | 22.60 | 090 |
| 32320 | | A | Free/remove chest lining | 23.96 | NA | 12.16 | 3.23 | NA | 39.35 | 090 |
| 32400 | | A | Needle biopsy chest lining | 1.76 | 2.14 | 0.55 | 0.10 | 4.00 | 2.41 | 000 |
| 32402 | | A | Open biopsy chest lining | 7.55 | NA | 5.14 | 1.00 | NA | 13.69 | 090 |
| 32405 | | A | Biopsy, lung or mediastinum | 1.93 | 0.67 | 0.63 | 0.12 | 2.72 | 2.68 | 000 |
| 32420 | | A | Puncture/clear lung | 2.18 | NA | 0.68 | 0.14 | NA | 3.00 | 000 |
| 32440 | | A | Removal of lung | 24.96 | NA | 12.89 | 3.33 | NA | 41.18 | 090 |
| 32442 | | A | Sleeve pneumonectomy | 26.20 | NA | 14.75 | 3.14 | NA | 44.09 | 090 |
| 32445 | | A | Removal of lung | 25.05 | NA | 14.06 | 3.55 | NA | 42.66 | 090 |
| 32480 | | A | Partial removal of lung | 23.71 | NA | 12.05 | 3.16 | NA | 38.92 | 090 |
| 32482 | | A | Bilobectomy | 24.96 | NA | 12.90 | 3.30 | NA | 41.16 | 090 |
| 32484 | | A | Segmentectomy | 20.66 | NA | 11.38 | 2.82 | NA | 34.86 | 090 |
| 32486 | | A | Sleeve lobectomy | 23.88 | NA | 13.24 | 3.36 | NA | 40.48 | 090 |
| 32488 | | A | Completion pneumonectomy | 25.67 | NA | 13.78 | 3.55 | NA | 43.00 | 090 |
| 32491 | | R | Lung volume reduction | 21.22 | NA | 12.62 | 3.11 | NA | 36.95 | 090 |
| 32500 | | A | Partial removal of lung | 21.97 | NA | 12.35 | 2.92 | NA | 37.24 | 090 |
| 32501 | | A | Repair bronchus add-on | 4.68 | NA | 1.53 | 0.64 | NA | 6.85 | ZZZ |
| 32520 | | A | Remove lung & revise chest | 21.65 | NA | 11.31 | 2.91 | NA | 35.87 | 090 |
| 32522 | | A | Remove lung & revise chest | 24.16 | NA | 12.11 | 3.29 | NA | 39.56 | 090 |
| 32525 | | A | Remove lung & revise chest | 26.46 | NA | 12.79 | 3.49 | NA | 42.74 | 090 |
| 32540 | | A | Removal of lung lesion | 14.62 | NA | 9.63 | 1.96 | NA | 26.21 | 090 |
| 32601 | | A | Thoracoscopy, diagnostic | 5.45 | NA | 2.35 | 0.73 | NA | 8.53 | 000 |
| 32602 | | A | Thoracoscopy, diagnostic | 5.95 | NA | 2.51 | 0.80 | NA | 9.26 | 000 |
| 32603 | | A | Thoracoscopy, diagnostic | 7.80 | NA | 3.03 | 1.09 | NA | 11.92 | 000 |
| 32604 | | A | Thoracoscopy, diagnostic | 8.77 | NA | 3.44 | 1.12 | NA | 13.33 | 000 |
| 32605 | | A | Thoracoscopy, diagnostic | 6.92 | NA | 2.90 | 0.91 | NA | 10.73 | 000 |
| 32606 | | A | Thoracoscopy, diagnostic | 8.39 | NA | 3.33 | 0.85 | NA | 12.57 | 000 |
| 32650 | | A | Thoracoscopy, surgical | 10.73 | NA | 6.76 | 1.44 | NA | 18.93 | 090 |
| 32651 | | A | Thoracoscopy, surgical | 12.89 | NA | 7.23 | 1.75 | NA | 21.87 | 090 |
| 32652 | | A | Thoracoscopy, surgical | 18.63 | NA | 10.14 | 2.53 | NA | 31.30 | 090 |
| 32653 | | A | Thoracoscopy, surgical | 12.85 | NA | 6.97 | 1.76 | NA | 21.58 | 090 |
| 32654 | | A | Thoracoscopy, surgical | 12.42 | NA | 7.53 | 1.64 | NA | 21.59 | 090 |
| 32655 | | A | Thoracoscopy, surgical | 13.08 | NA | 7.24 | 1.75 | NA | 22.07 | 090 |
| 32656 | | A | Thoracoscopy, surgical | 12.89 | NA | 7.93 | 1.80 | NA | 22.62 | 090 |
| 32657 | | A | Thoracoscopy, surgical | 13.63 | NA | 7.68 | 1.86 | NA | 23.17 | 090 |
| 32658 | | A | Thoracoscopy, surgical | 11.61 | NA | 7.35 | 1.62 | NA | 20.58 | 090 |
| 32659 | | A | Thoracoscopy, surgical | 11.57 | NA | 7.45 | 1.55 | NA | 20.57 | 090 |
| 32660 | | A | Thoracoscopy, surgical | 17.40 | NA | 9.47 | 1.87 | NA | 28.74 | 090 |
| 32661 | | A | Thoracoscopy, surgical | 13.23 | NA | 7.79 | 1.77 | NA | 22.79 | 090 |
| 32662 | | A | Thoracoscopy, surgical | 16.42 | NA | 8.81 | 2.26 | NA | 27.49 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 32663 | | A | Thoracoscopy, surgical | 18.44 | NA | 10.75 | 2.56 | NA | 31.75 | 090 |
| 32664 | | A | Thoracoscopy, surgical | 14.18 | NA | 7.63 | 2.06 | NA | 23.87 | 090 |
| 32665 | | A | Thoracoscopy, surgical | 15.52 | NA | 8.13 | 2.03 | NA | 25.68 | 090 |
| 32800 | | A | Repair lung hernia | 13.67 | NA | 7.45 | 1.91 | NA | 23.03 | 090 |
| 32810 | | A | Close chest after drainage | 13.03 | NA | 7.55 | 1.83 | NA | 22.41 | 090 |
| 32815 | | A | Close bronchial fistula | 23.12 | NA | 10.99 | 3.11 | NA | 37.22 | 090 |
| 32820 | | A | Reconstruct injured chest | 21.45 | NA | 12.22 | 3.02 | NA | 36.69 | 090 |
| 32851 | | A | Lung transplant, single | 38.57 | NA | 27.68 | 5.44 | NA | 71.69 | 090 |
| 32852 | | A | Lung transplant with bypass | 41.74 | NA | 33.18 | 5.79 | NA | 80.71 | 090 |
| 32853 | | A | Lung transplant, double | 47.74 | NA | 31.75 | 6.35 | NA | 85.84 | 090 |
| 32854 | | A | Lung transplant with bypass | 50.90 | NA | 34.78 | 7.07 | NA | 92.75 | 090 |
| 32900 | | A | Removal of rib(s) | 20.24 | NA | 9.90 | 2.79 | NA | 32.93 | 090 |
| 32905 | | A | Revise & repair chest wall | 20.72 | NA | 10.14 | 2.87 | NA | 33.73 | 090 |
| 32906 | | A | Revise & repair chest wall | 26.73 | NA | 12.08 | 3.74 | NA | 42.55 | 090 |
| 32940 | | A | Revision of lung | 19.40 | NA | 9.49 | 2.66 | NA | 31.55 | 090 |
| 32960 | | A | Therapeutic pneumothorax | 1.84 | 1.76 | 0.57 | 0.19 | 3.79 | 2.60 | 000 |
| 32997 | | A | Total lung lavage | 5.99 | NA | 1.90 | 0.42 | NA | 8.31 | 000 |
| 33010 | | A | Drainage of heart sac | 2.24 | NA | 0.78 | 0.15 | NA | 3.17 | 000 |
| 33011 | | A | Repeat drainage of heart sac | 2.24 | NA | 0.81 | 0.17 | NA | 3.22 | 000 |
| 33015 | | A | Incision of heart sac | 6.79 | NA | 4.95 | 0.64 | NA | 12.38 | 090 |
| 33020 | | A | Incision of heart sac | 12.59 | NA | 6.80 | 1.62 | NA | 21.01 | 090 |
| 33025 | | A | Incision of heart sac | 12.07 | NA | 6.36 | 1.60 | NA | 20.03 | 090 |
| 33030 | | A | Partial removal of heart sac | 18.68 | NA | 9.54 | 2.53 | NA | 30.75 | 090 |
| 33031 | | A | Partial removal of heart sac | 21.76 | NA | 10.05 | 2.89 | NA | 34.70 | 090 |
| 33050 | | A | Removal of heart sac lesion | 14.34 | NA | 7.86 | 1.83 | NA | 24.03 | 090 |
| 33120 | | A | Removal of heart lesion | 24.52 | NA | 11.62 | 3.25 | NA | 39.39 | 090 |
| 33130 | | A | Removal of heart lesion | 21.36 | NA | 10.14 | 2.80 | NA | 34.30 | 090 |
| 33140 | | A | Heart revascularize (tmr) | 19.97 | NA | 10.89 | 2.66 | NA | 33.52 | 090 |
| 33141 | | A | Heart tmr w/other procedure | 4.83 | NA | 1.57 | 0.62 | NA | 7.02 | ZZZ |
| 33200 | | A | Insertion of heart pacemaker | 12.46 | NA | 6.94 | 1.52 | NA | 20.92 | 090 |
| 33201 | | A | Insertion of heart pacemaker | 10.16 | NA | 6.69 | 1.18 | NA | 18.03 | 090 |
| 33206 | | A | Insertion of heart pacemaker | 6.66 | NA | 4.54 | 0.54 | NA | 11.74 | 090 |
| 33207 | | A | Insertion of heart pacemaker | 8.03 | NA | 4.73 | 0.63 | NA | 13.39 | 090 |
| 33208 | | A | Insertion of heart pacemaker | 8.12 | NA | 4.84 | 0.60 | NA | 13.56 | 090 |
| 33210 | | A | Insertion of heart electrode | 3.30 | NA | 1.25 | 0.20 | NA | 4.75 | 000 |
| 33211 | | A | Insertion of heart electrode | 3.39 | NA | 1.31 | 0.23 | NA | 4.93 | 000 |
| 33212 | | A | Insertion of pulse generator | 5.51 | NA | 3.40 | 0.47 | NA | 9.38 | 090 |
| 33213 | | A | Insertion of pulse generator | 6.36 | NA | 3.76 | 0.50 | NA | 10.62 | 090 |
| 33214 | | A | Upgrade of pacemaker system | 7.74 | NA | 4.97 | 0.58 | NA | 13.29 | 090 |
| 33215 | | A | Reposition pacing-defib lead | 4.75 | NA | 3.18 | 0.39 | NA | 8.32 | 090 |
| 33216 | | A | Insert lead pace-defib, one | 5.77 | NA | 4.28 | 0.39 | NA | 10.44 | 090 |
| 33217 | | A | Insert lead pace-defib, dual | 5.74 | NA | 4.31 | 0.43 | NA | 10.48 | 090 |
| 33218 | | A | Repair lead pace-defib, one | 5.43 | NA | 4.34 | 0.43 | NA | 10.20 | 090 |
| 33220 | | A | Repair lead pace-defib, dual | 5.51 | NA | 4.31 | 0.43 | NA | 10.25 | 090 |
| 33222 | | A | Revise pocket, pacemaker | 4.95 | NA | 4.34 | 0.42 | NA | 9.71 | 090 |
| 33223 | | A | Revise pocket, pacing-defib | 6.45 | NA | 4.61 | 0.47 | NA | 11.53 | 090 |
| 33224 | | A | Insert pacing lead & connect | 9.04 | NA | 3.99 | 0.43 | NA | 13.46 | 000 |
| 33225 | | A | L ventric pacing lead add-on | 8.33 | NA | 3.25 | 0.43 | NA | 12.01 | ZZZ |
| 33226 | | A | Reposition l ventric lead | 8.68 | NA | 3.81 | 0.43 | NA | 12.92 | 000 |
| 33233 | | A | Removal of pacemaker system | 3.29 | NA | 3.28 | 0.24 | NA | 6.81 | 090 |
| 33234 | | A | Removal of pacemaker system | 7.81 | NA | 4.92 | 0.60 | NA | 13.33 | 090 |
| 33235 | | A | Removal pacemaker electrode | 9.39 | NA | 6.82 | 0.76 | NA | 16.97 | 090 |
| 33236 | | A | Remove electrode/thoracotomy | 12.58 | NA | 7.45 | 1.72 | NA | 21.75 | 090 |
| 33237 | | A | Remove electrode/thoracotomy | 13.69 | NA | 7.79 | 1.63 | NA | 23.11 | 090 |
| 33238 | | A | Remove electrode/thoracotomy | 15.20 | NA | 8.22 | 1.94 | NA | 25.36 | 090 |
| 33240 | | A | Insert pulse generator | 7.59 | NA | 4.63 | 0.50 | NA | 12.72 | 090 |
| 33241 | | A | Remove pulse generator | 3.24 | NA | 2.97 | 0.22 | NA | 6.43 | 090 |
| 33243 | | A | Remove eltrd/thoracotomy | 22.61 | NA | 11.45 | 2.80 | NA | 36.86 | 090 |
| 33244 | | A | Remove eltrd, transven | 13.74 | NA | 8.90 | 1.02 | NA | 23.66 | 090 |
| 33245 | | A | Insert epic eltrd pace-defib | 14.28 | NA | 7.99 | 1.85 | NA | 24.12 | 090 |
| 33246 | | A | Insert epic eltrd/generator | 20.68 | NA | 10.35 | 2.46 | NA | 33.49 | 090 |
| 33249 | | A | Eltrd/insert pace-defib | 14.21 | NA | 8.44 | 0.86 | NA | 23.51 | 090 |
| 33250 | | A | Ablate heart dysrhythm focus | 21.82 | NA | 11.05 | 2.79 | NA | 35.66 | 090 |
| 33251 | | A | Ablate heart dysrhythm focus | 24.84 | NA | 11.68 | 2.87 | NA | 39.39 | 090 |
| 33253 | | A | Reconstruct atria | 31.01 | NA | 13.84 | 4.04 | NA | 48.89 | 090 |
| 33261 | | A | Ablate heart dysrhythm focus | 24.84 | NA | 11.79 | 2.82 | NA | 39.45 | 090 |
| 33282 | | A | Implant pat-active ht record | 4.16 | NA | 4.07 | 0.25 | NA | 8.48 | 090 |
| 33284 | | A | Remove pat-active ht record | 2.50 | NA | 3.55 | 0.16 | NA | 6.21 | 090 |
| 33300 | | A | Repair of heart wound | 17.89 | NA | 9.25 | 2.33 | NA | 29.47 | 090 |
| 33305 | | A | Repair of heart wound | 21.41 | NA | 10.64 | 2.79 | NA | 34.84 | 090 |
| 33310 | | A | Exploratory heart surgery | 18.48 | NA | 9.60 | 2.58 | NA | 30.66 | 090 |
| 33315 | | A | Exploratory heart surgery | 22.34 | NA | 10.90 | 2.87 | NA | 36.11 | 090 |
| 33320 | | A | Repair major blood vessel(s) | 16.76 | NA | 8.25 | 1.83 | NA | 26.84 | 090 |
| 33321 | | A | Repair major vessel | 20.17 | NA | 9.81 | 2.69 | NA | 32.67 | 090 |
| 33322 | | A | Repair major blood vessel(s) | 20.59 | NA | 10.38 | 2.65 | NA | 33.62 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 33330 | | A | Insert major vessel graft | 21.40 | NA | 10.28 | 2.65 | NA | 34.33 | 090 |
| 33332 | | A | Insert major vessel graft | 23.92 | NA | 10.53 | 3.11 | NA | 37.56 | 090 |
| 33335 | | A | Insert major vessel graft | 29.96 | NA | 13.35 | 3.86 | NA | 47.17 | 090 |
| 33400 | | A | Repair of aortic valve | 28.46 | NA | 15.65 | 3.69 | NA | 47.80 | 090 |
| 33401 | | A | Valvuloplasty, open | 23.87 | NA | 13.50 | 1.30 | NA | 38.67 | 090 |
| 33403 | | A | Valvuloplasty, w/cp bypass | 24.85 | NA | 14.30 | 3.53 | NA | 42.68 | 090 |
| 33404 | | A | Prepare heart-aorta conduit | 28.50 | NA | 14.53 | 4.02 | NA | 47.05 | 090 |
| 33405 | | A | Replacement of aortic valve | 34.95 | NA | 18.28 | 4.55 | NA | 57.78 | 090 |
| 33406 | | A | Replacement of aortic valve | 37.44 | NA | 19.11 | 4.93 | NA | 61.48 | 090 |
| 33410 | | A | Replacement of aortic valve | 32.41 | NA | 16.58 | 4.05 | NA | 53.04 | 090 |
| 33411 | | A | Replacement of aortic valve | 36.20 | NA | 18.74 | 4.86 | NA | 59.80 | 090 |
| 33412 | | A | Replacement of aortic valve | 41.94 | NA | 20.40 | 5.61 | NA | 67.95 | 090 |
| 33413 | | A | Replacement of aortic valve | 43.43 | NA | 20.80 | 5.94 | NA | 70.17 | 090 |
| 33414 | | A | Repair of aortic valve | 30.30 | NA | 14.15 | 4.00 | NA | 48.45 | 090 |
| 33415 | | A | Revision, subvalvular tissue | 27.11 | NA | 12.05 | 3.56 | NA | 42.72 | 090 |
| 33416 | | A | Revise ventricle muscle | 30.30 | NA | 13.52 | 4.14 | NA | 47.96 | 090 |
| 33417 | | A | Repair of aortic valve | 28.49 | NA | 13.63 | 3.96 | NA | 46.08 | 090 |
| 33420 | | A | Revision of mitral valve | 22.67 | NA | 9.61 | 1.89 | NA | 34.17 | 090 |
| 33422 | | A | Revision of mitral valve | 25.90 | NA | 13.64 | 3.39 | NA | 42.93 | 090 |
| 33425 | | A | Repair of mitral valve | 26.96 | NA | 13.05 | 3.59 | NA | 43.60 | 090 |
| 33426 | | A | Repair of mitral valve | 32.95 | NA | 17.13 | 4.25 | NA | 54.33 | 090 |
| 33427 | | A | Repair of mitral valve | 39.94 | NA | 19.35 | 5.27 | NA | 64.56 | 090 |
| 33430 | | A | Replacement of mitral valve | 33.45 | NA | 17.29 | 4.36 | NA | 55.10 | 090 |
| 33460 | | A | Revision of tricuspid valve | 23.56 | NA | 11.32 | 3.23 | NA | 38.11 | 090 |
| 33463 | | A | Valvuloplasty, tricuspid | 25.58 | NA | 12.92 | 3.36 | NA | 41.86 | 090 |
| 33464 | | A | Valvuloplasty, tricuspid | 27.29 | NA | 13.53 | 3.52 | NA | 44.34 | 090 |
| 33465 | | A | Replace tricuspid valve | 28.75 | NA | 12.98 | 3.88 | NA | 45.61 | 090 |
| 33468 | | A | Revision of tricuspid valve | 30.07 | NA | 13.68 | 4.35 | NA | 48.10 | 090 |
| 33470 | | A | Revision of pulmonary valve | 20.78 | NA | 10.71 | 2.01 | NA | 33.50 | 090 |
| 33471 | | A | Valvotomy, pulmonary valve | 22.22 | NA | 9.77 | 3.31 | NA | 35.30 | 090 |
| 33472 | | A | Revision of pulmonary valve | 22.22 | NA | 11.89 | 3.11 | NA | 37.22 | 090 |
| 33474 | | A | Revision of pulmonary valve | 23.01 | NA | 10.89 | 2.70 | NA | 36.60 | 090 |
| 33475 | | A | Replacement, pulmonary valve | 32.95 | NA | 15.41 | 4.30 | NA | 52.66 | 090 |
| 33476 | | A | Revision of heart chamber | 25.73 | NA | 11.97 | 2.97 | NA | 40.67 | 090 |
| 33478 | | A | Revision of heart chamber | 26.70 | NA | 13.06 | 3.85 | NA | 43.61 | 090 |
| 33496 | | A | Repair, prosth valve clot | 27.21 | NA | 12.76 | 3.60 | NA | 43.57 | 090 |
| 33500 | | A | Repair heart vessel fistula | 25.51 | NA | 11.47 | 3.33 | NA | 40.31 | 090 |
| 33501 | | A | Repair heart vessel fistula | 17.75 | NA | 8.29 | 2.04 | NA | 28.08 | 090 |
| 33502 | | A | Coronary artery correction | 21.01 | NA | 11.10 | 2.11 | NA | 34.22 | 090 |
| 33503 | | A | Coronary artery graft | 21.75 | NA | 9.78 | 1.84 | NA | 33.37 | 090 |
| 33504 | | A | Coronary artery graft | 24.62 | NA | 11.84 | 3.32 | NA | 39.78 | 090 |
| 33505 | | A | Repair artery w/tunnel | 26.80 | NA | 12.93 | 2.67 | NA | 42.40 | 090 |
| 33506 | | A | Repair artery, translocation | 35.45 | NA | 14.59 | 3.85 | NA | 53.89 | 090 |
| 33508 | | A | Endoscopic vein harvest | 0.31 | NA | 0.10 | 0.88 | NA | 1.29 | ZZZ |
| 33510 | | A | CABG, vein, single | 28.96 | NA | 16.33 | 3.75 | NA | 49.04 | 090 |
| 33511 | | A | CABG, vein, two | 29.96 | NA | 17.07 | 3.83 | NA | 50.86 | 090 |
| 33512 | | A | CABG, vein, three | 31.75 | NA | 17.60 | 4.13 | NA | 53.48 | 090 |
| 33513 | | A | CABG, vein, four | 31.95 | NA | 17.78 | 4.16 | NA | 53.89 | 090 |
| 33514 | | A | CABG, vein, five | 32.70 | NA | 18.05 | 4.00 | NA | 54.75 | 090 |
| 33516 | | A | Cabg, vein, six or more | 34.95 | NA | 18.79 | 4.51 | NA | 58.25 | 090 |
| 33517 | | A | CABG, artery-vein, single | 2.57 | NA | 0.84 | 0.33 | NA | 3.74 | ZZZ |
| 33518 | | A | CABG, artery-vein, two | 4.84 | NA | 1.58 | 0.63 | NA | 7.05 | ZZZ |
| 33519 | | A | CABG, artery-vein, three | 7.11 | NA | 2.32 | 0.92 | NA | 10.35 | ZZZ |
| 33521 | | A | CABG, artery-vein, four | 9.39 | NA | 3.07 | 1.20 | NA | 13.66 | ZZZ |
| 33522 | | A | CABG, artery-vein, five | 11.65 | NA | 3.80 | 1.49 | NA | 16.94 | ZZZ |
| 33523 | | A | Cabg, art-vein, six or more | 13.93 | NA | 4.52 | 1.81 | NA | 20.26 | ZZZ |
| 33530 | | A | Coronary artery, bypass/reop | 5.85 | NA | 1.90 | 0.77 | NA | 8.52 | ZZZ |
| 33533 | | A | CABG, arterial, single | 29.96 | NA | 16.46 | 3.86 | NA | 50.28 | 090 |
| 33534 | | A | CABG, arterial, two | 32.15 | NA | 17.70 | 4.13 | NA | 53.98 | 090 |
| 33535 | | A | CABG, arterial, three | 34.45 | NA | 18.13 | 4.43 | NA | 57.01 | 090 |
| 33536 | | A | Cabg, arterial, four or more | 37.44 | NA | 18.28 | 4.60 | NA | 60.32 | 090 |
| 33542 | | A | Removal of heart lesion | 28.81 | NA | 13.01 | 3.79 | NA | 45.61 | 090 |
| 33545 | | A | Repair of heart damage | 36.72 | NA | 15.64 | 4.81 | NA | 57.17 | 090 |
| 33572 | | A | Open coronary endarterectomy | 4.44 | NA | 1.45 | 0.58 | NA | 6.47 | ZZZ |
| 33600 | | A | Closure of valve | 29.47 | NA | 12.55 | 4.13 | NA | 46.15 | 090 |
| 33602 | | A | Closure of valve | 28.50 | NA | 12.46 | 3.25 | NA | 44.21 | 090 |
| 33606 | | A | Anastomosis/artery-aorta | 30.69 | NA | 13.69 | 4.33 | NA | 48.71 | 090 |
| 33608 | | A | Repair anomaly w/conduit | 31.04 | NA | 14.11 | 4.41 | NA | 49.56 | 090 |
| 33610 | | A | Repair by enlargement | 30.56 | NA | 13.66 | 4.56 | NA | 48.78 | 090 |
| 33611 | | A | Repair double ventricle | 33.95 | NA | 14.15 | 4.11 | NA | 52.21 | 090 |
| 33612 | | A | Repair double ventricle | 34.95 | NA | 15.17 | 5.18 | NA | 55.30 | 090 |
| 33615 | | A | Repair, modified fontan | 33.95 | NA | 13.27 | 2.90 | NA | 50.12 | 090 |
| 33617 | | A | Repair single ventricle | 36.94 | NA | 16.02 | 4.88 | NA | 57.84 | 090 |
| 33619 | | A | Repair single ventricle | 44.93 | NA | 20.82 | 3.60 | NA | 69.35 | 090 |
| 33641 | | A | Repair heart septum defect | 21.36 | NA | 9.59 | 2.73 | NA | 33.68 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 33645 | | A | Revision of heart veins | 24.78 | NA | 11.78 | 3.26 | NA | 39.82 | 090 |
| 33647 | | A | Repair heart septum defects | 28.69 | NA | 13.79 | 3.12 | NA | 45.60 | 090 |
| 33660 | | A | Repair of heart defects | 29.96 | NA | 13.50 | 3.88 | NA | 47.34 | 090 |
| 33665 | | A | Repair of heart defects | 28.56 | NA | 13.85 | 4.21 | NA | 46.62 | 090 |
| 33670 | | A | Repair of heart chambers | 34.95 | NA | 13.20 | 3.47 | NA | 51.62 | 090 |
| 33681 | | A | Repair heart septum defect | 30.56 | NA | 14.69 | 4.03 | NA | 49.28 | 090 |
| 33684 | | A | Repair heart septum defect | 29.61 | NA | 13.63 | 4.08 | NA | 47.32 | 090 |
| 33688 | | A | Repair heart septum defect | 30.57 | NA | 10.52 | 4.39 | NA | 45.48 | 090 |
| 33690 | | A | Reinforce pulmonary artery | 19.52 | NA | 10.19 | 2.66 | NA | 32.37 | 090 |
| 33692 | | A | Repair of heart defects | 30.70 | NA | 13.94 | 4.58 | NA | 49.22 | 090 |
| 33694 | | A | Repair of heart defects | 33.95 | NA | 14.23 | 3.71 | NA | 51.89 | 090 |
| 33697 | | A | Repair of heart defects | 35.95 | NA | 14.87 | 4.32 | NA | 55.14 | 090 |
| 33702 | | A | Repair of heart defects | 26.50 | NA | 12.58 | 4.00 | NA | 43.08 | 090 |
| 33710 | | A | Repair of heart defects | 29.67 | NA | 14.00 | 3.01 | NA | 46.68 | 090 |
| 33720 | | A | Repair of heart defect | 26.52 | NA | 12.29 | 3.60 | NA | 42.41 | 090 |
| 33722 | | A | Repair of heart defect | 28.37 | NA | 13.88 | 4.33 | NA | 46.58 | 090 |
| 33730 | | A | Repair heart-vein defect(s) | 34.20 | NA | 14.13 | 4.32 | NA | 52.65 | 090 |
| 33732 | | A | Repair heart-vein defect | 28.12 | NA | 13.41 | 2.88 | NA | 44.41 | 090 |
| 33735 | | A | Revision of heart chamber | 21.36 | NA | 9.06 | 1.56 | NA | 31.98 | 090 |
| 33736 | | A | Revision of heart chamber | 23.48 | NA | 11.87 | 2.50 | NA | 37.85 | 090 |
| 33737 | | A | Revision of heart chamber | 21.73 | NA | 10.95 | 3.30 | NA | 35.98 | 090 |
| 33750 | | A | Major vessel shunt | 21.38 | NA | 10.24 | 2.56 | NA | 34.18 | 090 |
| 33755 | | A | Major vessel shunt | 21.76 | NA | 8.82 | 3.24 | NA | 33.82 | 090 |
| 33762 | | A | Major vessel shunt | 21.76 | NA | 10.17 | 3.18 | NA | 35.11 | 090 |
| 33764 | | A | Major vessel shunt & graft | 21.76 | NA | 10.25 | 2.15 | NA | 34.16 | 090 |
| 33766 | | A | Major vessel shunt | 22.73 | NA | 11.68 | 3.39 | NA | 37.80 | 090 |
| 33767 | | A | Major vessel shunt | 24.46 | NA | 11.75 | 2.74 | NA | 38.95 | 090 |
| 33770 | | A | Repair great vessels defect | 36.94 | NA | 14.69 | 5.42 | NA | 57.05 | 090 |
| 33771 | | A | Repair great vessels defect | 34.60 | NA | 12.42 | 5.63 | NA | 52.65 | 090 |
| 33774 | | A | Repair great vessels defect | 30.93 | NA | 14.75 | 4.70 | NA | 50.38 | 090 |
| 33775 | | A | Repair great vessels defect | 32.15 | NA | 15.02 | 5.23 | NA | 52.40 | 090 |
| 33776 | | A | Repair great vessels defect | 33.99 | NA | 15.80 | 5.52 | NA | 55.31 | 090 |
| 33777 | | A | Repair great vessels defect | 33.41 | NA | 14.87 | 5.44 | NA | 53.72 | 090 |
| 33778 | | A | Repair great vessels defect | 39.94 | NA | 16.89 | 5.83 | NA | 62.66 | 090 |
| 33779 | | A | Repair great vessels defect | 36.16 | NA | 15.39 | 1.74 | NA | 53.29 | 090 |
| 33780 | | A | Repair great vessels defect | 41.69 | NA | 19.06 | 5.15 | NA | 65.90 | 090 |
| 33781 | | A | Repair great vessels defect | 36.40 | NA | 13.48 | 5.92 | NA | 55.80 | 090 |
| 33786 | | A | Repair arterial trunk | 38.94 | NA | 16.70 | 2.03 | NA | 57.67 | 090 |
| 33788 | | A | Revision of pulmonary artery | 26.58 | NA | 11.95 | 4.02 | NA | 42.55 | 090 |
| 33800 | | A | Aortic suspension | 16.22 | NA | 8.16 | 2.28 | NA | 26.66 | 090 |
| 33802 | | A | Repair vessel defect | 17.63 | NA | 9.24 | 1.66 | NA | 28.53 | 090 |
| 33803 | | A | Repair vessel defect | 19.57 | NA | 9.78 | 3.17 | NA | 32.52 | 090 |
| 33813 | | A | Repair septal defect | 20.62 | NA | 10.93 | 1.13 | NA | 32.68 | 090 |
| 33814 | | A | Repair septal defect | 25.73 | NA | 12.66 | 3.56 | NA | 41.95 | 090 |
| 33820 | | A | Revise major vessel | 16.27 | NA | 8.39 | 2.19 | NA | 26.85 | 090 |
| 33822 | | A | Revise major vessel | 17.29 | NA | 8.98 | 1.92 | NA | 28.19 | 090 |
| 33824 | | A | Revise major vessel | 19.49 | NA | 10.01 | 2.91 | NA | 32.41 | 090 |
| 33840 | | A | Remove aorta constriction | 20.60 | NA | 10.31 | 2.45 | NA | 33.36 | 090 |
| 33845 | | A | Remove aorta constriction | 22.09 | NA | 11.36 | 3.13 | NA | 36.58 | 090 |
| 33851 | | A | Remove aorta constriction | 21.24 | NA | 10.71 | 2.81 | NA | 34.76 | 090 |
| 33852 | | A | Repair septal defect | 23.67 | NA | 11.38 | 2.55 | NA | 37.60 | 090 |
| 33853 | | A | Repair septal defect | 31.67 | NA | 14.84 | 4.13 | NA | 50.64 | 090 |
| 33860 | | A | Ascending aortic graft | 37.94 | NA | 16.46 | 5.05 | NA | 59.45 | 090 |
| 33861 | | A | Ascending aortic graft | 41.94 | NA | 17.72 | 5.45 | NA | 65.11 | 090 |
| 33863 | | A | Ascending aortic graft | 44.93 | NA | 18.70 | 5.46 | NA | 69.09 | 090 |
| 33870 | | A | Transverse aortic arch graft | 43.93 | NA | 18.39 | 5.96 | NA | 68.28 | 090 |
| 33875 | | A | Thoracic aortic graft | 33.01 | NA | 14.11 | 4.43 | NA | 51.55 | 090 |
| 33877 | | A | Thoracoabdominal graft | 42.54 | NA | 16.33 | 5.46 | NA | 64.33 | 090 |
| 33910 | | A | Remove lung artery emboli | 24.55 | NA | 11.45 | 3.32 | NA | 39.32 | 090 |
| 33915 | | A | Remove lung artery emboli | 20.99 | NA | 9.64 | 1.73 | NA | 32.36 | 090 |
| 33916 | | A | Surgery of great vessel | 25.79 | NA | 11.37 | 3.47 | NA | 40.63 | 090 |
| 33917 | | A | Repair pulmonary artery | 24.46 | NA | 12.21 | 3.25 | NA | 39.92 | 090 |
| 33918 | | A | Repair pulmonary atresia | 26.41 | NA | 12.13 | 4.12 | NA | 42.66 | 090 |
| 33919 | | A | Repair pulmonary atresia | 39.94 | NA | 17.52 | 4.45 | NA | 61.91 | 090 |
| 33920 | | A | Repair pulmonary atresia | 31.90 | NA | 13.85 | 3.50 | NA | 49.25 | 090 |
| 33922 | | A | Transect pulmonary artery | 23.48 | NA | 10.92 | 3.25 | NA | 37.65 | 090 |
| 33924 | | A | Remove pulmonary shunt | 5.49 | NA | 1.83 | 0.70 | NA | 8.02 | ZZZ |
| 33935 | | R | Transplantation, heart/lung | 60.87 | NA | 28.77 | 9.19 | NA | 98.83 | 090 |
| 33945 | | R | Transplantation of heart | 42.04 | NA | 21.38 | 5.91 | NA | 69.33 | 090 |
| 33960 | | A | External circulation assist | 19.33 | NA | 4.90 | 2.46 | NA | 26.69 | 000 |
| 33961 | | A | External circulation assist | 10.91 | NA | 3.61 | 1.08 | NA | 15.60 | ZZZ |
| 33967 | | A | Insert ia percut device | 4.84 | NA | 1.83 | 0.35 | NA | 7.02 | 000 |
| 33968 | | A | Remove aortic assist device | 0.64 | NA | 0.23 | 0.06 | NA | 0.93 | 000 |
| 33970 | | A | Aortic circulation assist | 6.74 | NA | 2.28 | 0.81 | NA | 9.83 | 000 |
| 33971 | | A | Aortic circulation assist | 9.68 | NA | 6.03 | 1.21 | NA | 16.92 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 33973 | | A | Insert balloon device | 9.75 | NA | 3.30 | 1.18 | NA | 14.23 | 000 |
| 33974 | | A | Remove intra-aortic balloon | 14.39 | NA | 7.91 | 1.71 | NA | 24.01 | 090 |
| 33975 | | A | Implant ventricular device | 20.97 | NA | 6.27 | 2.95 | NA | 30.19 | XXX |
| 33976 | | A | Implant ventricular device | 22.97 | NA | 7.53 | 2.73 | NA | 33.23 | XXX |
| 33977 | | A | Remove ventricular device | 19.26 | NA | 11.08 | 2.68 | NA | 33.02 | 090 |
| 33978 | | A | Remove ventricular device | 21.70 | NA | 11.75 | 3.03 | NA | 36.48 | 090 |
| 33979 | | A | Insert intracorporeal device | 45.93 | NA | 14.89 | 4.80 | NA | 65.62 | XXX |
| 33980 | | A | Remove intracorporeal device | 56.17 | NA | 25.22 | 5.55 | NA | 86.94 | 090 |
| 34001 | | A | Removal of artery clot | 12.89 | NA | 6.71 | 1.76 | NA | 21.36 | 090 |
| 34051 | | A | Removal of artery clot | 15.19 | NA | 7.77 | 2.20 | NA | 25.16 | 090 |
| 34101 | | A | Removal of artery clot | 9.99 | NA | 5.35 | 1.36 | NA | 16.70 | 090 |
| 34111 | | A | Removal of arm artery clot | 9.99 | NA | 5.35 | 1.36 | NA | 16.70 | 090 |
| 34151 | | A | Removal of artery clot | 24.96 | NA | 10.39 | 3.34 | NA | 38.69 | 090 |
| 34201 | | A | Removal of artery clot | 10.01 | NA | 5.41 | 1.38 | NA | 16.80 | 090 |
| 34203 | | A | Removal of leg artery clot | 16.48 | NA | 8.05 | 2.25 | NA | 26.78 | 090 |
| 34401 | | A | Removal of vein clot | 24.96 | NA | 10.65 | 3.00 | NA | 38.61 | 090 |
| 34421 | | A | Removal of vein clot | 11.98 | NA | 6.28 | 1.48 | NA | 19.74 | 090 |
| 34451 | | A | Removal of vein clot | 26.96 | NA | 11.42 | 3.65 | NA | 42.03 | 090 |
| 34471 | | A | Removal of vein clot | 10.16 | NA | 5.31 | 0.88 | NA | 16.35 | 090 |
| 34490 | | A | Removal of vein clot | 9.85 | NA | 5.43 | 1.34 | NA | 16.62 | 090 |
| 34501 | | A | Repair valve, femoral vein | 15.98 | NA | 8.50 | 2.31 | NA | 26.79 | 090 |
| 34502 | | A | Reconstruct vena cava | 26.91 | NA | 12.28 | 3.41 | NA | 42.60 | 090 |
| 34510 | | A | Transposition of vein valve | 18.92 | NA | 9.43 | 2.39 | NA | 30.74 | 090 |
| 34520 | | A | Cross-over vein graft | 17.92 | NA | 8.48 | 1.63 | NA | 28.03 | 090 |
| 34530 | | A | Leg vein fusion | 16.62 | NA | 8.61 | 2.16 | NA | 27.39 | 090 |
| 34800 | | A | Endovasc abdo repair w/tube | 20.72 | NA | 9.15 | 2.35 | NA | 32.22 | 090 |
| 34802 | | A | Endovasc abdo repr w/device | 22.97 | NA | 9.77 | 2.34 | NA | 35.08 | 090 |
| 34804 | | A | Endovasc abdo repr w/device | 22.97 | NA | 9.79 | 2.35 | NA | 35.11 | 090 |
| 34805 | | A | Endovasc abdo repair w/pros | 21.85 | NA | 9.66 | 1.99 | NA | 33.50 | 090 |
| 34808 | | A | Endovasc abdo occlud device | 4.12 | NA | 1.37 | 0.50 | NA | 5.99 | ZZZ |
| 34812 | | A | Xpose for endoprosth, femorl | 6.74 | NA | 2.23 | 1.09 | NA | 10.06 | 000 |
| 34813 | | A | Femoral endovas graft add-on | 4.79 | NA | 1.57 | 0.65 | NA | 7.01 | ZZZ |
| 34820 | | A | Xpose for endoprosth, iliac | 9.74 | NA | 3.23 | 1.35 | NA | 14.32 | 000 |
| 34825 | | A | Endovasc extend prosth, init | 11.98 | NA | 6.13 | 1.29 | NA | 19.40 | 090 |
| 34826 | | A | Endovasc exten prosth, add-l | 4.12 | NA | 1.37 | 0.45 | NA | 5.94 | ZZZ |
| 34830 | | A | Open aortic tube prosth repr | 32.54 | NA | 13.68 | 3.75 | NA | 49.97 | 090 |
| 34831 | | A | Open aortoiliac prosth repr | 35.29 | NA | 11.73 | 3.95 | NA | 50.97 | 090 |
| 34832 | | A | Open aortofemor prosth repr | 35.29 | NA | 14.60 | 4.05 | NA | 53.94 | 090 |
| 34833 | | A | Xpose for endoprosth, iliac | 11.98 | NA | 4.42 | 0.84 | NA | 17.24 | 000 |
| 34834 | | A | Xpose, endoprosth, brachial | 5.34 | NA | 2.19 | 0.59 | NA | 8.12 | 000 |
| 34900 | | A | Endovasc iliac repr w/graft | 16.36 | NA | 7.59 | 1.80 | NA | 25.75 | 090 |
| 35001 | | A | Repair defect of artery | 19.61 | NA | 9.54 | 2.64 | NA | 31.79 | 090 |
| 35002 | | A | Repair artery rupture, neck | 20.97 | NA | 9.68 | 2.38 | NA | 33.03 | 090 |
| 35005 | | A | Repair defect of artery | 18.09 | NA | 8.83 | 2.29 | NA | 29.21 | 090 |
| 35011 | | A | Repair defect of artery | 17.97 | NA | 7.97 | 2.42 | NA | 28.36 | 090 |
| 35013 | | A | Repair artery rupture, arm | 21.97 | NA | 9.66 | 2.98 | NA | 34.61 | 090 |
| 35021 | | A | Repair defect of artery | 19.62 | NA | 9.41 | 2.43 | NA | 31.46 | 090 |
| 35022 | | A | Repair artery rupture, chest | 23.15 | NA | 9.86 | 2.32 | NA | 35.33 | 090 |
| 35045 | | A | Repair defect of arm artery | 17.54 | NA | 7.53 | 2.38 | NA | 27.45 | 090 |
| 35081 | | A | Repair defect of artery | 27.97 | NA | 11.44 | 3.66 | NA | 43.07 | 090 |
| 35082 | | A | Repair artery rupture, aorta | 38.44 | NA | 15.27 | 5.10 | NA | 58.81 | 090 |
| 35091 | | A | Repair defect of artery | 35.35 | NA | 13.55 | 4.76 | NA | 53.66 | 090 |
| 35092 | | A | Repair artery rupture, aorta | 44.93 | NA | 17.61 | 5.97 | NA | 68.51 | 090 |
| 35102 | | A | Repair defect of artery | 30.71 | NA | 12.34 | 4.09 | NA | 47.14 | 090 |
| 35103 | | A | Repair artery rupture, groin | 40.44 | NA | 15.82 | 5.49 | NA | 61.75 | 090 |
| 35111 | | A | Repair defect of artery | 24.96 | NA | 10.45 | 3.35 | NA | 38.76 | 090 |
| 35112 | | A | Repair artery rupture,spleen | 29.96 | NA | 11.95 | 3.89 | NA | 45.80 | 090 |
| 35121 | | A | Repair defect of artery | 29.96 | NA | 12.35 | 4.05 | NA | 46.36 | 090 |
| 35122 | | A | Repair artery rupture, belly | 34.95 | NA | 13.78 | 4.48 | NA | 53.21 | 090 |
| 35131 | | A | Repair defect of artery | 24.96 | NA | 10.73 | 3.49 | NA | 39.18 | 090 |
| 35132 | | A | Repair artery rupture, groin | 29.96 | NA | 12.36 | 4.07 | NA | 46.39 | 090 |
| 35141 | | A | Repair defect of artery | 19.97 | NA | 8.90 | 2.72 | NA | 31.59 | 090 |
| 35142 | | A | Repair artery rupture, thigh | 23.27 | NA | 10.35 | 3.11 | NA | 36.73 | 090 |
| 35151 | | A | Repair defect of artery | 22.61 | NA | 9.98 | 3.04 | NA | 35.63 | 090 |
| 35152 | | A | Repair artery rupture, knee | 25.58 | NA | 11.36 | 3.35 | NA | 40.29 | 090 |
| 35161 | | A | Repair defect of artery | 18.73 | NA | 9.13 | 2.48 | NA | 30.34 | 090 |
| 35162 | | A | Repair artery rupture | 19.75 | NA | 9.56 | 2.75 | NA | 32.06 | 090 |
| 35180 | | A | Repair blood vessel lesion | 13.60 | NA | 6.94 | 1.97 | NA | 22.51 | 090 |
| 35182 | | A | Repair blood vessel lesion | 29.96 | NA | 12.78 | 4.09 | NA | 46.83 | 090 |
| 35184 | | A | Repair blood vessel lesion | 17.97 | NA | 8.29 | 2.45 | NA | 28.71 | 090 |
| 35188 | | A | Repair blood vessel lesion | 14.26 | NA | 7.62 | 1.98 | NA | 23.86 | 090 |
| 35189 | | A | Repair blood vessel lesion | 27.96 | NA | 11.94 | 3.68 | NA | 43.58 | 090 |
| 35190 | | A | Repair blood vessel lesion | 12.73 | NA | 6.47 | 1.71 | NA | 20.91 | 090 |
| 35201 | | A | Repair blood vessel lesion | 16.12 | NA | 7.98 | 2.13 | NA | 26.23 | 090 |
| 35206 | | A | Repair blood vessel lesion | 13.23 | NA | 6.57 | 1.83 | NA | 21.63 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 35207 | | A | Repair blood vessel lesion | 10.13 | NA | 7.53 | 1.46 | NA | 19.12 | 090 |
| 35211 | | A | Repair blood vessel lesion | 22.09 | NA | 10.64 | 2.89 | NA | 35.62 | 090 |
| 35216 | | A | Repair blood vessel lesion | 18.72 | NA | 8.99 | 2.49 | NA | 30.20 | 090 |
| 35221 | | A | Repair blood vessel lesion | 24.35 | NA | 9.92 | 3.20 | NA | 37.47 | 090 |
| 35226 | | A | Repair blood vessel lesion | 14.48 | NA | 7.46 | 1.89 | NA | 23.83 | 090 |
| 35231 | | A | Repair blood vessel lesion | 19.97 | NA | 9.75 | 2.74 | NA | 32.46 | 090 |
| 35236 | | A | Repair blood vessel lesion | 17.08 | NA | 7.90 | 2.35 | NA | 27.33 | 090 |
| 35241 | | A | Repair blood vessel lesion | 23.09 | NA | 11.14 | 3.00 | NA | 37.23 | 090 |
| 35246 | | A | Repair blood vessel lesion | 26.41 | NA | 11.43 | 3.21 | NA | 41.05 | 090 |
| 35251 | | A | Repair blood vessel lesion | 30.15 | NA | 11.77 | 3.99 | NA | 45.91 | 090 |
| 35256 | | A | Repair blood vessel lesion | 18.33 | NA | 8.37 | 2.51 | NA | 29.21 | 090 |
| 35261 | | A | Repair blood vessel lesion | 17.77 | NA | 8.00 | 2.41 | NA | 28.18 | 090 |
| 35266 | | A | Repair blood vessel lesion | 14.89 | NA | 7.01 | 1.98 | NA | 23.88 | 090 |
| 35271 | | A | Repair blood vessel lesion | 22.09 | NA | 10.53 | 2.99 | NA | 35.61 | 090 |
| 35276 | | A | Repair blood vessel lesion | 24.21 | NA | 11.22 | 3.24 | NA | 38.67 | 090 |
| 35281 | | A | Repair blood vessel lesion | 27.96 | NA | 11.69 | 3.73 | NA | 43.38 | 090 |
| 35286 | | A | Repair blood vessel lesion | 16.14 | NA | 8.07 | 2.22 | NA | 26.43 | 090 |
| 35301 | | A | Rechanneling of artery | 18.67 | NA | 8.44 | 2.52 | NA | 29.63 | 090 |
| 35311 | | A | Rechanneling of artery | 26.96 | NA | 11.73 | 3.47 | NA | 42.16 | 090 |
| 35321 | | A | Rechanneling of artery | 15.98 | NA | 7.37 | 2.18 | NA | 25.53 | 090 |
| 35331 | | A | Rechanneling of artery | 26.16 | NA | 11.22 | 3.56 | NA | 40.94 | 090 |
| 35341 | | A | Rechanneling of artery | 25.07 | NA | 10.85 | 3.44 | NA | 39.36 | 090 |
| 35351 | | A | Rechanneling of artery | 22.97 | NA | 9.58 | 3.16 | NA | 35.71 | 090 |
| 35355 | | A | Rechanneling of artery | 18.47 | NA | 8.08 | 2.51 | NA | 29.06 | 090 |
| 35361 | | A | Rechanneling of artery | 28.16 | NA | 11.69 | 3.84 | NA | 43.69 | 090 |
| 35363 | | A | Rechanneling of artery | 30.15 | NA | 12.56 | 4.16 | NA | 46.87 | 090 |
| 35371 | | A | Rechanneling of artery | 14.70 | NA | 6.94 | 2.01 | NA | 23.65 | 090 |
| 35372 | | A | Rechanneling of artery | 17.97 | NA | 8.04 | 2.47 | NA | 28.48 | 090 |
| 35381 | | A | Rechanneling of artery | 15.79 | NA | 7.81 | 2.14 | NA | 25.74 | 090 |
| 35390 | | A | Reoperation, carotid add-on | 3.19 | NA | 1.06 | 0.43 | NA | 4.68 | ZZZ |
| 35400 | | A | Angioscopy | 3.00 | NA | 1.11 | 0.42 | NA | 4.53 | ZZZ |
| 35450 | | A | Repair arterial blockage | 10.05 | NA | 3.55 | 1.24 | NA | 14.84 | 000 |
| 35452 | | A | Repair arterial blockage | 6.90 | NA | 2.60 | 0.82 | NA | 10.32 | 000 |
| 35454 | | A | Repair arterial blockage | 6.03 | NA | 2.31 | 0.82 | NA | 9.16 | 000 |
| 35456 | | A | Repair arterial blockage | 7.34 | NA | 2.76 | 0.99 | NA | 11.09 | 000 |
| 35458 | | A | Repair arterial blockage | 9.48 | NA | 3.46 | 1.21 | NA | 14.15 | 000 |
| 35459 | | A | Repair arterial blockage | 8.62 | NA | 3.16 | 1.16 | NA | 12.94 | 000 |
| 35460 | | A | Repair venous blockage | 6.03 | NA | 2.26 | 0.82 | NA | 9.11 | 000 |
| 35470 | | A | Repair arterial blockage | 8.62 | 90.69 | 3.34 | 0.70 | 100.01 | 12.66 | 000 |
| 35471 | | A | Repair arterial blockage | 10.05 | 102.73 | 3.94 | 0.69 | 113.47 | 14.68 | 000 |
| 35472 | | A | Repair arterial blockage | 6.90 | 65.72 | 2.74 | 0.59 | 73.21 | 10.23 | 000 |
| 35473 | | A | Repair arterial blockage | 6.03 | 61.03 | 2.42 | 0.51 | 67.57 | 8.96 | 000 |
| 35474 | | A | Repair arterial blockage | 7.35 | 89.50 | 2.89 | 0.56 | 97.41 | 10.80 | 000 |
| 35475 | | R | Repair arterial blockage | 9.48 | 56.75 | 3.55 | 0.63 | 66.86 | 13.66 | 000 |
| 35476 | | A | Repair venous blockage | 6.03 | 45.31 | 2.35 | 0.39 | 51.73 | 8.77 | 000 |
| 35480 | | A | Atherectomy, open | 11.06 | NA | 4.03 | 1.27 | NA | 16.36 | 000 |
| 35481 | | A | Atherectomy, open | 7.60 | NA | 2.87 | 0.99 | NA | 11.46 | 000 |
| 35482 | | A | Atherectomy, open | 6.64 | NA | 2.56 | 0.85 | NA | 10.05 | 000 |
| 35483 | | A | Atherectomy, open | 8.09 | NA | 3.02 | 1.05 | NA | 12.16 | 000 |
| 35484 | | A | Atherectomy, open | 10.42 | NA | 3.76 | 1.28 | NA | 15.46 | 000 |
| 35485 | | A | Atherectomy, open | 9.48 | NA | 3.53 | 1.30 | NA | 14.31 | 000 |
| 35490 | | A | Atherectomy, percutaneous | 11.06 | NA | 4.69 | 0.63 | NA | 16.38 | 000 |
| 35491 | | A | Atherectomy, percutaneous | 7.60 | NA | 3.28 | 0.51 | NA | 11.39 | 000 |
| 35492 | | A | Atherectomy, percutaneous | 6.64 | NA | 3.19 | 0.42 | NA | 10.25 | 000 |
| 35493 | | A | Atherectomy, percutaneous | 8.09 | NA | 3.80 | 0.57 | NA | 12.46 | 000 |
| 35494 | | A | Atherectomy, percutaneous | 10.42 | NA | 4.45 | 0.79 | NA | 15.66 | 000 |
| 35495 | | A | Atherectomy, percutaneous | 9.48 | NA | 4.38 | 0.69 | NA | 14.55 | 000 |
| 35500 | | A | Harvest vein for bypass | 6.44 | NA | 2.02 | 0.88 | NA | 9.34 | ZZZ |
| 35501 | | A | Artery bypass graft | 19.16 | NA | 8.46 | 2.67 | NA | 30.29 | 090 |
| 35506 | | A | Artery bypass graft | 19.64 | NA | 9.45 | 2.69 | NA | 31.78 | 090 |
| 35507 | | A | Artery bypass graft | 19.64 | NA | 9.41 | 2.66 | NA | 31.71 | 090 |
| 35508 | | A | Artery bypass graft | 18.62 | NA | 9.43 | 2.43 | NA | 30.48 | 090 |
| 35509 | | A | Artery bypass graft | 18.04 | NA | 8.75 | 2.47 | NA | 29.26 | 090 |
| 35510 | | A | Artery bypass graft | 22.97 | NA | 10.16 | 2.10 | NA | 35.23 | 090 |
| 35511 | | A | Artery bypass graft | 21.17 | NA | 9.34 | 2.38 | NA | 32.89 | 090 |
| 35512 | | A | Artery bypass graft | 22.47 | NA | 9.99 | 2.10 | NA | 34.56 | 090 |
| 35515 | | A | Artery bypass graft | 18.62 | NA | 9.27 | 2.50 | NA | 30.39 | 090 |
| 35516 | | A | Artery bypass graft | 16.30 | NA | 6.80 | 2.19 | NA | 25.29 | 090 |
| 35518 | | A | Artery bypass graft | 21.17 | NA | 8.96 | 2.84 | NA | 32.97 | 090 |
| 35521 | | A | Artery bypass graft | 22.17 | NA | 9.82 | 2.98 | NA | 34.97 | 090 |
| 35522 | | A | Artery bypass graft | 21.73 | NA | 9.74 | 2.10 | NA | 33.57 | 090 |
| 35525 | | A | Artery bypass graft | 20.60 | NA | 9.36 | 2.10 | NA | 32.06 | 090 |
| 35526 | | A | Artery bypass graft | 29.91 | NA | 12.49 | 2.43 | NA | 44.83 | 090 |
| 35531 | | A | Artery bypass graft | 36.15 | NA | 14.46 | 5.00 | NA | 55.61 | 090 |
| 35533 | | A | Artery bypass graft | 27.96 | NA | 11.71 | 3.59 | NA | 43.26 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 35536 | | A | Artery bypass graft | 31.65 | NA | 12.92 | 4.36 | NA | 48.93 | 090 |
| 35541 | | A | Artery bypass graft | 25.76 | NA | 11.19 | 3.49 | NA | 40.44 | 090 |
| 35546 | | A | Artery bypass graft | 25.50 | NA | 10.85 | 2.66 | NA | 39.01 | 090 |
| 35548 | | A | Artery bypass graft | 21.54 | NA | 9.41 | 2.84 | NA | 33.79 | 090 |
| 35549 | | A | Artery bypass graft | 23.31 | NA | 10.37 | 3.18 | NA | 36.86 | 090 |
| 35551 | | A | Artery bypass graft | 26.63 | NA | 11.48 | 3.71 | NA | 41.82 | 090 |
| 35556 | | A | Artery bypass graft | 21.73 | NA | 9.71 | 2.86 | NA | 34.30 | 090 |
| 35558 | | A | Artery bypass graft | 21.17 | NA | 9.53 | 2.83 | NA | 33.53 | 090 |
| 35560 | | A | Artery bypass graft | 31.95 | NA | 13.29 | 4.40 | NA | 49.64 | 090 |
| 35563 | | A | Artery bypass graft | 24.16 | NA | 10.50 | 3.39 | NA | 38.05 | 090 |
| 35565 | | A | Artery bypass graft | 23.17 | NA | 10.12 | 3.14 | NA | 36.43 | 090 |
| 35566 | | A | Artery bypass graft | 26.88 | NA | 11.37 | 3.63 | NA | 41.88 | 090 |
| 35571 | | A | Artery bypass graft | 24.02 | NA | 10.84 | 3.26 | NA | 38.12 | 090 |
| 35572 | | A | Harvest femoropopliteal vein | 6.81 | NA | 2.23 | 0.76 | NA | 9.80 | ZZZ |
| 35582 | | A | Vein bypass graft | 27.09 | NA | 11.55 | 3.32 | NA | 41.96 | 090 |
| 35583 | | A | Vein bypass graft | 22.34 | NA | 10.15 | 2.97 | NA | 35.46 | 090 |
| 35585 | | A | Vein bypass graft | 28.35 | NA | 12.23 | 3.81 | NA | 44.39 | 090 |
| 35587 | | A | Vein bypass graft | 24.71 | NA | 11.44 | 3.34 | NA | 39.49 | 090 |
| 35600 | | A | Harvest artery for cabg | 4.94 | NA | 1.62 | 0.64 | NA | 7.20 | ZZZ |
| 35601 | | A | Artery bypass graft | 17.47 | NA | 8.61 | 2.36 | NA | 28.44 | 090 |
| 35606 | | A | Artery bypass graft | 18.68 | NA | 9.00 | 2.52 | NA | 30.20 | 090 |
| 35612 | | A | Artery bypass graft | 15.74 | NA | 7.88 | 2.10 | NA | 25.72 | 090 |
| 35616 | | A | Artery bypass graft | 15.68 | NA | 8.10 | 2.18 | NA | 25.96 | 090 |
| 35621 | | A | Artery bypass graft | 19.97 | NA | 8.67 | 2.76 | NA | 31.40 | 090 |
| 35623 | | A | Bypass graft, not vein | 23.96 | NA | 10.48 | 3.30 | NA | 37.74 | 090 |
| 35626 | | A | Artery bypass graft | 27.71 | NA | 11.96 | 3.80 | NA | 43.47 | 090 |
| 35631 | | A | Artery bypass graft | 33.95 | NA | 13.81 | 4.64 | NA | 52.40 | 090 |
| 35636 | | A | Artery bypass graft | 29.46 | NA | 12.28 | 3.84 | NA | 45.58 | 090 |
| 35641 | | A | Artery bypass graft | 24.53 | NA | 11.05 | 3.28 | NA | 38.86 | 090 |
| 35642 | | A | Artery bypass graft | 17.95 | NA | 8.67 | 1.88 | NA | 28.50 | 090 |
| 35645 | | A | Artery bypass graft | 17.44 | NA | 8.27 | 2.21 | NA | 27.92 | 090 |
| 35646 | | A | Artery bypass graft | 30.95 | NA | 13.08 | 4.20 | NA | 48.23 | 090 |
| 35647 | | A | Artery bypass graft | 27.96 | NA | 11.76 | 3.78 | NA | 43.50 | 090 |
| 35650 | | A | Artery bypass graft | 18.97 | NA | 8.35 | 2.55 | NA | 29.87 | 090 |
| 35651 | | A | Artery bypass graft | 25.00 | NA | 10.73 | 3.08 | NA | 38.81 | 090 |
| 35654 | | A | Artery bypass graft | 24.96 | NA | 10.63 | 3.40 | NA | 38.99 | 090 |
| 35656 | | A | Artery bypass graft | 19.50 | NA | 8.60 | 2.61 | NA | 30.71 | 090 |
| 35661 | | A | Artery bypass graft | 18.97 | NA | 8.91 | 2.56 | NA | 30.44 | 090 |
| 35663 | | A | Artery bypass graft | 21.97 | NA | 9.96 | 2.99 | NA | 34.92 | 090 |
| 35665 | | A | Artery bypass graft | 20.97 | NA | 9.43 | 2.84 | NA | 33.24 | 090 |
| 35666 | | A | Artery bypass graft | 22.16 | NA | 10.64 | 3.00 | NA | 35.80 | 090 |
| 35671 | | A | Artery bypass graft | 19.30 | NA | 9.36 | 2.62 | NA | 31.28 | 090 |
| 35681 | | A | Composite bypass graft | 1.60 | NA | 0.53 | 0.20 | NA | 2.33 | ZZZ |
| 35682 | | A | Composite bypass graft | 7.19 | NA | 2.38 | 0.95 | NA | 10.52 | ZZZ |
| 35683 | | A | Composite bypass graft | 8.49 | NA | 2.81 | 1.10 | NA | 12.40 | ZZZ |
| 35685 | | A | Bypass graft patency/patch | 4.04 | NA | 1.35 | 0.56 | NA | 5.95 | ZZZ |
| 35686 | | A | Bypass graft/av fist patency | 3.34 | NA | 1.12 | 0.47 | NA | 4.93 | ZZZ |
| 35691 | | A | Arterial transposition | 18.02 | NA | 8.39 | 2.46 | NA | 28.87 | 090 |
| 35693 | | A | Arterial transposition | 15.34 | NA | 7.71 | 2.07 | NA | 25.12 | 090 |
| 35694 | | A | Arterial transposition | 19.13 | NA | 8.59 | 2.63 | NA | 30.35 | 090 |
| 35695 | | A | Arterial transposition | 19.13 | NA | 8.54 | 2.70 | NA | 30.37 | 090 |
| 35697 | | A | Reimplant artery each | 3.00 | NA | 1.02 | 0.41 | NA | 4.43 | ZZZ |
| 35700 | | A | Reoperation, bypass graft | 3.08 | NA | 1.02 | 0.42 | NA | 4.52 | ZZZ |
| 35701 | | A | Exploration, carotid artery | 8.49 | NA | 5.15 | 1.16 | NA | 14.80 | 090 |
| 35721 | | A | Exploration, femoral artery | 7.17 | NA | 4.45 | 0.99 | NA | 12.61 | 090 |
| 35741 | | A | Exploration popliteal artery | 7.99 | NA | 4.68 | 1.08 | NA | 13.75 | 090 |
| 35761 | | A | Exploration of artery/vein | 5.36 | NA | 4.04 | 0.73 | NA | 10.13 | 090 |
| 35800 | | A | Explore neck vessels | 7.01 | NA | 4.65 | 0.93 | NA | 12.59 | 090 |
| 35820 | | A | Explore chest vessels | 12.86 | NA | 7.18 | 1.72 | NA | 21.76 | 090 |
| 35840 | | A | Explore abdominal vessels | 9.76 | NA | 5.28 | 1.27 | NA | 16.31 | 090 |
| 35860 | | A | Explore limb vessels | 5.54 | NA | 4.03 | 0.75 | NA | 10.32 | 090 |
| 35870 | | A | Repair vessel graft defect | 22.14 | NA | 9.75 | 2.89 | NA | 34.78 | 090 |
| 35875 | | A | Removal of clot in graft | 10.11 | NA | 5.20 | 1.36 | NA | 16.67 | 090 |
| 35876 | | A | Removal of clot in graft | 16.97 | NA | 7.54 | 2.28 | NA | 26.79 | 090 |
| 35879 | | A | Revise graft w/vein | 15.98 | NA | 7.71 | 2.16 | NA | 25.85 | 090 |
| 35881 | | A | Revise graft w/vein | 17.97 | NA | 8.68 | 2.42 | NA | 29.07 | 090 |
| 35901 | | A | Excision, graft, neck | 8.18 | NA | 5.32 | 1.09 | NA | 14.59 | 090 |
| 35903 | | A | Excision, graft, extremity | 9.38 | NA | 6.18 | 1.27 | NA | 16.83 | 090 |
| 35905 | | A | Excision, graft, thorax | 31.20 | NA | 13.18 | 4.40 | NA | 48.78 | 090 |
| 35907 | | A | Excision, graft, abdomen | 34.95 | NA | 14.15 | 4.76 | NA | 53.86 | 090 |
| 36000 | | A | Place needle in vein | 0.18 | 0.60 | 0.05 | 0.01 | 0.79 | 0.24 | XXX |
| 36002 | | A | Pseudoaneurysm injection trt | 1.96 | 2.87 | 0.97 | 0.18 | 5.01 | 3.11 | 000 |
| 36005 | | A | Injection ext venography | 0.95 | 7.89 | 0.31 | 0.06 | 8.90 | 1.32 | 000 |
| 36010 | | A | Place catheter in vein | 2.43 | 20.07 | 0.79 | 0.20 | 22.70 | 3.42 | XXX |
| 36011 | | A | Place catheter in vein | 3.14 | 28.80 | 1.06 | 0.24 | 32.18 | 4.44 | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 36012 | | A | Place catheter in vein | 3.51 | 19.13 | 1.19 | 0.23 | 22.87 | 4.93 | XXX |
| 36013 | | A | Place catheter in artery | 2.52 | 22.22 | 0.69 | 0.25 | 24.99 | 3.46 | XXX |
| 36014 | | A | Place catheter in artery | 3.02 | 20.50 | 1.03 | 0.20 | 23.72 | 4.25 | XXX |
| 36015 | | A | Place catheter in artery | 3.51 | 24.30 | 1.19 | 0.22 | 28.03 | 4.92 | XXX |
| 36100 | | A | Establish access to artery | 3.02 | 12.32 | 1.11 | 0.28 | 15.62 | 4.41 | XXX |
| 36120 | | A | Establish access to artery | 2.01 | 10.85 | 0.64 | 0.15 | 13.01 | 2.80 | XXX |
| 36140 | | A | Establish access to artery | 2.01 | 13.05 | 0.64 | 0.16 | 15.22 | 2.81 | XXX |
| 36145 | | A | Artery to vein shunt | 2.01 | 12.75 | 0.66 | 0.13 | 14.89 | 2.80 | XXX |
| 36160 | | A | Establish access to aorta | 2.52 | 13.81 | 0.84 | 0.25 | 16.58 | 3.61 | XXX |
| 36200 | | A | Place catheter in aorta | 3.02 | 16.90 | 1.01 | 0.23 | 20.15 | 4.26 | XXX |
| 36215 | | A | Place catheter in artery | 4.67 | 27.75 | 1.60 | 0.31 | 32.73 | 6.58 | XXX |
| 36216 | | A | Place catheter in artery | 5.27 | 29.86 | 1.79 | 0.36 | 35.49 | 7.42 | XXX |
| 36217 | | A | Place catheter in artery | 6.29 | 56.62 | 2.17 | 0.44 | 63.35 | 8.90 | XXX |
| 36218 | | A | Place catheter in artery | 1.01 | 5.18 | 0.34 | 0.07 | 6.26 | 1.42 | ZZZ |
| 36245 | | A | Place catheter in artery | 4.67 | 33.09 | 1.68 | 0.33 | 38.09 | 6.68 | XXX |
| 36246 | | A | Place catheter in artery | 5.27 | 30.97 | 1.81 | 0.38 | 36.62 | 7.46 | XXX |
| 36247 | | A | Place catheter in artery | 6.29 | 50.83 | 2.14 | 0.47 | 57.59 | 8.90 | XXX |
| 36248 | | A | Place catheter in artery | 1.01 | 4.12 | 0.34 | 0.07 | 5.20 | 1.42 | ZZZ |
| 36260 | | A | Insertion of infusion pump | 9.70 | NA | 4.91 | 1.26 | NA | 15.87 | 090 |
| 36261 | | A | Revision of infusion pump | 5.44 | NA | 3.68 | 0.62 | NA | 9.74 | 090 |
| 36262 | | A | Removal of infusion pump | 4.01 | NA | 2.75 | 0.52 | NA | 7.28 | 090 |
| 36400 | | A | Bl draw < 3 yrs fem/jugular | 0.38 | 0.28 | 0.09 | 0.03 | 0.69 | 0.50 | XXX |
| 36405 | | A | Bl draw < 3 yrs scalp vein | 0.31 | 0.26 | 0.08 | 0.02 | 0.59 | 0.41 | XXX |
| 36406 | | A | Bl draw < 3 yrs other vein | 0.18 | 0.29 | 0.05 | 0.01 | 0.48 | 0.24 | XXX |
| 36410 | | A | Non-routine bl draw > 3 yrs | 0.18 | 0.30 | 0.05 | 0.01 | 0.49 | 0.24 | XXX |
| 36420 | | A | Vein access cutdown < 1 yr | 1.01 | 0.34 | 0.27 | 0.06 | 1.41 | 1.34 | XXX |
| 36425 | | A | Vein access cutdown > 1 yr | 0.76 | NA | 0.22 | 0.06 | NA | 1.04 | XXX |
| 36430 | | A | Blood transfusion service | 0.00 | 1.00 | NA | 0.06 | 1.06 | NA | XXX |
| 36440 | | A | Bl push transfuse, 2 yr or < | 1.03 | NA | 0.29 | 0.07 | NA | 1.39 | XXX |
| 36450 | | A | Bl exchange/transfuse, nb | 2.23 | NA | 0.70 | 0.10 | NA | 3.03 | XXX |
| 36455 | | A | Bl exchange/transfuse non-nb | 2.43 | NA | 1.01 | 0.14 | NA | 3.58 | XXX |
| 36460 | | A | Transfusion service, fetal | 6.58 | NA | 2.24 | 0.88 | NA | 9.70 | XXX |
| 36470 | | A | Injection therapy of vein | 1.09 | 2.69 | 0.73 | 0.13 | 3.91 | 1.95 | 010 |
| 36471 | | A | Injection therapy of veins | 1.57 | 3.08 | 0.96 | 0.19 | 4.84 | 2.72 | 010 |
| 36481 | | A | Insertion of catheter, vein | 6.98 | 6.04 | 2.58 | 0.48 | 13.50 | 10.04 | 000 |
| 36500 | | A | Insertion of catheter, vein | 3.51 | NA | 1.36 | 0.24 | NA | 5.11 | 000 |
| 36510 | | A | Insertion of catheter, vein | 1.09 | 3.95 | 0.61 | 0.08 | 5.12 | 1.78 | 000 |
| 36511 | | A | Apheresis wbc | 1.74 | NA | 0.73 | 0.08 | NA | 2.55 | 000 |
| 36512 | | A | Apheresis rbc | 1.74 | NA | 0.74 | 0.08 | NA | 2.56 | 000 |
| 36513 | | A | Apheresis platelets | 1.74 | NA | 0.73 | 0.08 | NA | 2.55 | 000 |
| 36514 | | A | Apheresis plasma | 1.74 | 17.69 | 0.71 | 0.08 | 19.51 | 2.53 | 000 |
| 36515 | | A | Apheresis, adsorp/reinfuse | 1.74 | 65.03 | 0.65 | 0.08 | 66.85 | 2.47 | 000 |
| 36516 | | A | Apheresis, selective | 1.22 | 84.13 | 0.48 | 0.08 | 85.43 | 1.78 | 000 |
| 36522 | | A | Photopheresis | 1.67 | 30.87 | 1.13 | 0.14 | 32.68 | 2.94 | 000 |
| 36550 | | A | Declot vascular device | 0.00 | 0.40 | NA | 0.37 | 0.77 | NA | XXX |
| 36555 | | A | Insert non-tunnel cv cath | 2.68 | 5.80 | 0.80 | 0.12 | 8.60 | 3.60 | 000 |
| 36556 | | A | Insert non-tunnel cv cath | 2.50 | 5.75 | 0.74 | 0.19 | 8.44 | 3.43 | 000 |
| 36557 | | A | Insert tunneled cv cath | 5.09 | 21.23 | 2.64 | 0.58 | 26.90 | 8.31 | 010 |
| 36558 | | A | Insert tunneled cv cath | 4.79 | 21.12 | 2.54 | 0.58 | 26.49 | 7.91 | 010 |
| 36560 | | A | Insert tunneled cv cath | 6.24 | 29.79 | 3.03 | 0.58 | 36.61 | 9.85 | 010 |
| 36561 | | A | Insert tunneled cv cath | 5.99 | 29.70 | 2.94 | 0.58 | 36.27 | 9.51 | 010 |
| 36563 | | A | Insert tunneled cv cath | 6.19 | 26.76 | 2.98 | 0.83 | 33.78 | 10.00 | 010 |
| 36565 | | A | Insert tunneled cv cath | 5.99 | 24.81 | 2.94 | 0.58 | 31.38 | 9.51 | 010 |
| 36566 | | A | Insert tunneled cv cath | 6.49 | 25.60 | 3.11 | 0.58 | 32.67 | 10.18 | 010 |
| 36568 | | A | Insert tunneled cv cath | 1.92 | 7.60 | 0.58 | 0.12 | 9.64 | 2.62 | 000 |
| 36569 | | A | Insert tunneled cv cath | 1.82 | 7.42 | 0.57 | 0.19 | 9.43 | 2.58 | 000 |
| 36570 | | A | Insert tunneled cv cath | 5.31 | 33.30 | 2.72 | 0.58 | 39.19 | 8.61 | 010 |
| 36571 | | A | Insert tunneled cv cath | 5.29 | 33.38 | 2.71 | 0.58 | 39.25 | 8.58 | 010 |
| 36575 | | A | Repair tunneled cv cath | 0.67 | 4.07 | 0.26 | 0.22 | 4.96 | 1.15 | 000 |
| 36576 | | A | Repair tunneled cv cath | 3.19 | 6.98 | 1.83 | 0.21 | 10.38 | 5.23 | 010 |
| 36578 | | A | Replace tunneled cv cath | 3.49 | 11.20 | 2.30 | 0.21 | 14.90 | 6.00 | 010 |
| 36580 | | A | Replace tunneled cv cath | 1.31 | 7.08 | 0.41 | 0.19 | 8.58 | 1.91 | 000 |
| 36581 | | A | Replace tunneled cv cath | 3.43 | 19.63 | 1.91 | 0.21 | 23.27 | 5.55 | 010 |
| 36582 | | A | Replace tunneled cv cath | 5.19 | 26.19 | 2.85 | 0.21 | 31.59 | 8.25 | 010 |
| 36583 | | A | Replace tunneled cv cath | 5.24 | 26.21 | 2.87 | 0.20 | 31.65 | 8.31 | 010 |
| 36584 | | A | Replace tunneled cv cath | 1.20 | 7.11 | 0.55 | 0.19 | 8.50 | 1.94 | 000 |
| 36585 | | A | Replace tunneled cv cath | 4.79 | 28.01 | 2.72 | 0.21 | 33.01 | 7.72 | 010 |
| 36589 | | A | Removal tunneled cv cath | 2.27 | 2.24 | 1.39 | 0.25 | 4.76 | 3.91 | 010 |
| 36590 | | A | Removal tunneled cv cath | 3.30 | 3.38 | 1.72 | 0.43 | 7.11 | 5.45 | 010 |
| 36595 | | A | Mech remov tunneled cv cath | 3.59 | 17.42 | 1.45 | 0.33 | 21.34 | 5.37 | 000 |
| 36596 | | A | Mech remov tunneled cv cath | 0.75 | 3.71 | 0.50 | 0.39 | 4.85 | 1.64 | 000 |
| 36597 | | A | Reposition venous catheter | 1.21 | 2.41 | 0.44 | 0.08 | 3.70 | 1.73 | 000 |
| 36600 | | A | Withdrawal of arterial blood | 0.32 | 0.49 | 0.09 | 0.02 | 0.83 | 0.43 | XXX |
| 36620 | | A | Insertion catheter, artery | 1.15 | NA | 0.23 | 0.07 | NA | 1.45 | 000 |
| 36625 | | A | Insertion catheter, artery | 2.11 | NA | 0.53 | 0.21 | NA | 2.85 | 000 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 36640 | | A | Insertion catheter, artery | 2.10 | NA | 1.05 | 0.22 | NA | 3.37 | 000 |
| 36660 | | A | Insertion catheter, artery | 1.40 | NA | 0.44 | 0.09 | NA | 1.93 | 000 |
| 36680 | | A | Insert needle, bone cavity | 1.20 | NA | 0.49 | 0.13 | NA | 1.82 | 000 |
| 36800 | | A | Insertion of cannula | 2.43 | NA | 1.80 | 0.23 | NA | 4.46 | 000 |
| 36810 | | A | Insertion of cannula | 3.96 | NA | 1.68 | 0.47 | NA | 6.11 | 000 |
| 36815 | | A | Insertion of cannula | 2.62 | NA | 1.17 | 0.33 | NA | 4.12 | 000 |
| 36819 | | A | Av fusion/uppr arm vein | 13.98 | NA | 6.36 | 1.87 | NA | 22.21 | 090 |
| 36820 | | A | Av fusion/forearm vein | 13.98 | NA | 6.37 | 1.88 | NA | 22.23 | 090 |
| 36821 | | A | Av fusion direct any site | 8.92 | NA | 4.67 | 1.18 | NA | 14.77 | 090 |
| 36822 | | A | Insertion of cannula(s) | 5.41 | NA | 4.41 | 0.73 | NA | 10.55 | 090 |
| 36823 | | A | Insertion of cannula(s) | 20.97 | NA | 9.38 | 2.64 | NA | 32.99 | 090 |
| 36825 | | A | Artery-vein autograft | 9.83 | NA | 5.07 | 1.29 | NA | 16.19 | 090 |
| 36830 | | A | Artery-vein nonautograft | 11.98 | NA | 5.25 | 1.60 | NA | 18.83 | 090 |
| 36831 | | A | Open thrombect av fistula | 7.99 | NA | 3.94 | 1.07 | NA | 13.00 | 090 |
| 36832 | | A | Av fistula revision, open | 10.48 | NA | 4.74 | 1.39 | NA | 16.61 | 090 |
| 36833 | | A | Av fistula revision | 11.93 | NA | 5.21 | 1.60 | NA | 18.74 | 090 |
| 36834 | | A | Repair A-V aneurysm | 9.92 | NA | 4.79 | 1.34 | NA | 16.05 | 090 |
| 36835 | | A | Artery to vein shunt | 7.14 | NA | 4.34 | 0.99 | NA | 12.47 | 090 |
| 36838 | | A | Dist revas ligation, hemo | 20.60 | NA | 9.37 | 2.99 | NA | 32.96 | 090 |
| 36860 | | A | External cannula declotting | 2.01 | 1.77 | 0.67 | 0.13 | 3.91 | 2.81 | 000 |
| 36861 | | A | Cannula declotting | 2.52 | NA | 1.49 | 0.25 | NA | 4.26 | 000 |
| 36870 | | A | Percut thrombect av fistula | 5.15 | 32.39 | 3.14 | 0.33 | 37.87 | 8.62 | 090 |
| 37140 | | A | Revision of circulation | 23.56 | NA | 10.46 | 1.71 | NA | 35.73 | 090 |
| 37145 | | A | Revision of circulation | 24.57 | NA | 10.87 | 2.99 | NA | 38.43 | 090 |
| 37160 | | A | Revision of circulation | 21.57 | NA | 9.25 | 2.79 | NA | 33.61 | 090 |
| 37180 | | A | Revision of circulation | 24.57 | NA | 10.29 | 3.12 | NA | 37.98 | 090 |
| 37181 | | A | Splice spleen/kidney veins | 26.64 | NA | 10.99 | 3.37 | NA | 41.00 | 090 |
| 37182 | | A | Insert hepatic shunt (tips) | 16.97 | NA | 6.04 | 0.59 | NA | 23.60 | 000 |
| 37183 | | A | Remove hepatic shunt (tips) | 7.99 | NA | 3.01 | 0.59 | NA | 11.59 | 000 |
| 37195 | | A | Thrombolytic therapy, stroke | 0.00 | 8.04 | NA | 0.46 | 8.50 | NA | XXX |
| 37200 | | A | Transcatheter biopsy | 4.55 | NA | 1.49 | 0.27 | NA | 6.31 | 000 |
| 37201 | | A | Transcatheter therapy infuse | 4.99 | NA | 2.54 | 0.35 | NA | 7.88 | 000 |
| 37202 | | A | Transcatheter therapy infuse | 5.67 | NA | 3.02 | 0.53 | NA | 9.22 | 000 |
| 37203 | | A | Transcatheter retrieval | 5.02 | 33.39 | 2.03 | 0.33 | 38.74 | 7.38 | 000 |
| 37204 | | A | Transcatheter occlusion | 18.11 | NA | 5.89 | 1.37 | NA | 25.37 | 000 |
| 37205 | | A | Transcatheter stent | 8.27 | NA | 3.75 | 0.59 | NA | 12.61 | 000 |
| 37206 | | A | Transcatheter stent add-on | 4.12 | NA | 1.43 | 0.31 | NA | 5.86 | ZZZ |
| 37207 | | A | Transcatheter stent | 8.27 | NA | 3.15 | 1.10 | NA | 12.52 | 000 |
| 37208 | | A | Transcatheter stent add-on | 4.12 | NA | 1.38 | 0.55 | NA | 6.05 | ZZZ |
| 37209 | | A | Exchange arterial catheter | 2.27 | NA | 0.74 | 0.16 | NA | 3.17 | 000 |
| 37250 | | A | Iv us first vessel add-on | 2.10 | NA | 0.75 | 0.20 | NA | 3.05 | ZZZ |
| 37251 | | A | Iv us each add vessel add-on | 1.60 | NA | 0.55 | 0.19 | NA | 2.34 | ZZZ |
| 37500 | | A | Endoscopy ligate perf veins | 10.98 | NA | 6.88 | 0.48 | NA | 18.34 | 090 |
| 37565 | | A | Ligation of neck vein | 10.86 | NA | 5.61 | 1.31 | NA | 17.78 | 090 |
| 37600 | | A | Ligation of neck artery | 11.23 | NA | 6.62 | 1.30 | NA | 19.15 | 090 |
| 37605 | | A | Ligation of neck artery | 13.09 | NA | 6.90 | 1.93 | NA | 21.92 | 090 |
| 37606 | | A | Ligation of neck artery | 6.27 | NA | 4.56 | 0.94 | NA | 11.77 | 090 |
| 37607 | | A | Ligation of a-v fistula | 6.15 | NA | 3.57 | 0.83 | NA | 10.55 | 090 |
| 37609 | | A | Temporal artery procedure | 3.00 | 4.51 | 1.96 | 0.36 | 7.87 | 5.32 | 010 |
| 37615 | | A | Ligation of neck artery | 5.72 | NA | 4.10 | 0.69 | NA | 10.51 | 090 |
| 37616 | | A | Ligation of chest artery | 16.47 | NA | 8.10 | 2.19 | NA | 26.76 | 090 |
| 37617 | | A | Ligation of abdomen artery | 22.03 | NA | 9.17 | 2.85 | NA | 34.05 | 090 |
| 37618 | | A | Ligation of extremity artery | 4.83 | NA | 3.62 | 0.65 | NA | 9.10 | 090 |
| 37620 | | A | Revision of major vein | 10.54 | NA | 5.70 | 0.94 | NA | 17.18 | 090 |
| 37650 | | A | Revision of major vein | 7.79 | NA | 4.69 | 1.05 | NA | 13.53 | 090 |
| 37660 | | A | Revision of major vein | 20.97 | NA | 9.05 | 2.60 | NA | 32.62 | 090 |
| 37700 | | A | Revise leg vein | 3.72 | NA | 2.80 | 0.52 | NA | 7.04 | 090 |
| 37720 | | A | Removal of leg vein | 5.65 | NA | 3.71 | 0.79 | NA | 10.15 | 090 |
| 37730 | | A | Removal of leg veins | 7.32 | NA | 4.26 | 0.97 | NA | 12.55 | 090 |
| 37735 | | A | Removal of leg veins/lesion | 10.51 | NA | 5.50 | 1.48 | NA | 17.49 | 090 |
| 37760 | | A | Ligation, leg veins, open | 10.45 | NA | 5.35 | 1.38 | NA | 17.18 | 090 |
| 37765 | | A | Phleb veins - extrem - to 20 | 7.34 | NA | 4.61 | 0.48 | NA | 12.43 | 090 |
| 37766 | | A | Phleb veins - extrem 20+ | 9.29 | NA | 5.31 | 0.48 | NA | 15.08 | 090 |
| 37780 | | A | Revision of leg vein | 3.83 | NA | 2.86 | 0.54 | NA | 7.23 | 090 |
| 37785 | | A | Ligate/divide/excise vein | 3.83 | 5.22 | 2.73 | 0.53 | 9.58 | 7.09 | 090 |
| 37788 | | A | Revascularization, penis | 21.98 | NA | 9.18 | 1.56 | NA | 32.72 | 090 |
| 37790 | | A | Penile venous occlusion | 8.33 | NA | 4.47 | 0.62 | NA | 13.42 | 090 |
| 38100 | | A | Removal of spleen, total | 14.48 | NA | 6.19 | 1.85 | NA | 22.52 | 090 |
| 38101 | | A | Removal of spleen, partial | 15.29 | NA | 6.54 | 2.01 | NA | 23.84 | 090 |
| 38102 | | A | Removal of spleen, total | 4.79 | NA | 1.63 | 0.61 | NA | 7.03 | ZZZ |
| 38115 | | A | Repair of ruptured spleen | 15.80 | NA | 6.65 | 1.97 | NA | 24.42 | 090 |
| 38120 | | A | Laparoscopy, splenectomy | 16.97 | NA | 7.38 | 2.18 | NA | 26.53 | 090 |
| 38200 | | A | Injection for spleen x-ray | 2.64 | NA | 0.89 | 0.17 | NA | 3.70 | 000 |
| 38205 | | R | Harvest allogenic stem cells | 1.50 | NA | 0.68 | 0.06 | NA | 2.24 | 000 |
| 38206 | | R | Harvest auto stem cells | 1.50 | NA | 0.67 | 0.06 | NA | 2.23 | 000 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 38220 | | A | Bone marrow aspiration | 1.08 | 3.97 | 0.52 | 0.06 | 5.11 | 1.66 | XXX |
| 38221 | | A | Bone marrow biopsy | 1.37 | 4.19 | 0.65 | 0.07 | 5.63 | 2.09 | XXX |
| 38230 | | R | Bone marrow collection | 4.53 | NA | 3.27 | 0.33 | NA | 8.13 | 010 |
| 38240 | | R | Bone marrow/stem transplant | 2.24 | NA | 1.03 | 0.11 | NA | 3.38 | XXX |
| 38241 | | R | Bone marrow/stem transplant | 2.24 | NA | 1.04 | 0.11 | NA | 3.39 | XXX |
| 38242 | | A | Lymphocyte infuse transplant | 1.71 | NA | 0.78 | 0.07 | NA | 2.56 | 000 |
| 38300 | | A | Drainage, lymph node lesion | 1.99 | 4.36 | 2.06 | 0.22 | 6.57 | 4.27 | 010 |
| 38305 | | A | Drainage, lymph node lesion | 5.99 | NA | 4.47 | 0.60 | NA | 11.06 | 090 |
| 38308 | | A | Incision of lymph channels | 6.44 | NA | 3.76 | 0.85 | NA | 11.05 | 090 |
| 38380 | | A | Thoracic duct procedure | 7.45 | NA | 5.68 | 0.80 | NA | 13.93 | 090 |
| 38381 | | A | Thoracic duct procedure | 12.86 | NA | 6.90 | 1.81 | NA | 21.57 | 090 |
| 38382 | | A | Thoracic duct procedure | 10.06 | NA | 5.79 | 1.40 | NA | 17.25 | 090 |
| 38500 | | A | Biopsy/removal, lymph nodes | 3.74 | 3.71 | 2.08 | 0.48 | 7.93 | 6.30 | 010 |
| 38505 | | A | Needle biopsy, lymph nodes | 1.14 | 2.06 | 0.79 | 0.10 | 3.30 | 2.03 | 000 |
| 38510 | | A | Biopsy/removal, lymph nodes | 6.42 | 5.54 | 3.48 | 0.74 | 12.70 | 10.64 | 010 |
| 38520 | | A | Biopsy/removal, lymph nodes | 6.66 | NA | 4.06 | 0.84 | NA | 11.56 | 090 |
| 38525 | | A | Biopsy/removal, lymph nodes | 6.06 | NA | 3.33 | 0.79 | NA | 10.18 | 090 |
| 38530 | | A | Biopsy/removal, lymph nodes | 7.97 | NA | 4.43 | 1.06 | NA | 13.46 | 090 |
| 38542 | | A | Explore deep node(s), neck | 5.90 | NA | 4.48 | 0.63 | NA | 11.01 | 090 |
| 38550 | | A | Removal, neck/armpit lesion | 6.91 | NA | 3.96 | 0.87 | NA | 11.74 | 090 |
| 38555 | | A | Removal, neck/armpit lesion | 14.12 | NA | 8.57 | 1.67 | NA | 24.36 | 090 |
| 38562 | | A | Removal, pelvic lymph nodes | 10.47 | NA | 5.79 | 1.21 | NA | 17.47 | 090 |
| 38564 | | A | Removal, abdomen lymph nodes | 10.81 | NA | 5.27 | 1.31 | NA | 17.39 | 090 |
| 38570 | | A | Laparoscopy, lymph node biop | 9.24 | NA | 3.97 | 1.12 | NA | 14.33 | 010 |
| 38571 | | A | Laparoscopy, lymphadenectomy | 14.66 | NA | 5.64 | 1.20 | NA | 21.50 | 010 |
| 38572 | | A | Laparoscopy, lymphadenectomy | 16.57 | NA | 7.07 | 1.89 | NA | 25.53 | 010 |
| 38700 | | A | Removal of lymph nodes, neck | 8.23 | NA | 6.22 | 0.76 | NA | 15.21 | 090 |
| 38720 | | A | Removal of lymph nodes, neck | 13.59 | NA | 9.35 | 1.24 | NA | 24.18 | 090 |
| 38724 | | A | Removal of lymph nodes, neck | 14.52 | NA | 9.82 | 1.32 | NA | 25.66 | 090 |
| 38740 | | A | Remove armpit lymph nodes | 10.01 | NA | 4.98 | 1.30 | NA | 16.29 | 090 |
| 38745 | | A | Remove armpit lymph nodes | 13.08 | NA | 6.14 | 1.68 | NA | 20.90 | 090 |
| 38746 | | A | Remove thoracic lymph nodes | 4.88 | NA | 1.61 | 0.67 | NA | 7.16 | ZZZ |
| 38747 | | A | Remove abdominal lymph nodes | 4.88 | NA | 1.66 | 0.62 | NA | 7.16 | ZZZ |
| 38760 | | A | Remove groin lymph nodes | 12.93 | NA | 6.16 | 1.65 | NA | 20.74 | 090 |
| 38765 | | A | Remove groin lymph nodes | 19.95 | NA | 8.85 | 2.44 | NA | 31.24 | 090 |
| 38770 | | A | Remove pelvis lymph nodes | 13.21 | NA | 5.76 | 1.37 | NA | 20.34 | 090 |
| 38780 | | A | Remove abdomen lymph nodes | 16.57 | NA | 8.22 | 1.88 | NA | 26.67 | 090 |
| 38790 | | A | Inject for lymphatic x-ray | 1.29 | 7.42 | 0.76 | 0.13 | 8.84 | 2.18 | 000 |
| 38792 | | A | Identify sentinel node | 0.52 | NA | 0.44 | 0.06 | NA | 1.02 | 000 |
| 38794 | | A | Access thoracic lymph duct | 4.44 | NA | 3.43 | 0.21 | NA | 8.08 | 090 |
| 39000 | | A | Exploration of chest | 6.09 | NA | 4.68 | 0.83 | NA | 11.60 | 090 |
| 39010 | | A | Exploration of chest | 11.77 | NA | 6.64 | 1.59 | NA | 20.00 | 090 |
| 39200 | | A | Removal chest lesion | 13.60 | NA | 6.78 | 1.82 | NA | 22.20 | 090 |
| 39220 | | A | Removal chest lesion | 17.39 | NA | 8.50 | 2.23 | NA | 28.12 | 090 |
| 39400 | | A | Visualization of chest | 5.60 | NA | 4.85 | 0.79 | NA | 11.24 | 010 |
| 39501 | | A | Repair diaphragm laceration | 13.17 | NA | 6.48 | 1.68 | NA | 21.33 | 090 |
| 39502 | | A | Repair paraesophageal hernia | 16.31 | NA | 7.16 | 2.10 | NA | 25.57 | 090 |
| 39503 | | A | Repair of diaphragm hernia | 94.86 | NA | 33.37 | 11.59 | NA | 139.82 | 090 |
| 39520 | | A | Repair of diaphragm hernia | 16.08 | NA | 8.06 | 2.10 | NA | 26.24 | 090 |
| 39530 | | A | Repair of diaphragm hernia | 15.39 | NA | 7.15 | 1.97 | NA | 24.51 | 090 |
| 39531 | | A | Repair of diaphragm hernia | 16.40 | NA | 7.40 | 2.10 | NA | 25.90 | 090 |
| 39540 | | A | Repair of diaphragm hernia | 13.30 | NA | 6.25 | 1.67 | NA | 21.22 | 090 |
| 39541 | | A | Repair of diaphragm hernia | 14.39 | NA | 6.60 | 1.86 | NA | 22.85 | 090 |
| 39545 | | A | Revision of diaphragm | 13.35 | NA | 7.57 | 1.81 | NA | 22.73 | 090 |
| 39560 | | A | Resect diaphragm, simple | 11.98 | NA | 6.31 | 1.55 | NA | 19.84 | 090 |
| 39561 | | A | Resect diaphragm, complex | 17.47 | NA | 9.35 | 2.27 | NA | 29.09 | 090 |
| 40490 | | A | Biopsy of lip | 1.22 | 1.63 | 0.61 | 0.11 | 2.96 | 1.94 | 000 |
| 40500 | | A | Partial excision of lip | 4.27 | 6.90 | 4.33 | 0.45 | 11.62 | 9.05 | 090 |
| 40510 | | A | Partial excision of lip | 4.69 | 6.61 | 4.01 | 0.51 | 11.81 | 9.21 | 090 |
| 40520 | | A | Partial excision of lip | 4.66 | 7.53 | 4.10 | 0.55 | 12.74 | 9.31 | 090 |
| 40525 | | A | Reconstruct lip with flap | 7.54 | NA | 6.29 | 0.88 | NA | 14.71 | 090 |
| 40527 | | A | Reconstruct lip with flap | 9.12 | NA | 7.33 | 1.01 | NA | 17.46 | 090 |
| 40530 | | A | Partial removal of lip | 5.39 | 7.81 | 4.57 | 0.60 | 13.80 | 10.56 | 090 |
| 40650 | | A | Repair lip | 3.63 | 6.79 | 3.32 | 0.39 | 10.81 | 7.34 | 090 |
| 40652 | | A | Repair lip | 4.25 | 7.74 | 4.27 | 0.53 | 12.52 | 9.05 | 090 |
| 40654 | | A | Repair lip | 5.30 | 8.59 | 4.93 | 0.67 | 14.56 | 10.90 | 090 |
| 40700 | | A | Repair cleft lip/nasal | 12.77 | NA | 9.06 | 1.08 | NA | 22.91 | 090 |
| 40701 | | A | Repair cleft lip/nasal | 15.83 | NA | 11.30 | 2.36 | NA | 29.49 | 090 |
| 40702 | | A | Repair cleft lip/nasal | 13.02 | NA | 8.27 | 0.92 | NA | 22.21 | 090 |
| 40720 | | A | Repair cleft lip/nasal | 13.53 | NA | 9.86 | 1.74 | NA | 25.13 | 090 |
| 40761 | | A | Repair cleft lip/nasal | 14.70 | NA | 10.24 | 1.70 | NA | 26.64 | 090 |
| 40800 | | A | Drainage of mouth lesion | 1.17 | 2.97 | 1.77 | 0.12 | 4.26 | 3.06 | 010 |
| 40801 | | A | Drainage of mouth lesion | 2.53 | 4.01 | 2.74 | 0.32 | 6.86 | 5.59 | 010 |
| 40804 | | A | Removal, foreign body, mouth | 1.24 | 3.41 | 1.87 | 0.12 | 4.77 | 3.23 | 010 |
| 40805 | | A | Removal, foreign body, mouth | 2.69 | 4.48 | 2.81 | 0.29 | 7.46 | 5.79 | 010 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 40806 | | A | Incision of lip fold | 0.31 | 1.83 | 0.50 | 0.03 | 2.17 | 0.84 | 000 |
| 40808 | | A | Biopsy of mouth lesion | 0.96 | 2.65 | 1.48 | 0.10 | 3.71 | 2.54 | 010 |
| 40810 | | A | Excision of mouth lesion | 1.31 | 2.88 | 1.66 | 0.13 | 4.32 | 3.10 | 010 |
| 40812 | | A | Excise/repair mouth lesion | 2.31 | 3.71 | 2.40 | 0.28 | 6.30 | 4.99 | 010 |
| 40814 | | A | Excise/repair mouth lesion | 3.41 | 4.94 | 3.89 | 0.40 | 8.75 | 7.70 | 090 |
| 40816 | | A | Excision of mouth lesion | 3.66 | 5.17 | 3.99 | 0.39 | 9.22 | 8.04 | 090 |
| 40818 | | A | Excise oral mucosa for graft | 2.41 | 5.17 | 3.97 | 0.21 | 7.79 | 6.59 | 090 |
| 40819 | | A | Excise lip or cheek fold | 2.41 | 4.08 | 3.09 | 0.27 | 6.76 | 5.77 | 090 |
| 40820 | | A | Treatment of mouth lesion | 1.28 | 3.93 | 2.44 | 0.12 | 5.33 | 3.84 | 010 |
| 40830 | | A | Repair mouth laceration | 1.76 | 3.73 | 2.11 | 0.17 | 5.66 | 4.04 | 010 |
| 40831 | | A | Repair mouth laceration | 2.46 | 4.65 | 3.05 | 0.28 | 7.39 | 5.79 | 010 |
| 40840 | | R | Reconstruction of mouth | 8.72 | 9.77 | 6.96 | 0.98 | 19.47 | 16.66 | 090 |
| 40842 | | R | Reconstruction of mouth | 8.72 | 10.04 | 6.78 | 0.94 | 19.70 | 16.44 | 090 |
| 40843 | | R | Reconstruction of mouth | 12.08 | 11.93 | 7.80 | 1.39 | 25.40 | 21.27 | 090 |
| 40844 | | R | Reconstruction of mouth | 15.99 | 15.74 | 11.55 | 2.12 | 33.85 | 29.66 | 090 |
| 40845 | | R | Reconstruction of mouth | 18.55 | 17.03 | 13.19 | 2.02 | 37.60 | 33.76 | 090 |
| 41000 | | A | Drainage of mouth lesion | 1.30 | 2.32 | 1.41 | 0.12 | 3.74 | 2.83 | 010 |
| 41005 | | A | Drainage of mouth lesion | 1.26 | 3.33 | 1.73 | 0.15 | 4.74 | 3.14 | 010 |
| 41006 | | A | Drainage of mouth lesion | 3.24 | 4.79 | 3.16 | 0.34 | 8.37 | 6.74 | 090 |
| 41007 | | A | Drainage of mouth lesion | 3.10 | 5.11 | 3.02 | 0.34 | 8.55 | 6.46 | 090 |
| 41008 | | A | Drainage of mouth lesion | 3.36 | 4.67 | 3.20 | 0.44 | 8.47 | 7.00 | 090 |
| 41009 | | A | Drainage of mouth lesion | 3.58 | 4.96 | 3.56 | 0.45 | 8.99 | 7.59 | 090 |
| 41010 | | A | Incision of tongue fold | 1.06 | 3.44 | 1.60 | 0.09 | 4.59 | 2.75 | 010 |
| 41015 | | A | Drainage of mouth lesion | 3.95 | 5.39 | 4.14 | 0.49 | 9.83 | 8.58 | 090 |
| 41016 | | A | Drainage of mouth lesion | 4.06 | 5.60 | 4.22 | 0.51 | 10.17 | 8.79 | 090 |
| 41017 | | A | Drainage of mouth lesion | 4.06 | 5.62 | 4.30 | 0.53 | 10.21 | 8.89 | 090 |
| 41018 | | A | Drainage of mouth lesion | 5.09 | 6.13 | 4.58 | 0.65 | 11.87 | 10.32 | 090 |
| 41100 | | A | Biopsy of tongue | 1.63 | 2.42 | 1.42 | 0.15 | 4.20 | 3.20 | 010 |
| 41105 | | A | Biopsy of tongue | 1.42 | 2.30 | 1.32 | 0.13 | 3.85 | 2.87 | 010 |
| 41108 | | A | Biopsy of floor of mouth | 1.05 | 2.07 | 1.13 | 0.10 | 3.22 | 2.28 | 010 |
| 41110 | | A | Excision of tongue lesion | 1.51 | 2.99 | 1.64 | 0.13 | 4.63 | 3.28 | 010 |
| 41112 | | A | Excision of tongue lesion | 2.73 | 4.46 | 3.22 | 0.28 | 7.47 | 6.23 | 090 |
| 41113 | | A | Excision of tongue lesion | 3.19 | 4.73 | 3.46 | 0.35 | 8.27 | 7.00 | 090 |
| 41114 | | A | Excision of tongue lesion | 8.46 | NA | 7.18 | 0.84 | NA | 16.48 | 090 |
| 41115 | | A | Excision of tongue fold | 1.74 | 3.28 | 1.85 | 0.19 | 5.21 | 3.78 | 010 |
| 41116 | | A | Excision of mouth lesion | 2.44 | 4.35 | 2.80 | 0.23 | 7.02 | 5.47 | 090 |
| 41120 | | A | Partial removal of tongue | 9.76 | NA | 15.31 | 0.84 | NA | 25.91 | 090 |
| 41130 | | A | Partial removal of tongue | 11.13 | NA | 16.19 | 0.96 | NA | 28.28 | 090 |
| 41135 | | A | Tongue and neck surgery | 23.06 | NA | 23.23 | 2.01 | NA | 48.30 | 090 |
| 41140 | | A | Removal of tongue | 25.46 | NA | 26.66 | 2.50 | NA | 54.62 | 090 |
| 41145 | | A | Tongue removal, neck surgery | 30.01 | NA | 30.53 | 2.59 | NA | 63.13 | 090 |
| 41150 | | A | Tongue, mouth, jaw surgery | 23.01 | NA | 24.70 | 2.05 | NA | 49.76 | 090 |
| 41153 | | A | Tongue, mouth, neck surgery | 23.73 | NA | 25.01 | 2.10 | NA | 50.84 | 090 |
| 41155 | | A | Tongue, jaw, & neck surgery | 27.68 | NA | 26.79 | 2.44 | NA | 56.91 | 090 |
| 41250 | | A | Repair tongue laceration | 1.91 | 2.76 | 1.19 | 0.18 | 4.85 | 3.28 | 010 |
| 41251 | | A | Repair tongue laceration | 2.27 | 3.27 | 1.56 | 0.22 | 5.76 | 4.05 | 010 |
| 41252 | | A | Repair tongue laceration | 2.97 | 3.89 | 2.26 | 0.31 | 7.17 | 5.54 | 010 |
| 41500 | | A | Fixation of tongue | 3.70 | NA | 7.45 | 0.32 | NA | 11.47 | 090 |
| 41510 | | A | Tongue to lip surgery | 3.41 | NA | 7.99 | 0.38 | NA | 11.78 | 090 |
| 41520 | | A | Reconstruction, tongue fold | 2.73 | 4.62 | 3.61 | 0.27 | 7.62 | 6.61 | 090 |
| 41800 | | A | Drainage of gum lesion | 1.17 | 2.59 | 1.29 | 0.12 | 3.88 | 2.58 | 010 |
| 41805 | | A | Removal foreign body, gum | 1.24 | 2.67 | 2.22 | 0.15 | 4.06 | 3.61 | 010 |
| 41806 | | A | Removal foreign body,jawbone | 2.69 | 3.58 | 3.03 | 0.35 | 6.62 | 6.07 | 010 |
| 41822 | | R | Excision of gum lesion | 2.31 | 3.88 | 1.86 | 0.34 | 6.53 | 4.51 | 010 |
| 41823 | | R | Excision of gum lesion | 3.30 | 5.56 | 4.00 | 0.44 | 9.30 | 7.74 | 090 |
| 41825 | | A | Excision of gum lesion | 1.31 | 3.06 | 2.24 | 0.15 | 4.52 | 3.70 | 010 |
| 41826 | | A | Excision of gum lesion | 2.31 | 2.43 | 2.10 | 0.30 | 5.04 | 4.71 | 010 |
| 41827 | | A | Excision of gum lesion | 3.41 | 5.51 | 3.66 | 0.37 | 9.29 | 7.44 | 090 |
| 41828 | | R | Excision of gum lesion | 3.09 | 3.80 | 2.96 | 0.44 | 7.33 | 6.49 | 010 |
| 41830 | | R | Removal of gum tissue | 3.34 | 4.95 | 3.62 | 0.45 | 8.74 | 7.41 | 010 |
| 41872 | | R | Repair gum | 2.59 | 5.01 | 3.45 | 0.22 | 7.82 | 6.26 | 090 |
| 41874 | | R | Repair tooth socket | 3.09 | 4.83 | 3.17 | 0.45 | 8.37 | 6.71 | 090 |
| 42000 | | A | Drainage mouth roof lesion | 1.23 | 2.57 | 1.26 | 0.11 | 3.91 | 2.60 | 010 |
| 42100 | | A | Biopsy roof of mouth | 1.31 | 2.08 | 1.36 | 0.13 | 3.52 | 2.80 | 010 |
| 42104 | | A | Excision lesion, mouth roof | 1.64 | 2.53 | 1.55 | 0.16 | 4.33 | 3.35 | 010 |
| 42106 | | A | Excision lesion, mouth roof | 2.10 | 3.22 | 2.44 | 0.25 | 5.57 | 4.79 | 010 |
| 42107 | | A | Excision lesion, mouth roof | 4.43 | 5.70 | 3.94 | 0.46 | 10.59 | 8.83 | 090 |
| 42120 | | A | Remove palate/lesion | 6.16 | NA | 11.77 | 0.53 | NA | 18.46 | 090 |
| 42140 | | A | Excision of uvula | 1.62 | 3.72 | 2.09 | 0.13 | 5.47 | 3.84 | 090 |
| 42145 | | A | Repair palate, pharynx/uvula | 8.04 | NA | 7.49 | 0.66 | NA | 16.19 | 090 |
| 42160 | | A | Treatment mouth roof lesion | 1.80 | 4.25 | 2.29 | 0.16 | 6.21 | 4.25 | 010 |
| 42180 | | A | Repair palate | 2.50 | 3.07 | 2.10 | 0.21 | 5.78 | 4.81 | 010 |
| 42182 | | A | Repair palate | 3.82 | 3.87 | 3.02 | 0.40 | 8.09 | 7.24 | 010 |
| 42200 | | A | Reconstruct cleft palate | 11.98 | NA | 10.20 | 1.22 | NA | 23.40 | 090 |
| 42205 | | A | Reconstruct cleft palate | 13.27 | NA | 10.06 | 1.44 | NA | 24.77 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 42210 | | A | Reconstruct cleft palate | 14.48 | NA | 11.44 | 2.00 | NA | 27.92 | 090 |
| 42215 | | A | Reconstruct cleft palate | 8.81 | NA | 9.05 | 1.31 | NA | 19.17 | 090 |
| 42220 | | A | Reconstruct cleft palate | 7.01 | NA | 6.77 | 0.49 | NA | 14.27 | 090 |
| 42225 | | A | Reconstruct cleft palate | 9.53 | NA | 16.94 | 0.97 | NA | 27.44 | 090 |
| 42226 | | A | Lengthening of palate | 9.99 | NA | 14.63 | 0.89 | NA | 25.51 | 090 |
| 42227 | | A | Lengthening of palate | 9.51 | NA | 15.40 | 1.02 | NA | 25.93 | 090 |
| 42235 | | A | Repair palate | 7.86 | NA | 11.86 | 0.82 | NA | 20.54 | 090 |
| 42260 | | A | Repair nose to lip fistula | 9.79 | 10.17 | 7.06 | 0.98 | 20.94 | 17.83 | 090 |
| 42280 | | A | Preparation, palate mold | 1.54 | 1.95 | 1.14 | 0.21 | 3.70 | 2.89 | 010 |
| 42281 | | A | Insertion, palate prosthesis | 1.93 | 2.62 | 1.87 | 0.16 | 4.71 | 3.96 | 010 |
| 42300 | | A | Drainage of salivary gland | 1.93 | 2.82 | 1.81 | 0.17 | 4.92 | 3.91 | 010 |
| 42305 | | A | Drainage of salivary gland | 6.06 | NA | 4.72 | 0.53 | NA | 11.31 | 090 |
| 42310 | | A | Drainage of salivary gland | 1.56 | 2.26 | 1.54 | 0.15 | 3.97 | 3.25 | 010 |
| 42320 | | A | Drainage of salivary gland | 2.35 | 3.26 | 2.09 | 0.23 | 5.84 | 4.67 | 010 |
| 42325 | | A | Create salivary cyst drain | 2.75 | 4.61 | 2.31 | 0.22 | 7.58 | 5.28 | 090 |
| 42326 | | A | Create salivary cyst drain | 3.77 | 5.89 | 3.16 | 0.23 | 9.89 | 7.16 | 090 |
| 42330 | | A | Removal of salivary stone | 2.21 | 3.14 | 1.84 | 0.19 | 5.54 | 4.24 | 010 |
| 42335 | | A | Removal of salivary stone | 3.31 | 4.90 | 3.14 | 0.30 | 8.51 | 6.75 | 090 |
| 42340 | | A | Removal of salivary stone | 4.59 | 6.04 | 3.93 | 0.41 | 11.04 | 8.93 | 090 |
| 42400 | | A | Biopsy of salivary gland | 0.78 | 1.65 | 0.72 | 0.06 | 2.49 | 1.56 | 000 |
| 42405 | | A | Biopsy of salivary gland | 3.29 | 4.02 | 2.45 | 0.29 | 7.60 | 6.03 | 010 |
| 42408 | | A | Excision of salivary cyst | 4.53 | 5.90 | 3.61 | 0.42 | 10.85 | 8.56 | 090 |
| 42409 | | A | Drainage of salivary cyst | 2.81 | 4.52 | 2.76 | 0.23 | 7.56 | 5.80 | 090 |
| 42410 | | A | Excise parotid gland/lesion | 9.33 | NA | 6.21 | 0.93 | NA | 16.47 | 090 |
| 42415 | | A | Excise parotid gland/lesion | 16.86 | NA | 10.84 | 1.49 | NA | 29.19 | 090 |
| 42420 | | A | Excise parotid gland/lesion | 19.56 | NA | 12.35 | 1.72 | NA | 33.63 | 090 |
| 42425 | | A | Excise parotid gland/lesion | 13.00 | NA | 8.60 | 1.14 | NA | 22.74 | 090 |
| 42426 | | A | Excise parotid gland/lesion | 21.23 | NA | 12.99 | 1.86 | NA | 36.08 | 090 |
| 42440 | | A | Excise submaxillary gland | 6.96 | NA | 4.79 | 0.61 | NA | 12.36 | 090 |
| 42450 | | A | Excise sublingual gland | 4.61 | 5.89 | 4.24 | 0.42 | 10.92 | 9.27 | 090 |
| 42500 | | A | Repair salivary duct | 4.29 | 5.67 | 4.18 | 0.41 | 10.37 | 8.88 | 090 |
| 42505 | | A | Repair salivary duct | 6.17 | 7.12 | 5.35 | 0.56 | 13.85 | 12.08 | 090 |
| 42507 | | A | Parotid duct diversion | 6.10 | NA | 6.53 | 0.49 | NA | 13.12 | 090 |
| 42508 | | A | Parotid duct diversion | 9.09 | NA | 8.34 | 0.74 | NA | 18.17 | 090 |
| 42509 | | A | Parotid duct diversion | 11.52 | NA | 10.17 | 1.50 | NA | 23.19 | 090 |
| 42510 | | A | Parotid duct diversion | 8.14 | NA | 7.78 | 0.66 | NA | 16.58 | 090 |
| 42550 | | A | Injection for salivary x-ray | 1.25 | 3.25 | 0.41 | 0.08 | 4.58 | 1.74 | 000 |
| 42600 | | A | Closure of salivary fistula | 4.81 | 6.57 | 4.12 | 0.40 | 11.78 | 9.33 | 090 |
| 42650 | | A | Dilation of salivary duct | 0.77 | 1.10 | 0.71 | 0.07 | 1.94 | 1.55 | 000 |
| 42660 | | A | Dilation of salivary duct | 1.13 | 1.35 | 0.85 | 0.09 | 2.57 | 2.07 | 000 |
| 42665 | | A | Ligation of salivary duct | 2.53 | 4.16 | 2.59 | 0.21 | 6.90 | 5.33 | 090 |
| 42700 | | A | Drainage of tonsil abscess | 1.62 | 2.65 | 1.71 | 0.13 | 4.40 | 3.46 | 010 |
| 42720 | | A | Drainage of throat abscess | 5.41 | 4.82 | 3.78 | 0.48 | 10.71 | 9.67 | 010 |
| 42725 | | A | Drainage of throat abscess | 10.70 | NA | 8.21 | 0.96 | NA | 19.87 | 090 |
| 42800 | | A | Biopsy of throat | 1.39 | 2.18 | 1.40 | 0.12 | 3.69 | 2.91 | 010 |
| 42802 | | A | Biopsy of throat | 1.54 | 4.77 | 2.06 | 0.13 | 6.44 | 3.73 | 010 |
| 42804 | | A | Biopsy of upper nose/throat | 1.24 | 3.74 | 1.73 | 0.10 | 5.08 | 3.07 | 010 |
| 42806 | | A | Biopsy of upper nose/throat | 1.58 | 4.08 | 1.93 | 0.13 | 5.79 | 3.64 | 010 |
| 42808 | | A | Excise pharynx lesion | 2.30 | 3.09 | 1.93 | 0.19 | 5.58 | 4.42 | 010 |
| 42809 | | A | Remove pharynx foreign body | 1.81 | 2.33 | 1.35 | 0.16 | 4.30 | 3.32 | 010 |
| 42810 | | A | Excision of neck cyst | 3.25 | 5.71 | 3.54 | 0.31 | 9.27 | 7.10 | 090 |
| 42815 | | A | Excision of neck cyst | 7.06 | NA | 6.40 | 0.63 | NA | 14.09 | 090 |
| 42820 | | A | Remove tonsils and adenoids | 3.90 | NA | 3.29 | 0.33 | NA | 7.52 | 090 |
| 42821 | | A | Remove tonsils and adenoids | 4.28 | NA | 3.50 | 0.35 | NA | 8.13 | 090 |
| 42825 | | A | Removal of tonsils | 3.41 | NA | 3.17 | 0.28 | NA | 6.86 | 090 |
| 42826 | | A | Removal of tonsils | 3.37 | NA | 3.03 | 0.28 | NA | 6.68 | 090 |
| 42830 | | A | Removal of adenoids | 2.57 | NA | 2.56 | 0.21 | NA | 5.34 | 090 |
| 42831 | | A | Removal of adenoids | 2.71 | NA | 2.84 | 0.22 | NA | 5.77 | 090 |
| 42835 | | A | Removal of adenoids | 2.30 | NA | 2.46 | 0.21 | NA | 4.97 | 090 |
| 42836 | | A | Removal of adenoids | 3.18 | NA | 2.95 | 0.26 | NA | 6.39 | 090 |
| 42842 | | A | Extensive surgery of throat | 8.75 | NA | 10.99 | 0.72 | NA | 20.46 | 090 |
| 42844 | | A | Extensive surgery of throat | 14.29 | NA | 16.23 | 1.24 | NA | 31.76 | 090 |
| 42845 | | A | Extensive surgery of throat | 24.25 | NA | 23.17 | 2.07 | NA | 49.49 | 090 |
| 42860 | | A | Excision of tonsil tags | 2.22 | NA | 2.40 | 0.19 | NA | 4.81 | 090 |
| 42870 | | A | Excision of lingual tonsil | 5.39 | NA | 8.57 | 0.45 | NA | 14.41 | 090 |
| 42890 | | A | Partial removal of pharynx | 12.92 | NA | 14.15 | 1.10 | NA | 28.17 | 090 |
| 42892 | | A | Revision of pharyngeal walls | 15.81 | NA | 17.17 | 1.33 | NA | 34.31 | 090 |
| 42894 | | A | Revision of pharyngeal walls | 22.85 | NA | 22.01 | 1.91 | NA | 46.77 | 090 |
| 42900 | | A | Repair throat wound | 5.24 | NA | 3.66 | 0.55 | NA | 9.45 | 010 |
| 42950 | | A | Reconstruction of throat | 8.09 | NA | 11.85 | 0.72 | NA | 20.66 | 090 |
| 42953 | | A | Repair throat, esophagus | 8.95 | NA | 17.22 | 0.88 | NA | 27.05 | 090 |
| 42955 | | A | Surgical opening of throat | 7.38 | NA | 10.69 | 0.70 | NA | 18.77 | 090 |
| 42960 | | A | Control throat bleeding | 2.33 | NA | 1.95 | 0.18 | NA | 4.46 | 010 |
| 42961 | | A | Control throat bleeding | 5.58 | NA | 4.96 | 0.46 | NA | 11.00 | 090 |
| 42962 | | A | Control throat bleeding | 7.13 | NA | 5.91 | 0.62 | NA | 13.66 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 42970 | | A | Control nose/throat bleeding | 5.42 | NA | 4.22 | 0.40 | NA | 10.04 | 090 |
| 42971 | | A | Control nose/throat bleeding | 6.20 | NA | 5.12 | 0.54 | NA | 11.86 | 090 |
| 42972 | | A | Control nose/throat bleeding | 7.19 | NA | 5.69 | 0.59 | NA | 13.47 | 090 |
| 43020 | | A | Incision of esophagus | 8.08 | NA | 5.41 | 0.92 | NA | 14.41 | 090 |
| 43030 | | A | Throat muscle surgery | 7.68 | NA | 5.48 | 0.70 | NA | 13.86 | 090 |
| 43045 | | A | Incision of esophagus | 20.09 | NA | 10.71 | 2.22 | NA | 33.02 | 090 |
| 43100 | | A | Excision of esophagus lesion | 9.18 | NA | 6.23 | 0.98 | NA | 16.39 | 090 |
| 43101 | | A | Excision of esophagus lesion | 16.22 | NA | 7.89 | 2.09 | NA | 26.20 | 090 |
| 43107 | | A | Removal of esophagus | 39.94 | NA | 17.05 | 5.03 | NA | 62.02 | 090 |
| 43108 | | A | Removal of esophagus | 34.14 | NA | 14.21 | 4.27 | NA | 52.62 | 090 |
| 43112 | | A | Removal of esophagus | 43.43 | NA | 18.14 | 5.61 | NA | 67.18 | 090 |
| 43113 | | A | Removal of esophagus | 35.22 | NA | 15.11 | 4.43 | NA | 54.76 | 090 |
| 43116 | | A | Partial removal of esophagus | 31.17 | NA | 16.69 | 3.02 | NA | 50.88 | 090 |
| 43117 | | A | Partial removal of esophagus | 39.94 | NA | 16.29 | 4.98 | NA | 61.21 | 090 |
| 43118 | | A | Partial removal of esophagus | 33.15 | NA | 13.79 | 4.27 | NA | 51.21 | 090 |
| 43121 | | A | Partial removal of esophagus | 29.15 | NA | 12.68 | 4.06 | NA | 45.89 | 090 |
| 43122 | | A | Partial removal of esophagus | 39.94 | NA | 16.40 | 5.11 | NA | 61.45 | 090 |
| 43123 | | A | Partial removal of esophagus | 33.15 | NA | 14.10 | 4.49 | NA | 51.74 | 090 |
| 43124 | | A | Removal of esophagus | 27.28 | NA | 13.09 | 3.28 | NA | 43.65 | 090 |
| 43130 | | A | Removal of esophagus pouch | 11.73 | NA | 7.57 | 1.22 | NA | 20.52 | 090 |
| 43135 | | A | Removal of esophagus pouch | 16.08 | NA | 8.11 | 2.16 | NA | 26.35 | 090 |
| 43200 | | A | Esophagus endoscopy | 1.59 | 4.15 | 1.07 | 0.13 | 5.87 | 2.79 | 000 |
| 43201 | | A | Esoph scope w/submucous inj | 2.09 | 4.61 | 1.10 | 0.13 | 6.83 | 3.32 | 000 |
| 43202 | | A | Esophagus endoscopy, biopsy | 1.89 | 5.59 | 0.94 | 0.16 | 7.64 | 2.99 | 000 |
| 43204 | | A | Esoph scope w/sclerosis inj | 3.76 | NA | 1.52 | 0.30 | NA | 5.58 | 000 |
| 43205 | | A | Esophagus endoscopy/ligation | 3.78 | NA | 1.52 | 0.29 | NA | 5.59 | 000 |
| 43215 | | A | Esophagus endoscopy | 2.60 | NA | 1.20 | 0.23 | NA | 4.03 | 000 |
| 43216 | | A | Esophagus endoscopy/lesion | 2.40 | NA | 1.19 | 0.20 | NA | 3.79 | 000 |
| 43217 | | A | Esophagus endoscopy | 2.90 | 7.02 | 1.19 | 0.25 | 10.17 | 4.34 | 000 |
| 43219 | | A | Esophagus endoscopy | 2.80 | NA | 1.35 | 0.23 | NA | 4.38 | 000 |
| 43220 | | A | Esoph endoscopy, dilation | 2.10 | NA | 0.97 | 0.17 | NA | 3.24 | 000 |
| 43226 | | A | Esoph endoscopy, dilation | 2.34 | NA | 1.03 | 0.19 | NA | 3.56 | 000 |
| 43227 | | A | Esoph endoscopy, repair | 3.59 | NA | 1.45 | 0.28 | NA | 5.32 | 000 |
| 43228 | | A | Esoph endoscopy, ablation | 3.76 | NA | 1.55 | 0.35 | NA | 5.66 | 000 |
| 43231 | | A | Esoph endoscopy w/us exam | 3.19 | NA | 1.31 | 0.23 | NA | 4.73 | 000 |
| 43232 | | A | Esoph endoscopy w/us fn bx | 4.47 | NA | 1.81 | 0.31 | NA | 6.59 | 000 |
| 43234 | | A | Upper GI endoscopy, exam | 2.01 | 5.37 | 0.87 | 0.17 | 7.55 | 3.05 | 000 |
| 43235 | | A | Uppr gi endoscopy, diagnosis | 2.39 | 5.22 | 1.02 | 0.19 | 7.80 | 3.60 | 000 |
| 43236 | | A | Uppr gi scope w/submuc inj | 2.92 | 6.45 | 1.22 | 0.19 | 9.56 | 4.33 | 000 |
| 43237 | | A | Endoscopic us exam, esoph | 3.98 | NA | 1.59 | 0.43 | NA | 6.00 | 000 |
| 43238 | | A | Uppr gi endoscopy w/us fn bx | 5.02 | NA | 1.96 | 0.43 | NA | 7.41 | 000 |
| 43239 | | A | Upper GI endoscopy, biopsy | 2.87 | 5.77 | 1.19 | 0.23 | 8.87 | 4.29 | 000 |
| 43240 | | A | Esoph endoscope w/drain cyst | 6.85 | NA | 2.60 | 0.54 | NA | 9.99 | 000 |
| 43241 | | A | Upper GI endoscopy with tube | 2.59 | NA | 1.10 | 0.21 | NA | 3.90 | 000 |
| 43242 | | A | Uppr gi endoscopy w/us fn bx | 7.30 | NA | 2.73 | 0.53 | NA | 10.56 | 000 |
| 43243 | | A | Upper gi endoscopy & inject | 4.56 | NA | 1.79 | 0.34 | NA | 6.69 | 000 |
| 43244 | | A | Upper GI endoscopy/ligation | 5.04 | NA | 1.96 | 0.37 | NA | 7.37 | 000 |
| 43245 | | A | Uppr gi scope dilate strictr | 3.18 | NA | 1.30 | 0.28 | NA | 4.76 | 000 |
| 43246 | | A | Place gastrostomy tube | 4.32 | NA | 1.69 | 0.34 | NA | 6.35 | 000 |
| 43247 | | A | Operative upper GI endoscopy | 3.38 | NA | 1.37 | 0.27 | NA | 5.02 | 000 |
| 43248 | | A | Uppr gi endoscopy/guide wire | 3.15 | NA | 1.31 | 0.24 | NA | 4.70 | 000 |
| 43249 | | A | Esoph endoscopy, dilation | 2.90 | NA | 1.21 | 0.22 | NA | 4.33 | 000 |
| 43250 | | A | Upper GI endoscopy/tumor | 3.20 | NA | 1.31 | 0.26 | NA | 4.77 | 000 |
| 43251 | | A | Operative upper GI endoscopy | 3.69 | NA | 1.48 | 0.29 | NA | 5.46 | 000 |
| 43255 | | A | Operative upper GI endoscopy | 4.81 | NA | 1.88 | 0.36 | NA | 7.05 | 000 |
| 43256 | | A | Uppr gi endoscopy w stent | 4.34 | NA | 1.71 | 0.37 | NA | 6.42 | 000 |
| 43258 | | A | Operative upper GI endoscopy | 4.54 | NA | 1.78 | 0.35 | NA | 6.67 | 000 |
| 43259 | | A | Endoscopic ultrasound exam | 5.19 | NA | 1.99 | 0.36 | NA | 7.54 | 000 |
| 43260 | | A | Endo cholangiopancreatograph | 5.95 | NA | 2.28 | 0.44 | NA | 8.67 | 000 |
| 43261 | | A | Endo cholangiopancreatograph | 6.26 | NA | 2.39 | 0.46 | NA | 9.11 | 000 |
| 43262 | | A | Endo cholangiopancreatograph | 7.38 | NA | 2.78 | 0.55 | NA | 10.71 | 000 |
| 43263 | | A | Endo cholangiopancreatograph | 7.28 | NA | 2.76 | 0.55 | NA | 10.59 | 000 |
| 43264 | | A | Endo cholangiopancreatograph | 8.89 | NA | 3.31 | 0.66 | NA | 12.86 | 000 |
| 43265 | | A | Endo cholangiopancreatograph | 10.00 | NA | 3.69 | 0.74 | NA | 14.43 | 000 |
| 43267 | | A | Endo cholangiopancreatograph | 7.38 | NA | 2.78 | 0.56 | NA | 10.72 | 000 |
| 43268 | | A | Endo cholangiopancreatograph | 7.38 | NA | 2.88 | 0.55 | NA | 10.81 | 000 |
| 43269 | | A | Endo cholangiopancreatograph | 8.20 | NA | 3.07 | 0.61 | NA | 11.88 | 000 |
| 43271 | | A | Endo cholangiopancreatograph | 7.38 | NA | 2.77 | 0.54 | NA | 10.69 | 000 |
| 43272 | | A | Endo cholangiopancreatograph | 7.38 | NA | 2.78 | 0.55 | NA | 10.71 | 000 |
| 43280 | | A | Laparoscopy, fundoplasty | 17.22 | NA | 7.28 | 2.20 | NA | 26.70 | 090 |
| 43300 | | A | Repair of esophagus | 9.13 | NA | 6.45 | 1.01 | NA | 16.59 | 090 |
| 43305 | | A | Repair esophagus and fistula | 17.36 | NA | 10.72 | 1.53 | NA | 29.61 | 090 |
| 43310 | | A | Repair of esophagus | 25.35 | NA | 11.08 | 3.44 | NA | 39.87 | 090 |
| 43312 | | A | Repair esophagus and fistula | 28.38 | NA | 11.93 | 3.43 | NA | 43.74 | 090 |
| 43313 | | A | Esophagoplasty congenital | 45.21 | NA | 18.82 | 6.55 | NA | 70.58 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 43314 | | A | Tracheo-esophagoplasty cong | 50.19 | NA | 19.15 | 6.67 | NA | 76.01 | 090 |
| 43320 | | A | Fuse esophagus & stomach | 19.90 | NA | 9.21 | 2.41 | NA | 31.52 | 090 |
| 43324 | | A | Revise esophagus & stomach | 20.54 | NA | 8.77 | 2.59 | NA | 31.90 | 090 |
| 43325 | | A | Revise esophagus & stomach | 20.03 | NA | 8.79 | 2.54 | NA | 31.36 | 090 |
| 43326 | | A | Revise esophagus & stomach | 19.71 | NA | 9.29 | 2.63 | NA | 31.63 | 090 |
| 43330 | | A | Repair of esophagus | 19.74 | NA | 8.54 | 2.51 | NA | 30.79 | 090 |
| 43331 | | A | Repair of esophagus | 20.10 | NA | 9.79 | 2.65 | NA | 32.54 | 090 |
| 43340 | | A | Fuse esophagus & intestine | 19.58 | NA | 8.97 | 2.49 | NA | 31.04 | 090 |
| 43341 | | A | Fuse esophagus & intestine | 20.82 | NA | 10.03 | 2.89 | NA | 33.74 | 090 |
| 43350 | | A | Surgical opening, esophagus | 15.76 | NA | 8.46 | 1.78 | NA | 26.00 | 090 |
| 43351 | | A | Surgical opening, esophagus | 18.32 | NA | 9.79 | 2.46 | NA | 30.57 | 090 |
| 43352 | | A | Surgical opening, esophagus | 15.24 | NA | 8.39 | 1.85 | NA | 25.48 | 090 |
| 43360 | | A | Gastrointestinal repair | 35.65 | NA | 15.07 | 4.26 | NA | 54.98 | 090 |
| 43361 | | A | Gastrointestinal repair | 40.44 | NA | 16.88 | 4.52 | NA | 61.84 | 090 |
| 43400 | | A | Ligate esophagus veins | 21.17 | NA | 9.45 | 2.04 | NA | 32.66 | 090 |
| 43401 | | A | Esophagus surgery for veins | 22.06 | NA | 9.49 | 2.61 | NA | 34.16 | 090 |
| 43405 | | A | Ligate/staple esophagus | 19.98 | NA | 9.57 | 2.56 | NA | 32.11 | 090 |
| 43410 | | A | Repair esophagus wound | 13.45 | NA | 7.64 | 1.63 | NA | 22.72 | 090 |
| 43415 | | A | Repair esophagus wound | 24.96 | NA | 11.73 | 3.34 | NA | 40.03 | 090 |
| 43420 | | A | Repair esophagus opening | 14.33 | NA | 7.45 | 1.38 | NA | 23.16 | 090 |
| 43425 | | A | Repair esophagus opening | 21.00 | NA | 9.97 | 2.62 | NA | 33.59 | 090 |
| 43450 | | A | Dilate esophagus | 1.38 | 2.67 | 0.69 | 0.11 | 4.16 | 2.18 | 000 |
| 43453 | | A | Dilate esophagus | 1.51 | 6.11 | 0.73 | 0.11 | 7.73 | 2.35 | 000 |
| 43456 | | A | Dilate esophagus | 2.57 | 13.83 | 1.10 | 0.20 | 16.60 | 3.87 | 000 |
| 43458 | | A | Dilate esophagus | 3.06 | 6.69 | 1.28 | 0.25 | 10.00 | 4.59 | 000 |
| 43460 | | A | Pressure treatment esophagus | 3.79 | NA | 1.48 | 0.31 | NA | 5.58 | 000 |
| 43500 | | A | Surgical opening of stomach | 11.03 | NA | 4.98 | 1.39 | NA | 17.40 | 090 |
| 43501 | | A | Surgical repair of stomach | 20.01 | NA | 8.31 | 2.57 | NA | 30.89 | 090 |
| 43502 | | A | Surgical repair of stomach | 23.10 | NA | 9.45 | 2.75 | NA | 35.30 | 090 |
| 43510 | | A | Surgical opening of stomach | 13.06 | NA | 6.61 | 1.54 | NA | 21.21 | 090 |
| 43520 | | A | Incision of pyloric muscle | 9.98 | NA | 5.27 | 1.30 | NA | 16.55 | 090 |
| 43600 | | A | Biopsy of stomach | 1.91 | NA | 0.66 | 0.15 | NA | 2.72 | 000 |
| 43605 | | A | Biopsy of stomach | 11.96 | NA | 5.28 | 1.54 | NA | 18.78 | 090 |
| 43610 | | A | Excision of stomach lesion | 14.58 | NA | 6.16 | 1.88 | NA | 22.62 | 090 |
| 43611 | | A | Excision of stomach lesion | 17.81 | NA | 7.56 | 2.30 | NA | 27.67 | 090 |
| 43620 | | A | Removal of stomach | 29.99 | NA | 11.80 | 3.85 | NA | 45.64 | 090 |
| 43621 | | A | Removal of stomach | 30.68 | NA | 11.98 | 3.94 | NA | 46.60 | 090 |
| 43622 | | A | Removal of stomach | 32.48 | NA | 12.58 | 4.17 | NA | 49.23 | 090 |
| 43631 | | A | Removal of stomach, partial | 22.56 | NA | 9.15 | 2.90 | NA | 34.61 | 090 |
| 43632 | | A | Removal of stomach, partial | 22.56 | NA | 9.15 | 2.90 | NA | 34.61 | 090 |
| 43633 | | A | Removal of stomach, partial | 23.07 | NA | 9.32 | 2.96 | NA | 35.35 | 090 |
| 43634 | | A | Removal of stomach, partial | 25.08 | NA | 10.08 | 3.13 | NA | 38.29 | 090 |
| 43635 | | A | Removal of stomach, partial | 2.06 | NA | 0.70 | 0.27 | NA | 3.03 | ZZZ |
| 43638 | | A | Removal of stomach, partial | 28.96 | NA | 11.87 | 3.72 | NA | 44.55 | 090 |
| 43639 | | A | Removal of stomach, partial | 29.61 | NA | 11.68 | 3.78 | NA | 45.07 | 090 |
| 43640 | | A | Vagotomy & pylorus repair | 16.99 | NA | 7.26 | 2.19 | NA | 26.44 | 090 |
| 43641 | | A | Vagotomy & pylorus repair | 17.24 | NA | 7.37 | 2.16 | NA | 26.77 | 090 |
| 43651 | | A | Laparoscopy, vagus nerve | 10.13 | NA | 4.76 | 1.32 | NA | 16.21 | 090 |
| 43652 | | A | Laparoscopy, vagus nerve | 12.13 | NA | 5.75 | 1.51 | NA | 19.39 | 090 |
| 43653 | | A | Laparoscopy, gastrostomy | 7.72 | NA | 4.19 | 0.98 | NA | 12.89 | 090 |
| 43750 | | A | Place gastrostomy tube | 4.48 | NA | 2.19 | 0.43 | NA | 7.10 | 010 |
| 43752 | | A | Nasal/orogastric w/stent | 0.68 | 0.23 | 0.22 | 0.02 | 0.93 | 0.92 | 000 |
| 43760 | | A | Change gastrostomy tube | 1.10 | 2.10 | 0.45 | 0.09 | 3.29 | 1.64 | 000 |
| 43761 | | A | Reposition gastrostomy tube | 2.01 | 1.19 | 0.66 | 0.14 | 3.34 | 2.81 | 000 |
| 43800 | | A | Reconstruction of pylorus | 13.67 | NA | 5.91 | 1.76 | NA | 21.34 | 090 |
| 43810 | | A | Fusion of stomach and bowel | 14.63 | NA | 6.19 | 1.91 | NA | 22.73 | 090 |
| 43820 | | A | Fusion of stomach and bowel | 15.35 | NA | 6.42 | 1.96 | NA | 23.73 | 090 |
| 43825 | | A | Fusion of stomach and bowel | 19.19 | NA | 8.01 | 2.45 | NA | 29.65 | 090 |
| 43830 | | A | Place gastrostomy tube | 9.52 | NA | 4.85 | 1.18 | NA | 15.55 | 090 |
| 43831 | | A | Place gastrostomy tube | 7.83 | NA | 4.52 | 1.00 | NA | 13.35 | 090 |
| 43832 | | A | Place gastrostomy tube | 15.58 | NA | 6.86 | 1.94 | NA | 24.38 | 090 |
| 43840 | | A | Repair of stomach lesion | 15.54 | NA | 6.77 | 2.00 | NA | 24.31 | 090 |
| 43842 | | A | Gastroplasty for obesity | 18.44 | NA | 7.95 | 2.40 | NA | 28.79 | 090 |
| 43843 | | A | Gastroplasty for obesity | 18.62 | NA | 7.91 | 2.45 | NA | 28.98 | 090 |
| 43846 | | A | Gastric bypass for obesity | 24.01 | NA | 10.17 | 3.09 | NA | 37.27 | 090 |
| 43847 | | A | Gastric bypass for obesity | 26.88 | NA | 11.07 | 3.49 | NA | 41.44 | 090 |
| 43848 | | A | Revision gastroplasty | 29.35 | NA | 11.99 | 3.80 | NA | 45.14 | 090 |
| 43850 | | A | Revise stomach-bowel fusion | 24.68 | NA | 9.81 | 3.17 | NA | 37.66 | 090 |
| 43855 | | A | Revise stomach-bowel fusion | 26.12 | NA | 10.32 | 3.43 | NA | 39.87 | 090 |
| 43860 | | A | Revise stomach-bowel fusion | 24.96 | NA | 9.97 | 3.19 | NA | 38.12 | 090 |
| 43865 | | A | Revise stomach-bowel fusion | 26.48 | NA | 10.50 | 3.46 | NA | 40.44 | 090 |
| 43870 | | A | Repair stomach opening | 9.68 | NA | 4.53 | 1.21 | NA | 15.42 | 090 |
| 43880 | | A | Repair stomach-bowel fistula | 24.61 | NA | 9.90 | 3.11 | NA | 37.62 | 090 |
| 44005 | | A | Freeing of bowel adhesion | 16.21 | NA | 6.73 | 2.06 | NA | 25.00 | 090 |
| 44010 | | A | Incision of small bowel | 12.50 | NA | 5.46 | 1.60 | NA | 19.56 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 44015 | | A | Insert needle cath bowel | 2.62 | NA | 0.88 | 0.33 | NA | 3.83 | ZZZ |
| 44020 | | A | Explore small intestine | 13.97 | NA | 5.94 | 1.77 | NA | 21.68 | 090 |
| 44021 | | A | Decompress small bowel | 14.06 | NA | 5.98 | 1.78 | NA | 21.82 | 090 |
| 44025 | | A | Incision of large bowel | 14.26 | NA | 6.03 | 1.81 | NA | 22.10 | 090 |
| 44050 | | A | Reduce bowel obstruction | 14.01 | NA | 5.96 | 1.79 | NA | 21.76 | 090 |
| 44055 | | A | Correct malrotation of bowel | 21.97 | NA | 8.73 | 2.81 | NA | 33.51 | 090 |
| 44100 | | A | Biopsy of bowel | 2.01 | NA | 0.71 | 0.17 | NA | 2.89 | 000 |
| 44110 | | A | Excise intestine lesion(s) | 11.79 | NA | 5.24 | 1.48 | NA | 18.51 | 090 |
| 44111 | | A | Excision of bowel lesion(s) | 14.27 | NA | 6.12 | 1.80 | NA | 22.19 | 090 |
| 44120 | | A | Removal of small intestine | 16.97 | NA | 7.08 | 2.13 | NA | 26.18 | 090 |
| 44121 | | A | Removal of small intestine | 4.44 | NA | 1.52 | 0.55 | NA | 6.51 | ZZZ |
| 44125 | | A | Removal of small intestine | 17.51 | NA | 7.26 | 2.19 | NA | 26.96 | 090 |
| 44126 | | A | Enterectomy w/o taper, cong | 35.45 | NA | 14.10 | 4.60 | NA | 54.15 | 090 |
| 44127 | | A | Enterectomy w/taper, cong | 40.94 | NA | 15.69 | 5.41 | NA | 62.04 | 090 |
| 44128 | | A | Enterectomy cong, add-on | 4.44 | NA | 1.53 | 0.59 | NA | 6.56 | ZZZ |
| 44130 | | A | Bowel to bowel fusion | 14.47 | NA | 6.22 | 1.80 | NA | 22.49 | 090 |
| 44139 | | A | Mobilization of colon | 2.23 | NA | 0.76 | 0.28 | NA | 3.27 | ZZZ |
| 44140 | | A | Partial removal of colon | 20.97 | NA | 8.64 | 2.62 | NA | 32.23 | 090 |
| 44141 | | A | Partial removal of colon | 19.48 | NA | 10.04 | 2.42 | NA | 31.94 | 090 |
| 44143 | | A | Partial removal of colon | 22.96 | NA | 10.69 | 2.91 | NA | 36.56 | 090 |
| 44144 | | A | Partial removal of colon | 21.50 | NA | 9.62 | 2.71 | NA | 33.83 | 090 |
| 44145 | | A | Partial removal of colon | 26.38 | NA | 10.80 | 3.22 | NA | 40.40 | 090 |
| 44146 | | A | Partial removal of colon | 27.50 | NA | 12.85 | 3.35 | NA | 43.70 | 090 |
| 44147 | | A | Partial removal of colon | 20.68 | NA | 8.68 | 2.48 | NA | 31.84 | 090 |
| 44150 | | A | Removal of colon | 23.91 | NA | 12.03 | 2.98 | NA | 38.92 | 090 |
| 44151 | | A | Removal of colon/ileostomy | 26.84 | NA | 13.39 | 3.39 | NA | 43.62 | 090 |
| 44152 | | A | Removal of colon/ileostomy | 27.79 | NA | 11.59 | 3.40 | NA | 42.78 | 090 |
| 44153 | | A | Removal of colon/ileostomy | 30.54 | NA | 14.38 | 3.30 | NA | 48.22 | 090 |
| 44155 | | A | Removal of colon/ileostomy | 27.82 | NA | 13.30 | 3.25 | NA | 44.37 | 090 |
| 44156 | | A | Removal of colon/ileostomy | 30.74 | NA | 15.03 | 3.95 | NA | 49.72 | 090 |
| 44160 | | A | Removal of colon | 18.59 | NA | 7.74 | 2.31 | NA | 28.64 | 090 |
| 44200 | | A | Laparoscopy, enterolysis | 14.42 | NA | 6.19 | 1.75 | NA | 22.36 | 090 |
| 44201 | | A | Laparoscopy, jejunostomy | 9.77 | NA | 4.66 | 1.25 | NA | 15.68 | 090 |
| 44202 | | A | Lap resect s/intestine singl | 22.01 | NA | 8.92 | 2.71 | NA | 33.64 | 090 |
| 44203 | | A | Lap resect s/intestine, addl | 4.44 | NA | 1.49 | 0.56 | NA | 6.49 | ZZZ |
| 44204 | | A | Laparo partial colectomy | 25.04 | NA | 9.94 | 3.05 | NA | 38.03 | 090 |
| 44205 | | A | Lap colectomy part w/ileum | 22.20 | NA | 8.83 | 2.69 | NA | 33.72 | 090 |
| 44206 | | A | Lap part colectomy w/stoma | 26.96 | NA | 11.22 | 2.91 | NA | 41.09 | 090 |
| 44207 | | A | L colectomy/coloproctostomy | 29.96 | NA | 11.46 | 3.22 | NA | 44.64 | 090 |
| 44208 | | A | L colectomy/coloproctostomy | 31.95 | NA | 13.09 | 3.35 | NA | 48.39 | 090 |
| 44210 | | A | Laparo total proctocolectomy | 27.96 | NA | 11.83 | 2.98 | NA | 42.77 | 090 |
| 44211 | | A | Laparo total proctocolectomy | 34.95 | NA | 14.61 | 3.35 | NA | 52.91 | 090 |
| 44212 | | A | Laparo total proctocolectomy | 32.45 | NA | 13.59 | 3.25 | NA | 49.29 | 090 |
| 44300 | | A | Open bowel to skin | 12.09 | NA | 5.49 | 1.55 | NA | 19.13 | 090 |
| 44310 | | A | Ileostomy/jejunostomy | 15.93 | NA | 6.69 | 1.94 | NA | 24.56 | 090 |
| 44312 | | A | Revision of ileostomy | 8.01 | NA | 3.99 | 0.90 | NA | 12.90 | 090 |
| 44314 | | A | Revision of ileostomy | 15.03 | NA | 6.55 | 1.73 | NA | 23.31 | 090 |
| 44316 | | A | Devise bowel pouch | 21.06 | NA | 8.54 | 2.41 | NA | 32.01 | 090 |
| 44320 | | A | Colostomy | 17.61 | NA | 7.65 | 2.21 | NA | 27.47 | 090 |
| 44322 | | A | Colostomy with biopsies | 11.96 | NA | 8.59 | 1.51 | NA | 22.06 | 090 |
| 44340 | | A | Revision of colostomy | 7.71 | NA | 4.27 | 0.97 | NA | 12.95 | 090 |
| 44345 | | A | Revision of colostomy | 15.41 | NA | 6.88 | 1.92 | NA | 24.21 | 090 |
| 44346 | | A | Revision of colostomy | 16.96 | NA | 7.38 | 2.07 | NA | 26.41 | 090 |
| 44360 | | A | Small bowel endoscopy | 2.59 | NA | 1.10 | 0.19 | NA | 3.88 | 000 |
| 44361 | | A | Small bowel endoscopy/biopsy | 2.87 | NA | 1.20 | 0.21 | NA | 4.28 | 000 |
| 44363 | | A | Small bowel endoscopy | 3.49 | NA | 1.38 | 0.26 | NA | 5.13 | 000 |
| 44364 | | A | Small bowel endoscopy | 3.73 | NA | 1.49 | 0.28 | NA | 5.50 | 000 |
| 44365 | | A | Small bowel endoscopy | 3.31 | NA | 1.36 | 0.25 | NA | 4.92 | 000 |
| 44366 | | A | Small bowel endoscopy | 4.40 | NA | 1.73 | 0.32 | NA | 6.45 | 000 |
| 44369 | | A | Small bowel endoscopy | 4.51 | NA | 1.73 | 0.34 | NA | 6.58 | 000 |
| 44370 | | A | Small bowel endoscopy/stent | 4.79 | NA | 1.97 | 0.36 | NA | 7.12 | 000 |
| 44372 | | A | Small bowel endoscopy | 4.40 | NA | 1.72 | 0.35 | NA | 6.47 | 000 |
| 44373 | | A | Small bowel endoscopy | 3.49 | NA | 1.42 | 0.26 | NA | 5.17 | 000 |
| 44376 | | A | Small bowel endoscopy | 5.25 | NA | 2.02 | 0.41 | NA | 7.68 | 000 |
| 44377 | | A | Small bowel endoscopy/biopsy | 5.52 | NA | 2.13 | 0.40 | NA | 8.05 | 000 |
| 44378 | | A | Small bowel endoscopy | 7.12 | NA | 2.69 | 0.53 | NA | 10.34 | 000 |
| 44379 | | A | S bowel endoscope w/stent | 7.46 | NA | 2.91 | 0.55 | NA | 10.92 | 000 |
| 44380 | | A | Small bowel endoscopy | 1.05 | NA | 0.55 | 0.08 | NA | 1.68 | 000 |
| 44382 | | A | Small bowel endoscopy | 1.27 | NA | 0.63 | 0.12 | NA | 2.02 | 000 |
| 44383 | | A | Ileoscopy w/stent | 2.94 | NA | 1.27 | 0.24 | NA | 4.45 | 000 |
| 44385 | | A | Endoscopy of bowel pouch | 1.82 | 3.35 | 0.75 | 0.15 | 5.32 | 2.72 | 000 |
| 44386 | | A | Endoscopy, bowel pouch/biop | 2.12 | 6.68 | 0.88 | 0.19 | 8.99 | 3.19 | 000 |
| 44388 | | A | Colonoscopy | 2.82 | 5.14 | 1.15 | 0.26 | 8.22 | 4.23 | 000 |
| 44389 | | A | Colonoscopy with biopsy | 3.13 | 6.70 | 1.27 | 0.27 | 10.10 | 4.67 | 000 |
| 44390 | | A | Colonoscopy for foreign body | 3.82 | 7.19 | 1.49 | 0.30 | 11.31 | 5.61 | 000 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 44391 | | A | Colonoscopy for bleeding | 4.31 | 8.84 | 1.69 | 0.34 | 13.49 | 6.34 | 000 |
| 44392 | | A | Colonoscopy & polypectomy | 3.81 | 6.66 | 1.49 | 0.34 | 10.81 | 5.64 | 000 |
| 44393 | | A | Colonoscopy, lesion removal | 4.83 | 6.99 | 1.86 | 0.41 | 12.23 | 7.10 | 000 |
| 44394 | | A | Colonoscopy w/snare | 4.42 | 7.90 | 1.72 | 0.39 | 12.71 | 6.53 | 000 |
| 44397 | | A | Colonoscopy w/stent | 4.70 | NA | 1.78 | 0.42 | NA | 6.90 | 000 |
| 44500 | | A | Intro, gastrointestinal tube | 0.49 | NA | 0.16 | 0.03 | NA | 0.68 | 000 |
| 44602 | | A | Suture, small intestine | 16.01 | NA | 6.38 | 2.00 | NA | 24.39 | 090 |
| 44603 | | A | Suture, small intestine | 18.63 | NA | 7.26 | 2.37 | NA | 28.26 | 090 |
| 44604 | | A | Suture, large intestine | 16.01 | NA | 6.45 | 2.02 | NA | 24.48 | 090 |
| 44605 | | A | Repair of bowel lesion | 19.50 | NA | 8.38 | 2.46 | NA | 30.34 | 090 |
| 44615 | | A | Intestinal stricturoplasty | 15.91 | NA | 6.67 | 1.99 | NA | 24.57 | 090 |
| 44620 | | A | Repair bowel opening | 12.18 | NA | 5.32 | 1.47 | NA | 18.97 | 090 |
| 44625 | | A | Repair bowel opening | 15.03 | NA | 6.30 | 1.82 | NA | 23.15 | 090 |
| 44626 | | A | Repair bowel opening | 25.32 | NA | 9.80 | 3.19 | NA | 38.31 | 090 |
| 44640 | | A | Repair bowel-skin fistula | 21.62 | NA | 8.57 | 2.71 | NA | 32.90 | 090 |
| 44650 | | A | Repair bowel fistula | 22.54 | NA | 8.87 | 2.79 | NA | 34.20 | 090 |
| 44660 | | A | Repair bowel-bladder fistula | 21.33 | NA | 8.33 | 2.21 | NA | 31.87 | 090 |
| 44661 | | A | Repair bowel-bladder fistula | 24.77 | NA | 9.54 | 2.80 | NA | 37.11 | 090 |
| 44680 | | A | Surgical revision, intestine | 15.38 | NA | 6.44 | 1.95 | NA | 23.77 | 090 |
| 44700 | | A | Suspend bowel w/prosthesis | 16.09 | NA | 6.65 | 1.79 | NA | 24.53 | 090 |
| 44701 | | A | Intraop colon lavage add-on | 3.10 | NA | 1.05 | 0.28 | NA | 4.43 | ZZZ |
| 44800 | | A | Excision of bowel pouch | 11.21 | NA | 5.39 | 1.40 | NA | 18.00 | 090 |
| 44820 | | A | Excision of mesentery lesion | 12.07 | NA | 5.48 | 1.53 | NA | 19.08 | 090 |
| 44850 | | A | Repair of mesentery | 10.72 | NA | 5.00 | 1.35 | NA | 17.07 | 090 |
| 44900 | | A | Drain app abscess, open | 10.12 | NA | 4.70 | 1.29 | NA | 16.11 | 090 |
| 44901 | | A | Drain app abscess, percut | 3.37 | 28.20 | 1.11 | 0.22 | 31.79 | 4.70 | 000 |
| 44950 | | A | Appendectomy | 9.99 | NA | 4.31 | 1.27 | NA | 15.57 | 090 |
| 44955 | | A | Appendectomy add-on | 1.53 | NA | 0.54 | 0.19 | NA | 2.26 | ZZZ |
| 44960 | | A | Appendectomy | 12.32 | NA | 5.34 | 1.59 | NA | 19.25 | 090 |
| 44970 | | A | Laparoscopy, appendectomy | 8.69 | NA | 4.21 | 1.12 | NA | 14.02 | 090 |
| 45000 | | A | Drainage of pelvic abscess | 4.51 | NA | 2.96 | 0.50 | NA | 7.97 | 090 |
| 45005 | | A | Drainage of rectal abscess | 1.99 | 4.08 | 1.59 | 0.24 | 6.31 | 3.82 | 010 |
| 45020 | | A | Drainage of rectal abscess | 4.71 | NA | 3.28 | 0.53 | NA | 8.52 | 090 |
| 45100 | | A | Biopsy of rectum | 3.67 | NA | 2.37 | 0.41 | NA | 6.45 | 090 |
| 45108 | | A | Removal of anorectal lesion | 4.75 | NA | 2.78 | 0.59 | NA | 8.12 | 090 |
| 45110 | | A | Removal of rectum | 27.96 | NA | 12.39 | 3.35 | NA | 43.70 | 090 |
| 45111 | | A | Partial removal of rectum | 16.46 | NA | 7.17 | 2.00 | NA | 25.63 | 090 |
| 45112 | | A | Removal of rectum | 30.49 | NA | 11.75 | 3.51 | NA | 45.75 | 090 |
| 45113 | | A | Partial proctectomy | 30.53 | NA | 12.59 | 3.53 | NA | 46.65 | 090 |
| 45114 | | A | Partial removal of rectum | 27.28 | NA | 10.85 | 3.32 | NA | 41.45 | 090 |
| 45116 | | A | Partial removal of rectum | 24.54 | NA | 10.01 | 2.90 | NA | 37.45 | 090 |
| 45119 | | A | Remove rectum w/reservoir | 30.79 | NA | 12.44 | 3.30 | NA | 46.53 | 090 |
| 45120 | | A | Removal of rectum | 24.56 | NA | 10.12 | 3.04 | NA | 37.72 | 090 |
| 45121 | | A | Removal of rectum and colon | 27.00 | NA | 11.10 | 3.37 | NA | 41.47 | 090 |
| 45123 | | A | Partial proctectomy | 16.68 | NA | 6.85 | 1.85 | NA | 25.38 | 090 |
| 45126 | | A | Pelvic exenteration | 45.09 | NA | 19.20 | 4.86 | NA | 69.15 | 090 |
| 45130 | | A | Excision of rectal prolapse | 16.42 | NA | 6.76 | 1.75 | NA | 24.93 | 090 |
| 45135 | | A | Excision of rectal prolapse | 19.25 | NA | 8.42 | 2.33 | NA | 30.00 | 090 |
| 45136 | | A | Excise ileoanal reservior | 27.26 | NA | 12.45 | 2.93 | NA | 42.64 | 090 |
| 45150 | | A | Excision of rectal stricture | 5.66 | NA | 2.97 | 0.58 | NA | 9.21 | 090 |
| 45160 | | A | Excision of rectal lesion | 15.30 | NA | 6.64 | 1.64 | NA | 23.58 | 090 |
| 45170 | | A | Excision of rectal lesion | 11.47 | NA | 5.24 | 1.35 | NA | 18.06 | 090 |
| 45190 | | A | Destruction, rectal tumor | 9.73 | NA | 4.66 | 1.13 | NA | 15.52 | 090 |
| 45300 | | A | Proctosigmoidoscopy dx | 0.38 | 1.55 | 0.29 | 0.04 | 1.97 | 0.71 | 000 |
| 45303 | | A | Proctosigmoidoscopy dilate | 0.44 | 18.84 | 0.33 | 0.04 | 19.32 | 0.81 | 000 |
| 45305 | | A | Proctosigmoidoscopy w/bx | 1.01 | 2.65 | 0.50 | 0.11 | 3.77 | 1.62 | 000 |
| 45307 | | A | Proctosigmoidoscopy fb | 0.94 | 3.07 | 0.48 | 0.10 | 4.11 | 1.52 | 000 |
| 45308 | | A | Proctosigmoidoscopy removal | 0.83 | 2.00 | 0.44 | 0.09 | 2.92 | 1.36 | 000 |
| 45309 | | A | Proctosigmoidoscopy removal | 2.01 | 2.83 | 0.84 | 0.22 | 5.06 | 3.07 | 000 |
| 45315 | | A | Proctosigmoidoscopy removal | 1.40 | 2.89 | 0.64 | 0.16 | 4.45 | 2.20 | 000 |
| 45317 | | A | Proctosigmoidoscopy bleed | 1.50 | 2.44 | 0.66 | 0.15 | 4.09 | 2.31 | 000 |
| 45320 | | A | Proctosigmoidoscopy ablate | 1.58 | 2.93 | 0.71 | 0.15 | 4.66 | 2.44 | 000 |
| 45321 | | A | Proctosigmoidoscopy volvul | 1.17 | NA | 0.56 | 0.13 | NA | 1.86 | 000 |
| 45327 | | A | Proctosigmoidoscopy w/stent | 1.65 | NA | 0.69 | 0.16 | NA | 2.50 | 000 |
| 45330 | | A | Diagnostic sigmoidoscopy | 0.96 | 2.30 | 0.50 | 0.08 | 3.34 | 1.54 | 000 |
| 45331 | | A | Sigmoidoscopy and biopsy | 1.15 | 3.11 | 0.59 | 0.09 | 4.35 | 1.83 | 000 |
| 45332 | | A | Sigmoidoscopy w/fb removal | 1.79 | 5.05 | 0.80 | 0.15 | 6.99 | 2.74 | 000 |
| 45333 | | A | Sigmoidoscopy & polypectomy | 1.79 | 4.91 | 0.80 | 0.15 | 6.85 | 2.74 | 000 |
| 45334 | | A | Sigmoidoscopy for bleeding | 2.73 | NA | 1.14 | 0.21 | NA | 4.08 | 000 |
| 45335 | | A | Sigmoidoscopy w/submuc inj | 1.46 | 3.22 | 0.69 | 0.04 | 4.72 | 2.19 | 000 |
| 45337 | | A | Sigmoidoscopy & decompress | 2.36 | NA | 1.00 | 0.22 | NA | 3.58 | 000 |
| 45338 | | A | Sigmoidoscopy w/tumr remove | 2.34 | 5.24 | 1.00 | 0.20 | 7.78 | 3.54 | 000 |
| 45339 | | A | Sigmoidoscopy w/ablate tumr | 3.14 | 3.47 | 1.28 | 0.26 | 6.87 | 4.68 | 000 |
| 45340 | | A | Sig w/balloon dilation | 1.89 | 6.18 | 0.83 | 0.04 | 8.11 | 2.76 | 000 |
| 45341 | | A | Sigmoidoscopy w/ultrasound | 2.60 | NA | 1.07 | 0.20 | NA | 3.87 | 000 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 45342 | | A | Sigmoidoscopy w/us guide bx | 4.05 | NA | 1.55 | 0.30 | NA | 5.90 | 000 |
| 45345 | | A | Sigmoidoscopy w/stent | 2.92 | NA | 1.16 | 0.24 | NA | 4.32 | 000 |
| 45355 | | A | Surgical colonoscopy | 3.51 | NA | 1.38 | 0.35 | NA | 5.24 | 000 |
| 45378 | | A | Diagnostic colonoscopy | 3.69 | 6.20 | 1.47 | 0.24 | 10.13 | 5.40 | 000 |
| 45378 | 53 | A | Diagnostic colonoscopy | 0.96 | 2.30 | 0.50 | 0.08 | 3.34 | 1.54 | 000 |
| 45379 | | A | Colonoscopy w/fb removal | 4.68 | 7.75 | 1.81 | 0.38 | 12.81 | 6.87 | 000 |
| 45380 | | A | Colonoscopy and biopsy | 4.43 | 7.26 | 1.73 | 0.35 | 12.04 | 6.51 | 000 |
| 45381 | | A | Colonoscopy, submucous inj | 4.19 | 7.17 | 1.65 | 0.31 | 11.67 | 6.15 | 000 |
| 45382 | | A | Colonoscopy/control bleeding | 5.68 | 10.01 | 2.18 | 0.43 | 16.12 | 8.29 | 000 |
| 45383 | | A | Lesion removal colonoscopy | 5.86 | 7.99 | 2.22 | 0.48 | 14.33 | 8.56 | 000 |
| 45384 | | A | Lesion remove colonoscopy | 4.69 | 6.85 | 1.82 | 0.38 | 11.92 | 6.89 | 000 |
| 45385 | | A | Lesion removal colonoscopy | 5.30 | 7.86 | 2.03 | 0.42 | 13.58 | 7.75 | 000 |
| 45386 | | A | Colonoscopy dilate stricture | 4.57 | 12.46 | 1.77 | 0.31 | 17.34 | 6.65 | 000 |
| 45387 | | A | Colonoscopy w/stent | 5.90 | NA | 2.33 | 0.49 | NA | 8.72 | 000 |
| 45500 | | A | Repair of rectum | 7.28 | NA | 3.58 | 0.73 | NA | 11.59 | 090 |
| 45505 | | A | Repair of rectum | 7.57 | NA | 3.86 | 0.83 | NA | 12.26 | 090 |
| 45520 | | A | Treatment of rectal prolapse | 0.55 | 1.65 | 0.37 | 0.05 | 2.25 | 0.97 | 000 |
| 45540 | | A | Correct rectal prolapse | 16.25 | NA | 6.82 | 1.84 | NA | 24.91 | 090 |
| 45541 | | A | Correct rectal prolapse | 13.38 | NA | 5.96 | 1.53 | NA | 20.87 | 090 |
| 45550 | | A | Repair rectum/remove sigmoid | 22.97 | NA | 9.23 | 2.61 | NA | 34.81 | 090 |
| 45560 | | A | Repair of rectocele | 10.56 | NA | 5.09 | 1.14 | NA | 16.79 | 090 |
| 45562 | | A | Exploration/repair of rectum | 15.36 | NA | 7.00 | 1.81 | NA | 24.17 | 090 |
| 45563 | | A | Exploration/repair of rectum | 23.43 | NA | 10.52 | 2.95 | NA | 36.90 | 090 |
| 45800 | | A | Repair rect/bladder fistula | 17.74 | NA | 7.45 | 1.89 | NA | 27.08 | 090 |
| 45805 | | A | Repair fistula w/colostomy | 20.75 | NA | 9.52 | 2.32 | NA | 32.59 | 090 |
| 45820 | | A | Repair rectourethral fistula | 18.45 | NA | 7.64 | 1.66 | NA | 27.75 | 090 |
| 45825 | | A | Repair fistula w/colostomy | 21.22 | NA | 9.83 | 2.15 | NA | 33.20 | 090 |
| 45900 | | A | Reduction of rectal prolapse | 2.61 | NA | 1.51 | 0.29 | NA | 4.41 | 010 |
| 45905 | | A | Dilation of anal sphincter | 2.30 | NA | 1.43 | 0.27 | NA | 4.00 | 010 |
| 45910 | | A | Dilation of rectal narrowing | 2.80 | NA | 1.67 | 0.28 | NA | 4.75 | 010 |
| 45915 | | A | Remove rectal obstruction | 3.14 | 4.36 | 2.10 | 0.30 | 7.80 | 5.54 | 010 |
| 46020 | | A | Placement of seton | 2.90 | 2.35 | 1.86 | 0.35 | 5.60 | 5.11 | 010 |
| 46030 | | A | Removal of rectal marker | 1.23 | 1.35 | 0.71 | 0.14 | 2.72 | 2.08 | 010 |
| 46040 | | A | Incision of rectal abscess | 4.95 | 5.52 | 3.61 | 0.60 | 11.07 | 9.16 | 090 |
| 46045 | | A | Incision of rectal abscess | 4.31 | NA | 2.91 | 0.53 | NA | 7.75 | 090 |
| 46050 | | A | Incision of anal abscess | 1.19 | 2.56 | 0.85 | 0.14 | 3.89 | 2.18 | 010 |
| 46060 | | A | Incision of rectal abscess | 5.68 | NA | 3.28 | 0.67 | NA | 9.63 | 090 |
| 46070 | | A | Incision of anal septum | 2.71 | NA | 1.86 | 0.20 | NA | 4.77 | 090 |
| 46080 | | A | Incision of anal sphincter | 2.49 | 2.38 | 1.13 | 0.30 | 5.17 | 3.92 | 010 |
| 46083 | | A | Incise external hemorrhoid | 1.40 | 2.55 | 0.94 | 0.15 | 4.10 | 2.49 | 010 |
| 46200 | | A | Removal of anal fissure | 3.41 | 3.87 | 2.88 | 0.39 | 7.67 | 6.68 | 090 |
| 46210 | | A | Removal of anal crypt | 2.67 | 5.16 | 2.64 | 0.31 | 8.14 | 5.62 | 090 |
| 46211 | | A | Removal of anal crypts | 4.24 | 5.44 | 3.52 | 0.52 | 10.20 | 8.28 | 090 |
| 46220 | | A | Removal of anal tag | 1.56 | 2.22 | 0.93 | 0.18 | 3.96 | 2.67 | 010 |
| 46221 | | A | Ligation of hemorrhoid(s) | 2.04 | 2.65 | 1.75 | 0.22 | 4.91 | 4.01 | 010 |
| 46230 | | A | Removal of anal tags | 2.57 | 3.00 | 1.27 | 0.29 | 5.86 | 4.13 | 010 |
| 46250 | | A | Hemorrhoidectomy | 3.88 | 5.34 | 2.62 | 0.46 | 9.68 | 6.96 | 090 |
| 46255 | | A | Hemorrhoidectomy | 4.59 | 5.87 | 2.84 | 0.57 | 11.03 | 8.00 | 090 |
| 46257 | | A | Remove hemorrhoids & fissure | 5.39 | NA | 2.89 | 0.64 | NA | 8.92 | 090 |
| 46258 | | A | Remove hemorrhoids & fistula | 5.72 | NA | 3.29 | 0.68 | NA | 9.69 | 090 |
| 46260 | | A | Hemorrhoidectomy | 6.36 | NA | 3.23 | 0.75 | NA | 10.34 | 090 |
| 46261 | | A | Remove hemorrhoids & fissure | 7.07 | NA | 3.64 | 0.81 | NA | 11.52 | 090 |
| 46262 | | A | Remove hemorrhoids & fistula | 7.49 | NA | 3.77 | 0.85 | NA | 12.11 | 090 |
| 46270 | | A | Removal of anal fistula | 3.71 | 5.02 | 2.85 | 0.46 | 9.19 | 7.02 | 090 |
| 46275 | | A | Removal of anal fistula | 4.55 | 4.65 | 2.98 | 0.51 | 9.71 | 8.04 | 090 |
| 46280 | | A | Removal of anal fistula | 5.97 | NA | 3.29 | 0.66 | NA | 9.92 | 090 |
| 46285 | | A | Removal of anal fistula | 4.08 | 3.76 | 2.75 | 0.45 | 8.29 | 7.28 | 090 |
| 46288 | | A | Repair anal fistula | 7.12 | NA | 3.71 | 0.79 | NA | 11.62 | 090 |
| 46320 | | A | Removal of hemorrhoid clot | 1.61 | 2.14 | 0.86 | 0.17 | 3.92 | 2.64 | 010 |
| 46500 | | A | Injection into hemorrhoid(s) | 1.61 | 2.12 | 1.16 | 0.16 | 3.89 | 2.93 | 010 |
| 46600 | | A | Diagnostic anoscopy | 0.50 | 1.57 | 0.35 | 0.05 | 2.12 | 0.90 | 000 |
| 46604 | | A | Anoscopy and dilation | 1.31 | 9.16 | 0.62 | 0.13 | 10.60 | 2.06 | 000 |
| 46606 | | A | Anoscopy and biopsy | 0.81 | 3.81 | 0.43 | 0.09 | 4.71 | 1.33 | 000 |
| 46608 | | A | Anoscopy, remove for body | 1.51 | 4.44 | 0.65 | 0.16 | 6.11 | 2.32 | 000 |
| 46610 | | A | Anoscopy, remove lesion | 1.32 | 4.05 | 0.61 | 0.15 | 5.52 | 2.08 | 000 |
| 46611 | | A | Anoscopy | 1.81 | 3.36 | 0.78 | 0.19 | 5.36 | 2.78 | 000 |
| 46612 | | A | Anoscopy, remove lesions | 2.34 | 5.21 | 0.98 | 0.28 | 7.83 | 3.60 | 000 |
| 46614 | | A | Anoscopy, control bleeding | 2.01 | 2.33 | 0.84 | 0.20 | 4.54 | 3.05 | 000 |
| 46615 | | A | Anoscopy | 2.68 | 2.50 | 1.07 | 0.32 | 5.50 | 4.07 | 000 |
| 46700 | | A | Repair of anal stricture | 9.12 | NA | 4.23 | 0.93 | NA | 14.28 | 090 |
| 46705 | | A | Repair of anal stricture | 6.89 | NA | 3.72 | 0.91 | NA | 11.52 | 090 |
| 46706 | | A | Repr of anal fistula w/glue | 2.39 | NA | 1.25 | 0.51 | NA | 4.15 | 010 |
| 46715 | | A | Repair of anovaginal fistula | 7.19 | NA | 3.61 | 0.92 | NA | 11.72 | 090 |
| 46716 | | A | Repair of anovaginal fistula | 15.05 | NA | 7.95 | 1.57 | NA | 24.57 | 090 |
| 46730 | | A | Construction of absent anus | 26.71 | NA | 11.99 | 1.71 | NA | 40.41 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 46735 | | A | Construction of absent anus | 32.12 | NA | 13.51 | 3.18 | NA | 48.81 | 090 |
| 46740 | | A | Construction of absent anus | 29.96 | NA | 13.16 | 2.89 | NA | 46.01 | 090 |
| 46742 | | A | Repair of imperforated anus | 35.75 | NA | 17.47 | 4.73 | NA | 57.95 | 090 |
| 46744 | | A | Repair of cloacal anomaly | 52.55 | NA | 21.07 | 3.83 | NA | 77.45 | 090 |
| 46746 | | A | Repair of cloacal anomaly | 58.13 | NA | 25.05 | 3.03 | NA | 86.21 | 090 |
| 46748 | | A | Repair of cloacal anomaly | 64.11 | NA | 23.66 | 3.34 | NA | 91.11 | 090 |
| 46750 | | A | Repair of anal sphincter | 10.23 | NA | 5.08 | 1.13 | NA | 16.44 | 090 |
| 46751 | | A | Repair of anal sphincter | 8.76 | NA | 5.50 | 0.94 | NA | 15.20 | 090 |
| 46753 | | A | Reconstruction of anus | 8.28 | NA | 3.86 | 0.97 | NA | 13.11 | 090 |
| 46754 | | A | Removal of suture from anus | 2.20 | 3.66 | 1.68 | 0.19 | 6.05 | 4.07 | 010 |
| 46760 | | A | Repair of anal sphincter | 14.41 | NA | 7.09 | 1.57 | NA | 23.07 | 090 |
| 46761 | | A | Repair of anal sphincter | 13.82 | NA | 6.04 | 1.48 | NA | 21.34 | 090 |
| 46762 | | A | Implant artificial sphincter | 12.69 | NA | 5.53 | 1.24 | NA | 19.46 | 090 |
| 46900 | | A | Destruction, anal lesion(s) | 1.91 | 2.59 | 1.28 | 0.18 | 4.68 | 3.37 | 010 |
| 46910 | | A | Destruction, anal lesion(s) | 1.86 | 2.92 | 1.06 | 0.19 | 4.97 | 3.11 | 010 |
| 46916 | | A | Cryosurgery, anal lesion(s) | 1.86 | 3.17 | 1.40 | 0.16 | 5.19 | 3.42 | 010 |
| 46917 | | A | Laser surgery, anal lesions | 1.86 | 9.19 | 1.12 | 0.21 | 11.26 | 3.19 | 010 |
| 46922 | | A | Excision of anal lesion(s) | 1.86 | 3.29 | 1.08 | 0.21 | 5.36 | 3.15 | 010 |
| 46924 | | A | Destruction, anal lesion(s) | 2.76 | 8.72 | 1.36 | 0.27 | 11.75 | 4.39 | 010 |
| 46934 | | A | Destruction of hemorrhoids | 3.50 | 5.10 | 2.97 | 0.31 | 8.91 | 6.78 | 090 |
| 46935 | | A | Destruction of hemorrhoids | 2.43 | 3.49 | 1.21 | 0.22 | 6.14 | 3.86 | 010 |
| 46936 | | A | Destruction of hemorrhoids | 3.68 | 4.89 | 2.50 | 0.36 | 8.93 | 6.54 | 090 |
| 46937 | | A | Cryotherapy of rectal lesion | 2.69 | 2.77 | 1.23 | 0.28 | 5.74 | 4.20 | 010 |
| 46938 | | A | Cryotherapy of rectal lesion | 4.65 | 4.00 | 3.06 | 0.58 | 9.23 | 8.29 | 090 |
| 46940 | | A | Treatment of anal fissure | 2.32 | 1.99 | 1.09 | 0.22 | 4.53 | 3.63 | 010 |
| 46942 | | A | Treatment of anal fissure | 2.04 | 1.83 | 1.02 | 0.19 | 4.06 | 3.25 | 010 |
| 46945 | | A | Ligation of hemorrhoids | 1.84 | 3.36 | 2.49 | 0.19 | 5.39 | 4.52 | 090 |
| 46946 | | A | Ligation of hemorrhoids | 2.58 | 3.79 | 2.40 | 0.26 | 6.63 | 5.24 | 090 |
| 47000 | | A | Needle biopsy of liver | 1.90 | 3.07 | 0.63 | 0.12 | 5.09 | 2.65 | 000 |
| 47001 | | A | Needle biopsy, liver add-on | 1.90 | NA | 0.65 | 0.24 | NA | 2.79 | ZZZ |
| 47010 | | A | Open drainage, liver lesion | 15.99 | NA | 8.40 | 1.74 | NA | 26.13 | 090 |
| 47011 | | A | Percut drain, liver lesion | 3.69 | NA | 1.20 | 0.23 | NA | 5.12 | 000 |
| 47015 | | A | Inject/aspirate liver cyst | 15.09 | NA | 7.49 | 1.78 | NA | 24.36 | 090 |
| 47100 | | A | Wedge biopsy of liver | 11.65 | NA | 6.04 | 1.48 | NA | 19.17 | 090 |
| 47120 | | A | Partial removal of liver | 35.45 | NA | 15.15 | 4.53 | NA | 55.13 | 090 |
| 47122 | | A | Extensive removal of liver | 55.05 | NA | 21.45 | 6.99 | NA | 83.49 | 090 |
| 47125 | | A | Partial removal of liver | 49.12 | NA | 19.51 | 6.23 | NA | 74.86 | 090 |
| 47130 | | A | Partial removal of liver | 53.27 | NA | 20.97 | 6.80 | NA | 81.04 | 090 |
| 47135 | | R | Transplantation of liver | 81.40 | NA | 31.49 | 9.89 | NA | 122.78 | 090 |
| 47136 | | R | Transplantation of liver | 68.50 | NA | 26.99 | 8.36 | NA | 103.85 | 090 |
| 47140 | | A | Partial removal, donor liver | 54.92 | NA | 22.25 | 4.87 | NA | 82.04 | 090 |
| 47141 | | A | Partial removal, donor liver | 67.40 | NA | 26.87 | 4.87 | NA | 99.14 | 090 |
| 47142 | | A | Partial removal, donor liver | 74.89 | NA | 29.43 | 4.87 | NA | 109.19 | 090 |
| 47300 | | A | Surgery for liver lesion | 15.06 | NA | 7.23 | 1.91 | NA | 24.20 | 090 |
| 47350 | | A | Repair liver wound | 19.53 | NA | 8.86 | 2.48 | NA | 30.87 | 090 |
| 47360 | | A | Repair liver wound | 26.88 | NA | 11.59 | 3.35 | NA | 41.82 | 090 |
| 47361 | | A | Repair liver wound | 47.05 | NA | 18.51 | 5.77 | NA | 71.33 | 090 |
| 47362 | | A | Repair liver wound | 18.48 | NA | 8.73 | 2.31 | NA | 29.52 | 090 |
| 47370 | | A | Laparo ablate liver tumor rf | 19.66 | NA | 8.13 | 2.27 | NA | 30.06 | 090 |
| 47371 | | A | Laparo ablate liver cryosurg | 19.66 | NA | 8.14 | 2.11 | NA | 29.91 | 090 |
| 47380 | | A | Open ablate liver tumor rf | 22.97 | NA | 9.34 | 2.69 | NA | 35.00 | 090 |
| 47381 | | A | Open ablate liver tumor cryo | 23.24 | NA | 9.58 | 2.39 | NA | 35.21 | 090 |
| 47382 | | A | Percut ablate liver rf | 15.17 | NA | 6.06 | 0.80 | NA | 22.03 | 010 |
| 47400 | | A | Incision of liver duct | 32.44 | NA | 13.43 | 3.46 | NA | 49.33 | 090 |
| 47420 | | A | Incision of bile duct | 19.85 | NA | 8.75 | 2.54 | NA | 31.14 | 090 |
| 47425 | | A | Incision of bile duct | 19.80 | NA | 8.81 | 2.46 | NA | 31.07 | 090 |
| 47460 | | A | Incise bile duct sphincter | 18.01 | NA | 8.38 | 2.00 | NA | 28.39 | 090 |
| 47480 | | A | Incision of gallbladder | 10.80 | NA | 5.92 | 1.38 | NA | 18.10 | 090 |
| 47490 | | A | Incision of gallbladder | 7.22 | NA | 5.58 | 0.44 | NA | 13.24 | 090 |
| 47500 | | A | Injection for liver x-rays | 1.96 | NA | 0.64 | 0.12 | NA | 2.72 | 000 |
| 47505 | | A | Injection for liver x-rays | 0.76 | NA | 0.25 | 0.05 | NA | 1.06 | 000 |
| 47510 | | A | Insert catheter, bile duct | 7.82 | NA | 5.00 | 0.50 | NA | 13.32 | 090 |
| 47511 | | A | Insert bile duct drain | 10.48 | NA | 5.07 | 0.64 | NA | 16.19 | 090 |
| 47525 | | A | Change bile duct catheter | 5.54 | 12.22 | 2.80 | 0.33 | 18.09 | 8.67 | 010 |
| 47530 | | A | Revise/reinsert bile tube | 5.84 | 25.23 | 3.70 | 0.38 | 31.45 | 9.92 | 090 |
| 47550 | | A | Bile duct endoscopy add-on | 3.02 | NA | 1.02 | 0.39 | NA | 4.43 | ZZZ |
| 47552 | | A | Biliary endoscopy thru skin | 6.03 | NA | 2.40 | 0.44 | NA | 8.87 | 000 |
| 47553 | | A | Biliary endoscopy thru skin | 6.34 | NA | 2.06 | 0.41 | NA | 8.81 | 000 |
| 47554 | | A | Biliary endoscopy thru skin | 9.05 | NA | 3.38 | 0.96 | NA | 13.39 | 000 |
| 47555 | | A | Biliary endoscopy thru skin | 7.55 | NA | 2.45 | 0.46 | NA | 10.46 | 000 |
| 47556 | | A | Biliary endoscopy thru skin | 8.55 | NA | 2.77 | 0.51 | NA | 11.83 | 000 |
| 47560 | | A | Laparoscopy w/cholangio | 4.88 | NA | 1.66 | 0.59 | NA | 7.13 | 000 |
| 47561 | | A | Laparo w/cholangio/biopsy | 5.17 | NA | 1.91 | 0.65 | NA | 7.73 | 000 |
| 47562 | | A | Laparoscopic cholecystectomy | 11.07 | NA | 4.98 | 1.42 | NA | 17.47 | 090 |
| 47563 | | A | Laparo cholecystectomy/graph | 11.92 | NA | 5.29 | 1.52 | NA | 18.73 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 47564 | | A | Laparo cholecystectomy/explr | 14.21 | NA | 5.94 | 1.82 | NA | 21.97 | 090 |
| 47570 | | A | Laparo cholecystoenterostomy | 12.56 | NA | 5.36 | 1.60 | NA | 19.52 | 090 |
| 47600 | | A | Removal of gallbladder | 13.56 | NA | 6.15 | 1.73 | NA | 21.44 | 090 |
| 47605 | | A | Removal of gallbladder | 14.67 | NA | 6.50 | 1.88 | NA | 23.05 | 090 |
| 47610 | | A | Removal of gallbladder | 18.79 | NA | 7.94 | 2.41 | NA | 29.14 | 090 |
| 47612 | | A | Removal of gallbladder | 18.75 | NA | 7.88 | 2.40 | NA | 29.03 | 090 |
| 47620 | | A | Removal of gallbladder | 20.61 | NA | 8.52 | 2.68 | NA | 31.81 | 090 |
| 47630 | | A | Remove bile duct stone | 9.10 | NA | 4.86 | 0.69 | NA | 14.65 | 090 |
| 47700 | | A | Exploration of bile ducts | 15.60 | NA | 7.43 | 1.89 | NA | 24.92 | 090 |
| 47701 | | A | Bile duct revision | 27.77 | NA | 11.49 | 3.55 | NA | 42.81 | 090 |
| 47711 | | A | Excision of bile duct tumor | 23.00 | NA | 9.92 | 2.93 | NA | 35.85 | 090 |
| 47712 | | A | Excision of bile duct tumor | 30.19 | NA | 12.41 | 3.93 | NA | 46.53 | 090 |
| 47715 | | A | Excision of bile duct cyst | 18.77 | NA | 8.42 | 2.38 | NA | 29.57 | 090 |
| 47716 | | A | Fusion of bile duct cyst | 16.42 | NA | 7.83 | 2.08 | NA | 26.33 | 090 |
| 47720 | | A | Fuse gallbladder & bowel | 15.89 | NA | 7.48 | 2.03 | NA | 25.40 | 090 |
| 47721 | | A | Fuse upper gi structures | 19.09 | NA | 8.57 | 2.46 | NA | 30.12 | 090 |
| 47740 | | A | Fuse gallbladder & bowel | 18.45 | NA | 8.38 | 2.43 | NA | 29.26 | 090 |
| 47741 | | A | Fuse gallbladder & bowel | 21.31 | NA | 9.28 | 2.63 | NA | 33.22 | 090 |
| 47760 | | A | Fuse bile ducts and bowel | 25.81 | NA | 10.84 | 3.32 | NA | 39.97 | 090 |
| 47765 | | A | Fuse liver ducts & bowel | 24.84 | NA | 10.80 | 3.21 | NA | 38.85 | 090 |
| 47780 | | A | Fuse bile ducts and bowel | 26.46 | NA | 11.20 | 3.43 | NA | 41.09 | 090 |
| 47785 | | A | Fuse bile ducts and bowel | 31.13 | NA | 12.91 | 4.04 | NA | 48.08 | 090 |
| 47800 | | A | Reconstruction of bile ducts | 23.27 | NA | 10.06 | 2.94 | NA | 36.27 | 090 |
| 47801 | | A | Placement, bile duct support | 15.15 | NA | 8.15 | 1.24 | NA | 24.54 | 090 |
| 47802 | | A | Fuse liver duct & intestine | 21.52 | NA | 9.68 | 2.73 | NA | 33.93 | 090 |
| 47900 | | A | Suture bile duct injury | 19.87 | NA | 8.87 | 2.57 | NA | 31.31 | 090 |
| 48000 | | A | Drainage of abdomen | 28.03 | NA | 11.49 | 3.40 | NA | 42.92 | 090 |
| 48001 | | A | Placement of drain, pancreas | 35.40 | NA | 13.87 | 4.47 | NA | 53.74 | 090 |
| 48005 | | A | Resect/debride pancreas | 42.11 | NA | 16.53 | 5.41 | NA | 64.05 | 090 |
| 48020 | | A | Removal of pancreatic stone | 15.68 | NA | 7.29 | 2.12 | NA | 25.09 | 090 |
| 48100 | | A | Biopsy of pancreas, open | 12.21 | NA | 5.61 | 1.54 | NA | 19.36 | 090 |
| 48102 | | A | Needle biopsy, pancreas | 4.67 | 7.95 | 1.94 | 0.29 | 12.91 | 6.90 | 010 |
| 48120 | | A | Removal of pancreas lesion | 15.83 | NA | 6.86 | 1.98 | NA | 24.67 | 090 |
| 48140 | | A | Partial removal of pancreas | 22.91 | NA | 9.53 | 2.91 | NA | 35.35 | 090 |
| 48145 | | A | Partial removal of pancreas | 23.98 | NA | 9.84 | 3.09 | NA | 36.91 | 090 |
| 48146 | | A | Pancreatectomy | 26.36 | NA | 11.98 | 3.40 | NA | 41.74 | 090 |
| 48148 | | A | Removal of pancreatic duct | 17.31 | NA | 7.62 | 2.20 | NA | 27.13 | 090 |
| 48150 | | A | Partial removal of pancreas | 47.93 | NA | 19.49 | 6.18 | NA | 73.60 | 090 |
| 48152 | | A | Pancreatectomy | 43.68 | NA | 18.20 | 5.68 | NA | 67.56 | 090 |
| 48153 | | A | Pancreatectomy | 47.82 | NA | 19.54 | 6.19 | NA | 73.55 | 090 |
| 48154 | | A | Pancreatectomy | 44.03 | NA | 18.23 | 5.74 | NA | 68.00 | 090 |
| 48155 | | A | Removal of pancreas | 24.60 | NA | 11.69 | 3.14 | NA | 39.43 | 090 |
| 48180 | | A | Fuse pancreas and bowel | 24.68 | NA | 10.16 | 3.22 | NA | 38.06 | 090 |
| 48400 | | A | Injection, intraop add-on | 1.95 | NA | 0.64 | 0.16 | NA | 2.75 | ZZZ |
| 48500 | | A | Surgery of pancreatic cyst | 15.26 | NA | 7.34 | 2.04 | NA | 24.64 | 090 |
| 48510 | | A | Drain pancreatic pseudocyst | 14.29 | NA | 7.43 | 1.80 | NA | 23.52 | 090 |
| 48511 | | A | Drain pancreatic pseudocyst | 3.99 | 21.20 | 1.30 | 0.25 | 25.44 | 5.54 | 000 |
| 48520 | | A | Fuse pancreas cyst and bowel | 15.57 | NA | 6.70 | 1.99 | NA | 24.26 | 090 |
| 48540 | | A | Fuse pancreas cyst and bowel | 19.69 | NA | 8.11 | 2.50 | NA | 30.30 | 090 |
| 48545 | | A | Pancreatorrhaphy | 18.15 | NA | 7.99 | 2.30 | NA | 28.44 | 090 |
| 48547 | | A | Duodenal exclusion | 25.79 | NA | 10.48 | 3.28 | NA | 39.55 | 090 |
| 48554 | | R | Transpl allograft pancreas | 34.12 | NA | 18.29 | 4.19 | NA | 56.60 | 090 |
| 48556 | | A | Removal, allograft pancreas | 15.69 | NA | 8.07 | 1.96 | NA | 25.72 | 090 |
| 49000 | | A | Exploration of abdomen | 11.66 | NA | 5.38 | 1.44 | NA | 18.48 | 090 |
| 49002 | | A | Reopening of abdomen | 10.47 | NA | 5.04 | 1.33 | NA | 16.84 | 090 |
| 49010 | | A | Exploration behind abdomen | 12.26 | NA | 5.91 | 1.49 | NA | 19.66 | 090 |
| 49020 | | A | Drain abdominal abscess | 22.81 | NA | 10.19 | 2.71 | NA | 35.71 | 090 |
| 49021 | | A | Drain abdominal abscess | 3.37 | 21.58 | 1.11 | 0.21 | 25.16 | 4.69 | 000 |
| 49040 | | A | Drain, open, abdom abscess | 13.50 | NA | 6.44 | 1.65 | NA | 21.59 | 090 |
| 49041 | | A | Drain, percut, abdom abscess | 3.99 | 19.76 | 1.31 | 0.25 | 24.00 | 5.55 | 000 |
| 49060 | | A | Drain, open, retrop abscess | 15.84 | NA | 7.44 | 1.64 | NA | 24.92 | 090 |
| 49061 | | A | Drain, percut, retroper absc | 3.69 | 19.95 | 1.21 | 0.22 | 23.86 | 5.12 | 000 |
| 49062 | | A | Drain to peritoneal cavity | 11.34 | NA | 5.46 | 1.40 | NA | 18.20 | 090 |
| 49080 | | A | Puncture, peritoneal cavity | 1.35 | 4.15 | 0.45 | 0.09 | 5.59 | 1.89 | 000 |
| 49081 | | A | Removal of abdominal fluid | 1.26 | 2.66 | 0.43 | 0.09 | 4.01 | 1.78 | 000 |
| 49085 | | A | Remove abdomen foreign body | 12.12 | NA | 5.51 | 1.43 | NA | 19.06 | 090 |
| 49180 | | A | Biopsy, abdominal mass | 1.73 | 3.14 | 0.56 | 0.11 | 4.98 | 2.40 | 000 |
| 49200 | | A | Removal of abdominal lesion | 10.23 | NA | 5.05 | 1.14 | NA | 16.42 | 090 |
| 49201 | | A | Remove abdom lesion, complex | 14.82 | NA | 7.06 | 1.77 | NA | 23.65 | 090 |
| 49215 | | A | Excise sacral spine tumor | 33.45 | NA | 14.04 | 4.29 | NA | 51.78 | 090 |
| 49220 | | A | Multiple surgery, abdomen | 14.86 | NA | 6.65 | 1.83 | NA | 23.34 | 090 |
| 49250 | | A | Excision of umbilicus | 8.34 | NA | 4.30 | 1.05 | NA | 13.69 | 090 |
| 49255 | | A | Removal of omentum | 11.12 | NA | 5.63 | 1.39 | NA | 18.14 | 090 |
| 49320 | | A | Diag laparo separate proc | 5.09 | NA | 2.63 | 0.63 | NA | 8.35 | 010 |
| 49321 | | A | Laparoscopy, biopsy | 5.39 | NA | 2.64 | 0.68 | NA | 8.71 | 010 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 49322 | | A | Laparoscopy, aspiration | 5.69 | NA | 2.99 | 0.70 | NA | 9.38 | 010 |
| 49323 | | A | Laparo drain lymphocele | 9.47 | NA | 4.49 | 1.12 | NA | 15.08 | 090 |
| 49400 | | A | Air injection into abdomen | 1.88 | 3.16 | 0.62 | 0.16 | 5.20 | 2.66 | 000 |
| 49419 | | A | Insrt abdom cath for chemotx | 6.64 | NA | 3.55 | 0.70 | NA | 10.89 | 090 |
| 49420 | | A | Insert abdom drain, temp | 2.22 | NA | 1.09 | 0.21 | NA | 3.52 | 000 |
| 49421 | | A | Insert abdom drain, perm | 5.53 | NA | 3.17 | 0.70 | NA | 9.40 | 090 |
| 49422 | | A | Remove perm cannula/catheter | 6.24 | NA | 2.89 | 0.80 | NA | 9.93 | 010 |
| 49423 | | A | Exchange drainage catheter | 1.46 | 14.40 | 0.52 | 0.09 | 15.95 | 2.07 | 000 |
| 49424 | | A | Assess cyst, contrast inject | 0.76 | 3.92 | 0.29 | 0.05 | 4.73 | 1.10 | 000 |
| 49425 | | A | Insert abdomen-venous drain | 11.35 | NA | 5.62 | 1.52 | NA | 18.49 | 090 |
| 49426 | | A | Revise abdomen-venous shunt | 9.62 | NA | 4.78 | 1.23 | NA | 15.63 | 090 |
| 49427 | | A | Injection, abdominal shunt | 0.89 | NA | 0.30 | 0.06 | NA | 1.25 | 000 |
| 49428 | | A | Ligation of shunt | 6.05 | NA | 3.92 | 0.84 | NA | 10.81 | 010 |
| 49429 | | A | Removal of shunt | 7.39 | NA | 3.42 | 0.99 | NA | 11.80 | 010 |
| 49491 | | A | Rpr hern preemie reduc | 11.11 | NA | 5.04 | 1.47 | NA | 17.62 | 090 |
| 49492 | | A | Rpr ing hern premie, blocked | 14.01 | NA | 6.10 | 1.64 | NA | 21.75 | 090 |
| 49495 | | A | Rpr ing hernia baby, reduc | 5.88 | NA | 2.97 | 0.78 | NA | 9.63 | 090 |
| 49496 | | A | Rpr ing hernia baby, blocked | 8.78 | NA | 4.33 | 1.10 | NA | 14.21 | 090 |
| 49500 | | A | Rpr ing hernia, init, reduce | 5.47 | NA | 3.13 | 0.62 | NA | 9.22 | 090 |
| 49501 | | A | Rpr ing hernia, init blocked | 8.87 | NA | 4.21 | 1.13 | NA | 14.21 | 090 |
| 49505 | | A | Prp i/hern init reduc>5 yr | 7.59 | NA | 3.75 | 0.99 | NA | 12.33 | 090 |
| 49507 | | A | Prp i/hern init block>5 yr | 9.56 | NA | 4.50 | 1.24 | NA | 15.30 | 090 |
| 49520 | | A | Rerepair ing hernia, reduce | 9.62 | NA | 4.46 | 1.24 | NA | 15.32 | 090 |
| 49521 | | A | Rerepair ing hernia, blocked | 11.95 | NA | 5.25 | 1.56 | NA | 18.76 | 090 |
| 49525 | | A | Repair ing hernia, sliding | 8.56 | NA | 4.10 | 1.09 | NA | 13.75 | 090 |
| 49540 | | A | Repair lumbar hernia | 10.37 | NA | 4.77 | 1.34 | NA | 16.48 | 090 |
| 49550 | | A | Rpr rem hernia, init, reduce | 8.62 | NA | 4.14 | 1.12 | NA | 13.88 | 090 |
| 49553 | | A | Rpr fem hernia, init blocked | 9.43 | NA | 4.43 | 1.22 | NA | 15.08 | 090 |
| 49555 | | A | Rerepair fem hernia, reduce | 9.02 | NA | 4.29 | 1.17 | NA | 14.48 | 090 |
| 49557 | | A | Rerepair fem hernia, blocked | 11.13 | NA | 5.00 | 1.44 | NA | 17.57 | 090 |
| 49560 | | A | Rpr ventral hern init, reduc | 11.55 | NA | 5.17 | 1.48 | NA | 18.20 | 090 |
| 49561 | | A | Rpr ventral hern init, block | 14.23 | NA | 6.07 | 1.83 | NA | 22.13 | 090 |
| 49565 | | A | Rerepair ventrl hern, reduce | 11.55 | NA | 5.24 | 1.48 | NA | 18.27 | 090 |
| 49566 | | A | Rerepair ventrl hern, block | 14.38 | NA | 6.14 | 1.85 | NA | 22.37 | 090 |
| 49568 | | A | Hernia repair w/mesh | 4.88 | NA | 1.67 | 0.63 | NA | 7.18 | ZZZ |
| 49570 | | A | Rpr epigastric hern, reduce | 5.68 | NA | 3.18 | 0.73 | NA | 9.59 | 090 |
| 49572 | | A | Rpr epigastric hern, blocked | 6.72 | NA | 3.48 | 0.86 | NA | 11.06 | 090 |
| 49580 | | A | Rpr umbil hern, reduc < 5 yr | 4.10 | NA | 2.62 | 0.52 | NA | 7.24 | 090 |
| 49582 | | A | Rpr umbil hern, block < 5 yr | 6.64 | NA | 3.51 | 0.86 | NA | 11.01 | 090 |
| 49585 | | A | Rpr umbil hern, reduc > 5 yr | 6.22 | NA | 3.32 | 0.79 | NA | 10.33 | 090 |
| 49587 | | A | Rpr umbil hern, block > 5 yr | 7.55 | NA | 3.75 | 0.97 | NA | 12.27 | 090 |
| 49590 | | A | Repair spigilian hernia | 8.53 | NA | 4.11 | 1.09 | NA | 13.73 | 090 |
| 49600 | | A | Repair umbilical lesion | 10.94 | NA | 5.35 | 1.31 | NA | 17.60 | 090 |
| 49605 | | A | Repair umbilical lesion | 75.89 | NA | 28.48 | 9.95 | NA | 114.32 | 090 |
| 49606 | | A | Repair umbilical lesion | 18.57 | NA | 7.72 | 2.43 | NA | 28.72 | 090 |
| 49610 | | A | Repair umbilical lesion | 10.48 | NA | 5.24 | 0.57 | NA | 16.29 | 090 |
| 49611 | | A | Repair umbilical lesion | 8.91 | NA | 7.31 | 0.78 | NA | 17.00 | 090 |
| 49650 | | A | Laparo hernia repair initial | 6.26 | NA | 3.20 | 0.90 | NA | 10.36 | 090 |
| 49651 | | A | Laparo hernia repair recur | 8.23 | NA | 4.06 | 1.10 | NA | 13.39 | 090 |
| 49900 | | A | Repair of abdominal wall | 12.26 | NA | 6.23 | 1.55 | NA | 20.04 | 090 |
| 49904 | | A | Omental flap, extra-abdom | 19.97 | NA | 15.17 | 2.52 | NA | 37.66 | 090 |
| 49905 | | A | Omental flap, intra-abdom | 6.54 | NA | 2.29 | 0.79 | NA | 9.62 | ZZZ |
| 50010 | | A | Exploration of kidney | 10.96 | NA | 5.21 | 0.93 | NA | 17.10 | 090 |
| 50020 | | A | Renal abscess, open drain | 14.64 | NA | 7.73 | 1.27 | NA | 23.64 | 090 |
| 50021 | | A | Renal abscess, percut drain | 3.37 | 21.89 | 1.10 | 0.20 | 25.46 | 4.67 | 000 |
| 50040 | | A | Drainage of kidney | 14.92 | NA | 6.80 | 1.03 | NA | 22.75 | 090 |
| 50045 | | A | Exploration of kidney | 15.44 | NA | 6.59 | 1.24 | NA | 23.27 | 090 |
| 50060 | | A | Removal of kidney stone | 19.27 | NA | 7.81 | 1.46 | NA | 28.54 | 090 |
| 50065 | | A | Incision of kidney | 20.76 | NA | 6.09 | 1.48 | NA | 28.33 | 090 |
| 50070 | | A | Incision of kidney | 20.29 | NA | 8.20 | 1.48 | NA | 29.97 | 090 |
| 50075 | | A | Removal of kidney stone | 25.30 | NA | 9.88 | 1.93 | NA | 37.11 | 090 |
| 50080 | | A | Removal of kidney stone | 14.69 | NA | 6.27 | 1.04 | NA | 22.00 | 090 |
| 50081 | | A | Removal of kidney stone | 21.77 | NA | 8.74 | 1.57 | NA | 32.08 | 090 |
| 50100 | | A | Revise kidney blood vessels | 16.07 | NA | 7.77 | 1.78 | NA | 25.62 | 090 |
| 50120 | | A | Exploration of kidney | 15.89 | NA | 6.75 | 1.19 | NA | 23.83 | 090 |
| 50125 | | A | Explore and drain kidney | 16.50 | NA | 6.96 | 1.34 | NA | 24.80 | 090 |
| 50130 | | A | Removal of kidney stone | 17.26 | NA | 7.16 | 1.30 | NA | 25.72 | 090 |
| 50135 | | A | Exploration of kidney | 19.15 | NA | 7.76 | 1.43 | NA | 28.34 | 090 |
| 50200 | | A | Biopsy of kidney | 2.63 | NA | 1.29 | 0.16 | NA | 4.08 | 000 |
| 50205 | | A | Biopsy of kidney | 11.29 | NA | 5.01 | 1.28 | NA | 17.58 | 090 |
| 50220 | | A | Remove kidney, open | 17.12 | NA | 7.22 | 1.44 | NA | 25.78 | 090 |
| 50225 | | A | Removal kidney open, complex | 20.20 | NA | 8.13 | 1.58 | NA | 29.91 | 090 |
| 50230 | | A | Removal kidney open, radical | 22.04 | NA | 8.56 | 1.70 | NA | 32.30 | 090 |
| 50234 | | A | Removal of kidney & ureter | 22.37 | NA | 8.81 | 1.67 | NA | 32.85 | 090 |
| 50236 | | A | Removal of kidney & ureter | 24.82 | NA | 10.23 | 1.88 | NA | 36.93 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 50240 | | A | Partial removal of kidney | 21.97 | NA | 8.99 | 1.66 | NA | 32.62 | 090 |
| 50280 | | A | Removal of kidney lesion | 15.65 | NA | 6.67 | 1.29 | NA | 23.61 | 090 |
| 50290 | | A | Removal of kidney lesion | 14.71 | NA | 6.45 | 1.22 | NA | 22.38 | 090 |
| 50320 | | A | Removal of donor kidney | 22.18 | NA | 10.66 | 2.33 | NA | 35.17 | 090 |
| 50340 | | A | Removal of kidney | 12.13 | NA | 6.49 | 1.66 | NA | 20.28 | 090 |
| 50360 | | A | Transplantation of kidney | 31.48 | NA | 15.48 | 3.73 | NA | 50.69 | 090 |
| 50365 | | A | Transplantation of kidney | 36.75 | NA | 18.26 | 4.25 | NA | 59.26 | 090 |
| 50370 | | A | Remove transplanted kidney | 13.70 | NA | 7.15 | 1.55 | NA | 22.40 | 090 |
| 50380 | | A | Reimplantation of kidney | 20.73 | NA | 12.06 | 2.53 | NA | 35.32 | 090 |
| 50390 | | A | Drainage of kidney lesion | 1.96 | NA | 0.64 | 0.12 | NA | 2.72 | 000 |
| 50392 | | A | Insert kidney drain | 3.37 | NA | 1.52 | 0.21 | NA | 5.10 | 000 |
| 50393 | | A | Insert ureteral tube | 4.15 | NA | 1.77 | 0.26 | NA | 6.18 | 000 |
| 50394 | | A | Injection for kidney x-ray | 0.76 | 3.04 | 0.66 | 0.05 | 3.85 | 1.47 | 000 |
| 50395 | | A | Create passage to kidney | 3.37 | NA | 1.50 | 0.21 | NA | 5.08 | 000 |
| 50396 | | A | Measure kidney pressure | 2.09 | NA | 1.08 | 0.13 | NA | 3.30 | 000 |
| 50398 | | A | Change kidney tube | 1.46 | 16.30 | 0.52 | 0.09 | 17.85 | 2.07 | 000 |
| 50400 | | A | Revision of kidney/ureter | 19.47 | NA | 7.86 | 1.49 | NA | 28.82 | 090 |
| 50405 | | A | Revision of kidney/ureter | 23.89 | NA | 9.01 | 1.79 | NA | 34.69 | 090 |
| 50500 | | A | Repair of kidney wound | 19.54 | NA | 8.39 | 1.96 | NA | 29.89 | 090 |
| 50520 | | A | Close kidney-skin fistula | 17.20 | NA | 7.41 | 1.55 | NA | 26.16 | 090 |
| 50525 | | A | Repair renal-abdomen fistula | 22.24 | NA | 8.99 | 2.30 | NA | 33.53 | 090 |
| 50526 | | A | Repair renal-abdomen fistula | 23.98 | NA | 9.84 | 4.17 | NA | 37.99 | 090 |
| 50540 | | A | Revision of horseshoe kidney | 19.90 | NA | 8.32 | 1.76 | NA | 29.98 | 090 |
| 50541 | | A | Laparo ablate renal cyst | 15.98 | NA | 6.47 | 1.22 | NA | 23.67 | 090 |
| 50542 | | A | Laparo ablate renal mass | 19.97 | NA | 8.11 | 1.66 | NA | 29.74 | 090 |
| 50543 | | A | Laparo partial nephrectomy | 25.46 | NA | 10.17 | 1.66 | NA | 37.29 | 090 |
| 50544 | | A | Laparoscopy, pyeloplasty | 22.37 | NA | 8.51 | 1.69 | NA | 32.57 | 090 |
| 50545 | | A | Laparo radical nephrectomy | 23.96 | NA | 9.17 | 1.82 | NA | 34.95 | 090 |
| 50546 | | A | Laparoscopic nephrectomy | 20.45 | NA | 8.35 | 1.60 | NA | 30.40 | 090 |
| 50547 | | A | Laparo removal donor kidney | 25.46 | NA | 11.10 | 2.80 | NA | 39.36 | 090 |
| 50548 | | A | Laparo remove w/ ureter | 24.36 | NA | 9.15 | 1.84 | NA | 35.35 | 090 |
| 50551 | | A | Kidney endoscopy | 5.59 | 4.14 | 1.96 | 0.40 | 10.13 | 7.95 | 000 |
| 50553 | | A | Kidney endoscopy | 5.98 | 4.35 | 2.16 | 0.39 | 10.72 | 8.53 | 000 |
| 50555 | | A | Kidney endoscopy & biopsy | 6.52 | 4.82 | 2.33 | 0.49 | 11.83 | 9.34 | 000 |
| 50557 | | A | Kidney endoscopy & treatment | 6.61 | 4.57 | 2.29 | 0.48 | 11.66 | 9.38 | 000 |
| 50559 | | A | Renal endoscopy/radiotracer | 6.77 | 5.30 | 2.78 | 0.41 | 12.48 | 9.96 | 000 |
| 50561 | | A | Kidney endoscopy & treatment | 7.58 | 5.08 | 2.64 | 0.55 | 13.21 | 10.77 | 000 |
| 50562 | | A | Renal scope w/tumor resect | 10.90 | NA | 4.27 | 0.48 | NA | 15.65 | 090 |
| 50570 | | A | Kidney endoscopy | 9.53 | NA | 3.20 | 0.66 | NA | 13.39 | 000 |
| 50572 | | A | Kidney endoscopy | 10.33 | NA | 3.49 | 0.87 | NA | 14.69 | 000 |
| 50574 | | A | Kidney endoscopy & biopsy | 11.00 | NA | 3.74 | 0.74 | NA | 15.48 | 000 |
| 50575 | | A | Kidney endoscopy | 13.96 | NA | 4.62 | 1.00 | NA | 19.58 | 000 |
| 50576 | | A | Kidney endoscopy & treatment | 10.97 | NA | 3.65 | 0.76 | NA | 15.38 | 000 |
| 50578 | | A | Renal endoscopy/radiotracer | 11.33 | NA | 3.79 | 0.81 | NA | 15.93 | 000 |
| 50580 | | A | Kidney endoscopy & treatment | 11.84 | NA | 3.95 | 0.84 | NA | 16.63 | 000 |
| 50590 | | A | Fragmenting of kidney stone | 9.08 | 12.49 | 4.11 | 0.66 | 22.23 | 13.85 | 090 |
| 50600 | | A | Exploration of ureter | 15.82 | NA | 6.66 | 1.34 | NA | 23.82 | 090 |
| 50605 | | A | Insert ureteral support | 15.44 | NA | 6.73 | 1.44 | NA | 23.61 | 090 |
| 50610 | | A | Removal of ureter stone | 15.90 | NA | 6.96 | 1.28 | NA | 24.14 | 090 |
| 50620 | | A | Removal of ureter stone | 15.14 | NA | 6.32 | 1.12 | NA | 22.58 | 090 |
| 50630 | | A | Removal of ureter stone | 14.92 | NA | 6.27 | 1.14 | NA | 22.33 | 090 |
| 50650 | | A | Removal of ureter | 17.38 | NA | 7.21 | 1.26 | NA | 25.85 | 090 |
| 50660 | | A | Removal of ureter | 19.52 | NA | 7.94 | 1.55 | NA | 29.01 | 090 |
| 50684 | | A | Injection for ureter x-ray | 0.76 | 5.00 | 0.47 | 0.05 | 5.81 | 1.28 | 000 |
| 50686 | | A | Measure ureter pressure | 1.51 | 3.43 | 0.82 | 0.11 | 5.05 | 2.44 | 000 |
| 50688 | | A | Change of ureter tube | 1.17 | NA | 1.06 | 0.07 | NA | 2.30 | 010 |
| 50690 | | A | Injection for ureter x-ray | 1.16 | 1.80 | 0.72 | 0.08 | 3.04 | 1.96 | 000 |
| 50700 | | A | Revision of ureter | 15.19 | NA | 7.10 | 1.25 | NA | 23.54 | 090 |
| 50715 | | A | Release of ureter | 18.87 | NA | 8.73 | 2.06 | NA | 29.66 | 090 |
| 50722 | | A | Release of ureter | 16.33 | NA | 7.80 | 1.88 | NA | 26.01 | 090 |
| 50725 | | A | Release/revise ureter | 18.46 | NA | 8.04 | 1.58 | NA | 28.08 | 090 |
| 50727 | | A | Revise ureter | 8.17 | NA | 4.27 | 0.65 | NA | 13.09 | 090 |
| 50728 | | A | Revise ureter | 12.00 | NA | 5.55 | 1.05 | NA | 18.60 | 090 |
| 50740 | | A | Fusion of ureter & kidney | 18.39 | NA | 7.73 | 1.88 | NA | 28.00 | 090 |
| 50750 | | A | Fusion of ureter & kidney | 19.48 | NA | 7.97 | 1.54 | NA | 28.99 | 090 |
| 50760 | | A | Fusion of ureters | 18.39 | NA | 7.67 | 1.53 | NA | 27.59 | 090 |
| 50770 | | A | Splicing of ureters | 19.48 | NA | 7.96 | 1.61 | NA | 29.05 | 090 |
| 50780 | | A | Reimplant ureter in bladder | 18.33 | NA | 7.58 | 1.59 | NA | 27.50 | 090 |
| 50782 | | A | Reimplant ureter in bladder | 19.51 | NA | 8.80 | 1.61 | NA | 29.92 | 090 |
| 50783 | | A | Reimplant ureter in bladder | 20.52 | NA | 8.20 | 1.64 | NA | 30.36 | 090 |
| 50785 | | A | Reimplant ureter in bladder | 20.49 | NA | 8.28 | 1.63 | NA | 30.40 | 090 |
| 50800 | | A | Implant ureter in bowel | 14.50 | NA | 6.46 | 1.23 | NA | 22.19 | 090 |
| 50810 | | A | Fusion of ureter & bowel | 20.02 | NA | 9.08 | 2.16 | NA | 31.26 | 090 |
| 50815 | | A | Urine shunt to intestine | 19.90 | NA | 8.43 | 1.62 | NA | 29.95 | 090 |
| 50820 | | A | Construct bowel bladder | 21.86 | NA | 8.62 | 1.83 | NA | 32.31 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 50825 | | A | Construct bowel bladder | 28.14 | NA | 11.10 | 2.14 | NA | 41.38 | 090 |
| 50830 | | A | Revise urine flow | 31.23 | NA | 12.15 | 2.58 | NA | 45.96 | 090 |
| 50840 | | A | Replace ureter by bowel | 19.97 | NA | 8.42 | 1.56 | NA | 29.95 | 090 |
| 50845 | | A | Appendico-vesicostomy | 20.86 | NA | 8.89 | 1.53 | NA | 31.28 | 090 |
| 50860 | | A | Transplant ureter to skin | 15.34 | NA | 6.61 | 1.21 | NA | 23.16 | 090 |
| 50900 | | A | Repair of ureter | 13.60 | NA | 6.13 | 1.26 | NA | 20.99 | 090 |
| 50920 | | A | Closure ureter/skin fistula | 14.31 | NA | 6.56 | 1.13 | NA | 22.00 | 090 |
| 50930 | | A | Closure ureter/bowel fistula | 18.69 | NA | 7.96 | 1.28 | NA | 27.93 | 090 |
| 50940 | | A | Release of ureter | 14.49 | NA | 6.39 | 1.40 | NA | 22.28 | 090 |
| 50945 | | A | Laparoscopy ureterolithotomy | 16.97 | NA | 7.02 | 1.18 | NA | 25.17 | 090 |
| 50947 | | A | Laparo new ureter/bladder | 24.46 | NA | 9.66 | 1.97 | NA | 36.09 | 090 |
| 50948 | | A | Laparo new ureter/bladder | 22.47 | NA | 8.67 | 1.60 | NA | 32.74 | 090 |
| 50951 | | A | Endoscopy of ureter | 5.83 | 4.28 | 2.05 | 0.42 | 10.53 | 8.30 | 000 |
| 50953 | | A | Endoscopy of ureter | 6.23 | 4.40 | 2.36 | 0.44 | 11.07 | 9.03 | 000 |
| 50955 | | A | Ureter endoscopy & biopsy | 6.74 | 6.66 | 2.68 | 0.46 | 13.86 | 9.88 | 000 |
| 50957 | | A | Ureter endoscopy & treatment | 6.78 | 4.56 | 2.37 | 0.48 | 11.82 | 9.63 | 000 |
| 50959 | | A | Ureter endoscopy & tracer | 4.39 | NA | 1.88 | 0.25 | NA | 6.52 | 000 |
| 50961 | | A | Ureter endoscopy & treatment | 6.04 | 4.36 | 2.18 | 0.42 | 10.82 | 8.64 | 000 |
| 50970 | | A | Ureter endoscopy | 7.13 | NA | 2.45 | 0.50 | NA | 10.08 | 000 |
| 50972 | | A | Ureter endoscopy & catheter | 6.88 | NA | 2.46 | 0.50 | NA | 9.84 | 000 |
| 50974 | | A | Ureter endoscopy & biopsy | 9.16 | NA | 3.10 | 0.63 | NA | 12.89 | 000 |
| 50976 | | A | Ureter endoscopy & treatment | 9.03 | NA | 3.06 | 0.64 | NA | 12.73 | 000 |
| 50978 | | A | Ureter endoscopy & tracer | 5.09 | NA | 1.83 | 0.36 | NA | 7.28 | 000 |
| 50980 | | A | Ureter endoscopy & treatment | 6.84 | NA | 2.36 | 0.51 | NA | 9.71 | 000 |
| 51000 | | A | Drainage of bladder | 0.78 | 1.97 | 0.24 | 0.06 | 2.81 | 1.08 | 000 |
| 51005 | | A | Drainage of bladder | 1.02 | 4.75 | 0.34 | 0.09 | 5.86 | 1.45 | 000 |
| 51010 | | A | Drainage of bladder | 3.52 | 5.59 | 1.87 | 0.28 | 9.39 | 5.67 | 010 |
| 51020 | | A | Incise & treat bladder | 6.70 | NA | 3.91 | 0.53 | NA | 11.14 | 090 |
| 51030 | | A | Incise & treat bladder | 6.76 | NA | 4.04 | 0.56 | NA | 11.36 | 090 |
| 51040 | | A | Incise & drain bladder | 4.39 | NA | 2.82 | 0.33 | NA | 7.54 | 090 |
| 51045 | | A | Incise bladder/drain ureter | 6.76 | NA | 4.00 | 0.58 | NA | 11.34 | 090 |
| 51050 | | A | Removal of bladder stone | 6.91 | NA | 3.69 | 0.50 | NA | 11.10 | 090 |
| 51060 | | A | Removal of ureter stone | 8.84 | NA | 4.56 | 0.68 | NA | 14.08 | 090 |
| 51065 | | A | Remove ureter calculus | 8.84 | NA | 4.40 | 0.67 | NA | 13.91 | 090 |
| 51080 | | A | Drainage of bladder abscess | 5.95 | NA | 3.61 | 0.47 | NA | 10.03 | 090 |
| 51500 | | A | Removal of bladder cyst | 10.12 | NA | 5.03 | 1.10 | NA | 16.25 | 090 |
| 51520 | | A | Removal of bladder lesion | 9.28 | NA | 4.72 | 0.72 | NA | 14.72 | 090 |
| 51525 | | A | Removal of bladder lesion | 13.95 | NA | 6.17 | 1.05 | NA | 21.17 | 090 |
| 51530 | | A | Removal of bladder lesion | 12.36 | NA | 5.80 | 1.12 | NA | 19.28 | 090 |
| 51535 | | A | Repair of ureter lesion | 12.55 | NA | 6.16 | 1.20 | NA | 19.91 | 090 |
| 51550 | | A | Partial removal of bladder | 15.64 | NA | 6.78 | 1.37 | NA | 23.79 | 090 |
| 51555 | | A | Partial removal of bladder | 21.20 | NA | 8.71 | 1.80 | NA | 31.71 | 090 |
| 51565 | | A | Revise bladder & ureter(s) | 21.59 | NA | 9.01 | 1.69 | NA | 32.29 | 090 |
| 51570 | | A | Removal of bladder | 24.20 | NA | 9.81 | 1.89 | NA | 35.90 | 090 |
| 51575 | | A | Removal of bladder & nodes | 30.40 | NA | 12.10 | 2.27 | NA | 44.77 | 090 |
| 51580 | | A | Remove bladder/revise tract | 31.03 | NA | 12.58 | 2.29 | NA | 45.90 | 090 |
| 51585 | | A | Removal of bladder & nodes | 35.18 | NA | 13.77 | 2.80 | NA | 51.75 | 090 |
| 51590 | | A | Remove bladder/revise tract | 32.61 | NA | 12.69 | 2.43 | NA | 47.73 | 090 |
| 51595 | | A | Remove bladder/revise tract | 37.08 | NA | 14.19 | 2.74 | NA | 54.01 | 090 |
| 51596 | | A | Remove bladder/create pouch | 39.46 | NA | 15.30 | 2.88 | NA | 57.64 | 090 |
| 51597 | | A | Removal of pelvic structures | 38.29 | NA | 14.91 | 2.97 | NA | 56.17 | 090 |
| 51600 | | A | Injection for bladder x-ray | 0.88 | 5.08 | 0.29 | 0.06 | 6.02 | 1.23 | 000 |
| 51605 | | A | Preparation for bladder xray | 0.64 | 6.03 | 0.35 | 0.04 | 6.71 | 1.03 | 000 |
| 51610 | | A | Injection for bladder x-ray | 1.05 | 2.33 | 0.60 | 0.07 | 3.45 | 1.72 | 000 |
| 51700 | | A | Irrigation of bladder | 0.88 | 1.60 | 0.28 | 0.06 | 2.54 | 1.22 | 000 |
| 51701 | | A | Insert bladder catheter | 0.50 | 1.57 | 0.19 | 0.04 | 2.11 | 0.73 | 000 |
| 51702 | | A | Insert temp bladder cath | 0.50 | 2.08 | 0.24 | 0.04 | 2.62 | 0.78 | 000 |
| 51703 | | A | Insert bladder cath, complex | 1.47 | 2.72 | 0.56 | 0.08 | 4.27 | 2.11 | 000 |
| 51705 | | A | Change of bladder tube | 1.02 | 2.27 | 0.62 | 0.07 | 3.36 | 1.71 | 010 |
| 51710 | | A | Change of bladder tube | 1.49 | 3.32 | 0.77 | 0.11 | 4.92 | 2.37 | 010 |
| 51715 | | A | Endoscopic injection/implant | 3.73 | 3.88 | 1.35 | 0.29 | 7.90 | 5.37 | 000 |
| 51720 | | A | Treatment of bladder lesion | 1.96 | 1.74 | 0.69 | 0.14 | 3.84 | 2.79 | 000 |
| 51725 | | A | Simple cystometrogram | 1.51 | 5.58 | NA | 0.16 | 7.25 | NA | 000 |
| 51725 | 26 | A | Simple cystometrogram | 1.51 | 0.49 | 0.49 | 0.12 | 2.12 | 2.12 | 000 |
| 51725 | TC | A | Simple cystometrogram | 0.00 | 5.09 | NA | 0.04 | 5.13 | NA | 000 |
| 51726 | | A | Complex cystometrogram | 1.71 | 7.48 | NA | 0.18 | 9.37 | NA | 000 |
| 51726 | 26 | A | Complex cystometrogram | 1.71 | 0.56 | 0.56 | 0.13 | 2.40 | 2.40 | 000 |
| 51726 | TC | A | Complex cystometrogram | 0.00 | 6.92 | NA | 0.05 | 6.97 | NA | 000 |
| 51736 | | A | Urine flow measurement | 0.61 | 0.58 | NA | 0.06 | 1.25 | NA | 000 |
| 51736 | 26 | A | Urine flow measurement | 0.61 | 0.20 | 0.20 | 0.05 | 0.86 | 0.86 | 000 |
| 51736 | TC | A | Urine flow measurement | 0.00 | 0.38 | NA | 0.01 | 0.39 | NA | 000 |
| 51741 | | A | Electro-uroflowmetry, first | 1.14 | 0.80 | NA | 0.11 | 2.05 | NA | 000 |
| 51741 | 26 | A | Electro-uroflowmetry, first | 1.14 | 0.37 | 0.37 | 0.09 | 1.60 | 1.60 | 000 |
| 51741 | TC | A | Electro-uroflowmetry, first | 0.00 | 0.43 | NA | 0.02 | 0.45 | NA | 000 |
| 51772 | | A | Urethra pressure profile | 1.61 | 5.58 | NA | 0.19 | 7.38 | NA | 000 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 51772 | 26 | A | Urethra pressure profile | 1.61 | 0.55 | 0.55 | 0.14 | 2.30 | 2.30 | 000 |
| 51772 | TC | A | Urethra pressure profile | 0.00 | 5.03 | NA | 0.05 | 5.08 | NA | 000 |
| 51784 | | A | Anal/urinary muscle study | 1.53 | 3.99 | NA | 0.16 | 5.68 | NA | 000 |
| 51784 | 26 | A | Anal/urinary muscle study | 1.53 | 0.50 | 0.50 | 0.12 | 2.15 | 2.15 | 000 |
| 51784 | TC | A | Anal/urinary muscle study | 0.00 | 3.48 | NA | 0.04 | 3.52 | NA | 000 |
| 51785 | | A | Anal/urinary muscle study | 1.53 | 4.44 | NA | 0.15 | 6.12 | NA | 000 |
| 51785 | 26 | A | Anal/urinary muscle study | 1.53 | 0.50 | 0.50 | 0.11 | 2.14 | 2.14 | 000 |
| 51785 | TC | A | Anal/urinary muscle study | 0.00 | 3.94 | NA | 0.04 | 3.98 | NA | 000 |
| 51792 | | A | Urinary reflex study | 1.10 | 5.99 | NA | 0.20 | 7.29 | NA | 000 |
| 51792 | 26 | A | Urinary reflex study | 1.10 | 0.41 | 0.41 | 0.07 | 1.58 | 1.58 | 000 |
| 51792 | TC | A | Urinary reflex study | 0.00 | 5.57 | NA | 0.13 | 5.70 | NA | 000 |
| 51795 | | A | Urine voiding pressure study | 1.53 | 7.28 | NA | 0.22 | 9.03 | NA | 000 |
| 51795 | 26 | A | Urine voiding pressure study | 1.53 | 0.50 | 0.50 | 0.12 | 2.15 | 2.15 | 000 |
| 51795 | TC | A | Urine voiding pressure study | 0.00 | 6.78 | NA | 0.10 | 6.88 | NA | 000 |
| 51797 | | A | Intraabdominal pressure test | 1.60 | 5.76 | NA | 0.17 | 7.53 | NA | 000 |
| 51797 | 26 | A | Intraabdominal pressure test | 1.60 | 0.52 | 0.52 | 0.12 | 2.24 | 2.24 | 000 |
| 51797 | TC | A | Intraabdominal pressure test | 0.00 | 5.23 | NA | 0.05 | 5.28 | NA | 000 |
| 51798 | | A | Us urine capacity measure | 0.00 | 0.34 | NA | 0.08 | 0.42 | NA | XXX |
| 51800 | | A | Revision of bladder/urethra | 17.39 | NA | 7.60 | 1.38 | NA | 26.37 | 090 |
| 51820 | | A | Revision of urinary tract | 17.86 | NA | 8.38 | 1.90 | NA | 28.14 | 090 |
| 51840 | | A | Attach bladder/urethra | 10.69 | NA | 5.56 | 1.10 | NA | 17.35 | 090 |
| 51841 | | A | Attach bladder/urethra | 13.01 | NA | 6.37 | 1.30 | NA | 20.68 | 090 |
| 51845 | | A | Repair bladder neck | 9.72 | NA | 4.80 | 0.81 | NA | 15.33 | 090 |
| 51860 | | A | Repair of bladder wound | 12.00 | NA | 5.83 | 1.20 | NA | 19.03 | 090 |
| 51865 | | A | Repair of bladder wound | 15.02 | NA | 6.74 | 1.33 | NA | 23.09 | 090 |
| 51880 | | A | Repair of bladder opening | 7.65 | NA | 4.02 | 0.70 | NA | 12.37 | 090 |
| 51900 | | A | Repair bladder/vagina lesion | 12.95 | NA | 6.13 | 1.15 | NA | 20.23 | 090 |
| 51920 | | A | Close bladder-uterus fistula | 11.79 | NA | 5.68 | 0.90 | NA | 18.37 | 090 |
| 51925 | | A | Hysterectomy/bladder repair | 15.56 | NA | 8.75 | 1.38 | NA | 25.69 | 090 |
| 51940 | | A | Correction of bladder defect | 28.39 | NA | 12.23 | 2.39 | NA | 43.01 | 090 |
| 51960 | | A | Revision of bladder & bowel | 22.98 | NA | 9.74 | 1.73 | NA | 34.45 | 090 |
| 51980 | | A | Construct bladder opening | 11.34 | NA | 5.42 | 0.88 | NA | 17.64 | 090 |
| 51990 | | A | Laparo urethral suspension | 12.48 | NA | 6.13 | 1.41 | NA | 20.02 | 090 |
| 51992 | | A | Laparo sling operation | 13.99 | NA | 6.19 | 1.36 | NA | 21.54 | 090 |
| 52000 | | A | Cystoscopy | 2.01 | 3.29 | 0.76 | 0.15 | 5.45 | 2.92 | 000 |
| 52001 | | A | Cystoscopy, removal of clots | 5.44 | 5.06 | 1.86 | 0.17 | 10.67 | 7.47 | 000 |
| 52005 | | A | Cystoscopy & ureter catheter | 2.37 | 5.54 | 0.89 | 0.17 | 8.08 | 3.43 | 000 |
| 52007 | | A | Cystoscopy and biopsy | 3.02 | 16.43 | 1.15 | 0.22 | 19.67 | 4.39 | 000 |
| 52010 | | A | Cystoscopy & duct catheter | 3.02 | 10.81 | 1.15 | 0.22 | 14.05 | 4.39 | 000 |
| 52204 | | A | Cystoscopy | 2.37 | 14.45 | 0.90 | 0.17 | 16.99 | 3.44 | 000 |
| 52214 | | A | Cystoscopy and treatment | 3.70 | 37.93 | 1.33 | 0.27 | 41.90 | 5.30 | 000 |
| 52224 | | A | Cystoscopy and treatment | 3.14 | 36.30 | 1.15 | 0.22 | 39.66 | 4.51 | 000 |
| 52234 | | A | Cystoscopy and treatment | 4.62 | NA | 1.65 | 0.33 | NA | 6.60 | 000 |
| 52235 | | A | Cystoscopy and treatment | 5.44 | NA | 1.93 | 0.39 | NA | 7.76 | 000 |
| 52240 | | A | Cystoscopy and treatment | 9.71 | NA | 3.29 | 0.69 | NA | 13.69 | 000 |
| 52250 | | A | Cystoscopy and radiotracer | 4.49 | NA | 1.65 | 0.33 | NA | 6.47 | 000 |
| 52260 | | A | Cystoscopy and treatment | 3.91 | NA | 1.42 | 0.29 | NA | 5.62 | 000 |
| 52265 | | A | Cystoscopy and treatment | 2.94 | 13.28 | 1.11 | 0.22 | 16.44 | 4.27 | 000 |
| 52270 | | A | Cystoscopy & revise urethra | 3.36 | 10.99 | 1.24 | 0.24 | 14.59 | 4.84 | 000 |
| 52275 | | A | Cystoscopy & revise urethra | 4.69 | 15.48 | 1.66 | 0.34 | 20.51 | 6.69 | 000 |
| 52276 | | A | Cystoscopy and treatment | 4.99 | NA | 1.78 | 0.36 | NA | 7.13 | 000 |
| 52277 | | A | Cystoscopy and treatment | 6.16 | NA | 2.22 | 0.45 | NA | 8.83 | 000 |
| 52281 | | A | Cystoscopy and treatment | 2.80 | 7.07 | 1.08 | 0.20 | 10.07 | 4.08 | 000 |
| 52282 | | A | Cystoscopy, implant stent | 6.39 | NA | 2.23 | 0.46 | NA | 9.08 | 000 |
| 52283 | | A | Cystoscopy and treatment | 3.73 | 3.94 | 1.38 | 0.27 | 7.94 | 5.38 | 000 |
| 52285 | | A | Cystoscopy and treatment | 3.60 | 4.00 | 1.33 | 0.27 | 7.87 | 5.20 | 000 |
| 52290 | | A | Cystoscopy and treatment | 4.58 | NA | 1.65 | 0.33 | NA | 6.56 | 000 |
| 52300 | | A | Cystoscopy and treatment | 5.30 | NA | 1.90 | 0.38 | NA | 7.58 | 000 |
| 52301 | | A | Cystoscopy and treatment | 5.50 | NA | 1.99 | 0.48 | NA | 7.97 | 000 |
| 52305 | | A | Cystoscopy and treatment | 5.30 | NA | 1.85 | 0.39 | NA | 7.54 | 000 |
| 52310 | | A | Cystoscopy and treatment | 2.81 | 4.68 | 1.03 | 0.20 | 7.69 | 4.04 | 000 |
| 52315 | | A | Cystoscopy and treatment | 5.20 | 8.68 | 1.83 | 0.37 | 14.25 | 7.40 | 000 |
| 52317 | | A | Remove bladder stone | 6.71 | 28.82 | 2.27 | 0.48 | 36.01 | 9.46 | 000 |
| 52318 | | A | Remove bladder stone | 9.18 | NA | 3.09 | 0.66 | NA | 12.93 | 000 |
| 52320 | | A | Cystoscopy and treatment | 4.69 | NA | 1.63 | 0.34 | NA | 6.66 | 000 |
| 52325 | | A | Cystoscopy, stone removal | 6.15 | NA | 2.10 | 0.44 | NA | 8.69 | 000 |
| 52327 | | A | Cystoscopy, inject material | 5.18 | 31.67 | 1.81 | 0.39 | 37.24 | 7.38 | 000 |
| 52330 | | A | Cystoscopy and treatment | 5.03 | 38.66 | 1.74 | 0.36 | 44.05 | 7.13 | 000 |
| 52332 | | A | Cystoscopy and treatment | 2.83 | 5.73 | 1.05 | 0.21 | 8.77 | 4.09 | 000 |
| 52334 | | A | Create passage to kidney | 4.82 | NA | 1.73 | 0.34 | NA | 6.89 | 000 |
| 52341 | | A | Cysto w/ureter stricture tx | 5.99 | NA | 2.21 | 0.43 | NA | 8.63 | 000 |
| 52342 | | A | Cysto w/up stricture tx | 6.49 | NA | 2.34 | 0.47 | NA | 9.30 | 000 |
| 52343 | | A | Cysto w/renal stricture tx | 7.19 | NA | 2.57 | 0.51 | NA | 10.27 | 000 |
| 52344 | | A | Cysto/uretero, stone remove | 7.69 | NA | 2.79 | 0.56 | NA | 11.04 | 000 |
| 52345 | | A | Cysto/uretero w/up stricture | 8.19 | NA | 2.95 | 0.58 | NA | 11.72 | 000 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 52346 | | A | Cystouretero w/renal strict | 9.22 | NA | 3.27 | 0.67 | NA | 13.16 | 000 |
| 52347 | | A | Cystoscopy, resect ducts | 5.27 | NA | 1.70 | 0.38 | NA | 7.35 | 000 |
| 52351 | | A | Cystouretero & or pyeloscope | 5.85 | NA | 2.14 | 0.42 | NA | 8.41 | 000 |
| 52352 | | A | Cystouretero w/stone remove | 6.87 | NA | 2.50 | 0.49 | NA | 9.86 | 000 |
| 52353 | | A | Cystouretero w/lithotripsy | 7.96 | NA | 2.85 | 0.57 | NA | 11.38 | 000 |
| 52354 | | A | Cystouretero w/biopsy | 7.33 | NA | 2.66 | 0.53 | NA | 10.52 | 000 |
| 52355 | | A | Cystouretero w/excise tumor | 8.81 | NA | 3.13 | 0.63 | NA | 12.57 | 000 |
| 52400 | | A | Cystouretero w/congen repr | 9.67 | NA | 3.75 | 0.69 | NA | 14.11 | 090 |
| 52450 | | A | Incision of prostate | 7.63 | NA | 3.68 | 0.55 | NA | 11.86 | 090 |
| 52500 | | A | Revision of bladder neck | 8.46 | NA | 3.92 | 0.60 | NA | 12.98 | 090 |
| 52510 | | A | Dilation prostatic urethra | 6.71 | NA | 3.12 | 0.49 | NA | 10.32 | 090 |
| 52601 | | A | Prostatectomy (TURP) | 12.35 | NA | 5.11 | 0.88 | NA | 18.34 | 090 |
| 52606 | | A | Control postop bleeding | 8.12 | NA | 3.55 | 0.58 | NA | 12.25 | 090 |
| 52612 | | A | Prostatectomy, first stage | 7.97 | NA | 3.74 | 0.57 | NA | 12.28 | 090 |
| 52614 | | A | Prostatectomy, second stage | 6.83 | NA | 3.35 | 0.49 | NA | 10.67 | 090 |
| 52620 | | A | Remove residual prostate | 6.60 | NA | 2.98 | 0.47 | NA | 10.05 | 090 |
| 52630 | | A | Remove prostate regrowth | 7.25 | NA | 3.19 | 0.52 | NA | 10.96 | 090 |
| 52640 | | A | Relieve bladder contracture | 6.61 | NA | 2.96 | 0.47 | NA | 10.04 | 090 |
| 52647 | | A | Laser surgery of prostate | 10.34 | 73.74 | 4.53 | 0.74 | 84.82 | 15.61 | 090 |
| 52648 | | A | Laser surgery of prostate | 11.19 | NA | 4.79 | 0.80 | NA | 16.78 | 090 |
| 52700 | | A | Drainage of prostate abscess | 6.79 | NA | 3.18 | 0.49 | NA | 10.46 | 090 |
| 53000 | | A | Incision of urethra | 2.28 | NA | 1.55 | 0.16 | NA | 3.99 | 010 |
| 53010 | | A | Incision of urethra | 3.63 | NA | 2.97 | 0.26 | NA | 6.86 | 090 |
| 53020 | | A | Incision of urethra | 1.77 | 2.99 | 0.67 | 0.13 | 4.89 | 2.57 | 000 |
| 53025 | | A | Incision of urethra | 1.13 | 3.71 | 0.51 | 0.09 | 4.93 | 1.73 | 000 |
| 53040 | | A | Drainage of urethra abscess | 6.39 | NA | 3.43 | 0.47 | NA | 10.29 | 090 |
| 53060 | | A | Drainage of urethra abscess | 2.63 | 2.09 | 1.37 | 0.27 | 4.99 | 4.27 | 010 |
| 53080 | | A | Drainage of urinary leakage | 6.28 | NA | 6.06 | 0.55 | NA | 12.89 | 090 |
| 53085 | | A | Drainage of urinary leakage | 10.25 | NA | 7.45 | 0.92 | NA | 18.62 | 090 |
| 53200 | | A | Biopsy of urethra | 2.59 | 1.32 | 0.98 | 0.20 | 4.11 | 3.77 | 000 |
| 53210 | | A | Removal of urethra | 12.55 | NA | 5.91 | 1.00 | NA | 19.46 | 090 |
| 53215 | | A | Removal of urethra | 15.56 | NA | 6.69 | 1.13 | NA | 23.38 | 090 |
| 53220 | | A | Treatment of urethra lesion | 6.99 | NA | 3.79 | 0.54 | NA | 11.32 | 090 |
| 53230 | | A | Removal of urethra lesion | 9.57 | NA | 4.76 | 0.72 | NA | 15.05 | 090 |
| 53235 | | A | Removal of urethra lesion | 10.12 | NA | 4.96 | 0.79 | NA | 15.87 | 090 |
| 53240 | | A | Surgery for urethra pouch | 6.44 | NA | 3.59 | 0.54 | NA | 10.57 | 090 |
| 53250 | | A | Removal of urethra gland | 5.88 | NA | 3.35 | 0.50 | NA | 9.73 | 090 |
| 53260 | | A | Treatment of urethra lesion | 2.98 | 2.25 | 1.42 | 0.26 | 5.49 | 4.66 | 010 |
| 53265 | | A | Treatment of urethra lesion | 3.12 | 2.71 | 1.42 | 0.24 | 6.07 | 4.78 | 010 |
| 53270 | | A | Removal of urethra gland | 3.09 | 2.20 | 1.54 | 0.32 | 5.61 | 4.95 | 010 |
| 53275 | | A | Repair of urethra defect | 4.52 | NA | 2.24 | 0.33 | NA | 7.09 | 010 |
| 53400 | | A | Revise urethra, stage 1 | 12.75 | NA | 6.02 | 1.04 | NA | 19.81 | 090 |
| 53405 | | A | Revise urethra, stage 2 | 14.46 | NA | 6.37 | 1.22 | NA | 22.05 | 090 |
| 53410 | | A | Reconstruction of urethra | 16.42 | NA | 7.12 | 1.21 | NA | 24.75 | 090 |
| 53415 | | A | Reconstruction of urethra | 19.38 | NA | 7.40 | 1.46 | NA | 28.24 | 090 |
| 53420 | | A | Reconstruct urethra, stage 1 | 14.06 | NA | 6.43 | 0.98 | NA | 21.47 | 090 |
| 53425 | | A | Reconstruct urethra, stage 2 | 15.96 | NA | 6.96 | 1.16 | NA | 24.08 | 090 |
| 53430 | | A | Reconstruction of urethra | 16.32 | NA | 7.05 | 1.27 | NA | 24.64 | 090 |
| 53431 | | A | Reconstruct urethra/bladder | 19.86 | NA | 8.09 | 1.44 | NA | 29.39 | 090 |
| 53440 | | A | Male sling procedure | 13.60 | NA | 5.97 | 0.89 | NA | 20.46 | 090 |
| 53442 | | A | Remove/revise male sling | 11.55 | NA | 5.45 | 0.61 | NA | 17.61 | 090 |
| 53444 | | A | Insert tandem cuff | 13.38 | NA | 5.87 | 0.99 | NA | 20.24 | 090 |
| 53445 | | A | Insert uro/ves nck sphincter | 14.04 | NA | 7.14 | 1.03 | NA | 22.21 | 090 |
| 53446 | | A | Remove uro sphincter | 10.21 | NA | 5.21 | 0.74 | NA | 16.16 | 090 |
| 53447 | | A | Remove/replace ur sphincter | 13.47 | NA | 6.41 | 0.98 | NA | 20.86 | 090 |
| 53448 | | A | Remov/replc ur sphinctr comp | 21.12 | NA | 9.03 | 1.51 | NA | 31.66 | 090 |
| 53449 | | A | Repair uro sphincter | 9.69 | NA | 4.77 | 0.65 | NA | 15.11 | 090 |
| 53450 | | A | Revision of urethra | 6.13 | NA | 3.35 | 0.44 | NA | 9.92 | 090 |
| 53460 | | A | Revision of urethra | 7.11 | NA | 3.75 | 0.53 | NA | 11.39 | 090 |
| 53500 | | A | Urethrlys, transvag w/ scope | 12.19 | NA | 6.19 | 0.91 | NA | 19.29 | 090 |
| 53502 | | A | Repair of urethra injury | 7.62 | NA | 4.06 | 0.63 | NA | 12.31 | 090 |
| 53505 | | A | Repair of urethra injury | 7.62 | NA | 3.92 | 0.55 | NA | 12.09 | 090 |
| 53510 | | A | Repair of urethra injury | 10.09 | NA | 5.23 | 0.74 | NA | 16.06 | 090 |
| 53515 | | A | Repair of urethra injury | 13.29 | NA | 5.98 | 0.95 | NA | 20.22 | 090 |
| 53520 | | A | Repair of urethra defect | 8.67 | NA | 4.53 | 0.64 | NA | 13.84 | 090 |
| 53600 | | A | Dilate urethra stricture | 1.21 | 1.14 | 0.42 | 0.09 | 2.44 | 1.72 | 000 |
| 53601 | | A | Dilate urethra stricture | 0.98 | 1.26 | 0.37 | 0.07 | 2.31 | 1.42 | 000 |
| 53605 | | A | Dilate urethra stricture | 1.28 | NA | 0.41 | 0.09 | NA | 1.78 | 000 |
| 53620 | | A | Dilate urethra stricture | 1.62 | 1.99 | 0.59 | 0.12 | 3.73 | 2.33 | 000 |
| 53621 | | A | Dilate urethra stricture | 1.35 | 2.06 | 0.49 | 0.10 | 3.51 | 1.94 | 000 |
| 53660 | | A | Dilation of urethra | 0.71 | 1.31 | 0.31 | 0.05 | 2.07 | 1.07 | 000 |
| 53661 | | A | Dilation of urethra | 0.72 | 1.30 | 0.29 | 0.05 | 2.07 | 1.06 | 000 |
| 53665 | | A | Dilation of urethra | 0.76 | NA | 0.25 | 0.06 | NA | 1.07 | 000 |
| 53850 | | A | Prostatic microwave thermotx | 9.44 | 94.10 | 3.94 | 0.67 | 104.21 | 14.05 | 090 |
| 53852 | | A | Prostatic rf thermotx | 9.87 | 88.49 | 4.37 | 0.70 | 99.06 | 14.94 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 53853 | | A | Prostatic water thermother | 5.23 | 55.09 | 2.85 | 0.29 | 60.61 | 8.37 | 090 |
| 54000 | | A | Slitting of prepuce | 1.54 | 2.91 | 0.93 | 0.11 | 4.56 | 2.58 | 010 |
| 54001 | | A | Slitting of prepuce | 2.19 | 3.18 | 1.11 | 0.16 | 5.53 | 3.46 | 010 |
| 54015 | | A | Drain penis lesion | 5.31 | NA | 2.55 | 0.40 | NA | 8.26 | 010 |
| 54050 | | A | Destruction, penis lesion(s) | 1.24 | 1.67 | 1.04 | 0.10 | 3.01 | 2.38 | 010 |
| 54055 | | A | Destruction, penis lesion(s) | 1.22 | 1.57 | 0.80 | 0.09 | 2.88 | 2.11 | 010 |
| 54056 | | A | Cryosurgery, penis lesion(s) | 1.24 | 1.70 | 1.14 | 0.10 | 3.04 | 2.48 | 010 |
| 54057 | | A | Laser surg, penis lesion(s) | 1.24 | 2.22 | 0.83 | 0.09 | 3.55 | 2.16 | 010 |
| 54060 | | A | Excision of penis lesion(s) | 1.93 | 3.09 | 1.06 | 0.15 | 5.17 | 3.14 | 010 |
| 54065 | | A | Destruction, penis lesion(s) | 2.42 | 2.63 | 1.23 | 0.19 | 5.24 | 3.84 | 010 |
| 54100 | | A | Biopsy of penis | 1.90 | 2.82 | 0.82 | 0.15 | 4.87 | 2.87 | 000 |
| 54105 | | A | Biopsy of penis | 3.49 | 4.28 | 1.93 | 0.25 | 8.02 | 5.67 | 010 |
| 54110 | | A | Treatment of penis lesion | 10.11 | NA | 4.75 | 0.74 | NA | 15.60 | 090 |
| 54111 | | A | Treat penis lesion, graft | 13.55 | NA | 5.75 | 0.96 | NA | 20.26 | 090 |
| 54112 | | A | Treat penis lesion, graft | 15.84 | NA | 6.78 | 1.13 | NA | 23.75 | 090 |
| 54115 | | A | Treatment of penis lesion | 6.14 | 4.37 | 3.45 | 0.44 | 10.95 | 10.03 | 090 |
| 54120 | | A | Partial removal of penis | 9.96 | NA | 4.67 | 0.72 | NA | 15.35 | 090 |
| 54125 | | A | Removal of penis | 13.51 | NA | 5.82 | 0.99 | NA | 20.32 | 090 |
| 54130 | | A | Remove penis & nodes | 20.11 | NA | 8.16 | 1.43 | NA | 29.70 | 090 |
| 54135 | | A | Remove penis & nodes | 26.32 | NA | 10.15 | 1.87 | NA | 38.34 | 090 |
| 54150 | | A | Circumcision | 1.81 | 4.53 | 0.97 | 0.19 | 6.53 | 2.97 | 010 |
| 54152 | | A | Circumcision | 2.31 | NA | 1.20 | 0.19 | NA | 3.70 | 010 |
| 54160 | | A | Circumcision | 2.48 | 4.13 | 1.09 | 0.19 | 6.80 | 3.76 | 010 |
| 54161 | | A | Circumcision | 3.27 | NA | 1.56 | 0.24 | NA | 5.07 | 010 |
| 54162 | | A | Lysis penil circumic lesion | 3.00 | 4.63 | 1.44 | 0.22 | 7.85 | 4.66 | 010 |
| 54163 | | A | Repair of circumcision | 3.00 | NA | 2.00 | 0.22 | NA | 5.22 | 010 |
| 54164 | | A | Frenulotomy of penis | 2.50 | NA | 1.83 | 0.18 | NA | 4.51 | 010 |
| 54200 | | A | Treatment of penis lesion | 1.06 | 1.79 | 0.98 | 0.08 | 2.93 | 2.12 | 010 |
| 54205 | | A | Treatment of penis lesion | 7.92 | NA | 4.73 | 0.56 | NA | 13.21 | 090 |
| 54220 | | A | Treatment of penis lesion | 2.42 | 3.83 | 0.95 | 0.18 | 6.43 | 3.55 | 000 |
| 54230 | | A | Prepare penis study | 1.34 | 1.08 | 0.63 | 0.10 | 2.52 | 2.07 | 000 |
| 54231 | | A | Dynamic cavernosometry | 2.04 | 1.38 | 0.87 | 0.15 | 3.57 | 3.06 | 000 |
| 54235 | | A | Penile injection | 1.19 | 0.96 | 0.58 | 0.09 | 2.24 | 1.86 | 000 |
| 54240 | | A | Penis study | 1.31 | 1.01 | NA | 0.17 | 2.49 | NA | 000 |
| 54240 | 26 | A | Penis study | 1.31 | 0.43 | 0.43 | 0.11 | 1.85 | 1.85 | 000 |
| 54240 | TC | A | Penis study | 0.00 | 0.59 | NA | 0.06 | 0.65 | NA | 000 |
| 54250 | | A | Penis study | 2.22 | 0.92 | NA | 0.19 | 3.33 | NA | 000 |
| 54250 | 26 | A | Penis study | 2.22 | 0.71 | 0.71 | 0.17 | 3.10 | 3.10 | 000 |
| 54250 | TC | A | Penis study | 0.00 | 0.21 | NA | 0.02 | 0.23 | NA | 000 |
| 54300 | | A | Revision of penis | 10.39 | NA | 5.65 | 0.74 | NA | 16.78 | 090 |
| 54304 | | A | Revision of penis | 12.47 | NA | 6.43 | 0.92 | NA | 19.82 | 090 |
| 54308 | | A | Reconstruction of urethra | 11.81 | NA | 6.05 | 0.84 | NA | 18.70 | 090 |
| 54312 | | A | Reconstruction of urethra | 13.55 | NA | 7.07 | 0.96 | NA | 21.58 | 090 |
| 54316 | | A | Reconstruction of urethra | 16.79 | NA | 8.05 | 1.21 | NA | 26.05 | 090 |
| 54318 | | A | Reconstruction of urethra | 11.23 | NA | 5.88 | 0.80 | NA | 17.91 | 090 |
| 54322 | | A | Reconstruction of urethra | 12.99 | NA | 6.53 | 0.99 | NA | 20.51 | 090 |
| 54324 | | A | Reconstruction of urethra | 16.29 | NA | 8.10 | 1.48 | NA | 25.87 | 090 |
| 54326 | | A | Reconstruction of urethra | 15.70 | NA | 7.89 | 1.12 | NA | 24.71 | 090 |
| 54328 | | A | Revise penis/urethra | 15.63 | NA | 7.33 | 1.11 | NA | 24.07 | 090 |
| 54332 | | A | Revise penis/urethra | 17.05 | NA | 7.82 | 1.21 | NA | 26.08 | 090 |
| 54336 | | A | Revise penis/urethra | 20.01 | NA | 10.59 | 1.42 | NA | 32.02 | 090 |
| 54340 | | A | Secondary urethral surgery | 8.90 | NA | 5.16 | 0.59 | NA | 14.65 | 090 |
| 54344 | | A | Secondary urethral surgery | 15.92 | NA | 7.86 | 1.13 | NA | 24.91 | 090 |
| 54348 | | A | Secondary urethral surgery | 17.12 | NA | 8.48 | 1.18 | NA | 26.78 | 090 |
| 54352 | | A | Reconstruct urethra/penis | 24.70 | NA | 11.36 | 1.81 | NA | 37.87 | 090 |
| 54360 | | A | Penis plastic surgery | 11.91 | NA | 6.08 | 0.86 | NA | 18.85 | 090 |
| 54380 | | A | Repair penis | 13.16 | NA | 6.78 | 1.00 | NA | 20.94 | 090 |
| 54385 | | A | Repair penis | 15.37 | NA | 8.57 | 1.20 | NA | 25.14 | 090 |
| 54390 | | A | Repair penis and bladder | 21.58 | NA | 9.47 | 1.28 | NA | 32.33 | 090 |
| 54400 | | A | Insert semi-rigid prosthesis | 8.98 | NA | 4.40 | 0.65 | NA | 14.03 | 090 |
| 54401 | | A | Insert self-contd prosthesis | 10.26 | NA | 5.75 | 0.73 | NA | 16.74 | 090 |
| 54405 | | A | Insert multi-comp penis pros | 13.41 | NA | 5.98 | 0.99 | NA | 20.38 | 090 |
| 54406 | | A | Remove muti-comp penis pros | 12.08 | NA | 5.41 | 0.88 | NA | 18.37 | 090 |
| 54408 | | A | Repair multi-comp penis pros | 12.73 | NA | 5.72 | 0.92 | NA | 19.37 | 090 |
| 54410 | | A | Remove/replace penis prosth | 15.48 | NA | 6.61 | 1.13 | NA | 23.22 | 090 |
| 54411 | | A | Remov/replc penis pros, comp | 15.98 | NA | 7.02 | 1.17 | NA | 24.17 | 090 |
| 54415 | | A | Remove self-contd penis pros | 8.19 | NA | 4.18 | 0.59 | NA | 12.96 | 090 |
| 54416 | | A | Remv/repl penis contain pros | 10.85 | NA | 5.36 | 0.79 | NA | 17.00 | 090 |
| 54417 | | A | Remv/replc penis pros, compl | 14.17 | NA | 6.15 | 1.01 | NA | 21.33 | 090 |
| 54420 | | A | Revision of penis | 11.40 | NA | 5.63 | 0.91 | NA | 17.94 | 090 |
| 54430 | | A | Revision of penis | 10.13 | NA | 5.16 | 0.73 | NA | 16.02 | 090 |
| 54435 | | A | Revision of penis | 6.11 | NA | 3.66 | 0.47 | NA | 10.24 | 090 |
| 54450 | | A | Preputial stretching | 1.12 | 0.95 | 0.44 | 0.08 | 2.15 | 1.64 | 000 |
| 54500 | | A | Biopsy of testis | 1.31 | 0.60 | 0.56 | 0.11 | 2.02 | 1.98 | 000 |
| 54505 | | A | Biopsy of testis | 3.45 | NA | 1.91 | 0.28 | NA | 5.64 | 010 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 54512 | | A | Excise lesion testis | 8.57 | NA | 4.12 | 0.65 | NA | 13.34 | 090 |
| 54520 | | A | Removal of testis | 5.22 | NA | 2.81 | 0.50 | NA | 8.53 | 090 |
| 54522 | | A | Orchiectomy, partial | 9.49 | NA | 4.85 | 0.91 | NA | 15.25 | 090 |
| 54530 | | A | Removal of testis | 8.57 | NA | 4.26 | 0.68 | NA | 13.51 | 090 |
| 54535 | | A | Extensive testis surgery | 12.14 | NA | 5.59 | 1.09 | NA | 18.82 | 090 |
| 54550 | | A | Exploration for testis | 7.77 | NA | 3.84 | 0.63 | NA | 12.24 | 090 |
| 54560 | | A | Exploration for testis | 11.11 | NA | 5.20 | 0.96 | NA | 17.27 | 090 |
| 54600 | | A | Reduce testis torsion | 7.00 | NA | 3.57 | 0.53 | NA | 11.10 | 090 |
| 54620 | | A | Suspension of testis | 4.89 | NA | 2.43 | 0.42 | NA | 7.74 | 010 |
| 54640 | | A | Suspension of testis | 6.89 | NA | 3.76 | 0.63 | NA | 11.28 | 090 |
| 54650 | | A | Orchiopexy (Fowler-Stephens) | 11.43 | NA | 5.45 | 1.41 | NA | 18.29 | 090 |
| 54660 | | A | Revision of testis | 5.10 | NA | 3.01 | 0.40 | NA | 8.51 | 090 |
| 54670 | | A | Repair testis injury | 6.40 | NA | 3.56 | 0.50 | NA | 10.46 | 090 |
| 54680 | | A | Relocation of testis(es) | 12.63 | NA | 6.22 | 1.23 | NA | 20.08 | 090 |
| 54690 | | A | Laparoscopy, orchiectomy | 10.94 | NA | 4.99 | 1.23 | NA | 17.16 | 090 |
| 54692 | | A | Laparoscopy, orchiopexy | 12.86 | NA | 5.40 | 1.05 | NA | 19.31 | 090 |
| 54700 | | A | Drainage of scrotum | 3.42 | NA | 1.93 | 0.28 | NA | 5.63 | 010 |
| 54800 | | A | Biopsy of epididymis | 2.33 | 0.94 | 0.89 | 0.22 | 3.49 | 3.44 | 000 |
| 54820 | | A | Exploration of epididymis | 5.13 | NA | 2.96 | 0.39 | NA | 8.48 | 090 |
| 54830 | | A | Remove epididymis lesion | 5.37 | NA | 3.04 | 0.42 | NA | 8.83 | 090 |
| 54840 | | A | Remove epididymis lesion | 5.19 | NA | 2.80 | 0.37 | NA | 8.36 | 090 |
| 54860 | | A | Removal of epididymis | 6.31 | NA | 3.33 | 0.46 | NA | 10.10 | 090 |
| 54861 | | A | Removal of epididymis | 8.89 | NA | 4.33 | 0.64 | NA | 13.86 | 090 |
| 54900 | | A | Fusion of spermatic ducts | 13.18 | NA | 5.80 | 1.62 | NA | 20.60 | 090 |
| 54901 | | A | Fusion of spermatic ducts | 17.91 | NA | 7.55 | 1.28 | NA | 26.74 | 090 |
| 55000 | | A | Drainage of hydrocele | 1.43 | 2.06 | 0.65 | 0.12 | 3.61 | 2.20 | 000 |
| 55040 | | A | Removal of hydrocele | 5.35 | NA | 2.92 | 0.44 | NA | 8.71 | 090 |
| 55041 | | A | Removal of hydroceles | 7.73 | NA | 3.98 | 0.60 | NA | 12.31 | 090 |
| 55060 | | A | Repair of hydrocele | 5.51 | NA | 3.09 | 0.46 | NA | 9.06 | 090 |
| 55100 | | A | Drainage of scrotum abscess | 2.13 | 3.67 | 1.56 | 0.17 | 5.97 | 3.86 | 010 |
| 55110 | | A | Explore scrotum | 5.69 | NA | 3.12 | 0.45 | NA | 9.26 | 090 |
| 55120 | | A | Removal of scrotum lesion | 5.08 | NA | 2.94 | 0.39 | NA | 8.41 | 090 |
| 55150 | | A | Removal of scrotum | 7.21 | NA | 3.83 | 0.58 | NA | 11.62 | 090 |
| 55175 | | A | Revision of scrotum | 5.23 | NA | 3.00 | 0.40 | NA | 8.63 | 090 |
| 55180 | | A | Revision of scrotum | 10.70 | NA | 5.34 | 0.85 | NA | 16.89 | 090 |
| 55200 | | A | Incision of sperm duct | 4.23 | 12.26 | 2.37 | 0.30 | 16.79 | 6.90 | 090 |
| 55250 | | A | Removal of sperm duct(s) | 3.29 | 11.44 | 2.21 | 0.26 | 14.99 | 5.76 | 090 |
| 55300 | | A | Prepare, sperm duct x-ray | 3.50 | NA | 1.31 | 0.26 | NA | 5.07 | 000 |
| 55400 | | A | Repair of sperm duct | 8.48 | NA | 4.05 | 0.74 | NA | 13.27 | 090 |
| 55450 | | A | Ligation of sperm duct | 4.11 | 6.96 | 1.86 | 0.29 | 11.36 | 6.26 | 010 |
| 55500 | | A | Removal of hydrocele | 5.58 | NA | 3.11 | 0.55 | NA | 9.24 | 090 |
| 55520 | | A | Removal of sperm cord lesion | 6.02 | NA | 3.28 | 0.73 | NA | 10.03 | 090 |
| 55530 | | A | Revise spermatic cord veins | 5.65 | NA | 3.03 | 0.46 | NA | 9.14 | 090 |
| 55535 | | A | Revise spermatic cord veins | 6.55 | NA | 3.41 | 0.53 | NA | 10.49 | 090 |
| 55540 | | A | Revise hernia & sperm veins | 7.66 | NA | 3.83 | 0.94 | NA | 12.43 | 090 |
| 55550 | | A | Laparo ligate spermatic vein | 6.56 | NA | 3.29 | 0.66 | NA | 10.51 | 090 |
| 55600 | | A | Incise sperm duct pouch | 6.37 | NA | 3.35 | 0.59 | NA | 10.31 | 090 |
| 55605 | | A | Incise sperm duct pouch | 7.95 | NA | 4.32 | 0.97 | NA | 13.24 | 090 |
| 55650 | | A | Remove sperm duct pouch | 11.78 | NA | 5.29 | 0.95 | NA | 18.02 | 090 |
| 55680 | | A | Remove sperm pouch lesion | 5.18 | NA | 2.98 | 0.47 | NA | 8.63 | 090 |
| 55700 | | A | Biopsy of prostate | 1.57 | 4.18 | 0.64 | 0.11 | 5.86 | 2.32 | 000 |
| 55705 | | A | Biopsy of prostate | 4.56 | NA | 2.29 | 0.33 | NA | 7.18 | 010 |
| 55720 | | A | Drainage of prostate abscess | 7.63 | NA | 3.88 | 0.55 | NA | 12.06 | 090 |
| 55725 | | A | Drainage of prostate abscess | 8.67 | NA | 4.55 | 0.74 | NA | 13.96 | 090 |
| 55801 | | A | Removal of prostate | 17.77 | NA | 7.65 | 1.37 | NA | 26.79 | 090 |
| 55810 | | A | Extensive prostate surgery | 22.55 | NA | 8.99 | 1.66 | NA | 33.20 | 090 |
| 55812 | | A | Extensive prostate surgery | 27.47 | NA | 11.03 | 2.22 | NA | 40.72 | 090 |
| 55815 | | A | Extensive prostate surgery | 30.41 | NA | 11.94 | 2.39 | NA | 44.74 | 090 |
| 55821 | | A | Removal of prostate | 14.23 | NA | 6.24 | 1.05 | NA | 21.52 | 090 |
| 55831 | | A | Removal of prostate | 15.60 | NA | 6.69 | 1.16 | NA | 23.45 | 090 |
| 55840 | | A | Extensive prostate surgery | 22.66 | NA | 9.33 | 1.68 | NA | 33.67 | 090 |
| 55842 | | A | Extensive prostate surgery | 24.34 | NA | 9.89 | 1.82 | NA | 36.05 | 090 |
| 55845 | | A | Extensive prostate surgery | 28.51 | NA | 10.99 | 2.13 | NA | 41.63 | 090 |
| 55859 | | A | Percut/needle insert, pros | 12.50 | NA | 5.87 | 0.88 | NA | 19.25 | 090 |
| 55860 | | A | Surgical exposure, prostate | 14.43 | NA | 6.45 | 0.99 | NA | 21.87 | 090 |
| 55862 | | A | Extensive prostate surgery | 18.36 | NA | 7.88 | 1.31 | NA | 27.55 | 090 |
| 55865 | | A | Extensive prostate surgery | 22.84 | NA | 9.29 | 1.73 | NA | 33.86 | 090 |
| 55866 | | A | Laparo radical prostatectomy | 30.69 | NA | 11.68 | 1.68 | NA | 44.05 | 090 |
| 55870 | | A | Electroejaculation | 2.58 | 1.53 | 1.08 | 0.17 | 4.28 | 3.83 | 000 |
| 55873 | | A | Cryoablate prostate | 19.44 | NA | 8.92 | 1.39 | NA | 29.75 | 090 |
| 56405 | | A | I & D of vulva/perineum | 1.44 | 1.33 | 1.14 | 0.17 | 2.94 | 2.75 | 010 |
| 56420 | | A | Drainage of gland abscess | 1.39 | 2.28 | 1.05 | 0.15 | 3.82 | 2.59 | 010 |
| 56440 | | A | Surgery for vulva lesion | 2.84 | NA | 1.71 | 0.34 | NA | 4.89 | 010 |
| 56441 | | A | Lysis of labial lesion(s) | 1.97 | 1.81 | 1.42 | 0.19 | 3.97 | 3.58 | 010 |
| 56501 | | A | Destroy, vulva lesions, sim | 1.53 | 1.78 | 1.25 | 0.18 | 3.49 | 2.96 | 010 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 56515 | | A | Destroy vulva lesion/s compl | 2.76 | 2.55 | 1.81 | 0.32 | 5.63 | 4.89 | 010 |
| 56605 | | A | Biopsy of vulva/perineum | 1.10 | 1.08 | 0.46 | 0.13 | 2.31 | 1.69 | 000 |
| 56606 | | A | Biopsy of vulva/perineum | 0.55 | 0.49 | 0.22 | 0.07 | 1.11 | 0.84 | ZZZ |
| 56620 | | A | Partial removal of vulva | 7.46 | NA | 4.83 | 0.89 | NA | 13.18 | 090 |
| 56625 | | A | Complete removal of vulva | 8.39 | NA | 5.39 | 1.00 | NA | 14.78 | 090 |
| 56630 | | A | Extensive vulva surgery | 12.34 | NA | 6.96 | 1.45 | NA | 20.75 | 090 |
| 56631 | | A | Extensive vulva surgery | 16.18 | NA | 8.98 | 1.92 | NA | 27.08 | 090 |
| 56632 | | A | Extensive vulva surgery | 20.26 | NA | 9.64 | 2.35 | NA | 32.25 | 090 |
| 56633 | | A | Extensive vulva surgery | 16.45 | NA | 8.71 | 1.93 | NA | 27.09 | 090 |
| 56634 | | A | Extensive vulva surgery | 17.85 | NA | 9.60 | 2.09 | NA | 29.54 | 090 |
| 56637 | | A | Extensive vulva surgery | 21.94 | NA | 11.24 | 2.56 | NA | 35.74 | 090 |
| 56640 | | A | Extensive vulva surgery | 22.14 | NA | 10.78 | 2.61 | NA | 35.53 | 090 |
| 56700 | | A | Partial removal of hymen | 2.52 | NA | 1.83 | 0.29 | NA | 4.64 | 010 |
| 56720 | | A | Incision of hymen | 0.68 | NA | 0.51 | 0.08 | NA | 1.27 | 000 |
| 56740 | | A | Remove vagina gland lesion | 4.56 | NA | 2.56 | 0.55 | NA | 7.67 | 010 |
| 56800 | | A | Repair of vagina | 3.88 | NA | 2.18 | 0.44 | NA | 6.50 | 010 |
| 56805 | | A | Repair clitoris | 18.83 | NA | 9.38 | 2.08 | NA | 30.29 | 090 |
| 56810 | | A | Repair of perineum | 4.12 | NA | 2.29 | 0.48 | NA | 6.89 | 010 |
| 56820 | | A | Exam of vulva w/scope | 1.50 | 1.32 | 0.65 | 0.11 | 2.93 | 2.26 | 000 |
| 56821 | | A | Exam/biopsy of vulva w/scope | 2.05 | 1.76 | 0.91 | 0.15 | 3.96 | 3.11 | 000 |
| 57000 | | A | Exploration of vagina | 2.97 | NA | 1.72 | 0.30 | NA | 4.99 | 010 |
| 57010 | | A | Drainage of pelvic abscess | 6.02 | NA | 3.83 | 0.69 | NA | 10.54 | 090 |
| 57020 | | A | Drainage of pelvic fluid | 1.50 | 0.95 | 0.59 | 0.18 | 2.63 | 2.27 | 000 |
| 57022 | | A | I & d vaginal hematoma, pp | 2.56 | NA | 1.50 | 0.27 | NA | 4.33 | 010 |
| 57023 | | A | I & d vag hematoma, non-ob | 4.74 | NA | 2.57 | 0.55 | NA | 7.86 | 010 |
| 57061 | | A | Destroy vag lesions, simple | 1.25 | 1.66 | 1.12 | 0.15 | 3.06 | 2.52 | 010 |
| 57065 | | A | Destroy vag lesions, complex | 2.61 | 2.30 | 1.68 | 0.31 | 5.22 | 4.60 | 010 |
| 57100 | | A | Biopsy of vagina | 1.20 | 1.09 | 0.48 | 0.14 | 2.43 | 1.82 | 000 |
| 57105 | | A | Biopsy of vagina | 1.69 | 1.79 | 1.43 | 0.20 | 3.68 | 3.32 | 010 |
| 57106 | | A | Remove vagina wall, partial | 6.35 | NA | 4.19 | 0.73 | NA | 11.27 | 090 |
| 57107 | | A | Remove vagina tissue, part | 22.97 | NA | 10.45 | 2.67 | NA | 36.09 | 090 |
| 57109 | | A | Vaginectomy partial w/nodes | 26.96 | NA | 11.28 | 3.10 | NA | 41.34 | 090 |
| 57110 | | A | Remove vagina wall, complete | 14.27 | NA | 7.28 | 1.67 | NA | 23.22 | 090 |
| 57111 | | A | Remove vagina tissue, compl | 26.96 | NA | 12.58 | 2.95 | NA | 42.49 | 090 |
| 57112 | | A | Vaginectomy w/nodes, compl | 28.96 | NA | 12.12 | 2.61 | NA | 43.69 | 090 |
| 57120 | | A | Closure of vagina | 7.40 | NA | 4.62 | 0.87 | NA | 12.89 | 090 |
| 57130 | | A | Remove vagina lesion | 2.43 | 2.16 | 1.54 | 0.27 | 4.86 | 4.24 | 010 |
| 57135 | | A | Remove vagina lesion | 2.67 | 2.27 | 1.65 | 0.31 | 5.25 | 4.63 | 010 |
| 57150 | | A | Treat vagina infection | 0.55 | 1.10 | 0.21 | 0.07 | 1.72 | 0.83 | 000 |
| 57155 | | A | Insert uteri tandems/ovoids | 6.26 | NA | 4.61 | 0.45 | NA | 11.32 | 090 |
| 57160 | | A | Insert pessary/other device | 0.89 | 1.01 | 0.34 | 0.10 | 2.00 | 1.33 | 000 |
| 57170 | | A | Fitting of diaphragm/cap | 0.91 | 1.49 | 0.33 | 0.11 | 2.51 | 1.35 | 000 |
| 57180 | | A | Treat vaginal bleeding | 1.58 | 2.17 | 1.27 | 0.18 | 3.93 | 3.03 | 010 |
| 57200 | | A | Repair of vagina | 3.93 | NA | 2.89 | 0.45 | NA | 7.27 | 090 |
| 57210 | | A | Repair vagina/perineum | 5.16 | NA | 3.43 | 0.61 | NA | 9.20 | 090 |
| 57220 | | A | Revision of urethra | 4.30 | NA | 3.10 | 0.50 | NA | 7.90 | 090 |
| 57230 | | A | Repair of urethral lesion | 5.63 | NA | 3.40 | 0.57 | NA | 9.60 | 090 |
| 57240 | | A | Repair bladder & vagina | 6.06 | NA | 3.81 | 0.62 | NA | 10.49 | 090 |
| 57250 | | A | Repair rectum & vagina | 5.52 | NA | 3.57 | 0.64 | NA | 9.73 | 090 |
| 57260 | | A | Repair of vagina | 8.26 | NA | 4.83 | 0.96 | NA | 14.05 | 090 |
| 57265 | | A | Extensive repair of vagina | 11.32 | NA | 6.03 | 1.32 | NA | 18.67 | 090 |
| 57268 | | A | Repair of bowel bulge | 6.75 | NA | 4.19 | 0.78 | NA | 11.72 | 090 |
| 57270 | | A | Repair of bowel pouch | 12.09 | NA | 6.24 | 1.39 | NA | 19.72 | 090 |
| 57280 | | A | Suspension of vagina | 15.02 | NA | 7.35 | 1.65 | NA | 24.02 | 090 |
| 57282 | | A | Repair of vaginal prolapse | 8.85 | NA | 5.29 | 1.02 | NA | 15.16 | 090 |
| 57284 | | A | Repair paravaginal defect | 12.68 | NA | 7.13 | 1.44 | NA | 21.25 | 090 |
| 57287 | | A | Revise/remove sling repair | 10.69 | NA | 5.46 | 0.91 | NA | 17.06 | 090 |
| 57288 | | A | Repair bladder defect | 13.00 | NA | 5.90 | 1.14 | NA | 20.04 | 090 |
| 57289 | | A | Repair bladder & vagina | 11.56 | NA | 6.03 | 1.17 | NA | 18.76 | 090 |
| 57291 | | A | Construction of vagina | 7.94 | NA | 4.92 | 0.94 | NA | 13.80 | 090 |
| 57292 | | A | Construct vagina with graft | 13.07 | NA | 6.93 | 1.57 | NA | 21.57 | 090 |
| 57300 | | A | Repair rectum-vagina fistula | 7.60 | NA | 4.29 | 0.88 | NA | 12.77 | 090 |
| 57305 | | A | Repair rectum-vagina fistula | 13.75 | NA | 6.26 | 1.67 | NA | 21.68 | 090 |
| 57307 | | A | Fistula repair & colostomy | 15.91 | NA | 7.02 | 1.96 | NA | 24.89 | 090 |
| 57308 | | A | Fistula repair, transperine | 9.93 | NA | 5.13 | 1.12 | NA | 16.18 | 090 |
| 57310 | | A | Repair urethrovaginal lesion | 6.77 | NA | 3.86 | 0.57 | NA | 11.20 | 090 |
| 57311 | | A | Repair urethrovaginal lesion | 7.97 | NA | 4.14 | 0.68 | NA | 12.79 | 090 |
| 57320 | | A | Repair bladder-vagina lesion | 8.00 | NA | 4.39 | 0.65 | NA | 13.04 | 090 |
| 57330 | | A | Repair bladder-vagina lesion | 12.33 | NA | 5.73 | 1.07 | NA | 19.13 | 090 |
| 57335 | | A | Repair vagina | 18.70 | NA | 9.03 | 1.84 | NA | 29.57 | 090 |
| 57400 | | A | Dilation of vagina | 2.27 | NA | 1.11 | 0.26 | NA | 3.64 | 000 |
| 57410 | | A | Pelvic examination | 1.75 | 2.02 | 0.89 | 0.17 | 3.94 | 2.81 | 000 |
| 57415 | | A | Remove vaginal foreign body | 2.17 | NA | 1.43 | 0.23 | NA | 3.83 | 010 |
| 57420 | | A | Exam of vagina w/scope | 1.60 | 1.36 | 0.67 | 0.11 | 3.07 | 2.38 | 000 |
| 57421 | | A | Exam/biopsy of vag w/scope | 2.20 | 1.85 | 0.96 | 0.15 | 4.20 | 3.31 | 000 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 57425 | | A | Laparoscopy, surg, colpopexy | 15.73 | NA | 6.63 | 1.74 | NA | 24.10 | 090 |
| 57452 | | A | Exam of cervix w/scope | 1.50 | 1.29 | 0.77 | 0.11 | 2.90 | 2.38 | 000 |
| 57454 | | A | Bx/curett of cervix w/scope | 2.33 | 1.64 | 1.15 | 0.15 | 4.12 | 3.63 | 000 |
| 57455 | | A | Biopsy of cervix w/scope | 1.99 | 1.72 | 0.87 | 0.15 | 3.86 | 3.01 | 000 |
| 57456 | | A | Endocerv curettage w/scope | 1.85 | 1.65 | 0.82 | 0.15 | 3.65 | 2.82 | 000 |
| 57460 | | A | Bx of cervix w/scope, leep | 2.83 | 5.85 | 1.37 | 0.33 | 9.01 | 4.53 | 000 |
| 57461 | | A | Conz of cervix w/scope, leep | 3.43 | 6.11 | 1.47 | 0.33 | 9.87 | 5.23 | 000 |
| 57500 | | A | Biopsy of cervix | 0.97 | 2.55 | 0.63 | 0.11 | 3.63 | 1.71 | 000 |
| 57505 | | A | Endocervical curettage | 1.14 | 1.47 | 1.10 | 0.13 | 2.74 | 2.37 | 010 |
| 57510 | | A | Cauterization of cervix | 1.90 | 1.57 | 1.04 | 0.22 | 3.69 | 3.16 | 010 |
| 57511 | | A | Cryocautery of cervix | 1.90 | 1.83 | 1.38 | 0.22 | 3.95 | 3.50 | 010 |
| 57513 | | A | Laser surgery of cervix | 1.90 | 1.73 | 1.41 | 0.23 | 3.86 | 3.54 | 010 |
| 57520 | | A | Conization of cervix | 4.03 | 3.93 | 2.88 | 0.48 | 8.44 | 7.39 | 090 |
| 57522 | | A | Conization of cervix | 3.35 | 3.15 | 2.46 | 0.40 | 6.90 | 6.21 | 090 |
| 57530 | | A | Removal of cervix | 4.78 | NA | 3.42 | 0.56 | NA | 8.76 | 090 |
| 57531 | | A | Removal of cervix, radical | 27.96 | NA | 13.18 | 3.29 | NA | 44.43 | 090 |
| 57540 | | A | Removal of residual cervix | 12.20 | NA | 6.24 | 1.39 | NA | 19.83 | 090 |
| 57545 | | A | Remove cervix/repair pelvis | 13.01 | NA | 6.67 | 1.57 | NA | 21.25 | 090 |
| 57550 | | A | Removal of residual cervix | 5.52 | NA | 3.85 | 0.67 | NA | 10.04 | 090 |
| 57555 | | A | Remove cervix/repair vagina | 8.94 | NA | 5.11 | 1.08 | NA | 15.13 | 090 |
| 57556 | | A | Remove cervix, repair bowel | 8.36 | NA | 4.87 | 0.95 | NA | 14.18 | 090 |
| 57700 | | A | Revision of cervix | 3.54 | NA | 3.08 | 0.40 | NA | 7.02 | 090 |
| 57720 | | A | Revision of cervix | 4.12 | NA | 3.14 | 0.49 | NA | 7.75 | 090 |
| 57800 | | A | Dilation of cervical canal | 0.77 | 0.76 | 0.47 | 0.09 | 1.62 | 1.33 | 000 |
| 57820 | | A | D & c of residual cervix | 1.67 | 1.48 | 1.14 | 0.20 | 3.35 | 3.01 | 010 |
| 58100 | | A | Biopsy of uterus lining | 1.53 | 1.32 | 0.72 | 0.18 | 3.03 | 2.43 | 000 |
| 58120 | | A | Dilation and curettage | 3.27 | 2.30 | 1.87 | 0.39 | 5.96 | 5.53 | 010 |
| 58140 | | A | Myomectomy abdom method | 14.58 | NA | 7.10 | 1.77 | NA | 23.45 | 090 |
| 58145 | | A | Myomectomy vag method | 8.03 | NA | 4.82 | 0.96 | NA | 13.81 | 090 |
| 58146 | | A | Myomectomy abdom complex | 18.97 | NA | 8.90 | 1.77 | NA | 29.64 | 090 |
| 58150 | | A | Total hysterectomy | 15.22 | NA | 7.48 | 1.81 | NA | 24.51 | 090 |
| 58152 | | A | Total hysterectomy | 20.57 | NA | 9.83 | 2.39 | NA | 32.79 | 090 |
| 58180 | | A | Partial hysterectomy | 15.27 | NA | 7.44 | 1.83 | NA | 24.54 | 090 |
| 58200 | | A | Extensive hysterectomy | 21.56 | NA | 10.00 | 2.52 | NA | 34.08 | 090 |
| 58210 | | A | Extensive hysterectomy | 28.81 | NA | 13.20 | 3.31 | NA | 45.32 | 090 |
| 58240 | | A | Removal of pelvis contents | 38.33 | NA | 17.63 | 4.33 | NA | 60.29 | 090 |
| 58260 | | A | Vaginal hysterectomy | 12.96 | NA | 6.68 | 1.54 | NA | 21.18 | 090 |
| 58262 | | A | Vag hyst including t/o | 14.75 | NA | 7.36 | 1.75 | NA | 23.86 | 090 |
| 58263 | | A | Vag hyst w/t/o & vag repair | 16.04 | NA | 7.86 | 1.90 | NA | 25.80 | 090 |
| 58267 | | A | Vag hyst w/urinary repair | 17.01 | NA | 8.36 | 2.01 | NA | 27.38 | 090 |
| 58270 | | A | Vag hyst w/enterocele repair | 14.24 | NA | 7.05 | 1.69 | NA | 22.98 | 090 |
| 58275 | | A | Hysterectomy/revise vagina | 15.74 | NA | 7.75 | 1.86 | NA | 25.35 | 090 |
| 58280 | | A | Hysterectomy/revise vagina | 16.98 | NA | 8.23 | 1.99 | NA | 27.20 | 090 |
| 58285 | | A | Extensive hysterectomy | 22.23 | NA | 9.97 | 2.65 | NA | 34.85 | 090 |
| 58290 | | A | Vag hyst complex | 18.97 | NA | 9.10 | 1.48 | NA | 29.55 | 090 |
| 58291 | | A | Vag hyst incl t/o, complex | 20.76 | NA | 9.86 | 1.75 | NA | 32.37 | 090 |
| 58292 | | A | Vag hyst t/o & repair, compl | 22.05 | NA | 10.34 | 1.90 | NA | 34.29 | 090 |
| 58293 | | A | Vag hyst w/uro repair, compl | 23.03 | NA | 10.66 | 2.01 | NA | 35.70 | 090 |
| 58294 | | A | Vag hyst w/enterocele, compl | 20.25 | NA | 9.54 | 1.69 | NA | 31.48 | 090 |
| 58301 | | A | Remove intrauterine device | 1.27 | 1.32 | 0.48 | 0.14 | 2.73 | 1.89 | 000 |
| 58321 | | A | Artificial insemination | 0.92 | 1.15 | 0.37 | 0.11 | 2.18 | 1.40 | 000 |
| 58322 | | A | Artificial insemination | 1.10 | 1.21 | 0.42 | 0.13 | 2.44 | 1.65 | 000 |
| 58323 | | A | Sperm washing | 0.23 | 0.53 | 0.09 | 0.03 | 0.79 | 0.35 | 000 |
| 58340 | | A | Catheter for hysterography | 0.88 | 3.16 | 0.65 | 0.09 | 4.13 | 1.62 | 000 |
| 58345 | | A | Reopen fallopian tube | 4.65 | NA | 2.43 | 0.33 | NA | 7.41 | 010 |
| 58346 | | A | Insert heyman uteri capsule | 6.74 | NA | 3.93 | 0.79 | NA | 11.46 | 090 |
| 58350 | | A | Reopen fallopian tube | 1.01 | 1.49 | 0.93 | 0.12 | 2.62 | 2.06 | 010 |
| 58353 | | A | Endometr ablate, thermal | 3.55 | 35.73 | 2.04 | 0.42 | 39.70 | 6.01 | 010 |
| 58400 | | A | Suspension of uterus | 6.35 | NA | 3.96 | 0.75 | NA | 11.06 | 090 |
| 58410 | | A | Suspension of uterus | 12.71 | NA | 6.46 | 1.37 | NA | 20.54 | 090 |
| 58520 | | A | Repair of ruptured uterus | 11.90 | NA | 6.04 | 1.32 | NA | 19.26 | 090 |
| 58540 | | A | Revision of uterus | 14.62 | NA | 6.95 | 1.76 | NA | 23.33 | 090 |
| 58545 | | A | Laparoscopic myomectomy | 14.58 | NA | 7.21 | 1.71 | NA | 23.50 | 090 |
| 58546 | | A | Laparo-myomectomy, complex | 18.97 | NA | 9.05 | 1.71 | NA | 29.73 | 090 |
| 58550 | | A | Laparo-asst vag hysterectomy | 14.17 | NA | 7.28 | 1.70 | NA | 23.15 | 090 |
| 58552 | | A | Laparo-vag hyst incl t/o | 15.98 | NA | 8.00 | 1.70 | NA | 25.68 | 090 |
| 58553 | | A | Laparo-vag hyst, complex | 18.97 | NA | 8.93 | 1.54 | NA | 29.44 | 090 |
| 58554 | | A | Laparo-vag hyst w/t/o, compl | 21.97 | NA | 10.41 | 1.54 | NA | 33.92 | 090 |
| 58555 | | A | Hysteroscopy, dx, sep proc | 3.33 | 2.19 | 1.55 | 0.40 | 5.92 | 5.28 | 000 |
| 58558 | | A | Hysteroscopy, biopsy | 4.74 | NA | 2.17 | 0.57 | NA | 7.48 | 000 |
| 58559 | | A | Hysteroscopy, lysis | 6.16 | NA | 2.72 | 0.73 | NA | 9.61 | 000 |
| 58560 | | A | Hysteroscopy, resect septum | 6.99 | NA | 3.07 | 0.84 | NA | 10.90 | 000 |
| 58561 | | A | Hysteroscopy, remove myoma | 9.99 | NA | 4.27 | 1.18 | NA | 15.44 | 000 |
| 58562 | | A | Hysteroscopy, remove fb | 5.20 | NA | 2.34 | 0.62 | NA | 8.16 | 000 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 58563 | | A | Hysteroscopy, ablation | 6.16 | 56.02 | 2.74 | 0.74 | 62.92 | 9.64 | 000 |
| 58600 | | A | Division of fallopian tube | 5.59 | NA | 3.35 | 0.67 | NA | 9.61 | 090 |
| 58605 | | A | Division of fallopian tube | 4.99 | NA | 3.14 | 0.59 | NA | 8.72 | 090 |
| 58611 | | A | Ligate oviduct(s) add-on | 1.45 | NA | 0.57 | 0.17 | NA | 2.19 | ZZZ |
| 58615 | | A | Occlude fallopian tube(s) | 3.89 | NA | 2.71 | 0.48 | NA | 7.08 | 010 |
| 58660 | | A | Laparoscopy, lysis | 11.27 | NA | 5.25 | 1.38 | NA | 17.90 | 090 |
| 58661 | | A | Laparoscopy, remove adnexa | 11.03 | NA | 5.11 | 1.31 | NA | 17.45 | 010 |
| 58662 | | A | Laparoscopy, excise lesions | 11.77 | NA | 5.78 | 1.42 | NA | 18.97 | 090 |
| 58670 | | A | Laparoscopy, tubal cautery | 5.59 | NA | 3.27 | 0.66 | NA | 9.52 | 090 |
| 58671 | | A | Laparoscopy, tubal block | 5.59 | NA | 3.28 | 0.67 | NA | 9.54 | 090 |
| 58672 | | A | Laparoscopy, fimbrioplasty | 12.86 | NA | 6.21 | 1.49 | NA | 20.56 | 090 |
| 58673 | | A | Laparoscopy, salpingostomy | 13.72 | NA | 6.59 | 1.68 | NA | 21.99 | 090 |
| 58700 | | A | Removal of fallopian tube | 12.03 | NA | 5.99 | 1.47 | NA | 19.49 | 090 |
| 58720 | | A | Removal of ovary/tube(s) | 11.34 | NA | 5.79 | 1.36 | NA | 18.49 | 090 |
| 58740 | | A | Revise fallopian tube(s) | 13.98 | NA | 7.13 | 1.68 | NA | 22.79 | 090 |
| 58750 | | A | Repair oviduct | 14.82 | NA | 7.37 | 1.72 | NA | 23.91 | 090 |
| 58752 | | A | Revise ovarian tube(s) | 14.82 | NA | 6.96 | 1.82 | NA | 23.60 | 090 |
| 58760 | | A | Remove tubal obstruction | 13.11 | NA | 6.71 | 1.53 | NA | 21.35 | 090 |
| 58770 | | A | Create new tubal opening | 13.95 | NA | 6.91 | 1.52 | NA | 22.38 | 090 |
| 58800 | | A | Drainage of ovarian cyst(s) | 4.13 | 3.64 | 2.90 | 0.47 | 8.24 | 7.50 | 090 |
| 58805 | | A | Drainage of ovarian cyst(s) | 5.87 | NA | 3.53 | 0.66 | NA | 10.06 | 090 |
| 58820 | | A | Drain ovary abscess, open | 4.21 | NA | 3.32 | 0.41 | NA | 7.94 | 090 |
| 58822 | | A | Drain ovary abscess, percut | 10.11 | NA | 5.22 | 1.23 | NA | 16.56 | 090 |
| 58823 | | A | Drain pelvic abscess, percut | 3.37 | 21.77 | 1.12 | 0.25 | 25.39 | 4.74 | 000 |
| 58825 | | A | Transposition, ovary(s) | 10.96 | NA | 5.80 | 1.33 | NA | 18.09 | 090 |
| 58900 | | A | Biopsy of ovary(s) | 5.98 | NA | 3.59 | 0.70 | NA | 10.27 | 090 |
| 58920 | | A | Partial removal of ovary(s) | 11.34 | NA | 5.60 | 1.37 | NA | 18.31 | 090 |
| 58925 | | A | Removal of ovarian cyst(s) | 11.34 | NA | 5.69 | 1.39 | NA | 18.42 | 090 |
| 58940 | | A | Removal of ovary(s) | 7.28 | NA | 4.12 | 0.88 | NA | 12.28 | 090 |
| 58943 | | A | Removal of ovary(s) | 18.40 | NA | 8.73 | 2.19 | NA | 29.32 | 090 |
| 58950 | | A | Resect ovarian malignancy | 16.90 | NA | 8.48 | 2.01 | NA | 27.39 | 090 |
| 58951 | | A | Resect ovarian malignancy | 22.35 | NA | 10.52 | 2.62 | NA | 35.49 | 090 |
| 58952 | | A | Resect ovarian malignancy | 24.97 | NA | 11.83 | 2.96 | NA | 39.76 | 090 |
| 58953 | | A | Tah, rad dissect for debulk | 31.95 | NA | 14.54 | 3.77 | NA | 50.26 | 090 |
| 58954 | | A | Tah rad debulk/lymph remove | 34.95 | NA | 15.68 | 4.14 | NA | 54.77 | 090 |
| 58960 | | A | Exploration of abdomen | 14.63 | NA | 7.44 | 1.74 | NA | 23.81 | 090 |
| 58970 | | A | Retrieval of oocyte | 3.52 | 2.31 | 1.49 | 0.29 | 6.12 | 5.30 | 000 |
| 58976 | | A | Transfer of embryo | 3.82 | 2.65 | 1.82 | 0.47 | 6.94 | 6.11 | 000 |
| 59000 | | A | Amniocentesis, diagnostic | 1.30 | 2.08 | 0.67 | 0.31 | 3.69 | 2.28 | 000 |
| 59001 | | A | Amniocentesis, therapeutic | 3.00 | NA | 1.40 | 0.71 | NA | 5.11 | 000 |
| 59012 | | A | Fetal cord puncture,prenatal | 3.44 | NA | 1.53 | 0.82 | NA | 5.79 | 000 |
| 59015 | | A | Chorion biopsy | 2.20 | 1.56 | 1.04 | 0.52 | 4.28 | 3.76 | 000 |
| 59020 | | A | Fetal contract stress test | 0.66 | 0.78 | NA | 0.26 | 1.70 | NA | 000 |
| 59020 | 26 | A | Fetal contract stress test | 0.66 | 0.26 | 0.26 | 0.16 | 1.08 | 1.08 | 000 |
| 59020 | TC | A | Fetal contract stress test | 0.00 | 0.52 | NA | 0.10 | 0.62 | NA | 000 |
| 59025 | | A | Fetal non-stress test | 0.53 | 0.44 | NA | 0.15 | 1.12 | NA | 000 |
| 59025 | 26 | A | Fetal non-stress test | 0.53 | 0.21 | 0.21 | 0.13 | 0.87 | 0.87 | 000 |
| 59025 | TC | A | Fetal non-stress test | 0.00 | 0.23 | NA | 0.02 | 0.25 | NA | 000 |
| 59030 | | A | Fetal scalp blood sample | 1.99 | NA | 0.77 | 0.47 | NA | 3.23 | 000 |
| 59050 | | A | Fetal monitor w/report | 0.89 | NA | 0.35 | 0.21 | NA | 1.45 | XXX |
| 59051 | | A | Fetal monitor/interpret only | 0.74 | NA | 0.29 | 0.18 | NA | 1.21 | XXX |
| 59070 | | A | Transabdom amnioinfus w/ us | 5.24 | 5.06 | 2.29 | 0.28 | 10.58 | 7.81 | 000 |
| 59072 | | A | Umbilical cord occlud w/ us | 8.99 | NA | 3.11 | 0.16 | NA | 12.26 | 000 |
| 59074 | | A | Fetal fluid drainage w/ us | 5.24 | 4.47 | 2.29 | 0.28 | 9.99 | 7.81 | 000 |
| 59076 | | A | Fetal shunt placement, w/ us | 8.99 | NA | 3.11 | 0.16 | NA | 12.26 | 000 |
| 59100 | | A | Remove uterus lesion | 12.33 | NA | 6.46 | 2.93 | NA | 21.72 | 090 |
| 59120 | | A | Treat ectopic pregnancy | 11.47 | NA | 6.24 | 2.73 | NA | 20.44 | 090 |
| 59121 | | A | Treat ectopic pregnancy | 11.65 | NA | 6.32 | 2.77 | NA | 20.74 | 090 |
| 59130 | | A | Treat ectopic pregnancy | 14.20 | NA | 4.86 | 1.96 | NA | 21.02 | 090 |
| 59135 | | A | Treat ectopic pregnancy | 13.86 | NA | 7.22 | 3.00 | NA | 24.08 | 090 |
| 59136 | | A | Treat ectopic pregnancy | 13.16 | NA | 6.61 | 2.85 | NA | 22.62 | 090 |
| 59140 | | A | Treat ectopic pregnancy | 5.45 | 2.20 | 2.20 | 1.30 | 8.95 | 8.95 | 090 |
| 59150 | | A | Treat ectopic pregnancy | 11.65 | NA | 6.02 | 2.77 | NA | 20.44 | 090 |
| 59151 | | A | Treat ectopic pregnancy | 11.47 | NA | 6.06 | 2.73 | NA | 20.26 | 090 |
| 59160 | | A | D & c after delivery | 2.71 | 3.29 | 2.13 | 0.64 | 6.64 | 5.48 | 010 |
| 59200 | | A | Insert cervical dilator | 0.79 | 1.19 | 0.30 | 0.19 | 2.17 | 1.28 | 000 |
| 59300 | | A | Episiotomy or vaginal repair | 2.41 | 2.20 | 0.95 | 0.57 | 5.18 | 3.93 | 000 |
| 59320 | | A | Revision of cervix | 2.48 | NA | 1.24 | 0.59 | NA | 4.31 | 000 |
| 59325 | | A | Revision of cervix | 4.06 | NA | 1.89 | 0.88 | NA | 6.83 | 000 |
| 59350 | | A | Repair of uterus | 4.94 | NA | 1.86 | 1.18 | NA | 7.98 | 000 |
| 59400 | | A | Obstetrical care | 23.03 | NA | 15.35 | 5.48 | NA | 43.86 | MMM |
| 59409 | | A | Obstetrical care | 13.48 | NA | 5.29 | 3.21 | NA | 21.98 | MMM |
| 59410 | | A | Obstetrical care | 14.76 | NA | 6.29 | 3.51 | NA | 24.56 | MMM |
| 59412 | | A | Antepartum manipulation | 1.71 | NA | 0.81 | 0.41 | NA | 2.93 | MMM |
| 59414 | | A | Deliver placenta | 1.61 | NA | 0.64 | 0.38 | NA | 2.63 | MMM |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 59425 | | A | Antepartum care only | 4.80 | 4.22 | 1.85 | 1.14 | 10.16 | 7.79 | MMM |
| 59426 | | A | Antepartum care only | 8.27 | 7.58 | 3.21 | 1.97 | 17.82 | 13.45 | MMM |
| 59430 | | A | Care after delivery | 2.13 | 1.23 | 0.93 | 0.51 | 3.87 | 3.57 | MMM |
| 59510 | | A | Cesarean delivery | 26.18 | NA | 17.26 | 6.23 | NA | 49.67 | MMM |
| 59514 | | A | Cesarean delivery only | 15.95 | NA | 6.19 | 3.79 | NA | 25.93 | MMM |
| 59515 | | A | Cesarean delivery | 17.34 | NA | 7.81 | 4.13 | NA | 29.28 | MMM |
| 59525 | | A | Remove uterus after cesarean | 8.53 | NA | 3.29 | 2.03 | NA | 13.85 | ZZZ |
| 59610 | | A | Vbac delivery | 24.58 | NA | 15.89 | 5.85 | NA | 46.32 | MMM |
| 59612 | | A | Vbac delivery only | 15.04 | NA | 6.03 | 3.58 | NA | 24.65 | MMM |
| 59614 | | A | Vbac care after delivery | 16.32 | NA | 6.91 | 3.88 | NA | 27.11 | MMM |
| 59618 | | A | Attempted vbac delivery | 27.74 | NA | 18.29 | 6.60 | NA | 52.63 | MMM |
| 59620 | | A | Attempted vbac delivery only | 17.50 | NA | 6.74 | 4.17 | NA | 28.41 | MMM |
| 59622 | | A | Attempted vbac after care | 18.90 | NA | 8.61 | 4.50 | NA | 32.01 | MMM |
| 59812 | | A | Treatment of miscarriage | 4.00 | NA | 2.54 | 0.95 | NA | 7.49 | 090 |
| 59820 | | A | Care of miscarriage | 4.00 | 4.43 | 3.56 | 0.95 | 9.38 | 8.51 | 090 |
| 59821 | | A | Treatment of miscarriage | 4.46 | 4.26 | 3.40 | 1.06 | 9.78 | 8.92 | 090 |
| 59830 | | A | Treat uterus infection | 6.10 | NA | 3.99 | 1.45 | NA | 11.54 | 090 |
| 59840 | | R | Abortion | 3.01 | NA | 2.12 | 0.72 | NA | 5.85 | 010 |
| 59841 | | R | Abortion | 5.23 | 2.56 | 2.56 | 1.25 | 9.04 | 9.04 | 010 |
| 59850 | | R | Abortion | 5.90 | NA | 3.25 | 1.28 | NA | 10.43 | 090 |
| 59851 | | R | Abortion | 5.92 | NA | 3.73 | 1.41 | NA | 11.06 | 090 |
| 59852 | | R | Abortion | 8.23 | NA | 5.05 | 1.79 | NA | 15.07 | 090 |
| 59855 | | R | Abortion | 6.11 | NA | 3.55 | 1.45 | NA | 11.11 | 090 |
| 59856 | | R | Abortion | 7.47 | NA | 4.05 | 1.62 | NA | 13.14 | 090 |
| 59857 | | R | Abortion | 9.28 | NA | 4.59 | 2.00 | NA | 15.87 | 090 |
| 59866 | | R | Abortion (mpr) | 3.99 | NA | 1.82 | 0.87 | NA | 6.68 | 000 |
| 59870 | | A | Evacuate mole of uterus | 6.00 | NA | 4.42 | 1.43 | NA | 11.85 | 090 |
| 59871 | | A | Remove cerclage suture | 2.13 | 1.74 | 1.13 | 0.51 | 4.38 | 3.77 | 000 |
| 60000 | | A | Drain thyroid/tongue cyst | 1.76 | 1.94 | 1.73 | 0.14 | 3.84 | 3.63 | 010 |
| 60001 | | A | Aspirate/inject thyriod cyst | 0.97 | 1.43 | 0.33 | 0.08 | 2.48 | 1.38 | 000 |
| 60100 | | A | Biopsy of thyroid | 1.56 | 1.40 | 0.53 | 0.10 | 3.06 | 2.19 | 000 |
| 60200 | | A | Remove thyroid lesion | 9.54 | NA | 6.08 | 1.01 | NA | 16.63 | 090 |
| 60210 | | A | Partial thyroid excision | 10.86 | NA | 5.72 | 1.24 | NA | 17.82 | 090 |
| 60212 | | A | Partial thyroid excision | 16.01 | NA | 7.75 | 1.59 | NA | 25.35 | 090 |
| 60220 | | A | Partial removal of thyroid | 11.88 | NA | 6.24 | 1.34 | NA | 19.46 | 090 |
| 60225 | | A | Partial removal of thyroid | 14.17 | NA | 7.48 | 1.65 | NA | 23.30 | 090 |
| 60240 | | A | Removal of thyroid | 16.04 | NA | 7.68 | 1.84 | NA | 25.56 | 090 |
| 60252 | | A | Removal of thyroid | 20.54 | NA | 10.20 | 2.28 | NA | 33.02 | 090 |
| 60254 | | A | Extensive thyroid surgery | 26.95 | NA | 14.28 | 2.75 | NA | 43.98 | 090 |
| 60260 | | A | Repeat thyroid surgery | 17.44 | NA | 8.77 | 1.94 | NA | 28.15 | 090 |
| 60270 | | A | Removal of thyroid | 20.24 | NA | 10.56 | 2.27 | NA | 33.07 | 090 |
| 60271 | | A | Removal of thyroid | 16.80 | NA | 8.70 | 1.83 | NA | 27.33 | 090 |
| 60280 | | A | Remove thyroid duct lesion | 5.86 | NA | 4.78 | 0.53 | NA | 11.17 | 090 |
| 60281 | | A | Remove thyroid duct lesion | 8.52 | NA | 5.94 | 0.80 | NA | 15.26 | 090 |
| 60500 | | A | Explore parathyroid glands | 16.21 | NA | 7.47 | 1.98 | NA | 25.66 | 090 |
| 60502 | | A | Re-explore parathyroids | 20.32 | NA | 9.41 | 2.50 | NA | 32.23 | 090 |
| 60505 | | A | Explore parathyroid glands | 21.46 | NA | 11.03 | 2.65 | NA | 35.14 | 090 |
| 60512 | | A | Autotransplant parathyroid | 4.44 | NA | 1.62 | 0.54 | NA | 6.60 | ZZZ |
| 60520 | | A | Removal of thymus gland | 16.78 | NA | 8.31 | 2.16 | NA | 27.25 | 090 |
| 60521 | | A | Removal of thymus gland | 18.84 | NA | 9.57 | 1.92 | NA | 30.33 | 090 |
| 60522 | | A | Removal of thymus gland | 23.06 | NA | 11.28 | 3.13 | NA | 37.47 | 090 |
| 60540 | | A | Explore adrenal gland | 17.00 | NA | 7.58 | 1.75 | NA | 26.33 | 090 |
| 60545 | | A | Explore adrenal gland | 19.85 | NA | 8.54 | 2.05 | NA | 30.44 | 090 |
| 60600 | | A | Remove carotid body lesion | 17.90 | NA | 10.76 | 2.15 | NA | 30.81 | 090 |
| 60605 | | A | Remove carotid body lesion | 20.21 | NA | 12.59 | 2.45 | NA | 35.25 | 090 |
| 60650 | | A | Laparoscopy adrenalectomy | 19.97 | NA | 7.95 | 2.32 | NA | 30.24 | 090 |
| 61000 | | A | Remove cranial cavity fluid | 1.58 | NA | 0.96 | 0.17 | NA | 2.71 | 000 |
| 61001 | | A | Remove cranial cavity fluid | 1.49 | NA | 1.07 | 0.18 | NA | 2.74 | 000 |
| 61020 | | A | Remove brain cavity fluid | 1.51 | NA | 1.35 | 0.30 | NA | 3.16 | 000 |
| 61026 | | A | Injection into brain canal | 1.69 | NA | 1.40 | 0.25 | NA | 3.34 | 000 |
| 61050 | | A | Remove brain canal fluid | 1.51 | NA | 1.27 | 0.12 | NA | 2.90 | 000 |
| 61055 | | A | Injection into brain canal | 2.10 | NA | 1.43 | 0.16 | NA | 3.69 | 000 |
| 61070 | | A | Brain canal shunt procedure | 0.89 | NA | 1.03 | 0.14 | NA | 2.06 | 000 |
| 61105 | | A | Twist drill hole | 5.13 | NA | 3.93 | 1.26 | NA | 10.32 | 090 |
| 61107 | | A | Drill skull for implantation | 4.99 | NA | 2.52 | 1.24 | NA | 8.75 | 000 |
| 61108 | | A | Drill skull for drainage | 10.17 | NA | 7.13 | 2.53 | NA | 19.83 | 090 |
| 61120 | | A | Burr hole for puncture | 8.75 | NA | 5.99 | 2.04 | NA | 16.78 | 090 |
| 61140 | | A | Pierce skull for biopsy | 15.88 | NA | 9.87 | 3.63 | NA | 29.38 | 090 |
| 61150 | | A | Pierce skull for drainage | 17.54 | NA | 10.36 | 3.95 | NA | 31.85 | 090 |
| 61151 | | A | Pierce skull for drainage | 12.40 | NA | 7.81 | 2.97 | NA | 23.18 | 090 |
| 61154 | | A | Pierce skull & remove clot | 14.97 | NA | 9.47 | 3.76 | NA | 28.20 | 090 |
| 61156 | | A | Pierce skull for drainage | 16.30 | NA | 9.82 | 4.03 | NA | 30.15 | 090 |
| 61210 | | A | Pierce skull, implant device | 5.83 | NA | 2.91 | 1.45 | NA | 10.19 | 000 |
| 61215 | | A | Insert brain-fluid device | 4.88 | NA | 4.00 | 1.21 | NA | 10.09 | 090 |
| 61250 | | A | Pierce skull & explore | 10.40 | NA | 6.84 | 2.15 | NA | 19.39 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 61253 | | A | Pierce skull & explore | 12.34 | NA | 7.72 | 2.01 | NA | 22.07 | 090 |
| 61304 | | A | Open skull for exploration | 21.93 | NA | 12.83 | 4.96 | NA | 39.72 | 090 |
| 61305 | | A | Open skull for exploration | 26.57 | NA | 15.30 | 6.08 | NA | 47.95 | 090 |
| 61312 | | A | Open skull for drainage | 24.53 | NA | 15.03 | 5.60 | NA | 45.16 | 090 |
| 61313 | | A | Open skull for drainage | 24.89 | NA | 14.79 | 5.79 | NA | 45.47 | 090 |
| 61314 | | A | Open skull for drainage | 24.19 | NA | 13.03 | 5.53 | NA | 42.75 | 090 |
| 61315 | | A | Open skull for drainage | 27.64 | NA | 16.00 | 6.33 | NA | 49.97 | 090 |
| 61316 | | A | Implt cran bone flap to abdo | 1.39 | NA | 0.60 | 0.52 | NA | 2.51 | ZZZ |
| 61320 | | A | Open skull for drainage | 25.58 | NA | 14.74 | 5.81 | NA | 46.13 | 090 |
| 61321 | | A | Open skull for drainage | 28.46 | NA | 16.11 | 6.55 | NA | 51.12 | 090 |
| 61322 | | A | Decompressive craniotomy | 29.46 | NA | 15.68 | 6.02 | NA | 51.16 | 090 |
| 61323 | | A | Decompressive lobectomy | 30.95 | NA | 16.13 | 6.02 | NA | 53.10 | 090 |
| 61330 | | A | Decompress eye socket | 23.29 | NA | 13.70 | 3.67 | NA | 40.66 | 090 |
| 61332 | | A | Explore/biopsy eye socket | 27.24 | NA | 15.57 | 4.76 | NA | 47.57 | 090 |
| 61333 | | A | Explore orbit/remove lesion | 27.91 | NA | 15.55 | 3.55 | NA | 47.01 | 090 |
| 61334 | | A | Explore orbit/remove object | 18.24 | NA | 10.62 | 3.15 | NA | 32.01 | 090 |
| 61340 | | A | Subtemporal decompression | 18.63 | NA | 11.12 | 4.26 | NA | 34.01 | 090 |
| 61343 | | A | Incise skull (press relief) | 29.73 | NA | 16.81 | 6.70 | NA | 53.24 | 090 |
| 61345 | | A | Relieve cranial pressure | 27.16 | NA | 15.40 | 5.70 | NA | 48.26 | 090 |
| 61440 | | A | Incise skull for surgery | 26.59 | NA | 14.21 | 6.88 | NA | 47.68 | 090 |
| 61450 | | A | Incise skull for surgery | 25.91 | NA | 14.28 | 5.43 | NA | 45.62 | 090 |
| 61458 | | A | Incise skull for brain wound | 27.25 | NA | 15.50 | 6.24 | NA | 48.99 | 090 |
| 61460 | | A | Incise skull for surgery | 28.35 | NA | 16.40 | 5.35 | NA | 50.10 | 090 |
| 61470 | | A | Incise skull for surgery | 26.02 | NA | 13.85 | 6.74 | NA | 46.61 | 090 |
| 61480 | | A | Incise skull for surgery | 26.45 | NA | 15.27 | 6.10 | NA | 47.82 | 090 |
| 61490 | | A | Incise skull for surgery | 25.62 | NA | 14.32 | 6.26 | NA | 46.20 | 090 |
| 61500 | | A | Removal of skull lesion | 17.89 | NA | 10.80 | 3.71 | NA | 32.40 | 090 |
| 61501 | | A | Remove infected skull bone | 14.82 | NA | 9.21 | 3.00 | NA | 27.03 | 090 |
| 61510 | | A | Removal of brain lesion | 28.41 | NA | 16.68 | 6.49 | NA | 51.58 | 090 |
| 61512 | | A | Remove brain lining lesion | 35.04 | NA | 19.66 | 8.06 | NA | 62.76 | 090 |
| 61514 | | A | Removal of brain abscess | 25.22 | NA | 14.42 | 6.01 | NA | 45.65 | 090 |
| 61516 | | A | Removal of brain lesion | 24.57 | NA | 14.27 | 5.43 | NA | 44.27 | 090 |
| 61517 | | A | Implt brain chemotx add-on | 1.38 | NA | 0.64 | 0.10 | NA | 2.12 | ZZZ |
| 61518 | | A | Removal of brain lesion | 37.26 | NA | 21.09 | 8.46 | NA | 66.81 | 090 |
| 61519 | | A | Remove brain lining lesion | 41.33 | NA | 22.64 | 9.61 | NA | 73.58 | 090 |
| 61520 | | A | Removal of brain lesion | 54.76 | NA | 30.31 | 10.02 | NA | 95.09 | 090 |
| 61521 | | A | Removal of brain lesion | 44.41 | NA | 24.21 | 9.76 | NA | 78.38 | 090 |
| 61522 | | A | Removal of brain abscess | 29.41 | NA | 16.42 | 6.78 | NA | 52.61 | 090 |
| 61524 | | A | Removal of brain lesion | 27.82 | NA | 15.67 | 6.02 | NA | 49.51 | 090 |
| 61526 | | A | Removal of brain lesion | 52.09 | NA | 29.46 | 7.10 | NA | 88.65 | 090 |
| 61530 | | A | Removal of brain lesion | 43.79 | NA | 25.06 | 5.67 | NA | 74.52 | 090 |
| 61531 | | A | Implant brain electrodes | 14.61 | NA | 9.13 | 3.60 | NA | 27.34 | 090 |
| 61533 | | A | Implant brain electrodes | 19.68 | NA | 11.54 | 4.43 | NA | 35.65 | 090 |
| 61534 | | A | Removal of brain lesion | 20.94 | NA | 12.10 | 5.32 | NA | 38.36 | 090 |
| 61535 | | A | Remove brain electrodes | 11.61 | NA | 7.43 | 2.81 | NA | 21.85 | 090 |
| 61536 | | A | Removal of brain lesion | 35.47 | NA | 19.78 | 7.56 | NA | 62.81 | 090 |
| 61537 | | A | Removal of brain tissue | 24.96 | NA | 14.72 | 6.05 | NA | 45.73 | 090 |
| 61538 | | A | Removal of brain tissue | 26.77 | NA | 15.31 | 6.05 | NA | 48.13 | 090 |
| 61539 | | A | Removal of brain tissue | 32.03 | NA | 17.77 | 7.41 | NA | 57.21 | 090 |
| 61540 | | A | Removal of brain tissue | 29.96 | NA | 17.23 | 7.41 | NA | 54.60 | 090 |
| 61541 | | A | Incision of brain tissue | 28.81 | NA | 16.20 | 6.10 | NA | 51.11 | 090 |
| 61542 | | A | Removal of brain tissue | 30.97 | NA | 17.82 | 7.83 | NA | 56.62 | 090 |
| 61543 | | A | Removal of brain tissue | 29.18 | NA | 16.39 | 6.58 | NA | 52.15 | 090 |
| 61544 | | A | Remove & treat brain lesion | 25.46 | NA | 13.84 | 5.73 | NA | 45.03 | 090 |
| 61545 | | A | Excision of brain tumor | 43.73 | NA | 24.21 | 10.03 | NA | 77.97 | 090 |
| 61546 | | A | Removal of pituitary gland | 31.25 | NA | 17.49 | 7.15 | NA | 55.89 | 090 |
| 61548 | | A | Removal of pituitary gland | 21.50 | NA | 12.79 | 3.31 | NA | 37.60 | 090 |
| 61550 | | A | Release of skull seams | 14.63 | NA | 6.98 | 1.37 | NA | 22.98 | 090 |
| 61552 | | A | Release of skull seams | 19.53 | NA | 9.14 | 5.06 | NA | 33.73 | 090 |
| 61556 | | A | Incise skull/sutures | 22.23 | NA | 11.37 | 5.12 | NA | 38.72 | 090 |
| 61557 | | A | Incise skull/sutures | 22.35 | NA | 13.62 | 5.79 | NA | 41.76 | 090 |
| 61558 | | A | Excision of skull/sutures | 25.54 | NA | 14.18 | 3.15 | NA | 42.87 | 090 |
| 61559 | | A | Excision of skull/sutures | 32.74 | NA | 19.30 | 2.01 | NA | 54.05 | 090 |
| 61563 | | A | Excision of skull tumor | 26.79 | NA | 15.25 | 5.75 | NA | 47.79 | 090 |
| 61564 | | A | Excision of skull tumor | 33.78 | NA | 18.27 | 8.28 | NA | 60.33 | 090 |
| 61566 | | A | Removal of brain tissue | 30.95 | NA | 17.75 | 6.05 | NA | 54.75 | 090 |
| 61567 | | A | Incision of brain tissue | 35.45 | NA | 20.66 | 6.49 | NA | 62.60 | 090 |
| 61570 | | A | Remove foreign body, brain | 24.56 | NA | 13.90 | 5.07 | NA | 43.53 | 090 |
| 61571 | | A | Incise skull for brain wound | 26.35 | NA | 15.13 | 5.77 | NA | 47.25 | 090 |
| 61575 | | A | Skull base/brainstem surgery | 34.31 | NA | 19.64 | 5.42 | NA | 59.37 | 090 |
| 61576 | | A | Skull base/brainstem surgery | 52.35 | NA | 34.69 | 5.80 | NA | 92.84 | 090 |
| 61580 | | A | Craniofacial approach, skull | 30.30 | NA | 25.50 | 3.37 | NA | 59.17 | 090 |
| 61581 | | A | Craniofacial approach, skull | 34.55 | NA | 23.42 | 3.30 | NA | 61.27 | 090 |
| 61582 | | A | Craniofacial approach, skull | 31.61 | NA | 27.28 | 6.96 | NA | 65.85 | 090 |
| 61583 | | A | Craniofacial approach, skull | 36.16 | NA | 25.08 | 8.12 | NA | 69.36 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 61584 | | A | Orbitocranial approach/skull | 34.60 | NA | 24.48 | 7.51 | NA | 66.59 | 090 |
| 61585 | | A | Orbitocranial approach/skull | 38.55 | NA | 26.44 | 7.50 | NA | 72.49 | 090 |
| 61586 | | A | Resect nasopharynx, skull | 25.06 | NA | 22.52 | 4.95 | NA | 52.53 | 090 |
| 61590 | | A | Infratemporal approach/skull | 41.72 | NA | 28.54 | 5.11 | NA | 75.37 | 090 |
| 61591 | | A | Infratemporal approach/skull | 43.61 | NA | 29.45 | 5.64 | NA | 78.70 | 090 |
| 61592 | | A | Orbitocranial approach/skull | 39.58 | NA | 26.46 | 8.93 | NA | 74.97 | 090 |
| 61595 | | A | Transtemporal approach/skull | 29.53 | NA | 22.27 | 3.81 | NA | 55.61 | 090 |
| 61596 | | A | Transcochlear approach/skull | 35.58 | NA | 24.37 | 4.83 | NA | 64.78 | 090 |
| 61597 | | A | Transcondylar approach/skull | 37.90 | NA | 22.96 | 8.56 | NA | 69.42 | 090 |
| 61598 | | A | Transpetrosal approach/skull | 33.36 | NA | 23.18 | 5.50 | NA | 62.04 | 090 |
| 61600 | | A | Resect/excise cranial lesion | 25.81 | NA | 19.72 | 3.60 | NA | 49.13 | 090 |
| 61601 | | A | Resect/excise cranial lesion | 27.85 | NA | 20.46 | 6.16 | NA | 54.47 | 090 |
| 61605 | | A | Resect/excise cranial lesion | 29.29 | NA | 21.89 | 2.90 | NA | 54.08 | 090 |
| 61606 | | A | Resect/excise cranial lesion | 38.77 | NA | 25.10 | 8.22 | NA | 72.09 | 090 |
| 61607 | | A | Resect/excise cranial lesion | 36.22 | NA | 23.74 | 6.58 | NA | 66.54 | 090 |
| 61608 | | A | Resect/excise cranial lesion | 42.04 | NA | 26.54 | 9.67 | NA | 78.25 | 090 |
| 61609 | | A | Transect artery, sinus | 9.88 | NA | 4.85 | 1.57 | NA | 16.30 | ZZZ |
| 61610 | | A | Transect artery, sinus | 29.63 | NA | 13.11 | 4.25 | NA | 46.99 | ZZZ |
| 61611 | | A | Transect artery, sinus | 7.41 | NA | 3.81 | 1.87 | NA | 13.09 | ZZZ |
| 61612 | | A | Transect artery, sinus | 27.84 | NA | 13.29 | 2.08 | NA | 43.21 | ZZZ |
| 61613 | | A | Remove aneurysm, sinus | 40.80 | NA | 26.22 | 8.76 | NA | 75.78 | 090 |
| 61615 | | A | Resect/excise lesion, skull | 32.02 | NA | 22.66 | 5.07 | NA | 59.75 | 090 |
| 61616 | | A | Resect/excise lesion, skull | 43.27 | NA | 28.59 | 8.13 | NA | 79.99 | 090 |
| 61618 | | A | Repair dura | 16.96 | NA | 10.46 | 3.42 | NA | 30.84 | 090 |
| 61619 | | A | Repair dura | 20.68 | NA | 12.25 | 3.41 | NA | 36.34 | 090 |
| 61623 | | A | Endovasc tempory vessel occl | 9.95 | NA | 4.07 | 0.60 | NA | 14.62 | 000 |
| 61624 | | A | Transcath occlusion, cns | 20.12 | NA | 6.88 | 1.84 | NA | 28.84 | 000 |
| 61626 | | A | Transcath occlusion, non-cns | 16.60 | NA | 5.50 | 1.17 | NA | 23.27 | 000 |
| 61680 | | A | Intracranial vessel surgery | 30.66 | NA | 17.44 | 7.03 | NA | 55.13 | 090 |
| 61682 | | A | Intracranial vessel surgery | 61.48 | NA | 32.20 | 14.22 | NA | 107.90 | 090 |
| 61684 | | A | Intracranial vessel surgery | 39.75 | NA | 21.99 | 9.24 | NA | 70.98 | 090 |
| 61686 | | A | Intracranial vessel surgery | 64.39 | NA | 34.70 | 14.04 | NA | 113.13 | 090 |
| 61690 | | A | Intracranial vessel surgery | 29.27 | NA | 16.72 | 7.58 | NA | 53.57 | 090 |
| 61692 | | A | Intracranial vessel surgery | 51.79 | NA | 27.47 | 11.64 | NA | 90.90 | 090 |
| 61697 | | A | Brain aneurysm repr, complx | 50.44 | NA | 27.98 | 12.05 | NA | 90.47 | 090 |
| 61698 | | A | Brain aneurysm repr, complx | 48.34 | NA | 26.67 | 11.01 | NA | 86.02 | 090 |
| 61700 | | A | Brain aneurysm repr, simple | 50.44 | NA | 27.78 | 11.94 | NA | 90.16 | 090 |
| 61702 | | A | Inner skull vessel surgery | 48.34 | NA | 26.02 | 11.56 | NA | 85.92 | 090 |
| 61703 | | A | Clamp neck artery | 17.44 | NA | 10.48 | 3.72 | NA | 31.64 | 090 |
| 61705 | | A | Revise circulation to head | 36.15 | NA | 19.24 | 8.11 | NA | 63.50 | 090 |
| 61708 | | A | Revise circulation to head | 35.25 | NA | 15.14 | 2.67 | NA | 53.06 | 090 |
| 61710 | | A | Revise circulation to head | 29.63 | NA | 13.63 | 3.78 | NA | 47.04 | 090 |
| 61711 | | A | Fusion of skull arteries | 36.28 | NA | 19.80 | 8.36 | NA | 64.44 | 090 |
| 61720 | | A | Incise skull/brain surgery | 16.74 | NA | 9.98 | 3.55 | NA | 30.27 | 090 |
| 61735 | | A | Incise skull/brain surgery | 20.40 | NA | 12.16 | 3.83 | NA | 36.39 | 090 |
| 61750 | | A | Incise skull/brain biopsy | 18.17 | NA | 10.61 | 4.48 | NA | 33.26 | 090 |
| 61751 | | A | Brain biopsy w/ct/mr guide | 17.59 | NA | 10.82 | 4.34 | NA | 32.75 | 090 |
| 61760 | | A | Implant brain electrodes | 22.24 | NA | 8.73 | 5.49 | NA | 36.46 | 090 |
| 61770 | | A | Incise skull for treatment | 21.41 | NA | 12.26 | 4.44 | NA | 38.11 | 090 |
| 61790 | | A | Treat trigeminal nerve | 10.84 | NA | 5.92 | 2.66 | NA | 19.42 | 090 |
| 61791 | | A | Treat trigeminal tract | 14.59 | NA | 8.92 | 3.51 | NA | 27.02 | 090 |
| 61793 | | A | Focus radiation beam | 17.21 | NA | 10.13 | 4.22 | NA | 31.56 | 090 |
| 61795 | | A | Brain surgery using computer | 4.03 | NA | 2.03 | 0.80 | NA | 6.86 | ZZZ |
| 61850 | | A | Implant neuroelectrodes | 12.37 | NA | 7.68 | 1.98 | NA | 22.03 | 090 |
| 61860 | | A | Implant neuroelectrodes | 20.84 | NA | 12.07 | 4.87 | NA | 37.78 | 090 |
| 61863 | | A | Implant neuroelectrode | 18.97 | NA | 11.76 | 4.66 | NA | 35.39 | 090 |
| 61864 | | A | Implant neuroelectrde, add-l | 4.49 | NA | 2.27 | 4.66 | NA | 11.42 | ZZZ |
| 61867 | | A | Implant neuroelectrode | 31.29 | NA | 18.00 | 4.66 | NA | 53.95 | 090 |
| 61868 | | A | Implant neuroelectrde, add-l | 7.91 | NA | 4.01 | 4.66 | NA | 16.58 | ZZZ |
| 61870 | | A | Implant neuroelectrodes | 14.92 | NA | 9.73 | 2.05 | NA | 26.70 | 090 |
| 61875 | | A | Implant neuroelectrodes | 15.04 | NA | 8.57 | 2.39 | NA | 26.00 | 090 |
| 61880 | | A | Revise/remove neuroelectrode | 6.28 | NA | 4.59 | 1.50 | NA | 12.37 | 090 |
| 61885 | | A | Implant neurostim one array | 5.84 | NA | 5.31 | 1.35 | NA | 12.50 | 090 |
| 61886 | | A | Implant neurostim arrays | 7.99 | NA | 6.36 | 1.78 | NA | 16.13 | 090 |
| 61888 | | A | Revise/remove neuroreceiver | 5.06 | NA | 3.67 | 1.22 | NA | 9.95 | 010 |
| 62000 | | A | Treat skull fracture | 12.51 | NA | 5.50 | 1.28 | NA | 19.29 | 090 |
| 62005 | | A | Treat skull fracture | 16.15 | NA | 8.79 | 3.26 | NA | 28.20 | 090 |
| 62010 | | A | Treatment of head injury | 19.78 | NA | 11.70 | 4.64 | NA | 36.12 | 090 |
| 62100 | | A | Repair brain fluid leakage | 22.00 | NA | 12.80 | 4.71 | NA | 39.51 | 090 |
| 62115 | | A | Reduction of skull defect | 21.63 | NA | 11.64 | 5.46 | NA | 38.73 | 090 |
| 62116 | | A | Reduction of skull defect | 23.55 | NA | 13.36 | 1.92 | NA | 38.83 | 090 |
| 62117 | | A | Reduction of skull defect | 26.56 | NA | 15.37 | 6.88 | NA | 48.81 | 090 |
| 62120 | | A | Repair skull cavity lesion | 23.31 | NA | 18.61 | 2.64 | NA | 44.56 | 090 |
| 62121 | | A | Incise skull repair | 21.55 | NA | 15.41 | 3.49 | NA | 40.45 | 090 |
| 62140 | | A | Repair of skull defect | 13.49 | NA | 8.33 | 3.02 | NA | 24.84 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 62141 | | A | Repair of skull defect | 14.89 | NA | 9.06 | 3.26 | NA | 27.21 | 090 |
| 62142 | | A | Remove skull plate/flap | 10.77 | NA | 7.00 | 2.41 | NA | 20.18 | 090 |
| 62143 | | A | Replace skull plate/flap | 13.03 | NA | 8.05 | 3.02 | NA | 24.10 | 090 |
| 62145 | | A | Repair of skull & brain | 18.79 | NA | 10.90 | 3.77 | NA | 33.46 | 090 |
| 62146 | | A | Repair of skull with graft | 16.10 | NA | 9.64 | 3.20 | NA | 28.94 | 090 |
| 62147 | | A | Repair of skull with graft | 19.31 | NA | 11.32 | 4.35 | NA | 34.98 | 090 |
| 62148 | | A | Retr bone flap to fix skull | 2.00 | NA | 0.86 | 0.52 | NA | 3.38 | ZZZ |
| 62160 | | A | Neuroendoscopy add-on | 3.00 | NA | 1.53 | 0.63 | NA | 5.16 | ZZZ |
| 62161 | | A | Dissect brain w/scope | 19.97 | NA | 12.08 | 4.46 | NA | 36.51 | 090 |
| 62162 | | A | Remove colloid cyst w/scope | 25.21 | NA | 15.07 | 6.96 | NA | 47.24 | 090 |
| 62163 | | A | Neuroendoscopy w/fb removal | 15.48 | NA | 9.91 | 4.46 | NA | 29.85 | 090 |
| 62164 | | A | Remove brain tumor w/scope | 27.46 | NA | 14.95 | 6.96 | NA | 49.37 | 090 |
| 62165 | | A | Remove pituit tumor w/scope | 21.97 | NA | 13.34 | 4.38 | NA | 39.69 | 090 |
| 62180 | | A | Establish brain cavity shunt | 21.03 | NA | 12.29 | 4.55 | NA | 37.87 | 090 |
| 62190 | | A | Establish brain cavity shunt | 11.05 | NA | 7.09 | 2.67 | NA | 20.81 | 090 |
| 62192 | | A | Establish brain cavity shunt | 12.23 | NA | 7.63 | 2.79 | NA | 22.65 | 090 |
| 62194 | | A | Replace/irrigate catheter | 5.02 | NA | 2.44 | 0.62 | NA | 8.08 | 010 |
| 62200 | | A | Establish brain cavity shunt | 18.29 | NA | 10.85 | 4.45 | NA | 33.59 | 090 |
| 62201 | | A | Brain cavity shunt w/scope | 14.84 | NA | 9.45 | 2.88 | NA | 27.17 | 090 |
| 62220 | | A | Establish brain cavity shunt | 12.98 | NA | 8.00 | 2.85 | NA | 23.83 | 090 |
| 62223 | | A | Establish brain cavity shunt | 12.85 | NA | 8.25 | 2.83 | NA | 23.93 | 090 |
| 62225 | | A | Replace/irrigate catheter | 5.40 | NA | 4.10 | 1.32 | NA | 10.82 | 090 |
| 62230 | | A | Replace/revise brain shunt | 10.52 | NA | 6.49 | 2.40 | NA | 19.41 | 090 |
| 62252 | | A | Csf shunt reprogram | 0.74 | 1.47 | NA | 0.20 | 2.41 | NA | XXX |
| 62252 | 26 | A | Csf shunt reprogram | 0.74 | 0.37 | 0.37 | 0.18 | 1.29 | 1.29 | XXX |
| 62252 | TC | A | Csf shunt reprogram | 0.00 | 1.10 | NA | 0.02 | 1.12 | NA | XXX |
| 62256 | | A | Remove brain cavity shunt | 6.59 | NA | 4.71 | 1.57 | NA | 12.87 | 090 |
| 62258 | | A | Replace brain cavity shunt | 14.52 | NA | 8.71 | 3.27 | NA | 26.50 | 090 |
| 62263 | | A | Epidural lysis mult sessions | 6.13 | 12.79 | 3.22 | 0.40 | 19.32 | 9.75 | 010 |
| 62264 | | A | Epidural lysis on single day | 4.42 | 7.75 | 1.42 | 0.40 | 12.57 | 6.24 | 010 |
| 62268 | | A | Drain spinal cord cyst | 4.73 | 11.63 | 2.14 | 0.31 | 16.67 | 7.18 | 000 |
| 62269 | | A | Needle biopsy, spinal cord | 5.01 | 15.11 | 1.97 | 0.39 | 20.51 | 7.37 | 000 |
| 62270 | | A | Spinal fluid tap, diagnostic | 1.13 | 2.98 | 0.56 | 0.08 | 4.19 | 1.77 | 000 |
| 62272 | | A | Drain cerebro spinal fluid | 1.35 | 3.60 | 0.71 | 0.17 | 5.12 | 2.23 | 000 |
| 62273 | | A | Treat epidural spine lesion | 2.15 | 2.73 | 0.72 | 0.14 | 5.02 | 3.01 | 000 |
| 62280 | | A | Treat spinal cord lesion | 2.63 | 6.99 | 1.01 | 0.23 | 9.85 | 3.87 | 010 |
| 62281 | | A | Treat spinal cord lesion | 2.66 | 5.70 | 0.90 | 0.18 | 8.54 | 3.74 | 010 |
| 62282 | | A | Treat spinal canal lesion | 2.33 | 8.43 | 0.92 | 0.17 | 10.93 | 3.42 | 010 |
| 62284 | | A | Injection for myelogram | 1.54 | 5.02 | 0.68 | 0.13 | 6.69 | 2.35 | 000 |
| 62287 | | A | Percutaneous diskectomy | 8.07 | NA | 5.55 | 0.69 | NA | 14.31 | 090 |
| 62290 | | A | Inject for spine disk x-ray | 3.00 | 7.19 | 1.38 | 0.26 | 10.45 | 4.64 | 000 |
| 62291 | | A | Inject for spine disk x-ray | 2.91 | 5.99 | 1.23 | 0.28 | 9.18 | 4.42 | 000 |
| 62292 | | A | Injection into disk lesion | 7.85 | NA | 4.49 | 0.84 | NA | 13.18 | 090 |
| 62294 | | A | Injection into spinal artery | 11.81 | NA | 5.59 | 1.38 | NA | 18.78 | 090 |
| 62310 | | A | Inject spine c/t | 1.91 | 4.85 | 0.65 | 0.12 | 6.88 | 2.68 | 000 |
| 62311 | | A | Inject spine l/s (cd) | 1.54 | 4.94 | 0.60 | 0.10 | 6.58 | 2.24 | 000 |
| 62318 | | A | Inject spine w/cath, c/t | 2.04 | 5.76 | 0.65 | 0.13 | 7.93 | 2.82 | 000 |
| 62319 | | A | Inject spine w/cath l/s (cd) | 1.87 | 5.03 | 0.61 | 0.12 | 7.02 | 2.60 | 000 |
| 62350 | | A | Implant spinal canal cath | 6.86 | NA | 3.97 | 0.86 | NA | 11.69 | 090 |
| 62351 | | A | Implant spinal canal cath | 9.99 | NA | 7.12 | 1.88 | NA | 18.99 | 090 |
| 62355 | | A | Remove spinal canal catheter | 5.44 | NA | 3.18 | 0.69 | NA | 9.31 | 090 |
| 62360 | | A | Insert spine infusion device | 2.62 | NA | 2.71 | 0.33 | NA | 5.66 | 090 |
| 62361 | | A | Implant spine infusion pump | 5.41 | NA | 3.94 | 0.69 | NA | 10.04 | 090 |
| 62362 | | A | Implant spine infusion pump | 7.03 | NA | 4.37 | 1.08 | NA | 12.48 | 090 |
| 62365 | | A | Remove spine infusion device | 5.41 | NA | 3.59 | 0.77 | NA | 9.77 | 090 |
| 62367 | 26 | A | Analyze spine infusion pump | 0.48 | 0.13 | 0.13 | 0.03 | 0.64 | 0.64 | XXX |
| 62368 | 26 | A | Analyze spine infusion pump | 0.75 | 0.19 | 0.19 | 0.06 | 1.00 | 1.00 | XXX |
| 63001 | | A | Removal of spinal lamina | 15.80 | NA | 9.50 | 3.30 | NA | 28.60 | 090 |
| 63003 | | A | Removal of spinal lamina | 15.93 | NA | 9.85 | 3.41 | NA | 29.19 | 090 |
| 63005 | | A | Removal of spinal lamina | 14.90 | NA | 9.96 | 2.77 | NA | 27.63 | 090 |
| 63011 | | A | Removal of spinal lamina | 14.50 | NA | 8.27 | 3.17 | NA | 25.94 | 090 |
| 63012 | | A | Removal of spinal lamina | 15.38 | NA | 10.11 | 3.04 | NA | 28.53 | 090 |
| 63015 | | A | Removal of spinal lamina | 19.32 | NA | 11.86 | 4.14 | NA | 35.32 | 090 |
| 63016 | | A | Removal of spinal lamina | 19.17 | NA | 11.77 | 4.03 | NA | 34.97 | 090 |
| 63017 | | A | Removal of spinal lamina | 15.92 | NA | 10.38 | 3.20 | NA | 29.50 | 090 |
| 63020 | | A | Neck spine disk surgery | 14.79 | NA | 9.66 | 3.29 | NA | 27.74 | 090 |
| 63030 | | A | Low back disk surgery | 11.98 | NA | 8.41 | 2.43 | NA | 22.82 | 090 |
| 63035 | | A | Spinal disk surgery add-on | 3.15 | NA | 1.59 | 0.67 | NA | 5.41 | ZZZ |
| 63040 | | A | Laminotomy, single cervical | 18.78 | NA | 11.49 | 4.07 | NA | 34.34 | 090 |
| 63042 | | A | Laminotomy, single lumbar | 17.44 | NA | 11.32 | 3.58 | NA | 32.34 | 090 |
| 63045 | | A | Removal of spinal lamina | 16.48 | NA | 10.34 | 3.47 | NA | 30.29 | 090 |
| 63046 | | A | Removal of spinal lamina | 15.78 | NA | 10.17 | 3.17 | NA | 29.12 | 090 |
| 63047 | | A | Removal of spinal lamina | 14.59 | NA | 9.88 | 2.77 | NA | 27.24 | 090 |
| 63048 | | A | Remove spinal lamina add-on | 3.26 | NA | 1.66 | 0.63 | NA | 5.55 | ZZZ |
| 63055 | | A | Decompress spinal cord | 21.96 | NA | 13.12 | 4.73 | NA | 39.81 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 63056 | | A | Decompress spinal cord | 20.33 | NA | 12.54 | 4.07 | NA | 36.94 | 090 |
| 63057 | | A | Decompress spine cord add-on | 5.25 | NA | 2.63 | 1.11 | NA | 8.99 | ZZZ |
| 63064 | | A | Decompress spinal cord | 24.57 | NA | 14.41 | 5.05 | NA | 44.03 | 090 |
| 63066 | | A | Decompress spine cord add-on | 3.26 | NA | 1.66 | 0.66 | NA | 5.58 | ZZZ |
| 63075 | | A | Neck spine disk surgery | 19.38 | NA | 12.07 | 3.95 | NA | 35.40 | 090 |
| 63076 | | A | Neck spine disk surgery | 4.04 | NA | 2.05 | 0.82 | NA | 6.91 | ZZZ |
| 63077 | | A | Spine disk surgery, thorax | 21.41 | NA | 12.77 | 3.41 | NA | 37.59 | 090 |
| 63078 | | A | Spine disk surgery, thorax | 3.28 | NA | 1.63 | 0.53 | NA | 5.44 | ZZZ |
| 63081 | | A | Removal of vertebral body | 23.69 | NA | 14.30 | 4.86 | NA | 42.85 | 090 |
| 63082 | | A | Remove vertebral body add-on | 4.36 | NA | 2.22 | 0.91 | NA | 7.49 | ZZZ |
| 63085 | | A | Removal of vertebral body | 26.88 | NA | 15.45 | 4.23 | NA | 46.56 | 090 |
| 63086 | | A | Remove vertebral body add-on | 3.19 | NA | 1.59 | 0.57 | NA | 5.35 | ZZZ |
| 63087 | | A | Removal of vertebral body | 35.52 | NA | 19.43 | 5.70 | NA | 60.65 | 090 |
| 63088 | | A | Remove vertebral body add-on | 4.32 | NA | 2.17 | 0.72 | NA | 7.21 | ZZZ |
| 63090 | | A | Removal of vertebral body | 28.12 | NA | 16.01 | 4.09 | NA | 48.22 | 090 |
| 63091 | | A | Remove vertebral body add-on | 3.03 | NA | 1.45 | 0.47 | NA | 4.95 | ZZZ |
| 63101 | | A | Removal of vertebral body | 31.95 | NA | 19.28 | 5.05 | NA | 56.28 | 090 |
| 63102 | | A | Removal of vertebral body | 31.95 | NA | 19.28 | 5.05 | NA | 56.28 | 090 |
| 63103 | | A | Remove vertebral body add-on | 3.89 | NA | 2.03 | 0.66 | NA | 6.58 | ZZZ |
| 63170 | | A | Incise spinal cord tract(s) | 19.80 | NA | 12.08 | 4.48 | NA | 36.36 | 090 |
| 63172 | | A | Drainage of spinal cyst | 17.63 | NA | 10.90 | 4.06 | NA | 32.59 | 090 |
| 63173 | | A | Drainage of spinal cyst | 21.96 | NA | 13.06 | 4.95 | NA | 39.97 | 090 |
| 63180 | | A | Revise spinal cord ligaments | 18.24 | NA | 11.24 | 2.46 | NA | 31.94 | 090 |
| 63182 | | A | Revise spinal cord ligaments | 20.47 | NA | 11.18 | 3.47 | NA | 35.12 | 090 |
| 63185 | | A | Incise spinal column/nerves | 15.02 | NA | 8.29 | 2.22 | NA | 25.53 | 090 |
| 63190 | | A | Incise spinal column/nerves | 17.42 | NA | 10.34 | 3.35 | NA | 31.11 | 090 |
| 63191 | | A | Incise spinal column/nerves | 17.51 | NA | 10.71 | 4.53 | NA | 32.75 | 090 |
| 63194 | | A | Incise spinal column & cord | 19.16 | NA | 11.93 | 3.82 | NA | 34.91 | 090 |
| 63195 | | A | Incise spinal column & cord | 18.81 | NA | 11.26 | 4.37 | NA | 34.44 | 090 |
| 63196 | | A | Incise spinal column & cord | 22.27 | NA | 13.60 | 5.62 | NA | 41.49 | 090 |
| 63197 | | A | Incise spinal column & cord | 21.08 | NA | 12.41 | 4.20 | NA | 37.69 | 090 |
| 63198 | | A | Incise spinal column & cord | 25.34 | NA | 8.58 | 6.40 | NA | 40.32 | 090 |
| 63199 | | A | Incise spinal column & cord | 26.85 | NA | 15.23 | 6.78 | NA | 48.86 | 090 |
| 63200 | | A | Release of spinal cord | 19.15 | NA | 11.50 | 4.31 | NA | 34.96 | 090 |
| 63250 | | A | Revise spinal cord vessels | 40.70 | NA | 19.92 | 8.81 | NA | 69.43 | 090 |
| 63251 | | A | Revise spinal cord vessels | 41.14 | NA | 22.57 | 9.46 | NA | 73.17 | 090 |
| 63252 | | A | Revise spinal cord vessels | 41.13 | NA | 22.22 | 9.52 | NA | 72.87 | 090 |
| 63265 | | A | Excise intraspinal lesion | 21.53 | NA | 12.76 | 4.85 | NA | 39.14 | 090 |
| 63266 | | A | Excise intraspinal lesion | 22.27 | NA | 13.18 | 4.89 | NA | 40.34 | 090 |
| 63267 | | A | Excise intraspinal lesion | 17.92 | NA | 11.07 | 3.79 | NA | 32.78 | 090 |
| 63268 | | A | Excise intraspinal lesion | 18.49 | NA | 10.38 | 3.01 | NA | 31.88 | 090 |
| 63270 | | A | Excise intraspinal lesion | 26.76 | NA | 15.46 | 5.94 | NA | 48.16 | 090 |
| 63271 | | A | Excise intraspinal lesion | 26.88 | NA | 15.56 | 6.38 | NA | 48.82 | 090 |
| 63272 | | A | Excise intraspinal lesion | 25.28 | NA | 14.68 | 5.41 | NA | 45.37 | 090 |
| 63273 | | A | Excise intraspinal lesion | 24.25 | NA | 14.33 | 6.05 | NA | 44.63 | 090 |
| 63275 | | A | Biopsy/excise spinal tumor | 23.64 | NA | 13.77 | 5.20 | NA | 42.61 | 090 |
| 63276 | | A | Biopsy/excise spinal tumor | 23.41 | NA | 13.67 | 5.16 | NA | 42.24 | 090 |
| 63277 | | A | Biopsy/excise spinal tumor | 20.80 | NA | 12.51 | 4.32 | NA | 37.63 | 090 |
| 63278 | | A | Biopsy/excise spinal tumor | 20.53 | NA | 12.38 | 4.07 | NA | 36.98 | 090 |
| 63280 | | A | Biopsy/excise spinal tumor | 28.31 | NA | 16.30 | 6.47 | NA | 51.08 | 090 |
| 63281 | | A | Biopsy/excise spinal tumor | 28.01 | NA | 16.16 | 6.41 | NA | 50.58 | 090 |
| 63282 | | A | Biopsy/excise spinal tumor | 26.35 | NA | 15.32 | 6.03 | NA | 47.70 | 090 |
| 63283 | | A | Biopsy/excise spinal tumor | 24.96 | NA | 14.65 | 5.64 | NA | 45.25 | 090 |
| 63285 | | A | Biopsy/excise spinal tumor | 35.95 | NA | 19.92 | 9.19 | NA | 65.06 | 090 |
| 63286 | | A | Biopsy/excise spinal tumor | 35.58 | NA | 19.88 | 8.10 | NA | 63.56 | 090 |
| 63287 | | A | Biopsy/excise spinal tumor | 36.64 | NA | 20.41 | 8.00 | NA | 65.05 | 090 |
| 63290 | | A | Biopsy/excise spinal tumor | 37.32 | NA | 20.57 | 9.00 | NA | 66.89 | 090 |
| 63300 | | A | Removal of vertebral body | 24.39 | NA | 14.29 | 4.92 | NA | 43.60 | 090 |
| 63301 | | A | Removal of vertebral body | 27.56 | NA | 15.54 | 5.21 | NA | 48.31 | 090 |
| 63302 | | A | Removal of vertebral body | 27.77 | NA | 15.83 | 5.11 | NA | 48.71 | 090 |
| 63303 | | A | Removal of vertebral body | 30.45 | NA | 16.89 | 4.99 | NA | 52.33 | 090 |
| 63304 | | A | Removal of vertebral body | 30.28 | NA | 17.26 | 6.03 | NA | 53.57 | 090 |
| 63305 | | A | Removal of vertebral body | 31.98 | NA | 18.03 | 5.92 | NA | 55.93 | 090 |
| 63306 | | A | Removal of vertebral body | 32.17 | NA | 17.78 | 6.13 | NA | 56.08 | 090 |
| 63307 | | A | Removal of vertebral body | 31.58 | NA | 16.79 | 4.80 | NA | 53.17 | 090 |
| 63308 | | A | Remove vertebral body add-on | 5.24 | NA | 2.60 | 1.15 | NA | 8.99 | ZZZ |
| 63600 | | A | Remove spinal cord lesion | 14.00 | NA | 5.41 | 1.29 | NA | 20.70 | 090 |
| 63610 | | A | Stimulation of spinal cord | 8.72 | 59.95 | 2.25 | 0.55 | 69.22 | 11.52 | 000 |
| 63615 | | A | Remove lesion of spinal cord | 16.26 | NA | 9.30 | 1.89 | NA | 27.45 | 090 |
| 63650 | | A | Implant neuroelectrodes | 6.73 | NA | 3.19 | 0.54 | NA | 10.46 | 090 |
| 63655 | | A | Implant neuroelectrodes | 10.27 | NA | 6.90 | 2.07 | NA | 19.24 | 090 |
| 63660 | | A | Revise/remove neuroelectrode | 6.15 | NA | 3.63 | 0.80 | NA | 10.58 | 090 |
| 63685 | | A | Implant neuroreceiver | 7.03 | NA | 4.16 | 0.99 | NA | 12.18 | 090 |
| 63688 | | A | Revise/remove neuroreceiver | 5.38 | NA | 3.57 | 0.85 | NA | 9.80 | 090 |
| 63700 | | A | Repair of spinal herniation | 16.51 | NA | 10.29 | 3.14 | NA | 29.94 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 63702 | | A | Repair of spinal herniation | 18.45 | NA | 11.05 | 3.43 | NA | 32.93 | 090 |
| 63704 | | A | Repair of spinal herniation | 21.15 | NA | 12.90 | 4.54 | NA | 38.59 | 090 |
| 63706 | | A | Repair of spinal herniation | 24.07 | NA | 13.58 | 5.45 | NA | 43.10 | 090 |
| 63707 | | A | Repair spinal fluid leakage | 11.24 | NA | 7.70 | 2.18 | NA | 21.12 | 090 |
| 63709 | | A | Repair spinal fluid leakage | 14.30 | NA | 9.39 | 2.77 | NA | 26.46 | 090 |
| 63710 | | A | Graft repair of spine defect | 14.05 | NA | 9.04 | 3.02 | NA | 26.11 | 090 |
| 63740 | | A | Install spinal shunt | 11.34 | NA | 7.35 | 2.44 | NA | 21.13 | 090 |
| 63741 | | A | Install spinal shunt | 8.24 | NA | 4.76 | 1.69 | NA | 14.69 | 090 |
| 63744 | | A | Revision of spinal shunt | 8.09 | NA | 5.26 | 1.54 | NA | 14.89 | 090 |
| 63746 | | A | Removal of spinal shunt | 6.42 | NA | 3.79 | 1.60 | NA | 11.81 | 090 |
| 64400 | | A | N block inj, trigeminal | 1.11 | 1.89 | 0.43 | 0.09 | 3.09 | 1.63 | 000 |
| 64402 | | A | N block inj, facial | 1.25 | 1.62 | 0.60 | 0.08 | 2.95 | 1.93 | 000 |
| 64405 | | A | N block inj, occipital | 1.32 | 1.46 | 0.46 | 0.09 | 2.87 | 1.87 | 000 |
| 64408 | | A | N block inj, vagus | 1.41 | 1.58 | 0.85 | 0.09 | 3.08 | 2.35 | 000 |
| 64410 | | A | N block inj, phrenic | 1.43 | 2.52 | 0.47 | 0.09 | 4.04 | 1.99 | 000 |
| 64412 | | A | N block inj, spinal accessor | 1.18 | 2.66 | 0.43 | 0.08 | 3.92 | 1.69 | 000 |
| 64413 | | A | N block inj, cervical plexus | 1.40 | 1.85 | 0.50 | 0.10 | 3.35 | 2.00 | 000 |
| 64415 | | A | N block inj, brachial plexus | 1.48 | 2.81 | 0.46 | 0.10 | 4.39 | 2.04 | 000 |
| 64416 | | A | N block cont infuse, b plex | 3.49 | NA | 0.79 | 0.10 | NA | 4.38 | 010 |
| 64417 | | A | N block inj, axillary | 1.44 | 3.04 | 0.49 | 0.12 | 4.60 | 2.05 | 000 |
| 64418 | | A | N block inj, suprascapular | 1.32 | 2.63 | 0.44 | 0.08 | 4.03 | 1.84 | 000 |
| 64420 | | A | N block inj, intercost, sng | 1.18 | 3.98 | 0.42 | 0.08 | 5.24 | 1.68 | 000 |
| 64421 | | A | N block inj, intercost, mlt | 1.68 | 6.19 | 0.52 | 0.12 | 7.99 | 2.32 | 000 |
| 64425 | | A | N block inj ilio-ing/hypogi | 1.75 | 1.65 | 0.54 | 0.14 | 3.54 | 2.43 | 000 |
| 64430 | | A | N block inj, pudendal | 1.46 | 2.51 | 0.55 | 0.11 | 4.08 | 2.12 | 000 |
| 64435 | | A | N block inj, paracervical | 1.45 | 2.52 | 0.69 | 0.17 | 4.14 | 2.31 | 000 |
| 64445 | | A | N block inj, sciatic, sng | 1.48 | 2.68 | 0.50 | 0.10 | 4.26 | 2.08 | 000 |
| 64446 | | A | N blk inj, sciatic, cont inf | 3.25 | NA | 1.01 | 0.10 | NA | 4.36 | 010 |
| 64447 | | A | N block inj fem, single | 1.50 | NA | 0.43 | 0.10 | NA | 2.03 | 000 |
| 64448 | | A | N block inj fem, cont inf | 3.00 | NA | 0.81 | 0.10 | NA | 3.91 | 010 |
| 64449 | | A | N block inj, lumbar plexus | 3.00 | NA | 0.96 | 0.10 | NA | 4.06 | 010 |
| 64450 | | A | N block, other peripheral | 1.27 | 1.24 | 0.48 | 0.10 | 2.61 | 1.85 | 000 |
| 64470 | | A | Inj paravertebral c/t | 1.85 | 7.29 | 0.72 | 0.14 | 9.28 | 2.71 | 000 |
| 64472 | | A | Inj paravertebral c/t add-on | 1.29 | 2.35 | 0.34 | 0.09 | 3.73 | 1.72 | ZZZ |
| 64475 | | A | Inj paravertebral l/s | 1.41 | 6.93 | 0.63 | 0.11 | 8.45 | 2.15 | 000 |
| 64476 | | A | Inj paravertebral l/s add-on | 0.98 | 2.14 | 0.24 | 0.08 | 3.20 | 1.30 | ZZZ |
| 64479 | | A | Inj foramen epidural c/t | 2.20 | 7.56 | 0.89 | 0.16 | 9.92 | 3.25 | 000 |
| 64480 | | A | Inj foramen epidural add-on | 1.54 | 2.87 | 0.47 | 0.12 | 4.53 | 2.13 | ZZZ |
| 64483 | | A | Inj foramen epidural l/s | 1.90 | 7.95 | 0.83 | 0.12 | 9.97 | 2.85 | 000 |
| 64484 | | A | Inj foramen epidural add-on | 1.33 | 3.31 | 0.37 | 0.09 | 4.73 | 1.79 | ZZZ |
| 64505 | | A | N block, spenopalatine gangl | 1.36 | 1.25 | 0.66 | 0.09 | 2.70 | 2.11 | 000 |
| 64508 | | A | N block, carotid sinus s/p | 1.12 | 3.39 | 0.74 | 0.09 | 4.60 | 1.95 | 000 |
| 64510 | | A | N block, stellate ganglion | 1.22 | 3.51 | 0.51 | 0.08 | 4.81 | 1.81 | 000 |
| 64517 | | A | N block inj, hypogas plxs | 2.20 | 2.73 | 0.87 | 0.11 | 5.04 | 3.18 | 000 |
| 64520 | | A | N block, lumbar/thoracic | 1.35 | 5.21 | 0.55 | 0.09 | 6.65 | 1.99 | 000 |
| 64530 | | A | N block inj, celiac pelus | 1.58 | 4.49 | 0.66 | 0.10 | 6.17 | 2.34 | 000 |
| 64550 | | A | Apply neurostimulator | 0.18 | 0.28 | 0.05 | 0.01 | 0.47 | 0.24 | 000 |
| 64553 | | A | Implant neuroelectrodes | 2.31 | 2.83 | 1.85 | 0.23 | 5.37 | 4.39 | 010 |
| 64555 | | A | Implant neuroelectrodes | 2.27 | 3.11 | 1.20 | 0.23 | 5.61 | 3.70 | 010 |
| 64560 | | A | Implant neuroelectrodes | 2.36 | 2.66 | 1.30 | 0.24 | 5.26 | 3.90 | 010 |
| 64561 | | A | Implant neuroelectrodes | 6.73 | 30.03 | 2.82 | 0.51 | 37.27 | 10.06 | 010 |
| 64565 | | A | Implant neuroelectrodes | 1.76 | 3.30 | 1.26 | 0.10 | 5.16 | 3.12 | 010 |
| 64573 | | A | Implant neuroelectrodes | 7.49 | NA | 5.25 | 1.48 | NA | 14.22 | 090 |
| 64575 | | A | Implant neuroelectrodes | 4.34 | NA | 2.69 | 0.45 | NA | 7.48 | 090 |
| 64577 | | A | Implant neuroelectrodes | 4.61 | NA | 3.30 | 0.61 | NA | 8.52 | 090 |
| 64580 | | A | Implant neuroelectrodes | 4.11 | NA | 3.57 | 0.23 | NA | 7.91 | 090 |
| 64581 | | A | Implant neuroelectrodes | 13.48 | NA | 5.36 | 1.05 | NA | 19.89 | 090 |
| 64585 | | A | Revise/remove neuroelectrode | 2.06 | 11.26 | 2.14 | 0.22 | 13.54 | 4.42 | 010 |
| 64590 | | A | Implant neuroreceiver | 2.40 | 7.15 | 2.28 | 0.23 | 9.78 | 4.91 | 010 |
| 64595 | | A | Revise/remove neuroreceiver | 1.73 | 10.42 | 1.93 | 0.22 | 12.37 | 3.88 | 010 |
| 64600 | | A | Injection treatment of nerve | 3.44 | 9.36 | 1.66 | 0.33 | 13.13 | 5.43 | 010 |
| 64605 | | A | Injection treatment of nerve | 5.60 | 9.58 | 2.19 | 0.92 | 16.10 | 8.71 | 010 |
| 64610 | | A | Injection treatment of nerve | 7.15 | 8.92 | 3.71 | 1.35 | 17.42 | 12.21 | 010 |
| 64612 | | A | Destroy nerve, face muscle | 1.96 | 2.48 | 1.32 | 0.12 | 4.56 | 3.40 | 010 |
| 64613 | | A | Destroy nerve, spine muscle | 1.96 | 2.90 | 1.22 | 0.12 | 4.98 | 3.30 | 010 |
| 64614 | | A | Destroy nerve, extrem musc | 2.20 | 3.21 | 1.31 | 0.12 | 5.53 | 3.63 | 010 |
| 64620 | | A | Injection treatment of nerve | 2.84 | 5.13 | 1.34 | 0.20 | 8.17 | 4.38 | 010 |
| 64622 | | A | Destr paravertebrl nerve l/s | 3.00 | 7.82 | 1.38 | 0.21 | 11.03 | 4.59 | 010 |
| 64623 | | A | Destr paravertebral n add-on | 0.99 | 2.98 | 0.22 | 0.07 | 4.04 | 1.28 | ZZZ |
| 64626 | | A | Destr paravertebrl nerve c/t | 3.28 | 7.84 | 1.98 | 0.22 | 11.34 | 5.48 | 010 |
| 64627 | | A | Destr paravertebral n add-on | 1.16 | 4.58 | 0.27 | 0.08 | 5.82 | 1.51 | ZZZ |
| 64630 | | A | Injection treatment of nerve | 3.00 | 2.73 | 1.42 | 0.23 | 5.96 | 4.65 | 010 |
| 64640 | | A | Injection treatment of nerve | 2.76 | 4.19 | 1.85 | 0.19 | 7.14 | 4.80 | 010 |
| 64680 | | A | Injection treatment of nerve | 2.62 | 6.75 | 1.44 | 0.18 | 9.55 | 4.24 | 010 |
| 64681 | | A | Injection treatment of nerve | 3.54 | 9.36 | 2.06 | 0.19 | 13.09 | 5.79 | 010 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 64702 | | A | Revise finger/toe nerve | 4.22 | NA | 3.86 | 0.60 | NA | 8.68 | 090 |
| 64704 | | A | Revise hand/foot nerve | 4.56 | NA | 3.31 | 0.47 | NA | 8.34 | 090 |
| 64708 | | A | Revise arm/leg nerve | 6.11 | NA | 4.87 | 0.92 | NA | 11.90 | 090 |
| 64712 | | A | Revision of sciatic nerve | 7.74 | NA | 4.98 | 0.98 | NA | 13.70 | 090 |
| 64713 | | A | Revision of arm nerve(s) | 10.98 | NA | 5.88 | 1.68 | NA | 18.54 | 090 |
| 64714 | | A | Revise low back nerve(s) | 10.31 | NA | 4.23 | 1.04 | NA | 15.58 | 090 |
| 64716 | | A | Revision of cranial nerve | 6.30 | NA | 5.96 | 0.64 | NA | 12.90 | 090 |
| 64718 | | A | Revise ulnar nerve at elbow | 5.98 | NA | 5.98 | 1.03 | NA | 12.99 | 090 |
| 64719 | | A | Revise ulnar nerve at wrist | 4.84 | NA | 4.53 | 0.78 | NA | 10.15 | 090 |
| 64721 | | A | Carpal tunnel surgery | 4.28 | NA | 5.35 | 0.72 | NA | 10.35 | 090 |
| 64722 | | A | Relieve pressure on nerve(s) | 4.69 | NA | 3.06 | 0.45 | NA | 8.20 | 090 |
| 64726 | | A | Release foot/toe nerve | 4.17 | NA | 2.80 | 0.40 | NA | 7.37 | 090 |
| 64727 | | A | Internal nerve revision | 3.10 | NA | 1.50 | 0.49 | NA | 5.09 | ZZZ |
| 64732 | | A | Incision of brow nerve | 4.40 | NA | 3.52 | 0.81 | NA | 8.73 | 090 |
| 64734 | | A | Incision of cheek nerve | 4.91 | NA | 4.05 | 0.95 | NA | 9.91 | 090 |
| 64736 | | A | Incision of chin nerve | 4.59 | NA | 4.03 | 0.64 | NA | 9.26 | 090 |
| 64738 | | A | Incision of jaw nerve | 5.72 | NA | 4.61 | 1.24 | NA | 11.57 | 090 |
| 64740 | | A | Incision of tongue nerve | 5.58 | NA | 5.11 | 0.57 | NA | 11.26 | 090 |
| 64742 | | A | Incision of facial nerve | 6.21 | NA | 4.70 | 0.57 | NA | 11.48 | 090 |
| 64744 | | A | Incise nerve, back of head | 5.23 | NA | 3.78 | 1.03 | NA | 10.04 | 090 |
| 64746 | | A | Incise diaphragm nerve | 5.92 | NA | 4.51 | 0.82 | NA | 11.25 | 090 |
| 64752 | | A | Incision of vagus nerve | 7.05 | NA | 4.30 | 0.89 | NA | 12.24 | 090 |
| 64755 | | A | Incision of stomach nerves | 13.50 | NA | 5.65 | 1.63 | NA | 20.78 | 090 |
| 64760 | | A | Incision of vagus nerve | 6.95 | NA | 3.48 | 0.79 | NA | 11.22 | 090 |
| 64761 | | A | Incision of pelvis nerve | 6.40 | NA | 3.54 | 0.45 | NA | 10.39 | 090 |
| 64763 | | A | Incise hip/thigh nerve | 6.92 | NA | 5.23 | 0.98 | NA | 13.13 | 090 |
| 64766 | | A | Incise hip/thigh nerve | 8.66 | NA | 5.26 | 1.11 | NA | 15.03 | 090 |
| 64771 | | A | Sever cranial nerve | 7.34 | NA | 5.56 | 1.04 | NA | 13.94 | 090 |
| 64772 | | A | Incision of spinal nerve | 7.20 | NA | 4.93 | 1.25 | NA | 13.38 | 090 |
| 64774 | | A | Remove skin nerve lesion | 5.16 | NA | 3.83 | 0.63 | NA | 9.62 | 090 |
| 64776 | | A | Remove digit nerve lesion | 5.11 | NA | 3.70 | 0.66 | NA | 9.47 | 090 |
| 64778 | | A | Digit nerve surgery add-on | 3.11 | NA | 1.50 | 0.46 | NA | 5.07 | ZZZ |
| 64782 | | A | Remove limb nerve lesion | 6.22 | NA | 3.77 | 0.71 | NA | 10.70 | 090 |
| 64783 | | A | Limb nerve surgery add-on | 3.71 | NA | 1.83 | 0.52 | NA | 6.06 | ZZZ |
| 64784 | | A | Remove nerve lesion | 9.81 | NA | 6.60 | 1.39 | NA | 17.80 | 090 |
| 64786 | | A | Remove sciatic nerve lesion | 15.44 | NA | 9.84 | 2.52 | NA | 27.80 | 090 |
| 64787 | | A | Implant nerve end | 4.29 | NA | 2.11 | 0.56 | NA | 6.96 | ZZZ |
| 64788 | | A | Remove skin nerve lesion | 4.60 | NA | 3.48 | 0.64 | NA | 8.72 | 090 |
| 64790 | | A | Removal of nerve lesion | 11.29 | NA | 7.20 | 1.76 | NA | 20.25 | 090 |
| 64792 | | A | Removal of nerve lesion | 14.90 | NA | 8.82 | 2.29 | NA | 26.01 | 090 |
| 64795 | | A | Biopsy of nerve | 3.01 | NA | 1.58 | 0.50 | NA | 5.09 | 000 |
| 64802 | | A | Remove sympathetic nerves | 9.14 | NA | 5.15 | 1.17 | NA | 15.46 | 090 |
| 64804 | | A | Remove sympathetic nerves | 14.62 | NA | 7.17 | 1.99 | NA | 23.78 | 090 |
| 64809 | | A | Remove sympathetic nerves | 13.65 | NA | 5.77 | 1.79 | NA | 21.21 | 090 |
| 64818 | | A | Remove sympathetic nerves | 10.28 | NA | 5.29 | 1.32 | NA | 16.89 | 090 |
| 64820 | | A | Remove sympathetic nerves | 10.35 | NA | 7.14 | 1.54 | NA | 19.03 | 090 |
| 64821 | | A | Remove sympathetic nerves | 8.74 | NA | 7.33 | 1.38 | NA | 17.45 | 090 |
| 64822 | | A | Remove sympathetic nerves | 8.74 | NA | 7.22 | 1.33 | NA | 17.29 | 090 |
| 64823 | | A | Remove sympathetic nerves | 10.35 | NA | 8.13 | 1.58 | NA | 20.06 | 090 |
| 64831 | | A | Repair of digit nerve | 9.43 | NA | 7.08 | 1.40 | NA | 17.91 | 090 |
| 64832 | | A | Repair nerve add-on | 5.65 | NA | 2.93 | 0.83 | NA | 9.41 | ZZZ |
| 64834 | | A | Repair of hand or foot nerve | 10.17 | NA | 7.09 | 1.57 | NA | 18.83 | 090 |
| 64835 | | A | Repair of hand or foot nerve | 10.92 | NA | 7.70 | 1.61 | NA | 20.23 | 090 |
| 64836 | | A | Repair of hand or foot nerve | 10.92 | NA | 7.67 | 1.63 | NA | 20.22 | 090 |
| 64837 | | A | Repair nerve add-on | 6.25 | NA | 3.22 | 0.95 | NA | 10.42 | ZZZ |
| 64840 | | A | Repair of leg nerve | 13.00 | NA | 8.25 | 1.44 | NA | 22.69 | 090 |
| 64856 | | A | Repair/transpose nerve | 13.78 | NA | 9.18 | 2.06 | NA | 25.02 | 090 |
| 64857 | | A | Repair arm/leg nerve | 14.47 | NA | 9.63 | 2.22 | NA | 26.32 | 090 |
| 64858 | | A | Repair sciatic nerve | 16.47 | NA | 10.77 | 2.98 | NA | 30.22 | 090 |
| 64859 | | A | Nerve surgery | 4.25 | NA | 2.19 | 0.59 | NA | 7.03 | ZZZ |
| 64861 | | A | Repair of arm nerves | 19.21 | NA | 11.78 | 4.24 | NA | 35.23 | 090 |
| 64862 | | A | Repair of low back nerves | 19.41 | NA | 11.93 | 2.98 | NA | 34.32 | 090 |
| 64864 | | A | Repair of facial nerve | 12.53 | NA | 8.75 | 1.35 | NA | 22.63 | 090 |
| 64865 | | A | Repair of facial nerve | 15.22 | NA | 13.44 | 1.82 | NA | 30.48 | 090 |
| 64866 | | A | Fusion of facial/other nerve | 15.72 | NA | 13.10 | 1.63 | NA | 30.45 | 090 |
| 64868 | | A | Fusion of facial/other nerve | 14.02 | NA | 11.39 | 1.64 | NA | 27.05 | 090 |
| 64870 | | A | Fusion of facial/other nerve | 15.97 | NA | 8.72 | 0.80 | NA | 25.49 | 090 |
| 64872 | | A | Subsequent repair of nerve | 1.99 | NA | 1.08 | 0.28 | NA | 3.35 | ZZZ |
| 64874 | | A | Repair & revise nerve add-on | 2.98 | NA | 1.53 | 0.41 | NA | 4.92 | ZZZ |
| 64876 | | A | Repair nerve/shorten bone | 3.37 | NA | 1.27 | 0.47 | NA | 5.11 | ZZZ |
| 64885 | | A | Nerve graft, head or neck | 17.50 | NA | 11.59 | 1.69 | NA | 30.78 | 090 |
| 64886 | | A | Nerve graft, head or neck | 20.72 | NA | 13.52 | 2.06 | NA | 36.30 | 090 |
| 64890 | | A | Nerve graft, hand or foot | 15.13 | NA | 9.99 | 2.24 | NA | 27.36 | 090 |
| 64891 | | A | Nerve graft, hand or foot | 16.12 | NA | 7.60 | 1.38 | NA | 25.10 | 090 |
| 64892 | | A | Nerve graft, arm or leg | 14.63 | NA | 8.87 | 1.97 | NA | 25.47 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 64893 | | A | Nerve graft, arm or leg | 15.58 | NA | 9.87 | 2.28 | NA | 27.73 | 090 |
| 64895 | | A | Nerve graft, hand or foot | 19.22 | NA | 9.65 | 2.43 | NA | 31.30 | 090 |
| 64896 | | A | Nerve graft, hand or foot | 20.46 | NA | 11.00 | 1.97 | NA | 33.43 | 090 |
| 64897 | | A | Nerve graft, arm or leg | 18.21 | NA | 10.69 | 2.61 | NA | 31.51 | 090 |
| 64898 | | A | Nerve graft, arm or leg | 19.47 | NA | 11.79 | 2.14 | NA | 33.40 | 090 |
| 64901 | | A | Nerve graft add-on | 10.20 | NA | 5.25 | 1.22 | NA | 16.67 | ZZZ |
| 64902 | | A | Nerve graft add-on | 11.81 | NA | 5.95 | 1.43 | NA | 19.19 | ZZZ |
| 64905 | | A | Nerve pedicle transfer | 14.00 | NA | 8.50 | 1.53 | NA | 24.03 | 090 |
| 64907 | | A | Nerve pedicle transfer | 18.80 | NA | 12.50 | 2.16 | NA | 33.46 | 090 |
| 65091 | | A | Revise eye | 6.45 | NA | 8.37 | 0.34 | NA | 15.16 | 090 |
| 65093 | | A | Revise eye with implant | 6.86 | NA | 8.73 | 0.36 | NA | 15.95 | 090 |
| 65101 | | A | Removal of eye | 7.02 | NA | 9.55 | 0.37 | NA | 16.94 | 090 |
| 65103 | | A | Remove eye/insert implant | 7.56 | NA | 9.75 | 0.39 | NA | 17.70 | 090 |
| 65105 | | A | Remove eye/attach implant | 8.48 | NA | 10.48 | 0.44 | NA | 19.40 | 090 |
| 65110 | | A | Removal of eye | 13.93 | NA | 13.66 | 0.86 | NA | 28.45 | 090 |
| 65112 | | A | Remove eye/revise socket | 16.36 | NA | 16.08 | 0.98 | NA | 33.42 | 090 |
| 65114 | | A | Remove eye/revise socket | 17.50 | NA | 16.31 | 1.07 | NA | 34.88 | 090 |
| 65125 | | A | Revise ocular implant | 3.12 | 8.84 | 3.59 | 0.18 | 12.14 | 6.89 | 090 |
| 65130 | | A | Insert ocular implant | 7.14 | NA | 9.18 | 0.38 | NA | 16.70 | 090 |
| 65135 | | A | Insert ocular implant | 7.32 | NA | 9.32 | 0.38 | NA | 17.02 | 090 |
| 65140 | | A | Attach ocular implant | 8.01 | NA | 9.88 | 0.43 | NA | 18.32 | 090 |
| 65150 | | A | Revise ocular implant | 6.25 | NA | 7.99 | 0.35 | NA | 14.59 | 090 |
| 65155 | | A | Reinsert ocular implant | 8.65 | NA | 10.48 | 0.50 | NA | 19.63 | 090 |
| 65175 | | A | Removal of ocular implant | 6.27 | NA | 8.49 | 0.34 | NA | 15.10 | 090 |
| 65205 | | A | Remove foreign body from eye | 0.71 | 0.64 | 0.30 | 0.04 | 1.39 | 1.05 | 000 |
| 65210 | | A | Remove foreign body from eye | 0.84 | 0.81 | 0.38 | 0.04 | 1.69 | 1.26 | 000 |
| 65220 | | A | Remove foreign body from eye | 0.71 | 0.65 | 0.29 | 0.05 | 1.41 | 1.05 | 000 |
| 65222 | | A | Remove foreign body from eye | 0.93 | 0.89 | 0.38 | 0.05 | 1.87 | 1.36 | 000 |
| 65235 | | A | Remove foreign body from eye | 7.56 | NA | 6.74 | 0.38 | NA | 14.68 | 090 |
| 65260 | | A | Remove foreign body from eye | 10.94 | NA | 9.65 | 0.56 | NA | 21.15 | 090 |
| 65265 | | A | Remove foreign body from eye | 12.57 | NA | 10.63 | 0.66 | NA | 23.86 | 090 |
| 65270 | | A | Repair of eye wound | 1.90 | 5.24 | 1.39 | 0.10 | 7.24 | 3.39 | 010 |
| 65272 | | A | Repair of eye wound | 3.81 | 7.73 | 3.29 | 0.20 | 11.74 | 7.30 | 090 |
| 65273 | | A | Repair of eye wound | 4.35 | NA | 3.57 | 0.25 | NA | 8.17 | 090 |
| 65275 | | A | Repair of eye wound | 5.33 | 6.33 | 3.95 | 0.30 | 11.96 | 9.58 | 090 |
| 65280 | | A | Repair of eye wound | 7.65 | NA | 6.23 | 0.39 | NA | 14.27 | 090 |
| 65285 | | A | Repair of eye wound | 12.88 | NA | 9.20 | 0.65 | NA | 22.73 | 090 |
| 65286 | | A | Repair of eye wound | 5.50 | 11.17 | 4.62 | 0.28 | 16.95 | 10.40 | 090 |
| 65290 | | A | Repair of eye socket wound | 5.40 | NA | 4.73 | 0.36 | NA | 10.49 | 090 |
| 65400 | | A | Removal of eye lesion | 6.05 | 8.33 | 6.12 | 0.30 | 14.68 | 12.47 | 090 |
| 65410 | | A | Biopsy of cornea | 1.47 | 2.11 | 0.97 | 0.07 | 3.65 | 2.51 | 000 |
| 65420 | | A | Removal of eye lesion | 4.16 | 8.86 | 4.44 | 0.21 | 13.23 | 8.81 | 090 |
| 65426 | | A | Removal of eye lesion | 5.24 | 10.19 | 4.92 | 0.26 | 15.69 | 10.42 | 090 |
| 65430 | | A | Corneal smear | 1.47 | 1.29 | 0.98 | 0.07 | 2.83 | 2.52 | 000 |
| 65435 | | A | Curette/treat cornea | 0.92 | 1.00 | 0.71 | 0.05 | 1.97 | 1.68 | 000 |
| 65436 | | A | Curette/treat cornea | 4.18 | 4.10 | 3.67 | 0.21 | 8.49 | 8.06 | 090 |
| 65450 | | A | Treatment of corneal lesion | 3.27 | 4.03 | 3.86 | 0.17 | 7.47 | 7.30 | 090 |
| 65600 | | A | Revision of cornea | 3.39 | 5.49 | 3.03 | 0.17 | 9.05 | 6.59 | 090 |
| 65710 | | A | Corneal transplant | 12.33 | NA | 11.43 | 0.62 | NA | 24.38 | 090 |
| 65730 | | A | Corneal transplant | 14.23 | NA | 11.83 | 0.71 | NA | 26.77 | 090 |
| 65750 | | A | Corneal transplant | 14.98 | NA | 12.29 | 0.75 | NA | 28.02 | 090 |
| 65755 | | A | Corneal transplant | 14.87 | NA | 12.22 | 0.74 | NA | 27.83 | 090 |
| 65770 | | A | Revise cornea with implant | 17.53 | NA | 13.20 | 0.87 | NA | 31.60 | 090 |
| 65772 | | A | Correction of astigmatism | 4.28 | 5.53 | 4.13 | 0.21 | 10.02 | 8.62 | 090 |
| 65775 | | A | Correction of astigmatism | 5.78 | NA | 6.25 | 0.29 | NA | 12.32 | 090 |
| 65780 | | A | Ocular reconst, transplant | 10.23 | NA | 10.30 | 0.45 | NA | 20.98 | 090 |
| 65781 | | A | Ocular reconst, transplant | 17.64 | NA | 13.67 | 0.45 | NA | 31.76 | 090 |
| 65782 | | A | Ocular reconst, transplant | 14.98 | NA | 11.99 | 0.45 | NA | 27.42 | 090 |
| 65800 | | A | Drainage of eye | 1.91 | 1.79 | 1.18 | 0.10 | 3.80 | 3.19 | 000 |
| 65805 | | A | Drainage of eye | 1.91 | 2.17 | 1.18 | 0.10 | 4.18 | 3.19 | 000 |
| 65810 | | A | Drainage of eye | 4.86 | NA | 4.70 | 0.25 | NA | 9.81 | 090 |
| 65815 | | A | Drainage of eye | 5.04 | 10.02 | 4.81 | 0.26 | 15.32 | 10.11 | 090 |
| 65820 | | A | Relieve inner eye pressure | 8.12 | NA | 9.06 | 0.42 | NA | 17.60 | 090 |
| 65850 | | A | Incision of eye | 10.50 | NA | 8.44 | 0.52 | NA | 19.46 | 090 |
| 65855 | | A | Laser surgery of eye | 3.84 | 4.32 | 3.10 | 0.19 | 8.35 | 7.13 | 010 |
| 65860 | | A | Incise inner eye adhesions | 3.54 | 4.05 | 2.50 | 0.18 | 7.77 | 6.22 | 090 |
| 65865 | | A | Incise inner eye adhesions | 5.59 | NA | 5.63 | 0.28 | NA | 11.50 | 090 |
| 65870 | | A | Incise inner eye adhesions | 6.26 | NA | 6.41 | 0.31 | NA | 12.98 | 090 |
| 65875 | | A | Incise inner eye adhesions | 6.53 | NA | 6.80 | 0.33 | NA | 13.66 | 090 |
| 65880 | | A | Incise inner eye adhesions | 7.08 | NA | 7.04 | 0.35 | NA | 14.47 | 090 |
| 65900 | | A | Remove eye lesion | 10.91 | NA | 10.42 | 0.56 | NA | 21.89 | 090 |
| 65920 | | A | Remove implant of eye | 8.39 | NA | 8.17 | 0.42 | NA | 16.98 | 090 |
| 65930 | | A | Remove blood clot from eye | 7.43 | NA | 6.84 | 0.37 | NA | 14.64 | 090 |
| 66020 | | A | Injection treatment of eye | 1.59 | 3.13 | 1.43 | 0.08 | 4.80 | 3.10 | 010 |
| 66030 | | A | Injection treatment of eye | 1.25 | 2.97 | 1.28 | 0.06 | 4.28 | 2.59 | 010 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 66130 | | A | Remove eye lesion | 7.68 | 9.64 | 5.60 | 0.39 | 17.71 | 13.67 | 090 |
| 66150 | | A | Glaucoma surgery | 8.29 | NA | 9.41 | 0.44 | NA | 18.14 | 090 |
| 66155 | | A | Glaucoma surgery | 8.28 | NA | 9.37 | 0.43 | NA | 18.08 | 090 |
| 66160 | | A | Glaucoma surgery | 10.15 | NA | 10.20 | 0.52 | NA | 20.87 | 090 |
| 66165 | | A | Glaucoma surgery | 8.00 | NA | 9.24 | 0.42 | NA | 17.66 | 090 |
| 66170 | | A | Glaucoma surgery | 12.14 | NA | 12.23 | 0.61 | NA | 24.98 | 090 |
| 66172 | | A | Incision of eye | 15.02 | NA | 15.21 | 0.75 | NA | 30.98 | 090 |
| 66180 | | A | Implant eye shunt | 14.53 | NA | 10.76 | 0.73 | NA | 26.02 | 090 |
| 66185 | | A | Revise eye shunt | 8.13 | NA | 7.38 | 0.41 | NA | 15.92 | 090 |
| 66220 | | A | Repair eye lesion | 7.76 | NA | 7.11 | 0.41 | NA | 15.28 | 090 |
| 66225 | | A | Repair/graft eye lesion | 11.03 | NA | 8.73 | 0.55 | NA | 20.31 | 090 |
| 66250 | | A | Follow-up surgery of eye | 5.97 | 11.71 | 5.48 | 0.30 | 17.98 | 11.75 | 090 |
| 66500 | | A | Incision of iris | 3.70 | NA | 4.65 | 0.19 | NA | 8.54 | 090 |
| 66505 | | A | Incision of iris | 4.07 | NA | 4.99 | 0.20 | NA | 9.26 | 090 |
| 66600 | | A | Remove iris and lesion | 8.67 | NA | 8.23 | 0.44 | NA | 17.34 | 090 |
| 66605 | | A | Removal of iris | 12.77 | NA | 10.02 | 0.79 | NA | 23.58 | 090 |
| 66625 | | A | Removal of iris | 5.12 | NA | 4.73 | 0.27 | NA | 10.12 | 090 |
| 66630 | | A | Removal of iris | 6.15 | NA | 5.70 | 0.31 | NA | 12.16 | 090 |
| 66635 | | A | Removal of iris | 6.24 | NA | 5.74 | 0.32 | NA | 12.30 | 090 |
| 66680 | | A | Repair iris & ciliary body | 5.43 | NA | 5.27 | 0.27 | NA | 10.97 | 090 |
| 66682 | | A | Repair iris & ciliary body | 6.20 | NA | 6.61 | 0.31 | NA | 13.12 | 090 |
| 66700 | | A | Destruction, ciliary body | 4.77 | 5.25 | 3.93 | 0.25 | 10.27 | 8.95 | 090 |
| 66710 | | A | Destruction, ciliary body | 4.77 | 5.17 | 3.84 | 0.24 | 10.18 | 8.85 | 090 |
| 66720 | | A | Destruction, ciliary body | 4.77 | 5.82 | 4.71 | 0.26 | 10.85 | 9.74 | 090 |
| 66740 | | A | Destruction, ciliary body | 4.77 | 5.09 | 3.97 | 0.24 | 10.10 | 8.98 | 090 |
| 66761 | | A | Revision of iris | 4.06 | 5.59 | 4.31 | 0.21 | 9.86 | 8.58 | 090 |
| 66762 | | A | Revision of iris | 4.57 | 5.66 | 4.28 | 0.23 | 10.46 | 9.08 | 090 |
| 66770 | | A | Removal of inner eye lesion | 5.17 | 6.09 | 4.80 | 0.26 | 11.52 | 10.23 | 090 |
| 66820 | | A | Incision, secondary cataract | 3.88 | NA | 5.83 | 0.19 | NA | 9.90 | 090 |
| 66821 | | A | After cataract laser surgery | 2.35 | 3.81 | 3.63 | 0.11 | 6.27 | 6.09 | 090 |
| 66825 | | A | Reposition intraocular lens | 8.22 | NA | 9.07 | 0.40 | NA | 17.69 | 090 |
| 66830 | | A | Removal of lens lesion | 8.19 | NA | 6.95 | 0.40 | NA | 15.54 | 090 |
| 66840 | | A | Removal of lens material | 7.90 | NA | 6.86 | 0.39 | NA | 15.15 | 090 |
| 66850 | | A | Removal of lens material | 9.10 | NA | 7.64 | 0.45 | NA | 17.19 | 090 |
| 66852 | | A | Removal of lens material | 9.96 | NA | 8.10 | 0.50 | NA | 18.56 | 090 |
| 66920 | | A | Extraction of lens | 8.85 | NA | 7.30 | 0.44 | NA | 16.59 | 090 |
| 66930 | | A | Extraction of lens | 10.16 | NA | 8.14 | 0.51 | NA | 18.81 | 090 |
| 66940 | | A | Extraction of lens | 8.92 | NA | 7.67 | 0.44 | NA | 17.03 | 090 |
| 66982 | | A | Cataract surgery, complex | 13.48 | NA | 9.86 | 0.63 | NA | 23.97 | 090 |
| 66983 | | A | Cataract surg w/iol, 1 stage | 8.98 | NA | 6.11 | 0.21 | NA | 15.30 | 090 |
| 66984 | | A | Cataract surg w/iol, 1 stage | 10.21 | NA | 7.41 | 0.42 | NA | 18.04 | 090 |
| 66985 | | A | Insert lens prosthesis | 8.38 | NA | 7.45 | 0.39 | NA | 16.22 | 090 |
| 66986 | | A | Exchange lens prosthesis | 12.26 | NA | 9.17 | 0.60 | NA | 22.03 | 090 |
| 66990 | | A | Ophthalmic endoscope add-on | 1.51 | NA | 0.69 | 0.07 | NA | 2.27 | ZZZ |
| 67005 | | A | Partial removal of eye fluid | 5.69 | NA | 4.37 | 0.29 | NA | 10.35 | 090 |
| 67010 | | A | Partial removal of eye fluid | 6.86 | NA | 4.91 | 0.34 | NA | 12.11 | 090 |
| 67015 | | A | Release of eye fluid | 6.91 | NA | 6.46 | 0.35 | NA | 13.72 | 090 |
| 67025 | | A | Replace eye fluid | 6.83 | 9.24 | 6.22 | 0.34 | 16.41 | 13.39 | 090 |
| 67027 | | A | Implant eye drug system | 10.83 | NA | 8.00 | 0.55 | NA | 19.38 | 090 |
| 67028 | | A | Injection eye drug | 2.52 | 2.70 | 1.45 | 0.13 | 5.35 | 4.10 | 000 |
| 67030 | | A | Incise inner eye strands | 4.83 | NA | 5.85 | 0.25 | NA | 10.93 | 090 |
| 67031 | | A | Laser surgery, eye strands | 3.66 | 4.61 | 3.64 | 0.18 | 8.45 | 7.48 | 090 |
| 67036 | | A | Removal of inner eye fluid | 11.87 | NA | 9.12 | 0.60 | NA | 21.59 | 090 |
| 67038 | | A | Strip retinal membrane | 21.21 | NA | 15.49 | 1.07 | NA | 37.77 | 090 |
| 67039 | | A | Laser treatment of retina | 14.50 | NA | 12.18 | 0.73 | NA | 27.41 | 090 |
| 67040 | | A | Laser treatment of retina | 17.20 | NA | 13.68 | 0.87 | NA | 31.75 | 090 |
| 67101 | | A | Repair detached retina | 7.52 | 9.13 | 6.53 | 0.38 | 17.03 | 14.43 | 090 |
| 67105 | | A | Repair detached retina | 7.40 | 8.09 | 6.15 | 0.37 | 15.86 | 13.92 | 090 |
| 67107 | | A | Repair detached retina | 14.82 | NA | 11.30 | 0.74 | NA | 26.86 | 090 |
| 67108 | | A | Repair detached retina | 20.79 | NA | 14.41 | 1.05 | NA | 36.25 | 090 |
| 67110 | | A | Repair detached retina | 8.80 | 10.24 | 7.39 | 0.44 | 19.48 | 16.63 | 090 |
| 67112 | | A | Rerepair detached retina | 16.83 | NA | 11.81 | 0.85 | NA | 29.49 | 090 |
| 67115 | | A | Release encircling material | 4.98 | NA | 5.08 | 0.25 | NA | 10.31 | 090 |
| 67120 | | A | Remove eye implant material | 5.97 | 8.59 | 5.52 | 0.30 | 14.86 | 11.79 | 090 |
| 67121 | | A | Remove eye implant material | 10.65 | NA | 8.53 | 0.53 | NA | 19.71 | 090 |
| 67141 | | A | Treatment of retina | 5.19 | 5.85 | 4.86 | 0.26 | 11.30 | 10.31 | 090 |
| 67145 | | A | Treatment of retina | 5.36 | 5.72 | 4.93 | 0.27 | 11.35 | 10.56 | 090 |
| 67208 | | A | Treatment of retinal lesion | 6.69 | 6.12 | 5.51 | 0.34 | 13.15 | 12.54 | 090 |
| 67210 | | A | Treatment of retinal lesion | 8.81 | 6.58 | 5.87 | 0.44 | 15.83 | 15.12 | 090 |
| 67218 | | A | Treatment of retinal lesion | 18.50 | NA | 12.15 | 0.93 | NA | 31.58 | 090 |
| 67220 | | A | Treatment of choroid lesion | 13.11 | 10.43 | 9.01 | 0.66 | 24.20 | 22.78 | 090 |
| 67221 | | R | Ocular photodynamic ther | 4.00 | 4.34 | 1.80 | 0.20 | 8.54 | 6.00 | 000 |
| 67225 | | A | Eye photodynamic ther add-on | 0.47 | 0.25 | 0.21 | 0.02 | 0.74 | 0.70 | ZZZ |
| 67227 | | A | Treatment of retinal lesion | 6.57 | 6.58 | 5.52 | 0.33 | 13.48 | 12.42 | 090 |
| 67228 | | A | Treatment of retinal lesion | 12.72 | 11.49 | 8.54 | 0.64 | 24.85 | 21.90 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 67250 | | A | Reinforce eye wall | 8.65 | NA | 9.18 | 0.43 | NA | 18.26 | 090 |
| 67255 | | A | Reinforce/graft eye wall | 8.89 | NA | 9.91 | 0.45 | NA | 19.25 | 090 |
| 67311 | | A | Revise eye muscle | 6.64 | NA | 6.02 | 0.37 | NA | 13.03 | 090 |
| 67312 | | A | Revise two eye muscles | 8.53 | NA | 6.75 | 0.44 | NA | 15.72 | 090 |
| 67314 | | A | Revise eye muscle | 7.51 | NA | 6.55 | 0.40 | NA | 14.46 | 090 |
| 67316 | | A | Revise two eye muscles | 9.65 | NA | 7.50 | 0.51 | NA | 17.66 | 090 |
| 67318 | | A | Revise eye muscle(s) | 7.84 | NA | 6.93 | 0.41 | NA | 15.18 | 090 |
| 67320 | | A | Revise eye muscle(s) add-on | 4.32 | NA | 1.95 | 0.23 | NA | 6.50 | ZZZ |
| 67331 | | A | Eye surgery follow-up add-on | 4.05 | NA | 1.82 | 0.21 | NA | 6.08 | ZZZ |
| 67332 | | A | Rerevise eye muscles add-on | 4.48 | NA | 2.02 | 0.24 | NA | 6.74 | ZZZ |
| 67334 | | A | Revise eye muscle w/suture | 3.97 | NA | 1.79 | 0.20 | NA | 5.96 | ZZZ |
| 67335 | | A | Eye suture during surgery | 2.49 | NA | 1.12 | 0.13 | NA | 3.74 | ZZZ |
| 67340 | | A | Revise eye muscle add-on | 4.92 | NA | 2.20 | 0.26 | NA | 7.38 | ZZZ |
| 67343 | | A | Release eye tissue | 7.34 | NA | 6.50 | 0.42 | NA | 14.26 | 090 |
| 67345 | | A | Destroy nerve of eye muscle | 2.96 | 2.58 | 2.01 | 0.18 | 5.72 | 5.15 | 010 |
| 67350 | | A | Biopsy eye muscle | 2.87 | NA | 1.86 | 0.15 | NA | 4.88 | 000 |
| 67400 | | A | Explore/biopsy eye socket | 9.75 | NA | 11.27 | 0.58 | NA | 21.60 | 090 |
| 67405 | | A | Explore/drain eye socket | 7.92 | NA | 9.78 | 0.49 | NA | 18.19 | 090 |
| 67412 | | A | Explore/treat eye socket | 9.49 | NA | 10.95 | 0.53 | NA | 20.97 | 090 |
| 67413 | | A | Explore/treat eye socket | 9.99 | NA | 10.78 | 0.56 | NA | 21.33 | 090 |
| 67414 | | A | Explr/decompress eye socket | 11.11 | NA | 12.06 | 0.66 | NA | 23.83 | 090 |
| 67415 | | A | Aspiration, orbital contents | 1.76 | NA | 0.76 | 0.09 | NA | 2.61 | 000 |
| 67420 | | A | Explore/treat eye socket | 20.03 | NA | 17.39 | 1.21 | NA | 38.63 | 090 |
| 67430 | | A | Explore/treat eye socket | 13.37 | NA | 15.08 | 0.84 | NA | 29.29 | 090 |
| 67440 | | A | Explore/drain eye socket | 13.07 | NA | 14.27 | 0.76 | NA | 28.10 | 090 |
| 67445 | | A | Explr/decompress eye socket | 14.40 | NA | 13.93 | 0.92 | NA | 29.25 | 090 |
| 67450 | | A | Explore/biopsy eye socket | 13.49 | NA | 14.71 | 0.75 | NA | 28.95 | 090 |
| 67500 | | A | Inject/treat eye socket | 0.79 | 0.67 | 0.29 | 0.05 | 1.51 | 1.13 | 000 |
| 67505 | | A | Inject/treat eye socket | 0.82 | 0.69 | 0.31 | 0.05 | 1.56 | 1.18 | 000 |
| 67515 | | A | Inject/treat eye socket | 0.61 | 0.59 | 0.38 | 0.03 | 1.23 | 1.02 | 000 |
| 67550 | | A | Insert eye socket implant | 10.17 | NA | 11.29 | 0.66 | NA | 22.12 | 090 |
| 67560 | | A | Revise eye socket implant | 10.58 | NA | 11.37 | 0.70 | NA | 22.65 | 090 |
| 67570 | | A | Decompress optic nerve | 13.56 | NA | 13.60 | 0.82 | NA | 27.98 | 090 |
| 67700 | | A | Drainage of eyelid abscess | 1.35 | 6.05 | 1.27 | 0.07 | 7.47 | 2.69 | 010 |
| 67710 | | A | Incision of eyelid | 1.02 | 5.40 | 1.20 | 0.05 | 6.47 | 2.27 | 010 |
| 67715 | | A | Incision of eyelid fold | 1.22 | 5.39 | 1.29 | 0.06 | 6.67 | 2.57 | 010 |
| 67800 | | A | Remove eyelid lesion | 1.38 | 1.62 | 1.03 | 0.07 | 3.07 | 2.48 | 010 |
| 67801 | | A | Remove eyelid lesions | 1.88 | 1.96 | 1.26 | 0.10 | 3.94 | 3.24 | 010 |
| 67805 | | A | Remove eyelid lesions | 2.22 | 2.52 | 1.64 | 0.12 | 4.86 | 3.98 | 010 |
| 67808 | | A | Remove eyelid lesion(s) | 3.79 | NA | 3.77 | 0.21 | NA | 7.77 | 090 |
| 67810 | | A | Biopsy of eyelid | 1.48 | 3.34 | 0.67 | 0.11 | 4.93 | 2.26 | 000 |
| 67820 | | A | Revise eyelashes | 0.89 | 0.60 | 0.56 | 0.04 | 1.53 | 1.49 | 000 |
| 67825 | | A | Revise eyelashes | 1.38 | 1.73 | 1.41 | 0.07 | 3.18 | 2.86 | 010 |
| 67830 | | A | Revise eyelashes | 1.70 | 5.55 | 1.50 | 0.09 | 7.34 | 3.29 | 010 |
| 67835 | | A | Revise eyelashes | 5.55 | NA | 4.61 | 0.29 | NA | 10.45 | 090 |
| 67840 | | A | Remove eyelid lesion | 2.04 | 5.49 | 1.65 | 0.11 | 7.64 | 3.80 | 010 |
| 67850 | | A | Treat eyelid lesion | 1.69 | 3.37 | 1.46 | 0.11 | 5.17 | 3.26 | 010 |
| 67875 | | A | Closure of eyelid by suture | 1.35 | 3.31 | 0.94 | 0.08 | 4.74 | 2.37 | 000 |
| 67880 | | A | Revision of eyelid | 3.79 | 6.63 | 3.79 | 0.20 | 10.62 | 7.78 | 090 |
| 67882 | | A | Revision of eyelid | 5.06 | 7.65 | 4.80 | 0.27 | 12.98 | 10.13 | 090 |
| 67900 | | A | Repair brow defect | 6.13 | 9.05 | 5.23 | 0.39 | 15.57 | 11.75 | 090 |
| 67901 | | A | Repair eyelid defect | 6.96 | NA | 5.38 | 0.53 | NA | 12.87 | 090 |
| 67902 | | A | Repair eyelid defect | 7.02 | NA | 5.44 | 0.46 | NA | 12.92 | 090 |
| 67903 | | A | Repair eyelid defect | 6.36 | 9.58 | 5.47 | 0.44 | 16.38 | 12.27 | 090 |
| 67904 | | A | Repair eyelid defect | 6.25 | 9.69 | 5.22 | 0.41 | 16.35 | 11.88 | 090 |
| 67906 | | A | Repair eyelid defect | 6.78 | 5.39 | 5.02 | 0.44 | 12.61 | 12.24 | 090 |
| 67908 | | A | Repair eyelid defect | 5.12 | 7.04 | 5.24 | 0.30 | 12.46 | 10.66 | 090 |
| 67909 | | A | Revise eyelid defect | 5.39 | 8.03 | 4.93 | 0.32 | 13.74 | 10.64 | 090 |
| 67911 | | A | Revise eyelid defect | 5.26 | NA | 4.77 | 0.31 | NA | 10.34 | 090 |
| 67912 | | A | Correction eyelid w/ implant | 5.67 | 18.69 | 5.46 | 0.28 | 24.64 | 11.41 | 090 |
| 67914 | | A | Repair eyelid defect | 3.67 | 6.35 | 3.04 | 0.21 | 10.23 | 6.92 | 090 |
| 67915 | | A | Repair eyelid defect | 3.18 | 6.00 | 2.80 | 0.17 | 9.35 | 6.15 | 090 |
| 67916 | | A | Repair eyelid defect | 5.30 | 8.06 | 4.76 | 0.30 | 13.66 | 10.36 | 090 |
| 67917 | | A | Repair eyelid defect | 6.01 | 8.47 | 5.07 | 0.37 | 14.85 | 11.45 | 090 |
| 67921 | | A | Repair eyelid defect | 3.39 | 6.21 | 2.89 | 0.18 | 9.78 | 6.46 | 090 |
| 67922 | | A | Repair eyelid defect | 3.06 | 5.93 | 2.75 | 0.16 | 9.15 | 5.97 | 090 |
| 67923 | | A | Repair eyelid defect | 5.87 | 8.14 | 4.97 | 0.32 | 14.33 | 11.16 | 090 |
| 67924 | | A | Repair eyelid defect | 5.78 | 8.94 | 4.68 | 0.32 | 15.04 | 10.78 | 090 |
| 67930 | | A | Repair eyelid wound | 3.60 | 5.74 | 2.17 | 0.20 | 9.54 | 5.97 | 010 |
| 67935 | | A | Repair eyelid wound | 6.21 | 8.53 | 4.40 | 0.39 | 15.13 | 11.00 | 090 |
| 67938 | | A | Remove eyelid foreign body | 1.33 | 5.40 | 1.27 | 0.07 | 6.80 | 2.67 | 010 |
| 67950 | | A | Revision of eyelid | 5.81 | 8.63 | 5.19 | 0.36 | 14.80 | 11.36 | 090 |
| 67961 | | A | Revision of eyelid | 5.68 | 8.68 | 5.01 | 0.33 | 14.69 | 11.02 | 090 |
| 67966 | | A | Revision of eyelid | 6.56 | 9.13 | 5.53 | 0.39 | 16.08 | 12.48 | 090 |
| 67971 | | A | Reconstruction of eyelid | 9.78 | NA | 7.27 | 0.54 | NA | 17.59 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 67973 | | A | Reconstruction of eyelid | 12.85 | NA | 9.29 | 0.73 | NA | 22.87 | 090 |
| 67974 | | A | Reconstruction of eyelid | 12.82 | NA | 9.21 | 0.70 | NA | 22.73 | 090 |
| 67975 | | A | Reconstruction of eyelid | 9.12 | NA | 6.94 | 0.49 | NA | 16.55 | 090 |
| 68020 | | A | Incise/drain eyelid lining | 1.37 | 1.41 | 1.21 | 0.07 | 2.85 | 2.65 | 010 |
| 68040 | | A | Treatment of eyelid lesions | 0.85 | 0.71 | 0.43 | 0.04 | 1.60 | 1.32 | 000 |
| 68100 | | A | Biopsy of eyelid lining | 1.35 | 3.25 | 0.95 | 0.07 | 4.67 | 2.37 | 000 |
| 68110 | | A | Remove eyelid lining lesion | 1.77 | 4.10 | 1.64 | 0.09 | 5.96 | 3.50 | 010 |
| 68115 | | A | Remove eyelid lining lesion | 2.36 | 5.97 | 1.91 | 0.12 | 8.45 | 4.39 | 010 |
| 68130 | | A | Remove eyelid lining lesion | 4.92 | 8.72 | 4.59 | 0.25 | 13.89 | 9.76 | 090 |
| 68135 | | A | Remove eyelid lining lesion | 1.84 | 1.81 | 1.65 | 0.09 | 3.74 | 3.58 | 010 |
| 68200 | | A | Treat eyelid by injection | 0.49 | 0.54 | 0.33 | 0.02 | 1.05 | 0.84 | 000 |
| 68320 | | A | Revise/graft eyelid lining | 5.36 | 11.29 | 5.52 | 0.29 | 16.94 | 11.17 | 090 |
| 68325 | | A | Revise/graft eyelid lining | 7.35 | NA | 6.53 | 0.41 | NA | 14.29 | 090 |
| 68326 | | A | Revise/graft eyelid lining | 7.14 | NA | 6.40 | 0.38 | NA | 13.92 | 090 |
| 68328 | | A | Revise/graft eyelid lining | 8.17 | NA | 7.26 | 0.55 | NA | 15.98 | 090 |
| 68330 | | A | Revise eyelid lining | 4.82 | 9.41 | 4.71 | 0.25 | 14.48 | 9.78 | 090 |
| 68335 | | A | Revise/graft eyelid lining | 7.18 | NA | 6.37 | 0.36 | NA | 13.91 | 090 |
| 68340 | | A | Separate eyelid adhesions | 4.16 | 8.89 | 4.10 | 0.21 | 13.26 | 8.47 | 090 |
| 68360 | | A | Revise eyelid lining | 4.36 | 8.05 | 4.18 | 0.22 | 12.63 | 8.76 | 090 |
| 68362 | | A | Revise eyelid lining | 7.33 | NA | 6.40 | 0.37 | NA | 14.10 | 090 |
| 68371 | | A | Harvest eye tissue, alograft | 4.89 | NA | 4.73 | 0.45 | NA | 10.07 | 010 |
| 68400 | | A | Incise/drain tear gland | 1.69 | 5.92 | 1.83 | 0.09 | 7.70 | 3.61 | 010 |
| 68420 | | A | Incise/drain tear sac | 2.30 | 6.22 | 2.11 | 0.12 | 8.64 | 4.53 | 010 |
| 68440 | | A | Incise tear duct opening | 0.94 | 2.09 | 1.27 | 0.05 | 3.08 | 2.26 | 010 |
| 68500 | | A | Removal of tear gland | 11.00 | NA | 9.73 | 0.63 | NA | 21.36 | 090 |
| 68505 | | A | Partial removal, tear gland | 10.92 | NA | 10.59 | 0.61 | NA | 22.12 | 090 |
| 68510 | | A | Biopsy of tear gland | 4.60 | 7.35 | 2.09 | 0.24 | 12.19 | 6.93 | 000 |
| 68520 | | A | Removal of tear sac | 7.50 | NA | 7.41 | 0.39 | NA | 15.30 | 090 |
| 68525 | | A | Biopsy of tear sac | 4.42 | NA | 2.01 | 0.24 | NA | 6.67 | 000 |
| 68530 | | A | Clearance of tear duct | 3.65 | 8.19 | 2.64 | 0.20 | 12.04 | 6.49 | 010 |
| 68540 | | A | Remove tear gland lesion | 10.58 | NA | 9.38 | 0.53 | NA | 20.49 | 090 |
| 68550 | | A | Remove tear gland lesion | 13.24 | NA | 11.33 | 0.66 | NA | 25.23 | 090 |
| 68700 | | A | Repair tear ducts | 6.59 | NA | 5.97 | 0.35 | NA | 12.91 | 090 |
| 68705 | | A | Revise tear duct opening | 2.06 | 4.19 | 1.78 | 0.10 | 6.35 | 3.94 | 010 |
| 68720 | | A | Create tear sac drain | 8.95 | NA | 7.86 | 0.50 | NA | 17.31 | 090 |
| 68745 | | A | Create tear duct drain | 8.62 | NA | 7.86 | 0.43 | NA | 16.91 | 090 |
| 68750 | | A | Create tear duct drain | 8.65 | NA | 8.27 | 0.46 | NA | 17.38 | 090 |
| 68760 | | A | Close tear duct opening | 1.73 | 3.55 | 1.63 | 0.09 | 5.37 | 3.45 | 010 |
| 68761 | | A | Close tear duct opening | 1.36 | 2.27 | 1.32 | 0.07 | 3.70 | 2.75 | 010 |
| 68770 | | A | Close tear system fistula | 7.01 | 3.17 | 3.17 | 0.36 | 10.54 | 10.54 | 090 |
| 68801 | | A | Dilate tear duct opening | 0.94 | 1.95 | 1.48 | 0.05 | 2.94 | 2.47 | 010 |
| 68810 | | A | Probe nasolacrimal duct | 1.90 | 3.66 | 2.67 | 0.11 | 5.67 | 4.68 | 010 |
| 68811 | | A | Probe nasolacrimal duct | 2.35 | NA | 2.40 | 0.14 | NA | 4.89 | 010 |
| 68815 | | A | Probe nasolacrimal duct | 3.20 | 8.27 | 2.81 | 0.18 | 11.65 | 6.19 | 010 |
| 68840 | | A | Explore/irrigate tear ducts | 1.25 | 1.61 | 1.12 | 0.06 | 2.92 | 2.43 | 010 |
| 68850 | | A | Injection for tear sac x-ray | 0.80 | 0.88 | 0.67 | 0.04 | 1.72 | 1.51 | 000 |
| 69000 | | A | Drain external ear lesion | 1.45 | 2.89 | 1.38 | 0.12 | 4.46 | 2.95 | 010 |
| 69005 | | A | Drain external ear lesion | 2.11 | 2.93 | 1.83 | 0.18 | 5.22 | 4.12 | 010 |
| 69020 | | A | Drain outer ear canal lesion | 1.48 | 3.97 | 2.07 | 0.12 | 5.57 | 3.67 | 010 |
| 69100 | | A | Biopsy of external ear | 0.81 | 1.71 | 0.39 | 0.07 | 2.59 | 1.27 | 000 |
| 69105 | | A | Biopsy of external ear canal | 0.85 | 2.32 | 0.77 | 0.07 | 3.24 | 1.69 | 000 |
| 69110 | | A | Remove external ear, partial | 3.43 | 6.73 | 4.46 | 0.34 | 10.50 | 8.23 | 090 |
| 69120 | | A | Removal of external ear | 4.04 | NA | 6.16 | 0.39 | NA | 10.59 | 090 |
| 69140 | | A | Remove ear canal lesion(s) | 7.96 | NA | 13.21 | 0.67 | NA | 21.84 | 090 |
| 69145 | | A | Remove ear canal lesion(s) | 2.62 | 5.73 | 3.28 | 0.22 | 8.57 | 6.12 | 090 |
| 69150 | | A | Extensive ear canal surgery | 13.41 | NA | 13.32 | 1.27 | NA | 28.00 | 090 |
| 69155 | | A | Extensive ear/neck surgery | 20.77 | NA | 19.43 | 1.84 | NA | 42.04 | 090 |
| 69200 | | A | Clear outer ear canal | 0.77 | 2.38 | 0.56 | 0.06 | 3.21 | 1.39 | 000 |
| 69205 | | A | Clear outer ear canal | 1.20 | NA | 1.35 | 0.10 | NA | 2.65 | 010 |
| 69210 | | A | Remove impacted ear wax | 0.61 | 0.63 | 0.23 | 0.05 | 1.29 | 0.89 | 000 |
| 69220 | | A | Clean out mastoid cavity | 0.83 | 2.35 | 0.74 | 0.07 | 3.25 | 1.64 | 000 |
| 69222 | | A | Clean out mastoid cavity | 1.40 | 3.82 | 2.05 | 0.12 | 5.34 | 3.57 | 010 |
| 69300 | | R | Revise external ear | 6.35 | NA | 4.21 | 0.75 | NA | 11.31 | YYY |
| 69310 | | A | Rebuild outer ear canal | 10.77 | NA | 16.18 | 0.89 | NA | 27.84 | 090 |
| 69320 | | A | Rebuild outer ear canal | 16.93 | NA | 21.71 | 1.45 | NA | 40.09 | 090 |
| 69400 | | A | Inflate middle ear canal | 0.83 | 2.16 | 0.67 | 0.07 | 3.06 | 1.57 | 000 |
| 69401 | | A | Inflate middle ear canal | 0.63 | 1.24 | 0.65 | 0.05 | 1.92 | 1.33 | 000 |
| 69405 | | A | Catheterize middle ear canal | 2.63 | 3.46 | 2.29 | 0.21 | 6.30 | 5.13 | 010 |
| 69410 | | A | Inset middle ear (baffle) | 0.33 | 2.12 | 0.48 | 0.03 | 2.48 | 0.84 | 000 |
| 69420 | | A | Incision of eardrum | 1.33 | 3.12 | 1.58 | 0.11 | 4.56 | 3.02 | 010 |
| 69421 | | A | Incision of eardrum | 1.73 | NA | 2.15 | 0.16 | NA | 4.04 | 010 |
| 69424 | | A | Remove ventilating tube | 0.85 | 2.17 | 0.68 | 0.07 | 3.09 | 1.60 | 000 |
| 69433 | | A | Create eardrum opening | 1.52 | 3.09 | 1.64 | 0.13 | 4.74 | 3.29 | 010 |
| 69436 | | A | Create eardrum opening | 1.96 | NA | 2.27 | 0.19 | NA | 4.42 | 010 |
| 69440 | | A | Exploration of middle ear | 7.56 | NA | 8.71 | 0.62 | NA | 16.89 | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 69450 | | A | Eardrum revision | 5.56 | NA | 6.99 | 0.45 | NA | 13.00 | 090 |
| 69501 | | A | Mastoidectomy | 9.06 | NA | 8.96 | 0.76 | NA | 18.78 | 090 |
| 69502 | | A | Mastoidectomy | 12.36 | NA | 11.54 | 1.03 | NA | 24.93 | 090 |
| 69505 | | A | Remove mastoid structures | 12.97 | NA | 17.11 | 1.08 | NA | 31.16 | 090 |
| 69511 | | A | Extensive mastoid surgery | 13.50 | NA | 17.39 | 1.09 | NA | 31.98 | 090 |
| 69530 | | A | Extensive mastoid surgery | 19.16 | NA | 21.52 | 1.44 | NA | 42.12 | 090 |
| 69535 | | A | Remove part of temporal bone | 36.09 | NA | 31.85 | 2.98 | NA | 70.92 | 090 |
| 69540 | | A | Remove ear lesion | 1.20 | 3.71 | 1.95 | 0.10 | 5.01 | 3.25 | 010 |
| 69550 | | A | Remove ear lesion | 10.97 | NA | 14.79 | 0.90 | NA | 26.66 | 090 |
| 69552 | | A | Remove ear lesion | 19.43 | NA | 20.60 | 1.55 | NA | 41.58 | 090 |
| 69554 | | A | Remove ear lesion | 33.11 | NA | 30.18 | 2.94 | NA | 66.23 | 090 |
| 69601 | | A | Mastoid surgery revision | 13.22 | NA | 12.60 | 1.07 | NA | 26.89 | 090 |
| 69602 | | A | Mastoid surgery revision | 13.56 | NA | 13.16 | 1.05 | NA | 27.77 | 090 |
| 69603 | | A | Mastoid surgery revision | 14.00 | NA | 18.26 | 1.14 | NA | 33.40 | 090 |
| 69604 | | A | Mastoid surgery revision | 14.00 | NA | 13.63 | 0.92 | NA | 28.55 | 090 |
| 69605 | | A | Mastoid surgery revision | 18.46 | NA | 20.85 | 1.51 | NA | 40.82 | 090 |
| 69610 | | A | Repair of eardrum | 4.42 | 5.50 | 3.26 | 0.36 | 10.28 | 8.04 | 010 |
| 69620 | | A | Repair of eardrum | 5.88 | 11.03 | 6.25 | 0.48 | 17.39 | 12.61 | 090 |
| 69631 | | A | Repair eardrum structures | 9.85 | NA | 11.13 | 0.81 | NA | 21.79 | 090 |
| 69632 | | A | Rebuild eardrum structures | 12.73 | NA | 13.39 | 1.04 | NA | 27.16 | 090 |
| 69633 | | A | Rebuild eardrum structures | 12.08 | NA | 12.97 | 0.99 | NA | 26.04 | 090 |
| 69635 | | A | Repair eardrum structures | 13.31 | NA | 16.66 | 1.08 | NA | 31.05 | 090 |
| 69636 | | A | Rebuild eardrum structures | 15.20 | NA | 19.18 | 1.23 | NA | 35.61 | 090 |
| 69637 | | A | Rebuild eardrum structures | 15.09 | NA | 19.11 | 1.25 | NA | 35.45 | 090 |
| 69641 | | A | Revise middle ear & mastoid | 12.69 | NA | 12.70 | 1.04 | NA | 26.43 | 090 |
| 69642 | | A | Revise middle ear & mastoid | 16.81 | NA | 16.19 | 1.37 | NA | 34.37 | 090 |
| 69643 | | A | Revise middle ear & mastoid | 15.30 | NA | 14.73 | 1.26 | NA | 31.29 | 090 |
| 69644 | | A | Revise middle ear & mastoid | 16.94 | NA | 20.30 | 1.38 | NA | 38.62 | 090 |
| 69645 | | A | Revise middle ear & mastoid | 16.36 | NA | 19.92 | 1.35 | NA | 37.63 | 090 |
| 69646 | | A | Revise middle ear & mastoid | 17.96 | NA | 20.65 | 1.48 | NA | 40.09 | 090 |
| 69650 | | A | Release middle ear bone | 9.65 | NA | 9.85 | 0.78 | NA | 20.28 | 090 |
| 69660 | | A | Revise middle ear bone | 11.88 | NA | 11.13 | 0.95 | NA | 23.96 | 090 |
| 69661 | | A | Revise middle ear bone | 15.72 | NA | 14.62 | 1.29 | NA | 31.63 | 090 |
| 69662 | | A | Revise middle ear bone | 15.42 | NA | 13.68 | 1.26 | NA | 30.36 | 090 |
| 69666 | | A | Repair middle ear structures | 9.74 | NA | 9.91 | 0.79 | NA | 20.44 | 090 |
| 69667 | | A | Repair middle ear structures | 9.75 | NA | 9.92 | 0.79 | NA | 20.46 | 090 |
| 69670 | | A | Remove mastoid air cells | 11.49 | NA | 11.65 | 0.96 | NA | 24.10 | 090 |
| 69676 | | A | Remove middle ear nerve | 9.51 | NA | 10.67 | 0.84 | NA | 21.02 | 090 |
| 69700 | | A | Close mastoid fistula | 8.22 | NA | 9.20 | 0.66 | NA | 18.08 | 090 |
| 69711 | | A | Remove/repair hearing aid | 10.42 | NA | 10.74 | 0.85 | NA | 22.01 | 090 |
| 69714 | | A | Implant temple bone w/stimul | 13.98 | NA | 12.61 | 1.21 | NA | 27.80 | 090 |
| 69715 | | A | Temple bne implnt w/stimulat | 18.22 | NA | 14.96 | 1.49 | NA | 34.67 | 090 |
| 69717 | | A | Temple bone implant revision | 14.96 | NA | 14.46 | 1.35 | NA | 30.77 | 090 |
| 69718 | | A | Revise temple bone implant | 18.47 | NA | 15.26 | 1.62 | NA | 35.35 | 090 |
| 69720 | | A | Release facial nerve | 14.36 | NA | 14.43 | 1.24 | NA | 30.03 | 090 |
| 69725 | | A | Release facial nerve | 25.34 | NA | 20.02 | 2.29 | NA | 47.65 | 090 |
| 69740 | | A | Repair facial nerve | 15.94 | NA | 13.37 | 1.58 | NA | 30.89 | 090 |
| 69745 | | A | Repair facial nerve | 16.66 | NA | 14.91 | 1.36 | NA | 32.93 | 090 |
| 69801 | | A | Incise inner ear | 8.55 | NA | 9.41 | 0.70 | NA | 18.66 | 090 |
| 69802 | | A | Incise inner ear | 13.08 | NA | 12.25 | 1.07 | NA | 26.40 | 090 |
| 69805 | | A | Explore inner ear | 13.80 | NA | 11.82 | 1.16 | NA | 26.78 | 090 |
| 69806 | | A | Explore inner ear | 12.33 | NA | 10.99 | 1.04 | NA | 24.36 | 090 |
| 69820 | | A | Establish inner ear window | 10.32 | NA | 11.19 | 0.82 | NA | 22.33 | 090 |
| 69840 | | A | Revise inner ear window | 10.24 | NA | 13.15 | 0.74 | NA | 24.13 | 090 |
| 69905 | | A | Remove inner ear | 11.08 | NA | 11.29 | 0.90 | NA | 23.27 | 090 |
| 69910 | | A | Remove inner ear & mastoid | 13.61 | NA | 11.88 | 1.10 | NA | 26.59 | 090 |
| 69915 | | A | Incise inner ear nerve | 21.20 | NA | 16.39 | 1.70 | NA | 39.29 | 090 |
| 69930 | | A | Implant cochlear device | 16.78 | NA | 14.68 | 1.38 | NA | 32.84 | 090 |
| 69950 | | A | Incise inner ear nerve | 25.60 | NA | 18.82 | 3.07 | NA | 47.49 | 090 |
| 69955 | | A | Release facial nerve | 27.00 | NA | 21.29 | 2.77 | NA | 51.06 | 090 |
| 69960 | | A | Release inner ear canal | 27.00 | NA | 19.98 | 2.69 | NA | 49.67 | 090 |
| 69970 | | A | Remove inner ear lesion | 29.99 | NA | 23.17 | 2.73 | NA | 55.89 | 090 |
| 69990 | | R | Microsurgery add-on | 3.46 | NA | 1.78 | 0.81 | NA | 6.05 | ZZZ |
| 70010 | | A | Contrast x-ray of brain | 1.19 | 4.72 | NA | 0.28 | 6.19 | NA | XXX |
| 70010 | 26 | A | Contrast x-ray of brain | 1.19 | 0.39 | 0.39 | 0.06 | 1.64 | 1.64 | XXX |
| 70010 | TC | A | Contrast x-ray of brain | 0.00 | 4.32 | NA | 0.22 | 4.54 | NA | XXX |
| 70015 | | A | Contrast x-ray of brain | 1.19 | 1.74 | NA | 0.14 | 3.07 | NA | XXX |
| 70015 | 26 | A | Contrast x-ray of brain | 1.19 | 0.39 | 0.39 | 0.06 | 1.64 | 1.64 | XXX |
| 70015 | TC | A | Contrast x-ray of brain | 0.00 | 1.35 | NA | 0.08 | 1.43 | NA | XXX |
| 70030 | | A | X-ray eye for foreign body | 0.17 | 0.47 | NA | 0.03 | 0.67 | NA | XXX |
| 70030 | 26 | A | X-ray eye for foreign body | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 70030 | TC | A | X-ray eye for foreign body | 0.00 | 0.42 | NA | 0.02 | 0.44 | NA | XXX |
| 70100 | | A | X-ray exam of jaw | 0.18 | 0.58 | NA | 0.03 | 0.79 | NA | XXX |
| 70100 | 26 | A | X-ray exam of jaw | 0.18 | 0.06 | 0.06 | 0.01 | 0.25 | 0.25 | XXX |
| 70100 | TC | A | X-ray exam of jaw | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 70110 | | A | X-ray exam of jaw | 0.25 | 0.70 | NA | 0.05 | 1.00 | NA | XXX |
| 70110 | 26 | A | X-ray exam of jaw | 0.25 | 0.08 | 0.08 | 0.01 | 0.34 | 0.34 | XXX |
| 70110 | TC | A | X-ray exam of jaw | 0.00 | 0.62 | NA | 0.04 | 0.66 | NA | XXX |
| 70120 | | A | X-ray exam of mastoids | 0.18 | 0.68 | NA | 0.05 | 0.91 | NA | XXX |
| 70120 | 26 | A | X-ray exam of mastoids | 0.18 | 0.06 | 0.06 | 0.01 | 0.25 | 0.25 | XXX |
| 70120 | TC | A | X-ray exam of mastoids | 0.00 | 0.62 | NA | 0.04 | 0.66 | NA | XXX |
| 70130 | | A | X-ray exam of mastoids | 0.34 | 0.89 | NA | 0.07 | 1.30 | NA | XXX |
| 70130 | 26 | A | X-ray exam of mastoids | 0.34 | 0.11 | 0.11 | 0.02 | 0.47 | 0.47 | XXX |
| 70130 | TC | A | X-ray exam of mastoids | 0.00 | 0.78 | NA | 0.05 | 0.83 | NA | XXX |
| 70134 | | A | X-ray exam of middle ear | 0.34 | 0.85 | NA | 0.07 | 1.26 | NA | XXX |
| 70134 | 26 | A | X-ray exam of middle ear | 0.34 | 0.11 | 0.11 | 0.02 | 0.47 | 0.47 | XXX |
| 70134 | TC | A | X-ray exam of middle ear | 0.00 | 0.73 | NA | 0.05 | 0.78 | NA | XXX |
| 70140 | | A | X-ray exam of facial bones | 0.19 | 0.68 | NA | 0.05 | 0.92 | NA | XXX |
| 70140 | 26 | A | X-ray exam of facial bones | 0.19 | 0.06 | 0.06 | 0.01 | 0.26 | 0.26 | XXX |
| 70140 | TC | A | X-ray exam of facial bones | 0.00 | 0.62 | NA | 0.04 | 0.66 | NA | XXX |
| 70150 | | A | X-ray exam of facial bones | 0.26 | 0.87 | NA | 0.06 | 1.19 | NA | XXX |
| 70150 | 26 | A | X-ray exam of facial bones | 0.26 | 0.08 | 0.08 | 0.01 | 0.35 | 0.35 | XXX |
| 70150 | TC | A | X-ray exam of facial bones | 0.00 | 0.78 | NA | 0.05 | 0.83 | NA | XXX |
| 70160 | | A | X-ray exam of nasal bones | 0.17 | 0.58 | NA | 0.03 | 0.78 | NA | XXX |
| 70160 | 26 | A | X-ray exam of nasal bones | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 70160 | TC | A | X-ray exam of nasal bones | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 70170 | | A | X-ray exam of tear duct | 0.30 | 1.04 | NA | 0.07 | 1.41 | NA | XXX |
| 70170 | 26 | A | X-ray exam of tear duct | 0.30 | 0.10 | 0.10 | 0.01 | 0.41 | 0.41 | XXX |
| 70170 | TC | A | X-ray exam of tear duct | 0.00 | 0.95 | NA | 0.06 | 1.01 | NA | XXX |
| 70190 | | A | X-ray exam of eye sockets | 0.21 | 0.69 | NA | 0.05 | 0.95 | NA | XXX |
| 70190 | 26 | A | X-ray exam of eye sockets | 0.21 | 0.07 | 0.07 | 0.01 | 0.29 | 0.29 | XXX |
| 70190 | TC | A | X-ray exam of eye sockets | 0.00 | 0.62 | NA | 0.04 | 0.66 | NA | XXX |
| 70200 | | A | X-ray exam of eye sockets | 0.28 | 0.87 | NA | 0.06 | 1.21 | NA | XXX |
| 70200 | 26 | A | X-ray exam of eye sockets | 0.28 | 0.09 | 0.09 | 0.01 | 0.38 | 0.38 | XXX |
| 70200 | TC | A | X-ray exam of eye sockets | 0.00 | 0.78 | NA | 0.05 | 0.83 | NA | XXX |
| 70210 | | A | X-ray exam of sinuses | 0.17 | 0.67 | NA | 0.05 | 0.89 | NA | XXX |
| 70210 | 26 | A | X-ray exam of sinuses | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 70210 | TC | A | X-ray exam of sinuses | 0.00 | 0.62 | NA | 0.04 | 0.66 | NA | XXX |
| 70220 | | A | X-ray exam of sinuses | 0.25 | 0.86 | NA | 0.06 | 1.17 | NA | XXX |
| 70220 | 26 | A | X-ray exam of sinuses | 0.25 | 0.08 | 0.08 | 0.01 | 0.34 | 0.34 | XXX |
| 70220 | TC | A | X-ray exam of sinuses | 0.00 | 0.78 | NA | 0.05 | 0.83 | NA | XXX |
| 70240 | | A | X-ray exam, pituitary saddle | 0.19 | 0.48 | NA | 0.03 | 0.70 | NA | XXX |
| 70240 | 26 | A | X-ray exam, pituitary saddle | 0.19 | 0.06 | 0.06 | 0.01 | 0.26 | 0.26 | XXX |
| 70240 | TC | A | X-ray exam, pituitary saddle | 0.00 | 0.42 | NA | 0.02 | 0.44 | NA | XXX |
| 70250 | | A | X-ray exam of skull | 0.24 | 0.70 | NA | 0.05 | 0.99 | NA | XXX |
| 70250 | 26 | A | X-ray exam of skull | 0.24 | 0.08 | 0.08 | 0.01 | 0.33 | 0.33 | XXX |
| 70250 | TC | A | X-ray exam of skull | 0.00 | 0.62 | NA | 0.04 | 0.66 | NA | XXX |
| 70260 | | A | X-ray exam of skull | 0.34 | 1.00 | NA | 0.08 | 1.42 | NA | XXX |
| 70260 | 26 | A | X-ray exam of skull | 0.34 | 0.11 | 0.11 | 0.02 | 0.47 | 0.47 | XXX |
| 70260 | TC | A | X-ray exam of skull | 0.00 | 0.89 | NA | 0.06 | 0.95 | NA | XXX |
| 70300 | | A | X-ray exam of teeth | 0.10 | 0.31 | NA | 0.03 | 0.44 | NA | XXX |
| 70300 | 26 | A | X-ray exam of teeth | 0.10 | 0.05 | 0.05 | 0.01 | 0.16 | 0.16 | XXX |
| 70300 | TC | A | X-ray exam of teeth | 0.00 | 0.26 | NA | 0.02 | 0.28 | NA | XXX |
| 70310 | | A | X-ray exam of teeth | 0.16 | 0.49 | NA | 0.03 | 0.68 | NA | XXX |
| 70310 | 26 | A | X-ray exam of teeth | 0.16 | 0.08 | 0.08 | 0.01 | 0.25 | 0.25 | XXX |
| 70310 | TC | A | X-ray exam of teeth | 0.00 | 0.42 | NA | 0.02 | 0.44 | NA | XXX |
| 70320 | | A | Full mouth x-ray of teeth | 0.22 | 0.86 | NA | 0.06 | 1.14 | NA | XXX |
| 70320 | 26 | A | Full mouth x-ray of teeth | 0.22 | 0.08 | 0.08 | 0.01 | 0.31 | 0.31 | XXX |
| 70320 | TC | A | Full mouth x-ray of teeth | 0.00 | 0.78 | NA | 0.05 | 0.83 | NA | XXX |
| 70328 | | A | X-ray exam of jaw joint | 0.18 | 0.55 | NA | 0.03 | 0.76 | NA | XXX |
| 70328 | 26 | A | X-ray exam of jaw joint | 0.18 | 0.06 | 0.06 | 0.01 | 0.25 | 0.25 | XXX |
| 70328 | TC | A | X-ray exam of jaw joint | 0.00 | 0.49 | NA | 0.02 | 0.51 | NA | XXX |
| 70330 | | A | X-ray exam of jaw joints | 0.24 | 0.92 | NA | 0.06 | 1.22 | NA | XXX |
| 70330 | 26 | A | X-ray exam of jaw joints | 0.24 | 0.08 | 0.08 | 0.01 | 0.33 | 0.33 | XXX |
| 70330 | TC | A | X-ray exam of jaw joints | 0.00 | 0.84 | NA | 0.05 | 0.89 | NA | XXX |
| 70332 | | A | X-ray exam of jaw joint | 0.54 | 2.29 | NA | 0.15 | 2.98 | NA | XXX |
| 70332 | 26 | A | X-ray exam of jaw joint | 0.54 | 0.20 | 0.20 | 0.03 | 0.77 | 0.77 | XXX |
| 70332 | TC | A | X-ray exam of jaw joint | 0.00 | 2.09 | NA | 0.12 | 2.21 | NA | XXX |
| 70336 | | A | Magnetic image, jaw joint | 1.48 | 11.67 | NA | 0.66 | 13.81 | NA | XXX |
| 70336 | 26 | A | Magnetic image, jaw joint | 1.48 | 0.49 | 0.49 | 0.07 | 2.04 | 2.04 | XXX |
| 70336 | TC | A | Magnetic image, jaw joint | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 70350 | | A | X-ray head for orthodontia | 0.17 | 0.45 | NA | 0.03 | 0.65 | NA | XXX |
| 70350 | 26 | A | X-ray head for orthodontia | 0.17 | 0.07 | 0.07 | 0.01 | 0.25 | 0.25 | XXX |
| 70350 | TC | A | X-ray head for orthodontia | 0.00 | 0.38 | NA | 0.02 | 0.40 | NA | XXX |
| 70355 | | A | Panoramic x-ray of jaws | 0.20 | 0.64 | NA | 0.05 | 0.89 | NA | XXX |
| 70355 | 26 | A | Panoramic x-ray of jaws | 0.20 | 0.07 | 0.07 | 0.01 | 0.28 | 0.28 | XXX |
| 70355 | TC | A | Panoramic x-ray of jaws | 0.00 | 0.57 | NA | 0.04 | 0.61 | NA | XXX |
| 70360 | | A | X-ray exam of neck | 0.17 | 0.47 | NA | 0.03 | 0.67 | NA | XXX |
| 70360 | 26 | A | X-ray exam of neck | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 70360 | TC | A | X-ray exam of neck | 0.00 | 0.42 | NA | 0.02 | 0.44 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 70370 | | A | Throat x-ray & fluoroscopy | 0.32 | 1.41 | NA | 0.08 | 1.81 | NA | XXX |
| 70370 | 26 | A | Throat x-ray & fluoroscopy | 0.32 | 0.10 | 0.10 | 0.01 | 0.43 | 0.43 | XXX |
| 70370 | TC | A | Throat x-ray & fluoroscopy | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 70371 | | A | Speech evaluation, complex | 0.84 | 2.37 | NA | 0.16 | 3.37 | NA | XXX |
| 70371 | 26 | A | Speech evaluation, complex | 0.84 | 0.27 | 0.27 | 0.04 | 1.15 | 1.15 | XXX |
| 70371 | TC | A | Speech evaluation, complex | 0.00 | 2.09 | NA | 0.12 | 2.21 | NA | XXX |
| 70373 | | A | Contrast x-ray of larynx | 0.44 | 1.92 | NA | 0.13 | 2.49 | NA | XXX |
| 70373 | 26 | A | Contrast x-ray of larynx | 0.44 | 0.14 | 0.14 | 0.02 | 0.60 | 0.60 | XXX |
| 70373 | TC | A | Contrast x-ray of larynx | 0.00 | 1.78 | NA | 0.11 | 1.89 | NA | XXX |
| 70380 | | A | X-ray exam of salivary gland | 0.17 | 0.72 | NA | 0.05 | 0.94 | NA | XXX |
| 70380 | 26 | A | X-ray exam of salivary gland | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 70380 | TC | A | X-ray exam of salivary gland | 0.00 | 0.67 | NA | 0.04 | 0.71 | NA | XXX |
| 70390 | | A | X-ray exam of salivary duct | 0.38 | 1.90 | NA | 0.13 | 2.41 | NA | XXX |
| 70390 | 26 | A | X-ray exam of salivary duct | 0.38 | 0.12 | 0.12 | 0.02 | 0.52 | 0.52 | XXX |
| 70390 | TC | A | X-ray exam of salivary duct | 0.00 | 1.78 | NA | 0.11 | 1.89 | NA | XXX |
| 70450 | | A | Ct head/brain w/o dye | 0.85 | 4.99 | NA | 0.29 | 6.13 | NA | XXX |
| 70450 | 26 | A | Ct head/brain w/o dye | 0.85 | 0.28 | 0.28 | 0.04 | 1.17 | 1.17 | XXX |
| 70450 | TC | A | Ct head/brain w/o dye | 0.00 | 4.71 | NA | 0.25 | 4.96 | NA | XXX |
| 70460 | | A | Ct head/brain w/dye | 1.13 | 6.02 | NA | 0.35 | 7.50 | NA | XXX |
| 70460 | 26 | A | Ct head/brain w/dye | 1.13 | 0.37 | 0.37 | 0.05 | 1.55 | 1.55 | XXX |
| 70460 | TC | A | Ct head/brain w/dye | 0.00 | 5.65 | NA | 0.30 | 5.95 | NA | XXX |
| 70470 | | A | Ct head/brain w/o & w/ dye | 1.27 | 7.47 | NA | 0.43 | 9.17 | NA | XXX |
| 70470 | 26 | A | Ct head/brain w/o & w/ dye | 1.27 | 0.42 | 0.42 | 0.06 | 1.75 | 1.75 | XXX |
| 70470 | TC | A | Ct head/brain w/o & w/ dye | 0.00 | 7.06 | NA | 0.37 | 7.43 | NA | XXX |
| 70480 | | A | Ct orbit/ear/fossa w/o dye | 1.28 | 5.13 | NA | 0.31 | 6.72 | NA | XXX |
| 70480 | 26 | A | Ct orbit/ear/fossa w/o dye | 1.28 | 0.42 | 0.42 | 0.06 | 1.76 | 1.76 | XXX |
| 70480 | TC | A | Ct orbit/ear/fossa w/o dye | 0.00 | 4.71 | NA | 0.25 | 4.96 | NA | XXX |
| 70481 | | A | Ct orbit/ear/fossa w/dye | 1.38 | 6.10 | NA | 0.36 | 7.84 | NA | XXX |
| 70481 | 26 | A | Ct orbit/ear/fossa w/dye | 1.38 | 0.45 | 0.45 | 0.06 | 1.89 | 1.89 | XXX |
| 70481 | TC | A | Ct orbit/ear/fossa w/dye | 0.00 | 5.65 | NA | 0.30 | 5.95 | NA | XXX |
| 70482 | | A | Ct orbit/ear/fossa w/o&w dye | 1.45 | 7.53 | NA | 0.44 | 9.42 | NA | XXX |
| 70482 | 26 | A | Ct orbit/ear/fossa w/o&w dye | 1.45 | 0.47 | 0.47 | 0.07 | 1.99 | 1.99 | XXX |
| 70482 | TC | A | Ct orbit/ear/fossa w/o&w dye | 0.00 | 7.06 | NA | 0.37 | 7.43 | NA | XXX |
| 70486 | | A | Ct maxillofacial w/o dye | 1.14 | 5.08 | NA | 0.30 | 6.52 | NA | XXX |
| 70486 | 26 | A | Ct maxillofacial w/o dye | 1.14 | 0.37 | 0.37 | 0.05 | 1.56 | 1.56 | XXX |
| 70486 | TC | A | Ct maxillofacial w/o dye | 0.00 | 4.71 | NA | 0.25 | 4.96 | NA | XXX |
| 70487 | | A | Ct maxillofacial w/dye | 1.30 | 6.07 | NA | 0.36 | 7.73 | NA | XXX |
| 70487 | 26 | A | Ct maxillofacial w/dye | 1.30 | 0.43 | 0.43 | 0.06 | 1.79 | 1.79 | XXX |
| 70487 | TC | A | Ct maxillofacial w/dye | 0.00 | 5.65 | NA | 0.30 | 5.95 | NA | XXX |
| 70488 | | A | Ct maxillofacial w/o & w dye | 1.42 | 7.52 | NA | 0.43 | 9.37 | NA | XXX |
| 70488 | 26 | A | Ct maxillofacial w/o & w dye | 1.42 | 0.46 | 0.46 | 0.06 | 1.94 | 1.94 | XXX |
| 70488 | TC | A | Ct maxillofacial w/o & w dye | 0.00 | 7.06 | NA | 0.37 | 7.43 | NA | XXX |
| 70490 | | A | Ct soft tissue neck w/o dye | 1.28 | 5.13 | NA | 0.31 | 6.72 | NA | XXX |
| 70490 | 26 | A | Ct soft tissue neck w/o dye | 1.28 | 0.42 | 0.42 | 0.06 | 1.76 | 1.76 | XXX |
| 70490 | TC | A | Ct soft tissue neck w/o dye | 0.00 | 4.71 | NA | 0.25 | 4.96 | NA | XXX |
| 70491 | | A | Ct soft tissue neck w/dye | 1.38 | 6.10 | NA | 0.36 | 7.84 | NA | XXX |
| 70491 | 26 | A | Ct soft tissue neck w/dye | 1.38 | 0.45 | 0.45 | 0.06 | 1.89 | 1.89 | XXX |
| 70491 | TC | A | Ct soft tissue neck w/dye | 0.00 | 5.65 | NA | 0.30 | 5.95 | NA | XXX |
| 70492 | | A | Ct sft tsue nck w/o & w/dye | 1.45 | 7.53 | NA | 0.44 | 9.42 | NA | XXX |
| 70492 | 26 | A | Ct sft tsue nck w/o & w/dye | 1.45 | 0.47 | 0.47 | 0.07 | 1.99 | 1.99 | XXX |
| 70492 | TC | A | Ct sft tsue nck w/o & w/dye | 0.00 | 7.06 | NA | 0.37 | 7.43 | NA | XXX |
| 70496 | | A | Ct angiography, head | 1.75 | 11.16 | NA | 0.66 | 13.57 | NA | XXX |
| 70496 | 26 | A | Ct angiography, head | 1.75 | 0.57 | 0.57 | 0.08 | 2.40 | 2.40 | XXX |
| 70496 | TC | A | Ct angiography, head | 0.00 | 10.59 | NA | 0.58 | 11.17 | NA | XXX |
| 70498 | | A | Ct angiography, neck | 1.75 | 11.16 | NA | 0.66 | 13.57 | NA | XXX |
| 70498 | 26 | A | Ct angiography, neck | 1.75 | 0.57 | 0.57 | 0.08 | 2.40 | 2.40 | XXX |
| 70498 | TC | A | Ct angiography, neck | 0.00 | 10.59 | NA | 0.58 | 11.17 | NA | XXX |
| 70540 | | A | Mri orbit/face/neck w/o dye | 1.35 | 11.63 | NA | 0.45 | 13.43 | NA | XXX |
| 70540 | 26 | A | Mri orbit/face/neck w/o dye | 1.35 | 0.44 | 0.44 | 0.06 | 1.85 | 1.85 | XXX |
| 70540 | TC | A | Mri orbit/face/neck w/o dye | 0.00 | 11.19 | NA | 0.39 | 11.58 | NA | XXX |
| 70542 | | A | Mri orbit/face/neck w/dye | 1.62 | 13.95 | NA | 0.54 | 16.11 | NA | XXX |
| 70542 | 26 | A | Mri orbit/face/neck w/dye | 1.62 | 0.53 | 0.53 | 0.07 | 2.22 | 2.22 | XXX |
| 70542 | TC | A | Mri orbit/face/neck w/dye | 0.00 | 13.42 | NA | 0.47 | 13.89 | NA | XXX |
| 70543 | | A | Mri orbt/fac/nck w/o & w dye | 2.15 | 25.55 | NA | 0.94 | 28.64 | NA | XXX |
| 70543 | 26 | A | Mri orbt/fac/nck w/o & w dye | 2.15 | 0.71 | 0.71 | 0.10 | 2.96 | 2.96 | XXX |
| 70543 | TC | A | Mri orbt/fac/nck w/o & w dye | 0.00 | 24.84 | NA | 0.84 | 25.68 | NA | XXX |
| 70544 | | A | Mr angiography head w/o dye | 1.20 | 11.58 | NA | 0.64 | 13.42 | NA | XXX |
| 70544 | 26 | A | Mr angiography head w/o dye | 1.20 | 0.39 | 0.39 | 0.05 | 1.64 | 1.64 | XXX |
| 70544 | TC | A | Mr angiography head w/o dye | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 70545 | | A | Mr angiography head w/dye | 1.20 | 11.58 | NA | 0.65 | 13.43 | NA | XXX |
| 70545 | 26 | A | Mr angiography head w/dye | 1.20 | 0.39 | 0.39 | 0.06 | 1.65 | 1.65 | XXX |
| 70545 | TC | A | Mr angiography head w/dye | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 70546 | | A | Mr angiograph head w/o&w dye | 1.80 | 22.96 | NA | 0.67 | 25.43 | NA | XXX |
| 70546 | 26 | A | Mr angiograph head w/o&w dye | 1.80 | 0.59 | 0.59 | 0.08 | 2.47 | 2.47 | XXX |
| 70546 | TC | A | Mr angiograph head w/o&w dye | 0.00 | 22.37 | NA | 0.59 | 22.96 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 70547 | | A | Mr angiography neck w/o dye | 1.20 | 11.58 | NA | 0.64 | 13.42 | NA | XXX |
| 70547 | 26 | A | Mr angiography neck w/o dye | 1.20 | 0.39 | 0.39 | 0.05 | 1.64 | 1.64 | XXX |
| 70547 | TC | A | Mr angiography neck w/o dye | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 70548 | | A | Mr angiography neck w/dye | 1.20 | 11.58 | NA | 0.64 | 13.42 | NA | XXX |
| 70548 | 26 | A | Mr angiography neck w/dye | 1.20 | 0.39 | 0.39 | 0.05 | 1.64 | 1.64 | XXX |
| 70548 | TC | A | Mr angiography neck w/dye | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 70549 | | A | Mr angiograph neck w/o&w dye | 1.80 | 22.97 | NA | 0.67 | 25.44 | NA | XXX |
| 70549 | 26 | A | Mr angiograph neck w/o&w dye | 1.80 | 0.59 | 0.59 | 0.08 | 2.47 | 2.47 | XXX |
| 70549 | TC | A | Mr angiograph neck w/o&w dye | 0.00 | 22.37 | NA | 0.59 | 22.96 | NA | XXX |
| 70551 | | A | Mri brain w/o dye | 1.48 | 11.67 | NA | 0.66 | 13.81 | NA | XXX |
| 70551 | 26 | A | Mri brain w/o dye | 1.48 | 0.49 | 0.49 | 0.07 | 2.04 | 2.04 | XXX |
| 70551 | TC | A | Mri brain w/o dye | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 70552 | | A | Mri brain w/ dye | 1.78 | 14.01 | NA | 0.79 | 16.58 | NA | XXX |
| 70552 | 26 | A | Mri brain w/ dye | 1.78 | 0.59 | 0.59 | 0.09 | 2.46 | 2.46 | XXX |
| 70552 | TC | A | Mri brain w/ dye | 0.00 | 13.42 | NA | 0.70 | 14.12 | NA | XXX |
| 70553 | | A | Mri brain w/o & w/ dye | 2.36 | 25.62 | NA | 1.42 | 29.40 | NA | XXX |
| 70553 | 26 | A | Mri brain w/o & w/ dye | 2.36 | 0.77 | 0.77 | 0.11 | 3.24 | 3.24 | XXX |
| 70553 | TC | A | Mri brain w/o & w/ dye | 0.00 | 24.84 | NA | 1.31 | 26.15 | NA | XXX |
| 70557 | 26 | A | Mri brain w/o dye | 2.90 | 1.12 | 1.12 | 0.08 | 4.10 | 4.10 | XXX |
| 70558 | 26 | A | Mri brain w/ dye | 3.20 | 1.23 | 1.23 | 0.10 | 4.53 | 4.53 | XXX |
| 70559 | 26 | A | Mri brain w/o & w/ dye | 3.20 | 1.23 | 1.23 | 0.12 | 4.55 | 4.55 | XXX |
| 71010 | | A | Chest x-ray | 0.18 | 0.53 | NA | 0.03 | 0.74 | NA | XXX |
| 71010 | 26 | A | Chest x-ray | 0.18 | 0.06 | 0.06 | 0.01 | 0.25 | 0.25 | XXX |
| 71010 | TC | A | Chest x-ray | 0.00 | 0.47 | NA | 0.02 | 0.49 | NA | XXX |
| 71015 | | A | Chest x-ray | 0.21 | 0.59 | NA | 0.03 | 0.83 | NA | XXX |
| 71015 | 26 | A | Chest x-ray | 0.21 | 0.07 | 0.07 | 0.01 | 0.29 | 0.29 | XXX |
| 71015 | TC | A | Chest x-ray | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 71020 | | A | Chest x-ray | 0.22 | 0.69 | NA | 0.05 | 0.96 | NA | XXX |
| 71020 | 26 | A | Chest x-ray | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| 71020 | TC | A | Chest x-ray | 0.00 | 0.62 | NA | 0.04 | 0.66 | NA | XXX |
| 71021 | | A | Chest x-ray | 0.27 | 0.82 | NA | 0.06 | 1.15 | NA | XXX |
| 71021 | 26 | A | Chest x-ray | 0.27 | 0.09 | 0.09 | 0.01 | 0.37 | 0.37 | XXX |
| 71021 | TC | A | Chest x-ray | 0.00 | 0.73 | NA | 0.05 | 0.78 | NA | XXX |
| 71022 | | A | Chest x-ray | 0.31 | 0.83 | NA | 0.06 | 1.20 | NA | XXX |
| 71022 | 26 | A | Chest x-ray | 0.31 | 0.10 | 0.10 | 0.01 | 0.42 | 0.42 | XXX |
| 71022 | TC | A | Chest x-ray | 0.00 | 0.73 | NA | 0.05 | 0.78 | NA | XXX |
| 71023 | | A | Chest x-ray and fluoroscopy | 0.38 | 0.91 | NA | 0.07 | 1.36 | NA | XXX |
| 71023 | 26 | A | Chest x-ray and fluoroscopy | 0.38 | 0.13 | 0.13 | 0.02 | 0.53 | 0.53 | XXX |
| 71023 | TC | A | Chest x-ray and fluoroscopy | 0.00 | 0.78 | NA | 0.05 | 0.83 | NA | XXX |
| 71030 | | A | Chest x-ray | 0.31 | 0.88 | NA | 0.06 | 1.25 | NA | XXX |
| 71030 | 26 | A | Chest x-ray | 0.31 | 0.10 | 0.10 | 0.01 | 0.42 | 0.42 | XXX |
| 71030 | TC | A | Chest x-ray | 0.00 | 0.78 | NA | 0.05 | 0.83 | NA | XXX |
| 71034 | | A | Chest x-ray and fluoroscopy | 0.46 | 1.60 | NA | 0.10 | 2.16 | NA | XXX |
| 71034 | 26 | A | Chest x-ray and fluoroscopy | 0.46 | 0.16 | 0.16 | 0.02 | 0.64 | 0.64 | XXX |
| 71034 | TC | A | Chest x-ray and fluoroscopy | 0.00 | 1.44 | NA | 0.08 | 1.52 | NA | XXX |
| 71035 | | A | Chest x-ray | 0.18 | 0.58 | NA | 0.03 | 0.79 | NA | XXX |
| 71035 | 26 | A | Chest x-ray | 0.18 | 0.06 | 0.06 | 0.01 | 0.25 | 0.25 | XXX |
| 71035 | TC | A | Chest x-ray | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 71040 | | A | Contrast x-ray of bronchi | 0.58 | 1.65 | NA | 0.11 | 2.34 | NA | XXX |
| 71040 | 26 | A | Contrast x-ray of bronchi | 0.58 | 0.19 | 0.19 | 0.03 | 0.80 | 0.80 | XXX |
| 71040 | TC | A | Contrast x-ray of bronchi | 0.00 | 1.46 | NA | 0.08 | 1.54 | NA | XXX |
| 71060 | | A | Contrast x-ray of bronchi | 0.74 | 2.44 | NA | 0.17 | 3.35 | NA | XXX |
| 71060 | 26 | A | Contrast x-ray of bronchi | 0.74 | 0.24 | 0.24 | 0.04 | 1.02 | 1.02 | XXX |
| 71060 | TC | A | Contrast x-ray of bronchi | 0.00 | 2.20 | NA | 0.13 | 2.33 | NA | XXX |
| 71090 | | A | X-ray & pacemaker insertion | 0.54 | 1.89 | NA | 0.13 | 2.56 | NA | XXX |
| 71090 | 26 | A | X-ray & pacemaker insertion | 0.54 | 0.21 | 0.21 | 0.02 | 0.77 | 0.77 | XXX |
| 71090 | TC | A | X-ray & pacemaker insertion | 0.00 | 1.68 | NA | 0.11 | 1.79 | NA | XXX |
| 71100 | | A | X-ray exam of ribs | 0.22 | 0.64 | NA | 0.05 | 0.91 | NA | XXX |
| 71100 | 26 | A | X-ray exam of ribs | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| 71100 | TC | A | X-ray exam of ribs | 0.00 | 0.57 | NA | 0.04 | 0.61 | NA | XXX |
| 71101 | | A | X-ray exam of ribs/chest | 0.27 | 0.75 | NA | 0.05 | 1.07 | NA | XXX |
| 71101 | 26 | A | X-ray exam of ribs/chest | 0.27 | 0.09 | 0.09 | 0.01 | 0.37 | 0.37 | XXX |
| 71101 | TC | A | X-ray exam of ribs/chest | 0.00 | 0.67 | NA | 0.04 | 0.71 | NA | XXX |
| 71110 | | A | X-ray exam of ribs | 0.27 | 0.87 | NA | 0.06 | 1.20 | NA | XXX |
| 71110 | 26 | A | X-ray exam of ribs | 0.27 | 0.09 | 0.09 | 0.01 | 0.37 | 0.37 | XXX |
| 71110 | TC | A | X-ray exam of ribs | 0.00 | 0.78 | NA | 0.05 | 0.83 | NA | XXX |
| 71111 | | A | X-ray exam of ribs/ chest | 0.32 | 0.99 | NA | 0.07 | 1.38 | NA | XXX |
| 71111 | 26 | A | X-ray exam of ribs/ chest | 0.32 | 0.10 | 0.10 | 0.01 | 0.43 | 0.43 | XXX |
| 71111 | TC | A | X-ray exam of ribs/ chest | 0.00 | 0.89 | NA | 0.06 | 0.95 | NA | XXX |
| 71120 | | A | X-ray exam of breastbone | 0.20 | 0.71 | NA | 0.05 | 0.96 | NA | XXX |
| 71120 | 26 | A | X-ray exam of breastbone | 0.20 | 0.07 | 0.07 | 0.01 | 0.28 | 0.28 | XXX |
| 71120 | TC | A | X-ray exam of breastbone | 0.00 | 0.65 | NA | 0.04 | 0.69 | NA | XXX |
| 71130 | | A | X-ray exam of breastbone | 0.22 | 0.78 | NA | 0.05 | 1.05 | NA | XXX |
| 71130 | 26 | A | X-ray exam of breastbone | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| 71130 | TC | A | X-ray exam of breastbone | 0.00 | 0.70 | NA | 0.04 | 0.74 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 71250 | | A | Ct thorax w/o dye | 1.16 | 6.28 | NA | 0.36 | 7.80 | NA | XXX |
| 71250 | 26 | A | Ct thorax w/o dye | 1.16 | 0.38 | 0.38 | 0.05 | 1.59 | 1.59 | XXX |
| 71250 | TC | A | Ct thorax w/o dye | 0.00 | 5.90 | NA | 0.31 | 6.21 | NA | XXX |
| 71260 | | A | Ct thorax w/dye | 1.24 | 7.46 | NA | 0.43 | 9.13 | NA | XXX |
| 71260 | 26 | A | Ct thorax w/dye | 1.24 | 0.40 | 0.40 | 0.06 | 1.70 | 1.70 | XXX |
| 71260 | TC | A | Ct thorax w/dye | 0.00 | 7.06 | NA | 0.37 | 7.43 | NA | XXX |
| 71270 | | A | Ct thorax w/o & w/ dye | 1.38 | 9.28 | NA | 0.52 | 11.18 | NA | XXX |
| 71270 | 26 | A | Ct thorax w/o & w/ dye | 1.38 | 0.45 | 0.45 | 0.06 | 1.89 | 1.89 | XXX |
| 71270 | TC | A | Ct thorax w/o & w/ dye | 0.00 | 8.83 | NA | 0.46 | 9.29 | NA | XXX |
| 71275 | | A | Ct angiography, chest | 1.92 | 12.99 | NA | 0.48 | 15.39 | NA | XXX |
| 71275 | 26 | A | Ct angiography, chest | 1.92 | 0.63 | 0.63 | 0.09 | 2.64 | 2.64 | XXX |
| 71275 | TC | A | Ct angiography, chest | 0.00 | 12.36 | NA | 0.39 | 12.75 | NA | XXX |
| 71550 | | A | Mri chest w/o dye | 1.46 | 11.66 | NA | 0.52 | 13.64 | NA | XXX |
| 71550 | 26 | A | Mri chest w/o dye | 1.46 | 0.48 | 0.48 | 0.07 | 2.01 | 2.01 | XXX |
| 71550 | TC | A | Mri chest w/o dye | 0.00 | 11.19 | NA | 0.45 | 11.64 | NA | XXX |
| 71551 | | A | Mri chest w/dye | 1.73 | 13.98 | NA | 0.60 | 16.31 | NA | XXX |
| 71551 | 26 | A | Mri chest w/dye | 1.73 | 0.56 | 0.56 | 0.08 | 2.37 | 2.37 | XXX |
| 71551 | TC | A | Mri chest w/dye | 0.00 | 13.42 | NA | 0.52 | 13.94 | NA | XXX |
| 71552 | | A | Mri chest w/o & w/dye | 2.26 | 25.58 | NA | 0.78 | 28.62 | NA | XXX |
| 71552 | 26 | A | Mri chest w/o & w/dye | 2.26 | 0.74 | 0.74 | 0.10 | 3.10 | 3.10 | XXX |
| 71552 | TC | A | Mri chest w/o & w/dye | 0.00 | 24.84 | NA | 0.68 | 25.52 | NA | XXX |
| 71555 | | R | Mri angio chest w or w/o dye | 1.81 | 11.78 | NA | 0.67 | 14.26 | NA | XXX |
| 71555 | 26 | R | Mri angio chest w or w/o dye | 1.81 | 0.60 | 0.60 | 0.08 | 2.49 | 2.49 | XXX |
| 71555 | TC | R | Mri angio chest w or w/o dye | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 72010 | | A | X-ray exam of spine | 0.45 | 1.17 | NA | 0.08 | 1.70 | NA | XXX |
| 72010 | 26 | A | X-ray exam of spine | 0.45 | 0.15 | 0.15 | 0.02 | 0.62 | 0.62 | XXX |
| 72010 | TC | A | X-ray exam of spine | 0.00 | 1.02 | NA | 0.06 | 1.08 | NA | XXX |
| 72020 | | A | X-ray exam of spine | 0.15 | 0.46 | NA | 0.03 | 0.64 | NA | XXX |
| 72020 | 26 | A | X-ray exam of spine | 0.15 | 0.05 | 0.05 | 0.01 | 0.21 | 0.21 | XXX |
| 72020 | TC | A | X-ray exam of spine | 0.00 | 0.42 | NA | 0.02 | 0.44 | NA | XXX |
| 72040 | | A | X-ray exam of neck spine | 0.22 | 0.67 | NA | 0.05 | 0.94 | NA | XXX |
| 72040 | 26 | A | X-ray exam of neck spine | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| 72040 | TC | A | X-ray exam of neck spine | 0.00 | 0.60 | NA | 0.04 | 0.64 | NA | XXX |
| 72050 | | A | X-ray exam of neck spine | 0.31 | 0.99 | NA | 0.07 | 1.37 | NA | XXX |
| 72050 | 26 | A | X-ray exam of neck spine | 0.31 | 0.10 | 0.10 | 0.01 | 0.42 | 0.42 | XXX |
| 72050 | TC | A | X-ray exam of neck spine | 0.00 | 0.89 | NA | 0.06 | 0.95 | NA | XXX |
| 72052 | | A | X-ray exam of neck spine | 0.36 | 1.25 | NA | 0.08 | 1.69 | NA | XXX |
| 72052 | 26 | A | X-ray exam of neck spine | 0.36 | 0.12 | 0.12 | 0.02 | 0.50 | 0.50 | XXX |
| 72052 | TC | A | X-ray exam of neck spine | 0.00 | 1.13 | NA | 0.06 | 1.19 | NA | XXX |
| 72069 | | A | X-ray exam of trunk spine | 0.22 | 0.57 | NA | 0.03 | 0.82 | NA | XXX |
| 72069 | 26 | A | X-ray exam of trunk spine | 0.22 | 0.08 | 0.08 | 0.01 | 0.31 | 0.31 | XXX |
| 72069 | TC | A | X-ray exam of trunk spine | 0.00 | 0.49 | NA | 0.02 | 0.51 | NA | XXX |
| 72070 | | A | X-ray exam of thoracic spine | 0.22 | 0.72 | NA | 0.05 | 0.99 | NA | XXX |
| 72070 | 26 | A | X-ray exam of thoracic spine | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| 72070 | TC | A | X-ray exam of thoracic spine | 0.00 | 0.65 | NA | 0.04 | 0.69 | NA | XXX |
| 72072 | | A | X-ray exam of thoracic spine | 0.22 | 0.81 | NA | 0.06 | 1.09 | NA | XXX |
| 72072 | 26 | A | X-ray exam of thoracic spine | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| 72072 | TC | A | X-ray exam of thoracic spine | 0.00 | 0.73 | NA | 0.05 | 0.78 | NA | XXX |
| 72074 | | A | X-ray exam of thoracic spine | 0.22 | 0.98 | NA | 0.07 | 1.27 | NA | XXX |
| 72074 | 26 | A | X-ray exam of thoracic spine | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| 72074 | TC | A | X-ray exam of thoracic spine | 0.00 | 0.91 | NA | 0.06 | 0.97 | NA | XXX |
| 72080 | | A | X-ray exam of trunk spine | 0.22 | 0.74 | NA | 0.05 | 1.01 | NA | XXX |
| 72080 | 26 | A | X-ray exam of trunk spine | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| 72080 | TC | A | X-ray exam of trunk spine | 0.00 | 0.67 | NA | 0.04 | 0.71 | NA | XXX |
| 72090 | | A | X-ray exam of trunk spine | 0.28 | 0.76 | NA | 0.05 | 1.09 | NA | XXX |
| 72090 | 26 | A | X-ray exam of trunk spine | 0.28 | 0.09 | 0.09 | 0.01 | 0.38 | 0.38 | XXX |
| 72090 | TC | A | X-ray exam of trunk spine | 0.00 | 0.67 | NA | 0.04 | 0.71 | NA | XXX |
| 72100 | | A | X-ray exam of lower spine | 0.22 | 0.74 | NA | 0.05 | 1.01 | NA | XXX |
| 72100 | 26 | A | X-ray exam of lower spine | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| 72100 | TC | A | X-ray exam of lower spine | 0.00 | 0.67 | NA | 0.04 | 0.71 | NA | XXX |
| 72110 | | A | X-ray exam of lower spine | 0.31 | 1.01 | NA | 0.07 | 1.39 | NA | XXX |
| 72110 | 26 | A | X-ray exam of lower spine | 0.31 | 0.10 | 0.10 | 0.01 | 0.42 | 0.42 | XXX |
| 72110 | TC | A | X-ray exam of lower spine | 0.00 | 0.91 | NA | 0.06 | 0.97 | NA | XXX |
| 72114 | | A | X-ray exam of lower spine | 0.36 | 1.31 | NA | 0.08 | 1.75 | NA | XXX |
| 72114 | 26 | A | X-ray exam of lower spine | 0.36 | 0.12 | 0.12 | 0.02 | 0.50 | 0.50 | XXX |
| 72114 | TC | A | X-ray exam of lower spine | 0.00 | 1.19 | NA | 0.06 | 1.25 | NA | XXX |
| 72120 | | A | X-ray exam of lower spine | 0.22 | 0.96 | NA | 0.07 | 1.25 | NA | XXX |
| 72120 | 26 | A | X-ray exam of lower spine | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| 72120 | TC | A | X-ray exam of lower spine | 0.00 | 0.89 | NA | 0.06 | 0.95 | NA | XXX |
| 72125 | | A | Ct neck spine w/o dye | 1.16 | 6.28 | NA | 0.36 | 7.80 | NA | XXX |
| 72125 | 26 | A | Ct neck spine w/o dye | 1.16 | 0.38 | 0.38 | 0.05 | 1.59 | 1.59 | XXX |
| 72125 | TC | A | Ct neck spine w/o dye | 0.00 | 5.90 | NA | 0.31 | 6.21 | NA | XXX |
| 72126 | | A | Ct neck spine w/dye | 1.22 | 7.45 | NA | 0.43 | 9.10 | NA | XXX |
| 72126 | 26 | A | Ct neck spine w/dye | 1.22 | 0.40 | 0.40 | 0.06 | 1.68 | 1.68 | XXX |
| 72126 | TC | A | Ct neck spine w/dye | 0.00 | 7.06 | NA | 0.37 | 7.43 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 72127 | | A | Ct neck spine w/o & w/dye | 1.27 | 9.25 | NA | 0.52 | 11.04 | NA | XXX |
| 72127 | 26 | A | Ct neck spine w/o & w/dye | 1.27 | 0.42 | 0.42 | 0.06 | 1.75 | 1.75 | XXX |
| 72127 | TC | A | Ct neck spine w/o & w/dye | 0.00 | 8.83 | NA | 0.46 | 9.29 | NA | XXX |
| 72128 | | A | Ct chest spine w/o dye | 1.16 | 6.28 | NA | 0.36 | 7.80 | NA | XXX |
| 72128 | 26 | A | Ct chest spine w/o dye | 1.16 | 0.38 | 0.38 | 0.05 | 1.59 | 1.59 | XXX |
| 72128 | TC | A | Ct chest spine w/o dye | 0.00 | 5.90 | NA | 0.31 | 6.21 | NA | XXX |
| 72129 | | A | Ct chest spine w/dye | 1.22 | 7.45 | NA | 0.43 | 9.10 | NA | XXX |
| 72129 | 26 | A | Ct chest spine w/dye | 1.22 | 0.40 | 0.40 | 0.06 | 1.68 | 1.68 | XXX |
| 72129 | TC | A | Ct chest spine w/dye | 0.00 | 7.06 | NA | 0.37 | 7.43 | NA | XXX |
| 72130 | | A | Ct chest spine w/o & w/dye | 1.27 | 9.25 | NA | 0.52 | 11.04 | NA | XXX |
| 72130 | 26 | A | Ct chest spine w/o & w/dye | 1.27 | 0.42 | 0.42 | 0.06 | 1.75 | 1.75 | XXX |
| 72130 | TC | A | Ct chest spine w/o & w/dye | 0.00 | 8.83 | NA | 0.46 | 9.29 | NA | XXX |
| 72131 | | A | Ct lumbar spine w/o dye | 1.16 | 6.28 | NA | 0.36 | 7.80 | NA | XXX |
| 72131 | 26 | A | Ct lumbar spine w/o dye | 1.16 | 0.38 | 0.38 | 0.05 | 1.59 | 1.59 | XXX |
| 72131 | TC | A | Ct lumbar spine w/o dye | 0.00 | 5.90 | NA | 0.31 | 6.21 | NA | XXX |
| 72132 | | A | Ct lumbar spine w/dye | 1.22 | 7.45 | NA | 0.43 | 9.10 | NA | XXX |
| 72132 | 26 | A | Ct lumbar spine w/dye | 1.22 | 0.40 | 0.40 | 0.06 | 1.68 | 1.68 | XXX |
| 72132 | TC | A | Ct lumbar spine w/dye | 0.00 | 7.06 | NA | 0.37 | 7.43 | NA | XXX |
| 72133 | | A | Ct lumbar spine w/o & w/dye | 1.27 | 9.25 | NA | 0.52 | 11.04 | NA | XXX |
| 72133 | 26 | A | Ct lumbar spine w/o & w/dye | 1.27 | 0.42 | 0.42 | 0.06 | 1.75 | 1.75 | XXX |
| 72133 | TC | A | Ct lumbar spine w/o & w/dye | 0.00 | 8.83 | NA | 0.46 | 9.29 | NA | XXX |
| 72141 | | A | Mri neck spine w/o dye | 1.60 | 11.71 | NA | 0.66 | 13.97 | NA | XXX |
| 72141 | 26 | A | Mri neck spine w/o dye | 1.60 | 0.53 | 0.53 | 0.07 | 2.20 | 2.20 | XXX |
| 72141 | TC | A | Mri neck spine w/o dye | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 72142 | | A | Mri neck spine w/dye | 1.92 | 14.06 | NA | 0.79 | 16.77 | NA | XXX |
| 72142 | 26 | A | Mri neck spine w/dye | 1.92 | 0.64 | 0.64 | 0.09 | 2.65 | 2.65 | XXX |
| 72142 | TC | A | Mri neck spine w/dye | 0.00 | 13.42 | NA | 0.70 | 14.12 | NA | XXX |
| 72146 | | A | Mri chest spine w/o dye | 1.60 | 12.95 | NA | 0.71 | 15.26 | NA | XXX |
| 72146 | 26 | A | Mri chest spine w/o dye | 1.60 | 0.52 | 0.52 | 0.07 | 2.19 | 2.19 | XXX |
| 72146 | TC | A | Mri chest spine w/o dye | 0.00 | 12.42 | NA | 0.64 | 13.06 | NA | XXX |
| 72147 | | A | Mri chest spine w/dye | 1.92 | 14.05 | NA | 0.79 | 16.76 | NA | XXX |
| 72147 | 26 | A | Mri chest spine w/dye | 1.92 | 0.63 | 0.63 | 0.09 | 2.64 | 2.64 | XXX |
| 72147 | TC | A | Mri chest spine w/dye | 0.00 | 13.42 | NA | 0.70 | 14.12 | NA | XXX |
| 72148 | | A | Mri lumbar spine w/o dye | 1.48 | 12.91 | NA | 0.71 | 15.10 | NA | XXX |
| 72148 | 26 | A | Mri lumbar spine w/o dye | 1.48 | 0.49 | 0.49 | 0.07 | 2.04 | 2.04 | XXX |
| 72148 | TC | A | Mri lumbar spine w/o dye | 0.00 | 12.42 | NA | 0.64 | 13.06 | NA | XXX |
| 72149 | | A | Mri lumbar spine w/dye | 1.78 | 14.01 | NA | 0.79 | 16.58 | NA | XXX |
| 72149 | 26 | A | Mri lumbar spine w/dye | 1.78 | 0.59 | 0.59 | 0.09 | 2.46 | 2.46 | XXX |
| 72149 | TC | A | Mri lumbar spine w/dye | 0.00 | 13.42 | NA | 0.70 | 14.12 | NA | XXX |
| 72156 | | A | Mri neck spine w/o & w/dye | 2.57 | 25.69 | NA | 1.43 | 29.69 | NA | XXX |
| 72156 | 26 | A | Mri neck spine w/o & w/dye | 2.57 | 0.85 | 0.85 | 0.12 | 3.54 | 3.54 | XXX |
| 72156 | TC | A | Mri neck spine w/o & w/dye | 0.00 | 24.84 | NA | 1.31 | 26.15 | NA | XXX |
| 72157 | | A | Mri chest spine w/o & w/dye | 2.57 | 25.68 | NA | 1.43 | 29.68 | NA | XXX |
| 72157 | 26 | A | Mri chest spine w/o & w/dye | 2.57 | 0.84 | 0.84 | 0.12 | 3.53 | 3.53 | XXX |
| 72157 | TC | A | Mri chest spine w/o & w/dye | 0.00 | 24.84 | NA | 1.31 | 26.15 | NA | XXX |
| 72158 | | A | Mri lumbar spine w/o & w/dye | 2.36 | 25.62 | NA | 1.42 | 29.40 | NA | XXX |
| 72158 | 26 | A | Mri lumbar spine w/o & w/dye | 2.36 | 0.77 | 0.77 | 0.11 | 3.24 | 3.24 | XXX |
| 72158 | TC | A | Mri lumbar spine w/o & w/dye | 0.00 | 24.84 | NA | 1.31 | 26.15 | NA | XXX |
| 72170 | | A | X-ray exam of pelvis | 0.17 | 0.58 | NA | 0.03 | 0.78 | NA | XXX |
| 72170 | 26 | A | X-ray exam of pelvis | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 72170 | TC | A | X-ray exam of pelvis | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 72190 | | A | X-ray exam of pelvis | 0.21 | 0.74 | NA | 0.05 | 1.00 | NA | XXX |
| 72190 | 26 | A | X-ray exam of pelvis | 0.21 | 0.07 | 0.07 | 0.01 | 0.29 | 0.29 | XXX |
| 72190 | TC | A | X-ray exam of pelvis | 0.00 | 0.67 | NA | 0.04 | 0.71 | NA | XXX |
| 72191 | | A | Ct angiograph pelv w/o&w/dye | 1.81 | 12.60 | NA | 0.47 | 14.88 | NA | XXX |
| 72191 | 26 | A | Ct angiograph pelv w/o&w/dye | 1.81 | 0.60 | 0.60 | 0.08 | 2.49 | 2.49 | XXX |
| 72191 | TC | A | Ct angiograph pelv w/o&w/dye | 0.00 | 12.01 | NA | 0.39 | 12.40 | NA | XXX |
| 72192 | | A | Ct pelvis w/o dye | 1.09 | 6.25 | NA | 0.36 | 7.70 | NA | XXX |
| 72192 | 26 | A | Ct pelvis w/o dye | 1.09 | 0.36 | 0.36 | 0.05 | 1.50 | 1.50 | XXX |
| 72192 | TC | A | Ct pelvis w/o dye | 0.00 | 5.90 | NA | 0.31 | 6.21 | NA | XXX |
| 72193 | | A | Ct pelvis w/dye | 1.16 | 7.21 | NA | 0.41 | 8.78 | NA | XXX |
| 72193 | 26 | A | Ct pelvis w/dye | 1.16 | 0.38 | 0.38 | 0.05 | 1.59 | 1.59 | XXX |
| 72193 | TC | A | Ct pelvis w/dye | 0.00 | 6.83 | NA | 0.36 | 7.19 | NA | XXX |
| 72194 | | A | Ct pelvis w/o & w/dye | 1.22 | 8.87 | NA | 0.48 | 10.57 | NA | XXX |
| 72194 | 26 | A | Ct pelvis w/o & w/dye | 1.22 | 0.40 | 0.40 | 0.05 | 1.67 | 1.67 | XXX |
| 72194 | TC | A | Ct pelvis w/o & w/dye | 0.00 | 8.47 | NA | 0.43 | 8.90 | NA | XXX |
| 72195 | | A | Mri pelvis w/o dye | 1.46 | 11.66 | NA | 0.52 | 13.64 | NA | XXX |
| 72195 | 26 | A | Mri pelvis w/o dye | 1.46 | 0.48 | 0.48 | 0.07 | 2.01 | 2.01 | XXX |
| 72195 | TC | A | Mri pelvis w/o dye | 0.00 | 11.19 | NA | 0.45 | 11.64 | NA | XXX |
| 72196 | | A | Mri pelvis w/dye | 1.73 | 13.98 | NA | 0.60 | 16.31 | NA | XXX |
| 72196 | 26 | A | Mri pelvis w/dye | 1.73 | 0.56 | 0.56 | 0.08 | 2.37 | 2.37 | XXX |
| 72196 | TC | A | Mri pelvis w/dye | 0.00 | 13.42 | NA | 0.52 | 13.94 | NA | XXX |
| 72197 | | A | Mri pelvis w/o & w/dye | 2.26 | 25.58 | NA | 1.02 | 28.86 | NA | XXX |
| 72197 | 26 | A | Mri pelvis w/o & w/dye | 2.26 | 0.74 | 0.74 | 0.10 | 3.10 | 3.10 | XXX |
| 72197 | TC | A | Mri pelvis w/o & w/dye | 0.00 | 24.84 | NA | 0.92 | 25.76 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 72198 | | A | Mr angio pelvis w/o & w/dye | 1.80 | 11.77 | NA | 0.69 | 14.26 | NA | XXX |
| 72198 | 26 | A | Mr angio pelvis w/o & w/dye | 1.80 | 0.59 | 0.59 | 0.10 | 2.49 | 2.49 | XXX |
| 72198 | TC | A | Mr angio pelvis w/o & w/dye | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 72200 | | A | X-ray exam sacroiliac joints | 0.17 | 0.58 | NA | 0.03 | 0.78 | NA | XXX |
| 72200 | 26 | A | X-ray exam sacroiliac joints | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 72200 | TC | A | X-ray exam sacroiliac joints | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 72202 | | A | X-ray exam sacroiliac joints | 0.19 | 0.68 | NA | 0.05 | 0.92 | NA | XXX |
| 72202 | 26 | A | X-ray exam sacroiliac joints | 0.19 | 0.06 | 0.06 | 0.01 | 0.26 | 0.26 | XXX |
| 72202 | TC | A | X-ray exam sacroiliac joints | 0.00 | 0.62 | NA | 0.04 | 0.66 | NA | XXX |
| 72220 | | A | X-ray exam of tailbone | 0.17 | 0.63 | NA | 0.05 | 0.85 | NA | XXX |
| 72220 | 26 | A | X-ray exam of tailbone | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 72220 | TC | A | X-ray exam of tailbone | 0.00 | 0.57 | NA | 0.04 | 0.61 | NA | XXX |
| 72240 | | A | Contrast x-ray of neck spine | 0.91 | 5.03 | NA | 0.29 | 6.23 | NA | XXX |
| 72240 | 26 | A | Contrast x-ray of neck spine | 0.91 | 0.29 | 0.29 | 0.04 | 1.24 | 1.24 | XXX |
| 72240 | TC | A | Contrast x-ray of neck spine | 0.00 | 4.74 | NA | 0.25 | 4.99 | NA | XXX |
| 72255 | | A | Contrast x-ray, thorax spine | 0.91 | 4.59 | NA | 0.26 | 5.76 | NA | XXX |
| 72255 | 26 | A | Contrast x-ray, thorax spine | 0.91 | 0.27 | 0.27 | 0.04 | 1.22 | 1.22 | XXX |
| 72255 | TC | A | Contrast x-ray, thorax spine | 0.00 | 4.32 | NA | 0.22 | 4.54 | NA | XXX |
| 72265 | | A | Contrast x-ray, lower spine | 0.83 | 4.32 | NA | 0.26 | 5.41 | NA | XXX |
| 72265 | 26 | A | Contrast x-ray, lower spine | 0.83 | 0.25 | 0.25 | 0.04 | 1.12 | 1.12 | XXX |
| 72265 | TC | A | Contrast x-ray, lower spine | 0.00 | 4.06 | NA | 0.22 | 4.28 | NA | XXX |
| 72270 | | A | Contrast x-ray, spine | 1.33 | 6.51 | NA | 0.40 | 8.24 | NA | XXX |
| 72270 | 26 | A | Contrast x-ray, spine | 1.33 | 0.42 | 0.42 | 0.07 | 1.82 | 1.82 | XXX |
| 72270 | TC | A | Contrast x-ray, spine | 0.00 | 6.09 | NA | 0.33 | 6.42 | NA | XXX |
| 72275 | | A | Epidurography | 0.76 | 2.29 | NA | 0.27 | 3.32 | NA | XXX |
| 72275 | 26 | A | Epidurography | 0.76 | 0.20 | 0.20 | 0.05 | 1.01 | 1.01 | XXX |
| 72275 | TC | A | Epidurography | 0.00 | 2.09 | NA | 0.22 | 2.31 | NA | XXX |
| 72285 | | A | X-ray c/t spine disk | 1.16 | 8.72 | NA | 0.50 | 10.38 | NA | XXX |
| 72285 | 26 | A | X-ray c/t spine disk | 1.16 | 0.35 | 0.35 | 0.07 | 1.58 | 1.58 | XXX |
| 72285 | TC | A | X-ray c/t spine disk | 0.00 | 8.37 | NA | 0.43 | 8.80 | NA | XXX |
| 72295 | | A | X-ray of lower spine disk | 0.83 | 8.11 | NA | 0.46 | 9.40 | NA | XXX |
| 72295 | 26 | A | X-ray of lower spine disk | 0.83 | 0.27 | 0.27 | 0.06 | 1.16 | 1.16 | XXX |
| 72295 | TC | A | X-ray of lower spine disk | 0.00 | 7.85 | NA | 0.40 | 8.25 | NA | XXX |
| 73000 | | A | X-ray exam of collar bone | 0.16 | 0.57 | NA | 0.03 | 0.76 | NA | XXX |
| 73000 | 26 | A | X-ray exam of collar bone | 0.16 | 0.05 | 0.05 | 0.01 | 0.22 | 0.22 | XXX |
| 73000 | TC | A | X-ray exam of collar bone | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 73010 | | A | X-ray exam of shoulder blade | 0.17 | 0.58 | NA | 0.03 | 0.78 | NA | XXX |
| 73010 | 26 | A | X-ray exam of shoulder blade | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 73010 | TC | A | X-ray exam of shoulder blade | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 73020 | | A | X-ray exam of shoulder | 0.15 | 0.52 | NA | 0.03 | 0.70 | NA | XXX |
| 73020 | 26 | A | X-ray exam of shoulder | 0.15 | 0.05 | 0.05 | 0.01 | 0.21 | 0.21 | XXX |
| 73020 | TC | A | X-ray exam of shoulder | 0.00 | 0.47 | NA | 0.02 | 0.49 | NA | XXX |
| 73030 | | A | X-ray exam of shoulder | 0.18 | 0.63 | NA | 0.05 | 0.86 | NA | XXX |
| 73030 | 26 | A | X-ray exam of shoulder | 0.18 | 0.06 | 0.06 | 0.01 | 0.25 | 0.25 | XXX |
| 73030 | TC | A | X-ray exam of shoulder | 0.00 | 0.57 | NA | 0.04 | 0.61 | NA | XXX |
| 73040 | | A | Contrast x-ray of shoulder | 0.54 | 2.27 | NA | 0.14 | 2.95 | NA | XXX |
| 73040 | 26 | A | Contrast x-ray of shoulder | 0.54 | 0.18 | 0.18 | 0.02 | 0.74 | 0.74 | XXX |
| 73040 | TC | A | Contrast x-ray of shoulder | 0.00 | 2.09 | NA | 0.12 | 2.21 | NA | XXX |
| 73050 | | A | X-ray exam of shoulders | 0.20 | 0.73 | NA | 0.05 | 0.98 | NA | XXX |
| 73050 | 26 | A | X-ray exam of shoulders | 0.20 | 0.07 | 0.07 | 0.01 | 0.28 | 0.28 | XXX |
| 73050 | TC | A | X-ray exam of shoulders | 0.00 | 0.67 | NA | 0.04 | 0.71 | NA | XXX |
| 73060 | | A | X-ray exam of humerus | 0.17 | 0.63 | NA | 0.05 | 0.85 | NA | XXX |
| 73060 | 26 | A | X-ray exam of humerus | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 73060 | TC | A | X-ray exam of humerus | 0.00 | 0.57 | NA | 0.04 | 0.61 | NA | XXX |
| 73070 | | A | X-ray exam of elbow | 0.15 | 0.57 | NA | 0.03 | 0.75 | NA | XXX |
| 73070 | 26 | A | X-ray exam of elbow | 0.15 | 0.05 | 0.05 | 0.01 | 0.21 | 0.21 | XXX |
| 73070 | TC | A | X-ray exam of elbow | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 73080 | | A | X-ray exam of elbow | 0.17 | 0.63 | NA | 0.05 | 0.85 | NA | XXX |
| 73080 | 26 | A | X-ray exam of elbow | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 73080 | TC | A | X-ray exam of elbow | 0.00 | 0.57 | NA | 0.04 | 0.61 | NA | XXX |
| 73085 | | A | Contrast x-ray of elbow | 0.54 | 2.28 | NA | 0.15 | 2.97 | NA | XXX |
| 73085 | 26 | A | Contrast x-ray of elbow | 0.54 | 0.18 | 0.18 | 0.03 | 0.75 | 0.75 | XXX |
| 73085 | TC | A | Contrast x-ray of elbow | 0.00 | 2.09 | NA | 0.12 | 2.21 | NA | XXX |
| 73090 | | A | X-ray exam of forearm | 0.16 | 0.57 | NA | 0.03 | 0.76 | NA | XXX |
| 73090 | 26 | A | X-ray exam of forearm | 0.16 | 0.05 | 0.05 | 0.01 | 0.22 | 0.22 | XXX |
| 73090 | TC | A | X-ray exam of forearm | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 73092 | | A | X-ray exam of arm, infant | 0.16 | 0.54 | NA | 0.03 | 0.73 | NA | XXX |
| 73092 | 26 | A | X-ray exam of arm, infant | 0.16 | 0.05 | 0.05 | 0.01 | 0.22 | 0.22 | XXX |
| 73092 | TC | A | X-ray exam of arm, infant | 0.00 | 0.49 | NA | 0.02 | 0.51 | NA | XXX |
| 73100 | | A | X-ray exam of wrist | 0.16 | 0.55 | NA | 0.03 | 0.74 | NA | XXX |
| 73100 | 26 | A | X-ray exam of wrist | 0.16 | 0.05 | 0.05 | 0.01 | 0.22 | 0.22 | XXX |
| 73100 | TC | A | X-ray exam of wrist | 0.00 | 0.49 | NA | 0.02 | 0.51 | NA | XXX |
| 73110 | | A | X-ray exam of wrist | 0.17 | 0.59 | NA | 0.03 | 0.79 | NA | XXX |
| 73110 | 26 | A | X-ray exam of wrist | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 73110 | TC | A | X-ray exam of wrist | 0.00 | 0.53 | NA | 0.02 | 0.55 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 73115 | | A | Contrast x-ray of wrist | 0.54 | 1.76 | NA | 0.13 | 2.43 | NA | XXX |
| 73115 | 26 | A | Contrast x-ray of wrist | 0.54 | 0.18 | 0.18 | 0.03 | 0.75 | 0.75 | XXX |
| 73115 | TC | A | Contrast x-ray of wrist | 0.00 | 1.57 | NA | 0.10 | 1.67 | NA | XXX |
| 73120 | | A | X-ray exam of hand | 0.16 | 0.55 | NA | 0.03 | 0.74 | NA | XXX |
| 73120 | 26 | A | X-ray exam of hand | 0.16 | 0.05 | 0.05 | 0.01 | 0.22 | 0.22 | XXX |
| 73120 | TC | A | X-ray exam of hand | 0.00 | 0.49 | NA | 0.02 | 0.51 | NA | XXX |
| 73130 | | A | X-ray exam of hand | 0.17 | 0.59 | NA | 0.03 | 0.79 | NA | XXX |
| 73130 | 26 | A | X-ray exam of hand | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 73130 | TC | A | X-ray exam of hand | 0.00 | 0.53 | NA | 0.02 | 0.55 | NA | XXX |
| 73140 | | A | X-ray exam of finger(s) | 0.13 | 0.46 | NA | 0.03 | 0.62 | NA | XXX |
| 73140 | 26 | A | X-ray exam of finger(s) | 0.13 | 0.04 | 0.04 | 0.01 | 0.18 | 0.18 | XXX |
| 73140 | TC | A | X-ray exam of finger(s) | 0.00 | 0.42 | NA | 0.02 | 0.44 | NA | XXX |
| 73200 | | A | Ct upper extremity w/o dye | 1.09 | 5.31 | NA | 0.30 | 6.70 | NA | XXX |
| 73200 | 26 | A | Ct upper extremity w/o dye | 1.09 | 0.36 | 0.36 | 0.05 | 1.50 | 1.50 | XXX |
| 73200 | TC | A | Ct upper extremity w/o dye | 0.00 | 4.95 | NA | 0.25 | 5.20 | NA | XXX |
| 73201 | | A | Ct upper extremity w/dye | 1.16 | 6.28 | NA | 0.36 | 7.80 | NA | XXX |
| 73201 | 26 | A | Ct upper extremity w/dye | 1.16 | 0.38 | 0.38 | 0.05 | 1.59 | 1.59 | XXX |
| 73201 | TC | A | Ct upper extremity w/dye | 0.00 | 5.90 | NA | 0.31 | 6.21 | NA | XXX |
| 73202 | | A | Ct uppr extremity w/o&w/dye | 1.22 | 7.81 | NA | 0.44 | 9.47 | NA | XXX |
| 73202 | 26 | A | Ct uppr extremity w/o&w/dye | 1.22 | 0.40 | 0.40 | 0.05 | 1.67 | 1.67 | XXX |
| 73202 | TC | A | Ct uppr extremity w/o&w/dye | 0.00 | 7.41 | NA | 0.39 | 7.80 | NA | XXX |
| 73206 | | A | Ct angio upr extrm w/o&w/dye | 1.81 | 11.54 | NA | 0.47 | 13.82 | NA | XXX |
| 73206 | 26 | A | Ct angio upr extrm w/o&w/dye | 1.81 | 0.59 | 0.59 | 0.08 | 2.48 | 2.48 | XXX |
| 73206 | TC | A | Ct angio upr extrm w/o&w/dye | 0.00 | 10.94 | NA | 0.39 | 11.33 | NA | XXX |
| 73218 | | A | Mri upper extremity w/o dye | 1.35 | 11.63 | NA | 0.45 | 13.43 | NA | XXX |
| 73218 | 26 | A | Mri upper extremity w/o dye | 1.35 | 0.44 | 0.44 | 0.06 | 1.85 | 1.85 | XXX |
| 73218 | TC | A | Mri upper extremity w/o dye | 0.00 | 11.19 | NA | 0.39 | 11.58 | NA | XXX |
| 73219 | | A | Mri upper extremity w/dye | 1.62 | 13.95 | NA | 0.54 | 16.11 | NA | XXX |
| 73219 | 26 | A | Mri upper extremity w/dye | 1.62 | 0.53 | 0.53 | 0.07 | 2.22 | 2.22 | XXX |
| 73219 | TC | A | Mri upper extremity w/dye | 0.00 | 13.42 | NA | 0.47 | 13.89 | NA | XXX |
| 73220 | | A | Mri uppr extremity w/o&w/dye | 2.15 | 25.55 | NA | 0.94 | 28.64 | NA | XXX |
| 73220 | 26 | A | Mri uppr extremity w/o&w/dye | 2.15 | 0.71 | 0.71 | 0.10 | 2.96 | 2.96 | XXX |
| 73220 | TC | A | Mri uppr extremity w/o&w/dye | 0.00 | 24.84 | NA | 0.84 | 25.68 | NA | XXX |
| 73221 | | A | Mri joint upr extrem w/o dye | 1.35 | 11.63 | NA | 0.45 | 13.43 | NA | XXX |
| 73221 | 26 | A | Mri joint upr extrem w/o dye | 1.35 | 0.44 | 0.44 | 0.06 | 1.85 | 1.85 | XXX |
| 73221 | TC | A | Mri joint upr extrem w/o dye | 0.00 | 11.19 | NA | 0.39 | 11.58 | NA | XXX |
| 73222 | | A | Mri joint upr extrem w/dye | 1.62 | 13.95 | NA | 0.54 | 16.11 | NA | XXX |
| 73222 | 26 | A | Mri joint upr extrem w/dye | 1.62 | 0.53 | 0.53 | 0.07 | 2.22 | 2.22 | XXX |
| 73222 | TC | A | Mri joint upr extrem w/dye | 0.00 | 13.42 | NA | 0.47 | 13.89 | NA | XXX |
| 73223 | | A | Mri joint upr extr w/o&w/dye | 2.15 | 25.55 | NA | 0.94 | 28.64 | NA | XXX |
| 73223 | 26 | A | Mri joint upr extr w/o&w/dye | 2.15 | 0.71 | 0.71 | 0.10 | 2.96 | 2.96 | XXX |
| 73223 | TC | A | Mri joint upr extr w/o&w/dye | 0.00 | 24.84 | NA | 0.84 | 25.68 | NA | XXX |
| 73500 | | A | X-ray exam of hip | 0.17 | 0.53 | NA | 0.03 | 0.73 | NA | XXX |
| 73500 | 26 | A | X-ray exam of hip | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 73500 | TC | A | X-ray exam of hip | 0.00 | 0.47 | NA | 0.02 | 0.49 | NA | XXX |
| 73510 | | A | X-ray exam of hip | 0.21 | 0.64 | NA | 0.05 | 0.90 | NA | XXX |
| 73510 | 26 | A | X-ray exam of hip | 0.21 | 0.07 | 0.07 | 0.01 | 0.29 | 0.29 | XXX |
| 73510 | TC | A | X-ray exam of hip | 0.00 | 0.57 | NA | 0.04 | 0.61 | NA | XXX |
| 73520 | | A | X-ray exam of hips | 0.26 | 0.75 | NA | 0.05 | 1.06 | NA | XXX |
| 73520 | 26 | A | X-ray exam of hips | 0.26 | 0.09 | 0.09 | 0.01 | 0.36 | 0.36 | XXX |
| 73520 | TC | A | X-ray exam of hips | 0.00 | 0.67 | NA | 0.04 | 0.71 | NA | XXX |
| 73525 | | A | Contrast x-ray of hip | 0.54 | 2.27 | NA | 0.15 | 2.96 | NA | XXX |
| 73525 | 26 | A | Contrast x-ray of hip | 0.54 | 0.18 | 0.18 | 0.03 | 0.75 | 0.75 | XXX |
| 73525 | TC | A | Contrast x-ray of hip | 0.00 | 2.09 | NA | 0.12 | 2.21 | NA | XXX |
| 73530 | | A | X-ray exam of hip | 0.29 | 0.62 | NA | 0.03 | 0.94 | NA | XXX |
| 73530 | 26 | A | X-ray exam of hip | 0.29 | 0.10 | 0.10 | 0.01 | 0.40 | 0.40 | XXX |
| 73530 | TC | A | X-ray exam of hip | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 73540 | | A | X-ray exam of pelvis & hips | 0.20 | 0.64 | NA | 0.05 | 0.89 | NA | XXX |
| 73540 | 26 | A | X-ray exam of pelvis & hips | 0.20 | 0.07 | 0.07 | 0.01 | 0.28 | 0.28 | XXX |
| 73540 | TC | A | X-ray exam of pelvis & hips | 0.00 | 0.57 | NA | 0.04 | 0.61 | NA | XXX |
| 73542 | | A | X-ray exam, sacroiliac joint | 0.59 | 2.25 | NA | 0.15 | 2.99 | NA | XXX |
| 73542 | 26 | A | X-ray exam, sacroiliac joint | 0.59 | 0.16 | 0.16 | 0.03 | 0.78 | 0.78 | XXX |
| 73542 | TC | A | X-ray exam, sacroiliac joint | 0.00 | 2.09 | NA | 0.12 | 2.21 | NA | XXX |
| 73550 | | A | X-ray exam of thigh | 0.17 | 0.63 | NA | 0.05 | 0.85 | NA | XXX |
| 73550 | 26 | A | X-ray exam of thigh | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 73550 | TC | A | X-ray exam of thigh | 0.00 | 0.57 | NA | 0.04 | 0.61 | NA | XXX |
| 73560 | | A | X-ray exam of knee, 1 or 2 | 0.17 | 0.58 | NA | 0.03 | 0.78 | NA | XXX |
| 73560 | 26 | A | X-ray exam of knee, 1 or 2 | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 73560 | TC | A | X-ray exam of knee, 1 or 2 | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 73562 | | A | X-ray exam of knee, 3 | 0.18 | 0.63 | NA | 0.05 | 0.86 | NA | XXX |
| 73562 | 26 | A | X-ray exam of knee, 3 | 0.18 | 0.06 | 0.06 | 0.01 | 0.25 | 0.25 | XXX |
| 73562 | TC | A | X-ray exam of knee, 3 | 0.00 | 0.57 | NA | 0.04 | 0.61 | NA | XXX |
| 73564 | | A | X-ray exam, knee, 4 or more | 0.22 | 0.69 | NA | 0.05 | 0.96 | NA | XXX |
| 73564 | 26 | A | X-ray exam, knee, 4 or more | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| 73564 | TC | A | X-ray exam, knee, 4 or more | 0.00 | 0.62 | NA | 0.04 | 0.66 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 73565 | | A | X-ray exam of knees | 0.17 | 0.55 | NA | 0.03 | 0.75 | NA | XXX |
| 73565 | 26 | A | X-ray exam of knees | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 73565 | TC | A | X-ray exam of knees | 0.00 | 0.49 | NA | 0.02 | 0.51 | NA | XXX |
| 73580 | | A | Contrast x-ray of knee joint | 0.54 | 2.79 | NA | 0.17 | 3.50 | NA | XXX |
| 73580 | 26 | A | Contrast x-ray of knee joint | 0.54 | 0.17 | 0.17 | 0.03 | 0.74 | 0.74 | XXX |
| 73580 | TC | A | Contrast x-ray of knee joint | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 73590 | | A | X-ray exam of lower leg | 0.17 | 0.58 | NA | 0.03 | 0.78 | NA | XXX |
| 73590 | 26 | A | X-ray exam of lower leg | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 73590 | TC | A | X-ray exam of lower leg | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 73592 | | A | X-ray exam of leg, infant | 0.16 | 0.55 | NA | 0.03 | 0.74 | NA | XXX |
| 73592 | 26 | A | X-ray exam of leg, infant | 0.16 | 0.05 | 0.05 | 0.01 | 0.22 | 0.22 | XXX |
| 73592 | TC | A | X-ray exam of leg, infant | 0.00 | 0.49 | NA | 0.02 | 0.51 | NA | XXX |
| 73600 | | A | X-ray exam of ankle | 0.16 | 0.55 | NA | 0.03 | 0.74 | NA | XXX |
| 73600 | 26 | A | X-ray exam of ankle | 0.16 | 0.05 | 0.05 | 0.01 | 0.22 | 0.22 | XXX |
| 73600 | TC | A | X-ray exam of ankle | 0.00 | 0.49 | NA | 0.02 | 0.51 | NA | XXX |
| 73610 | | A | X-ray exam of ankle | 0.17 | 0.59 | NA | 0.03 | 0.79 | NA | XXX |
| 73610 | 26 | A | X-ray exam of ankle | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 73610 | TC | A | X-ray exam of ankle | 0.00 | 0.53 | NA | 0.02 | 0.55 | NA | XXX |
| 73615 | | A | Contrast x-ray of ankle | 0.54 | 2.28 | NA | 0.15 | 2.97 | NA | XXX |
| 73615 | 26 | A | Contrast x-ray of ankle | 0.54 | 0.18 | 0.18 | 0.03 | 0.75 | 0.75 | XXX |
| 73615 | TC | A | Contrast x-ray of ankle | 0.00 | 2.09 | NA | 0.12 | 2.21 | NA | XXX |
| 73620 | | A | X-ray exam of foot | 0.16 | 0.55 | NA | 0.03 | 0.74 | NA | XXX |
| 73620 | 26 | A | X-ray exam of foot | 0.16 | 0.05 | 0.05 | 0.01 | 0.22 | 0.22 | XXX |
| 73620 | TC | A | X-ray exam of foot | 0.00 | 0.49 | NA | 0.02 | 0.51 | NA | XXX |
| 73630 | | A | X-ray exam of foot | 0.17 | 0.59 | NA | 0.03 | 0.79 | NA | XXX |
| 73630 | 26 | A | X-ray exam of foot | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 73630 | TC | A | X-ray exam of foot | 0.00 | 0.53 | NA | 0.02 | 0.55 | NA | XXX |
| 73650 | | A | X-ray exam of heel | 0.16 | 0.53 | NA | 0.03 | 0.72 | NA | XXX |
| 73650 | 26 | A | X-ray exam of heel | 0.16 | 0.05 | 0.05 | 0.01 | 0.22 | 0.22 | XXX |
| 73650 | TC | A | X-ray exam of heel | 0.00 | 0.47 | NA | 0.02 | 0.49 | NA | XXX |
| 73660 | | A | X-ray exam of toe(s) | 0.13 | 0.46 | NA | 0.03 | 0.62 | NA | XXX |
| 73660 | 26 | A | X-ray exam of toe(s) | 0.13 | 0.04 | 0.04 | 0.01 | 0.18 | 0.18 | XXX |
| 73660 | TC | A | X-ray exam of toe(s) | 0.00 | 0.42 | NA | 0.02 | 0.44 | NA | XXX |
| 73700 | | A | Ct lower extremity w/o dye | 1.09 | 5.31 | NA | 0.30 | 6.70 | NA | XXX |
| 73700 | 26 | A | Ct lower extremity w/o dye | 1.09 | 0.36 | 0.36 | 0.05 | 1.50 | 1.50 | XXX |
| 73700 | TC | A | Ct lower extremity w/o dye | 0.00 | 4.95 | NA | 0.25 | 5.20 | NA | XXX |
| 73701 | | A | Ct lower extremity w/dye | 1.16 | 6.28 | NA | 0.36 | 7.80 | NA | XXX |
| 73701 | 26 | A | Ct lower extremity w/dye | 1.16 | 0.38 | 0.38 | 0.05 | 1.59 | 1.59 | XXX |
| 73701 | TC | A | Ct lower extremity w/dye | 0.00 | 5.90 | NA | 0.31 | 6.21 | NA | XXX |
| 73702 | | A | Ct lwr extremity w/o&w/dye | 1.22 | 7.81 | NA | 0.45 | 9.48 | NA | XXX |
| 73702 | 26 | A | Ct lwr extremity w/o&w/dye | 1.22 | 0.40 | 0.40 | 0.06 | 1.68 | 1.68 | XXX |
| 73702 | TC | A | Ct lwr extremity w/o&w/dye | 0.00 | 7.41 | NA | 0.39 | 7.80 | NA | XXX |
| 73706 | | A | Ct angio lwr extr w/o&w/dye | 1.90 | 11.57 | NA | 0.48 | 13.95 | NA | XXX |
| 73706 | 26 | A | Ct angio lwr extr w/o&w/dye | 1.90 | 0.62 | 0.62 | 0.09 | 2.61 | 2.61 | XXX |
| 73706 | TC | A | Ct angio lwr extr w/o&w/dye | 0.00 | 10.94 | NA | 0.39 | 11.33 | NA | XXX |
| 73718 | | A | Mri lower extremity w/o dye | 1.35 | 11.63 | NA | 0.45 | 13.43 | NA | XXX |
| 73718 | 26 | A | Mri lower extremity w/o dye | 1.35 | 0.44 | 0.44 | 0.06 | 1.85 | 1.85 | XXX |
| 73718 | TC | A | Mri lower extremity w/o dye | 0.00 | 11.19 | NA | 0.39 | 11.58 | NA | XXX |
| 73719 | | A | Mri lower extremity w/dye | 1.62 | 13.95 | NA | 0.54 | 16.11 | NA | XXX |
| 73719 | 26 | A | Mri lower extremity w/dye | 1.62 | 0.53 | 0.53 | 0.07 | 2.22 | 2.22 | XXX |
| 73719 | TC | A | Mri lower extremity w/dye | 0.00 | 13.42 | NA | 0.47 | 13.89 | NA | XXX |
| 73720 | | A | Mri lwr extremity w/o&w/dye | 2.15 | 25.55 | NA | 0.94 | 28.64 | NA | XXX |
| 73720 | 26 | A | Mri lwr extremity w/o&w/dye | 2.15 | 0.70 | 0.70 | 0.10 | 2.95 | 2.95 | XXX |
| 73720 | TC | A | Mri lwr extremity w/o&w/dye | 0.00 | 24.84 | NA | 0.84 | 25.68 | NA | XXX |
| 73721 | | A | Mri jnt of lwr extre w/o dye | 1.35 | 11.63 | NA | 0.45 | 13.43 | NA | XXX |
| 73721 | 26 | A | Mri jnt of lwr extre w/o dye | 1.35 | 0.44 | 0.44 | 0.06 | 1.85 | 1.85 | XXX |
| 73721 | TC | A | Mri jnt of lwr extre w/o dye | 0.00 | 11.19 | NA | 0.39 | 11.58 | NA | XXX |
| 73722 | | A | Mri joint of lwr extr w/dye | 1.62 | 13.95 | NA | 0.55 | 16.12 | NA | XXX |
| 73722 | 26 | A | Mri joint of lwr extr w/dye | 1.62 | 0.53 | 0.53 | 0.08 | 2.23 | 2.23 | XXX |
| 73722 | TC | A | Mri joint of lwr extr w/dye | 0.00 | 13.42 | NA | 0.47 | 13.89 | NA | XXX |
| 73723 | | A | Mri joint lwr extr w/o&w/dye | 2.15 | 25.55 | NA | 0.94 | 28.64 | NA | XXX |
| 73723 | 26 | A | Mri joint lwr extr w/o&w/dye | 2.15 | 0.71 | 0.71 | 0.10 | 2.96 | 2.96 | XXX |
| 73723 | TC | A | Mri joint lwr extr w/o&w/dye | 0.00 | 24.84 | NA | 0.84 | 25.68 | NA | XXX |
| 73725 | | R | Mr ang lwr ext w or w/o dye | 1.82 | 11.78 | NA | 0.67 | 14.27 | NA | XXX |
| 73725 | 26 | R | Mr ang lwr ext w or w/o dye | 1.82 | 0.60 | 0.60 | 0.08 | 2.50 | 2.50 | XXX |
| 73725 | TC | R | Mr ang lwr ext w or w/o dye | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 74000 | | A | X-ray exam of abdomen | 0.18 | 0.58 | NA | 0.03 | 0.79 | NA | XXX |
| 74000 | 26 | A | X-ray exam of abdomen | 0.18 | 0.06 | 0.06 | 0.01 | 0.25 | 0.25 | XXX |
| 74000 | TC | A | X-ray exam of abdomen | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 74010 | | A | X-ray exam of abdomen | 0.23 | 0.64 | NA | 0.05 | 0.92 | NA | XXX |
| 74010 | 26 | A | X-ray exam of abdomen | 0.23 | 0.07 | 0.07 | 0.01 | 0.31 | 0.31 | XXX |
| 74010 | TC | A | X-ray exam of abdomen | 0.00 | 0.57 | NA | 0.04 | 0.61 | NA | XXX |
| 74020 | | A | X-ray exam of abdomen | 0.27 | 0.71 | NA | 0.05 | 1.03 | NA | XXX |
| 74020 | 26 | A | X-ray exam of abdomen | 0.27 | 0.09 | 0.09 | 0.01 | 0.37 | 0.37 | XXX |
| 74020 | TC | A | X-ray exam of abdomen | 0.00 | 0.62 | NA | 0.04 | 0.66 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 74022 | | A | X-ray exam series, abdomen | 0.32 | 0.84 | NA | 0.06 | 1.22 | NA | XXX |
| 74022 | 26 | A | X-ray exam series, abdomen | 0.32 | 0.10 | 0.10 | 0.01 | 0.43 | 0.43 | XXX |
| 74022 | TC | A | X-ray exam series, abdomen | 0.00 | 0.73 | NA | 0.05 | 0.78 | NA | XXX |
| 74150 | | A | Ct abdomen w/o dye | 1.19 | 6.03 | NA | 0.35 | 7.57 | NA | XXX |
| 74150 | 26 | A | Ct abdomen w/o dye | 1.19 | 0.39 | 0.39 | 0.05 | 1.63 | 1.63 | XXX |
| 74150 | TC | A | Ct abdomen w/o dye | 0.00 | 5.65 | NA | 0.30 | 5.95 | NA | XXX |
| 74160 | | A | Ct abdomen w/dye | 1.27 | 7.25 | NA | 0.42 | 8.94 | NA | XXX |
| 74160 | 26 | A | Ct abdomen w/dye | 1.27 | 0.41 | 0.41 | 0.06 | 1.74 | 1.74 | XXX |
| 74160 | TC | A | Ct abdomen w/dye | 0.00 | 6.83 | NA | 0.36 | 7.19 | NA | XXX |
| 74170 | | A | Ct abdomen w/o &w /dye | 1.40 | 8.93 | NA | 0.49 | 10.82 | NA | XXX |
| 74170 | 26 | A | Ct abdomen w/o &w /dye | 1.40 | 0.46 | 0.46 | 0.06 | 1.92 | 1.92 | XXX |
| 74170 | TC | A | Ct abdomen w/o &w /dye | 0.00 | 8.47 | NA | 0.43 | 8.90 | NA | XXX |
| 74175 | | A | Ct angio abdom w/o & w/dye | 1.90 | 12.63 | NA | 0.48 | 15.01 | NA | XXX |
| 74175 | 26 | A | Ct angio abdom w/o & w/dye | 1.90 | 0.62 | 0.62 | 0.09 | 2.61 | 2.61 | XXX |
| 74175 | TC | A | Ct angio abdom w/o & w/dye | 0.00 | 12.01 | NA | 0.39 | 12.40 | NA | XXX |
| 74181 | | A | Mri abdomen w/o dye | 1.46 | 11.66 | NA | 0.52 | 13.64 | NA | XXX |
| 74181 | 26 | A | Mri abdomen w/o dye | 1.46 | 0.48 | 0.48 | 0.07 | 2.01 | 2.01 | XXX |
| 74181 | TC | A | Mri abdomen w/o dye | 0.00 | 11.19 | NA | 0.45 | 11.64 | NA | XXX |
| 74182 | | A | Mri abdomen w/dye | 1.73 | 13.98 | NA | 0.60 | 16.31 | NA | XXX |
| 74182 | 26 | A | Mri abdomen w/dye | 1.73 | 0.56 | 0.56 | 0.08 | 2.37 | 2.37 | XXX |
| 74182 | TC | A | Mri abdomen w/dye | 0.00 | 13.42 | NA | 0.52 | 13.94 | NA | XXX |
| 74183 | | A | Mri abdomen w/o & w/dye | 2.26 | 25.58 | NA | 1.02 | 28.86 | NA | XXX |
| 74183 | 26 | A | Mri abdomen w/o & w/dye | 2.26 | 0.74 | 0.74 | 0.10 | 3.10 | 3.10 | XXX |
| 74183 | TC | A | Mri abdomen w/o & w/dye | 0.00 | 24.84 | NA | 0.92 | 25.76 | NA | XXX |
| 74185 | | R | Mri angio, abdom w orw/o dye | 1.80 | 11.78 | NA | 0.67 | 14.25 | NA | XXX |
| 74185 | 26 | R | Mri angio, abdom w orw/o dye | 1.80 | 0.59 | 0.59 | 0.08 | 2.47 | 2.47 | XXX |
| 74185 | TC | R | Mri angio, abdom w orw/o dye | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 74190 | | A | X-ray exam of peritoneum | 0.48 | 1.46 | NA | 0.09 | 2.03 | NA | XXX |
| 74190 | 26 | A | X-ray exam of peritoneum | 0.48 | 0.16 | 0.16 | 0.02 | 0.66 | 0.66 | XXX |
| 74190 | TC | A | X-ray exam of peritoneum | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 74210 | | A | Contrst x-ray exam of throat | 0.36 | 1.30 | NA | 0.08 | 1.74 | NA | XXX |
| 74210 | 26 | A | Contrst x-ray exam of throat | 0.36 | 0.12 | 0.12 | 0.02 | 0.50 | 0.50 | XXX |
| 74210 | TC | A | Contrst x-ray exam of throat | 0.00 | 1.19 | NA | 0.06 | 1.25 | NA | XXX |
| 74220 | | A | Contrast x-ray, esophagus | 0.46 | 1.34 | NA | 0.08 | 1.88 | NA | XXX |
| 74220 | 26 | A | Contrast x-ray, esophagus | 0.46 | 0.15 | 0.15 | 0.02 | 0.63 | 0.63 | XXX |
| 74220 | TC | A | Contrast x-ray, esophagus | 0.00 | 1.19 | NA | 0.06 | 1.25 | NA | XXX |
| 74230 | | A | Cine/vid x-ray, throat/esoph | 0.53 | 1.48 | NA | 0.09 | 2.10 | NA | XXX |
| 74230 | 26 | A | Cine/vid x-ray, throat/esoph | 0.53 | 0.17 | 0.17 | 0.02 | 0.72 | 0.72 | XXX |
| 74230 | TC | A | Cine/vid x-ray, throat/esoph | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 74235 | | A | Remove esophagus obstruction | 1.19 | 3.01 | NA | 0.19 | 4.39 | NA | XXX |
| 74235 | 26 | A | Remove esophagus obstruction | 1.19 | 0.39 | 0.39 | 0.05 | 1.63 | 1.63 | XXX |
| 74235 | TC | A | Remove esophagus obstruction | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 74240 | | A | X-ray exam, upper gi tract | 0.69 | 1.68 | NA | 0.11 | 2.48 | NA | XXX |
| 74240 | 26 | A | X-ray exam, upper gi tract | 0.69 | 0.22 | 0.22 | 0.03 | 0.94 | 0.94 | XXX |
| 74240 | TC | A | X-ray exam, upper gi tract | 0.00 | 1.46 | NA | 0.08 | 1.54 | NA | XXX |
| 74241 | | A | X-ray exam, upper gi tract | 0.69 | 1.71 | NA | 0.11 | 2.51 | NA | XXX |
| 74241 | 26 | A | X-ray exam, upper gi tract | 0.69 | 0.22 | 0.22 | 0.03 | 0.94 | 0.94 | XXX |
| 74241 | TC | A | X-ray exam, upper gi tract | 0.00 | 1.49 | NA | 0.08 | 1.57 | NA | XXX |
| 74245 | | A | X-ray exam, upper gi tract | 0.91 | 2.67 | NA | 0.17 | 3.75 | NA | XXX |
| 74245 | 26 | A | X-ray exam, upper gi tract | 0.91 | 0.30 | 0.30 | 0.04 | 1.25 | 1.25 | XXX |
| 74245 | TC | A | X-ray exam, upper gi tract | 0.00 | 2.37 | NA | 0.13 | 2.50 | NA | XXX |
| 74246 | | A | Contrst x-ray uppr gi tract | 0.69 | 1.87 | NA | 0.13 | 2.69 | NA | XXX |
| 74246 | 26 | A | Contrst x-ray uppr gi tract | 0.69 | 0.23 | 0.23 | 0.03 | 0.95 | 0.95 | XXX |
| 74246 | TC | A | Contrst x-ray uppr gi tract | 0.00 | 1.64 | NA | 0.10 | 1.74 | NA | XXX |
| 74247 | | A | Contrst x-ray uppr gi tract | 0.69 | 1.90 | NA | 0.14 | 2.73 | NA | XXX |
| 74247 | 26 | A | Contrst x-ray uppr gi tract | 0.69 | 0.23 | 0.23 | 0.03 | 0.95 | 0.95 | XXX |
| 74247 | TC | A | Contrst x-ray uppr gi tract | 0.00 | 1.68 | NA | 0.11 | 1.79 | NA | XXX |
| 74249 | | A | Contrst x-ray uppr gi tract | 0.91 | 2.86 | NA | 0.18 | 3.95 | NA | XXX |
| 74249 | 26 | A | Contrst x-ray uppr gi tract | 0.91 | 0.30 | 0.30 | 0.04 | 1.25 | 1.25 | XXX |
| 74249 | TC | A | Contrst x-ray uppr gi tract | 0.00 | 2.57 | NA | 0.14 | 2.71 | NA | XXX |
| 74250 | | A | X-ray exam of small bowel | 0.47 | 1.46 | NA | 0.09 | 2.02 | NA | XXX |
| 74250 | 26 | A | X-ray exam of small bowel | 0.47 | 0.15 | 0.15 | 0.02 | 0.64 | 0.64 | XXX |
| 74250 | TC | A | X-ray exam of small bowel | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 74251 | | A | X-ray exam of small bowel | 0.69 | 1.53 | NA | 0.10 | 2.32 | NA | XXX |
| 74251 | 26 | A | X-ray exam of small bowel | 0.69 | 0.22 | 0.22 | 0.03 | 0.94 | 0.94 | XXX |
| 74251 | TC | A | X-ray exam of small bowel | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 74260 | | A | X-ray exam of small bowel | 0.50 | 1.65 | NA | 0.10 | 2.25 | NA | XXX |
| 74260 | 26 | A | X-ray exam of small bowel | 0.50 | 0.16 | 0.16 | 0.02 | 0.68 | 0.68 | XXX |
| 74260 | TC | A | X-ray exam of small bowel | 0.00 | 1.49 | NA | 0.08 | 1.57 | NA | XXX |
| 74270 | | A | Contrast x-ray exam of colon | 0.69 | 1.92 | NA | 0.14 | 2.75 | NA | XXX |
| 74270 | 26 | A | Contrast x-ray exam of colon | 0.69 | 0.22 | 0.22 | 0.03 | 0.94 | 0.94 | XXX |
| 74270 | TC | A | Contrast x-ray exam of colon | 0.00 | 1.70 | NA | 0.11 | 1.81 | NA | XXX |
| 74280 | | A | Contrast x-ray exam of colon | 0.99 | 2.55 | NA | 0.17 | 3.71 | NA | XXX |
| 74280 | 26 | A | Contrast x-ray exam of colon | 0.99 | 0.32 | 0.32 | 0.04 | 1.35 | 1.35 | XXX |
| 74280 | TC | A | Contrast x-ray exam of colon | 0.00 | 2.23 | NA | 0.13 | 2.36 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 74283 | | A | Contrast x-ray exam of colon | 2.02 | 3.22 | NA | 0.23 | 5.47 | NA | XXX |
| 74283 | 26 | A | Contrast x-ray exam of colon | 2.02 | 0.66 | 0.66 | 0.09 | 2.77 | 2.77 | XXX |
| 74283 | TC | A | Contrast x-ray exam of colon | 0.00 | 2.56 | NA | 0.14 | 2.70 | NA | XXX |
| 74290 | | A | Contrast x-ray, gallbladder | 0.32 | 0.84 | NA | 0.06 | 1.22 | NA | XXX |
| 74290 | 26 | A | Contrast x-ray, gallbladder | 0.32 | 0.10 | 0.10 | 0.01 | 0.43 | 0.43 | XXX |
| 74290 | TC | A | Contrast x-ray, gallbladder | 0.00 | 0.73 | NA | 0.05 | 0.78 | NA | XXX |
| 74291 | | A | Contrast x-rays, gallbladder | 0.20 | 0.48 | NA | 0.03 | 0.71 | NA | XXX |
| 74291 | 26 | A | Contrast x-rays, gallbladder | 0.20 | 0.07 | 0.07 | 0.01 | 0.28 | 0.28 | XXX |
| 74291 | TC | A | Contrast x-rays, gallbladder | 0.00 | 0.42 | NA | 0.02 | 0.44 | NA | XXX |
| 74300 | 26 | A | X-ray bile ducts/pancreas | 0.36 | 0.12 | 0.12 | 0.02 | 0.50 | 0.50 | XXX |
| 74301 | 26 | A | X-rays at surgery add-on | 0.21 | 0.07 | 0.07 | 0.01 | 0.29 | 0.29 | ZZZ |
| 74305 | | A | X-ray bile ducts/pancreas | 0.42 | 0.92 | NA | 0.07 | 1.41 | NA | XXX |
| 74305 | 26 | A | X-ray bile ducts/pancreas | 0.42 | 0.14 | 0.14 | 0.02 | 0.58 | 0.58 | XXX |
| 74305 | TC | A | X-ray bile ducts/pancreas | 0.00 | 0.78 | NA | 0.05 | 0.83 | NA | XXX |
| 74320 | | A | Contrast x-ray of bile ducts | 0.54 | 3.32 | NA | 0.19 | 4.05 | NA | XXX |
| 74320 | 26 | A | Contrast x-ray of bile ducts | 0.54 | 0.18 | 0.18 | 0.02 | 0.74 | 0.74 | XXX |
| 74320 | TC | A | Contrast x-ray of bile ducts | 0.00 | 3.15 | NA | 0.17 | 3.32 | NA | XXX |
| 74327 | | A | X-ray bile stone removal | 0.70 | 1.98 | NA | 0.14 | 2.82 | NA | XXX |
| 74327 | 26 | A | X-ray bile stone removal | 0.70 | 0.23 | 0.23 | 0.03 | 0.96 | 0.96 | XXX |
| 74327 | TC | A | X-ray bile stone removal | 0.00 | 1.76 | NA | 0.11 | 1.87 | NA | XXX |
| 74328 | | A | X-ray bile duct endoscopy | 0.70 | 3.38 | NA | 0.20 | 4.28 | NA | XXX |
| 74328 | 26 | A | X-ray bile duct endoscopy | 0.70 | 0.23 | 0.23 | 0.03 | 0.96 | 0.96 | XXX |
| 74328 | TC | A | X-ray bile duct endoscopy | 0.00 | 3.15 | NA | 0.17 | 3.32 | NA | XXX |
| 74329 | | A | X-ray for pancreas endoscopy | 0.70 | 3.38 | NA | 0.20 | 4.28 | NA | XXX |
| 74329 | 26 | A | X-ray for pancreas endoscopy | 0.70 | 0.23 | 0.23 | 0.03 | 0.96 | 0.96 | XXX |
| 74329 | TC | A | X-ray for pancreas endoscopy | 0.00 | 3.15 | NA | 0.17 | 3.32 | NA | XXX |
| 74330 | | A | X-ray bile/panc endoscopy | 0.90 | 3.44 | NA | 0.21 | 4.55 | NA | XXX |
| 74330 | 26 | A | X-ray bile/panc endoscopy | 0.90 | 0.29 | 0.29 | 0.04 | 1.23 | 1.23 | XXX |
| 74330 | TC | A | X-ray bile/panc endoscopy | 0.00 | 3.15 | NA | 0.17 | 3.32 | NA | XXX |
| 74340 | | A | X-ray guide for GI tube | 0.54 | 2.79 | NA | 0.16 | 3.49 | NA | XXX |
| 74340 | 26 | A | X-ray guide for GI tube | 0.54 | 0.18 | 0.18 | 0.02 | 0.74 | 0.74 | XXX |
| 74340 | TC | A | X-ray guide for GI tube | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 74350 | | A | X-ray guide, stomach tube | 0.76 | 3.39 | NA | 0.20 | 4.35 | NA | XXX |
| 74350 | 26 | A | X-ray guide, stomach tube | 0.76 | 0.25 | 0.25 | 0.03 | 1.04 | 1.04 | XXX |
| 74350 | TC | A | X-ray guide, stomach tube | 0.00 | 3.15 | NA | 0.17 | 3.32 | NA | XXX |
| 74355 | | A | X-ray guide, intestinal tube | 0.76 | 2.86 | NA | 0.17 | 3.79 | NA | XXX |
| 74355 | 26 | A | X-ray guide, intestinal tube | 0.76 | 0.25 | 0.25 | 0.03 | 1.04 | 1.04 | XXX |
| 74355 | TC | A | X-ray guide, intestinal tube | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 74360 | | A | X-ray guide, GI dilation | 0.54 | 3.33 | NA | 0.19 | 4.06 | NA | XXX |
| 74360 | 26 | A | X-ray guide, GI dilation | 0.54 | 0.19 | 0.19 | 0.02 | 0.75 | 0.75 | XXX |
| 74360 | TC | A | X-ray guide, GI dilation | 0.00 | 3.15 | NA | 0.17 | 3.32 | NA | XXX |
| 74363 | | A | X-ray, bile duct dilation | 0.88 | 6.38 | NA | 0.37 | 7.63 | NA | XXX |
| 74363 | 26 | A | X-ray, bile duct dilation | 0.88 | 0.29 | 0.29 | 0.04 | 1.21 | 1.21 | XXX |
| 74363 | TC | A | X-ray, bile duct dilation | 0.00 | 6.09 | NA | 0.33 | 6.42 | NA | XXX |
| 74400 | | A | Contrst x-ray, urinary tract | 0.49 | 1.84 | NA | 0.13 | 2.46 | NA | XXX |
| 74400 | 26 | A | Contrst x-ray, urinary tract | 0.49 | 0.16 | 0.16 | 0.02 | 0.67 | 0.67 | XXX |
| 74400 | TC | A | Contrst x-ray, urinary tract | 0.00 | 1.68 | NA | 0.11 | 1.79 | NA | XXX |
| 74410 | | A | Contrst x-ray, urinary tract | 0.49 | 2.11 | NA | 0.13 | 2.73 | NA | XXX |
| 74410 | 26 | A | Contrst x-ray, urinary tract | 0.49 | 0.16 | 0.16 | 0.02 | 0.67 | 0.67 | XXX |
| 74410 | TC | A | Contrst x-ray, urinary tract | 0.00 | 1.95 | NA | 0.11 | 2.06 | NA | XXX |
| 74415 | | A | Contrst x-ray, urinary tract | 0.49 | 2.27 | NA | 0.14 | 2.90 | NA | XXX |
| 74415 | 26 | A | Contrst x-ray, urinary tract | 0.49 | 0.16 | 0.16 | 0.02 | 0.67 | 0.67 | XXX |
| 74415 | TC | A | Contrst x-ray, urinary tract | 0.00 | 2.11 | NA | 0.12 | 2.23 | NA | XXX |
| 74420 | | A | Contrst x-ray, urinary tract | 0.36 | 2.73 | NA | 0.16 | 3.25 | NA | XXX |
| 74420 | 26 | A | Contrst x-ray, urinary tract | 0.36 | 0.12 | 0.12 | 0.02 | 0.50 | 0.50 | XXX |
| 74420 | TC | A | Contrst x-ray, urinary tract | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 74425 | | A | Contrst x-ray, urinary tract | 0.36 | 1.42 | NA | 0.09 | 1.87 | NA | XXX |
| 74425 | 26 | A | Contrst x-ray, urinary tract | 0.36 | 0.12 | 0.12 | 0.02 | 0.50 | 0.50 | XXX |
| 74425 | TC | A | Contrst x-ray, urinary tract | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 74430 | | A | Contrast x-ray, bladder | 0.32 | 1.16 | NA | 0.08 | 1.56 | NA | XXX |
| 74430 | 26 | A | Contrast x-ray, bladder | 0.32 | 0.10 | 0.10 | 0.02 | 0.44 | 0.44 | XXX |
| 74430 | TC | A | Contrast x-ray, bladder | 0.00 | 1.05 | NA | 0.06 | 1.11 | NA | XXX |
| 74440 | | A | X-ray, male genital tract | 0.38 | 1.25 | NA | 0.08 | 1.71 | NA | XXX |
| 74440 | 26 | A | X-ray, male genital tract | 0.38 | 0.12 | 0.12 | 0.02 | 0.52 | 0.52 | XXX |
| 74440 | TC | A | X-ray, male genital tract | 0.00 | 1.13 | NA | 0.06 | 1.19 | NA | XXX |
| 74445 | | A | X-ray exam of penis | 1.14 | 1.50 | NA | 0.12 | 2.76 | NA | XXX |
| 74445 | 26 | A | X-ray exam of penis | 1.14 | 0.37 | 0.37 | 0.06 | 1.57 | 1.57 | XXX |
| 74445 | TC | A | X-ray exam of penis | 0.00 | 1.13 | NA | 0.06 | 1.19 | NA | XXX |
| 74450 | | A | X-ray, urethra/bladder | 0.33 | 1.56 | NA | 0.10 | 1.99 | NA | XXX |
| 74450 | 26 | A | X-ray, urethra/bladder | 0.33 | 0.11 | 0.11 | 0.02 | 0.46 | 0.46 | XXX |
| 74450 | TC | A | X-ray, urethra/bladder | 0.00 | 1.46 | NA | 0.08 | 1.54 | NA | XXX |
| 74455 | | A | X-ray, urethra/bladder | 0.33 | 1.68 | NA | 0.12 | 2.13 | NA | XXX |
| 74455 | 26 | A | X-ray, urethra/bladder | 0.33 | 0.11 | 0.11 | 0.02 | 0.46 | 0.46 | XXX |
| 74455 | TC | A | X-ray, urethra/bladder | 0.00 | 1.57 | NA | 0.10 | 1.67 | NA | XXX |
| 74470 | | A | X-ray exam of kidney lesion | 0.54 | 1.42 | NA | 0.10 | 2.06 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 74470 | 26 | A | X-ray exam of kidney lesion | 0.54 | 0.18 | 0.18 | 0.03 | 0.75 | 0.75 | XXX |
| 74470 | TC | A | X-ray exam of kidney lesion | 0.00 | 1.25 | NA | 0.07 | 1.32 | NA | XXX |
| 74475 | | A | X-ray control, cath insert | 0.54 | 4.24 | NA | 0.24 | 5.02 | NA | XXX |
| 74475 | 26 | A | X-ray control, cath insert | 0.54 | 0.18 | 0.18 | 0.02 | 0.74 | 0.74 | XXX |
| 74475 | TC | A | X-ray control, cath insert | 0.00 | 4.06 | NA | 0.22 | 4.28 | NA | XXX |
| 74480 | | A | X-ray control, cath insert | 0.54 | 4.24 | NA | 0.24 | 5.02 | NA | XXX |
| 74480 | 26 | A | X-ray control, cath insert | 0.54 | 0.18 | 0.18 | 0.02 | 0.74 | 0.74 | XXX |
| 74480 | TC | A | X-ray control, cath insert | 0.00 | 4.06 | NA | 0.22 | 4.28 | NA | XXX |
| 74485 | | A | X-ray guide, GU dilation | 0.54 | 3.32 | NA | 0.20 | 4.06 | NA | XXX |
| 74485 | 26 | A | X-ray guide, GU dilation | 0.54 | 0.17 | 0.17 | 0.03 | 0.74 | 0.74 | XXX |
| 74485 | TC | A | X-ray guide, GU dilation | 0.00 | 3.15 | NA | 0.17 | 3.32 | NA | XXX |
| 74710 | | A | X-ray measurement of pelvis | 0.34 | 1.16 | NA | 0.08 | 1.58 | NA | XXX |
| 74710 | 26 | A | X-ray measurement of pelvis | 0.34 | 0.11 | 0.11 | 0.02 | 0.47 | 0.47 | XXX |
| 74710 | TC | A | X-ray measurement of pelvis | 0.00 | 1.05 | NA | 0.06 | 1.11 | NA | XXX |
| 74740 | | A | X-ray, female genital tract | 0.38 | 1.43 | NA | 0.09 | 1.90 | NA | XXX |
| 74740 | 26 | A | X-ray, female genital tract | 0.38 | 0.13 | 0.13 | 0.02 | 0.53 | 0.53 | XXX |
| 74740 | TC | A | X-ray, female genital tract | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 74742 | | A | X-ray, fallopian tube | 0.61 | 3.35 | NA | 0.20 | 4.16 | NA | XXX |
| 74742 | 26 | A | X-ray, fallopian tube | 0.61 | 0.20 | 0.20 | 0.03 | 0.84 | 0.84 | XXX |
| 74742 | TC | A | X-ray, fallopian tube | 0.00 | 3.15 | NA | 0.17 | 3.32 | NA | XXX |
| 74775 | | A | X-ray exam of perineum | 0.62 | 1.66 | NA | 0.11 | 2.39 | NA | XXX |
| 74775 | 26 | A | X-ray exam of perineum | 0.62 | 0.21 | 0.21 | 0.03 | 0.86 | 0.86 | XXX |
| 74775 | TC | A | X-ray exam of perineum | 0.00 | 1.46 | NA | 0.08 | 1.54 | NA | XXX |
| 75552 | | A | Heart mri for morph w/o dye | 1.60 | 11.71 | NA | 0.66 | 13.97 | NA | XXX |
| 75552 | 26 | A | Heart mri for morph w/o dye | 1.60 | 0.53 | 0.53 | 0.07 | 2.20 | 2.20 | XXX |
| 75552 | TC | A | Heart mri for morph w/o dye | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 75553 | | A | Heart mri for morph w/dye | 2.00 | 11.84 | NA | 0.68 | 14.52 | NA | XXX |
| 75553 | 26 | A | Heart mri for morph w/dye | 2.00 | 0.65 | 0.65 | 0.09 | 2.74 | 2.74 | XXX |
| 75553 | TC | A | Heart mri for morph w/dye | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 75554 | | A | Cardiac MRI/function | 1.83 | 11.83 | NA | 0.66 | 14.32 | NA | XXX |
| 75554 | 26 | A | Cardiac MRI/function | 1.83 | 0.64 | 0.64 | 0.07 | 2.54 | 2.54 | XXX |
| 75554 | TC | A | Cardiac MRI/function | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 75555 | | A | Cardiac MRI/limited study | 1.74 | 11.82 | NA | 0.66 | 14.22 | NA | XXX |
| 75555 | 26 | A | Cardiac MRI/limited study | 1.74 | 0.64 | 0.64 | 0.07 | 2.45 | 2.45 | XXX |
| 75555 | TC | A | Cardiac MRI/limited study | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 75600 | | A | Contrast x-ray exam of aorta | 0.49 | 12.76 | NA | 0.67 | 13.92 | NA | XXX |
| 75600 | 26 | A | Contrast x-ray exam of aorta | 0.49 | 0.19 | 0.19 | 0.02 | 0.70 | 0.70 | XXX |
| 75600 | TC | A | Contrast x-ray exam of aorta | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75605 | | A | Contrast x-ray exam of aorta | 1.14 | 12.97 | NA | 0.70 | 14.81 | NA | XXX |
| 75605 | 26 | A | Contrast x-ray exam of aorta | 1.14 | 0.40 | 0.40 | 0.05 | 1.59 | 1.59 | XXX |
| 75605 | TC | A | Contrast x-ray exam of aorta | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75625 | | A | Contrast x-ray exam of aorta | 1.14 | 12.95 | NA | 0.71 | 14.80 | NA | XXX |
| 75625 | 26 | A | Contrast x-ray exam of aorta | 1.14 | 0.38 | 0.38 | 0.06 | 1.58 | 1.58 | XXX |
| 75625 | TC | A | Contrast x-ray exam of aorta | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75630 | | A | X-ray aorta, leg arteries | 1.79 | 13.72 | NA | 0.79 | 16.30 | NA | XXX |
| 75630 | 26 | A | X-ray aorta, leg arteries | 1.79 | 0.61 | 0.61 | 0.10 | 2.50 | 2.50 | XXX |
| 75630 | TC | A | X-ray aorta, leg arteries | 0.00 | 13.11 | NA | 0.69 | 13.80 | NA | XXX |
| 75635 | | A | Ct angio abdominal arteries | 2.40 | 16.68 | NA | 0.50 | 19.58 | NA | XXX |
| 75635 | 26 | A | Ct angio abdominal arteries | 2.40 | 0.79 | 0.79 | 0.11 | 3.30 | 3.30 | XXX |
| 75635 | TC | A | Ct angio abdominal arteries | 0.00 | 15.89 | NA | 0.39 | 16.28 | NA | XXX |
| 75650 | | A | Artery x-rays, head & neck | 1.49 | 13.07 | NA | 0.72 | 15.28 | NA | XXX |
| 75650 | 26 | A | Artery x-rays, head & neck | 1.49 | 0.49 | 0.49 | 0.07 | 2.05 | 2.05 | XXX |
| 75650 | TC | A | Artery x-rays, head & neck | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75658 | | A | Artery x-rays, arm | 1.31 | 13.05 | NA | 0.72 | 15.08 | NA | XXX |
| 75658 | 26 | A | Artery x-rays, arm | 1.31 | 0.47 | 0.47 | 0.07 | 1.85 | 1.85 | XXX |
| 75658 | TC | A | Artery x-rays, arm | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75660 | | A | Artery x-rays, head & neck | 1.31 | 13.02 | NA | 0.72 | 15.05 | NA | XXX |
| 75660 | 26 | A | Artery x-rays, head & neck | 1.31 | 0.44 | 0.44 | 0.07 | 1.82 | 1.82 | XXX |
| 75660 | TC | A | Artery x-rays, head & neck | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75662 | | A | Artery x-rays, head & neck | 1.66 | 13.17 | NA | 0.73 | 15.56 | NA | XXX |
| 75662 | 26 | A | Artery x-rays, head & neck | 1.66 | 0.59 | 0.59 | 0.08 | 2.33 | 2.33 | XXX |
| 75662 | TC | A | Artery x-rays, head & neck | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75665 | | A | Artery x-rays, head & neck | 1.31 | 13.01 | NA | 0.74 | 15.06 | NA | XXX |
| 75665 | 26 | A | Artery x-rays, head & neck | 1.31 | 0.44 | 0.44 | 0.09 | 1.84 | 1.84 | XXX |
| 75665 | TC | A | Artery x-rays, head & neck | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75671 | | A | Artery x-rays, head & neck | 1.66 | 13.12 | NA | 0.73 | 15.51 | NA | XXX |
| 75671 | 26 | A | Artery x-rays, head & neck | 1.66 | 0.55 | 0.55 | 0.08 | 2.29 | 2.29 | XXX |
| 75671 | TC | A | Artery x-rays, head & neck | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75676 | | A | Artery x-rays, neck | 1.31 | 13.01 | NA | 0.73 | 15.05 | NA | XXX |
| 75676 | 26 | A | Artery x-rays, neck | 1.31 | 0.44 | 0.44 | 0.08 | 1.83 | 1.83 | XXX |
| 75676 | TC | A | Artery x-rays, neck | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75680 | | A | Artery x-rays, neck | 1.66 | 13.12 | NA | 0.73 | 15.51 | NA | XXX |
| 75680 | 26 | A | Artery x-rays, neck | 1.66 | 0.55 | 0.55 | 0.08 | 2.29 | 2.29 | XXX |
| 75680 | TC | A | Artery x-rays, neck | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75685 | | A | Artery x-rays, spine | 1.31 | 13.01 | NA | 0.72 | 15.04 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 75685 | 26 | A | Artery x-rays, spine | 1.31 | 0.43 | 0.43 | 0.07 | 1.81 | 1.81 | XXX |
| 75685 | TC | A | Artery x-rays, spine | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75705 | | A | Artery x-rays, spine | 2.18 | 13.31 | NA | 0.78 | 16.27 | NA | XXX |
| 75705 | 26 | A | Artery x-rays, spine | 2.18 | 0.73 | 0.73 | 0.13 | 3.04 | 3.04 | XXX |
| 75705 | TC | A | Artery x-rays, spine | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75710 | | A | Artery x-rays, arm/leg | 1.14 | 12.96 | NA | 0.71 | 14.81 | NA | XXX |
| 75710 | 26 | A | Artery x-rays, arm/leg | 1.14 | 0.39 | 0.39 | 0.06 | 1.59 | 1.59 | XXX |
| 75710 | TC | A | Artery x-rays, arm/leg | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75716 | | A | Artery x-rays, arms/legs | 1.31 | 13.01 | NA | 0.72 | 15.04 | NA | XXX |
| 75716 | 26 | A | Artery x-rays, arms/legs | 1.31 | 0.43 | 0.43 | 0.07 | 1.81 | 1.81 | XXX |
| 75716 | TC | A | Artery x-rays, arms/legs | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75722 | | A | Artery x-rays, kidney | 1.14 | 12.97 | NA | 0.71 | 14.82 | NA | XXX |
| 75722 | 26 | A | Artery x-rays, kidney | 1.14 | 0.40 | 0.40 | 0.06 | 1.60 | 1.60 | XXX |
| 75722 | TC | A | Artery x-rays, kidney | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75724 | | A | Artery x-rays, kidneys | 1.49 | 13.13 | NA | 0.71 | 15.33 | NA | XXX |
| 75724 | 26 | A | Artery x-rays, kidneys | 1.49 | 0.56 | 0.56 | 0.06 | 2.11 | 2.11 | XXX |
| 75724 | TC | A | Artery x-rays, kidneys | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75726 | | A | Artery x-rays, abdomen | 1.14 | 12.95 | NA | 0.70 | 14.79 | NA | XXX |
| 75726 | 26 | A | Artery x-rays, abdomen | 1.14 | 0.37 | 0.37 | 0.05 | 1.56 | 1.56 | XXX |
| 75726 | TC | A | Artery x-rays, abdomen | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75731 | | A | Artery x-rays, adrenal gland | 1.14 | 12.95 | NA | 0.70 | 14.79 | NA | XXX |
| 75731 | 26 | A | Artery x-rays, adrenal gland | 1.14 | 0.37 | 0.37 | 0.05 | 1.56 | 1.56 | XXX |
| 75731 | TC | A | Artery x-rays, adrenal gland | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75733 | | A | Artery x-rays, adrenals | 1.31 | 13.01 | NA | 0.70 | 15.02 | NA | XXX |
| 75733 | 26 | A | Artery x-rays, adrenals | 1.31 | 0.43 | 0.43 | 0.05 | 1.79 | 1.79 | XXX |
| 75733 | TC | A | Artery x-rays, adrenals | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75736 | | A | Artery x-rays, pelvis | 1.14 | 12.95 | NA | 0.71 | 14.80 | NA | XXX |
| 75736 | 26 | A | Artery x-rays, pelvis | 1.14 | 0.37 | 0.37 | 0.06 | 1.57 | 1.57 | XXX |
| 75736 | TC | A | Artery x-rays, pelvis | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75741 | | A | Artery x-rays, lung | 1.31 | 13.01 | NA | 0.71 | 15.03 | NA | XXX |
| 75741 | 26 | A | Artery x-rays, lung | 1.31 | 0.43 | 0.43 | 0.06 | 1.80 | 1.80 | XXX |
| 75741 | TC | A | Artery x-rays, lung | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75743 | | A | Artery x-rays, lungs | 1.66 | 13.12 | NA | 0.73 | 15.51 | NA | XXX |
| 75743 | 26 | A | Artery x-rays, lungs | 1.66 | 0.54 | 0.54 | 0.08 | 2.28 | 2.28 | XXX |
| 75743 | TC | A | Artery x-rays, lungs | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75746 | | A | Artery x-rays, lung | 1.14 | 12.95 | NA | 0.70 | 14.79 | NA | XXX |
| 75746 | 26 | A | Artery x-rays, lung | 1.14 | 0.38 | 0.38 | 0.05 | 1.57 | 1.57 | XXX |
| 75746 | TC | A | Artery x-rays, lung | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75756 | | A | Artery x-rays, chest | 1.14 | 13.02 | NA | 0.69 | 14.85 | NA | XXX |
| 75756 | 26 | A | Artery x-rays, chest | 1.14 | 0.45 | 0.45 | 0.04 | 1.63 | 1.63 | XXX |
| 75756 | TC | A | Artery x-rays, chest | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75774 | | A | Artery x-ray, each vessel | 0.36 | 12.70 | NA | 0.67 | 13.73 | NA | ZZZ |
| 75774 | 26 | A | Artery x-ray, each vessel | 0.36 | 0.12 | 0.12 | 0.02 | 0.50 | 0.50 | ZZZ |
| 75774 | TC | A | Artery x-ray, each vessel | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | ZZZ |
| 75790 | | A | Visualize A-V shunt | 1.84 | 1.95 | NA | 0.18 | 3.97 | NA | XXX |
| 75790 | 26 | A | Visualize A-V shunt | 1.84 | 0.60 | 0.60 | 0.10 | 2.54 | 2.54 | XXX |
| 75790 | TC | A | Visualize A-V shunt | 0.00 | 1.35 | NA | 0.08 | 1.43 | NA | XXX |
| 75801 | | A | Lymph vessel x-ray, arm/leg | 0.81 | 5.67 | NA | 0.37 | 6.85 | NA | XXX |
| 75801 | 26 | A | Lymph vessel x-ray, arm/leg | 0.81 | 0.27 | 0.27 | 0.08 | 1.16 | 1.16 | XXX |
| 75801 | TC | A | Lymph vessel x-ray, arm/leg | 0.00 | 5.40 | NA | 0.29 | 5.69 | NA | XXX |
| 75803 | | A | Lymph vessel x-ray,arms/legs | 1.17 | 5.79 | NA | 0.34 | 7.30 | NA | XXX |
| 75803 | 26 | A | Lymph vessel x-ray,arms/legs | 1.17 | 0.38 | 0.38 | 0.05 | 1.60 | 1.60 | XXX |
| 75803 | TC | A | Lymph vessel x-ray,arms/legs | 0.00 | 5.40 | NA | 0.29 | 5.69 | NA | XXX |
| 75805 | | A | Lymph vessel x-ray, trunk | 0.81 | 6.36 | NA | 0.38 | 7.55 | NA | XXX |
| 75805 | 26 | A | Lymph vessel x-ray, trunk | 0.81 | 0.27 | 0.27 | 0.05 | 1.13 | 1.13 | XXX |
| 75805 | TC | A | Lymph vessel x-ray, trunk | 0.00 | 6.09 | NA | 0.33 | 6.42 | NA | XXX |
| 75807 | | A | Lymph vessel x-ray, trunk | 1.17 | 6.47 | NA | 0.39 | 8.03 | NA | XXX |
| 75807 | 26 | A | Lymph vessel x-ray, trunk | 1.17 | 0.38 | 0.38 | 0.06 | 1.61 | 1.61 | XXX |
| 75807 | TC | A | Lymph vessel x-ray, trunk | 0.00 | 6.09 | NA | 0.33 | 6.42 | NA | XXX |
| 75809 | | A | Nonvascular shunt, x-ray | 0.47 | 0.94 | NA | 0.07 | 1.48 | NA | XXX |
| 75809 | 26 | A | Nonvascular shunt, x-ray | 0.47 | 0.15 | 0.15 | 0.02 | 0.64 | 0.64 | XXX |
| 75809 | TC | A | Nonvascular shunt, x-ray | 0.00 | 0.78 | NA | 0.05 | 0.83 | NA | XXX |
| 75810 | | A | Vein x-ray, spleen/liver | 1.14 | 12.95 | NA | 0.70 | 14.79 | NA | XXX |
| 75810 | 26 | A | Vein x-ray, spleen/liver | 1.14 | 0.37 | 0.37 | 0.05 | 1.56 | 1.56 | XXX |
| 75810 | TC | A | Vein x-ray, spleen/liver | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75820 | | A | Vein x-ray, arm/leg | 0.70 | 1.17 | NA | 0.10 | 1.97 | NA | XXX |
| 75820 | 26 | A | Vein x-ray, arm/leg | 0.70 | 0.23 | 0.23 | 0.04 | 0.97 | 0.97 | XXX |
| 75820 | TC | A | Vein x-ray, arm/leg | 0.00 | 0.95 | NA | 0.06 | 1.01 | NA | XXX |
| 75822 | | A | Vein x-ray, arms/legs | 1.06 | 1.82 | NA | 0.13 | 3.01 | NA | XXX |
| 75822 | 26 | A | Vein x-ray, arms/legs | 1.06 | 0.35 | 0.35 | 0.05 | 1.46 | 1.46 | XXX |
| 75822 | TC | A | Vein x-ray, arms/legs | 0.00 | 1.48 | NA | 0.08 | 1.56 | NA | XXX |
| 75825 | | A | Vein x-ray, trunk | 1.14 | 12.95 | NA | 0.72 | 14.81 | NA | XXX |
| 75825 | 26 | A | Vein x-ray, trunk | 1.14 | 0.37 | 0.37 | 0.07 | 1.58 | 1.58 | XXX |
| 75825 | TC | A | Vein x-ray, trunk | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75827 | | A | Vein x-ray, chest | 1.14 | 12.95 | NA | 0.71 | 14.80 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 75827 | 26 | A | Vein x-ray, chest | 1.14 | 0.37 | 0.37 | 0.06 | 1.57 | 1.57 | XXX |
| 75827 | TC | A | Vein x-ray, chest | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75831 | | A | Vein x-ray, kidney | 1.14 | 12.94 | NA | 0.70 | 14.78 | NA | XXX |
| 75831 | 26 | A | Vein x-ray, kidney | 1.14 | 0.37 | 0.37 | 0.06 | 1.57 | 1.57 | XXX |
| 75831 | TC | A | Vein x-ray, kidney | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75833 | | A | Vein x-ray, kidneys | 1.49 | 13.06 | NA | 0.73 | 15.28 | NA | XXX |
| 75833 | 26 | A | Vein x-ray, kidneys | 1.49 | 0.49 | 0.49 | 0.08 | 2.06 | 2.06 | XXX |
| 75833 | TC | A | Vein x-ray, kidneys | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75840 | | A | Vein x-ray, adrenal gland | 1.14 | 12.95 | NA | 0.70 | 14.79 | NA | XXX |
| 75840 | 26 | A | Vein x-ray, adrenal gland | 1.14 | 0.38 | 0.38 | 0.05 | 1.57 | 1.57 | XXX |
| 75840 | TC | A | Vein x-ray, adrenal gland | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75842 | | A | Vein x-ray, adrenal glands | 1.49 | 13.06 | NA | 0.73 | 15.28 | NA | XXX |
| 75842 | 26 | A | Vein x-ray, adrenal glands | 1.49 | 0.48 | 0.48 | 0.08 | 2.05 | 2.05 | XXX |
| 75842 | TC | A | Vein x-ray, adrenal glands | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75860 | | A | Vein x-ray, neck | 1.14 | 12.97 | NA | 0.70 | 14.81 | NA | XXX |
| 75860 | 26 | A | Vein x-ray, neck | 1.14 | 0.39 | 0.39 | 0.05 | 1.58 | 1.58 | XXX |
| 75860 | TC | A | Vein x-ray, neck | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75870 | | A | Vein x-ray, skull | 1.14 | 12.96 | NA | 0.71 | 14.81 | NA | XXX |
| 75870 | 26 | A | Vein x-ray, skull | 1.14 | 0.39 | 0.39 | 0.06 | 1.59 | 1.59 | XXX |
| 75870 | TC | A | Vein x-ray, skull | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75872 | | A | Vein x-ray, skull | 1.14 | 12.95 | NA | 0.76 | 14.85 | NA | XXX |
| 75872 | 26 | A | Vein x-ray, skull | 1.14 | 0.37 | 0.37 | 0.11 | 1.62 | 1.62 | XXX |
| 75872 | TC | A | Vein x-ray, skull | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75880 | | A | Vein x-ray, eye socket | 0.70 | 1.18 | NA | 0.10 | 1.98 | NA | XXX |
| 75880 | 26 | A | Vein x-ray, eye socket | 0.70 | 0.23 | 0.23 | 0.04 | 0.97 | 0.97 | XXX |
| 75880 | TC | A | Vein x-ray, eye socket | 0.00 | 0.95 | NA | 0.06 | 1.01 | NA | XXX |
| 75885 | | A | Vein x-ray, liver | 1.44 | 13.04 | NA | 0.72 | 15.20 | NA | XXX |
| 75885 | 26 | A | Vein x-ray, liver | 1.44 | 0.47 | 0.47 | 0.07 | 1.98 | 1.98 | XXX |
| 75885 | TC | A | Vein x-ray, liver | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75887 | | A | Vein x-ray, liver | 1.44 | 13.04 | NA | 0.72 | 15.20 | NA | XXX |
| 75887 | 26 | A | Vein x-ray, liver | 1.44 | 0.47 | 0.47 | 0.07 | 1.98 | 1.98 | XXX |
| 75887 | TC | A | Vein x-ray, liver | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75889 | | A | Vein x-ray, liver | 1.14 | 12.95 | NA | 0.70 | 14.79 | NA | XXX |
| 75889 | 26 | A | Vein x-ray, liver | 1.14 | 0.37 | 0.37 | 0.05 | 1.56 | 1.56 | XXX |
| 75889 | TC | A | Vein x-ray, liver | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75891 | | A | Vein x-ray, liver | 1.14 | 12.95 | NA | 0.70 | 14.79 | NA | XXX |
| 75891 | 26 | A | Vein x-ray, liver | 1.14 | 0.37 | 0.37 | 0.05 | 1.56 | 1.56 | XXX |
| 75891 | TC | A | Vein x-ray, liver | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75893 | | A | Venous sampling by catheter | 0.54 | 12.75 | NA | 0.68 | 13.97 | NA | XXX |
| 75893 | 26 | A | Venous sampling by catheter | 0.54 | 0.18 | 0.18 | 0.03 | 0.75 | 0.75 | XXX |
| 75893 | TC | A | Venous sampling by catheter | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75894 | | A | X-rays, transcath therapy | 1.31 | 24.52 | NA | 1.35 | 27.18 | NA | XXX |
| 75894 | 26 | A | X-rays, transcath therapy | 1.31 | 0.43 | 0.43 | 0.08 | 1.82 | 1.82 | XXX |
| 75894 | TC | A | X-rays, transcath therapy | 0.00 | 24.09 | NA | 1.27 | 25.36 | NA | XXX |
| 75896 | | A | X-rays, transcath therapy | 1.31 | 21.40 | NA | 1.16 | 23.87 | NA | XXX |
| 75896 | 26 | A | X-rays, transcath therapy | 1.31 | 0.45 | 0.45 | 0.06 | 1.82 | 1.82 | XXX |
| 75896 | TC | A | X-rays, transcath therapy | 0.00 | 20.95 | NA | 1.10 | 22.05 | NA | XXX |
| 75898 | | A | Follow-up angiography | 1.65 | 1.60 | NA | 0.14 | 3.39 | NA | XXX |
| 75898 | 26 | A | Follow-up angiography | 1.65 | 0.55 | 0.55 | 0.08 | 2.28 | 2.28 | XXX |
| 75898 | TC | A | Follow-up angiography | 0.00 | 1.05 | NA | 0.06 | 1.11 | NA | XXX |
| 75900 | | A | Arterial catheter exchange | 0.49 | 21.09 | NA | 1.14 | 22.72 | NA | XXX |
| 75900 | 26 | A | Arterial catheter exchange | 0.49 | 0.16 | 0.16 | 0.03 | 0.68 | 0.68 | XXX |
| 75900 | TC | A | Arterial catheter exchange | 0.00 | 20.93 | NA | 1.11 | 22.04 | NA | XXX |
| 75901 | | A | Remove cva device obstruct | 0.49 | 1.46 | NA | 1.04 | 2.99 | NA | XXX |
| 75901 | 26 | A | Remove cva device obstruct | 0.49 | 0.16 | 0.16 | 0.21 | 0.86 | 0.86 | XXX |
| 75901 | TC | A | Remove cva device obstruct | 0.00 | 1.30 | NA | 0.83 | 2.13 | NA | XXX |
| 75902 | | A | Remove cva lumen obstruct | 0.39 | 1.43 | NA | 0.86 | 2.68 | NA | XXX |
| 75902 | 26 | A | Remove cva lumen obstruct | 0.39 | 0.13 | 0.13 | 0.03 | 0.55 | 0.55 | XXX |
| 75902 | TC | A | Remove cva lumen obstruct | 0.00 | 1.30 | NA | 0.83 | 2.13 | NA | XXX |
| 75940 | | A | X-ray placement, vein filter | 0.54 | 12.75 | NA | 0.68 | 13.97 | NA | XXX |
| 75940 | 26 | A | X-ray placement, vein filter | 0.54 | 0.18 | 0.18 | 0.03 | 0.75 | 0.75 | XXX |
| 75940 | TC | A | X-ray placement, vein filter | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | XXX |
| 75945 | | A | Intravascular us | 0.40 | 4.70 | NA | 0.27 | 5.37 | NA | XXX |
| 75945 | 26 | A | Intravascular us | 0.40 | 0.14 | 0.14 | 0.03 | 0.57 | 0.57 | XXX |
| 75945 | TC | A | Intravascular us | 0.00 | 4.56 | NA | 0.24 | 4.80 | NA | XXX |
| 75946 | | A | Intravascular us add-on | 0.40 | 2.42 | NA | 0.18 | 3.00 | NA | ZZZ |
| 75946 | 26 | A | Intravascular us add-on | 0.40 | 0.14 | 0.14 | 0.05 | 0.59 | 0.59 | ZZZ |
| 75946 | TC | A | Intravascular us add-on | 0.00 | 2.29 | NA | 0.13 | 2.42 | NA | ZZZ |
| 75952 | 26 | A | Endovasc repair abdom aorta | 4.49 | 1.49 | 1.49 | 0.43 | 6.41 | 6.41 | XXX |
| 75953 | 26 | A | Abdom aneurysm endovas rpr | 1.36 | 0.45 | 0.45 | 0.13 | 1.94 | 1.94 | XXX |
| 75954 | 26 | A | Iliac aneurysm endovas rpr | 2.25 | 0.77 | 0.77 | 0.05 | 3.07 | 3.07 | XXX |
| 75960 | | A | Transcatheter intro, stent | 0.82 | 15.16 | NA | 0.82 | 16.80 | NA | XXX |
| 75960 | 26 | A | Transcatheter intro, stent | 0.82 | 0.28 | 0.28 | 0.05 | 1.15 | 1.15 | XXX |
| 75960 | TC | A | Transcatheter intro, stent | 0.00 | 14.87 | NA | 0.77 | 15.64 | NA | XXX |
| 75961 | | A | Retrieval, broken catheter | 4.24 | 11.87 | NA | 0.76 | 16.87 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 75961 | 26 | A | Retrieval, broken catheter | 4.24 | 1.39 | 1.39 | 0.21 | 5.84 | 5.84 | XXX |
| 75961 | TC | A | Retrieval, broken catheter | 0.00 | 10.48 | NA | 0.55 | 11.03 | NA | XXX |
| 75962 | | A | Repair arterial blockage | 0.54 | 15.90 | NA | 0.86 | 17.30 | NA | XXX |
| 75962 | 26 | A | Repair arterial blockage | 0.54 | 0.18 | 0.18 | 0.03 | 0.75 | 0.75 | XXX |
| 75962 | TC | A | Repair arterial blockage | 0.00 | 15.71 | NA | 0.83 | 16.54 | NA | XXX |
| 75964 | | A | Repair artery blockage, each | 0.36 | 8.50 | NA | 0.45 | 9.31 | NA | ZZZ |
| 75964 | 26 | A | Repair artery blockage, each | 0.36 | 0.12 | 0.12 | 0.02 | 0.50 | 0.50 | ZZZ |
| 75964 | TC | A | Repair artery blockage, each | 0.00 | 8.38 | NA | 0.43 | 8.81 | NA | ZZZ |
| 75966 | | A | Repair arterial blockage | 1.31 | 16.18 | NA | 0.89 | 18.38 | NA | XXX |
| 75966 | 26 | A | Repair arterial blockage | 1.31 | 0.46 | 0.46 | 0.06 | 1.83 | 1.83 | XXX |
| 75966 | TC | A | Repair arterial blockage | 0.00 | 15.71 | NA | 0.83 | 16.54 | NA | XXX |
| 75968 | | A | Repair artery blockage, each | 0.36 | 8.51 | NA | 0.45 | 9.32 | NA | ZZZ |
| 75968 | 26 | A | Repair artery blockage, each | 0.36 | 0.13 | 0.13 | 0.02 | 0.51 | 0.51 | ZZZ |
| 75968 | TC | A | Repair artery blockage, each | 0.00 | 8.38 | NA | 0.43 | 8.81 | NA | ZZZ |
| 75970 | | A | Vascular biopsy | 0.83 | 11.80 | NA | 0.64 | 13.27 | NA | XXX |
| 75970 | 26 | A | Vascular biopsy | 0.83 | 0.28 | 0.28 | 0.04 | 1.15 | 1.15 | XXX |
| 75970 | TC | A | Vascular biopsy | 0.00 | 11.52 | NA | 0.60 | 12.12 | NA | XXX |
| 75978 | | A | Repair venous blockage | 0.54 | 15.89 | NA | 0.86 | 17.29 | NA | XXX |
| 75978 | 26 | A | Repair venous blockage | 0.54 | 0.18 | 0.18 | 0.03 | 0.75 | 0.75 | XXX |
| 75978 | TC | A | Repair venous blockage | 0.00 | 15.71 | NA | 0.83 | 16.54 | NA | XXX |
| 75980 | | A | Contrast xray exam bile duct | 1.44 | 5.87 | NA | 0.36 | 7.67 | NA | XXX |
| 75980 | 26 | A | Contrast xray exam bile duct | 1.44 | 0.47 | 0.47 | 0.07 | 1.98 | 1.98 | XXX |
| 75980 | TC | A | Contrast xray exam bile duct | 0.00 | 5.40 | NA | 0.29 | 5.69 | NA | XXX |
| 75982 | | A | Contrast xray exam bile duct | 1.44 | 6.56 | NA | 0.40 | 8.40 | NA | XXX |
| 75982 | 26 | A | Contrast xray exam bile duct | 1.44 | 0.47 | 0.47 | 0.07 | 1.98 | 1.98 | XXX |
| 75982 | TC | A | Contrast xray exam bile duct | 0.00 | 6.09 | NA | 0.33 | 6.42 | NA | XXX |
| 75984 | | A | Xray control catheter change | 0.72 | 2.18 | NA | 0.14 | 3.04 | NA | XXX |
| 75984 | 26 | A | Xray control catheter change | 0.72 | 0.23 | 0.23 | 0.03 | 0.98 | 0.98 | XXX |
| 75984 | TC | A | Xray control catheter change | 0.00 | 1.95 | NA | 0.11 | 2.06 | NA | XXX |
| 75989 | | A | Abscess drainage under x-ray | 1.19 | 3.53 | NA | 0.22 | 4.94 | NA | XXX |
| 75989 | 26 | A | Abscess drainage under x-ray | 1.19 | 0.39 | 0.39 | 0.05 | 1.63 | 1.63 | XXX |
| 75989 | TC | A | Abscess drainage under x-ray | 0.00 | 3.15 | NA | 0.17 | 3.32 | NA | XXX |
| 75992 | | A | Atherectomy, x-ray exam | 0.54 | 15.90 | NA | 0.86 | 17.30 | NA | XXX |
| 75992 | 26 | A | Atherectomy, x-ray exam | 0.54 | 0.19 | 0.19 | 0.03 | 0.76 | 0.76 | XXX |
| 75992 | TC | A | Atherectomy, x-ray exam | 0.00 | 15.71 | NA | 0.83 | 16.54 | NA | XXX |
| 75993 | | A | Atherectomy, x-ray exam | 0.36 | 8.51 | NA | 0.45 | 9.32 | NA | ZZZ |
| 75993 | 26 | A | Atherectomy, x-ray exam | 0.36 | 0.13 | 0.13 | 0.02 | 0.51 | 0.51 | ZZZ |
| 75993 | TC | A | Atherectomy, x-ray exam | 0.00 | 8.38 | NA | 0.43 | 8.81 | NA | ZZZ |
| 75994 | | A | Atherectomy, x-ray exam | 1.31 | 16.18 | NA | 0.87 | 18.36 | NA | XXX |
| 75994 | 26 | A | Atherectomy, x-ray exam | 1.31 | 0.46 | 0.46 | 0.04 | 1.81 | 1.81 | XXX |
| 75994 | TC | A | Atherectomy, x-ray exam | 0.00 | 15.71 | NA | 0.83 | 16.54 | NA | XXX |
| 75995 | | A | Atherectomy, x-ray exam | 1.31 | 16.18 | NA | 0.91 | 18.40 | NA | XXX |
| 75995 | 26 | A | Atherectomy, x-ray exam | 1.31 | 0.47 | 0.47 | 0.08 | 1.86 | 1.86 | XXX |
| 75995 | TC | A | Atherectomy, x-ray exam | 0.00 | 15.71 | NA | 0.83 | 16.54 | NA | XXX |
| 75996 | | A | Atherectomy, x-ray exam | 0.36 | 8.50 | NA | 0.44 | 9.30 | NA | ZZZ |
| 75996 | 26 | A | Atherectomy, x-ray exam | 0.36 | 0.12 | 0.12 | 0.01 | 0.49 | 0.49 | ZZZ |
| 75996 | TC | A | Atherectomy, x-ray exam | 0.00 | 8.38 | NA | 0.43 | 8.81 | NA | ZZZ |
| 75998 | | A | Fluoroguide for vein device | 0.38 | 1.43 | NA | 0.11 | 1.92 | NA | ZZZ |
| 75998 | 26 | A | Fluoroguide for vein device | 0.38 | 0.13 | 0.13 | 0.01 | 0.52 | 0.52 | ZZZ |
| 75998 | TC | A | Fluoroguide for vein device | 0.00 | 1.30 | NA | 0.10 | 1.40 | NA | ZZZ |
| 76000 | | A | Fluoroscope examination | 0.17 | 1.36 | NA | 0.08 | 1.61 | NA | XXX |
| 76000 | 26 | A | Fluoroscope examination | 0.17 | 0.05 | 0.05 | 0.01 | 0.23 | 0.23 | XXX |
| 76000 | TC | A | Fluoroscope examination | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 76001 | | A | Fluoroscope exam, extensive | 0.67 | 2.84 | NA | 0.18 | 3.69 | NA | XXX |
| 76001 | 26 | A | Fluoroscope exam, extensive | 0.67 | 0.22 | 0.22 | 0.04 | 0.93 | 0.93 | XXX |
| 76001 | TC | A | Fluoroscope exam, extensive | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 76003 | | A | Needle localization by x-ray | 0.54 | 1.47 | NA | 0.10 | 2.11 | NA | XXX |
| 76003 | 26 | A | Needle localization by x-ray | 0.54 | 0.17 | 0.17 | 0.03 | 0.74 | 0.74 | XXX |
| 76003 | TC | A | Needle localization by x-ray | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 76005 | | A | Fluoroguide for spine inject | 0.60 | 1.46 | NA | 0.11 | 2.17 | NA | XXX |
| 76005 | 26 | A | Fluoroguide for spine inject | 0.60 | 0.15 | 0.15 | 0.04 | 0.79 | 0.79 | XXX |
| 76005 | TC | A | Fluoroguide for spine inject | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 76006 | | A | X-ray stress view | 0.41 | 0.18 | 0.18 | 0.06 | 0.65 | 0.65 | XXX |
| 76010 | | A | X-ray, nose to rectum | 0.18 | 0.58 | NA | 0.03 | 0.79 | NA | XXX |
| 76010 | 26 | A | X-ray, nose to rectum | 0.18 | 0.06 | 0.06 | 0.01 | 0.25 | 0.25 | XXX |
| 76010 | TC | A | X-ray, nose to rectum | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 76012 | 26 | A | Percut vertebroplasty fluor | 1.31 | 0.47 | 0.47 | 0.09 | 1.87 | 1.87 | XXX |
| 76013 | 26 | A | Percut vertebroplasty, ct | 1.38 | 0.47 | 0.47 | 0.08 | 1.93 | 1.93 | XXX |
| 76020 | | A | X-rays for bone age | 0.19 | 0.58 | NA | 0.03 | 0.80 | NA | XXX |
| 76020 | 26 | A | X-rays for bone age | 0.19 | 0.06 | 0.06 | 0.01 | 0.26 | 0.26 | XXX |
| 76020 | TC | A | X-rays for bone age | 0.00 | 0.52 | NA | 0.02 | 0.54 | NA | XXX |
| 76040 | | A | X-rays, bone evaluation | 0.27 | 0.87 | NA | 0.06 | 1.20 | NA | XXX |
| 76040 | 26 | A | X-rays, bone evaluation | 0.27 | 0.09 | 0.09 | 0.01 | 0.37 | 0.37 | XXX |
| 76040 | TC | A | X-rays, bone evaluation | 0.00 | 0.78 | NA | 0.05 | 0.83 | NA | XXX |
| 76061 | | A | X-rays, bone survey | 0.45 | 1.14 | NA | 0.08 | 1.67 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 76061 | 26 | A | X-rays, bone survey | 0.45 | 0.15 | 0.15 | 0.02 | 0.62 | 0.62 | XXX |
| 76061 | TC | A | X-rays, bone survey | 0.00 | 0.99 | NA | 0.06 | 1.05 | NA | XXX |
| 76062 | | A | X-rays, bone survey | 0.54 | 1.61 | NA | 0.10 | 2.25 | NA | XXX |
| 76062 | 26 | A | X-rays, bone survey | 0.54 | 0.18 | 0.18 | 0.02 | 0.74 | 0.74 | XXX |
| 76062 | TC | A | X-rays, bone survey | 0.00 | 1.44 | NA | 0.08 | 1.52 | NA | XXX |
| 76065 | | A | X-rays, bone evaluation | 0.70 | 0.97 | NA | 0.08 | 1.75 | NA | XXX |
| 76065 | 26 | A | X-rays, bone evaluation | 0.70 | 0.23 | 0.23 | 0.03 | 0.96 | 0.96 | XXX |
| 76065 | TC | A | X-rays, bone evaluation | 0.00 | 0.73 | NA | 0.05 | 0.78 | NA | XXX |
| 76066 | | A | Joint survey, single view | 0.31 | 1.21 | NA | 0.08 | 1.60 | NA | XXX |
| 76066 | 26 | A | Joint survey, single view | 0.31 | 0.10 | 0.10 | 0.02 | 0.43 | 0.43 | XXX |
| 76066 | TC | A | Joint survey, single view | 0.00 | 1.11 | NA | 0.06 | 1.17 | NA | XXX |
| 76070 | | A | Ct bone density, axial | 0.25 | 3.03 | NA | 0.17 | 3.45 | NA | XXX |
| 76070 | 26 | A | Ct bone density, axial | 0.25 | 0.08 | 0.08 | 0.01 | 0.34 | 0.34 | XXX |
| 76070 | TC | A | Ct bone density, axial | 0.00 | 2.94 | NA | 0.16 | 3.10 | NA | XXX |
| 76071 | | A | Ct bone density, peripheral | 0.22 | 3.02 | NA | 0.06 | 3.30 | NA | XXX |
| 76071 | 26 | A | Ct bone density, peripheral | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| 76071 | TC | A | Ct bone density, peripheral | 0.00 | 2.94 | NA | 0.05 | 2.99 | NA | XXX |
| 76075 | | A | Dexa, axial skeleton study | 0.30 | 3.19 | NA | 0.18 | 3.67 | NA | XXX |
| 76075 | 26 | A | Dexa, axial skeleton study | 0.30 | 0.10 | 0.10 | 0.01 | 0.41 | 0.41 | XXX |
| 76075 | TC | A | Dexa, axial skeleton study | 0.00 | 3.09 | NA | 0.17 | 3.26 | NA | XXX |
| 76076 | | A | Dexa, peripheral study | 0.22 | 0.83 | NA | 0.06 | 1.11 | NA | XXX |
| 76076 | 26 | A | Dexa, peripheral study | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| 76076 | TC | A | Dexa, peripheral study | 0.00 | 0.75 | NA | 0.05 | 0.80 | NA | XXX |
| 76078 | | A | Radiographic absorptiometry | 0.20 | 0.82 | NA | 0.06 | 1.08 | NA | XXX |
| 76078 | 26 | A | Radiographic absorptiometry | 0.20 | 0.07 | 0.07 | 0.01 | 0.28 | 0.28 | XXX |
| 76078 | TC | A | Radiographic absorptiometry | 0.00 | 0.75 | NA | 0.05 | 0.80 | NA | XXX |
| 76080 | | A | X-ray exam of fistula | 0.54 | 1.23 | NA | 0.08 | 1.85 | NA | XXX |
| 76080 | 26 | A | X-ray exam of fistula | 0.54 | 0.18 | 0.18 | 0.02 | 0.74 | 0.74 | XXX |
| 76080 | TC | A | X-ray exam of fistula | 0.00 | 1.05 | NA | 0.06 | 1.11 | NA | XXX |
| 76082 | | A | Computer mammogram add-on | 0.06 | 0.43 | NA | 0.01 | 0.50 | NA | ZZZ |
| 76082 | 26 | A | Computer mammogram add-on | 0.06 | 0.02 | 0.02 | 0.00 | 0.08 | 0.08 | ZZZ |
| 76082 | TC | A | Computer mammogram add-on | 0.00 | 0.42 | NA | 0.01 | 0.43 | NA | ZZZ |
| 76083 | | A | Computer mammogram add-on | 0.06 | 0.43 | NA | 0.01 | 0.50 | NA | ZZZ |
| 76083 | 26 | A | Computer mammogram add-on | 0.06 | 0.02 | 0.02 | 0.00 | 0.08 | 0.08 | ZZZ |
| 76083 | TC | A | Computer mammogram add-on | 0.00 | 0.42 | NA | 0.01 | 0.43 | NA | ZZZ |
| 76086 | | A | X-ray of mammary duct | 0.36 | 2.73 | NA | 0.16 | 3.25 | NA | XXX |
| 76086 | 26 | A | X-ray of mammary duct | 0.36 | 0.12 | 0.12 | 0.02 | 0.50 | 0.50 | XXX |
| 76086 | TC | A | X-ray of mammary duct | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 76088 | | A | X-ray of mammary ducts | 0.45 | 3.80 | NA | 0.21 | 4.46 | NA | XXX |
| 76088 | 26 | A | X-ray of mammary ducts | 0.45 | 0.15 | 0.15 | 0.02 | 0.62 | 0.62 | XXX |
| 76088 | TC | A | X-ray of mammary ducts | 0.00 | 3.66 | NA | 0.19 | 3.85 | NA | XXX |
| 76090 | | A | Mammogram, one breast | 0.70 | 1.28 | NA | 0.09 | 2.07 | NA | XXX |
| 76090 | 26 | A | Mammogram, one breast | 0.70 | 0.23 | 0.23 | 0.03 | 0.96 | 0.96 | XXX |
| 76090 | TC | A | Mammogram, one breast | 0.00 | 1.05 | NA | 0.06 | 1.11 | NA | XXX |
| 76091 | | A | Mammogram, both breasts | 0.87 | 1.59 | NA | 0.11 | 2.57 | NA | XXX |
| 76091 | 26 | A | Mammogram, both breasts | 0.87 | 0.28 | 0.28 | 0.04 | 1.19 | 1.19 | XXX |
| 76091 | TC | A | Mammogram, both breasts | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 76092 | | A | Mammogram, screening | 0.70 | 1.45 | NA | 0.10 | 2.25 | NA | XXX |
| 76092 | 26 | A | Mammogram, screening | 0.70 | 0.23 | 0.23 | 0.03 | 0.96 | 0.96 | XXX |
| 76092 | TC | A | Mammogram, screening | 0.00 | 1.23 | NA | 0.07 | 1.30 | NA | XXX |
| 76093 | | A | Magnetic image, breast | 1.63 | 18.13 | NA | 0.99 | 20.75 | NA | XXX |
| 76093 | 26 | A | Magnetic image, breast | 1.63 | 0.53 | 0.53 | 0.07 | 2.23 | 2.23 | XXX |
| 76093 | TC | A | Magnetic image, breast | 0.00 | 17.59 | NA | 0.92 | 18.51 | NA | XXX |
| 76094 | | A | Magnetic image, both breasts | 1.63 | 24.40 | NA | 1.31 | 27.34 | NA | XXX |
| 76094 | 26 | A | Magnetic image, both breasts | 1.63 | 0.53 | 0.53 | 0.07 | 2.23 | 2.23 | XXX |
| 76094 | TC | A | Magnetic image, both breasts | 0.00 | 23.87 | NA | 1.24 | 25.11 | NA | XXX |
| 76095 | | A | Stereotactic breast biopsy | 1.59 | 7.67 | NA | 0.47 | 9.73 | NA | XXX |
| 76095 | 26 | A | Stereotactic breast biopsy | 1.59 | 0.52 | 0.52 | 0.10 | 2.21 | 2.21 | XXX |
| 76095 | TC | A | Stereotactic breast biopsy | 0.00 | 7.15 | NA | 0.37 | 7.52 | NA | XXX |
| 76096 | | A | X-ray of needle wire, breast | 0.56 | 1.49 | NA | 0.10 | 2.15 | NA | XXX |
| 76096 | 26 | A | X-ray of needle wire, breast | 0.56 | 0.18 | 0.18 | 0.03 | 0.77 | 0.77 | XXX |
| 76096 | TC | A | X-ray of needle wire, breast | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 76098 | | A | X-ray exam, breast specimen | 0.16 | 0.47 | NA | 0.03 | 0.66 | NA | XXX |
| 76098 | 26 | A | X-ray exam, breast specimen | 0.16 | 0.05 | 0.05 | 0.01 | 0.22 | 0.22 | XXX |
| 76098 | TC | A | X-ray exam, breast specimen | 0.00 | 0.42 | NA | 0.02 | 0.44 | NA | XXX |
| 76100 | | A | X-ray exam of body section | 0.58 | 1.43 | NA | 0.10 | 2.11 | NA | XXX |
| 76100 | 26 | A | X-ray exam of body section | 0.58 | 0.19 | 0.19 | 0.03 | 0.80 | 0.80 | XXX |
| 76100 | TC | A | X-ray exam of body section | 0.00 | 1.25 | NA | 0.07 | 1.32 | NA | XXX |
| 76101 | | A | Complex body section x-ray | 0.58 | 1.61 | NA | 0.11 | 2.30 | NA | XXX |
| 76101 | 26 | A | Complex body section x-ray | 0.58 | 0.19 | 0.19 | 0.03 | 0.80 | 0.80 | XXX |
| 76101 | TC | A | Complex body section x-ray | 0.00 | 1.42 | NA | 0.08 | 1.50 | NA | XXX |
| 76102 | | A | Complex body section x-rays | 0.58 | 1.92 | NA | 0.14 | 2.64 | NA | XXX |
| 76102 | 26 | A | Complex body section x-rays | 0.58 | 0.19 | 0.19 | 0.03 | 0.80 | 0.80 | XXX |
| 76102 | TC | A | Complex body section x-rays | 0.00 | 1.73 | NA | 0.11 | 1.84 | NA | XXX |
| 76120 | | A | Cine/video x-rays | 0.38 | 1.18 | NA | 0.08 | 1.64 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 76120 | 26 | A | Cine/video x-rays | 0.38 | 0.13 | 0.13 | 0.02 | 0.53 | 0.53 | XXX |
| 76120 | TC | A | Cine/video x-rays | 0.00 | 1.05 | NA | 0.06 | 1.11 | NA | XXX |
| 76125 | | A | Cine/video x-rays add-on | 0.27 | 0.87 | NA | 0.06 | 1.20 | NA | ZZZ |
| 76125 | 26 | A | Cine/video x-rays add-on | 0.27 | 0.09 | 0.09 | 0.01 | 0.37 | 0.37 | ZZZ |
| 76125 | TC | A | Cine/video x-rays add-on | 0.00 | 0.78 | NA | 0.05 | 0.83 | NA | ZZZ |
| 76150 | | A | X-ray exam, dry process | 0.00 | 0.42 | NA | 0.02 | 0.44 | NA | XXX |
| 76355 | | A | Ct scan for localization | 1.21 | 8.64 | NA | 0.48 | 10.33 | NA | XXX |
| 76355 | 26 | A | Ct scan for localization | 1.21 | 0.40 | 0.40 | 0.06 | 1.67 | 1.67 | XXX |
| 76355 | TC | A | Ct scan for localization | 0.00 | 8.24 | NA | 0.42 | 8.66 | NA | XXX |
| 76360 | | A | Ct scan for needle biopsy | 1.16 | 8.62 | NA | 0.47 | 10.25 | NA | XXX |
| 76360 | 26 | A | Ct scan for needle biopsy | 1.16 | 0.38 | 0.38 | 0.05 | 1.59 | 1.59 | XXX |
| 76360 | TC | A | Ct scan for needle biopsy | 0.00 | 8.24 | NA | 0.42 | 8.66 | NA | XXX |
| 76362 | | A | Ct guide for tissue ablation | 3.99 | 9.54 | NA | 1.64 | 15.17 | NA | XXX |
| 76362 | 26 | A | Ct guide for tissue ablation | 3.99 | 1.30 | 1.30 | 0.18 | 5.47 | 5.47 | XXX |
| 76362 | TC | A | Ct guide for tissue ablation | 0.00 | 8.24 | NA | 1.46 | 9.70 | NA | XXX |
| 76370 | | A | Ct scan for therapy guide | 0.85 | 3.22 | NA | 0.20 | 4.27 | NA | XXX |
| 76370 | 26 | A | Ct scan for therapy guide | 0.85 | 0.28 | 0.28 | 0.04 | 1.17 | 1.17 | XXX |
| 76370 | TC | A | Ct scan for therapy guide | 0.00 | 2.94 | NA | 0.16 | 3.10 | NA | XXX |
| 76375 | | A | 3d/holograph reconstr add-on | 0.16 | 3.58 | NA | 0.19 | 3.93 | NA | XXX |
| 76375 | 26 | A | 3d/holograph reconstr add-on | 0.16 | 0.05 | 0.05 | 0.01 | 0.22 | 0.22 | XXX |
| 76375 | TC | A | 3d/holograph reconstr add-on | 0.00 | 3.53 | NA | 0.18 | 3.71 | NA | XXX |
| 76380 | | A | CAT scan follow-up study | 0.98 | 3.81 | NA | 0.22 | 5.01 | NA | XXX |
| 76380 | 26 | A | CAT scan follow-up study | 0.98 | 0.32 | 0.32 | 0.04 | 1.34 | 1.34 | XXX |
| 76380 | TC | A | CAT scan follow-up study | 0.00 | 3.49 | NA | 0.18 | 3.67 | NA | XXX |
| 76393 | | A | Mr guidance for needle place | 1.50 | 11.68 | NA | 0.65 | 13.83 | NA | XXX |
| 76393 | 26 | A | Mr guidance for needle place | 1.50 | 0.50 | 0.50 | 0.10 | 2.10 | 2.10 | XXX |
| 76393 | TC | A | Mr guidance for needle place | 0.00 | 11.19 | NA | 0.55 | 11.74 | NA | XXX |
| 76394 | | A | Mri for tissue ablation | 4.24 | 12.57 | NA | 1.80 | 18.61 | NA | XXX |
| 76394 | 26 | A | Mri for tissue ablation | 4.24 | 1.38 | 1.38 | 0.24 | 5.86 | 5.86 | XXX |
| 76394 | TC | A | Mri for tissue ablation | 0.00 | 11.19 | NA | 1.56 | 12.75 | NA | XXX |
| 76400 | | A | Magnetic image, bone marrow | 1.60 | 11.71 | NA | 0.66 | 13.97 | NA | XXX |
| 76400 | 26 | A | Magnetic image, bone marrow | 1.60 | 0.52 | 0.52 | 0.07 | 2.19 | 2.19 | XXX |
| 76400 | TC | A | Magnetic image, bone marrow | 0.00 | 11.19 | NA | 0.59 | 11.78 | NA | XXX |
| 76506 | | A | Echo exam of head | 0.63 | 1.66 | NA | 0.12 | 2.41 | NA | XXX |
| 76506 | 26 | A | Echo exam of head | 0.63 | 0.24 | 0.24 | 0.04 | 0.91 | 0.91 | XXX |
| 76506 | TC | A | Echo exam of head | 0.00 | 1.42 | NA | 0.08 | 1.50 | NA | XXX |
| 76511 | | A | Echo exam of eye | 0.94 | 1.85 | NA | 0.10 | 2.89 | NA | XXX |
| 76511 | 26 | A | Echo exam of eye | 0.94 | 0.40 | 0.40 | 0.03 | 1.37 | 1.37 | XXX |
| 76511 | TC | A | Echo exam of eye | 0.00 | 1.45 | NA | 0.07 | 1.52 | NA | XXX |
| 76512 | | A | Echo exam of eye | 0.66 | 1.73 | NA | 0.12 | 2.51 | NA | XXX |
| 76512 | 26 | A | Echo exam of eye | 0.66 | 0.29 | 0.29 | 0.02 | 0.97 | 0.97 | XXX |
| 76512 | TC | A | Echo exam of eye | 0.00 | 1.44 | NA | 0.10 | 1.54 | NA | XXX |
| 76513 | | A | Echo exam of eye, water bath | 0.66 | 1.82 | NA | 0.12 | 2.60 | NA | XXX |
| 76513 | 26 | A | Echo exam of eye, water bath | 0.66 | 0.29 | 0.29 | 0.02 | 0.97 | 0.97 | XXX |
| 76513 | TC | A | Echo exam of eye, water bath | 0.00 | 1.52 | NA | 0.10 | 1.62 | NA | XXX |
| 76514 | | A | Echo exam of eye, thickness | 0.17 | 0.13 | NA | 0.02 | 0.32 | NA | XXX |
| 76514 | 26 | A | Echo exam of eye, thickness | 0.17 | 0.08 | 0.08 | 0.01 | 0.26 | 0.26 | XXX |
| 76514 | TC | A | Echo exam of eye, thickness | 0.00 | 0.05 | NA | 0.01 | 0.06 | NA | XXX |
| 76516 | | A | Echo exam of eye | 0.54 | 1.46 | NA | 0.08 | 2.08 | NA | XXX |
| 76516 | 26 | A | Echo exam of eye | 0.54 | 0.24 | 0.24 | 0.01 | 0.79 | 0.79 | XXX |
| 76516 | TC | A | Echo exam of eye | 0.00 | 1.22 | NA | 0.07 | 1.29 | NA | XXX |
| 76519 | | A | Echo exam of eye | 0.54 | 1.56 | NA | 0.08 | 2.18 | NA | XXX |
| 76519 | 26 | A | Echo exam of eye | 0.54 | 0.24 | 0.24 | 0.01 | 0.79 | 0.79 | XXX |
| 76519 | TC | A | Echo exam of eye | 0.00 | 1.32 | NA | 0.07 | 1.39 | NA | XXX |
| 76529 | | A | Echo exam of eye | 0.57 | 1.38 | NA | 0.10 | 2.05 | NA | XXX |
| 76529 | 26 | A | Echo exam of eye | 0.57 | 0.24 | 0.24 | 0.02 | 0.83 | 0.83 | XXX |
| 76529 | TC | A | Echo exam of eye | 0.00 | 1.14 | NA | 0.08 | 1.22 | NA | XXX |
| 76536 | | A | Us exam of head and neck | 0.56 | 1.60 | NA | 0.11 | 2.27 | NA | XXX |
| 76536 | 26 | A | Us exam of head and neck | 0.56 | 0.18 | 0.18 | 0.03 | 0.77 | 0.77 | XXX |
| 76536 | TC | A | Us exam of head and neck | 0.00 | 1.42 | NA | 0.08 | 1.50 | NA | XXX |
| 76604 | | A | Us exam, chest, b-scan | 0.55 | 1.48 | NA | 0.10 | 2.13 | NA | XXX |
| 76604 | 26 | A | Us exam, chest, b-scan | 0.55 | 0.18 | 0.18 | 0.03 | 0.76 | 0.76 | XXX |
| 76604 | TC | A | Us exam, chest, b-scan | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 76645 | | A | Us exam, breast(s) | 0.54 | 1.23 | NA | 0.08 | 1.85 | NA | XXX |
| 76645 | 26 | A | Us exam, breast(s) | 0.54 | 0.18 | 0.18 | 0.02 | 0.74 | 0.74 | XXX |
| 76645 | TC | A | Us exam, breast(s) | 0.00 | 1.05 | NA | 0.06 | 1.11 | NA | XXX |
| 76700 | | A | Us exam, abdom, complete | 0.81 | 2.23 | NA | 0.15 | 3.19 | NA | XXX |
| 76700 | 26 | A | Us exam, abdom, complete | 0.81 | 0.26 | 0.26 | 0.04 | 1.11 | 1.11 | XXX |
| 76700 | TC | A | Us exam, abdom, complete | 0.00 | 1.97 | NA | 0.11 | 2.08 | NA | XXX |
| 76705 | | A | Echo exam of abdomen | 0.59 | 1.61 | NA | 0.11 | 2.31 | NA | XXX |
| 76705 | 26 | A | Echo exam of abdomen | 0.59 | 0.19 | 0.19 | 0.03 | 0.81 | 0.81 | XXX |
| 76705 | TC | A | Echo exam of abdomen | 0.00 | 1.42 | NA | 0.08 | 1.50 | NA | XXX |
| 76770 | | A | Us exam abdo back wall, comp | 0.74 | 2.21 | NA | 0.14 | 3.09 | NA | XXX |
| 76770 | 26 | A | Us exam abdo back wall, comp | 0.74 | 0.24 | 0.24 | 0.03 | 1.01 | 1.01 | XXX |
| 76770 | TC | A | Us exam abdo back wall, comp | 0.00 | 1.97 | NA | 0.11 | 2.08 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 76775 | | A | Us exam abdo back wall, lim | 0.58 | 1.61 | NA | 0.11 | 2.30 | NA | XXX |
| 76775 | 26 | A | Us exam abdo back wall, lim | 0.58 | 0.19 | 0.19 | 0.03 | 0.80 | 0.80 | XXX |
| 76775 | TC | A | Us exam abdo back wall, lim | 0.00 | 1.42 | NA | 0.08 | 1.50 | NA | XXX |
| 76778 | | A | Us exam kidney transplant | 0.74 | 2.21 | NA | 0.14 | 3.09 | NA | XXX |
| 76778 | 26 | A | Us exam kidney transplant | 0.74 | 0.24 | 0.24 | 0.03 | 1.01 | 1.01 | XXX |
| 76778 | TC | A | Us exam kidney transplant | 0.00 | 1.97 | NA | 0.11 | 2.08 | NA | XXX |
| 76800 | | A | Us exam, spinal canal | 1.13 | 1.76 | NA | 0.14 | 3.03 | NA | XXX |
| 76800 | 26 | A | Us exam, spinal canal | 1.13 | 0.34 | 0.34 | 0.06 | 1.53 | 1.53 | XXX |
| 76800 | TC | A | Us exam, spinal canal | 0.00 | 1.42 | NA | 0.08 | 1.50 | NA | XXX |
| 76801 | | A | Ob us < 14 wks, single fetus | 0.99 | 2.43 | NA | 0.17 | 3.59 | NA | XXX |
| 76801 | 26 | A | Ob us < 14 wks, single fetus | 0.99 | 0.34 | 0.34 | 0.05 | 1.38 | 1.38 | XXX |
| 76801 | TC | A | Ob us < 14 wks, single fetus | 0.00 | 2.09 | NA | 0.12 | 2.21 | NA | XXX |
| 76802 | | A | Ob us < 14 wks, add-l fetus | 0.83 | 1.34 | NA | 0.17 | 2.34 | NA | ZZZ |
| 76802 | 26 | A | Ob us < 14 wks, add-l fetus | 0.83 | 0.29 | 0.29 | 0.05 | 1.17 | 1.17 | ZZZ |
| 76802 | TC | A | Ob us < 14 wks, add-l fetus | 0.00 | 1.05 | NA | 0.12 | 1.17 | NA | ZZZ |
| 76805 | | A | Ob us >/= 14 wks, sngl fetus | 0.99 | 2.43 | NA | 0.17 | 3.59 | NA | XXX |
| 76805 | 26 | A | Ob us >/= 14 wks, sngl fetus | 0.99 | 0.34 | 0.34 | 0.05 | 1.38 | 1.38 | XXX |
| 76805 | TC | A | Ob us >/= 14 wks, sngl fetus | 0.00 | 2.09 | NA | 0.12 | 2.21 | NA | XXX |
| 76810 | | A | Ob us >/= 14 wks, addl fetus | 0.98 | 1.39 | NA | 0.31 | 2.68 | NA | ZZZ |
| 76810 | 26 | A | Ob us >/= 14 wks, addl fetus | 0.98 | 0.34 | 0.34 | 0.09 | 1.41 | 1.41 | ZZZ |
| 76810 | TC | A | Ob us >/= 14 wks, addl fetus | 0.00 | 1.05 | NA | 0.22 | 1.27 | NA | ZZZ |
| 76811 | | A | Ob us, detailed, sngl fetus | 1.90 | 4.23 | NA | 0.48 | 6.61 | NA | XXX |
| 76811 | 26 | A | Ob us, detailed, sngl fetus | 1.90 | 0.71 | 0.71 | 0.05 | 2.66 | 2.66 | XXX |
| 76811 | TC | A | Ob us, detailed, sngl fetus | 0.00 | 3.52 | NA | 0.43 | 3.95 | NA | XXX |
| 76812 | | A | Ob us, detailed, addl fetus | 1.78 | 1.71 | NA | 0.50 | 3.99 | NA | ZZZ |
| 76812 | 26 | A | Ob us, detailed, addl fetus | 1.78 | 0.66 | 0.66 | 0.09 | 2.53 | 2.53 | ZZZ |
| 76812 | TC | A | Ob us, detailed, addl fetus | 0.00 | 1.05 | NA | 0.41 | 1.46 | NA | ZZZ |
| 76815 | | A | Ob us, limited, fetus(s) | 0.65 | 1.65 | NA | 0.11 | 2.41 | NA | XXX |
| 76815 | 26 | A | Ob us, limited, fetus(s) | 0.65 | 0.23 | 0.23 | 0.03 | 0.91 | 0.91 | XXX |
| 76815 | TC | A | Ob us, limited, fetus(s) | 0.00 | 1.42 | NA | 0.08 | 1.50 | NA | XXX |
| 76816 | | A | Ob us, follow-up, per fetus | 0.85 | 1.42 | NA | 0.09 | 2.36 | NA | XXX |
| 76816 | 26 | A | Ob us, follow-up, per fetus | 0.85 | 0.31 | 0.31 | 0.03 | 1.19 | 1.19 | XXX |
| 76816 | TC | A | Ob us, follow-up, per fetus | 0.00 | 1.11 | NA | 0.06 | 1.17 | NA | XXX |
| 76817 | | A | Transvaginal us, obstetric | 0.75 | 1.78 | NA | 0.09 | 2.62 | NA | XXX |
| 76817 | 26 | A | Transvaginal us, obstetric | 0.75 | 0.26 | 0.26 | 0.03 | 1.04 | 1.04 | XXX |
| 76817 | TC | A | Transvaginal us, obstetric | 0.00 | 1.52 | NA | 0.06 | 1.58 | NA | XXX |
| 76818 | | A | Fetal biophys profile w/nst | 1.05 | 2.00 | NA | 0.15 | 3.20 | NA | XXX |
| 76818 | 26 | A | Fetal biophys profile w/nst | 1.05 | 0.39 | 0.39 | 0.05 | 1.49 | 1.49 | XXX |
| 76818 | TC | A | Fetal biophys profile w/nst | 0.00 | 1.61 | NA | 0.10 | 1.71 | NA | XXX |
| 76819 | | A | Fetal biophys profil w/o nst | 0.77 | 1.89 | NA | 0.14 | 2.80 | NA | XXX |
| 76819 | 26 | A | Fetal biophys profil w/o nst | 0.77 | 0.28 | 0.28 | 0.04 | 1.09 | 1.09 | XXX |
| 76819 | TC | A | Fetal biophys profil w/o nst | 0.00 | 1.61 | NA | 0.10 | 1.71 | NA | XXX |
| 76825 | | A | Echo exam of fetal heart | 1.67 | 2.57 | NA | 0.18 | 4.42 | NA | XXX |
| 76825 | 26 | A | Echo exam of fetal heart | 1.67 | 0.60 | 0.60 | 0.07 | 2.34 | 2.34 | XXX |
| 76825 | TC | A | Echo exam of fetal heart | 0.00 | 1.97 | NA | 0.11 | 2.08 | NA | XXX |
| 76826 | | A | Echo exam of fetal heart | 0.83 | 0.99 | NA | 0.09 | 1.91 | NA | XXX |
| 76826 | 26 | A | Echo exam of fetal heart | 0.83 | 0.29 | 0.29 | 0.04 | 1.16 | 1.16 | XXX |
| 76826 | TC | A | Echo exam of fetal heart | 0.00 | 0.70 | NA | 0.05 | 0.75 | NA | XXX |
| 76827 | | A | Echo exam of fetal heart | 0.58 | 1.93 | NA | 0.15 | 2.66 | NA | XXX |
| 76827 | 26 | A | Echo exam of fetal heart | 0.58 | 0.21 | 0.21 | 0.03 | 0.82 | 0.82 | XXX |
| 76827 | TC | A | Echo exam of fetal heart | 0.00 | 1.72 | NA | 0.12 | 1.84 | NA | XXX |
| 76828 | | A | Echo exam of fetal heart | 0.56 | 1.32 | NA | 0.11 | 1.99 | NA | XXX |
| 76828 | 26 | A | Echo exam of fetal heart | 0.56 | 0.21 | 0.21 | 0.03 | 0.80 | 0.80 | XXX |
| 76828 | TC | A | Echo exam of fetal heart | 0.00 | 1.11 | NA | 0.08 | 1.19 | NA | XXX |
| 76830 | | A | Transvaginal us, non-ob | 0.69 | 1.74 | NA | 0.13 | 2.56 | NA | XXX |
| 76830 | 26 | A | Transvaginal us, non-ob | 0.69 | 0.23 | 0.23 | 0.03 | 0.95 | 0.95 | XXX |
| 76830 | TC | A | Transvaginal us, non-ob | 0.00 | 1.52 | NA | 0.10 | 1.62 | NA | XXX |
| 76831 | | A | Echo exam, uterus | 0.72 | 1.77 | NA | 0.13 | 2.62 | NA | XXX |
| 76831 | 26 | A | Echo exam, uterus | 0.72 | 0.25 | 0.25 | 0.03 | 1.00 | 1.00 | XXX |
| 76831 | TC | A | Echo exam, uterus | 0.00 | 1.52 | NA | 0.10 | 1.62 | NA | XXX |
| 76856 | | A | Us exam, pelvic, complete | 0.69 | 1.74 | NA | 0.13 | 2.56 | NA | XXX |
| 76856 | 26 | A | Us exam, pelvic, complete | 0.69 | 0.23 | 0.23 | 0.03 | 0.95 | 0.95 | XXX |
| 76856 | TC | A | Us exam, pelvic, complete | 0.00 | 1.52 | NA | 0.10 | 1.62 | NA | XXX |
| 76857 | | A | Us exam, pelvic, limited | 0.38 | 1.83 | NA | 0.08 | 2.29 | NA | XXX |
| 76857 | 26 | A | Us exam, pelvic, limited | 0.38 | 0.12 | 0.12 | 0.02 | 0.52 | 0.52 | XXX |
| 76857 | TC | A | Us exam, pelvic, limited | 0.00 | 1.70 | NA | 0.06 | 1.76 | NA | XXX |
| 76870 | | A | Us exam, scrotum | 0.64 | 1.72 | NA | 0.13 | 2.49 | NA | XXX |
| 76870 | 26 | A | Us exam, scrotum | 0.64 | 0.21 | 0.21 | 0.03 | 0.88 | 0.88 | XXX |
| 76870 | TC | A | Us exam, scrotum | 0.00 | 1.52 | NA | 0.10 | 1.62 | NA | XXX |
| 76872 | | A | Us, transrectal | 0.69 | 2.25 | NA | 0.14 | 3.08 | NA | XXX |
| 76872 | 26 | A | Us, transrectal | 0.69 | 0.22 | 0.22 | 0.04 | 0.95 | 0.95 | XXX |
| 76872 | TC | A | Us, transrectal | 0.00 | 2.02 | NA | 0.10 | 2.12 | NA | XXX |
| 76873 | | A | Echograp trans r, pros study | 1.55 | 2.59 | NA | 0.25 | 4.39 | NA | XXX |
| 76873 | 26 | A | Echograp trans r, pros study | 1.55 | 0.50 | 0.50 | 0.09 | 2.14 | 2.14 | XXX |
| 76873 | TC | A | Echograp trans r, pros study | 0.00 | 2.09 | NA | 0.16 | 2.25 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 76880 | | A | Us exam, extremity | 0.59 | 1.61 | NA | 0.11 | 2.31 | NA | XXX |
| 76880 | 26 | A | Us exam, extremity | 0.59 | 0.19 | 0.19 | 0.03 | 0.81 | 0.81 | XXX |
| 76880 | TC | A | Us exam, extremity | 0.00 | 1.42 | NA | 0.08 | 1.50 | NA | XXX |
| 76885 | | A | Us exam infant hips, dynamic | 0.74 | 1.76 | NA | 0.13 | 2.63 | NA | XXX |
| 76885 | 26 | A | Us exam infant hips, dynamic | 0.74 | 0.24 | 0.24 | 0.03 | 1.01 | 1.01 | XXX |
| 76885 | TC | A | Us exam infant hips, dynamic | 0.00 | 1.52 | NA | 0.10 | 1.62 | NA | XXX |
| 76886 | | A | Us exam infant hips, static | 0.62 | 1.62 | NA | 0.11 | 2.35 | NA | XXX |
| 76886 | 26 | A | Us exam infant hips, static | 0.62 | 0.20 | 0.20 | 0.03 | 0.85 | 0.85 | XXX |
| 76886 | TC | A | Us exam infant hips, static | 0.00 | 1.42 | NA | 0.08 | 1.50 | NA | XXX |
| 76930 | | A | Echo guide, cardiocentesis | 0.67 | 1.77 | NA | 0.12 | 2.56 | NA | XXX |
| 76930 | 26 | A | Echo guide, cardiocentesis | 0.67 | 0.25 | 0.25 | 0.02 | 0.94 | 0.94 | XXX |
| 76930 | TC | A | Echo guide, cardiocentesis | 0.00 | 1.52 | NA | 0.10 | 1.62 | NA | XXX |
| 76932 | | A | Echo guide for heart biopsy | 0.67 | 1.77 | NA | 0.12 | 2.56 | NA | XXX |
| 76932 | 26 | A | Echo guide for heart biopsy | 0.67 | 0.25 | 0.25 | 0.02 | 0.94 | 0.94 | XXX |
| 76932 | TC | A | Echo guide for heart biopsy | 0.00 | 1.52 | NA | 0.10 | 1.62 | NA | XXX |
| 76936 | | A | Echo guide for artery repair | 1.99 | 6.94 | NA | 0.47 | 9.40 | NA | XXX |
| 76936 | 26 | A | Echo guide for artery repair | 1.99 | 0.66 | 0.66 | 0.13 | 2.78 | 2.78 | XXX |
| 76936 | TC | A | Echo guide for artery repair | 0.00 | 6.28 | NA | 0.34 | 6.62 | NA | XXX |
| 76937 | | A | Us guide, vascular access | 0.30 | 0.47 | NA | 0.13 | 0.90 | NA | ZZZ |
| 76937 | 26 | A | Us guide, vascular access | 0.30 | 0.10 | 0.10 | 0.03 | 0.43 | 0.43 | ZZZ |
| 76937 | TC | A | Us guide, vascular access | 0.00 | 0.38 | NA | 0.10 | 0.48 | NA | ZZZ |
| 76940 | | A | Us guide, tissue ablation | 2.00 | 2.17 | NA | 0.48 | 4.65 | NA | XXX |
| 76940 | 26 | A | Us guide, tissue ablation | 2.00 | 0.65 | 0.65 | 0.19 | 2.84 | 2.84 | XXX |
| 76940 | TC | A | Us guide, tissue ablation | 0.00 | 1.52 | NA | 0.29 | 1.81 | NA | XXX |
| 76941 | | A | Echo guide for transfusion | 1.34 | 2.00 | NA | 0.14 | 3.48 | NA | XXX |
| 76941 | 26 | A | Echo guide for transfusion | 1.34 | 0.47 | 0.47 | 0.06 | 1.87 | 1.87 | XXX |
| 76941 | TC | A | Echo guide for transfusion | 0.00 | 1.52 | NA | 0.08 | 1.60 | NA | XXX |
| 76942 | | A | Echo guide for biopsy | 0.67 | 3.03 | NA | 0.13 | 3.83 | NA | XXX |
| 76942 | 26 | A | Echo guide for biopsy | 0.67 | 0.22 | 0.22 | 0.03 | 0.92 | 0.92 | XXX |
| 76942 | TC | A | Echo guide for biopsy | 0.00 | 2.81 | NA | 0.10 | 2.91 | NA | XXX |
| 76945 | | A | Echo guide, villus sampling | 0.67 | 1.75 | NA | 0.11 | 2.53 | NA | XXX |
| 76945 | 26 | A | Echo guide, villus sampling | 0.67 | 0.22 | 0.22 | 0.03 | 0.92 | 0.92 | XXX |
| 76945 | TC | A | Echo guide, villus sampling | 0.00 | 1.52 | NA | 0.08 | 1.60 | NA | XXX |
| 76946 | | A | Echo guide for amniocentesis | 0.38 | 1.66 | NA | 0.12 | 2.16 | NA | XXX |
| 76946 | 26 | A | Echo guide for amniocentesis | 0.38 | 0.14 | 0.14 | 0.02 | 0.54 | 0.54 | XXX |
| 76946 | TC | A | Echo guide for amniocentesis | 0.00 | 1.52 | NA | 0.10 | 1.62 | NA | XXX |
| 76948 | | A | Echo guide, ova aspiration | 0.38 | 1.64 | NA | 0.12 | 2.14 | NA | XXX |
| 76948 | 26 | A | Echo guide, ova aspiration | 0.38 | 0.13 | 0.13 | 0.02 | 0.53 | 0.53 | XXX |
| 76948 | TC | A | Echo guide, ova aspiration | 0.00 | 1.52 | NA | 0.10 | 1.62 | NA | XXX |
| 76950 | | A | Echo guidance radiotherapy | 0.58 | 1.49 | NA | 0.10 | 2.17 | NA | XXX |
| 76950 | 26 | A | Echo guidance radiotherapy | 0.58 | 0.19 | 0.19 | 0.03 | 0.80 | 0.80 | XXX |
| 76950 | TC | A | Echo guidance radiotherapy | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 76965 | | A | Echo guidance radiotherapy | 1.34 | 5.99 | NA | 0.38 | 7.71 | NA | XXX |
| 76965 | 26 | A | Echo guidance radiotherapy | 1.34 | 0.43 | 0.43 | 0.09 | 1.86 | 1.86 | XXX |
| 76965 | TC | A | Echo guidance radiotherapy | 0.00 | 5.56 | NA | 0.29 | 5.85 | NA | XXX |
| 76970 | | A | Ultrasound exam follow-up | 0.40 | 1.18 | NA | 0.08 | 1.66 | NA | XXX |
| 76970 | 26 | A | Ultrasound exam follow-up | 0.40 | 0.13 | 0.13 | 0.02 | 0.55 | 0.55 | XXX |
| 76970 | TC | A | Ultrasound exam follow-up | 0.00 | 1.05 | NA | 0.06 | 1.11 | NA | XXX |
| 76975 | | A | GI endoscopic ultrasound | 0.81 | 1.79 | NA | 0.14 | 2.74 | NA | XXX |
| 76975 | 26 | A | GI endoscopic ultrasound | 0.81 | 0.28 | 0.28 | 0.04 | 1.13 | 1.13 | XXX |
| 76975 | TC | A | GI endoscopic ultrasound | 0.00 | 1.52 | NA | 0.10 | 1.62 | NA | XXX |
| 76977 | | A | Us bone density measure | 0.05 | 0.84 | NA | 0.05 | 0.94 | NA | XXX |
| 76977 | 26 | A | Us bone density measure | 0.05 | 0.02 | 0.02 | 0.00 | 0.07 | 0.07 | XXX |
| 76977 | TC | A | Us bone density measure | 0.00 | 0.82 | NA | 0.05 | 0.87 | NA | XXX |
| 76986 | | A | Ultrasound guide intraoper | 1.20 | 3.01 | NA | 0.24 | 4.45 | NA | XXX |
| 76986 | 26 | A | Ultrasound guide intraoper | 1.20 | 0.40 | 0.40 | 0.10 | 1.70 | 1.70 | XXX |
| 76986 | TC | A | Ultrasound guide intraoper | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 77261 | | A | Radiation therapy planning | 1.39 | 0.51 | 0.51 | 0.07 | 1.97 | 1.97 | XXX |
| 77262 | | A | Radiation therapy planning | 2.11 | 0.76 | 0.76 | 0.11 | 2.98 | 2.98 | XXX |
| 77263 | | A | Radiation therapy planning | 3.14 | 1.11 | 1.11 | 0.16 | 4.41 | 4.41 | XXX |
| 77280 | | A | Set radiation therapy field | 0.70 | 3.69 | NA | 0.22 | 4.61 | NA | XXX |
| 77280 | 26 | A | Set radiation therapy field | 0.70 | 0.22 | 0.22 | 0.04 | 0.96 | 0.96 | XXX |
| 77280 | TC | A | Set radiation therapy field | 0.00 | 3.46 | NA | 0.18 | 3.64 | NA | XXX |
| 77285 | | A | Set radiation therapy field | 1.05 | 5.89 | NA | 0.35 | 7.29 | NA | XXX |
| 77285 | 26 | A | Set radiation therapy field | 1.05 | 0.34 | 0.34 | 0.05 | 1.44 | 1.44 | XXX |
| 77285 | TC | A | Set radiation therapy field | 0.00 | 5.56 | NA | 0.30 | 5.86 | NA | XXX |
| 77290 | | A | Set radiation therapy field | 1.56 | 6.99 | NA | 0.43 | 8.98 | NA | XXX |
| 77290 | 26 | A | Set radiation therapy field | 1.56 | 0.50 | 0.50 | 0.08 | 2.14 | 2.14 | XXX |
| 77290 | TC | A | Set radiation therapy field | 0.00 | 6.50 | NA | 0.35 | 6.85 | NA | XXX |
| 77295 | | A | Set radiation therapy field | 4.56 | 29.34 | NA | 1.72 | 35.62 | NA | XXX |
| 77295 | 26 | A | Set radiation therapy field | 4.56 | 1.46 | 1.46 | 0.24 | 6.26 | 6.26 | XXX |
| 77295 | TC | A | Set radiation therapy field | 0.00 | 27.88 | NA | 1.48 | 29.36 | NA | XXX |
| 77300 | | A | Radiation therapy dose plan | 0.62 | 1.54 | NA | 0.10 | 2.26 | NA | XXX |
| 77300 | 26 | A | Radiation therapy dose plan | 0.62 | 0.20 | 0.20 | 0.03 | 0.85 | 0.85 | XXX |
| 77300 | TC | A | Radiation therapy dose plan | 0.00 | 1.34 | NA | 0.07 | 1.41 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 77301 | | A | Radiotherapy dose plan, imrt | 7.99 | 30.44 | NA | 1.88 | 40.31 | NA | XXX |
| 77301 | 26 | A | Radiotherapy dose plan, imrt | 7.99 | 2.55 | 2.55 | 0.40 | 10.94 | 10.94 | XXX |
| 77301 | TC | A | Radiotherapy dose plan, imrt | 0.00 | 27.88 | NA | 1.48 | 29.36 | NA | XXX |
| 77305 | | A | Teletx isodose plan simple | 0.70 | 2.08 | NA | 0.15 | 2.93 | NA | XXX |
| 77305 | 26 | A | Teletx isodose plan simple | 0.70 | 0.23 | 0.23 | 0.04 | 0.97 | 0.97 | XXX |
| 77305 | TC | A | Teletx isodose plan simple | 0.00 | 1.85 | NA | 0.11 | 1.96 | NA | XXX |
| 77310 | | A | Teletx isodose plan intermed | 1.05 | 2.66 | NA | 0.18 | 3.89 | NA | XXX |
| 77310 | 26 | A | Teletx isodose plan intermed | 1.05 | 0.34 | 0.34 | 0.05 | 1.44 | 1.44 | XXX |
| 77310 | TC | A | Teletx isodose plan intermed | 0.00 | 2.33 | NA | 0.13 | 2.46 | NA | XXX |
| 77315 | | A | Teletx isodose plan complex | 1.56 | 3.15 | NA | 0.22 | 4.93 | NA | XXX |
| 77315 | 26 | A | Teletx isodose plan complex | 1.56 | 0.50 | 0.50 | 0.08 | 2.14 | 2.14 | XXX |
| 77315 | TC | A | Teletx isodose plan complex | 0.00 | 2.65 | NA | 0.14 | 2.79 | NA | XXX |
| 77321 | | A | Special teletx port plan | 0.95 | 4.34 | NA | 0.26 | 5.55 | NA | XXX |
| 77321 | 26 | A | Special teletx port plan | 0.95 | 0.30 | 0.30 | 0.05 | 1.30 | 1.30 | XXX |
| 77321 | TC | A | Special teletx port plan | 0.00 | 4.03 | NA | 0.21 | 4.24 | NA | XXX |
| 77326 | | A | Brachytx isodose calc simp | 0.93 | 2.65 | NA | 0.18 | 3.76 | NA | XXX |
| 77326 | 26 | A | Brachytx isodose calc simp | 0.93 | 0.30 | 0.30 | 0.05 | 1.28 | 1.28 | XXX |
| 77326 | TC | A | Brachytx isodose calc simp | 0.00 | 2.35 | NA | 0.13 | 2.48 | NA | XXX |
| 77327 | | A | Brachytx isodose calc interm | 1.39 | 3.91 | NA | 0.25 | 5.55 | NA | XXX |
| 77327 | 26 | A | Brachytx isodose calc interm | 1.39 | 0.44 | 0.44 | 0.07 | 1.90 | 1.90 | XXX |
| 77327 | TC | A | Brachytx isodose calc interm | 0.00 | 3.46 | NA | 0.18 | 3.64 | NA | XXX |
| 77328 | | A | Brachytx isodose plan compl | 2.09 | 5.62 | NA | 0.36 | 8.07 | NA | XXX |
| 77328 | 26 | A | Brachytx isodose plan compl | 2.09 | 0.67 | 0.67 | 0.11 | 2.87 | 2.87 | XXX |
| 77328 | TC | A | Brachytx isodose plan compl | 0.00 | 4.95 | NA | 0.25 | 5.20 | NA | XXX |
| 77331 | | A | Special radiation dosimetry | 0.87 | 0.78 | NA | 0.06 | 1.71 | NA | XXX |
| 77331 | 26 | A | Special radiation dosimetry | 0.87 | 0.28 | 0.28 | 0.04 | 1.19 | 1.19 | XXX |
| 77331 | TC | A | Special radiation dosimetry | 0.00 | 0.50 | NA | 0.02 | 0.52 | NA | XXX |
| 77332 | | A | Radiation treatment aid(s) | 0.54 | 1.51 | NA | 0.10 | 2.15 | NA | XXX |
| 77332 | 26 | A | Radiation treatment aid(s) | 0.54 | 0.17 | 0.17 | 0.03 | 0.74 | 0.74 | XXX |
| 77332 | TC | A | Radiation treatment aid(s) | 0.00 | 1.34 | NA | 0.07 | 1.41 | NA | XXX |
| 77333 | | A | Radiation treatment aid(s) | 0.84 | 2.16 | NA | 0.15 | 3.15 | NA | XXX |
| 77333 | 26 | A | Radiation treatment aid(s) | 0.84 | 0.27 | 0.27 | 0.04 | 1.15 | 1.15 | XXX |
| 77333 | TC | A | Radiation treatment aid(s) | 0.00 | 1.89 | NA | 0.11 | 2.00 | NA | XXX |
| 77334 | | A | Radiation treatment aid(s) | 1.24 | 3.64 | NA | 0.23 | 5.11 | NA | XXX |
| 77334 | 26 | A | Radiation treatment aid(s) | 1.24 | 0.40 | 0.40 | 0.06 | 1.70 | 1.70 | XXX |
| 77334 | TC | A | Radiation treatment aid(s) | 0.00 | 3.24 | NA | 0.17 | 3.41 | NA | XXX |
| 77336 | | A | Radiation physics consult | 0.00 | 2.97 | NA | 0.16 | 3.13 | NA | XXX |
| 77370 | | A | Radiation physics consult | 0.00 | 3.48 | NA | 0.18 | 3.66 | NA | XXX |
| 77401 | | A | Radiation treatment delivery | 0.00 | 1.77 | NA | 0.11 | 1.88 | NA | XXX |
| 77402 | | A | Radiation treatment delivery | 0.00 | 1.77 | NA | 0.11 | 1.88 | NA | XXX |
| 77403 | | A | Radiation treatment delivery | 0.00 | 1.77 | NA | 0.11 | 1.88 | NA | XXX |
| 77404 | | A | Radiation treatment delivery | 0.00 | 1.77 | NA | 0.11 | 1.88 | NA | XXX |
| 77406 | | A | Radiation treatment delivery | 0.00 | 1.77 | NA | 0.11 | 1.88 | NA | XXX |
| 77407 | | A | Radiation treatment delivery | 0.00 | 2.08 | NA | 0.12 | 2.20 | NA | XXX |
| 77408 | | A | Radiation treatment delivery | 0.00 | 2.08 | NA | 0.12 | 2.20 | NA | XXX |
| 77409 | | A | Radiation treatment delivery | 0.00 | 2.08 | NA | 0.12 | 2.20 | NA | XXX |
| 77411 | | A | Radiation treatment delivery | 0.00 | 2.08 | NA | 0.12 | 2.20 | NA | XXX |
| 77412 | | A | Radiation treatment delivery | 0.00 | 2.33 | NA | 0.13 | 2.46 | NA | XXX |
| 77413 | | A | Radiation treatment delivery | 0.00 | 2.33 | NA | 0.13 | 2.46 | NA | XXX |
| 77414 | | A | Radiation treatment delivery | 0.00 | 2.33 | NA | 0.13 | 2.46 | NA | XXX |
| 77416 | | A | Radiation treatment delivery | 0.00 | 2.33 | NA | 0.13 | 2.46 | NA | XXX |
| 77417 | | A | Radiology port film(s) | 0.00 | 0.59 | NA | 0.04 | 0.63 | NA | XXX |
| 77418 | | A | Radiation tx delivery, imrt | 0.00 | 17.95 | NA | 0.13 | 18.08 | NA | XXX |
| 77427 | | A | Radiation tx management, x5 | 3.31 | 1.06 | 1.06 | 0.17 | 4.54 | 4.54 | 090 |
| 77431 | | A | Radiation therapy management | 1.81 | 0.68 | 0.68 | 0.09 | 2.58 | 2.58 | XXX |
| 77432 | | A | Stereotactic radiation trmt | 7.92 | 2.91 | 2.91 | 0.42 | 11.25 | 11.25 | XXX |
| 77470 | | A | Special radiation treatment | 2.09 | 11.79 | NA | 0.70 | 14.58 | NA | XXX |
| 77470 | 26 | A | Special radiation treatment | 2.09 | 0.67 | 0.67 | 0.11 | 2.87 | 2.87 | XXX |
| 77470 | TC | A | Special radiation treatment | 0.00 | 11.13 | NA | 0.59 | 11.72 | NA | XXX |
| 77600 | | R | Hyperthermia treatment | 1.56 | 3.54 | NA | 0.24 | 5.34 | NA | XXX |
| 77600 | 26 | R | Hyperthermia treatment | 1.56 | 0.50 | 0.50 | 0.08 | 2.14 | 2.14 | XXX |
| 77600 | TC | R | Hyperthermia treatment | 0.00 | 3.04 | NA | 0.16 | 3.20 | NA | XXX |
| 77605 | | R | Hyperthermia treatment | 2.09 | 4.72 | NA | 0.33 | 7.14 | NA | XXX |
| 77605 | 26 | R | Hyperthermia treatment | 2.09 | 0.66 | 0.66 | 0.11 | 2.86 | 2.86 | XXX |
| 77605 | TC | R | Hyperthermia treatment | 0.00 | 4.05 | NA | 0.22 | 4.27 | NA | XXX |
| 77610 | | R | Hyperthermia treatment | 1.56 | 3.55 | NA | 0.24 | 5.35 | NA | XXX |
| 77610 | 26 | R | Hyperthermia treatment | 1.56 | 0.51 | 0.51 | 0.07 | 2.14 | 2.14 | XXX |
| 77610 | TC | R | Hyperthermia treatment | 0.00 | 3.04 | NA | 0.16 | 3.20 | NA | XXX |
| 77615 | | R | Hyperthermia treatment | 2.09 | 4.72 | NA | 0.33 | 7.14 | NA | XXX |
| 77615 | 26 | R | Hyperthermia treatment | 2.09 | 0.66 | 0.66 | 0.11 | 2.86 | 2.86 | XXX |
| 77615 | TC | R | Hyperthermia treatment | 0.00 | 4.05 | NA | 0.22 | 4.27 | NA | XXX |
| 77620 | | R | Hyperthermia treatment | 1.56 | 3.56 | NA | 0.23 | 5.35 | NA | XXX |
| 77620 | 26 | R | Hyperthermia treatment | 1.56 | 0.52 | 0.52 | 0.19 | 2.27 | 2.27 | XXX |
| 77620 | TC | R | Hyperthermia treatment | 0.00 | 3.04 | NA | 0.16 | 3.20 | NA | XXX |
| 77750 | | A | Infuse radioactive materials | 4.90 | 2.91 | NA | 0.32 | 8.13 | NA | 090 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 77750 | 26 | A | Infuse radioactive materials | 4.90 | 1.58 | 1.58 | 0.25 | 6.73 | 6.73 | 090 |
| 77750 | TC | A | Infuse radioactive materials | 0.00 | 1.33 | NA | 0.07 | 1.40 | NA | 090 |
| 77761 | | A | Apply intrcav radiat simple | 3.80 | 3.59 | NA | 0.33 | 7.72 | NA | 090 |
| 77761 | 26 | A | Apply intrcav radiat simple | 3.80 | 1.09 | 1.09 | 0.19 | 5.08 | 5.08 | 090 |
| 77761 | TC | A | Apply intrcav radiat simple | 0.00 | 2.50 | NA | 0.14 | 2.64 | NA | 090 |
| 77762 | | A | Apply intrcav radiat interm | 5.71 | 5.43 | NA | 0.48 | 11.62 | NA | 090 |
| 77762 | 26 | A | Apply intrcav radiat interm | 5.71 | 1.83 | 1.83 | 0.29 | 7.83 | 7.83 | 090 |
| 77762 | TC | A | Apply intrcav radiat interm | 0.00 | 3.60 | NA | 0.19 | 3.79 | NA | 090 |
| 77763 | | A | Apply intrcav radiat compl | 8.56 | 7.21 | NA | 0.67 | 16.44 | NA | 090 |
| 77763 | 26 | A | Apply intrcav radiat compl | 8.56 | 2.73 | 2.73 | 0.44 | 11.73 | 11.73 | 090 |
| 77763 | TC | A | Apply intrcav radiat compl | 0.00 | 4.48 | NA | 0.23 | 4.71 | NA | 090 |
| 77776 | | A | Apply interstit radiat simpl | 4.65 | 3.12 | NA | 0.48 | 8.25 | NA | 090 |
| 77776 | 26 | A | Apply interstit radiat simpl | 4.65 | 0.95 | 0.95 | 0.35 | 5.95 | 5.95 | 090 |
| 77776 | TC | A | Apply interstit radiat simpl | 0.00 | 2.17 | NA | 0.13 | 2.30 | NA | 090 |
| 77777 | | A | Apply interstit radiat inter | 7.47 | 6.59 | NA | 0.62 | 14.68 | NA | 090 |
| 77777 | 26 | A | Apply interstit radiat inter | 7.47 | 2.37 | 2.37 | 0.40 | 10.24 | 10.24 | 090 |
| 77777 | TC | A | Apply interstit radiat inter | 0.00 | 4.23 | NA | 0.22 | 4.45 | NA | 090 |
| 77778 | | A | Apply interstit radiat compl | 11.17 | 8.69 | NA | 0.85 | 20.71 | NA | 090 |
| 77778 | 26 | A | Apply interstit radiat compl | 11.17 | 3.56 | 3.56 | 0.58 | 15.31 | 15.31 | 090 |
| 77778 | TC | A | Apply interstit radiat compl | 0.00 | 5.12 | NA | 0.27 | 5.39 | NA | 090 |
| 77781 | | A | High intensity brachytherapy | 1.66 | 20.80 | NA | 1.14 | 23.60 | NA | 090 |
| 77781 | 26 | A | High intensity brachytherapy | 1.66 | 0.53 | 0.53 | 0.08 | 2.27 | 2.27 | 090 |
| 77781 | TC | A | High intensity brachytherapy | 0.00 | 20.27 | NA | 1.06 | 21.33 | NA | 090 |
| 77782 | | A | High intensity brachytherapy | 2.49 | 21.07 | NA | 1.19 | 24.75 | NA | 090 |
| 77782 | 26 | A | High intensity brachytherapy | 2.49 | 0.80 | 0.80 | 0.13 | 3.42 | 3.42 | 090 |
| 77782 | TC | A | High intensity brachytherapy | 0.00 | 20.27 | NA | 1.06 | 21.33 | NA | 090 |
| 77783 | | A | High intensity brachytherapy | 3.72 | 21.46 | NA | 1.25 | 26.43 | NA | 090 |
| 77783 | 26 | A | High intensity brachytherapy | 3.72 | 1.19 | 1.19 | 0.19 | 5.10 | 5.10 | 090 |
| 77783 | TC | A | High intensity brachytherapy | 0.00 | 20.27 | NA | 1.06 | 21.33 | NA | 090 |
| 77784 | | A | High intensity brachytherapy | 5.60 | 22.06 | NA | 1.35 | 29.01 | NA | 090 |
| 77784 | 26 | A | High intensity brachytherapy | 5.60 | 1.79 | 1.79 | 0.29 | 7.68 | 7.68 | 090 |
| 77784 | TC | A | High intensity brachytherapy | 0.00 | 20.27 | NA | 1.06 | 21.33 | NA | 090 |
| 77789 | | A | Apply surface radiation | 1.12 | 0.82 | NA | 0.08 | 2.02 | NA | 000 |
| 77789 | 26 | A | Apply surface radiation | 1.12 | 0.37 | 0.37 | 0.06 | 1.55 | 1.55 | 000 |
| 77789 | TC | A | Apply surface radiation | 0.00 | 0.45 | NA | 0.02 | 0.47 | NA | 000 |
| 77790 | | A | Radiation handling | 1.05 | 0.84 | NA | 0.07 | 1.96 | NA | XXX |
| 77790 | 26 | A | Radiation handling | 1.05 | 0.34 | 0.34 | 0.05 | 1.44 | 1.44 | XXX |
| 77790 | TC | A | Radiation handling | 0.00 | 0.50 | NA | 0.02 | 0.52 | NA | XXX |
| 78000 | | A | Thyroid, single uptake | 0.19 | 1.03 | NA | 0.07 | 1.29 | NA | XXX |
| 78000 | 26 | A | Thyroid, single uptake | 0.19 | 0.06 | 0.06 | 0.01 | 0.26 | 0.26 | XXX |
| 78000 | TC | A | Thyroid, single uptake | 0.00 | 0.97 | NA | 0.06 | 1.03 | NA | XXX |
| 78001 | | A | Thyroid, multiple uptakes | 0.26 | 1.39 | NA | 0.08 | 1.73 | NA | XXX |
| 78001 | 26 | A | Thyroid, multiple uptakes | 0.26 | 0.09 | 0.09 | 0.01 | 0.36 | 0.36 | XXX |
| 78001 | TC | A | Thyroid, multiple uptakes | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 78003 | | A | Thyroid suppress/stimul | 0.33 | 1.07 | NA | 0.07 | 1.47 | NA | XXX |
| 78003 | 26 | A | Thyroid suppress/stimul | 0.33 | 0.11 | 0.11 | 0.01 | 0.45 | 0.45 | XXX |
| 78003 | TC | A | Thyroid suppress/stimul | 0.00 | 0.97 | NA | 0.06 | 1.03 | NA | XXX |
| 78006 | | A | Thyroid imaging with uptake | 0.49 | 2.54 | NA | 0.15 | 3.18 | NA | XXX |
| 78006 | 26 | A | Thyroid imaging with uptake | 0.49 | 0.16 | 0.16 | 0.02 | 0.67 | 0.67 | XXX |
| 78006 | TC | A | Thyroid imaging with uptake | 0.00 | 2.37 | NA | 0.13 | 2.50 | NA | XXX |
| 78007 | | A | Thyroid image, mult uptakes | 0.50 | 2.73 | NA | 0.16 | 3.39 | NA | XXX |
| 78007 | 26 | A | Thyroid image, mult uptakes | 0.50 | 0.17 | 0.17 | 0.02 | 0.69 | 0.69 | XXX |
| 78007 | TC | A | Thyroid image, mult uptakes | 0.00 | 2.57 | NA | 0.14 | 2.71 | NA | XXX |
| 78010 | | A | Thyroid imaging | 0.39 | 1.94 | NA | 0.13 | 2.46 | NA | XXX |
| 78010 | 26 | A | Thyroid imaging | 0.39 | 0.13 | 0.13 | 0.02 | 0.54 | 0.54 | XXX |
| 78010 | TC | A | Thyroid imaging | 0.00 | 1.81 | NA | 0.11 | 1.92 | NA | XXX |
| 78011 | | A | Thyroid imaging with flow | 0.45 | 2.55 | NA | 0.15 | 3.15 | NA | XXX |
| 78011 | 26 | A | Thyroid imaging with flow | 0.45 | 0.15 | 0.15 | 0.02 | 0.62 | 0.62 | XXX |
| 78011 | TC | A | Thyroid imaging with flow | 0.00 | 2.40 | NA | 0.13 | 2.53 | NA | XXX |
| 78015 | | A | Thyroid met imaging | 0.67 | 2.79 | NA | 0.17 | 3.63 | NA | XXX |
| 78015 | 26 | A | Thyroid met imaging | 0.67 | 0.23 | 0.23 | 0.03 | 0.93 | 0.93 | XXX |
| 78015 | TC | A | Thyroid met imaging | 0.00 | 2.57 | NA | 0.14 | 2.71 | NA | XXX |
| 78016 | | A | Thyroid met imaging/studies | 0.82 | 3.76 | NA | 0.21 | 4.79 | NA | XXX |
| 78016 | 26 | A | Thyroid met imaging/studies | 0.82 | 0.28 | 0.28 | 0.03 | 1.13 | 1.13 | XXX |
| 78016 | TC | A | Thyroid met imaging/studies | 0.00 | 3.47 | NA | 0.18 | 3.65 | NA | XXX |
| 78018 | | A | Thyroid met imaging, body | 0.86 | 5.71 | NA | 0.33 | 6.90 | NA | XXX |
| 78018 | 26 | A | Thyroid met imaging, body | 0.86 | 0.29 | 0.29 | 0.04 | 1.19 | 1.19 | XXX |
| 78018 | TC | A | Thyroid met imaging, body | 0.00 | 5.41 | NA | 0.29 | 5.70 | NA | XXX |
| 78020 | | A | Thyroid met uptake | 0.60 | 1.51 | NA | 0.17 | 2.28 | NA | ZZZ |
| 78020 | 26 | A | Thyroid met uptake | 0.60 | 0.21 | 0.21 | 0.03 | 0.84 | 0.84 | ZZZ |
| 78020 | TC | A | Thyroid met uptake | 0.00 | 1.30 | NA | 0.14 | 1.44 | NA | ZZZ |
| 78070 | | A | Parathyroid nuclear imaging | 0.82 | 4.54 | NA | 0.15 | 5.51 | NA | XXX |
| 78070 | 26 | A | Parathyroid nuclear imaging | 0.82 | 0.28 | 0.28 | 0.04 | 1.14 | 1.14 | XXX |
| 78070 | TC | A | Parathyroid nuclear imaging | 0.00 | 4.27 | NA | 0.11 | 4.38 | NA | XXX |
| 78075 | | A | Adrenal nuclear imaging | 0.74 | 5.68 | NA | 0.32 | 6.74 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 78075 | 26 | A | Adrenal nuclear imaging | 0.74 | 0.26 | 0.26 | 0.03 | 1.03 | 1.03 | XXX |
| 78075 | TC | A | Adrenal nuclear imaging | 0.00 | 5.41 | NA | 0.29 | 5.70 | NA | XXX |
| 78102 | | A | Bone marrow imaging, ltd | 0.55 | 2.23 | NA | 0.14 | 2.92 | NA | XXX |
| 78102 | 26 | A | Bone marrow imaging, ltd | 0.55 | 0.19 | 0.19 | 0.02 | 0.76 | 0.76 | XXX |
| 78102 | TC | A | Bone marrow imaging, ltd | 0.00 | 2.04 | NA | 0.12 | 2.16 | NA | XXX |
| 78103 | | A | Bone marrow imaging, mult | 0.75 | 3.42 | NA | 0.20 | 4.37 | NA | XXX |
| 78103 | 26 | A | Bone marrow imaging, mult | 0.75 | 0.26 | 0.26 | 0.03 | 1.04 | 1.04 | XXX |
| 78103 | TC | A | Bone marrow imaging, mult | 0.00 | 3.17 | NA | 0.17 | 3.34 | NA | XXX |
| 78104 | | A | Bone marrow imaging, body | 0.80 | 4.33 | NA | 0.26 | 5.39 | NA | XXX |
| 78104 | 26 | A | Bone marrow imaging, body | 0.80 | 0.27 | 0.27 | 0.04 | 1.11 | 1.11 | XXX |
| 78104 | TC | A | Bone marrow imaging, body | 0.00 | 4.06 | NA | 0.22 | 4.28 | NA | XXX |
| 78110 | | A | Plasma volume, single | 0.19 | 1.02 | NA | 0.07 | 1.28 | NA | XXX |
| 78110 | 26 | A | Plasma volume, single | 0.19 | 0.07 | 0.07 | 0.01 | 0.27 | 0.27 | XXX |
| 78110 | TC | A | Plasma volume, single | 0.00 | 0.95 | NA | 0.06 | 1.01 | NA | XXX |
| 78111 | | A | Plasma volume, multiple | 0.22 | 2.65 | NA | 0.15 | 3.02 | NA | XXX |
| 78111 | 26 | A | Plasma volume, multiple | 0.22 | 0.08 | 0.08 | 0.01 | 0.31 | 0.31 | XXX |
| 78111 | TC | A | Plasma volume, multiple | 0.00 | 2.57 | NA | 0.14 | 2.71 | NA | XXX |
| 78120 | | A | Red cell mass, single | 0.23 | 1.81 | NA | 0.12 | 2.16 | NA | XXX |
| 78120 | 26 | A | Red cell mass, single | 0.23 | 0.08 | 0.08 | 0.01 | 0.32 | 0.32 | XXX |
| 78120 | TC | A | Red cell mass, single | 0.00 | 1.73 | NA | 0.11 | 1.84 | NA | XXX |
| 78121 | | A | Red cell mass, multiple | 0.32 | 3.02 | NA | 0.15 | 3.49 | NA | XXX |
| 78121 | 26 | A | Red cell mass, multiple | 0.32 | 0.11 | 0.11 | 0.01 | 0.44 | 0.44 | XXX |
| 78121 | TC | A | Red cell mass, multiple | 0.00 | 2.91 | NA | 0.14 | 3.05 | NA | XXX |
| 78122 | | A | Blood volume | 0.45 | 4.75 | NA | 0.26 | 5.46 | NA | XXX |
| 78122 | 26 | A | Blood volume | 0.45 | 0.16 | 0.16 | 0.02 | 0.63 | 0.63 | XXX |
| 78122 | TC | A | Blood volume | 0.00 | 4.59 | NA | 0.24 | 4.83 | NA | XXX |
| 78130 | | A | Red cell survival study | 0.61 | 3.06 | NA | 0.17 | 3.84 | NA | XXX |
| 78130 | 26 | A | Red cell survival study | 0.61 | 0.21 | 0.21 | 0.03 | 0.85 | 0.85 | XXX |
| 78130 | TC | A | Red cell survival study | 0.00 | 2.85 | NA | 0.14 | 2.99 | NA | XXX |
| 78135 | | A | Red cell survival kinetics | 0.64 | 5.08 | NA | 0.28 | 6.00 | NA | XXX |
| 78135 | 26 | A | Red cell survival kinetics | 0.64 | 0.22 | 0.22 | 0.03 | 0.89 | 0.89 | XXX |
| 78135 | TC | A | Red cell survival kinetics | 0.00 | 4.86 | NA | 0.25 | 5.11 | NA | XXX |
| 78140 | | A | Red cell sequestration | 0.61 | 4.13 | NA | 0.24 | 4.98 | NA | XXX |
| 78140 | 26 | A | Red cell sequestration | 0.61 | 0.20 | 0.20 | 0.03 | 0.84 | 0.84 | XXX |
| 78140 | TC | A | Red cell sequestration | 0.00 | 3.93 | NA | 0.21 | 4.14 | NA | XXX |
| 78160 | | A | Plasma iron turnover | 0.33 | 3.78 | NA | 0.20 | 4.31 | NA | XXX |
| 78160 | 26 | A | Plasma iron turnover | 0.33 | 0.12 | 0.12 | 0.01 | 0.46 | 0.46 | XXX |
| 78160 | TC | A | Plasma iron turnover | 0.00 | 3.66 | NA | 0.19 | 3.85 | NA | XXX |
| 78162 | | A | Radioiron absorption exam | 0.45 | 3.38 | NA | 0.18 | 4.01 | NA | XXX |
| 78162 | 26 | A | Radioiron absorption exam | 0.45 | 0.19 | 0.19 | 0.01 | 0.65 | 0.65 | XXX |
| 78162 | TC | A | Radioiron absorption exam | 0.00 | 3.19 | NA | 0.17 | 3.36 | NA | XXX |
| 78170 | | A | Red cell iron utilization | 0.41 | 5.44 | NA | 0.30 | 6.15 | NA | XXX |
| 78170 | 26 | A | Red cell iron utilization | 0.41 | 0.14 | 0.14 | 0.02 | 0.57 | 0.57 | XXX |
| 78170 | TC | A | Red cell iron utilization | 0.00 | 5.30 | NA | 0.28 | 5.58 | NA | XXX |
| 78172 | 26 | A | Total body iron estimation | 0.53 | 0.17 | 0.17 | 0.02 | 0.72 | 0.72 | XXX |
| 78185 | | A | Spleen imaging | 0.40 | 2.49 | NA | 0.15 | 3.04 | NA | XXX |
| 78185 | 26 | A | Spleen imaging | 0.40 | 0.14 | 0.14 | 0.02 | 0.56 | 0.56 | XXX |
| 78185 | TC | A | Spleen imaging | 0.00 | 2.35 | NA | 0.13 | 2.48 | NA | XXX |
| 78190 | | A | Platelet survival, kinetics | 1.09 | 6.10 | NA | 0.34 | 7.53 | NA | XXX |
| 78190 | 26 | A | Platelet survival, kinetics | 1.09 | 0.39 | 0.39 | 0.04 | 1.52 | 1.52 | XXX |
| 78190 | TC | A | Platelet survival, kinetics | 0.00 | 5.70 | NA | 0.30 | 6.00 | NA | XXX |
| 78191 | | A | Platelet survival | 0.61 | 7.53 | NA | 0.40 | 8.54 | NA | XXX |
| 78191 | 26 | A | Platelet survival | 0.61 | 0.20 | 0.20 | 0.03 | 0.84 | 0.84 | XXX |
| 78191 | TC | A | Platelet survival | 0.00 | 7.33 | NA | 0.37 | 7.70 | NA | XXX |
| 78195 | | A | Lymph system imaging | 1.20 | 4.47 | NA | 0.28 | 5.95 | NA | XXX |
| 78195 | 26 | A | Lymph system imaging | 1.20 | 0.41 | 0.41 | 0.06 | 1.67 | 1.67 | XXX |
| 78195 | TC | A | Lymph system imaging | 0.00 | 4.06 | NA | 0.22 | 4.28 | NA | XXX |
| 78201 | | A | Liver imaging | 0.44 | 2.50 | NA | 0.15 | 3.09 | NA | XXX |
| 78201 | 26 | A | Liver imaging | 0.44 | 0.15 | 0.15 | 0.02 | 0.61 | 0.61 | XXX |
| 78201 | TC | A | Liver imaging | 0.00 | 2.35 | NA | 0.13 | 2.48 | NA | XXX |
| 78202 | | A | Liver imaging with flow | 0.51 | 3.05 | NA | 0.16 | 3.72 | NA | XXX |
| 78202 | 26 | A | Liver imaging with flow | 0.51 | 0.17 | 0.17 | 0.02 | 0.70 | 0.70 | XXX |
| 78202 | TC | A | Liver imaging with flow | 0.00 | 2.88 | NA | 0.14 | 3.02 | NA | XXX |
| 78205 | | A | Liver imaging (3D) | 0.71 | 6.14 | NA | 0.34 | 7.19 | NA | XXX |
| 78205 | 26 | A | Liver imaging (3D) | 0.71 | 0.24 | 0.24 | 0.03 | 0.98 | 0.98 | XXX |
| 78205 | TC | A | Liver imaging (3D) | 0.00 | 5.90 | NA | 0.31 | 6.21 | NA | XXX |
| 78206 | | A | Liver image (3d) with flow | 0.96 | 6.23 | NA | 0.15 | 7.34 | NA | XXX |
| 78206 | 26 | A | Liver image (3d) with flow | 0.96 | 0.33 | 0.33 | 0.04 | 1.33 | 1.33 | XXX |
| 78206 | TC | A | Liver image (3d) with flow | 0.00 | 5.90 | NA | 0.11 | 6.01 | NA | XXX |
| 78215 | | A | Liver and spleen imaging | 0.49 | 3.10 | NA | 0.16 | 3.75 | NA | XXX |
| 78215 | 26 | A | Liver and spleen imaging | 0.49 | 0.16 | 0.16 | 0.02 | 0.67 | 0.67 | XXX |
| 78215 | TC | A | Liver and spleen imaging | 0.00 | 2.93 | NA | 0.14 | 3.07 | NA | XXX |
| 78216 | | A | Liver & spleen image/flow | 0.57 | 3.67 | NA | 0.20 | 4.44 | NA | XXX |
| 78216 | 26 | A | Liver & spleen image/flow | 0.57 | 0.19 | 0.19 | 0.02 | 0.78 | 0.78 | XXX |
| 78216 | TC | A | Liver & spleen image/flow | 0.00 | 3.47 | NA | 0.18 | 3.65 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 78220 | | A | Liver function study | 0.49 | 3.88 | NA | 0.21 | 4.58 | NA | XXX |
| 78220 | 26 | A | Liver function study | 0.49 | 0.16 | 0.16 | 0.02 | 0.67 | 0.67 | XXX |
| 78220 | TC | A | Liver function study | 0.00 | 3.72 | NA | 0.19 | 3.91 | NA | XXX |
| 78223 | | A | Hepatobiliary imaging | 0.84 | 3.94 | NA | 0.23 | 5.01 | NA | XXX |
| 78223 | 26 | A | Hepatobiliary imaging | 0.84 | 0.28 | 0.28 | 0.04 | 1.16 | 1.16 | XXX |
| 78223 | TC | A | Hepatobiliary imaging | 0.00 | 3.66 | NA | 0.19 | 3.85 | NA | XXX |
| 78230 | | A | Salivary gland imaging | 0.45 | 2.32 | NA | 0.15 | 2.92 | NA | XXX |
| 78230 | 26 | A | Salivary gland imaging | 0.45 | 0.15 | 0.15 | 0.02 | 0.62 | 0.62 | XXX |
| 78230 | TC | A | Salivary gland imaging | 0.00 | 2.17 | NA | 0.13 | 2.30 | NA | XXX |
| 78231 | | A | Serial salivary imaging | 0.52 | 3.35 | NA | 0.19 | 4.06 | NA | XXX |
| 78231 | 26 | A | Serial salivary imaging | 0.52 | 0.18 | 0.18 | 0.02 | 0.72 | 0.72 | XXX |
| 78231 | TC | A | Serial salivary imaging | 0.00 | 3.17 | NA | 0.17 | 3.34 | NA | XXX |
| 78232 | | A | Salivary gland function exam | 0.47 | 3.70 | NA | 0.20 | 4.37 | NA | XXX |
| 78232 | 26 | A | Salivary gland function exam | 0.47 | 0.16 | 0.16 | 0.02 | 0.65 | 0.65 | XXX |
| 78232 | TC | A | Salivary gland function exam | 0.00 | 3.53 | NA | 0.18 | 3.71 | NA | XXX |
| 78258 | | A | Esophageal motility study | 0.74 | 3.12 | NA | 0.17 | 4.03 | NA | XXX |
| 78258 | 26 | A | Esophageal motility study | 0.74 | 0.25 | 0.25 | 0.03 | 1.02 | 1.02 | XXX |
| 78258 | TC | A | Esophageal motility study | 0.00 | 2.88 | NA | 0.14 | 3.02 | NA | XXX |
| 78261 | | A | Gastric mucosa imaging | 0.69 | 4.33 | NA | 0.25 | 5.27 | NA | XXX |
| 78261 | 26 | A | Gastric mucosa imaging | 0.69 | 0.24 | 0.24 | 0.03 | 0.96 | 0.96 | XXX |
| 78261 | TC | A | Gastric mucosa imaging | 0.00 | 4.09 | NA | 0.22 | 4.31 | NA | XXX |
| 78262 | | A | Gastroesophageal reflux exam | 0.68 | 4.48 | NA | 0.25 | 5.41 | NA | XXX |
| 78262 | 26 | A | Gastroesophageal reflux exam | 0.68 | 0.23 | 0.23 | 0.03 | 0.94 | 0.94 | XXX |
| 78262 | TC | A | Gastroesophageal reflux exam | 0.00 | 4.25 | NA | 0.22 | 4.47 | NA | XXX |
| 78264 | | A | Gastric emptying study | 0.78 | 4.38 | NA | 0.25 | 5.41 | NA | XXX |
| 78264 | 26 | A | Gastric emptying study | 0.78 | 0.26 | 0.26 | 0.03 | 1.07 | 1.07 | XXX |
| 78264 | TC | A | Gastric emptying study | 0.00 | 4.12 | NA | 0.22 | 4.34 | NA | XXX |
| 78270 | | A | Vit B-12 absorption exam | 0.20 | 1.61 | NA | 0.11 | 1.92 | NA | XXX |
| 78270 | 26 | A | Vit B-12 absorption exam | 0.20 | 0.07 | 0.07 | 0.01 | 0.28 | 0.28 | XXX |
| 78270 | TC | A | Vit B-12 absorption exam | 0.00 | 1.54 | NA | 0.10 | 1.64 | NA | XXX |
| 78271 | | A | Vit b-12 absrp exam, int fac | 0.20 | 1.71 | NA | 0.11 | 2.02 | NA | XXX |
| 78271 | 26 | A | Vit b-12 absrp exam, int fac | 0.20 | 0.07 | 0.07 | 0.01 | 0.28 | 0.28 | XXX |
| 78271 | TC | A | Vit b-12 absrp exam, int fac | 0.00 | 1.64 | NA | 0.10 | 1.74 | NA | XXX |
| 78272 | | A | Vit B-12 absorp, combined | 0.27 | 2.41 | NA | 0.14 | 2.82 | NA | XXX |
| 78272 | 26 | A | Vit B-12 absorp, combined | 0.27 | 0.09 | 0.09 | 0.01 | 0.37 | 0.37 | XXX |
| 78272 | TC | A | Vit B-12 absorp, combined | 0.00 | 2.32 | NA | 0.13 | 2.45 | NA | XXX |
| 78278 | | A | Acute GI blood loss imaging | 0.99 | 5.19 | NA | 0.29 | 6.47 | NA | XXX |
| 78278 | 26 | A | Acute GI blood loss imaging | 0.99 | 0.33 | 0.33 | 0.04 | 1.36 | 1.36 | XXX |
| 78278 | TC | A | Acute GI blood loss imaging | 0.00 | 4.86 | NA | 0.25 | 5.11 | NA | XXX |
| 78282 | 26 | A | GI protein loss exam | 0.38 | 0.13 | 0.13 | 0.02 | 0.53 | 0.53 | XXX |
| 78290 | | A | Meckel-s divert exam | 0.68 | 3.27 | NA | 0.19 | 4.14 | NA | XXX |
| 78290 | 26 | A | Meckel-s divert exam | 0.68 | 0.23 | 0.23 | 0.03 | 0.94 | 0.94 | XXX |
| 78290 | TC | A | Meckel-s divert exam | 0.00 | 3.04 | NA | 0.16 | 3.20 | NA | XXX |
| 78291 | | A | Leveen/shunt patency exam | 0.88 | 3.36 | NA | 0.20 | 4.44 | NA | XXX |
| 78291 | 26 | A | Leveen/shunt patency exam | 0.88 | 0.30 | 0.30 | 0.04 | 1.22 | 1.22 | XXX |
| 78291 | TC | A | Leveen/shunt patency exam | 0.00 | 3.06 | NA | 0.16 | 3.22 | NA | XXX |
| 78300 | | A | Bone imaging, limited area | 0.62 | 2.69 | NA | 0.17 | 3.48 | NA | XXX |
| 78300 | 26 | A | Bone imaging, limited area | 0.62 | 0.21 | 0.21 | 0.03 | 0.86 | 0.86 | XXX |
| 78300 | TC | A | Bone imaging, limited area | 0.00 | 2.48 | NA | 0.14 | 2.62 | NA | XXX |
| 78305 | | A | Bone imaging, multiple areas | 0.83 | 3.93 | NA | 0.23 | 4.99 | NA | XXX |
| 78305 | 26 | A | Bone imaging, multiple areas | 0.83 | 0.28 | 0.28 | 0.04 | 1.15 | 1.15 | XXX |
| 78305 | TC | A | Bone imaging, multiple areas | 0.00 | 3.66 | NA | 0.19 | 3.85 | NA | XXX |
| 78306 | | A | Bone imaging, whole body | 0.86 | 4.55 | NA | 0.26 | 5.67 | NA | XXX |
| 78306 | 26 | A | Bone imaging, whole body | 0.86 | 0.29 | 0.29 | 0.04 | 1.19 | 1.19 | XXX |
| 78306 | TC | A | Bone imaging, whole body | 0.00 | 4.27 | NA | 0.22 | 4.49 | NA | XXX |
| 78315 | | A | Bone imaging, 3 phase | 1.02 | 5.11 | NA | 0.29 | 6.42 | NA | XXX |
| 78315 | 26 | A | Bone imaging, 3 phase | 1.02 | 0.34 | 0.34 | 0.04 | 1.40 | 1.40 | XXX |
| 78315 | TC | A | Bone imaging, 3 phase | 0.00 | 4.77 | NA | 0.25 | 5.02 | NA | XXX |
| 78320 | | A | Bone imaging (3D) | 1.04 | 6.26 | NA | 0.36 | 7.66 | NA | XXX |
| 78320 | 26 | A | Bone imaging (3D) | 1.04 | 0.36 | 0.36 | 0.05 | 1.45 | 1.45 | XXX |
| 78320 | TC | A | Bone imaging (3D) | 0.00 | 5.90 | NA | 0.31 | 6.21 | NA | XXX |
| 78350 | | A | Bone mineral, single photon | 0.22 | 0.83 | NA | 0.06 | 1.11 | NA | XXX |
| 78350 | 26 | A | Bone mineral, single photon | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| 78350 | TC | A | Bone mineral, single photon | 0.00 | 0.75 | NA | 0.05 | 0.80 | NA | XXX |
| 78414 | 26 | A | Non-imaging heart function | 0.45 | 0.16 | 0.16 | 0.02 | 0.63 | 0.63 | XXX |
| 78428 | | A | Cardiac shunt imaging | 0.78 | 2.54 | NA | 0.16 | 3.48 | NA | XXX |
| 78428 | 26 | A | Cardiac shunt imaging | 0.78 | 0.29 | 0.29 | 0.03 | 1.10 | 1.10 | XXX |
| 78428 | TC | A | Cardiac shunt imaging | 0.00 | 2.25 | NA | 0.13 | 2.38 | NA | XXX |
| 78445 | | A | Vascular flow imaging | 0.49 | 2.02 | NA | 0.13 | 2.64 | NA | XXX |
| 78445 | 26 | A | Vascular flow imaging | 0.49 | 0.17 | 0.17 | 0.02 | 0.68 | 0.68 | XXX |
| 78445 | TC | A | Vascular flow imaging | 0.00 | 1.85 | NA | 0.11 | 1.96 | NA | XXX |
| 78455 | | A | Venous thrombosis study | 0.73 | 4.22 | NA | 0.24 | 5.19 | NA | XXX |
| 78455 | 26 | A | Venous thrombosis study | 0.73 | 0.25 | 0.25 | 0.03 | 1.01 | 1.01 | XXX |
| 78455 | TC | A | Venous thrombosis study | 0.00 | 3.98 | NA | 0.21 | 4.19 | NA | XXX |
| 78456 | | A | Acute venous thrombus image | 1.00 | 4.32 | NA | 0.33 | 5.65 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 78456 | 26 | A | Acute venous thrombus image | 1.00 | 0.34 | 0.34 | 0.04 | 1.38 | 1.38 | XXX |
| 78456 | TC | A | Acute venous thrombus image | 0.00 | 3.98 | NA | 0.29 | 4.27 | NA | XXX |
| 78457 | | A | Venous thrombosis imaging | 0.77 | 2.91 | NA | 0.18 | 3.86 | NA | XXX |
| 78457 | 26 | A | Venous thrombosis imaging | 0.77 | 0.26 | 0.26 | 0.04 | 1.07 | 1.07 | XXX |
| 78457 | TC | A | Venous thrombosis imaging | 0.00 | 2.65 | NA | 0.14 | 2.79 | NA | XXX |
| 78458 | | A | Ven thrombosis images, bilat | 0.90 | 4.34 | NA | 0.25 | 5.49 | NA | XXX |
| 78458 | 26 | A | Ven thrombosis images, bilat | 0.90 | 0.32 | 0.32 | 0.04 | 1.26 | 1.26 | XXX |
| 78458 | TC | A | Ven thrombosis images, bilat | 0.00 | 4.02 | NA | 0.21 | 4.23 | NA | XXX |
| 78459 | 26 | R | Heart muscle imaging (PET) | 1.50 | 0.57 | 0.57 | 0.06 | 2.13 | 2.13 | XXX |
| 78460 | | A | Heart muscle blood, single | 0.86 | 2.65 | NA | 0.17 | 3.68 | NA | XXX |
| 78460 | 26 | A | Heart muscle blood, single | 0.86 | 0.29 | 0.29 | 0.04 | 1.19 | 1.19 | XXX |
| 78460 | TC | A | Heart muscle blood, single | 0.00 | 2.35 | NA | 0.13 | 2.48 | NA | XXX |
| 78461 | | A | Heart muscle blood, multiple | 1.23 | 5.14 | NA | 0.30 | 6.67 | NA | XXX |
| 78461 | 26 | A | Heart muscle blood, multiple | 1.23 | 0.43 | 0.43 | 0.05 | 1.71 | 1.71 | XXX |
| 78461 | TC | A | Heart muscle blood, multiple | 0.00 | 4.71 | NA | 0.25 | 4.96 | NA | XXX |
| 78464 | | A | Heart image (3d), single | 1.09 | 7.44 | NA | 0.41 | 8.94 | NA | XXX |
| 78464 | 26 | A | Heart image (3d), single | 1.09 | 0.38 | 0.38 | 0.04 | 1.51 | 1.51 | XXX |
| 78464 | TC | A | Heart image (3d), single | 0.00 | 7.06 | NA | 0.37 | 7.43 | NA | XXX |
| 78465 | | A | Heart image (3d), multiple | 1.46 | 12.30 | NA | 0.68 | 14.44 | NA | XXX |
| 78465 | 26 | A | Heart image (3d), multiple | 1.46 | 0.52 | 0.52 | 0.06 | 2.04 | 2.04 | XXX |
| 78465 | TC | A | Heart image (3d), multiple | 0.00 | 11.77 | NA | 0.62 | 12.39 | NA | XXX |
| 78466 | | A | Heart infarct image | 0.69 | 2.86 | NA | 0.17 | 3.72 | NA | XXX |
| 78466 | 26 | A | Heart infarct image | 0.69 | 0.24 | 0.24 | 0.03 | 0.96 | 0.96 | XXX |
| 78466 | TC | A | Heart infarct image | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 78468 | | A | Heart infarct image (ef) | 0.80 | 3.93 | NA | 0.22 | 4.95 | NA | XXX |
| 78468 | 26 | A | Heart infarct image (ef) | 0.80 | 0.27 | 0.27 | 0.03 | 1.10 | 1.10 | XXX |
| 78468 | TC | A | Heart infarct image (ef) | 0.00 | 3.66 | NA | 0.19 | 3.85 | NA | XXX |
| 78469 | | A | Heart infarct image (3D) | 0.92 | 5.53 | NA | 0.31 | 6.76 | NA | XXX |
| 78469 | 26 | A | Heart infarct image (3D) | 0.92 | 0.31 | 0.31 | 0.03 | 1.26 | 1.26 | XXX |
| 78469 | TC | A | Heart infarct image (3D) | 0.00 | 5.21 | NA | 0.28 | 5.49 | NA | XXX |
| 78472 | | A | Gated heart, planar, single | 0.98 | 5.84 | NA | 0.34 | 7.16 | NA | XXX |
| 78472 | 26 | A | Gated heart, planar, single | 0.98 | 0.34 | 0.34 | 0.04 | 1.36 | 1.36 | XXX |
| 78472 | TC | A | Gated heart, planar, single | 0.00 | 5.50 | NA | 0.30 | 5.80 | NA | XXX |
| 78473 | | A | Gated heart, multiple | 1.47 | 8.75 | NA | 0.48 | 10.70 | NA | XXX |
| 78473 | 26 | A | Gated heart, multiple | 1.47 | 0.51 | 0.51 | 0.06 | 2.04 | 2.04 | XXX |
| 78473 | TC | A | Gated heart, multiple | 0.00 | 8.24 | NA | 0.42 | 8.66 | NA | XXX |
| 78478 | | A | Heart wall motion add-on | 0.62 | 1.78 | NA | 0.12 | 2.52 | NA | XXX |
| 78478 | 26 | A | Heart wall motion add-on | 0.62 | 0.22 | 0.22 | 0.02 | 0.86 | 0.86 | XXX |
| 78478 | TC | A | Heart wall motion add-on | 0.00 | 1.55 | NA | 0.10 | 1.65 | NA | XXX |
| 78480 | | A | Heart function add-on | 0.62 | 1.78 | NA | 0.12 | 2.52 | NA | XXX |
| 78480 | 26 | A | Heart function add-on | 0.62 | 0.22 | 0.22 | 0.02 | 0.86 | 0.86 | XXX |
| 78480 | TC | A | Heart function add-on | 0.00 | 1.55 | NA | 0.10 | 1.65 | NA | XXX |
| 78481 | | A | Heart first pass, single | 0.98 | 5.57 | NA | 0.32 | 6.87 | NA | XXX |
| 78481 | 26 | A | Heart first pass, single | 0.98 | 0.36 | 0.36 | 0.04 | 1.38 | 1.38 | XXX |
| 78481 | TC | A | Heart first pass, single | 0.00 | 5.21 | NA | 0.28 | 5.49 | NA | XXX |
| 78483 | | A | Heart first pass, multiple | 1.47 | 8.39 | NA | 0.46 | 10.32 | NA | XXX |
| 78483 | 26 | A | Heart first pass, multiple | 1.47 | 0.54 | 0.54 | 0.05 | 2.06 | 2.06 | XXX |
| 78483 | TC | A | Heart first pass, multiple | 0.00 | 7.86 | NA | 0.41 | 8.27 | NA | XXX |
| 78494 | | A | Heart image, spect | 1.19 | 7.47 | NA | 0.35 | 9.01 | NA | XXX |
| 78494 | 26 | A | Heart image, spect | 1.19 | 0.42 | 0.42 | 0.05 | 1.66 | 1.66 | XXX |
| 78494 | TC | A | Heart image, spect | 0.00 | 7.06 | NA | 0.30 | 7.36 | NA | XXX |
| 78496 | | A | Heart first pass add-on | 0.50 | 7.24 | NA | 0.32 | 8.06 | NA | ZZZ |
| 78496 | 26 | A | Heart first pass add-on | 0.50 | 0.18 | 0.18 | 0.02 | 0.70 | 0.70 | ZZZ |
| 78496 | TC | A | Heart first pass add-on | 0.00 | 7.06 | NA | 0.30 | 7.36 | NA | ZZZ |
| 78580 | | A | Lung perfusion imaging | 0.74 | 3.67 | NA | 0.21 | 4.62 | NA | XXX |
| 78580 | 26 | A | Lung perfusion imaging | 0.74 | 0.25 | 0.25 | 0.03 | 1.02 | 1.02 | XXX |
| 78580 | TC | A | Lung perfusion imaging | 0.00 | 3.43 | NA | 0.18 | 3.61 | NA | XXX |
| 78584 | | A | Lung V/Q image single breath | 0.99 | 3.52 | NA | 0.21 | 4.72 | NA | XXX |
| 78584 | 26 | A | Lung V/Q image single breath | 0.99 | 0.32 | 0.32 | 0.04 | 1.35 | 1.35 | XXX |
| 78584 | TC | A | Lung V/Q image single breath | 0.00 | 3.19 | NA | 0.17 | 3.36 | NA | XXX |
| 78585 | | A | Lung V/Q imaging | 1.09 | 5.99 | NA | 0.35 | 7.43 | NA | XXX |
| 78585 | 26 | A | Lung V/Q imaging | 1.09 | 0.36 | 0.36 | 0.05 | 1.50 | 1.50 | XXX |
| 78585 | TC | A | Lung V/Q imaging | 0.00 | 5.63 | NA | 0.30 | 5.93 | NA | XXX |
| 78586 | | A | Aerosol lung image, single | 0.40 | 2.72 | NA | 0.16 | 3.28 | NA | XXX |
| 78586 | 26 | A | Aerosol lung image, single | 0.40 | 0.13 | 0.13 | 0.02 | 0.55 | 0.55 | XXX |
| 78586 | TC | A | Aerosol lung image, single | 0.00 | 2.59 | NA | 0.14 | 2.73 | NA | XXX |
| 78587 | | A | Aerosol lung image, multiple | 0.49 | 2.96 | NA | 0.16 | 3.61 | NA | XXX |
| 78587 | 26 | A | Aerosol lung image, multiple | 0.49 | 0.16 | 0.16 | 0.02 | 0.67 | 0.67 | XXX |
| 78587 | TC | A | Aerosol lung image, multiple | 0.00 | 2.80 | NA | 0.14 | 2.94 | NA | XXX |
| 78588 | | A | Perfusion lung image | 1.09 | 3.56 | NA | 0.23 | 4.88 | NA | XXX |
| 78588 | 26 | A | Perfusion lung image | 1.09 | 0.36 | 0.36 | 0.05 | 1.50 | 1.50 | XXX |
| 78588 | TC | A | Perfusion lung image | 0.00 | 3.19 | NA | 0.18 | 3.37 | NA | XXX |
| 78591 | | A | Vent image, 1 breath, 1 proj | 0.40 | 2.98 | NA | 0.16 | 3.54 | NA | XXX |
| 78591 | 26 | A | Vent image, 1 breath, 1 proj | 0.40 | 0.13 | 0.13 | 0.02 | 0.55 | 0.55 | XXX |
| 78591 | TC | A | Vent image, 1 breath, 1 proj | 0.00 | 2.85 | NA | 0.14 | 2.99 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 78593 | | A | Vent image, 1 proj, gas | 0.49 | 3.61 | NA | 0.20 | 4.30 | NA | XXX |
| 78593 | 26 | A | Vent image, 1 proj, gas | 0.49 | 0.16 | 0.16 | 0.02 | 0.67 | 0.67 | XXX |
| 78593 | TC | A | Vent image, 1 proj, gas | 0.00 | 3.45 | NA | 0.18 | 3.63 | NA | XXX |
| 78594 | | A | Vent image, mult proj, gas | 0.53 | 5.15 | NA | 0.27 | 5.95 | NA | XXX |
| 78594 | 26 | A | Vent image, mult proj, gas | 0.53 | 0.18 | 0.18 | 0.02 | 0.73 | 0.73 | XXX |
| 78594 | TC | A | Vent image, mult proj, gas | 0.00 | 4.97 | NA | 0.25 | 5.22 | NA | XXX |
| 78596 | | A | Lung differential function | 1.27 | 7.48 | NA | 0.43 | 9.18 | NA | XXX |
| 78596 | 26 | A | Lung differential function | 1.27 | 0.42 | 0.42 | 0.06 | 1.75 | 1.75 | XXX |
| 78596 | TC | A | Lung differential function | 0.00 | 7.06 | NA | 0.37 | 7.43 | NA | XXX |
| 78600 | | A | Brain imaging, ltd static | 0.44 | 3.03 | NA | 0.16 | 3.63 | NA | XXX |
| 78600 | 26 | A | Brain imaging, ltd static | 0.44 | 0.15 | 0.15 | 0.02 | 0.61 | 0.61 | XXX |
| 78600 | TC | A | Brain imaging, ltd static | 0.00 | 2.88 | NA | 0.14 | 3.02 | NA | XXX |
| 78601 | | A | Brain imaging, ltd w/flow | 0.51 | 3.57 | NA | 0.20 | 4.28 | NA | XXX |
| 78601 | 26 | A | Brain imaging, ltd w/flow | 0.51 | 0.17 | 0.17 | 0.02 | 0.70 | 0.70 | XXX |
| 78601 | TC | A | Brain imaging, ltd w/flow | 0.00 | 3.40 | NA | 0.18 | 3.58 | NA | XXX |
| 78605 | | A | Brain imaging, complete | 0.53 | 3.58 | NA | 0.20 | 4.31 | NA | XXX |
| 78605 | 26 | A | Brain imaging, complete | 0.53 | 0.18 | 0.18 | 0.02 | 0.73 | 0.73 | XXX |
| 78605 | TC | A | Brain imaging, complete | 0.00 | 3.40 | NA | 0.18 | 3.58 | NA | XXX |
| 78606 | | A | Brain imaging, compl w/flow | 0.64 | 4.07 | NA | 0.24 | 4.95 | NA | XXX |
| 78606 | 26 | A | Brain imaging, compl w/flow | 0.64 | 0.21 | 0.21 | 0.03 | 0.88 | 0.88 | XXX |
| 78606 | TC | A | Brain imaging, compl w/flow | 0.00 | 3.86 | NA | 0.21 | 4.07 | NA | XXX |
| 78607 | | A | Brain imaging (3D) | 1.23 | 6.97 | NA | 0.40 | 8.60 | NA | XXX |
| 78607 | 26 | A | Brain imaging (3D) | 1.23 | 0.43 | 0.43 | 0.05 | 1.71 | 1.71 | XXX |
| 78607 | TC | A | Brain imaging (3D) | 0.00 | 6.54 | NA | 0.35 | 6.89 | NA | XXX |
| 78610 | | A | Brain flow imaging only | 0.30 | 1.68 | NA | 0.11 | 2.09 | NA | XXX |
| 78610 | 26 | A | Brain flow imaging only | 0.30 | 0.11 | 0.11 | 0.01 | 0.42 | 0.42 | XXX |
| 78610 | TC | A | Brain flow imaging only | 0.00 | 1.57 | NA | 0.10 | 1.67 | NA | XXX |
| 78615 | | A | Cerebral vascular flow image | 0.42 | 3.99 | NA | 0.23 | 4.64 | NA | XXX |
| 78615 | 26 | A | Cerebral vascular flow image | 0.42 | 0.15 | 0.15 | 0.02 | 0.59 | 0.59 | XXX |
| 78615 | TC | A | Cerebral vascular flow image | 0.00 | 3.84 | NA | 0.21 | 4.05 | NA | XXX |
| 78630 | | A | Cerebrospinal fluid scan | 0.68 | 5.26 | NA | 0.30 | 6.24 | NA | XXX |
| 78630 | 26 | A | Cerebrospinal fluid scan | 0.68 | 0.23 | 0.23 | 0.03 | 0.94 | 0.94 | XXX |
| 78630 | TC | A | Cerebrospinal fluid scan | 0.00 | 5.03 | NA | 0.27 | 5.30 | NA | XXX |
| 78635 | | A | CSF ventriculography | 0.61 | 2.77 | NA | 0.16 | 3.54 | NA | XXX |
| 78635 | 26 | A | CSF ventriculography | 0.61 | 0.23 | 0.23 | 0.02 | 0.86 | 0.86 | XXX |
| 78635 | TC | A | CSF ventriculography | 0.00 | 2.54 | NA | 0.14 | 2.68 | NA | XXX |
| 78645 | | A | CSF shunt evaluation | 0.57 | 3.62 | NA | 0.20 | 4.39 | NA | XXX |
| 78645 | 26 | A | CSF shunt evaluation | 0.57 | 0.19 | 0.19 | 0.02 | 0.78 | 0.78 | XXX |
| 78645 | TC | A | CSF shunt evaluation | 0.00 | 3.43 | NA | 0.18 | 3.61 | NA | XXX |
| 78647 | | A | Cerebrospinal fluid scan | 0.90 | 6.21 | NA | 0.35 | 7.46 | NA | XXX |
| 78647 | 26 | A | Cerebrospinal fluid scan | 0.90 | 0.31 | 0.31 | 0.04 | 1.25 | 1.25 | XXX |
| 78647 | TC | A | Cerebrospinal fluid scan | 0.00 | 5.90 | NA | 0.31 | 6.21 | NA | XXX |
| 78650 | | A | CSF leakage imaging | 0.61 | 4.84 | NA | 0.27 | 5.72 | NA | XXX |
| 78650 | 26 | A | CSF leakage imaging | 0.61 | 0.21 | 0.21 | 0.03 | 0.85 | 0.85 | XXX |
| 78650 | TC | A | CSF leakage imaging | 0.00 | 4.63 | NA | 0.24 | 4.87 | NA | XXX |
| 78660 | | A | Nuclear exam of tear flow | 0.53 | 2.29 | NA | 0.14 | 2.96 | NA | XXX |
| 78660 | 26 | A | Nuclear exam of tear flow | 0.53 | 0.18 | 0.18 | 0.02 | 0.73 | 0.73 | XXX |
| 78660 | TC | A | Nuclear exam of tear flow | 0.00 | 2.11 | NA | 0.12 | 2.23 | NA | XXX |
| 78700 | | A | Kidney imaging, static | 0.45 | 3.19 | NA | 0.18 | 3.82 | NA | XXX |
| 78700 | 26 | A | Kidney imaging, static | 0.45 | 0.15 | 0.15 | 0.02 | 0.62 | 0.62 | XXX |
| 78700 | TC | A | Kidney imaging, static | 0.00 | 3.04 | NA | 0.16 | 3.20 | NA | XXX |
| 78701 | | A | Kidney imaging with flow | 0.49 | 3.71 | NA | 0.20 | 4.40 | NA | XXX |
| 78701 | 26 | A | Kidney imaging with flow | 0.49 | 0.16 | 0.16 | 0.02 | 0.67 | 0.67 | XXX |
| 78701 | TC | A | Kidney imaging with flow | 0.00 | 3.55 | NA | 0.18 | 3.73 | NA | XXX |
| 78704 | | A | Imaging renogram | 0.74 | 4.19 | NA | 0.24 | 5.17 | NA | XXX |
| 78704 | 26 | A | Imaging renogram | 0.74 | 0.25 | 0.25 | 0.03 | 1.02 | 1.02 | XXX |
| 78704 | TC | A | Imaging renogram | 0.00 | 3.95 | NA | 0.21 | 4.16 | NA | XXX |
| 78707 | | A | Kidney flow/function image | 0.96 | 4.78 | NA | 0.27 | 6.01 | NA | XXX |
| 78707 | 26 | A | Kidney flow/function image | 0.96 | 0.32 | 0.32 | 0.04 | 1.32 | 1.32 | XXX |
| 78707 | TC | A | Kidney flow/function image | 0.00 | 4.46 | NA | 0.23 | 4.69 | NA | XXX |
| 78708 | | A | Kidney flow/function image | 1.21 | 4.87 | NA | 0.28 | 6.36 | NA | XXX |
| 78708 | 26 | A | Kidney flow/function image | 1.21 | 0.41 | 0.41 | 0.05 | 1.67 | 1.67 | XXX |
| 78708 | TC | A | Kidney flow/function image | 0.00 | 4.46 | NA | 0.23 | 4.69 | NA | XXX |
| 78709 | | A | Kidney flow/function image | 1.41 | 4.93 | NA | 0.29 | 6.63 | NA | XXX |
| 78709 | 26 | A | Kidney flow/function image | 1.41 | 0.47 | 0.47 | 0.06 | 1.94 | 1.94 | XXX |
| 78709 | TC | A | Kidney flow/function image | 0.00 | 4.46 | NA | 0.23 | 4.69 | NA | XXX |
| 78710 | | A | Kidney imaging (3D) | 0.66 | 6.12 | NA | 0.34 | 7.12 | NA | XXX |
| 78710 | 26 | A | Kidney imaging (3D) | 0.66 | 0.22 | 0.22 | 0.03 | 0.91 | 0.91 | XXX |
| 78710 | TC | A | Kidney imaging (3D) | 0.00 | 5.90 | NA | 0.31 | 6.21 | NA | XXX |
| 78715 | | A | Renal vascular flow exam | 0.30 | 1.68 | NA | 0.11 | 2.09 | NA | XXX |
| 78715 | 26 | A | Renal vascular flow exam | 0.30 | 0.11 | 0.11 | 0.01 | 0.42 | 0.42 | XXX |
| 78715 | TC | A | Renal vascular flow exam | 0.00 | 1.57 | NA | 0.10 | 1.67 | NA | XXX |
| 78725 | | A | Kidney function study | 0.38 | 1.90 | NA | 0.13 | 2.41 | NA | XXX |
| 78725 | 26 | A | Kidney function study | 0.38 | 0.13 | 0.13 | 0.02 | 0.53 | 0.53 | XXX |
| 78725 | TC | A | Kidney function study | 0.00 | 1.78 | NA | 0.11 | 1.89 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 78730 | | A | Urinary bladder retention | 0.36 | 1.58 | NA | 0.10 | 2.04 | NA | XXX |
| 78730 | 26 | A | Urinary bladder retention | 0.36 | 0.12 | 0.12 | 0.02 | 0.50 | 0.50 | XXX |
| 78730 | TC | A | Urinary bladder retention | 0.00 | 1.46 | NA | 0.08 | 1.54 | NA | XXX |
| 78740 | | A | Ureteral reflux study | 0.57 | 2.30 | NA | 0.15 | 3.02 | NA | XXX |
| 78740 | 26 | A | Ureteral reflux study | 0.57 | 0.19 | 0.19 | 0.03 | 0.79 | 0.79 | XXX |
| 78740 | TC | A | Ureteral reflux study | 0.00 | 2.11 | NA | 0.12 | 2.23 | NA | XXX |
| 78760 | | A | Testicular imaging | 0.66 | 2.89 | NA | 0.17 | 3.72 | NA | XXX |
| 78760 | 26 | A | Testicular imaging | 0.66 | 0.22 | 0.22 | 0.03 | 0.91 | 0.91 | XXX |
| 78760 | TC | A | Testicular imaging | 0.00 | 2.67 | NA | 0.14 | 2.81 | NA | XXX |
| 78761 | | A | Testicular imaging/flow | 0.71 | 3.43 | NA | 0.20 | 4.34 | NA | XXX |
| 78761 | 26 | A | Testicular imaging/flow | 0.71 | 0.24 | 0.24 | 0.03 | 0.98 | 0.98 | XXX |
| 78761 | TC | A | Testicular imaging/flow | 0.00 | 3.19 | NA | 0.17 | 3.36 | NA | XXX |
| 78800 | | A | Tumor imaging, limited area | 0.66 | 3.62 | NA | 0.22 | 4.50 | NA | XXX |
| 78800 | 26 | A | Tumor imaging, limited area | 0.66 | 0.22 | 0.22 | 0.04 | 0.92 | 0.92 | XXX |
| 78800 | TC | A | Tumor imaging, limited area | 0.00 | 3.40 | NA | 0.18 | 3.58 | NA | XXX |
| 78801 | | A | Tumor imaging, mult areas | 0.79 | 4.48 | NA | 0.27 | 5.54 | NA | XXX |
| 78801 | 26 | A | Tumor imaging, mult areas | 0.79 | 0.27 | 0.27 | 0.05 | 1.11 | 1.11 | XXX |
| 78801 | TC | A | Tumor imaging, mult areas | 0.00 | 4.22 | NA | 0.22 | 4.44 | NA | XXX |
| 78802 | | A | Tumor imaging, whole body | 0.86 | 5.81 | NA | 0.34 | 7.01 | NA | XXX |
| 78802 | 26 | A | Tumor imaging, whole body | 0.86 | 0.29 | 0.29 | 0.04 | 1.19 | 1.19 | XXX |
| 78802 | TC | A | Tumor imaging, whole body | 0.00 | 5.52 | NA | 0.30 | 5.82 | NA | XXX |
| 78803 | | A | Tumor imaging (3D) | 1.09 | 6.93 | NA | 0.40 | 8.42 | NA | XXX |
| 78803 | 26 | A | Tumor imaging (3D) | 1.09 | 0.38 | 0.38 | 0.05 | 1.52 | 1.52 | XXX |
| 78803 | TC | A | Tumor imaging (3D) | 0.00 | 6.54 | NA | 0.35 | 6.89 | NA | XXX |
| 78804 | | A | Tumor imaging, whole body | 1.07 | 11.41 | NA | 0.34 | 12.82 | NA | XXX |
| 78804 | 26 | A | Tumor imaging, whole body | 1.07 | 0.37 | 0.37 | 0.04 | 1.48 | 1.48 | XXX |
| 78804 | TC | A | Tumor imaging, whole body | 0.00 | 11.04 | NA | 0.30 | 11.34 | NA | XXX |
| 78805 | | A | Abscess imaging, ltd area | 0.73 | 3.65 | NA | 0.21 | 4.59 | NA | XXX |
| 78805 | 26 | A | Abscess imaging, ltd area | 0.73 | 0.25 | 0.25 | 0.03 | 1.01 | 1.01 | XXX |
| 78805 | TC | A | Abscess imaging, ltd area | 0.00 | 3.40 | NA | 0.18 | 3.58 | NA | XXX |
| 78806 | | A | Abscess imaging, whole body | 0.86 | 6.71 | NA | 0.39 | 7.96 | NA | XXX |
| 78806 | 26 | A | Abscess imaging, whole body | 0.86 | 0.29 | 0.29 | 0.04 | 1.19 | 1.19 | XXX |
| 78806 | TC | A | Abscess imaging, whole body | 0.00 | 6.42 | NA | 0.35 | 6.77 | NA | XXX |
| 78807 | | A | Nuclear localization/abscess | 1.09 | 6.93 | NA | 0.40 | 8.42 | NA | XXX |
| 78807 | 26 | A | Nuclear localization/abscess | 1.09 | 0.39 | 0.39 | 0.05 | 1.53 | 1.53 | XXX |
| 78807 | TC | A | Nuclear localization/abscess | 0.00 | 6.54 | NA | 0.35 | 6.89 | NA | XXX |
| 78890 | | B | Nuclear medicine data proc | 0.05 | 1.32 | NA | 0.07 | 1.44 | NA | XXX |
| 78890 | 26 | B | Nuclear medicine data proc | 0.05 | 0.02 | 0.02 | 0.01 | 0.08 | 0.08 | XXX |
| 78890 | TC | B | Nuclear medicine data proc | 0.00 | 1.30 | NA | 0.06 | 1.36 | NA | XXX |
| 78891 | | B | Nuclear med data proc | 0.10 | 2.65 | NA | 0.14 | 2.89 | NA | XXX |
| 78891 | 26 | B | Nuclear med data proc | 0.10 | 0.04 | 0.04 | 0.01 | 0.15 | 0.15 | XXX |
| 78891 | TC | B | Nuclear med data proc | 0.00 | 2.62 | NA | 0.13 | 2.75 | NA | XXX |
| 79000 | | A | Init hyperthyroid therapy | 1.80 | 3.22 | NA | 0.22 | 5.24 | NA | XXX |
| 79000 | 26 | A | Init hyperthyroid therapy | 1.80 | 0.60 | 0.60 | 0.08 | 2.48 | 2.48 | XXX |
| 79000 | TC | A | Init hyperthyroid therapy | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 79001 | | A | Repeat hyperthyroid therapy | 1.05 | 1.66 | NA | 0.12 | 2.83 | NA | XXX |
| 79001 | 26 | A | Repeat hyperthyroid therapy | 1.05 | 0.36 | 0.36 | 0.05 | 1.46 | 1.46 | XXX |
| 79001 | TC | A | Repeat hyperthyroid therapy | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 79020 | | A | Thyroid ablation | 1.81 | 3.21 | NA | 0.22 | 5.24 | NA | XXX |
| 79020 | 26 | A | Thyroid ablation | 1.81 | 0.60 | 0.60 | 0.08 | 2.49 | 2.49 | XXX |
| 79020 | TC | A | Thyroid ablation | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 79030 | | A | Thyroid ablation, carcinoma | 2.10 | 3.32 | NA | 0.23 | 5.65 | NA | XXX |
| 79030 | 26 | A | Thyroid ablation, carcinoma | 2.10 | 0.71 | 0.71 | 0.09 | 2.90 | 2.90 | XXX |
| 79030 | TC | A | Thyroid ablation, carcinoma | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 79035 | | A | Thyroid metastatic therapy | 2.52 | 3.49 | NA | 0.25 | 6.26 | NA | XXX |
| 79035 | 26 | A | Thyroid metastatic therapy | 2.52 | 0.87 | 0.87 | 0.11 | 3.50 | 3.50 | XXX |
| 79035 | TC | A | Thyroid metastatic therapy | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 79100 | | A | Hematopoetic nuclear therapy | 1.32 | 3.08 | NA | 0.20 | 4.60 | NA | XXX |
| 79100 | 26 | A | Hematopoetic nuclear therapy | 1.32 | 0.46 | 0.46 | 0.06 | 1.84 | 1.84 | XXX |
| 79100 | TC | A | Hematopoetic nuclear therapy | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 79200 | | A | Intracavitary nuclear trmt | 1.99 | 3.30 | NA | 0.23 | 5.52 | NA | XXX |
| 79200 | 26 | A | Intracavitary nuclear trmt | 1.99 | 0.69 | 0.69 | 0.09 | 2.77 | 2.77 | XXX |
| 79200 | TC | A | Intracavitary nuclear trmt | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 79300 | 26 | A | Interstitial nuclear therapy | 1.60 | 0.56 | 0.56 | 0.08 | 2.24 | 2.24 | XXX |
| 79400 | | A | Nonhemato nuclear therapy | 1.96 | 3.29 | NA | 0.23 | 5.48 | NA | XXX |
| 79400 | 26 | A | Nonhemato nuclear therapy | 1.96 | 0.67 | 0.67 | 0.09 | 2.72 | 2.72 | XXX |
| 79400 | TC | A | Nonhemato nuclear therapy | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 79403 | | A | Hematopoetic nuclear therapy | 2.25 | 5.16 | NA | 0.24 | 7.65 | NA | XXX |
| 79403 | 26 | A | Hematopoetic nuclear therapy | 2.25 | 0.89 | 0.89 | 0.10 | 3.24 | 3.24 | XXX |
| 79403 | TC | A | Hematopoetic nuclear therapy | 0.00 | 4.27 | NA | 0.14 | 4.41 | NA | XXX |
| 79420 | 26 | A | Intravascular nuclear ther | 1.51 | 0.49 | 0.49 | 0.07 | 2.07 | 2.07 | XXX |
| 79440 | | A | Nuclear joint therapy | 1.99 | 3.34 | NA | 0.24 | 5.57 | NA | XXX |
| 79440 | 26 | A | Nuclear joint therapy | 1.99 | 0.72 | 0.72 | 0.10 | 2.81 | 2.81 | XXX |
| 79440 | TC | A | Nuclear joint therapy | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 80500 | | A | Lab pathology consultation | 0.37 | 0.21 | 0.16 | 0.01 | 0.59 | 0.54 | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 80502 | | A | Lab pathology consultation | 1.33 | 0.55 | 0.55 | 0.06 | 1.94 | 1.94 | XXX |
| 83020 | 26 | A | Hemoglobin electrophoresis | 0.37 | 0.15 | 0.15 | 0.01 | 0.53 | 0.53 | XXX |
| 83912 | 26 | A | Genetic examination | 0.37 | 0.12 | 0.12 | 0.01 | 0.50 | 0.50 | XXX |
| 84165 | 26 | A | Electrophoreisis of proteins | 0.37 | 0.14 | 0.14 | 0.01 | 0.52 | 0.52 | XXX |
| 84181 | 26 | A | Western blot test | 0.37 | 0.14 | 0.14 | 0.02 | 0.53 | 0.53 | XXX |
| 84182 | 26 | A | Protein, western blot test | 0.37 | 0.16 | 0.16 | 0.01 | 0.54 | 0.54 | XXX |
| 85060 | | A | Blood smear interpretation | 0.45 | 0.18 | 0.18 | 0.02 | 0.65 | 0.65 | XXX |
| 85097 | | A | Bone marrow interpretation | 0.94 | 2.02 | 0.42 | 0.04 | 3.00 | 1.40 | XXX |
| 85390 | 26 | A | Fibrinolysins screen | 0.37 | 0.13 | 0.13 | 0.02 | 0.52 | 0.52 | XXX |
| 85396 | | A | Clotting assay, whole blood | 0.37 | NA | 0.16 | 0.04 | NA | 0.57 | XXX |
| 85576 | 26 | A | Blood platelet aggregation | 0.37 | 0.16 | 0.16 | 0.02 | 0.55 | 0.55 | XXX |
| 86077 | | A | Physician blood bank service | 0.94 | 0.40 | 0.40 | 0.04 | 1.38 | 1.38 | XXX |
| 86078 | | A | Physician blood bank service | 0.94 | 0.47 | 0.41 | 0.04 | 1.45 | 1.39 | XXX |
| 86079 | | A | Physician blood bank service | 0.94 | 0.45 | 0.41 | 0.04 | 1.43 | 1.39 | XXX |
| 86255 | 26 | A | Fluorescent antibody, screen | 0.37 | 0.16 | 0.16 | 0.01 | 0.54 | 0.54 | XXX |
| 86256 | 26 | A | Fluorescent antibody, titer | 0.37 | 0.15 | 0.15 | 0.01 | 0.53 | 0.53 | XXX |
| 86320 | 26 | A | Serum immunoelectrophoresis | 0.37 | 0.15 | 0.15 | 0.01 | 0.53 | 0.53 | XXX |
| 86325 | 26 | A | Other immunoelectrophoresis | 0.37 | 0.13 | 0.13 | 0.01 | 0.51 | 0.51 | XXX |
| 86327 | 26 | A | Immunoelectrophoresis assay | 0.42 | 0.18 | 0.18 | 0.02 | 0.62 | 0.62 | XXX |
| 86334 | 26 | A | Immunofixation procedure | 0.37 | 0.16 | 0.16 | 0.01 | 0.54 | 0.54 | XXX |
| 86490 | | A | Coccidioidomycosis skin test | 0.00 | 0.29 | NA | 0.02 | 0.31 | NA | XXX |
| 86510 | | A | Histoplasmosis skin test | 0.00 | 0.32 | NA | 0.02 | 0.34 | NA | XXX |
| 86580 | | A | TB intradermal test | 0.00 | 0.25 | NA | 0.02 | 0.27 | NA | XXX |
| 86585 | | A | TB tine test | 0.00 | 0.20 | NA | 0.01 | 0.21 | NA | XXX |
| 87164 | 26 | A | Dark field examination | 0.37 | 0.12 | 0.12 | 0.01 | 0.50 | 0.50 | XXX |
| 87207 | 26 | A | Smear, special stain | 0.37 | 0.16 | 0.16 | 0.01 | 0.54 | 0.54 | XXX |
| 88104 | | A | Cytopathology, fluids | 0.56 | 0.86 | NA | 0.04 | 1.46 | NA | XXX |
| 88104 | 26 | A | Cytopathology, fluids | 0.56 | 0.24 | 0.24 | 0.02 | 0.82 | 0.82 | XXX |
| 88104 | TC | A | Cytopathology, fluids | 0.00 | 0.62 | NA | 0.02 | 0.64 | NA | XXX |
| 88106 | | A | Cytopathology, fluids | 0.56 | 1.37 | NA | 0.04 | 1.97 | NA | XXX |
| 88106 | 26 | A | Cytopathology, fluids | 0.56 | 0.24 | 0.24 | 0.02 | 0.82 | 0.82 | XXX |
| 88106 | TC | A | Cytopathology, fluids | 0.00 | 1.13 | NA | 0.02 | 1.15 | NA | XXX |
| 88107 | | A | Cytopathology, fluids | 0.76 | 1.56 | NA | 0.05 | 2.37 | NA | XXX |
| 88107 | 26 | A | Cytopathology, fluids | 0.76 | 0.33 | 0.33 | 0.03 | 1.12 | 1.12 | XXX |
| 88107 | TC | A | Cytopathology, fluids | 0.00 | 1.23 | NA | 0.02 | 1.25 | NA | XXX |
| 88108 | | A | Cytopath, concentrate tech | 0.56 | 1.22 | NA | 0.04 | 1.82 | NA | XXX |
| 88108 | 26 | A | Cytopath, concentrate tech | 0.56 | 0.24 | 0.24 | 0.02 | 0.82 | 0.82 | XXX |
| 88108 | TC | A | Cytopath, concentrate tech | 0.00 | 0.98 | NA | 0.02 | 1.00 | NA | XXX |
| 88112 | | A | Cytopath, cell enhance tech | 1.18 | 1.98 | NA | 0.04 | 3.20 | NA | XXX |
| 88112 | 26 | A | Cytopath, cell enhance tech | 1.18 | 0.51 | 0.51 | 0.02 | 1.71 | 1.71 | XXX |
| 88112 | TC | A | Cytopath, cell enhance tech | 0.00 | 1.47 | NA | 0.02 | 1.49 | NA | XXX |
| 88125 | | A | Forensic cytopathology | 0.26 | 0.09 | NA | 0.02 | 0.37 | NA | XXX |
| 88125 | 26 | A | Forensic cytopathology | 0.26 | 0.11 | 0.11 | 0.01 | 0.38 | 0.38 | XXX |
| 88125 | TC | A | Forensic cytopathology | 0.00 | -0.03 | NA | 0.01 | -0.02 | NA | XXX |
| 88141 | | A | Cytopath, c/v, interpret | 0.42 | 0.15 | 0.15 | 0.02 | 0.59 | 0.59 | XXX |
| 88160 | | A | Cytopath smear, other source | 0.50 | 0.85 | NA | 0.04 | 1.39 | NA | XXX |
| 88160 | 26 | A | Cytopath smear, other source | 0.50 | 0.22 | 0.22 | 0.02 | 0.74 | 0.74 | XXX |
| 88160 | TC | A | Cytopath smear, other source | 0.00 | 0.63 | NA | 0.02 | 0.65 | NA | XXX |
| 88161 | | A | Cytopath smear, other source | 0.50 | 0.95 | NA | 0.04 | 1.49 | NA | XXX |
| 88161 | 26 | A | Cytopath smear, other source | 0.50 | 0.21 | 0.21 | 0.02 | 0.73 | 0.73 | XXX |
| 88161 | TC | A | Cytopath smear, other source | 0.00 | 0.74 | NA | 0.02 | 0.76 | NA | XXX |
| 88162 | | A | Cytopath smear, other source | 0.76 | 1.04 | NA | 0.05 | 1.85 | NA | XXX |
| 88162 | 26 | A | Cytopath smear, other source | 0.76 | 0.33 | 0.33 | 0.03 | 1.12 | 1.12 | XXX |
| 88162 | TC | A | Cytopath smear, other source | 0.00 | 0.71 | NA | 0.02 | 0.73 | NA | XXX |
| 88172 | | A | Cytopathology eval of fna | 0.60 | 0.74 | NA | 0.04 | 1.38 | NA | XXX |
| 88172 | 26 | A | Cytopathology eval of fna | 0.60 | 0.26 | 0.26 | 0.02 | 0.88 | 0.88 | XXX |
| 88172 | TC | A | Cytopathology eval of fna | 0.00 | 0.48 | NA | 0.02 | 0.50 | NA | XXX |
| 88173 | | A | Cytopath eval, fna, report | 1.39 | 2.18 | NA | 0.07 | 3.64 | NA | XXX |
| 88173 | 26 | A | Cytopath eval, fna, report | 1.39 | 0.60 | 0.60 | 0.05 | 2.04 | 2.04 | XXX |
| 88173 | TC | A | Cytopath eval, fna, report | 0.00 | 1.58 | NA | 0.02 | 1.60 | NA | XXX |
| 88180 | | A | Cell marker study | 0.36 | 1.27 | NA | 0.03 | 1.66 | NA | XXX |
| 88180 | 26 | A | Cell marker study | 0.36 | 0.16 | 0.16 | 0.01 | 0.53 | 0.53 | XXX |
| 88180 | TC | A | Cell marker study | 0.00 | 1.11 | NA | 0.02 | 1.13 | NA | XXX |
| 88182 | | A | Cell marker study | 0.77 | 2.04 | NA | 0.07 | 2.88 | NA | XXX |
| 88182 | 26 | A | Cell marker study | 0.77 | 0.33 | 0.33 | 0.03 | 1.13 | 1.13 | XXX |
| 88182 | TC | A | Cell marker study | 0.00 | 1.70 | NA | 0.04 | 1.74 | NA | XXX |
| 88291 | | A | Cyto/molecular report | 0.52 | 0.18 | 0.18 | 0.03 | 0.73 | 0.73 | XXX |
| 88300 | | A | Surgical path, gross | 0.08 | 0.46 | NA | 0.01 | 0.55 | NA | XXX |
| 88300 | 26 | A | Surgical path, gross | 0.08 | 0.03 | 0.03 | 0.00 | 0.11 | 0.11 | XXX |
| 88300 | TC | A | Surgical path, gross | 0.00 | 0.42 | NA | 0.01 | 0.43 | NA | XXX |
| 88302 | | A | Tissue exam by pathologist | 0.13 | 1.03 | NA | 0.02 | 1.18 | NA | XXX |
| 88302 | 26 | A | Tissue exam by pathologist | 0.13 | 0.06 | 0.06 | 0.00 | 0.19 | 0.19 | XXX |
| 88302 | TC | A | Tissue exam by pathologist | 0.00 | 0.97 | NA | 0.02 | 0.99 | NA | XXX |
| 88304 | | A | Tissue exam by pathologist | 0.22 | 1.34 | NA | 0.03 | 1.59 | NA | XXX |
| 88304 | 26 | A | Tissue exam by pathologist | 0.22 | 0.10 | 0.10 | 0.01 | 0.33 | 0.33 | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 88304 | TC | A | Tissue exam by pathologist | 0.00 | 1.24 | NA | 0.02 | 1.26 | NA | XXX |
| 88305 | | A | Tissue exam by pathologist | 0.75 | 1.92 | NA | 0.07 | 2.74 | NA | XXX |
| 88305 | 26 | A | Tissue exam by pathologist | 0.75 | 0.33 | 0.33 | 0.03 | 1.11 | 1.11 | XXX |
| 88305 | TC | A | Tissue exam by pathologist | 0.00 | 1.59 | NA | 0.04 | 1.63 | NA | XXX |
| 88307 | | A | Tissue exam by pathologist | 1.59 | 3.16 | NA | 0.12 | 4.87 | NA | XXX |
| 88307 | 26 | A | Tissue exam by pathologist | 1.59 | 0.69 | 0.69 | 0.06 | 2.34 | 2.34 | XXX |
| 88307 | TC | A | Tissue exam by pathologist | 0.00 | 2.47 | NA | 0.06 | 2.53 | NA | XXX |
| 88309 | | A | Tissue exam by pathologist | 2.28 | 4.41 | NA | 0.15 | 6.84 | NA | XXX |
| 88309 | 26 | A | Tissue exam by pathologist | 2.28 | 0.99 | 0.99 | 0.09 | 3.36 | 3.36 | XXX |
| 88309 | TC | A | Tissue exam by pathologist | 0.00 | 3.43 | NA | 0.06 | 3.49 | NA | XXX |
| 88311 | | A | Decalcify tissue | 0.24 | 0.24 | NA | 0.02 | 0.50 | NA | XXX |
| 88311 | 26 | A | Decalcify tissue | 0.24 | 0.10 | 0.10 | 0.01 | 0.35 | 0.35 | XXX |
| 88311 | TC | A | Decalcify tissue | 0.00 | 0.13 | NA | 0.01 | 0.14 | NA | XXX |
| 88312 | | A | Special stains | 0.54 | 1.52 | NA | 0.03 | 2.09 | NA | XXX |
| 88312 | 26 | A | Special stains | 0.54 | 0.23 | 0.23 | 0.02 | 0.79 | 0.79 | XXX |
| 88312 | TC | A | Special stains | 0.00 | 1.28 | NA | 0.01 | 1.29 | NA | XXX |
| 88313 | | A | Special stains | 0.24 | 1.25 | NA | 0.02 | 1.51 | NA | XXX |
| 88313 | 26 | A | Special stains | 0.24 | 0.10 | 0.10 | 0.01 | 0.35 | 0.35 | XXX |
| 88313 | TC | A | Special stains | 0.00 | 1.14 | NA | 0.01 | 1.15 | NA | XXX |
| 88314 | | A | Histochemical stain | 0.45 | 2.05 | NA | 0.04 | 2.54 | NA | XXX |
| 88314 | 26 | A | Histochemical stain | 0.45 | 0.19 | 0.19 | 0.02 | 0.66 | 0.66 | XXX |
| 88314 | TC | A | Histochemical stain | 0.00 | 1.86 | NA | 0.02 | 1.88 | NA | XXX |
| 88318 | | A | Chemical histochemistry | 0.42 | 1.66 | NA | 0.03 | 2.11 | NA | XXX |
| 88318 | 26 | A | Chemical histochemistry | 0.42 | 0.18 | 0.18 | 0.02 | 0.62 | 0.62 | XXX |
| 88318 | TC | A | Chemical histochemistry | 0.00 | 1.48 | NA | 0.01 | 1.49 | NA | XXX |
| 88319 | | A | Enzyme histochemistry | 0.53 | 3.44 | NA | 0.04 | 4.01 | NA | XXX |
| 88319 | 26 | A | Enzyme histochemistry | 0.53 | 0.23 | 0.23 | 0.02 | 0.78 | 0.78 | XXX |
| 88319 | TC | A | Enzyme histochemistry | 0.00 | 3.21 | NA | 0.02 | 3.23 | NA | XXX |
| 88321 | | A | Microslide consultation | 1.30 | 0.80 | 0.56 | 0.05 | 2.15 | 1.91 | XXX |
| 88323 | | A | Microslide consultation | 1.35 | 1.80 | NA | 0.07 | 3.22 | NA | XXX |
| 88323 | 26 | A | Microslide consultation | 1.35 | 0.58 | 0.58 | 0.05 | 1.98 | 1.98 | XXX |
| 88323 | TC | A | Microslide consultation | 0.00 | 1.22 | NA | 0.02 | 1.24 | NA | XXX |
| 88325 | | A | Comprehensive review of data | 2.22 | 2.97 | 0.96 | 0.10 | 5.29 | 3.28 | XXX |
| 88329 | | A | Path consult introp | 0.67 | 0.65 | 0.29 | 0.03 | 1.35 | 0.99 | XXX |
| 88331 | | A | Path consult intraop, 1 bloc | 1.19 | 1.11 | NA | 0.09 | 2.39 | NA | XXX |
| 88331 | 26 | A | Path consult intraop, 1 bloc | 1.19 | 0.52 | 0.52 | 0.05 | 1.76 | 1.76 | XXX |
| 88331 | TC | A | Path consult intraop, 1 bloc | 0.00 | 0.60 | NA | 0.04 | 0.64 | NA | XXX |
| 88332 | | A | Path consult intraop, add-l | 0.59 | 0.46 | NA | 0.04 | 1.09 | NA | XXX |
| 88332 | 26 | A | Path consult intraop, add-l | 0.59 | 0.26 | 0.26 | 0.02 | 0.87 | 0.87 | XXX |
| 88332 | TC | A | Path consult intraop, add-l | 0.00 | 0.21 | NA | 0.02 | 0.23 | NA | XXX |
| 88342 | | A | Immunohistochemistry | 0.85 | 1.48 | NA | 0.05 | 2.38 | NA | XXX |
| 88342 | 26 | A | Immunohistochemistry | 0.85 | 0.37 | 0.37 | 0.03 | 1.25 | 1.25 | XXX |
| 88342 | TC | A | Immunohistochemistry | 0.00 | 1.11 | NA | 0.02 | 1.13 | NA | XXX |
| 88346 | | A | Immunofluorescent study | 0.86 | 1.57 | NA | 0.05 | 2.48 | NA | XXX |
| 88346 | 26 | A | Immunofluorescent study | 0.86 | 0.37 | 0.37 | 0.03 | 1.26 | 1.26 | XXX |
| 88346 | TC | A | Immunofluorescent study | 0.00 | 1.21 | NA | 0.02 | 1.23 | NA | XXX |
| 88347 | | A | Immunofluorescent study | 0.86 | 1.27 | NA | 0.05 | 2.18 | NA | XXX |
| 88347 | 26 | A | Immunofluorescent study | 0.86 | 0.35 | 0.35 | 0.03 | 1.24 | 1.24 | XXX |
| 88347 | TC | A | Immunofluorescent study | 0.00 | 0.92 | NA | 0.02 | 0.94 | NA | XXX |
| 88348 | | A | Electron microscopy | 1.51 | 9.58 | NA | 0.13 | 11.22 | NA | XXX |
| 88348 | 26 | A | Electron microscopy | 1.51 | 0.65 | 0.65 | 0.06 | 2.22 | 2.22 | XXX |
| 88348 | TC | A | Electron microscopy | 0.00 | 8.93 | NA | 0.07 | 9.00 | NA | XXX |
| 88349 | | A | Scanning electron microscopy | 0.76 | 3.67 | NA | 0.09 | 4.52 | NA | XXX |
| 88349 | 26 | A | Scanning electron microscopy | 0.76 | 0.33 | 0.33 | 0.03 | 1.12 | 1.12 | XXX |
| 88349 | TC | A | Scanning electron microscopy | 0.00 | 3.34 | NA | 0.06 | 3.40 | NA | XXX |
| 88355 | | A | Analysis, skeletal muscle | 1.85 | 6.71 | NA | 0.13 | 8.69 | NA | XXX |
| 88355 | 26 | A | Analysis, skeletal muscle | 1.85 | 0.80 | 0.80 | 0.07 | 2.72 | 2.72 | XXX |
| 88355 | TC | A | Analysis, skeletal muscle | 0.00 | 5.91 | NA | 0.06 | 5.97 | NA | XXX |
| 88356 | | A | Analysis, nerve | 3.02 | 3.80 | NA | 0.20 | 7.02 | NA | XXX |
| 88356 | 26 | A | Analysis, nerve | 3.02 | 1.27 | 1.27 | 0.13 | 4.42 | 4.42 | XXX |
| 88356 | TC | A | Analysis, nerve | 0.00 | 2.53 | NA | 0.07 | 2.60 | NA | XXX |
| 88358 | | A | Analysis, tumor | 0.95 | 0.71 | NA | 0.18 | 1.84 | NA | XXX |
| 88358 | 26 | A | Analysis, tumor | 0.95 | 0.41 | 0.41 | 0.11 | 1.47 | 1.47 | XXX |
| 88358 | TC | A | Analysis, tumor | 0.00 | 0.30 | NA | 0.07 | 0.37 | NA | XXX |
| 88361 | | A | Immunohistochemistry, tumor | 0.94 | 2.59 | NA | 0.18 | 3.71 | NA | XXX |
| 88361 | 26 | A | Immunohistochemistry, tumor | 0.94 | 0.40 | 0.40 | 0.11 | 1.45 | 1.45 | XXX |
| 88361 | TC | A | Immunohistochemistry, tumor | 0.00 | 2.19 | NA | 0.07 | 2.26 | NA | XXX |
| 88362 | | A | Nerve teasing preparations | 2.17 | 4.73 | NA | 0.15 | 7.05 | NA | XXX |
| 88362 | 26 | A | Nerve teasing preparations | 2.17 | 0.92 | 0.92 | 0.09 | 3.18 | 3.18 | XXX |
| 88362 | TC | A | Nerve teasing preparations | 0.00 | 3.80 | NA | 0.06 | 3.86 | NA | XXX |
| 88365 | | A | Tissue hybridization | 0.93 | 3.04 | NA | 0.06 | 4.03 | NA | XXX |
| 88365 | 26 | A | Tissue hybridization | 0.93 | 0.40 | 0.40 | 0.04 | 1.37 | 1.37 | XXX |
| 88365 | TC | A | Tissue hybridization | 0.00 | 2.63 | NA | 0.02 | 2.65 | NA | XXX |
| 88371 | 26 | A | Protein, western blot tissue | 0.37 | 0.13 | 0.13 | 0.02 | 0.52 | 0.52 | XXX |
| 88372 | 26 | A | Protein analysis w/probe | 0.37 | 0.16 | 0.16 | 0.01 | 0.54 | 0.54 | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 89060 | 26 | A | Exam,synovial fluid crystals | 0.37 | 0.16 | 0.16 | 0.01 | 0.54 | 0.54 | XXX |
| 89100 | | A | Sample intestinal contents | 0.60 | 1.85 | 0.21 | 0.03 | 2.48 | 0.84 | XXX |
| 89105 | | A | Sample intestinal contents | 0.50 | 2.24 | 0.17 | 0.02 | 2.76 | 0.69 | XXX |
| 89130 | | A | Sample stomach contents | 0.45 | 1.74 | 0.13 | 0.03 | 2.22 | 0.61 | XXX |
| 89132 | | A | Sample stomach contents | 0.19 | 1.54 | 0.06 | 0.01 | 1.74 | 0.26 | XXX |
| 89135 | | A | Sample stomach contents | 0.79 | 1.91 | 0.25 | 0.03 | 2.73 | 1.07 | XXX |
| 89136 | | A | Sample stomach contents | 0.21 | 1.78 | 0.09 | 0.01 | 2.00 | 0.31 | XXX |
| 89140 | | A | Sample stomach contents | 0.94 | 2.12 | 0.27 | 0.04 | 3.10 | 1.25 | XXX |
| 89141 | | A | Sample stomach contents | 0.85 | 2.82 | 0.34 | 0.03 | 3.70 | 1.22 | XXX |
| 89220 | | A | Sputum specimen collection | 0.00 | NA | NA | 0.00 | NA | NA | XXX |
| 89230 | | A | Collect sweat for test | 0.00 | NA | NA | 0.00 | NA | NA | XXX |
| 90471 | | A | Immunization admin | 0.00 | 0.20 | NA | 0.01 | 0.21 | NA | XXX |
| 90472 | | A | Immunization admin, each add | 0.00 | 0.14 | NA | 0.01 | 0.15 | NA | ZZZ |
| 90780 | | A | IV infusion therapy, 1 hour | 0.17 | 2.14 | NA | 0.07 | 2.38 | NA | XXX |
| 90781 | | A | IV infusion, additional hour | 0.17 | 0.46 | NA | 0.04 | 0.67 | NA | ZZZ |
| 90782 | | T | Injection, sc/im | 0.17 | 0.31 | NA | 0.01 | 0.49 | NA | XXX |
| 90783 | | T | Injection, ia | 0.17 | 0.32 | NA | 0.02 | 0.51 | NA | XXX |
| 90784 | | T | Injection, iv | 0.17 | 0.80 | NA | 0.04 | 1.01 | NA | XXX |
| 90788 | | T | Injection of antibiotic | 0.17 | 0.27 | NA | 0.01 | 0.45 | NA | XXX |
| 90801 | | A | Psy dx interview | 2.80 | 1.17 | 0.93 | 0.08 | 4.05 | 3.81 | XXX |
| 90802 | | A | Intac psy dx interview | 3.01 | 1.20 | 0.97 | 0.08 | 4.29 | 4.06 | XXX |
| 90804 | | A | Psytx, office, 20-30 min | 1.21 | 0.49 | 0.38 | 0.03 | 1.73 | 1.62 | XXX |
| 90805 | | A | Psytx, off, 20-30 min w/e&m | 1.37 | 0.50 | 0.42 | 0.04 | 1.91 | 1.83 | XXX |
| 90806 | | A | Psytx, off, 45-50 min | 1.86 | 0.70 | 0.60 | 0.05 | 2.61 | 2.51 | XXX |
| 90807 | | A | Psytx, off, 45-50 min w/e&m | 2.02 | 0.70 | 0.63 | 0.05 | 2.77 | 2.70 | XXX |
| 90808 | | A | Psytx, office, 75-80 min | 2.79 | 1.02 | 0.90 | 0.07 | 3.88 | 3.76 | XXX |
| 90809 | | A | Psytx, off, 75-80, w/e&m | 2.95 | 1.00 | 0.92 | 0.08 | 4.03 | 3.95 | XXX |
| 90810 | | A | Intac psytx, off, 20-30 min | 1.32 | 0.51 | 0.42 | 0.04 | 1.87 | 1.78 | XXX |
| 90811 | | A | Intac psytx, 20-30, w/e&m | 1.48 | 0.57 | 0.46 | 0.04 | 2.09 | 1.98 | XXX |
| 90812 | | A | Intac psytx, off, 45-50 min | 1.97 | 0.78 | 0.64 | 0.05 | 2.80 | 2.66 | XXX |
| 90813 | | A | Intac psytx, 45-50 min w/e&m | 2.13 | 0.77 | 0.67 | 0.05 | 2.95 | 2.85 | XXX |
| 90814 | | A | Intac psytx, off, 75-80 min | 2.90 | 1.10 | 0.98 | 0.07 | 4.07 | 3.95 | XXX |
| 90815 | | A | Intac psytx, 75-80 w/e&m | 3.06 | 1.05 | 0.95 | 0.07 | 4.18 | 4.08 | XXX |
| 90816 | | A | Psytx, hosp, 20-30 min | 1.25 | NA | 0.46 | 0.03 | NA | 1.74 | XXX |
| 90817 | | A | Psytx, hosp, 20-30 min w/e&m | 1.41 | NA | 0.46 | 0.04 | NA | 1.91 | XXX |
| 90818 | | A | Psytx, hosp, 45-50 min | 1.89 | NA | 0.69 | 0.05 | NA | 2.63 | XXX |
| 90819 | | A | Psytx, hosp, 45-50 min w/e&m | 2.05 | NA | 0.65 | 0.05 | NA | 2.75 | XXX |
| 90821 | | A | Psytx, hosp, 75-80 min | 2.83 | NA | 1.00 | 0.07 | NA | 3.90 | XXX |
| 90822 | | A | Psytx, hosp, 75-80 min w/e&m | 2.99 | NA | 0.94 | 0.09 | NA | 4.02 | XXX |
| 90823 | | A | Intac psytx, hosp, 20-30 min | 1.36 | NA | 0.48 | 0.03 | NA | 1.87 | XXX |
| 90824 | | A | Intac psytx, hsp 20-30 w/e&m | 1.52 | NA | 0.49 | 0.04 | NA | 2.05 | XXX |
| 90826 | | A | Intac psytx, hosp, 45-50 min | 2.01 | NA | 0.72 | 0.05 | NA | 2.78 | XXX |
| 90827 | | A | Intac psytx, hsp 45-50 w/e&m | 2.16 | NA | 0.68 | 0.05 | NA | 2.89 | XXX |
| 90828 | | A | Intac psytx, hosp, 75-80 min | 2.94 | NA | 1.06 | 0.07 | NA | 4.07 | XXX |
| 90829 | | A | Intac psytx, hsp 75-80 w/e&m | 3.10 | NA | 0.98 | 0.07 | NA | 4.15 | XXX |
| 90845 | | A | Psychoanalysis | 1.79 | 0.58 | 0.55 | 0.04 | 2.41 | 2.38 | XXX |
| 90846 | | R | Family psytx w/o patient | 1.83 | 0.65 | 0.64 | 0.05 | 2.53 | 2.52 | XXX |
| 90847 | | R | Family psytx w/patient | 2.21 | 0.81 | 0.76 | 0.06 | 3.08 | 3.03 | XXX |
| 90849 | | R | Multiple family group psytx | 0.59 | 0.27 | 0.24 | 0.02 | 0.88 | 0.85 | XXX |
| 90853 | | A | Group psychotherapy | 0.59 | 0.25 | 0.23 | 0.02 | 0.86 | 0.84 | XXX |
| 90857 | | A | Intac group psytx | 0.63 | 0.29 | 0.25 | 0.02 | 0.94 | 0.90 | XXX |
| 90862 | | A | Medication management | 0.95 | 0.40 | 0.32 | 0.03 | 1.38 | 1.30 | XXX |
| 90865 | | A | Narcosynthesis | 2.84 | 1.38 | 0.91 | 0.11 | 4.33 | 3.86 | XXX |
| 90870 | | A | Electroconvulsive therapy | 1.88 | 1.43 | 0.59 | 0.05 | 3.36 | 2.52 | 000 |
| 90880 | | A | Hypnotherapy | 2.19 | 1.04 | 0.69 | 0.06 | 3.29 | 2.94 | XXX |
| 90885 | | B | Psy evaluation of records | 0.97 | 0.37 | 0.37 | 0.02 | 1.36 | 1.36 | XXX |
| 90887 | | B | Consultation with family | 1.48 | 0.82 | 0.56 | 0.04 | 2.34 | 2.08 | XXX |
| 90901 | | A | Biofeedback train, any meth | 0.41 | 0.65 | 0.14 | 0.02 | 1.08 | 0.57 | 000 |
| 90911 | | A | Biofeedback peri/uro/rectal | 0.89 | 1.56 | 0.31 | 0.06 | 2.51 | 1.26 | 000 |
| 90918 | | A | ESRD related services, month | 11.16 | 7.29 | 7.29 | 0.36 | 18.81 | 18.81 | XXX |
| 90919 | | A | ESRD related services, month | 8.53 | 4.04 | 4.04 | 0.29 | 12.86 | 12.86 | XXX |
| 90920 | | A | ESRD related services, month | 7.26 | 3.78 | 3.78 | 0.23 | 11.27 | 11.27 | XXX |
| 90921 | | A | ESRD related services, month | 4.46 | 2.45 | 2.45 | 0.14 | 7.05 | 7.05 | XXX |
| 90922 | | A | ESRD related services, day | 0.37 | 0.21 | 0.21 | 0.01 | 0.59 | 0.59 | XXX |
| 90923 | | A | Esrd related services, day | 0.28 | 0.13 | 0.13 | 0.01 | 0.42 | 0.42 | XXX |
| 90924 | | A | Esrd related services, day | 0.24 | 0.12 | 0.12 | 0.01 | 0.37 | 0.37 | XXX |
| 90925 | | A | Esrd related services, day | 0.15 | 0.08 | 0.08 | 0.01 | 0.24 | 0.24 | XXX |
| 90935 | | A | Hemodialysis, one evaluation | 1.22 | NA | 0.67 | 0.04 | NA | 1.93 | 000 |
| 90937 | | A | Hemodialysis, repeated eval | 2.11 | NA | 0.97 | 0.08 | NA | 3.16 | 000 |
| 90945 | | A | Dialysis, one evaluation | 1.28 | NA | 0.69 | 0.05 | NA | 2.02 | 000 |
| 90947 | | A | Dialysis, repeated eval | 2.16 | NA | 1.00 | 0.08 | NA | 3.24 | 000 |
| 90997 | | A | Hemoperfusion | 1.84 | NA | 0.66 | 0.06 | NA | 2.56 | 000 |
| 91000 | | A | Esophageal intubation | 0.73 | 0.32 | NA | 0.04 | 1.09 | NA | 000 |
| 91000 | 26 | A | Esophageal intubation | 0.73 | 0.24 | 0.24 | 0.03 | 1.00 | 1.00 | 000 |
| 91000 | TC | A | Esophageal intubation | 0.00 | 0.08 | NA | 0.01 | 0.09 | NA | 000 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 91010 | | A | Esophagus motility study | 1.25 | 4.45 | NA | 0.12 | 5.82 | NA | 000 |
| 91010 | 26 | A | Esophagus motility study | 1.25 | 0.44 | 0.44 | 0.06 | 1.75 | 1.75 | 000 |
| 91010 | TC | A | Esophagus motility study | 0.00 | 4.01 | NA | 0.06 | 4.07 | NA | 000 |
| 91011 | | A | Esophagus motility study | 1.50 | 5.27 | NA | 0.13 | 6.90 | NA | 000 |
| 91011 | 26 | A | Esophagus motility study | 1.50 | 0.53 | 0.53 | 0.07 | 2.10 | 2.10 | 000 |
| 91011 | TC | A | Esophagus motility study | 0.00 | 4.74 | NA | 0.06 | 4.80 | NA | 000 |
| 91012 | | A | Esophagus motility study | 1.46 | 5.79 | NA | 0.14 | 7.39 | NA | 000 |
| 91012 | 26 | A | Esophagus motility study | 1.46 | 0.51 | 0.51 | 0.07 | 2.04 | 2.04 | 000 |
| 91012 | TC | A | Esophagus motility study | 0.00 | 5.28 | NA | 0.07 | 5.35 | NA | 000 |
| 91020 | | A | Gastric motility | 1.44 | 4.58 | NA | 0.13 | 6.15 | NA | 000 |
| 91020 | 26 | A | Gastric motility | 1.44 | 0.49 | 0.49 | 0.07 | 2.00 | 2.00 | 000 |
| 91020 | TC | A | Gastric motility | 0.00 | 4.10 | NA | 0.06 | 4.16 | NA | 000 |
| 91030 | | A | Acid perfusion of esophagus | 0.91 | 2.45 | NA | 0.06 | 3.42 | NA | 000 |
| 91030 | 26 | A | Acid perfusion of esophagus | 0.91 | 0.32 | 0.32 | 0.04 | 1.27 | 1.27 | 000 |
| 91030 | TC | A | Acid perfusion of esophagus | 0.00 | 2.13 | NA | 0.02 | 2.15 | NA | 000 |
| 91032 | | A | Esophagus, acid reflux test | 1.21 | 4.16 | NA | 0.12 | 5.49 | NA | 000 |
| 91032 | 26 | A | Esophagus, acid reflux test | 1.21 | 0.42 | 0.42 | 0.06 | 1.69 | 1.69 | 000 |
| 91032 | TC | A | Esophagus, acid reflux test | 0.00 | 3.74 | NA | 0.06 | 3.80 | NA | 000 |
| 91033 | | A | Prolonged acid reflux test | 1.30 | 4.24 | NA | 0.18 | 5.72 | NA | 000 |
| 91033 | 26 | A | Prolonged acid reflux test | 1.30 | 0.45 | 0.45 | 0.07 | 1.82 | 1.82 | 000 |
| 91033 | TC | A | Prolonged acid reflux test | 0.00 | 3.78 | NA | 0.11 | 3.89 | NA | 000 |
| 91052 | | A | Gastric analysis test | 0.79 | 2.47 | NA | 0.06 | 3.32 | NA | 000 |
| 91052 | 26 | A | Gastric analysis test | 0.79 | 0.28 | 0.28 | 0.04 | 1.11 | 1.11 | 000 |
| 91052 | TC | A | Gastric analysis test | 0.00 | 2.19 | NA | 0.02 | 2.21 | NA | 000 |
| 91055 | | A | Gastric intubation for smear | 0.94 | 2.94 | NA | 0.07 | 3.95 | NA | 000 |
| 91055 | 26 | A | Gastric intubation for smear | 0.94 | 0.27 | 0.27 | 0.05 | 1.26 | 1.26 | 000 |
| 91055 | TC | A | Gastric intubation for smear | 0.00 | 2.67 | NA | 0.02 | 2.69 | NA | 000 |
| 91060 | | A | Gastric saline load test | 0.45 | 1.98 | NA | 0.04 | 2.47 | NA | 000 |
| 91060 | 26 | A | Gastric saline load test | 0.45 | 0.14 | 0.14 | 0.02 | 0.61 | 0.61 | 000 |
| 91060 | TC | A | Gastric saline load test | 0.00 | 1.84 | NA | 0.02 | 1.86 | NA | 000 |
| 91065 | | A | Breath hydrogen test | 0.20 | 1.47 | NA | 0.03 | 1.70 | NA | 000 |
| 91065 | 26 | A | Breath hydrogen test | 0.20 | 0.07 | 0.07 | 0.01 | 0.28 | 0.28 | 000 |
| 91065 | TC | A | Breath hydrogen test | 0.00 | 1.40 | NA | 0.02 | 1.42 | NA | 000 |
| 91100 | | A | Pass intestine bleeding tube | 1.08 | 2.85 | 0.28 | 0.07 | 4.00 | 1.43 | 000 |
| 91105 | | A | Gastric intubation treatment | 0.37 | 2.13 | 0.09 | 0.03 | 2.53 | 0.49 | 000 |
| 91110 | | A | Gi tract capsule endoscopy | 3.64 | 22.19 | NA | 0.09 | 25.92 | NA | XXX |
| 91110 | 26 | A | Gi tract capsule endoscopy | 3.64 | 1.27 | 1.27 | 0.02 | 4.93 | 4.93 | XXX |
| 91110 | TC | A | Gi tract capsule endoscopy | 0.00 | 20.92 | NA | 0.07 | 20.99 | NA | XXX |
| 91122 | | A | Anal pressure record | 1.77 | 5.10 | NA | 0.20 | 7.07 | NA | 000 |
| 91122 | 26 | A | Anal pressure record | 1.77 | 0.60 | 0.60 | 0.12 | 2.49 | 2.49 | 000 |
| 91122 | TC | A | Anal pressure record | 0.00 | 4.50 | NA | 0.08 | 4.58 | NA | 000 |
| 91132 | 26 | A | Electrogastrography | 0.52 | 0.18 | 0.18 | 0.03 | 0.73 | 0.73 | XXX |
| 91133 | 26 | A | Electrogastrography w/test | 0.66 | 0.23 | 0.23 | 0.03 | 0.92 | 0.92 | XXX |
| 92002 | | A | Eye exam, new patient | 0.88 | 0.97 | 0.34 | 0.02 | 1.87 | 1.24 | XXX |
| 92004 | | A | Eye exam, new patient | 1.67 | 1.70 | 0.67 | 0.05 | 3.42 | 2.39 | XXX |
| 92012 | | A | Eye exam established pat | 0.67 | 1.03 | 0.29 | 0.02 | 1.72 | 0.98 | XXX |
| 92014 | | A | Eye exam & treatment | 1.10 | 1.41 | 0.47 | 0.03 | 2.54 | 1.60 | XXX |
| 92018 | | A | New eye exam & treatment | 2.50 | NA | 1.07 | 0.07 | NA | 3.64 | XXX |
| 92019 | | A | Eye exam & treatment | 1.31 | NA | 0.56 | 0.04 | NA | 1.91 | XXX |
| 92020 | | A | Special eye evaluation | 0.37 | 0.34 | 0.16 | 0.01 | 0.72 | 0.54 | XXX |
| 92060 | | A | Special eye evaluation | 0.69 | 0.74 | NA | 0.03 | 1.46 | NA | XXX |
| 92060 | 26 | A | Special eye evaluation | 0.69 | 0.29 | 0.29 | 0.02 | 1.00 | 1.00 | XXX |
| 92060 | TC | A | Special eye evaluation | 0.00 | 0.45 | NA | 0.01 | 0.46 | NA | XXX |
| 92065 | | A | Orthoptic/pleoptic training | 0.37 | 0.55 | NA | 0.02 | 0.94 | NA | XXX |
| 92065 | 26 | A | Orthoptic/pleoptic training | 0.37 | 0.15 | 0.15 | 0.01 | 0.53 | 0.53 | XXX |
| 92065 | TC | A | Orthoptic/pleoptic training | 0.00 | 0.40 | NA | 0.01 | 0.41 | NA | XXX |
| 92070 | | A | Fitting of contact lens | 0.70 | 1.07 | 0.32 | 0.02 | 1.79 | 1.04 | XXX |
| 92081 | | A | Visual field examination(s) | 0.36 | 0.95 | NA | 0.02 | 1.33 | NA | XXX |
| 92081 | 26 | A | Visual field examination(s) | 0.36 | 0.15 | 0.15 | 0.01 | 0.52 | 0.52 | XXX |
| 92081 | TC | A | Visual field examination(s) | 0.00 | 0.79 | NA | 0.01 | 0.80 | NA | XXX |
| 92082 | | A | Visual field examination(s) | 0.44 | 1.23 | NA | 0.02 | 1.69 | NA | XXX |
| 92082 | 26 | A | Visual field examination(s) | 0.44 | 0.19 | 0.19 | 0.01 | 0.64 | 0.64 | XXX |
| 92082 | TC | A | Visual field examination(s) | 0.00 | 1.05 | NA | 0.01 | 1.06 | NA | XXX |
| 92083 | | A | Visual field examination(s) | 0.50 | 1.43 | NA | 0.02 | 1.95 | NA | XXX |
| 92083 | 26 | A | Visual field examination(s) | 0.50 | 0.22 | 0.22 | 0.01 | 0.73 | 0.73 | XXX |
| 92083 | TC | A | Visual field examination(s) | 0.00 | 1.21 | NA | 0.01 | 1.22 | NA | XXX |
| 92100 | | A | Serial tonometry exam(s) | 0.92 | 1.35 | 0.36 | 0.03 | 2.30 | 1.31 | XXX |
| 92120 | | A | Tonography & eye evaluation | 0.81 | 1.07 | 0.32 | 0.02 | 1.90 | 1.15 | XXX |
| 92130 | | A | Water provocation tonography | 0.81 | 1.28 | 0.37 | 0.02 | 2.11 | 1.20 | XXX |
| 92135 | | A | Opthalmic dx imaging | 0.35 | 0.80 | NA | 0.02 | 1.17 | NA | XXX |
| 92135 | 26 | A | Opthalmic dx imaging | 0.35 | 0.15 | 0.15 | 0.01 | 0.51 | 0.51 | XXX |
| 92135 | TC | A | Opthalmic dx imaging | 0.00 | 0.65 | NA | 0.01 | 0.66 | NA | XXX |
| 92136 | | A | Ophthalmic biometry | 0.54 | 1.54 | NA | 0.08 | 2.16 | NA | XXX |
| 92136 | 26 | A | Ophthalmic biometry | 0.54 | 0.24 | 0.24 | 0.01 | 0.79 | 0.79 | XXX |
| 92136 | TC | A | Ophthalmic biometry | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 92140 | | A | Glaucoma provocative tests | 0.50 | 0.99 | 0.21 | 0.01 | 1.50 | 0.72 | XXX |
| 92225 | | A | Special eye exam, initial | 0.38 | 0.22 | 0.16 | 0.01 | 0.61 | 0.55 | XXX |
| 92226 | | A | Special eye exam, subsequent | 0.33 | 0.21 | 0.14 | 0.01 | 0.55 | 0.48 | XXX |
| 92230 | | A | Eye exam with photos | 0.60 | 1.54 | 0.20 | 0.02 | 2.16 | 0.82 | XXX |
| 92235 | | A | Eye exam with photos | 0.81 | 2.61 | NA | 0.08 | 3.50 | NA | XXX |
| 92235 | 26 | A | Eye exam with photos | 0.81 | 0.37 | 0.37 | 0.02 | 1.20 | 1.20 | XXX |
| 92235 | TC | A | Eye exam with photos | 0.00 | 2.25 | NA | 0.06 | 2.31 | NA | XXX |
| 92240 | | A | Icg angiography | 1.10 | 6.13 | NA | 0.09 | 7.32 | NA | XXX |
| 92240 | 26 | A | Icg angiography | 1.10 | 0.50 | 0.50 | 0.03 | 1.63 | 1.63 | XXX |
| 92240 | TC | A | Icg angiography | 0.00 | 5.64 | NA | 0.06 | 5.70 | NA | XXX |
| 92250 | | A | Eye exam with photos | 0.44 | 1.53 | NA | 0.02 | 1.99 | NA | XXX |
| 92250 | 26 | A | Eye exam with photos | 0.44 | 0.19 | 0.19 | 0.01 | 0.64 | 0.64 | XXX |
| 92250 | TC | A | Eye exam with photos | 0.00 | 1.34 | NA | 0.01 | 1.35 | NA | XXX |
| 92260 | | A | Ophthalmoscopy/dynamometry | 0.20 | 0.26 | 0.09 | 0.01 | 0.47 | 0.30 | XXX |
| 92265 | | A | Eye muscle evaluation | 0.81 | 1.51 | NA | 0.06 | 2.38 | NA | XXX |
| 92265 | 26 | A | Eye muscle evaluation | 0.81 | 0.28 | 0.28 | 0.04 | 1.13 | 1.13 | XXX |
| 92265 | TC | A | Eye muscle evaluation | 0.00 | 1.23 | NA | 0.02 | 1.25 | NA | XXX |
| 92270 | | A | Electro-oculography | 0.81 | 1.54 | NA | 0.05 | 2.40 | NA | XXX |
| 92270 | 26 | A | Electro-oculography | 0.81 | 0.33 | 0.33 | 0.03 | 1.17 | 1.17 | XXX |
| 92270 | TC | A | Electro-oculography | 0.00 | 1.21 | NA | 0.02 | 1.23 | NA | XXX |
| 92275 | | A | Electroretinography | 1.01 | 1.94 | NA | 0.05 | 3.00 | NA | XXX |
| 92275 | 26 | A | Electroretinography | 1.01 | 0.43 | 0.43 | 0.03 | 1.47 | 1.47 | XXX |
| 92275 | TC | A | Electroretinography | 0.00 | 1.52 | NA | 0.02 | 1.54 | NA | XXX |
| 92283 | | A | Color vision examination | 0.17 | 0.84 | NA | 0.02 | 1.03 | NA | XXX |
| 92283 | 26 | A | Color vision examination | 0.17 | 0.07 | 0.07 | 0.01 | 0.25 | 0.25 | XXX |
| 92283 | TC | A | Color vision examination | 0.00 | 0.77 | NA | 0.01 | 0.78 | NA | XXX |
| 92284 | | A | Dark adaptation eye exam | 0.24 | 1.88 | NA | 0.02 | 2.14 | NA | XXX |
| 92284 | 26 | A | Dark adaptation eye exam | 0.24 | 0.08 | 0.08 | 0.01 | 0.33 | 0.33 | XXX |
| 92284 | TC | A | Dark adaptation eye exam | 0.00 | 1.80 | NA | 0.01 | 1.81 | NA | XXX |
| 92285 | | A | Eye photography | 0.20 | 0.99 | NA | 0.02 | 1.21 | NA | XXX |
| 92285 | 26 | A | Eye photography | 0.20 | 0.09 | 0.09 | 0.01 | 0.30 | 0.30 | XXX |
| 92285 | TC | A | Eye photography | 0.00 | 0.91 | NA | 0.01 | 0.92 | NA | XXX |
| 92286 | | A | Internal eye photography | 0.66 | 3.07 | NA | 0.04 | 3.77 | NA | XXX |
| 92286 | 26 | A | Internal eye photography | 0.66 | 0.29 | 0.29 | 0.02 | 0.97 | 0.97 | XXX |
| 92286 | TC | A | Internal eye photography | 0.00 | 2.78 | NA | 0.02 | 2.80 | NA | XXX |
| 92287 | | A | Internal eye photography | 0.81 | 2.39 | 0.31 | 0.02 | 3.22 | 1.14 | XXX |
| 92311 | | A | Contact lens fitting | 1.08 | 1.10 | 0.35 | 0.04 | 2.22 | 1.47 | XXX |
| 92312 | | A | Contact lens fitting | 1.26 | 1.08 | 0.49 | 0.04 | 2.38 | 1.79 | XXX |
| 92313 | | A | Contact lens fitting | 0.92 | 1.07 | 0.28 | 0.02 | 2.01 | 1.22 | XXX |
| 92315 | | A | Prescription of contact lens | 0.45 | 0.85 | 0.16 | 0.01 | 1.31 | 0.62 | XXX |
| 92316 | | A | Prescription of contact lens | 0.68 | 0.91 | 0.29 | 0.02 | 1.61 | 0.99 | XXX |
| 92317 | | A | Prescription of contact lens | 0.45 | 0.94 | 0.15 | 0.01 | 1.40 | 0.61 | XXX |
| 92325 | | A | Modification of contact lens | 0.00 | 0.40 | NA | 0.01 | 0.41 | NA | XXX |
| 92326 | | A | Replacement of contact lens | 0.00 | 1.63 | NA | 0.06 | 1.69 | NA | XXX |
| 92330 | | A | Fitting of artificial eye | 1.08 | 0.99 | 0.32 | 0.03 | 2.10 | 1.43 | XXX |
| 92335 | | A | Fitting of artificial eye | 0.45 | 0.91 | 0.16 | 0.02 | 1.38 | 0.63 | XXX |
| 92352 | | B | Special spectacles fitting | 0.37 | 0.68 | 0.14 | 0.01 | 1.06 | 0.52 | XXX |
| 92353 | | B | Special spectacles fitting | 0.50 | 0.73 | 0.19 | 0.02 | 1.25 | 0.71 | XXX |
| 92354 | | B | Special spectacles fitting | 0.00 | 8.84 | NA | 0.10 | 8.94 | NA | XXX |
| 92355 | | B | Special spectacles fitting | 0.00 | 4.32 | NA | 0.01 | 4.33 | NA | XXX |
| 92358 | | B | Eye prosthesis service | 0.00 | 0.97 | NA | 0.05 | 1.02 | NA | XXX |
| 92371 | | B | Repair & adjust spectacles | 0.00 | 0.62 | NA | 0.02 | 0.64 | NA | XXX |
| 92502 | | A | Ear and throat examination | 1.51 | NA | 1.11 | 0.05 | NA | 2.67 | 000 |
| 92504 | | A | Ear microscopy examination | 0.18 | 0.50 | 0.09 | 0.01 | 0.69 | 0.28 | XXX |
| 92506 | | A | Speech/hearing evaluation | 0.86 | 2.60 | 0.40 | 0.03 | 3.49 | 1.29 | XXX |
| 92507 | | A | Speech/hearing therapy | 0.52 | 1.12 | 0.23 | 0.02 | 1.66 | 0.77 | XXX |
| 92508 | | A | Speech/hearing therapy | 0.26 | 0.51 | 0.12 | 0.01 | 0.78 | 0.39 | XXX |
| 92511 | | A | Nasopharyngoscopy | 0.84 | 3.32 | 0.78 | 0.03 | 4.19 | 1.65 | 000 |
| 92512 | | A | Nasal function studies | 0.55 | 1.14 | 0.18 | 0.02 | 1.71 | 0.75 | XXX |
| 92516 | | A | Facial nerve function test | 0.43 | 1.17 | 0.22 | 0.02 | 1.62 | 0.67 | XXX |
| 92520 | | A | Laryngeal function studies | 0.76 | 0.51 | 0.39 | 0.03 | 1.30 | 1.18 | XXX |
| 92526 | | A | Oral function therapy | 0.55 | 1.64 | 0.20 | 0.02 | 2.21 | 0.77 | XXX |
| 92541 | | A | Spontaneous nystagmus test | 0.40 | 1.03 | NA | 0.04 | 1.47 | NA | XXX |
| 92541 | 26 | A | Spontaneous nystagmus test | 0.40 | 0.19 | 0.19 | 0.02 | 0.61 | 0.61 | XXX |
| 92541 | TC | A | Spontaneous nystagmus test | 0.00 | 0.84 | NA | 0.02 | 0.86 | NA | XXX |
| 92542 | | A | Positional nystagmus test | 0.33 | 1.14 | NA | 0.03 | 1.50 | NA | XXX |
| 92542 | 26 | A | Positional nystagmus test | 0.33 | 0.16 | 0.16 | 0.01 | 0.50 | 0.50 | XXX |
| 92542 | TC | A | Positional nystagmus test | 0.00 | 0.98 | NA | 0.02 | 1.00 | NA | XXX |
| 92543 | | A | Caloric vestibular test | 0.10 | 0.57 | NA | 0.01 | 0.68 | NA | XXX |
| 92543 | 26 | A | Caloric vestibular test | 0.10 | 0.05 | 0.05 | 0.00 | 0.15 | 0.15 | XXX |
| 92543 | TC | A | Caloric vestibular test | 0.00 | 0.52 | NA | 0.01 | 0.53 | NA | XXX |
| 92544 | | A | Optokinetic nystagmus test | 0.26 | 0.90 | NA | 0.03 | 1.19 | NA | XXX |
| 92544 | 26 | A | Optokinetic nystagmus test | 0.26 | 0.12 | 0.12 | 0.01 | 0.39 | 0.39 | XXX |
| 92544 | TC | A | Optokinetic nystagmus test | 0.00 | 0.78 | NA | 0.02 | 0.80 | NA | XXX |
| 92545 | | A | Oscillating tracking test | 0.23 | 0.80 | NA | 0.03 | 1.06 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 92545 | 26 | A | Oscillating tracking test | 0.23 | 0.11 | 0.11 | 0.01 | 0.35 | 0.35 | XXX |
| 92545 | TC | A | Oscillating tracking test | 0.00 | 0.69 | NA | 0.02 | 0.71 | NA | XXX |
| 92546 | | A | Sinusoidal rotational test | 0.29 | 1.99 | NA | 0.03 | 2.31 | NA | XXX |
| 92546 | 26 | A | Sinusoidal rotational test | 0.29 | 0.13 | 0.13 | 0.01 | 0.43 | 0.43 | XXX |
| 92546 | TC | A | Sinusoidal rotational test | 0.00 | 1.86 | NA | 0.02 | 1.88 | NA | XXX |
| 92547 | | A | Supplemental electrical test | 0.00 | 0.08 | NA | 0.06 | 0.14 | NA | ZZZ |
| 92548 | | A | Posturography | 0.50 | 2.26 | NA | 0.15 | 2.91 | NA | XXX |
| 92548 | 26 | A | Posturography | 0.50 | 0.26 | 0.26 | 0.02 | 0.78 | 0.78 | XXX |
| 92548 | TC | A | Posturography | 0.00 | 2.00 | NA | 0.13 | 2.13 | NA | XXX |
| 92552 | | A | Pure tone audiometry, air | 0.00 | 0.44 | NA | 0.04 | 0.48 | NA | XXX |
| 92553 | | A | Audiometry, air & bone | 0.00 | 0.66 | NA | 0.06 | 0.72 | NA | XXX |
| 92555 | | A | Speech threshold audiometry | 0.00 | 0.38 | NA | 0.04 | 0.42 | NA | XXX |
| 92556 | | A | Speech audiometry, complete | 0.00 | 0.57 | NA | 0.06 | 0.63 | NA | XXX |
| 92557 | | A | Comprehensive hearing test | 0.00 | 1.19 | NA | 0.12 | 1.31 | NA | XXX |
| 92561 | | A | Bekesy audiometry, diagnosis | 0.00 | 0.71 | NA | 0.06 | 0.77 | NA | XXX |
| 92562 | | A | Loudness balance test | 0.00 | 0.41 | NA | 0.04 | 0.45 | NA | XXX |
| 92563 | | A | Tone decay hearing test | 0.00 | 0.38 | NA | 0.04 | 0.42 | NA | XXX |
| 92564 | | A | Sisi hearing test | 0.00 | 0.47 | NA | 0.05 | 0.52 | NA | XXX |
| 92565 | | A | Stenger test, pure tone | 0.00 | 0.40 | NA | 0.04 | 0.44 | NA | XXX |
| 92567 | | A | Tympanometry | 0.00 | 0.52 | NA | 0.06 | 0.58 | NA | XXX |
| 92568 | | A | Acoustic reflex testing | 0.00 | 0.38 | NA | 0.04 | 0.42 | NA | XXX |
| 92569 | | A | Acoustic reflex decay test | 0.00 | 0.41 | NA | 0.04 | 0.45 | NA | XXX |
| 92571 | | A | Filtered speech hearing test | 0.00 | 0.39 | NA | 0.04 | 0.43 | NA | XXX |
| 92572 | | A | Staggered spondaic word test | 0.00 | 0.09 | NA | 0.01 | 0.10 | NA | XXX |
| 92573 | | A | Lombard test | 0.00 | 0.35 | NA | 0.04 | 0.39 | NA | XXX |
| 92575 | | A | Sensorineural acuity test | 0.00 | 0.30 | NA | 0.02 | 0.32 | NA | XXX |
| 92576 | | A | Synthetic sentence test | 0.00 | 0.44 | NA | 0.05 | 0.49 | NA | XXX |
| 92577 | | A | Stenger test, speech | 0.00 | 0.71 | NA | 0.07 | 0.78 | NA | XXX |
| 92579 | | A | Visual audiometry (vra) | 0.00 | 0.72 | NA | 0.06 | 0.78 | NA | XXX |
| 92582 | | A | Conditioning play audiometry | 0.00 | 0.72 | NA | 0.06 | 0.78 | NA | XXX |
| 92583 | | A | Select picture audiometry | 0.00 | 0.89 | NA | 0.08 | 0.97 | NA | XXX |
| 92584 | | A | Electrocochleography | 0.00 | 2.47 | NA | 0.21 | 2.68 | NA | XXX |
| 92585 | | A | Auditor evoke potent, compre | 0.50 | 2.06 | NA | 0.17 | 2.73 | NA | XXX |
| 92585 | 26 | A | Auditor evoke potent, compre | 0.50 | 0.21 | 0.21 | 0.03 | 0.74 | 0.74 | XXX |
| 92585 | TC | A | Auditor evoke potent, compre | 0.00 | 1.84 | NA | 0.14 | 1.98 | NA | XXX |
| 92586 | | A | Auditor evoke potent, limit | 0.00 | 1.84 | NA | 0.14 | 1.98 | NA | XXX |
| 92587 | | A | Evoked auditory test | 0.13 | 1.37 | NA | 0.11 | 1.61 | NA | XXX |
| 92587 | 26 | A | Evoked auditory test | 0.13 | 0.06 | 0.06 | 0.00 | 0.19 | 0.19 | XXX |
| 92587 | TC | A | Evoked auditory test | 0.00 | 1.30 | NA | 0.11 | 1.41 | NA | XXX |
| 92588 | | A | Evoked auditory test | 0.36 | 1.63 | NA | 0.14 | 2.13 | NA | XXX |
| 92588 | 26 | A | Evoked auditory test | 0.36 | 0.16 | 0.16 | 0.01 | 0.53 | 0.53 | XXX |
| 92588 | TC | A | Evoked auditory test | 0.00 | 1.47 | NA | 0.13 | 1.60 | NA | XXX |
| 92589 | | A | Auditory function test(s) | 0.00 | 0.53 | NA | 0.06 | 0.59 | NA | XXX |
| 92596 | | A | Ear protector evaluation | 0.00 | 0.59 | NA | 0.06 | 0.65 | NA | XXX |
| 92597 | | A | Oral speech device eval | 0.86 | 1.69 | 0.45 | 0.05 | 2.60 | 1.36 | XXX |
| 92601 | | A | Cochlear implt f/up exam < 7 | 0.00 | 3.51 | NA | 0.05 | 3.56 | NA | XXX |
| 92602 | | A | Reprogram cochlear implt < 7 | 0.00 | 2.38 | NA | 0.05 | 2.43 | NA | XXX |
| 92603 | | A | Cochlear implt f/up exam 7 > | 0.00 | 2.15 | NA | 0.05 | 2.20 | NA | XXX |
| 92604 | | A | Reprogram cochlear implt 7 > | 0.00 | 1.35 | NA | 0.05 | 1.40 | NA | XXX |
| 92607 | | A | Ex for speech device rx, 1hr | 0.00 | 3.08 | NA | 0.04 | 3.12 | NA | XXX |
| 92608 | | A | Ex for speech device rx addl | 0.00 | 0.56 | NA | 0.04 | 0.60 | NA | XXX |
| 92609 | | A | Use of speech device service | 0.00 | 1.65 | NA | 0.03 | 1.68 | NA | XXX |
| 92610 | | A | Evaluate swallowing function | 0.00 | 3.43 | NA | 0.06 | 3.49 | NA | XXX |
| 92611 | | A | Motion fluoroscopy/swallow | 0.00 | 3.43 | NA | 0.07 | 3.50 | NA | XXX |
| 92612 | | A | Endoscopy swallow tst (fees) | 1.27 | 2.75 | 0.66 | 0.08 | 4.10 | 2.01 | XXX |
| 92613 | | A | Endoscopy swallow tst (fees) | 0.71 | 0.40 | 0.39 | 0.05 | 1.16 | 1.15 | XXX |
| 92614 | | A | Laryngoscopic sensory test | 1.27 | 2.00 | 0.66 | 0.08 | 3.35 | 2.01 | XXX |
| 92615 | | A | Eval laryngoscopy sense tst | 0.63 | 0.35 | 0.35 | 0.05 | 1.03 | 1.03 | XXX |
| 92616 | | A | Fees w/laryngeal sense test | 1.88 | 2.67 | 0.99 | 0.08 | 4.63 | 2.95 | XXX |
| 92617 | | A | Interprt fees/laryngeal test | 0.79 | 0.44 | 0.44 | 0.05 | 1.28 | 1.28 | XXX |
| 92950 | | A | Heart/lung resuscitation cpr | 3.79 | 4.25 | 0.97 | 0.26 | 8.30 | 5.02 | 000 |
| 92953 | | A | Temporary external pacing | 0.23 | NA | 0.07 | 0.01 | NA | 0.31 | 000 |
| 92960 | | A | Cardioversion electric, ext | 2.25 | 6.45 | 1.17 | 0.08 | 8.78 | 3.50 | 000 |
| 92961 | | A | Cardioversion, electric, int | 4.59 | NA | 2.07 | 0.27 | NA | 6.93 | 000 |
| 92970 | | A | Cardioassist, internal | 3.51 | NA | 1.05 | 0.19 | NA | 4.75 | 000 |
| 92971 | | A | Cardioassist, external | 1.77 | NA | 0.85 | 0.06 | NA | 2.68 | 000 |
| 92973 | | A | Percut coronary thrombectomy | 3.28 | NA | 1.29 | 0.11 | NA | 4.68 | ZZZ |
| 92974 | | A | Cath place, cardio brachytx | 3.00 | NA | 1.18 | 0.10 | NA | 4.28 | ZZZ |
| 92975 | | A | Dissolve clot, heart vessel | 7.24 | NA | 2.80 | 0.23 | NA | 10.27 | 000 |
| 92977 | | A | Dissolve clot, heart vessel | 0.00 | 8.04 | NA | 0.46 | 8.50 | NA | XXX |
| 92978 | | A | Intravasc us, heart add-on | 1.80 | 5.26 | NA | 0.30 | 7.36 | NA | ZZZ |
| 92978 | 26 | A | Intravasc us, heart add-on | 1.80 | 0.71 | 0.71 | 0.06 | 2.57 | 2.57 | ZZZ |
| 92978 | TC | A | Intravasc us, heart add-on | 0.00 | 4.56 | NA | 0.24 | 4.80 | NA | ZZZ |
| 92979 | | A | Intravasc us, heart add-on | 1.44 | 2.85 | NA | 0.20 | 4.49 | NA | ZZZ |
| 92979 | 26 | A | Intravasc us, heart add-on | 1.44 | 0.56 | 0.56 | 0.07 | 2.07 | 2.07 | ZZZ |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 92979 | TC | A | Intravasc us, heart add-on | 0.00 | 2.29 | NA | 0.13 | 2.42 | NA | ZZZ |
| 92980 | | A | Insert intracoronary stent | 14.82 | NA | 6.03 | 1.04 | NA | 21.89 | 000 |
| 92981 | | A | Insert intracoronary stent | 4.16 | NA | 1.63 | 0.29 | NA | 6.08 | ZZZ |
| 92982 | | A | Coronary artery dilation | 10.96 | NA | 4.52 | 0.77 | NA | 16.25 | 000 |
| 92984 | | A | Coronary artery dilation | 2.97 | NA | 1.16 | 0.21 | NA | 4.34 | ZZZ |
| 92986 | | A | Revision of aortic valve | 21.77 | NA | 11.85 | 1.52 | NA | 35.14 | 090 |
| 92987 | | A | Revision of mitral valve | 22.67 | NA | 12.23 | 1.58 | NA | 36.48 | 090 |
| 92990 | | A | Revision of pulmonary valve | 17.31 | NA | 9.83 | 1.21 | NA | 28.35 | 090 |
| 92995 | | A | Coronary atherectomy | 12.07 | NA | 4.95 | 0.84 | NA | 17.86 | 000 |
| 92996 | | A | Coronary atherectomy add-on | 3.26 | NA | 1.27 | 0.23 | NA | 4.76 | ZZZ |
| 92997 | | A | Pul art balloon repr, percut | 11.98 | NA | 4.81 | 0.84 | NA | 17.63 | 000 |
| 92998 | | A | Pul art balloon repr, percut | 5.99 | NA | 2.20 | 0.42 | NA | 8.61 | ZZZ |
| 93000 | | A | Electrocardiogram, complete | 0.17 | 0.51 | NA | 0.03 | 0.71 | NA | XXX |
| 93005 | | A | Electrocardiogram, tracing | 0.00 | 0.45 | NA | 0.02 | 0.47 | NA | XXX |
| 93010 | | A | Electrocardiogram report | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| 93012 | | A | Transmission of ecg | 0.00 | 6.00 | NA | 0.18 | 6.18 | NA | XXX |
| 93014 | | A | Report on transmitted ecg | 0.52 | 0.19 | 0.19 | 0.02 | 0.73 | 0.73 | XXX |
| 93015 | | A | Cardiovascular stress test | 0.75 | 1.96 | NA | 0.14 | 2.85 | NA | XXX |
| 93016 | | A | Cardiovascular stress test | 0.45 | 0.17 | 0.17 | 0.02 | 0.64 | 0.64 | XXX |
| 93017 | | A | Cardiovascular stress test | 0.00 | 1.68 | NA | 0.11 | 1.79 | NA | XXX |
| 93018 | | A | Cardiovascular stress test | 0.30 | 0.11 | 0.11 | 0.01 | 0.42 | 0.42 | XXX |
| 93024 | | A | Cardiac drug stress test | 1.17 | 1.57 | NA | 0.13 | 2.87 | NA | XXX |
| 93024 | 26 | A | Cardiac drug stress test | 1.17 | 0.45 | 0.45 | 0.05 | 1.67 | 1.67 | XXX |
| 93024 | TC | A | Cardiac drug stress test | 0.00 | 1.12 | NA | 0.08 | 1.20 | NA | XXX |
| 93025 | | A | Microvolt t-wave assess | 0.75 | 7.84 | NA | 0.14 | 8.73 | NA | XXX |
| 93025 | 26 | A | Microvolt t-wave assess | 0.75 | 0.29 | 0.29 | 0.03 | 1.07 | 1.07 | XXX |
| 93025 | TC | A | Microvolt t-wave assess | 0.00 | 7.55 | NA | 0.11 | 7.66 | NA | XXX |
| 93040 | | A | Rhythm ECG with report | 0.16 | 0.19 | NA | 0.02 | 0.37 | NA | XXX |
| 93041 | | A | Rhythm ECG, tracing | 0.00 | 0.14 | NA | 0.01 | 0.15 | NA | XXX |
| 93042 | | A | Rhythm ECG, report | 0.16 | 0.05 | 0.05 | 0.01 | 0.22 | 0.22 | XXX |
| 93224 | | A | ECG monitor/report, 24 hrs | 0.52 | 3.61 | NA | 0.24 | 4.37 | NA | XXX |
| 93225 | | A | ECG monitor/record, 24 hrs | 0.00 | 1.24 | NA | 0.08 | 1.32 | NA | XXX |
| 93226 | | A | ECG monitor/report, 24 hrs | 0.00 | 2.18 | NA | 0.14 | 2.32 | NA | XXX |
| 93227 | | A | ECG monitor/review, 24 hrs | 0.52 | 0.19 | 0.19 | 0.02 | 0.73 | 0.73 | XXX |
| 93230 | | A | ECG monitor/report, 24 hrs | 0.52 | 3.88 | NA | 0.26 | 4.66 | NA | XXX |
| 93231 | | A | Ecg monitor/record, 24 hrs | 0.00 | 1.52 | NA | 0.11 | 1.63 | NA | XXX |
| 93232 | | A | ECG monitor/report, 24 hrs | 0.00 | 2.17 | NA | 0.13 | 2.30 | NA | XXX |
| 93233 | | A | ECG monitor/review, 24 hrs | 0.52 | 0.19 | 0.19 | 0.02 | 0.73 | 0.73 | XXX |
| 93235 | | A | ECG monitor/report, 24 hrs | 0.45 | 2.78 | NA | 0.16 | 3.39 | NA | XXX |
| 93236 | | A | ECG monitor/report, 24 hrs | 0.00 | 2.62 | NA | 0.14 | 2.76 | NA | XXX |
| 93237 | | A | ECG monitor/review, 24 hrs | 0.45 | 0.16 | 0.16 | 0.02 | 0.63 | 0.63 | XXX |
| 93268 | | A | ECG record/review | 0.52 | 7.43 | NA | 0.28 | 8.23 | NA | XXX |
| 93270 | | A | ECG recording | 0.00 | 1.24 | NA | 0.08 | 1.32 | NA | XXX |
| 93271 | | A | Ecg/monitoring and analysis | 0.00 | 6.00 | NA | 0.18 | 6.18 | NA | XXX |
| 93272 | | A | Ecg/review, interpret only | 0.52 | 0.19 | 0.19 | 0.02 | 0.73 | 0.73 | XXX |
| 93278 | | A | ECG/signal-averaged | 0.25 | 1.24 | NA | 0.12 | 1.61 | NA | XXX |
| 93278 | 26 | A | ECG/signal-averaged | 0.25 | 0.10 | 0.10 | 0.01 | 0.36 | 0.36 | XXX |
| 93278 | TC | A | ECG/signal-averaged | 0.00 | 1.15 | NA | 0.11 | 1.26 | NA | XXX |
| 93303 | | A | Echo transthoracic | 1.30 | 4.33 | NA | 0.28 | 5.91 | NA | XXX |
| 93303 | 26 | A | Echo transthoracic | 1.30 | 0.48 | 0.48 | 0.05 | 1.83 | 1.83 | XXX |
| 93303 | TC | A | Echo transthoracic | 0.00 | 3.85 | NA | 0.23 | 4.08 | NA | XXX |
| 93304 | | A | Echo transthoracic | 0.75 | 2.22 | NA | 0.16 | 3.13 | NA | XXX |
| 93304 | 26 | A | Echo transthoracic | 0.75 | 0.28 | 0.28 | 0.03 | 1.06 | 1.06 | XXX |
| 93304 | TC | A | Echo transthoracic | 0.00 | 1.94 | NA | 0.13 | 2.07 | NA | XXX |
| 93307 | | A | Echo exam of heart | 0.92 | 4.20 | NA | 0.26 | 5.38 | NA | XXX |
| 93307 | 26 | A | Echo exam of heart | 0.92 | 0.35 | 0.35 | 0.03 | 1.30 | 1.30 | XXX |
| 93307 | TC | A | Echo exam of heart | 0.00 | 3.85 | NA | 0.23 | 4.08 | NA | XXX |
| 93308 | | A | Echo exam of heart | 0.53 | 2.14 | NA | 0.15 | 2.82 | NA | XXX |
| 93308 | 26 | A | Echo exam of heart | 0.53 | 0.20 | 0.20 | 0.02 | 0.75 | 0.75 | XXX |
| 93308 | TC | A | Echo exam of heart | 0.00 | 1.94 | NA | 0.13 | 2.07 | NA | XXX |
| 93312 | | A | Echo transesophageal | 2.20 | 4.56 | NA | 0.37 | 7.13 | NA | XXX |
| 93312 | 26 | A | Echo transesophageal | 2.20 | 0.79 | 0.79 | 0.08 | 3.07 | 3.07 | XXX |
| 93312 | TC | A | Echo transesophageal | 0.00 | 3.77 | NA | 0.29 | 4.06 | NA | XXX |
| 93313 | | A | Echo transesophageal | 0.95 | NA | 0.21 | 0.06 | NA | 1.22 | XXX |
| 93314 | | A | Echo transesophageal | 1.25 | 4.24 | NA | 0.34 | 5.83 | NA | XXX |
| 93314 | 26 | A | Echo transesophageal | 1.25 | 0.47 | 0.47 | 0.05 | 1.77 | 1.77 | XXX |
| 93314 | TC | A | Echo transesophageal | 0.00 | 3.77 | NA | 0.29 | 4.06 | NA | XXX |
| 93315 | 26 | A | Echo transesophageal | 2.78 | 1.01 | 1.01 | 0.13 | 3.92 | 3.92 | XXX |
| 93316 | | A | Echo transesophageal | 0.95 | NA | 0.23 | 0.05 | NA | 1.23 | XXX |
| 93317 | 26 | A | Echo transesophageal | 1.83 | 0.66 | 0.66 | 0.09 | 2.58 | 2.58 | XXX |
| 93318 | 26 | A | Echo transesophageal intraop | 2.20 | 0.48 | 0.48 | 0.13 | 2.81 | 2.81 | XXX |
| 93320 | | A | Doppler echo exam, heart | 0.38 | 1.85 | NA | 0.13 | 2.36 | NA | ZZZ |
| 93320 | 26 | A | Doppler echo exam, heart | 0.38 | 0.15 | 0.15 | 0.01 | 0.54 | 0.54 | ZZZ |
| 93320 | TC | A | Doppler echo exam, heart | 0.00 | 1.71 | NA | 0.12 | 1.83 | NA | ZZZ |
| 93321 | | A | Doppler echo exam, heart | 0.15 | 1.17 | NA | 0.09 | 1.41 | NA | ZZZ |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 93321 | 26 | A | Doppler echo exam, heart | 0.15 | 0.06 | 0.06 | 0.01 | 0.22 | 0.22 | ZZZ |
| 93321 | TC | A | Doppler echo exam, heart | 0.00 | 1.11 | NA | 0.08 | 1.19 | NA | ZZZ |
| 93325 | | A | Doppler color flow add-on | 0.07 | 2.92 | NA | 0.21 | 3.20 | NA | ZZZ |
| 93325 | 26 | A | Doppler color flow add-on | 0.07 | 0.03 | 0.03 | 0.00 | 0.10 | 0.10 | ZZZ |
| 93325 | TC | A | Doppler color flow add-on | 0.00 | 2.90 | NA | 0.21 | 3.11 | NA | ZZZ |
| 93350 | | A | Echo transthoracic | 1.48 | 2.32 | NA | 0.18 | 3.98 | NA | XXX |
| 93350 | 26 | A | Echo transthoracic | 1.48 | 0.57 | 0.57 | 0.05 | 2.10 | 2.10 | XXX |
| 93350 | TC | A | Echo transthoracic | 0.00 | 1.76 | NA | 0.13 | 1.89 | NA | XXX |
| 93501 | | A | Right heart catheterization | 3.02 | 18.02 | NA | 1.26 | 22.30 | NA | 000 |
| 93501 | 26 | A | Right heart catheterization | 3.02 | 1.15 | 1.15 | 0.21 | 4.38 | 4.38 | 000 |
| 93501 | TC | A | Right heart catheterization | 0.00 | 16.87 | NA | 1.05 | 17.92 | NA | 000 |
| 93503 | | A | Insert/place heart catheter | 2.91 | NA | 0.68 | 0.20 | NA | 3.79 | 000 |
| 93505 | | A | Biopsy of heart lining | 4.37 | 3.66 | NA | 0.48 | 8.51 | NA | 000 |
| 93505 | 26 | A | Biopsy of heart lining | 4.37 | 1.68 | 1.68 | 0.32 | 6.37 | 6.37 | 000 |
| 93505 | TC | A | Biopsy of heart lining | 0.00 | 1.98 | NA | 0.16 | 2.14 | NA | 000 |
| 93508 | | A | Cath placement, angiography | 4.09 | 14.65 | NA | 0.94 | 19.68 | NA | 000 |
| 93508 | 26 | A | Cath placement, angiography | 4.09 | 2.07 | 2.07 | 0.29 | 6.45 | 6.45 | 000 |
| 93508 | TC | A | Cath placement, angiography | 0.00 | 12.58 | NA | 0.65 | 13.23 | NA | 000 |
| 93510 | | A | Left heart catheterization | 4.32 | 39.06 | NA | 2.60 | 45.98 | NA | 000 |
| 93510 | 26 | A | Left heart catheterization | 4.32 | 2.17 | 2.17 | 0.30 | 6.79 | 6.79 | 000 |
| 93510 | TC | A | Left heart catheterization | 0.00 | 36.89 | NA | 2.30 | 39.19 | NA | 000 |
| 93511 | | A | Left heart catheterization | 5.02 | 38.35 | NA | 2.58 | 45.95 | NA | 000 |
| 93511 | 26 | A | Left heart catheterization | 5.02 | 2.44 | 2.44 | 0.35 | 7.81 | 7.81 | 000 |
| 93511 | TC | A | Left heart catheterization | 0.00 | 35.91 | NA | 2.23 | 38.14 | NA | 000 |
| 93514 | | A | Left heart catheterization | 7.04 | 39.03 | NA | 2.72 | 48.79 | NA | 000 |
| 93514 | 26 | A | Left heart catheterization | 7.04 | 3.12 | 3.12 | 0.49 | 10.65 | 10.65 | 000 |
| 93514 | TC | A | Left heart catheterization | 0.00 | 35.91 | NA | 2.23 | 38.14 | NA | 000 |
| 93524 | | A | Left heart catheterization | 6.94 | 50.10 | NA | 3.42 | 60.46 | NA | 000 |
| 93524 | 26 | A | Left heart catheterization | 6.94 | 3.17 | 3.17 | 0.49 | 10.60 | 10.60 | 000 |
| 93524 | TC | A | Left heart catheterization | 0.00 | 46.93 | NA | 2.93 | 49.86 | NA | 000 |
| 93526 | | A | Rt & Lt heart catheters | 5.98 | 51.02 | NA | 3.44 | 60.44 | NA | 000 |
| 93526 | 26 | A | Rt & Lt heart catheters | 5.98 | 2.81 | 2.81 | 0.42 | 9.21 | 9.21 | 000 |
| 93526 | TC | A | Rt & Lt heart catheters | 0.00 | 48.21 | NA | 3.02 | 51.23 | NA | 000 |
| 93527 | | A | Rt & Lt heart catheters | 7.27 | 50.24 | NA | 3.44 | 60.95 | NA | 000 |
| 93527 | 26 | A | Rt & Lt heart catheters | 7.27 | 3.31 | 3.31 | 0.51 | 11.09 | 11.09 | 000 |
| 93527 | TC | A | Rt & Lt heart catheters | 0.00 | 46.93 | NA | 2.93 | 49.86 | NA | 000 |
| 93528 | | A | Rt & Lt heart catheters | 8.99 | 50.95 | NA | 3.56 | 63.50 | NA | 000 |
| 93528 | 26 | A | Rt & Lt heart catheters | 8.99 | 4.02 | 4.02 | 0.63 | 13.64 | 13.64 | 000 |
| 93528 | TC | A | Rt & Lt heart catheters | 0.00 | 46.93 | NA | 2.93 | 49.86 | NA | 000 |
| 93529 | | A | Rt, lt heart catheterization | 4.79 | 49.20 | NA | 3.26 | 57.25 | NA | 000 |
| 93529 | 26 | A | Rt, lt heart catheterization | 4.79 | 2.27 | 2.27 | 0.33 | 7.39 | 7.39 | 000 |
| 93529 | TC | A | Rt, lt heart catheterization | 0.00 | 46.93 | NA | 2.93 | 49.86 | NA | 000 |
| 93530 | | A | Rt heart cath, congenital | 4.22 | 18.80 | NA | 1.35 | 24.37 | NA | 000 |
| 93530 | 26 | A | Rt heart cath, congenital | 4.22 | 1.93 | 1.93 | 0.30 | 6.45 | 6.45 | 000 |
| 93530 | TC | A | Rt heart cath, congenital | 0.00 | 16.87 | NA | 1.05 | 17.92 | NA | 000 |
| 93531 | | A | R & l heart cath, congenital | 8.34 | 51.79 | NA | 3.60 | 63.73 | NA | 000 |
| 93531 | 26 | A | R & l heart cath, congenital | 8.34 | 3.58 | 3.58 | 0.58 | 12.50 | 12.50 | 000 |
| 93531 | TC | A | R & l heart cath, congenital | 0.00 | 48.21 | NA | 3.02 | 51.23 | NA | 000 |
| 93532 | | A | R & l heart cath, congenital | 9.99 | 51.17 | NA | 3.63 | 64.79 | NA | 000 |
| 93532 | 26 | A | R & l heart cath, congenital | 9.99 | 4.25 | 4.25 | 0.70 | 14.94 | 14.94 | 000 |
| 93532 | TC | A | R & l heart cath, congenital | 0.00 | 46.93 | NA | 2.93 | 49.86 | NA | 000 |
| 93533 | | A | R & l heart cath, congenital | 6.69 | 49.72 | NA | 3.40 | 59.81 | NA | 000 |
| 93533 | 26 | A | R & l heart cath, congenital | 6.69 | 2.80 | 2.80 | 0.47 | 9.96 | 9.96 | 000 |
| 93533 | TC | A | R & l heart cath, congenital | 0.00 | 46.93 | NA | 2.93 | 49.86 | NA | 000 |
| 93539 | | A | Injection, cardiac cath | 0.40 | NA | 0.16 | 0.01 | NA | 0.57 | 000 |
| 93540 | | A | Injection, cardiac cath | 0.43 | NA | 0.17 | 0.01 | NA | 0.61 | 000 |
| 93541 | | A | Injection for lung angiogram | 0.29 | NA | 0.11 | 0.01 | NA | 0.41 | 000 |
| 93542 | | A | Injection for heart x-rays | 0.29 | NA | 0.11 | 0.01 | NA | 0.41 | 000 |
| 93543 | | A | Injection for heart x-rays | 0.29 | NA | 0.11 | 0.01 | NA | 0.41 | 000 |
| 93544 | | A | Injection for aortography | 0.25 | NA | 0.10 | 0.01 | NA | 0.36 | 000 |
| 93545 | | A | Inject for coronary x-rays | 0.40 | NA | 0.16 | 0.01 | NA | 0.57 | 000 |
| 93555 | | A | Imaging, cardiac cath | 0.81 | 6.58 | NA | 0.37 | 7.76 | NA | XXX |
| 93555 | 26 | A | Imaging, cardiac cath | 0.81 | 0.32 | 0.32 | 0.03 | 1.16 | 1.16 | XXX |
| 93555 | TC | A | Imaging, cardiac cath | 0.00 | 6.26 | NA | 0.34 | 6.60 | NA | XXX |
| 93556 | | A | Imaging, cardiac cath | 0.83 | 10.20 | NA | 0.54 | 11.57 | NA | XXX |
| 93556 | 26 | A | Imaging, cardiac cath | 0.83 | 0.32 | 0.32 | 0.03 | 1.18 | 1.18 | XXX |
| 93556 | TC | A | Imaging, cardiac cath | 0.00 | 9.87 | NA | 0.51 | 10.38 | NA | XXX |
| 93561 | | A | Cardiac output measurement | 0.50 | 0.68 | NA | 0.09 | 1.27 | NA | 000 |
| 93561 | 26 | A | Cardiac output measurement | 0.50 | 0.16 | 0.16 | 0.03 | 0.69 | 0.69 | 000 |
| 93561 | TC | A | Cardiac output measurement | 0.00 | 0.52 | NA | 0.06 | 0.58 | NA | 000 |
| 93562 | | A | Cardiac output measurement | 0.16 | 0.37 | NA | 0.05 | 0.58 | NA | 000 |
| 93562 | 26 | A | Cardiac output measurement | 0.16 | 0.05 | 0.05 | 0.01 | 0.22 | 0.22 | 000 |
| 93562 | TC | A | Cardiac output measurement | 0.00 | 0.32 | NA | 0.04 | 0.36 | NA | 000 |
| 93571 | | A | Heart flow reserve measure | 1.80 | 5.24 | NA | 0.30 | 7.34 | NA | ZZZ |
| 93571 | 26 | A | Heart flow reserve measure | 1.80 | 0.68 | 0.68 | 0.06 | 2.54 | 2.54 | ZZZ |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 93571 | TC | A | Heart flow reserve measure | 0.00 | 4.56 | NA | 0.24 | 4.80 | NA | ZZZ |
| 93572 | | A | Heart flow reserve measure | 1.44 | 2.79 | NA | 0.18 | 4.41 | NA | ZZZ |
| 93572 | 26 | A | Heart flow reserve measure | 1.44 | 0.50 | 0.50 | 0.05 | 1.99 | 1.99 | ZZZ |
| 93572 | TC | A | Heart flow reserve measure | 0.00 | 2.29 | NA | 0.13 | 2.42 | NA | ZZZ |
| 93580 | | A | Transcath closure of asd | 17.97 | NA | 7.37 | 1.37 | NA | 26.71 | 000 |
| 93581 | | A | Transcath closure of vsd | 24.39 | NA | 9.38 | 1.37 | NA | 35.14 | 000 |
| 93600 | | A | Bundle of His recording | 2.12 | 2.78 | NA | 0.29 | 5.19 | NA | 000 |
| 93600 | 26 | A | Bundle of His recording | 2.12 | 0.83 | 0.83 | 0.16 | 3.11 | 3.11 | 000 |
| 93600 | TC | A | Bundle of His recording | 0.00 | 1.95 | NA | 0.13 | 2.08 | NA | 000 |
| 93602 | | A | Intra-atrial recording | 2.12 | 1.93 | NA | 0.24 | 4.29 | NA | 000 |
| 93602 | 26 | A | Intra-atrial recording | 2.12 | 0.82 | 0.82 | 0.17 | 3.11 | 3.11 | 000 |
| 93602 | TC | A | Intra-atrial recording | 0.00 | 1.11 | NA | 0.07 | 1.18 | NA | 000 |
| 93603 | | A | Right ventricular recording | 2.12 | 2.49 | NA | 0.29 | 4.90 | NA | 000 |
| 93603 | 26 | A | Right ventricular recording | 2.12 | 0.81 | 0.81 | 0.18 | 3.11 | 3.11 | 000 |
| 93603 | TC | A | Right ventricular recording | 0.00 | 1.68 | NA | 0.11 | 1.79 | NA | 000 |
| 93609 | | A | Map tachycardia, add-on | 4.99 | 4.65 | NA | 0.50 | 10.14 | NA | ZZZ |
| 93609 | 26 | A | Map tachycardia, add-on | 4.99 | 1.94 | 1.94 | 0.33 | 7.26 | 7.26 | ZZZ |
| 93609 | TC | A | Map tachycardia, add-on | 0.00 | 2.71 | NA | 0.17 | 2.88 | NA | ZZZ |
| 93610 | | A | Intra-atrial pacing | 3.02 | 2.51 | NA | 0.35 | 5.88 | NA | 000 |
| 93610 | 26 | A | Intra-atrial pacing | 3.02 | 1.16 | 1.16 | 0.25 | 4.43 | 4.43 | 000 |
| 93610 | TC | A | Intra-atrial pacing | 0.00 | 1.35 | NA | 0.10 | 1.45 | NA | 000 |
| 93612 | | A | Intraventricular pacing | 3.02 | 2.77 | NA | 0.36 | 6.15 | NA | 000 |
| 93612 | 26 | A | Intraventricular pacing | 3.02 | 1.16 | 1.16 | 0.25 | 4.43 | 4.43 | 000 |
| 93612 | TC | A | Intraventricular pacing | 0.00 | 1.61 | NA | 0.11 | 1.72 | NA | 000 |
| 93613 | | A | Electrophys map 3d, add-on | 6.99 | NA | 2.75 | 0.63 | NA | 10.37 | ZZZ |
| 93615 | | A | Esophageal recording | 0.99 | 0.58 | NA | 0.05 | 1.62 | NA | 000 |
| 93615 | 26 | A | Esophageal recording | 0.99 | 0.27 | 0.27 | 0.03 | 1.29 | 1.29 | 000 |
| 93615 | TC | A | Esophageal recording | 0.00 | 0.32 | NA | 0.02 | 0.34 | NA | 000 |
| 93616 | | A | Esophageal recording | 1.49 | 0.74 | NA | 0.10 | 2.33 | NA | 000 |
| 93616 | 26 | A | Esophageal recording | 1.49 | 0.43 | 0.43 | 0.08 | 2.00 | 2.00 | 000 |
| 93616 | TC | A | Esophageal recording | 0.00 | 0.32 | NA | 0.02 | 0.34 | NA | 000 |
| 93618 | | A | Heart rhythm pacing | 4.25 | 5.62 | NA | 0.54 | 10.41 | NA | 000 |
| 93618 | 26 | A | Heart rhythm pacing | 4.25 | 1.66 | 1.66 | 0.30 | 6.21 | 6.21 | 000 |
| 93618 | TC | A | Heart rhythm pacing | 0.00 | 3.96 | NA | 0.24 | 4.20 | NA | 000 |
| 93619 | | A | Electrophysiology evaluation | 7.31 | 10.87 | NA | 0.98 | 19.16 | NA | 000 |
| 93619 | 26 | A | Electrophysiology evaluation | 7.31 | 3.18 | 3.18 | 0.51 | 11.00 | 11.00 | 000 |
| 93619 | TC | A | Electrophysiology evaluation | 0.00 | 7.69 | NA | 0.47 | 8.16 | NA | 000 |
| 93620 | 26 | A | Electrophysiology evaluation | 11.57 | 4.83 | 4.83 | 0.81 | 17.21 | 17.21 | 000 |
| 93621 | 26 | A | Electrophysiology evaluation | 2.10 | 0.82 | 0.82 | 0.15 | 3.07 | 3.07 | ZZZ |
| 93622 | 26 | A | Electrophysiology evaluation | 3.10 | 1.20 | 1.20 | 0.22 | 4.52 | 4.52 | ZZZ |
| 93623 | 26 | A | Stimulation, pacing heart | 2.85 | 1.11 | 1.11 | 0.20 | 4.16 | 4.16 | ZZZ |
| 93624 | | A | Electrophysiologic study | 4.80 | 4.17 | NA | 0.47 | 9.44 | NA | 000 |
| 93624 | 26 | A | Electrophysiologic study | 4.80 | 2.19 | 2.19 | 0.34 | 7.33 | 7.33 | 000 |
| 93624 | TC | A | Electrophysiologic study | 0.00 | 1.98 | NA | 0.13 | 2.11 | NA | 000 |
| 93631 | | A | Heart pacing, mapping | 7.59 | 8.90 | NA | 1.47 | 17.96 | NA | 000 |
| 93631 | 26 | A | Heart pacing, mapping | 7.59 | 2.76 | 2.76 | 0.85 | 11.20 | 11.20 | 000 |
| 93631 | TC | A | Heart pacing, mapping | 0.00 | 6.14 | NA | 0.62 | 6.76 | NA | 000 |
| 93640 | | A | Evaluation heart device | 3.51 | 8.52 | NA | 0.67 | 12.70 | NA | 000 |
| 93640 | 26 | A | Evaluation heart device | 3.51 | 1.36 | 1.36 | 0.25 | 5.12 | 5.12 | 000 |
| 93640 | TC | A | Evaluation heart device | 0.00 | 7.16 | NA | 0.42 | 7.58 | NA | 000 |
| 93641 | | A | Electrophysiology evaluation | 5.92 | 9.46 | NA | 0.84 | 16.22 | NA | 000 |
| 93641 | 26 | A | Electrophysiology evaluation | 5.92 | 2.30 | 2.30 | 0.42 | 8.64 | 8.64 | 000 |
| 93641 | TC | A | Electrophysiology evaluation | 0.00 | 7.16 | NA | 0.42 | 7.58 | NA | 000 |
| 93642 | | A | Electrophysiology evaluation | 4.88 | 9.37 | NA | 0.58 | 14.83 | NA | 000 |
| 93642 | 26 | A | Electrophysiology evaluation | 4.88 | 2.21 | 2.21 | 0.16 | 7.25 | 7.25 | 000 |
| 93642 | TC | A | Electrophysiology evaluation | 0.00 | 7.16 | NA | 0.42 | 7.58 | NA | 000 |
| 93650 | | A | Ablate heart dysrhythm focus | 10.49 | NA | 4.42 | 0.74 | NA | 15.65 | 000 |
| 93651 | | A | Ablate heart dysrhythm focus | 16.23 | NA | 6.31 | 1.13 | NA | 23.67 | 000 |
| 93652 | | A | Ablate heart dysrhythm focus | 17.65 | NA | 6.86 | 1.23 | NA | 25.74 | 000 |
| 93660 | | A | Tilt table evaluation | 1.89 | 2.42 | NA | 0.08 | 4.39 | NA | 000 |
| 93660 | 26 | A | Tilt table evaluation | 1.89 | 0.74 | 0.74 | 0.06 | 2.69 | 2.69 | 000 |
| 93660 | TC | A | Tilt table evaluation | 0.00 | 1.68 | NA | 0.02 | 1.70 | NA | 000 |
| 93662 | 26 | A | Intracardiac ecg (ice) | 2.80 | 1.10 | 1.10 | 0.09 | 3.99 | 3.99 | ZZZ |
| 93701 | | A | Bioimpedance, thoracic | 0.17 | 1.00 | NA | 0.02 | 1.19 | NA | XXX |
| 93701 | 26 | A | Bioimpedance, thoracic | 0.17 | 0.07 | 0.07 | 0.01 | 0.25 | 0.25 | XXX |
| 93701 | TC | A | Bioimpedance, thoracic | 0.00 | 0.94 | NA | 0.01 | 0.95 | NA | XXX |
| 93720 | | A | Total body plethysmography | 0.17 | 1.16 | NA | 0.07 | 1.40 | NA | XXX |
| 93721 | | A | Plethysmography tracing | 0.00 | 0.70 | NA | 0.06 | 0.76 | NA | XXX |
| 93722 | | A | Plethysmography report | 0.17 | 0.05 | 0.05 | 0.01 | 0.23 | 0.23 | XXX |
| 93724 | | A | Analyze pacemaker system | 4.88 | 5.86 | NA | 0.43 | 11.17 | NA | 000 |
| 93724 | 26 | A | Analyze pacemaker system | 4.88 | 1.91 | 1.91 | 0.19 | 6.98 | 6.98 | 000 |
| 93724 | TC | A | Analyze pacemaker system | 0.00 | 3.96 | NA | 0.24 | 4.20 | NA | 000 |
| 93727 | | A | Analyze ilr system | 0.52 | 0.20 | 0.20 | 0.02 | 0.74 | 0.74 | XXX |
| 93731 | | A | Analyze pacemaker system | 0.45 | 0.67 | NA | 0.06 | 1.18 | NA | XXX |
| 93731 | 26 | A | Analyze pacemaker system | 0.45 | 0.17 | 0.17 | 0.02 | 0.64 | 0.64 | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 93731 | TC | A | Analyze pacemaker system | 0.00 | 0.49 | NA | 0.04 | 0.53 | NA | XXX |
| 93732 | | A | Analyze pacemaker system | 0.92 | 0.86 | NA | 0.07 | 1.85 | NA | XXX |
| 93732 | 26 | A | Analyze pacemaker system | 0.92 | 0.35 | 0.35 | 0.03 | 1.30 | 1.30 | XXX |
| 93732 | TC | A | Analyze pacemaker system | 0.00 | 0.51 | NA | 0.04 | 0.55 | NA | XXX |
| 93733 | | A | Telephone analy, pacemaker | 0.17 | 0.79 | NA | 0.07 | 1.03 | NA | XXX |
| 93733 | 26 | A | Telephone analy, pacemaker | 0.17 | 0.07 | 0.07 | 0.01 | 0.25 | 0.25 | XXX |
| 93733 | TC | A | Telephone analy, pacemaker | 0.00 | 0.72 | NA | 0.06 | 0.78 | NA | XXX |
| 93734 | | A | Analyze pacemaker system | 0.38 | 0.49 | NA | 0.03 | 0.90 | NA | XXX |
| 93734 | 26 | A | Analyze pacemaker system | 0.38 | 0.14 | 0.14 | 0.01 | 0.53 | 0.53 | XXX |
| 93734 | TC | A | Analyze pacemaker system | 0.00 | 0.35 | NA | 0.02 | 0.37 | NA | XXX |
| 93735 | | A | Analyze pacemaker system | 0.74 | 0.73 | NA | 0.07 | 1.54 | NA | XXX |
| 93735 | 26 | A | Analyze pacemaker system | 0.74 | 0.28 | 0.28 | 0.03 | 1.05 | 1.05 | XXX |
| 93735 | TC | A | Analyze pacemaker system | 0.00 | 0.44 | NA | 0.04 | 0.48 | NA | XXX |
| 93736 | | A | Telephonic analy, pacemaker | 0.15 | 0.69 | NA | 0.07 | 0.91 | NA | XXX |
| 93736 | 26 | A | Telephonic analy, pacemaker | 0.15 | 0.06 | 0.06 | 0.01 | 0.22 | 0.22 | XXX |
| 93736 | TC | A | Telephonic analy, pacemaker | 0.00 | 0.63 | NA | 0.06 | 0.69 | NA | XXX |
| 93740 | | B | Temperature gradient studies | 0.16 | 0.19 | NA | 0.02 | 0.37 | NA | XXX |
| 93740 | 26 | B | Temperature gradient studies | 0.16 | 0.04 | 0.04 | 0.01 | 0.21 | 0.21 | XXX |
| 93740 | TC | B | Temperature gradient studies | 0.00 | 0.15 | NA | 0.01 | 0.16 | NA | XXX |
| 93741 | | A | Analyze ht pace device sngl | 0.80 | 0.98 | NA | 0.07 | 1.85 | NA | XXX |
| 93741 | 26 | A | Analyze ht pace device sngl | 0.80 | 0.31 | 0.31 | 0.03 | 1.14 | 1.14 | XXX |
| 93741 | TC | A | Analyze ht pace device sngl | 0.00 | 0.67 | NA | 0.04 | 0.71 | NA | XXX |
| 93742 | | A | Analyze ht pace device sngl | 0.91 | 1.02 | NA | 0.07 | 2.00 | NA | XXX |
| 93742 | 26 | A | Analyze ht pace device sngl | 0.91 | 0.36 | 0.36 | 0.03 | 1.30 | 1.30 | XXX |
| 93742 | TC | A | Analyze ht pace device sngl | 0.00 | 0.67 | NA | 0.04 | 0.71 | NA | XXX |
| 93743 | | A | Analyze ht pace device dual | 1.03 | 1.13 | NA | 0.08 | 2.24 | NA | XXX |
| 93743 | 26 | A | Analyze ht pace device dual | 1.03 | 0.40 | 0.40 | 0.04 | 1.47 | 1.47 | XXX |
| 93743 | TC | A | Analyze ht pace device dual | 0.00 | 0.73 | NA | 0.04 | 0.77 | NA | XXX |
| 93744 | | A | Analyze ht pace device dual | 1.18 | 1.12 | NA | 0.08 | 2.38 | NA | XXX |
| 93744 | 26 | A | Analyze ht pace device dual | 1.18 | 0.46 | 0.46 | 0.04 | 1.68 | 1.68 | XXX |
| 93744 | TC | A | Analyze ht pace device dual | 0.00 | 0.67 | NA | 0.04 | 0.71 | NA | XXX |
| 93770 | | B | Measure venous pressure | 0.16 | 0.08 | NA | 0.02 | 0.26 | NA | XXX |
| 93770 | 26 | B | Measure venous pressure | 0.16 | 0.05 | 0.05 | 0.01 | 0.22 | 0.22 | XXX |
| 93770 | TC | B | Measure venous pressure | 0.00 | 0.03 | NA | 0.01 | 0.04 | NA | XXX |
| 93784 | | A | Ambulatory BP monitoring | 0.38 | 1.55 | NA | 0.03 | 1.96 | NA | XXX |
| 93786 | | A | Ambulatory BP recording | 0.00 | 0.91 | NA | 0.01 | 0.92 | NA | XXX |
| 93788 | | A | Ambulatory BP analysis | 0.00 | 0.51 | NA | 0.01 | 0.52 | NA | XXX |
| 93790 | | A | Review/report BP recording | 0.38 | 0.13 | 0.13 | 0.01 | 0.52 | 0.52 | XXX |
| 93797 | | A | Cardiac rehab | 0.18 | 0.30 | 0.07 | 0.01 | 0.49 | 0.26 | 000 |
| 93798 | | A | Cardiac rehab/monitor | 0.28 | 0.47 | 0.11 | 0.01 | 0.76 | 0.40 | 000 |
| 93875 | | A | Extracranial study | 0.22 | 2.10 | NA | 0.12 | 2.44 | NA | XXX |
| 93875 | 26 | A | Extracranial study | 0.22 | 0.08 | 0.08 | 0.01 | 0.31 | 0.31 | XXX |
| 93875 | TC | A | Extracranial study | 0.00 | 2.02 | NA | 0.11 | 2.13 | NA | XXX |
| 93880 | | A | Extracranial study | 0.60 | 5.06 | NA | 0.39 | 6.05 | NA | XXX |
| 93880 | 26 | A | Extracranial study | 0.60 | 0.20 | 0.20 | 0.04 | 0.84 | 0.84 | XXX |
| 93880 | TC | A | Extracranial study | 0.00 | 4.85 | NA | 0.35 | 5.20 | NA | XXX |
| 93882 | | A | Extracranial study | 0.40 | 3.31 | NA | 0.26 | 3.97 | NA | XXX |
| 93882 | 26 | A | Extracranial study | 0.40 | 0.14 | 0.14 | 0.04 | 0.58 | 0.58 | XXX |
| 93882 | TC | A | Extracranial study | 0.00 | 3.17 | NA | 0.22 | 3.39 | NA | XXX |
| 93886 | | A | Intracranial study | 0.94 | 6.05 | NA | 0.45 | 7.44 | NA | XXX |
| 93886 | 26 | A | Intracranial study | 0.94 | 0.37 | 0.37 | 0.06 | 1.37 | 1.37 | XXX |
| 93886 | TC | A | Intracranial study | 0.00 | 5.68 | NA | 0.39 | 6.07 | NA | XXX |
| 93888 | | A | Intracranial study | 0.62 | 3.85 | NA | 0.32 | 4.79 | NA | XXX |
| 93888 | 26 | A | Intracranial study | 0.62 | 0.23 | 0.23 | 0.05 | 0.90 | 0.90 | XXX |
| 93888 | TC | A | Intracranial study | 0.00 | 3.62 | NA | 0.27 | 3.89 | NA | XXX |
| 93922 | | A | Extremity study | 0.25 | 2.43 | NA | 0.15 | 2.83 | NA | XXX |
| 93922 | 26 | A | Extremity study | 0.25 | 0.08 | 0.08 | 0.02 | 0.35 | 0.35 | XXX |
| 93922 | TC | A | Extremity study | 0.00 | 2.34 | NA | 0.13 | 2.47 | NA | XXX |
| 93923 | | A | Extremity study | 0.45 | 3.68 | NA | 0.26 | 4.39 | NA | XXX |
| 93923 | 26 | A | Extremity study | 0.45 | 0.15 | 0.15 | 0.04 | 0.64 | 0.64 | XXX |
| 93923 | TC | A | Extremity study | 0.00 | 3.53 | NA | 0.22 | 3.75 | NA | XXX |
| 93924 | | A | Extremity study | 0.50 | 4.42 | NA | 0.30 | 5.22 | NA | XXX |
| 93924 | 26 | A | Extremity study | 0.50 | 0.17 | 0.17 | 0.05 | 0.72 | 0.72 | XXX |
| 93924 | TC | A | Extremity study | 0.00 | 4.25 | NA | 0.25 | 4.50 | NA | XXX |
| 93925 | | A | Lower extremity study | 0.58 | 6.11 | NA | 0.39 | 7.08 | NA | XXX |
| 93925 | 26 | A | Lower extremity study | 0.58 | 0.20 | 0.20 | 0.04 | 0.82 | 0.82 | XXX |
| 93925 | TC | A | Lower extremity study | 0.00 | 5.91 | NA | 0.35 | 6.26 | NA | XXX |
| 93926 | | A | Lower extremity study | 0.39 | 3.82 | NA | 0.27 | 4.48 | NA | XXX |
| 93926 | 26 | A | Lower extremity study | 0.39 | 0.13 | 0.13 | 0.04 | 0.56 | 0.56 | XXX |
| 93926 | TC | A | Lower extremity study | 0.00 | 3.69 | NA | 0.23 | 3.92 | NA | XXX |
| 93930 | | A | Upper extremity study | 0.46 | 4.85 | NA | 0.41 | 5.72 | NA | XXX |
| 93930 | 26 | A | Upper extremity study | 0.46 | 0.16 | 0.16 | 0.04 | 0.66 | 0.66 | XXX |
| 93930 | TC | A | Upper extremity study | 0.00 | 4.69 | NA | 0.37 | 5.06 | NA | XXX |
| 93931 | | A | Upper extremity study | 0.31 | 3.22 | NA | 0.27 | 3.80 | NA | XXX |
| 93931 | 26 | A | Upper extremity study | 0.31 | 0.10 | 0.10 | 0.03 | 0.44 | 0.44 | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 93931 | TC | A | Upper extremity study | 0.00 | 3.12 | NA | 0.24 | 3.36 | NA | XXX |
| 93965 | | A | Extremity study | 0.35 | 2.48 | NA | 0.14 | 2.97 | NA | XXX |
| 93965 | 26 | A | Extremity study | 0.35 | 0.12 | 0.12 | 0.02 | 0.49 | 0.49 | XXX |
| 93965 | TC | A | Extremity study | 0.00 | 2.36 | NA | 0.12 | 2.48 | NA | XXX |
| 93970 | | A | Extremity study | 0.68 | 4.77 | NA | 0.45 | 5.90 | NA | XXX |
| 93970 | 26 | A | Extremity study | 0.68 | 0.23 | 0.23 | 0.05 | 0.96 | 0.96 | XXX |
| 93970 | TC | A | Extremity study | 0.00 | 4.54 | NA | 0.40 | 4.94 | NA | XXX |
| 93971 | | A | Extremity study | 0.45 | 3.28 | NA | 0.30 | 4.03 | NA | XXX |
| 93971 | 26 | A | Extremity study | 0.45 | 0.15 | 0.15 | 0.03 | 0.63 | 0.63 | XXX |
| 93971 | TC | A | Extremity study | 0.00 | 3.13 | NA | 0.27 | 3.40 | NA | XXX |
| 93975 | | A | Vascular study | 1.80 | 6.91 | NA | 0.56 | 9.27 | NA | XXX |
| 93975 | 26 | A | Vascular study | 1.80 | 0.60 | 0.60 | 0.13 | 2.53 | 2.53 | XXX |
| 93975 | TC | A | Vascular study | 0.00 | 6.32 | NA | 0.43 | 6.75 | NA | XXX |
| 93976 | | A | Vascular study | 1.21 | 3.92 | NA | 0.36 | 5.49 | NA | XXX |
| 93976 | 26 | A | Vascular study | 1.21 | 0.40 | 0.40 | 0.06 | 1.67 | 1.67 | XXX |
| 93976 | TC | A | Vascular study | 0.00 | 3.52 | NA | 0.30 | 3.82 | NA | XXX |
| 93978 | | A | Vascular study | 0.65 | 4.17 | NA | 0.43 | 5.25 | NA | XXX |
| 93978 | 26 | A | Vascular study | 0.65 | 0.22 | 0.22 | 0.06 | 0.93 | 0.93 | XXX |
| 93978 | TC | A | Vascular study | 0.00 | 3.95 | NA | 0.37 | 4.32 | NA | XXX |
| 93979 | | A | Vascular study | 0.44 | 3.00 | NA | 0.28 | 3.72 | NA | XXX |
| 93979 | 26 | A | Vascular study | 0.44 | 0.15 | 0.15 | 0.04 | 0.63 | 0.63 | XXX |
| 93979 | TC | A | Vascular study | 0.00 | 2.85 | NA | 0.24 | 3.09 | NA | XXX |
| 93980 | | A | Penile vascular study | 1.25 | 2.88 | NA | 0.43 | 4.56 | NA | XXX |
| 93980 | 26 | A | Penile vascular study | 1.25 | 0.41 | 0.41 | 0.09 | 1.75 | 1.75 | XXX |
| 93980 | TC | A | Penile vascular study | 0.00 | 2.48 | NA | 0.34 | 2.82 | NA | XXX |
| 93981 | | A | Penile vascular study | 0.44 | 2.96 | NA | 0.33 | 3.73 | NA | XXX |
| 93981 | 26 | A | Penile vascular study | 0.44 | 0.14 | 0.14 | 0.02 | 0.60 | 0.60 | XXX |
| 93981 | TC | A | Penile vascular study | 0.00 | 2.81 | NA | 0.31 | 3.12 | NA | XXX |
| 93990 | | A | Doppler flow testing | 0.25 | 3.76 | NA | 0.26 | 4.27 | NA | XXX |
| 93990 | 26 | A | Doppler flow testing | 0.25 | 0.09 | 0.09 | 0.03 | 0.37 | 0.37 | XXX |
| 93990 | TC | A | Doppler flow testing | 0.00 | 3.67 | NA | 0.23 | 3.90 | NA | XXX |
| 94010 | | A | Breathing capacity test | 0.17 | 0.69 | NA | 0.03 | 0.89 | NA | XXX |
| 94010 | 26 | A | Breathing capacity test | 0.17 | 0.05 | 0.05 | 0.01 | 0.23 | 0.23 | XXX |
| 94010 | TC | A | Breathing capacity test | 0.00 | 0.63 | NA | 0.02 | 0.65 | NA | XXX |
| 94014 | | A | Patient recorded spirometry | 0.52 | 0.77 | NA | 0.04 | 1.33 | NA | XXX |
| 94015 | | A | Patient recorded spirometry | 0.00 | 0.60 | NA | 0.01 | 0.61 | NA | XXX |
| 94016 | | A | Review patient spirometry | 0.52 | 0.16 | 0.16 | 0.03 | 0.71 | 0.71 | XXX |
| 94060 | | A | Evaluation of wheezing | 0.31 | 1.10 | NA | 0.07 | 1.48 | NA | XXX |
| 94060 | 26 | A | Evaluation of wheezing | 0.31 | 0.09 | 0.09 | 0.01 | 0.41 | 0.41 | XXX |
| 94060 | TC | A | Evaluation of wheezing | 0.00 | 1.01 | NA | 0.06 | 1.07 | NA | XXX |
| 94070 | | A | Evaluation of wheezing | 0.60 | 0.84 | NA | 0.13 | 1.57 | NA | XXX |
| 94070 | 26 | A | Evaluation of wheezing | 0.60 | 0.18 | 0.18 | 0.03 | 0.81 | 0.81 | XXX |
| 94070 | TC | A | Evaluation of wheezing | 0.00 | 0.66 | NA | 0.10 | 0.76 | NA | XXX |
| 94150 | | B | Vital capacity test | 0.07 | 0.48 | NA | 0.02 | 0.57 | NA | XXX |
| 94150 | 26 | B | Vital capacity test | 0.07 | 0.03 | 0.03 | 0.01 | 0.11 | 0.11 | XXX |
| 94150 | TC | B | Vital capacity test | 0.00 | 0.45 | NA | 0.01 | 0.46 | NA | XXX |
| 94200 | | A | Lung function test (MBC/MVV) | 0.11 | 0.46 | NA | 0.03 | 0.60 | NA | XXX |
| 94200 | 26 | A | Lung function test (MBC/MVV) | 0.11 | 0.03 | 0.03 | 0.01 | 0.15 | 0.15 | XXX |
| 94200 | TC | A | Lung function test (MBC/MVV) | 0.00 | 0.42 | NA | 0.02 | 0.44 | NA | XXX |
| 94240 | | A | Residual lung capacity | 0.26 | 0.67 | NA | 0.06 | 0.99 | NA | XXX |
| 94240 | 26 | A | Residual lung capacity | 0.26 | 0.08 | 0.08 | 0.01 | 0.35 | 0.35 | XXX |
| 94240 | TC | A | Residual lung capacity | 0.00 | 0.59 | NA | 0.05 | 0.64 | NA | XXX |
| 94250 | | A | Expired gas collection | 0.11 | 0.65 | NA | 0.02 | 0.78 | NA | XXX |
| 94250 | 26 | A | Expired gas collection | 0.11 | 0.03 | 0.03 | 0.01 | 0.15 | 0.15 | XXX |
| 94250 | TC | A | Expired gas collection | 0.00 | 0.62 | NA | 0.01 | 0.63 | NA | XXX |
| 94260 | | A | Thoracic gas volume | 0.13 | 0.59 | NA | 0.05 | 0.77 | NA | XXX |
| 94260 | 26 | A | Thoracic gas volume | 0.13 | 0.04 | 0.04 | 0.01 | 0.18 | 0.18 | XXX |
| 94260 | TC | A | Thoracic gas volume | 0.00 | 0.55 | NA | 0.04 | 0.59 | NA | XXX |
| 94350 | | A | Lung nitrogen washout curve | 0.26 | 0.77 | NA | 0.05 | 1.08 | NA | XXX |
| 94350 | 26 | A | Lung nitrogen washout curve | 0.26 | 0.08 | 0.08 | 0.01 | 0.35 | 0.35 | XXX |
| 94350 | TC | A | Lung nitrogen washout curve | 0.00 | 0.70 | NA | 0.04 | 0.74 | NA | XXX |
| 94360 | | A | Measure airflow resistance | 0.26 | 0.71 | NA | 0.07 | 1.04 | NA | XXX |
| 94360 | 26 | A | Measure airflow resistance | 0.26 | 0.08 | 0.08 | 0.01 | 0.35 | 0.35 | XXX |
| 94360 | TC | A | Measure airflow resistance | 0.00 | 0.63 | NA | 0.06 | 0.69 | NA | XXX |
| 94370 | | A | Breath airway closing volume | 0.26 | 0.74 | NA | 0.03 | 1.03 | NA | XXX |
| 94370 | 26 | A | Breath airway closing volume | 0.26 | 0.08 | 0.08 | 0.01 | 0.35 | 0.35 | XXX |
| 94370 | TC | A | Breath airway closing volume | 0.00 | 0.66 | NA | 0.02 | 0.68 | NA | XXX |
| 94375 | | A | Respiratory flow volume loop | 0.31 | 0.62 | NA | 0.03 | 0.96 | NA | XXX |
| 94375 | 26 | A | Respiratory flow volume loop | 0.31 | 0.09 | 0.09 | 0.01 | 0.41 | 0.41 | XXX |
| 94375 | TC | A | Respiratory flow volume loop | 0.00 | 0.53 | NA | 0.02 | 0.55 | NA | XXX |
| 94400 | | A | CO2 breathing response curve | 0.40 | 0.86 | NA | 0.09 | 1.35 | NA | XXX |
| 94400 | 26 | A | CO2 breathing response curve | 0.40 | 0.12 | 0.12 | 0.03 | 0.55 | 0.55 | XXX |
| 94400 | TC | A | CO2 breathing response curve | 0.00 | 0.74 | NA | 0.06 | 0.80 | NA | XXX |
| 94450 | | A | Hypoxia response curve | 0.40 | 0.87 | NA | 0.04 | 1.31 | NA | XXX |
| 94450 | 26 | A | Hypoxia response curve | 0.40 | 0.12 | 0.12 | 0.02 | 0.54 | 0.54 | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 94450 | TC | A | Hypoxia response curve | 0.00 | 0.75 | NA | 0.02 | 0.77 | NA | XXX |
| 94620 | | A | Pulmonary stress test/simple | 0.64 | 2.54 | NA | 0.13 | 3.31 | NA | XXX |
| 94620 | 26 | A | Pulmonary stress test/simple | 0.64 | 0.20 | 0.20 | 0.03 | 0.87 | 0.87 | XXX |
| 94620 | TC | A | Pulmonary stress test/simple | 0.00 | 2.34 | NA | 0.10 | 2.44 | NA | XXX |
| 94621 | | A | Pulm stress test/complex | 1.42 | 2.24 | NA | 0.16 | 3.82 | NA | XXX |
| 94621 | 26 | A | Pulm stress test/complex | 1.42 | 0.43 | 0.43 | 0.06 | 1.91 | 1.91 | XXX |
| 94621 | TC | A | Pulm stress test/complex | 0.00 | 1.80 | NA | 0.10 | 1.90 | NA | XXX |
| 94640 | | A | Airway inhalation treatment | 0.00 | 0.31 | NA | 0.02 | 0.33 | NA | XXX |
| 94656 | | A | Initial ventilator mgmt | 1.22 | 1.18 | 0.31 | 0.07 | 2.47 | 1.60 | XXX |
| 94657 | | A | Continued ventilator mgmt | 0.83 | 1.00 | 0.25 | 0.04 | 1.87 | 1.12 | XXX |
| 94660 | | A | Pos airway pressure, CPAP | 0.76 | 0.66 | 0.23 | 0.04 | 1.46 | 1.03 | XXX |
| 94662 | | A | Neg press ventilation, cnp | 0.76 | NA | 0.23 | 0.06 | NA | 1.05 | XXX |
| 94664 | | A | Evaluate pt use of inhaler | 0.00 | 0.32 | NA | 0.04 | 0.36 | NA | XXX |
| 94667 | | A | Chest wall manipulation | 0.00 | 0.54 | NA | 0.05 | 0.59 | NA | XXX |
| 94668 | | A | Chest wall manipulation | 0.00 | 0.46 | NA | 0.02 | 0.48 | NA | XXX |
| 94680 | | A | Exhaled air analysis, o2 | 0.26 | 1.89 | NA | 0.07 | 2.22 | NA | XXX |
| 94680 | 26 | A | Exhaled air analysis, o2 | 0.26 | 0.08 | 0.08 | 0.01 | 0.35 | 0.35 | XXX |
| 94680 | TC | A | Exhaled air analysis, o2 | 0.00 | 1.81 | NA | 0.06 | 1.87 | NA | XXX |
| 94681 | | A | Exhaled air analysis, o2/co2 | 0.20 | 2.58 | NA | 0.13 | 2.91 | NA | XXX |
| 94681 | 26 | A | Exhaled air analysis, o2/co2 | 0.20 | 0.06 | 0.06 | 0.01 | 0.27 | 0.27 | XXX |
| 94681 | TC | A | Exhaled air analysis, o2/co2 | 0.00 | 2.52 | NA | 0.12 | 2.64 | NA | XXX |
| 94690 | | A | Exhaled air analysis | 0.07 | 2.02 | NA | 0.04 | 2.13 | NA | XXX |
| 94690 | 26 | A | Exhaled air analysis | 0.07 | 0.02 | 0.02 | 0.00 | 0.09 | 0.09 | XXX |
| 94690 | TC | A | Exhaled air analysis | 0.00 | 2.00 | NA | 0.04 | 2.04 | NA | XXX |
| 94720 | | A | Monoxide diffusing capacity | 0.26 | 1.02 | NA | 0.07 | 1.35 | NA | XXX |
| 94720 | 26 | A | Monoxide diffusing capacity | 0.26 | 0.08 | 0.08 | 0.01 | 0.35 | 0.35 | XXX |
| 94720 | TC | A | Monoxide diffusing capacity | 0.00 | 0.94 | NA | 0.06 | 1.00 | NA | XXX |
| 94725 | | A | Membrane diffusion capacity | 0.26 | 2.94 | NA | 0.13 | 3.33 | NA | XXX |
| 94725 | 26 | A | Membrane diffusion capacity | 0.26 | 0.08 | 0.08 | 0.01 | 0.35 | 0.35 | XXX |
| 94725 | TC | A | Membrane diffusion capacity | 0.00 | 2.86 | NA | 0.12 | 2.98 | NA | XXX |
| 94750 | | A | Pulmonary compliance study | 0.23 | 1.35 | NA | 0.05 | 1.63 | NA | XXX |
| 94750 | 26 | A | Pulmonary compliance study | 0.23 | 0.07 | 0.07 | 0.01 | 0.31 | 0.31 | XXX |
| 94750 | TC | A | Pulmonary compliance study | 0.00 | 1.29 | NA | 0.04 | 1.33 | NA | XXX |
| 94760 | | T | Measure blood oxygen level | 0.00 | 0.04 | NA | 0.02 | 0.06 | NA | XXX |
| 94761 | | T | Measure blood oxygen level | 0.00 | 0.07 | NA | 0.06 | 0.13 | NA | XXX |
| 94762 | | A | Measure blood oxygen level | 0.00 | 0.49 | NA | 0.10 | 0.59 | NA | XXX |
| 94770 | | A | Exhaled carbon dioxide test | 0.15 | 0.76 | NA | 0.08 | 0.99 | NA | XXX |
| 94770 | 26 | A | Exhaled carbon dioxide test | 0.15 | 0.04 | 0.04 | 0.01 | 0.20 | 0.20 | XXX |
| 94770 | TC | A | Exhaled carbon dioxide test | 0.00 | 0.72 | NA | 0.07 | 0.79 | NA | XXX |
| 95004 | | A | Percut allergy skin tests | 0.00 | 0.10 | NA | 0.01 | 0.11 | NA | XXX |
| 95010 | | A | Percut allergy titrate test | 0.15 | 0.32 | 0.06 | 0.00 | 0.47 | 0.21 | XXX |
| 95015 | | A | Id allergy titrate-drug/bug | 0.15 | 0.14 | 0.06 | 0.01 | 0.30 | 0.22 | XXX |
| 95024 | | A | Id allergy test, drug/bug | 0.00 | 0.14 | NA | 0.01 | 0.15 | NA | XXX |
| 95027 | | A | Id allergy titrate-airborne | 0.00 | 0.14 | NA | 0.01 | 0.15 | NA | XXX |
| 95028 | | A | Id allergy test-delayed type | 0.00 | 0.23 | NA | 0.01 | 0.24 | NA | XXX |
| 95044 | | A | Allergy patch tests | 0.00 | 0.20 | NA | 0.01 | 0.21 | NA | XXX |
| 95052 | | A | Photo patch test | 0.00 | 0.25 | NA | 0.01 | 0.26 | NA | XXX |
| 95056 | | A | Photosensitivity tests | 0.00 | 0.17 | NA | 0.01 | 0.18 | NA | XXX |
| 95060 | | A | Eye allergy tests | 0.00 | 0.35 | NA | 0.02 | 0.37 | NA | XXX |
| 95065 | | A | Nose allergy test | 0.00 | 0.20 | NA | 0.01 | 0.21 | NA | XXX |
| 95070 | | A | Bronchial allergy tests | 0.00 | 2.28 | NA | 0.02 | 2.30 | NA | XXX |
| 95071 | | A | Bronchial allergy tests | 0.00 | 2.91 | NA | 0.02 | 2.93 | NA | XXX |
| 95075 | | A | Ingestion challenge test | 0.95 | 0.83 | 0.38 | 0.03 | 1.81 | 1.36 | XXX |
| 95078 | | A | Provocative testing | 0.00 | 0.25 | NA | 0.02 | 0.27 | NA | XXX |
| 95115 | | A | Immunotherapy, one injection | 0.00 | 0.39 | NA | 0.02 | 0.41 | NA | 000 |
| 95117 | | A | Immunotherapy injections | 0.00 | 0.50 | NA | 0.02 | 0.52 | NA | 000 |
| 95144 | | A | Antigen therapy services | 0.06 | 0.19 | 0.02 | 0.00 | 0.25 | 0.08 | 000 |
| 95145 | | A | Antigen therapy services | 0.06 | 0.32 | 0.02 | 0.00 | 0.38 | 0.08 | 000 |
| 95146 | | A | Antigen therapy services | 0.06 | 0.44 | 0.03 | 0.00 | 0.50 | 0.09 | 000 |
| 95147 | | A | Antigen therapy services | 0.06 | 0.42 | 0.02 | 0.00 | 0.48 | 0.08 | 000 |
| 95148 | | A | Antigen therapy services | 0.06 | 0.58 | 0.03 | 0.00 | 0.64 | 0.09 | 000 |
| 95149 | | A | Antigen therapy services | 0.06 | 0.80 | 0.03 | 0.00 | 0.86 | 0.09 | 000 |
| 95165 | | A | Antigen therapy services | 0.06 | 0.19 | 0.02 | 0.00 | 0.25 | 0.08 | 000 |
| 95170 | | A | Antigen therapy services | 0.06 | 0.13 | 0.02 | 0.00 | 0.19 | 0.08 | 000 |
| 95180 | | A | Rapid desensitization | 2.01 | 2.05 | 0.93 | 0.05 | 4.11 | 2.99 | 000 |
| 95250 | | A | Glucose monitoring, cont | 0.00 | 4.22 | NA | 0.01 | 4.23 | NA | XXX |
| 95805 | | A | Multiple sleep latency test | 1.88 | 18.00 | NA | 0.43 | 20.31 | NA | XXX |
| 95805 | 26 | A | Multiple sleep latency test | 1.88 | 0.66 | 0.66 | 0.09 | 2.63 | 2.63 | XXX |
| 95805 | TC | A | Multiple sleep latency test | 0.00 | 17.35 | NA | 0.34 | 17.69 | NA | XXX |
| 95806 | | A | Sleep study, unattended | 1.66 | 3.40 | NA | 0.39 | 5.45 | NA | XXX |
| 95806 | 26 | A | Sleep study, unattended | 1.66 | 0.53 | 0.53 | 0.08 | 2.27 | 2.27 | XXX |
| 95806 | TC | A | Sleep study, unattended | 0.00 | 2.87 | NA | 0.31 | 3.18 | NA | XXX |
| 95807 | | A | Sleep study, attended | 1.66 | 12.10 | NA | 0.50 | 14.26 | NA | XXX |
| 95807 | 26 | A | Sleep study, attended | 1.66 | 0.53 | 0.53 | 0.08 | 2.27 | 2.27 | XXX |
| 95807 | TC | A | Sleep study, attended | 0.00 | 11.57 | NA | 0.42 | 11.99 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 95808 | | A | Polysomnography, 1-3 | 2.65 | 13.54 | NA | 0.55 | 16.74 | NA | XXX |
| 95808 | 26 | A | Polysomnography, 1-3 | 2.65 | 0.92 | 0.92 | 0.13 | 3.70 | 3.70 | XXX |
| 95808 | TC | A | Polysomnography, 1-3 | 0.00 | 12.62 | NA | 0.42 | 13.04 | NA | XXX |
| 95810 | | A | Polysomnography, 4 or more | 3.52 | 18.02 | NA | 0.59 | 22.13 | NA | XXX |
| 95810 | 26 | A | Polysomnography, 4 or more | 3.52 | 1.18 | 1.18 | 0.17 | 4.87 | 4.87 | XXX |
| 95810 | TC | A | Polysomnography, 4 or more | 0.00 | 16.84 | NA | 0.42 | 17.26 | NA | XXX |
| 95811 | | A | Polysomnography w/cpap | 3.79 | 19.53 | NA | 0.61 | 23.93 | NA | XXX |
| 95811 | 26 | A | Polysomnography w/cpap | 3.79 | 1.27 | 1.27 | 0.18 | 5.24 | 5.24 | XXX |
| 95811 | TC | A | Polysomnography w/cpap | 0.00 | 18.26 | NA | 0.43 | 18.69 | NA | XXX |
| 95812 | | A | Eeg, 41-60 minutes | 1.08 | 4.03 | NA | 0.17 | 5.28 | NA | XXX |
| 95812 | 26 | A | Eeg, 41-60 minutes | 1.08 | 0.45 | 0.45 | 0.06 | 1.59 | 1.59 | XXX |
| 95812 | TC | A | Eeg, 41-60 minutes | 0.00 | 3.58 | NA | 0.11 | 3.69 | NA | XXX |
| 95813 | | A | Eeg, over 1 hour | 1.73 | 5.04 | NA | 0.21 | 6.98 | NA | XXX |
| 95813 | 26 | A | Eeg, over 1 hour | 1.73 | 0.70 | 0.70 | 0.10 | 2.53 | 2.53 | XXX |
| 95813 | TC | A | Eeg, over 1 hour | 0.00 | 4.35 | NA | 0.11 | 4.46 | NA | XXX |
| 95816 | | A | Eeg, awake and drowsy | 1.08 | 4.78 | NA | 0.16 | 6.02 | NA | XXX |
| 95816 | 26 | A | Eeg, awake and drowsy | 1.08 | 0.46 | 0.46 | 0.06 | 1.60 | 1.60 | XXX |
| 95816 | TC | A | Eeg, awake and drowsy | 0.00 | 4.32 | NA | 0.10 | 4.42 | NA | XXX |
| 95819 | | A | Eeg, awake and asleep | 1.08 | 2.76 | NA | 0.16 | 4.00 | NA | XXX |
| 95819 | 26 | A | Eeg, awake and asleep | 1.08 | 0.46 | 0.46 | 0.06 | 1.60 | 1.60 | XXX |
| 95819 | TC | A | Eeg, awake and asleep | 0.00 | 2.30 | NA | 0.10 | 2.40 | NA | XXX |
| 95822 | | A | Eeg, coma or sleep only | 1.08 | 4.63 | NA | 0.19 | 5.90 | NA | XXX |
| 95822 | 26 | A | Eeg, coma or sleep only | 1.08 | 0.46 | 0.46 | 0.06 | 1.60 | 1.60 | XXX |
| 95822 | TC | A | Eeg, coma or sleep only | 0.00 | 4.18 | NA | 0.13 | 4.31 | NA | XXX |
| 95824 | 26 | A | Eeg, cerebral death only | 0.74 | 0.31 | 0.31 | 0.04 | 1.09 | 1.09 | XXX |
| 95827 | | A | Eeg, all night recording | 1.08 | 2.69 | NA | 0.20 | 3.97 | NA | XXX |
| 95827 | 26 | A | Eeg, all night recording | 1.08 | 0.41 | 0.41 | 0.06 | 1.55 | 1.55 | XXX |
| 95827 | TC | A | Eeg, all night recording | 0.00 | 2.29 | NA | 0.14 | 2.43 | NA | XXX |
| 95829 | | A | Surgery electrocorticogram | 6.20 | 31.16 | NA | 0.51 | 37.87 | NA | XXX |
| 95829 | 26 | A | Surgery electrocorticogram | 6.20 | 2.31 | 2.31 | 0.49 | 9.00 | 9.00 | XXX |
| 95829 | TC | A | Surgery electrocorticogram | 0.00 | 28.85 | NA | 0.02 | 28.87 | NA | XXX |
| 95830 | | A | Insert electrodes for EEG | 1.70 | 3.29 | 0.73 | 0.10 | 5.09 | 2.53 | XXX |
| 95831 | | A | Limb muscle testing, manual | 0.28 | 0.46 | 0.13 | 0.02 | 0.76 | 0.43 | XXX |
| 95832 | | A | Hand muscle testing, manual | 0.29 | 0.33 | 0.12 | 0.02 | 0.64 | 0.43 | XXX |
| 95833 | | A | Body muscle testing, manual | 0.47 | 0.59 | 0.23 | 0.02 | 1.08 | 0.72 | XXX |
| 95834 | | A | Body muscle testing, manual | 0.60 | 0.64 | 0.28 | 0.03 | 1.27 | 0.91 | XXX |
| 95851 | | A | Range of motion measurements | 0.16 | 0.37 | 0.08 | 0.01 | 0.54 | 0.25 | XXX |
| 95852 | | A | Range of motion measurements | 0.11 | 0.26 | 0.05 | 0.01 | 0.38 | 0.17 | XXX |
| 95857 | | A | Tensilon test | 0.53 | 0.60 | 0.23 | 0.03 | 1.16 | 0.79 | XXX |
| 95858 | | A | Tensilon test & myogram | 1.56 | 1.06 | NA | 0.12 | 2.74 | NA | XXX |
| 95858 | 26 | A | Tensilon test & myogram | 1.56 | 0.67 | 0.67 | 0.08 | 2.31 | 2.31 | XXX |
| 95858 | TC | A | Tensilon test & myogram | 0.00 | 0.40 | NA | 0.04 | 0.44 | NA | XXX |
| 95860 | | A | Muscle test, one limb | 0.96 | 1.43 | NA | 0.07 | 2.46 | NA | XXX |
| 95860 | 26 | A | Muscle test, one limb | 0.96 | 0.42 | 0.42 | 0.05 | 1.43 | 1.43 | XXX |
| 95860 | TC | A | Muscle test, one limb | 0.00 | 1.01 | NA | 0.02 | 1.03 | NA | XXX |
| 95861 | | A | Muscle test, 2 limbs | 1.54 | 1.41 | NA | 0.14 | 3.09 | NA | XXX |
| 95861 | 26 | A | Muscle test, 2 limbs | 1.54 | 0.67 | 0.67 | 0.08 | 2.29 | 2.29 | XXX |
| 95861 | TC | A | Muscle test, 2 limbs | 0.00 | 0.73 | NA | 0.06 | 0.79 | NA | XXX |
| 95863 | | A | Muscle test, 3 limbs | 1.87 | 1.74 | NA | 0.15 | 3.76 | NA | XXX |
| 95863 | 26 | A | Muscle test, 3 limbs | 1.87 | 0.80 | 0.80 | 0.09 | 2.76 | 2.76 | XXX |
| 95863 | TC | A | Muscle test, 3 limbs | 0.00 | 0.94 | NA | 0.06 | 1.00 | NA | XXX |
| 95864 | | A | Muscle test, 4 limbs | 1.99 | 2.64 | NA | 0.22 | 4.85 | NA | XXX |
| 95864 | 26 | A | Muscle test, 4 limbs | 1.99 | 0.87 | 0.87 | 0.10 | 2.96 | 2.96 | XXX |
| 95864 | TC | A | Muscle test, 4 limbs | 0.00 | 1.78 | NA | 0.12 | 1.90 | NA | XXX |
| 95867 | | A | Muscle test cran nerv unilat | 0.79 | 0.92 | NA | 0.08 | 1.79 | NA | XXX |
| 95867 | 26 | A | Muscle test cran nerv unilat | 0.79 | 0.35 | 0.35 | 0.04 | 1.18 | 1.18 | XXX |
| 95867 | TC | A | Muscle test cran nerv unilat | 0.00 | 0.58 | NA | 0.04 | 0.62 | NA | XXX |
| 95868 | | A | Muscle test cran nerve bilat | 1.18 | 1.21 | NA | 0.11 | 2.50 | NA | XXX |
| 95868 | 26 | A | Muscle test cran nerve bilat | 1.18 | 0.51 | 0.51 | 0.06 | 1.75 | 1.75 | XXX |
| 95868 | TC | A | Muscle test cran nerve bilat | 0.00 | 0.69 | NA | 0.05 | 0.74 | NA | XXX |
| 95869 | | A | Muscle test, thor paraspinal | 0.37 | 0.37 | NA | 0.04 | 0.78 | NA | XXX |
| 95869 | 26 | A | Muscle test, thor paraspinal | 0.37 | 0.16 | 0.16 | 0.02 | 0.55 | 0.55 | XXX |
| 95869 | TC | A | Muscle test, thor paraspinal | 0.00 | 0.21 | NA | 0.02 | 0.23 | NA | XXX |
| 95870 | | A | Muscle test, nonparaspinal | 0.37 | 0.37 | NA | 0.04 | 0.78 | NA | XXX |
| 95870 | 26 | A | Muscle test, nonparaspinal | 0.37 | 0.16 | 0.16 | 0.02 | 0.55 | 0.55 | XXX |
| 95870 | TC | A | Muscle test, nonparaspinal | 0.00 | 0.21 | NA | 0.02 | 0.23 | NA | XXX |
| 95872 | | A | Muscle test, one fiber | 1.50 | 1.23 | NA | 0.14 | 2.87 | NA | XXX |
| 95872 | 26 | A | Muscle test, one fiber | 1.50 | 0.63 | 0.63 | 0.09 | 2.22 | 2.22 | XXX |
| 95872 | TC | A | Muscle test, one fiber | 0.00 | 0.60 | NA | 0.05 | 0.65 | NA | XXX |
| 95875 | | A | Limb exercise test | 1.10 | 1.45 | NA | 0.14 | 2.69 | NA | XXX |
| 95875 | 26 | A | Limb exercise test | 1.10 | 0.47 | 0.47 | 0.08 | 1.65 | 1.65 | XXX |
| 95875 | TC | A | Limb exercise test | 0.00 | 0.98 | NA | 0.06 | 1.04 | NA | XXX |
| 95900 | | A | Motor nerve conduction test | 0.42 | 1.26 | NA | 0.04 | 1.72 | NA | XXX |
| 95900 | 26 | A | Motor nerve conduction test | 0.42 | 0.18 | 0.18 | 0.02 | 0.62 | 0.62 | XXX |
| 95900 | TC | A | Motor nerve conduction test | 0.00 | 1.08 | NA | 0.02 | 1.10 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 95903 | | A | Motor nerve conduction test | 0.60 | 1.20 | NA | 0.05 | 1.85 | NA | XXX |
| 95903 | 26 | A | Motor nerve conduction test | 0.60 | 0.26 | 0.26 | 0.03 | 0.89 | 0.89 | XXX |
| 95903 | TC | A | Motor nerve conduction test | 0.00 | 0.94 | NA | 0.02 | 0.96 | NA | XXX |
| 95904 | | A | Sense nerve conduction test | 0.34 | 1.09 | NA | 0.04 | 1.47 | NA | XXX |
| 95904 | 26 | A | Sense nerve conduction test | 0.34 | 0.15 | 0.15 | 0.02 | 0.51 | 0.51 | XXX |
| 95904 | TC | A | Sense nerve conduction test | 0.00 | 0.95 | NA | 0.02 | 0.97 | NA | XXX |
| 95920 | | A | Intraop nerve test add-on | 2.11 | 2.23 | NA | 0.24 | 4.58 | NA | ZZZ |
| 95920 | 26 | A | Intraop nerve test add-on | 2.11 | 0.93 | 0.93 | 0.17 | 3.21 | 3.21 | ZZZ |
| 95920 | TC | A | Intraop nerve test add-on | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | ZZZ |
| 95921 | | A | Autonomic nerv function test | 0.90 | 0.70 | NA | 0.06 | 1.66 | NA | XXX |
| 95921 | 26 | A | Autonomic nerv function test | 0.90 | 0.33 | 0.33 | 0.04 | 1.27 | 1.27 | XXX |
| 95921 | TC | A | Autonomic nerv function test | 0.00 | 0.38 | NA | 0.02 | 0.40 | NA | XXX |
| 95922 | | A | Autonomic nerv function test | 0.96 | 0.78 | NA | 0.07 | 1.81 | NA | XXX |
| 95922 | 26 | A | Autonomic nerv function test | 0.96 | 0.40 | 0.40 | 0.05 | 1.41 | 1.41 | XXX |
| 95922 | TC | A | Autonomic nerv function test | 0.00 | 0.38 | NA | 0.02 | 0.40 | NA | XXX |
| 95923 | | A | Autonomic nerv function test | 0.90 | 1.95 | NA | 0.07 | 2.92 | NA | XXX |
| 95923 | 26 | A | Autonomic nerv function test | 0.90 | 0.38 | 0.38 | 0.05 | 1.33 | 1.33 | XXX |
| 95923 | TC | A | Autonomic nerv function test | 0.00 | 1.57 | NA | 0.02 | 1.59 | NA | XXX |
| 95925 | | A | Somatosensory testing | 0.54 | 1.13 | NA | 0.09 | 1.76 | NA | XXX |
| 95925 | 26 | A | Somatosensory testing | 0.54 | 0.22 | 0.22 | 0.03 | 0.79 | 0.79 | XXX |
| 95925 | TC | A | Somatosensory testing | 0.00 | 0.91 | NA | 0.06 | 0.97 | NA | XXX |
| 95926 | | A | Somatosensory testing | 0.54 | 1.14 | NA | 0.09 | 1.77 | NA | XXX |
| 95926 | 26 | A | Somatosensory testing | 0.54 | 0.23 | 0.23 | 0.03 | 0.80 | 0.80 | XXX |
| 95926 | TC | A | Somatosensory testing | 0.00 | 0.91 | NA | 0.06 | 0.97 | NA | XXX |
| 95927 | | A | Somatosensory testing | 0.54 | 1.16 | NA | 0.09 | 1.79 | NA | XXX |
| 95927 | 26 | A | Somatosensory testing | 0.54 | 0.25 | 0.25 | 0.03 | 0.82 | 0.82 | XXX |
| 95927 | TC | A | Somatosensory testing | 0.00 | 0.91 | NA | 0.06 | 0.97 | NA | XXX |
| 95930 | | A | Visual evoked potential test | 0.35 | 2.25 | NA | 0.03 | 2.63 | NA | XXX |
| 95930 | 26 | A | Visual evoked potential test | 0.35 | 0.15 | 0.15 | 0.02 | 0.52 | 0.52 | XXX |
| 95930 | TC | A | Visual evoked potential test | 0.00 | 2.10 | NA | 0.01 | 2.11 | NA | XXX |
| 95933 | | A | Blink reflex test | 0.59 | 1.02 | NA | 0.10 | 1.71 | NA | XXX |
| 95933 | 26 | A | Blink reflex test | 0.59 | 0.24 | 0.24 | 0.04 | 0.87 | 0.87 | XXX |
| 95933 | TC | A | Blink reflex test | 0.00 | 0.78 | NA | 0.06 | 0.84 | NA | XXX |
| 95934 | | A | H-reflex test | 0.51 | 0.43 | NA | 0.04 | 0.98 | NA | XXX |
| 95934 | 26 | A | H-reflex test | 0.51 | 0.22 | 0.22 | 0.02 | 0.75 | 0.75 | XXX |
| 95934 | TC | A | H-reflex test | 0.00 | 0.21 | NA | 0.02 | 0.23 | NA | XXX |
| 95936 | | A | H-reflex test | 0.55 | 0.45 | NA | 0.05 | 1.05 | NA | XXX |
| 95936 | 26 | A | H-reflex test | 0.55 | 0.24 | 0.24 | 0.03 | 0.82 | 0.82 | XXX |
| 95936 | TC | A | H-reflex test | 0.00 | 0.21 | NA | 0.02 | 0.23 | NA | XXX |
| 95937 | | A | Neuromuscular junction test | 0.65 | 0.60 | NA | 0.08 | 1.33 | NA | XXX |
| 95937 | 26 | A | Neuromuscular junction test | 0.65 | 0.27 | 0.27 | 0.06 | 0.98 | 0.98 | XXX |
| 95937 | TC | A | Neuromuscular junction test | 0.00 | 0.34 | NA | 0.02 | 0.36 | NA | XXX |
| 95950 | | A | Ambulatory eeg monitoring | 1.51 | 4.98 | NA | 0.51 | 7.00 | NA | XXX |
| 95950 | 26 | A | Ambulatory eeg monitoring | 1.51 | 0.63 | 0.63 | 0.08 | 2.22 | 2.22 | XXX |
| 95950 | TC | A | Ambulatory eeg monitoring | 0.00 | 4.35 | NA | 0.43 | 4.78 | NA | XXX |
| 95951 | 26 | A | EEG monitoring/videorecord | 5.99 | 2.54 | 2.54 | 0.34 | 8.87 | 8.87 | XXX |
| 95953 | | A | EEG monitoring/computer | 3.08 | 7.61 | NA | 0.61 | 11.30 | NA | XXX |
| 95953 | 26 | A | EEG monitoring/computer | 3.08 | 1.29 | 1.29 | 0.18 | 4.55 | 4.55 | XXX |
| 95953 | TC | A | EEG monitoring/computer | 0.00 | 6.32 | NA | 0.43 | 6.75 | NA | XXX |
| 95954 | | A | EEG monitoring/giving drugs | 2.45 | 4.28 | NA | 0.19 | 6.92 | NA | XXX |
| 95954 | 26 | A | EEG monitoring/giving drugs | 2.45 | 1.04 | 1.04 | 0.13 | 3.62 | 3.62 | XXX |
| 95954 | TC | A | EEG monitoring/giving drugs | 0.00 | 3.24 | NA | 0.06 | 3.30 | NA | XXX |
| 95955 | | A | EEG during surgery | 1.01 | 2.32 | NA | 0.23 | 3.56 | NA | XXX |
| 95955 | 26 | A | EEG during surgery | 1.01 | 0.36 | 0.36 | 0.06 | 1.43 | 1.43 | XXX |
| 95955 | TC | A | EEG during surgery | 0.00 | 1.96 | NA | 0.17 | 2.13 | NA | XXX |
| 95956 | | A | Eeg monitoring, cable/radio | 3.08 | 15.93 | NA | 0.60 | 19.61 | NA | XXX |
| 95956 | 26 | A | Eeg monitoring, cable/radio | 3.08 | 1.30 | 1.30 | 0.17 | 4.55 | 4.55 | XXX |
| 95956 | TC | A | Eeg monitoring, cable/radio | 0.00 | 14.63 | NA | 0.43 | 15.06 | NA | XXX |
| 95957 | | A | EEG digital analysis | 1.98 | 2.55 | NA | 0.23 | 4.76 | NA | XXX |
| 95957 | 26 | A | EEG digital analysis | 1.98 | 0.85 | 0.85 | 0.11 | 2.94 | 2.94 | XXX |
| 95957 | TC | A | EEG digital analysis | 0.00 | 1.70 | NA | 0.12 | 1.82 | NA | XXX |
| 95958 | | A | EEG monitoring/function test | 4.24 | 3.47 | NA | 0.39 | 8.10 | NA | XXX |
| 95958 | 26 | A | EEG monitoring/function test | 4.24 | 1.73 | 1.73 | 0.26 | 6.23 | 6.23 | XXX |
| 95958 | TC | A | EEG monitoring/function test | 0.00 | 1.74 | NA | 0.13 | 1.87 | NA | XXX |
| 95961 | | A | Electrode stimulation, brain | 2.97 | 2.62 | NA | 0.53 | 6.12 | NA | XXX |
| 95961 | 26 | A | Electrode stimulation, brain | 2.97 | 1.32 | 1.32 | 0.46 | 4.75 | 4.75 | XXX |
| 95961 | TC | A | Electrode stimulation, brain | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | XXX |
| 95962 | | A | Electrode stim, brain add-on | 3.21 | 2.69 | NA | 0.38 | 6.28 | NA | ZZZ |
| 95962 | 26 | A | Electrode stim, brain add-on | 3.21 | 1.39 | 1.39 | 0.31 | 4.91 | 4.91 | ZZZ |
| 95962 | TC | A | Electrode stim, brain add-on | 0.00 | 1.30 | NA | 0.07 | 1.37 | NA | ZZZ |
| 95965 | 26 | A | Meg, spontaneous | 7.99 | 3.41 | 3.41 | 0.41 | 11.81 | 11.81 | XXX |
| 95966 | 26 | A | Meg, evoked, single | 3.99 | 1.71 | 1.71 | 0.21 | 5.91 | 5.91 | XXX |
| 95967 | 26 | A | Meg, evoked, each add-l | 3.49 | 1.18 | 1.18 | 0.16 | 4.83 | 4.83 | ZZZ |
| 95970 | | A | Analyze neurostim, no prog | 0.45 | 0.86 | 0.14 | 0.03 | 1.34 | 0.62 | XXX |
| 95971 | | A | Analyze neurostim, simple | 0.78 | 0.68 | 0.22 | 0.07 | 1.53 | 1.07 | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 95972 | | A | Analyze neurostim, complex | 1.50 | 1.21 | 0.49 | 0.14 | 2.85 | 2.13 | XXX |
| 95973 | | A | Analyze neurostim, complex | 0.92 | 0.62 | 0.34 | 0.07 | 1.61 | 1.33 | ZZZ |
| 95974 | | A | Cranial neurostim, complex | 3.00 | 1.70 | 1.29 | 0.18 | 4.88 | 4.47 | XXX |
| 95975 | | A | Cranial neurostim, complex | 1.70 | 0.89 | 0.73 | 0.11 | 2.70 | 2.54 | ZZZ |
| 95990 | | A | Spin/brain pump refil & main | 0.00 | 1.50 | NA | 0.06 | 1.56 | NA | XXX |
| 95991 | | A | Spin/brain pump refil & main | 0.77 | 1.53 | 0.17 | 0.06 | 2.36 | 1.00 | XXX |
| 96000 | | A | Motion analysis, video/3d | 1.80 | NA | 0.53 | 0.05 | NA | 2.38 | XXX |
| 96001 | | A | Motion test w/ft press meas | 2.15 | NA | 0.66 | 0.06 | NA | 2.87 | XXX |
| 96002 | | A | Dynamic surface emg | 0.41 | NA | 0.15 | 0.01 | NA | 0.57 | XXX |
| 96003 | | A | Dynamic fine wire emg | 0.37 | NA | 0.12 | 0.04 | NA | 0.53 | XXX |
| 96004 | | A | Phys review of motion tests | 2.14 | 0.94 | 0.94 | 0.07 | 3.15 | 3.15 | XXX |
| 96100 | | A | Psychological testing | 0.00 | 1.76 | NA | 0.18 | 1.94 | NA | XXX |
| 96105 | | A | Assessment of aphasia | 0.00 | 1.76 | NA | 0.18 | 1.94 | NA | XXX |
| 96110 | | A | Developmental test, lim | 0.00 | 0.18 | NA | 0.18 | 0.36 | NA | XXX |
| 96111 | | A | Developmental test, extend | 2.60 | 1.05 | NA | 0.18 | 3.83 | NA | XXX |
| 96115 | | A | Neurobehavior status exam | 0.00 | 1.76 | NA | 0.18 | 1.94 | NA | XXX |
| 96117 | | A | Neuropsych test battery | 0.00 | 1.76 | NA | 0.18 | 1.94 | NA | XXX |
| 96150 | | A | Assess lth/behave, init | 0.50 | 0.18 | 0.18 | 0.01 | 0.69 | 0.69 | XXX |
| 96151 | | A | Assess hlth/behave, subseq | 0.48 | 0.18 | 0.17 | 0.01 | 0.67 | 0.66 | XXX |
| 96152 | | A | Intervene hlth/behave, indiv | 0.46 | 0.17 | 0.16 | 0.01 | 0.64 | 0.63 | XXX |
| 96153 | | A | Intervene hlth/behave, group | 0.10 | 0.04 | 0.03 | 0.00 | 0.14 | 0.13 | XXX |
| 96154 | | A | Interv hlth/behav, fam w/pt | 0.45 | 0.17 | 0.16 | 0.01 | 0.63 | 0.62 | XXX |
| 96400 | | A | Chemotherapy, sc/im | 0.17 | 1.13 | NA | 0.01 | 1.31 | NA | XXX |
| 96405 | | A | Intralesional chemo admin | 0.52 | 2.33 | 0.24 | 0.03 | 2.88 | 0.79 | 000 |
| 96406 | | A | Intralesional chemo admin | 0.80 | 3.11 | 0.29 | 0.03 | 3.94 | 1.12 | 000 |
| 96408 | | A | Chemotherapy, push technique | 0.17 | 2.92 | NA | 0.06 | 3.15 | NA | XXX |
| 96410 | | A | Chemotherapy,infusion method | 0.17 | 4.15 | NA | 0.08 | 4.40 | NA | XXX |
| 96412 | | A | Chemo, infuse method add-on | 0.17 | 0.73 | NA | 0.07 | 0.97 | NA | ZZZ |
| 96414 | | A | Chemo, infuse method add-on | 0.17 | 5.23 | NA | 0.08 | 5.48 | NA | XXX |
| 96420 | | A | Chemotherapy, push technique | 0.17 | 2.82 | NA | 0.08 | 3.07 | NA | XXX |
| 96422 | | A | Chemotherapy,infusion method | 0.17 | 5.18 | NA | 0.08 | 5.43 | NA | XXX |
| 96423 | | A | Chemo, infuse method add-on | 0.17 | 2.00 | NA | 0.02 | 2.19 | NA | ZZZ |
| 96425 | | A | Chemotherapy,infusion method | 0.17 | 4.74 | NA | 0.08 | 4.99 | NA | XXX |
| 96440 | | A | Chemotherapy, intracavitary | 2.37 | 8.44 | 1.24 | 0.16 | 10.97 | 3.77 | 000 |
| 96445 | | A | Chemotherapy, intracavitary | 2.20 | 8.56 | 1.19 | 0.12 | 10.88 | 3.51 | 000 |
| 96450 | | A | Chemotherapy, into CNS | 1.89 | 7.37 | 1.09 | 0.09 | 9.35 | 3.07 | 000 |
| 96520 | | A | Port pump refill & main | 0.17 | 3.94 | NA | 0.06 | 4.17 | NA | XXX |
| 96530 | | A | Syst pump refill & main | 0.17 | 2.86 | NA | 0.06 | 3.09 | NA | XXX |
| 96542 | | A | Chemotherapy injection | 1.42 | 4.45 | 0.65 | 0.07 | 5.94 | 2.14 | XXX |
| 96567 | | A | Photodynamic tx, skin | 0.00 | 0.94 | NA | 0.04 | 0.98 | NA | XXX |
| 96570 | | A | Photodynamic tx, 30 min | 1.10 | NA | 0.37 | 0.11 | NA | 1.58 | ZZZ |
| 96571 | | A | Photodynamic tx, addl 15 min | 0.55 | NA | 0.19 | 0.03 | NA | 0.77 | ZZZ |
| 96900 | | A | Ultraviolet light therapy | 0.00 | 0.44 | NA | 0.02 | 0.46 | NA | XXX |
| 96902 | | B | Trichogram | 0.41 | 0.18 | 0.15 | 0.01 | 0.60 | 0.57 | XXX |
| 96910 | | A | Photochemotherapy with UV-B | 0.00 | 0.99 | NA | 0.04 | 1.03 | NA | XXX |
| 96912 | | A | Photochemotherapy with UV-A | 0.00 | 1.26 | NA | 0.05 | 1.31 | NA | XXX |
| 96913 | | A | Photochemotherapy, UV-A or B | 0.00 | 1.68 | NA | 0.10 | 1.78 | NA | XXX |
| 96920 | | A | Laser tx, skin < 250 sq cm | 1.15 | 2.52 | 0.56 | 0.11 | 3.78 | 1.82 | 000 |
| 96921 | | A | Laser tx, skin 250-500 sq cm | 1.17 | 2.60 | 0.57 | 0.11 | 3.88 | 1.85 | 000 |
| 96922 | | A | Laser tx, skin > 500 sq cm | 2.10 | 3.48 | 0.62 | 0.19 | 5.77 | 2.91 | 000 |
| 97001 | | A | Pt evaluation | 1.20 | 0.75 | 0.45 | 0.06 | 2.01 | 1.71 | XXX |
| 97002 | | A | Pt re-evaluation | 0.60 | 0.45 | 0.23 | 0.02 | 1.07 | 0.85 | XXX |
| 97003 | | A | Ot evaluation | 1.20 | 0.88 | 0.40 | 0.07 | 2.15 | 1.67 | XXX |
| 97004 | | A | Ot re-evaluation | 0.60 | 0.67 | 0.19 | 0.02 | 1.29 | 0.81 | XXX |
| 97010 | | B | Hot or cold packs therapy | 0.06 | 0.05 | NA | 0.01 | 0.12 | NA | XXX |
| 97012 | | A | Mechanical traction therapy | 0.25 | 0.13 | NA | 0.01 | 0.39 | NA | XXX |
| 97016 | | A | Vasopneumatic device therapy | 0.18 | 0.18 | NA | 0.01 | 0.37 | NA | XXX |
| 97018 | | A | Paraffin bath therapy | 0.06 | 0.10 | NA | 0.00 | 0.16 | NA | XXX |
| 97020 | | A | Microwave therapy | 0.06 | 0.05 | NA | 0.00 | 0.11 | NA | XXX |
| 97022 | | A | Whirlpool therapy | 0.17 | 0.21 | NA | 0.01 | 0.39 | NA | XXX |
| 97024 | | A | Diathermy treatment | 0.06 | 0.07 | NA | 0.00 | 0.13 | NA | XXX |
| 97026 | | A | Infrared therapy | 0.06 | 0.06 | NA | 0.00 | 0.12 | NA | XXX |
| 97028 | | A | Ultraviolet therapy | 0.08 | 0.07 | NA | 0.00 | 0.15 | NA | XXX |
| 97032 | | A | Electrical stimulation | 0.25 | 0.16 | NA | 0.01 | 0.42 | NA | XXX |
| 97033 | | A | Electric current therapy | 0.26 | 0.27 | NA | 0.01 | 0.54 | NA | XXX |
| 97034 | | A | Contrast bath therapy | 0.21 | 0.15 | NA | 0.01 | 0.37 | NA | XXX |
| 97035 | | A | Ultrasound therapy | 0.21 | 0.10 | NA | 0.01 | 0.32 | NA | XXX |
| 97036 | | A | Hydrotherapy | 0.28 | 0.32 | NA | 0.01 | 0.61 | NA | XXX |
| 97039 | | A | Physical therapy treatment | 0.20 | 0.10 | NA | 0.01 | 0.31 | NA | XXX |
| 97110 | | A | Therapeutic exercises | 0.45 | 0.27 | NA | 0.02 | 0.74 | NA | XXX |
| 97112 | | A | Neuromuscular reeducation | 0.45 | 0.31 | NA | 0.02 | 0.78 | NA | XXX |
| 97113 | | A | Aquatic therapy/exercises | 0.44 | 0.39 | NA | 0.02 | 0.85 | NA | XXX |
| 97116 | | A | Gait training therapy | 0.40 | 0.24 | NA | 0.01 | 0.65 | NA | XXX |
| 97124 | | A | Massage therapy | 0.35 | 0.23 | NA | 0.01 | 0.59 | NA | XXX |
| 97139 | | A | Physical medicine procedure | 0.21 | 0.20 | NA | 0.01 | 0.42 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 97140 | | A | Manual therapy | 0.43 | 0.25 | NA | 0.02 | 0.70 | NA | XXX |
| 97150 | | A | Group therapeutic procedures | 0.27 | 0.18 | NA | 0.02 | 0.47 | NA | XXX |
| 97504 | | A | Orthotic training | 0.45 | 0.33 | NA | 0.03 | 0.81 | NA | XXX |
| 97520 | | A | Prosthetic training | 0.45 | 0.27 | NA | 0.02 | 0.74 | NA | XXX |
| 97530 | | A | Therapeutic activities | 0.44 | 0.32 | NA | 0.02 | 0.78 | NA | XXX |
| 97532 | | A | Cognitive skills development | 0.44 | 0.20 | NA | 0.01 | 0.65 | NA | XXX |
| 97533 | | A | Sensory integration | 0.44 | 0.24 | NA | 0.01 | 0.69 | NA | XXX |
| 97535 | | A | Self care mngment training | 0.45 | 0.33 | NA | 0.01 | 0.79 | NA | XXX |
| 97537 | | A | Community/work reintegration | 0.45 | 0.26 | NA | 0.01 | 0.72 | NA | XXX |
| 97542 | | A | Wheelchair mngment training | 0.45 | 0.28 | NA | 0.01 | 0.74 | NA | XXX |
| 97601 | | A | Wound(s) care, selective | 0.50 | 0.49 | NA | 0.03 | 1.02 | NA | XXX |
| 97703 | | A | Prosthetic checkout | 0.25 | 0.41 | NA | 0.02 | 0.68 | NA | XXX |
| 97750 | | A | Physical performance test | 0.45 | 0.32 | NA | 0.02 | 0.79 | NA | XXX |
| 97755 | | A | Assistive technology assess | 0.62 | 0.28 | NA | 0.02 | 0.92 | NA | XXX |
| 97802 | | A | Medical nutrition, indiv, in | 0.00 | 0.47 | NA | 0.01 | 0.48 | NA | XXX |
| 97803 | | A | Med nutrition, indiv, subseq | 0.00 | 0.47 | NA | 0.01 | 0.48 | NA | XXX |
| 97804 | | A | Medical nutrition, group | 0.00 | 0.18 | NA | 0.01 | 0.19 | NA | XXX |
| 98925 | | A | Osteopathic manipulation | 0.45 | 0.32 | 0.14 | 0.02 | 0.79 | 0.61 | 000 |
| 98926 | | A | Osteopathic manipulation | 0.65 | 0.42 | 0.25 | 0.03 | 1.10 | 0.93 | 000 |
| 98927 | | A | Osteopathic manipulation | 0.87 | 0.51 | 0.29 | 0.03 | 1.41 | 1.19 | 000 |
| 98928 | | A | Osteopathic manipulation | 1.03 | 0.60 | 0.34 | 0.04 | 1.67 | 1.41 | 000 |
| 98929 | | A | Osteopathic manipulation | 1.19 | 0.68 | 0.37 | 0.05 | 1.92 | 1.61 | 000 |
| 98940 | | A | Chiropractic manipulation | 0.45 | 0.23 | 0.12 | 0.01 | 0.69 | 0.58 | 000 |
| 98941 | | A | Chiropractic manipulation | 0.65 | 0.30 | 0.17 | 0.02 | 0.97 | 0.84 | 000 |
| 98942 | | A | Chiropractic manipulation | 0.87 | 0.36 | 0.23 | 0.02 | 1.25 | 1.12 | 000 |
| 99141 | | B | Sedation, iv/im or inhalant | 0.80 | 1.89 | 0.38 | 0.05 | 2.74 | 1.23 | XXX |
| 99142 | | B | Sedation, oral/rectal/nasal | 0.60 | 0.96 | 0.31 | 0.04 | 1.60 | 0.95 | XXX |
| 99170 | | A | Anogenital exam, child | 1.75 | 1.80 | 0.55 | 0.10 | 3.65 | 2.40 | 000 |
| 99175 | | A | Induction of vomiting | 0.00 | 1.39 | NA | 0.10 | 1.49 | NA | XXX |
| 99183 | | A | Hyperbaric oxygen therapy | 2.34 | 4.07 | 0.72 | 0.16 | 6.57 | 3.22 | XXX |
| 99185 | | A | Regional hypothermia | 0.00 | 0.64 | NA | 0.04 | 0.68 | NA | XXX |
| 99186 | | A | Total body hypothermia | 0.00 | 1.78 | NA | 0.45 | 2.23 | NA | XXX |
| 99195 | | A | Phlebotomy | 0.00 | 0.44 | NA | 0.02 | 0.46 | NA | XXX |
| 99201 | | A | Office/outpatient visit, new | 0.45 | 0.50 | 0.15 | 0.03 | 0.98 | 0.63 | XXX |
| 99202 | | A | Office/outpatient visit, new | 0.88 | 0.79 | 0.31 | 0.05 | 1.72 | 1.24 | XXX |
| 99203 | | A | Office/outpatient visit, new | 1.34 | 1.14 | 0.48 | 0.09 | 2.57 | 1.91 | XXX |
| 99204 | | A | Office/outpatient visit, new | 2.00 | 1.51 | 0.71 | 0.12 | 3.63 | 2.83 | XXX |
| 99205 | | A | Office/outpatient visit, new | 2.67 | 1.79 | 0.94 | 0.15 | 4.61 | 3.76 | XXX |
| 99211 | | A | Office/outpatient visit, est | 0.17 | 0.40 | 0.06 | 0.01 | 0.58 | 0.24 | XXX |
| 99212 | | A | Office/outpatient visit, est | 0.45 | 0.54 | 0.16 | 0.03 | 1.02 | 0.64 | XXX |
| 99213 | | A | Office/outpatient visit, est | 0.67 | 0.70 | 0.23 | 0.03 | 1.40 | 0.93 | XXX |
| 99214 | | A | Office/outpatient visit, est | 1.10 | 1.04 | 0.40 | 0.05 | 2.19 | 1.55 | XXX |
| 99215 | | A | Office/outpatient visit, est | 1.77 | 1.34 | 0.65 | 0.09 | 3.20 | 2.51 | XXX |
| 99217 | | A | Observation care discharge | 1.28 | NA | 0.53 | 0.06 | NA | 1.87 | XXX |
| 99218 | | A | Observation care | 1.28 | NA | 0.44 | 0.06 | NA | 1.78 | XXX |
| 99219 | | A | Observation care | 2.14 | NA | 0.72 | 0.10 | NA | 2.96 | XXX |
| 99220 | | A | Observation care | 2.99 | NA | 1.02 | 0.14 | NA | 4.15 | XXX |
| 99221 | | A | Initial hospital care | 1.28 | NA | 0.45 | 0.07 | NA | 1.80 | XXX |
| 99222 | | A | Initial hospital care | 2.14 | NA | 0.74 | 0.10 | NA | 2.98 | XXX |
| 99223 | | A | Initial hospital care | 2.99 | NA | 1.03 | 0.13 | NA | 4.15 | XXX |
| 99231 | | A | Subsequent hospital care | 0.64 | NA | 0.23 | 0.03 | NA | 0.90 | XXX |
| 99232 | | A | Subsequent hospital care | 1.06 | NA | 0.37 | 0.05 | NA | 1.48 | XXX |
| 99233 | | A | Subsequent hospital care | 1.51 | NA | 0.52 | 0.07 | NA | 2.10 | XXX |
| 99234 | | A | Observ/hosp same date | 2.56 | NA | 0.88 | 0.13 | NA | 3.57 | XXX |
| 99235 | | A | Observ/hosp same date | 3.41 | NA | 1.15 | 0.16 | NA | 4.72 | XXX |
| 99236 | | A | Observ/hosp same date | 4.26 | NA | 1.44 | 0.20 | NA | 5.90 | XXX |
| 99238 | | A | Hospital discharge day | 1.28 | NA | 0.54 | 0.05 | NA | 1.87 | XXX |
| 99239 | | A | Hospital discharge day | 1.75 | NA | 0.60 | 0.07 | NA | 2.42 | XXX |
| 99241 | | A | Office consultation | 0.64 | 0.64 | 0.22 | 0.05 | 1.33 | 0.91 | XXX |
| 99242 | | A | Office consultation | 1.29 | 1.05 | 0.46 | 0.10 | 2.44 | 1.85 | XXX |
| 99243 | | A | Office consultation | 1.72 | 1.39 | 0.63 | 0.13 | 3.24 | 2.48 | XXX |
| 99244 | | A | Office consultation | 2.58 | 1.82 | 0.92 | 0.16 | 4.56 | 3.66 | XXX |
| 99245 | | A | Office consultation | 3.42 | 2.29 | 1.24 | 0.21 | 5.92 | 4.87 | XXX |
| 99251 | | A | Initial inpatient consult | 0.66 | NA | 0.24 | 0.05 | NA | 0.95 | XXX |
| 99252 | | A | Initial inpatient consult | 1.32 | NA | 0.50 | 0.10 | NA | 1.92 | XXX |
| 99253 | | A | Initial inpatient consult | 1.82 | NA | 0.68 | 0.11 | NA | 2.61 | XXX |
| 99254 | | A | Initial inpatient consult | 2.64 | NA | 0.98 | 0.13 | NA | 3.75 | XXX |
| 99255 | | A | Initial inpatient consult | 3.64 | NA | 1.34 | 0.18 | NA | 5.16 | XXX |
| 99261 | | A | Follow-up inpatient consult | 0.42 | NA | 0.15 | 0.02 | NA | 0.59 | XXX |
| 99262 | | A | Follow-up inpatient consult | 0.85 | NA | 0.31 | 0.04 | NA | 1.20 | XXX |
| 99263 | | A | Follow-up inpatient consult | 1.27 | NA | 0.45 | 0.06 | NA | 1.78 | XXX |
| 99271 | | A | Confirmatory consultation | 0.45 | 0.56 | 0.16 | 0.03 | 1.04 | 0.64 | XXX |
| 99272 | | A | Confirmatory consultation | 0.84 | 0.83 | 0.31 | 0.06 | 1.73 | 1.21 | XXX |
| 99273 | | A | Confirmatory consultation | 1.19 | 1.12 | 0.45 | 0.10 | 2.41 | 1.74 | XXX |
| 99274 | | A | Confirmatory consultation | 1.73 | 1.38 | 0.64 | 0.12 | 3.23 | 2.49 | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 99275 | | A | Confirmatory consultation | 2.31 | 1.66 | 0.84 | 0.15 | 4.12 | 3.30 | XXX |
| 99281 | | A | Emergency dept visit | 0.33 | NA | 0.09 | 0.02 | NA | 0.44 | XXX |
| 99282 | | A | Emergency dept visit | 0.55 | NA | 0.14 | 0.04 | NA | 0.73 | XXX |
| 99283 | | A | Emergency dept visit | 1.24 | NA | 0.31 | 0.09 | NA | 1.64 | XXX |
| 99284 | | A | Emergency dept visit | 1.95 | NA | 0.47 | 0.14 | NA | 2.56 | XXX |
| 99285 | | A | Emergency dept visit | 3.06 | NA | 0.72 | 0.23 | NA | 4.01 | XXX |
| 99289 | | A | Ped crit care transport | 4.79 | NA | 1.45 | 0.17 | NA | 6.41 | XXX |
| 99290 | | A | Ped crit care transport addl | 2.40 | NA | 0.81 | 0.08 | NA | 3.29 | ZZZ |
| 99291 | | A | Critical care, first hour | 3.99 | 2.59 | 1.28 | 0.21 | 6.79 | 5.48 | XXX |
| 99292 | | A | Critical care, add-l 30 min | 2.00 | 0.91 | 0.63 | 0.11 | 3.02 | 2.74 | ZZZ |
| 99293 | | A | Ped critical care, initial | 15.98 | NA | 4.74 | 0.21 | NA | 20.93 | XXX |
| 99294 | | A | Ped critical care, subseq | 7.99 | NA | 2.39 | 0.21 | NA | 10.59 | XXX |
| 99295 | | A | Neonate crit care, initial | 18.46 | NA | 5.35 | 1.00 | NA | 24.81 | XXX |
| 99296 | | A | Neonate critical care subseq | 7.99 | NA | 2.53 | 0.34 | NA | 10.86 | XXX |
| 99298 | | A | Ic for lbw infant < 1500 gm | 2.75 | NA | 0.93 | 0.14 | NA | 3.82 | XXX |
| 99299 | | A | Ic, lbw infant 1500-2500 gm | 2.50 | NA | 0.85 | 0.12 | NA | 3.47 | XXX |
| 99301 | | A | Nursing facility care | 1.20 | 0.50 | 0.50 | 0.05 | 1.75 | 1.75 | XXX |
| 99302 | | A | Nursing facility care | 1.61 | 0.64 | 0.64 | 0.07 | 2.32 | 2.32 | XXX |
| 99303 | | A | Nursing facility care | 2.01 | 0.76 | 0.76 | 0.09 | 2.86 | 2.86 | XXX |
| 99311 | | A | Nursing fac care, subseq | 0.60 | 0.28 | 0.28 | 0.03 | 0.91 | 0.91 | XXX |
| 99312 | | A | Nursing fac care, subseq | 1.00 | 0.45 | 0.45 | 0.05 | 1.50 | 1.50 | XXX |
| 99313 | | A | Nursing fac care, subseq | 1.42 | 0.62 | 0.62 | 0.07 | 2.11 | 2.11 | XXX |
| 99315 | | A | Nursing fac discharge day | 1.13 | 0.46 | 0.46 | 0.05 | 1.64 | 1.64 | XXX |
| 99316 | | A | Nursing fac discharge day | 1.50 | 0.59 | 0.59 | 0.07 | 2.16 | 2.16 | XXX |
| 99321 | | A | Rest home visit, new patient | 0.71 | 0.34 | NA | 0.04 | 1.09 | NA | XXX |
| 99322 | | A | Rest home visit, new patient | 1.01 | 0.46 | NA | 0.06 | 1.53 | NA | XXX |
| 99323 | | A | Rest home visit, new patient | 1.28 | 0.55 | NA | 0.06 | 1.89 | NA | XXX |
| 99331 | | A | Rest home visit, est pat | 0.60 | 0.32 | NA | 0.03 | 0.95 | NA | XXX |
| 99332 | | A | Rest home visit, est pat | 0.80 | 0.39 | NA | 0.04 | 1.23 | NA | XXX |
| 99333 | | A | Rest home visit, est pat | 1.00 | 0.46 | NA | 0.05 | 1.51 | NA | XXX |
| 99341 | | A | Home visit, new patient | 1.01 | 0.48 | NA | 0.06 | 1.55 | NA | XXX |
| 99342 | | A | Home visit, new patient | 1.52 | 0.68 | NA | 0.09 | 2.29 | NA | XXX |
| 99343 | | A | Home visit, new patient | 2.27 | 0.94 | NA | 0.12 | 3.33 | NA | XXX |
| 99344 | | A | Home visit, new patient | 3.03 | 1.18 | NA | 0.15 | 4.36 | NA | XXX |
| 99345 | | A | Home visit, new patient | 3.78 | 1.43 | NA | 0.18 | 5.39 | NA | XXX |
| 99347 | | A | Home visit, est patient | 0.76 | 0.40 | NA | 0.04 | 1.20 | NA | XXX |
| 99348 | | A | Home visit, est patient | 1.26 | 0.58 | NA | 0.06 | 1.90 | NA | XXX |
| 99349 | | A | Home visit, est patient | 2.02 | 0.84 | NA | 0.10 | 2.96 | NA | XXX |
| 99350 | | A | Home visit, est patient | 3.03 | 1.18 | NA | 0.15 | 4.36 | NA | XXX |
| 99354 | | A | Prolonged service, office | 1.77 | 0.77 | 0.65 | 0.08 | 2.62 | 2.50 | ZZZ |
| 99355 | | A | Prolonged service, office | 1.77 | 0.75 | 0.62 | 0.08 | 2.60 | 2.47 | ZZZ |
| 99356 | | A | Prolonged service, inpatient | 1.71 | NA | 0.62 | 0.08 | NA | 2.41 | ZZZ |
| 99357 | | A | Prolonged service, inpatient | 1.71 | NA | 0.63 | 0.08 | NA | 2.42 | ZZZ |
| 99374 | | B | Home health care supervision | 1.10 | 0.70 | 0.42 | 0.05 | 1.85 | 1.57 | XXX |
| 99377 | | B | Hospice care supervision | 1.10 | 0.70 | 0.42 | 0.05 | 1.85 | 1.57 | XXX |
| 99379 | | B | Nursing fac care supervision | 1.10 | 0.70 | 0.42 | 0.04 | 1.84 | 1.56 | XXX |
| 99380 | | B | Nursing fac care supervision | 1.73 | 1.00 | 0.65 | 0.06 | 2.79 | 2.44 | XXX |
| 99431 | | A | Initial care, normal newborn | 1.17 | NA | 0.38 | 0.04 | NA | 1.59 | XXX |
| 99432 | | A | Newborn care, not in hosp | 1.26 | 0.93 | 0.40 | 0.05 | 2.24 | 1.71 | XXX |
| 99433 | | A | Normal newborn care/hospital | 0.62 | NA | 0.20 | 0.03 | NA | 0.85 | XXX |
| 99435 | | A | Newborn discharge day hosp | 1.50 | NA | 0.59 | 0.06 | NA | 2.15 | XXX |
| 99436 | | A | Attendance, birth | 1.50 | NA | 0.47 | 0.11 | NA | 2.08 | XXX |
| 99440 | | A | Newborn resuscitation | 2.93 | NA | 0.93 | 0.13 | NA | 3.99 | XXX |
| G0030 | 26 | A | PET imaging prev PET single | 1.50 | 0.58 | 0.58 | 0.05 | 2.13 | 2.13 | XXX |
| G0031 | 26 | A | PET imaging prev PET multple | 1.87 | 0.72 | 0.72 | 0.07 | 2.66 | 2.66 | XXX |
| G0032 | 26 | A | PET follow SPECT 78464 singl | 1.50 | 0.54 | 0.54 | 0.07 | 2.11 | 2.11 | XXX |
| G0033 | 26 | A | PET follow SPECT 78464 mult | 1.87 | 0.73 | 0.73 | 0.07 | 2.67 | 2.67 | XXX |
| G0034 | 26 | A | PET follow SPECT 76865 singl | 1.50 | 0.57 | 0.57 | 0.05 | 2.12 | 2.12 | XXX |
| G0035 | 26 | A | PET follow SPECT 78465 mult | 1.87 | 0.72 | 0.72 | 0.07 | 2.66 | 2.66 | XXX |
| G0036 | 26 | A | PET follow cornry angio sing | 1.50 | 0.56 | 0.56 | 0.05 | 2.11 | 2.11 | XXX |
| G0037 | 26 | A | PET follow cornry angio mult | 1.87 | 0.71 | 0.71 | 0.06 | 2.64 | 2.64 | XXX |
| G0038 | 26 | A | PET follow myocard perf sing | 1.50 | 0.52 | 0.52 | 0.06 | 2.08 | 2.08 | XXX |
| G0039 | 26 | A | PET follow myocard perf mult | 1.87 | 0.71 | 0.71 | 0.07 | 2.65 | 2.65 | XXX |
| G0040 | 26 | A | PET follow stress echo singl | 1.50 | 0.59 | 0.59 | 0.07 | 2.16 | 2.16 | XXX |
| G0041 | 26 | A | PET follow stress echo mult | 1.87 | 0.73 | 0.73 | 0.07 | 2.67 | 2.67 | XXX |
| G0042 | 26 | A | PET follow ventriculogm sing | 1.50 | 0.61 | 0.61 | 0.05 | 2.16 | 2.16 | XXX |
| G0043 | 26 | A | PET follow ventriculogm mult | 1.87 | 0.75 | 0.75 | 0.06 | 2.68 | 2.68 | XXX |
| G0044 | 26 | A | PET following rest ECG singl | 1.50 | 0.59 | 0.59 | 0.05 | 2.14 | 2.14 | XXX |
| G0045 | 26 | A | PET following rest ECG mult | 1.87 | 0.72 | 0.72 | 0.06 | 2.65 | 2.65 | XXX |
| G0046 | 26 | A | PET follow stress ECG singl | 1.50 | 0.59 | 0.59 | 0.05 | 2.14 | 2.14 | XXX |
| G0047 | 26 | A | PET follow stress ECG mult | 1.87 | 0.73 | 0.73 | 0.06 | 2.66 | 2.66 | XXX |
| G0101 | | A | CA screen;pelvic/breast exam | 0.45 | 0.52 | 0.17 | 0.02 | 0.99 | 0.64 | XXX |
| G0102 | | A | Prostate ca screening; dre | 0.17 | 0.40 | 0.06 | 0.01 | 0.58 | 0.24 | XXX |
| G0104 | | A | CA screen;flexi sigmoidscope | 0.96 | 2.30 | 0.50 | 0.08 | 3.34 | 1.54 | 000 |
| G0105 | | A | Colorectal scrn; hi risk ind | 3.69 | 6.20 | 1.47 | 0.24 | 10.13 | 5.40 | 000 |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| G0105 | 53 | A | Colorectal scrn; hi risk ind | 0.96 | 2.30 | 0.50 | 0.08 | 3.34 | 1.54 | 000 |
| G0106 | | A | Colon CA screen;barium enema | 0.99 | 2.55 | NA | 0.17 | 3.71 | NA | XXX |
| G0106 | 26 | A | Colon CA screen;barium enema | 0.99 | 0.32 | 0.32 | 0.04 | 1.35 | 1.35 | XXX |
| G0106 | TC | A | Colon CA screen;barium enema | 0.00 | 2.23 | NA | 0.13 | 2.36 | NA | XXX |
| G0108 | | A | Diab manage trn per indiv | 0.00 | 0.83 | NA | 0.01 | 0.84 | NA | XXX |
| G0109 | | A | Diab manage trn ind/group | 0.00 | 0.48 | NA | 0.01 | 0.49 | NA | XXX |
| G0110 | | R | Nett pulm-rehab educ; ind | 0.90 | 0.68 | 0.29 | 0.04 | 1.62 | 1.23 | XXX |
| G0111 | | R | Nett pulm-rehab educ; group | 0.27 | 0.29 | 0.13 | 0.01 | 0.57 | 0.41 | XXX |
| G0112 | | R | Nett;nutrition guid, initial | 1.72 | 1.21 | 0.65 | 0.07 | 3.00 | 2.44 | XXX |
| G0113 | | R | Nett;nutrition guid,subseqnt | 1.29 | 0.82 | 0.41 | 0.05 | 2.16 | 1.75 | XXX |
| G0114 | | R | Nett; psychosocial consult | 1.20 | 0.48 | 0.37 | 0.04 | 1.72 | 1.61 | XXX |
| G0115 | | R | Nett; psychological testing | 1.20 | 0.84 | 0.37 | 0.03 | 2.07 | 1.60 | XXX |
| G0116 | | R | Nett; psychosocial counsel | 1.11 | 0.98 | 0.33 | 0.03 | 2.12 | 1.47 | XXX |
| G0117 | | T | Glaucoma scrn hgh risk direc | 0.45 | 0.72 | 0.19 | 0.01 | 1.18 | 0.65 | XXX |
| G0118 | | T | Glaucoma scrn hgh risk direc | 0.17 | 0.53 | 0.06 | 0.00 | 0.70 | 0.23 | XXX |
| G0120 | | A | Colon ca scrn; barium enema | 0.99 | 2.55 | NA | 0.17 | 3.71 | NA | XXX |
| G0120 | 26 | A | Colon ca scrn; barium enema | 0.99 | 0.32 | 0.32 | 0.04 | 1.35 | 1.35 | XXX |
| G0120 | TC | A | Colon ca scrn; barium enema | 0.00 | 2.23 | NA | 0.13 | 2.36 | NA | XXX |
| G0121 | | A | Colon ca scrn not hi rsk ind | 3.69 | 6.20 | 1.47 | 0.24 | 10.13 | 5.40 | 000 |
| G0121 | 53 | A | Colon ca scrn not hi rsk ind | 0.96 | 2.30 | 0.50 | 0.08 | 3.34 | 1.54 | 000 |
| G0124 | | A | Screen c/v thin layer by MD | 0.42 | 0.15 | 0.15 | 0.02 | 0.59 | 0.59 | XXX |
| G0125 | 26 | A | PET image pulmonary nodule | 1.50 | 0.52 | 0.52 | 0.07 | 2.09 | 2.09 | XXX |
| G0127 | | R | Trim nail(s) | 0.17 | 0.25 | 0.07 | 0.01 | 0.43 | 0.25 | 000 |
| G0128 | | R | CORF skilled nursing service | 0.08 | 0.03 | 0.03 | 0.01 | 0.12 | 0.12 | XXX |
| G0130 | | A | Single energy x-ray study | 0.22 | 0.87 | NA | 0.06 | 1.15 | NA | XXX |
| G0130 | 26 | A | Single energy x-ray study | 0.22 | 0.07 | 0.07 | 0.01 | 0.30 | 0.30 | XXX |
| G0130 | TC | A | Single energy x-ray study | 0.00 | 0.80 | NA | 0.05 | 0.85 | NA | XXX |
| G0141 | | A | Scr c/v cyto,autosys and md | 0.42 | 0.15 | 0.15 | 0.02 | 0.59 | 0.59 | XXX |
| G0166 | | A | Extrnl counterpulse, per tx | 0.07 | 3.22 | 0.03 | 0.00 | 3.29 | 0.10 | XXX |
| G0168 | | A | Wound closure by adhesive | 0.45 | 1.94 | 0.22 | 0.03 | 2.42 | 0.70 | 000 |
| G0179 | | A | MD recertification HHA PT | 0.45 | 1.06 | NA | 0.02 | 1.53 | NA | XXX |
| G0180 | | A | MD certification HHA patient | 0.67 | 1.29 | NA | 0.04 | 2.00 | NA | XXX |
| G0181 | | A | Home health care supervision | 1.73 | 1.51 | NA | 0.08 | 3.32 | NA | XXX |
| G0182 | | A | Hospice care supervision | 1.73 | 1.71 | NA | 0.07 | 3.51 | NA | XXX |
| G0202 | | A | Screeningmammographydigital | 0.70 | 2.77 | NA | 0.10 | 3.57 | NA | XXX |
| G0202 | 26 | A | Screeningmammographydigital | 0.70 | 0.23 | 0.23 | 0.03 | 0.96 | 0.96 | XXX |
| G0202 | TC | A | Screeningmammographydigital | 0.00 | 2.54 | NA | 0.07 | 2.61 | NA | XXX |
| G0204 | | A | Diagnosticmammographydigital | 0.87 | 2.78 | NA | 0.11 | 3.76 | NA | XXX |
| G0204 | 26 | A | Diagnosticmammographydigital | 0.87 | 0.28 | 0.28 | 0.04 | 1.19 | 1.19 | XXX |
| G0204 | TC | A | Diagnosticmammographydigital | 0.00 | 2.50 | NA | 0.07 | 2.57 | NA | XXX |
| G0206 | | A | Diagnosticmammographydigital | 0.70 | 2.25 | NA | 0.09 | 3.04 | NA | XXX |
| G0206 | 26 | A | Diagnosticmammographydigital | 0.70 | 0.23 | 0.23 | 0.03 | 0.96 | 0.96 | XXX |
| G0206 | TC | A | Diagnosticmammographydigital | 0.00 | 2.02 | NA | 0.06 | 2.08 | NA | XXX |
| G0210 | 26 | A | PET img wholebody dxlung | 1.50 | 0.51 | 0.51 | 0.07 | 2.08 | 2.08 | XXX |
| G0211 | 26 | A | PET img wholbody init lung | 1.50 | 0.51 | 0.51 | 0.07 | 2.08 | 2.08 | XXX |
| G0212 | 26 | A | PET img wholebod restag lung | 1.50 | 0.51 | 0.51 | 0.06 | 2.07 | 2.07 | XXX |
| G0213 | 26 | A | PET img wholbody dx | 1.50 | 0.51 | 0.51 | 0.07 | 2.08 | 2.08 | XXX |
| G0214 | 26 | A | PET img wholebod init | 1.50 | 0.51 | 0.51 | 0.07 | 2.08 | 2.08 | XXX |
| G0215 | 26 | A | PETimg wholebod restag | 1.50 | 0.51 | 0.51 | 0.06 | 2.07 | 2.07 | XXX |
| G0216 | 26 | A | PET img wholebod dx melanoma | 1.50 | 0.51 | 0.51 | 0.06 | 2.07 | 2.07 | XXX |
| G0217 | 26 | A | PET img wholebod init melan | 1.50 | 0.51 | 0.51 | 0.06 | 2.07 | 2.07 | XXX |
| G0218 | 26 | A | PET img wholebod restag mela | 1.50 | 0.52 | 0.52 | 0.06 | 2.08 | 2.08 | XXX |
| G0220 | 26 | A | PET img wholebod dx lymphoma | 1.50 | 0.51 | 0.51 | 0.06 | 2.07 | 2.07 | XXX |
| G0221 | 26 | A | PET imag wholbod init lympho | 1.50 | 0.51 | 0.51 | 0.07 | 2.08 | 2.08 | XXX |
| G0222 | 26 | A | PET imag wholbod resta lymph | 1.50 | 0.52 | 0.52 | 0.06 | 2.08 | 2.08 | XXX |
| G0223 | 26 | A | PET imag wholbod reg dx head | 1.50 | 0.51 | 0.51 | 0.06 | 2.07 | 2.07 | XXX |
| G0224 | 26 | A | PET imag wholbod reg ini hea | 1.50 | 0.51 | 0.51 | 0.06 | 2.07 | 2.07 | XXX |
| G0225 | 26 | A | PET whol restag headneckonly | 1.50 | 0.52 | 0.52 | 0.06 | 2.08 | 2.08 | XXX |
| G0226 | 26 | A | PET img wholbody dx esophagl | 1.50 | 0.53 | 0.53 | 0.06 | 2.09 | 2.09 | XXX |
| G0227 | 26 | A | PET img wholbod ini esophage | 1.50 | 0.52 | 0.52 | 0.06 | 2.08 | 2.08 | XXX |
| G0228 | 26 | A | PET img wholbod restg esopha | 1.50 | 0.51 | 0.51 | 0.06 | 2.07 | 2.07 | XXX |
| G0229 | 26 | A | PET img metaboloc brain pres | 1.50 | 0.52 | 0.52 | 0.07 | 2.09 | 2.09 | XXX |
| G0230 | 26 | A | PET myocard viability post | 1.50 | 0.53 | 0.53 | 0.06 | 2.09 | 2.09 | XXX |
| G0231 | 26 | A | PET WhBD colorec; gamma cam | 1.50 | 0.51 | 0.51 | 0.06 | 2.07 | 2.07 | XXX |
| G0232 | 26 | A | PET whbd lymphoma; gamma cam | 1.50 | 0.52 | 0.52 | 0.06 | 2.08 | 2.08 | XXX |
| G0233 | 26 | A | PET whbd melanoma; gamma cam | 1.50 | 0.52 | 0.52 | 0.06 | 2.08 | 2.08 | XXX |
| G0234 | 26 | A | PET WhBD pulm nod; gamma cam | 1.50 | 0.52 | 0.52 | 0.06 | 2.08 | 2.08 | XXX |
| G0237 | | A | Therapeutic procd strg endur | 0.00 | 0.47 | NA | 0.02 | 0.49 | NA | XXX |
| G0238 | | A | Oth resp proc, indiv | 0.00 | 0.47 | NA | 0.02 | 0.49 | NA | XXX |
| G0239 | | A | Oth resp proc, group | 0.00 | 0.32 | NA | 0.02 | 0.34 | NA | XXX |
| G0245 | | R | Initial foot exam pt lops | 0.88 | 0.79 | 0.31 | 0.05 | 1.72 | 1.24 | XXX |
| G0246 | | R | Followup eval of foot pt lop | 0.45 | 0.54 | 0.16 | 0.03 | 1.02 | 0.64 | XXX |
| G0247 | | R | Routine footcare pt w lops | 0.50 | 0.52 | 0.21 | 0.03 | 1.05 | 0.74 | ZZZ |
| G0248 | | R | Demonstrate use home inr mon | 0.00 | 6.61 | NA | 0.01 | 6.62 | NA | XXX |
| G0249 | | R | Provide test material,equipm | 0.00 | 3.97 | NA | 0.01 | 3.98 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare Payments.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

| CPT [1]/ HCPCS [2] | MOD | Status | Description | Physician work RVUs [3] | Non-facility PE RVUs | Facility PE RVUs | Mal-practice RVUs | Non-facility Total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| G0250 | | R | MD review interpret of test | 0.18 | 0.06 | 0.06 | 0.01 | 0.25 | 0.25 | XXX |
| G0253 | 26 | A | PET image brst dection recur | 1.87 | 0.63 | 0.63 | 0.06 | 2.56 | 2.56 | XXX |
| G0254 | 26 | A | PET image brst eval to tx | 1.87 | 0.65 | 0.65 | 0.06 | 2.58 | 2.58 | XXX |
| G0268 | | A | Removal of impacted wax md | 0.61 | 0.63 | 0.24 | 0.02 | 1.26 | 0.87 | 000 |
| G0270 | | A | MNT subs tx for change dx | 0.00 | 0.47 | NA | 0.01 | 0.48 | NA | XXX |
| G0271 | | A | Group MNT 2 or more 30 mins | 0.00 | 0.18 | NA | 0.01 | 0.19 | NA | XXX |
| G0275 | | A | Renal angio, cardiac cath | 0.25 | NA | 0.10 | 0.01 | NA | 0.36 | ZZZ |
| G0278 | | A | Iliac art angio,cardiac cath | 0.25 | NA | 0.10 | 0.01 | NA | 0.36 | ZZZ |
| G0281 | | A | Elec stim unattend for press | 0.18 | 0.11 | NA | 0.01 | 0.30 | NA | XXX |
| G0283 | | A | Elec stim other than wound | 0.18 | 0.11 | NA | 0.01 | 0.30 | NA | XXX |
| G0288 | | A | Recon, CTA for surg plan | 0.00 | 10.60 | NA | 0.18 | 10.78 | NA | XXX |
| G0289 | | A | Arthro, loose body + chondro | 1.48 | NA | 0.80 | 0.33 | NA | 2.61 | ZZZ |
| G0296 | 26 | A | PET imge restag thyrod cance | 1.87 | 0.71 | 0.71 | 0.08 | 2.66 | 2.66 | XXX |
| G0308 | | A | ESRD related svc 4+mo<2yrs | 12.74 | 8.54 | 8.54 | 0.42 | 21.70 | 21.70 | XXX |
| G0309 | | A | ESRD related svc 2-3mo<2yrs | 10.61 | 7.10 | 7.10 | 0.36 | 18.07 | 18.07 | XXX |
| G0310 | | A | ESRD related svc 1 visit<2yr | 8.49 | 5.68 | 5.68 | 0.28 | 14.45 | 14.45 | XXX |
| G0311 | | A | ESRD related svs 4+mo 2-11yr | 9.73 | 4.72 | 4.72 | 0.34 | 14.79 | 14.79 | XXX |
| G0312 | | A | ESRD relate svs 2-3 mo 2-11y | 8.11 | 3.92 | 3.92 | 0.29 | 12.32 | 12.32 | XXX |
| G0313 | | A | ESRD related svs 1 mon 2-11y | 6.49 | 3.14 | 3.14 | 0.22 | 9.85 | 9.85 | XXX |
| G0314 | | A | ESRD related svs 4+ mo 12-19 | 8.28 | 4.42 | 4.42 | 0.27 | 12.97 | 12.97 | XXX |
| G0315 | | A | ESRD related svs 2-3mo 12-19 | 6.90 | 3.67 | 3.67 | 0.23 | 10.80 | 10.80 | XXX |
| G0316 | | A | ESRD relate svs 1 vist 12-19 | 5.52 | 2.94 | 2.94 | 0.17 | 8.63 | 8.63 | XXX |
| G0317 | | A | ESRD related svs 4+mo 20+yrs | 5.09 | 2.86 | 2.86 | 0.17 | 8.12 | 8.12 | XXX |
| G0318 | | A | ESRD related svs 2-3 mo 20+y | 4.24 | 2.38 | 2.38 | 0.14 | 6.76 | 6.76 | XXX |
| G0319 | | A | ESRD related svs 1 visit 20+ | 3.39 | 1.90 | 1.90 | 0.11 | 5.40 | 5.40 | XXX |
| G0320 | | A | ESRD related svs home under2 | 10.61 | 7.10 | 7.10 | 0.36 | 18.07 | 18.07 | XXX |
| G0321 | | A | ESRDrelatedsvs home mo 2-11y | 8.11 | 3.92 | 3.92 | 0.23 | 12.26 | 12.26 | XXX |
| G0322 | | A | ESRD relate svs home mo12-19 | 6.90 | 3.67 | 3.67 | 0.29 | 10.86 | 10.86 | XXX |
| G0323 | | A | ESRD related svs home mo 20+ | 4.24 | 2.38 | 2.38 | 0.14 | 6.76 | 6.76 | XXX |
| G0324 | | A | ESRD related svs home/dy<2y | 0.35 | 0.24 | 0.24 | 0.01 | 0.60 | 0.60 | XXX |
| G0325 | | A | ESRD relate home/dy 2-11 yr | 0.23 | 0.12 | 0.12 | 0.01 | 0.36 | 0.36 | XXX |
| G0326 | | A | ESRD relate home/dy 12-19y | 0.27 | 0.13 | 0.13 | 0.01 | 0.41 | 0.41 | XXX |
| G0327 | | A | ESRD relate home/dy 20+yrs | 0.14 | 0.08 | 0.08 | 0.01 | 0.23 | 0.23 | XXX |
| G0329 | | A | Electromagntic tx for ulcers | 0.06 | 0.12 | 0.02 | 0.01 | 0.19 | 0.09 | XXX |
| G0XX1 | | A | Bone marrow aspir | 0.16 | 0.21 | 0.08 | 0.04 | 0.41 | 0.28 | ZZZ |
| G0XX2 | | A | Preventative exam | 1.51 | 1.65 | 0.54 | 0.13 | 3.29 | 2.18 | XXX |
| G0XX3 | | A | Venous mapping | 0.45 | 3.28 | NA | 0.30 | 4.03 | NA | XXX |
| G0XX3 | 26 | A | Venous mapping | 0.45 | 0.15 | 0.15 | 0.03 | 0.63 | 0.63 | XXX |
| G0XX3 | TC | A | Venous mapping | 0.00 | 3.13 | NA | 0.27 | 3.40 | NA | XXX |
| G0XX4 | | X | Hospice, pre-elect | 1.34 | 0.00 | 0.00 | 0.10 | 1.44 | 1.44 | XXX |
| M0064 | | A | Visit for drug monitoring | 0.37 | 0.34 | 0.12 | 0.01 | 0.72 | 0.50 | XXX |
| P3001 | | A | Screening pap smear by phys | 0.42 | 0.15 | 0.15 | 0.02 | 0.59 | 0.59 | XXX |
| Q0035 | | A | Cardiokymography | 0.17 | 0.45 | NA | 0.03 | 0.65 | NA | XXX |
| Q0035 | 26 | A | Cardiokymography | 0.17 | 0.06 | 0.06 | 0.01 | 0.24 | 0.24 | XXX |
| Q0035 | TC | A | Cardiokymography | 0.00 | 0.39 | NA | 0.02 | 0.41 | NA | XXX |
| Q0091 | | A | Obtaining screen pap smear | 0.37 | 0.67 | 0.14 | 0.02 | 1.06 | 0.53 | XXX |
| Q0092 | | A | Set up port xray equipment | 0.00 | 0.32 | NA | 0.01 | 0.33 | NA | XXX |

[1] CPT codes and descriptions only are copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 2004 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payment.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS

| CPT code | Short descriptors |
|---|---|
| 00100 | Disability examination |
| 00102 | Anesth, salivary gland |
| 00103 | Anesth, repair of cleft lip |
| 00120 | Anesth, blepharoplasty |
| 00126 | Anesth, ear surgery |
| 00140 | Anesth, tympanotomy |
| 00142 | Anesth, procedures on eye |
| 00144 | Anesth, lens surgery |
| 00145 | Anesth, corneal transplant |
| 00147 | Anesth, vitreoretinal surg |
| 00148 | Anesth, iridectomy |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 00160 | Anesth, eye exam |
| 00162 | Anesth, nose/sinus surgery |
| 00164 | Anesth, nose/sinus surgery |
| 00170 | Anesth, biopsy of nose |
| 00172 | Anesth, procedure on mouth |
| 00174 | Anesth, cleft palate repair |
| 00176 | Anesth, pharyngeal surgery |
| 00190 | Anesth, pharyngeal surgery |
| 00192 | Anesth, face/skull bone surg |
| 00210 | Anesth, facial bone surgery |
| 00212 | Anesth, open head surgery |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 00214 | Anesth, skull drainage |
| 00215 | Anesth, skull drainage |
| 00216 | Anesth, skull repair/fract |
| 00218 | Anesth, head vessel surgery |
| 00220 | Anesth, special head surgery |
| 00222 | Anesth, intrcrn nerve |
| 00300 | Anesth, head nerve surgery |
| 00320 | Anesth, head/neck/ptrunk |
| 00322 | Anesth, neck organ, 1 & over |
| 00326 | Anesth, biopsy of thyroid |
| 00350 | Anesth, larynx/trach, < 1 yr |

Some of these codes have previously been refined and additional refinements were made by the PEAC.
All anesthesia codes were reviewed with the exception of 00104 abd 00124.
CPT codes and descriptions are copyright 2004 by the AMA, all rights reserved.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 00352 | Anesth, neck vessel surgery |
| 00400 | Anesth, neck vessel surgery |
| 00402 | Anesth, skin, ext/per/atrunk |
| 00404 | Anesth, surgery of breast |
| 00406 | Anesth, surgery of breast |
| 00410 | Anesth, surgery of breast |
| 00450 | Anesth, correct heart rhythm |
| 00452 | Anesth, surgery of shoulder |
| 00454 | Anesth, surgery of shoulder |
| 00470 | Anesth, collar bone biopsy |
| 00472 | Anesth, removal of rib |
| 00474 | Anesth, chest wall repair |
| 00500 | Anesth, surgery of rib(s) |
| 00520 | Anesth, esophageal surgery |
| 00522 | Anesth, chest procedure |
| 00524 | Anesth, chest lining biopsy |
| 00528 | Anesth, chest drainage |
| 00529 | Anesth, chest partition view |
| 00530 | Anesth, chest partition view |
| 00532 | Anesth, pacemaker insertion |
| 00534 | Anesth, vascular access |
| 00537 | Anesth, cardioverter/defib |
| 00539 | Anesth, cardiac electrophys |
| 00540 | Anesth, trach-bronch reconst |
| 00541 | Anesth, chest surgery |
| 00542 | Anesth, one lung ventilation |
| 00546 | Anesth, release of lung |
| 00548 | Anesth, lung,chest wall surg |
| 00550 | Anesth, trachea,bronchi surg |
| 00560 | Anesth, sternal debridement |
| 00562 | Anesth, open heart surgery |
| 00563 | Anesth, open heart surgery |
| 00566 | Anesth, heart proc w/pump |
| 00580 | Anesth, cabg w/o pump |
| 00600 | Anesth, heart/lung transplnt |
| 00604 | Anesth, spine, cord surgery |
| 00620 | Anesth, sitting procedure |
| 00622 | Anesth, spine, cord surgery |
| 00630 | Anesth, removal of nerves |
| 00632 | Anesth, spine, cord surgery |
| 00634 | Anesth, removal of nerves |
| 00635 | Anesth for chemonucleolysis |
| 00640 | Anesth, lumbar puncture |
| 00670 | Anesth, spine manipulation |
| 00700 | Anesth, spine, cord surgery |
| 00702 | Anesth, abdominal wall surg |
| 00730 | Anesth, for liver biopsy |
| 00740 | Anesth, abdominal wall surg |
| 00750 | Anesth, upper gi visualize |
| 00752 | Anesth, repair of hernia |
| 00754 | Anesth, repair of hernia |
| 00756 | Anesth, repair of hernia |
| 00770 | Anesth, repair of hernia |
| 00790 | Anesth, blood vessel repair |
| 00792 | Anesth, surg upper abdomen |
| 00794 | Anesth, hemorr/excise liver |
| 00796 | Anesth, pancreas removal |
| 00797 | Anesth, for liver transplant |
| 00800 | Anesth, surgery for obesity |
| 00802 | Anesth, abdominal wall surg |
| 00810 | Anesth, fat layer removal |
| 00820 | Anesth, low intestine scope |
| 00830 | Anesth, abdominal wall surg |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 00832 | Anesth, repair of hernia |
| 00834 | Anesth, repair of hernia |
| 00836 | Anesth, hernia repair< 1 yr |
| 00840 | Anesth hernia repair preemie |
| 00842 | Anesth, surg lower abdomen |
| 00844 | Anesth, amniocentesis |
| 00846 | Anesth, pelvis surgery |
| 00848 | Anesth, hysterectomy |
| 00851 | Anesth, pelvic organ surg |
| 00860 | Anesth, tubal ligation |
| 00862 | Anesth, surgery of abdomen |
| 00864 | Anesth, kidney/ureter surg |
| 00865 | Anesth, removal of bladder |
| 00866 | Anesth, removal of prostate |
| 00868 | Anesth, removal of adrenal |
| 00870 | Anesth, kidney transplant |
| 00872 | Anesth, bladder stone surg |
| 00873 | Anesth kidney stone destruct |
| 00880 | Anesth kidney stone destruct |
| 00882 | Anesth, abdomen vessel surg |
| 00902 | Anesth, major vein ligation |
| 00904 | Anesth, anorectal surgery |
| 00906 | Anesth, perineal surgery |
| 00908 | Anesth, removal of vulva |
| 00910 | Anesth, removal of prostate |
| 00912 | Anesth, bladder surgery |
| 00914 | Anesth, bladder tumor surg |
| 00916 | Anesth, removal of prostate |
| 00918 | Anesth, bleeding control |
| 00920 | Anesth, stone removal |
| 00921 | Anesth, genitalia surgery |
| 00922 | Anesth, vasectomy |
| 00924 | Anesth, sperm duct surgery |
| 00926 | Anesth, testis exploration |
| 00928 | Anesth, removal of testis |
| 00930 | Anesth, removal of testis |
| 00932 | Anesth, testis suspension |
| 00934 | Anesth, amputation of penis |
| 00936 | Anesth, penis, nodes removal |
| 00938 | Anesth, penis, nodes removal |
| 00940 | Anesth, insert penis device |
| 00942 | Anesth, vaginal procedures |
| 00944 | Anesth, surg on vag/urethral |
| 00948 | Anesth, vaginal hysterectomy |
| 00950 | Anesth, repair of cervix |
| 00952 | Anesth, vaginal endoscopy |
| 01112 | Anesth, hysteroscope/graph |
| 01120 | Anesth, bone aspirate/bx |
| 01130 | Anesth, pelvis surgery |
| 01140 | Anesth, body cast procedure |
| 01150 | Anesth, amputation at pelvis |
| 01160 | Anesth, pelvic tumor surgery |
| 01170 | Anesth, pelvis procedure |
| 01173 | Anesth, pelvis surgery |
| 01180 | Anesth, fx repair, pelvis |
| 01190 | Anesth, pelvis nerve removal |
| 01200 | Anesth, pelvis nerve removal |
| 01202 | Anesth, hip joint procedure |
| 01210 | Anesth, arthroscopy of hip |
| 01212 | Anesth, hip joint surgery |
| 01214 | Anesth, hip disarticulation |
| 01215 | Anesth, hip arthroplasty |
| 01220 | Anesth, revise hip repair |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 01230 | Anesth, procedure on femur |
| 01232 | Anesth, surgery of femur |
| 01234 | Anesth, amputation of femur |
| 01250 | Anesth, radical femur surg |
| 01260 | Anesth, upper leg surgery |
| 01270 | Anesth, upper leg veins surg |
| 01272 | Anesth, thigh arteries surg |
| 01274 | Anesth, femoral artery surg |
| 01320 | Anesth, femoral embolectomy |
| 01340 | Anesth, knee area surgery |
| 01360 | Anesth, knee area procedure |
| 01380 | Anesth, knee area surgery |
| 01382 | Anesth, knee joint procedure |
| 01390 | Anesth, dx knee arthroscopy |
| 01392 | Anesth, knee area procedure |
| 01400 | Anesth, knee area surgery |
| 01402 | Anesth, knee joint surgery |
| 01404 | Anesth, knee arthroplasty |
| 01420 | Anesth, amputation at knee |
| 01430 | Anesth, knee joint casting |
| 01432 | Anesth, knee veins surgery |
| 01440 | Anesth, knee vessel surg |
| 01442 | Anesth, knee arteries surg |
| 01444 | Anesth, knee artery surg |
| 01462 | Anesth, knee artery repair |
| 01464 | Anesth, lower leg procedure |
| 01470 | Anesth, ankle/ft arthroscopy |
| 01472 | Anesth, lower leg surgery |
| 01474 | Anesth, achilles tendon surg |
| 01480 | Anesth, lower leg surgery |
| 01482 | Anesth, lower leg bone surg |
| 01484 | Anesth, radical leg surgery |
| 01486 | Anesth, lower leg revision |
| 01490 | Anesth, ankle replacement |
| 01500 | Anesth, lower leg casting |
| 01502 | Anesth, leg arteries surg |
| 01520 | Anesth, lwr leg embolectomy |
| 01522 | Anesth, lower leg vein surg |
| 01610 | Anesth, lower leg vein surg |
| 01620 | Anesth, surgery of shoulder |
| 01622 | Anesth, shoulder procedure |
| 01630 | Anes dx shoulder arthroscopy |
| 01632 | Anesth, surgery of shoulder |
| 01634 | Anesth, surgery of shoulder |
| 01636 | Anesth, shoulder joint amput |
| 01638 | Anesth, forequarter amput |
| 01650 | Anesth, shoulder replacement |
| 01652 | Anesth, shoulder artery surg |
| 01654 | Anesth, shoulder vessel surg |
| 01656 | Anesth, shoulder vessel surg |
| 01670 | Anesth, arm-leg vessel surg |
| 01680 | Anesth, shoulder vein surg |
| 01682 | Anesth, shoulder casting |
| 01710 | Anesth, airplane cast |
| 01712 | Anesth, elbow area surgery |
| 01714 | Anesth, uppr arm tendon surg |
| 01716 | Anesth, uppr arm tendon surg |
| 01730 | Anesth, biceps tendon repair |
| 01732 | Anesth, uppr arm procedure |
| 01740 | Anesth, dx elbow arthroscopy |
| 01742 | Anesth, upper arm surgery |
| 01744 | Anesth, humerus surgery |
| 01756 | Anesth, humerus repair |

Some of these codes have previously been refined and additional refinements were made by the PEAC.
All anesthesia codes were reviewed with the exception of 00104 abd 00124.
CPT codes and descriptions are copyright 2004 by the AMA, all rights reserved.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 01758 | Anesth, radical humerus surg |
| 01760 | Anesth, humeral lesion surg |
| 01770 | Anesth, elbow replacement |
| 01772 | Anesth, uppr arm artery surg |
| 01780 | Anesth, uppr arm embolectomy |
| 01782 | Anesth, upper arm vein surg |
| 01810 | Anesth, uppr arm vein repair |
| 01820 | Anesth, lower arm surgery |
| 01829 | Anesth, lower arm procedure |
| 01830 | Anesth, dx wrist arthroscopy |
| 01832 | Anesth, lower arm surgery |
| 01840 | Anesth, wrist replacement |
| 01842 | Anesth, lwr arm artery surg |
| 01844 | Anesth, lwr arm embolectomy |
| 01850 | Anesth, vascular shunt surg |
| 01852 | Anesth, lower arm vein surg |
| 01860 | Anesth, lwr arm vein repair |
| 01905 | Anesth, lower arm casting |
| 01916 | Anes, spine inject, x-ray/re |
| 01920 | Anesth, dx arteriography |
| 01922 | Anesth, catheterize heart |
| 01924 | Anesth, cat or MRI scan |
| 01925 | Anes, ther interven rad, art |
| 01926 | Anes, ther interven rad, car |
| 01930 | Anes, tx interv rad hrt/cran |
| 01931 | Anes, ther interven rad, vei |
| 01932 | Anes, ther interven rad, tip |
| 01933 | Anes, tx interv rad, th vein |
| 01951 | Anes, tx interv rad, cran v |
| 01952 | Anesth, burn, less 4 percent |
| 01953 | Anesth, burn, 4-9 percent |
| 01958 | Anesth, burn, each 9 percent |
| 01960 | Anesth, antepartum manipul |
| 01961 | Anesth, vaginal delivery |
| 01962 | Anesth, cs delivery |
| 01963 | Anesth, emer hysterectomy |
| 01964 | Anesth, cs hysterectomy |
| 01967 | Anesth, abortion procedures |
| 01968 | Anesth/analg, vag delivery |
| 01969 | Anes/analg cs deliver add-on |
| 01990 | Anesth/analg cs hyst add-on |
| 01991 | Support for organ donor |
| 01992 | Anesth, nerve block/inj |
| 01995 | Anesth, n block/inj, prone |
| 01996 | Regional anesthesia limb |
| 01999 | Hosp manage cont drug admin |
| 10120 | Remove foreign body |
| 10121 | Remove foreign body |
| 10140 | Drainage of hematoma/fluid |
| 10160 | Puncture drainage of lesion |
| 10180 | Complex drainage, wound |
| 11010 | Debride skin, fx |
| 11011 | Debride skin/muscle, fx |
| 11012 | Debride skin/muscle/bone, fx |
| 11740 | Drain blood from under nail |
| 11755 | Biopsy, nail unit |
| 11760 | Repair of nail bed |
| 11762 | Reconstruction of nail bed |
| 11765 | Excision of nail fold, toe |
| 11772 | Removal of pilonidal lesion |
| 11920 | Correct skin color defects |
| 11921 | Correct skin color defects |
| 11922 | Correct skin color defects |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 11971 | Remove tissue expander(s) |
| 12020 | Closure of split wound |
| 12021 | Closure of split wound |
| 12036 | Layer closure of wound(s) |
| 12037 | Layer closure of wound(s) |
| 12045 | Layer closure of wound(s) |
| 13100 | Repair of wound or lesion |
| 13101 | Repair of wound or lesion |
| 13102 | Repair wound/lesion add-on |
| 13120 | Repair of wound or lesion |
| 13121 | Repair of wound or lesion |
| 13122 | Repair wound/lesion add-on |
| 13131 | Repair of wound or lesion |
| 13132 | Repair of wound or lesion |
| 13133 | Repair wound/lesion add-on |
| 13150 | Repair of wound or lesion |
| 13151 | Repair of wound or lesion |
| 13152 | Repair of wound or lesion |
| 13153 | Repair wound/lesion add-on |
| 14000 | Skin tissue rearrangement |
| 14001 | Skin tissue rearrangement |
| 14020 | Skin tissue rearrangement |
| 14021 | Skin tissue rearrangement |
| 14040 | Skin tissue rearrangement |
| 14060 | Skin tissue rearrangement |
| 15050 | Skin pinch graft |
| 15200 | Skin full graft |
| 15201 | Skin full graft add-on |
| 15220 | Skin full graft |
| 15221 | Skin full graft add-on |
| 15240 | Skin full graft |
| 15241 | Skin full graft add-on |
| 15260 | Skin full graft |
| 15350 | Skin homograft |
| 15351 | Skin homograft add-on |
| 15400 | Skin heterograft |
| 15401 | Skin heterograft add-on |
| 15570 | Form skin pedicle flap |
| 15572 | Form skin pedicle flap |
| 15574 | Form skin pedicle flap |
| 15576 | Form skin pedicle flap |
| 15600 | Skin graft |
| 15610 | Skin graft |
| 15620 | Skin graft |
| 15630 | Skin graft |
| 15650 | Transfer skin pedicle flap |
| 15740 | Island pedicle flap graft |
| 15760 | Composite skin graft |
| 15780 | Abrasion treatment of skin |
| 15781 | Abrasion treatment of skin |
| 15782 | Abrasion treatment of skin |
| 15783 | Abrasion treatment of skin |
| 15786 | Abrasion, lesion, single |
| 15787 | Abrasion, lesions, add-on |
| 15788 | Chemical peel, face, epiderm |
| 15789 | Chemical peel, face, dermal |
| 15792 | Chemical peel, nonfacial |
| 15793 | Chemical peel, nonfacial |
| 15810 | Salabrasion |
| 15811 | Salabrasion |
| 15835 | Excise excessive skin tissue |
| 15837 | Excise excessive skin tissue |
| 15839 | Excise excessive skin tissue |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 15860 | Test for blood flow in graft |
| 19000 | Drainage of breast lesion |
| 19001 | Drain breast lesion add-on |
| 19020 | Incision of breast lesion |
| 19030 | Injection for breast x-ray |
| 19110 | Nipple exploration |
| 19112 | Excise breast duct fistula |
| 19291 | Place needle wire, breast |
| 19295 | Place breast clip, percut |
| 19350 | Breast reconstruction |
| 19355 | Correct inverted nipple(s) |
| 20000 | Incision of abscess |
| 20005 | Incision of deep abscess |
| 20100 | Explore wound, neck |
| 20101 | Explore wound, chest |
| 20102 | Explore wound, abdomen |
| 20103 | Explore wound, extremity |
| 20150 | Excise epiphyseal bar |
| 20206 | Needle biopsy, muscle |
| 20220 | Bone biopsy, trocar/needle |
| 20225 | Bone biopsy, trocar/needle |
| 20240 | Bone biopsy, excisional |
| 20245 | Bone biopsy, excisional |
| 20250 | Open bone biopsy |
| 20251 | Open bone biopsy |
| 20520 | Removal of foreign body |
| 20525 | Removal of foreign body |
| 20615 | Treatment of bone cyst |
| 20650 | Insert and remove bone pin |
| 20670 | Removal of support implant |
| 20680 | Removal of support implant |
| 20690 | Apply bone fixation device |
| 20694 | Remove bone fixation device |
| 20900 | Removal of bone for graft |
| 20910 | Remove cartilage for graft |
| 20922 | Removal of fascia for graft |
| 20950 | Fluid pressure, muscle |
| 20972 | Bone/skin graft, metatarsal |
| 20974 | Electrical bone stimulation |
| 20975 | Electrical bone stimulation |
| 21025 | Excision of bone, lower jaw |
| 21026 | Excision of facial bone(s) |
| 21029 | Contour of face bone lesion |
| 21030 | Excise max/zygoma b9 tumor |
| 21031 | Remove exostosis, mandible |
| 21032 | Remove exostosis, maxilla |
| 21034 | Excise max/zygoma mlg tumor |
| 21040 | Excise mandible lesion |
| 21044 | Removal of jaw bone lesion |
| 21045 | Extensive jaw surgery |
| 21050 | Removal of jaw joint |
| 21060 | Remove jaw joint cartilage |
| 21070 | Remove coronoid process |
| 21100 | Maxillofacial fixation |
| 21110 | Interdental fixation |
| 21116 | Injection, jaw joint x-ray |
| 21120 | Reconstruction of chin |
| 21121 | Reconstruction of chin |
| 21122 | Reconstruction of chin |
| 21123 | Reconstruction of chin |
| 21125 | Augmentation, lower jaw bone |
| 21127 | Augmentation, lower jaw bone |
| 21137 | Reduction of forehead |

Some of these codes have previously been refined and additional refinements were made by the PEAC.
All anesthesia codes were reviewed with the exception of 00104 abd 00124.
CPT codes and descriptions are copyright 2004 by the AMA, all rights reserved.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 21138 | Reduction of forehead |
| 21139 | Reduction of forehead |
| 21143 | Reconstruct midface, lefort |
| 21150 | Reconstruct midface, lefort |
| 21151 | Reconstruct midface, lefort |
| 21154 | Reconstruct midface, lefort |
| 21155 | Reconstruct midface, lefort |
| 21159 | Reconstruct midface, lefort |
| 21160 | Reconstruct midface, lefort |
| 21188 | Reconstruction of midface |
| 21195 | Reconst lwr jaw w/o fixation |
| 21196 | Reconst lwr jaw w/fixation |
| 21198 | Reconstr lwr jaw segment |
| 21206 | Reconstruct upper jaw bone |
| 21208 | Augmentation of facial bones |
| 21209 | Reduction of facial bones |
| 21210 | Face bone graft |
| 21215 | Lower jaw bone graft |
| 21235 | Ear cartilage graft |
| 21244 | Reconstruction of lower jaw |
| 21245 | Reconstruction of jaw |
| 21246 | Reconstruction of jaw |
| 21248 | Reconstruction of jaw |
| 21249 | Reconstruction of jaw |
| 21255 | Reconstruct lower jaw bone |
| 21260 | Revise eye sockets |
| 21261 | Revise eye sockets |
| 21263 | Revise eye sockets |
| 21267 | Revise eye sockets |
| 21268 | Revise eye sockets |
| 21270 | Augmentation, cheek bone |
| 21295 | Revision of jaw muscle/bone |
| 21296 | Revision of jaw muscle/bone |
| 21315 | Treatment of nose fracture |
| 21320 | Treatment of nose fracture |
| 21325 | Treatment of nose fracture |
| 21330 | Treatment of nose fracture |
| 21335 | Treatment of nose fracture |
| 21336 | Treat nasal septal fracture |
| 21337 | Treat nasal septal fracture |
| 21338 | Treat nasoethmoid fracture |
| 21339 | Treat nasoethmoid fracture |
| 21343 | Treatment of sinus fracture |
| 21344 | Treatment of sinus fracture |
| 21345 | Treat nose/jaw fracture |
| 21346 | Treat nose/jaw fracture |
| 21347 | Treat nose/jaw fracture |
| 21355 | Treat cheek bone fracture |
| 21356 | Treat cheek bone fracture |
| 21360 | Treat cheek bone fracture |
| 21365 | Treat cheek bone fracture |
| 21385 | Treat eye socket fracture |
| 21386 | Treat eye socket fracture |
| 21387 | Treat eye socket fracture |
| 21400 | Treat eye socket fracture |
| 21401 | Treat eye socket fracture |
| 21421 | Treat mouth roof fracture |
| 21422 | Treat mouth roof fracture |
| 21423 | Treat mouth roof fracture |
| 21431 | Treat craniofacial fracture |
| 21432 | Treat craniofacial fracture |
| 21440 | Treat dental ridge fracture |
| 21445 | Treat dental ridge fracture |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 21450 | Treat lower jaw fracture |
| 21451 | Treat lower jaw fracture |
| 21452 | Treat lower jaw fracture |
| 21453 | Treat lower jaw fracture |
| 21461 | Treat lower jaw fracture |
| 21462 | Treat lower jaw fracture |
| 21485 | Reset dislocated jaw |
| 21493 | Treat hyoid bone fracture |
| 21494 | Treat hyoid bone fracture |
| 21495 | Treat hyoid bone fracture |
| 21497 | Interdental wiring |
| 21501 | Drain neck/chest lesion |
| 21555 | Remove lesion, neck/chest |
| 21700 | Revision of neck muscle |
| 21720 | Revision of neck muscle |
| 21800 | Treatment of rib fracture |
| 21820 | Treat sternum fracture |
| 21925 | Biopsy soft tissue of back |
| 21930 | Remove lesion, back or flank |
| 22305 | Treat spine process fracture |
| 22310 | Treat spine fracture |
| 22315 | Treat spine fracture |
| 23000 | Removal of calcium deposits |
| 23030 | Drain shoulder lesion |
| 23031 | Drain shoulder bursa |
| 23065 | Biopsy shoulder tissues |
| 23066 | Biopsy shoulder tissues |
| 23075 | Removal of shoulder lesion |
| 23330 | Remove shoulder foreign body |
| 23350 | Injection for shoulder x-ray |
| 23500 | Treat clavicle fracture |
| 23505 | Treat clavicle fracture |
| 23520 | Treat clavicle dislocation |
| 23525 | Treat clavicle dislocation |
| 23540 | Treat clavicle dislocation |
| 23545 | Treat clavicle dislocation |
| 23570 | Treat shoulder blade fx |
| 23575 | Treat shoulder blade fx |
| 23600 | Treat humerus fracture |
| 23605 | Treat humerus fracture |
| 23620 | Treat humerus fracture |
| 23625 | Treat humerus fracture |
| 23650 | Treat shoulder dislocation |
| 23665 | Treat dislocation/fracture |
| 23675 | Treat dislocation/fracture |
| 23700 | Fixation of shoulder |
| 23921 | Amputation follow-up surgery |
| 23930 | Drainage of arm lesion |
| 23931 | Drainage of arm bursa |
| 24065 | Biopsy arm/elbow soft tissue |
| 24066 | Biopsy arm/elbow soft tissue |
| 24075 | Remove arm/elbow lesion |
| 24200 | Removal of arm foreign body |
| 24201 | Removal of arm foreign body |
| 24220 | Injection for elbow x-ray |
| 24500 | Treat humerus fracture |
| 24505 | Treat humerus fracture |
| 24530 | Treat humerus fracture |
| 24535 | Treat humerus fracture |
| 24560 | Treat humerus fracture |
| 24565 | Treat humerus fracture |
| 24576 | Treat humerus fracture |
| 24577 | Treat humerus fracture |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 24600 | Treat elbow dislocation |
| 24640 | Treat elbow dislocation |
| 24650 | Treat radius fracture |
| 24655 | Treat radius fracture |
| 24670 | Treat ulnar fracture |
| 24675 | Treat ulnar fracture |
| 25065 | Biopsy forearm soft tissues |
| 25246 | Injection for wrist x-ray |
| 25500 | Treat fracture of radius |
| 25505 | Treat fracture of radius |
| 25520 | Treat fracture of radius |
| 25530 | Treat fracture of ulna |
| 25535 | Treat fracture of ulna |
| 25560 | Treat fracture radius & ulna |
| 25565 | Treat fracture radius & ulna |
| 25600 | Treat fracture radius/ulna |
| 25605 | Treat fracture radius/ulna |
| 25622 | Treat wrist bone fracture |
| 25624 | Treat wrist bone fracture |
| 25630 | Treat wrist bone fracture |
| 25635 | Treat wrist bone fracture |
| 25650 | Treat wrist bone fracture |
| 25675 | Treat wrist dislocation |
| 26600 | Treat metacarpal fracture |
| 26605 | Treat metacarpal fracture |
| 26641 | Treat thumb dislocation |
| 26645 | Treat thumb fracture |
| 26670 | Treat hand dislocation |
| 26675 | Treat hand dislocation |
| 26700 | Treat knuckle dislocation |
| 26705 | Treat knuckle dislocation |
| 26720 | Treat finger fracture, each |
| 26725 | Treat finger fracture, each |
| 26740 | Treat finger fracture, each |
| 26742 | Treat finger fracture, each |
| 26750 | Treat finger fracture, each |
| 26755 | Treat finger fracture, each |
| 26770 | Treat finger dislocation |
| 26775 | Treat finger dislocation |
| 26863 | Fuse/graft added joint |
| 26991 | Drainage of pelvis bursa |
| 27040 | Biopsy of soft tissues |
| 27047 | Remove hip/pelvis lesion |
| 27086 | Remove hip foreign body |
| 27093 | Injection for hip x-ray |
| 27095 | Injection for hip x-ray |
| 27193 | Treat pelvic ring fracture |
| 27194 | Treat pelvic ring fracture |
| 27200 | Treat tail bone fracture |
| 27220 | Treat hip socket fracture |
| 27230 | Treat thigh fracture |
| 27246 | Treat thigh fracture |
| 27256 | Treat hip dislocation |
| 27257 | Treat hip dislocation |
| 27275 | Manipulation of hip joint |
| 27301 | Drain thigh/knee lesion |
| 27323 | Biopsy, thigh soft tissues |
| 27327 | Removal of thigh lesion |
| 27370 | Injection for knee x-ray |
| 27372 | Removal of foreign body |
| 27500 | Treatment of thigh fracture |
| 27501 | Treatment of thigh fracture |
| 27508 | Treatment of thigh fracture |

Some of these codes have previously been refined and additional refinements were made by the PEAC.
All anesthesia codes were reviewed with the exception of 00104 abd 00124.
CPT codes and descriptions are copyright 2004 by the AMA, all rights reserved.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 27516 | Treat thigh fx growth plate |
| 27517 | Treat thigh fx growth plate |
| 27520 | Treat kneecap fracture |
| 27530 | Treat knee fracture |
| 27532 | Treat knee fracture |
| 27538 | Treat knee fracture(s) |
| 27550 | Treat knee dislocation |
| 27560 | Treat kneecap dislocation |
| 27570 | Fixation of knee joint |
| 27603 | Drain lower leg lesion |
| 27604 | Drain lower leg bursa |
| 27605 | Incision of achilles tendon |
| 27606 | Incision of achilles tendon |
| 27613 | Biopsy lower leg soft tissue |
| 27614 | Biopsy lower leg soft tissue |
| 27618 | Remove lower leg lesion |
| 27619 | Remove lower leg lesion |
| 27630 | Removal of tendon lesion |
| 27648 | Injection for ankle x-ray |
| 27656 | Repair leg fascia defect |
| 27658 | Repair of leg tendon, each |
| 27659 | Repair of leg tendon, each |
| 27664 | Repair of leg tendon, each |
| 27665 | Repair of leg tendon, each |
| 27685 | Revision of lower leg tendon |
| 27686 | Revise lower leg tendons |
| 27692 | Revise additional leg tendon |
| 27730 | Repair of tibia epiphysis |
| 27732 | Repair of fibula epiphysis |
| 27740 | Repair of leg epiphyses |
| 27742 | Repair of leg epiphyses |
| 27750 | Treatment of tibia fracture |
| 27752 | Treatment of tibia fracture |
| 27760 | Treatment of ankle fracture |
| 27762 | Treatment of ankle fracture |
| 27780 | Treatment of fibula fracture |
| 27781 | Treatment of fibula fracture |
| 27786 | Treatment of ankle fracture |
| 27788 | Treatment of ankle fracture |
| 27808 | Treatment of ankle fracture |
| 27810 | Treatment of ankle fracture |
| 27816 | Treatment of ankle fracture |
| 27818 | Treatment of ankle fracture |
| 27824 | Treat lower leg fracture |
| 27825 | Treat lower leg fracture |
| 27830 | Treat lower leg dislocation |
| 27860 | Fixation of ankle joint |
| 28001 | Drainage of bursa of foot |
| 28002 | Treatment of foot infection |
| 28003 | Treatment of foot infection |
| 28008 | Incision of foot fascia |
| 28010 | Incision of toe tendon |
| 28011 | Incision of toe tendons |
| 28020 | Exploration of foot joint |
| 28022 | Exploration of foot joint |
| 28024 | Exploration of toe joint |
| 28035 | Decompression of tibia nerve |
| 28043 | Excision of foot lesion |
| 28045 | Excision of foot lesion |
| 28046 | Resection of tumor, foot |
| 28050 | Biopsy of foot joint lining |
| 28052 | Biopsy of foot joint lining |
| 28054 | Biopsy of toe joint lining |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 28060 | Partial removal, foot fascia |
| 28062 | Removal of foot fascia |
| 28070 | Removal of foot joint lining |
| 28072 | Removal of foot joint lining |
| 28080 | Removal of foot lesion |
| 28086 | Excise foot tendon sheath |
| 28088 | Excise foot tendon sheath |
| 28090 | Removal of foot lesion |
| 28092 | Removal of toe lesions |
| 28100 | Removal of ankle/heel lesion |
| 28103 | Remove/graft foot lesion |
| 28104 | Removal of foot lesion |
| 28107 | Remove/graft foot lesion |
| 28108 | Removal of toe lesions |
| 28110 | Part removal of metatarsal |
| 28111 | Part removal of metatarsal |
| 28112 | Part removal of metatarsal |
| 28113 | Part removal of metatarsal |
| 28114 | Removal of metatarsal heads |
| 28116 | Revision of foot |
| 28118 | Removal of heel bone |
| 28119 | Removal of heel spur |
| 28120 | Part removal of ankle/heel |
| 28122 | Partial removal of foot bone |
| 28124 | Partial removal of toe |
| 28126 | Partial removal of toe |
| 28140 | Removal of metatarsal |
| 28150 | Removal of toe |
| 28153 | Partial removal of toe |
| 28160 | Partial removal of toe |
| 28173 | Extensive foot surgery |
| 28175 | Extensive foot surgery |
| 28190 | Removal of foot foreign body |
| 28192 | Removal of foot foreign body |
| 28193 | Removal of foot foreign body |
| 28200 | Repair of foot tendon |
| 28202 | Repair/graft of foot tendon |
| 28208 | Repair of foot tendon |
| 28210 | Repair/graft of foot tendon |
| 28220 | Release of foot tendon |
| 28222 | Release of foot tendons |
| 28225 | Release of foot tendon |
| 28226 | Release of foot tendons |
| 28230 | Incision of foot tendon(s) |
| 28232 | Incision of toe tendon |
| 28234 | Incision of foot tendon |
| 28238 | Revision of foot tendon |
| 28288 | Partial removal of foot bone |
| 28289 | Repair hallux rigidus |
| 28290 | Correction of bunion |
| 28292 | Correction of bunion |
| 28294 | Correction of bunion |
| 28296 | Correction of bunion |
| 28297 | Correction of bunion |
| 28298 | Correction of bunion |
| 28299 | Correction of bunion |
| 28300 | Incision of heel bone |
| 28302 | Incision of ankle bone |
| 28305 | Incise/graft midfoot bones |
| 28400 | Treatment of heel fracture |
| 28405 | Treatment of heel fracture |
| 28430 | Treatment of ankle fracture |
| 28435 | Treatment of ankle fracture |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 28450 | Treat midfoot fracture, each |
| 28455 | Treat midfoot fracture, each |
| 28470 | Treat metatarsal fracture |
| 28475 | Treat metatarsal fracture |
| 28490 | Treat big toe fracture |
| 28495 | Treat big toe fracture |
| 28510 | Treatment of toe fracture |
| 28515 | Treatment of toe fracture |
| 28530 | Treat sesamoid bone fracture |
| 28540 | Treat foot dislocation |
| 28545 | Treat foot dislocation |
| 28570 | Treat foot dislocation |
| 28575 | Treat foot dislocation |
| 28600 | Treat foot dislocation |
| 28605 | Treat foot dislocation |
| 28630 | Treat toe dislocation |
| 28635 | Treat toe dislocation |
| 28636 | Treat toe dislocation |
| 28660 | Treat toe dislocation |
| 28665 | Treat toe dislocation |
| 30115 | Removal of nose polyp(s) |
| 30117 | Removal of intranasal lesion |
| 30118 | Removal of intranasal lesion |
| 30120 | Revision of nose |
| 30124 | Removal of nose lesion |
| 30125 | Removal of nose lesion |
| 30130 | Removal of turbinate bones |
| 30140 | Removal of turbinate bones |
| 30150 | Partial removal of nose |
| 30160 | Removal of nose |
| 30320 | Remove nasal foreign body |
| 30400 | Reconstruction of nose |
| 30410 | Reconstruction of nose |
| 30420 | Reconstruction of nose |
| 30430 | Revision of nose |
| 30435 | Revision of nose |
| 30450 | Revision of nose |
| 30460 | Revision of nose |
| 30462 | Revision of nose |
| 30465 | Repair nasal stenosis |
| 30520 | Repair of nasal septum |
| 30540 | Repair nasal defect |
| 30545 | Repair nasal defect |
| 30580 | Repair upper jaw fistula |
| 30600 | Repair mouth/nose fistula |
| 30620 | Intranasal reconstruction |
| 30630 | Repair nasal septum defect |
| 30801 | Cauterization, inner nose |
| 30802 | Cauterization, inner nose |
| 30915 | Ligation, nasal sinus artery |
| 30920 | Ligation, upper jaw artery |
| 31020 | Exploration, maxillary sinus |
| 31030 | Exploration, maxillary sinus |
| 31032 | Explore sinus, remove polyps |
| 31040 | Exploration behind upper jaw |
| 31050 | Exploration, sphenoid sinus |
| 31051 | Sphenoid sinus surgery |
| 31070 | Exploration of frontal sinus |
| 31075 | Exploration of frontal sinus |
| 31080 | Removal of frontal sinus |
| 31081 | Removal of frontal sinus |
| 31084 | Removal of frontal sinus |
| 31085 | Removal of frontal sinus |

Some of these codes have previously been refined and additional refinements were made by the PEAC.
All anesthesia codes were reviewed with the exception of 00104 abd 00124.
CPT codes and descriptions are copyright 2004 by the AMA, all rights reserved.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 31086 | Removal of frontal sinus |
| 31087 | Removal of frontal sinus |
| 31090 | Exploration of sinuses |
| 31200 | Removal of ethmoid sinus |
| 31201 | Removal of ethmoid sinus |
| 31205 | Removal of ethmoid sinus |
| 31225 | Removal of upper jaw |
| 31230 | Removal of upper jaw |
| 31300 | Removal of larynx lesion |
| 31320 | Diagnostic incision, larynx |
| 31360 | Removal of larynx |
| 31365 | Removal of larynx |
| 31367 | Partial removal of larynx |
| 31368 | Partial removal of larynx |
| 31370 | Partial removal of larynx |
| 31375 | Partial removal of larynx |
| 31380 | Partial removal of larynx |
| 31382 | Partial removal of larynx |
| 31390 | Removal of larynx & pharynx |
| 31395 | Reconstruct larynx & pharynx |
| 31400 | Revision of larynx |
| 31420 | Removal of epiglottis |
| 31502 | Change of windpipe airway |
| 31580 | Revision of larynx |
| 31582 | Revision of larynx |
| 31584 | Treat larynx fracture |
| 31585 | Treat larynx fracture |
| 31586 | Treat larynx fracture |
| 31587 | Revision of larynx |
| 31588 | Revision of larynx |
| 31590 | Reinnervate larynx |
| 31595 | Larynx nerve surgery |
| 31610 | Incision of windpipe |
| 31611 | Surgery/speech prosthesis |
| 31613 | Repair windpipe opening |
| 31614 | Repair windpipe opening |
| 31622 | Dx bronchoscope/wash |
| 31623 | Dx bronchoscope/brush |
| 31624 | Dx bronchoscope/lavage |
| 31625 | Bronchoscopy w/biopsy(s) |
| 31628 | Bronchoscopy/lung bx, each |
| 31629 | Bronchoscopy/needle bx, each |
| 31630 | Bronchoscopy dilate/fx repr |
| 31631 | Bronchoscopy, dilate w/stent |
| 31635 | Bronchoscopy w/fb removal |
| 31640 | Bronchoscopy w/tumor excise |
| 31641 | Bronchoscopy, treat blockage |
| 31643 | Diag bronchoscope/catheter |
| 31645 | Bronchoscopy, clear airways |
| 31646 | Bronchoscopy, reclear airway |
| 31656 | Bronchoscopy, inj for x-ray |
| 31708 | Instill airway contrast dye |
| 31710 | Insertion of airway catheter |
| 31715 | Injection for bronchus x-ray |
| 31717 | Bronchial brush biopsy |
| 31720 | Clearance of airways |
| 31725 | Clearance of airways |
| 31750 | Repair of windpipe |
| 31755 | Repair of windpipe |
| 31800 | Repair of windpipe injury |
| 31820 | Closure of windpipe lesion |
| 31825 | Repair of windpipe defect |
| 31830 | Revise windpipe scar |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 32002 | Treatment of collapsed lung |
| 32020 | Insertion of chest tube |
| 32201 | Drain, percut, lung lesion |
| 32400 | Needle biopsy chest lining |
| 32405 | Biopsy, lung or mediastinum |
| 32420 | Puncture/clear lung |
| 32851 | Lung transplant, single |
| 32852 | Lung transplant with bypass |
| 32853 | Lung transplant, double |
| 32854 | Lung transplant with bypass |
| 33010 | Drainage of heart sac |
| 33011 | Repeat drainage of heart sac |
| 33210 | Insertion of heart electrode |
| 33211 | Insertion of heart electrode |
| 33225 | L ventric pacing lead add-on |
| 33508 | Endoscopic vein harvest |
| 33935 | Transplantation, heart/lung |
| 33945 | Transplantation of heart |
| 33960 | External circulation assist |
| 33967 | Insert ia percut device |
| 33968 | Remove aortic assist device |
| 33970 | Aortic circulation assist |
| 33973 | Insert balloon device |
| 33975 | Implant ventricular device |
| 33976 | Implant ventricular device |
| 33979 | Insert intracorporeal device |
| 35450 | Repair arterial blockage |
| 35452 | Repair arterial blockage |
| 35454 | Repair arterial blockage |
| 35456 | Repair arterial blockage |
| 35458 | Repair arterial blockage |
| 35459 | Repair arterial blockage |
| 35460 | Repair venous blockage |
| 35470 | Repair arterial blockage |
| 35471 | Repair arterial blockage |
| 35472 | Repair arterial blockage |
| 35473 | Repair arterial blockage |
| 35474 | Repair arterial blockage |
| 35475 | Repair arterial blockage |
| 35476 | Repair venous blockage |
| 35480 | Atherectomy, open |
| 35481 | Atherectomy, open |
| 35482 | Atherectomy, open |
| 35483 | Atherectomy, open |
| 35484 | Atherectomy, open |
| 35485 | Atherectomy, open |
| 35572 | Harvest femoropopliteal vein |
| 35697 | Reimplant artery each |
| 36010 | Place catheter in vein |
| 36011 | Place catheter in vein |
| 36012 | Place catheter in vein |
| 36013 | Place catheter in artery |
| 36014 | Place catheter in artery |
| 36015 | Place catheter in artery |
| 36100 | Establish access to artery |
| 36120 | Establish access to artery |
| 36140 | Establish access to artery |
| 36145 | Artery to vein shunt |
| 36160 | Establish access to aorta |
| 36200 | Place catheter in aorta |
| 36215 | Place catheter in artery |
| 36216 | Place catheter in artery |
| 36217 | Place catheter in artery |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 36218 | Place catheter in artery |
| 36245 | Place catheter in artery |
| 36246 | Place catheter in artery |
| 36247 | Place catheter in artery |
| 36248 | Place catheter in artery |
| 36420 | Vein access cutdown < 1 yr |
| 36430 | Blood transfusion service |
| 36481 | Insertion of catheter, vein |
| 36500 | Insertion of catheter, vein |
| 36514 | Apheresis plasma |
| 36515 | Apheresis, adsorp/reinfuse |
| 36516 | Apheresis, selective |
| 36625 | Insertion catheter, artery |
| 36680 | Insert needle, bone cavity |
| 37195 | Thrombolytic therapy, stroke |
| 37200 | Transcatheter biopsy |
| 37203 | Transcatheter retrieval |
| 37204 | Transcatheter occlusion |
| 37209 | Exchange arterial catheter |
| 37785 | Ligate/divide/excise vein |
| 38200 | Injection for spleen x-ray |
| 38204 | Bl donor search management |
| 38205 | Harvest allogenic stem cells |
| 38206 | Harvest auto stem cells |
| 38207 | Cryopreserve stem cells |
| 38208 | Thaw preserved stem cells |
| 38209 | Wash harvest stem cells |
| 38210 | T-cell depletion of harvest |
| 38211 | Tumor cell deplete of harvst |
| 38212 | Rbc depletion of harvest |
| 38213 | Platelet deplete of harvest |
| 38214 | Volume deplete of harvest |
| 38215 | Harvest stem cell concentrte |
| 38240 | Bone marrow/stem transplant |
| 38241 | Bone marrow/stem transplant |
| 38242 | Lymphocyte infuse transplant |
| 38305 | Drainage, lymph node lesion |
| 38308 | Incision of lymph channels |
| 38380 | Thoracic duct procedure |
| 38520 | Biopsy/removal, lymph nodes |
| 38542 | Explore deep node(s), neck |
| 38700 | Removal of lymph nodes, neck |
| 38720 | Removal of lymph nodes, neck |
| 38724 | Removal of lymph nodes, neck |
| 40500 | Partial excision of lip |
| 40510 | Partial excision of lip |
| 40520 | Partial excision of lip |
| 40525 | Reconstruct lip with flap |
| 40527 | Reconstruct lip with flap |
| 40530 | Partial removal of lip |
| 40650 | Repair lip |
| 40652 | Repair lip |
| 40654 | Repair lip |
| 40700 | Repair cleft lip/nasal |
| 40701 | Repair cleft lip/nasal |
| 40702 | Repair cleft lip/nasal |
| 40720 | Repair cleft lip/nasal |
| 40761 | Repair cleft lip/nasal |
| 40800 | Drainage of mouth lesion |
| 40801 | Drainage of mouth lesion |
| 40804 | Removal, foreign body, mouth |
| 40805 | Removal, foreign body, mouth |
| 40806 | Incision of lip fold |

Some of these codes have previously been refined and additional refinements were made by the PEAC.
All anesthesia codes were reviewed with the exception of 00104 abd 00124.
CPT codes and descriptions are copyright 2004 by the AMA, all rights reserved.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 40808 | Biopsy of mouth lesion |
| 40810 | Excision of mouth lesion |
| 40812 | Excise/repair mouth lesion |
| 40814 | Excise/repair mouth lesion |
| 40816 | Excision of mouth lesion |
| 40818 | Excise oral mucosa for graft |
| 40819 | Excise lip or cheek fold |
| 40820 | Treatment of mouth lesion |
| 40830 | Repair mouth laceration |
| 40831 | Repair mouth laceration |
| 40840 | Reconstruction of mouth |
| 40842 | Reconstruction of mouth |
| 40843 | Reconstruction of mouth |
| 40844 | Reconstruction of mouth |
| 40845 | Reconstruction of mouth |
| 41005 | Drainage of mouth lesion |
| 41006 | Drainage of mouth lesion |
| 41007 | Drainage of mouth lesion |
| 41008 | Drainage of mouth lesion |
| 41009 | Drainage of mouth lesion |
| 41010 | Incision of tongue fold |
| 41015 | Drainage of mouth lesion |
| 41016 | Drainage of mouth lesion |
| 41017 | Drainage of mouth lesion |
| 41018 | Drainage of mouth lesion |
| 41110 | Excision of tongue lesion |
| 41112 | Excision of tongue lesion |
| 41113 | Excision of tongue lesion |
| 41114 | Excision of tongue lesion |
| 41115 | Excision of tongue fold |
| 41116 | Excision of mouth lesion |
| 41120 | Partial removal of tongue |
| 41130 | Partial removal of tongue |
| 41135 | Tongue and neck surgery |
| 41140 | Removal of tongue |
| 41145 | Tongue removal, neck surgery |
| 41150 | Tongue, mouth, jaw surgery |
| 41153 | Tongue, mouth, neck surgery |
| 41155 | Tongue, jaw, & neck surgery |
| 41500 | Fixation of tongue |
| 41510 | Tongue to lip surgery |
| 41520 | Reconstruction, tongue fold |
| 41823 | Excision of gum lesion |
| 41827 | Excision of gum lesion |
| 41872 | Repair gum |
| 41874 | Repair tooth socket |
| 42107 | Excision lesion, mouth roof |
| 42120 | Remove palate/lesion |
| 42140 | Excision of uvula |
| 42145 | Repair palate, pharynx/uvula |
| 42200 | Reconstruct cleft palate |
| 42205 | Reconstruct cleft palate |
| 42210 | Reconstruct cleft palate |
| 42215 | Reconstruct cleft palate |
| 42220 | Reconstruct cleft palate |
| 42225 | Reconstruct cleft palate |
| 42226 | Lengthening of palate |
| 42227 | Lengthening of palate |
| 42235 | Repair palate |
| 42260 | Repair nose to lip fistula |
| 42305 | Drainage of salivary gland |
| 42325 | Create salivary cyst drain |
| 42326 | Create salivary cyst drain |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 42335 | Removal of salivary stone |
| 42340 | Removal of salivary stone |
| 42408 | Excision of salivary cyst |
| 42409 | Drainage of salivary cyst |
| 42410 | Excise parotid gland/lesion |
| 42415 | Excise parotid gland/lesion |
| 42420 | Excise parotid gland/lesion |
| 42425 | Excise parotid gland/lesion |
| 42426 | Excise parotid gland/lesion |
| 42440 | Excise submaxillary gland |
| 42450 | Excise sublingual gland |
| 42500 | Repair salivary duct |
| 42505 | Repair salivary duct |
| 42507 | Parotid duct diversion |
| 42508 | Parotid duct diversion |
| 42509 | Parotid duct diversion |
| 42510 | Parotid duct diversion |
| 42550 | Injection for salivary x-ray |
| 42600 | Closure of salivary fistula |
| 42665 | Ligation of salivary duct |
| 42725 | Drainage of throat abscess |
| 42810 | Excision of neck cyst |
| 42815 | Excision of neck cyst |
| 42820 | Remove tonsils and adenoids |
| 42821 | Remove tonsils and adenoids |
| 42825 | Removal of tonsils |
| 42826 | Removal of tonsils |
| 42830 | Removal of adenoids |
| 42831 | Removal of adenoids |
| 42835 | Removal of adenoids |
| 42836 | Removal of adenoids |
| 42842 | Extensive surgery of throat |
| 42844 | Extensive surgery of throat |
| 42845 | Extensive surgery of throat |
| 42860 | Excision of tonsil tags |
| 42870 | Excision of lingual tonsil |
| 42890 | Partial removal of pharynx |
| 42892 | Revision of pharyngeal walls |
| 42894 | Revision of pharyngeal walls |
| 42950 | Reconstruction of throat |
| 42953 | Repair throat, esophagus |
| 42955 | Surgical opening of throat |
| 42961 | Control throat bleeding |
| 42962 | Control throat bleeding |
| 42970 | Control nose/throat bleeding |
| 42971 | Control nose/throat bleeding |
| 42972 | Control nose/throat bleeding |
| 43020 | Incision of esophagus |
| 43030 | Throat muscle surgery |
| 43600 | Biopsy of stomach |
| 43761 | Reposition gastrostomy tube |
| 44100 | Biopsy of bowel |
| 44385 | Endoscopy of bowel pouch |
| 44386 | Endoscopy, bowel pouch/biop |
| 44500 | Intro, gastrointestinal tube |
| 44701 | Intraop colon lavage add-on |
| 44901 | Drain app abscess, percut |
| 45005 | Drainage of rectal abscess |
| 45520 | Treatment of rectal prolapse |
| 45915 | Remove rectal obstruction |
| 46040 | Incision of rectal abscess |
| 46200 | Removal of anal fissure |
| 46210 | Removal of anal crypt |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 46211 | Removal of anal crypts |
| 46221 | Ligation of hemorrhoid(s) |
| 46250 | Hemorrhoidectomy |
| 46255 | Hemorrhoidectomy |
| 46270 | Removal of anal fistula |
| 46275 | Removal of anal fistula |
| 46285 | Removal of anal fistula |
| 46500 | Injection into hemorrhoid(s) |
| 46900 | Destruction, anal lesion(s) |
| 46910 | Destruction, anal lesion(s) |
| 46934 | Destruction of hemorrhoids |
| 46936 | Destruction of hemorrhoids |
| 46938 | Cryotherapy of rectal lesion |
| 46945 | Ligation of hemorrhoids |
| 46946 | Ligation of hemorrhoids |
| 47135 | Transplantation of liver |
| 47136 | Transplantation of liver |
| 47140 | Partial removal, donor liver |
| 47141 | Partial removal, donor liver |
| 47142 | Partial removal, donor liver |
| 47500 | Injection for liver x-rays |
| 47525 | Change bile duct catheter |
| 47530 | Revise/reinsert bile tube |
| 47553 | Biliary endoscopy thru skin |
| 47556 | Biliary endoscopy thru skin |
| 47561 | Laparo w/cholangio/biopsy |
| 48511 | Drain pancreatic pseudocyst |
| 48554 | Transpl allograft pancreas |
| 48556 | Removal, allograft pancreas |
| 49021 | Drain abdominal abscess |
| 49041 | Drain, percut, abdom abscess |
| 49061 | Drain, percut, retroper absc |
| 49400 | Air injection into abdomen |
| 49423 | Exchange drainage catheter |
| 49424 | Assess cyst, contrast inject |
| 49427 | Injection, abdominal shunt |
| 49505 | Prp i/hern init reduc>5 yr |
| 50010 | Exploration of kidney |
| 50020 | Renal abscess, open drain |
| 50021 | Renal abscess, percut drain |
| 50040 | Drainage of kidney |
| 50045 | Exploration of kidney |
| 50060 | Removal of kidney stone |
| 50065 | Incision of kidney |
| 50070 | Incision of kidney |
| 50075 | Removal of kidney stone |
| 50080 | Removal of kidney stone |
| 50081 | Removal of kidney stone |
| 50100 | Revise kidney blood vessels |
| 50120 | Exploration of kidney |
| 50125 | Explore and drain kidney |
| 50130 | Removal of kidney stone |
| 50135 | Exploration of kidney |
| 50200 | Biopsy of kidney |
| 50205 | Biopsy of kidney |
| 50220 | Remove kidney, open |
| 50225 | Removal kidney open, complex |
| 50230 | Removal kidney open, radical |
| 50234 | Removal of kidney & ureter |
| 50236 | Removal of kidney & ureter |
| 50240 | Partial removal of kidney |
| 50280 | Removal of kidney lesion |
| 50290 | Removal of kidney lesion |

Some of these codes have previously been refined and additional refinements were made by the PEAC.
All anesthesia codes were reviewed with the exception of 00104 abd 00124.
CPT codes and descriptions are copyright 2004 by the AMA, all rights reserved.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 50300 | Removal of donor kidney |
| 50320 | Removal of donor kidney |
| 50340 | Removal of kidney |
| 50360 | Transplantation of kidney |
| 50365 | Transplantation of kidney |
| 50370 | Remove transplanted kidney |
| 50380 | Reimplantation of kidney |
| 50390 | Drainage of kidney lesion |
| 50392 | Insert kidney drain |
| 50393 | Insert ureteral tube |
| 50394 | Injection for kidney x-ray |
| 50395 | Create passage to kidney |
| 50396 | Measure kidney pressure |
| 50398 | Change kidney tube |
| 50400 | Revision of kidney/ureter |
| 50405 | Revision of kidney/ureter |
| 50500 | Repair of kidney wound |
| 50520 | Close kidney-skin fistula |
| 50525 | Repair renal-abdomen fistula |
| 50526 | Repair renal-abdomen fistula |
| 50540 | Revision of horseshoe kidney |
| 50541 | Laparo ablate renal cyst |
| 50542 | Laparo ablate renal mass |
| 50544 | Laparoscopy, pyeloplasty |
| 50545 | Laparo radical nephrectomy |
| 50546 | Laparoscopic nephrectomy |
| 50547 | Laparo removal donor kidney |
| 50548 | Laparo remove w/ ureter |
| 50551 | Kidney endoscopy |
| 50553 | Kidney endoscopy |
| 50555 | Kidney endoscopy & biopsy |
| 50555 | Kidney endoscopy & biopsy |
| 50557 | Kidney endoscopy & treatment |
| 50559 | Renal endoscopy/radiotracer |
| 50561 | Kidney endoscopy & treatment |
| 50562 | Renal scope w/tumor resect |
| 50570 | Kidney endoscopy |
| 50572 | Kidney endoscopy |
| 50574 | Kidney endoscopy & biopsy |
| 50575 | Kidney endoscopy |
| 50576 | Kidney endoscopy & treatment |
| 50578 | Renal endoscopy/radiotracer |
| 50580 | Kidney endoscopy & treatment |
| 50590 | Fragmenting of kidney stone |
| 50600 | Exploration of ureter |
| 50605 | Insert ureteral support |
| 50610 | Removal of ureter stone |
| 50620 | Removal of ureter stone |
| 50630 | Removal of ureter stone |
| 50650 | Removal of ureter |
| 50660 | Removal of ureter |
| 50684 | Injection for ureter x-ray |
| 50686 | Measure ureter pressure |
| 50688 | Change of ureter tube |
| 50690 | Injection for ureter x-ray |
| 50700 | Revision of ureter |
| 50715 | Release of ureter |
| 50722 | Release of ureter |
| 50725 | Release/revise ureter |
| 50727 | Revise ureter |
| 50728 | Revise ureter |
| 50740 | Fusion of ureter & kidney |
| 50750 | Fusion of ureter & kidney |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 50760 | Fusion of ureters |
| 50770 | Splicing of ureters |
| 50780 | Reimplant ureter in bladder |
| 50782 | Reimplant ureter in bladder |
| 50783 | Reimplant ureter in bladder |
| 50785 | Reimplant ureter in bladder |
| 50800 | Implant ureter in bowel |
| 50810 | Fusion of ureter & bowel |
| 50815 | Urine shunt to intestine |
| 50820 | Construct bowel bladder |
| 50825 | Construct bowel bladder |
| 50830 | Revise urine flow |
| 50840 | Replace ureter by bowel |
| 50845 | Appendico-vesicostomy |
| 50860 | Transplant ureter to skin |
| 50900 | Repair of ureter |
| 50920 | Closure ureter/skin fistula |
| 50930 | Closure ureter/bowel fistula |
| 50940 | Release of ureter |
| 50945 | Laparoscopy ureterolithotomy |
| 50947 | Laparo new ureter/bladder |
| 50948 | Laparo new ureter/bladder |
| 50949 | Laparoscope proc, ureter |
| 50951 | Endoscopy of ureter |
| 50953 | Endoscopy of ureter |
| 50955 | Ureter endoscopy & biopsy |
| 50957 | Ureter endoscopy & treatment |
| 50959 | Ureter endoscopy & tracer |
| 50961 | Ureter endoscopy & treatment |
| 50970 | Ureter endoscopy |
| 50972 | Ureter endoscopy & catheter |
| 50974 | Ureter endoscopy & biopsy |
| 50976 | Ureter endoscopy & treatment |
| 50978 | Ureter endoscopy & tracer |
| 50980 | Ureter endoscopy & treatment |
| 52007 | Cystoscopy and biopsy |
| 52010 | Cystoscopy & duct catheter |
| 52204 | Cystoscopy |
| 52214 | Cystoscopy and treatment |
| 52224 | Cystoscopy and treatment |
| 52234 | Cystoscopy and treatment |
| 52235 | Cystoscopy and treatment |
| 52240 | Cystoscopy and treatment |
| 52265 | Cystoscopy and treatment |
| 52270 | Cystoscopy & revise urethra |
| 52275 | Cystoscopy & revise urethra |
| 52310 | Cystoscopy and treatment |
| 52315 | Cystoscopy and treatment |
| 52317 | Remove bladder stone |
| 52327 | Cystoscopy, inject material |
| 52330 | Cystoscopy and treatment |
| 52332 | Cystoscopy and treatment |
| 53040 | Drainage of urethra abscess |
| 53060 | Drainage of urethra abscess |
| 53200 | Biopsy of urethra |
| 53260 | Treatment of urethra lesion |
| 53265 | Treatment of urethra lesion |
| 53270 | Removal of urethra gland |
| 53605 | Dilate urethra stricture |
| 53665 | Dilation of urethra |
| 53850 | Prostatic microwave thermotx |
| 53852 | Prostatic rf thermotx |
| 53853 | Prostatic water thermother |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 54000 | Slitting of prepuce |
| 54001 | Slitting of prepuce |
| 54056 | Cryosurgery, penis lesion(s) |
| 54057 | Laser surg, penis lesion(s) |
| 54060 | Excision of penis lesion(s) |
| 54065 | Destruction, penis lesion(s) |
| 54105 | Biopsy of penis |
| 54110 | Treatment of penis lesion |
| 54111 | Treat penis lesion, graft |
| 54112 | Treat penis lesion, graft |
| 54115 | Treatment of penis lesion |
| 54120 | Partial removal of penis |
| 54125 | Removal of penis |
| 54130 | Remove penis & nodes |
| 54135 | Remove penis & nodes |
| 54150 | Circumcision |
| 54160 | Circumcision |
| 54162 | Lysis penil circumic lesion |
| 55110 | Explore scrotum |
| 55120 | Removal of scrotum lesion |
| 55150 | Removal of scrotum |
| 55175 | Revision of scrotum |
| 55180 | Revision of scrotum |
| 55200 | Incision of sperm duct |
| 55250 | Removal of sperm duct(s) |
| 55400 | Repair of sperm duct |
| 56605 | Biopsy of vulva/perineum |
| 56700 | Partial removal of hymen |
| 56720 | Incision of hymen |
| 56740 | Remove vagina gland lesion |
| 57100 | Biopsy of vagina |
| 57105 | Biopsy of vagina |
| 57160 | Insert pessary/other device |
| 57400 | Dilation of vagina |
| 57452 | Exam of cervix w/scope |
| 57454 | Bx/curett of cervix w/scope |
| 57460 | Bx of cervix w/scope, leep |
| 57500 | Biopsy of cervix |
| 57520 | Conization of cervix |
| 57522 | Conization of cervix |
| 58555 | Hysteroscopy, dx, sep proc |
| 58558 | Hysteroscopy, biopsy |
| 58559 | Hysteroscopy, lysis |
| 58560 | Hysteroscopy, resect septum |
| 58561 | Hysteroscopy, remove myoma |
| 58562 | Hysteroscopy, remove fb |
| 58800 | Drainage of ovarian cyst(s) |
| 58823 | Drain pelvic abscess, percut |
| 59030 | Fetal scalp blood sample |
| 59140 | Treat ectopic pregnancy |
| 59320 | Revision of cervix |
| 59325 | Revision of cervix |
| 59350 | Repair of uterus |
| 59820 | Care of miscarriage |
| 59821 | Treatment of miscarriage |
| 61107 | Drill skull for implantation |
| 61210 | Pierce skull, implant device |
| 61316 | Implt cran bone flap to abdo |
| 61517 | Implt brain chemotx add-on |
| 61576 | Skull base/brainstem surgery |
| 61864 | Implant neuroelectrde, add'l |
| 61868 | Implant neuroelectrde, add'l |
| 62120 | Repair skull cavity lesion |

Some of these codes have previously been refined and additional refinements were made by the PEAC.
All anesthesia codes were reviewed with the exception of 00104 abd 00124.
CPT codes and descriptions are copyright 2004 by the AMA, all rights reserved.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 62121 | Incise skull repair |
| 62148 | Retr bone flap to fix skull |
| 62160 | Neuroendoscopy add-on |
| 62270 | Spinal fluid tap, diagnostic |
| 62272 | Drain cerebro spinal fluid |
| 62273 | Treat epidural spine lesion |
| 62280 | Treat spinal cord lesion |
| 62281 | Treat spinal cord lesion |
| 62282 | Treat spinal canal lesion |
| 62284 | Injection for myelogram |
| 62290 | Inject for spine disk x-ray |
| 62291 | Inject for spine disk x-ray |
| 62310 | Inject spine c/t |
| 62311 | Inject spine l/s (cd) |
| 62318 | Inject spine w/cath, c/t |
| 62319 | Inject spine w/cath l/s (cd) |
| 62367 | Analyze spine infusion pump |
| 62368 | Analyze spine infusion pump |
| 63048 | Remove spinal lamina add-on |
| 63057 | Decompress spine cord add-on |
| 63066 | Decompress spine cord add-on |
| 63076 | Neck spine disk surgery |
| 63078 | Spine disk surgery, thorax |
| 63082 | Remove vertebral body add-on |
| 63086 | Remove vertebral body add-on |
| 63088 | Remove vertebral body add-on |
| 63091 | Remove vertebral body add-on |
| 63103 | Remove vertebral body add-on |
| 63308 | Remove vertebral body add-on |
| 64400 | N block inj, trigeminal |
| 64402 | N block inj, facial |
| 64405 | N block inj, occipital |
| 64408 | N block inj, vagus |
| 64410 | N block inj, phrenic |
| 64412 | N block inj, spinal accessor |
| 64413 | N block inj, cervical plexus |
| 64415 | N block inj, brachial plexus |
| 64417 | N block inj, axillary |
| 64418 | N block inj, suprascapular |
| 64420 | N block inj, intercost, sng |
| 64421 | N block inj, intercost, mlt |
| 64425 | N block inj ilio-ing/hypogi |
| 64430 | N block inj, pudendal |
| 64435 | N block inj, paracervical |
| 64445 | N block inj, sciatic, sng |
| 64450 | N block, other peripheral |
| 64470 | Inj paravertebral c/t |
| 64472 | Inj paravertebral c/t add-on |
| 64475 | Inj paravertebral l/s |
| 64476 | Inj paravertebral l/s add-on |
| 64479 | Inj foramen epidural c/t |
| 64480 | Inj foramen epidural add-on |
| 64483 | Inj foramen epidural l/s |
| 64484 | Inj foramen epidural add-on |
| 64505 | N block, spenopalatine gangl |
| 64508 | N block, carotid sinus s/p |
| 64510 | N block, stellate ganglion |
| 64520 | N block, lumbar/thoracic |
| 64530 | N block inj, celiac pelus |
| 64561 | Implant neuroelectrodes |
| 64600 | Injection treatment of nerve |
| 64605 | Injection treatment of nerve |
| 64610 | Injection treatment of nerve |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 64612 | Destroy nerve, face muscle |
| 64613 | Destroy nerve, spine muscle |
| 64614 | Destroy nerve, extrem musc |
| 64620 | Injection treatment of nerve |
| 64622 | Destr paravertebrl nerve l/s |
| 64623 | Destr paravertebral n add-on |
| 64626 | Destr paravertebrl nerve c/t |
| 64627 | Destr paravertebral n add-on |
| 64630 | Injection treatment of nerve |
| 64640 | Injection treatment of nerve |
| 64680 | Injection treatment of nerve |
| 64716 | Revision of cranial nerve |
| 64740 | Incision of tongue nerve |
| 64778 | Digit nerve surgery add-on |
| 64864 | Repair of facial nerve |
| 64865 | Repair of facial nerve |
| 64866 | Fusion of facial/other nerve |
| 64868 | Fusion of facial/other nerve |
| 64885 | Nerve graft, head or neck |
| 64886 | Nerve graft, head or neck |
| 65125 | Revise ocular implant |
| 65205 | Remove foreign body from eye |
| 65210 | Remove foreign body from eye |
| 65220 | Remove foreign body from eye |
| 65222 | Remove foreign body from eye |
| 65270 | Repair of eye wound |
| 65272 | Repair of eye wound |
| 65273 | Repair of eye wound |
| 65275 | Repair of eye wound |
| 65280 | Repair of eye wound |
| 65285 | Repair of eye wound |
| 65286 | Repair of eye wound |
| 65290 | Repair of eye socket wound |
| 65400 | Removal of eye lesion |
| 65410 | Biopsy of cornea |
| 65420 | Removal of eye lesion |
| 65426 | Removal of eye lesion |
| 65430 | Corneal smear |
| 65435 | Curette/treat cornea |
| 65436 | Curette/treat cornea |
| 65450 | Treatment of corneal lesion |
| 65600 | Revision of cornea |
| 65771 | Radial keratotomy |
| 65772 | Correction of astigmatism |
| 65800 | Drainage of eye |
| 65805 | Drainage of eye |
| 65810 | Drainage of eye |
| 65815 | Drainage of eye |
| 65855 | Laser surgery of eye |
| 65860 | Incise inner eye adhesions |
| 66020 | Injection treatment of eye |
| 66030 | Injection treatment of eye |
| 66130 | Remove eye lesion |
| 66250 | Follow-up surgery of eye |
| 66625 | Removal of iris |
| 66630 | Removal of iris |
| 66635 | Removal of iris |
| 66990 | Ophthalmic endoscope add-on |
| 67025 | Replace eye fluid |
| 67027 | Implant eye drug system |
| 67028 | Injection eye drug |
| 67031 | Laser surgery, eye strands |
| 67101 | Repair detached retina |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 67105 | Repair detached retina |
| 67107 | Repair detached retina |
| 67108 | Repair detached retina |
| 67110 | Repair detached retina |
| 67112 | Rerepair detached retina |
| 67115 | Release encircling material |
| 67120 | Remove eye implant material |
| 67121 | Remove eye implant material |
| 67141 | Treatment of retina |
| 67145 | Treatment of retina |
| 67345 | Destroy nerve of eye muscle |
| 67500 | Inject/treat eye socket |
| 67505 | Inject/treat eye socket |
| 67515 | Inject/treat eye socket |
| 67700 | Drainage of eyelid abscess |
| 67710 | Incision of eyelid |
| 67715 | Incision of eyelid fold |
| 67800 | Remove eyelid lesion |
| 67801 | Remove eyelid lesions |
| 67805 | Remove eyelid lesions |
| 67808 | Remove eyelid lesion(s) |
| 67820 | Revise eyelashes |
| 67825 | Revise eyelashes |
| 67830 | Revise eyelashes |
| 67840 | Remove eyelid lesion |
| 67850 | Treat eyelid lesion |
| 67875 | Closure of eyelid by suture |
| 67880 | Revision of eyelid |
| 67882 | Revision of eyelid |
| 67900 | Repair brow defect |
| 67901 | Repair eyelid defect |
| 67902 | Repair eyelid defect |
| 67903 | Repair eyelid defect |
| 67904 | Repair eyelid defect |
| 67906 | Repair eyelid defect |
| 67908 | Repair eyelid defect |
| 67909 | Repair eyelid defect |
| 67911 | Repair eyelid defect |
| 67914 | Repair eyelid defect |
| 67915 | Repair eyelid defect |
| 67916 | Repair eyelid defect |
| 67917 | Repair eyelid defect |
| 67921 | Repair eyelid defect |
| 67922 | Repair eyelid defect |
| 67923 | Repair eyelid defect |
| 67924 | Repair eyelid defect |
| 67930 | Repair eyelid wound |
| 67935 | Repair eyelid wound |
| 67938 | Remove eyelid foreign body |
| 67950 | Revision of eyelid |
| 67961 | Revision of eyelid |
| 67966 | Revision of eyelid |
| 67971 | Reconstruction of eyelid |
| 67973 | Reconstruction of eyelid |
| 67974 | Reconstruction of eyelid |
| 67975 | Reconstruction of eyelid |
| 68020 | Incise/drain eyelid lining |
| 68040 | Treatment of eyelid lesions |
| 68100 | Biopsy of eyelid lining |
| 68110 | Remove eyelid lining lesion |
| 68115 | Remove eyelid lining lesion |
| 68130 | Remove eyelid lining lesion |
| 68135 | Remove eyelid lining lesion |

Some of these codes have previously been refined and additional refinements were made by the PEAC.
All anesthesia codes were reviewed with the exception of 00104 abd 00124.
CPT codes and descriptions are copyright 2004 by the AMA, all rights reserved.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 68200 | Treat eyelid by injection |
| 68320 | Revise/graft eyelid lining |
| 68325 | Revise/graft eyelid lining |
| 68326 | Revise/graft eyelid lining |
| 68328 | Revise/graft eyelid lining |
| 68330 | Revise eyelid lining |
| 68335 | Revise/graft eyelid lining |
| 68340 | Separate eyelid adhesions |
| 68360 | Revise eyelid lining |
| 68362 | Revise eyelid lining |
| 68440 | Incise tear duct opening |
| 68700 | Repair tear ducts |
| 68705 | Revise tear duct opening |
| 68760 | Close tear duct opening |
| 68761 | Close tear duct opening |
| 68770 | Close tear duct opening |
| 68801 | Dilate tear duct opening |
| 68810 | Probe nasolacrimal duct |
| 68811 | Probe nasolacrimal duct |
| 68815 | Probe nasolacrimal duct |
| 68840 | Explore/irrigate tear ducts |
| 68850 | Injection for tear sac x-ray |
| 69110 | Remove external ear, partial |
| 69120 | Removal of external ear |
| 69140 | Remove ear canal lesion(s) |
| 69145 | Remove ear canal lesion(s) |
| 69150 | Extensive ear canal surgery |
| 69155 | Extensive ear/neck surgery |
| 69310 | Rebuild outer ear canal |
| 69320 | Rebuild outer ear canal |
| 69440 | Exploration of middle ear |
| 69450 | Eardrum revision |
| 69501 | Mastoidectomy |
| 69502 | Mastoidectomy |
| 69505 | Remove mastoid structures |
| 69511 | Extensive mastoid surgery |
| 69530 | Extensive mastoid surgery |
| 69535 | Remove part of temporal bone |
| 69550 | Remove ear lesion |
| 69552 | Remove ear lesion |
| 69554 | Remove ear lesion |
| 69601 | Mastoid surgery revision |
| 69602 | Mastoid surgery revision |
| 69603 | Mastoid surgery revision |
| 69604 | Mastoid surgery revision |
| 69605 | Mastoid surgery revision |
| 69620 | Repair of eardrum |
| 69631 | Repair eardrum structures |
| 69632 | Rebuild eardrum structures |
| 69633 | Rebuild eardrum structures |
| 69635 | Repair eardrum structures |
| 69636 | Rebuild eardrum structures |
| 69637 | Rebuild eardrum structures |
| 69641 | Revise middle ear & mastoid |
| 69642 | Revise middle ear & mastoid |
| 69643 | Revise middle ear & mastoid |
| 69644 | Revise middle ear & mastoid |
| 69645 | Revise middle ear & mastoid |
| 69646 | Revise middle ear & mastoid |
| 69650 | Release middle ear bone |
| 69660 | Revise middle ear bone |
| 69661 | Revise middle ear bone |
| 69662 | Revise middle ear bone |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 69666 | Repair middle ear structures |
| 69667 | Repair middle ear structures |
| 69670 | Remove mastoid air cells |
| 69676 | Remove middle ear nerve |
| 69700 | Close mastoid fistula |
| 69711 | Remove/repair hearing aid |
| 69714 | Implant temple bone w/stimul |
| 69715 | Temple bne implnt w/stimulat |
| 69717 | Temple bone implant revision |
| 69718 | Revise temple bone implant |
| 69720 | Release facial nerve |
| 69725 | Release facial nerve |
| 69740 | Repair facial nerve |
| 69745 | Repair facial nerve |
| 69801 | Incise inner ear |
| 69802 | Incise inner ear |
| 69805 | Explore inner ear |
| 69806 | Explore inner ear |
| 69820 | Establish inner ear window |
| 69840 | Revise inner ear window |
| 69905 | Remove inner ear |
| 69910 | Remove inner ear & mastoid |
| 69915 | Incise inner ear nerve |
| 69930 | Implant cochlear device |
| 69950 | Incise inner ear nerve |
| 69955 | Release facial nerve |
| 69960 | Release inner ear canal |
| 69970 | Remove inner ear lesion |
| 69990 | Microsurgery add-on |
| 70010 | Contrast x-ray of brain |
| 70015 | Contrast x-ray of brain |
| 70030 | X-ray eye for foreign body |
| 70100 | X-ray exam of jaw |
| 70110 | X-ray exam of jaw |
| 70120 | X-ray exam of mastoids |
| 70130 | X-ray exam of mastoids |
| 70134 | X-ray exam of middle ear |
| 70140 | X-ray exam of facial bones |
| 70150 | X-ray exam of facial bones |
| 70160 | X-ray exam of nasal bones |
| 70170 | X-ray exam of tear duct |
| 70190 | X-ray exam of eye sockets |
| 70200 | X-ray exam of eye sockets |
| 70210 | X-ray exam of sinuses |
| 70220 | X-ray exam of sinuses |
| 70240 | X-ray exam, pituitary saddle |
| 70250 | X-ray exam of skull |
| 70260 | X-ray exam of skull |
| 70300 | X-ray exam of teeth |
| 70310 | X-ray exam of teeth |
| 70320 | Full mouth x-ray of teeth |
| 70328 | X-ray exam of jaw joint |
| 70330 | X-ray exam of jaw joints |
| 70332 | X-ray exam of jaw joint |
| 70350 | X-ray head for orthodontia |
| 70355 | Panoramic x-ray of jaws |
| 70360 | X-ray exam of neck |
| 70370 | Throat x-ray & fluoroscopy |
| 70371 | Speech evaluation, complex |
| 70373 | Contrast x-ray of larynx |
| 70380 | X-ray exam of salivary gland |
| 70390 | X-ray exam of salivary duct |
| 70450 | Ct head/brain w/o dye |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 70460 | Ct head/brain w/dye |
| 70470 | Ct head/brain w/o & w/ dye |
| 70480 | Ct orbit/ear/fossa w/o dye |
| 70481 | Ct orbit/ear/fossa w/dye |
| 70482 | Ct orbit/ear/fossa w/o&w dye |
| 70486 | Ct maxillofacial w/o dye |
| 70487 | Ct maxillofacial w/dye |
| 70488 | Ct maxillofacial w/o & w dye |
| 70490 | Ct soft tissue neck w/o dye |
| 70491 | Ct soft tissue neck w/dye |
| 70492 | Ct sft tsue nck w/o & w/dye |
| 70542 | Mri orbit/face/neck w/dye |
| 70543 | Mri orbt/fac/nck w/o & w dye |
| 70552 | Mri brain w/ dye |
| 70553 | Mri brain w/o & w/ dye |
| 70557 | Mri brain w/o dye |
| 70558 | Mri brain w/ dye |
| 70559 | Mri brain w/o & w/ dye |
| 71010 | Chest x-ray |
| 71015 | Chest x-ray |
| 71020 | Chest x-ray |
| 71021 | Chest x-ray |
| 71022 | Chest x-ray |
| 71023 | Chest x-ray and fluoroscopy |
| 71030 | Chest x-ray |
| 71034 | Chest x-ray and fluoroscopy |
| 71035 | Chest x-ray |
| 71040 | Contrast x-ray of bronchi |
| 71060 | Contrast x-ray of bronchi |
| 71090 | X-ray & pacemaker insertion |
| 71100 | X-ray exam of ribs |
| 71101 | X-ray exam of ribs/chest |
| 71110 | X-ray exam of ribs |
| 71111 | X-ray exam of ribs/ chest |
| 71120 | X-ray exam of breastbone |
| 71130 | X-ray exam of breastbone |
| 71250 | Ct thorax w/o dye |
| 71260 | Ct thorax w/dye |
| 71270 | Ct thorax w/o & w/ dye |
| 71551 | Mri chest w/dye |
| 71552 | Mri chest w/o & w/dye |
| 71555 | Mri angio chest w or w/o dye |
| 72010 | X-ray exam of spine |
| 72020 | X-ray exam of spine |
| 72040 | X-ray exam of neck spine |
| 72050 | X-ray exam of neck spine |
| 72052 | X-ray exam of neck spine |
| 72069 | X-ray exam of trunk spine |
| 72070 | X-ray exam of thoracic spine |
| 72072 | X-ray exam of thoracic spine |
| 72074 | X-ray exam of thoracic spine |
| 72080 | X-ray exam of trunk spine |
| 72090 | X-ray exam of trunk spine |
| 72100 | X-ray exam of lower spine |
| 72110 | X-ray exam of lower spine |
| 72114 | X-ray exam of lower spine |
| 72120 | X-ray exam of lower spine |
| 72125 | Ct neck spine w/o dye |
| 72126 | Ct neck spine w/dye |
| 72127 | Ct neck spine w/o & w/dye |
| 72128 | Ct chest spine w/o dye |
| 72129 | Ct chest spine w/dye |
| 72130 | Ct chest spine w/o & w/dye |

Some of these codes have previously been refined and additional refinements were made by the PEAC.
All anesthesia codes were reviewed with the exception of 00104 abd 00124.
CPT codes and descriptions are copyright 2004 by the AMA, all rights reserved.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 72131 | Ct lumbar spine w/o dye |
| 72132 | Ct lumbar spine w/dye |
| 72133 | Ct lumbar spine w/o & w/dye |
| 72142 | Mri neck spine w/dye |
| 72147 | Mri chest spine w/dye |
| 72149 | Mri lumbar spine w/dye |
| 72156 | Mri neck spine w/o & w/dye |
| 72157 | Mri chest spine w/o & w/dye |
| 72158 | Mri lumbar spine w/o & w/dye |
| 72159 | Mr angio spine w/o&w/dye |
| 72170 | X-ray exam of pelvis |
| 72190 | X-ray exam of pelvis |
| 72192 | Ct pelvis w/o dye |
| 72193 | Ct pelvis w/dye |
| 72194 | Ct pelvis w/o & w/dye |
| 72196 | Mri pelvis w/dye |
| 72197 | Mri pelvis w/o & w/dye |
| 72198 | Mr angio pelvis w/o & w/dye |
| 72200 | X-ray exam sacroiliac joints |
| 72202 | X-ray exam sacroiliac joints |
| 72220 | X-ray exam of tailbone |
| 72240 | Contrast x-ray of neck spine |
| 72255 | Contrast x-ray, thorax spine |
| 72270 | Contrast x-ray, spine |
| 72275 | Epidurography |
| 72285 | X-ray c/t spine disk |
| 72295 | X-ray of lower spine disk |
| 73000 | X-ray exam of collar bone |
| 73010 | X-ray exam of shoulder blade |
| 73020 | X-ray exam of shoulder |
| 73030 | X-ray exam of shoulder |
| 73040 | Contrast x-ray of shoulder |
| 73050 | X-ray exam of shoulders |
| 73060 | X-ray exam of humerus |
| 73070 | X-ray exam of elbow |
| 73080 | X-ray exam of elbow |
| 73085 | Contrast x-ray of elbow |
| 73090 | X-ray exam of forearm |
| 73092 | X-ray exam of arm, infant |
| 73100 | X-ray exam of wrist |
| 73110 | X-ray exam of wrist |
| 73115 | Contrast x-ray of wrist |
| 73120 | X-ray exam of hand |
| 73130 | X-ray exam of hand |
| 73140 | X-ray exam of finger(s) |
| 73200 | Ct upper extremity w/o dye |
| 73201 | Ct upper extremity w/dye |
| 73202 | Ct uppr extremity w/o&w/dye |
| 73219 | Mri upper extremity w/dye |
| 73220 | Mri uppr extremity w/o&w/dye |
| 73222 | Mri joint upr extrem w/dye |
| 73223 | Mri joint upr extr w/o&w/dye |
| 73225 | Mr angio upr extr w/o&w/dye |
| 73500 | X-ray exam of hip |
| 73510 | X-ray exam of hip |
| 73520 | X-ray exam of hips |
| 73525 | Contrast x-ray of hip |
| 73530 | X-ray exam of hip |
| 73540 | X-ray exam of pelvis & hips |
| 73542 | X-ray exam, sacroiliac joint |
| 73550 | X-ray exam of thigh |
| 73560 | X-ray exam of knee, 1 or 2 |
| 73562 | X-ray exam of knee, 3 |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 73564 | X-ray exam, knee, 4 or more |
| 73565 | X-ray exam of knees |
| 73580 | Contrast x-ray of knee joint |
| 73590 | X-ray exam of lower leg |
| 73592 | X-ray exam of leg, infant |
| 73600 | X-ray exam of ankle |
| 73610 | X-ray exam of ankle |
| 73615 | Contrast x-ray of ankle |
| 73620 | X-ray exam of foot |
| 73630 | X-ray exam of foot |
| 73650 | X-ray exam of heel |
| 73660 | X-ray exam of toe(s) |
| 73700 | Ct lower extremity w/o dye |
| 73701 | Ct lower extremity w/dye |
| 73702 | Ct lwr extremity w/o&w/dye |
| 73719 | Mri lower extremity w/dye |
| 73720 | Mri lwr extremity w/o&w/dye |
| 73722 | Mri joint of lwr extr w/dye |
| 73723 | Mri joint lwr extr w/o&w/dye |
| 73725 | Mr ang lwr ext w or w/o dye |
| 74000 | X-ray exam of abdomen |
| 74010 | X-ray exam of abdomen |
| 74020 | X-ray exam of abdomen |
| 74022 | X-ray exam series, abdomen |
| 74150 | Ct abdomen w/o dye |
| 74160 | Ct abdomen w/dye |
| 74170 | Ct abdomen w/o &w /dye |
| 74182 | Mri abdomen w/dye |
| 74183 | Mri abdomen w/o & w/dye |
| 74185 | Mri angio, abdom w orw/o dye |
| 74190 | X-ray exam of peritoneum |
| 74210 | Contrst x-ray exam of throat |
| 74220 | Contrast x-ray, esophagus |
| 74230 | Cine/vid x-ray, throat/esoph |
| 74235 | Remove esophagus obstruction |
| 74240 | X-ray exam, upper gi tract |
| 74241 | X-ray exam, upper gi tract |
| 74245 | X-ray exam, upper gi tract |
| 74246 | Contrst x-ray uppr gi tract |
| 74247 | Contrst x-ray uppr gi tract |
| 74249 | Contrst x-ray uppr gi tract |
| 74251 | X-ray exam of small bowel |
| 74260 | X-ray exam of small bowel |
| 74270 | Contrast x-ray exam of colon |
| 74280 | Contrast x-ray exam of colon |
| 74283 | Contrast x-ray exam of colon |
| 74290 | Contrast x-ray, gallbladder |
| 74291 | Contrast x-rays, gallbladder |
| 74300 | X-ray bile ducts/pancreas |
| 74305 | X-ray bile ducts/pancreas |
| 74320 | Contrast x-ray of bile ducts |
| 74327 | X-ray bile stone removal |
| 74328 | X-ray bile duct endoscopy |
| 74329 | X-ray for pancreas endoscopy |
| 74330 | X-ray bile/panc endoscopy |
| 74340 | X-ray guide for GI tube |
| 74350 | X-ray guide, stomach tube |
| 74355 | X-ray guide, intestinal tube |
| 74360 | X-ray guide, GI dilation |
| 74363 | X-ray, bile duct dilation |
| 74420 | Contrst x-ray, urinary tract |
| 74425 | Contrst x-ray, urinary tract |
| 74440 | X-ray, male genital tract |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 74445 | X-ray exam of penis |
| 74450 | X-ray, urethra/bladder |
| 74470 | X-ray exam of kidney lesion |
| 74475 | X-ray control, cath insert |
| 74480 | X-ray control, cath insert |
| 74485 | X-ray guide, GU dilation |
| 74710 | X-ray measurement of pelvis |
| 74742 | X-ray, fallopian tube |
| 74775 | X-ray exam of perineum |
| 75553 | Heart mri for morph w/dye |
| 75556 | Cardiac MRI/flow mapping |
| 75600 | Contrast x-ray exam of aorta |
| 75605 | Contrast x-ray exam of aorta |
| 75625 | Contrast x-ray exam of aorta |
| 75630 | X-ray aorta, leg arteries |
| 75650 | Artery x-rays, head & neck |
| 75658 | Artery x-rays, arm |
| 75660 | Artery x-rays, head & neck |
| 75662 | Artery x-rays, head & neck |
| 75665 | Artery x-rays, head & neck |
| 75671 | Artery x-rays, head & neck |
| 75676 | Artery x-rays, neck |
| 75680 | Artery x-rays, neck |
| 75685 | Artery x-rays, spine |
| 75705 | Artery x-rays, spine |
| 74250 | X-ray exam of small bowel |
| 75710 | Artery x-rays, arm/leg |
| 75716 | Artery x-rays, arms/legs |
| 75722 | Artery x-rays, kidney |
| 75724 | Artery x-rays, kidneys |
| 75726 | Artery x-rays, abdomen |
| 75731 | Artery x-rays, adrenal gland |
| 75733 | Artery x-rays, adrenals |
| 75736 | Artery x-rays, pelvis |
| 75741 | Artery x-rays, lung |
| 75743 | Artery x-rays, lungs |
| 75746 | Artery x-rays, lung |
| 75756 | Artery x-rays, chest |
| 75774 | Artery x-ray, each vessel |
| 75790 | Visualize A-V shunt |
| 75801 | Lymph vessel x-ray, arm/leg |
| 75803 | Lymph vessel x-ray,arms/legs |
| 75805 | Lymph vessel x-ray, trunk |
| 75807 | Lymph vessel x-ray, trunk |
| 75809 | Nonvascular shunt, x-ray |
| 75810 | Vein x-ray, spleen/liver |
| 75820 | Vein x-ray, arm/leg |
| 75822 | Vein x-ray, arms/legs |
| 75825 | Vein x-ray, trunk |
| 75827 | Vein x-ray, chest |
| 75831 | Vein x-ray, kidney |
| 75833 | Vein x-ray, kidneys |
| 75840 | Vein x-ray, adrenal gland |
| 75842 | Vein x-ray, adrenal glands |
| 75860 | Vein x-ray, neck |
| 75870 | Vein x-ray, skull |
| 75872 | Vein x-ray, skull |
| 75880 | Vein x-ray, eye socket |
| 75885 | Vein x-ray, liver |
| 75887 | Vein x-ray, liver |
| 75889 | Vein x-ray, liver |
| 75891 | Vein x-ray, liver |
| 75893 | Venous sampling by catheter |

Some of these codes have previously been refined and additional refinements were made by the PEAC.
All anesthesia codes were reviewed with the exception of 00104 abd 00124.
CPT codes and descriptions are copyright 2004 by the AMA, all rights reserved.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 75894 | X-rays, transcath therapy |
| 75896 | X-rays, transcath therapy |
| 75898 | Follow-up angiography |
| 75900 | Arterial catheter exchange |
| 75940 | X-ray placement, vein filter |
| 75952 | Endovasc repair abdom aorta |
| 75953 | Abdom aneurysm endovas rpr |
| 75954 | Iliac aneurysm endovas rpr |
| 75960 | Transcatheter intro, stent |
| 75961 | Retrieval, broken catheter |
| 75962 | Repair arterial blockage |
| 75964 | Repair artery blockage, each |
| 75966 | Repair arterial blockage |
| 75968 | Repair artery blockage, each |
| 75970 | Vascular biopsy |
| 75978 | Repair venous blockage |
| 75980 | Contrast xray exam bile duct |
| 75982 | Contrast xray exam bile duct |
| 75984 | Xray control catheter change |
| 75989 | Abscess drainage under x-ray |
| 75992 | Atherectomy, x-ray exam |
| 75993 | Atherectomy, x-ray exam |
| 75994 | Atherectomy, x-ray exam |
| 75995 | Atherectomy, x-ray exam |
| 75996 | Atherectomy, x-ray exam |
| 76001 | Fluoroscope exam, extensive |
| 76003 | Needle localization by x-ray |
| 76005 | Fluoroguide for spine inject |
| 76006 | X-ray stress view |
| 76010 | X-ray, nose to rectum |
| 76012 | Percut vertebroplasty fluor |
| 76013 | Percut vertebroplasty, ct |
| 76020 | X-rays for bone age |
| 76040 | X-rays, bone evaluation |
| 76061 | X-rays, bone survey |
| 76062 | X-rays, bone survey |
| 76065 | X-rays, bone evaluation |
| 76066 | Joint survey, single view |
| 76070 | Ct bone density, axial |
| 76075 | Dexa, axial skeleton study |
| 76076 | Dexa, peripheral study |
| 76078 | Radiographic absorptiometry |
| 76080 | X-ray exam of fistula |
| 76086 | X-ray of mammary duct |
| 76088 | X-ray of mammary ducts |
| 76090 | Mammogram, one breast |
| 76091 | Mammogram, both breasts |
| 76092 | Mammogram, screening |
| 76093 | Magnetic image, breast |
| 76094 | Magnetic image, both breasts |
| 76095 | Stereotactic breast biopsy |
| 76096 | X-ray of needle wire, breast |
| 76096 | X-ray of needle wire, breast |
| 76098 | X-ray exam, breast specimen |
| 76100 | X-ray exam of body section |
| 76101 | Complex body section x-ray |
| 76102 | Complex body section x-rays |
| 76350 | Special x-ray contrast study |
| 76355 | Ct scan for localization |
| 76360 | Ct scan for needle biopsy |
| 76362 | Ct guide for tissue ablation |
| 76362 | Ct guide for tissue ablation |
| 76370 | Ct scan for therapy guide |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 76375 | 3d/holograph reconstr add-on |
| 76380 | CAT scan follow-up study |
| 76390 | Mr spectroscopy |
| 76394 | Mri for tissue ablation |
| 76394 | Mri for tissue ablation |
| 76604 | Us exam, chest, b-scan |
| 76645 | Us exam, breast(s) |
| 76700 | Us exam, abdom, complete |
| 76705 | Echo exam of abdomen |
| 76775 | Us exam abdo back wall, lim |
| 76800 | Us exam, spinal canal |
| 76886 | Us exam infant hips, static |
| 76932 | Echo guide for heart biopsy |
| 76936 | Echo guide for artery repair |
| 76941 | Us guide, tissue ablation |
| 76941 | Echo guide for transfusion |
| 76945 | Echo guide for transfusion |
| 76946 | Echo guide, villus sampling |
| 76948 | Echo guide for amniocentesis |
| 76950 | Echo guide, ova aspiration |
| 76965 | Echo guidance radiotherapy |
| 76970 | Echo guidance radiotherapy |
| 76977 | Ultrasound exam follow-up |
| 76986 | Us bone density measure |
| 77295 | Ultrasound guide intraoper |
| 77326 | Set radiation therapy field |
| 77327 | Brachytx isodose calc simp |
| 77328 | Brachytx isodose calc interm |
| 77427 | Brachytx isodose plan compl |
| 77431 | Radiation tx management, x5 |
| 77470 | Stereotactic radiation trmt |
| 77600 | Special radiation treatment |
| 77605 | Hyperthermia treatment |
| 77610 | Hyperthermia treatment |
| 77615 | Hyperthermia treatment |
| 77620 | Hyperthermia treatment |
| 77750 | Hyperthermia treatment |
| 77761 | Infuse radioactive materials |
| 77762 | Apply intrcav radiat simple |
| 77763 | Apply intrcav radiat interm |
| 77776 | Apply intrcav radiat compl |
| 77777 | Apply interstit radiat simpl |
| 77778 | Apply interstit radiat inter |
| 77790 | Apply surface radiation |
| 78000 | Radiation handling |
| 78001 | Thyroid, single uptake |
| 78003 | Thyroid, multiple uptakes |
| 78006 | Thyroid suppress/stimul |
| 78007 | Thyroid imaging with uptake |
| 78010 | Thyroid image, mult uptakes |
| 78011 | Thyroid imaging |
| 78015 | Thyroid imaging with flow |
| 78016 | Thyroid met imaging |
| 78018 | Thyroid met imaging/studies |
| 78020 | Thyroid met imaging, body |
| 78070 | Thyroid met uptake |
| 78075 | Parathyroid nuclear imaging |
| 78102 | Adrenal nuclear imaging |
| 78103 | Bone marrow imaging, ltd |
| 78104 | Bone marrow imaging, mult |
| 78110 | Bone marrow imaging, body |
| 78111 | Plasma volume, single |
| 78120 | Plasma volume, multiple |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 78121 | Red cell mass, single |
| 78122 | Red cell mass, multiple |
| 78130 | Blood volume |
| 78135 | Red cell survival study |
| 78140 | Red cell survival kinetics |
| 78185 | Total body iron estimation |
| 78190 | Spleen imaging |
| 78191 | Platelet survival, kinetics |
| 78195 | Platelet survival |
| 78201 | Lymph system imaging |
| 78202 | Liver imaging |
| 78205 | Liver imaging with flow |
| 78215 | Liver image (3d) with flow |
| 78216 | Liver and spleen imaging |
| 78220 | Liver & spleen image/flow |
| 78223 | Liver function study |
| 78230 | Hepatobiliary imaging |
| 78231 | Salivary gland imaging |
| 78232 | Serial salivary imaging |
| 78258 | Salivary gland function exam |
| 78261 | Esophageal motility study |
| 78262 | Gastric mucosa imaging |
| 78264 | Gastroesophageal reflux exam |
| 78270 | Gastric emptying study |
| 78271 | Vit B-12 absorption exam |
| 78272 | Vit b-12 absrp exam, int fac |
| 78278 | Vit B-12 absorp, combined |
| 78290 | GI protein loss exam |
| 78291 | Meckel's divert exam |
| 78300 | Leveen/shunt patency exam |
| 78305 | Bone imaging, limited area |
| 78306 | Bone imaging, multiple areas |
| 78315 | Bone imaging, whole body |
| 78320 | Bone imaging, 3 phase |
| 78428 | Bone mineral, dual photon |
| 78445 | Cardiac shunt imaging |
| 78456 | Venous thrombosis study |
| 78457 | Acute venous thrombus image |
| 78458 | Venous thrombosis imaging |
| 78460 | Ven thrombosis images, bilat |
| 78461 | Heart muscle blood, single |
| 78464 | Heart muscle blood, multiple |
| 78466 | Heart image (3d), single |
| 78468 | Heart infarct image |
| 78469 | Heart infarct image (ef) |
| 78472 | Heart infarct image (3D) |
| 78473 | Gated heart, planar, single |
| 78478 | Gated heart, multiple |
| 78480 | Heart wall motion add-on |
| 78481 | Heart function add-on |
| 78483 | Heart first pass, single |
| 78494 | Heart first pass, multiple |
| 78496 | Heart image, spect |
| 78580 | Heart first pass add-on |
| 78584 | Lung perfusion imaging |
| 78585 | Lung V/Q image single breath |
| 78586 | Lung V/Q imaging |
| 78587 | Aerosol lung image, single |
| 78588 | Aerosol lung image, multiple |
| 78591 | Perfusion lung image |
| 78593 | Vent image, 1 breath, 1 proj |
| 78594 | Vent image, 1 proj, gas |
| 78596 | Vent image, mult proj, gas |

Some of these codes have previously been refined and additional refinements were made by the PEAC.
All anesthesia codes were reviewed with the exception of 00104 abd 00124.
CPT codes and descriptions are copyright 2004 by the AMA, all rights reserved.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 78601 | Brain imaging, ltd static |
| 78605 | Brain imaging, ltd w/flow |
| 78606 | Brain imaging, complete |
| 78610 | Brain imaging (3D) |
| 78615 | Brain flow imaging only |
| 78630 | Cerebral vascular flow image |
| 78635 | Cerebrospinal fluid scan |
| 78645 | CSF ventriculography |
| 78650 | Cerebrospinal fluid scan |
| 78660 | CSF leakage imaging |
| 78700 | Nuclear exam of tear flow |
| 78701 | Kidney imaging, static |
| 78704 | Kidney imaging with flow |
| 78707 | Imaging renogram |
| 78708 | Kidney flow/function image |
| 78709 | Kidney flow/function image |
| 78710 | Kidney flow/function image |
| 78715 | Kidney imaging (3D) |
| 78725 | Renal vascular flow exam |
| 78730 | Kidney function study |
| 78740 | Urinary bladder retention |
| 78760 | Ureteral reflux study |
| 78761 | Testicular imaging |
| 78800 | Testicular imaging/flow |
| 78801 | Tumor imaging, limited area |
| 78802 | Tumor imaging, mult areas |
| 78804 | Tumor imaging (3D) |
| 78805 | Tumor imaging, whole body |
| 78806 | Abscess imaging, ltd area |
| 78890 | Nuclear localization/abscess |
| 78891 | Nuclear medicine data proc |
| 85396 | Nuclear joint therapy |
| 88125 | TB tine test |
| 88141 | Forensic cytopathology |
| 88348 | Cytopath, c/v, interpret |
| 88349 | Electron microscopy |
| 90865 | Sample stomach contents |
| 90870 | Narcosynthesis |
| 90875 | Electroconvulsive therapy |
| 90876 | Psychophysiological therapy |
| 90885 | Hypnotherapy |
| 91000 | Psy evaluation of records |
| 91010 | Esophageal intubation |
| 91011 | Esophagus motility study |
| 91012 | Esophagus motility study |
| 91020 | Esophagus motility study |
| 91030 | Gastric motility |
| 91052 | Prolonged acid reflux test |
| 91055 | Gastric analysis test |
| 91060 | Gastric intubation for smear |
| 91065 | Gastric saline load test |
| 91100 | Breath hydrogen test |
| 91105 | Pass intestine bleeding tube |
| 91122 | Gastric intubation treatment |
| 91123 | Anal pressure record |
| 91132 | Irrigate fecal impaction |
| 91133 | Electrogastrography |
| 92325 | Prescription of contact lens |
| 92326 | Modification of contact lens |
| 92354 | Fitting of artificial eye |
| 92355 | Special spectacles fitting |
| 92358 | Special spectacles fitting |
| 92371 | Eye prosthesis service |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 92392 | Repair & adjust spectacles |
| 92393 | Supply of low vision aids |
| 92395 | Supply of artificial eye |
| 92512 | Supply of contact lenses |
| 92516 | Nasal function studies |
| 92547 | Facial nerve function test |
| 92548 | Supplemental electrical test |
| 92565 | Posturography |
| 92571 | Stenger test, pure tone |
| 92572 | Filtered speech hearing test |
| 92573 | Staggered spondaic word test |
| 92575 | Lombard test |
| 92576 | Sensorineural acuity test |
| 92577 | Synthetic sentence test |
| 92579 | Stenger test, speech |
| 92582 | Visual audiometry (vra) |
| 92583 | Conditioning play audiometry |
| 92584 | Select picture audiometry |
| 92585 | Electrocochleography |
| 92586 | Auditor evoke potent, compre |
| 92587 | Auditor evoke potent, limit |
| 92588 | Evoked auditory test |
| 92596 | Evoked auditory test |
| 92950 | Oral speech device eval |
| 92975 | Cardioassist, external |
| 93012 | Dissolve clot, heart vessel |
| 93014 | Transmission of ecg |
| 93224 | Cardiac drug stress test |
| 93225 | ECG monitor/report, 24 hrs |
| 93226 | ECG monitor/record, 24 hrs |
| 93227 | ECG monitor/report, 24 hrs |
| 93230 | ECG monitor/review, 24 hrs |
| 93231 | ECG monitor/report, 24 hrs |
| 93232 | Ecg monitor/record, 24 hrs |
| 93235 | ECG monitor/report, 24 hrs |
| 93236 | ECG monitor/report, 24 hrs |
| 93237 | ECG monitor/report, 24 hrs |
| 93268 | ECG monitor/review, 24 hrs |
| 93270 | ECG record/review |
| 93271 | ECG recording |
| 93272 | Ecg/monitoring and analysis |
| 93278 | Ecg/review, interpret only |
| 93318 | Echo transesophageal |
| 93501 | Echo transesophageal intraop |
| 93505 | Right heart catheterization |
| 93508 | Biopsy of heart lining |
| 93510 | Cath placement, angiography |
| 93526 | Left heart catheterization |
| 93555 | R & l heart cath, congenital |
| 93556 | Imaging, cardiac cath |
| 93609 | Heart flow reserve measure |
| 93613 | Map tachycardia, add-on |
| 93660 | Electrophys map 3d, add-on |
| 93721 | Tilt table evaluation |
| 93724 | Plethysmography tracing |
| 93727 | Analyze pacemaker system |
| 93731 | Analyze ilr system |
| 93732 | Analyze pacemaker system |
| 93734 | Analyze pacemaker system |
| 93735 | Analyze pacemaker system |
| 93741 | Analyze pacemaker system |
| 93742 | Analyze ht pace device sngl |
| 93743 | Analyze ht pace device sngl |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 93744 | Analyze ht pace device dual |
| 93798 | Cardiac rehab |
| 93980 | Cardiac rehab/monitor |
| 93981 | Penile vascular study |
| 94070 | Review patient spirometry |
| 94450 | CO2 breathing response curve |
| 94770 | Pulmonary compliance study |
| 95044 | Breath recording, infant |
| 95052 | Allergy patch tests |
| 95056 | Photo patch test |
| 95070 | Photosensitivity tests |
| 95180 | Ingestion challenge test |
| 95250 | Rapid desensitization |
| 95806 | Multiple sleep latency test |
| 95819 | Sleep study, attended |
| 95824 | Eeg, awake and asleep |
| 95824 | Eeg, cerebral death only |
| 95827 | Eeg, cerebral death only |
| 95858 | Tensilon test |
| 95869 | Tensilon test & myogram |
| 95872 | Muscle test, thor paraspinal |
| 95920 | Limb exercise test |
| 95925 | Intraop nerve test add-on |
| 95926 | Somatosensory testing |
| 95927 | Somatosensory testing |
| 95930 | Somatosensory testing |
| 95936 | Visual evoked potential test |
| 95957 | Eeg monitoring, cable/radio |
| 95958 | EEG digital analysis |
| 95961 | EEG monitoring/function test |
| 95962 | Electrode stimulation, brain |
| 95970 | Meg, evoked, each add'l |
| 95971 | Analyze neurostim, no prog |
| 95972 | Analyze neurostim, simple |
| 95973 | Analyze neurostim, complex |
| 95974 | Analyze neurostim, complex |
| 95975 | Cranial neurostim, complex |
| 96902 | Ultraviolet light therapy |
| 99026 | Wound(s) care, selective |
| 99027 | In-hospital on call service |
| 99170 | Out-of-hosp on call service |
| 99175 | Anogenital exam, child |
| 99183 | Induction of vomiting |
| 99217 | Total body hypothermia |
| 99218 | Observation care discharge |
| 99219 | Observation care |
| 99220 | Observation care |
| 99221 | Observation care |
| 99222 | Initial hospital care |
| 99223 | Initial hospital care |
| 99231 | Initial hospital care |
| 99232 | Subsequent hospital care |
| 99233 | Subsequent hospital care |
| 99234 | Subsequent hospital care |
| 99235 | Observ/hosp same date |
| 99236 | Observ/hosp same date |
| 99238 | Observ/hosp same date |
| 99239 | Hospital discharge day |
| 99251 | Office consultation |
| 99252 | Initial inpatient consult |
| 99253 | Initial inpatient consult |
| 99254 | Initial inpatient consult |
| 99255 | Initial inpatient consult |

Some of these codes have previously been refined and additional refinements were made by the PEAC.
All anesthesia codes were reviewed with the exception of 00104 abd 00124.
CPT codes and descriptions are copyright 2004 by the AMA, all rights reserved.

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 99261 | Initial inpatient consult |
| 99262 | Follow-up inpatient consult |
| 99263 | Follow-up inpatient consult |
| 99271 | Follow-up inpatient consult |
| 99272 | Confirmatory consultation |
| 99273 | Confirmatory consultation |
| 99274 | Confirmatory consultation |
| 99275 | Confirmatory consultation |
| 99281 | Confirmatory consultation |
| 99282 | Emergency dept visit |
| 99283 | Emergency dept visit |
| 99284 | Emergency dept visit |
| 99285 | Emergency dept visit |
| 99288 | Emergency dept visit |
| 99289 | Direct advanced life support |
| 99290 | Ped crit care transport |
| 99291 | Ped crit care transport addl |
| 99292 | Critical care, first hour |
| 99293 | Critical care, add'l 30 min |
| 99294 | Ped critical care, initial |
| 99295 | Ped critical care, subseq |
| 99296 | Neonate crit care, initial |
| 99298 | Neonate critical care subseq |
| 99299 | lc for lbw infant < 1500 gm |
| 99301 | lc, lbw infant 1500-2500 gm |
| 99302 | Nursing facility care |
| 99303 | Nursing facility care |
| 99311 | Nursing facility care |
| 99312 | Nursing fac care, subseq |
| 99313 | Nursing fac care, subseq |
| 99315 | Nursing fac care, subseq |
| 99316 | Nursing fac discharge day |
| 99321 | Nursing fac discharge day |
| 99322 | Rest home visit, new patient |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 99323 | Rest home visit, new patient |
| 99331 | Rest home visit, new patient |
| 99332 | Rest home visit, est pat |
| 99333 | Rest home visit, est pat |
| 99341 | Rest home visit, est pat |
| 99342 | Home visit, new patient |
| 99343 | Home visit, new patient |
| 99344 | Home visit, new patient |
| 99345 | Home visit, new patient |
| 99347 | Home visit, new patient |
| 99348 | Home visit, est patient |
| 99349 | Home visit, est patient |
| 99350 | Home visit, est patient |
| 99354 | Home visit, est patient |
| 99355 | Prolonged service, office |
| 99356 | Prolonged service, office |
| 99357 | Prolonged service, inpatient |
| 99358 | Prolonged service, inpatient |
| 99359 | Prolonged serv, w/o contact |
| 99360 | Prolonged serv, w/o contact |
| 99361 | Physician standby services |
| 99362 | Physician/team conference |
| 99371 | Physician/team conference |
| 99372 | Physician phone consultation |
| 99373 | Physician phone consultation |
| 99374 | Physician phone consultation |
| 99375 | Home health care supervision |
| 99377 | Home health care supervision |
| 99378 | Hospice care supervision |
| 99379 | Hospice care supervision |
| 99380 | Nursing fac care supervision |
| 99381 | Nursing fac care supervision |
| 99382 | Prev visit, new, infant |
| 99383 | Prev visit, new, age 1-4 |

ADDENDUM C.—CODES FOR WHICH WE RECEIVED PEAC RECOMMENDATIONS ON PRACTICE EXPENSE DIRECT COST INPUTS—Continued

| CPT code | Short descriptors |
|---|---|
| 99384 | Prev visit, new, age 5-11 |
| 99385 | Prev visit, new, age 12-17 |
| 99386 | Prev visit, new, age 18-39 |
| 99387 | Prev visit, new, age 40-64 |
| 99391 | Prev visit, new, 65 & over |
| 99392 | Prev visit, est, infant |
| 99393 | Prev visit, est, age 1-4 |
| 99394 | Prev visit, est, age 5-11 |
| 99395 | Prev visit, est, age 12-17 |
| 99396 | Prev visit, est, age 18-39 |
| 99397 | Prev visit, est, age 40-64 |
| 99401 | Prev visit, est, 65 & over |
| 99402 | Preventive counseling, indiv |
| 99403 | Preventive counseling, indiv |
| 99404 | Preventive counseling, indiv |
| 99411 | Preventive counseling, indiv |
| 99412 | Preventive counseling, group |
| 99420 | Preventive counseling, group |
| 99431 | Health risk assessment test |
| 99432 | Initial care, normal newborn |
| 99433 | Newborn care, not in hosp |
| 99435 | Normal newborn care/hospital |
| 99436 | Newborn discharge day hosp |
| 99440 | Attendance, birth |
| 99450 | Newborn resuscitation |
| 99455 | Life/disability evaluation |
| 99456 | Disability examination |

Some of these codes have previously been refined and additional refinements were made by the PEAC.

All anesthesia codes were reviewed with the exception of 00104 abd 00124.

CPT codes and descriptions are copyright 2004 by the AMA, all rights reserved.

ADDENDUM D.—PROPOSED CHANGES TO PRACTICE EXPENSE EQUIPMENT DESCRIPTION, LIFE, AND PRICING

| Equip code | 2004 practice expense equipment details | | | 2005 practice expense supply details (proposed) | | | |
|---|---|---|---|---|---|---|---|
| | Description | Life | Price | Description | Life | Price | Equipment category |
| E54006 ..... | 22 channel EEG (split to separate systems) | 7.0 | $44,310.00 | EEG, digital, prolonged testing system (computer w-remote camera). | 7 | $46,750.00 | Other Equipment |
| E54006 ..... | 22 channel EEG (split to separate systems) | 7.0 | $44,310.00 | EEG, digital, standard testing system (computer hardware & software). | 7 | $21,000.00 | Other Equipment |
| E54004 + .. | 22 channel EMG-EP machine | 7.0 | $66,650.00 | EMG-NCV-EP system, 8 channel | 10 | $59,500.00 | Other Equipment |
| E51028 ..... | 2-D Scanning Densitometer | 5.0 | $6,000.00 | Deleted through PEAC refinement. | ..... | ..... | No Details |
| E55002 ..... | 3 Channel ECG machine | 5.0 | $4,800.00 | ECG, 3-channel | 7 | $1,845.42 | Other Equipment |
| E55005 ..... | 3 channel ECG/BP monitor | 5.0 | $3,895.00 | ECG, 3-channel (with SpO2, NIBP, temp, resp). | 7 | $4,322.50 | Other Equipment |
| E51034 ..... | 30 cm Water Phantom w/ Manual positioner | 5.0 | $2,850.00 | Deleted through PEAC refinement. | ..... | ..... | No Details |
| E50002 ..... | 35mm camera | 5.0 | $1,150.00 | camera, 35mm system (medical grade) | 5 | $1,106.50 | Documentation |
| E13623 ..... | 37*, 60*, 90* degree oven | 10.0 | $682.00 | oven, convection (lab) | 10 | $640.73 | Laboratory |
| | 3-D Phantom | 5.0 | $1,084.00 | phantom, 3-D | 10 | $1,084.00 | Radiology |
| E51032 ..... | 3-D Water Scanning Phantom | 5.0 | $56,000.00 | Deleted through PEAC refinement. | ..... | ..... | No Details |
| E71025 ..... | ABR machine, (Mikolay or Biologic) | 7.0 | $23,000.00 | ABR-auditory brainstem response system | 7 | $27,000.00 | Other Equipment |
| | Accelerator, 4 MV | 5.0 | $1,600,000.00 | accelerator, 4-6 MV | 7 | $1,408,491.00 | Radiology |
| | Accelerator, 6 MV | 5.0 | $1,770,708.00 | accelerator, 4-6 MV | 7 | $1,408,491.00 | Radiology |
| | Accelerator, 18 MV | 5.0 | $1,741,018.00 | accelerator, 6-18 MV | 7 | $1,832,941.00 | Radiology |
| | Accelerator, 20 MV | 5.0 | | | | | |
| | accelerator, 6-18 MV | 7 | $1,832,941.00 | Radiology. | | | |
| E52020 ..... | Acusonic Sequoia C0256 | 5.0 | $250,000.00 | ultrasound, echocardiography w-4 transducers (Sequoia C256). | 5 | $248,000.00 | Other Equipment |
| | Adjustable computer table | 7.0 | $895.00 | table, motorized (for instruments-equipment) | 15 | $895.00 | Furniture |
| | ADL kit | 7.0 | $587.00 | kit, ADL | 10 | $586.50 | Other Equipment |
| | ADL kit | 10.0 | $586.00 | kit, ADL | 10 | $586.50 | Other Equipment |
| | aerosol machine | 5.0 | ..... | Deleted (less than $500) | ..... | ..... | No Details |
| | air compressor, safety | 10.0 | $575.00 | air compressor, safety | 12 | $575.00 | Other Equipment |
| E30026 ..... | Albarran bridge | 7.5 | $975.00 | Albarran deflecting bridge, single channel | 3 | $988.00 | Scope |
| | alternans system, CH2000 | 8.0 | $29,400.00 | cardiac monitor w-treadmill (microvolt, CH2000). | 10 | $32,600.00 | Other Equipment |
| | ambulation kit (canes, walker, mirror, balance board, crutches, safety belt). | 10.0 | $750.00 | kit, ambulation | 10 | $763.70 | Other Equipment |
| E52015 ..... | a-mode ultrasonic biometry unit | 5.0 | $6,950.00 | ultrasonic biometry, A-scan | 5 | $5,247.50 | Other Equipment |
| | aneroid barometer | 5.0 | $550.00 | barometer, aneroid | 7 | $587.50 | Radiology |
| E30025 ..... | anesthesia machine | 7.0 | $49,035.00 | anesthesia machine (w-vaporizers) | 7 | $60,000.00 | Other Equipment |
| E51084 ..... | angiographic room | 5.0 | $1,580,000.00 | room, angiography | 5 | $1,386,816.00 | Room - Lane |
| E71010 ..... | anomaloscopes - diagnostic | 5.0 | $10,500.00 | anomaloscope, diagnostic (HMC) | 10 | $6,146.00 | Other Equipment |
| E13116 ..... | anoscope & light source | 3.0 | $550.00 | anoscope with light source | 3 | $657.62 | Scope |
| E51038 ..... | Anthropomorphic Phantom | 5.0 | $8,250.00 | Deleted through PEAC refinement. | ..... | ..... | No Details |
| E51066 ..... | Applicator sets for HDR | 5.0 | $3,333.00 | Deleted through PEAC refinement. | ..... | ..... | No Details |
| E51068 ..... | Applicator sets for LDR | 5.0 | $2,723.00 | Deleted through PEAC refinement. | ..... | ..... | No Details |
| E72001 ..... | argon laser | 5.0 | $45,000.00 | laser, argon (w-slit lamp adapter) | 5 | $32,900.00 | Other Equipment |
| E72002 ..... | argon-krypton laser | 5.0 | $65,000.00 | laser, argon-kripton | 5 | $85,000.00 | Other Equipment |
| E55035 ..... | ART signal averaging machine | 7.5 | $8,250.00 | ECG signal averaging system | 5 | $8,250.00 | Other Equipment |
| | audio system, MRI | 10.0 | $16,000.00 | intercom (incl. master, pt substation, power, wiring). | 10 | $1,630.00 | Other Equipment |
| E71029 ..... | audiometer | 7.0 | $5,495.00 | audiometer, clinical-diagnostic | 10 | $6,250.00 | Other Equipment |
| E71011 ..... | auto lensometer | 5.0 | $2,095.00 | lensometer, auto | 7 | $2,995.00 | Other Equipment |
| E71026 ..... | Autoacustic Emission Equipment | 7.0 | $7,995.00 | OAE-otoacoustic emission system | 7 | $7,780.00 | Other Equipment |
| E55024 ..... | Autobox V6200 | 8.0 | $22,985.00 | Vmax 62j (body plethysmograph autobox) | 8 | $21,055.00 | Other Equipment |
| | automated radio frequency generator | 5.0 | $30,000.00 | radiofrequency generator, TUNA procedure | 5 | $16,500.00 | Other Equipment |
| E52016 ..... | b scan ultrasonography | 5.0 | $24,975.00 | ultrasonic biometry, B-scan | 5 | $12,500.00 | Other Equipment |
| E13604 ..... | balance | 7.0 | $2,400.00 | balance, analytic | 10 | $4,001.67 | Laboratory |

ADDENDUM D.—PROPOSED CHANGES TO PRACTICE EXPENSE EQUIPMENT DESCRIPTION, LIFE, AND PRICING—Continued

| Equip code | 2004 practice expense equipment details | | | 2005 practice expense supply details (proposed) | | | |
|---|---|---|---|---|---|---|---|
| | Description | Life | Price | Description | Life | Price | Equipment category |
| | balance board | 10.0 | $600.00 | balance board | 15 | $509.66 | Other Equipment |
| | balance master | 10.0 | $12,500.00 | balance assessment-retraining system (Balance Master). | 5 | $13,500.00 | Other Equipment |
| | balance scales | 10.0 | $995.00 | balance, scale | 7 | $768.50 | Laboratory |
| | balance, analytic | 7.0 | $5,570.00 | balance, analytic | 10 | $4,001.67 | Laboratory |
| E51004 | basic radiology room | 5.0 | $150,000.00 | room, basic radiology | 5 | $150,000.00 | Room - Lane |
| E92002 | bath tub | 10.0 | $1,224.00 | bath tub | 10 | $1,150.00 | Furniture |
| | bath, paraffin, institutional | 10.0 | $3,349.00 | paraffin bath, hand-foot (institutional) | 7 | $2,406.50 | Other Equipment |
| | beat-to-beat bp unit | 7.0 | $14,900.00 | arterial tonometry monitor (Colin Pilot) | 7 | $14,900.00 | Other Equipment |
| E50005 | Bio Impedance Body Weight Analysis Machine. | 7.0 | $4,490.00 | body analysis machine, bioimpedence | 10 | $2,151.32 | Other Equipment |
| | biohazard hood | 10.0 | $7,612.00 | hood, biohazard | 10 | $6,884.25 | Laboratory |
| | bladder scanner with cart | 5.0 | $11,445.00 | ultrasound, noninvasive bladder scanner w-cart. | 5 | $11,450.00 | Other Equipment |
| E72005 | Blepharoplasty Tray | 4.0 | $1,949.53 | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| | body analysis machine, bioimpedence | 7.0 | $2,700.00 | body analysis machine, bioimpedence | 10 | $2,151.32 | Other Equipment |
| | Body Plethysmography Unit | 8.0 | $45,000.00 | Vmax 22d and 62j (PFT equip, autobox, computer system). | 8 | $47,930.00 | Other Equipment |
| | bone drill system, surgical, small bone (Stryker). | 4.0 | $8,979.00 | drill system, surgical, small-micro (Stryker) | 3 | $8,979.00 | Other Equipment |
| | bone saw, electric (Stryker) | 7.5 | $6,080.00 | saw, surgical, electric (Stryker) | 10 | $6,080.00 | Other Equipment |
| | BTE primus | 10.0 | $45,820.00 | rehab and testing system (BTE primus) | 5 | $45,820.00 | Other Equipment |
| | CAD processor unit | 8.0 | $210,000.00 | CAD processor unit (mammography) | 5 | $210,000.00 | Documentation |
| | Calibrated Chamber | 5.0 | $500.00 | calibration (AAPM ADCL), ion chamber | 5 | $500.00 | Radiology |
| | Calibration Computer with Software | 5.0 | $5,500.00 | electrometer, PC-based, dual channel | 5 | $5,675.00 | Radiology |
| | calibration equipment | 5.0 | $5,000.00 | electrometer, PC-based, dual channel | 5 | $5,675.00 | Radiology |
| | caloric irrigator | 7.0 | $4,875.00 | caloric stimulator, air or water | 7 | $5,950.00 | Other Equipment |
| E55017 | camera (autoswitching) with 16X zoom lens | 5.0 | $6,300.00 | camera, remote-autoswitching | 5 | $5,250.00 | Documentation |
| | camera, retinal topcon | 5.0 | $78,000.00 | camera, retinal (TRC 50IX, w-ICG, filters, motor drives). | 5 | $37,000.00 | Documentation |
| E13611 | carbon coater | 7.5 | $6,200.00 | Deleted (part of new system) | | | No Details |
| | cardiac gating device | 5.0 | $40,000.00 | ECG R-wave trigger (gating) device | 7 | $5,671.00 | Other Equipment |
| E55016 | cardiac monitor - 12 lead- stress test monitor and treadmill. | 5.0 | $18,726.00 | cardiac monitor w-treadmill (12-lead PC-based ECG). | 10 | $14,271.03 | Other Equipment |
| E53005 | Cardiac Nuclear Camera System | 7.5 | $675,000.00 | camera system, cardiac, nuclear | 5 | $675,000.00 | Documentation |
| E55018 | cardiac output monitor | 7.5 | $22,790.00 | ICG monitoring system (impedance cardiography). | 5 | $28,625.00 | Other Equipment |
| E53003 | Cardiac Phantom | 7.5 | $3,990.00 | phantom, SPECT with cardiac insert | 10 | $3,042.00 | Radiology |
| E53026 | Cardiofocal Collimators (1Set) | 5.0 | $29,990.00 | collimator, cardiofocal set | 7 | $29,990.00 | Radiology |
| | cardio-pulmonary stress testing system | 8.0 | $58,751.00 | Vmax 29c (cardio-pulm stress test equip, treadmill, computer system). | 8 | $58,751.00 | Other Equipment |
| | cardio-respiratory monitor | 5.0 | $12,000.00 | ECG, 3-channel (with SpO2, NIBP, temp, resp). | 7 | $4,322.50 | Other Equipment |
| | cart heating pan, Splint-Form 2000 | 10.0 | $790.00 | water bath, thermoplastic softener (20in x 12in). | 7 | $722.36 | Radiology |
| | cart, laboratory | 10.0 | $585.00 | cart, laboratory | 10 | $677.83 | Furniture |
| | cast cart | 10.0 | $5,000.00 | cast cart | 10 | $3,808.00 | Other Equipment |
| E30022 | cast cutter | 7.0 | $1,295.00 | cast cutter | 10 | $1,160.62 | Other Equipment |
| | cast table | 10.0 | $25,000.00 | casting table attachment, hip-spica cast | 10 | $4,099.00 | Furniture |
| | cast vacuum | 7.0 | $1,476.00 | cast vacuum | 8 | $1,475.50 | Other Equipment |
| | casting frame | 10.0 | $12,500.00 | casting table attachment, Risser | 10 | $2,538.00 | Furniture |
| E72007 | Cataract Tray | 4.0 | $11,261.33 | Deleted through PEAC refinement. | | | No Details |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| E71112 | Central (Pod) Equipment Lane | 7.0 | $30,442.01 | lane, central pod (oph) | 7 | $23,029.00 | Room - Lane |
| E13656 | centrifuge | 7.0 | $3,250.00 | centrifuge (with rotor) | 7 | $4,291.65 | Laboratory |
| | Cerrobend melting pots | 7.0 | $1,500.00 | alloy melter, digital, 3 gallon | 7 | $1,393.00 | Radiology |
| E53046 | Cesium 137 sources (6-10mg, 6-15mg, 6-20 mg, 2-25mg, 2-5mg) 3m. | 7.0 | $43,580.00 | Deleted through PEAC refinement. | | | No Details |
| | chair, medical recliner (chemo, phlebotomy) | 10.0 | $829.03 | chair, medical recliner | 10 | $829.03 | Furniture |
| | chair, phlebotomy-injection | 10 | 1200 | chair, medical recliner | 10 | $829.03 | Furniture |
| E91004 | Chemo couch | 10.0 | $895.00 | chair, medical recliner | 10 | $829.03 | Furniture |
| E51086 | chest room | 5.0 | $200,000.00 | Deleted through PEAC refinement. | | | No Details |
| E30007 | CO2 laser | 5.0 | $42,500.00 | laser, CO2 (Star X) | 5 | $7,795.00 | Other Equipment |
| E55025 | CO2 monitor | 7.0 | $7,495.00 | CO2 respiratory profile monitor | 7 | $7,995.00 | Other Equipment |
| E53002 | Colbalt-57 sheet flood source | 0.5 | $2,790.00 | Cobalt-57 Flood Source (47cm dia) (10 mCi) | 5 | $2,243.00 | Radiology |
| E53002 | Colbalt-57 sheet flood source | 7.5 | $2,790.00 | Cobalt-57 Flood Source (47cm dia) (10 mCi) | 5 | $2,243.00 | Radiology |
| E53002 | Colbalt-57 sheet flood source | 8.0 | $2,790.00 | Cobalt-57 Flood Source (47cm dia) (10 mCi) | 5 | $2,243.00 | Radiology |
| E13110 | colonoscope, video (SPLIT: scope and video system). | 3.0 | $54,590.00 | videoscope, colonoscopy | 3 | $23,650.00 | Scope |
| E13401 | colposcope | 3.0 | $4,550.00 | colposcope | 8 | $3,946.67 | Scope |
| E71013 | computer and VDT and software | 5.0 | $9,000.00 | computer and VDT and software | 5 | $9,000.00 | Documentation |
| E92013 | computerized spinal range of motion device | 10.0 | $9,995.00 | range of motion (spinal) device and software (Myo-Logic). | 5 | $7,995.00 | Other Equipment |
| E71014 | corneal topography unit | 5.0 | $17,950.00 | topography unit, corneal (Magellan) | 7 | $13,495.00 | Other Equipment |
| | CPAP/BiPAP remote clinical unit | 7.0 | | CPAP/BiPAP remote clinical unit | 7 | | Other Equipment |
| E13609 | critical point dryer | 10.0 | $8,000.00 | Deleted through PEAC refinement. | | | No Details |
| E30015 | cryostat | 7.0 | $13,950.00 | cryostat | 7 | $17,197.50 | Other Equipment |
| E30014 | cryostat knife sharpener | 7.0 | $6,234.00 | microtome sharpener | 10 | $6,400.00 | Radiology |
| | cryosurgery equipment package | 7.5 | $2,750.00 | cryosurgery equipment (for liquid nitrogen) | 10 | $2,394.30 | Other Equipment |
| | cryosurgery system, non-ophthalmic | 7.5 | $1,608.00 | cryosurgery system, non-ophthalmic | 10 | $1,607.50 | Other Equipment |
| | cryosurgery system, ophthalmic | 7.5 | $5,245.00 | cryosurgery system, ophthalmic | 7 | $5,245.00 | Other Equipment |
| | cryo-thermal unit | 7.5 | | cryo-thermal unit | 10 | | Other Equipment |
| | csf shunt reprogramming device (hand-held) | 5.0 | $1,500.00 | CSF shunt programmer unit | 7 | $2,392.00 | Other Equipment |
| E51082 | CT Room | 5.0 | $1,000,000.00 | room, CT | 5 | $981,045.00 | Room - Lane |
| E51018 | CT-Based Virtual Simulator | 5.0 | $900,000.00 | IMRT CT-based simulator | 5 | $975,000.00 | Radiology |
| E13657 | cytology thin prep processor | 7.5 | $35,000.00 | cytology thinlayer processor (ThinPrep) | 7 | $54,000.00 | Laboratory |
| E51054 | Daily Output QA Device, RMI (RBA-5) | 5.0 | $5,795.00 | Deleted through PEAC refinement. | | | No Details |
| E13658 | dark field microscope | 7.0 | $4,500.00 | microscope, polarized (dark field) | 7 | $5,374.50 | Laboratory |
| | data acquisition beat-to-beat analysis system | 7.0 | $14,496.00 | arterial tonometry acquisition system (WR Testworks). | 7 | $14,500.00 | Other Equipment |
| | data acquisition/q-sart recording system | 7.0 | $22,228.00 | QSART acquisition system (Q-Sweat) | 5 | $28,000.00 | Other Equipment |
| | decloaking chamber | 7.5 | $875.00 | decloaking chamber (DC2002) | 7 | $1,249.00 | Laboratory |
| | decloaking chamber (DC2002) | 7.5 | $1,249.00 | decloaking chamber (DC2002) | 7 | $1,249.00 | Laboratory |
| E71001 | dedicated slit lamp for argon laser | 10.0 | $6,561.00 | slit lamp (Haag-Streit), dedicated to laser use. | 10 | $7,435.00 | Other Equipment |
| | defibrillator | 5.0 | | defibrillator | 5 | $2,853.33 | Other Equipment |
| | DELETED | | | Deleted through PEAC refinement. | | | No Details |
| E51078 | Dental X-ray | 5.0 | $80,000.00 | Deleted through PEAC refinement. | | | No Details |
| | dermatome | 5.0 | $4,030.00 | dermatome, electric | 10 | $4,399.00 | Other Equipment |
| E71102 | Designed for Vision loupes | 7.0 | $600.00 | loupes, standard, up to 3.5x | 7 | $836.67 | Other Equipment |
| E53036 | Detector (Probe) | 5.0 | $14,000.00 | Detector (Probe) | 5 | $14,000.00 | Radiology |
| E51010 | DEXA Unit Dual Energy X-ray Absorptiometry. | 5.0 | $49,500.00 | densitometry unit, whole body, DXA | 5 | $41,000.00 | Radiology |
| | dialysis access flow monitor | 5.0 | $10,000.00 | dialysis access flow monitor | 5 | $10,000.00 | Other Equipment |
| E13659 | diamond knife | 10.0 | $3,100.00 | diamond knife (4.0-4.4mm) (electron microscopy). | 7 | $3,400.00 | Laboratory |
| E13660 | diamond knife resharpener | 7.0 | $1,795.00 | Deleted through PEAC refinement. | | | No Details |
| E52002 | diasonic software | 5.0 | $35,000.00 | fetal monitor software | 5 | $35,000.00 | Other Equipment |
| E71015 | diathermy machine | 5.0 | $3,120.00 | diathermy, short wave (AutoTherm 395) | 10 | $8,185.00 | Other Equipment |
| E71015 | diathermy machine | 5.0 | $10,000.00 | diathermy, short wave (AutoTherm 395) | 10 | $8,185.00 | Other Equipment |
| | differential analyzer | 7.0 | $38,500.00 | differential analyzer, hematology | 7 | $37,216.67 | Laboratory |
| | differential counter, hematology | 7.0 | $1,238.00 | differential tally counter, 12-channel | 5 | $672.73 | Laboratory |

ADDENDUM D.—PROPOSED CHANGES TO PRACTICE EXPENSE EQUIPMENT DESCRIPTION, LIFE, AND PRICING—Continued

| Equip code | 2004 practice expense equipment details | | | 2005 practice expense supply details (proposed) | | | |
|---|---|---|---|---|---|---|---|
| | Description | Life | Price | Description | Life | Price | Equipment category |
| E52007 | Digital Aquisition Unit (Nova Microsonics Image Vue DCR or TomTec Freeland P90). | 5.0 | $29,900.00 | ultrasound, echocardiography digital acquisition (Novo Microsonics, TomTec). | 5 | $29,900.00 | Other Equipment |
| | digital camera | 5.0 | $800.00 | camera, digital (6 mexapixel) | 5 | $946.16 | Documentation |
| E51020 | Digital Camera | 5.0 | $300,000.00 | Deleted through PEAC refinement. | | | No Details |
| | digital camera package | 5.0 | $3,060.00 | camera, digital system, 12 megapixel (medical grade). | 5 | $3,570.98 | Documentation |
| E13113 | digitrapper (24-hr ambulatory pH monitor by Cynectics). | 10.0 | $9,685.00 | pH recorder, 24-hr ambulatory (Digitrapper) | 5 | $6,900.00 | Other Equipment |
| | discogram pressure monitor | 7.0 | | discogram pressure monitor | 7 | $600.00 | Other Equipment |
| | dissecting instrument kit | 5.0 | $596.00 | instrument pack, basic ($500-$1499) | 4 | $500.00 | Other Equipment |
| | DNA image analyzer (ACIS) | 7.0 | $200,000.00 | DNA image analyzer (ACIS) | 7 | $200,000.00 | Laboratory |
| | DNA image analyzer (ACIS) | 7.5 | $200,000.00 | DNA image analyzer (ACIS) | 7 | $200,000.00 | Laboratory |
| E30016 | doppler | 5.0 | $1,350.00 | doppler (fetal or vascular) | 5 | $708.22 | Other Equipment |
| | dose calibration source vial set (Cs137, Co57, and Ba137). | 5.0 | $1,159.00 | dose calibration source vial set (Cs137, Co57, and Ba137). | 5 | $1,159.00 | Radiology |
| E51064 | Dose Callibrator w/ Lead Glass Sheild & Ce-137 Standard. | 5.0 | $6,000.00 | dose calibrator (Atomlab) | 5 | $5,496.67 | Radiology |
| | Dosimetry software | 5.0 | $21,000.00 | radiation therapy dosimetry software (Argus QC). | 5 | $21,000.00 | Radiology |
| E53034 | Dual Photon Densitometer/Computer | 5.0 | $65,000.00 | densitometry unit, whole body, DPA | 5 | $65,000.00 | Radiology |
| | dust extractor | 10.0 | $1,982.00 | dust extractor | 8 | $500.00 | Other Equipment |
| | Dynavox/Dynamyte Wireless Backup and computer backup. | 7.0 | $549.00 | augmentative communication - DynaBeam access w-memory backup. | 7 | $604.00 | Other Equipment |
| | Dynovox 3100 | 7.0 | $6,995.00 | augmentative communication - DynaVox 3100. | 7 | $7,295.00 | Other Equipment |
| E55009 | ECG Burdick EK-10 | 7.0 | $1,985.50 | ECG, 1-channel (Burdick) | 7 | $1,506.00 | Other Equipment |
| | EECP system | 5.0 | $180,000.00 | EECP, external counterpulsation system | 7 | $150,000.00 | Other Equipment |
| E11015 | electric bed | 12.0 | $2,024.00 | bed, hospital, electric | 12 | $1,746.52 | Furniture |
| E11010 | electric table | 15.0 | $935.71 | table, motorized (for instruments-equipment).doc. | 15 | $895.00 | Furniture |
| E30005 | electrocautery | 7.0 | $995.00 | electrocautery-hyfrecator, up to 45 watts | 10 | $975.08 | Other Equipment |
| | electrogastrography machine system | 10.0 | $20,750.00 | EGG monitoring system | 7 | $32,900.00 | Other Equipment |
| | electro-oculography machine | 10.0 | $50,000.00 | EOG, ERG, VEP electrodiagnostic unit | 7 | $33,500.00 | Other Equipment |
| | electro-retinography machine | 10.0 | $50,000.00 | EOG, ERG, VEP electrodiagnostic unit | 7 | $33,500.00 | Other Equipment |
| E30008 | electro-surgical device | 7.0 | $1,225.00 | electrosurgical generator, up to 120 watts | 7 | $1,838.42 | Other Equipment |
| E13641 | embedding station | 8.0 | $8,200.00 | tissue embedding center | 8 | $9,096.67 | Laboratory |
| | EMG biofeedback continence training system (Pathway CTS2000). | 5.0 | $11,750.00 | EMG biofeedback continence training system (Pathway CTS2000). | 8 | $11,750.00 | Other Equipment |
| E54012 | EMG botox | 7.0 | $1,500.00 | EMG botox | 7 | $1,500.00 | Other Equipment |
| E54007 | EMG Machine | 7.0 | $21,157.50 | EMG-NCV-EP system, 2-4 channel | 10 | $18,288.63 | Other Equipment |
| | EMG, surface system (OT, PT, clinician) (Therapist System). | 7.0 | $10,995.00 | EMG, surface system (OT, PT, clinician) (Therapist System). | 8 | $9,995.00 | Other Equipment |
| E13118 | endoscope, rigid, cystoscopy | 3.0 | $3,365.00 | endoscope, rigid, cystoscopy | 3 | $3,394.00 | Scope |
| E13402 | endoscope, rigid, hysteroscopy | 3.0 | $8,878.00 | endoscope, rigid, hysteroscopy | 3 | $4,990.50 | Scope |
| | endoscope, rigid, laryngoscopy | 3.0 | $5,080.00 | endoscope, rigid, laryngoscopy | 3 | $3,095.67 | Scope |
| | endoscope, rigid, otology | 3.0 | $2,456.88 | endoscope, rigid, otology | 7 | $2,456.88 | Scope |
| | endoscope, rigid, sigmoidoscopy | 3.0 | $841.00 | endoscope, rigid, sigmoidoscopy | 3 | $841.38 | Scope |
| E13126 | endoscope, rigid, sinoscopy | 3.0 | $5,080.00 | endoscope, rigid, sinoscopy | 7 | $2,414.17 | Scope |
| | endoscope, rigid, sinoscopy | 3.0 | $5,080.00 | endoscope, rigid, sinoscopy | 7 | $2,414.17 | Scope |
| E11005 | endoscopy stretcher | 10.0 | $1,010.00 | stretcher, endoscopy | 10 | $2,414.00 | Furniture |
| E71027 | ENG Recorder | 7.0 | $19,900.00 | ENG recording system | 5 | $19,900.00 | Other Equipment |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | environmental module - car | 10.0 | $30,000.00 | environmental module - car | 15 | $33,750.00 | Room - Lane |
| | environmental module - kitchen | 10.0 | $50,000.00 | environmental module - kitchen | 15 | $56,250.00 | Room - Lane |
| | environmental module - the workshop | 10.0 | $20,000.00 | environmental module - the workshop | 15 | $22,500.00 | Room - Lane |
| | ergonomic kit | 10.0 | $2,285.00 | kit, ergonomic (office) | 10 | $2,285.48 | Other Equipment |
| E13114 | esophogeal motility monitor (physiograph ) | 10.0 | $22,865.00 | Deleted through PEAC refinement. | | | No Details |
| | evaluation system for upper extremity/hand | 10.0 | $16,500.00 | evaluation system for upper extremity-hand (Greenleaf). | 5 | $17,495.00 | Other Equipment |
| | exam chair, reclining | 15.0 | $1,000.00 | chair, medical recliner | 10 | $829.03 | Furniture |
| E30006 | exam lamp | 10.0 | $1,850.00 | light, exam | 10 | $1,630.12 | Other Equipment |
| E71109 | Exam Lane | 7.0 | $31,046.15 | lane, exam (oph) | 7 | $30,453.33 | Room - Lane |
| E11001 | exam table | 15.0 | $1,360.00 | table, exam | 15 | $1,338.17 | Furniture |
| | exercise kit aquatic (boots, fins, gloves,weights, cuffs, spine safety board). | 5.0 | $500.00 | kit, aquatic exercise | 10 | $500.00 | Other Equipment |
| | exercise staircase | 10.0 | $870.00 | stairs, ambulation training | 15 | $793.67 | Other Equipment |
| | exercise staircase | 15.0 | $870.00 | stairs, ambulation training | 15 | $793.67 | Other Equipment |
| E71016 | external 35 mm camera with medical lenses | 5.0 | $10,795.00 | camera, 35mm system (medical grade) | 5 | $1,106.50 | Documentation |
| E51062 | External Microwave Applicators (set of 5), BSD. | 10.0 | $7,250.00 | Deleted through PEAC refinement. | | | No Details |
| | Farmer Chamber | 5.0 | $1,500.00 | chamber, Farmer-type | 7 | $1,169.38 | Radiology |
| E71002 | Farnsworth-Munsell 100-Hue Test or Nagel anomoscoope, McBeth light. | 7.5 | $556.00 | Farnsworth-Munsell 100-Hue color vision test w/software. | 7 | $626.50 | Other Equipment |
| E13404 | fetal monitor | 5.0 | $9,435.00 | fetal monitor | 5 | $5,415.95 | Other Equipment |
| E11006 | fiberoptic exam light (combine with source) | 10.0 | $608.75 | light, fiberoptic headlight w-source | 5 | $1,992.92 | Other Equipment |
| E13123 | fiberscope, flexible, bronchoscopy | 3.0 | $9,700.00 | fiberscope, flexible, bronchoscopy | 3 | $14,175.00 | Scope |
| | fiberscope, flexible, bronchoscopy | 3.0 | $14,175.00 | fiberscope, flexible, bronchoscopy | 3 | $14,175.00 | Scope |
| | fiberscope, flexible, bronchoscopy w-forceps (SPLIT: Scope/Forceps). | 3.0 | $10,943.33 | fiberscope, flexible, bronchoscopy | 3 | $14,175.00 | Scope |
| | fiberscope, flexible, cystoscopy | 3.0 | $7,410.00 | fiberscope, flexible, cystoscopy | 3 | $7,408.33 | Scope |
| E13117 | fiberscope, flexible, cystoscopy, with light source. | 3.0 | $7,760.00 | fiberscope, flexible, cystoscopy, with light source. | 3 | $9,082.50 | Scope |
| E13124 | fiberscope, flexible, rhinolaryngoscopy | 3.0 | $5,080.00 | fiberscope, flexible, rhinolaryngoscopy | 3 | $6,301.93 | Scope |
| | fiberscope, flexible, rhinolaryngoscopy | 3.0 | $5,080.00 | fiberscope, flexible, rhinolaryngoscopy | 3 | $6,301.93 | Scope |
| E13101 | fiberscope, flexible, sigmoidoscopy | 3.0 | $5,803.00 | fiberscope, flexible, sigmoidoscopy | 3 | $5,803.33 | Scope |
| | fiberscope, flexible, sigmoidoscopy | 3.0 | $5,803.00 | fiberscope, flexible, sigmoidoscopy | 3 | $5,803.33 | Scope |
| E13121 | fiberscope, flexible, ureteroscopy | 3.0 | $12,920.00 | fiberscope, flexible, ureteroscopy | 3 | $12,595.00 | Scope |
| | film alternator | 10.0 | $30,000.00 | film alternator (motorized film viewbox) | 10 | $27,500.00 | Radiology |
| | Film Densitometer | 5.0 | $1,580.00 | densitometer, film | 5 | $1,435.00 | Radiology |
| | film dosimetry equipment for IMRT | 5.0 | $28,500.00 | film dosimetry equipment-software (RIT) | 5 | $30,840.00 | Radiology |
| | film printer, laser | 5.0 | $45,000.00 | film processor, dry, laser | 8 | $69,950.00 | Documentation |
| | film processor, precision calibrated | 8.0 | $25,000.00 | film processor, wet | 8 | $26,325.00 | Documentation |
| | fistula probes, set of 4 | 5.0 | $560.00 | Deleted (less than $500) | | | No Details |
| E13616 | flow cytometer | 5.0 | $11,000.00 | flow cytometer | 5 | $119,850.00 | Laboratory |
| E13639 | fluorescence microscope | 7.0 | $12,000.00 | microscope, fluorescence | 7 | $9,468.48 | Laboratory |
| E51070 | Fluroscopic unit, Mobile C-Arm | 5.0 | $205,000.00 | fluoroscopic system, mobile C-Arm | 8 | $73,000.00 | Radiology |
| | food models | 5.0 | $700.00 | food models | 4 | $700.00 | Other Equipment |
| E30021 | foot & ankle surgery instrument pack | 4.0 | $1,530.40 | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| | forceps, biopsy | 4.0 | $1,310.00 | endoscope forceps, biopsy | 3 | $1,243.33 | Scope |
| | forceps, grasping | 4.0 | $735.00 | endoscope forceps, grasping | 3 | $745.67 | Scope |
| E71103 | full diameter trial lens set | 7.5 | $1,180.00 | lens set, trial, full diameter, w-frame | 10 | $904.93 | Other Equipment |
| E13613 | fume hood | 10.0 | $6,500.00 | hood, fume | 15 | $4,778.46 | Laboratory |
| | gamma counter, automatic | 7.5 | $17,900.00 | gamma counter, automatic | 7 | $17,665.00 | Radiology |
| E71003 | Ganzfeld stimulator | 10.0 | $45,000.00 | Ganzfeld stimulator | 7 | $8,750.00 | Other Equipment |
| | gas cylinders | 5.0 | $8,000.00 | laser gas cylinder (for excimer) | 5 | $1,140.00 | Other Equipment |
| E13104 | gastro cautery unit | 7.0 | $5,450.00 | electrosurgical generator, gastrocautery | 7 | $11,375.00 | Other Equipment |
| E13106 | gastroscope video (SPLIT: scope and video system). | 3.0 | $52,990.00 | videoscope, gastroscopy | 3 | $21,598.33 | Scope |
| E55022 | Gating Device | 5.0 | $3,625.00 | ECG R-wave trigger (gating) device | 7 | $5,671.00 | Other Equipment |
| | generator, constant current | 3.0 | $950.00 | generator, constant current | 20 | $950.00 | Other Equipment |

ADDENDUM D.—PROPOSED CHANGES TO PRACTICE EXPENSE EQUIPMENT DESCRIPTION, LIFE, AND PRICING—Continued

| Equip code | 2004 practice expense equipment details | | | 2005 practice expense supply details (proposed) | | | |
|---|---|---|---|---|---|---|---|
| | Description | Life | Price | Description | Life | Price | Equipment category |
| | glucose monitor continuous (incl.accessories). | 5.0 | $2,613.00 | glucose continuous monitoring system | 5 | $2,465.00 | Other Equipment |
| E13666 | GLX linear stainer | 7.5 | $6,995.00 | slide stainer, automated, standard throughput. | 7 | $8,265.64 | Laboratory |
| E13637 | grossing station | 10.0 | $23,391.00 | grossing station w-heavy duty disposal | 20 | $20,175.50 | Laboratory |
| | halogen light (Edit light type) | 5.0 | $5,080.00 | light source, xenon | 5 | $6,723.33 | Other Equipment |
| | halogen light cable | 5.0 | | Deleted (part of new system) | | | No Details |
| | hand dexterity/sensory/strength kit | 7.0 | $1,407.00 | kit, hand dexterity, sensory, strength | 10 | $1,561.40 | Other Equipment |
| | Hand Held Voice | 7.0 | $645.00 | augmentative communication - Hand Held Voice. | 7 | $695.00 | Other Equipment |
| | Hand Measurement Kit (dynamometers, goniometers, etc). | 7.0 | $600.00 | kit, hand evaluation | 10 | $617.65 | Other Equipment |
| | hand-case instrument set | 4.0 | $2,000.00 | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| E51072 | HDR Afterload System, Nucletron - Oldelft | 5.0 | $375,000.00 | HDR Afterload System, Nucletron - Oldelft | 7 | $375,000.00 | Radiology |
| | headmaster adapters (Accessibility) | 5.0 | $1,675.00 | augmentative communication - HeadMaster w-adapters. | 7 | $1,695.00 | Other Equipment |
| E53006 | Heavy Duty Imaging Table | 7.5 | $4,550.00 | table, imaging | 15 | $5,188.33 | Furniture |
| | heavy-duty disposer | 5.0 | $1,506.00 | Deleted (part of new system) | | | No Details |
| E71037 | hilger nerve stimulator | 7.5 | $1,805.00 | Deleted through PEAC refinement. | | | No Details |
| E55008 | Holter Monitor | 7.0 | $2,590.00 | holter monitor | 7 | $1,413.43 | Other Equipment |
| E55015 | Holter monitor reader | 7.0 | $14,995.00 | holter analysys system | 7 | $8,815.58 | Other Equipment |
| E55015 | Holter monitor reader | 7.0 | $14,995.00 | holter system with one recorder | 7 | $11,303.90 | Other Equipment |
| | hood, biohazard | 10.0 | $7,612.00 | hood, biohazard | 10 | $6,884.25 | Laboratory |
| | hot wire cutter, Heustis | 7.0 | $28,600.00 | Huestis block cutting machine w-attachments | 15 | $22,030.00 | Radiology |
| E92016 | Hubbard tank | 15.0 | $17,000.00 | whirlpool (Hubbard tank) | 10 | $15,195.00 | Furniture |
| E71005 | Humphrey field analyzer (or octopus) | 7.5 | $27,950.00 | Humphrey field analyzer | 7 | $27,000.00 | Other Equipment |
| E92006 | hydroculator, cold | 10.0 | $1,675.00 | hydrocollator, cold | 10 | $1,910.50 | Other Equipment |
| E92007 | hydroculator, hot | 10.0 | $1,265.00 | hydrocollator, hot | 10 | $1,090.17 | Other Equipment |
| E55033 | Hydrogen gas analyzer | 7.5 | $6,117.00 | breath hydrogen analyzer (MicroLyzer) | 8 | $4,895.00 | Other Equipment |
| | hyperbaric chamber | 10.0 | $125,000.00 | hyperbaric chamber | 15 | $125,000.00 | Other Equipment |
| E13652 | image analyzer (CAS system) | 5.0 | $92,000.00 | image analyzer (CAS system) | 5 | $92,000.00 | Laboratory |
| | Immittance bridge | 7.0 | $6,900.00 | immittance, middle-ear analyzer | 10 | $4,995.00 | Other Equipment |
| | impedance meter | 7.0 | $1,312.00 | impedance meter, 32-channel | 7 | $1,120.00 | Other Equipment |
| | IMRT physics tools | 5.0 | $55,485.00 | IMRT physics tools | 5 | $55,485.00 | Radiology |
| E92012 | inclinometer | 10.0 | $520.00 | Deleted (less than $500) | | | No Details |
| | incubator | 10.0 | $795.00 | incubator | 10 | $837.30 | Laboratory |
| E13631 | incubator (CO2) | 10.0 | $6,000.00 | incubator, CO2 (dry-wall) | 10 | $5,842.99 | Laboratory |
| | infrared ceiling lamps/temperature control | 3.0 | $2,000.00 | light, infra-red, ceiling mount | 10 | $555.00 | Other Equipment |
| E30023 | infrared coagulator | 7.0 | $3,550.00 | infrared coagulator (with hand applicator) | 10 | $3,087.50 | Other Equipment |
| | infrared illuminator | 7.0 | $1,050.00 | Deleted (part of new system) | | | No Details |
| E91001 | infusion pump | 10.0 | $4,150.00 | IV infusion pump | 10 | $2,384.45 | Other Equipment |
| | INR monitor, home | 4.0 | $2,000.00 | INR monitor, home | 5 | $2,000.00 | Other Equipment |
| | instrument pack, basic (auricle) | 4.0 | $500.00 | instrument pack, basic ($500-$1499) | 4 | $500.00 | Other Equipment |
| | instrument pack, basic (EPF) | 4.0 | $1,200.00 | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| | instrument pack, basic (surgery) | 4.0 | $500.00 | instrument pack, basic ($500-$1499) | 4 | $500.00 | Other Equipment |
| | instrument pack, medium (ear) | 4.0 | $1,500.00 | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| | instrument pack, medium (intraoral biopsy) | 4.0 | $1,500.00 | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| | instrument pack, medium (nasal endoscopy) | 4.0 | $1,500.00 | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| | instrument pack, medium (nasal) | 4.0 | $1,500.00 | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| | instrument pack, medium (otology POV) | 4.0 | $1,500.00 | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| | instrument pack, medium (surgery) | 4.0 | $1,500.00 | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| E92009 | Intellect High Voltage electrical stimulator | 10.0 | $1,395.00 | electrotherapy stimulator, high volt, 2 channel. | 7 | $1,923.00 | Other Equipment |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | Intellikeys | 7.0 | $525.00 | augmentative communication - IntelliKeys, Overlay, ClickIt. | 7 | $560.00 | Other Equipment |
| E92020 | Intercom | 10.0 | $10,000.00 | intercom (incl. master, pt substation, power, wiring). | 10 | $1,630.00 | Other Equipment |
| | intestinal imaging workstation Other Equipment. | 7.0 | $25,400.00 | intestinal imaging workstation | 5 | | |
| E51042 | Ion Chamber Array | 5.0 | $6,445.00 | Deleted through PEAC refinement. | | | No Details |
| E71030 | iontophoresis machine | 7.5 | $1,500.00 | iontophoresis machine | 8 | $995.00 | Other Equipment |
| | isoalign device | 5.0 | $950.00 | isocentric beam alignment device | 5 | $995.00 | Radiology |
| E92014 | isokinetic strenghthening equipment | 10.0 | $29,823.00 | exercise equipment (treadmill, bike, stepper, UBE, pulleys, balance board). | 15 | $12,710.00 | Other Equipment |
| | isokinetic testing equipment | 7.0 | $45,820.00 | rehab and testing system (BTE primus) | 5 | $45,820.00 | Other Equipment |
| E50003 | isokinetometer | 10.0 | $11,995.00 | isokinetic evaluation system (Cybex NORM) | 5 | $39,900.00 | Other Equipment |
| E91008 | IVAC Injection Automatic Pump | 5.0 | $2,500.00 | IVAC Injection Automatic Pump | 10 | $2,500.00 | Other Equipment |
| E55010 | King of Hearts-20 (Instromedix) | 7.0 | $1,750.00 | Deleted through PEAC refinement. | | | No Details |
| | kit, capsule endoscopy recorder | | $6,950.00 | kit, capsule endoscopy recorder | 10 | $6,950.00 | Other Equipment |
| | lacrimal probes | 4.0 | | Deleted (less than $500) | | | No Details |
| | laryngeal injector | 4.0 | $1,032.00 | kit, laryngeal injector | 3 | $1,032.00 | Other Equipment |
| E13405 | laser | 5.0 | $23,500.00 | laser (gs, uro, obg, ge) (Indigo Optima) | 5 | $59,890.00 | Other Equipment |
| | laser generator | 5.0 | $54,890.00 | laser (gs, uro, obg, ge) (Indigo Optima) | 5 | $59,890.00 | Other Equipment |
| | laser printer for CT angiography | 5.0 | $71,400.00 | film processor, dry, laser | 8 | $69,950.00 | Documentation |
| | Laser Targeting System | 5.0 | $11,625.00 | laser targeting system (4 diodes) | 5 | $10,350.00 | Radiology |
| | laser, ablation (gs, uro, obg, ge) (Indigo Optima). | 5.0 | $59,890.00 | laser (gs, uro, obg, ge) (Indigo Optima) | 5 | $59,890.00 | Other Equipment |
| | laser, diode, for patient positioning (Probe) | 5.0 | $7,678.00 | laser, diode, for patient positioning (Probe) | 5 | $7,678.00 | Radiology |
| | laser, excimer | 5.0 | $155,000.00 | laser, excimer | 5 | $160,000.00 | Other Equipment |
| E53001 | lead safe | 20.0 | $3,375.00 | safe, storage, lead-lined | 15 | $3,850.00 | Radiology |
| E13403 | LEEP system | 7.0 | $4,670.00 | electrosurgical system (w-smoke evac) (LEEP, Quantum). | 7 | $4,283.00 | Other Equipment |
| E55014 | life signs receiving center | 7.0 | $3,800.00 | pacemaker receiving software (GEMS Lite) | 5 | $3,995.00 | Other Equipment |
| | lift, chair and sling | 10.0 | $3,000.00 | lift, hydraulic, chair | 10 | $4,848.65 | Furniture |
| | lift, hydraulic | 10.0 | $4,730.00 | lift, hydraulic, chair | 10 | $4,848.65 | Furniture |
| | light for photodynamic therapy, 400MW (BLU-U). | 5.0 | $15,759.00 | light, external PDT, w-probe set (LumaCare) | 5 | $8,810.00 | Other Equipment |
| E13122 | light source (combine with headlight) | 3.0 | $1,700.00 | light, fiberoptic headlight w-source | 5 | $1,992.92 | Other Equipment |
| | light, infrared | 3.0 | $500.00 | light, infra-red, pole mount | 10 | $512.50 | Other Equipment |
| | light, ultraviolet | 3.0 | $630.00 | light, ultra-violet | 10 | $618.22 | Other Equipment |
| E51056 | Linear Accelerator - Cliniac-2100 | 5.0 | $1,600,000.00 | accelerator, 6-18 MV | 7 | $1,832,941.00 | Radiology |
| E30010 | Liquid Nitro Tank w/ Cryac | 10.0 | $1,529.00 | cryosurgery system, non-ophthalmic | 10 | $1,607.50 | Other Equipment |
| E30024 | lithotriptor | 5.0 | $1,375,000.00 | lithotriptor, with C-arm (ESWL) | 5 | $440,000.00 | Other Equipment |
| E11001 | low mat table | 10.0 | $5,000.00 | table, mat, hi-lo, 6 x 8 platform | 15 | $4,521.67 | Furniture |
| | low mat table | 10.0 | $5,000.00 | table, mat, hi-lo, 6 x 8 platform | 15 | $4,521.67 | Furniture |
| | mammatome driver | 5.0 | $27,750.00 | breast biopsy device w-system (Mammotome). | 5 | $29,862.00 | Other Equipment |
| | mammography cassettes (4) | 5.0 | | Deleted (less than $500) | | | No Details |
| E51016 | Mammography Room | 5.0 | $130,000.00 | room, mammography | 5 | $130,000.00 | Room - Lane |
| | mayo stand | 7.0 | $585.00 | mayo stand | 15 | $530.76 | Furniture |
| E30019 | McGrowan ligator/Bander | 7.0 | $625.00 | Deleted through PEAC refinement. | | | No Details |
| E92010 | mechanical traction | 10.0 | $2,090.00 | traction system (hi-low table, digital unit, accessories). | 10 | $5,654.83 | Other Equipment |
| | medium energy collimator (siemens 05232868). | 5.0 | $14,000.00 | collimator, medium energy (set of 2) | 7 | $14,000.00 | Radiology |
| E13608 | microprobe EDS x-ray analysis | 7.0 | $42,500.00 | Deleted (part of new system) | | | No Details |
| E13662 | Microscope camera Konan SP 9000 | 5.0 | $6,995.00 | camera system, specular microscope | 5 | $26,100.00 | Laboratory |
| E13601 | microscope, compound | 7.0 | $11,600.00 | microscope, compound | 7 | $11,621.35 | Laboratory |
| E13606 | microscope, dissecting | 7.0 | $1,700.00 | microscope, binocular - dissecting | 7 | $956.00 | Laboratory |
| E13618 | microtome | 7.0 | $31,500.00 | microtome | 7 | $13,369.00 | Radiology |
| E13619 | microtome knife sharpener | 7.0 | $7,200.00 | microtome sharpener | 10 | $6,400.00 | Radiology |
| | microwave | 10.0 | | diathermy, microwave | 10 | | Other Equipment |

ADDENDUM D.—PROPOSED CHANGES TO PRACTICE EXPENSE EQUIPMENT DESCRIPTION, LIFE, AND PRICING—Continued

| Equip code | 2004 practice expense equipment details | | | 2005 practice expense supply details (proposed) | | | |
|---|---|---|---|---|---|---|---|
| | Description | Life | Price | Description | Life | Price | Equipment category |
| E51060 | Microwave Hypothermia System, BSD | 10.0 | $550,000.00 | Deleted through PEAC refinement. | | | No Details |
| | mimic/controllers/crane | 5.0 | $448,680.00 | collimator, multileaf system w-autocrane (MIMiC). | 7 | $355,030.00 | Radiology |
| E72004 | Minor Equipment Pack | 4.0 | $1,082.95 | instrument pack, basic ($500-$1499) | 4 | $500.00 | Other Equipment |
| E72006 | Minor Surgical Pack | 4.0 | $1,596.88 | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| E30020 | minor surgical tray | 4.0 | $572.20 | instrument pack, basic ($500-$1499) | 4 | $500.00 | Other Equipment |
| E53008 | Mobile Source Storage Safes | 20.0 | $3,650.00 | Deleted through PEAC refinement. | | | No Details |
| E92017 | mobolization/manipulation table | 10.0 | $9,315.00 | table, mobolization-manipulation (Lloyd's) | 15 | $8,195.00 | Furniture |
| | motor coordination kit | 10.0 | $643.00 | kit, motor coordination | 10 | $643.75 | Other Equipment |
| | Mount/wheel chair | 7.0 | $830.00 | augmentative communication - DynaVox wheelchair mount.doc. | 7 | $765.00 | Other Equipment |
| E51058 | MR Room | 5.0 | $3,140,000.00 | room, MR | 5 | $1,961,375.00 | Room - Lane |
| | nasal pressure transducer | 7.0 | $525.00 | transducer, pressure, airflow sensor | 7 | $582.50 | Other Equipment |
| | naturally speaking software, dragon (Accessibility). | 5.0 | $696.00 | augmentative communication - Dragon Naturally-Speaking. | 7 | $699.95 | Other Equipment |
| E91010 | Negative Flow Hood | 10.0 | $2,000.00 | hood, negative flow | 15 | $2,400.00 | Laboratory |
| E30028 | nerve stimulator | 7.5 | $523.80 | nerve stimulator (eg, for nerve block) | 7 | $572.30 | Other Equipment |
| E12002 | neurobehavioral status instrument-average | 7.5 | $717.00 | neurobehavioral status instrument-average | 5 | $717.00 | Other Equipment |
| | new item | | | biofeedback equipment | 8 | | Other Equipment |
| | new item | | | blood warmer | 7 | $3,840.00 | Other Equipment |
| | new item | | | breast biopsy imaging system, stereotactic (imager, table, software). | 5 | $234,000.00 | Other Equipment |
| | new item | | | camera, digital system, for electron microscopy. | 5 | $41,000.00 | Documentation |
| | new item | | | cell separator system | 6 | $59,320.00 | Other Equipment |
| | new item | | | chair, thyroid imaging | 10 | $2,200.00 | Furniture |
| | new item | | | CO2 infrared analyzer (COSMO) | 7 | $4,500.00 | Other Equipment |
| | new item | | | computer workstation, 3D hyperthermia treatment planning. | 5 | $98,000.00 | Documentation |
| | new item | | | computer workstation, 3D radiation treatment planning. | 5 | $130,216.50 | Documentation |
| | new item | | | computer workstation, 3D reconstruction CT-MR. | 5 | $45,926.00 | Documentation |
| | new item | | | computer workstation, brachytherapy treatment planning. | 5 | $105,403.00 | Documentation |
| | new item | | | computer workstation, cardiac cath monitoring. | 5 | $94,000.00 | Documentation |
| | new item | | | computer workstation, MRA post processing | 5 | | Documentation |
| | new item | | | contrast media warmer | 7 | $552.00 | Other Equipment |
| | new item | | | cortical bipolar-biphasic stimulating equipment. | 7 | | Other Equipment |
| | new item | | | crash cart (unstocked) | 10 | $868.50 | Furniture |
| | new item | | | cryosurgical probe, retina | 7 | $1,984.00 | Other Equipment |
| | new item | | | defibrillator w-ECG monitor | 5 | $3,150.67 | Other Equipment |
| | new item | | | densitometry unit, peripheral, SXA | 5 | $22,096.00 | Radiology |
| | new item | | | densitometry unit, peripheral, ultrasound | 5 | $13,225.00 | Radiology |
| | new item | | | dermabrader (Osada) | 10 | $1,590.00 | Other Equipment |
| | new item | | | drill, ophthalmology | 3 | | Other Equipment |
| | new item | | | EEG analysis software | 5 | $82,000.00 | Other Equipment |
| | new item | | | EEG monitor, digital, portable | 7 | | Other Equipment |
| | new item | | | electroconvulsive therapy machine | 5 | | Other Equipment |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | new item | | | external fixation, craniofacial halo (BlueDevice). | 4 | $5,146.00 | Other Equipment |
| | new item | | | external fixation, mandible (Joe Hall Morris) | 4 | $4,508.00 | Other Equipment |
| | new item | | | gamma camera system, single-dual head | 5 | $406,816.80 | Radiology |
| | new item | | | hyperthermia system, RF-deep and microwave. | 5 | $790,353.00 | Radiology |
| | new item | | | hyperthermia system, ultrasound, external | 5 | $360,000.00 | Radiology |
| | new item | | | hyperthermia system, ultrasound, intracavitary. | 5 | $250,000.00 | Radiology |
| | new item | | | intracavitary applicator set (tandem and ovoids). | 4 | $10,321.50 | Radiology |
| | new item | | | intra-compartmental pressure monitor device | 7 | $1,737.00 | Other Equipment |
| | new item | | | lens set, fitting, low vision | 10 | $4,750.00 | Other Equipment |
| | new item | | | liposorber system | 7 | $7,800.00 | Other Equipment |
| | new item | | | mammography reporting software | 5 | | Documentation |
| | new item | | | manometry system (computer, transducers, catheter). | 5 | $39,400.00 | Other Equipment |
| | new item | | | micropigmentation (tattoo) system | 7 | $2,550.00 | Other Equipment |
| | new item | | | microscope, electron, transmission (TEM) | 7 | $319,290.00 | Laboratory |
| | new item | | | microtome, ultra | 7 | $25,950.00 | Radiology |
| | new item | | | nuclide rod source set | 5 | $1,395.00 | Radiology |
| | new item | | | oximeter, whole blood | 5 | $6,950.00 | Other Equipment |
| | new item | | | oxygen system, portable | 8 | $569.89 | Other Equipment |
| | new item | | | phantom, mammography-accreditation | 10 | $674.00 | Radiology |
| | new item | | | phantom, QCT densitometry | 10 | $5,464.00 | Radiology |
| | new item | | | pump, water perfusion (for manometry) | 7 | $7,307.00 | Other Equipment |
| | new item | | | radiation L-block tabletop shield | 10 | $725.00 | Radiology |
| | new item | | | radiusgauge | 7 | $1,234.00 | Other Equipment |
| | new item | | | resectoscope, continuous flow | 3 | $1,200.00 | Scope |
| | new item | | | RGP lens modification unit | 7 | $540.00 | Other Equipment |
| | new item | | | rhinomanometer system (w-transducers and software). | 7 | $10,800.00 | Other Equipment |
| | new item | | | sleep screening system, ambulatory (incl. hardware, software). | 5 | $14,877.25 | Other Equipment |
| | new item | | | stepper, stabilizer, template (for brachytherapy treatment). | 7 | $18,550.00 | Radiology |
| | new item | | | stirrups (for brachytherapy table) | 10 | $3,876.00 | Radiology |
| | new item | | | stretcher chair | 10 | $3,133.00 | Furniture |
| | new item | | | table, brachytherapy treatment | 15 | $28,900.00 | Furniture |
| | new item | | | table, cystoscopy | 15 | | Furniture |
| | new item | | | thyroid uptake system | 5 | $13,995.00 | Radiology |
| | new item | | | urethrotome, optical | 3 | $1,881.00 | Scope |
| | new item | | | vacuum deposition system (Auto306) | 7 | $38,070.00 | Laboratory |
| | new item | | | x-ray, dental, intra-oral | 5 | $3,869.00 | Radiology |
| | new item | | | x-ray, dental, panoramic | 5 | $24,405.00 | Radiology |
| | Non-amplified auditory trainer | 7.0 | $1,295.00 | augmentative communication - auditory trainer. | 7 | $1,096.00 | Other Equipment |
| E13406 | NST, Non Stress Test | 5.0 | $8,878.00 | fetal monitor | 5 | $5,415.95 | Other Equipment |
| | nuclear pharmacy management software (w-computer and printer) (NMIS). | 5.0 | $13,400.00 | computer workstation, nuclear pharmacy management (hardware and software). | 5 | $13,400.00 | Documentation |
| | Nucleus Crystal Integrity Testing System | 7.0 | $9,450.00 | cochlear implant testing system | 10 | $9,500.00 | Other Equipment |
| | Nucleus PCI | 7.0 | $8,000.00 | cochlear implant programming system | 7 | $9,000.00 | Other Equipment |
| | nutrition therapy software | 5.0 | $500.00 | nutrition therapy software (Nutritionist Pro) | 5 | $595.00 | Other Equipment |
| E13102 | Olympus halogen light | 3.0 | $950.00 | Deleted (part of new system) | | | No Details |
| E30013 | operating microscope | 7.0 | $5,400.00 | microscope, operating | 7 | $7,047.50 | Other Equipment |
| E71019 | ophthalmic telebinocular | 7.5 | $1,025.00 | telebinocular, ophthalmic | 7 | $1,014.33 | Other Equipment |
| | optical coherence biometer | 5.0 | $25,950.00 | Deleted through PEAC refinement. | | | No Details |
| | optical disk reader | 5.0 | $4,000.00 | optical drive (MO), external | 5 | $2,050.00 | Documentation |
| | optical fibers | 5.0 | $3,236.00 | laser optical delivery system (for excimer) | 5 | $1,500.00 | Other Equipment |

ADDENDUM D.—PROPOSED CHANGES TO PRACTICE EXPENSE EQUIPMENT DESCRIPTION, LIFE, AND PRICING—Continued

| Equip code | 2004 practice expense equipment details | | | 2005 practice expense supply details (proposed) | | | |
|---|---|---|---|---|---|---|---|
| | Description | Life | Price | Description | Life | Price | Equipment category |
| | Orthovoltage Machine | 5.0 | $140,000.00 | orthovoltage radiotherapy system | 5 | $140,000.00 | Radiology |
| | OSHA ventilated hood | 10.0 | $5,000.00 | OSHA ventilated hood | 15 | $5,000.00 | Radiology |
| E13602 | osmometer | 7.0 | $4,595.00 | Deleted through PEAC refinement. | | | No Details |
| | otoscope-ophthalmoscope | 3.0 | $505.00 | otoscope-ophthalmoscope (wall unit) | 10 | $694.00 | Other Equipment |
| E54008 | Oxford PT recorder | 7.0 | $6,940.00 | EEG recorder, ambulatory | 7 | $6,940.00 | Other Equipment |
| E54009 | Oxford review station | 7.0 | $44,950.00 | EEG review station, ambulatory | 5 | $44,950.00 | Other Equipment |
| | Oximetry Recorder, overnight/software | 5.0 | $3,660.00 | pulse oxymetry recording software (prolonged monitoring). | 5 | $3,660.00 | Other Equipment |
| | oxygen concentrator | 15.0 | $3,806.00 | oxygen concentrator (5-6 lpm) | 8 | $1,035.83 | Other Equipment |
| | oxygen tank | 10.0 | | Deleted (less than $500) | | | No Details |
| E55027 | Oxygen uptake expired gas analyzer | 7.0 | $46,000.00 | Vmax 229 (PFT equip, computer system) | 8 | $44,681.00 | Other Equipment |
| | pacemaker follow-up system (e.g. paceart) | 7.0 | $22,000.00 | pacemaker follow-up system (incl software and hardware) (Paceart). | 7 | $23,507.00 | Other Equipment |
| E71020 | pachometer | 5.0 | $3,650.00 | ultrasonic biometry, pachymeter | 5 | $3,945.00 | Other Equipment |
| E13638 | paraffin dispenser | 7.5 | $995.00 | paraffin dispenser (two-gallon) | 10 | $1,520.00 | Laboratory |
| | paraffin dispenser, 5 gal. | 7.0 | $1,995.00 | paraffin dispenser (five-gallon) | 10 | $2,222.50 | Laboratory |
| E92011 | parallel bars | 15.0 | $1,755.00 | parallel bars, platform mounted | 15 | $1,670.67 | Other Equipment |
| | PC server | 5.0 | $25,000.00 | computer, server | 5 | $25,000.00 | Documentation |
| E52003 | Pentium computer | 5.0 | $2,800.00 | computer, desktop, w-monitor | 5 | $2,501.00 | Documentation |
| | percutaneous neuro test stimulator | 4.0 | $795.00 | percutaneous neuro test stimulator | 7 | $795.00 | Other Equipment |
| | peripheral QCT scanner | 5.0 | $55,000.00 | densitometry unit, peripheral, QCT | 5 | $79,000.00 | Radiology |
| | pessary stock kit | 10.0 | $1,824.00 | Deleted (less than $500) | | | No Details |
| E13603 | pH meter | 7.0 | $1,000.00 | pH conductivity meter | 10 | $1,028.00 | Laboratory |
| | photochemotherapy unit & lamps (200 ea/yr) | 5.0 | $32,000.00 | phototherapy unit, whole body, UVA-UVB | 10 | $12,975.00 | Other Equipment |
| | photochemotherapy unit, hand/foot combo | 5.0 | $1,525.00 | phototherapy unit, hand-foot, UVA-UVB | 10 | $1,675.00 | Other Equipment |
| E13620 | photographic enlarger | 10.0 | $15,000.00 | photographic enlarger | 5 | $3,195.00 | Documentation |
| E13621 | photographic film processor | 10.0 | $6,000.00 | film processor (electron microscopy) | 8 | $4,400.00 | Laboratory |
| | physician analysis and viewing station | 7.5 | $35,000.00 | computer workstation, nuclear medicine analysis-viewing. | 5 | $55,097.00 | Documentation |
| | physician analysis/viewing station | 10.0 | $35,000.00 | computer workstation, nuclear medicine analysis-viewing. | 5 | $55,097.00 | Documentation |
| | physics support package for intensity modulated radiotherapy. | 5.0 | $12,500.00 | Deleted (weekly training cost) | | | No Details |
| E91011 | Plasma pheresis machine w/UV light source | 7.5 | $37,900.00 | plasma pheresis machine w/UV light source | 6 | $37,900.00 | Other Equipment |
| E11009 | pneumatic chairs | 15.0 | $697.60 | Deleted (less than $500) | | | No Details |
| | pneumatic tourniquet device | 5.0 | | tourniquet system (Zimmer1200) | 7 | $10,220.00 | Other Equipment |
| | pool cleaner | 10.0 | $1,500.00 | pool cleaner | 15 | $1,372.15 | Other Equipment |
| E11003 | Power Table | 7.5 | $6,939.00 | table, power | 10 | $6,153.63 | Furniture |
| E11003 | Power Table | 10.0 | $6,939.00 | table, power | 10 | $6,153.63 | Furniture |
| E11003 | Power Table | 15.0 | $6,939.00 | table, power | 10 | $6,153.63 | Furniture |
| E13622 | print washer | 10.0 | $670.00 | Deleted through PEAC refinement. | | | No Details |
| | Printer (HP) | 5.0 | $1,200.00 | printer, laser, paper | 5 | $1,199.00 | Documentation |
| | printer, dye, sublimated | 5.0 | $15,000.00 | printer, dye sublimation (photo, color) | 5 | $2,322.50 | Documentation |
| | printer, laser for CT | 5.0 | $75,000.00 | film processor, dry, laser | 8 | $69,950.00 | Documentation |
| | printer, laser for CT angiography | 5.0 | $71,400.00 | film processor, dry, laser | 8 | $69,950.00 | Documentation |
| E51080 | Processor (wet or dry) | 8.0 | $55,000.00 | film processor, wet | 8 | $26,325.00 | Documentation |
| E55011 | Programmer: Intermedics | 7.0 | $10,000.00 | Deleted through PEAC refinement. | | | No Details |
| E55013 | Programmers for Pacemakers | 7.0 | $10,000.00 | programmer, pacemaker | 7 | $10,000.00 | Other Equipment |
| E55012 | Programmers: Medtronic, CPI, Ventritex | 7.0 | $11,000.00 | programmer, for implanted medication pump (spine). | 7 | $1,975.00 | Other Equipment |
| E55012 | Programmers: Medtronic, CPI, Ventritex | 7.0 | $11,000.00 | programmer, neurostimulator (w-printer) | 7 | $1,975.00 | Other Equipment |
| E54011 | Pt. Bedroom Furniture | 12.0 | $1,824.00 | bedroom furniture (hospital bed, table, reclining chair). | 12 | $2,416.99 | Furniture |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| E30011 | pulse dye laser | 5.0 | $125,000.00 | laser, pulse dye | 5 | $78,500.00 | Other Equipment |
| E55003 | pulse oximeter | 5.0 | $885.00 | pulse oximeter w-printer | 7 | $1,207.18 | Other Equipment |
| | Radiation Source Meter | 7.0 | $600.00 | Deleted through PEAC refinement. | | | No Details |
| | Radiation Survey Meter | 7.0 | $1,117.00 | radiation survey meter | 8 | $756.25 | Radiology |
| | radiofrequency generator (NEURO) | 7.0 | $32,900.00 | radiofrequency generator (NEURO) | 5 | $32,900.00 | Other Equipment |
| E51005 | Radiographic/ fluoroscopic room | 5.0 | $475,000.00 | room, radiographic-fluoroscopic | 5 | $475,000.00 | Room - Lane |
| E51030 | Radiographic/Fluroscopic Evaluation Unit, RMI 4000. | 5.0 | $15,995.00 | Deleted through PEAC refinement. | | | No Details |
| | radiopharmaceutical receiving area | 5.0 | $51,545.00 | Deleted (split into separate equipment items) | | | No Details |
| E11011 | reclining exam chair with headrest | 10.0 | $4,495.00 | chair with headrest, exam, reclining | 15 | $4,836.33 | Furniture |
| E51022 | Record and verify Computer (Varian) | 5.0 | $60,000.00 | computer system, record and verify | 5 | $60,000.00 | Documentation |
| | remote monitoring service | 7.0 | $9,500.00 | remote monitoring service (neurodiagnostics) | 5 | $9,500.00 | Other Equipment |
| | respiratory plethysmograph | 7.0 | | Deleted (part of new system) | | | No Details |
| | retractor, hand | 4.0 | $1,566.20 | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| E54010 | review master | 7.0 | $23,500.00 | review master | 5 | $23,500.00 | Other Equipment |
| | review software (e.g. Prosolve) | 5.0 | $8,000.00 | ultrasound, echocardiography analyzer software (ProSolv). | 5 | $8,000.00 | Other Equipment |
| E52013 | Review Station: AG7300 SVHS,17in. | 5.0 | $899.99 | video SVHS VCR (medical grade) | 5 | $1,250.00 | Documentation |
| E71036 | Rhinomenometer | 7.5 | $3,150.00 | Deleted through PEAC refinement. | | | No Details |
| E72010 | Rigid Bone fixation system | 7.5 | $20,000.00 | Deleted through PEAC refinement. | | | No Details |
| E52014 | Rigiscan | 7.5 | $12,500.00 | nocturnal penile tumescence monitor (Rigiscan Plus). | 7 | $9,000.00 | Other Equipment |
| E13642 | robotic cover slipper | 7.5 | $32,288.00 | slide coverslipper, robotic | 7 | $30,143.00 | Laboratory |
| E51087 | Roesenthal dosimeter | 5.0 | $1,995.00 | dosimeter, aerosol provocation | 10 | $1,795.00 | Other Equipment |
| | rotation chair | 7.0 | $91,059.00 | CDP-computerized dynamic posturography system. | 7 | $86,957.50 | Other Equipment |
| E13643 | routine pap stainer | 7.0 | $20,000.00 | slide stainer, automated, high-volume throughput. | 7 | $14,085.68 | Laboratory |
| | RVS System | 7.0 | $54,000.00 | radiation virtual simulation system | 5 | $54,000.00 | Radiology |
| E50006 | scale, high capacity | 10.0 | $1,995.00 | scale, high capacity (800 lb) | 10 | $1,726.33 | Furniture |
| | scale, new born electronic | 7.0 | $1,276.00 | scale, new born, digital | 15 | $1,279.41 | Furniture |
| E13607 | scanning electron microscope | 7.0 | $120,000.00 | microscope, electron, scanning (SEM) (with microprobe and x-ray microanalyzer). | 7 | $178,725.00 | Laboratory |
| | Scanning Laser Device | 5.0 | $60,000.00 | tomographic device, optical coherence (OCT). | 7 | $49,950.00 | Other Equipment |
| | scope washer | 7.0 | | endoscope disinfector, rigid or fiberoptic, w-cart. | 7 | $18,802.00 | Scope |
| E71111 | Screening Lane | 7.0 | $28,234.95 | lane, screening (oph) | 7 | $28,463.33 | Room - Lane |
| E54003 | Seizure Detection Device | 7.0 | $21,000.00 | EEG, digital, prolonged testing system (computer w-remote camera). | 7 | $46,750.00 | Other Equipment |
| | sensitometer | 5.0 | $2,500.00 | sensitometer, film | 10 | $1,050.00 | Radiology |
| | sensory integration equipment | 8.0 | $3,600.00 | sensory integration equip (eg, ball pit, glider, trampoline, ramp). | 15 | $3,600.00 | Other Equipment |
| | sensory kit | 10.0 | $677.00 | kit, sensory | 10 | $677.35 | Other Equipment |
| E72008 | septoplasty tray | 4.0 | $725.76 | Deleted through PEAC refinement. | | | No Details |
| | shock wave machine | 5.0 | $450,000.00 | shock wave system | 5 | $350,000.00 | Other Equipment |
| E13103 | sigmoidoscopic equipment cart | 10.0 | $3,340.00 | cart, endoscopy imaging equipment | 10 | $2,793.00 | Scope |
| | simple ear instrument pack | 4.0 | | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| | simple ear instrumentation pack | 4.0 | | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| | Simulator, Varian | 5.0 | $595,000.00 | IMRT x-ray-fluoroscopic-based simulator | 5 | $598,120.00 | Radiology |
| E51024 | Simulator, Ximatron CF w/last Image hold | 5.0 | $450,000.00 | Deleted through PEAC refinement. | | | No Details |
| E53018 | Single Head Anger Scintillation Camera | 5.0 | $300,000.00 | gamma camera system, single-dual head | 5 | $406,816.80 | Radiology |
| E53020 | Single Head or Dual Head Camera | 5.0 | $575,000.00 | gamma camera system, single-dual head | 5 | $406,816.80 | Radiology |
| E53032 | Single Photon Densitometer/Computer | 5.0 | $22,500.00 | densitometry unit, whole body, SPA | 5 | $22,500.00 | Radiology |
| E71028 | Sinusoidal Harmonic Acceleration Chair | 7.0 | $70,080.00 | CDP-computerized dynamic posturography system. | 7 | $86,957.50 | Other Equipment |
| | sleep kit (includes snore sensor & leg kit) | 7.0 | $630.00 | Deleted (less than $500) | | | No Details |
| E13644 | slide dryer oven | 10.0 | $695.00 | slide dryer | 10 | $962.50 | Laboratory |
| E13645 | slide etcher | 7.5 | $9,400.00 | slide etcher-labeler | 7 | $15,836.67 | Laboratory |

ADDENDUM D.—PROPOSED CHANGES TO PRACTICE EXPENSE EQUIPMENT DESCRIPTION, LIFE, AND PRICING—Continued

| Equip code | 2004 practice expense equipment details | | | 2005 practice expense supply details (proposed) | | | |
|---|---|---|---|---|---|---|---|
| | Description | Life | Price | Description | Life | Price | Equipment category |
| E13617 | slide stainer | 7.0 | $13,000.00 | slide stainer, automated, high-volume throughput. | 7 | $14,085.68 | Laboratory |
| | smoke evacuation system | 10.0 | | Deleted (part of new system) | | | No Details |
| | soft tissue procedure pack | 4.0 | $539.00 | instrument pack, basic ($500-$1499) | 4 | $500.00 | Other Equipment |
| E30003 | soft tissue tray | 4.0 | $1,559.40 | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| E52009 | Software (Paceart) | 5.0 | $6,000.00 | pacemaker follow-up system (incl software and hardware) (Paceart). | 7 | $23,507.00 | Other Equipment |
| | software, MR/PET/CT fusion | 5.0 | $60,000.00 | computer software, MR/PET/CT fusion | 5 | $60,000.00 | Documentation |
| | software-woodcock johnson test/cognitive abilities. | 5.0 | $728.00 | cognitive abilities testing software (Woodcock Johnson). | 5 | $558.00 | Other Equipment |
| E51046 | Solid Water Calibration Phantom | 5.0 | $2,000.00 | phantom, solid water calibration check | 10 | $2,109.50 | Radiology |
| E13646 | solvent recycling system | 7.5 | $22,000.00 | solvent recycling system | 7 | $13,995.00 | Laboratory |
| E13614 | sonicator | 7.5 | $600.00 | Deleted through PEAC refinement. | | | No Details |
| E52010 | Sony Color Video Printer | 5.0 | $10,500.00 | Deleted (part of new system) | | | No Details |
| E52010 | Sony Color Video Printer (combine with system). | 5.0 | $10,500.00 | video printer, color (Sony medical grade) | 4 | $2,295.00 | Documentation |
| E71031 | sound proof booth- double walled | 7.5 | $11,900.00 | audiometric soundproof booth (exam and control rooms). | 15 | $33,518.00 | Other Equipment |
| | sounds and followers set, leforte, 12-24 french. | 4.0 | $508.00 | instrument pack, basic ($500-$1499) | 4 | $500.00 | Other Equipment |
| | sounds, female (set) | 4.0 | $1,736.00 | instrument pack, medium ($1500 and up) | 4 | $1,500.00 | Other Equipment |
| | sounds, male (set) | 4.0 | $1,104.00 | instrument pack, basic ($500-$1499) | 4 | $500.00 | Other Equipment |
| | sounds, VanBurden | 4.0 | $1,104.00 | instrument pack, basic ($500-$1499) | 4 | $500.00 | Other Equipment |
| | source, 10 Ci Ir 192 | 3.0 | $22,000.00 | source, 10 Ci Ir 192 | 5 | $22,000.00 | Radiology |
| E53028 | SPECT Three head Camera | 5.0 | $565,000.00 | gamma camera system, single-dual head | 5 | $406,816.80 | Radiology |
| | spirometry instrument | 8.0 | $37,974.00 | Vmax 29s (spirometry testing equip, computer system). | 8 | $26,875.00 | Other Equipment |
| E13610 | sputter coater | 7.5 | $6,000.00 | Deleted (part of new system) | | | No Details |
| | stainer, automated hematology | 7.0 | $8,253.00 | slide stainer, automated, standard throughput. | 7 | $8,265.64 | Laboratory |
| | stairs, exercise | 10.0 | $870.00 | stairs, ambulation training | 15 | $793.67 | Other Equipment |
| | stereotactic frame /tongs | 5.0 | | cranial-skull tongs (Gardner-Wells) | 5 | $542.00 | Other Equipment |
| | stimulator with probe | 8.0 | | Deleted (less than $500) | | | No Details |
| E11002 | stretcher | 5.0 | $2,664.00 | stretcher | 10 | $1,915.00 | Furniture |
| E11002 | stretcher | 10.0 | $2,664.00 | stretcher | 10 | $1,915.00 | Furniture |
| | strontium-90 applicator | 4.0 | $8,599.00 | strontium-90 applicator | 5 | $8,599.00 | Other Equipment |
| | suction and pressure cabinet, ENT (SMR) | 15.0 | $3,195.00 | suction and pressure cabinet, ENT (SMR) | 10 | $3,495.00 | Other Equipment |
| E30001 | suction machine, Gomco | 10.0 | $732.20 | suction machine (Gomco) | 10 | $743.21 | Other Equipment |
| E72009 | surgical drill system | 7.5 | $19,800.00 | drill system, surgical, large (Stryker) | 10 | $15,933.00 | Other Equipment |
| E30009 | surgical lamp | 10.0 | $3,650.00 | light, surgical | 10 | $4,489.13 | Furniture |
| E30018 | surgical loupes | 10.0 | $1,300.00 | loupes, surgical, prism, up to 8.0x | 7 | $1,398.33 | Other Equipment |
| E53004 | Survey Meter | 7.5 | $650.00 | radiation survey meter | 8 | $756.25 | Radiology |
| | suspension system for sensory integration equipment. | 8.0 | $2,500.00 | sensory integration equipment, suspension system. | 10 | $2,500.00 | Other Equipment |
| E52012 | SVHS video recorder | 5.0 | $599.00 | Deleted (part of new system) | | | No Details |
| E52012 | SVHS video recorder | 5.0 | $599.00 | video SVHS VCR (medical grade) | 5 | $1,250.00 | Documentation |
| | swimming pool for aquatic therapy | 10.0 | $37,500.00 | aquatic therapy pool | 15 | $36,000.00 | Other Equipment |
| | switch kit | 5.0 | $1,910.00 | augmentative communication - AT switches (eg, arm, tongue, pneumatic). | 7 | $1,910.00 | Other Equipment |
| | table, back, mobile | 10.0 | $709.00 | table, instrument, mobile | 15 | $634.00 | Furniture |
| | table, fluoroscopy (Hydra Vision 64kW) | 10.0 | $281,600.00 | table, fluoroscopy | 15 | $281,600.00 | Furniture |
| | table, OR, tilt | 10.0 | $1,010.00 | table, power | 10 | $6,153.63 | Furniture |
| | table, pedestal for OT | 15.0 | $795.00 | table, for seated OT therapy | 15 | $718.67 | Furniture |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | table, traction with leg rest | 10.0 | $3,770.00 | Deleted (part of new system) | | | No Details |
| | table, treatment/work, adjustable height | 10.0 | $2,905.00 | table, treatment, hi-lo | 15 | $2,361.67 | Furniture |
| | Tech Speak | 7.0 | $645.00 | augmentative communication - Tech Speak | 7 | $645.00 | Other Equipment |
| | TEE transducer | 5.0 | $45,000.00 | ultrasound, transducer (TEE Omniplane II) | 5 | $45,000.00 | Other Equipment |
| | test, clerical comprehension (Valpar) | 10.0 | $2,680.00 | work samples, clerical comprehension (Valpar 5). | 7 | $2,680.00 | Other Equipment |
| | test, fine finger dexterity (Valpar) | 10.0 | $725.00 | work samples, fine finger dexterity (Valpar 204). | 7 | $725.00 | Other Equipment |
| | test, physical capacity and mobility (Valpar) | 10.0 | $725.00 | work samples, physical capacity (Valpar 201) | 7 | $725.00 | Other Equipment |
| E92023 | Therapeutic exercise equipment set | 15.0 | $12,260.00 | exercise equipment (treadmill, bike, stepper, UBE, pulleys, balance board). | 15 | $12,710.00 | Other Equipment |
| E92001 | therapeutic ultrasound unit | 7.0 | $1,995.00 | ultrasound unit, therapeutic | 7 | $1,304.33 | Other Equipment |
| | Tilt Table | 10.0 | $6,995.00 | table, tilt (w-trendelenberg) | 15 | $7,695.00 | Furniture |
| E13649 | tissue processing fume hood | 7.5 | $6,400.00 | hood, fume | 15 | $4,778.46 | Laboratory |
| E13650 | tissue processor | 7.0 | $39,500.00 | tissue processor | 7 | $33,593.00 | Laboratory |
| | TLD oven/annealing furnace | 5.0 | $1,960.00 | TLD annealing furnace | 7 | $2,536.00 | Laboratory |
| E51048 | TLD Reader | 5.0 | $13,000.00 | TLD Reader | 7 | $14,390.00 | Laboratory |
| | Tonography Unit | 5.0 | $10,065.00 | tonography unit | 7 | $6,195.00 | Other Equipment |
| | tool set, valpar | 7.0 | $1,765.00 | work samples, small tools (Valpar 1) | 7 | $1,765.00 | Other Equipment |
| | topcon TRC 50 E | 5.0 | $28,790.00 | camera, retinal (TRC 50IX, w-ICG, filters, motor drives). | 5 | $37,000.00 | Documentation |
| | tourniquet device, pneumatic | 7.0 | $12,500.00 | tourniquet system (Zimmer1200) | 7 | $10,220.00 | Other Equipment |
| | Tracher 2000 | 7.0 | $1,895.00 | augmentative communication - Tracker 2000 | 7 | $1,795.00 | Other Equipment |
| | transthoracic echo probe, pediatric, 8 mHz | 5.0 | $15,000.00 | Deleted (part of new system) | | | No Details |
| | treadmill | 10.0 | $4,700.00 | treadmill | 8 | $4,446.11 | Other Equipment |
| E55020 | Treadmill w/ ECG Monitor | 8.0 | $16,000.00 | cardiac monitor w-treadmill (12-lead PC-based ECG). | 10 | $14,271.03 | Other Equipment |
| E51050 | Treatment Planning Computer-3D (Focus) | 5.0 | $221,500.00 | computer workstation, 3D teletherapy treatment planning. | 5 | $221,500.00 | Documentation |
| | treatment planning system for intensity modulated radiotherapy. | 5.0 | $350,000.00 | treatment planning system, IMRT (Corvus w-Peregrine 3D Monte Carlo). | 5 | $350,545.00 | Documentation |
| | Treatment Vault | 7.0 | $550,670.00 | radiation treatment vault | 15 | $550,670.00 | Radiology |
| | TUMT device | 5.0 | $60,000.00 | TUMT system control unit | 7 | $29,995.00 | Other Equipment |
| E71032 | tympanometer with printer | 7.0 | $2,700.00 | tympanometer with printer | 10 | $2,648.53 | Other Equipment |
| | ultrasonic biometry, pachymeter | 5.0 | $3,945.00 | ultrasonic biometry, pachymeter | 5 | $3,945.00 | Other Equipment |
| E13663 | ultrasonic instrument cleaner | 7.5 | $945.00 | Deleted (indirect) | | | No Details |
| E52019 | Ultrasonic nebulizer | 10.0 | $1,000.00 | Deleted (CPT action) | | | No Details |
| E52001 | ultrasound color doppler, transducers and vaginal probe. | 5.0 | $155,000.00 | ultrasound color doppler, transducers and vaginal probe. | 5 | $155,000.00 | Other Equipment |
| E52018 | Ultrasound Room | 5.0 | $272,000.00 | room, ultrasound, general | 5 | $369,945.00 | Room - Lane |
| | ultrasound table | 10.0 | $4,495.00 | table, ultrasound | 15 | $5,823.33 | Furniture |
| | Ultrasound Unit | 5.0 | $30,000.00 | ultrasound unit, Shimadzu | 5 | $29,999.00 | Other Equipment |
| E52005 | ultrasound, shimatsu | 5.0 | $35,000.00 | ultrasound unit, Shimadzu | 5 | $29,999.00 | Other Equipment |
| | urethotome, otis | 3.0 | $1,735.00 | urethrotome, Otis | 4 | $1,697.50 | Scope |
| E52006 | urodynamics machine, 4-channel video | 5.0 | $15,175.00 | urodynamics system, 4-channel | 5 | $30,733.00 | Other Equipment |
| | urodynamics machine, 6-channel video | 5.0 | $115,578.00 | urodynamics system, 6-channel, w-video | 5 | $115,578.00 | Other Equipment |
| | uroflowmeter, digital, w-chair (Microflo) | 5.0 | $2,758.00 | uroflowmeter, digital, w-chair | 7 | $2,758.00 | Other Equipment |
| | uterine thermal balloon ablation system (Thermachoice). | 5.0 | $8,500.00 | uterine thermal balloon ablation system (Thermachoice). | 7 | $8,500.00 | Other Equipment |
| | UV monitor/meter | 5.0 | $690.00 | phototherapy UVB measuring device | 10 | $690.00 | Other Equipment |
| | vacuum cart | 10.0 | | vacuum cart | 10 | | |
| | Other Equipment. | | | | | | |
| E13615 | vacuum dissector | 10.0 | $635.00 | Deleted through PEAC refinement. | | | No Details |
| E13627 | vacuum evaporator | 7.5 | $15,000.00 | Deleted (part of new system) | | | No Details |
| E13612 | vacuum oven | 10.0 | $3,000.00 | Deleted (part of new system) | | | No Details |
| E13624 | vacuum pump | 10.0 | $1,455.00 | vacuum pump | 7 | $1,840.00 | Laboratory |
| E92015 | Vasopneumatic device | 10.0 | $795.00 | vasopneumatic compression system | 10 | $632.48 | Other Equipment |
| E91003 | ventilator hood & blower | 10.0 | $602.55 | hood, ventilator with blower | 10 | $1,612.50 | Laboratory |

ADDENDUM D.—PROPOSED CHANGES TO PRACTICE EXPENSE EQUIPMENT DESCRIPTION, LIFE, AND PRICING—Continued

| Equip code | 2004 practice expense equipment details | | | 2005 practice expense supply details (proposed) | | | |
|---|---|---|---|---|---|---|---|
| | Description | Life | Price | Description | Life | Price | Equipment category |
| | video add-on camera system w-monitor (endoscopy). | 5.0 | $9,495.00 | video add-on camera system w-monitor (endoscopy). | 5 | $9,495.00 | Scope |
| E13635 | video camera | 5.0 | $1,000.00 | Deleted (part of new system) | | | No Details |
| E13635 | video camera (combine with system) | 5.0 | $1,000.00 | video add-on camera system w-monitor (endoscopy). | 5 | $9,495.00 | Scope |
| E13635 | video camera (combine with system) | 5.0 | $1,000.00 | video camera | 5 | $1,000.00 | Documentation |
| | video system, capsule endoscopy (software, computer, monitor, printer). | | $17,000.00 | video system, capsule endoscopy (software, computer, monitor, printer). | 5 | $17,000.00 | Scope |
| | video system, capsule endoscopy, booster drive w-accessories. | | $2,500.00 | video system, capsule endoscopy, booster drive w-accessories. | 5 | $2,500.00 | Scope |
| | video system, endoscopy (processor, digital capture, monitor, printer, cart). | 5.0 | $33,233.00 | video system, endoscopy (processor, digital capture, monitor, printer, cart). | 5 | $33,232.50 | Scope |
| | video system, FEES (scope, camera, light source, image capture, monitor, printer, cart). | 5.0 | $21,675.00 | video system, FEES (scope, camera, light source, image capture, monitor, printer, cart). | 5 | $21,675.00 | Scope |
| | video system, FEESST (scope, sensory stimulator, camera, light source, image capture, monitor, printer, cart). | 5.0 | $29,550.00 | video system, FEESST (scope, sensory stimulator, camera, light source, image capture, monitor, printer, cart). | 5 | $29,550.00 | Scope |
| | video system, stroboscopy (strobing platform, camera, digital recorder, monitor, printer, cart). | 5.0 | $25,310.00 | video system, stroboscopy (strobing platform, camera, digital recorder, monitor, printer, cart). | 5 | $25,310.00 | Scope |
| E71033 | visual response audiometry | 7.0 | $700.00 | VRA-visual reinforcment audiometry system | 5 | $1,550.00 | Other Equipment |
| E55023 | VMax 229 (split/combine systems) | 8.0 | $56,551.20 | Vmax 229 (spirometry testing equip, computer system). | 8 | $44,681.00 | Other Equipment |
| E55023 | VMax 229 (split/combine systems) | 8.0 | $56,551.20 | Vmax 29s (spirometry testing equip, computer system). | 8 | $26,875.00 | Other Equipment |
| | Voice Pal Max | 7.0 | $555.00 | augmentative communication - VoicePal Max | 7 | $555.00 | Other Equipment |
| E13648 | vortex mixer | 7.5 | $500.00 | Deleted (less than $500) | | | No Details |
| E54002 | Voyager acquisition station | 7.0 | $46,850.00 | sleep screening system, attended (w-resp plethysmography). | 5 | $22,000.00 | Other Equipment |
| | water bath | 10.0 | $750.00 | water bath, general purpose (lab) | 7 | $726.45 | Laboratory |
| | Water Bath Phantom with Drivers | 5.0 | $15,000.00 | phantom, water, includes remote motor drive | 10 | $3,070.00 | Radiology |
| | water bath, general purpose (lab) | 5.0 | $726.45 | water bath, general purpose (lab) | 7 | $726.45 | Laboratory |
| | Water Chiller | 7.0 | $28,000.00 | water chiller (radiation treatment) | 7 | $28,000.00 | Radiology |
| E51026 | Waterbath for Thermoplastic Immobilizer System. | 5.0 | $750.00 | water bath, thermoplastic softener (20in x 12in). | 7 | $722.36 | Radiology |
| | Waterbath, Medtech | 5.0 | $1,150.00 | water bath, thermoplastic softener (20in x 12in). | 7 | $722.36 | Radiology |
| E71008 | Weeks dark adaptometer | 5.0 | $16,100.00 | Weeks dark adaptometer | 7 | $2,950.00 | Other Equipment |
| E51076 | Well Counter | 5.0 | $3,955.00 | well counter | 7 | $3,955.00 | Radiology |
| E51074 | Well Ionization Chamber, Standard Imaging | 5.0 | $4,641.00 | Deleted through PEAC refinement. | | | No Details |
| E71108 | wheatstone trainer | 7.5 | $895.00 | stereo trainer (wheatstone) | 7 | $550.00 | Other Equipment |
| E92005 | whirlpool | 10.0 | $3,700.00 | whirlpool, lo-boy tank (whole body) | 10 | $3,296.40 | Furniture |
| | whitkit evaluation kit | 5.0 | $1,400.00 | augmentative communication - WhitKit head support. | 7 | $1,400.00 | Other Equipment |
| E53030 | Whole Body or Dual Head Camera | 5.0 | $575,000.00 | Deleted through PEAC refinement. | | | No Details |
| | WIT thermotherapy unit | 5.0 | $18,500.00 | WIT system (AquaTherm) | 7 | $16,400.00 | Other Equipment |
| | work bench, orthotic, mobile | 10.0 | $750.00 | cart-workbench, orthotic, mobile | 10 | $752.50 | Furniture |
| | work station, post processing for CT angiography. | 10.0 | $180,000.00 | Deleted (part of new system) | | | No Details |
| E53022 | Xenon Delivery System | 5.0 | $5,450.00 | Deleted through PEAC refinement. | | | No Details |
| | xenon light source - cable for endoscope | 3.0 | | | | | |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | light source, xenon | 5 | $6,723.33 | Other Equipment. | | | |
| E53024 | Xenon Monitor | 5.0 | $2,775.00 | Deleted through PEAC refinement. | | | No Details |
| E51003 | X-omat Film processor M35A | 8.0 | $10,900.00 | film processor, x-omat (Kodak 2000A) | 8 | $11,500.00 | Documentation |
| E51002 | X-omat film processor M6B | 8.0 | $26,832.00 | film processor, x-omat (M6B) | 8 | $34,865.00 | Documentation |
| E55032 | x-ray lift | 7.5 | $800.00 | lift, hydraulic, table assist | 10 | $1,111.00 | Furniture |
| E51001 | X-ray View Box 4 panel | 15.0 | $909.49 | x-ray view box, 4 panel | 10 | $889.17 | Radiology |
| E72000 | YAG laser | 5.0 | $40,000.00 | laser, YAG | 5 | $29,975.00 | Other Equipment |
| E71009 | Zeiss slit lamp camera | 10.0 | $7,495.00 | slit lamp (Haag-Streit) | 10 | $7,435.00 | Other Equipment |
| | zeiss visulas 690 PDT laser | 5.0 | $37,900.00 | laser, photodynamic therapy | 5 | $35,000.00 | Other Equipment |

ADDENDUM E.—REVISED 2005 OFFICE RENTAL INDEX VERSUS CURRENT OFFICE RENTAL INDEX BY 2004 FEE SCHEDULE AREA

| Carrier No. | Loc. No. | Locality name | Current rental index | Revised 2005 rental index | Difference | Percentage difference |
|---|---|---|---|---|---|---|
| 00510 | 00 | ALABAMA | 0.738 | 0.679 | -0.059 | -8.0 |
| 00831 | 01 | ALASKA | 1.249 | 1.141 | -0.108 | -8.6 |
| 31146 | 26 | ANAHEIM/SANTA ANA, CA | 1.422 | 1.586 | 0.164 | 11.5 |
| 00832 | 00 | ARIZONA | 1.000 | 1.034 | 0.034 | 3.4 |
| 00520 | 13 | ARKANSAS | 0.704 | 0.666 | -0.038 | -5.4 |
| 00511 | 01 | ATLANTA, GA | 1.136 | 1.271 | 0.135 | 11.9 |
| 00900 | 31 | AUSTIN, TX | 1.111 | 1.243 | 0.132 | 11.9 |
| 00901 | 01 | BALTIMORE/SURR. CNTYS, MD | 1.026 | 1.159 | 0.133 | 13.0 |
| 00900 | 20 | BEAUMONT, TX | 0.758 | 0.700 | -0.058 | -7.7 |
| 00900 | 09 | BRAZORIA, TX | 1.018 | 0.991 | -0.027 | -2.7 |
| 00952 | 16 | CHICAGO, IL | 1.216 | 1.274 | 0.058 | 4.8 |
| 00824 | 01 | COLORADO | 1.066 | 1.100 | 0.034 | 3.2 |
| 00591 | 00 | CONNECTICUT | 1.215 | 1.275 | 0.060 | 4.9 |
| 00900 | 11 | DALLAS, TX | 1.196 | 1.167 | -0.029 | -2.4 |
| 00903 | 01 | DC + MD/VA SUBURBS | 1.341 | 1.584 | 0.243 | 18.1 |
| 00902 | 01 | DELAWARE | 1.051 | 0.983 | -0.068 | -6.5 |
| 00953 | 01 | DETROIT, MI | 1.045 | 1.060 | 0.015 | 1.4 |
| 00952 | 12 | EAST ST. LOUIS, IL | 0.792 | 0.912 | 0.120 | 15.2 |
| 00590 | 03 | FORT LAUDERDALE, FL | 1.090 | 1.041 | -0.049 | -4.5 |
| 00900 | 28 | FORT WORTH, TX | 0.977 | 1.017 | 0.040 | 4.1 |
| 00900 | 15 | GALVESTON, TX | 0.924 | 0.901 | -0.023 | -2.5 |
| 00833 | 01 | HAWAII/GUAM | 1.389 | 1.186 | -0.203 | -14.6 |
| 00900 | 18 | HOUSTON, TX | 0.988 | 1.024 | 0.036 | 3.6 |
| 05130 | 00 | IDAHO | 0.791 | 0.730 | -0.061 | -7.7 |
| 00630 | 00 | INDIANA | 0.847 | 0.789 | -0.058 | -6.8 |
| 00826 | 00 | IOWA | 0.785 | 0.737 | -0.048 | -6.1 |
| 00650 | 00 | KANSAS* | 0.793 | 0.765 | -0.028 | -3.5 |
| 00740 | 04 | KANSAS* | 0.793 | 0.765 | -0.028 | -3.5 |
| 00660 | 00 | KENTUCKY | 0.721 | 0.685 | -0.036 | -5.0 |
| 31146 | 18 | LOS ANGELES, CA | 1.223 | 1.328 | 0.105 | 8.6 |
| 00803 | 01 | MANHATTAN, NY | 1.744 | 1.676 | -0.068 | -3.9 |
| 31140 | 03 | MARIN/NAPA/SOLANO, CA | 1.647 | 1.886 | 0.239 | 14.5 |
| 31143 | 01 | METROPOLITAN BOSTON | 1.504 | 1.809 | 0.305 | 20.3 |
| 00740 | 02 | METROPOLITAN KANSAS CITY, MO | 0.916 | 0.962 | 0.046 | 5.0 |
| 00865 | 01 | METROPOLITAN PHILADELPHIA, PA | 1.178 | 1.196 | 0.018 | 1.5 |
| 00523 | 01 | METROPOLITAN ST. LOUIS, MO | 0.814 | 0.949 | 0.135 | 16.6 |
| 00590 | 04 | MIAMI, FL | 1.139 | 1.117 | -0.022 | -1.9 |
| 00954 | 00 | MINNESOTA | 0.940 | 0.997 | 0.057 | 6.1 |
| 00512 | 00 | MISSISSIPPI | 0.690 | 0.667 | -0.023 | -3.3 |
| 00751 | 01 | MONTANA | 0.794 | 0.738 | -0.056 | -7.1 |
| 00655 | 00 | NEBRASKA | 0.817 | 0.748 | -0.069 | -8.4 |
| 00834 | 00 | NEVADA | 1.117 | 1.110 | -0.007 | -0.6 |
| 31144 | 40 | NEW HAMPSHIRE | 1.089 | 1.123 | 0.034 | 3.1 |
| 00521 | 05 | NEW MEXICO | 0.837 | 0.788 | -0.049 | -5.9 |
| 00528 | 01 | NEW ORLEANS, LA | 0.832 | 0.905 | 0.073 | 8.8 |
| 05535 | 00 | NORTH CAROLINA | 0.869 | 0.826 | -0.043 | -4.9 |
| 00820 | 01 | NORTH DAKOTA | 0.800 | 0.751 | -0.049 | -6.1 |
| 00805 | 01 | NORTHERN NJ | 1.399 | 1.421 | 0.022 | 1.6 |
| 00803 | 02 | NYC SUBURBS/LONG I., NY | 1.573 | 1.538 | -0.035 | -2.2 |
| 31140 | 07 | OAKLAND/BERKELEY, CA | 1.470 | 1.886 | 0.416 | 28.3 |
| 00883 | 00 | OHIO | 0.863 | 0.838 | -0.025 | -2.9 |
| 00522 | 00 | OKLAHOMA | 0.725 | 0.717 | -0.008 | -1.1 |
| 00835 | 01 | PORTLAND, OR | 1.120 | 1.058 | -0.062 | -5.5 |
| 00803 | 03 | POUGHKPSIE/N NYC SUBURBS, NY | 1.254 | 1.201 | -0.053 | -4.2 |
| 00973 | 20 | PUERTO RICO | 0.688 | 0.631 | -0.057 | -8.3 |
| 14330 | 04 | QUEENS, NY | 1.414 | 1.359 | -0.055 | -3.9 |
| 31146 | 99 | REST OF CALIFORNIA* | 1.050 | 1.110 | 0.060 | 5.7 |
| 31140 | 99 | REST OF CALIFORNIA* | 1.050 | 1.110 | 0.060 | 5.7 |
| 00590 | 99 | REST OF FLORIDA | 0.951 | 0.928 | -0.023 | -2.4 |
| 00511 | 99 | REST OF GEORGIA | 0.771 | 0.729 | -0.042 | -5.4 |
| 00952 | 99 | REST OF ILLINOIS | 0.797 | 0.741 | -0.056 | -7.0 |
| 00528 | 99 | REST OF LOUISIANA | 0.715 | 0.672 | -0.043 | -6.0 |
| 31142 | 99 | REST OF MAINE | 0.801 | 0.755 | -0.046 | -5.7 |
| 00901 | 99 | REST OF MARYLAND | 0.995 | 1.026 | 0.031 | 3.1 |
| 31143 | 99 | REST OF MASSACHUSETTS | 1.308 | 1.239 | -0.069 | -5.3 |
| 00953 | 99 | REST OF MICHIGAN | 0.848 | 0.799 | -0.049 | -5.8 |
| 00740 | 99 | REST OF MISSOURI* | 0.662 | 0.613 | -0.049 | -7.4 |
| 00523 | 99 | REST OF MISSOURI* | 0.662 | 0.613 | -0.049 | -7.4 |
| 00805 | 99 | REST OF NEW JERSEY | 1.312 | 1.256 | -0.056 | -4.3 |
| 00801 | 99 | REST OF NEW YORK | 0.875 | 0.812 | -0.063 | -7.2 |

ADDENDUM E.—REVISED 2005 OFFICE RENTAL INDEX VERSUS CURRENT OFFICE RENTAL INDEX BY 2004 FEE SCHEDULE AREA—Continued

| Carrier No. | Loc. No. | Locality name | Current rental index | Revised 2005 rental index | Difference | Percentage difference |
|---|---|---|---|---|---|---|
| 00835 | 99 | REST OF OREGON | 0.901 | 0.837 | -0.064 | -7.1 |
| 00865 | 99 | REST OF PENNSYLVANIA | 0.844 | 0.785 | -0.059 | -7.0 |
| 00900 | 99 | REST OF TEXAS | 0.795 | 0.759 | -0.036 | -4.5 |
| 00836 | 99 | REST OF WASHINGTON | 0.958 | 0.915 | -0.043 | -4.5 |
| 00870 | 01 | RHODE ISLAND | 1.098 | 0.931 | -0.167 | -15.2 |
| 31140 | 05 | SAN FRANCISCO, CA | 2.174 | 2.356 | 0.182 | 8.4 |
| 31140 | 06 | SAN MATEO, CA | 2.174 | 2.356 | 0.182 | 8.4 |
| 31140 | 09 | SANTA CLARA, CA | 1.949 | 2.416 | 0.467 | 24.0 |
| 00836 | 02 | SEATTLE (KING CNTY), WA | 1.232 | 1.234 | 0.002 | 0.2 |
| 00880 | 01 | SOUTH CAROLINA | 0.825 | 0.763 | -0.062 | -7.5 |
| 00820 | 02 | SOUTH DAKOTA | 0.853 | 0.801 | -0.052 | -6.1 |
| 31142 | 03 | SOUTHERN MAINE | 1.009 | 1.098 | 0.089 | 8.8 |
| 00952 | 15 | SUBURBAN CHICAGO, IL | 1.216 | 1.274 | 0.058 | 4.8 |
| 05440 | 35 | TENNESSEE | 0.800 | 0.748 | -0.052 | -6.5 |
| 00910 | 09 | UTAH | 0.978 | 0.950 | -0.028 | -2.9 |
| 31146 | 17 | VENTURA, CA | 1.294 | 1.484 | 0.190 | 14.7 |
| 31145 | 50 | VERMONT | 1.004 | 0.997 | -0.007 | -0.7 |
| 00973 | 50 | VIRGIN ISLANDS | 1.260 | 1.164 | -0.096 | -7.6 |
| 00904 | 00 | VIRGINIA | 0.892 | 0.933 | 0.041 | 4.6 |
| 00884 | 16 | WEST VIRGINIA | 0.685 | 0.634 | -0.051 | -7.4 |
| 00951 | 00 | WISCONSIN | 0.866 | 0.801 | -0.065 | -7.5 |
| 00825 | 21 | WYOMING | 0.799 | 0.751 | -0.048 | -6.0 |

**Note:** Revised Rental Indices Based Upon 2004 HUD FMR Data.

ADDENDUM F.—CURRENT GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY

| Carrier No. | Loc. No. | Locality name | Work GPCI | PE GPCI | MP GPCI |
|---|---|---|---|---|---|
| 00510 | 00 | ALABAMA | 1.000 | 0.870 | 0.779 |
| 00831 | 01 | ALASKA | 1.670 | 1.670 | 1.670 |
| 00832 | 00 | ARIZONA | 1.000 | 0.978 | 1.090 |
| 00520 | 13 | ARKANSAS | 1.000 | 0.847 | 0.389 |
| 31146 | 26 | ANAHEIM/SANTA ANA, CA | 1.037 | 1.184 | 0.955 |
| 31146 | 18 | LOS ANGELES, CA | 1.056 | 1.139 | 0.955 |
| 31140 | 03 | MARIN/NAPA/SOLANO, CA | 1.015 | 1.248 | 0.669 |
| 31140 | 07 | OAKLAND/BERKELEY, CA | 1.041 | 1.235 | 0.669 |
| 31140 | 05 | SAN FRANCISCO, CA | 1.068 | 1.458 | 0.669 |
| 31140 | 06 | SAN MATEO, CA | 1.048 | 1.432 | 0.663 |
| 31140 | 09 | SANTA CLARA, CA | 1.063 | 1.380 | 0.622 |
| 31146 | 17 | VENTURA, CA | 1.028 | 1.125 | 0.763 |
| 31146 | 99 | REST OF CALIFORNIA* | 1.007 | 1.034 | 0.740 |
| 31140 | 99 | REST OF CALIFORNIA* | 1.007 | 1.034 | 0.740 |
| 00824 | 01 | COLORADO | 1.000 | 0.992 | 0.821 |
| 00591 | 00 | CONNECTICUT | 1.050 | 1.156 | 0.933 |
| 00902 | 01 | DELAWARE | 1.019 | 1.035 | 0.802 |
| 00903 | 01 | DC + MD/VA SUBURBS | 1.050 | 1.166 | 0.917 |
| 00590 | 03 | FORT LAUDERDALE, FL | 1.000 | 1.018 | 1.790 |
| 00590 | 04 | MIAMI, FL | 1.015 | 1.052 | 2.399 |
| 00590 | 99 | REST OF FLORIDA | 1.000 | 0.946 | 1.268 |
| 00511 | 01 | ATLANTA, GA | 1.006 | 1.059 | 0.951 |
| 00511 | 99 | REST OF GEORGIA | 1.000 | 0.892 | 0.951 |
| 00833 | 01 | HAWAII/GUAM | 1.000 | 1.124 | 0.817 |
| 05130 | 00 | IDAHO | 1.000 | 0.881 | 0.478 |
| 00952 | 16 | CHICAGO, IL | 1.028 | 1.092 | 1.832 |
| 00952 | 12 | EAST ST. LOUIS, IL | 1.000 | 0.924 | 1.720 |
| 00952 | 15 | SUBURBAN CHICAGO, IL | 1.006 | 1.071 | 1.648 |
| 00952 | 99 | REST OF ILLINOIS | 1.000 | 0.889 | 1.175 |
| 00630 | 00 | INDIANA | 1.000 | 0.922 | 0.459 |
| 00826 | 00 | IOWA | 1.000 | 0.876 | 0.593 |
| 00650 | 00 | KANSAS* | 1.000 | 0.895 | 0.738 |
| 00740 | 04 | KANSAS* | 1.000 | 0.895 | 0.738 |
| 00660 | 00 | KENTUCKY | 1.000 | 0.866 | 0.875 |
| 00528 | 01 | NEW ORLEANS, LA | 1.000 | 0.945 | 1.240 |
| 00528 | 99 | REST OF LOUISIANA | 1.000 | 0.870 | 1.066 |
| 31142 | 03 | SOUTHERN MAINE | 1.000 | 0.999 | 0.652 |
| 31142 | 99 | REST OF MAINE | 1.000 | 0.910 | 0.652 |
| 00901 | 01 | BALTIMORE/SURR. CNTYS, MD | 1.021 | 1.038 | 0.931 |
| 00901 | 99 | REST OF MARYLAND | 1.000 | 0.972 | 0.767 |

ADDENDUM F.—CURRENT GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY—Continued

| Carrier No. | Loc. No. | Locality name | Work GPCI | PE GPCI | MP GPCI |
|---|---|---|---|---|---|
| 31143 | 01 | METROPOLITAN BOSTON | 1.041 | 1.239 | 0.803 |
| 31143 | 99 | REST OF MASSACHUSETTS | 1.010 | 1.129 | 0.803 |
| 00953 | 01 | DETROIT, MI | 1.043 | 1.038 | 2.741 |
| 00953 | 99 | REST OF MICHIGAN | 1.000 | 0.938 | 1.545 |
| 00954 | 00 | MINNESOTA | 1.000 | 0.974 | 0.431 |
| 00512 | 00 | MISSISSIPPI | 1.000 | 0.837 | 0.750 |
| 00740 | 02 | METROPOLITAN KANSAS CITY, MO | 1.000 | 0.967 | 0.896 |
| 00523 | 01 | METROPOLITAN ST. LOUIS, MO | 1.000 | 0.938 | 0.893 |
| 00740 | 99 | REST OF MISSOURI* | 1.000 | 0.825 | 0.842 |
| 00523 | 99 | REST OF MISSOURI* | 1.000 | 0.825 | 0.842 |
| 00751 | 01 | MONTANA | 1.000 | 0.876 | 0.815 |
| 00655 | 00 | NEBRASKA | 1.000 | 0.877 | 0.442 |
| 00834 | 00 | NEVADA | 1.005 | 1.039 | 1.138 |
| 31144 | 40 | NEW HAMPSHIRE | 1.000 | 1.030 | 0.883 |
| 00805 | 01 | NORTHERN NJ | 1.058 | 1.193 | 0.916 |
| 00805 | 99 | REST OF NEW JERSEY | 1.029 | 1.110 | 0.916 |
| 00521 | 05 | NEW MEXICO | 1.000 | 0.900 | 0.898 |
| 00803 | 01 | MANHATTAN, NY | 1.094 | 1.351 | 1.586 |
| 00803 | 02 | NYC SUBURBS/LONG I., NY | 1.068 | 1.251 | 1.869 |
| 00803 | 03 | POUGHKPSIE/N NYC SUBURBS, NY | 1.011 | 1.075 | 1.221 |
| 14330 | 04 | QUEENS, NY | 1.058 | 1.228 | 1.791 |
| 00801 | 99 | REST OF NEW YORK | 1.000 | 0.944 | 0.720 |
| 05535 | 00 | NORTH CAROLINA | 1.000 | 0.931 | 0.618 |
| 00820 | 01 | NORTH DAKOTA | 1.000 | 0.880 | 0.630 |
| 00883 | 00 | OHIO | 1.000 | 0.944 | 0.967 |
| 00522 | 00 | OKLAHOMA | 1.000 | 0.876 | 0.413 |
| 00835 | 01 | PORTLAND, OR | 1.000 | 1.049 | 0.438 |
| 00835 | 99 | REST OF OREGON | 1.000 | 0.933 | 0.438 |
| 00865 | 01 | METROPOLITAN PHILADELPHIA, PA | 1.023 | 1.092 | 1.400 |
| 00865 | 99 | REST OF PENNSYLVANIA | 1.000 | 0.929 | 0.790 |
| 00973 | 20 | PUERTO RICO | 1.000 | 0.712 | 0.268 |
| 00870 | 01 | RHODE ISLAND | 1.017 | 1.065 | 0.896 |
| 00880 | 01 | SOUTH CAROLINA | 1.000 | 0.904 | 0.336 |
| 00820 | 02 | SOUTH DAKOTA | 1.000 | 0.878 | 0.385 |
| 05440 | 35 | TENNESSEE | 1.000 | 0.900 | 0.612 |
| 00900 | 31 | AUSTIN, TX | 1.000 | 0.996 | 0.922 |
| 00900 | 20 | BEAUMONT, TX | 1.000 | 0.890 | 1.318 |
| 00900 | 09 | BRAZORIA, TX | 1.000 | 0.978 | 1.318 |
| 00900 | 11 | DALLAS, TX | 1.010 | 1.065 | 0.996 |
| 00900 | 28 | FORT WORTH, TX | 1.000 | 0.981 | 0.996 |
| 00900 | 15 | GALVESTON, TX | 1.000 | 0.969 | 1.318 |
| 00900 | 18 | HOUSTON, TX | 1.020 | 1.007 | 1.316 |
| 00900 | 99 | REST OF TEXAS | 1.000 | 0.880 | 1.047 |
| 00910 | 09 | UTAH | 1.000 | 0.941 | 0.653 |
| 31145 | 50 | VERMONT | 1.000 | 0.986 | 0.527 |
| 00973 | 50 | VIRGIN ISLANDS | 1.000 | 1.023 | 1.003 |
| 00904 | 00 | VIRGINIA | 1.000 | 0.938 | 0.540 |
| 00836 | 02 | SEATTLE (KING CNTY), WA | 1.005 | 1.100 | 0.803 |
| 00836 | 99 | REST OF WASHINGTON | 1.000 | 0.972 | 0.803 |
| 00884 | 16 | WEST VIRGINIA | 1.000 | 0.850 | 1.462 |
| 00951 | 00 | WISCONSIN | 1.000 | 0.929 | 0.865 |
| 00825 | 21 | WYOMING | 1.000 | 0.895 | 0.970 |

**Note:** Work GPCI is the 1/4 work GPCI required by section 1848(e)(1)(A)(iii) of the Act. 1.0 Floor on Work GPCI, 1.67 for all Alaska indices, set by MMA GPCIs are scaled by the following factors: Work= 0.9977, Practice Expense=0.9930, Malpractice Expense=1.0021.

ADDENDUM G.—PROPOSED 2005 GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY

| Carrier No. | Loc. No. | Locality name | Work GPCI | PE GPCI | MP GPCI |
|---|---|---|---|---|---|
| 00510 | 00 | ALABAMA | 1.000 | 0.860 | 0.779 |
| 00831 | 01 | ALASKA | 1.670 | 1.670 | 1.670 |
| 00832 | 00 | ARIZONA | 1.000 | 0.983 | 1.090 |
| 00520 | 13 | ARKANSAS | 1.000 | 0.841 | 0.389 |
| 31146 | 26 | ANAHEIM/SANTA ANA, CA | 1.036 | 1.203 | 0.955 |
| 31146 | 18 | LOS ANGELES, CA | 1.049 | 1.142 | 0.955 |
| 31140 | 03 | MARIN/NAPA/SOLANO, CA | 1.026 | 1.292 | 0.669 |
| 31140 | 07 | OAKLAND/BERKELEY, CA | 1.049 | 1.301 | 0.669 |
| 31140 | 05 | SAN FRANCISCO, CA | 1.066 | 1.498 | 0.669 |
| 31140 | 06 | SAN MATEO, CA | 1.062 | 1.482 | 0.663 |

ADDENDUM G.—PROPOSED 2005 GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY—Continued

| Carrier No. | Loc. No. | Locality name | Work GPCI | PE GPCI | MP GPCI |
|---|---|---|---|---|---|
| 31140 | 09 | SANTA CLARA, CA | 1.076 | 1.457 | 0.622 |
| 31146 | 17 | VENTURA, CA | 1.029 | 1.146 | 0.763 |
| 31146 | 99 | REST OF CALIFORNIA* | 1.007 | 1.039 | 0.740 |
| 31140 | 99 | REST OF CALIFORNIA* | 1.007 | 1.039 | 0.740 |
| 00824 | 01 | COLORADO | 1.000 | 1.004 | 0.821 |
| 00591 | 00 | CONNECTICUT | 1.044 | 1.161 | 0.933 |
| 00902 | 01 | DELAWARE | 1.016 | 1.027 | 0.802 |
| 00903 | 01 | DC + MD/VA SUBURBS | 1.051 | 1.202 | 0.917 |
| 00590 | 03 | FORT LAUDERDALE, FL | 1.000 | 1.005 | 1.790 |
| 00590 | 04 | MIAMI, FL | 1.007 | 1.036 | 2.399 |
| 00590 | 99 | REST OF FLORIDA | 1.000 | 0.941 | 1.268 |
| 00511 | 01 | ATLANTA, GA | 1.009 | 1.076 | 0.951 |
| 00511 | 99 | REST OF GEORGIA | 1.000 | 0.885 | 0.951 |
| 00833 | 01 | HAWAII/GUAM | 1.001 | 1.113 | 0.817 |
| 05130 | 00 | IDAHO | 1.000 | 0.874 | 0.478 |
| 00952 | 16 | CHICAGO, IL | 1.027 | 1.110 | 1.832 |
| 00952 | 12 | EAST ST. LOUIS, IL | 1.000 | 0.934 | 1.720 |
| 00952 | 15 | SUBURBAN CHICAGO, IL | 1.013 | 1.094 | 1.648 |
| 00952 | 99 | REST OF ILLINOIS | 1.000 | 0.883 | 1.175 |
| 00630 | 00 | INDIANA | 1.000 | 0.916 | 0.459 |
| 00826 | 00 | IOWA | 1.000 | 0.874 | 0.593 |
| 00650 | 00 | KANSAS* | 1.000 | 0.889 | 0.738 |
| 00740 | 04 | KANSAS* | 1.000 | 0.889 | 0.738 |
| 00660 | 00 | KENTUCKY | 1.000 | 0.862 | 0.875 |
| 00528 | 01 | NEW ORLEANS, LA | 1.000 | 0.947 | 1.240 |
| 00528 | 99 | REST OF LOUISIANA | 1.000 | 0.860 | 1.066 |
| 31142 | 03 | SOUTHERN MAINE | 1.000 | 1.006 | 0.652 |
| 31142 | 99 | REST OF MAINE | 1.000 | 0.899 | 0.652 |
| 00901 | 01 | BALTIMORE/SURR. CNTYS, MD | 1.017 | 1.054 | 0.931 |
| 00901 | 99 | REST OF MARYLAND | 1.000 | 0.974 | 0.767 |
| 31143 | 01 | METROPOLITAN BOSTON | 1.036 | 1.277 | 0.803 |
| 31143 | 99 | REST OF MASSACHUSETTS | 1.009 | 1.113 | 0.803 |
| 00953 | 01 | DETROIT, MI | 1.040 | 1.044 | 2.741 |
| 00953 | 99 | REST OF MICHIGAN | 1.000 | 0.930 | 1.545 |
| 00954 | 00 | MINNESOTA | 1.000 | 0.990 | 0.431 |
| 00512 | 00 | MISSISSIPPI | 1.000 | 0.840 | 0.750 |
| 00740 | 02 | METROPOLITAN KANSAS CITY, MO | 1.000 | 0.972 | 0.896 |
| 00523 | 01 | METROPOLITAN ST. LOUIS, MO | 1.000 | 0.949 | 0.893 |
| 00740 | 99 | REST OF MISSOURI* | 1.000 | 0.815 | 0.842 |
| 00523 | 99 | REST OF MISSOURI* | 1.000 | 0.815 | 0.842 |
| 00751 | 01 | MONTANA | 1.000 | 0.861 | 0.815 |
| 00655 | 00 | NEBRASKA | 1.000 | 0.878 | 0.442 |
| 00834 | 00 | NEVADA | 1.004 | 1.039 | 1.138 |
| 31144 | 40 | NEW HAMPSHIRE | 1.000 | 1.027 | 0.883 |
| 00805 | 01 | NORTHERN NJ | 1.058 | 1.204 | 0.916 |
| 00805 | 99 | REST OF NEW JERSEY | 1.036 | 1.114 | 0.916 |
| 00521 | 05 | NEW MEXICO | 1.000 | 0.895 | 0.898 |
| 00803 | 01 | MANHATTAN, NY | 1.080 | 1.346 | 1.586 |
| 00803 | 02 | NYC SUBURBS/LONG I., NY | 1.059 | 1.256 | 1.869 |
| 00803 | 03 | POUGHKPSIE/N NYC SUBURBS, NY | 1.012 | 1.072 | 1.221 |
| 14330 | 04 | QUEENS, NY | 1.045 | 1.210 | 1.791 |
| 00801 | 99 | REST OF NEW YORK | 1.000 | 0.934 | 0.720 |
| 05535 | 00 | NORTH CAROLINA | 1.000 | 0.928 | 0.618 |
| 00820 | 01 | NORTH DAKOTA | 1.000 | 0.871 | 0.630 |
| 00883 | 00 | OHIO | 1.000 | 0.940 | 0.967 |
| 00522 | 00 | OKLAHOMA | 1.000 | 0.867 | 0.413 |
| 00835 | 01 | PORTLAND, OR | 1.000 | 1.052 | 0.438 |
| 00835 | 99 | REST OF OREGON | 1.000 | 0.929 | 0.438 |
| 00865 | 01 | METROPOLITAN PHILADELPHIA, PA | 1.020 | 1.098 | 1.400 |
| 00865 | 99 | REST OF PENNSYLVANIA | 1.000 | 0.917 | 0.790 |
| 00973 | 20 | PUERTO RICO | 1.000 | 0.708 | 0.268 |
| 00870 | 01 | RHODE ISLAND | 1.030 | 1.028 | 0.896 |
| 00880 | 01 | SOUTH CAROLINA | 1.000 | 0.901 | 0.336 |
| 00820 | 02 | SOUTH DAKOTA | 1.000 | 0.878 | 0.385 |
| 05440 | 35 | TENNESSEE | 1.000 | 0.892 | 0.612 |
| 00900 | 31 | AUSTIN, TX | 1.000 | 1.025 | 0.922 |
| 00900 | 20 | BEAUMONT, TX | 1.000 | 0.877 | 1.318 |
| 00900 | 09 | BRAZORIA, TX | 1.008 | 0.971 | 1.318 |
| 00900 | 11 | DALLAS, TX | 1.011 | 1.064 | 0.996 |
| 00900 | 28 | FORT WORTH, TX | 1.000 | 0.985 | 0.996 |

ADDENDUM G.—PROPOSED 2005 GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY—Continued

| Carrier No. | Loc. No. | Locality name | Work GPCI | PE GPCI | MP GPCI |
|---|---|---|---|---|---|
| 00900 | 15 | GALVESTON, TX | 1.000 | 0.962 | 1.318 |
| 00900 | 18 | HOUSTON, TX | 1.020 | 1.012 | 1.316 |
| 00900 | 99 | REST OF TEXAS | 1.000 | 0.874 | 1.047 |
| 00910 | 09 | UTAH | 1.000 | 0.940 | 0.653 |
| 31145 | 50 | VERMONT | 1.000 | 0.979 | 0.527 |
| 00973 | 50 | VIRGIN ISLANDS | 1.000 | 1.008 | 1.003 |
| 00904 | 00 | VIRGINIA | 1.000 | 0.941 | 0.540 |
| 00836 | 02 | SEATTLE (KING CNTY), WA | 1.011 | 1.115 | 0.803 |
| 00836 | 99 | REST OF WASHINGTON | 1.000 | 0.975 | 0.803 |
| 00884 | 16 | WEST VIRGINIA | 1.000 | 0.836 | 1.462 |
| 00951 | 00 | WISCONSIN | 1.000 | 0.925 | 0.865 |
| 00825 | 21 | WYOMING | 1.000 | 0.875 | 0.970 |

**Note:** Work GPCI is the 1/4 work GPCI required by section 1848(e)(1)(A)(iii) of the Act. 1.0 Floor on Work GPCI, 1.67 for all Alaska indices, set by MMAMMA GPCIs are scaled by the following factors: Work= 0.9977, Practice Expense=0.9930, Malpractice Expense=1.0021.

ADDENDUM H.—PROPOSED 2006 GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY

| Carrier No. | Loc. No. | Locality name | Work GPCI | PE GPCI | MP GPCI |
|---|---|---|---|---|---|
| 00510 | 00 | ALABAMA | 1.000 | 0.850 | 0.752 |
| 00831 | 01 | ALASKA | 1.670 | 1.670 | 1.670 |
| 00832 | 00 | ARIZONA | 1.000 | 0.988 | 1.069 |
| 00520 | 13 | ARKANSAS | 1.000 | 0.835 | 0.438 |
| 31146 | 26 | ANAHEIM/SANTA ANA, CA | 1.036 | 1.223 | 0.954 |
| 31146 | 18 | LOS ANGELES, CA | 1.043 | 1.144 | 0.954 |
| 31140 | 03 | MARIN/NAPA/SOLANO, CA | 1.037 | 1.336 | 0.651 |
| 31140 | 07 | OAKLAND/BERKELEY, CA | 1.058 | 1.366 | 0.651 |
| 31140 | 05 | SAN FRANCISCO, CA | 1.064 | 1.539 | 0.651 |
| 31140 | 06 | SAN MATEO, CA | 1.076 | 1.531 | 0.639 |
| 31140 | 09 | SANTA CLARA, CA | 1.088 | 1.534 | 0.604 |
| 31146 | 17 | VENTURA, CA | 1.031 | 1.167 | 0.744 |
| 31146 | 99 | REST OF CALIFORNIA* | 1.007 | 1.044 | 0.733 |
| 31140 | 99 | REST OF CALIFORNIA* | 1.007 | 1.044 | 0.733 |
| 00824 | 01 | COLORADO | 1.000 | 1.016 | 0.803 |
| 00591 | 00 | CONNECTICUT | 1.039 | 1.167 | 0.900 |
| 00902 | 01 | DELAWARE | 1.013 | 1.020 | 0.892 |
| 00903 | 01 | DC + MD/VA SUBURBS | 1.052 | 1.238 | 0.926 |
| 00590 | 03 | FORT LAUDERDALE, FL | 1.000 | 0.992 | 1.703 |
| 00590 | 04 | MIAMI, FL | 1.000 | 1.020 | 2.269 |
| 00590 | 99 | REST OF FLORIDA | 1.000 | 0.936 | 1.272 |
| 00511 | 01 | ATLANTA, GA | 1.012 | 1.093 | 0.966 |
| 00511 | 99 | REST OF GEORGIA | 1.000 | 0.877 | 0.966 |
| 00833 | 01 | HAWAII/GUAM | 1.006 | 1.101 | 0.800 |
| 05130 | 00 | IDAHO | 1.000 | 0.868 | 0.459 |
| 00952 | 16 | CHICAGO, IL | 1.027 | 1.128 | 1.867 |
| 00952 | 12 | EAST ST. LOUIS, IL | 1.000 | 0.944 | 1.750 |
| 00952 | 15 | SUBURBAN CHICAGO, IL | 1.021 | 1.117 | 1.652 |
| 00952 | 99 | REST OF ILLINOIS | 1.000 | 0.877 | 1.193 |
| 00630 | 00 | INDIANA | 1.000 | 0.910 | 0.436 |
| 00826 | 00 | IOWA | 1.000 | 0.872 | 0.589 |
| 00650 | 00 | KANSAS* | 1.000 | 0.882 | 0.721 |
| 00740 | 04 | KANSAS* | 1.000 | 0.882 | 0.721 |
| 00660 | 00 | KENTUCKY | 1.000 | 0.858 | 0.873 |
| 00528 | 01 | NEW ORLEANS, LA | 1.000 | 0.950 | 1.197 |
| 00528 | 99 | REST OF LOUISIANA | 1.000 | 0.849 | 1.058 |
| 31142 | 03 | SOUTHERN MAINE | 1.000 | 1.013 | 0.637 |
| 31142 | 99 | REST OF MAINE | 1.000 | 0.888 | 0.637 |
| 00901 | 01 | BALTIMORE/SURR. CNTYS, MD | 1.014 | 1.070 | 0.947 |
| 00901 | 99 | REST OF MARYLAND | 1.000 | 0.977 | 0.760 |
| 31143 | 01 | METROPOLITAN BOSTON | 1.032 | 1.314 | 0.823 |
| 31143 | 99 | REST OF MASSACHUSETTS | 1.008 | 1.097 | 0.823 |
| 00953 | 01 | DETROIT, MI | 1.038 | 1.050 | 2.744 |
| 00953 | 99 | REST OF MICHIGAN | 1.000 | 0.923 | 1.518 |
| 00954 | 00 | MINNESOTA | 1.000 | 1.005 | 0.410 |
| 00512 | 00 | MISSISSIPPI | 1.000 | 0.843 | 0.722 |
| 00740 | 02 | METROPOLITAN KANSAS CITY, MO | 1.000 | 0.978 | 0.946 |
| 00523 | 01 | METROPOLITAN ST. LOUIS, MO | 1.000 | 0.961 | 0.941 |
| 00740 | 99 | REST OF MISSOURI* | 1.000 | 0.805 | 0.892 |

ADDENDUM H.—PROPOSED 2006 GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY—Continued

| Carrier No. | Loc. No. | Locality name | Work GPCI | PE GPCI | MP GPCI |
|---|---|---|---|---|---|
| 00523 | 99 | REST OF MISSOURI* | 1.000 | 0.805 | 0.892 |
| 00751 | 01 | MONTANA | 1.000 | 0.845 | 0.904 |
| 00655 | 00 | NEBRASKA | 1.000 | 0.879 | 0.454 |
| 00834 | 00 | NEVADA | 1.003 | 1.039 | 1.068 |
| 31144 | 40 | NEW HAMPSHIRE | 1.000 | 1.023 | 0.942 |
| 00805 | 01 | NORTHERN NJ | 1.059 | 1.215 | 0.973 |
| 00805 | 99 | REST OF NEW JERSEY | 1.043 | 1.117 | 0.973 |
| 00521 | 05 | NEW MEXICO | 1.000 | 0.890 | 0.895 |
| 00803 | 01 | MANHATTAN, NY | 1.067 | 1.341 | 1.504 |
| 00803 | 02 | NYC SUBURBS/LONG I., NY | 1.051 | 1.260 | 1.785 |
| 00803 | 03 | POUGHKPSIE/N NYC SUBURBS, NY | 1.013 | 1.070 | 1.167 |
| 14330 | 04 | QUEENS, NY | 1.032 | 1.192 | 1.710 |
| 00801 | 99 | REST OF NEW YORK | 1.000 | 0.923 | 0.677 |
| 05535 | 00 | NORTH CAROLINA | 1.000 | 0.926 | 0.640 |
| 00820 | 01 | NORTH DAKOTA | 1.000 | 0.862 | 0.602 |
| 00883 | 00 | OHIO | 1.000 | 0.937 | 0.976 |
| 00522 | 00 | OKLAHOMA | 1.000 | 0.858 | 0.382 |
| 00835 | 01 | PORTLAND, OR | 1.004 | 1.055 | 0.441 |
| 00835 | 99 | REST OF OREGON | 1.000 | 0.926 | 0.441 |
| 00865 | 01 | METROPOLITAN PHILADELPHIA, PA | 1.018 | 1.105 | 1.386 |
| 00865 | 99 | REST OF PENNSYLVANIA | 1.000 | 0.906 | 0.806 |
| 00973 | 20 | PUERTO RICO | 1.000 | 0.705 | 0.261 |
| 00870 | 01 | RHODE ISLAND | 1.044 | 0.992 | 0.909 |
| 00880 | 01 | SOUTH CAROLINA | 1.000 | 0.897 | 0.394 |
| 00820 | 02 | SOUTH DAKOTA | 1.000 | 0.879 | 0.365 |
| 05440 | 35 | TENNESSEE | 1.000 | 0.884 | 0.631 |
| 00900 | 31 | AUSTIN, TX | 1.000 | 1.053 | 0.986 |
| 00900 | 20 | BEAUMONT, TX | 1.000 | 0.864 | 1.298 |
| 00900 | 09 | BRAZORIA, TX | 1.025 | 0.964 | 1.298 |
| 00900 | 11 | DALLAS, TX | 1.013 | 1.063 | 1.061 |
| 00900 | 28 | FORT WORTH, TX | 1.000 | 0.989 | 1.061 |
| 00900 | 15 | GALVESTON, TX | 1.000 | 0.956 | 1.298 |
| 00900 | 18 | HOUSTON, TX | 1.020 | 1.017 | 1.297 |
| 00900 | 99 | REST OF TEXAS | 1.000 | 0.868 | 1.138 |
| 00910 | 09 | UTAH | 1.000 | 0.939 | 0.662 |
| 31145 | 50 | VERMONT | 1.000 | 0.972 | 0.514 |
| 00973 | 50 | VIRGIN ISLANDS | 1.000 | 0.993 | 1.003 |
| 00904 | 00 | VIRGINIA | 1.000 | 0.944 | 0.579 |
| 00836 | 02 | SEATTLE (KING CNTY), WA | 1.018 | 1.131 | 0.819 |
| 00836 | 99 | REST OF WASHINGTON | 1.000 | 0.979 | 0.819 |
| 00884 | 16 | WEST VIRGINIA | 1.000 | 0.822 | 1.547 |
| 00951 | 00 | WISCONSIN | 1.000 | 0.921 | 0.790 |
| 00825 | 21 | WYOMING | 1.000 | 0.856 | 0.935 |

**Note:** Work GPCI is the 1/4 work GPCI required by section 1848(e)(1)(A)(iii) of the Act. 1.0 Floor on Work GPCI, 1.67 for all Alaska indices, set by MMA GPCIs are scaled by the following factors: Work= 0.9977, Practice Expense=0.9930, Malpractice Expense=1.0021.

ADDENDUM I.—COMPARISON OF CURRENT 2004 GAFS TO PROPOSED 2005GAFS

[In descending order of difference]

| Carrier No. | Loc. No. | Locality name | Current 2004 GAF | Proposed 2005 GAF | Difference | Percent difference |
|---|---|---|---|---|---|---|
| 31140 | 09 | SANTA CLARA, CA | 1.184 | 1.225 | 0.040 | 3.41 |
| 31140 | 07 | OAKLAND/BERKELEY, CA | 1.111 | 1.144 | 0.033 | 2.96 |
| 31140 | 06 | SAN MATEO, CA | 1.201 | 1.230 | 0.029 | 2.44 |
| 31140 | 03 | MARIN/NAPA/SOLANO, CA | 1.104 | 1.128 | 0.025 | 2.25 |
| 31140 | 05 | SAN FRANCISCO, CA | 1.223 | 1.239 | 0.017 | 1.36 |
| 00903 | 01 | DC + MD/VA SUBURBS | 1.095 | 1.112 | 0.016 | 1.49 |
| 31143 | 01 | METROPOLITAN BOSTON | 1.118 | 1.132 | 0.014 | 1.24 |
| 00952 | 15 | SUBURBAN CHICAGO, IL | 1.059 | 1.073 | 0.014 | 1.31 |
| 00900 | 31 | AUSTIN, TX | 0.995 | 1.008 | 0.013 | 1.26 |
| 00836 | 02 | SEATTLE (KING CNTY), WA | 1.038 | 1.048 | 0.010 | 0.96 |
| 31146 | 17 | VENTURA, CA | 1.060 | 1.070 | 0.010 | 0.91 |
| 00511 | 01 | ATLANTA, GA | 1.027 | 1.036 | 0.009 | 0.88 |
| 31146 | 26 | ANAHEIM/SANTA ANA, CA | 1.098 | 1.106 | 0.008 | 0.72 |
| 00952 | 16 | CHICAGO, IL | 1.087 | 1.094 | 0.008 | 0.70 |
| 00954 | 00 | MINNESOTA | 0.967 | 0.974 | 0.007 | 0.70 |
| 00805 | 99 | REST OF NEW JERSEY | 1.060 | 1.065 | 0.005 | 0.50 |
| 00824 | 01 | COLORADO | 0.990 | 0.995 | 0.005 | 0.51 |

ADDENDUM I.—COMPARISON OF CURRENT 2004 GAFS TO PROPOSED 2005GAFS—Continued

[In descending order of difference]

| Carrier No. | Loc. No. | Locality name | Current 2004 GAF | Proposed 2005 GAF | Difference | Percent difference |
|---|---|---|---|---|---|---|
| 00805 | 01 | NORTHERN NJ | 1.111 | 1.116 | 0.005 | 0.45 |
| 00901 | 01 | BALTIMORE/SURR. CNTYS, MD | 1.025 | 1.030 | 0.005 | 0.48 |
| 00523 | 01 | METROPOLITAN ST. LOUIS, MO | 0.969 | 0.974 | 0.005 | 0.51 |
| 00952 | 12 | EAST ST. LOUIS, IL | 0.995 | 0.999 | 0.004 | 0.44 |
| 31142 | 03 | SOUTHERN MAINE | 0.986 | 0.989 | 0.003 | 0.31 |
| 00740 | 02 | METROPOLITAN KANSAS CITY, MO | 0.981 | 0.984 | 0.002 | 0.24 |
| 31146 | 99 | REST OF CALIFORNIA* | 1.008 | 1.011 | 0.002 | 0.22 |
| 31140 | 99 | REST OF CALIFORNIA* | 1.008 | 1.011 | 0.002 | 0.22 |
| 00900 | 18 | HOUSTON, TX | 1.026 | 1.028 | 0.002 | 0.21 |
| 00832 | 00 | ARIZONA | 0.994 | 0.996 | 0.002 | 0.20 |
| 00900 | 28 | FORT WORTH, TX | 0.992 | 0.993 | 0.002 | 0.16 |
| 00836 | 99 | REST OF WASHINGTON | 0.980 | 0.981 | 0.002 | 0.16 |
| 00512 | 00 | MISSISSIPPI | 0.919 | 0.920 | 0.002 | 0.16 |
| 00835 | 01 | PORTLAND, OR | 1.000 | 1.001 | 0.001 | 0.13 |
| 00904 | 00 | VIRGINIA | 0.955 | 0.956 | 0.001 | 0.14 |
| 00865 | 01 | METROPOLITAN PHILADELPHIA, PA | 1.067 | 1.069 | 0.001 | 0.12 |
| 00953 | 01 | DETROIT, MI | 1.106 | 1.107 | 0.001 | 0.10 |
| 00901 | 99 | REST OF MARYLAND | 0.979 | 0.980 | 0.001 | 0.11 |
| 00528 | 01 | NEW ORLEANS, LA | 0.985 | 0.986 | 0.001 | 0.10 |
| 00900 | 09 | BRAZORIA, TX | 1.003 | 1.004 | 0.001 | 0.09 |
| 00655 | 00 | NEBRASKA | 0.925 | 0.925 | 0.000 | 0.04 |
| 00900 | 11 | DALLAS, TX | 1.033 | 1.034 | 0.000 | 0.02 |
| 00831 | 01 | ALASKA | 1.670 | 1.670 | 0.000 | 0.00 |
| 00820 | 02 | SOUTH DAKOTA | 0.923 | 0.923 | 0.000 | -0.01 |
| 00910 | 09 | UTAH | 0.961 | 0.960 | 0.000 | -0.03 |
| 00834 | 00 | NEVADA | 1.025 | 1.024 | -0.001 | -0.05 |
| 00803 | 03 | POUGHKPSIE/N NYC SUBURBS, NY | 1.047 | 1.046 | -0.001 | -0.06 |
| 00591 | 00 | CONNECTICUT | 1.092 | 1.091 | -0.001 | -0.08 |
| 00826 | 00 | IOWA | 0.930 | 0.929 | -0.001 | -0.11 |
| 05535 | 00 | NORTH CAROLINA | 0.955 | 0.954 | -0.001 | -0.13 |
| 00880 | 01 | SOUTH CAROLINA | 0.932 | 0.931 | -0.001 | -0.14 |
| 31144 | 40 | NEW HAMPSHIRE | 1.009 | 1.007 | -0.001 | -0.13 |
| 00883 | 00 | OHIO | 0.974 | 0.973 | -0.002 | -0.17 |
| 00835 | 99 | REST OF OREGON | 0.949 | 0.947 | -0.002 | -0.18 |
| 00951 | 00 | WISCONSIN | 0.964 | 0.962 | -0.002 | -0.17 |
| 00973 | 20 | PUERTO RICO | 0.846 | 0.844 | -0.002 | -0.21 |
| 00660 | 00 | KENTUCKY | 0.937 | 0.935 | -0.002 | -0.20 |
| 00590 | 99 | REST OF FLORIDA | 0.987 | 0.985 | -0.002 | -0.21 |
| 00521 | 05 | NEW MEXICO | 0.952 | 0.950 | -0.002 | -0.23 |
| 31146 | 18 | LOS ANGELES, CA | 1.088 | 1.086 | -0.002 | -0.22 |
| 00630 | 00 | INDIANA | 0.945 | 0.942 | -0.003 | -0.27 |
| 00803 | 02 | NYC SUBURBS/LONG I., NY | 1.179 | 1.176 | -0.003 | -0.22 |
| 00650 | 00 | KANSAS* | 0.944 | 0.941 | -0.003 | -0.28 |
| 00740 | 04 | KANSAS* | 0.944 | 0.941 | -0.003 | -0.28 |
| 00952 | 99 | REST OF ILLINOIS | 0.958 | 0.956 | -0.003 | -0.28 |
| 00900 | 99 | REST OF TEXAS | 0.950 | 0.947 | -0.003 | -0.29 |
| 00520 | 13 | ARKANSAS | 0.910 | 0.907 | -0.003 | -0.31 |
| 00900 | 15 | GALVESTON, TX | 0.999 | 0.996 | -0.003 | -0.29 |
| 00511 | 99 | REST OF GEORGIA | 0.951 | 0.948 | -0.003 | -0.33 |
| 05130 | 00 | IDAHO | 0.928 | 0.925 | -0.003 | -0.34 |
| 31145 | 50 | VERMONT | 0.976 | 0.973 | -0.003 | -0.33 |
| 00953 | 99 | REST OF MICHIGAN | 0.994 | 0.990 | -0.003 | -0.34 |
| 05440 | 35 | TENNESSEE | 0.941 | 0.938 | -0.004 | -0.37 |
| 00820 | 01 | NORTH DAKOTA | 0.933 | 0.929 | -0.004 | -0.43 |
| 00522 | 00 | OKLAHOMA | 0.923 | 0.919 | -0.004 | -0.44 |
| 00740 | 99 | REST OF MISSOURI* | 0.917 | 0.913 | -0.004 | -0.46 |
| 00523 | 99 | REST OF MISSOURI* | 0.917 | 0.913 | -0.004 | -0.46 |
| 00801 | 99 | REST OF NEW YORK | 0.965 | 0.960 | -0.004 | -0.44 |
| 00833 | 01 | HAWAII/GUAM | 1.047 | 1.043 | -0.004 | -0.42 |
| 00510 | 00 | ALABAMA | 0.935 | 0.930 | -0.004 | -0.48 |
| 00528 | 99 | REST OF LOUISIANA | 0.946 | 0.941 | -0.004 | -0.48 |
| 31142 | 99 | REST OF MAINE | 0.947 | 0.942 | -0.005 | -0.51 |
| 00902 | 01 | DELAWARE | 1.018 | 1.013 | -0.005 | -0.49 |
| 00865 | 99 | REST OF PENNSYLVANIA | 0.961 | 0.956 | -0.005 | -0.54 |
| 00900 | 20 | BEAUMONT, TX | 0.964 | 0.959 | -0.006 | -0.59 |
| 00590 | 03 | FORT LAUDERDALE, FL | 1.038 | 1.033 | -0.006 | -0.55 |
| 00884 | 16 | WEST VIRGINIA | 0.953 | 0.946 | -0.006 | -0.66 |
| 00973 | 50 | VIRGIN ISLANDS | 1.010 | 1.004 | -0.007 | -0.65 |
| 00751 | 01 | MONTANA | 0.939 | 0.932 | -0.007 | -0.71 |
| 31143 | 99 | REST OF MASSACHUSETTS | 1.054 | 1.046 | -0.008 | -0.72 |

ADDENDUM I.—COMPARISON OF CURRENT 2004 GAFS TO PROPOSED 2005GAFS—Continued

[In descending order of difference]

| Carrier No. | Loc. No. | Locality name | Current 2004 GAF | Proposed 2005 GAF | Difference | Percent difference |
|---|---|---|---|---|---|---|
| 00825 | 21 | WYOMING | 0.953 | 0.944 | -0.009 | -0.92 |
| 00803 | 01 | MANHATTAN, NY | 1.225 | 1.216 | -0.009 | -0.75 |
| 00870 | 01 | RHODE ISLAND | 1.033 | 1.024 | -0.009 | -0.89 |
| 00590 | 04 | MIAMI, FL | 1.085 | 1.073 | -0.011 | -1.02 |
| 14330 | 04 | QUEENS, NY | 1.161 | 1.146 | -0.015 | -1.26 |

**Note:** GAFs based upon revised MEI weights as published in November 7, 2003 final rule; Work GPCI=52.466, Practice Expense GPCI=43.669, Malpractice GPCI=3.865

ADDENDUM J.—COMPARISON OF CURRENT 2004 GAFS TO PROPOSED 2006 GAFS

[in descending order of difference]

| Carrier No. | Loc. No. | Locality name | Current 2004 GAF | Proposed 2006 GAF | Difference | Percent difference |
|---|---|---|---|---|---|---|
| 31140 | 09 | SANTA CLARA, CA | 1.184 | 1.264 | 0.080 | 6.72 |
| 31140 | 07 | OAKLAND/BERKELEY, CA | 1.111 | 1.177 | 0.065 | 5.87 |
| 31140 | 06 | SAN MATEO, CA | 1.201 | 1.258 | 0.057 | 4.76 |
| 31140 | 03 | MARIN/NAPA/SOLANO, CA | 1.104 | 1.153 | 0.049 | 4.45 |
| 00903 | 01 | DC + MD/VA SUBURBS | 1.095 | 1.128 | 0.033 | 3.01 |
| 31140 | 05 | SAN FRANCISCO, CA | 1.223 | 1.255 | 0.033 | 2.68 |
| 31143 | 01 | METROPOLITAN BOSTON | 1.118 | 1.147 | 0.029 | 2.56 |
| 00952 | 15 | SUBURBAN CHICAGO, IL | 1.059 | 1.087 | 0.028 | 2.67 |
| 00900 | 31 | AUSTIN, TX | 0.995 | 1.023 | 0.027 | 2.74 |
| 00836 | 02 | SEATTLE (KING CNTY), WA | 1.038 | 1.060 | 0.021 | 2.04 |
| 31146 | 17 | VENTURA, CA | 1.060 | 1.079 | 0.019 | 1.80 |
| 00511 | 01 | ATLANTA, GA | 1.027 | 1.046 | 0.019 | 1.82 |
| 00952 | 16 | CHICAGO, IL | 1.087 | 1.104 | 0.017 | 1.54 |
| 31146 | 26 | ANAHEIM/SANTA ANA, CA | 1.098 | 1.114 | 0.017 | 1.51 |
| 00805 | 01 | NORTHERN NJ | 1.111 | 1.124 | 0.013 | 1.13 |
| 00954 | 00 | MINNESOTA | 0.967 | 0.979 | 0.013 | 1.29 |
| 00805 | 99 | REST OF NEW JERSEY | 1.060 | 1.073 | 0.012 | 1.18 |
| 00523 | 01 | METROPOLITAN ST. LOUIS, MO | 0.969 | 0.981 | 0.012 | 1.24 |
| 00901 | 01 | BALTIMORE/SURR. CNTYS, MD | 1.025 | 1.036 | 0.011 | 1.07 |
| 00952 | 12 | EAST ST. LOUIS, IL | 0.995 | 1.005 | 0.010 | 1.00 |
| 00824 | 01 | COLORADO | 0.990 | 0.999 | 0.010 | 0.97 |
| 00740 | 02 | METROPOLITAN KANSAS CITY, MO | 0.981 | 0.988 | 0.007 | 0.71 |
| 00900 | 09 | BRAZORIA, TX | 1.003 | 1.009 | 0.006 | 0.60 |
| 00900 | 28 | FORT WORTH, TX | 0.992 | 0.998 | 0.006 | 0.59 |
| 31142 | 03 | SOUTHERN MAINE | 0.986 | 0.992 | 0.006 | 0.56 |
| 00835 | 01 | PORTLAND, OR | 1.000 | 1.005 | 0.005 | 0.49 |
| 00904 | 00 | VIRGINIA | 0.955 | 0.959 | 0.004 | 0.43 |
| 31146 | 99 | REST OF CALIFORNIA* | 1.008 | 1.013 | 0.004 | 0.41 |
| 31140 | 99 | REST OF CALIFORNIA* | 1.008 | 1.013 | 0.004 | 0.41 |
| 00836 | 99 | REST OF WASHINGTON | 0.980 | 0.984 | 0.004 | 0.40 |
| 00900 | 18 | HOUSTON, TX | 1.026 | 1.029 | 0.004 | 0.35 |
| 00832 | 00 | ARIZONA | 0.994 | 0.997 | 0.003 | 0.34 |
| 00900 | 11 | DALLAS, TX | 1.033 | 1.037 | 0.003 | 0.32 |
| 00953 | 01 | DETROIT, MI | 1.106 | 1.109 | 0.003 | 0.25 |
| 00865 | 01 | METROPOLITAN PHILADELPHIA, PA | 1.067 | 1.070 | 0.003 | 0.26 |
| 00901 | 99 | REST OF MARYLAND | 0.979 | 0.981 | 0.002 | 0.22 |
| 00512 | 00 | MISSISSIPPI | 0.919 | 0.921 | 0.002 | 0.19 |
| 00655 | 00 | NEBRASKA | 0.925 | 0.926 | 0.001 | 0.13 |
| 00528 | 01 | NEW ORLEANS, LA | 0.985 | 0.986 | 0.001 | 0.07 |
| 00831 | 01 | ALASKA | 1.670 | 1.670 | 0.000 | 0.00 |
| 00910 | 09 | UTAH | 0.961 | 0.960 | 0.000 | -0.04 |
| 00820 | 02 | SOUTH DAKOTA | 0.923 | 0.923 | 0.000 | -0.05 |
| 31144 | 40 | NEW HAMPSHIRE | 1.009 | 1.008 | -0.001 | -0.08 |
| 00880 | 01 | SOUTH CAROLINA | 0.932 | 0.932 | -0.001 | -0.09 |
| 05535 | 00 | NORTH CAROLINA | 0.955 | 0.954 | -0.001 | -0.13 |
| 00900 | 99 | REST OF TEXAS | 0.950 | 0.948 | -0.002 | -0.19 |
| 00826 | 00 | IOWA | 0.930 | 0.928 | -0.002 | -0.22 |
| 00591 | 00 | CONNECTICUT | 1.092 | 1.090 | -0.002 | -0.20 |
| 00883 | 00 | OHIO | 0.974 | 0.972 | -0.003 | -0.27 |
| 00835 | 99 | REST OF OREGON | 0.949 | 0.946 | -0.003 | -0.30 |
| 00803 | 03 | POUGHKPSIE/N NYC SUBURBS, NY | 1.047 | 1.044 | -0.003 | -0.29 |
| 00973 | 20 | PUERTO RICO | 0.846 | 0.843 | -0.003 | -0.39 |
| 00520 | 13 | ARKANSAS | 0.910 | 0.906 | -0.004 | -0.39 |
| 00660 | 00 | KENTUCKY | 0.937 | 0.933 | -0.004 | -0.40 |
| 00834 | 00 | NEVADA | 1.025 | 1.021 | -0.004 | -0.36 |

ADDENDUM J.—COMPARISON OF CURRENT 2004 GAFS TO PROPOSED 2006 GAFS—Continued

[in descending order of difference]

| Carrier No. | Loc. No. | Locality name | Current 2004 GAF | Proposed 2006 GAF | Difference | Percent difference |
|---|---|---|---|---|---|---|
| 00590 | 99 | REST OF FLORIDA | 0.987 | 0.983 | -0.004 | -0.41 |
| 00521 | 05 | NEW MEXICO | 0.952 | 0.948 | -0.005 | -0.47 |
| 00952 | 99 | REST OF ILLINOIS | 0.958 | 0.954 | -0.005 | -0.48 |
| 31146 | 18 | LOS ANGELES, CA | 1.088 | 1.084 | -0.005 | -0.43 |
| 00511 | 99 | REST OF GEORGIA | 0.951 | 0.945 | -0.006 | -0.63 |
| 00630 | 00 | INDIANA | 0.945 | 0.939 | -0.006 | -0.64 |
| 00902 | 01 | DELAWARE | 1.018 | 1.011 | -0.006 | -0.61 |
| 00900 | 15 | GALVESTON, TX | 0.999 | 0.992 | -0.006 | -0.63 |
| 05440 | 35 | TENNESSEE | 0.941 | 0.935 | -0.006 | -0.67 |
| 00951 | 00 | WISCONSIN | 0.964 | 0.957 | -0.006 | -0.66 |
| 00650 | 00 | KANSAS* | 0.944 | 0.938 | -0.006 | -0.68 |
| 00740 | 04 | KANSAS* | 0.944 | 0.938 | -0.006 | -0.68 |
| 05130 | 00 | IDAHO | 0.928 | 0.921 | -0.007 | -0.70 |
| 00740 | 99 | REST OF MISSOURI* | 0.917 | 0.911 | -0.007 | -0.72 |
| 00523 | 99 | REST OF MISSOURI* | 0.917 | 0.911 | -0.007 | -0.72 |
| 31145 | 50 | VERMONT | 0.976 | 0.969 | -0.007 | -0.70 |
| 00953 | 99 | REST OF MICHIGAN | 0.994 | 0.986 | -0.007 | -0.75 |
| 00833 | 01 | HAWAII/GUAM | 1.047 | 1.040 | -0.008 | -0.74 |
| 00803 | 02 | NYC SUBURBS/LONG I., NY | 1.179 | 1.171 | -0.008 | -0.70 |
| 00820 | 01 | NORTH DAKOTA | 0.933 | 0.924 | -0.009 | -0.97 |
| 00884 | 16 | WEST VIRGINIA | 0.953 | 0.943 | -0.009 | -0.96 |
| 00522 | 00 | OKLAHOMA | 0.923 | 0.914 | -0.009 | -0.99 |
| 00865 | 99 | REST OF PENNSYLVANIA | 0.961 | 0.951 | -0.009 | -0.97 |
| 00528 | 99 | REST OF LOUISIANA | 0.946 | 0.936 | -0.010 | -1.02 |
| 00510 | 00 | ALABAMA | 0.935 | 0.925 | -0.010 | -1.06 |
| 31142 | 99 | REST OF MAINE | 0.947 | 0.937 | -0.010 | -1.07 |
| 00751 | 01 | MONTANA | 0.939 | 0.929 | -0.010 | -1.09 |
| 00801 | 99 | REST OF NEW YORK | 0.965 | 0.954 | -0.011 | -1.11 |
| 00900 | 20 | BEAUMONT, TX | 0.964 | 0.952 | -0.012 | -1.26 |
| 00973 | 50 | VIRGIN ISLANDS | 1.010 | 0.997 | -0.013 | -1.30 |
| 31143 | 99 | REST OF MASSACHUSETTS | 1.054 | 1.040 | -0.014 | -1.36 |
| 00590 | 03 | FORT LAUDERDALE, FL | 1.038 | 1.024 | -0.015 | -1.42 |
| 00870 | 01 | RHODE ISLAND | 1.033 | 1.016 | -0.017 | -1.65 |
| 00825 | 21 | WYOMING | 0.953 | 0.935 | -0.018 | -1.93 |
| 00803 | 01 | MANHATTAN, NY | 1.225 | 1.204 | -0.021 | -1.74 |
| 00590 | 04 | MIAMI, FL | 1.085 | 1.058 | -0.027 | -2.47 |
| 14330 | 04 | QUEENS, NY | 1.161 | 1.128 | -0.032 | -2.80 |

**Note:** GAFs based upon revised MEI weights as published in November 7, 2003 final rule; Work GPCI=52.466, Practice Expense GPCI=43.669, Malpractice GPCI=3.865

[FR Doc. 04–17312 Filed 7–27–04; 8:45 am]

**BILLING CODE 4120–01–P**

Federal Register

Thursday,
August 5, 2004

# Part III

# Department of the Interior

**Fish and Wildlife Service**

# Department of Commerce

**National Oceanic and Atmospheric Administration**

**50 CFR Part 402**

**Joint Counterpart Endangered Species Act Section 7 Consultation Regulations; Final Rule**

**DEPARTMENT OF THE INTERIOR**

**Fish and Wildlife Service**

**RIN 1018–AI95**

**DEPARTMENT OF COMMERCE**

**National Oceanic and Atmospheric Administration**

**RIN 0648–AQ69**

**50 CFR Part 402**

## Joint Counterpart Endangered Species Act Section 7 Consultation Regulations

**AGENCIES:** Fish and Wildlife Service, Interior; National Marine Fisheries Service, National Oceanic and Atmospheric Administration, Commerce.

**ACTION:** Final rule.

**SUMMARY:** This final rule, developed by the U.S. Department of the Interior, Fish and Wildlife Service (FWS) and the U.S. Department of Commerce, National Oceanic and Atmospheric Administration, National Marine Fisheries Service (NOAA Fisheries) (referred to jointly as ''Services'' and individually as ''Service''), after coordination with the Environmental Protection Agency (EPA) and the U.S. Department of Agriculture (USDA), codifies joint counterpart regulations for consultation under section 7 of the Endangered Species Act of 1973, as amended (16 U.S.C. 1531 *et seq.*) (ESA), for regulatory actions under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). Counterpart regulations, described in general terms in part 402, are intended to provide flexibility in the ways that a federal agency may meet its obligations under the ESA by creating alternative procedures to the section 7 consultation process described in subparts A and B of the same part. These counterpart regulations enhance the efficiency and effectiveness of the section 7 consultation process by increasing interagency cooperation and providing two optional alternatives for completing section 7 consultation for FIFRA regulatory actions. One alternative modifies the process for EPA to conduct informal consultation with the Service for those FIFRA actions that EPA determines are ''not likely to adversely affect'' any federally-protected threatened and endangered species (''listed species'') or critical habitat. The other alternative permits the Service to conduct formal consultation in a manner that more effectively takes advantage of EPA's substantial expertise in evaluating ecological effects of FIFRA regulatory actions on listed species and critical habitats.

**DATES:** This rule is effective September 7, 2004.

**ADDRESSES:** The complete file for this rule is available for inspection, by appointment, during normal business hours at the Division of Consultation, Habitat Conservation Planning, Recovery and State Grants, U.S. Fish and Wildlife Service, 4401 North Fairfax Drive, Room 420, Arlington, Virginia 22203.

**FOR FURTHER INFORMATION CONTACT:** Patrick Leonard, Chief, Division of Consultation, Habitat Conservation Planning, Recovery and State Grants, at the above address (Telephone 703/358–2171, Facsimile 703/358–1735) or Jim Lecky, Acting Senior Advisor for Intergovernmental Programs, NOAA Fisheries, 1315 East-West Highway, Silver Spring, MD 20910 (301/713–2239; facsimile 301/713–1940).

**SUPPLEMENTARY INFORMATION:** Through this final joint rulemaking, the FWS and NOAA adopt additional regulations to enhance the efficiency and effectiveness of the consultation process under section 7 of the ESA and to provide alternatives to the way EPA now consults with the Services under the ESA on regulatory actions under FIFRA involving pesticides. This Notice of Final Rulemaking, developed with assistance from EPA and the USDA, complements the Services' other consultation regulations in 50 CFR part 402. A rule providing an alternative consultation process for a specific Federal agency is called a ''counterpart regulation.'' See 50 CFR 402.04. The purpose of this rule is to improve interagency cooperation for regulatory actions under FIFRA involving pesticides, and provide optional, alternative approaches to consultation on pesticide actions that better integrate the consultation process under section 7 of the ESA with the processes for pesticide regulatory actions taken by EPA under FIFRA. By doing so, the Services expect the administration of the ESA and FIFRA will better protect threatened and endangered species and critical habitat with minimal disruption of the nation's access to products licensed under FIFRA that are necessary for the production of food and fiber and for health and disease protection. Additional supplementary information, including many of the documents mentioned in this Notice, is available on the Internet at *http://endangered.fws.gov/consultations/pesticides*.

### 1. The Endangered Species Act and Federal Agency Consultations With the Services

Congress enacted the ESA to establish a program for conservation of endangered and threatened species and the ecosystems on which they depend. 16 U.S.C. 1531(b). Section 7 of the ESA, 16 U.S.C. 1536, imposes obligations upon all Federal agencies to protect listed species or designated critical habitat. Section 7(a)(2) of the ESA, 16 U.S.C. 1536(a)(2) directs all Federal agencies, in consultation with and with the assistance of the Secretaries of the Interior and Commerce (delegated to the respective Services), to insure that any action authorized, funded, or carried out by such agency is not likely to jeopardize the continued existence of any listed species or result in the destruction or adverse modification of habitat of such species that has been designated as critical (''critical habitat''). 16 U.S.C. 1536(a)(2). In meeting this requirement, each agency is required to use the ''best scientific and commercial data available.'' 16 U.S.C. 1536(a)(2). The FWS and NOAA Fisheries are jointly responsible for administering the ESA.

The Services adopted joint consultation regulations set forth at 50 CFR part 402 (subparts A and B). These regulatory provisions require action agencies to consult with the Services on any Federal action that ''may affect'' a listed species or critical habitat. Consultation may be concluded ''informally'' if the action agency determines that the Federal action under consideration is ''not likely to adversely affect'' (NLAA) a listed species or critical habitat and the Service gives written concurrence. 50 CFR 402.13(a)(1). Such informal consultation fulfills the action agency's section 7 consultation obligation. 50 CFR 402.14(b)(1). Formal consultation, however, may always be pursued and is required if the action is likely to adversely affect a listed species or critical habitat or if the Service does not concur with an action agency's NLAA determination. During formal consultation, the action agency and Service examine the effects of the proposed action and the Service determines whether the proposed Federal action is likely to jeopardize the continued existence of any listed species or result in the destruction or adverse modification of critical habitat and whether incidental take of listed species is anticipated. 50 CFR 402.14(h), 402.14(i).

Under subparts A and B, the consultation process reviews a variety of

potential ''effects'' on listed species and habitat, including direct, indirect, and cumulative effects. ''Direct effects'' are those effects that will immediately flow from the proposed action. ''Indirect effects'' are those that will be caused by the proposed action, will occur later in time, but are still reasonably certain to occur. Additionally, examination of potential effects must also address ''interrelated'' and ''interdependent'' actions. 50 CFR 402.02. ''Cumulative effects'' are those effects of future State or private activities, not involving Federal activities, that are reasonably certain to occur within the area affected by the proposed action. 50 CFR 402.02. For a detailed explanation of these terms, refer to the Consultation Handbook jointly published by FWS and NOAA Fisheries, which further elaborates on the procedures followed by the Services when conducting section 7 consultations. *http://endangered.fws.gov/consultations/s7hndbk/s7hndbk.htm.*

At the conclusion of formal consultation, the Service will issue a biological opinion that details the effects of the action on the listed species or critical habitat, and states whether the action is likely to jeopardize the continued existence of a listed species or result in the destruction or adverse modification of critical habitat. If the Service finds an agency action is likely to cause any such effect, the biological opinion must also include reasonable and prudent alternatives, if any are available, that would avoid the effect. Where jeopardy or adverse modification of critical habitat is not likely to occur, but take of listed species is expected, the Service issues an incidental take statement that specifies reasonable and prudent measures and terms and conditions necessary to minimize incidental take. 16 U.S.C. 1536(b)(4). When the terms and conditions of the incidental take statement are followed, all incidental takings that occur are not subject to any prohibition against take that may otherwise apply. 16 U.S.C. 1538(a)(1); 1533(d). Following consultation, the action agency is responsible for implementing protections, if necessary, through its available authority.

Regulations at 50 CFR 402.04 provide that ''the consultation procedures may be superseded for a particular Federal agency by joint counterpart regulations among that agency, the Fish and Wildlife Service, and the National Marine Fisheries Service.'' The Services recognized that in certain instances, the section 7 consultation process can be improved by procedures that differ from the standard consultation process. The purpose of counterpart regulations therefore is to provide an approach that ''allow[s] individual Federal agencies to ''fine tune'' the general consultation framework to reflect their particular program responsibilities and obligations.'' 51 FR 19937 (June 3, 1986). At the same time, the preamble to the 1986 regulations for implementing section 7 of the ESA states that ''such counterpart regulations must retain the overall degree of protection afforded listed species required by the [ESA] and these regulations. Changes in the general consultation process must be designed to enhance its efficiency without elimination of ultimate Federal agency responsibility for compliance with section 7.'' Id. (quoting the preamble justification for the predecessor regulation).

**2. FIFRA and Pesticide Regulation**

FIFRA is the primary statute under which EPA regulates the use of pesticides in the United States. 7 U.S.C. 136 *et seq.* FIFRA defines a ''pesticide'' as ''* * * any substance or mixture of substances intended for preventing, destroying, repelling, or mitigating any pest. * * * FIFRA section 2(u). When a pesticide is sold or distributed, it is generally referred to as a ''pesticide product.'' Pesticides contain both ''active ingredients'' and ''inert ingredients.'' An ''active ingredient'' is ''* * * an ingredient which will prevent, destroy, repel, or mitigate any pest. ''* * * FIFRA section 2(a). Ingredients which are not active are referred to as ''inert ingredients'' or ''other ingredients.'' Under FIFRA, an ''inert ingredient'' is defined as ''an ingredient which is not active.'' FIFRA section 2(m). EPA uses the term, ''formulation,'' to refer to the particular combination of active and inert ingredients in a pesticide product. A pesticide ''use'' refers to the particular combination of circumstances under which a pesticide product may be applied, such as the rate, timing, method, and site of application.

*The statutory framework for regulation of new pesticide products.* FIFRA generally prohibits the sale or distribution of a pesticide product unless it has first been ''registered'' by EPA. FIFRA section 12(a)(1)(A). EPA issues a license, referred to as a ''registration,'' for each specific pesticide product allowed to be marketed; the registration approves sale of a product with a specific formulation, in a specific type of package, and with specific labeling limiting application to specific uses. Each product is evaluated on a case-by-case basis.

FIFRA requires a person seeking to register a pesticide to demonstrate that the proposed product meets the statutory standard. The proponent of use bears the burden of demonstrating that a pesticide meets this statutory standard. EPA may approve the unconditional registration of a pesticide product only if the agency determines, among other things, that use of the pesticide would not cause ''unreasonable adverse effects on the environment.'' FIFRA section 3(c)(5). The statute defines ''unreasonable adverse effects on the environment'' to include ''any unreasonable risk to man or the environment, taking into account the economic, social, and environmental costs and benefits of the use of any pesticide * * *.'' FIFRA section 2(bb). EPA has a broad duty under FIFRA to avoid unreasonable adverse effects on the environment generally, which includes consideration of effects to all species, whether or not federally protected.

When EPA registers a pesticide, it approves among other things a specific set of labeling for the product which contains directions for and restrictions on use of the product. Labeling includes any written or graphic material attached to the product container, *i.e.*, the label, as well as other material accompanying the product or referenced on the label. FIFRA section 2(p). FIFRA makes it unlawful for any person ''to use any registered pesticide in a manner inconsistent with its labeling.'' FIFRA section 12(a)(2)(G). Thus, directions and restrictions appearing on, or referenced in, a pesticide product label become enforceable Federal requirements subject to penalties for misuse. Under FIFRA, most States have primary responsibility for enforcement against pesticide misuse. See FIFRA section 26.

While most regulatory decisions allowing entry of new pesticide products into the marketplace are made by EPA in its FIFRA section 3 registration program, there are three other programs that can authorize the limited use of new pesticides. Under section 18 of FIFRA, EPA may allow the use of an unregistered pesticide product by a State or Federal agency when necessary to address an emergency situation. Under EPA's regulations, a petition for an exemption must establish that ''emergency conditions—defined as ''an urgent, non-routine situation that requires the use of a pesticide * * *''—exist and that no effective, currently registered pesticide or non-pesticidal pest control method is available. 40 CFR 166.4(d). The emergency exemption regulations provide that EPA will not approve a request unless EPA

determines, among other things, the use of the pesticide product will not cause unreasonable adverse effects on the environment. 40 CFR 166.25(b). In addition, under certain limited circumstances, States may approve a new use of a currently registered pesticide product to meet a ''special local need.'' FIFRA section 24(c). EPA's regulations limit States'' exercise of this authority only to the approval of products that contain active ingredients that are present in a currently approved pesticide product and give EPA broad authority to disapprove products intended for uses that are not closely related to existing uses. See 40 CFR 162.152. States must notify EPA when they exercise this authority and a State's registration shall not be effective for more than 90 days if disapproved by EPA within that period. FIFRA section 24(c)(2). Finally, EPA may issue an experimental use permit under FIFRA section 5 authorizing the limited use of an unregistered pesticide in field experiments to obtain data necessary to support an application for registration. See 40 CFR part 172.

*The statutory framework for regulation of existing pesticide products.* In addition to a registration program for new pesticide products, EPA conducts a ''reregistration'' program. Reregistration focuses on currently registered pesticides and involves a systematic reexamination of the scientific data to determine whether the pesticides continue to meet contemporary scientific and regulatory standards. See FIFRA section 4. As part of the reregistration process, EPA assesses whether there are adequate data to determine if the statutory standard is met. FIFRA gives EPA authority to require registrants to provide data if EPA ''determines [the] additional data are required to maintain in effect an existing registration of a pesticide.'' FIFRA section 3(c)(2)(B). (Imposition of such additional data requirements is subject to the provisions of the Paperwork Reduction Act, 44 U.S.C. 3501–3520). In the past, EPA has used this authority to require registrants to conduct studies that would provide additional data needed for the evaluation of potential hazards of and exposures to pesticide products. EPA uses such data to assess pesticide risks and to determine whether changes in the terms and conditions of registration would be appropriate. In many cases, EPA's reregistration review has concluded that additional risk mitigation measures were necessary to reduce potential harm to non-target plants and wildlife populations. Many registrants voluntarily have amended their products' registrations to implement these risk mitigation measures. If, however, registrants do not adopt needed risk mitigation, EPA may impose the requirements through cancellation or suspension proceedings, conducted pursuant to FIFRA section 6 and 40 CFR part 164.

EPA may issue a Notice of Intent to Cancel the registration of a pesticide if it appears at any time that the pesticide ''when used in accordance with widespread and commonly recognized practice, generally causes unreasonable adverse effects on the environment.'' FIFRA section 6(b). The registrant of a pesticide is required to submit to EPA additional factual information regarding unreasonable adverse effects. FIFRA section 6(a)(2); 40 CFR part 159. The decisions whether to approve a pesticide's entry into the marketplace and whether to retain a pesticide on the market are based on the most recent scientific information and the same standard: whether use of pesticide does not cause ''unreasonable adverse effects on the environment.'' FIFRA also contains provisions allowing EPA to ''suspend'' the registration and use of a pesticide, prior to the completion of a cancellation process, if use of the pesticide poses an ''imminent hazard.'' FIFRA section 6(c). FIFRA defines an ''imminent hazard'' as ''a situation which exists when the continued use of a pesticide during the time required for [a] cancellation proceeding would be likely to result in unreasonable adverse effects on the environment or will involve unreasonable hazard to the survival of a species declared endangered or threatened under [the Endangered Species Act].'' FIFRA section 2(1).

*EPA's approach to ecological risk assessment.* In deciding whether a pesticide product meets the statutory standards for registration or reregistration, EPA considers, among other things, the potential risks to non-target wildlife and plant species posed by use of the pesticide product. A more detailed description of EPA's approach appears in a paper titled: ''Overview of the Ecological Risk Assessment Process in the Office of Pesticide Programs, U.S. Environmental Protection Agency'' (''Overview Document'') (January 2004), and in documents referenced in that paper, all of which are part of the administrative record of this final rule. This document describes EPA's risk evaluation process which is based on the current science policy views of EPA's pesticide program, but it is not intended to be legally binding. In any decision under FIFRA, EPA may: (1) Conclude that the general approach to assessing ecological risks of a particular pesticide is inapplicable; or (2) consider factors or types of information other than those described in the Overview Document. If EPA uses a different approach to make an effects determination for a FIFRA action, EPA would provide a detailed explanation of its approach in the record for the action.

EPA's evaluation of such environmental risks follows the principles contained in its Guidelines for Ecological Risk Assessment. (EPA 1998). In 1986, EPA developed detailed guidance for the review and analysis of potential environmental risks from use of pesticide products. See Standard Evaluation Procedures (SEP) for Ecological Risk Assessment (EPA 1986). Since 1986, EPA has made many additions and refinements to the basic approach outlined in the SEP. All of EPA's risk assessment methods have included methodology for an assessment of potential risks to listed species.

EPA's approach to assessing risks of pesticides and framework for making regulatory decisions benefits from the advice of several advisory committees chartered under the Federal Advisory Committee Act (FACA). EPA routinely obtains independent, external, expert scientific peer review of its risk assessment methodologies from the FIFRA Scientific Advisory Panel (SAP). Authorized under FIFRA section 25(d), the SAP is chartered under FACA and consists of seven permanent members appointed by the EPA Administrator and additional ad hoc members who are selected to serve on panels addressing specific scientific issues to which they can contribute their expertise. The SAP provides EPA with recommendations and evaluations of data, models, and methodologies used in EPA's overall risk assessment processes that occur during registration and reregistration. Further information is available at: *http://www.epa.gov/scipoly/sap/.*

EPA also works with stakeholders in the regulated community and environmental and public health advocacy groups through two other FACA-chartered groups: the Pesticide Program Dialogue Committee (PPDC) and the Committee to Advise on Reassessment and Transition (CARAT). For further information see: *http://www.epa.gov/pesticides/ppdc/* and *http://www.epa.gov/pesticides/carat/.* These latter two advisory groups often address ways in which to make regulatory processes more reliable and efficient. All three advisory groups comply with the FACA requirements for

transparency and balanced participation.

EPA requires both new and existing pesticides to be supported by extensive information about the potential ecological risks of the pesticide product. Data requirements appear in EPA regulations at 40 CFR part 158. Laboratory studies conducted to generate data for EPA are subject to Good Laboratory Practice requirements that are designed to ensure that the results are reliable and of high quality. See 40 CFR part 160. EPA's scientists carefully review all data submissions and independently evaluate the potential risks of each pesticide. In situations raising novel or challenging scientific issues, EPA generally seeks outside peer review of its scientific assessments.

EPA requires extensive toxicity and environmental fate data and uses this information, together with field reports of adverse effects on wildlife caused by pesticides and other relevant information, to evaluate the potential hazards to non-target species, including listed species, of a pesticide intended for outdoor use. To assess potential hazard to non-target species, EPA requires a basic set of laboratory toxicity studies on an active ingredient using multiple surrogate species of birds, fish, aquatic invertebrates, non-target insects, and plants. In situations where additional, scientifically valid toxicity data related to effects on wildlife and aquatic organisms are available, EPA will consider them in establishing the toxicity endpoint for risk assessment. EPA conducts risk assessments using the toxicity endpoint from the most sensitive species tested. EPA also requires data from a series of laboratory and field studies of the environmental fate of both the active ingredients in a pesticide product and typical formulations containing the active ingredient. These studies provide data on both the parent active ingredient, as well as its environmental degradates.

EPA combines these data, along with information about how the pesticide product is intended to be used, to develop an estimate of the potential concentrations of residues of the active ingredient and significant environmental degradates in the environment (the Estimated Environmental Concentration or EEC). When estimating EEC, EPA makes conservative assumptions designed not to understate potential exposure in order to avoid the potential for underestimating risk.

When assessing risks to listed species and critical habitat, EPA evaluates data and risks in a tiered fashion. EPA compares its toxicity assessment of an active ingredient with the EEC. As part of a conservative initial risk screening, if this comparison demonstrates that the EEC is well below the amount of active ingredient that would be expected to cause harm to particular species or critical habitats, EPA concludes that the use of pesticide products containing that active ingredient would have ''no effect'' on those listed species or critical habitats. Most of EPA's focus is on the potential risks from exposure to the active ingredient and its significant environmental degradates. EPA also reviews the available information on the other ingredients in pesticide products and on the formulations themselves, to assess the potential for increased risk. If the conservative initial screening assessment indicates that a use of a pesticide may potentially affect a listed species or critical habitat, EPA conducts a more refined assessment looking at species-specific information and information about pesticide use in the area to determine whether, for example, there is spatial and temporal overlap of the pesticide use and species' habitat, such that adverse effects would appear likely.

If the initial comparison and subsequent refined assessments indicate that EPA's best estimate of the EEC for the active ingredient and/or significant environmental degradates could have toxic effects on a listed species or critical habitat, then EPA may require the pesticide applicant or registrant to supply additional laboratory and/or field data in order to refine the risk assessment, seek changes in the allowable use of the pesticide product that are sufficient to mitigate any potential risk, or request initiation of consultation with the Services. Higher tier toxicity data may include studies on the effects of a pesticide on other wildlife species and plants or studies of longer durations of exposure. The Agency may occasionally require higher tier studies to be conducted in the field under simulated or actual use conditions. EPA may also require additional information to improve its estimate of potential exposure. Possible risk mitigation measures include changes in the manner or timing of pesticide applications, the rate or frequency of applications, or geographical restrictions on use.

Between May and December 2003 inter-agency scientific teams from both Services and EPA carefully reviewed EPA's ecological risk assessment methodology, including earlier drafts of the Overview Document and the materials referenced therein. Based on this review, the Services have determined that the approach used by EPA will produce effects determinations that reliably assess the effects of pesticides on listed species and critical habitat pursuant to section 7 of the ESA and implementing regulations. The approach used by EPA addresses, where applicable, the informational and analytical requirements set forth at 50 CFR 402.14(c), relies upon the best scientific and commercial data available; and analyzes the best scientific and commercial data available by using sound, scientifically accepted practices for evaluating ecological effects. Additionally, the Services have concluded that the approach used by EPA should produce effects determinations that appropriately identify actions that are not likely to adversely effect listed species, and that are consistent with those that otherwise would be made by the Services. This approach also will produce all information necessary to initiate formal consultation where appropriate. Letter from S. Williams and W. Hogarth to Susan Hazen (January 2004).

**3. Public Law 100–478**

In 1988, Congress addressed the relationship between ESA and EPA's pesticide labeling program in section 1010 of Public Law 100–478 (October 7, 1988), which required EPA to conduct a study, and to provide Congress with a report of the results, on ways to implement EPA's endangered species pesticide labeling program in a manner that both complies with ESA and allows people to continue production of agricultural food and fiber commodities. This law provided a clear sense that Congress desires that EPA should fulfill its obligation to conserve listed species, while at the same time considering the needs of agriculture and other pesticide users. Accordingly, EPA and the Services have coordinated with USDA in developing these counterpart regulations to ensure that the consultation process is efficient and timely while remaining as protective as the existing regulations.

**4. Reasons for a Counterpart Regulation for EPA Pesticide Actions**

*Rationale for the rule as finalized.* In developing a process for conducting future ESA consultations on FIFRA pesticide regulatory actions, the Services and EPA recognized that EPA possesses, expertise and authority in the field of ecological risk assessment relative to pesticides. Under FIFRA, EPA makes decisions to allow new or continued use of a pesticide only after carefully examining extensive data on the potential risks that use of a pesticide

may pose to non-target fish, wildlife, and plant (''wildlife'') species. In addition, EPA's pesticide regulatory program may require companies to conduct studies needed for a risk assessment. As a result, EPA generally has a significant body of scientific information available with which to evaluate the hazards a pesticide may pose to non-target wildlife. Further, to perform its responsibilities under FIFRA, EPA maintains a staff of well-qualified scientists with many years of combined experience in assessing ecological risks. Finally, EPA has performed pioneering work in certain areas of ecological risk assessment, such as the development of exposure models and probabilistic risk assessment techniques.

In addition to EPA's strong scientific data bases and its expertise in the field of ecological risk assessment, EPA's decisions have characteristics that are rarely found in other section 7 consultations. Pesticide products typically are employed for multiple uses, and can potentially be used in many different parts of the country in different times of year. Thus, an ESA consultation on a pesticide registration must consider many different pesticide use patterns and determine whether wildlife species in many different locations throughout the country may be affected by such use. This broad scope of intended use of the product under review contrasts with the narrower geographical scope of most actions by Federal agencies that undergo section 7 consultation.

In addition, the number of annual pesticide decisions made by EPA was also a factor potentially affecting how best to improve the section 7 consultation process. In a typical year, EPA will make hundreds of significant decisions regarding pesticide registration. For example, in fiscal year (FY) 2003, EPA registered 31 new pesticide active ingredients; approved the addition of 334 new uses of previously registered active ingredients on over 1,500 different crops; and completed more than 6,500 more minor registration actions. EPA also completed re-registration assessments on 28 previously registered active ingredients, and processed nearly 500 emergency exemption requests in FY 2003. Numbers of actions in most of these categories have risen each year since FY 2000. The number of requests by EPA to initiate consultation on pesticide actions is expected to increase substantially in future years. The large number of consultations and their complexity is expected to require a significant level of resources, requiring careful use of resources by both EPA and the Services to effectively address issues of high biological priority and high priority to users in the most efficient manner possible. This rule is intended to make the consultation process more efficient because some FIFRA actions could be conducted pursuant to the alternative consultation procedures outlined in this rule.

These factors provided strong reasons for the Services to establish a counterpart rule for EPA FIFRA actions. New, streamlined procedures promise to be more efficient for both EPA and the Services, and potentially more protective of listed species, because they will allow EPA and the Services to focus more resources on those actions most likely to pose risk to listed species. The single greatest opportunity for efficiency in the consultation process is for the Services to take greater advantage of the extensive analysis produced by EPA in its ecological risk assessments of pesticides. Relying more heavily on the EPA's scientific work product, while at the same time assuring EPA's analysis meets the high scientific standards required by the ESA, will reduce the amount of work required from the Services in each consultation and therefore accelerate completion of consultations.

Further, those streamlined procedures are expected to enable EPA to more quickly implement any risk mitigation measures identified as necessary to protect species and critical habitat. Moreover, many of the applications submitted for registration of pesticide products containing new active ingredients involve pesticide formulations that have been developed to have less impact than the currently registered products with which they would compete. Thus, any improvements in the efficiency and effectiveness of the ESA review process that would allow EPA to make decisions more quickly, and therefore allow such new products in the market sooner, should generally benefit listed species, as well as more broadly provide benefits for human health and the environment. Finally, given the importance of maintaining the availability of pesticides for production of food and fiber, disease prevention and other purposes that are essential to the health and well-being of the American people, EPA and the Services believe that improved integration of the FIFRA registration/reregistration and section 7(a)(2) consultation processes under new counterpart regulations will be achieved in a way that avoids unnecessary burdens on pesticide users with no sacrifice to the protection of listed species.

**5. The Counterpart Regulations**

These counterpart regulations establish new methods of interagency coordination between EPA and the Services and create two new, optional, alternative approaches for EPA to fulfill its obligations to ensure that its actions under FIFRA are not likely to jeopardize the continued existence of listed species or destroy or adversely modify critical habitat. The rule offers an alternative approach when EPA determines that a FIFRA action is not likely to cause adverse effects on listed species or critical habitat, and an alternative approach to formal consultations. EPA could also elect to follow any of the existing procedures for early (§ 402.11), informal (§ 402.13), or formal consultation (§ 402.14) described in subpart B of part 402 for these actions.

*A. New Methods of Interagency Cooperation*

This counterpart rule establishes three additional methods (§§ 402.42(b), 402.43 and 402.44) of achieving the interagency cooperation that is the fundamental tenet of the section 7 consultation process. First, under § 402.43 EPA could request the Service to provide available information (or references thereto) describing the applicable environmental baseline for each species or habitat that EPA determines may be affected by a FIFRA action, and the Service would provide such information within 30 days of the request. This informational exchange would give EPA early and effective access to the Service's extensive biological database.

Second, under § 402.44 EPA may request the Service to designate a suitably-trained Service Representative (more than one Service employee may jointly serve in this capacity) to participate with EPA in the development of an ''effects determination'' for one or more of those species or habitats. The Service Representative will participate in all relevant discussions with the EPA team (in most cases in person), have access to all documentation and information used to prepare the effects determination (upon acceptance of the same confidentiality limitations applicable to EPA personnel), and have appropriate office and staff support to work effectively as part of the EPA team. The Service Representative will be expected to keep the Service informed at all times as to the progress and scope of the effects determination, and the Service may engage in additional coordination

with EPA as appropriate. In some cases, EPA may decide that it does not require the aid of a designated Service Representative, and may make an effects determination without that form of coordination.

Third, under § 402.42(b), EPA and the Services would establish new procedures for regular and timely exchanges of scientific information to achieve accurate and informed decision-making.

*B. Consultation on Actions That Are Not Likely to Adversely Affect Listed Species or Habitats*

The section 7 regulations in subpart B require an action agency to complete formal consultation with the Service on any proposed action that may affect a listed species or critical habitat, unless following either a biological assessment or informal consultation with the Service, the action agency makes a determination that the proposed action is not likely to adversely affect any listed species or critical habitat and obtains written concurrence from the Service for the NLAA determination. The alternative process contained in § 402.45 of these counterpart regulations will allow the Service to provide training, oversight, and monitoring to EPA through an alternative consultation agreement that enables EPA to make an NLAA determination for a FIFRA action without formal consultation or written concurrence from the Service. The Services recently adopted a similar approach for certain Federal actions implementing the National Fire Plan. 68 FR 68254 (December 8, 2003).

The new approach to interagency coordination between EPA and the Services is intended to be a flexible, adaptable scheme that will continually evolve and improve over time as scientific knowledge expands. For this reason, although the regulation will require the Service and EPA to have in effect an alternative consultation agreement before EPA can utilize the procedures of § 402.45, the alternative consultation agreement itself is not part of this rule, and the Services have concluded that the alternative consultation agreement will not constitute a rule subject to the notice and comment provisions of the Administrative Procedure Act, 5 U.S.C. 553. As articulated in proposed § 402.45(b), the required content of the alternative consultation agreement includes provisions and procedures to guide the Services and EPA in implementing this subsection. The alternative consultation agreement does not create or mandate standards for effects determinations; nor does it limit EPA's or the Services' discretion in developing and applying scientific methodologies. The alternative consultation agreement will be expected to undergo continuous modification and improvement. EPA and the Service will also be able to mutually agree to depart from the terms of the alternative consultation agreement in a particular case. Further, the alternative consultation agreement will not create any substantive or procedural rights or benefits that could be enforced by third parties against either the Services or EPA.

The Services believe that EPA's expertise in ecological risk assessments of pesticides, together with the safeguards built into the alternative consultation agreement, make case-by-case discussions and written concurrences in EPA's NLAA determinations unnecessary for FIFRA actions. The Services have carefully reviewed EPA's assessment methodologies and believe that when EPA follows its established approach to ecological risk assessment for pesticides EPA will correctly make determinations as to when a pesticide is or is not likely to adversely affect listed species or critical habitat. Requiring the Services to concur on a case by case basis on every NLAA determination made by EPA would unjustifiably divert much of the Services' consultation resources away from projects in greater need of consultation. The counterpart regulations will increase the Services' capability to focus on Federal actions requiring formal consultation by eliminating the requirement to provide written concurrence for actions within the scope of the counterpart regulations. EPA and the Services are committed to implementing this authority in a manner that will be equally as protective of listed species and critical habitat as the current procedures that require written concurrence from the Service.

These counterpart regulations provide an additional tool for accelerating EPA's ESA compliance activities, while providing equal or greater protection of listed species and critical habitat. Under current procedures, EPA already must complete and document a full ESA analysis to reach an NLAA determination. The counterpart regulations permit a FIFRA action to proceed following EPA's NLAA determination without an overlapping review by the Service, where the Service has provided specific training and oversight to achieve comparability between EPA's determination and the outcome of an overlapping review by the Service.

The approach outlined in these counterpart regulations is consistent with subpart B because it leaves the standards for making jeopardy and NLAA determinations unchanged. Further, when EPA operates under these counterpart regulations it will retain full responsibility for compliance with section 7 of the ESA.

Under this rule, EPA will enter into an alternative consultation agreement with either FWS, NOAA Fisheries or both. The alternative consultation agreement will include: (1) A description of the actions that EPA and the Service have taken to document the approach EPA uses to make determinations regarding the effects of its actions on listed species or critical habitat and to evaluate that approach for consistency with the ESA and applicable implementing regulations; (2) a description of the program for developing and maintaining the skills necessary within EPA to make NLAA determinations, including a jointly developed training program based on the needs of EPA; (3) provisions for incorporating new information and newly listed species or critical habitat into EPA's effects analysis on FIFRA actions; (4) processes that EPA and the Service will use to incorporate scientific advances into EPA's effects determinations; (5) a description of a mutually agreed upon program for periodic program evaluations; and (6) provisions for EPA to maintain a list of FIFRA actions for which EPA has made NLAA determinations. By following the procedures in these counterpart regulations, including the establishment of the alternative consultation agreement, EPA will fulfill its ESA section 7 consultation responsibility for actions covered under these regulations.

The purpose of the jointly developed training program between EPA and the Service is to ensure that EPA consistently interprets and applies the provisions of the ESA and the regulations (50 CFR part 402) relevant to these counterpart regulations with the expectation that EPA will reach the same conclusions as the Service. It is expected that the training program will rely upon the ESA Consultation Handbook as much as possible.

The Service will use monitoring and periodic program reviews to evaluate EPA's performance under the alternative consultation agreement at the end of the first year of implementation and then at intervals specified under the alternative consultation agreement. The Service will evaluate whether the implementation of this regulation by EPA continues to be consistent with the best scientific and commercial data

available and the ESA. The result of the periodic program review may be to recommend changes to EPA's implementation of the alternative consultation agreement. The Service will retain discretion for terminating the alternative consultation agreement if the requirements under the counterpart regulations are not met. However, any such suspension, modification, or termination will not affect the legal validity of determinations made prior to the suspension, modification, or termination.

Upon completion of an alternative consultation agreement, EPA and the Service will implement the training program outlined in the alternative consultation agreement. EPA will have full responsibility for the adequacy of its NLAA determinations since there would be no reviewable final agency action by the Service when EPA makes a NLAA determination for a FIFRA action.

The Services and EPA developed a draft of an alternative consultation agreement that addresses the topics identified in proposed § 402.45. This draft alternative consultation agreement is part of the administrative record of this rule, and was made available for the public to read to obtain a better understanding of how the Services anticipate the requirements of § 402.45 would be satisfied.

*C. New Optional Formal Consultation Process*

The counterpart regulations establish a new formal consultation process (§ 402.46) that will meet all statutory requirements and closely follow the procedural steps specified in the current subpart B process. The new process will combine the central concepts and procedures of the subpart B consultation process with innovations stemming from EPA's expertise in assessing the ecological effects of pesticide products.

The process relies on an effects determination that will be prepared by EPA according to analytical methodologies that the Services have reviewed and endorsed. The effects determination may be prepared, upon EPA's request, with the assistance of a Service Representative. While the contents of an effects determination will depend on the nature of the action, an effects determination submitted under § 402.46 or § 402.47 will contain the information described in § 402.14(c)(1)–(6) and a summary of the information on which the determination is based, detailing how the FIFRA action affects the listed species or critical habitat. EPA could also include three additional sections in an effects determination: (1) A conclusion whether or not the FIFRA action is likely to jeopardize the continued existence of any listed species or result in the destruction or adverse modification of critical habitat and a description of any reasonable and prudent alternatives that may be available; (2) a description of the impact of any anticipated incidental taking of such listed species resulting from the FIFRA action, reasonable and prudent measures considered necessary or appropriate to minimize such impact, and terms and conditions necessary to implement such measures; and (3) a summary of any information or recommendations from an applicant. An effects determination with the required information and the additional discretionary sections would contain the information currently provided by the Service in a biological opinion. All effects determinations will be based on the best scientific and commercial data available.

Once EPA has prepared an effects determination for the species and habitats that may be affected, it may initiate formal consultation on a FIFRA action under this section by delivering to the Service a written request for consultation. The written request will be accompanied by an effects determination as defined in § 402.40(b) and a list or summary of all references and data relied upon in the determination. The Service will be able on request to review any or all of the references and data relied upon in the determination as if it was in the Service's files. The time for conclusion of the consultation under section 7(b)(1) of the Act will run from the date the Service receives the written request from EPA. Any subsequent interchanges between the Service and EPA regarding the information submitted by EPA, including interchanges about the completeness of EPA's effects determination, will occur during consultation, and will not delay the initiation of consultation or extend the time for conclusion of the consultation unless EPA withdraws the request for consultation.

If EPA has prepared the effects determination without a designated Service Representative, the Service retains the discretion to determine within 45 days that additional available information would provide a better information base for the effects determination and may so notify EPA. After such a notification, EPA may revise the effects determination and resubmit it to the Service. The timing and form of EPA's resubmission are within its discretion, but the time limitations in section 7(b)(1) continue to apply. A request for additional information does not represent a finding by the Service that the effects determination was not based on the best scientific and commercial data available. Further, any requested additional information must actually be available to EPA during the specified consultation period. Where a designated Service Representative has participated in the development of the effects determination, the Service will rely upon its representative to identify all desired available information during the preparation of the determination, and this intermediate Service review during consultation is not needed. However, EPA at all times retains its duty to use the best scientific and commercial data available for its effects determinations, and the Services retain their duty to use the best scientific and commercial data available during consultation. Once an effects determination has been resubmitted following an additional information determination, the Service will proceed to conclude the consultation without further requests to EPA for additional information, although the Service may consider additional information at any time during the consultation process. If EPA advises the Service it will not resubmit a revised effects determination to the Service after the Service requests additional information, its initiation of consultation on the effects determination will be deemed withdrawn.

Within the later of 90 days after the Service receives EPA's written request for consultation or 45 days after the Service receives an effects determination resubmitted following an additional information determination by the Service, the Service will take one of three actions: (1) If the Service finds that the effects determination contains all required information and satisfies the requirements of section 7(b)(4) of the Act, and the Service concludes that the FIFRA action that is the subject of the consultation complies with section 7(a)(2) of the Act, the Service will issue a written statement adopting the effects determination; or (2) it may provide EPA a draft written statement modifying the effects determination and as modified adopting the effects determination; or (3) it may provide EPA a draft jeopardy biological opinion along with any reasonable and prudent alternatives if available. Providing these draft documents to EPA is consistent with current agency practice under other consultation procedures in Part 402. The deadlines for Service action are subject to section 7(b)(1) of the Act.

If the Service provides either the draft statement modifying the effects

determination or draft jeopardy opinion, EPA is required to make it available to any applicant upon request. The rule also accommodates EPA's existing discretion to make these draft documents available to the general public for comment within the time periods provided in this rule. The Service will on request meet with EPA and any applicant, each of which may submit written comments to the Service on the draft document within 30 days or a longer period if extended under section 7(b)(1) of the Act. The Service will issue a final biological opinion or final written statement within 45 days after EPA receives the draft opinion or statement from the Service unless the deadline is extended under section 7(b)(1) of the Act. Any such final opinion or statement will be signed by the Service Director, who may not delegate this authority beyond certain designated headquarters officials, and will constitute the opinion of the Secretary and the incidental take statement, reasonable and prudent measures, and terms and conditions under section 7(b) of the Act.

Where consultation on a FIFRA action will be unusually complex due to factors such as the geographic area or number of species that may be affected by the action, a special provision (§ 402.47) allows EPA, after conferring with the Service, to address the effects of the action through successive effects determinations addressing groupings or categories of species or habitats as established by EPA. This provision is needed because for some widely-used pesticides, delaying the initiation of consultation until adequate information is available for every species or habitat that may be affected by the pesticide may result in denying some of the most vulnerable species the benefits of the section 7 consultation process for as much as several years. Further, allowing geographic or other functional groupings of species lets EPA and the Service conduct related biological inquiries together in an efficient, coordinated manner. EPA will use this provision after conferring with the Services, and EPA and the Services intend to collaboratively identify priorities where use of this provision will most effectively address these biological goals. When successive effects determinations are prepared, EPA may initiate consultation based upon each such effects determination using the procedures in § 402.46(a). The procedure in § 402.46(b) and (c) will apply to the consultation. The written statement or opinion provided by the Service under § 402.46(c) will constitute a partial biological opinion as to the species or habitats that are the subject of the consultation. The partial biological opinion would describe the provisions relating to incidental take of such species for inclusion in an incidental take statement at the conclusion of consultation, giving users of pesticide products such as farmers and forest managers, nursery operators, and other pesticide users prompt and reliable guidance for minimizing incidental take of the species. EPA will also retain authority to use such a partial biological opinion, along with other available information, in making a finding under section 7(d) of the Act as to whether the FIFRA action constitutes an irreversible and irretrievable commitment of resources which has the effect of foreclosing the formulation or implementation of any reasonable and prudent alternative as to those species and habitats. After conclusion of all consultation on the FIFRA action, the previously-issued partial biological opinions will then collectively constitute the opinion of the Secretary and the incidental take statement, reasonable and prudent measures, and terms and conditions under section 7(b) of the Act unless a partial biological opinion were to be modified by the Service using the procedures in § 402.46(c). For pesticide products currently in use, this process will provide prompt guidance for substantial protection for vulnerable species without unduly disrupting longstanding patterns of pesticide use in agriculture, public health vector control or other important pesticide use patterns throughout the country that are vital to the health and welfare of the American people.

The Services emphasize that § 402.47 is not intended as an authorization for EPA to take actions, such as registration of pesticides containing new active ingredients or registration of new uses, without complying with the requirements of section 7(a)(2) of the Act. Rather, for certain complex FIFRA actions the provision strengthens EPA's and the Services' ability to establish the most effective sequence for completing EPA's consultation obligations through a series of focused consultations on specific species or habitats. EPA will not satisfy its procedural obligations under section 7(a)(2) of the ESA until all necessary consultations are completed. Likewise, a Service's issuance of a partial biological opinion following each such focused consultation will not represent the opinion of the Secretary or an incidental take statement under section 7(b) of the ESA until all required consultation is concluded on listed species and habitats.

The Services expect this provision may be used for FIFRA actions in a variety of circumstances. For example, after reviewing an action, EPA might identify differing levels of risk for different species, and might conclude that it would be prudent to seek Service advice on the impacts of concern through formal consultation while EPA continued to analyze the lesser risk concerns. In addition, if EPA needs to update completed consultations on pesticides by addressing impacts on more than one newly listed species, EPA might find it more efficient and effective to consider each species separately, even though a particular pesticide might impact more than one of the newly listed species. Nonetheless, EPA has advised the Services that EPA does not intend to register any new use or active ingredient until completion of consultation under section 7(a)(2) for all species affected by that action. However, like any action agency, EPA retains statutory authority to use appropriate information to make section 7(d) determinations under the ESA. In sum, the Services believe that it is advisable for the consultation process on these and other complex FIFRA actions to have flexibility, so that EPA and the Services can most efficiently and effectively protect listed species and habitats. EPA will only use the provision after conferring with the Service, which should further insure the continued effective and appropriate use of this authority.

This counterpart rule makes clear that the emergency consultation provisions in existing Service regulations are available to EPA for consultation on actions under FIFRA section 18 by providing that EPA could conduct consultation on actions involving requests for emergency exemptions under FIFRA section 18 under section 402.05 or another available consultation procedure. As provided in § 402.05, any required formal consultation on such an action will have to be initiated as soon as practicable after the emergency is under control. For the purposes of the consultation required in § 402.05(b), the definition of formal consultation in § 402.02 will include the procedures in § 402.46 in addition to those in subpart B.

The Services believe that EPA's statutory and regulatory standard for an ''emergency'' under FIFRA section 18 is generally comparable to the intended scope of emergency in § 402.05 and that, therefore, the overwhelming majority of FIFRA emergency exemption actions could properly be considered

emergencies for the purposes of § 402.05. Under EPA regulations, FIFRA section 18 emergency exemptions can only be issued for urgent, non-routine situations where a pesticide is needed to address, for example, significant risks to human health or the environment or significant economic loss. 40 CFR 166.1(a), 166.3(d). Pest problems of these dimensions will generally be encompassed within the provisions of § 402.05(a).

The Services' 1998 Joint Consultation Handbook (page 8–1) contains a passage suggesting that emergency actions under FIFRA may not usually qualify as emergencies ''unless there is a significant unexpected human health risk.'' While a significant unexpected human health risk will permit an emergency consultation under § 402.05, the quoted passage should not be read to mean that the emergency provisions in § 402.05 are available for FIFRA section 18 actions only where an unexpected human health risk is present. Such a narrow reading of the quoted passage is inconsistent with other statements in the Handbook and with past Service practice in comparable circumstances. The plain language of § 402.05 is not so limited, and can be read to encompass the kind of emergency situations that FIFRA section 18 contemplates even if no significant unexpected human health risk is present. The Services believe the use of § 402.05 by EPA for FIFRA section 18 actions under this rule will therefore be consistent with practices currently permitted under subpart B.

The counterpart rule contains other provisions to ensure full compliance with ESA requirements. After a consultation under this subpart has been concluded, EPA shall reinitiate consultation as required by § 402.16 as soon as practicable after a circumstance requiring reinitiation occurs, and may employ the procedures in this subpart or subpart B in any reinitiated consultation. EPA must comply with § 402.15 for all FIFRA actions subject to consultation under this subpart. EPA must prepare a biological assessment for FIFRA actions that constitute ''major construction activities'' to the extent required by § 402.12. The typical regulatory actions EPA takes under FIFRA (*e.g.*, registration, reregistration, section 18 approvals) do not, however, generally constitute ''major construction activities,'' and the Services are not aware of any current FIFRA activities that would meet this definition. This rule allows EPA to employ the conferencing procedures described in § 402.10 for any species proposed for listing or any habitat proposed for designation as critical habitat, and provides that for the purposes of § 402.10(d), the procedures in § 402.46 would be a permissible form of formal consultation.

**Summary of Comments Received**

On January 30, 2004, the Services proposed the rule that would establish joint counterpart regulations for consultation under section 7 of the ESA to streamline consultation on proposed actions under FIFRA. The comment period was to close on March 30, 2004 but was extended to April 16, 2004. The Services received more than 125,000 comments on the proposed rule from a large variety of entities, including States, agricultural entities, trade associations, industry, conservation groups, coalitions, and private individuals. The overwhelming majority of comments received were part of letter-writing and e-mail campaigns expressing, in a ratio of approximately 1:2, general support for or opposition to the proposal. The Services considered all of the information and recommendations received from all interested parties on the proposed regulations during the public comment period and appreciated the comments received on the proposed rule. The Services received numerous comments on the ACA, the Overview Document and other materials included in the rulemaking record that are neither part of the proposed counterpart regulations nor incorporated by reference into the regulations. Since these documents are not part of the regulations, the Services have only responded to them to the extent that the comments on these documents relate to the proposal to adopt the counterpart regulations.

The following is a summary of the comments received on the proposed counterpart regulations, and the Services' responses.

**General Comments**

*Comment:* The proposed rule should be withdrawn and the Services should instead enforce existing consultation rules.

*Response:* The Services believe that the counterpart regulations will complement the existing section 7 consultation process and therefore are promulgating the final rule.

*Comment:* The proposed counterpart regulations are an improvement over the current process and will: improve coordination of FIFRA actions and ESA evaluations; increase the speed and efficiency by which steps can be taken to protect species and/or their habitat; and improve the consistency of endangered species assessments for FIFRA-regulated products.

*Response:* The Services agree with these comments.

*Comment:* Several elements of the proposed rule were particularly impressive: clarification of the mechanisms by which the Services will get information to EPA on a timely basis; recognition that, in many cases, it is sensible for EPA to proceed with consultations on a phased basis; and confirmation that EPA retains authority to make section 7(d) decisions regarding pesticide impacts.

*Response:* The Services appreciate these comments.

*Comment:* The consultation process between the Environmental Protection Agency (EPA) and the Services should be strengthened.

*Response:* The Services agree that the section 7 consultation process with EPA should be strengthened. The intent of the rule is to enhance the efficiency and effectiveness of the consultation process through increased interagency cooperation.

*Comment:* There is no need to change the current consultation process system. In fact, there is inadequate justification for doing so. For the public to assess the need for the counterpart regulations, the document should include numbers of how many FIFRA actions resulted in ''no effect'', ''not likely to adversely affect'', and formal consultation, rather than simply how many FIFRA registrations take place. Instead of changing the rules, the Services and EPA should work to improve the existing process, and work with wildlife experts. Moreover, any efficiencies of time that might be gained are unnecessary, because the FIFRA registration process can take years and is compatible with the timeframes in section 7.

*Response:* The Services do not believe past practices are an indication of the future, and moreover it is difficult to foresee accurately how many FIFRA actions will need to undergo consultation. Nonetheless, the Services, EPA and the Department of Agriculture all agree that the number of consultations on FIFRA actions likely in coming years is so great that the Services could not complete the consultations under the existing processes and meet their other ESA duties in a timely manner with existing resources. The Services do not want to wait until the workload has already become too great before implementing the means to manage the workload more efficiently, and are taking the proactive step of adopting the counterpart regulations at this time. The Services

note that the counterpart regulations do not change the timeframes in section 7.

*Comment:* The proposed rule will favor the pesticide industry and is therefore not in the public interest.

*Response:* The Services disagree with this comment. The counterpart regulations will enable EPA and the Services to fully protect endangered species and will enable EPA to provide pesticide users the products they require to meet the needs of the American people.

*Comment:* Public Law 100–478 did more than express Congressional intent; it also established the goals of EPA's pesticide labeling program, including allowing persons to continue the production of agricultural food and fiber commodities and minimizing the impacts to persons engaged in agricultural food and fiber commodity production and other affected pesticide users and applicators.

*Response:* These counterpart regulations are intended to provide flexibility to EPA under the ESA by creating optional alternative procedures to the existing subpart B consultation process consistent with the goals of Public Law 100–478. These counterpart regulations will enhance the efficiency and effectiveness of the subpart B consultation process by increasing interagency cooperation and providing two optional alternatives for EPA's pesticide registration program. By providing EPA with more flexibility, impacts to persons engaged in agricultural food and fiber commodity production and other affected pesticide users and applicators will be minimized.

*Comment:* Pesticides are a source of risk to listed species and threaten their survival and recovery. Several commenters noted that pesticides have been found to disrupt the normal functions of immune and endocrine systems of various wildlife species, and even newer pesticides are still highly toxic. Another commenter provided the opposing view that, through EPA's registration process and voluntary withdrawals, the number of available pesticides has been greatly reduced, and the remaining pesticides are more pest-specific and less environmentally hazardous.

*Response:* The Services agree that some pesticide uses have the potential to affect listed species and critical habitat. These regulations are designed to assist EPA and the Services in evaluating these potential effects.

*Comment:* Pesticides are necessary in order to manage and control invasive plants, which otherwise degrade critical habitat and endanger susceptible species. Executive Order 13112 on Invasive Species requires all Federal agencies to identify agency action that may contribute to the spread of invasive species and to address the invasive species problem to the extent practical and consistent with their authorities and resources. Use of pesticides has reduced farms' footprints, improved soil conservation, and benefited wildlife.

*Response:* The Services agree that invasive species can be a threat to listed species, and recognize that use of pesticides can be beneficial, including the possibility of use to control invasive species. This Executive Order, however, does not relieve a federal agency from its obligations under section 7 of the ESA for its actions, including those for the purpose of controlling invasive species.

*Comment:* Pesticides should be banned in areas inhabited by listed species, except when licensed individuals are controlling invasive species that threaten native wildlife. Another commenter took an opposing position, suggesting that in certain circumstances ''for example, when a crop grows in close proximity to another crop for which pesticide use has been authorized ''a minimum level of pesticide use should be allowed without completing consultation. Yet another commenter suggested that the use of national standards for the protection of listed species frequently do not work due to the variety of special local circumstances.

*Response:* The Services consider these comments beyond the scope of the counterpart regulations, as we do not have the authority to generally ban the use of pesticides, nor do we have authority to authorize use of a pesticide. The Services note that, through the consultation process, the Services may recommend to EPA a wide range of measures to address identified effects to listed species caused by the use of pesticides, which may be tailored to local conditions.

*Comment:* Only 1 percent of pesticides reach their targets. There are other methods to promote successful agriculture that do not involve extensive pesticide use. EPA needs to give more than lip service to the identification of non-toxic alternatives.

*Response:* The Services understand that there are circumstances under which EPA considers non-toxic alternatives under FIFRA; however, the counterpart regulations will apply to EPA's consultation obligation with respect to FIFRA actions and do not address EPA's responsibilities under FIFRA. These counterpart regulations do not limit the ability of EPA to explore alternatives to the action that is subject to consultation.

*Comment:* The counterpart regulations do not provide the same overall degree of protection for listed species as the existing consultation rules in subpart B. If EPA is not required to obtain a written concurrence from the Services concerning its NLAA determinations, the Services will lose the opportunity to identify data gaps, additional studies, or mitigation measures.

*Response:* The Services disagree with this comment. The procedures authorized by these counterpart regulations will be as protective of listed species and critical habitat as the process established in subpart B. All consultations under the counterpart regulations will apply the same legal and biological standards as consultations under subpart B. The counterpart regulations merely provide an alternate process for meeting these procedural standards. The Services note that EPA would still have the option of involving the Service Representative to assist with development of effects determinations to identify data gaps, additional studies, or mitigation measures. Most important, through their review of EPA's ecological risk assessment approach, the Services have concluded the EPA's approach should produce effects determinations that appropriately identify actions that are not likely to adversely affect listed species or critical habitat, and with which the Services would likely concur.

*Comment:* The proposed counterpart regulations organize the consultation process. Such an organized process is favored over the unpredictability of litigation. Another commenter expressed the opposing point of view that reducing the Services' review of pesticide actions could increase litigation against EPA, because EPA would not enjoy the same deference to its risk assessments as the Services would receive, and therefore the FIFRA registrations may actually be delayed.

*Response:* The Services agree that a carefully structured consultation process is preferable to the unpredictability of litigation. While the Services cannot control litigation decisions made by the public, we do not believe that these counterpart regulations increase EPA's legal vulnerability under the ESA or change judicial review standards, and therefore predicted delays due to litigation would be a matter of speculation.

*Comment:* A primary purpose of the counterpart regulations must be to alleviate the threat of civil and criminal penalties under the ESA associated with

the pesticide use that has resulted from the lack of a final FIFRA endangered species program. The counterpart regulations must help ensure a timely and efficient pesticide registration process in addition to protection of listed species and their habitats.

*Response:* The proposed counterpart regulations will improve the effectiveness and efficiency of the consultation process for pesticides, which will result in more expeditious EPA determinations of NLAA and Service determinations regarding the authorization of incidental ''take'' of listed species, including any reasonable and prudent measures that are necessary or appropriate to minimize the impacts of such ''take.'' These regulations will also help ensure that registration and reregistration decisions for which ESA determinations must be made are completed in a timely manner. As a result, the counterpart regulations will improve upon EPA's ability to ensure that pesticide use directions are consistent with the requirements of the ESA and that users properly following pesticide use instructions are not at a theoretical risk of prosecution under the ESA.

*Comment:* Several commenters suggested that the provisions in § 402.45 for informal consultation on actions that are not likely to adversely affect listed species or critical habitat are not consistent with the legal requirements of the ESA. Commenters suggested that the ESA requires the Services to conduct a formal consultation on any FIFRA action: (1) That may affect a listed species (citing a 1978 congressional report on ESA amendments); or (2) that occurs in an area where a listed species is present even if there is no effect on a listed species; or (3) where EPA makes a no effect determination resulting from mitigation measures adopted by EPA. Another commenter stated the ESA requires the Service to issue a written concurrence for an action agency's not likely to adversely affect determination. A commenter also suggested that the decision in *NRDC* v. *Houston*, 146 F.3d 1118 (9th Cir. 1998) means that the ESA prohibits EPA from making NLAA determinations without consulting with the Services. Another commenter suggested that the counterpart regulations change the threshold for consultation from ''may affect'' to ''likely to adversely affect.''

*Response:* The Services disagree with these legal conclusions. The Services have concluded that the counterpart regulations do not violate the language or spirit of the ESA. The ESA does not contain an express statutory standard for determining when formal consultation under section 7 is required for a proposed agency action. The 1978 congressional report cited by the commenter in support of a ''may affect'' threshold for formal consultation addressed a draft bill that was not enacted by Congress. The ESA amendments adopted in 1978 do not contain the statutory language discussed in the congressional report. In 1986, the Services issued the subpart B regulations requiring formal consultation for an action that may affect a listed species or critical habitat, but allowing the use of alternative procedures to determine that an action is ''not likely to adversely affect'' (NLAA) listed species or critical habitat and thereby conclude the consultative process.

As stated in the 1986 regulations, § 402.01, ''Section 7(b) of the Act requires the Secretary, after the conclusion of early or formal consultation, to issue a written statement setting forth the Secretary's opinion detailing how the agency action affects listed species or critical habitat.'' However, neither informal consultation nor NLAA concurrence is specified in the ESA, and the ESA does not prescribe requirements directing how the Services should consult with federal agencies on NLAA actions. The Services have exercised their discretion through rulemaking to establish an alternate procedure for actions that are NLAA. The general informal consultation procedure in subpart B, with an individualized concurrence letter from the Services, reflects an exercise of the Services' discretion. Federal agencies and the Services have effectively employed this alternative to formal consultation several hundred thousand times over the past two decades for a myriad of diverse agency actions, and use of this alternative has been upheld in many court decisions. The counterpart regulations rely upon the fundamental structure in the subpart B regulations that created an informal consultative process for actions that are not likely to adversely affect listed species or designated critical habitat, and required formal consultation for other actions to ensure that 7(a)(2) requirements are met.

The counterpart regulations represent an alternative form of informal consultation for NLAA actions subject to § 402.45, creating a new, carefully-structured training, monitoring and oversight relationship between the Services and EPA as an alternative for the individual project-based concurrence system that was created in the subpart B regulatory framework. The counterpart regulations create a system where EPA uses a risk assessment methodology approved by the Services, engages in regular exchanges of scientific information with the Services, and its staff is trained and supervised to perform NLAA determinations just as the Services would in a concurrence letter, with less delay and equal protection for listed species and critical habitat.

The Services believe that through implementation of the ACA, and the provisions of § 402.45 for periodic review, oversight, and termination of the ACA by the Services if necessary, EPA is insuring, in consultation with and with the assistance of the Secretary, that FIFRA actions are not likely to jeopardize the continued existence of any listed species or result in the destruction or adverse modification of critical habitat. For these reasons, the Services believe that the counterpart regulations comply with the ESA.

As reflected in the record of this rulemaking, the Services have concluded that the approach to ecological risk assessment described in EPA's Overview Document is consistent with the ESA, and that this approach will produce effects determinations that reliably assess the effects of pesticides on listed species and critical habitat pursuant to section 7 of the ESA and implementing regulations (*See* Letter from S. Williams and W. Hogarth to S. Hazen, January 26, 2004). Accordingly, the Services' opinion, which has taken into account the provisions of section 7(b)(3), is that actions for which EPA makes NLAA determinations are not likely to jeopardize the continued existence of any listed species or result in the destruction or adverse modification of critical habitat. Morevoer, the Services have developed and discusses drafts of the Alternative Consultation Agreement with EPS. The Services and EPA believe that the draft ACA released to the public with the proposed counterpart regulations would, with little substantive alteration, form the basis for a future final ACA. The Services' confidence in the conclusions about the adequacy of EPA's future NLAA determinations is strengthened by the agencies consensus on the need for (and content of) detailed provisions in the ACA that will guide the implementation of § 402.45. Therefore, this alternative form of informal consultation does not require separate written concurrence for individual FIFRA actions. Interagency coordination will continue to occur on NLAA actions through the implementation of the ACA and the ongoing review and monitoring

program. The alternative form of informal consultation described in § 402.45 reflects the exercise of the Services' discretion tailored to the specific circumstances of FIFRA actions.

In any case when EPA determines that a FIFRA action may affect a listed species or critical habitat, EPA is required to follow either the provisions of these counterpart regulations, or the provisions of the existing subpart B regulations. Further, the counterpart regulations continue to require formal consultation, in the manner provided in the regulations, for FIFRA actions that are likely to adversely affect a listed species or critical habitat. Therefore, the counterpart regulations do not change the threshold for consultation, as one commenter believes.

The Services note that the court decision cited by a commenter involved consultation under subpart B where a concurrence letter from the Service is required to conclude informal consultation; the case does not interpret the ESA as creating a statutory duty for an action agency to obtain a concurrence letter from the Service on NLAA actions.

Finally, the Services note that under subpart B, neither informal nor formal consultation is required if a proposed agency action will have no effect on a listed species that is present within the action area, whether or not the ''no effect'' finding results from mitigation measures adopted by the action agency. Under subpart B, the Services do not review an action agency's finding that a proposed action will have no effect on listed species or critical habitat. The counterpart regulations carry forward the same provisions for ''no effect'' actions and are consistent with the requirements of section 7 of the ESA and the subpart B regulations.

*Comment:* Several commenters questioned the legal validity of § 402.46 and associated provisions on the ground that the section improperly delegates or transfers to EPA the Services' duty to prepare a biological opinion at the conclusion of formal consultation, or limits the Services' ability to reject an effects determination prepared by EPA for use as a biological opinion. Conversely, another commenter suggested that EPA should have the full responsibility for the adequacy of its effects determinations, and there should never be any reviewable agency action by the Services in a formal consultation on a FIFRA action, or at least the Services should have to meet a specified burden of proof to reject an EPA effects determination in a formal consultation.

*Response:* The counterpart regulations do not delegate or transfer to EPA or otherwise limit the Services' ability to fully perform any legal duty assigned by law to the Services. Section 7 of the ESA requires that formal consultation must conclude with an opinion issued by the Services based on the best scientific and commercial data available. The Services have retained full legal authority to perform this duty. The ESA does not prohibit an action agency from contributing to the biological analysis performed during consultation. The Services are taking advantage of EPA's expertise in ecological risk assessment by allowing EPA to prepare an effects determination that can serve as a biological opinion if approved by the Services. If in the judgment of the Service an effects determination does not contain the information required in a biological opinion, the Service will not consider it for use under §§ 402.46 or 402.47. The Services retain full and complete discretion to accept, modify or reject EPA's effects determinations, and the Services remain fully responsible for every biological opinion issued at the conclusion of formal consultation. While the Services expect EPA's effects determinations to be accurate, there is no requirement that the Services must automatically accept any effects determination, even if there is ''substantial evidence'' (a legal term of art) to support it; the Services must determine the adequacy and accuracy of every effects determination. The Services do not have to meet any specified burden of proof to issue a biological opinion disagreeing with an EPA effects determination. The Services believe requiring them to meet a specified burden of proof to reject an EPA determination is not consistent with their statutory responsibilities and therefore reject that approach. For clarification, the Services wish to note that the counterpart regulations as adopted do not completely follow an earlier approach suggested in the ANPR regarding automatic presumption of validity for EPA findings. For these reasons, under §§ 402.46 and 402.47, the Services' biological opinions constitute agency action by the Services as required by the ESA, although the Services agree that EPA has full responsibility for the adequacy of the effects determinations it prepares for FIFRA actions.

*Comment:* The provisions for partial consultation violate the ESA because a comprehensive biological opinion must be completed before initiation of the agency action, and this procedural requirement has substantive implications. Moreover, the provision allows EPA to use partial reviews to validate any subsequent determination that an allowed use does not violate the 7(d) restrictions.

*Response:* As noted previously, the Services emphasize that § 402.47 is not intended as an authorization for EPA to take actions, such as registration of pesticides containing new active ingredients or registration of new uses, without complying with the requirements of section 7(a)(2) of the Act. The provision does not reduce EPA's consultation duties compared to subpart B. Rather, for certain complex FIFRA actions the provision strengthens EPA's and the Services' ability to establish the most effective sequence for completing EPA's consultation obligations through a series of focused consultations on specific species or habitats. EPA will not satisfy its procedural obligations under section 7(a)(2) of the ESA until all necessary consultations are completed. Likewise, the Services' issuance of a partial biological opinion following each such focused consultation will not represent the opinion of the Secretary or operate as an incidental take statement under section 7(b) of the ESA until all required consultation is concluded on listed species and critical habitats. With regard to the possibility that EPA may use such partial biological opinions to validate a subsequent determination to proceed with an action, the Services note that, like any action agency, EPA retains statutory authority to use appropriate information to make section 7(d) determinations under the ESA.

*Comment:* The provision for successive effects determination provisions in § 402.47 violates section 7(d) of the ESA and is inconsistent with the central purpose of the ESA to preserve ecosystems upon which listed species depend.

*Response:* The Services disagree with this comment. The provisions of § 402.47 are carefully tailored to fulfill the purposes of the ESA and to comply with section 7(d), which allows the action agency, and not the Services, to determine whether an action can proceed before consultation is concluded.

*Comment:* The counterpart regulations should be expanded to address actions that would be exempt from any consultation. Not every FIFRA action will require an effects determination; the list of categorical exclusions should be incorporated as part of the ACA or the counterpart regulations.

*Response:* The Services have not accepted these suggestions. The action agency (here EPA) determines the agency actions on which it wishes to

consult and can make a no effect finding for an action without review by the Services. The ESA does not contain an express provision for categorical exclusions, a term employed under the National Environmental Policy Act. However, action agencies have the opportunity to conduct programmatic or other broad-scale reviews to identify individual actions that do not require any consultation.

*Comment:* The proposed counterpart regulations improperly transfer the primary duty to avoid jeopardy to listed species from the Services to EPA.

*Response:* The Services disagree with this comment. Under the ESA, action agencies have the independent legal duty to avoid activities that are likely to jeopardize listed species. The Services assist action agencies in meeting this duty through consultation, and will continue to do so under the new consultation procedures provided in these counterpart regulations.

*Comment:* The counterpart regulations will lessen EPA's duty or ability to avoid actions that are likely to jeopardize the continued existence of a listed species.

*Response:* The Services disagree with this comment. EPA's duty and ability to avoid jeopardy are unchanged. In fact, the Services believe EPA may be able to do a better job of avoiding jeopardy under the counterpart regulations because consultations can be completed faster and in greater numbers than may be possible under subpart B procedures.

*Comment:* EPA has failed to consult with the Services and failed to reinitiate consultation when required. Moreover, EPA has not responded appropriately to notification from the Services that certain pesticides may harm listed species. EPA has never integrated ESA compliance into its reregistration process and decisions. EPA has not fully implemented recommendations in past Biological Opinions, and has no program for protecting species from pesticides.

*Response:* While the Services are aware of these criticisms of EPA's past record of ESA compliance, the Services intend for these counterpart regulations to enable EPA to comply with the ESA more effectively in the future. These counterpart regulations do not alter EPA's substantive obligations under the ESA in the past or the future. The counterpart regulations recognize EPA's expertise in ecological risk assessment and are carefully tailored to take advantage of that expertise while providing training and meaningful oversight to ensure that EPA makes appropriate determinations. Further, the Services have reviewed EPA's ecological risk assessment process and concluded that it will appropriately integrate consideration of the effects on listed species and critical habitat into its regulatory processes under FIFRA.

*Comment:* EPA cannot be objective under FIFRA due to conflicting statutory mandates, scientific standards, and safeguards for listed species. Additionally, EPA lacks the legal authority under FIFRA to perform endangered species assessments and anyway, FIFRA legal standards of review are different than those of the ESA. Further, EPA's ties to industry are too close. EPA has displayed little independence, making it incapable of independent assessments.

*Response:* The Services disagree with this comment. The Services believe EPA is objective in its application of the risk assessment methodologies that have been endorsed by the Services. The Services have a variety of tools available to assure that EPA's effects determinations are objective and scientific and intend to use these tools to achieve that goal as necessary. The Services do not opine on the scope of legal authority of an action agency under the statutes it implements such as FIFRA or other separate legal requirements. EPA must also comply with the ESA, and the Services do not believe there is inherent conflict between the ESA and FIFRA that would prevent EPA from being able to do so.

*Comment:* It is imperative to develop an organized and scientifically defensible prioritization of previously registered products not yet consulted on. Further, EPA should give highest priority to currently registered pesticides for which EPA is actively preparing Reregistration Eligibility Decisions under FIFRA section 4 and to pesticides seeking new registration under FIFRA section 3. A number of these contain new active ingredients which would pose less environmental and public risks than the pesticide products they would replace, *e.g.*, products to replace the acutely toxic organophosphate insecticides or the fumigant, methyl bromide. A related comment stated that the rule and the ACA should either recognize EPA's existing priority-setting process for decisions concerning new registrations, or allow the agencies to develop a similar process.

*Response:* These comments are beyond the scope of the proposed rulemaking for the counterpart regulations. However, the Services note that the Services and EPA are discussing prioritization, although action agencies determine when to bring their actions to the Services.

*Comment:* EPA should be designated the lead regulatory agency in making pesticide product risk assessment and risk management determinations as they relate to the potential impact on endangered species or habitat.

*Response:* The Services agree that, within the confines of the ESA, EPA has initial responsibility for assessing impacts of pesticides to threatened and endangered species. The intent of the counterpart regulations is for the Services to take greater advantage of EPA's expertise in ecological risk assessment while continuing to exercise all duties required by the ESA.

*Comment:* Since FIFRA already provides a procedure for public input and comment, it would be duplicative to publish a **Federal Register** notice allowing input by the public in the alternative consultation process.

*Response:* The commenter has misconstrued the regulation. This regulation does not require such a notice to be published in the **Federal Register**.

*Comment:* The counterpart regulations should ensure that interagency exchanges and public disclosure of proprietary data and applicant-prepared summaries of data are consistent with section 10 of FIFRA and with EPA's information regulations at 40 CFR 2.209(c) regarding the treatment of confidential business information.

*Response:* The counerpart regulations do not alter in any respect the Government's obligations under either section 10 of FIFRA or EPA's information regulations regarding the protection of information that either may be, or has been determined to be, confidential business information. EPA regulations at 40 CFR part 2 address in detail the conditions under which such information may be shared by EPA with other government agencies, how such agencies must protect the information, and the circumstances under which such information is subject to public disclosure. Accordingly, the Services do not believe it necessary to revise the proposed rule to address this matter.

*Comment:* EPA should perform the risk assessment in the course of pesticide registration, in accordance with Service procedures. Should disagreement on the NLAA determination occur, the Services should have to carry the burden to overturn the determination and show that the EPA analysis was incorrect.

*Response:* The commenter has misconstrued the applicable procedures regarding NLAA determinations. Under these counterpart regulations EPA may make NLAA determinations without

obtaining written concurrence from the Services. The Services will conduct a review of EPA's program for making NLAA determinations in the course of their monitoring and oversight activities, for the purpose of determining whether EPA's program is based on the best scientific and commercial information available and is consistent with ESA and applicable implementing regulations.

*Comment:* If EPA and the Services are to agree on a risk assessment process that accomplishes both the goals of FIFRA registration and ESA section 7 consultation, then EPA should be able to employ the risk assessment process for both purposes with minimum oversight by the Services.

*Response:* The Services interpret this comment as an expression of support for the counterpart regulations and believe that, to the extent that the comment urges less oversight, the process and degree of oversight provided under the rule is appropriate.

*Comment:* Agencies should develop and adopt a specific plan for transitioning currently on-going consultations to the final counterpart regulations.

*Response:* Although the development of a plan is not required by the regulations, the Services recognize the appropriateness of coordinating with EPA to implement these counterpart regulations for any consultations not yet completed when these regulations take effect.

*Comment:* The Consultation Handbook should be replaced or rewritten to specifically apply to the counterpart regulations and the ACA.

*Response:* The Services will review the Consultation Handbook in order to ensure that it is consistent with the regulations.

*Comment:* The counterpart regulations do not provide enough time for thorough consultation.

*Response:* The counterpart regulations are consistent with the statutory timelines for consultation in section 7.

*Comment:* The proposed regulations do not adequately provide remedies for stakeholders in the event that action deadlines are not met during the consultation process.

*Response:* The Services are committed to meeting all deadlines imposed by the counterpart regulations and decline to provide additional enforcement remedies. However, the Services believe the new procedures will increase the timeliness of the consultation process.

*Comment:* Clarification is needed in the counterpart regulations as to how the ESA consultation process will affect EPA's ability to meet deadlines for pesticide registration and reregistration in FIFRA as established by the Pesticide Registration Improvement Act (PRIA) of 2003 and the Food Quality Protection Act (FQPA) of 1996.

*Response:* EPA has an obligation to comply with section 7(a)(2) in connection with certain pesticide regulatory actions it takes under FIFRA. The counterpart regulations do not alter that obligation nor do they alter any of EPA's obligations under FIFRA. The rule is intended, rather, to improve the effectiveness and efficiency of the consultation process. In turn, this should help ensure that EPA can, in a timely manner, make pesticide regulatory decisions for which ESA consultation is required. The counterpart regulations should, therefore, assist EPA in its efforts to meet the deadlines provided in PRIA and the FQPA.

*Comment:* Decisions on pesticide uses that have no effect or are not likely to adversely affect listed species should not be delayed until decisions have been made on uses that require formal consultation.

*Response:* Under both the existing regulations and the counterpart regulations, EPA retains the authority to identify the scope of its action, consistent with the definition of ''action'' in § 402.02. Consequently, EPA has the discretion to proceed to make decisions on certain uses determined to have no effect or to be NLAA once these determinations are made.

*Comment:* EPA's Office of Pesticide Programs (OPP) should work more closely with that agency's Office of Water.

*Response:* The Services are not in a position to direct the internal operations of EPA's offices.

*Comment:* The proposal should be expanded to include all appropriate federal agencies and activities, including, at a minimum, the U.S. Army Corps of Engineers and EPA's Offices of Wastewater Management and Wetlands, Oceans, and Watersheds. There is no need to place artificial limits on what activities may be eligible. The joint counterpart regulations should be expanded to include any federal agency that retains or develops in-house expertise on endangered or threatened species.

*Response:* The purpose of these counterpart regulations is for consultation under section 7 of the ESA for regulatory actions under FIFRA. It is beyond the scope of the counterpart regulations as proposed to include agency actions other than EPA regulatory actions under FIFRA.

*Comment:* The proposed ''no concurrence'' approach to NLAAs sets a bad precedent for other agencies and should therefore be avoided.

*Response:* These counterpart regulations are tailored to EPA's existing expertise and knowledge of pesticides regulated under FIFRA. If the Services adopt future counterpart regulations for other federal agencies, those rules would be based on each agency's capabilities and experience.

*Comment:* Separate consultation rules for FIFRA actions are warranted because such actions are fundamentally different from other federal agency actions subject to ESA section 7.

*Response:* The Services agree that counterpart regulations for FIFRA actions are warranted. Other federal agencies also consult on large and complex actions, and whether counterpart regulations would be appropriate for other agencies would be considered by the Services on a case-by-case basis.

*Comment:* It is troubling that EPA is not a cosponsor of these regulations. The final counterpart regulations should include an amendment to § 402.04 so that its first sentence reads as follows (new language italicized): ''The consultation procedures set forth * * * the National Marine Fisheries Service, *or by regulations promulgated by the Services alone in the event the action agency has concurred in that procedure*.'' The Services should also include a letter from the Administrator of EPA (or other appropriate Agency official) expressing the Agency's concurrence in the record of this proceeding.

*Response:* The proposal did not extend to subpart B, and the Services therefore decline to amend § 402.04 in this final rule. The Services note that EPA supported the development of the counterpart regulations and the Services do not believe the suggestions are legally necessary.

*Comment:* USDA should have the lead for developing processes that support an approach to determining pesticide exposure mitigation methods. Also, USDA should be included in some official capacity during consultation, to ensure knowledge of actual land management practices.

*Response:* EPA is the lead action agency; however, the Services have been assured that EPA will continue to collaborate with USDA as well as the Services in developing appropriate and necessary mitigation measures, and obtaining knowledge of land management practices.

*Comment:* EPA and the Services must coordinate with other offices and

agencies beyond USDA, as appropriate, when dealing with antimicrobials.

*Response:* The Services will endeavor to coordinate with other offices as appropriate.

*EPA's Ecological Risk Assessment Process*

A series of general comments stated the Services should not adopt the proposed rule because it is based on EPA's flawed approach to ecological risk assessment and EPA lacks expertise in key areas of ecological risk assessment.

*Comment:* It is necessary for the sake of consistency to include, either in the counterpart regulations or in the Overview Document, clearly described work flows of the screening-level risk assessment process.

*Response:* The Services disagree that the counterpart regulations must describe the details of the screening-level risk assessment process. The Services do not believe that a description of the workflow within the Overview Document is necessary to analyze the adequacy of the ecological risk assessment process.

*Comment:* EPA's approach generally is not adequate for identifying and quantifying the effects of pesticides, because it is not rigorous and not consistent with the current state of scientific knowledge. Because of these shortcomings, EPA will probably mistakenly determine that a pesticide either had no effect or was not likely to adversely affect listed species.

*Response:* The Services disagree that EPA does not have an adequate ecological risk assessment methodology. After an extensive and intensive review of EPA's approach to assessing the risks of pesticides to listed species and critical habitat, the Services concluded that EPA's approach ''will produce effects determinations that reliably assess the effects of pesticides on * * * listed species and critical habitat pursuant to section 7 of the ESA and implementing regulations.'' See Letter from Steve Williams, Director, FWS, and William Hogarth, Assistant Administrator, NMFS, to Susan B. Hazen, Principal Deputy Assistant Administrator, EPA, dated January 26, 2004 (Letter of January 26, 2004).

More specifically, in the Services' expert judgment, the approach used by EPA is rigorous; it is carefully described in the ''Overview of the Ecological Risk Assessment Process in the Office of Pesticide Programs, U.S. Environmental Protection Agency—Endangered and Threatened Species Effects Determinations'' January 23, 2004 (Overview Document) and the 81 support documents cited therein. In addition, EPA's risk assessments for individual chemicals are thoroughly documented, with the result that it is possible to identify the methodology used in each case.

The Services have also concluded that ''the approach used by OPP should produce effects determinations * * * that are consistent with those that otherwise would be made by the Services.'' Letter of January 26, 2004. This conclusion rests on the breadth of types of data that EPA will review and the manner in which EPA will analyze the data. EPA routinely requires a pesticide company to submit a substantial body of data in support of an application for registration. EPA will supplement this required database with information obtained through a systematic search of the open literature on the ecotoxicity of environmental substances. As recounted in detail in the Letter of January 26, 2004, EPA will examine this body of information for all of the types of potential impacts that an agency is required to consider under the ESA. Reliance on these sources of information is consistent with and should fulfill the statutory mandate to ''use the best scientific and commercial information available.''

The Services also disagree that EPA's approach to ecological risk assessment is inconsistent with current science. EPA's pesticide program routinely draws on the latest results from its Office of Research & Development (ORD) and other researchers in the fields of ecotoxicology and environmental fate assessment through participation in national and international professional, scientific conferences and symposia. EPA also works closely with the FIFRA Scientific Advisory Panel (SAP) to obtain expert, independent, external scientific peer review on every aspect of its approach to ecological risk assessment, as well as on specific pesticide assessments. See *http://www.epa.gov/scipoly/sap/* As a consequence of this active exchange of ideas and expertise with scientific leaders, EPA regularly makes changes to improve its methodologies to reflect current science.

*Comment:* Claims that EPA's risk assessment process is sufficient given the role played by the SAP are misplaced. As demonstrated in recent actions involving atrazine, EPA has demonstrated a willingness to ignore SAP conclusions.

*Response:* The Services appreciate the value that may be gained by EPA's use of the SAP as an independent peer review. However, the Services' conclusion about the adequacy of EPA's approach to ecological risk assessments is based on our independent review of the approach identified in the Overview Document, of which SAP review is only one part. Ultimately, this conclusion does not rely upon how EPA may have responded to any particular recommendation from the SAP.

*Comment:* An independent scientific panel with no ties to industry should be convened to review all pesticide registrations and only peer-reviewed data should be used in determinations.

*Response:* The Services note that although the ESA does not require the use of an outside scientific review panel, it is at EPA's discretion to do so during pesticide registration if it so chooses. The Services also note that limiting information considered to only peer reviewed data is contrary to the statutory requirement of the ESA which requires the use of the ''best scientific and commercial data available.''

*Comment:* EPA's approach to ecological risk assessment is deficient because it fails to identify up front, even generally, which listed species could potentially be affected by a particular pesticide, and thereby limits the effectiveness of its review by failing to account for species-specific and habitat-specific information in its assumptions, tests, and models. An additional comment suggested the need for more involvement at the field and regional level to capture such information.

*Response:* Based on the Services' review of the Overview Document, during its initial screen EPA will assess possible toxic effects on all species, including listed species, using the best scientific and commercial data available for this purpose. If EPA determines that any listed or non-listed species may be harmed by a pesticide, EPA will obtain and consider the best available information concerning species-specific and habitat-specific information to determine the extent of those effects on listed species. EPA will do so with the assistance of appropriate field and regional involvement of the Services. The Services believe this is a sound approach to analyze all potential risks to listed species, and disagree that this limits the effectiveness of EPA's review.

*Comment:* EPA fails to apply the precautionary principle to its regulation of pesticides. EPA assumes no risk to listed species when EPA lacks data. EPA should begin its assessment with the assumption the pesticide will harm listed species and require evidence to the contrary before allowing the chemical's use. Whenever EPA has a data gap, it should require registrants to provide the information necessary to fill that gap.

*Response:* The Services believe that EPA's ecological risk assessment approach is appropriately cautious in assessing the effects of pesticides to listed species. EPA will use the best scientific and commercial information available to assess risks and will consider all potential risks in light of that information.

More specifically, the assertion that EPA assumes no risk to listed species when EPA lacks data misconstrues EPA's approach in the absence of data. As explained in the Overview Document, EPA has identified a base set of information about a pesticide it considers sufficient to permit an evaluation of the potential risks posed by the pesticide, and has committed to supplement those data with information obtained from the public literature. The types of data required will vary depending on the use pattern of the product and chemical-specific characteristics of the pesticide. EPA requires these data to support the registration of a pesticide, and, unless the data are waived, EPA typically would not approve the use of a pesticide without the required data. If data beyond the base set are considered necessary, EPA will require the applicant to provide those data. The agency will use its best scientific judgments, on a case-by-case basis, and as discussed in detail in the Overview Document, EPA may employ assumptions to account for any uncertainty due to missing data, and many steps within EPA's approach use conservative assumptions.

The ESA does not require Federal agencies to eliminate all forms of uncertainty in assessing impacts to listed species or critical habitat, which would be a practical impossibility. Instead, the ESA requires that decisions be based on the best scientific and commercial data available. The Services agree that such decisions need to be made on a case-by-case basis, using best professional judgment that takes into account all of the available relevant information. The Services have discussed with EPA the need to document in a transparent manner how it addresses data gaps and how it employs assumptions to deal with the resulting uncertainty. The Services are satisfied that EPA's approach to this general subject, as described in the Overview Document, will result in appropriate assessments of the potential risks to listed species and critical habitat.

*Comment:* EPA's approach to ecological risk assessment is flawed because EPA relies on information supplied by registrants which is therefore biased, and also because EPA does not use the peer-reviewed public literature appropriately. EPA does not have a standard process for locating and obtaining data from the open literature and therefore fails to locate a significant percentage of the available literature. The commenter noted two instances in which EPA had failed either to locate or to use a published study that, the commenter believed, was relevant to the risk assessment for a pesticide.

*Response:* The Services devoted a considerable amount of attention to the manner in which EPA obtains information on which it bases its effects determination, including data from the open literature (including from both peer-reviewed and non-peer-reviewed sources). EPA is required to base its determinations on the best scientific and commercial data available. Therefore, to the extent that the information supplied by the registrant may be the best scientific and commercial data available, EPA is required to consider the information. As part of the discussions, EPA has committed to conducting literature searches using ECOTOX as part of its ecological risk assessments for pesticides. The ECOTOX database is a comprehensive system, maintained by EPA's ORD, that provides information on chemical effects on ecological species. The publicly available component of ECOTOX is widely used by other Federal, State, tribal and local government agencies (including the Services), international governmental agencies, the regulated community, the wider scientific research community and the public. As discussed in the Overview Document and the Letter of January 26, 2004, EPA's literature search will capture both studies in the publicly available component of ECOTOX and other studies that either have not yet been completely processed and entered into ECOTOX or were considered and rejected as inappropriate for inclusion in the public, web-based component.

Experience to date comparing the results of these broader ECOTOX searches conducted according to the Overview Document with other search strategies suggests that ECOTOX is at least as successful, if not more so, at locating relevant scientific information. Moreover, contrary to the comment, these comparisons indicate that ECOTOX does not fail to identify a significant portion of the relevant literature.

Finally, the Services do not find persuasive the comment stating that EPA did not consider a relevant study from the public literature. Whether or not that is accurate, it does not undermine the Services' conclusion, in the future, that EPA will use an acceptable approach to assessing ecological risks of pesticides. The Services note that EPA has committed to explaining in its risk assessments any decisions not to use a study obtained from the open literature or other source. Thus, if EPA obtains a study published in a scientific journal but decides not to make it part of the risk assessment database, the decision will be fully documented, and both the Services and the public would be able to evaluate the adequacy of EPA's justification. The Services believe this process will ensure that EPA handles studies from the open literature appropriately.

*Comment:* EPA excludes information generated using methodologies that do not conform exactly to the EPA's overly strict ''Good Laboratory Practices'' (GLP) guidelines.

*Response:* The comment mischaracterizes EPA's approach to the use of data from the public literature. As stated in the Overview Document, data from the open literature can be used in developing the risk assessment. Since such information is typically not collected using the EPA's GLP guidelines, it is normally considered ''supplemental information,'' meaning that a registrant usually could not satisfy its responsibilities to fulfill EPA's data requirements using such data, but that EPA could and would still use such data as appropriate in the risk assessment.

*Comment:* EPA relies inappropriately on ''surrogate species'' in its risk assessment. EPA typically has insufficient information about risks because the agency usually lacks testing using important classes of animals—namely amphibians, reptiles, marine mammals, and freshwater mussels—and, despite this limitation, EPA does not include any uncertainty factor to account for the possible variation in sensitivity across species which can be three orders of magnitude.

*Response:* The Services carefully examined EPA's use of toxicity data from tests with surrogate species. EPA's Overview Document identifies the approximately two dozen different animal and plant species that an applicant or registrant (commonly a pesticide company) is required to study in the standard battery of eco-toxicity tests on a pesticide. The commenters are correct that such species do not include any amphibian, reptilian, or fresh water mussel species. As discussed above, EPA will review the open literature, and it is possible that studies from that source may contain information on the toxicity of a pesticide to additional

species. EPA will use its best scientific judgment to choose the most appropriate surrogate for a listed species from all of the available data. Even with this extensive database, however, risk assessments necessarily must be based on testing with a finite number of species. When a species has not been tested, the data on surrogate species constitutes the best available scientific and commercial information to analyze the toxicological sensitivity of untested species.

Further, EPA has agreed to discuss in its risk assessments the uncertainties associated with use of surrogate species. EPA also committed to work with the Services to develop methods to increase the level of confidence in future assessments.

Finally, although not employed expressly to address uncertainties in relying on surrogate species, the Services note that throughout its risk assessment methodology EPA deliberately uses conservative assumptions that add in a measure of additional protections.

*Comment:* EPA's approach to ecological risk assessment ignores the potential for pesticides to cause adverse, non-fatal, ''sublethal'' effects on non-target plants and wildlife. In particular, the studies required by EPA are incapable of measuring effects on reproductive systems, immune systems, endocrine systems, and genetic integrity. In addition, one commenter argued that EPA would not consider data showing atrazine caused adverse effects on the sexual development of frogs.

*Response:* The Services disagree; as explained in EPA's Overview Document, the set of eco-toxicity studies required to support the registration of a pesticide include numerous sublethal endpoints, including the impact of the test substance on reproductive function, as well as endpoints related to body weight, body length, gross pathological effects, and behavioral abnormalities. In addition, EPA has committed to augment its required studies with any information obtained from the open literature, and to use such data on sublethal effects to the extent that sufficient and reliable information establishes a scientifically sound relationship between the effect and the survival or reproductive capacity of an organism. The Services have deemed appropriate the existing sublethal endpoints that are included by OPP in its risk assessment process, and the manner in which they are used for purposes of assessing potential sublethal effects.

In response to the comment concerning EPA's willingness to consider sublethal effects from atrazine, the Services note that, contrary to the comment, EPA has conducted its own review and subsequently has obtained an independent, external peer review of data on atrazine and sexual development of frogs. See SAP meeting on June 17–20, 2003, at *http://www.epa.gov/oscpmont/sap/2003/index.htm*. This series of reviews has led EPA to require the registrants of atrazine to perform additional studies to evaluate these possible effects.

*Comment:* EPA does not perform a substantial analysis of indirect effects of a pesticide on listed species. EPA had not documented its conclusion that exposure to pesticide concentrations less than ½ the LC50 would not cause effects on non-listed species that could indirectly affect a listed species dependent on that non-listed species. Moreover, EPA incorrectly assumes that where a pesticide has no direct effects on listed species, there is no potential for indirect effects.

*Response:* Although EPA may not have routinely and fully examined the potential indirect effects of a pesticide on listed species and critical habitat in the past, EPA has committed in its Overview Document to the systematic consideration of such indirect effects. The Services will, on request, provide EPA with information on listed species that will assist EPA in identifying the relevant biological and ecological relationships through which indirect effects might occur.

The commenter also misunderstands the approach to assessing indirect effects. The commenter apparently assumes that the direct-effects screening assessment considers only listed species. A conclusion that no indirect effects on a listed species would occur is based on the fact that indirect effects may only occur when some species—listed or nonlisted—other than the listed species is directly affected. The direct-effects screening assessment considers the full range of plant and animal species. If no species on which a listed species depends is directly affected, then the listed species would not be indirectly affected.

Contrary to the comment, EPA has explained in the Overview Document its approach to the use of different thresholds for listed and non-listed species. The Services are satisfied that the approach EPA intends to use in the future will produce an appropriate assessment of potential indirect effects.

*Comment:* EPA's approach to assessing impacts to critical habitat is inappropriate, because it assumes that if a pesticide will not have a direct effect on the listed species, then it will not affect the habitat. Moreover, this approach is faulty because it only considers the biological elements of the habitat, and does not take into account the negative impacts of pesticide contamination that would make an area unsuitable.

*Response:* The commenter misunderstands the approach to assessing risks to critical habitat. EPA uses the same approach to assessing the effects of a pesticide on critical habitat as it uses to assess direct effects on listed species. The difference, however, is that EPA looks at the effects on the principle constituent elements of the critical habitat—those elements of the habitat on which a listed species depends—rather than on the listed species itself. The Services disagree that a pesticide will have negative impacts without affecting any biological element of the habitat. Pesticides do not automatically have an effect simply as a consequence of their presence; rather, the presence of a pesticide in a portion of the habitat constitutes harm to habitat only to the extent it may negatively affect some biological component of that habitat, which is what EPA assesses.

*Comment:* Cumulative stressors and impacts to endangered and threatened species will no longer be fully addressed.

*Response:* The ecological risk assessment process as described in the Overview Document commits EPA to consider the environmental baseline when appropriate. As part of the environmental baseline, cumulative stressors and impacts to listed species will be considered.

*Comment:* EPA does not evaluate the potential effects of exposure either to inert ingredients in pesticide formulations or to substances formed by the environmental degradation of pesticides.

*Response:* The comments are incorrect. EPA's Overview Document describes the extensive information required to characterize the environmental fate of a pesticide, including the identification of any toxicologically significant degradation products/metabolites. In addition, absent information supporting a different conclusion, EPA assumes that any substance formed by the breakdown of a pesticide is as toxic as its parent compound. Although limited, EPA also receives information from pesticide applicants and registrants about individual inert ingredients in pesticide formulations. The ECOTOX literature search also captures information on mixtures containing pesticide active

ingredients. EPA has committed to review these data as part of its ecological risk assessments. Finally, the Overview Document spells out how EPA will use the data it obtains on the toxicity of pesticide formulations.

The Services recognize that more extensive information is typically available about pesticide active ingredients than inert ingredients, and therefore EPA has a more limited ability to assess the risks posed by these compounds to listed species. In light of these limitations, the Services have concluded that EPA's approach makes appropriate use of the best scientific and commercial information available to evaluate these types of substances.

*Comment:* Active ingredients are typically formulated with other, sometimes more toxic ''inert'' substances to make pesticide products and such products are then often mixed with adjuvants. EPA's risk assessment process fails to consider the effects of pesticide mixtures on endangered and threatened species. EPA does not assess the potential additive or synergistic effects of exposure to the combination of these substances. Such combinations are important because water monitoring data demonstrate the presence of multiple chemicals in many water samples and that many of the substances appearing in combination share a common mechanism of toxicity.

*Response:* While there often is very little or no information, EPA has committed to review the open literature for information on whether a pesticide formulation or other chemical mixture will be active in an additive, synergistic or antagonistic manner. If EPA identifies data demonstrating interactive effects, it will use the data in its ecological risk assessments to the extent possible. The Services believe this approach is scientifically appropriate and consistent with the ESA. The Services recognize, however, that this approach still leaves some scientific uncertainty about whether pesticides and other chemicals will interact to produce more serious effects than expected from exposure to individual compounds. There is no scientific consensus on how to address this source of uncertainty. Therefore the Services also think it is appropriate that EPA has committed to the identification of major sources of uncertainty in its risk assessments.

*Comment:* EPA does not appropriately consider cumulative effects as required under the ESA. Under the Federal Food, Drug, and Cosmetic Act (FFDCA), EPA is required to assess cumulative effects for food use pesticides and other substances sharing a common mechanism of toxicity.

*Response:* EPA's Overview Document contains a commitment to conduct a review of cumulative effects, as defined under the ESA, on those FIFRA actions for which EPA cannot conclude that the action is not likely to adversely affect listed species or critical habitat. Since the nature of any cumulative assessment will depend on the scope of the action being considered, the Services think that EPA has appropriately expressed an intention to evaluate such effects on a case-by-case basis. The Services and EPA intend to work together to ensure that an adequate evaluation of the cumulative effects is performed for an action.

The Services note that the meaning of the term, ''cumulative effects,'' under the ESA is very different from the way that term is used under the FFDCA. Under ESA, cumulative effects refers to the effects on listed species and critical habitat of future State and private activities reasonably certain to occur within the action area of the federal action subject to consultation. Under the FFDCA, EPA must consider the cumulative effects on humans that may result from exposure to the pesticide chemical and other substances sharing a common mechanism of toxicity. Thus, the two meanings are quite distinct, and the FFDCA use of the term should not be applied to assessments under the ESA.

*Comment:* The ''levels of concern'' (LOCs) used as criteria by EPA to determine whether potential pesticide exposure would pose a risk to a listed species are insufficiently explained and, at least in the case of diazinon, insufficiently protective. In particular, EPA has not justified its use of the 0.1 and 0.05 LOCs for endangered terrestrial and aquatic species, respectively, with acute toxicity values.

*Response:* As explained in detail in the Overview Document, EPA compares the estimated environmental concentrations expected to result from use of a pesticide with toxicity values observed in required studies and studies from the open literature. If the resulting ratio is less than the LOC, EPA concludes, under the ESA, that the exposure has ''no effect.'' The agency sets different LOCs for different taxa (birds and mammals vs. fish and other organisms), and durations of exposure (short term/acute vs. longer term/chronic).

EPA's Overview Document explains the scientific basis for regarding these LOCs as protective. In the case of the LOC of 0.1 for acute toxicity, this value means that for a pesticide with a typical toxicity profile (slope of the dose-response curve of 4.5) the estimated probability of mortality resulting from exposure to one tenth the value of the median lethal dose (LC50) is approximately 1/300,000. The Overview Document also contains estimates of the probability of mortality for the 0.05 LOC and for other values for the slope of the dose-response curve. The Services are satisfied both with this explanation and with the agency's conclusion that there would be no effect when the ratio of exposure to toxicity is at or below the established LOCs.

*Comment:* EPA does not estimate pesticide concentrations in surface water.

*Response:* The Services disagree; as EPA's Overview Document and other public comments make clear, EPA does develop estimates of pesticide concentrations in surface water.

*Comment:* The models EPA uses to estimate pesticide levels in water are likely to underestimate exposure because EPA uses inappropriately low model inputs.

*Response:* In the vast majority of cases, the estimates produced from EPA's models equal or exceed the amount of pesticide residue actually present in surface water. While there may be individual model inputs that do not correspond to the highest imaginable value that could be used, EPA's information indicates that the particular combination of central tendency input values and high end input values (many of which are not mentioned by the commenters) produces an estimate of the concentration of a pesticide in water that is likely substantially greater than occurs under real world conditions in most locations where a pesticide is used.

*Comment:* The input value for pesticide use is not sufficiently conservative because EPA considers only a single pesticide application, when in reality multiple applications may be allowed.

*Response:* This comment is incorrect; as described in the Overview Document, EPA's model assumes the maximum number of applications specified on the pesticide label.

*Comment:* EPA assumes homogenous distribution of pesticide residues, and this will understate residues when there is not complete and uniform mixing of residues in the waterbody. In particular, EPA's models do not account for pesticide residues that settle on surface water films of dust or particulate matter, remain in the water, or settle into sediment.

*Response:* EPA's model accounts for pesticide residue that drifts onto the pond, but it assumes homogenous

mixing of such residue throughout the water body. As described in the Overview Document, there are no scientific models currently capable of reflecting variability in short-term concentrations in different parts of the pond. Thus, the Services regard EPA's approach to reflect the use of the best scientific and commercial information available.

*Comment:* Listed species may be present in ponds smaller than the 10 hectare value used by EPA.

*Response:* The comment's description of the pond size used in EPA's model is incorrect. As described in the Overview Document, EPA's model assumes a very small pond (1 hectare surface area and 2 meters deep), receiving runoff from a 10 hectare field.

*Comment:* EPA assumes that runoff results from a single runoff event, when in reality runoff may occur following multiple runoff events.

*Response:* This comment is correct with respect to the initial tier model used by EPA, GENEEC. The basic GENEEC model calculates potential runoff following a single rainfall event, using a conservative assumption about total rainfall (6″ in 24 hours). If GENEEC suggests water concentrations that could pose concerns, EPA then employs a more sophisticated model, PRZM/EXAMS, which considers up to 30 years of recorded meteorological data, to place the receiving water body in a landscape receiving multiple rainfall events over the duration of the meteorological record. It is true that the PRZM/EXAMS model considers each rainfall as a single continuous event for each day that the available meteorological data has a record for a precipitation event.

*Comment:* EPA assumes no contribution from post-application volatilization, when in reality such volatilization may contribute significantly to residues in the receiving waterbody.

*Response:* The Services disagree with this comment. As the Overview Document states, losses from volatilization post-application in the field are typically taken into account.

*Comment:* EPA incorrectly assumes spray drift will contribute no more than 1% through ground application and 5% through aerial application, when data demonstrate spray drift accounts for higher loadings in some circumstances. A related comment stated that EPA's existing model estimates drift from aerial applications based on older technologies. EPA and the Services should take into account new technologies and procedures used by aerial applicators.

*Response:* EPA has committed to examining (and changing if appropriate) its spray drift assumption as part of the risk characterization component of a risk assessment. As described in the Overview Document, the values assumed by EPA tend to overstate exposure in the vast majority of situations, especially when the water body is not immediately adjacent to the treated field, as the model assumes. When appropriate data show the model overestimates drift, for example because new technologies reduce drift, or underestimates drift, EPA will adjust its exposure estimates appropriately.

*Comment:* EPA's model does not estimate runoff from urban use, and its models do not account for nonagricultural use. Moreover, EPA lacks data on the extent of use of pesticides in urban areas and therefore cannot develop accurate estimates of environmental exposure from such use.

*Response:* No adequate models currently exist that are specific to estimation of pesticide runoff from urban use, nor that are specific to some nonagricultural uses. Moreover, there is rarely accurate and complete information on the amounts of pesticides used in urban areas. In the absence of such data and models, EPA considers surface water monitoring results in the risk assessment process for urban use pesticides. If such surface water modeling data, when linked to surrounding land use information, suggest that existing modeling efforts may underestimate surface water loads in urban landscapes, the issue would be discussed in the risk characterization section of a risk assessment. This discussion would be accompanied by an analysis of how such data affects the agency's confidence in risk assessment conclusions. The Services think that this approach is consistent with the use of the best scientific and commercial data available to EPA.

*Comment:* EPA assessments are based on laboratory data and modeling, and EPA often ignores monitoring data or other studies that do not accord with its findings.

*Response:* The Services disagree. As described in the Overview Document, EPA routinely reviews information from monitoring programs and compares the results with its model estimates of environmental concentrations. Because many factors affect the usefulness of monitoring data, EPA decides on a case-by-case basis whether and how to use such information. Most commonly, EPA uses such data to help characterize the risk assessment by providing information about levels in water that reflect different use conditions and different locations from those modeled. If the monitoring data show higher confirmed detections than estimated by modeling, the higher monitoring values may be used in the risk assessment or the input values to the model may be reevaluated. EPA has committed to document fully the basis for its estimates of aquatic pesticide concentrations. The Services think that this approach is consistent with the use of the best scientific and commercial data available to EPA.

*Comment:* Some of the background documents regarding EPA's risk assessment process developed by both EPA and the Services for the proposed counterpart regulations are inconsistent with the Information Quality Act (IQA) and EPA's IQA guidelines and quality systems—particularly with regard to EPA's biased use of modeling projections over monitoring data. This commenter noted, however, that the proposed regulatory provisions are statutorily authorized, rational and should be promulgated as soon as possible.

*Response:* The Services agree, as this commenter noted, that the issues raised regarding the IQA do not suggest the need for modification to the provisions of the proposed rule. This commenter did not suggest that the IQA issues raised reflect upon EPA's ability to ensure that its NLAA determinations are accurate. The Services disagree, however, with this commenter's characterization that EPA's approach is biased against the use of monitoring data. As explained in both the Overview Document and the Services' review of that document, although EPA's experience is that monitoring data are seldom sufficiently robust for risk assessment purposes given the limited range of pesticide use scenarios they represent, EPA's practice is to use monitoring data to estimate exposure when such data are relevant, quantifiable and reliable.

*Comment:* EPA's ecological risk assessment methodology ignores potentially significant exposures through the dermal and inhalation routes. For example, terrestrial species could inhale pesticide spray or residues that have volatilized. The comments cited data to support the contention that air concentrations of pesticides are significant. Similarly, pesticide sprays could drift off-target and be deposited onto the fur or feathers of non-target organisms.

*Response:* The Services agree that EPA's approach to ecological risk assessment generally does not quantify the potential dermal and inhalation exposure of non-target wildlife. As EPA

has discussed in its Overview Document, current analysis of terrestrial species focuses exclusively on dietary exposure or expresses exposures as a generalized potentially available biomass of pesticide on a per unit area basis. The Services agree that the dietary exposure analysis is appropriate as a means of estimating dietary exposure. Potential exposure through inhalation or dermal contact currently constitutes an unknown for which the risk assessment provides no available information. EPA has developed proposals to analyze inhalation and dermal exposure for birds in such a way that it may be added to dietary exposure, and thus used in the development of a risk quotient. See *http://www.epa.gov/scipoly/sap/#march.* Similar proposals for other classes of species are expected in the future. EPA reports that it has received one of two SAP peer-review reports on its proposals, and that, when it has received both reports, it will evaluate the peer review suggestions and formulate a plan for implementing the new modeling techniques. The Services encourage the development and implementation of these proposals, following external peer-review by the FIFRA SAP.

The Services conclude that EPA's approach to incorporation of exposure estimates for non-oral routes is consistent with the ESA, in that EPA uses the best scientific and commercial information available. Pending implementation of these proposals, following external peer-review by the FIFRA SAP, the data on dietary exposure remains the best available quantified information provided through existing models.

*Comment:* EPA may underestimate exposure to the extent that pesticides are applied in ways or amounts other than as allowed on the label.

*Response:* While the Services recognize that misuse may occur, we believe it is reasonable to assume pesticides are used lawfully unless data demonstrate a widespread and commonly recognized pattern of misuse. In fact, as the Overview Document states, many pesticides are typically applied at lesser rates and frequency than permitted by the label.

*Comment:* EPA's exposure assessments do not account for movement of pesticides beyond the sites to which they are applied.

*Response:* As noted in the Overview Document, EPA's exposure assessments do consider off-target movement of pesticides through run-off and drift. These assessments are based on the concentration levels in or immediately adjacent to the site of application, where concentration levels would be highest. The Services agree that the modeling estimates and monitoring information used by EPA represent the best currently available information on exposure, and note that EPA has committed to adjusting these models where appropriate.

*Comment:* The model used by EPA to estimate drift of pesticides, ''AgDrift,'' is not completely transparent.

*Response:* EPA has sought independent, external scientific peer review of AgDrift and has held public SAP meetings at which it explained the basic structure of AgDrift. See *http://www.epa.gov/oscpmont/sap/1999/july/boom.pdf* and *http://www.epa.gov/oscpmont/sap/1997/december/spraydrift.htm*. These meetings and EPA's supporting documents provide the public with a comprehensive description of the manner in which the model was constructed and the data on which it is based. As a general matter, EPA and the Services support and strive to achieve fully transparent scientific analyses. To the extent, however, that certain information provided to EPA and the Services is subject to release restrictions under federal law, the Services and EPA must abide by those restrictions. Further, even if such release restrictions apply, the ESA does not authorize the Services or EPA to reject consideration of such information if it otherwise constitutes the best scientific and commercial data available.

*Comment:* EPA's exposure models have not been validated by monitoring data.

*Response:* Since the commenter did not identify a specific model, the Services will only address the comment in general terms. The Services have reviewed the appendices accompanying EPA's Overview Document. These appendices describe the extensive reviews undertaken by EPA and external peer review of the models EPA uses to estimate exposure to pesticides. These reviews typically involve, among other things, comparisons of model estimates to data produced by monitoring of compounds in the environment. These comparisons, as well as the extensive external peer review records, support EPA's assertions its models are scientifically sound and are not likely to underestimate potential exposure to pesticides.

*Comment:* EPA does not have the in-house biological expertise to accurately make ''may affect'' determinations. Another comment pointed out that EPA's Office of Pesticide Programs is the single best federal government entity with the greatest available in-house expertise and resources to apply towards endangered species/pesticide risk assessment and to make appropriate regulatory decisions that adequately protect endangered species from potential adverse effects of pesticides.

*Response:* The Services note that all federal agencies are required to make ''may affect'' determinations, and are presumed to have the expertise to do so. Furthermore, EPA has a large staff of scientists well-trained in a range of disciplines, who collectively possess the expertise to make accurate assessments of the potential effects of pesticide use on listed species and critical habitat. Finally, in order for EPA to exercise the provisions of § 402.45, the counterpart regulations require that the Services and EPA have in effect an Alternative Consultation Agreement that describes actions which the Services and EPA will take to ensure that personnel have adequate training to carry out their roles.

*Comment:* EPA has expertise in assessing the fate and transport of pesticides. EPA has expertise in toxicity and ecology but not in evaluation of indirect or sublethal effects. The Services have such expertise.

*Response:* The Services agree that EPA has expertise in assessing the toxicity and environmental fate and transport of pesticides. The Services also think the agency's expertise extends to the methodology used to assess indirect and sublethal effects, and that EPA has described its approach in its Overview Document.

*Comment:* EPA does not have expertise in the life cycle, habitat needs, and locations of listed species.

*Response:* The Services and EPA agree that the Services have greater expertise and knowledge about the biological attributes of listed species and their critical habitat than does EPA. Accordingly, the counterpart regulations contain three additional methods of achieving interagency cooperation that is the fundamental tenet of the section 7 consultation process. Two of these methods deal directly with making the Services' expertise in species biology available to EPA. First, EPA could request the Services to provide available information describing the environmental baseline for each species or habitat that EPA determines may be affected by a FIFRA action. The Services would promptly provide such information. In addition, EPA may request a Service to designate a suitably-trained Service Representative to participate with EPA in development of an effects determination for one or more species or habitats. Third, EPA and the

Services will establish new procedures for regular and timely exchanges of scientific information to achieve accurate and informed decision-making. In light of these methods, the Services conclude that EPA, through the Services, will have ready access to any additional biological information and insights that it would need to complete scientifically sound ecological risk assessments.

*Comment:* EPA does not have ongoing relationships with local and State wildlife agencies.

*Response:* EPA has worked with State and local wildlife agencies on a variety of issues, including providing protections for listed species and expects in the future to engage these and other stakeholders more widely in its pesticide regulatory programs. To the extent that EPA thinks that it needs help in developing these relationships, it can collaborate with the Services, either pursuant to the ACA or on a case-by-case basis working with the designated Service Representative.

*Comment:* Despite assertions to the contrary in the Overview Document, it will not be possible for EPA to perform ''site-specific'' risk assessments for listed species because data on species, habitat and pesticide use do not exist with which to perform such assessments. Moreover, EPA has not conducted adequate site-specific assessments in the past.

*Response:* EPA has committed in the Overview Document to use a variety of sources to obtain information that would be relevant to a more refined, site-specific assessment. If detailed information is not available, EPA would make the best assessment possible with the best scientific and commercial information available and characterize any uncertainty in its ecological risk assessment.

*Comment:* EPA has never implemented the approach to ecological risk assessment described in its Overview Document.

*Response:* Although past risk assessments have not contained every element described in the Overview, the Overview Document reflects the approach to ecological risk assessment that EPA intends to use in the future. In fact, the Overview contains a number of new elements that will strengthen the agency's future evaluations of pesticide impacts on listed species. EPA, however, has routinely been using many of the methodologies described in the Overview Document for a number of years. While some of the methodologies are relatively recent, EPA has experience with all elements of the methodologies described and has begun developing effects determinations using these new methodologies. Further, the rule provides a number of mechanisms the Services can use to ensure that EPA's program for making effects determinations under new subpart D is consistent with the requirements of the ESA.

*Comment:* Many of EPA's past assessments of ecological risks to listed species and critical habitat were not adequate under the ESA. Commenters cited several specific examples. The Services, in many past reviews of EPA's approach to ecological risk assessment, have disparaged EPA's methodologies and have concluded that they deal inadequately with a range of effects: sublethal effects of pesticide ingredients, indirect effects (alteration of the aquatic community structure), effects of inert ingredients and adjuvants, and additive and synergistic effects resulting from interactions among different chemical substances.

*Response:* EPA has committed to make effects determinations using the approach to ecological risk assessments reflected in the Overview Document: this approach differs from the approaches EPA has used in the past. The Services believe EPA's approach to ecological risk assessment in the future, as set forth in the Overview Document, addresses the specific concerns in the comment. The Services believe that past determinations are not a relevant measure of EPA's ability to produce adequate effects determinations, and are confident that future effects determinations using the methodologies identified in the Overview Document will fully comport with the ESA. Comments and responses above address the specific concerns identified in these comments.

*Comment:* EPA's risk assessment process has been demonstrated to be deficient in *NRDC* v. *Whitman* and other litigation.

*Response:* The Services disagree. First, the litigation cited by the comment has not resulted in any finding that EPA's process for risk assessment is deficient, and second, the risk assessment processes at issue in those lawsuits involved human health, not ecological risks.

*Comment:* The Government Accounting Office determined that EPA's risk assessment process is biased because it relies on advice of the Science Advisory Boards and it allows people to serve on the SAB who have conflicts of interest.

*Response:* The Services find this comment irrelevant. The Services' conclusion about the adequacy of EPA's approach to ecological risk assessments rest on the Services' independent review of that approach rather than endorsement of an EPA appointed advisory committee. In addition, none of the Science Advisory Boards reviewed by the GAO dealt with scientific issues involving assessment of the ecological risks of pesticides. In fact, EPA does not rely on the SAB for peer review of scientific issues involving pesticides; a separate federal advisory committee, the FIFRA Scientific Advisory Panel reviews such issues.

*Comment:* In the Overview Document, voluntary registrant label restrictions should be considered in screening-level risk assessment.

*Response:* To the extent that this comment requests that EPA include voluntary registrant label restrictions as part of its action, this comment is outside the scope of the counterpart regulations because the Services defer to the action agency to define the scope of the action. The Services note, however, that EPA's standard approach to ecological risk assessment takes into account any mandatory restrictions on the pesticide labeling voluntarily offered by an applicant or registrant and accepted by EPA. EPA then bases the estimates of exposure on these restrictions.

*Comment:* The proposed counterpart regulations must allow a more ''real world'' assessment of actual risks, as opposed to assuming that all pesticides are generally bad for the environment (which is the current model).

*Response:* The counterpart regulations do not prescribe use of any particular assumptions in EPA's approach to ecological risk assessment. The statute merely requires that effects determinations be based on the ''best scientific and commercial data available.'' EPA's Overview Document discusses in detail what data EPA uses, how the agency uses these data, and when and how EPA employs assumptions. The Services have determined that EPA's approach is consistent with the statutory mandate to use the best available scientific and commercial information.

**Section-by-Section Analysis**

*Section 402.40—Definitions*

*Comment:* The proposed counterpart regulations change the longstanding definition of ''best scientific and commercial data available'' and ''cumulative impacts'' in a way that is bad for species.

*Response:* The Services note that ''best scientific and commercial data available'' is not defined in the ESA or part 402 of the regulations and do not

intend to change the way that phrase has been applied in the past. The Services also note that the term ''cumulative impacts'' is not used in the ESA or in the counterpart regulations. The Services use the term ''cumulative effects'' as defined in § 402.02 and specifically reaffirm that definition.

*Comment:* The requirement for assessing cumulative effects should be waived or at least modified with a disclaimer noting that scientific methods for such assessment are not currently available. Other commenters requested clarification on the definition of ''cumulative effects'' or suggested that the definition was inappropriate.

*Response:* The term ''cumulative effects'' is defined in § 402.02 of the regulations. These counterpart regulations do not change or waive the existing definition or the requirement to analyze such effects. The Services are aware that the existing scientific tools to assess the combined or additive effects of pesticides are very rudimentary. The ESA requires use of the best ''available'' scientific data, and EPA is not expected to provide more information than is currently available. At the same time, EPA should use what information is available on cumulative effects.

*Comment:* The agencies should explicitly and broadly define the term ''applicant'' to include any and all registrants of pesticide products (in the context of FIFRA section 2(y)), applicants for registration, as well as multiple persons (because of complex business and legal relationships) involved in a given FIFRA action.

*Response:* There is a regulatory definition of ''applicant'' at 50 CFR 402.02. The Services will defer to EPA to determine, consistent with this definition, who qualifies as an ''applicant'' when dealing with regulatory actions under FIFRA.

*Comment:* The requirement that an effects determination contain the information described in § 402.14(c)(1)–(6) should be revised so that unnecessary reprinting of paper is avoided.

*Response:* The Services note that the effects determination submitted under § 402.46 or 402.47 must contain the information described in § 402.14(c)(1)–(6). However, it is not necessary to print a physical copy of all background information.

*Comment:* Section 402.40(b)(3) of the counterpart regulations should be revised so that EPA is required to consider any information or recommendations from an applicant, and not just be allowed to consider this information.

*Response:* Although EPA need not necessarily include all information in an effects determination, it is required to base its determinations on the best scientific and commercial data available. Therefore, to the extent that the information supplied by the applicant may be the best scientific and commercial data available, EPA is required to consider the information.

*Comment:* Participation of multiple Service Representatives will adversely impact the efficiencies that the proposed counterpart regulations are seeking.

*Response:* Authorizing the use of multiple Service Representatives is specifically intended to ensure efficiency, for example, by preventing delays if a specific Service Representative is unavailable. The Services will monitor this approach to avoid problems.

*Comment:* ''Agency action'' should be defined as a specific use of an active ingredient.

*Response:* The term ''action'' is defined in § 402.02. The Services defer to action agencies to define the action, consistent with this definition.

*Section 402.41—Purpose*

*Comment:* The penultimate sentence in § 402.41 should be revised to recognize that in many cases data generated by pesticide registrants and applicants will be the only reliable scientific and commercial data available and that it alone will be enough to support ESA decision-making. Furthermore, the phrase ''best scientific and commercial data available'' needs to be defined to clarify that ''best data'' does not mean ''all data'' and that suspect science should not be used in assessments.

*Response:* The Services recognize the possibility that the best, and only, data available could come from pesticide registrants and applicants. The ESA requires use of the ''best scientific and commercial data available.'' The Services note that making a determination as to what constitutes ''best scientific and commercial data'' may require a review of data available beyond that generated by pesticide registrants and applicants.

*Section 402.42—Scope and Applicability*

*Comment:* Section 402.42(a)(4) properly recognizes the potential value of the procedures that will be established by proposed § 402.47.

*Response:* The Services agree with this comment.

*Comment:* Additional detail should be included in the final counterpart regulations on the process to be followed for emergency exemptions.

*Response:* The Services believe that further definition is not needed in the counterpart regulations. The procedures in § 402.05 have been applied in the past to address a wide range of issues and should be sufficient here.

*Comment:* Delaying formal consultation is warranted for any type of emergency action. This provision should also apply to the effects determination EPA makes pursuant to ESA section 7(a)(2).

*Response:* The Services agree that if an action appropriately meets the definition of an ''emergency,'' delay of any required formal consultation is authorized. The Services have historically allowed action agencies to meet their consultation obligations through informal consultation for actions determined to be NLAA. Consistent with this interpretation a determination of NLAA by EPA under § 402.45 would be considered sufficient to meet the requirements of the counterpart regulations.

*Comment:* The Services should provide a more detailed explanation regarding the application of the proposed counterpart regulations to emergency exemptions issued to States under section 18 of FIFRA and to special local need registrations issued by States under section 24(c) of FIFRA. ESA consultation obligations should not extend to either of these activities, or should be left to independent States.

*Response:* Section 18 emergency exemptions issued by EPA are actions for the purposes of the ESA. Accordingly, EPA must satisfy the requirements of section 7(a)(2) with regard to those section 18 actions that may affect listed species. Emergency actions under FIFRA section 18 will, in the overwhelming majority of instances, fall within the scope of emergency actions addressed in 50 CFR 402.05, and EPA may, therefore, utilize either the emergency consultation procedures or other available procedures (including the new procedures set forth in §§ 402.45 and .46) to address its consultation obligations in a manner consistent with the need to expeditiously address the emergency.

With regard to section 24(c) registrations, this comment notes that the States, rather than EPA, issue these registrations, and that, therefore, ESA consultation obligations should not extend to section 24(c) registrations. It was not the Services' intention to suggest that State action in issuing section 24(c) registrations should be subject to the ESA consultation requirements. The consultation

obligation under section 7(a)(2) applies only to federal actions and federal agencies. States may, of course, contact the Services independently to discuss the potential effects of their actions on listed species. To the extent, however, that section 24(c) registrations are federal actions within EPA's purview, section 7(a)(2) applies to such registrations in the same manner as it applies to existing FIFRA section 3 registrations.

*Comment:* ''Reinitiation'' should be more clearly explained in the final counterpart regulations with detailed narrative on when such a procedure would occur.

*Response:* The counterpart regulations incorporate the existing rules in subpart B for reinitiation of consultation. These rules have been applied by federal agencies for almost two decades with relatively little difficulty, and should function adequately for FIFRA actions without further elaboration.

*Comment:* Private and State data should be considered a viable alternative to the Services' and EPA's data.

*Response:* Section 402.42(b) does not exclude any source from providing data. Information from all sources, including industry and States will be considered to satisfy the statutory requirement to use the best scientific and commercial data available.

*Section 402.43—Interagency Exchanges of Information*

*Comment:* A month should be eliminated from the assessment process by requiring the Services to provide EPA with both information on the presence of listed species or their critical habitat and information describing the applicable environmental baseline for the species or habitat 30 days after EPA's written request.

*Response:* The Services disagree with this comment. Baseline information is not always needed and therefore should not be asked for concurrently with presence of listed species or critical habitat data.

*Comment:* Additional information should be provided to EPA with a species list: specifically, any use of a pesticide in controlling exotics for the benefit of listed species.

*Response:* Species lists should include all listed species that may be affected positively or negatively.

*Comment:* The proposed regulations do not indicate how EPA or other affected parties could enforce deadlines for the Services to respond to EPA requests for information. The commenter suggested addressing this by either including language stating that wherever EPA has asked a Service for a response, and the regulations set a time period for providing that response, lack of a Service response can be taken by EPA as concurrence in EPA's position or as evidence that the Service has nothing to add to the decision-making process.

*Response:* The Services believe that the timelines noted in the counterpart regulations are sufficient enforcement. The Services are committed to meet all of the deadlines and expect to do so.

*Section 402.44—Advance Coordination for FIFRA Action*

*Comment:* The proposed language that states the designated Service Representative ''shall normally be available to complete advance coordination with EPA within 60 days' allows for too much leeway. The word ''normally'' should be deleted.

*Response:* The Services disagree with this comment. The word ''normally'' is included because of potential staffing limitations and availability. The Services believe that 60 days is reasonable.

*Comment:* A two-week timeframe for the Services to designate a Service Representative followed by a 60-day availability ''hold'' would add four months to the time it would take to implement an effects determination.

*Response:* The commenter has misconstrued the regulation. The counterpart regulations call for a Service Representative to be designated and provided to EPA within 14 days. The regulations also indicate that advance coordination normally will be completed within 60 days of the date of Service Representative designation. Further, the Services intend that Service Representatives will be available to work with EPA from the time they are designated until the coordination effort is complete.

*Comment:* EPA should have the option of reconsidering its request should the process of advance coordination become overly burdensome with too many Service Representatives involved in the advance coordination of a given FIFRA action.

*Response:* The Services note that nothing in the counterpart regulations prevents EPA from withdrawing a request for advance coordination.

*Comment:* Participation of Service Representatives in the effects determination is unnecessary and will likely delay the process. Another commenter expressed the opposite view, suggesting that the counterpart regulations should require early Service involvement to reduce the amount of work by avoiding unnecessary investigation of species that would not be exposed to or harmed by the pesticide.

*Response:* The Services believe participation by a Service Representative will lead to a more efficient consultation process, but believe that EPA should have the discretion to determine when to request early Service participation. If early participation by the Service does not prove helpful in a particular case, EPA retains the option of withdrawing its request.

*Comment:* ''Sufficient detail,'' as used in § 402.44(a), should be defined.

*Response:* As stated in the counterpart regulations, EPA's description of the planned FIFRA action must be sufficient enough to ''enable the Service to designate a representative with appropriate training and experience.'' The Services believe this text provides a basis for coordination with EPA on the issue.

*Comment:* Deadlines should be set for EPA to produce an effects determination.

*Response:* The Services disagree with this comment. It is not within the authority of the Services to tell EPA when effects determinations must be produced.

*Section 402.45—Alternative Consultation on FIFRA Actions That Are Not Likely to Adversely Affect Listed Species or Critical Habitat*

*Comment:* The proposal would allow EPA to ignore the environmental baseline when making a NLAA determination for an action. Thus, EPA would not add direct, indirect, and cumulative effects to the baseline as required by 50 CFR 402.14(c)(4) and 402.02.

*Response:* The commenter misconstrues the obligation of an action agency to consider the environmental baseline under the existing regulations in subpart B. Development of an environmental baseline is only required when the direct or indirect effects of a proposed action, in combination with any effects of interrelated or interdependent actions, are likely to adversely affect any listed species or designated critical habitat. If an action is not likely to adversely affect listed species or critical habitat (an NLAA determination) there would be no change to the environmental baseline and therefore no need to consider it.

*Comment:* The language in §1A402.45(a) should be changed from ''EPA need not initiate any additional consultation'' to ''need not initiate consultation'.

*Response:* The Services disagree with this comment. Since § 402.45(a)

describes an alternative form of informal consultation, the suggested phrase would be inaccurate.

*Comment:* Several elements of the ACA should be incorporated into the counterpart regulations: establishment of a framework for operation of the Coordination, Communication and Implementation Panel, identification of the number of members that will be drawn from the participating agencies and the positions from which those members will be chosen, requirement that all Panel meetings be open to the public, and the entire Guiding Principles section of the ACA. Furthermore, the final counterpart regulations should identify specifically who sits on the Coordination, Communication, and Implementation Panel, their respective roles, and the manner in which they are selected.

*Response:* The Services agree that these are relevant issues but believe that it is inappropriate to address such issues in a Federal regulation. Because these matters should involve administrative, internal operating procedures affecting only the Services and EPA and because the procedures may change over time, the Services believe these matters are more appropriately addressed through the ACA.

*Comment:* The Services violated the APA by failing to take comment from the public on the ACA. Because the draft ACA is not final, it offers no assurances that it represents the direction that EPA and the Services intend to go in a final ACA. The agencies are strongly urged to offer a more complete version of the ACA for public review and comment before it is finalized. Commenters expressed concern that the ACA might become a *de facto* regulation of pesticides.

*Response:* The Services disagree with this comment. A draft version of the ACA was made available to the public during the public comment period of the proposed rule. Further, the proposal provides that the final ACA will be made available to the public. It is important to note that the ACA is not a regulation, but rather, is an agreement intended to describe an interagency process for ensuring and documenting compliance with the terms of the counterpart regulations. As such, it does not establish any standards for compliance with the ESA nor can it serve to regulate pesticides.

*Comment:* Clarification is needed so that the procedures conducted by the Antimicrobial Division of OPP in its ecological risk assessments are included within the procedures that fulfill the requirements of the proposed 50 CFR 402.45(b)(2)(i).

*Response:* There is no need to clarify the regulations because the regulations state that the ACA shall describe actions that EPA and the Services have taken to ensure that EPA determinations regarding the effects of its actions under FIFRA, which would include determinations by EPA's Antimicrobial division, are consistent with the ESA and applicable implementing regulations.

*Comment:* EPA and Service personnel need to be sufficiently trained, including training of Service personnel by EPA in EPA's risk assessment process. Appropriate training and ''certification'' should be better described in the counterpart regulations.

*Response:* The Services agree that sufficient training is important and note that the counterpart regulations call for the ACA to describe actions that EPA and the Services intend to take to ensure that EPA and Service personnel are adequately trained. The required training must be adequate for EPA and Service personnel to carry out their respective roles but flexibility is necessary to accommodate a variety of roles and evolution of responsibilities. The Services disagree that additional specification of the training should be included within the counterpart regulations themselves.

*Comment:* EPA should not have to be trained by Service personnel on EPA's risk assessment process. Such a situation would be ''burdensome, bureaucratic and inefficient.''

*Response:* The Services would not train EPA employees on EPA's risk assessment process. The purpose of the training program is to ensure that EPA consistently interprets and applies the provisions of the ESA and the regulations (50 CFR part 402) relevant to these counterpart regulations with the expectation that EPA will reach the same conclusions as the Services. It is expected that the training program will rely upon the ESA Consultation Handbook as much as possible.

*Comment:* Criteria should be included in the counterpart regulations or in the ACA for determining which ''new information'' and ''relevant scientific advances'' qualify as best available data. Although new data should include all quality data regardless of the results they support, ''best available data'' are not equivalent to ''all data''.

*Response:* The Services do not believe that it is appropriate to include language in the counterpart regulations for determining which ''new information'' and ''relevant scientific advances'' qualify as best available data. The reader is referred to the earlier comment regarding § 402.41 in this ''Section-by-Section Analysis'' for a discussion on ''best scientific and commercial data available.''

*Comment:* An agreement should include procedures for reassessment of a NLAA determination and, as appropriate, reclassification to ''no effect'' or of ''likely to adversely affect'' with reclassification to NLAA or ''no effect.''

*Response:* The Services do not believe that this is necessary. EPA, as the action agency, retains discretion to revisit its determination.

*Comment:* The regulation does not define the ''necessary records'' that EPA must retain under § 402.45(b)(2)(vi), leaving undefined the entire basis for oversight and therefore acceptance of EPA's performance.

*Response:* The counterpart regulations do not instruct EPA and the Services which records EPA must maintain under the ACA, but leave to EPA and the Services discretion to determine which records are necessary to complete program evaluation. The Services expect, however, that the information EPA must already maintain for purposes of the Federal Records Act and judicial review will be sufficient to permit the Services to conduct appropriate periodic evaluations of EPA's process for making effects determinations.

*Comment:* A requirement that EPA's annual report on NLAA determinations be made public should be incorporated into § 402.45.

*Response:* The Services note that § 402.45(b)(4) states that ''[t]he alternative consultation agreement and any related oversight or monitoring reports shall be made available to the public to the extent provided by law.''

*Comment:* The provision in the counterpart regulations allowing deviation from the ACA undermines the value of the procedures and adds uncertainty as to whether listed species will be protected.

*Response:* The counterpart regulations specify that the parties may depart from the ACA in a particular case to the extent deemed necessary by both the EPA and the Services, ensuring to the satisfaction of the Services that any departure from its terms will be in full compliance with section 7 and the counterpart regulations.

*Comment:* Greater transparency of EPA's selection of data will reduce the burden of documentation.

*Response:* EPA and the Services will continue to work collaboratively to ensure transparency of data selection and to minimize documentation burdens.

*Comment:* The Services' review of implementation of counterpart regulations should be limited to reviewing whether EPA has followed the procedures for risk assessment agreed upon by the agencies. Allowing for review of all NLAA decisions appears to be inconsistent with the proposed counterpart regulations which say that EPA, not the Services, is responsible for the NLAA decisions.

*Response:* The Services agree that their review of EPA's compliance with the counterpart regulations should focus on implementation of the overall approach and that EPA is responsible for its NLAA determinations. This review, however, will almost certainly involve examination of selected NLAA effects determinations. The focus of this review will be on how EPA is performing under the rule and the ACA and may result in recommendations designed to strengthen EPA's program. While these recommendations may be relevant to assessing the adequacy of particular NLAA determinations, the Services do not intend their oversight efforts to involve a determination-by-determination evaluation of all individual NLAA determinations.

*Comment:* Allowing any agency to terminate the ACA provides no certainty to applicants, registrants or users that the provisions of the ACA and/or the counterpart regulations will be applicable in the future. The termination provisions should be ''tightened considerably.''

*Response:* While the Services recognize the concern that § 402.45 may not be available for use in the future, the Services believe meaningful oversight of EPA's activities under this section requires authority to terminate the ACA if, ''EPA fails to comply with the requirements of this subpart, section 7 of the ESA, or the terms of the alternative consultation agreement.'' Since it is difficult to anticipate all possible future circumstances, the Services further believe that these standards provide needed flexibility.

*Comment:* EPA should be given a period of time to take corrective action before the ACA could be terminated.

*Response:* The Services do not believe such language is required in the counterpart regulations but note that § 402.45(c) provides for possible corrective action.

*Comment:* The Services should revise proposed § 402.45(c) so that in the event that the Service Director exercises the authority to terminate an ACA, evaluations already underway in accordance with the existing ACA be allowed to continue. The commenter suggested that this would avoid disruption of schedules and waste of resources that applicants and EPA are likely to have committed.

*Response:* The Services disagree with making such changes to the counterpart regulations. Any termination of an ACA would legally end EPA's authority to make NLAA determinations concerning evaluations in process without concurrence from the Services. The Services agree that in the event an ACA is terminated some disruption is possible but the Services intend to structure termination of the ACA in a way in which appropriately considers disruptions.

*Comment:* If the Services terminate the ACA prior NLAAs should not be left in effect.

*Response:* The Services disagree with this comment. It is possible that the ACA may be terminated for reasons independent of the likely validity of any past NLAA determinations, and therefore requiring all previous NLAA determinations to be revisited would be an inappropriate investment of limited resources, and detract from the ability of the Services and EPA to consult on actions likely to adversely affect listed species. The Services also note that under 402.45, EPA is responsible for the validity of its NLAA determinations and would continue to be responsible for those NLAA determinations if the ACA is later terminated. Information creating uncertainty regarding the basis for an NLAA determination may lead to EPA's reconsideration of the determination, or be the basis for reinitiation of consultation with the Services. Additionally, termination of the ACA may create appropriate grounds for the Services to request reinitiation of consultation on any specific NLAA determination.

*Section 402.46—Optional Formal Consultation Procedure for FIFRA Actions*

*Comment:* Section 402.46(a) requires that a written request for consultation be accompanied by an ''effects determination prepared in accordance with § 402.40(b),'' which does not say how the effects determination is to be prepared, just what it should include.

*Response:* The Services do not intend to prescribe how EPA would prepare effects determinations; consequently, in response to this comment, the Services are changing the language in the final rule from ''prepared in accordance with'' to ''as defined in.''

*Comment:* The Services should provide EPA with any ''additional information'' at the time of notification under § 402.46(b).

*Response:* The counterpart regulations provide that the Services' shall describe the additional information in detail and shall identify a means for obtaining that information. The Services intend that EPA be able to obtain the additional information in an efficient manner, and believe it will frequently be more efficient for EPA to obtain it through an identified Website link or by accessing and retrieving selected values from a large database, for example, rather than through the Services. This provision, however, would not preclude a Service from providing the additional information directly, in cases where the Service feels that would be most efficient.

*Comment:* EPA should be given the ability to dispute the validity and relevance of any additional information sought by the Services and be given the opportunity to continue with the consultation in the absence of the requested additional information.

*Response:* As stated elsewhere in this preamble, EPA does have this ability. In response to a request for additional information EPA may choose to resubmit the original effects determination with an explanation as to why the requested information was not submitted.

*Comment:* A deadline for EPA to complete a revised effects determination should be included in the final counterpart regulations.

*Response:* The Services disagree with this comment and defer to EPA to decide how much time it needs to prepare a revised effects determination.

*Comment:* EPA should be required to provide biological opinions to applicants, or at least inform applicants of their availability, as soon as the biological opinions are received from the Services. Another commenter stated that the chemical industry should not be given elevated consultation status, while public input is minimized.

*Response:* Section 402.46(c)(2) of the proposed regulations provides that EPA shall, upon request of an applicant, provide the applicant with any draft biological opinion it receives from the Services. This section tracks the requirements of the existing consultation regulations at § 402.14(g)(5). As with the existing regulations, it leaves to EPA the discretion to develop any additional processes it determines may be appropriate to make draft opinions available to applicants and to the public. In the Services' experience, action agencies have used this provision in the existing regulations to ensure that applicants and the public have the ability to provide input in the

development of final biological opinions. The Services do not believe there is a need, therefore, to create an additional obligation for EPA in this regard.

*Comment:* State pesticide regulatory agencies should be designated as co-regulators with EPA and should be allowed full participation in the consultation process for species found in their States. These commenters noted that such agencies have primary responsibility for enforcing the misuse provisions of FIFRA as well as unique knowledge of agricultural and other pesticide related activity in their States and should, therefore, be involved in the development of mitigation measures for listed species.

*Response:* The ESA does not provide the Services with authority to designate States as ''co-regulators.'' While the alternative consultation processes in the counterpart regulations apply only to EPA's effects determinations for FIFRA actions, they do not limit EPA's existing ability to obtain input from State pesticide regulatory agencies to better inform the consultation process. Further, the scope of this rule is limited to the consultation process itself and does not, therefore, address EPA's approach for participation by States and others in the development and implementation of mitigation measures under FIFRA.

*Comment:* The procedures for applicant involvement during consultation should be formalized with a firm deadline for meeting with applicants and a requirement for written minutes of meetings attended by applicants.

*Response:* The Services recognize the desirability of meeting promptly with applicants who request a meeting during consultation, but decline to require a fixed deadline for such meetings as it may not be possible to achieve in all cases due to scheduling conflicts and other duties. Likewise, taking formal minutes of every meeting with an applicant would be unduly burdensome; any applicant who attends a meeting with the Service can document the matters discussed at the meeting and submit any written meeting notes to the Service for inclusion in the record.

*Comment:* The Services' authority to extend deadlines during consultation should be limited because they have overused their authority in the past.

*Response:* The Services agree that consultations should be completed as quickly as possible, but do not agree fully with this comment. The counterpart rules permit the Services to extend a consultation deadline only as permitted by section 7(b)(1) of the ESA.

*Comment:* To avoid additional delays, § 402.46(e) should be expanded to make it clear that the specified officials have authority to make decisions based on whatever information has been put before them within the deadlines set forth in the counterpart regulations.

*Response:* The ESA requires decisions to be based upon the best scientific and commercial data available. The Services believe the counterpart regulations establish procedures that will allow timely decisions based upon the best scientific and commercial data available.

*Comment:* It is inappropriate that final actions under § 402.46(e) can only be approved by political appointees.

*Response:* The comment misconstrues the counterpart regulations. Within each of the Services, decisions under § 402.46(e) can be delegated to a senior-level non-political employee.

*Section 402.47—Special Consultation Procedures for Complex FIFRA Actions*

*Comment:* Because procedures that are relatively routine in the world of FIFRA regulation are ''unusually complex'' in the context of the Services'' responsibilities, procedures described in proposed § 402.47 are likely to be more commonly invoked than some may expect.

*Response:* The Services agree that this is a possibility.

*Comment:* The successive effects determination process should be applied to new registrations in a manner that expedites approval of registrations for individual uses, use patterns, and use rates. Omitting evaluations of new pesticides under the phased approach to consultation will unduly delay issuance of many pending or future reduced-risk products. Another commenter expressed the opposing viewpoint that the counterpart regulations should expressly prohibit the use of this procedure for registration of new pesticides.

*Response:* The Services do not believe that any changes to the proposed rule are warranted. EPA has advised the Services that EPA does not intend to register any new use or active ingredient until completion of consultation under section 7(a)(2) for all species affected by that action. Thus, there should be no need to use the procedures in § 402.47 for applications seeking to register new active ingredients or new uses of currently registered pesticides. The Services note that EPA and the applicant, of course, retain discretion to define a FIFRA action to relate only to a specific subset of pesticide uses proposed in an application. So long as EPA fulfills its responsibilities under the ESA for all listed species and critical habitat, defining a FIFRA action in this manner could achieve the stated goal of the comment. The Services will work with EPA to expedite consultations on new pesticides to the extent possible.

*Comment:* EPA and the Services should explore ways to group listed species and/or pesticides in consultations. It might be possible to develop criteria to group listed species either taxonomically or by ecological function. Similarly, active ingredients could be organized into either chemically or toxicologically similar groups and consulted on by group, not individually.

*Response:* The Services note it is within EPA's discretion to define the action. Batching similar actions together is permitted under subpart B and in fact, the Services encourage batching where appropriate. If EPA wishes, the flexibility provided by § 402.47 may be used to assess affects of pesticides on groups of taxonomically or ecologically similar species.

*Comment:* Section 402.47 embodies too narrow a reading of the legal effects of a partial biological opinion, which should constitute a final biological opinion for the geographic area that was the subject of the opinion, providing immediate incidental take protection for the completed portions of a phased consultation. Also, effects determinations made by EPA should have incidental take protection.

*Response:* The Services believe that § 402.47 properly describes the legal effects of a partial biological opinion. Formal consultation on a proposed action is not concluded until all listed species or designated critical habitats that may be adversely affected by the action have been evaluated in a biological opinion. Incidental take protection is provided under section 7(b)(4) at the conclusion of consultation of the proposed action. However, the partial biological opinion would describe the provisions relating to incidental take of such species for inclusion in an incidental take statement at the conclusion of consultation, giving users of pesticide products such as farmers and forest managers, nursery operators, and other pesticide users prompt and reliable guidance for minimizing incidental take of the species. EPA has discretion to determine the geographic limit of any FIFRA action it may propose, and the Services will consult on the action as proposed.

**Revisions to the Proposed Rule**

In § 402.40(g), we deleted the second sentence which read, ''[t]he Service may designate more than one individual to serve jointly as a Service Representative.'' The change is made to remove redundancy with the first sentence which states that the ''*Service Representative* is the person or persons designated to participate in advance coordination as provided in this subpart.''

In § 402.45(c), we edited the penultimate sentence which read ''[t]he Service Director retains discretion to terminate the alternative consultation agreement . . .'' to read, ''[t]he Service Director retains discretion to terminate or suspend the alternative consultation agreement . . .'' The change is made to clarify the statement and make it consistent with the final sentence of the subsection which begins, ''[t]ermination, suspension, or modification of an alternative consultation . . .''

Language in § 402.46(a) was changed from ''[t]he written request shall be accompanied by an effects determination prepared in accordance with § 402.40(b)'' to ''[t]he written request shall be accompanied by an effects determination as defined in § 402.40(b).'' This change is intended to clarify that the Services do not intend to prescribe how EPA would prepare the effects determinations.

**Required Determinations**

*Regulatory Planning and Review*

In accordance with Executive Order 12866, this document is a significant rule because of the legal or policy issues it has raised; it was reviewed by the Office of Management and Budget (OMB) in accordance with the four criteria discussed below.

(a) This counterpart regulation will not have an annual economic effect of $100 million or more or adversely affect an economic sector, productivity, jobs, the environment, or other units of government.

(b) This counterpart regulation is not expected to create inconsistencies with other agencies' actions. FWS and NOAA Fisheries are responsible for carrying out the Act.

(c) This counterpart regulation is not expected to significantly affect entitlements, grants, user fees, loan programs, or the rights and obligations of their recipients.

(d) OMB has determined that this rule may raise novel legal or policy issues and, as a result, this rule has undergone OMB review.

*Regulatory Flexibility Act (5 U.S.C. 601 et seq.)*

Under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*, as amended by the Small Business Regulatory Enforcement Fairness Act (SBREFA) of 1996), whenever an agency is required to publish a notice of rulemaking for any proposed or final rule, it must prepare and make available for public comment a regulatory flexibility analysis that describes the effect of the rule on small entities (*i.e.*, small businesses, small organizations, and small government jurisdictions), unless the agency certifies that the rule will not have a significant economic impact on a substantial number of small entities. The Regulatory Flexibility Act requires Federal agencies to provide a statement of the factual basis for certifying that a rule will not have a significant economic impact on a substantial number of small entities.

Pursuant to the Regulatory Flexibility Act, the Secretaries of the Interior and Commerce certify that this regulation will not have a significant economic impact on a substantial number of small entities. The purpose of the rule is to increase the efficiency of the ESA section 7 consultation process for those activities involving pesticide regulation conducted by EPA. The proposed changes are expected to lead to the same protections for listed species as the section 7 consultation regulations at 50 CFR part 402.

Regulations at 50 CFR 402.04 provide that ''the consultation procedures may be superseded for a particular Federal agency by joint counterpart regulations among that agency, the Fish and Wildlife Service, and the National Marine Fisheries Service.'' The preamble to the 1986 regulations for implementing section 7 states that ''such counterpart regulations must retain the overall degree of protection afforded listed species required by the [ESA] and these regulations. Changes in the general consultation process must be designed to enhance its efficiency without elimination of ultimate Federal agency responsibility for compliance with section 7.'' The rule will not have a significant economic impact on a substantial number of small entities for the following reasons.

(1) The rule will modify procedures for formal section 7 consultation and remove the requirement for EPA to conduct informal consultation with and obtain written concurrence from FWS or NOAA Fisheries on those FIFRA actions it determines are NLAA listed species or critical habitat.

(2) The new consultation procedures may affect registrants, who provide EPA with the data used to assess the level of environmental risk. It is estimated that approximately two-thirds of the 1,850 pesticide registrants are small businesses. Because this rule is expected to streamline the consultation process and would therefore potentially accelerate the registration process for new pesticide products and the re-registration process for existing pesticides, these businesses are expected to experience no effect or a small positive effect as a result of this rule.

(3) Agricultural producers, many of which are small businesses, may be indirectly affected by this rule. Because this rule is expected to streamline the consultation process and would therefore potentially accelerate the registration process for new pesticide products pesticides and the re-registration process for existing pesticides, agricultural producers may experience a small indirect benefit from this rule.

Therefore, the Secretaries of the Interior and Commerce certify that this action will not have a significant economic impact on a substantial number of small businesses, organizations, or governments pursuant to the RFA.

*Executive Order 13211*

On May 18, 2001, the President issued an Executive Order (E.O. 13211) on regulations that significantly affect energy supply, distribution, and use. Executive Order 13211 requires agencies to prepare Statements of Energy Effects when undertaking certain actions. Although this rule is a significant action under Executive Order 12866, it is not expected to significantly affect energy supplies, distribution, or use. Therefore, this action is not a significant energy action and no Statement of Energy Effects is required.

*Unfunded Mandates Reform Act (2 U.S.C. 1501 et seq.)*

In accordance with the Unfunded Mandates Reform Act (2 U.S.C. 1501 *et seq.*):

(a) These counterpart regulations will not ''significantly or uniquely'' affect small governments. A Small Government Agency Plan is not required. We expect that these counterpart regulations will not result in any significant additional expenditures by entities that develop formalized conservation efforts.

(b) These counterpart regulations will not produce a Federal mandate on State, local, or tribal governments or the

private sector of $100 million or greater in any year; that is, it is not a ''significant regulatory action'' under the Unfunded Mandates Reform Act. These counterpart regulations impose no obligations on State, local, or tribal governments.

*Takings*

In accordance with Executive Order 12630, these counterpart regulations do not have significant takings implications. These counterpart regulations pertain solely to ESA section 7 consultation coordination procedures, and the procedures have no impact on personal property rights.

*Federalism*

In accordance with Executive Order 13132, these counterpart regulations do not have significant Federalism effects. A Federalism assessment is not required. In keeping with Department of the Interior and Commerce regulations under section 7 of the ESA, we coordinated development of these counterpart regulations with appropriate resource agencies throughout the United States.

*Civil Justice Reform*

In accordance with Executive Order 12988, this rule does not unduly burden the judicial system and meets the requirements of sections 3(a) and 3(b)(2) of the Order. We promulgate these counterpart regulations consistent with section 7 of the ESA.

*Paperwork Reduction Act*

This rule will not impose any new requirements for collection of information that require approval by the OMB under the Paperwork Reduction Act (44 U.S.C. 3501 *et seq.*). This rule will not impose new recordkeeping or reporting requirements on State or local governments, individuals, businesses, or organizations. We may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB Control Number.

*National Environmental Policy Act*

These counterpart regulations have been developed by FWS and NOAA Fisheries, along with EPA and USDA. The FWS and NOAA Fisheries are considered the lead Federal agencies for the preparation of this proposed rule, pursuant to 40 CFR 1501. We have analyzed these counterpart regulations in accordance with the criteria of the National Environmental Policy Act (NEPA), the Department of the Interior Manual (318 DM 2.2(g) and 6.3(D)), and National Oceanic and Atmospheric Administration (NOAA) Administrative Order 216–6 and have determined, after preparation of an environmental assessment, that the action does not have any significant effects. A Finding Of No Significant Impact has been prepared.

*Government-to-Government Relationship With Indian Tribes*

In accordance with the Secretarial Order 3206, ''American Indian Tribal Rights, Federal-Tribal Trust Responsibilities, and the Endangered Species Act'' (June 5, 1997); the President's memorandum of April 29, 1994, ''Government-to-Government Relations with NativeAmerican Tribal Governments'' (59 FR 22951); E.O. 13175; and the Department of the Interior's 512 DM 2, we understand that we must relate to recognized Federal Indian Tribes on a Government-to-Government basis. However, these counterpart regulations do not directly affect Tribal resources since only EPA regulatory actions are subject to the proposed provisions. The intent of these counterpart regulations is to streamline the consultation process; therefore, any indirect effect would be wholly beneficial.

**List of Subjects in 50 CFR Part 402**

Endangered and threatened species.

**Final Regulation Promulgation**

■ For the reasons set forth in the preamble, the Services amend part 402, title 50 of the Code of Federal Regulations as follows:

## PART 402—[AMENDED]

■ 1. The authority citation for part 402 continues to read as follows:

**Authority:** 16 U.S.C. 1531 *et seq.*

■ 2. Add a new subpart D to read as follows:

### Subpart D—Counterpart Regulations Governing Actions by the U.S. Environmental Protection Agency Under the Federal Insecticide, Fungicide and Rodenticide Act

Sec.

402.40 Definitions.
402.41 Purpose.
402.42 Scope and applicability
402.43 Interagency exchanges of information.
402.44 Advance coordination for FIFRA actions.
402.45 Alternative consultation on FIFRA actions that are not likely to adversely affect listed species or critical habitat.
402.46 Optional formal consultation procedure for FIFRA actions.
402.47 Special consultation procedures for complex FIFRA actions.
402.48 Conference on proposed species or proposed critical habitat.

### Subpart D—Counterpart Regulations Governing Actions by the U.S. Environmental Protection Agency Under the Federal Insecticide, Fungicide and Rodenticide Act

**§ 402.40 Definitions.**

The definitions in § 402.02 are applicable to this subpart. In addition, the following definitions are applicable only to this subpart.

(a) *Alternative consultation agreement* is the agreement described in § 402.45.

(b) *Effects determination* is a written determination by the U.S. Environmental Protection Agency (EPA) addressing the effects of a FIFRA action on listed species or critical habitat. The contents of an effects determination will depend on the nature of the action. An effects determination submitted under § 402.46 or § 402.47 shall contain the information described in § 402.14(c)(1)–(6) and a summary of the information on which the determination is based, detailing how the FIFRA action affects the listed species or critical habitat. EPA may consider the following additional sections for inclusion in an effects determination:

(1) A conclusion whether or not the FIFRA action is likely to jeopardize the continued existence of any listed species or result in the destruction or adverse modification of critical habitat and a description of any reasonable and prudent alternatives that may be available;

(2) A description of the impact of any anticipated incidental taking of such listed species resulting from the FIFRA action, reasonable and prudent measures considered necessary or appropriate to minimize such impact, and terms and conditions necessary to implement such measures; and

(3) A summary of any information or recommendations from an applicant. An effects determination shall be based on the best scientific and commercial data available.

(c) *FIFRA action* is an action by EPA to approve, permit or authorize the sale, distribution or use of a pesticide under sections 136–136y of the Federal Insecticide, Fungicide and Rodenticide Act, 7 U.S.C. 136 *et seq.* (FIFRA). In any consultation under this subpart, EPA shall determine the nature and scope of a FIFRA action.

(d) *Listed species* is a species listed as endangered or threatened under section 4 of the Act.

(e) *Partial biological opinion* is the document provided under § 402.47(a), pending the conclusion of consultation under § 402.47(b), stating the opinion of the Service as to whether or not a FIFRA action is likely to jeopardize the

continued existence of one or more listed species or result in the destruction or adverse modification of one or more critical habitats, and describing the impact of any anticipated incidental taking of such listed species resulting from the FIFRA action, reasonable and prudent measures considered necessary or appropriate to minimize such impact, and terms and conditions necessary to implement such measures.

(f) *Service Director* refers to the Director of the U.S. Fish and Wildlife Service or the Assistant Administrator for Fisheries for the National Oceanic and Atmospheric Administration.

(g) *Service Representative* is the person or persons designated to participate in advance coordination as provided in this subpart.

**§ 402.41 Purpose.**

The purpose of these counterpart regulations is to enhance the efficiency and effectiveness of the existing consultation process under section 7 of the Endangered Species Act (Act), 16 U.S.C. 1531 *et seq.*, by providing Fish and Wildlife Service and the National Marine Fisheries Service (referred to jointly as ''Services'' and individually as ''Service'') and EPA with additional means to satisfy the requirements of section 7(a)(2) of the Act for certain regulatory actions under FIFRA. These additional means will permit the Services and EPA to more effectively use the scientific and commercial data generated through the FIFRA regulatory process as part of the best scientific and commercial data available to protect listed species and critical habitat. The procedures authorized by these counterpart regulations will be as protective of listed species and critical habitat as the process established in subpart B of this part.

**§ 402.42 Scope and applicability.**

(a) *Available consultation procedures.* This subpart describes consultation procedures available to EPA to satisfy the obligations of section 7(a)(2) of the Act in addition to those in subpart B of this part for FIFRA actions authorized, funded, or carried out by EPA in which EPA has discretionary Federal involvement or control. EPA retains discretion to initiate early, informal, or formal consultation as described in §§ 402.11, 402.13, and 402.14 for any FIFRA action. The procedures in this subpart may be employed for FIFRA actions as follows:

(1) Interagency exchanges of information under § 402.43 and advance coordination under § 402.44 are available for any FIFRA action.

(2) Alternative consultation under § 402.45 is available for a listed species or critical habitat if EPA determines the FIFRA action is not likely to adversely affect the listed species or critical habitat.

(3) Optional formal consultation under § 402.46 is available for any FIFRA action with respect to any listed species or critical habitat.

(4) The special procedures in § 402.47 are available for consultations on FIFRA actions that will be unusually complex due to factors such as the geographic area or number of species that may be affected by the action.

(5) EPA shall engage in consultation as to all listed species and critical habitat that may be affected by a FIFRA action, and may in its discretion employ more than one of the available consultation procedures for a FIFRA action that may affect more than one listed species or critical habitat.

(6) EPA shall engage in consultation on actions involving requests for emergency exemptions under section 18 of FIFRA that may affect listed species or critical habitat, and may choose to do so under § 402.05 or other provisions of this subpart or subpart B of this part. Any required formal consultation shall be initiated as soon as practicable after the emergency is under control. For the purposes of § 402.05(b) the definition of formal consultation in § 402.02 includes the procedures in § 402.46.

(7) EPA must prepare a biological assessment for a FIFRA action to the extent required by § 402.12.

(8) EPA must comply with § 402.15 for all FIFRA actions.

(9) After a consultation under this subpart has been concluded, EPA shall reinitiate consultation as required by § 402.16 as soon as practicable after a circumstance requiring reinitiation occurs, and may employ the procedures in this subpart or subpart B of this part in any reinitiated consultation.

(b) *Exchanges of scientific information.* As part of any of the additional consultation procedures provided in this subpart, EPA and the Services shall establish mutually-agreeable procedures for regular and timely exchanges of scientific information to achieve accurate and informed decision-making under this subpart and to ensure that the FIFRA process considers the best scientific and commercial data available on listed species and critical habitat in a manner consistent with the requirements of FIFRA and ESA.

**§ 402.43 Interagency exchanges of information.**

EPA may convey to the Service a written request for a list of any listed species or critical habitat that may be present in any area that may be affected by a FIFRA action. Within 30 days of receipt of such a request the Service shall advise EPA in writing whether, based on the best scientific and commercial data available, any listed species or critical habitat may be present in any such area. EPA may thereafter request the Service to provide available information (or references thereto) describing the applicable environmental baseline for each species or habitat that EPA determines may be affected by a FIFRA action, and the Service shall provide such information within 30 days of the request.

**§ 402.44 Advance coordination for FIFRA actions.**

(a) *Advance coordination.* EPA may request the Service to designate a Service Representative to work with EPA in the development of an effects determination for one or more listed species or critical habitat. EPA shall make such a request in writing and shall provide sufficient detail as to a FIFRA action planned for consultation to enable the Service to designate a representative with appropriate training and experience who shall normally be available to complete advance coordination with EPA within 60 days of the date of designation. Within 14 days of receiving such a request, the Service shall advise EPA of the designated Service Representative.

(b) *Participation of Service Representative in preparation of effects determination.* The Service Representative designated under paragraph (a) of this section shall participate with EPA staff in the preparation of the effects determination identified under paragraph (a) of this section. EPA shall use its best efforts to include the designated Service Representative in all relevant discussions on the effects determination, to provide the designated Service Representative with access to all documentation used to prepare the effects determination, and to provide the designated Service Representative office and staff support sufficient to allow the Service Representative to participate meaningfully in the preparation of the effects determination. EPA shall consider all information timely identified by the designated Service Representative during the preparation of the effects determination.

**§ 402.45 Alternative consultation on FIFRA actions that are not likely to adversely affect listed species or critical habitat.**

(a) *Consultation obligations for FIFRA actions that are not likely to adversely affect listed species or critical habitat when alternative consultation agreement is in effect.* If EPA and the Service have entered into an alternative consultation agreement as provided below, EPA may make a determination that a FIFRA action is not likely to adversely affect a listed species or critical habitat without informal consultation or written concurrence from the Director, and upon making such a determination for a listed species or critical habitat, EPA need not initiate any additional consultation on that FIFRA action as to that listed species or critical habitat. As part of any subsequent request for formal consultation on that FIFRA action under this subpart or subpart B of this part, EPA shall include a list of all listed species and critical habitat for which EPA has concluded consultation under this section.

(b) *Procedures for adopting and implementing an alternative consultation agreement.* EPA and the Service may enter into an alternative consultation agreement using the following procedures:

(1) *Initiation.* EPA submits a written notification to the Service Director of its intent to enter into an alternative consultation agreement.

(2) *Required contents of the alternative consultation agreement.* The alternative consultation agreement will, at a minimum, include the following components:

(i) *Adequacy of EPA Determinations under the ESA.* The alternative consultation agreement shall describe actions that EPA and the Service have taken to ensure that EPA's determinations regarding the effects of its actions on listed species or critical habitat are consistent with the ESA and applicable implementing regulations.

(ii) *Training.* The alternative consultation agreement shall describe actions that EPA and the Service intend to take to ensure that EPA and Service personnel are adequately trained to carry out their respective roles under the alternative consultation agreement. The alternative consultation agreement shall provide that all effects determinations made by EPA under this subpart have been reviewed and concurred on by an EPA staff member who holds a current certification as having received appropriate training under the alternative consultation agreement.

(iii) *Incorporation of new information.* The alternative consultation agreement shall describe processes that EPA and the Service intend to use to ensure that new information relevant to EPA's effects determinations is timely and appropriately considered.

(iv) *Incorporation of scientific advances.* The alternative consultation agreement shall describe processes that EPA and the Service intend to use to ensure that the ecological risk assessment methodologies supporting EPA's effects determinations incorporate relevant scientific advances.

(v) *Oversight.* The alternative consultation agreement shall describe the program and associated record keeping procedures that the Service and EPA intend to use to evaluate EPA's processes for making effects determinations consistent with these regulations and the alternative consultation agreement. The alternative consultation agreement shall provide that the Service's oversight will be based on periodic evaluation of EPA's program for making effects determinations under this subpart. Periodic program evaluation will occur at the end of the first year following signature of the alternative consultation agreement and should normally occur at least every five years thereafter.

(vi) *Records.* The alternative consultation agreement shall include a provision for EPA to maintain a list of FIFRA actions for which EPA has made determinations under this section and to provide the list to the Services on request. EPA will also maintain the necessary records to allow the Service to complete program evaluations.

(vii) *Review of Alternative Consultation Agreement.* The alternative consultation agreement shall include provisions for regular review and, as appropriate, modification of the agreement by EPA and the Service, and for departure from its terms in a particular case to the extent deemed necessary by both EPA and the Service.

(3) *Training.* After EPA and the Service enter into the alternative consultation agreement, EPA and the Service will implement the training program outlined in the alternative consultation agreement to the mutual satisfaction of EPA and the Service.

(4) *Public availability.* The alternative consultation agreement and any related oversight or monitoring reports shall be made available to the public to the extent provided by law.

(c) *Oversight of alternative consultation agreement implementation.* Through the program evaluations set forth in the alternative consultation agreement, the Service will determine whether the implementation of this section by EPA is consistent with the best scientific and commercial information available, the ESA, and applicable implementing regulations. The Service Director may use the results of the program evaluations described in the alternative consultation agreement to recommend changes to EPA's implementation of the alternative consultation agreement. The Service Director retains discretion to terminate or suspend the alternative consultation agreement if, in using the procedures in this subpart, EPA fails to comply with the requirements of this subpart, section 7 of the ESA, or the terms of the alternative consultation agreement. Termination, suspension, or modification of an alternative consultation agreement does not affect the validity of any NLAA determinations made previously under the authority of this subpart.

**§ 402.46 Optional formal consultation procedure for FIFRA actions.**

(a) *Initiation of consultation.* EPA may initiate consultation on a FIFRA action under this section by delivering to the Service a written request for consultation. The written request shall be accompanied by an effects determination as defined in § 402.40(b) and a list or summary of all references and data relied upon in the determination. All such references and data shall be made available to the Service on request and shall constitute part of the Service's administrative record for the consultation. The time for conclusion of the consultation under section 7(b)(1) of the Act is calculated from the date the Service receives the written request from EPA. Any subsequent interchanges regarding EPA's submission, including interchanges about the completeness of the effects determination, shall occur during consultation and do not extend the time for conclusion of the consultation unless EPA withdraws the request for consultation.

(b) *Additional information determination.* For an effects determination prepared without advance coordination under § 402.44, the Service may determine that additional available information would provide a better information base for the effects determination, in which case the Service Director shall notify the EPA Administrator within 45 days of the date the Service receives the effects determination. The notification shall describe such additional information in detail, and shall identify a means for obtaining that information within the time period available for consultation.

EPA shall provide a copy of the Service Director's notification to any applicant. EPA may thereafter revise its effects determination, and may resubmit the revised effects determination to the Service. If EPA advises the Service it will not resubmit a revised effects determination to the Service, its initiation of consultation on the effects determination is deemed withdrawn.

(c) *Service responsibilities.* (1) Within the later of 90 days of the date the Service receives EPA's written request for consultation or 45 days of the date the Service receives an effects determination resubmitted under paragraph (b) of this section, and consistent with section 7(b)(1) of the Act, the Service shall take one of the following actions:

(i) If the Service finds that the effects determination contains the information required by § 402.40(b) and satisfies the requirements of section 7(b)(4) of the Act, and the Service concludes that the FIFRA action that is the subject of the consultation complies with section 7(a)(2) of the Act, the Service will issue a written statement adopting the effects determination; or

(ii) The Service will provide EPA a draft of a written statement modifying the effects determination, which shall meet the requirements of § 402.14(i), and as modified adopting the effects determination, and shall provide a detailed explanation of the scientific and commercial data and rationale supporting any modification it makes; or

(iii) The Service will provide EPA a draft of a biological opinion finding that the FIFRA action is likely to jeopardize the continued existence of a listed species or result in the destruction or adverse modification of critical habitat, and describing any reasonable and prudent alternatives if available.

(2) If the Service acts under paragraphs (c)(1)(ii) or (c)(1)(iii) of this section, EPA shall, on request from an applicant, provide the applicant a copy of the draft written statement or draft biological opinion received from the Service. The Service shall at the request of EPA or an applicant discuss with EPA and the applicant the Service's review and evaluation under this section, and the basis for its findings. EPA and any applicant may submit written comments to the Service within 30 days after EPA receives the draft written statement or opinion from the Service unless the Service, EPA and any applicant agree to an extended deadline consistent with section 7(b)(1) of the Act.

(3) The Service will issue a final written statement or final biological opinion within 45 days after EPA receives the draft statement or opinion from the Service unless the deadline is extended under section 7(b)(1) of the Act.

(d) *Opinion of the Secretary.* The written statement or opinion by the Service under paragraphs (c)(1) or (c)(3) of this section shall constitute the opinion of the Secretary and the incidental take statement, reasonable and prudent measures, and terms and conditions under section 7(b) of the Act.

(e) *Delegation of Authority for Service decisions.* Any written statement modifying an effects determination or any biological opinion issued under this section shall be signed by the Service Director and such authority may not be delegated below the level of Assistant Director for Endangered Species (FWS) or Director of Office of Protected Resources (NOAA Fisheries).

### § 402.47 Special consultation procedures for complex FIFRA actions.

(a) *Successive effects determinations.* If EPA determines after conferring with the Service that consultation on a FIFRA action will be unusually complex due to factors such as the geographic area or number of species that may be affected by the action, EPA may address the effects of the action through successive effects determinations under this subpart addressing groupings or categories of species or habitats as established by EPA. EPA may initiate consultation based upon each such effects determination using the procedure in § 402.46(a), and the provisions of § 402.46(b) and (c) shall apply to any such consultation. When consultation is conducted under this section, the written statement or opinion provided by the Service under § 402.46(c) constitutes a partial biological opinion as to the species or habitats that are the subject of the consultation. While not constituting completion of consultation under section 7(a)(2), EPA retains authority to use such a partial biological opinion along with other available information in making a finding under section 7(d) of the Act.

(b) *Opinion of the Secretary.* After conclusion of all consultation on the FIFRA action, the partial biological opinions issued under paragraph (a) of this section shall then collectively constitute the opinion of the Secretary and the incidental take statement, reasonable and prudent measures, and terms and conditions under section 7(b) of the Act except to the extent a partial biological opinion is modified by the Service in accordance with the procedures in § 402.46(c). The Service shall so advise EPA in writing upon issuance of the last partial biological opinion for the consultation.

### § 402.48 Conference on proposed species or proposed critical habitat.

EPA may employ the procedures described in § 402.10 to confer on any species proposed for listing or any habitat proposed for designation as critical habitat. For the purposes of § 402.10(d), the procedures in § 402.46 are a permissible form of formal consultation.

Dated: July 27, 2004.

**Julie A. MacDonald,**

*Acting Assistant Secretary for Fish and Wildlife and Parks, Department of the Interior.*

**William T. Hogarth,**

*Assistant Administrator for Fisheries, National Oceanic and Atmospheric Administration.*

[FR Doc. 04–17654 Filed 8–4–04; 8:45 am]

BILLING CODE 4310–55–P

# Reader Aids

**Federal Register**

Vol. 69, No. 150

Thursday, August 5, 2004

## CUSTOMER SERVICE AND INFORMATION

| | |
|---|---|
| **Federal Register/Code of Federal Regulations** | |
| General Information, indexes and other finding aids | **202–741–6000** |
| **Laws** | **741–6000** |
| **Presidential Documents** | |
| Executive orders and proclamations | **741–6000** |
| **The United States Government Manual** | **741–6000** |
| **Other Services** | |
| Electronic and on-line services (voice) | **741–6020** |
| Privacy Act Compilation | **741–6064** |
| Public Laws Update Service (numbers, dates, etc.) | **741–6043** |
| TTY for the deaf-and-hard-of-hearing | **741–6086** |

## ELECTRONIC RESEARCH

### World Wide Web

Full text of the daily Federal Register, CFR and other publications is located at: **http://www.gpoaccess.gov/nara/index.html**

Federal Register information and research tools, including Public Inspection List, indexes, and links to GPO Access are located at: **http://www.archives.gov/federal_register/**

### E-mail

**FEDREGTOC-L** (Federal Register Table of Contents LISTSERV) is an open e-mail service that provides subscribers with a digital form of the Federal Register Table of Contents. The digital form of the Federal Register Table of Contents includes HTML and PDF links to the full text of each document.

To join or leave, go to **http://listserv.access.gpo.gov** and select *Online mailing list archives, FEDREGTOC-L, Join or leave the list (orchange settings);* then follow the instructions.

**PENS** (Public Law Electronic Notification Service) is an e-mail service that notifies subscribers of recently enacted laws.

To subscribe, go to **http://listserv.gsa.gov/archives/publaws-l.html** and select *Join or leave the list* (or change settings); then follow the instructions.

**FEDREGTOC-L** and **PENS** are mailing lists only. We cannot respond to specific inquiries.

**Reference questions.** Send questions and comments about the Federal Register system to: **fedreg.info@nara.gov**

The Federal Register staff cannot interpret specific documents or regulations.

## FEDERAL REGISTER PAGES AND DATE, AUGUST

46095–46398 ..... 2
46399–46978 ..... 3
46979–47352 ..... 4
47353–47762 ..... 5

## CFR PARTS AFFECTED DURING AUGUST

At the end of each month, the Office of the Federal Register publishes separately a List of CFR Sections Affected (LSA), which lists parts and sections affected by documents published since the revision date of each title.

**3 CFR**

**Administrative Orders:**
Presidential Determinations:
No. 2004-40 of July 21, 2004 .....46399

**5 CFR**

531 .....47353

**10 CFR**

**Proposed Rules:**
50 .....46452
431 .....47486

**12 CFR**

229 .....47290

**14 CFR**

23 .....47354
39 .....46979
71 .....47357
73 .....47358
**Proposed Rules:**
39 .....46456, 47028, 47031, 47035, 47038, 47040, 47041, 47388, 47391, 47393

**21 CFR**

510 .....47360, 47361
522 .....47361, 47362
524 .....47361, 47363

**26 CFR**

1 .....46401, 46982, 47364
14a .....46401
602 .....46982
**Proposed Rules:**
1 .....47043, 47395

**29 CFR**

1910 .....46986

**33 CFR**

100 .....46994, 46996
117 .....46998
**Proposed Rules:**
117 .....47045
165 .....47047

**36 CFR**

242 .....46999

**37 CFR**

**Proposed Rules:**
202 .....47396

**38 CFR**

3 .....46426

**40 CFR**

9 .....47210
52 .....47365, 47366
63 .....47001
81 .....47366
122 .....47210
123 .....47210
124 .....47210
125 .....47210
180 .....47005, 47013, 47022
300 .....47377
**Proposed Rules:**
52 .....47399
63 .....47049
81 .....47399
180 .....47051
300 .....47068, 47072

**42 CFR**

**Proposed Rules:**
403 .....46632
405 .....47488
410 .....47488
411 .....46632, 47488
414 .....47488
417 .....46632, 46866
418 .....47488
422 .....46866
423 .....46632
424 .....47488
484 .....47488
486 .....47488

**44 CFR**

64 .....46435
67 .....46436, 46437

**46 CFR**

71 .....47378
114 .....47378
115 .....47378
125 .....47378
126 .....47378
167 .....47378
169 .....47378
175 .....47378
176 .....47378

**47 CFR**

0 .....46438
1 .....46438
2 .....46438
73 .....46447, 47385
90 .....46438
95 .....46438
**Proposed Rules:**
2 .....46462
73 .....46474, 46476, 47399
90 .....46462

**49 CFR**

375 .....47386
**Proposed Rules:**
171 .....47074

172.....47074
173.....47074
175.....47074
178.....47074
571.....47075

**50 CFR**

17.....47212, 47330
100.....46999
402.....47732
660.....46448
679 .....46451, 47025, 47026

## REMINDERS

The items in this list were editorially compiled as an aid to Federal Register users. Inclusion or exclusion from this list has no legal significance.

## RULES GOING INTO EFFECT AUGUST 5, 2004

**ADVISORY COUNCIL ON HISTORIC PRESERVATION**

**Historic Preservation, Advisory Council**

Historic properties protection; published 7-6-04

**ENVIRONMENTAL PROTECTION AGENCY**

Superfund program:

National oil and hazardous substances contingency plan—

National priorities list update; published 8-5-04

**HEALTH AND HUMAN SERVICES DEPARTMENT**

**Food and Drug Administration**

Animal drugs, feeds, and related products:

Ceftiofur; published 8-5-04

Gentamicin sulfate ophthalmic ointment; published 8-5-04

Romifidine hydrochloride injectable solution; published 8-5-04

Sponsor name and address changes—

Hess & Clark, Inc.; published 8-5-04

Sparhawk Laboratories, Inc.; published 8-5-04

**PERSONNEL MANAGEMENT OFFICE**

Pay under General Schedule:

Locality-based comparability payments; published 8-5-04

**SECURITIES AND EXCHANGE COMMISSION**

Investment companies:

Investment advisory contracts approval; disclosure requirements; published 6-30-04

**TRANSPORTATION DEPARTMENT**

**Federal Aviation Administration**

Airworthiness directives:

Airbus; published 7-1-04

Fokker; published 7-1-04

Gulfstream Aerospace LP; published 7-1-04

Class D airspace; published 5-20-04

Class D and Class E airspace; published 4-13-04

Class D and E airspace; published 4-19-04

Class E airspace; published 4-13-04

Correction; published 6-9-04

Class E airspace; correction; published 5-25-04

IFR altitudes; published 6-29-04

Restricted areas; published 5-28-04

VOR Federal airways; published 6-1-04

**TRANSPORTATION DEPARTMENT**

**Federal Motor Carrier Safety Administration**

Motor carrier safety standards:

Household goods transportation; consumer protection regulations

Correction; published 8-5-04

**TREASURY DEPARTMENT**

**Internal Revenue Service**

Income taxes:

Qualified dividend income; time and manner of making election to treat as investment income; published 8-5-04

## COMMENTS DUE NEXT WEEK

**AGRICULTURE DEPARTMENT**

**Agricultural Marketing Service**

Cotton classing, testing and standards:

Classification services to growers; 2004 user fees; Open for comments until further notice; published 5-28-04 [FR 04-12138]

**CHEMICAL SAFETY AND HAZARD INVESTIGATION BOARD**

Administrative claims; monetary damages filed under Federal Tort Claims Act; comments due by 8-16-04; published 6-17-04 [FR 04-13711]

**COMMERCE DEPARTMENT**

**National Oceanic and Atmospheric Administration**

Fishery conservation and management:

West Coast States and Western Pacific fisheries—

Pacific Coast groundfish; comments due by 8-17-04; published 6-18-04 [FR 04-13730]

Pacific Coast groundfish; comments due by 8-17-04; published 7-7-04 [FR 04-15256]

**COMMODITY FUTURES TRADING COMMISSION**

Commodity Exchange Act:

Speculative position limits; comments due by 8-16-04; published 6-17-04 [FR 04-13678]

**COURT SERVICES AND OFFENDER SUPERVISION AGENCY FOR THE DISTRICT OF COLUMBIA**

Semi-annual agenda; Open for comments until further notice; published 12-22-03 [FR 03-25121]

**DEFENSE DEPARTMENT**

Federal Acquisition Regulation (FAR):

Performance-based contracting use for services; incentives; comments due by 8-17-04; published 6-18-04 [FR 04-13618]

**ENERGY DEPARTMENT**

**Energy Efficiency and Renewable Energy Office**

Consumer products; energy conservation program:

Energy conservation standards—-

Commercial packaged boilers; test procedures and efficiency standards; Open for comments until further notice; published 12-30-99 [FR 04-17730]

**ENERGY DEPARTMENT**

**Federal Energy Regulatory Commission**

Electric rate and corporate regulation filings:

Virginia Electric & Power Co. et al.; Open for comments until further notice; published 10-1-03 [FR 03-24818]

**ENVIRONMENTAL PROTECTION AGENCY**

Air pollutants, hazardous; national emission standards:

List of hazardous air pollutants, petition process, lesser quantity designations, and source category list; comments due by 8-18-04; published 7-19-04 [FR 04-16335]

Air pollution control; new motor vehicles and engines:

Heavy duty diesel engines and vehicles; in-use emissions testing; comments due by 8-16-04; published 6-10-04 [FR 04-13179]

Heavy duty diesel engines and vehicles; in-use emissions testing; correction; comments due by 8-16-04; published 6-21-04 [FR 04-13930]

Air programs; approval and promulgation; State plans for designated facilities and pollutants:

New Jersey; comments due by 8-16-04; published 7-16-04 [FR 04-16208]

Air quality implementation plans; approval and promulgation; various States:

Montana; comments due by 8-19-04; published 7-20-04 [FR 04-16448]

Ohio; comments due by 8-19-04; published 7-20-04 [FR 04-16333]

Environmental statements; availability, etc.:

Coastal nonpoint pollution control program—

Minnesota and Texas; Open for comments until further notice; published 10-16-03 [FR 03-26087]

Pesticide programs:

Pesticide container and containment standards; comments due by 8-16-04; published 6-30-04 [FR 04-14463]

Pesticides; tolerances in food, animal feeds, and raw agricultural commodities:

Humates; comments due by 8-16-04; published 6-16-04 [FR 04-12913]

Solid waste:

Municipal solid waste landfill permit program—

Indiana; comments due by 8-16-04; published 7-16-04 [FR 04-16205]

Solid wastes:

Municipal solid waste landfill permit program—

Indiana; comments due by 8-16-04; published 7-16-04 [FR 04-16204]

Water pollution; effluent guidelines for point source categories:

Meat and poultry products processing facilities; Open for comments until further notice; published 12-30-99 [FR 04-12017]

**FEDERAL COMMUNICATIONS COMMISSION**

Digital television stations; table of assignments:

California; comments due by 8-16-04; published 7-1-04 [FR 04-15003]

Radio stations; table of assignments:
Arkansas and Massachusetts; comments due by 8-19-04; published 7-19-04 [FR 04-16366]
Florida; comments due by 8-19-04; published 7-19-04 [FR 04-16369]
Wisconsin; comments due by 8-19-04; published 7-19-04 [FR 04-16368]

**FEDERAL DEPOSIT INSURANCE CORPORATION**

Fair and Accurate Credit Transactions Act; implementation:
Fair credit reporting provisions; affiliate marketing; comments due by 8-16-04; published 7-15-04 [FR 04-15950]

**FEDERAL RESERVE SYSTEM**

Fair and Accurate Credit Transactions Act; implementation:
Fair credit reporting provisions (Regulation V); affiliate marketing; comments due by 8-16-04; published 7-15-04 [FR 04-15950]

**FEDERAL TRADE COMMISSION**

Fair and Accurate Credit Transactions Act; implementation:
Affiliate marketing; comments due by 8-16-04; published 6-15-04 [FR 04-13481]
Fair Credit and Reporting Act:
Summaries of consumer rights and notices of duties; comments due by 8-16-04; published 7-16-04 [FR 04-16010]

**GENERAL SERVICES ADMINISTRATION**

Acquisition regulations:
Debarment, suspension, and ineligibility requirements; comments due by 8-17-04; published 6-18-04 [FR 04-13762]
Federal Acquisition Regulation (FAR):
Performance-based contracting use for services; incentives; comments due by 8-17-04; published 6-18-04 [FR 04-13618]

**HEALTH AND HUMAN SERVICES DEPARTMENT**

**Food and Drug Administration**

Administrative rulings and decisions:
Ozone-depleting substances use; essential-use designations—
Albuterol used in oral pressurized metered-dose inhalers; removed; comments due by 8-16-04; published 6-16-04 [FR 04-13507]
General enforcement regulations:
Exports; notification and recordkeeping requirements; comments due by 8-16-04; published 6-1-04 [FR 04-12271]
Product jurisdiction:
Mode of action and primary mode of action of combination products; definitions; comments due by 8-20-04; published 6-24-04 [FR 04-14265]
Reports and guidance documents; availability, etc.:
Evaluating safety of antimicrobial new animal drugs with regard to their microbiological effects on bacteria of human health concern; Open for comments until further notice; published 10-27-03 [FR 03-27113]

**HOMELAND SECURITY DEPARTMENT**

**Coast Guard**

Anchorage regulations:
Maryland; Open for comments until further notice; published 1-14-04 [FR 04-00749]

**HOMELAND SECURITY DEPARTMENT**

**Immigration and Customs Enforcement Bureau**

Nonimmigrants; removal orders, countries to which aliens may be removed; comments due by 8-18-04; published 7-19-04 [FR 04-16193]

**HOUSING AND URBAN DEVELOPMENT DEPARTMENT**

Grants:
Faith-based organizations; participation in department programs; equal treatment of all program participants; comments due by 8-20-04; published 6-21-04 [FR 04-13874]
Mortgage and loan insurance programs:
Single family mortgage insurance—
National Housing Act; Hawaiian Home Lands; comments due by 8-16-04; published 6-15-04 [FR 04-13431]
Public and Indian housing:
Indian Housing Block Grant Program; minimum funding extension; comments due by 8-16-04; published 6-17-04 [FR 04-13721]

**INTERIOR DEPARTMENT**

**Surface Mining Reclamation and Enforcement Office**

Permanent program and abandoned mine land reclamation plan submissions:
Alaska; comments due by 8-18-04; published 7-19-04 [FR 04-16287]
Indiana; comments due by 8-18-04; published 7-19-04 [FR 04-16284]
Kentucky; comments due by 8-18-04; published 7-19-04 [FR 04-16286]
Maryland; comments due by 8-18-04; published 7-19-04 [FR 04-16285]
Texas; comments due by 8-18-04; published 7-19-04 [FR 04-16283]

**JUSTICE DEPARTMENT**

Nonimmigrants; removal orders, countries to which aliens may be removed; comments due by 8-18-04; published 7-19-04 [FR 04-16193]

**LABOR DEPARTMENT**

**Employment and Training Administration**

Aliens:
Labor certification for permanent employment in U.S.; backlog reduction; comments due by 8-20-04; published 7-21-04 [FR 04-16536]

**NATIONAL AERONAUTICS AND SPACE ADMINISTRATION**

Federal Acquisition Regulation (FAR):
Performance-based contracting use for services; incentives; comments due by 8-17-04; published 6-18-04 [FR 04-13618]

**NATIONAL CREDIT UNION ADMINISTRATION**

Fair and Accurate Credit Transactions Act; implementation:
Fair credit reporting; affiliate marketing; comments due by 8-16-04; published 7-15-04 [FR 04-15950]

**NUCLEAR REGULATORY COMMISSION**

Environmental statements; availability, etc.:
Fort Wayne State Developmental Center; Open for comments until further notice; published 5-10-04 [FR 04-10516]

**POSTAL SERVICE**

International Mail Manual:
International Priority Mail and International Surface Air Lift mailers; discontinuance of volume discount rates; comments due by 8-18-04; published 7-28-04 [FR 04-17124]

**SMALL BUSINESS ADMINISTRATION**

Disaster loan areas:
Maine; Open for comments until further notice; published 2-17-04 [FR 04-03374]

**STATE DEPARTMENT**

Consular services; fee schedule; comments due by 8-18-04; published 7-19-04 [FR 04-16363]

**OFFICE OF UNITED STATES TRADE REPRESENTATIVE**

**Trade Representative, Office of United States**

Generalized System of Preferences:
2003 Annual Product Review, 2002 Annual Country Practices Review, and previously deferred product decisions; petitions disposition; Open for comments until further notice; published 7-6-04 [FR 04-15361]

**TRANSPORTATION DEPARTMENT**

**Federal Aviation Administration**

Air carrier certification and operations:
Antidrug and alcohol misuse prevention programs for personnel engaged in specified aviation activities; comments due by 8-16-04; published 5-17-04 [FR 04-10815]
Airworthiness directives:
Airbus; comments due by 8-16-04; published 7-15-04 [FR 04-16031]
Empresa Brasileira de Aeronautica S.A. (EMBRAER); comments due by 8-16-04; published 7-22-04 [FR 04-16681]
Grob-Werke; comments due by 8-16-04; published 7-15-04 [FR 04-16097]
Honeywell; comments due by 8-16-04; published 6-16-04 [FR 04-13563]
Airworthiness standards:
Special conditions—
Learjet Inc., Model 55, 55B and 55C airplanes;

comments due by 8-16-04; published 7-15-04 [FR 04-16101]

Class E airspace; comments due by 8-16-04; published 7-2-04 [FR 04-15035]

**TRANSPORTATION DEPARTMENT**

**Federal Highway Administration**

Engineering and traffic operations:

Highway bridge replacement and rehabilitation program; comments due by 8-20-04; published 6-21-04 [FR 04-13839]

**TRANSPORTATION DEPARTMENT**

**Maritime Administration**

Subsidized vessels and operators:

Maritime Security Program; comments due by 8-19-04; published 7-20-04 [FR 04-16454]

**TREASURY DEPARTMENT**

**Comptroller of the Currency**

Fair and Accurate Credit Transactions Act; implementation:

Fair credit; affiliate marketing; comments due by 8-16-04; published 7-15-04 [FR 04-15950]

**TREASURY DEPARTMENT**

**Foreign Assets Control Office**

Cuban assets control regulations:

Commission for Assistance to a Free Cuba, recommendations; implementation; comments due by 8-16-04; published 6-16-04 [FR 04-13630]

**TREASURY DEPARTMENT**

**Internal Revenue Service**

Income taxes:

Safe harbor sale and leaseback transactions; uniform capitalization of interest expense; comments due by 8-18-04; published 5-20-04 [FR 04-11361]

**TREASURY DEPARTMENT**

**Thrift Supervision Office**

Fair and Accurate Credit Transactions Act; implementation:

Fair credit reporting; affiliate marketing; comments due by 8-16-04; published 7-15-04 [FR 04-15950]

## LIST OF PUBLIC LAWS

This is a continuing list of public bills from the current session of Congress which have become Federal laws. It may be used in conjunction with "PLUS" (Public Laws Update Service) on 202–741–6043. This list is also available online at *http://www.archives.gov/federal_register/public_laws/public_laws.html*.

The text of laws is not published in the **Federal Register** but may be ordered in "slip law" (individual pamphlet) form from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 (phone, 202–512–1808). The text will also be made available on the Internet from GPO Access at *http://www.gpoaccess.gov/plaws/index.html*. Some laws may not yet be available.

**H.R. 4363/P.L. 108–285**

Helping Hands for Homeownership Act of 2004 (Aug. 2, 2004; 118 Stat. 917)

**H.R. 4759/P.L. 108–286**

United States-Australia Free Trade Agreement Implementation Act (Aug. 3, 2004; 118 Stat. 919)

**Last List August 4, 2004**

## Public Laws Electronic Notification Service (PENS)

**PENS** is a free electronic mail notification service of newly enacted public laws. To subscribe, go to *http://listserv.gsa.gov/archives/publaws-l.html*

**Note:** This service is strictly for E-mail notification of new laws. The text of laws is not available through this service. **PENS** cannot respond to specific inquiries sent to this address.